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For the majority of my scientific career, I have been active in research using organic 
chemical methods and approaches to problems in biology and medicine, particularly as 
applied to the treatment and diagnosis of cancer. More than 70 papers have been 
published in refereed journals on this work, in addition to reviews and published 
contributions to conferences. One patent has been granted to me. As is usual for a 
medicinal chemist, the majority of my publications report both the chemical and 
biological aspects of the scientific work. For the publications with an essentially 
chemical theme, I led the research. For most of those with a more biological slant, I 
was the major chemical contributor to the collaboration; usually my medicinal 
chemical design led and shaped the direction of the project.
My work as a medicinal chemist has followed two principal themes, the chemistry and 
biology of JV-methyl compounds and exploitation of the physiological differences 
between solid tumours and normal tissues. Several smaller projects have also been 
undertaken, often as parts of collaborations. A developing area of research is 
discovery of new potent and tumour-selective inhibitors of DNA repair.
This compilation of my published work comprises all my scientific papers in refereed 
journals from 1982 to 1997, together with my reviews, book chapters and a patent. 
Three published conference abstracts are also included where the scientific findings 
have not subsequently been reported elsewhere in full papers.
Chemistry, anti-cancer activity and metabolism of iV-methyl compounds
My interest in the chemistry, anti-cancer activity and metabolism of iV-methyl 
compounds was kindled in 1980 when the one of the simplest compounds to contain 
this group, JV-methylformamide (NMF), was shown to have significant activity against 
murine tumours. This is a very small molecule (9 atoms only) and exploration of 
structure-activity relationships (SARs) was limited by the small number of functional 
groups that could be changed. Nevertheless, my team synthesised some 34 analogues 
but the structural requirements for antitumour activity were found to be very rigorous, 
only the parent being potent \publication IS], This unusual SAR, together with the 
lack of myelosuppression caused by NMF, indicated that NMF was a very unusual 
antitumour agent in terms of its (bio)molecular mechanisms of therapeutic and toxic 
action. Studies were therefore initiated to establish the course and products of 
metabolism of NMF in experimental animals and to attempt to relate the chemical 
reactivity of the major metabolites to the therapeutic activity and toxicity.
The established view at this time (early 1980s) was that most drugs and other agents 
containing A-methyl groups were metabolised by cytochrome P450-mediated 
oxidation at NCH3, giving the iV'-hydroxymethyl analogue as a relatively unstable
intermediate and that the final observed metabolites were the A^-desmethyl derivatives 
of the parents. Indeed, when # -[14C]-NMF was synthesised {publication 6] and 
administered to mice in an early study, W-[14C]-hydroxymethylformamide (HMF) was 
observed as a minor excreted metabolite {publication 2].
In parallel with these studies on NMF, discoveries were made concerning the metab­
olism of other jV-methyl compounds, extending our understanding of their biological 
fate. A^-Dimethylbenzamides, K -aryl-AyV-dimethylformamidines, A^-aryl-A^V-di- 
methyltriazenes and iV,-aryl-i\yV-dimethylureas (including the agrochemical monuron) 
were synthesised; all were converted to their W-hydroxymethyl analogues by murine 
hepatic microsomes {publication 1]. However, a new discovery was made that where 
the jV-hydroxymethyl metabolite was sufficiently stable, it could be oxidised further to 
the N-formyl metabolite {publication 3,5]. In contrast, metabolic reduction of the 
ketone carbonyl group of the experimental antitumour agent l-(4-acetylphenyl)-3,3- 
dimethyltriazene was observed {publication 4]; selective chemical reduction of this 
group was also achieved in the presence of the normally reductively sensitive triazene 
moiety {publication 7]. During an attempt to synthesise 1 -aryl-3-formyltriazenes as 
standards for these metabolic studies, we developed an efficient method for 
conversion of the arenediazonium compounds (and hence arylamines) to the parent 
arene, a process that is also amenable to regioselective introduction of deuterium and 
tritium {publication 16]. The metabolism of antitumour triazenes was reviewed 
[publication 27, 64]. Later, a trideuterio isotopomer of the experimental antitumour 
drug hexamethylmelamine was synthesised {publication 45]; biomimetic oxidation at 
the JV-methyl groups was shown by mass spectrometry to be subject to a large primary 
kinetic deuterium isotope effect [KDIE] {publication 55].
iV-Hydroxymethyl groups have the potential to form iminium ions under acidic 
conditions in vitro and the electrophilic reactivity of these ions may be important in 
the toxicity of N-methyl-containing compounds {publication 13] and in detoxifying 
conjugation reactions with, for example, glutathione. This electrophilic reactivity was 
also exploited in the chemical synthesis of a series of NCH2S-linked glutathione 
derivatives of amides and ureas {publication 9], performed by three undergraduate 
project students under my supervision. These observations led to more fundamental 
NMR studies on the conformations of jV-hydroxymethylamides in solution, 
establishing that hydrogen bonding is not the major determinant of rotamer population 
about the amide bond {publication 10], and a NMR, crystallographic and theoretical 
study on Af-methyl-2-nitroethenamines closely related to NMF {publication 11], 
showing that hydrogen-bonding is very important in their structure. Where an 
iV'-hydroxymethyl compound is not sufficiently stable to be used in biological 
experiments, the W-acetoxymethyl analogue may be used as a source of iminium ions 
[publication 19]. We discovered that oxidation of N-aroylglycines (hippuric acids) 
with lead(IV) acetate conveniently gives both JV-acetoxymethylbenzamides and N- 
formylbenzamides; the mechanism of this oxidative decarboxylation was also 
established using appropriate deuterium labelling experiments {publication 17].
The most important discovery in the field of the metabolism and toxicity of vV-alkyl- 
formamides was that NMF does not follow the usual metabolic fate of 7V-methyl- 
amides. HMF, when administered to mice, does not cause significant hepatotoxicity 
but hepatotoxicity is the dose-limiting toxicity of NMF in rodents and in humans.
[14C]-NMF gives rise to 
[14C]-labelled protein adducts 
in vivo {publication 21], 
indicating that NMF is 
metabolised to an electro- 
phile, but this electrophile 
was clearly not HMF. The 
search was started for the 
new metabolic pathway for 
A-alkylformamides that led 
to the hepatotoxic inter­
mediate. The antitumour 
metabolite was also un­
identified at this stage, NMF 
being devoid of cytotoxic 
activity in vitro. The first 
demonstration of this novel 
route came when A-acetyl-S^A-methylcarbamoyljcysteine was identified by proton 
NMR as a major urinary metabolite of NMF in mice; this compound had previously 
eluded identification owing to its high lability under even mildly basic conditions 
[publication 18]. Thus the major route of metabolism of NMF involved oxidation at 
the formyl group, rather than at the methyl group. This A-acetylcysteine derivative 
was likely to be a downstream (Phase 3) metabolite of the corresponding glutathione 
conjugate, ^-(A-methylcarbamoyOglutathione. Although this glutathione conjugate 
resisted chemical synthesis for some time [publication 33], it was identified as a 
biliary metabolite of NMF by mass spectrometry [publications 23, 29]. To investigate 
the metabolic pathways more thoroughly, I designed a series of experiments in which 
KDDEs would reveal information the mechanisms of the metabolic steps. A primary 
KDIE of approx. 6 was observed for the conversion NMF -> S-(A-methylcarbamoyl)- 
glutathione, after co-administration of OHCNHCH3 and ODCNHCD3 to the mice A 
similar KDIE was evident for the conversion of OHCNHCD3 and ODCNHCH3 to 
A-acetyl-S^A-trideuteriomethylcarbamoyljcysteine and A-acetyl-.S-(A-methyl- 
carbamoyl)cysteine, respectively. This was expected but more striking was the 
observation of a similar KDIE for the metabolism of OHCNHCD3 and ODCNHCH3 
to CD3NH2 and CH3NH2, respectively, showing that the methylamine previously 
observed as a metabolite of NMF had also arisen from oxidation at the formyl group, 
rather than hydrolysis of the amide bond [publication 23]. Thus the major initial route 
of metabolism of NMF was oxidation at the formyl group; parallel studies also 
showed that this was the case for A-ethylformamide [publication 22]. A-Ethyl- 
formamide is a potent hepatotoxin in mice but has no antitumour activity. 
Interestingly, the various isotopomers of NMF and DMF were resolvable during 
capillary gas chromatography, deuterium incorporation leading to changes in retention 
time that were consistent and were diagnostic of deuteration at the methyl groups or 
at the formyl group [publication 56], Publication 23 has proved to be my most highly 
cited paper to date.
Dimethylformamide (DMF), a common industrial chemical, is closely related in 
structure to NMF. It is largely devoid of antitumour activity in experimental activity, 
despite claims in the literature that NMF was the major metabolite of DMF. However,
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using proton NMR techniques directly on urine of mice which had received DMF, we 
were able to show that the major metabolite was, in fact, A-hydroxymethyl-TV-methyl- 
formamide (HMMF) which decomposes to NMF under the gas chromatographic 
conditions previously used [publication 14]. DMF is an hepatotoxin in man but not in 
rodents and an explanation for this was sought in the metabolites downstream from 
HMMF. A sulphur-containing metabolite of DMF in the urine of environmentally 
exposed workers was shown to be Ar-acetyl-<S-(Ar-methylcarbamoyl)cysteine, the same 
compound as was formed from NMF; thus the metabolic sequence DMF -» HMMF 
—> NMF —» iS'-(ALmethylcarbamoyl)glutathione —» Ar-acetyl-iS'-(Ar-methylcarbamoyl)- 
cysteine was established in humans [publications 22, 34]. The step HMMF —> NMF 
appeared to be much less efficient in rodents, correlating with the lower hepato­
toxicity caused by DMF in these species. Clearly, either the primary metabolite of 
NMF (possibly methyl isocyanate) and / or S-(V-methylcarbamoyl)glutathione were 
acting as electrophilic toxins in the liver. A paper correlating the hepatotoxicity 
caused by certain low molecular weight formamides and acetamides with the extent of 
metabolic oxidation at the formyl group unified our work in this area [publication 22] 
and suggested that the health monitoring of occupationally exposed workers in the 
chemical industry at that time was inappropriate. Three chapters were also 
contributed to widely used reference texts in environmental toxicology and safety 
[publications 30, 41, 42]. The metabolic oxidation of DMF and of NMF at both the 
methyl and the formyl groups was shown to be mediated by one cytochrome P450 
isozyme, CYP 2E1 [publication 55]; this is the isozyme which is responsible for the 
metabolism of ethanol and inhibition of ethanol metabolism by DMF and NMF may be 
responsible for the alcohol intolerance exhibited by some workers exposed to DMF.
The role of metabolic activation of formamides as hepatotoxins by oxidation of the 
formyl group to carbamoylating agents was confirmed by the profound isotope effect 
on hepatotoxicity when deuterium was present in the formyl group [publication 23]. 
In contrast, although the structure-antitumour activity relationships were veiy clear 
for the formamides, the identity of the therapeutically cytotoxic metabolite was never 
firmly established. Incorporation of deuterium at the formyl group did decrease the 
antitumour activity against some experimental tumours [unpublished data], 
suggesting that metabolic oxidation at formyl may also be required. Thus further drug 
design efforts to attempt to divorce the therapeutic activity from the toxicity may be 
futile. Unfortunately, no therapeutic activity could be demonstrated for NMF in phase 
I and phase II clinical trials; the formamide project thus came to an end.
Medicinal chemistry of hypoxic solid tumours
Regions of chronic and acute hypoxia (oxygen deficiency) are present in most solid 
tumours owing to the primitive state of the tumour vasculature. Viable cells in such 
tissue are relatively resistant to radiotherapy and to many chemotherapeutic strategies. 
Thus hypoxia represents both a therapeutic problem (resistance) and a therapeutic 
opportunity, a physiological difference between normal and tumour tissue which could 
be exploited for selective delivery of drugs or activation of prodrugs. The medicinal 
chemical approach to overcoming the resistance of hypoxic cells to the lethal effects 
of X- and y-radiation is to design an electron-affinic drug which will mimic the 
reactivity of molecular oxygen in abstracting electrons from ionised DNA. Much
important work by Professor Gerald Adams and 
others in the 1970s and early 1980s had established 
that the radiosensitising potency of many types of 
drug correlated with their one-electron redox 
potential Elj. The Roche compound misonidazole had 
shown some radiosensitising activity in the clinic but 
doses were limited by neurotoxicity; incorporation of 
an electrophilic aziridine group into the side-chain 
increased the radiosensitising potency by about 
10 fold in vitro but the new lead compound,
RSU 1069, caused unacceptable gastrointestinal 
toxicity in the clinic. On joining the MRC Radio- 
biology Unit, my team continued the development of 
prodrugs of RSU 1069, contributing to the 
identification of the corresponding bromoethyl- 
ammonium salt RB 6145 as the optimum prodrug 
which was equipotent with RSU 1069 as a radio- 
sensitiser but which was tolerated by experimental 
animals at higher doses and permitted oral administration [publication 39].
2-Nitroimidazoles, particularly those with electrophilic or weakly basic side-chain, 
were also selectively cytotoxic to hypoxic cells through metabolic reduction to 
electrophiles. A programme of synthesis and evaluation of other nitroheterocycles 
carrying electrophilic or tertiary amine side-chains largely confirmed the dependence 
of radiosensitising activity on redox potential but showed that selectivity and potency 
of the bioreductively activated cytotoxicity was largely confined to the 
nitroimidazoles, presumably the nitroheterocycles of higher redox potential were 
bioreduced in hypoxic cells but the reduction products were not cytotoxins 
[publications 38, 46, 47]. Interestingly, some of the 7V-(tertiary aminoalkyl)nitro- 
thiophenecarboxamides showed radiosensitising activity considerably in excess of the 
efficiency predicted by their E li values.
Returning to the parent 1-substituted 2-nitroimidazole lead compounds RSU 1069 
and RB 6145, a more detailed study of the effect on activity of small changes to the 
side-chains (introduction of methyl group at strategic points to vary the molecular 
conformations, pKas, etc.) required some difficult synthetic obstacles to be overcome 
[publication 57], Incorporation of the 3-aziridinyl-2-hydroxypropyl unit into a cyclo- 
hexane ring to lock the conformation was also investigated. During the course of the 
synthesis of the required 1,2,3-trisubstituted cyclohexane, a new method of 
controlling the diastereoselectivity of epoxidation reactions was developed in which 
the presence or absence of water would cause the reaction to proceed under steric or 
hydrogen-bonding control, respectively [publication 44], This approach gave 
compounds which were equipotent with RSU 1069 or were marginally more potent, 
the increase in potency was more than outweighed in terms of drug development by 
the increased difficulty of synthesis. RSU 1069 and RB 6145 contain chiral centres 
and were developed as racemic mixtures. Surprisingly, synthesis and evaluation of the 
individual R and S enantiomers revealed no significant differences in therapeutic or 
toxic activity, in contrast to many drugs acting by binding to chiral targets such as 
DNA [publication 57].
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2-[14C]-2-Nitroimidazoles had previously been shown to be highly sensitive to auto­
radiolysis, complete decomposition being seen in a few hours even at low specific 
activities. Hence, the requirement for biodistribution studies of tritiated isotopomers 
of RSU 1069, etanidazole and pimonidazole of high specific activity appeared to 
present a severe synthetic challenge - to carry out three steps of chemical synthesis 
and deliver the compounds for biological studies within 6 hours. Rapid and highly 
chemically and radiochemically efficient syntheses were developed to materials of 
200 mCi mmol'1 [publications 36, 37, 40]. In contrast to the [14C] isotopomers, these 
tritiated compounds proved to be stable for >1 year, permitting delivery to 
collaborating laboratories [publication 54].
The observation that the radioactivity associated with 1-substituted 2-nitroimidazoles 
is retained selectively in hypoxic tumour tissue led us to explore such compounds as 
tumour targetting systems. Boron neutron capture therapy of tumours relies on the 
capture of low energy “thermal” neutrons by the 10B isotope of boron. The outcome 
of this capture process is fission of the boron nucleus, giving 7Li and 4He nuclei with 
sufficient kinetic energy to allow the a-particle to travel approximately one cell 
diameter in tissue. Thus, when tumour tissue is irradiated with thermal neutrons, 
damage is confined to those cells containing 10B. Clinical studies of BNCT have met 
with mixed results, largely owing to lack of selectivity in the biodistribution of boron- 
containing drugs to tumours. In the early 1990s, we proposed that the selective 
retention of nitroimidazole derivatives may overcome this problem and a programme 
of synthesis and biological evaluation of nitroimidazoles linked to carboranes (clusters 
containing 10 boron atoms and 2 carbon atoms) was initiated. A number of difficulties 
were encountered in the syntheses, particularly associated with the instability of the 
nitroimidazole (an oxidising agent) to the boranes (reducing agents) required for 
assembly of the carboranes. My group was the first overcome these problems and to 
report an efficient process for construction of a nitroimidazole-carborane [publication 
49]. Subsequent improvements in the 1,3-dipolar cycloaddition chemistry, which 
joined the nitroimidazole and carborane moieties under very mild conditions, led to 
the synthesis of more hydrophilic constructs which were acceptable for biological 
evaluation [publications 60, 63]. New carbamate chemistry was also developed to 
enable this critical link to be made [publication 61] In collaboration with Dr. Pauline 
Wood of the MRC Radiobiology Unit, the biodistribution of boron in tumour-bearing 
mice was measured non-invasively by nB NMR spectroscopy in vivo. We were the 
first group in the UK to use this technique in which sequential measurements can be 
made of biodistribution of boron with time in individual mice; these studies revealed 
that boron is indeed retained in (hypoxic) solid tumours but is cleared rapidly from 
several normal tissues, with the exception of liver [publication 74], Isotopic labelling
O -N
Nitroimidazole-carborane with optimal biodistribution to tumour
of the leading nitroimidazole-carborane was achieved by development of a method 
involving highly selective deprotonation of the carborane 2-position [publication 62].
More recently, my group have sought to exploit selective bioreduction of nitrohetero­
cycles in hypoxic tumours by incorporating such units into prodrugs. In one paper, we 
report that S-2-amino-5-(2-aminoimidazol-l-yl)pentanoic acid is a competitive 
inhibitor of nitric oxide synthases (NOS) but that the corresponding 2-nitroimidazole 
is a weaker inhibitor, leading to the possibility of tumour-selective NOS inhibition 
[publication &Z] However, this strategy does require that the structural element 
which is the product of bioreduction is necessarily a part of the active drug. Much 
more useful would be a general prodrug system which comprised the required active 
drug with critical structural features masked by a nitroheterocyclylmethyl unit. 
(Bio)reduction of the nitroheterocycle then triggers release of active drug. The 
elegance of this approach is that it will be possible to modify the physical properties, 
e.g. water-solubility, by attachment of appropriate functional groups to the bio- 
reductive trigger moiety (the nitroheterocycle). In this way, formulation and 
biodistribution can be optimised without compromising the optimum structure of the 
delivered drug. We have synthesised nitrofuranylmethyl “prodrugs” of known DNA- 
repair inhibitors and BNCT agents and have demonstrated rapid release under 
chemically simulated bioreductive conditions [publication 82].
The vasculature of solid tumours is often poorly developed, particularly with respect 
to the structure of the walls of the vessels. The leakiness of the vessels, together with 
the lack of lymphatic drainage, leads to selective accumulation of soluble macro- 
molecular material in tumours [publication 77]. The optimum hydrodynamic radius 
for this so-called enhanced permeation and retention (EPR) effect corresponds to 
molecules of 10-50 KDa, depending on structure. Selective delivery of cytotoxins to 
tumours has been achieved by other groups by attachment to non-biodegradable poly­
acrylamide polymers, leading to interesting clinical results. Our approach to delivery 
of drugs and imaging agents is to use a biodegradable alternating co-polymer of poly­
ethylene glycol) and peptide units [publication 86]. In the course of this work, 
powerful new chemistry was developed for controlled attachment of porphyrins to the 
lysine and glutamic acid side-chains in the peptide units, giving the potential for 
selective delivery of paramagnetic manganese complexes for enhancement of contrast 
in magnetic resonance imaging [publication 67].
Serine hydroxymethyltransferase
Serine hydroxymethyltransferase (SHMT) is one of three enzymes in the folate cycle 
and catalyses the loss of a formaldehyde equivalent from serine, forming glycine in 
what is formally a reverse-Aldol reaction. The other two, dihydrofolate reductase 
(DHFR) and thymidylate synthetase (TS), have attracted the attention of medicinal 
chemists for many years and potent inhibitors of these enzymes are anticancer drugs 
widely used in the clinic. Inhibitors of this cycle inhibit de novo biosynthesis of DNA 
bases. In a short project, we attempted to design, synthesise and evaluate mechanism- 
based suicide inhibitors of SHMT, having established that the activities of the enzyme 
were much higher in tumours than in normal tissue [publication 24]. The first step in 
the mechanism is formation of an imine with the co-factor pyridoxal phosphate; 
cleavage of the a-P bond then forms a stabilised carbanion. A series of a-substituted
serines was synthesised in which formation of this carbanion was designed to lead to 
formation of an electrophile in the active site, inactivating the enzyme. Under my 
supervision, the graduate student achieved some challenging chemistry {publications 
26, 28] but all analogues were found to be either non-inhibitory or to be competitive 
reversible inhibitors; molecular modelling showed a good fit of the most potent 
inhibitor, a-ethenylserine, with the active site {publication 31].
Flavones
The identification, in the early 1980s, of the receptor-associated tyrosine kinases and 
of the natural product quercetin (3,3’,4’,5,7-pentahydroxyflavone) as an inhibitor led 
us to initiate a project to attempt to develop new flavones which may be more potent 
and selective for this novel anticancer target. More than 30 substituted flavones were 
synthesised, using a mixture of classical and new methods {publication 50], An NMR 
study on the intermediate l-(2-hydroxyaryl)-3-arylpropane-l,3-diones revealed some 
interesting tautomeric and conformational information {publication 55], The flavones 
were evaluated for their activity against the EGF receptor tyrosine kinase activity and 
for their selective cytotoxicity towards 3T3 cells transformed with the Abelson murine 
leukaemia virus. However, the cytotoxicity did not correlate well with inhibition of 
the kinase, suggesting an alternative mechanism of action for the optimum compound 
35 -amino-4 ’ -methoxyflavone.
Publication of the synthetic chemistry and these biological data led to many 
expressions of interest in the work and then to two valuable collaborations. Firstly, 
We supplied several of the more polar synthetic flavones to Dr. Wojciech Krol of the 
Department of Immunology and Microbiology at the Silesian School of Medicine, 
Zabrze, Poland. Dr. Krol and his group had been studying the effects of natural 
products on the function of macrophages as part of a larger programme on traditional 
therapies for inflammatory diseases. Several of the synthetic flavones were shown to 
inhibit the oxidative burst in stimulated murine macrophages, the most potent being 
3’-amino-45-hydroxyflavone {publication 66]. The profile of activities of the various 
flavones against generation of oxidising species by the macrophages was mirrored by 
the inhibitory activities against nitric oxide synthesis in these cells, suggesting a link 
between these two biochemical events {publications 69, 71, 76]. Secondly, in 
collaboration with Dr. Steven Safe of the Veterinary College, Texas A&M University, 
several of the substituted flavones were shown to be highly potent inhibitors both of 
CYP 1A1 (the arylhydrocarbon hydroxylase) and of the induction of this enzyme by 
the environmental pollutant tetrachlorodibenzodioxin (TCDD) {publications 65, 71]. 
The site at which these flavones compete with TCDD is the cytosolic arylhydrocarbon 
receptor which translocates to the nucleus when ligands are bound. Recent studies 
from another group have shown that this receptor protein may also be involved in the 
responses of cells to oxygen-deprivation and it is interesting to speculate that these 
antagonists may inhibit the protective adaptive response of malignant cells in hypoxic 
solid tumours.
T rifluoromethylheterocy cles
The trifluoromethyl group has applications in new pharmaceuticals and in agro­
chemicals, owing to its lipophilicity, acid-strengthening / base-weakening properties 
and its relative inertness to metabolism. As part of a collaboration with Professor 
Shiv P. Singh of Kurukshetra University, India, we were able to contribute to his 
structural and mechanistic work on the synthesis of trifluoromethylpyrazoles 
\publications 48, 84]. In my laboratory, we synthesised a series of trifluoromethyl 
pyrazoles, benzimidazoles and imidazopyridines and examined the effect of pH on 
their 19F NMR spectra {publication 75]. Most of these showed a difference of
1-2 ppm in chemical shift between the neutral heterocycle and the conjugate base. For 
two examples, the pKa for this equilibrium was near 7.0, i.e. near physiological pH. 
These compounds may therefore have applications in measuring pH in biological 
systems in vitro and in vivo by 19F NMR, particularly if attached to suitable tissue- or 
cell-specific targetting systems such as nitroimidazoles. During the synthetic work, a 
novel cyclisation of l,2,4-tris(benzamido)butene with trifluoroacetic anhydride to a 
5-trifluoromethyloxazole was discovered {publication 68] and a serious error in the 
literature was identified and corrected {publication 55].
Poly(ADP-ribose)poIymerase
Poly(ADP-ribose)polymerase (PARP) is abundant in all cell nuclei; it is an important 
regulatory enzyme and has a role in apoptosis. It catalyses the transfer of ADP-ribosyl 
units from NAD+ to growing poly(ADP-ribose) chains attached to carboxylate 
residues in target proteins, including PARP itself. One of its major cellular functions is 
to control the repair of damaged DNA and inhibition of PARP leads to inhibition of 
repair of DNA damaged by chemotherapeutic drugs or by radiation {publications 59, 
78]. PARP inhibitors can therefore act as chemopotentiating and radiopotentiating 
drugs. In a recently initiated programme, we have set out to design inhibitors which 
are more potent and more selective for tumour tissue {publications 79, 80].
Other chemical and biological research
During the course of my main themes of research a number of discoveries were made 
in synthetic and mechanistic chemistry. Chemical approaches were also used to 
contribute to a number of smaller collaborative projects.
An erroneous literature report on the reduction of 2-chloronitrobenzene with 
diethanolamine was corrected by careful separation and characterisation of the many 
products |publication 12]. 5-Ajyl-2,4-diaminopyrimidines are potent inhibitors of 
DHFR and protonation is important to their mode of binding to the target and to their 
bio-inactivation and excretion; a 13C NMR study revealed which nitrogen atoms were 
protonated and, in some cases, identified the order of protonation with decreasing pH 
of the medium {publication 25]. The azolotetrazinones, an important class of anti- 
tumour drugs including temozolomide (which shows good clinical activity against 
melanoma and gliomas) were discovered and developed at Aston University during 
the time that I was a member of the Cancer Research Campaign Chemotherapy Group
there. A comprehensive review of their chemistry and molecular mechanism of action 
was published in 1990 \publication 43].
In an attempt to exploit the different nutritional status of solid tumours, as compared 
to normal tissue, a mono(dichloroacetate) ester of glycerol was identified as a weak 
inhibitor of glycerol kinase |publication £]. Naphtho-l,4-quinones, including vitamin 
Ki and menadione, are hepatotoxins which had been proposed to act either by redox 
cycling or by acting as electrophiles. A series of 2,3-substituted naphtho-l,4-quinones 
was designed and synthesised and, in collaboration with Dr. David Ross, Dr. Peter 
Moldeus and Professor Sten Orrenius of the Karolinska Instituted Stockholm, the 
contribution of each mechanism of toxicity was assessed {publications 20,32].
A new and more efficient chemical derivatisation and HLPC analysis of cocaine and 
its metabolites was developed as a contribution to a research programme, led by 
Dr. Terry Jefferies of the University of Bath, on identifying and measuring drugs of 
abuse in human samples {publication 52]. Continuing the analytical theme, the 
synthesis of novel fluorescently tagged theophylline derivatives enabled a new 
automated immunoassay for theophylline to be set up for monitoring this widely used 
drug in biofluids {publication #5],
Methodological threads
Two methodological threads, NMR spectroscopy and isotopic labelling, run through 
the medicinal chemical programmes outlines above.
In addition to the traditional role of *H and 13C NMR in characterisation of 
compounds synthesised, several papers report the use of NMR techniques, such as 
and 19F-!H nuclear Overhauser effect measurements in studying the stereo­
chemistry, conformations and other structural properties of important molecules 
[publications 10, 11, 25, 35, 44, 48, 68, 84]. The biological applications of NMR 
have also been the principal or a subsidiary target in four project areas: direct 
NMR analysis of biofluids in for identification of drug metabolites {publications 14, 
18], polymer-bound porphyrinatomanganese(III) for MRI {publication 67],
development of a 19F NMR method for determination of pH in biological samples
[publication 75] and use of nB NMR in vivo for estimation of concentrations of 
boron in malignant and normal tissues {publication 75].
Isotopic labelling has been used for several applications in the chemical and bio­
chemical programmes. Syntheses of molecules containing 2H {publications 6 ,11 ,16 , 
17, 23, 36, 37, 62], 3H {publications 36, 37, 62], 14C {publication 6], 15N 
[publication 73] and 180  {publications 72, 6J] have been achieved. Mechanisms of 
chemical reactions have been investigated by deuterium labelling at critical sites on the 
substrates or by following incorporation of deuterium from reagents; KDIEs have also 
given valuable chemical mechanistic information. Isotopomers incorporating 
radioactive nuclei (3H and 14C) were used in pharmacokinetics and drug metabolism 
studies. Most interesting was the use of specific deuterium labelling and KDIEs in 
elucidating metabolic routes of drugs.
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Abstract—The metabolism of the Y-methyl moieties of aryldimethyiamines and Y-methyl compounds 
of the general formula Aryl-A'-N(Me):, where X  is either —N = N — (3-aryl-l,l-dimethyltriazenes). 
—NHCO— (Y'-aryl-Y,Y-dimethylureas) or — N = C H — (Y'-aryl-Y,Y-dimethylformamidines) was 
studied using mouse liver microsomes. Products of microsomal metabolism were reincubated with 
mouse liver homogenate devoid of microsomes and assayed colourimetrically for formaldehyde. This 
allows metabolically generated formaldehyde to be distinguished from formaldehyde precursors. 
Whereas the Y-methyl moieties of the aryldimethyltriazenes, formamidines and amines were metabolised 
to formaldehyde, the aryldimethylureas formed stable formaldehyde precursors upon metabolism. The 
products of metabolism of one such aryldimethylurea, the herbicide monuron (Y'-(4-chlorophenyl)- 
Y,Y-dimethylurea) were investigated using a high pressure liquid chromatographic method. Two 
metabolites were found on incubation of monuron with microsomes. one of which was identified as the 
Y-desmethyl compound by mass spectrometry. The other product showed chromatographic properties 
similar to 4-chlorophenylurea but resembled the monomethylaryl urea on mass spectral analysis. It is 
concluded that this metabolite is likely to be Y'-(4-chlorophenyl)-Y-hydroxymethyl-Y-methylurea. A 
urinary product of conjugative metabolism obtained after the administration of monuron to mice also 
gave the mass spectrum of the monomethyl compound after deconjugation which suggests that a 
conjugated Y-hydroxymethyl compound may have been formed in vivo.
The oxidative Y -dem ethvlation o f  drugs which con­
tain Y -m ethyl groups (A  in Fig. I) is a m etabolic 
pathway which is ubiquitous in xenobiochem istry. 
The pathway is considered to be initiated by the  
hydroxylation o f the methyl carbon to form an 
N -hydroxym ethyl or carbinolam ine compound (Fig. 
1, B ). T hese  Y-hydroxym ethyl com pounds are gen ­
erally thought to be unstable and to decom pose to  
yield the Y-desm ethyl com pound (Fig. 1. C) and 
form aldehyde [1]. It is probable that for the majority 
o f Y -m ethyl containing xenobiotics this reaction 
sequence occurs in the liver, an organ which is able 
to detox ify  the form aldehyde, a species which might 
otherw ise be toxic to peripheral cells [2],
Som e xenobiotics do, how ever, undergo oxidative 
Y -dem ethylation  to yield relatively stable 
Y -hydroxym ethyl com pounds, which are som etim es 
identified as their conjugates [3-11]. This is not 
altogether surprising given that the reaction between  
certain am ines or am ides and formaldehyde can give 
rise to characterisable. synthetic Y-hydroxymethyl 
com pounds o f  varying stability [12]. H owever, only  
certain am ines and am ides undergo this reaction, a 
fact which may be pertinent to the observation that
* Author to whom correspondence should be sent.
relatively few  Y -hydroxym ethyl com pounds have 
been isolated after the m etabolism  o f their progen­
itor Y-m ethyl com pounds.
W e wished to determ ine those m olecular features 
o f  Y-m ethyl containing xenobiotics which might pre­
dispose them  to  form characterisable Y-hydroxy- 
m ethyl com pounds and to estim ate the stability of 
the latter. T his was considered to be important for 
two reasons. Firstly, if stability was such that either 
the inherently reactive Y-hydroxym ethvl com pound  
or the form aldehyde form ed on its breakdown were 
available extrahepatically . such com pounds may 
present a potential toxicological hazard to the host. 
Secondly, certain Y -m ethyl containing antitum our 
drugs have been show n to form relatively stable 
Y-hydroxym ethyl com pounds which have been 
im plicated in their cytotoxicity [13]. Thus, an under­
standing o f the m olecular features which give rise 
to such com pounds m ay be useful in predicting the 
structures o f novel agents to be screened as potential 
antineoplastic drugs.
In this paper we report on the results obtained  
from a colourim etric assay [14] which distinguishes 
betw een free form aldehyde and its precursors such 
as Y -hydroxym ethyl com pounds, formed from the 
in vitro  m etabolism  o f  certain m odel com pounds
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Fig. 1. Metabolism of MN-dimethyl compounds.
which contain the TV-methyl group. In addition, 
selected com pounds have been subjected to HPLC  
(high pressure liquid chrom atographic) analysis after 
their m etabolism  in vitro , in order to  exam ine in 
more detail whether stable N-hydroxym ethyl com ­
pounds had been form ed. T he m odel com pounds 
where X  equals — N = N —  (triazenes), X  equals 
— NHCO—  (ureas), X  equals — N = C H —  (form- 
am idines), or where X  was absent (am ines). Our 
rationale for choosing these particular types o f  com ­
pound was based primarily on previous studies o f  
cytotoxic dim ethylaryltriazenes where synthetic car- 
binolam ines were shown to be relatively stable com ­
pounds [15], one o f which was isolated as a conjugate  
in the urine o f  rats given a dim ethylaryltriazene [11]. 
The ureas and form am idines are structurally similar 
to the aryltriazenes but the nitrogen bearing the 
methyl groupings is placed in different electronic  
and steric environm ents. The arylam ines were cho­
sen as sim pler m odels and were considered appro­
priate to this study as ev id en ce had been presented  
which suggests that a substituted arylamine, 3'- 
m ethvl-4-(m ethylam ino)-azobenzene (M A B ) may 
be m etabolised to a carbinolam ine [16].
MATERIALS AND METHODS
Animals and compounds. M ale B A L B c mice 
(20-25 g) were used for all m etabolism  experim ents. 
The aryl dim ethylam ines (Ia -e  Table 1) used in this 
study were obtained com m ercially. The 3-aryl-1,1- 
dim ethyltriazenes ( I la -e )  w ere prepared by treat­
ment of the appropriate aryldiazonium  salt with 
aqueous dim ethylam ine according to published pro­
cedures [17]. C ondensation o f anilines with 
dim ethylform am ide dim ethylacetal, generally by 
published m ethods [18], furnished the formam idines 
(I lia —f). I lia , b, d, e were isolated as their tosylate  
salts.
Ureas (IV a. b. e , f, g) in addition to jV'-(4- 
chlorophenyl)-/V-m ethylurea (V I) and 4-chloro- 
phenylurea (VII) were prepared by addition o f a 
solution o f the corresponding aryl isocyanate in d ie­
thyl ether or tetrahydrofuran to a large excess o f  
ethereal dim ethylam ine. M elting points were con­
sistent with published values [19-22].
/V'-(4-CvanophenyI)-/V.iV-dimethylurea (IVc): 4- 
cvanobenzoic acid (5 .88  g) was treated with boiling 
thionyl chloride (40 ml) and D M F  (100 ul) for 2 hr. 
Evaporation of excess reagent gave the crude ben­
zoyl chloride which, in acetone (50 m l), was added
to 20% w/v aqueous sodium azide (80 ml). The m ix­
ture was stirred for 10 min. then extracted with ether 
(2 x  100 m l). The com bined extracts were dried 
(N a2S0 4 ), filtered and the solvents evaporated to 
give the crude benzoyl azide ( i w  (Nujol): 2220, 
2180, 1690 cm -1). This material, in dry toluene  
(100 m l), was stirred at reflux for 1 hr. The resulting 
solution o f  the isocyanate, from this Curtius reaction, 
was added to a tenfold  excess o f ethereal dim ethyl­
am ine (300 m l). A fter  17 hr at am bient temperature, 
the solid was isolated and recrystallised from aqueous 
m ethanol to give the previously unreported N '-(4- 
cyanophenyl)-N ,jV -dim ethvlurea (4 .9 0 g; 65% ) as 
pale buff n eed les , MPt 152-153°. (Found: C 63.61% . 
H 5.63% ; N 22.9% . Calculated for C 10H „ N 3O: C 
63.48% ; H 5.86% ; N 22.21% .) i w  (Nujol): 3410, 
2260, 1730, 1600 c m -1. <5((CD3)2SO): 7.75 (4H ) s 
aryl-H , 7.1 (1H ) br N H . 3.40 (6H ) s N (C H 3)2. V- 
(4-Trifluorom ethylphenyl)-iV ,N -dim ethylurea [23] 
was prepared similarly (from  4-trifluoromethyl- 
benzoyl chloride) in 53% yield.
Assay fo r  form aldehyde and its precursors. The 
m etabolism  o f the /V-methyl com pounds was inves­
tigated essentially  as described in [14]. In this assay 
substrates are incubated with hepatic m icrosom es 
for 30 m in. At the end of the incubation period  
m icrosom es are precipitated by centrifugation and 
an aliquot o f  the supernatant is incubated with liver 
hom ogenate freed from m icrosom es. M etabolically  
generated form aldehyde is oxidised by the form al­
dehyde dehydrogenases which are abundant in 
m itochondria and liver cell cytosol, but virtually 
absent in m icrosom es [24], Form aldehyde precur­
sors. how ever, are not meta* 'Used by these 
enzym es, and are detectable anai, ..cally as form al­
dehyde at the end o f  the incubation. Both form al­
dehyde and form aldehyde precursors were quanti­
fied by the colourim etric m ethod according to Nash 
[25].
Substrate concentrations in the microsomal incu­
bations varied betw een 0.5 and 5 mM according to 
the degree o f  /V-dem ethylation o f the substrates. 
C oncentrations w ere used which gave substantial 
absorbance readings (> 0 .3  absorbance units) for 
Nash positive sp ecies at the end o f the microsomal 
incubations. Control incubations were carried out 
without cofactors, and without substrate in the 
m icrosom al incubations. Substrates were also incu­
bated with m icrosom e free hom ogenate and N A D  
in the presence and absence o f form aldehyde, to 
ensure that the substrates did not inhibit the removal 
of form aldehyde by aldehyde dehydrogenases, and
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la: R = phenyl 
b: R = 4-methylphenyl 
c: R = cyanophenyl 
d: R = pyridin-2-yl 




Ila: R = H 
b: R = CF3 
c: R = Cl 
d: R = COCHj 
e: R = C 0 2CHj
Aryldimethylureas IV
Ilia: R = H 
b: R = CHj 
c: R = CN 
d: R = CFj 
e: R = Cl 
f: R = SQ2NH2
IVa: R = H 
b: R = CH3 
c: R = CN 
d: R = CF3 
e: R = Cl 
f: R = Br 
g: R = OCH3
that the substrates them selves were not dem ethy- 
lated to Nash positive species by the m icrosom e-free  
hom ogenate .
Incubation mixtures were deprotein ized either by 
the addition o f  20% trichloroacetic acid as described  
in [14], or in the case o f incubations with acid labile 
triazenes as substrates with 0 .6  ml o f a 20% zinc 
sulphate solution follow ed by 0 .6  ml o f  a saturated  
barium hydroxide solution. It is noteworthy to point 
out difficulties in the application o f  the colourim etric 
assay for form aldehyde to studies o f  the metabolism  
o f  the dim ethyltriazenes. W e found that the triazene 
derivatives Ila . d and e (Table 1) on reaction with 
Nash reagent formed species which absorbed at 
412 nm , and thus superim posed the absorption o f  
the chrom ophore produced from form aldehyde and 
Nash reagent. Interpretation was possible except in 
the case o f  l ie  by using control incubations with 
triazenes and defining the conditions under which 
this led to high absorbance readings at 412 nm.
Metabolism o f  monuron. M etabolic incubations 
were perform ed in a final volum e o f 2.5 ml o f Earls 
buffer (pH  =  7.4) in which the final concentration  
o f m onuron was 1 mM. Cofactors were added to give 
a concentration o f N A D P H  1 mM and M gCl: 5 mM. 
H epatocytes were prepared according to the m ethod  
described in [26].
H P L C  analysis o f  monuron and its metabolites. 
M etabolic incubates or urine sam ples were prepared 
for analysis by the addition o f  an equal volum e o f  
cold m ethanol containing internal standard (N.N-  
dim ethyl-ATphenylurea). centrifuged and injected  
o n to  the H PLC colum n. Separation o f the m etab­
o lites was perform ed on a 4 .6  x  150 mm Ultrasphere  
O D S  colum n (Ci* reverse phase) using a linear gra­
dient elution system from 10% m ethanol/water to  
100% m ethanol over twenty m inutes, a m obile phase
flow rate of 1 m l/m inute and a u.v. detection svstem  
(A =  247 nm).
Chemical ionisation mass spectra. Chem ical ioni­
sation conditions were used as it was found that 
few er contam inating peaks were seen in the spectra 
com pared to those seen using electron im pact. The 
mass spectra were determ ined on a VG 7070 mass 
spectrom eter using isobutane as reagent gas. Spectra 
were run at a scan rate o f  1 second/decade and were 
processed using a V G  2035 data system .
M ass numbers and percentage intensities o f  the 
major fragments in the mass spectra o f com pounds  
and m etabolites referred to in the results section are 
as follow s.
V '-(4-C hlorophenyl)-N -m ethvlurea: m/z 185
(35C 1 -M H \ 100% ); m /z 187 (37C 1 -M H \ 34.4% ); 
m/z 168 (4.4% ); mjz 151 (9 .2% ), m/z 127 (Cl- 
C16H 4-NH 2+, 13.2% ). M etabolite with retention time 
identical with that o f  V '-(4-ch lorophenvl)-V - 
m ethylurea on H PLC analysis : m/z 185 (100% ); 
m/z 187 (36.2% ); m/z 168 (6.6% ); m/z 151 (8.7% ); 
m/z 127 (14.2% ). 4-Chlorophenvlurea: m/z 171 
(3SC !-M H *, 100% ); m /z 173 (37C 1 -M H \ 33.7% ); 
m/z 127 ( 35C1-C6H4NH2\  21.2% ). M etabolite with 
retention time identical with that o f 4-chlorophen- 
ylurea on H PLC analysis: m/z 185 (100% ); m/z 187 
(33 .9% ); m/z 168 (4 .3% ); m/z 151 (13.9% ); m/z 127 
(11.7% ).
Deconjugation o f  urine samples. Urine sam ples 
were collected  from m ice in m etabowl cages (Jen- 
cons, U .K .) after the injection of monuron  
200 m g/kg i.p . as a suspension in 10% DM SO /arachis
o il.
Enzym atic hydrolysis o f  urine sam ples was per­
form ed using 0 .2  ml o f  urine diluted to 2 ml with 
acetate buffer (pH  = 5) containing either /?-glucu- 
ronidase (5000 u) or sulfatase (150 u sulfatase and
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Fig. 2. Metabolism of Nash positive microsomal metabolites 
of dimethylaniline (la), 2-dimethylaminopyridine (Id), 
phenyldimethyltriazene (Ila), phenyldimethylformamidine 
(Ilia) and aryldimethylureas (IV a, b, d. e, g) by mouse 
liver homogenate free from microsomes, V indicates dis­
appearance of formaldehyde. Values are the mean of at 
least three experiments. Details of incubation conditions 
under Materials and Methods and in reference [14). Results 
are expressed as percentage of the Nash positive species 
generated during the microsomal incubation after subtrac­
tion of control values obtained with incubations devoid of
cofactors.
5000 u glucuronidase) (Sigm a, U .K .). The sam ples 
were incubated at 37° for 17 hr and prepared for 
H PLC analysis as described above.
RESULTS
A  number of jV-methyl containing m olecules 
(Table 1) were incubated with m ouse liver m icro­
som es and underwent oxidative N-dem ethylation to 
m etabolites which gave a positive reaction with Nash  
reagent and were thus characterised as free formal­
dehyde or precursors o f  form aldehyde. Three com ­
pounds were not m etabolized to species forming 
3,5-diacetyl-2,6-dim ethyl-l,4-d ihydropyridine, the 
coloured chrom ophore in the Nash reaction: 4- 
dim ethylam inopyridine ( le ) ,  /V'-(4-sulphonamido- 
phenyl)-N ,N -dim ethylform am idine (I llf)  and N'- 
(4-cyanophenyl)-iV,./V-dimethylurea ( IV c).
In order to test whether the species which gave  
a positive Nash reaction was free formaldehyde or 
a stable precursor o f  formaldehyde such as the N- 
hydroxym ethyl m etabolite B (Fig. 1), an aliquot o f  
the m icrosom al incubate was reincubated with 
m icrosom e-free liver hom ogenate as a source o f for­
m aldehyde oxidising enzym es. After 5 and 15 min 
the incubate was tested for residual Nash-positive 
species. Figure 2 shows the amount o f such species 
obtained on incubation o f  com pounds la . Id, Ila , 
I lia , IV a -g , and form aldehyde, with m icrosom e free 
liver hom ogenate. The Nash-positive m etabolites o f  
the 4-substituted derivatives o f dim ethylaniline lb , 
Ic, phenyldim ethyltriazenes Ilb -d  and phenyldim e­
thylform am idine Illb —e on exposure to the form al­
dehyde dehydrogenases in the microsom e free liver 
hom ogenate behaved in essentially the same way as 
their unsubstituted congeners la . Ila. and Ilia  and 
are not included in Fig. 2. The 4-substituted deriva­
tives o f phenyldim ethylurea IV a-g formed m etab­
olites which reacted with Nash reagent but were not 
substrates o f form aldehyde m etabolizing enzym es
(Fig. 2). This result led us to conclude that the 
aryldim ethylureas IV are m etabolised to  stable pre­
cursors o f  formaldehyde. In order to test if these  
precursors o f  formaldehyde were /V-hydroxymethvI 
com pounds, we subjected one derivative in this 
series, IV e, the herbicide m onuron , to a more 
detailed m etabolism  study. Figure 3 show s the high 
pressure liquid chromatogram o f  a sam ple o f  the 
incubation mixture o f monuron with m ouse liver 
m icrosom es compared with a chrom atogram  o f a 
solution containing reference com pounds. Two  
m etabolites were observed. O n m ass spectral inves­
tigation, on e  m etabolite was identified as the 
iV-demethylated derivative o f  IV e , AT-(4- 
chlorophenyl)-yV-methylurea (V I, Fig. 4 ). The other  
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Fig. 3. High pressure liquid chromatogram of (a) a mixture 
of monuron (IVe). .V'-(4-chlorophenyI)-jV-meihylurea 
(VI), 4-chloroaniline (VIII), 4-chlorophenylurca (VII) 
which were considered as possible metabolites and internal 
standard iV'-phcnyI-A’..V-dimethylurea (IVa). (b) An 
extract of an incubation mixture of monuron (IVe) with 
mouse liver microsomes fortified with an NADPH gener­
ating system.




Fig. 4. Metabolism of monuron.
m icrosom al incubate had a retention vol im e similar 
to that o f 4-chlorophenylurea (V II, F:g. 4). H ow ­
ever, on treatm ent with acid or on heating the sam ple 
this m etabolite decom posed with a corresponding  
increase in the am ount o f V'-(4-chlorophenyl)-/V- 
m ethylurea V I. The chem ical ionization mass spec­
trum o f this unstable m etabolite was identical with  
a synthetic sam ple o f /V'-(4-chlorophenyl)-/V-meth- 
ylurea. This suggested to  us the possibility that the  
hydroxym ethyl com pound V (Fig. 4) had indeed  
been form ed. This m etabolite was also found on  
incubation o f m onuron with w hole liver hom ogenate, 
9000 g supernatant and isolated m ouse hepatocytes. 
The major urinary m etabolite  o f m onuron was 4- 
chlorophenylurea V II, as identified by m ass spectral 
investigation o f the eluent obtained on high pressure 
liquid chrom atography o f a urine sam ple. A fter  
incubation o f urine sam ples with a mixture o f  
glucuronidase/sulfatase a m etabolite was identified  
which on H PLC analysis (Fig. 5) and mass spectral 
com parison was identical with /V'-(4- 
chlorophenyI)-/V-m ethylurea VI.
DISCUSSION
There is no doubt that som e xenobiotics containing  
/V-methyl m oieties are m etabolised to identifiable 
/V-hydroxymethyl com pounds. Such species have 
been identified as m etabolites o f a number o f /V- 
m ethyl-am ides [ 6 .7 .9 ] ,  /V-methyltriazenes [10 ,11] 
and /V-methylcarbazole [4]. The antineoplastic 
agents hexam ethylm elam ine and pentam ethylm e- 
iamine were m etabolized to form aldehyde precur­
sors [14] and /V-hvdroxym ethylpentam ethylm e- 
lamine has been identified as the m ajor in vitro 
m etabolite o f hexam ethylm elam ine [3]. M ueller and 
M iller [16] presented indirect evidence for the pres­
ence o f  an V-hydroxym ethyl m etabolite o f the  
arylamine derivative 3'-m ethyl-4-(m ethylam ino)- 
azobenzene (M A B ). Their interpretation was based  
on the m etabolic production o f form aldehyde and 
on the ability o f  glutathione to react with a m etabolic  
interm ediate to yield a water soluble azo dye which 
could be hydrolyzed subsequently to the water 
insoluble /V-dem ethylated am inoazo dye. It may be 
relevant that in all o f  these cases the /V-methyl group 
is attached to m olecules o f  electronegative character.
We investigated the in vitro m etabolism  of aryl­
amine derivatives Ia -e  (Table 1). one o f  which has 
the strongly electron-w ithdrawing cvano group in the 









Fig. 5. High pressure liquid chromatogram of (a) an extract 
of urine of mouse after administration of 200 mg/kg mon­
uron i.p .. (b) an extract of a sample of the same urine after 
incubation with glucuronidase/sulfatase. For the explana­
tion of the identifying numbers see legend to Fig. 3.
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mutagen like MAB [27], but could not find evidence 
for the metabolic generation of formaldehyde pre­
cursors of measurable stability. The yellow colour 
of substituted aminoazobenzene derivatives such as 
MAB interfered with the colourimetric assay and 
prevented investigation of the metabolism of these 
compounds. Changing the arylamine structure I 
(Table 1) by introducing a —N = N — or a 
— N = C H — moiety into the molecule between the 
V,V-dimethyl and the aryl portions of I, leads to the 
triazenes II and the formamidines III which were 
metabolised to species which, like the metabolites 
of the V,V-dimethylarylamines I, behaved biochemi­
cally like formaldehyde (Fig. 2). The failure of the 
assay to detect stable V-hydroxymethyl metabolites 
of dimethyltriazenes is puzzling, in view of the 
reported isolation of a glucuronide of an 
V-hydroxymethyl-V-methyltriazene as a urinary 
m etabolite of an aryl dimethyltriazene in the rat [11]. 
This may be due to species differences in metabolism, 
or may reflect a lack of conjugation in this micro­
somal system which could stabilise any V-hydroxy- 
methyl metabolites when produced. Whatever the 
explanation the difficulties involved in predicting the 
metabolic behaviour of compounds in vivo  from 
results obtained using in vitro model systems must 
be stressed.
The only compounds tested in this study which 
formed stable formaldehyde precursors were the 
urea derivatives IV (Table 1). liie se  molecules differ 
from the V, V-dimethylarylamines I in that they con­
tain an — NH—CO—  structure inserted between the 
aryl ring and the VfV-dimethylamino group which 
reduces the electron density at the nitrogen atom 
bearing the V-methyl group. Evidence that the stable 
formaldehyde precursors were V-hydroxymethyl 
compounds was corroborated by the results of the 
chromatographic and mass spectral investigation of 
an in vitro metabolite of V'-(4-chlorophenyl)-V, V- 
dimethylurea (IVe, monuron). This metabolite 
behaved chromatographically like 4-chlorophenyl- 
urea (VII, Fig. 4) but its mass spectrum identified 
it as V '-(4-chlorophenyl)-Vmethylurea (VI, Fig. 4). 
W e suggest, therefore, that it is V -(4 - 
chlorophenyl)-V-hydroxymethyl-V-methylurea (V, 
Fig. 4). The glucoside conjugate of this compound 
(V) was reported as a product of the metabolism of 
monuron in cotton plants [28], but our results are 
the first indication that this V-hydroxymethyl m etab­
olite of monuron is generated in animals. That a 
urinary metabolite o f monuron on enzymatic decon­
jugation was identified as the monomethyl com­
pound VI (Fig. 5) is also compatible with the sugges­
tion that its precursor was the carbinolamine V. It 
is conceivable that V after hydrolysis of its glucu­
ronide or sulphate derivatives decomposes on incu­
bation at 37° in acetate buffer (pH = 5) to the 
monomethyl derivative VI. Alternatively this pre­
cursor may be a conjugate of VI linked to the con­
jugating species via either of the two nitrogen atoms.
AH derivatives of IVa, except IVc. irrespective of 
the electron-withdrawing (IVa, e, f) or electron- 
donating (IVb, g) nature of the substitute formed 
metabolites which were formaldehyde precursors but 
not substrates of formaldehyde metabolising 
enzymes (Fig. 2). It therefore appears that the nature
of the substitute in the aryl ring of IV does not 
determine whether metabolism leads to a stable car­
binolamine or directly to formaldehyde, likewise the 
variation of substituents in the 4-position of the aryl 
moieties of the aryldimethyltriazenes II and the 
aryldimethylformamidines III does not change the 
instability of their m etabolic V-hydroxymethyl inter­
mediates. It is likely that several physicochemical 
factors influence the equilibrium which the carbi­
nolamine B (Fig. 1) maintains with formaldehyde 
[29] and its is possible that of all the factors involved 
the electronic environm ent of the V-hydroxymethyl 
moiety as influenced by para substitute in the aryl 
ring is only of minor im portance.
We have recently investigated the stability of 
the V-hydroxymethyl derivative of formamide, 
OHC-NHCH 2O H , and have found that it is surpris­
ingly stable and does not react as a formaldehyde 
precursor unless treated  with strong alkali [30]. 
Similarly, V-hydroxymethylbenzamide, (QHs-CO- 
NHCH2O H ) has been reported  to be very stable at 
physiological pH  [31], and we have evidence that 
V-hydroxymethylbenzamide is indeed a metabolite 
of V-methylbenzamide (QHs-CO-NH-CHs). These 
recent findings (to be presented in a future report) 
and the results discussed above underline the fact 
that the oxidative metabolism of the A;-methyl 
moiety in xenobiotic molecules is more complex than 
simply a pathway leading to the V-desmethyl com­
pound and formaldehyde. Depending on as yet 
unknown factors associated with the structure of the 
molecule m etabolites with V-hydroxymethyl groups 
can be generated with widely different stabilities 
under physiological conditions. Those of interm e­
diate stability may decom pose to  liberate formal­
dehyde at extrahepatic sites or may participate in 
endogenous metabolic pathways as ‘active formal­
dehyde’ [32], or may am inomethylate biologically 
important targets. A recent report of the metabolism 
of MAB suggests that further reactions of a conju­
gated methylol may be relevant to the carcinogenicity 
of MAB [33] and we would suggest that the putative 
carbinolamines formed from other V-methyl con­
taining carcinogens, such as dimethylnitrosamine. 
may similarly contribute to their toxicology, a 
hypothesis actively under investigation by us. 
Finally, it is also pertinent to stress the inadequacy 
of the colourimetric determ ination of formaldehyde 
when used to assess the metabolic V-demethylation 
of those substrates forming very stable V-hydroxy­
methyl compounds which do not react in the Nash 
test for formaldehyde.
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Studies of the Pharmacology of /V-Methylformamide in Mice1-2
C h a rle s  B rind ley , A n d reas  G esch er,*  E rn e s t S. H arpur, D avid R o ss , J o h n  A. S lack , M ichael D. 
T h read g ill, a n d  Helen W hitby3-4
When 400 mg/kg of ,4C-methyl-labeled A--methylformamide (NMF) was injected ip into 
mice, the curve for plasma concentration of radioactivity versus time was superimposable 
on the curve obtained by measuring unmetabolized NMF with gas-liquid chromatography 
during the first 24 hrs. Radioactivity in plasma was measurable for 8 days after NMF 
administration, but NMF was not measurable by gas chromatography beyond 24 hrs after 
administration. Radioactivity was eliminated from the plasma after 60 hrs, with an appar­
ent half-life of 71.1 hrs. Of the radioactivity injected with NMF, 73.6% was recovered in the 
urine in 24 hrs; 26.4% of this was unchanged NMF. Three percent of the administered radio­
activity was exhaled as UC02 in 7 hrs at a constant rate of 0.007% per min. One urinary 
metabolite was a stable precursor of formaldehyde, which decomposed to formaldehyde only 
after alkaline hydrolysis and may well be A:-(hydroxymethyl)-formamide. The areas under 
the plasma concentration versus time curve were estimated after ip, iv, and oral administra­
tion of NMF. The bioavailability of NMF was 1.01 after oral administration and 1.10 after 
ip administration. [Cancer Treat Rep 66:1957-1965, 1982]
The an titu m o r activ ity  of A-m ethvlform am ide (NM F) 
(OHC-NHCHa) aga in st m urine tum or models was firs t 
described  by C larke e t al in 1953 (1). In a clinical tr ia l. 
NM F w as found to  cause reversib le liver dam age in all 
seven p a tien ts  in whom it was tested  (2). We have re ­
cently  found N M F to  be active against the mouse o v ar­
ian reticu lum  cell sarcom a M5076 and the mouse TLX5 
lym phom a (3). T he animal tum ors th a t are  sensitive to 
NM F do not respond  to  trea tm en t with o th er .Y-alkyl 
d e riv a tiv es  of form am ide or with formamide itself.
The m echanism  by which NMF exerts  an titum or ac­
tiv ity  is unknow n. We found NMF to be cytotoxic only 
a t concentra tions >  0.5 m against TLX5 lymphoma cells 
in an in v itro-in  vivo bioassay (3). In th is bioassay, N -  
ethylform am ide (th e  ethyl analog of NM F). which is 
devoid o f an titu m o r activ ity  in vivo, exhibited cy to tox­
icity com parable to  th a t of NMF.
Since NM F possesses an titum or activity  against a 
considerable num ber of m urine tum ors and does not 
ap p ear to  be toxic to  the bone m arrow (4). it is a can­
d ida te for fu rth e r  clinical evaluation. To gain infor­
m ation th a t  m ay.facilitate the rational use of NM F in 
clinical tr ia ls , several aspects of its disposition in the
'R ec e iv ed  Mar 30. 19X2: rev ised  Ju ly  23. 19X2:accep ted  A ug lli. 19X2. 
S u p p o r te d  by g r a n t s  from th e M edical R esearch C ouncil and th e  
C an cer R esearch  C am paign  o f  G reat Britain.
fC RC  E x p erim en ta l C hem otherap y  R esearch  Group. D ep artm en t o f  
E’h arm acy . U n iv ers ity  o f  A ston . B irm ingham . England.
mouse w ere  stud ied . l4C-M ethvl-labeled NM F ("C - 
NM F) w as syn thesized  and th e  plasm a disposition of 
radioactivity was com pared w ith that of unlabeled NMF.
Renal excretion  and m etabolism  to CO> a re  two ob­
vious rou tes of elimination th a t a small molecular weight 
compound like N M F can undergo. T herefore, the ap­
pearance of rad ioactiv ity  a f te r  adm inistration  of ,4C- 
NM F w as stud ied  in the  urine and the b rea th . Special 
a tten tio n  w as given to identify ing products of the oxi­
dative m etabolism  of N M F in the urine, in view of our 
finding th a t form am ide is a u rinary  m etabolite (3).
T he b ioavailabilitv  of N M F a fte r ip o r oral adm inis­
tra tio n  w as also investiga ted  because in the an titum or 
te s ts , N M F  w as adm in istered  ip, w hereas in the  clinic. 
NM F m ay be given orally as well as iv or im. Finally, 
the influence of the  presence of the TLX5 lymphoma 
on th e  p lasm a disposition of NM F was investigated .
MATERIALS AND METHODS
NMF' and  form am ide w ere purchased from Aldrich 
Chem icals (UK): iV -(hydroxvm ethyl)-form am ide was 
syn thesized  by Mr. E. N. G ate in our laboratories ac-
‘W’e  th ank  D r. J . A . H ickm an for h is in terest in th is  w ork and Karen 
E n sor for h er  h e lp  w ith  th e  ch rom atograp h ic  d eterm in ation .
*H v p n n t  r c t / H c x i s  t o :  Dr. A. G esch er . D epartm ent o f  Pharm acy. I ni- 
v e r s itv  o f  A sto n  in B irm in gham . G osta  G reen. B irm ingham  B4 7ET. 
E n glan d .
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cording to a published method (5). "C -N M F  was p re ­
pared  by trea tm e n t of 1 'C-m ethvlam ine hydrochloride 
(Radiochem ical C en tre , A m ersham , UK) with ethyl for­
m ate and sodium carbonate: details of th e  synthetic pro­
c e d u re  w ill be p u b lis h e d  e ls e w h e re . D ru g s w e re  
adm in istered  in solution in s te rile  saline. Male CBA CA 
mice (20-25 g) w ere used throughout this study. A p­
proxim ately  10’* TLX5 cells from routine passage as 
ascites w ere inoculated sc in the  inguinal region of 20- 
g  mice.
M easurem en t o f  N M F  and total radioactivity in the 
p lasm a  and  u rine .—The d rug  was injected into a taii 
vein iv, adm inistered  ip, o r given by esophageal in tu ­
bation. T he doses adm inistered  w ere 400 mg/kg (equiv­
alen t to  1/2 x LD10 determ ined  by ip adm inistration) 
and 80 m g/kg. The am ount of radioactiv ity  injected into 
each m ouse w ith the  dose was e ith e r 5 or 15 jtCi. While 
mice w ere  under halothane anesthesia , blood sam ples 
(20 p.1) w ere collected into heparinized capillary tubes 
from th e  tip  of the  ta il for a t least ten  tim e in tervals 
following d ru g  adm inistration . In a control experim ent, 
blood was obtained w ithout anesthetiz ing  the anim als, 
and plasm a concentration  versus tim e profiles w ere not 
d iffe ren t from profiles derived from anesthetized  ani­
mals. P lasm a was obtained by centrifugation, and sam ­
ples w ere  diluted w ith acetone and centrifuged again. 
U rine was collected from  mice kept in metabolic cages 
(Jencons. UK). To minimize the risk of evaporative losses, 
th e  u rin ary  collection funnels w ere w ashed with 10 ml 
of w a te r  a f te r  2 -6 -h r in te rvals during  the  first 12 hrs 
and again  24, 48, and 72 hrs a f te r  d rug  adm inistration. 
F o r the  analysis by gas chrom atography (GC). 10 p.1 of 
blood or 100 |xl of diluted urine was fu rth e r  diluted w ith 
50 or 200 p.1 of acetone (including in ternal standard). 
R adioactiv ity  was counted a f te r  adding 10 p.1 of blood 
or 1 ml of d ilu ted  urine to  5 or 10 ml of NE260 M icellar 
sc in tillan t (New England N uclear, W Germany), in a 
P ackard  T rica rb  2660 scintillation counter using the ex ­
te rn a l standard ization  mode. The centrifuged plasma 
or u rine sam ples containing acetone w ith te tram ethy l- 
u rea as in te rnal s tan d ard  w ere analyzed by GC as de­
scribed previously (3). The lim it of detection  for NMF 
was 3-5  |xg/ml.
Breath ana lysis .—A fter iv adm inistration o f 1 ‘C-NMF, 
the mice w ere placed in a ir-tigh t metabolic cages and 
the exhaled radioactiv ity  was collected continually in a 
trapp ing  fluid th a t w as renew ed at frequent in tervals 
as previously described in reference 6. The trapping  
fluid did not contain m easurable am ounts of unm etab­
olized NM F as indicated by GC analysis, so th a t most 
of the  exhaled rad ioactiv ity  was considered to be in the 
form of 1 ‘CO-.
P h a rm a co k in e tic  a n a ly s is .— T he d ec lin e  in p lasm a  
co n cen tra tio n  o f  r a d io a ctiv ity  w ith  tim e  beyond *24 hrs 
a fter  d ru g  a d m in istra tio n  w a s m u ltiex p o n en tia l. T he  
d ec lin e  o f  p lasm a co n cen tra tio n  o f ra d io a ctiv ity  beyond
60 h rs  a f te r  adm inistra tion  of 1 ‘C-NM F w as considered 
to  re p re se n t th e  elim ination of d ru g  o r m etabolites, and 
in each anim al the  plasm a concentration values obtained 
beyond 60 h rs a fte r 14C-NM F adm inistra tion  w ere sub­
je c te d  to  a linear regression analysis th a t  afforded a 
line (correlation  coefficient >  0.98) from which a half- 
life w as com puted. The areas under the  plasm a concen­
tra tio n  versus tim e curves (AUC) for unchanged NM F 
up to  24 h rs a f te r  NM F adm inistration  w ere  estim ated  
by th e  trapezoidal rule. AUC and half-life values as well 
as recoveries of NMF and radioactivity  in th e  urine, as 
given in the  R esu lts section, a re  th e  m ean ± su  from 
a t le a s t five anim als. The bioavailability w as calculated.
using  m ean AUC data, from the  ra tio  A U C  ip o r o ial
AUC iv
A n a ly s is  o f  fo rm a ldehyde  precursors in  the u r in e .— 
U rine  sam ples w ere diluted and m ade alkaline by the 
addition  of 1 n NaOH (to pH 12), and liberated  form al­
dehyde was m easured colorimetrically according to Nash 
(7).
RESULTS
N M F (400 mg/kg) was injected ip and its  concentra­
tion  in plasm a was m easured by GC and com pared with 
th e  plasm a disposition of radioactiv ity  a f te r  adm inis­
tra tio n  of ‘"'C-NMF. F igure 1 shows th a t the  plasm a 
concentra tion  versus tim e plot of NM F as m easured by 
GC is very  sim ilar to  th a t of to tal rad ioactiv ity  during  
th e  f irs t 24 h rs  a f te r  d ru g  adm inistration. This suggests  
th a t  unchanged NM F is th e  main co n stitu en t of th e  to tal 
rad ioactiv ity  m easured in the plasma. GC estim ation  of 
N M F in plasm a sam ples collected beyond 24 hrs a fte r 
N M F adm inistra tion  was unreliable since levels w ere 
genera lly  n ea r o r below the  detection lim it of the assay. 
Radioactive species derived from “ C-NM F w ere, how­
ev e r, m easurab le in the  plasm a for 8 days a fte r  drug 
adm in istra tion  (fig 2). The apparen t concave dow nw ard 
cu rv a tu re  of th e  line up to  24 hrs on a sem ilog plot (fig 
1) su g g ests  th a t th e  d isappearance of th e  d rug  from 
plasm a does not obey firs t-o rder kinetics du ring  this 
tim e. H ow ever, th e  disposition of rad ioactiv ity  beyond 
24 h rs  can be described by a curve th a t appears to 
exh ib it f irs t-o rd e r kinetics w ith a t least tw o exponential 
com ponents (fig 2). R adioactivity was detec tab le  in the 
plasm a up to  192 h rs a f te r  adm inistra tion  of “ C-NM F, 
The decline of plasma concentration of radioactivity  with 
tim e betw een  60 and 192 hrs a f te r  d ru g  adm inistra tion  
is lin ea r and m ay well rep resen t th e  elim ination of ra ­
dioactiv ity , ie, of NM F and/or its m etabolites. (E lim i­
nation  ra te  constan t Kvi = 0.0097 * 0.0012 hr 
elim ination half-life = 71.1 ± 8.8 h rs .)
A to ta l o f 73.6% ± 6.8% of th e  rad ioactiv ity  was 
recovered  in th e  urine w ithin 24 hrs a f te r  ip adm inis­
tra tio n  of 400 m g/kg of 1 'C-NM F. F igu re  3 shows that
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F ic uk e  1.— Plasm a disposition  o f N M F m easured  by GC ( • )  and o f  to ta l rad ioactiv ity  
(O ) a fter ip adm in istration  o f 400 mg/Jcg o f N M F  or UC -N M F. C oncen tration s o f  ra ­
d ioactiv ity  are  exp ressed  as N M F eq u iva len ts. V alu es are th e m ean r  si> o f  0 .exp er­
im ents. excep t for the point w ithout an error bar. which is th e m ean o f  exp er im en ts.
26.4%  ±  2.9% o f  the rad ioactiv ity  in the urine w as  
unch anged  N M F and <  2% (not sh ow n in fig  3) o f the  
d o se  w a s e lim inated  as e ith er  form am ide, the N -d e-  
m eth y la ted  m etab o lite  o f N M F , or its N -h yd roxy-  
m e th y l p r e c u r so r , A % (h y d ro x y m eth y l)-fo rm a m id e  
(O H C N H C H 2OH); th e  la tter  also app ears as form am ide  
on GC determ in ation . Som e urinary m etab olites (or a 
m eta b o lite ) o f N M F  w ere hyd rolyzed  to form aldehyde  
w h en  urine sam p les w ere trea ted  w ith  N aO H , and th e  
h y d ro ly sa te  reacted  w ith N ash  rea g en t. In tw o e x p e r ­
im en ts, 4 .4  pm ols o f the m eta b o lites (exp ressed  as 
form aldehyde equivalen ts) w ere excreted  with the urine 
in 36  h r s . N - (H y d r o x y m e th y l) - fo r m a m id e  r e le a s e s  
form ald eh yde on alkaline h y d ro lysis , so the urinary  
form ald eh yde precu rsor m ay w ell be this carbinolam - 
in e . C o n tr o l  a n im a ls  an d  th o s e  th a t  r e c e iv e d  N - 
ethylform am ide did not ex crete  form aldehyde precur­
so rs  se n s it iv e  to  alkali.
R a d io a c tiv ity  ex h a led  w ith  th e  breath  as “ CO* after  
a d m in istra tio n  o f  400  m g/k g  o f  l4C -N M F  w as collected  
for 7 hrs. O nly 3% o f  th e  rad io a ctiv ity  injected w as  
e x h a led  d u rin g  th is  t im e , at a co n stan t rate  o f 0.007% / 
m in.
W h en  N M F  w a s ad m in istered  iv or orally , the d is­
app earance  o f  d ru g  from  plasm a w ith  tim e did not su b ­
sta n tia lly  d iffer  from  th e  d isap pearan ce o f NM F from  
th e  p lasm a a fter  ip in jection . In fig u res 4 and 5. graphs 
o f  N M F  plasm a c o n cen tra tio n s  p lotted  011 a linear scale  
a g a in st tim e a fter  a d m in istra tion  of tw o  iv (fig 4) and 
oral (fig  5) d o ses  o f  N M F  (80 and 400 m g kg) reveal 
a p p a ren tly  lin ear se c tio n s , w hich ind icate that zero-or­
d e r  k in etics  m ight p a rtia lly  g o v ern  th e se  plasm a d is ­
p o sitio n  profiles. T h e  tim e required for plasm a lev e ls  
to d ec lin e  from  p eak  con cen tra tio n s to 50% after  oral 
a d m in istra tio n  o f N M F  (fig  5) w a s 9 .5  hrs for the high  
d o se  and 8  hrs for th e  low  dose.
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F ic u r e  2 .— P lasm a d isposition  o f rad ioactivity after  ip adm inistration  
o f  400 m g/k g  o f  UC -N M F. V alu es are th e mean r  s n  o f 6 experim ents; 
th e  va lu es  w ith ou t error bars are the mean o f 3 exp er im en ts. Dashed  
line in d ica tes  th e  line obtained  by linear regression  an a lysis  o f points 
beyond  60 hrs a fter  drug adm inistration .
A U C  v a lu e s  w ere  calculated up to 24 hrs a fter  adm in­
istra tio n  o f 400 m g/kg  o f  N M F and w ere  5235 ±  1270 
pLg-hr-ml-1 a fter  iv administration, 5842 ±  783 fig-hr-ml*1 
a fter  ip adm inistration, and 5360 ±  1117 p.g-hr-ml~l after  
oral adm inistration. Thus, the system ic availability o f NMF' 
w as 1 .0 1  a fter  oral adm inistration and 1 .1 0  a fter  ip in­
jection .
M ice w ere  inoculated w ith the T L X 5 lym phom a, which 
is se n s itiv e  to  N M F (3). F ive days after tum or im plan­
tation (approxim ately half the lifespan o f untreated tu ­
m or-bearing m ice), a plasm a concentration versus tim e
profile w as determ ined after  ip injection o f NMF' in these  
mice. It w as v irtually  identical w ith  the profile seen  in 
normal m ice. T he A U C  calculated from the pro­
file in six tum or-bearing mice w as 6595 564 p-g-hr-ml' 1
and did not d iffer  s ig n ifican tly  from  the value obtained  
in norm al m ice.
DISCUSSION
R a d ioactiv ity  in jected  a s a s in g le  dose of 14C -N M F  
(400 m g/kg) w as d e te c te d  in p lasm a for 8  days a fter  
drug adm in istra tion , and th e  p lasm a radioactiv ity  con­
cen tration  v e rsu s  tim e  curve  (fig  2 ) sh o w s that a drug  
disp osition  ph ase  th a t can be descr ib ed  by first-order  
k in etics w as not rea ch ed  un til 24 h rs a fter  NM F adm in­
istra tion . A fte r  60 h rs, ra d io a ctiv ity  w as cleared from  
the p lasm a w ith  an app aren t ha lf-life  o f 71.1 hrs.
T he ph ysicochem ical natu re o f N M F  and its potentia l 
m etab o lites has so  far p rev en ted  th e  unequivocal iden­
tification  o f th e  rad io lab eled  sp ec ie s  p resen t in th is late  
phase o f N M F  d isp osition ; th e  high w ater:octanol par­
tition  coeffic ien t o f  N M F  and its  lik e ly  m etabolites (un­
published r e su lts )  p r e v en ts  e ffic ien t extraction  into  
organic so lv e n t and th e ir  h igh v o la tility  renders freeze- 
d ry in g  o f sa m p les inappropriate.
R ep ea ted  daily  adm in istration  o f high doses o f N M F  
w as required for optim al an titum or a ctiv ity  in m urine  
tum or m odels (3 ), and it is  lik ely  th a t to be e ffective  in 
p a tien ts, N M F  m ay h a v e  to  be g iv en  in high d oses on 
m ultidose sch ed u le s or by con stan t infusion. I f the long  
elim ination  half-life  o f  d ru g-d erived  sp ec ies observed  
in m ice (fig  2 ) is  a lso  found in m an, th en  repeated dosin g  
at freq uent in te rv a ls  w ill lead to  drug accum ulation. 
W hether  accum ulation  o f  N M F  or its  m etabolites is a 
p rereq u is ite  for i t s  a n titu m or efficacy  or the generation  
o f its  h e p a to to x ic ity  rem ains to  be elucidated.
T he plasm a d isp o sitio n  profile  o f rad ioactiv ity  during  
the first 24 h rs a fte r  d ru g  adm inistration  is v irtually  
su perim posab le  on th a t o f  un labeled  N M F  (fig 1), which  
sh o w s th a t on ly  a sm all am ount o f m etab o lite (s), if  any, 
appears in th e  p lasm a du rin g  th is  tim e. H ow ever, m e­
tab o lites  w ere  found in th e  urine (fig  3), which su g g es ts  
that a fter  th e ir  form ation , th e  m eta b o lites (w h atever  
th e ir  chem ical n a tu re) are rapidly elim inated into the  
urine.
The plasm a co n cen tra tio n  v ersu s tim e curves o f NMF' 
(as m easured  by  GC) w ith in  24 hrs a fter  ip (fig  1). iv , 
and oral a d m in istra tion  o f  400 m g/k g  exhib it a concave  
dow nw ard cu rv a tu re  w h en  p lotted  sem ilogarithm ically . 
T his curvatu re  w a s n o t se e n  in a prelim inary stu d y  of 
N M F plasm a le v e ls  (3) w h en  blood w as obtained by 
cardiac pu ncture. T h e  m athem atica l treatm ent o f th e se  
data, based  on lin ea r  k in etics , m ight not be appropriate  
and th e  con cep t o f  p lasm a elim ination  rates and half- 
lives cannot be u sed  to  d escr ib e  th ese  curves. W hen  
p lotted  u s in g  C a rtes ia n  co ord in ates, concentration v a l­
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Figure 3.— C um ulative urinary excretion  o f N M F  m easured by GC ( • )  and of total 
radioactivity (O ) a fte r  ip adm in istration  o f 400 m g/k g  o f  N M F or UC -N M F . exp ressed  
as % o f  dose ad m in istered . V alues are the m ean r  s n  o f  5 exp er im en ts. T h ere  w ere  
no m easurable le v e ls  o f  unchanged N M F in th e  urine a fter  24 hrs.
u es d u rin g  so m e p er iod s o f th e  d isp osition  appear to fit 
a s tr a ig h t lin e  (f ig s  4 and 5), which in d ica tes th a t N M F  
m igh t be e lim in a ted  at a fixed  rate in d ep en d en t o f its  
co n cen tra tion  in th e  plasm a (zero-order k in etics). N on ­
lin ear  p h a rm acok in etics are often  asso c ia ted  w ith  the  
sa tu ra tio n  o f  th e  p a th w a y s by which a d rug  is d istr ib ­
u ted  in or  e lim in a ted  from the body, e g , up take into  
t is su e s  or h ep a tic  m etab olism  (8 ). T he d ata  in fig s 4 and 
5 s u g g e s t  e ith e r  th a t  both d o ses are a b o v e  th e  sa tu rab le  
poin t or th a t  th e  rem oval p rocess is zero -o rd er  regard­
le s s  o f th e  d o se  in th e  first 24 hrs. W hen plasm a con­
c e n t r a t io n  v a l u e s  o b ta in e d  w it h in  24 h r s  a f t e r  
a d m in istra tion  o f  80  and 400 m g/kg o f N M F  are d ivided  
by th e  d o se  and th e  ratios are p lotted  a g a in st tim e (fig  
6 ), th e  r e su lt in g  cu rv es , although not su perim posed , 
are not co n sp icu o u sly  d ifferent from each  o th er  [non­
lin ear k in etics  m u st be su sp ected  if  th e  cu rv es are not 
su p erim p osab le  (8 )]. This d oes not fa c ilita te  a conclu­
sio n  a s to  w h eth er  or n o t th e  plasm a d isp o sitio n  o f N M F  
is  g o v ern ed  by n on lin ear  k in etics . N o fu rth er  a ttem p t 
has y e t  b een  m ade to  d e term in e  w hich m odel b est d e ­
sc r ib es  th e  p lasm a d isp o sitio n  of N M F . F u r th e r  stu d ies  
are req u ired  to  u n am b igu ou sly  e sta b lish  n o n lin earities  
in th e  p h a rm acok in etics o f  N M F . T o d efin e  th e  k inetic  
m odel for th e  d isp o sit io n  is im portant b eca u se  it m ay  
a llow  th e  pred iction  o f  d ru g  lev e ls  in th e  body and, as  
a co n seq u en ce , th e  p red iction  o f th era p eu tic  or un­
w a n ted  drug  e ffe c ts .
M ost o f th e  r a d io a ctiv ity  in jected  w ith  N M F  w'as e x ­
c re ted  into  th e  ur ine  w ith in  24 hrs (fig  3). O nly 26.4%  
o f th e  d ose  app eared  in  th e  urine as u n ch anged  NM F  
and <  2 % as form am id e [or N -(h y d ro x y m eth y l)-fo rm -  
am ide]. To id en tify  th e  urinary m eta b o lite (s)  o f  NM F  
is r e lev a n t in v iew  o f  th e  su g g es tio n  th at N M F  m ay 
req u ire  m etab o lic  a c tiv a tio n  to  e x er t i t s  an tin eo p la stic  
a c tiv ity  (3). S in ce  th e  m eta b o lite (s) w ere  c leared  from
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th e  blood rap id ly , it is p o ssib le  th a t th ey  a re  very  hy­
drophilic conjugates. Indeed, on a lkaline hydrolysis, urine 
o f  N M F -trea ted  m ice conta ined  a large  am ount of thiol 
com pounds, su g g estin g  the presence o f m etabolites with 
th io e th e r  stru c tu re , such as A A aeety lcvste in e  d er iva ­
t iv e s  (A . G esch er , unpublished o b serv a tio n ). One m e­
ta b o lite  w a s characterized  as a sta b le  precursor of 
fo rm ald eh yd e, p resum ab ly  N -(h yd roxym eth y l)-form -  
am ide. P re lim in ary  unpublished r e su lts  sh o w  that th is 
sp e c ie s  d o es  not p o ssess  th e  a n titu m o r  e fficacy  o f NM F  
and d oes th erefo re  not a p p ear  to  be an a c t iv e  m etab­
o lite . T he e v id en ce  for th e  p resen ce  in urine o f Ar-(hy- 
d r o x y m e th y D -fo r m a m id e  a s a m e ta b o l it e  o f  N M F  
su g g e s ts  th e  fo llow in g  m etab olic  schem e:
CH_0H
C -N  ♦ HCH0
NHF N-(hydroxymethyl)- formamide 
formamide
I t  is  pu zzlin g  that ra d io a ctiv ity  e x cr e te d  w ith  the  
b reath  as l4C 0 2, the final ox idation  produ ct o f  the NM F  
m eth yl m o iety , w as exhaled  at a constant rate  o f  0.0079c' 
m in du rin g  7 hrs a fter  d ru g  a d m in istra tion . T he MCOj 
e x h a la tio n  p a ttern  o b serv ed  w ith  , 4C -N M F  contrasts  
w ith  th e  p ro file s  rep orted  a fter  a d m in istra tion  of other  
d ru g s th a t un dergo  m etab olic  N -d em e th y la tio n , eg . 
h ex a m eth y lm ela m in e , am in op yrin e , and caffe ine. In 
th e se  c a se s , th e  lACO> ex h a la tio n  profiles reflect the  
plasm a d isp o sitio n  o f d ru g -d er iv ed  N -m e th y l m oieties  
(6 ). I t is  p o ssib le  that in th e  ca se  o f N M F , th e  A'-hv- 
d ro x y m e th y l m eta b o lite  is so  sta b le  th a t further m e­
t a b o l i s m  ( e g ,  c le a v a g e  o f  th e  N -C  b o n d  to  form  
form a ld eh y d e), since it d o es not occur sp ontan eou sly , 
is ca ta ly zed  by  an en zym e th at is sa tu ra ted  on adm in­
istra tio n  o f  large  d o ses o f  N M F . T h is m igh t lead to a 
s lo w  zero -o rd er  form ation o f C 0 2, probab ly  circum ­
v e n tin g  fr ee  form ald eh yde in th e  m etab olic  process, at 
a ra te  th a t  is  in d ep en d en t o f  p lasm a N M F  concentration  
and th a t in turn  d e term in es th e  ra te  at w h ich u CO.- 
a p p ears w ith  th e  breath.
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FltiURK i>.— I’lasma d isp osition  o f  NM F a fter  oral adm in istration  o f  Ml my ky i i or 41*0 
m g/kg (C ) o f  N M F. V alues a iv  th e mean -  >!■ o f  4-N m ice.
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Figure 6.—Plots of N M F plasm a con cen tra tion s d iv id ed  by the dost* against tim e after iv (A) or oral (B 1 
administration o f e ith er  ftf) mg.'kg (CD) or  400 m g k g <Ot o f  N M F. V alues are identical w ith the m ean values 
shown in figs 4 and o.
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Surmary
N -Form ylbenzam ide end benzam ide w ere c h a r a c t e r i s e d  by h igh p r e s s u r e  
l i q u id  ch rom atography  and mass sp e c tro m e try  a s  p ro d u c ts  o f th e  
m etabo lism  o f  N -hydroxym ethylbenzam ide in  in c u b a t io n  m ix tu re s  w ith  
mouse l i v e r  p r e p a r a t io n s  and I s o la te d  h e p a to c y te s .  T his b io t r a n s -  
fo r u e t io n ' o c c u rre d  p red o m in an tly  in  9000g and m icrosom al s u p e r n a ta n t  
f r a c t i o n s  and was a l s o  c a ta ly z e d  by h o r s e . l i v e r  a lc o h o l d eh y d ro g en ase  
f o r t i f i e d  w ith  NAD and c o u ld  be in h ib i t e d  by p y ra z o le .  U n lik e  N- 
hydrpxym ethylbenzam ide. w hich i s  v e ry  s t a b l e ,  N -form ylbenzam ide 
degraded  r a p id ly  t o  benzam ide in  b u f f e r  a t  pH 7 .4  w ith  a h a l f - l i f e  
o f  7 .8  m in . The i n s t a b i l i t y  o f  N -form ylbenzem ide and th e  t i n e  
c o u rse  o f  i t s  m e ta b o lic  g e n e ra t io n  to g e th e r  w ith  benzam ide s u g g e s t  
th a t  benzam ide i s  a c h e m ic a l breakdown p ro d u c t o f  N -fo rm ylbenzam lde. 
N-Form ylbenzam ide was a l s o  t e n t a t i v e l y  i d e n t i f i e d  a s  a u r in a ry  
m e ta b o li te  o f  N -hydroxym ethylbenzam ide. T h is  i s  th e  f i r s t  t im e  
th a t  an  N -hydroxym ethyl compound has been shown to  undergo m e tab o lism  
e i t h e r  ^ n  v i t r o  o r  i n  v iv o .
C e r ta in  N -m ethyl c o n ta in in g  x e n o b io t ic s .  p a r t i c u l a r l y  th o s e  w i th  a  N- 
m ethy l m o ie ty  s i t u a t e d  in  an  e le c tro n -w ith d ra w in g  en v ironm en t, fo rm  s t a b l e  N- 
hydroxym ethyl compounds on m etabo lism  in  v i t r o  ( 1 ,2 ) .  These s t a b l e  
•c a rb in o la m ln e s  may be o f  t o x l c o lo g lc a l  Im portance  b ecau se  they  may be 
t r a n s p o r t  form s o f  th e  c y to to x ic  a g e n t fo rm aldehyde ( 3 ) .  In  g e n e r a l .  
N -hydroxym ethyl compounds decompose r a p id ly  to  fo rm aldehyde and th e  N -des- 
(hydroxym ethy l)am ine  o r  am id e . The m e ta b o lic  f a t e  o f  s t a b le  N -hydroxym ethyl 
compounds i s  how ever n o t known. We th e r e f o r e  in v e s t i g a te d  th e  m e ta b o lism  o f  
a  r e p r e s e n ta t iv e  o f  su ch  an  N -m eth y lo l, N -hydroxym ethylbenzam ide, w h ich  
p o s s e s s e s  a h a l f  l i f e  o f  1 .1  x 104 min in  b u f f e r  a t  pH 7 .4  and 37°C (4 ) and 
i s  a  m ajo r in  v i t r o  m e ta b o l i te  o f  N -m ethylbenzam ide (0 . Ross e t  a l ,  
m a n u sc rip t in  p r e p a r a t i o n ) . We r e p o r t  h e re  t h a t  N -hydroxym ethylbenzam ide 
u n d erg o es f u r t h e r  m e tab o lism  and i s  b io tra n sfo rm e d  to  N -form ylbenzam lde, an  
u n s ta b le  s p e c ie s  w h ich  b re a k s  down c h e m ic a lly  to  benzam ide.
1The p re v io u s  p u b l i c a t i o n  i n  t h i s  s e r i e s  i s  r e f e r e n c e  No. 2 .
2S upported  by a  g r a n t  from  th e  M edical R esearch  C o u n c il .  The a u th o r s  th a n k  
John  Lamb f o r  th e  d e te r m in a t io n  o f  mass s p e c t r a .
3P re s e n te d  in  p a r t  a t  th e  8 th  European Workshop on Drug M e tab o lism , L ie g e .
Belgium , S eptem ber 1982.
‘‘To whom r e p r i n t  r e q u e s ts  sh o u ld  be a d d re s s e d .
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M a te r ia l s  and  M ethods
C hem ica ls  and a n im a ls . N -H ydroxym ethylbenzam ide was K in d ly  p ro v id e d  by 
£)r H. B undgaard , Royal D an ish  Schoo l o f  P harm acy , C openhagen, DenmarK. 
N -M ethylbenzam ide, benzam ide and  p y ra z o le  w ere  p u rc h a s e d  from  A ld r i c h  C hem ical 
C o ., D o rse t , U.K. N -Form ylbenzam ide was s y n th e s is e d  i n  c u r  l a b o r a t o r i e s  
e s s e n t i a l l y  a c c o rd in g  t o  p u b lis h e d  m ethods ( 5 ) .  G lu c o s e -6 -p h o s p h a te  (G 6P), 
g lu c o s e -6 -p h o s p h a te  d e h y d ro g e n a se  (GPDH), n ic o t in a m id e  a d e n in e  d i n u c l e o t i d e  
p h o sp h a te  (NAOP), and i t s  re d u c e d  form , NADPH, and  e q u in e  l i v e r  a l c o h o l  
d eh y d ro g en ase  w ere, p u rc h a s e d  from  Sigma U .K ., P o o le .  Male B alb  C m ice  
C20-25g) w ere u sed  f o r  a l l  e x p e r im e n ts .
In  v i t r o  m e tab o lism  s t u d i e s . L iv e rs  w ere  e x c i s e d ,  washed an d  hom ogenised  
in  0.25M s u c ro s e  t o  g iv e  a  20* w/v hom ogenate. L iv e r  f r a c t i o n s  w e re  p re p a r e d  
a c c o rd in g  to  th e  method o f  C in t i  e t  al_ ( 6 ) .  I n  a l l  e x p e r im e n ts  t h e  am ount o f  
each  l i v e r  f r a c t i o n  u sed  was e q u iv a le n t  t o  0 .2 5 g  o f  l i v e r  (w et w e ig h t ) .  
In c u b a t io n s  w ere p e rfo rm ed  i n  E a r l ' s  b u f f e r  (pH 7 .4 )  and  w ere f o r t i f i e d  w i th  
e i t h e r  1 mfl NAD, 0 .5  t o  1 mM NADPH and 5 mf1 m agnesium  c h lo r id e  o r  s u f f i c i e n t  
G6P, GPDH and NADP to  y i e l d  0 .5  to  1 mil NADPH.
H e p a to c y te s  w ere  p re p a re d  a c c o rd in g  t o  th e  m ethod  o f  R en ton  e t  a l  ( 7 )  and 
in c u b a t io n s  perfo rm ed  e s s e n t i a l l y  a s  d e s c r ib e d  in  ( 8 ) .  R e a c t io n s  w e re  s t a r t e d  
by th e  a d d i t io n  o f  N -hydroxym ethylbenzam ide in  0 .1 m l a c e to n e  t o  g iv e  a 
c o n c e n t r a t io n  o f  1 mM in  a  f i n a l  in c u b a t io n  volum e o f  2 .5 n l .  When p u r i f i e d  
h o rs e  l i v e r  a lc o h o l  d eh y d ro g e n a se  was u sed  a s  t h e  enzyme s o u r c e ,  1 .8  u n i t s  
w ere  u sed  p e r  In c u b a t io n  w ith  o r  w ith o u t t h e  a d d i t i o n  o f  p y r a z o le  1 mM 
In c u b a t io n s  w ere p e rfo rm ed  i n  a f i n a l  volum e o f  2 .5 m l E a r l ' s  b u f f e r  (pH 8 .8 )  
f o r  t h i r t y  m in u te s  a t  37°C , w ith  a t h r e e  m in u te  p r e - in c u b a t io n  p e r io d  p r i o r  to  
th e  a d d i t io n  o f  s u b s t r a t e .  A t th e  end o f  t h e  in c u b a t io n  p e r io d  t h e  r e a c t i o n s  
w ere  s to p p e d  by im m ersing  t h e  in c u b a te  i n  i c e ,  0 .1 5 m l o f  p -n i tr o b e n z a m id e  
(20Dpg/ml i n  a c e to n e )  w as added  a s  an i n t e r n a l  s t a n d a r d ,  and t h e  I n c u b a te  was 
th e n  e x t r a c te d  tw ic e  w ith '4 m l o f  e th y l  a c e t a t e .  The e x t r a c t s  w e re  e v a p o ra te d  
to  d ry n e s s  u n d e r  a s tre a m  o f  n it ro g e n  a t  room te m p e r a tu r e ,  r e - d i s s o l v e d  in  
3 0 0 p l o f  30* m e th a n o l/w a te r  and s u b je c te d  t o  l-PLC a n a l y s i s .
In  v iv o  m e tab o lism  s t u d i e s . 0 .1m l N -H ydroxym ethy lbenzam ide i n  10* DMS0/ 
a r a c h i s  o i l  was i n j e c t e d  i n t r a p e r i t o n e a l l y  i n t o  m ice  a t  a  d o se  o f  200m g/kg . 
C o n tro l  m ice  r e c e iv e d  o n ly  th e  v e h ic l e .  U r in e  was c o l l e c t e d  u s in g  m e ta b o l i c  
c a g e s  (J e n c o n s , U .K .) o v e r  a  p e r io d  o f  2 4 h . 0 .0 4 m l o f  p -n i tro b e n z a m id e
s o lu t io n  (500yg /m l) was th e n  added to  0 .5m l o f  b o th  c o n t r o l  and sa m p le  u r i n e .  
The u r in e  was th e n  e x t r a c t e d  tw ic e  w ith  1 .5 m l e th y l  a c e t a t e  and p r e p a r e d  f o r  
HPLC a n a ly s is  a s  d e s c r ib e d  above.
HPLC a n a l y s i s . S e p a r a t io n  o f  m e ta b o l i te s  w as p e rfo rm ed  u s in g  an  A lte x  
100A pixnp and a W aters r a d i a l  com pression  u n i t  e q u ip p e d  w ith  a C-jg-Sii r e v e r s e  
p h a se  colum n. The m o b ile  p h a se  was 30* m e th a n o l /w a te r ,  f lo w  r a t e  2ml m i n '1 , 
and  a U.V. d e t e c t io n  sy s te m  was u sed  (X=254nm). Column e lu a t e s  w e re  c o l l e c t e d ,  
e x t r a c te d  w ith  e th y l  a c e t a t e ,  c o n c e n tra te d  u n d e r  a s t r e a m  o f  n i t r o g e n ,  r e -  
d is s o lv e d  i n  a c e to n e  and s u b je c te d  to  m ass s p e c t r a l  a n a l y s i s .
C hem ical i o n i s a t i o n  m ass s p e c t r a . C hem ical i o n i s a t i o n  c o n d i t io n s  w ere  
u se d  b ecau se  a  common s o l v e n t  co n tam in an t (m /z 149) i n t e r f e r e d  w i th  t h e  
m o le c u la r  io n  p roduced  fro m  N -form ylbenzam lde when s p e c t r a  w ere  d e te rm in e d  in  
t h e  e le c t ro n - im p a c t  mode. The m ass s p e c t r a  w ere  d e te rm in e d  on a  VG7070 m ass 
s p e c tro m e te r  u s in g  i s o b u ta n e  a s  re a g e n t  g a s .  S p e c tr a  w ere  ru n  a t  a  s c a n  r a t e  
o f  1 se c o n d /d e c a d e  and w e re  p ro c e s se d  u s in g  a  VG2035 d a t a  sy s te m . S am ples 
w ere  a d n i t t e d  t o  th e  m ass sp e c tro m e te r  ( s o u rc e  te m p e r a tu r e  200°C) v i a  t h e  
d i r e c t  i n s e r t i o n  p ro b e .
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Recoveries of standard compounds. Recoveries of N-hydroxymethylbenzamide. 
N-formylbenzamide, benzamide, and p-nitrobenzamide from incubation mixtures 
and urine were greater than 87*.
Results
An HPLC method which separates N-hydroxymethylbenzamide and its 
derivatives was developed and used to investigate metabolites formed on 
incubation of N-hydroxymethylbenzamide with isolated hepatocytes and with 
various mouse liver fractions. Benzamide and N-formylbenzamide were the two 
major metabolites and Fig. 1 shows the extract of an incubation mixture 
containing 9000g supernatant fortified with NAD. The chromatographic eluate 
corresponding to the peak, with the retention time of authentic N-formyl­
benzamide was collected, end the mass spectra of this metabolite and N-formyl- 
benzamide were very similar, thus confirming that this metabolite was N-formyl­
benzamide. The three major fragments in the mass spectra of the reference 
compound and the metabolite together with their intensities (*) and assignments 
are: N-formylbenzamide, m/z 105 (100*. CgHgCO*'). m/z 150 (76.8*. f1H*)» m/z







High pressure liquid 
chromatogram of a] a 







b) an extract of a 
mixture of N-hydroxymethyl­
benzamide with liver 9000g 
supernatant and NAD, 
incubated for 30 min.
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FIG. 2
Time course of the metabolic generation of N-formylbenzamide (squares] and 
benzamide (circles] from N-hydroxymethylbenzamide (1mM] in incubations with 
mouse hepatocytes. The mixtures (2.5ml] contained Sx105 cells/ml. The values 
were obtained in a typical experiment and very similar graphs were obtained 
with hepatic 9000g supernatant.
TABLE I
Metabolism of N-Hydroxymethylbenzamide (1mM) in Various Liver Fractions and 
Hepatocytes
Liver Fraction
(equivalent to 250 mg of liver)
Amount of Metabolites Formed 
(N-Formylbenzamide and Benzamide)(pM)
Mitochondria 22 ± 29
9000g Supernatant 249 ± 53
Microsomes 25 ± 21
Microsomal Supernatant 152 ± 55
Hepatocytes* 273 ± 31
Liver fractions, but not hepatocytes, were fortified with 1mM NAD and incubated 
at 37°C for 30 min. *5x105 hepatocytes/ml were incubated for 90 min. The 
values are the mean ± S.0. of at least three experiments.




High pressure liquid 
chromatogram of a) an 
extract of control urine 
and b) an extract of urine 
from mice which had 
received N-hydroxymethyl­
benzamide [200 mg/kg).
The arrow indicates a peak 
with a retention volume 
identical to that of 
authentic N-formyl­
benzamide.
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TAELE II
The Effect of Pyrazole (1mM) and Nitrogen on the Metabolism of N-Hydro xyme thy 1- 
benzamidetlmM) by 9000g Supernatant and Horse Liver Alcohol Dehydrogenase (HLAD)
Enzyme Source Amount of Metabolites Formed 
(N-Formylbenzamide and Benzamide)(yM)
9000g Supernatant 211 ± 11
9000g Supernatant ♦ Pyrazole 0
9000g Supernatant ♦ Nitrogen 97 ± 38
HLAD 309 ± 22
HLAD ♦ Pyrazole 0
HLAD ♦ Nitrogen 364 ± 15
Mixtures were incubated including NAO 1mM at 37°C for 30 min. Values are mean 
± S.D. of at least three experiments.
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When a u th e n t i c  N -fo rm ylbenzam ide was in c u b a te d  a t  37°C in  E a r l ' s  b u f f e r ,  
pH 7 .4 ,  i t  h y d ro ly s e d  q u a n t i t a t i v e l y  t o  y i e l d  benzam ide (and p re su m ab ly  fo rm ic  
a c id )  w ith  a  h a l f - l i f e  o f  7 .8  ± 1 . 9  m in . T h is  h a l f - l i f e  was n o t a l t e r e d  in  
th e  p re s e n c e  o f  SOOOg s u p e r n a ta n t  and NAD i n d i c a t i n g  th a t  in  t h i s  sy s te m  th e  
p ro d u c t io n  o f  benzam ide from  N -fo rm ylbenzam ide i s  p u re ly  a c h e m ic a l p r o c e s s .
T h is  s u g g e s ts  t h a t  any  benzam ide form ed d u r in g  m e tab o lism  may be a p ro d u c t  o f  
t h e  d e g ra d a t io n  o f  N -fo rm y lbenzam ide  and th e  t im e -c o u rs e  o f  p ro d u c t io n  o f  
th e s e  two m e t a b o l i t e s  u s in g  i s o l a t e d  mouse h e p a to c y te s  (F ig . 2) s u p p o r ts  t h i s  
h y p o th e s is .
The b io t r a n s f o r m a t io n  o f  N -hydroxym ethylbenzam ide to  N -fo rm y lb en zam id e  
and benzam ide was o b se rv e d  in  i s o l a t e d  h e p a to c y te s .  SCOOg s u p e r n a ta n t ,  and  
m icrosom al s u p e r n a ta n t  b u t o n ly  t o  a  m in o r e x te n t  in  m icrosom al an d  
m ito c h o n d r ia l  f r a c t i o n s  (T a b le  I ) .  The r a t e  o f  m etab o lism  in  t h e  l i v e r  
s u p e r n a ta n t  p r e p a r a t i o n s  was g r e a t l y  enhanced  by th e  a d d i t io n  o f  e i t h e r  NAD, 
NADPH. o r  an  NADPH g e n e r a t in g  sy s te m . The a d d i t io n  o f  p y ra z o le ,  an  i n h i b i t o r  
o f  a lc o h o l  d e h y d ro g e n a se  ( 9 ) ,  to  t h e  9000g s u p e r n a ta n t  c o m p le te ly  a b o l i s h e d  
th e  m e ta b o lic  o x id a t io n  o f  N -hydroxym ethy lbenzam ide (T ab le  I I )  w h ich  s u g g e s ts  
th e  in v o lv em en t o f  d e h y d ro g e n a se  enzymes i n  t h i s  p ro c e s s .  P u r i f i e d  h o rs e  
l i v e r  a lc o h o l  d e h y d ro g e n a se  f o r t i f i e d  w ith  NAD c a ta ly s e d  th e  b io t r a n s f o r m a t io n  
o f  N -hydroxym ethy lbenzam ide w hich was a l s o  a b o l i s h e d  in  th e  p r e s e n c e  o f  
p y ra z o le .  When in c u b a t io n s  w ere p e rfo rm ed  i n  an  a tm osphere  o f  n i t r o g e n  
how ever, t h e  p r o d u c t s  o f  m e tab o lism  w ere  d e c re a s e d  by 501: i n  f o r t i f i e d  9000g 
s u p e r n a ta n t  b u t rem a in ed  unchanged  in  th e  c a s e  o f  th e  p u r i f i e d  enzym e. When 
benzam ide (1 mM) was u se d  a s  a  s u b s t r a t e  no N -form ylbenzam ide c o u ld  be  
d e te c te d  i n  any  o f  t h e  m e ta b o l i s in g  sy s tem s  u s e d .
F ig . 3 shows a  chrom atogram  o f  an  e x t r a c t  o f  u r in e  from  m ic e  w h ich  had 
r e c e iv e d  N -hyd roxym ethy lbenzam ide . The p re s e n c e  o f  a peak w hich  c o r r e s p o n d s  
t o  th e  r e t e n t i o n  volum e o f  a u th e n t i c  N -fo rm ylbenzam ide and i t s  a b s e n c e  i n  th e  
chrom atogram  o f  t h e  c o n t r o l  u r in e  s u g g e s ts  t h a t  t h e  fo rm a tio n  o f  N -fo rm y l­
benzam ide may a l s o  o c c u r  ^ n  v iv o . C o n f irm a tio n  o f  th e  i d e n t i t y  o f  t h i s  m in o r 
peak, in  th e  ch rom atogram  by m ass s p e c tro m e try  was n o t a t te m p te d .
D is c u s s io n
The c o n v e rs io n  o f  N -a lk y la m in e s  t o  c a rb in o la m in e s  and f u r t h e r  t o  am ides 
i s  a known m e ta b o l ic  t r a n s f o r m a t io n  and h as  been d e m o n s tra te d  e . g .  f o r  c y c lo ­
phospham ide (1 0 ) w h ere  th e  c a rb in o la m in e  i s  a  p h a rm a c o lo g ic a lly  a c t i v e  an d  th e  
am ide an I n a c t iv e  s p e c i e s  (1 1 ) .  I n  th e  c a s e  o f  N -raethyl d ru g s  m e t a b o l i c a l l y  
g e n e ra te d  c a rb in o la m in e s  a r e  o f t e n  f u g i t i v e  a g e n ts  and decom pose to  f o r m a l­
dehyde. Some N -m e th y l-c o n ta in in g  x e n o b lo t ic s  have  been shown t o  u n d e rg o  
m etabo lism  to  N -fo rm y l compounds e . g .  am in o p y rin e  (12 , 13) and c h lo r o to l u r o n  
(1 4 ) , and i n  t h e  l a t t e r  c a s e  th e  N -fo rm yl m e ta b o l i te  was s u g g e s te d  t o  b e  an 
in te r m e d ia te  i n  t h e  d e m e th y la t io n  p r o c e s s .
N -H ydroxym ethylbenzam ide i s  a m e ta b o l i te  o f  N -m ethylbenzam ide and  has 
been  u n e q u iv o c a l ly  shown h e re  t o  be  m e ta b o lis e d  to  N -fo rm y lb en zam id e . Thus we 
have d e m o n s tra te d  f o r  t h e  f i r s t  t im e  t h a t  an  N -hydroxym ethyl m e t a b o l i t e  o f  an  
N -m ethylam ide c a n  b e  f u r t h e r  m e ta b o lis e d  t o  an  N -form yl com pound. S uch  a 
mechanism h as  been  s u g g e s te d  a s  a  p o s s ib le  r o u t e  o f  a c t i v a t i o n  f o r  t h e  
c a rc in o g e n s  d lm e th y ln i t ro s a m ln e  and  m e th y lazoxym ethano l (15 ) an d  may t h e r e f o r e  
be  o f  t o x i c o lo g i c a l  im p o r ta n c e .
The o b s e r v a t io n  t h a t  N -fo rm ylbenzam ide i s  n o t  d e te c te d  when b en zam id e  i s  
u sed  a s  a s u b s t r a t e  i n  m e ta b o lic  in c u b a t io n s ,  s u g g e s ts  t h a t  any  N -fo x m y l- 
benzaraide p ro d u ced  a r i s e s  from  th e  b io t r a n s f o r m a t io n  o f t h e  N -h yd roxym ethy l 
g roup  and  n o t a s  a  r e s u l t  o f  m e ta b o lic  N -fo rm y la t io n . In  v iew  o f  t h i s  f i n d i n g  
and  th e  f a c t  t h a t  b o th  N -hyd ro x jm eth y lb en zam id e  and  N -fo rm y lbenzam ide  c a n  be
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detected as metabolites of N-methylbenzamide using isolated mouse hepatocytes 
(0. Ross, unpublished observation), we suggest the metabolic scheme in 
Fig. 4 for the N-methyl group in N-methylbenzamide. Although N-hydroxymethyl- 
benzamide does not break down chemically under these conditions, enzymic 
production of benzamide cannot be ruled out. N-Hydroxymethyl compounds are 
able to aminomethylate nucleophiles (15) and this process has recently been 
implicated as the mechanism whereby an N-methylene-glutathione conjugate was 
formed after administration of the carcinogen dimethylaminoazobenzene to rats 
(1 7).
The enzymes which catalysed the conversion of N-hydroxymethylbenzamide to 
N-formylbenzamide and benzamide were localised predominately in the soluble 
fraction of the cell. The results suggest that dehydrogenases may be the 
principal enzymes involved, although the non-specific co-factor requirements 
and the effect of nitrogen suggest that more than one enzyme system may be 
responsible.
Finally, it is pertinent to note that the N-formyl metabolite produced in 
this case is less stable than its N-hydroxymethyl precursor and decomposes to 
yield the corresponding amide. This shows that in certain cases both the N- 
hydroxymethyl and the N-formyl species can be intermediates in metabolic N- 




am inom ethylation  
o f  n u c le o p h i le s  (Nuc)




Metabolic scheme for N-methylbenzamide (R = benzoyl)
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Metabolism of the Anticancer Agent l-(4  
AcetylphenyI)-3,3-dimethyItriazene
P. Farina,X E. Benfenati, R. Reginato, L. T orti, and M. D’lncald
Istituto  di R icerche Farm acologiche ‘M ario N egri’. V ia  E ritrea  6 2 . 2 0 1 5 7  M ilan, Italy
M . D . T hreadgiil and A . G esch er
D epartm en t o f  Pharmacy, U niversity  o f A ston . B irm ingham . U K
High pressure liquid chromatography was used in combination with mass spectrometry to confirm that the 
main products of in vitro metabolism of l-(4-acetylphenyl)-3,3-dim ethyltriazene are l-(4-acetylphenyl-3- 
methyltriazene and 4-aminoacetophenone. In addition a novel metabolite, l-[4-(l-hydroxyethyl)-phenyl]-3,3- 
dimethyitriazene, possessing antituraour activity similar to the parent drug, was identified.
INTRODUCTION
1 -A ry l-3 ,3 -d im eth y l-tr ia zen es are com p ou n d s w hich  
h ave  sh ow n antitum our activity in experim en ta l anim al 
tu m o u rs1'2 and are possible candidates for clin ical 
in vestiga tion  in the near future. T his class of co m p o u n d s  
in c lu d es a num ber o f analogues w ith d ifferent su b ­
stitu en ts in the 4 -p o sitio n  of the arom atic ring. In terest  
in th e  m etab olism  o f  these com pounds arises from  the  
fact that th ey  are inactive per se but require m eta b o lic  
activation  for activ ity .3’4 In addition , there is still d o u b t  
as to  w h eth er  d ifferent substituents in fluence the m e ta ­
b o lism  and co n seq u en tly  the ph arm acological activ ity  
o f  th ese  dru gs .5
In th is study, w e use h igh-pressure liquid  
ch rom atograph y (H PL C ) and m ass sp ectrom etry  to  
confirm  that l(4 -a ce ty p h en y l)-3 -m eth y ltr ia zen e  
(CH3CO-MMT) and 4 -a m in o -a ceto p h en o n e  (CH3CO- 
P A ) are the m ain products of in vitro m etab o lism  o f 1 - 
(4 -acety lp h en y l)-3 ,3 -d im eth y tr ia zen e  (CH3CO-DMT) 
and  report the identification o f l- [4 - ( l-h y d r o x y e th y l) -  
p h en y l]-3 ,3 -d im eth y l-tr ia zen e  (CH3CHOH-DMT) as a 
no v e l m eta b o lite  possessing  antitum our activ ity  sim ilar  
to  that o f the parent drug.
EX PE R IM E N T A L
Drugs
l-(4 -A ce ty lp h e n y l)-tr ia z en es  (C H 3C O -D M T , C H 3C O -  
M M T) w ere syn thesized  by the usual m e th o d s . 3 
C H 3C H O H -D M T  w as prepared by lith ium  a lum in ium  
hydride reduction  o f C H 3C O -D M T .6 C H 3C O -P A  w as  
purchased from  B D H  C hem icals Ltd.
i  A uth or to  w hom  correspon d en ce should  be addressed. 
A b b rev ia tion s C H 3C O -D M T  = l- t4 -a ce ty !p h en y l)-3 .3 -d im e th y l-
tr iazen e. C H jC H O H -D M T  = l- [4 -U -h y d r o x y e th y l)p h e n y l]-3 .3 -d i-
m eth y ltr iazen e. C H jC O -P A  = 4 -a m w o -a ceto p h en o n e ; C H jC O -
M M T  = l(4 -a cety lp h en y l)-3 -m eth y ltr ia zen e . B S T F A  =  N.O- b is- 
(trim ethy lsily l)-tr iflu oroacetam id e. TM C S = tr im eth y lch lorosilan e.
D M S O  = d im eth y lsu lfox id e; N A D P H  = 0 -n ico iin a m id e -a d en in e  
d in u cleo tid e  p hosp h ate, reduced: A D H  = alchol d eh y d r o g en a se .
N A D H  = ^ -n ico tin am id e-ad en in e d m u d eo tid e . reduced
In vitro metabolism
C 5 7 B 1 / 6 J fem ale  m ice (20  ±  2 g  body w eigh t), o b ta in ed  
from  C harles R iver L aboratories, Italy, w ere k illed  and  
the liver w as im m ed iately  rem o v ed , w e ig h ed  and  
hom ogen ized  in ice-co ld  0 .1 5  m  p otassium  ch lo rid e  
buffer so lu tion  (pH  =  7 .4 ) in the ratio  o f  1 : 5  (w /v ) . T h e  
h om o g en a te  was centrifuged at 9 0 0 0  x  g  for 2 0  m in . 
Incubation w as started by add ition  o f su bstra te  
(CH3CO-DMT) in aceton e  (0 .1  m l) to  the su p ern atan t  
fraction (3 m l) w ith N A D P H  as co factor.
P rotein  w as determ ined  by th e  m eth o d  o f  L ow ry et 
a l?  using bov in e  serum  album in as a standard . C H 3C O -  
D M T  concen tration  w as 33  nm ol m l 1. In cu b a tio n s  
w ere carried out at 37  °C in a sh aken  flask in a w a ter  
bath in the p resence of atm osp heric  o x y g e n , or un der  
carbon m on o x id e  to  ach ieve  an aero b ic  co n d itio n s . A fte r  
30  m in, 1 ml a liquots o f the incub ation  m ixture w ere  
d ep rote in ized  by add ition  of ic e -co ld  a ce to n e  (1  m l). 
Sam ples w ere in jected  into  th e  h igh -p ressure  liqu id  
chrom atograph ic colum n after cen trifu gation  at 6 0 0  x  g  
for 3 m in.
High-pressure liquid chrom atographic analysis
CH3CO-DMT and the m eta b o lites  w ere  sep a ra ted  on  
a W aters chrom atograph m odel 4 4 0  eq u ip p ed  w ith  a 
3 4 0  nm  absorbance d etecto r  and a L ich rosorb  R P 1 8  
co lu m n (M erck , D arm stadt, W . G erm any). S ep a ra tio n  
o f co m p o u n d s w as ach ieved  w ith  a linear grad ien t s o l ­
vent system  o f a q u eou s aceton itr ile  co n ta in in g  d ie th y l- 
am ine (0 .0 1 % ). T h e  initial co m p o sitio n  o f the m o b ile  
phase w as 25%  aceton itr ile , the final (60%  a ceto n itr ile )  
being  reached  in 2 0  m in w ith a flow  rate o f 1 .7  ml m in  
T he e lu a tes  correspon d ing  to  CH3CO-DMT and the  
m eta b o lites  w ere co llected  from  the liquid c h r o m a to ­
graph and extracted  w ith h exan e  (5 v o lu m es). A fter  
evap oration  o f the organic so lv en t, the dry res id u es  
w ere stored  until m ass spectral analysis. In o rd er  to  
obta in  sufficient sam ple for m ass spectral id en tifica tio n , 
the produ cts of three incub ation  m ixtures w ere  p r o ­
cessed  in th is m anner and the e lu a te s  co m b in ed .
©  W iley  H eyd en  Ltd. 1983
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MS analysis (b) (o)
A n  L K B  2 0 9 1  m ass spectrom eter with an LK B 2 1 3 0  
co m p u ter  w as used for the gas chrom atographic m ass 
sp ec tro m e tr ic  analysis of CH3CO-DMT and CH3CO- 
MMT; for CH3CO-PA and the unknow n m etab olites, 
th e  d irec t in le t system  was used.
T h e  gas chrom atographic conditions w ere: colum n  
O V  1 3%  o n  G as Chrom Q 8 0 -1 0 0  m esh , 2 m long, 
2 m m  i.d .; separator tem perature 2 6 0  °C; e lectron  
im p a ct en erg y  7 0  eV ; helium  carrier gas flow rate 
2 5  m l m in _I. CH3CO-MMT was identified  as the  
tr im eth y lsily l derivative. This derivatization w as carried  
o u t w ith  B S T F A  in pyridine in the p resence o f 1 -2%  
T M C S  as cata lyst. A ll silyiating agents w ere purchased  
from  P ie r c e , R ockford , Illinois.
A ntitum our activity
M ice  r ece iv ed  an i.m . transplant o f 5 x  1 0 s viable cells  
o f M 5 0 7 6 / 7 3 A  ovarian reticular cell sarcom a, supplied  
by M a so n  R esearch  Institute, D C T -A n im al and H um an  
T u m o r  B an k , R ochester, M assachussetts, U S A .  
C H 3C O -D M T  and C H 3C O H -D M T  w ere d isso lved  in 
a m ix tu re  o f  T w een  80, D M SO  and sa line  (5 : 5 : 90)  
and in je c te d  i.p . at a dose of 20  m g kg -1  for 15 co n secu ­
tiv e  d a y s  startin g  on  day 7 after tum our im plantation. 
C o n tro l an im als received the veh icle  on ly . O n day 25  
after  tu m o u r  im plantation (the day correspon d ing  to  
th e  m ed ia n  survival tim es o f the contro ls), au top sies  
w e re  carried  o u t. Tum our, liver and ovaries w ere  gossly  
in sp ec te d  and  w eighed . O ther groups o f  anim als w ere  
u sed  to  e v a lu a te  the survival tim e as describ ed  by G eran  
et a / . 8
Enzym atic assay
C H 3C O -D M T  w as incubated with A D H  from  eq u in e  
liver  u n d er  th e  conditions described by E llio tt et a l 9 
T h e  c o n cen tra tio n s  were: C H 3C O -D M T  lO O p-gin l” 1, 
A D H  fo-g m l-1  and N A D H  4 0 0 p .g m l-1 . A D H  and  
N A D H  w ere  purchased from B oehringer, M annheim , 
F R G . T h e  final volum e was 5 ml of 3 m M  sod ium  p h o s­
p h a te  buffer (pH  =  7 .0 ). T he reaction w as carried out 
at 2 4  °C  in a shaken  flask in a w ater bath ex p o sed  to  
th e  a tm o sp h ere . A fter 7 h, m axim al form ation  of 
C H 3C H O H -D M T  was observed and 1 ml of the in cu b a­
tio n  m ixtu re  w as treated as described previously .
R E S U L T S  A N D  DISCUSSION____________________
F ig u re  1 sh o w s the H PLC chrom atogram  of the m e ta ­
b o lite s  prod u ced  from CH3CO-DMT by incubation  
w ith  a 9 0 0 0  x  g fraction of h om ogen ized  m urine liver
(a) w ith o u t and (b) with cofactor: peak I correspon ds  
to  CH3CO-PA, peak II to the unknow n m etab o lite , 
p ea k  III to  CH3CO-MMT and peak VI to  CH3CO- 
DMT. T h e  m ass spectrum  of CH3CO-DMT is show n  
in F ig . 2  and is that expected  for a l-a ry l-3 ,3 -d im e th y l-  
tr ia z e n e . 10 T h e  ion at m /z  191 is the m olecu lar ion  and  
lo ss  o f  a m eth yl radical leads to the ion at m /z  176. 
T h e  m eta sta b le  ion at m /z  113.1 correspon ds to  the
0 0 0 2 3
000  0
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F ig u r e  1. C h r o m a to g r a m s  o b ta in e d  in jec t in g  th e  d e p r o te in iz e d  
9 0 0 0  x g  m o u s e  liv er  m ix tu re  a fter  3 0  m in  in cu b a tio n  w it h o u t  (a) 
a n d  w ith  c o fa c to r  (b ). P eak  I c o r r e s p o n d s  to  CH3C 0 - P A  II to  
u n k n o w n  c o m p o u n d . Ill to  CH3CO-M M T a n d  IV to  CH3C O -D M T
d eco m p o sitio n  m /z  191 -*■ m /z  1 47 , with ejection  o f  a 
d im eth y lam in o  radical, w hereas the m etastable ion  at 
m /z  9 6 .3  ind ica tes the loss o f 2 8  u (probably N 2, in 
analogy  w ith  the lo ss sh ow n by CH3CHOH-DMT, see  
later) from  th e  ion  at m /z  147. T h e  resulting io n  at 
m /z  11 9  is th e  m ost abundant peak . Further lo ss  of 
2 8  u (probab ly  CO), ev id en ced  by the m etastab le  ion  
at m /z  6 9 .6 ,  y ie ld s th e  tropylium  ion (m /z  9 1 ) . A ll 
th ese  structures are p roposed  on  th e  basis of low  r e s o ­
lu tion  data , su pp orted  by the com parison b e tw e en  
a n a lo g u es (CH3CO-DMT and CH3-CHOH-DMT).
F igure 3 (a ) sh o w s the m ass spectrum  o f the com p o u n d  
co rresp on d in g  to  peak  III o f F igure 1(b) after sily la tio n  
w ith B S T F A . T h is peak  has the sam e HPLC reten tio n  
tim e as a u th en tic  CH3CO-MMT, as previously r ep o r ­
te d .4 In F ig. 3 (b ), the m ass spectrum  o f the trim ethylsilyl 
derivative  o f  au th en tic  CH3CO-MMT is show n an d  can  
be seen  to  b e  virtually  identical to  that in Fig. 3 (a ), thus  
confirm ing th e  p rev iou s assign m en t. In the m a ss  sp e c ­
trum  o f th e  tr im ethylsily lated  CH3CO-MMT, the  
m olecu lar  ion  at m /z  2 4 9  is o f lo w  abundance, lo ss  o f  
15 u (presum ab ly  CH3) yields anoth er low  abu nd ance  
fragm ent at m /z  2 3 4 . T h e  first m ajor fragm entation  of 
the m olecu lar  ion  is, how ever, a lo ss  o f 4 2  u to g iv e  the  
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F ig u r e  2 . E le c tr o n  im p a c t  m a s s  s p e c tr u m  o f CH3C O -O M T (IV) 
a fter  HPLC c o l le c t io n .
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F ig u r e  3 . E le c tro n  im p a c t  m a s s  s p e c tr u m  o f  (a) c o m p o n e n t  III 
a s  it s  tr im e th y ls ily l d e r iv a t iv e  a fter  HPLC c o l le c t io n ;  (b) CH3CO- 
M M T s ta n d a r d  a s  it s  tr im e th y ls ily l d er iv a tiv e .
fragm en tation  has b e e n  su g g ested 1 0 11 to  b e  characteris­
tic  o f m o n oary l m o n om eth y l triazenes but not trisub­
stitu ted  tr iazen es. It represents the loss o f  C H 2N 2 from  
th e  A tN H N N C H 3 tautom er giving the arylam ine, thus 
su g g estin g  that th e  sily la tion  procedure has converted  
th e  acetyl m o ie ty  to  th e  corresponding O -trim ethylsily l 
e n o l e th er  rather than effecting N -s ily la tio n  at the  
tr iazen e. T h e  base peak , at m /z  192, can then  be seen  
to  correspon d  to  lo ss o f C H 3N 3 leading to  th e  1-phenyl- 
1-trim eth y lsily lo x y -e th en e  cation . S ilicon -oxygen  bond  
fission then  furn ish es the tw o rem aining m ajor fragm ent 
io n s  at m /z  12 0  w ith  the transfer o f H and m /z  73  
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F ig u r e  4. E le c tro n  im p a c t  m a s s  s p e c tr u m  o f (a) c o m p o n e n t  I 
(d ire ct in le t s y s t e m )  a fter  HPLC c o lle c t io n ;  (b) C H jC O -PA  s ta n ­
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F igu re 5. E lectron  im p a c t  m a s s  s p e c tr u m  o f  (a ) c o m p o n e n t  II 
(d irect in le t s y s t e m )  a fter  HPLC c o l le c t io n ;  (b ) CH3CHOH -DM T  
s ta n d a rd  (d irect in le t  s y s te m ) .
Figure 4(a) sh ow s the m ass sp ectru m  (d irect insertion  
technique) o f the com pound co rresp o n d in g  to  peak  I 
of the H P L C  chrom atogram  (Fig. 1(b)). W e have p re ­
viously rep orted 4 that this com p o u n d  is C H 3C O -P A , 
on the basis o f com parisons o f H P L C  reten tio n  tim e. 
T he direct insertion m ass spectrum  o f  a com m ercial 
sam ple o f C H 3C O -P A  is sh ow n in F ig . 4 (b ) and  appears 
to  be identical to  that in Fig. 4 (a ), thus confirm ing  our  
interpretation . T h e  m olecular ion  is at m / z  1 3 5 , loss o f  
a m ethyl radical y ields the m ost a b u n d an t peak at 
m /z  120 , and loss o f  C H 3C O  gives th e  p ea k  at m /z  9 2 .
T h e unknow n m etab olite  (p ea k  II o f the  
chrom atogram  in Fig. 1(b)) exh ib ited  th e  d irect insertion  
m ass spectrum  presented  in F ig. 5 (a ). T h is  spectrum  
contains, inter a lia , a m olecular ion  at m /z  193 and  
abundant ions at m /z  149 and 1 2 1 . T h e se  ion s lie  at
IV
0  1 1 5  
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F igure 6. C h r o m a to g r a m  o b ta in e d  in je c t in g  th e  d e p r o te im z e d  
9 0 0 0  xg m o u s e  liver  m ix tu re  a fter  3 0  m in  in c u b a t io n  u n d er  CO  
f lo w . P eak  II c o r r e s p o n d s  to  u n k n o w n  c o m p o u n d  a n d  p eak  IV 
to  CH3C 0-D M T .
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2  u greater than the corresponding ions derived from  
C H 3C O -D M T , su ggestin g  that a m odification to the  
a ro m a tic  ring or to  the acetyl m oiety but not to the 
tr ia zen e  has taken place during m etabolism . W hen the  
in vitro experim en t w as carried out in an atm osphere  
o f  carbon  m o n ox id e , thus inhibiting oxidative m eta b o l­
ism  m ed ia ted  by cytoch rom e P 450 , peak II was again  
e v id en t  in the H P L C  trace w hereas peaks I and III 
(arisin g  from  d em eth y la ted  species) w ere absent (Fig. 
6 ). T h is  su ggests that m etabolism  giving the com pound  
o f  p eak  II is d u e  to  a reduction not involving haem  
c en tres  such as cytoch rom es. This hypothesis is su p ­
p o r ted  by ev id en ce  from  the experim ent in which  
C H 3C O -D M T  is treated  with a m ixture of A D H  and  
N A D H  w hich a lso  g ives a single product o f H PL C  
characteristics identical to  those o f peak II. T he identity  
o f  th is h itherto -unk now n was confirm ed as C H 3C H O H -  
D M T  by com parison  w ith authentic m aterial on the  
b a s is  o f  H P L C  reten tion  tim e and m ass spectrum . Figure  
5 (b ) sh ow s the m ass spectrum  of this syn thetic  
C H 3C H O H -D M T  w ith a prom inent m olecular ion at 
m / z  1 9 3 . By com paring this spectrum  with the spectrum  
o f  C H 3C O -D M T , w e suggest that the fragm entation of  
C H 3C H O H -D M T  occurs by tw o separate paths, one of 
high  and o n e  of low  abundance. T h e  m ajor route in ­
v o lv e s  the initial lo ss o f  44  u. (M e2N )  giving the 4 - ( l -  
h y d ro x y eth y l)b en zen e  d iazonium  ion (m /z  149), a p ro ­
cess  characteristic  o f 3 ,3 -tr im eth yltr iazenes . 1011
Loss o f m olecular nitrogen then yields an ion  of 
m /z  1 2 1  w hich  dehydrates to  g ive  the styryl carbonium  
ion at m /z  103. T his ion is the point o f convergen ce  
with the m inor pathw ay in which the dehydration  (to  
m /z  175) precedes the loss o f M e2N (to m /z  131) and  
N 2 (to  m /z  103). L oss o f acety len e  from  this base peak  
ion then furnishes the rem aining ion  o f high abundance  
at m /z  77 .
T he antitum our activity of C H 3C H O H -D M T  was 
found to  b e  slightly greater than that o f C H 3C O -D M T  
w hen tested  against the m urine ovarian reticular cell 
sarcom a M 5 0 7 6 . T he m ass o f the prim ary tum our w as  
only slightly  m odified by treatm ent ( 3 .9 ± 0 .2 g  for  
C H 3C O -D M T , 3 .3  ±  0 .2  g for C H 3C H O H -D M T  and 
4 .2  ±  0 .3  g for controls). B oth sh o w ed  clearcut an tim eta ­
static effects in that none of the treated  anim als o f each  
group sh o w ed  ev id en ce  of m etastases w hereas all c o n ­
trol an im als presented  m etastatic  invo lvem en t o f liver  
and ovary. T h e m edian survival tim e o f treated  m ice  
versus untreated  controls x  100 (T /C  • 100) w as sim ilar  
for both  com pounds: 141%  for C H 3C O -D M T  and  
138%  for C H 3C H O H -D M T .
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Abstract—The stability of metabolically-generated A/-(hydroxymethvl) compounds was investigated 
using a series of jV-methvlbenzamides as model substrates. /V-(Hydroxymethyl)-benzamide was char­
acterized as a major metabolite of /V-methylbenzamide in vitro, and was also identified as a urinary 
metabolite of .V-methylbenzamide. N-(Hydroxymethyl) compounds were also found as metabolites of 
4-chloro-/V-methyibenzamide and 4-r-butyl-/V-methylbenzamide in vitro. Thus substitution in the 4- 
position of the phenyl ring of derivatives of A/-(hydroxymethyl)-benzamide did not affect their stability 
sufficiently to cause degradation to formaldehyde under the conditions used. /V-(Hvdroxymethyl)-/V- 
methylbenzamide was identified as a metabolite of /V,/V-dimethylbenzamide in vitro. However, N- 
(hydroxymethyl)-jV-methylbenzamide was less stable than /V-(hydroxymethyl)-benzamide under alkaline 
conditions. Furthermore. jV-(hydroxymethyl)-/V-methyIbenzamide, unlike A'-(hvdroxymethyl)-benza- 
mide and its 4-substituted derivatives, was positive in the colorimetric assay for formaldehyde, presum­
ably because of its degradation to produce formaldehyde. Thus substitution on the nitrogen atom which 
bears the methyl group in /V-methylbenzamide markedly affected the stability of the /V-methylol 
produced during oxidative metabolism. /V-Formylbenzamide was identified as a metabolite of N- 
methylbenzamide in suspensions of mouse hepatocytes and also in vivo. The mechanism for its 
production probably involves the generation of /V-(hydroxymethyl)-benzamide.
/V-(Hydroxymethyl) or /V-methylol derivatives (A) 
o f  various am ines and amides can be synthesized by 
reaction o f the appropriate amine or amide with 
form aldehyde [1], The reaction is readily reversible 
in aqueous media [2]. It is therefore not surprising 
that /V-(hydroxymethvl) compounds produced dur­
ing the oxidative /V-demethvlation o f  /V-methyl-con- 
taining xenobiotics have been considered to be tran­
sient species which rapidly degrade to produce the 
/V-desmethyl compound (B) and formaldehyde (C ) 
[3 -4 ],
R 2N— C H 3- - - ~ |0I> R:N— C H O H ----------------►
A
r 2n h  + c h 2o
B C
H ow ever, it was shown as early as 1953, in one  
of the first studies of metabolic /V-demethylation in
* For No. II in this series see [24],
* Present address: Department of Forensic Medicine. 
Karolinska Institute. Stockholm. Sweden.
§ To whom correspondence should be addressed
Abbreviations used: BSTFA. .V.O-bis-(trimethylsilyl)- 
trifluorocetamide: HPLC: high pressure liquid chroma­
tography. GC-MS: gas chromatography-mass
spectrometry.
vitro, that the /V-(hydroxymethyl) derivative of 3- 
m ethyl-4-m ethylam inoazobenzene had sufficient sta­
bility to undergo further chemical reaction with glu­
tathione to form a m ethylene thioether [5], A lthough  
this conclusion was tentative, there have since been  
m any /V-(hydroxymethvl) interm ediates isolated  
during the m etabolism  of /V-methvl-containing com ­
pounds. The evidence pertaining to the formation  
and properties o f  these interm ediates has been  
recently summarized [6 ].
A  study of the conditions under which /V-(hydroxy- 
m ethyl) com pounds or alternatively form aldehyde  
are form ed as m etabolites o f xenobiotics bearing 
/V-methyl groups is toxicologically relevant, as such 
carbinolam ines are capable o f the am inom ethvlation  
of nucleophiles such as glutathione [7, 8 ] or may act 
as transport forms o f form aldehyde [9], a carcinogen  
[10]. In an attem pt to define those characteristics of 
a /V-m ethyl-containing com pound which predispose 
it to form a stable /V-(hvdroxymethyl) interm ediate 
during m etabolism , we have investigated the stability 
of both synthetic /V-(hydroxymethyl) com pounds and 
those produced during m etabolism  [6 . 11-14], Syn­
thetic /V-(hydroxymefhvl) com pounds have widely 
differing stabilities [15] but appear to be relatively 
stable when the /V-(hydroxvm ethyl) group is in an 
electron-deficient environm ent (16-18]. An exam ple 
o f such a stable /V-methvlol is /V-(hydroxvmethyl)-
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Fig. 1. D e r iv a tiv es  o f  A '-m eth y lb en zam id e  u sed  in th is  
stud y.
benzam ide. which can be readily synthesized [19J 
and has a half-life o f  21.1 hr in Earl’s buffer, pH 7.4, 
at 37° [6 ].
In this study we wished to test the hypothesis that 
the m etabolism  o f /V-methyl com pounds which have 
the /V-methyl m oiety in an electron-deficient 
environm ent leads to stable /V-(hydroxymethyl) 
derivatives and not to formaldehyde. A s m odel com ­
pounds, we chose /V-methylbenzamide [the methyl 
analogue o f /V-(hydroxym ethyl)-benzam ide), its 4- 
chloro and 4-r-butyl derivatives, and /V,/V-dimethyl- 
benzam ide (Fig. 1, A -D ). These derivatives o f N- 
m ethylbenzam ide possess substituents which influ­
ence the electron density in the am ide portion o f the 
m olecule [2 0 ], and thus may affect the stability o f  
m etabolites obtained by hydroxylation o f the carbon 
atom  of the /V-methyl m oiety.
MATERIALS AND METHODS
Chemicals. G lucose-6 -phosphate, glucose-6 -phos- 
phate dehydrogenase and N A D P  were purchased  
from Sigma Chemical Co. (P oo le , U .K .). All N- 
methyl-substituted benzam ides and their respective 
/V-desmethyl derivatives were prepared by reaction  
o f the appropriate benzoyl chloride with the corre­
sponding amine by the Schotten-B aum ann tech­
nique [21]. All Ar-(hydroxym ethyl)-benzam ides were 
prepared by treatment of the corresponding ben­
zam ide with excess aqueous form aldehyde (319c) in 
boiling tetrahydrofuran in the presence of potassium  
carbonate.
Animals. Male Balb c mice (20-25  g) were used 
for all experim ents.
In vitro metabolism. Liver fractions and hepato- 
cytes were prepared according to the m ethods 
described in [22] and [23], respectively. Incubations 
using liver fractions were performed in Earl’s buffer. 
pH 7.4 (2.5 ml) in the presence o f 5 mM MgCb and 
sufficient glucose-6 -phosphate, glucose-6 -phosphate  
dehydrogenase and N A D P  to yield 1 mM N A D P H . 
Reactions were started by the addition o f substrate 
in a volum e o f not m ore than 0 .1  ml o f the solvent 
indicated below. Substrate concentrations used  
were: A'-methylbenzamides 10 mM (m ethanol), 
except in the case o f  incubations with isolated 
hepatocytes where a concentration o f 1 mM (ace­
tone) was used: A.A’-dimethylbcnzamide 5 mM  
(acetone). M icrosomes were added to give co n cen ­
trations equivalent to I g  and 0.7 g wet liver 
weight/2.5 ml in the case of incubations containing  
/V-methylbenzamide and A/,A'-dimethylbenzamide, 
respectively. Supernatant (9000 g) was added to  give  
a concentration equivalent to 0.25 g wet liver 
weight/2.5 ml. Incubations with hepatocytes w ere  
performed as described previously [24],
At the end o f the incubation period, reactions 
were stopped by immersing the incubation m ixtures 
in ice. For HPLC analysis 0.15 ml of the appropriate  
internal standard (see below) was added and the  
mixtures were prepared as described previously [24]. 
For colorim etric analysis of formaldehyde equ iva l­
ents formed during microsomal m etabolism , m icro­
som es were removed by centrifugation at 2 7 .0 0 0 g 
for 20 min. Then to 2 ml o f the supernatant from  
duplicate incubations, either 0.25 ml Earl’s buffer. 
pH 7.4 , or 0.25 ml 1 M NaOH (to hydrolyse stable  
carbinolam ines) was added. The mixtures w ere left 
at room temperature for 5 min and were then assayed  
for form aldehvde according to the m ethod o f  Nash  
[25].
In vivo metabolism  V-M ethvlbenzamide was 
injected into mice i.p. in 0 .1m l o f 10% D M S O / 
arachis oil to give a dose o f 200 mg/kg. U rine was 
collected and prepared for analysis as described pre­
viously [24],
H P L C  analysis. Separation o f m etabolites was 
performed using an Altex 100A pump, a W aters 
radial com pression unit equipped with a C t>. 5 um 
reverse phase column and a Pye L C -U V  detector  
(A =  254 nm ). The conditions used for the separation  
of standard com pounds were: (a) A ./V-dim ethylben- 
zam ide, /V-methylbenzamide. /V-(hydroxvmethvl)- 
benzam ide and benzamide— mobile phase 30% 
m ethanol-w ater. flow rate 2 ml/min. internal stan­
dard 4-nitrobenzam ide 0.2 mg/ml in m ethanol:
(b) 4-chloro-/V-methylbenzamide. 4-chloro-/V- 
(hvdroxym ethyl)-benzam ide and 4-chloro- 
benzam ide— m obile phase 50% m ethanol-w ater. 
flow rate 1 .5m l/m in. internal standard 4-n itro­
benzam ide 0 .2  m g ml in methanol; (c) 4-r-butvl-/V- 
m ethylbenzam ide. 4-/-butyl-A;-(hydroxym ethyI)- 
benzam ide and 4-r-butylbenzamide— m obile phase  
57% m ethanol-w ater. flow rate 2 ml/min, internal 
standard 4-chlorobenzam ide 0.2 mg/ml in m ethanol.
Isolation and characterization o f metabolites. 
HPLC eluates corresponding to peaks w ith  the 
retention tim es o f  authentic standards were co llected  
from the colum n and evaporated to dryness under 
a stream o f nitrogen at room temperature. T he resi­
dues were dissolved in acetone (0.025 ml) and sub­
jected to mass spectral analysis. Samples w ere either  
admitted directly to the mass spectrom eter under 
chem ical ionization conditions (as described pre­
viously [24]) or where derivatized and analyzed bv 
electron impact G C -M S
Deri vat izat ion ol isolated metabolites. M etabolites  
and standard com pounds, chrom atographically iso ­
lated, were dissolved in pyridine (0 .0 5 m l) . and 
BSTFA (0.05 m l) was added. The m ixtures were  
heated at 60° for 15 min and subjected to G C -M S  
analysis.
G C -M S analysis G C-M S analysis was perform ed
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Fig. 2. High pressure liquid chromatograms of extracts of 
(a) a mixture of the following reference compounds: 1. 
V-hydroxymethylbenzamide: 2. benzamide: .'. internal 
standard: 4 .  A'-methylbenzamide: (b) a mixture of .V-meth- 
vlbenzamide (lOmM) with microsomcs and a NADPH- 
generating system, incubated for 50 min at 37°; and (c) as 
incubation mixture (b) but-omitting .V-methvlbenzamide.
using a Pye 204 gas chromatograph equipped with 
a fused silica SE52 capillary column linked to a VG  
7070 mass spectrom eter. The injector temperature 
was 250°. the column temperature was 100' initially 
increasing by 327m in for 5 min. A 1:10 split o f  
carrier gas (helium ) was used, the mass spectrometer 
source temperature was 2 2 0 '. and an electron energy 
of 70 eV  was used.
R K .S ll.T S
T he incubation o f .V-methvlbenzamide with micro-
som es and an N A D PH -generating system produced 
a m etabolite with a retention time identical to that 
o f /V-(hydroxymethyl)-benzamide ( 1 . Fig. 2). The 
identity o f this m etabolite was confirmed by com ­
parison with authentic /V-(hydroxymethyl)-benza- 
mide using G C -M S analysis after derivatization with 
BSTFA (Fig. 3). 4-Chloro-/V-methylbenzamide and 
4-r-butyl-N-m ethylbenzam ide were likewise m etab­
olized to their respective /V-(hydroxymethyl) deriva­
tives in m icrosom es. These m etabolites were char­
acterized by com parison o f their retention tim es with 
those o f authentic standards and, in the case o f 4- 
chloro-/V-(hydroxym ethyl)-benzam ide. m ass spec­
trometry (not show n). The extent of biotransfor­
mation o f jV-methylbenzamide and its 4-chloro and 
4-r-butyl derivatives to their respective /V-methylols 
and /V-desmethyl derivatives in microsomal and 
9000 g  supernatant fractions o f liver is shown in Table 
1.
A  chrom atogram  of an extract of the products of 
m etabolism  o f A'-methylbenzamide by isolated  
hepatocytes is shown in Fig. 4. jV-(hydroxy- 
m ethyl)-benzam ide ( 1 . Fig. 4 ), benzamide (2 . Fig. 
4) and /V-formylbenzamide (5, Fig. 4) were identified 
as m etabolites o f  N-m ethylbenzam ide (4. Fig. 4) on 
the basis o f their chromatographic retention times. 
T hese m etabolites were also detected in the urine 
o f mice which had received N-m ethylbenzam ide. 
200 mg/kg i.p . (Fig. 5). 4-Chloro-V-m ethylbenza- 
mide and 4-r-butyl-N-m ethylbenazm ide w ere also 
m etabolized to  their /V-(hydroxymethvl) derivatives 
by isolated hepatocytes and the extent o f their bio- 
transform ation com pared to that of /V-methyl­
benzam ide is show n in Table 2.
On incubation with m icrosom es, /V.A'.-dimethvI- 
benzam ide (4 , Fig. 6 ) produced a m etabolite (3 . Fig. 
6 ) with a retention time identical to that o f /V-meth­
ylbenzam ide and another m etabolite ( 1 . Fig. 6 ). The 
identity o f m etabolite 3 (Fig. 6 ) was confirm ed as 
/V-m ethylbenzamide by mass spectrometry. M etab­
olite 1 (Fig. 6 ) decom posed upon alkaline hydrolysis 
with a corresponding increase in the amount o f A’- 
m ethvlbenzam ide present in the mixture. The time 
course o f production o f m etabolites 1 and 3 (Fig. 6 ) 
is shown in Fig. 7, and indicates that the am ount of 
m etabolite 1 first increased and then decreased. The 
decrease was presum ably due to chemical degrada­
tion or further m etabolism  of m etabolite 1. M etab­
olite 1 was derivatized using BSTFA and subjected  
to G C -M S analysis. The mass spectrum obtained  
indicated that m etabolite 1 was /V-(hvdroxy- 
m ethyl)-/V-m ethylbenzam ide [m/z 237. M for 
Q H < C O N (C H 3)C H 2O S i(C H ,),. 6 1 .2 * :  m /z 222 
[C6H ,C O N (C H 3)C H ,O S i(C H 0 2 ) ' .  3 7 .5 * :  m i: 192 
[C6H 5C (O S i(C H 3) : )= N C H 3] \  4 0 .7 * ;  m /z 105. 
Q H 5C O *. 100% ). A ttem pts to synthesize A- 
hydroxym ethvl-A/-m ethylbenzam ide w ere not 
successful.
Form aldehyde, or a precursor which reacted like 
form aldehyde with Nash reagent, was generated dur­
ing the m icrosom al m etabolism  o f A'.V-dimeihyl- 
benzam ide and the am ount o f Nash-positive species 
in the incubation mixture increased after alkaline 
hydrolysis (T able 3). In the case o f A'-methylbenz­
am ide no form aldehyde could be detected in the 
m etabolism  m ixture unless alkaline hvdrolvsis was
1776 D. Ross et al.
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Fig. 3. Mass spectra of a peak (Rt = 8.8 min) produced during the GC-MS analysis of authentic V- 
hydroxymethylbenzamide (a) and an in vitro metabolite of /V-methylbenzamide with an identical 
retention time on HPLC (b). after derivatizanon with BSTFA
Table 1. The extent of \-demethylation of4-substiiuted /Y-methylbenzamuies 110 mM) in microsomal 












A-Methylbenzamide 2.8 2.9 0 0
4-Chloro-.V-methylbenzamide 1.7 17 0 0
4-f-Buiyl-.V-methylbenzamide 0.6 0.5 ti 0.2
* Mixtures contained either microsomes equivalent to 1 g wet liver weight or 9000£ supernatant 
equivalent to 0.25 a wet liver weight and sufficient cofactors to generate I mM NADPH. Mixtures 
were incubated at 37-' for 30 min.
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Fig. 4. High pressure liquid chromatograms of (a) an extract 
of a mixture of /V-methvlbenzamide (1 mM) with hepato­
cytes incubated at 37' for 90 min; and (b) an extract of an 
incubation of mixture omitting N-methylbenzamide (1. 
/V-hydroxymethylbenzamide; 2, benzamide; 3, internal 
standard; 4. /V-methylbenzamide; 5, /V-formylbenzamide)
P e t e n t ' O n  t i m e  ( m m )
Fig. 5. High pressure liquid chromatograms of extracts of 
(a) a mixture of reference compounds (for identification 
see legend to Fig. 4); (b) urine from mice which had 
received /V-methylbenzamide (4) 200 mg/kg i.p.; and (c) 
urine from mice which had received vehicle onlv.
Table 2 The metabolism of 4-substituted /V-methylbenzamides (1 mM) b\ isolated hepatocytes
% Metabolism' to
/V-(hvdroxymethvl) /V-desmethyl .V-formyl
Substrate derivative derivative derivative
/V-Methy!benzamide 10.5 2.5 •> ■>
4-Chloro- \  - methylbenzamidc S.6 6 9 n.d.
4-/-Butyl-.Y-methylbenzamide • n.d.
* After 90 mm incubation at 37° with 5 x 10' cells/ml.
+ Below 0.1%.
n.d.. Not determined.
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Fig. 6. High pressure liquid chromatograms of (a) an extract of a mixture of microsomes and a 
NADPH-generating system incubated for 30 min at 37°; (b) an extract of an identical incubation mixture 











Fig. 7. Time course of production of N-methyibenzamide 
(□ ) and an unidentified metabolite (O) during the metab­
olism of N.AZ-dimethylbenzamide (5 mM) in microsomes.
perform ed prior to the Nash reaction (Table 3). It 
was conceivable that the differences in the pro­
duction o f Nash-positive species during the m etab­
olism  o f /V-m ethvlbenzamide and .V./V-dimethyl- 
benzam ide were due to the different stabilities of 
their respective /V-(hydroxym ethyl) com pounds 
form ed during m etabolism . This was confirmed by 
an investigation o f  the stability o f  authentic ,V- 
(hydroxym ethyl)-benzam ide and m etabolically-gen- 
erated /V-(hydroxym ethyl)-A/-m ethylbenzam ide in 
various buffer system s at 37° (Fig. 8). The results 
show  that under alkaline conditions X- 
(hydroxym ethyl)-benzam ide is more stable than .V- 
(hydroxym ethyl)-/V-m ethylbenzam ide.
In all in vitro  incubations, no other m etabolites 
were identified when the pH o f the incubation m ix­
tures were adjusted to pH  2 and re-extracted after 
the normal extraction process had been perform ed. 
This im plies the absence o f phenolic m etabolites 
which may have been ionized at pH 7.4 and thus
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Table 3. Formaldehyde equivalents generated during the microsomal metabolism of N,N- 
dimcthylbenzamide (5 mM) and /V-methylbenzamide (10 mM), measured using the Nash 
reagent before and after alkaline hydrolysis




/V,/V-dimethylbenzamide (5 mM) 195 349
N-Methylbenzamide (10 mM) 0 90
Results are from one experiment, representative of three.
may not have been removed during the first extrac­
tion. When the pH  o f the urine of mice which had 
received /V-methylbenzamide was adjusted to  pH 2 
and re-extracted, the liquid chromatogram o f  the 
extract showed tw o major peaks which were not 
extracted from control urine adjusted to pH 2. The  
chemical ionization mass spectrum o f one o f  these  
m etabolites suggested that it may be hippuric acid 
[m/z 180, MH", 100%; mjz 135, (M H -C O O H )+, 
13%; m /z 105, Q H jC O ' 66% ]. Benzoic acid can be 
converted to hippuric acid in animals [26] and thus 
it is possible that this m etabolite was formed in vivo  
by enzym ic hydrolysis o f the amide moiety follow ed  
by conjugation with endogenous glycine.
DISCUSSION
Although there are many exam ples in the litera­
ture o f the biotransformation o f /V-methyl-containing 
xenobiotics to characterizable m etabolites which 
possess /V-(hydroxymethyl) groups (summarized in 
[6]), the conditions and structural requirements for 
their formation have not been studied. We report 
here that /V-(hydroxymethyl)-benzamide. a stable
com pound which can be readily synthesized from  
form aldehyde and benzam ide, is indeed a m ajor 
m etabolite in vitro and a minor m etabolite in v ivo  
o f /V-methylbenzamide. 4-Substitution in the phenyl 
ring o f /V-(hydroxymethyl)-benzamide alters its rate 
o f breakdown to produce form aldehyde [6. 19]. 
H ow ever, 4-chloro-/V-(hydroxym ethyl)-benzam ide  
and its 4-r-butyl derivatives both have half-lives in 
Earl’s buffer, pH 7.4, at 37® of greater than 9 hr [6]. 
Thus these  com pounds would be expected to be 
sufficiently stable to be isolated using the conditions 
described in this study. This was confirmed by the  
characterization o f /V-methylols during the m etab­
olism  in vitro  o f 4-chloro-/V-methylbenzamide and 
its 4-r-butyl derivative. Therefore although 4-substi­
tution in the phenyl ring of /V-m ethylbenzamides 
does result in quantitative differences in their m etab­
olism  (T ables 1 and 2), it does not alter the stability  
o f  the respective /V-methvlol derivatives sufficiently  
to cause qualitative differences in m etabolism , i.e .  
to affect whether a stable /V-(hydroxymethyl) co m ­
pound or formaldehyde is produced.
/V-(Hydroxym ethyl)-benzam ide and its 4-chloro  
and 5-r-butyl derivatives, like /V-(hydroxvm ethyl)- 


































Fig. 8. The stability of authentic A-(hydroxymethyl)-benzamide (□ ) and metabolically-gcnerated A’- 
(hvdroxymethvl)-/V-methvlbenzamide. (O) at 37° in the following buffer svsiem: A—Earl's. pH 7.4; 
B—0.01 M Tris. pH 7.4; C—0.01 M Tris. pH 9; D—0.01 Tris, pH 12; E—acetate. pH 5; F—acetate.
pH 2.8.
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A lternatively the lack of an amide hydrogen atom  
in /V-(hydroxymethyl)-/V-methyibenzamide may pre­
vent so lvent participation in hydrogen bonding and 
this may account for the difference in stabilities. 
Tanka et al. [27] have suggested that intramolecular 
hydrogen bonding of .V-(hydroxymethyl)-/V-phenyl- 
ureas (R  = Q H 5NH ) leads to their degradation as 
described below  and this may also apply to N- 







R ^ N H
R'
Fig. 9. Proposed scheme for the metabolism of the methyl 
groups of /V-methyl-substituied benzamides.
not react in the Nash assay. This assay detects for­
m aldehyde and is used routinely to m easure m etab­
olic /V-demethylation. Thus, assessm ent o f the /V- 
dem ethylation of these com pounds by m eans o f  the 
Nash reaction, without a confirmatory chrom ato­
graphic analysis, would produce erroneous results.
/V-Formylbcnzamide (5, Fig. 4 and 5 ), as w ell as 
/V-(hydroxymethyl)-benzamide (1, Figs, 4 and 5) and 
benzam ide (2, Figs. 4 and 5), were identified as 
m etabolites of /V-methylbenzamide (4, Figs. 4 and 
5) in hepatocytes and in vivo  on the basis o f chro­
matographic retention times. W e have shown pre­
viously that /V-(hydroxymethyl)-benzamide can be 
m etabolized in vitro to /V-formylbenzamide by 
pyrazole-sensitive dehydrogenases [24]. Unlike N- 
(hydroxym ethyl)-benzam ide, /V-formylbenzamide is 
an unstable species and degrades rapidly to  produce 
benzam ide. Thus it seem s probable that the route 
whereby /V-formylbenzamide and benzam ide are 
produced in vivo  involves the production and further 
m etabolism  of /V-(hydroxymethyl)-benzamide (see  
Fig. 9).
Surprisingly, another substituent on the nitrogen  
atom o f /V-methyibenzamide markedly affected the 
stability o f the /V-methylol produced during /V- 
dem ethylation. The /V-(hydroxymethyl) com pound  
produced during the metabolism o f A/,/V-dimethvl- 
benzam ide was an unstable species and degraded  
partly to produce formaldehyde under the conditions 
used for in vitro metabolism studies. /V- 
(Hydroxymethyl)-jV-methylbenzamide, unlike N- 
(hydroxym ethvl)-benzam ide. produced a positive  
response in the Nash test prior to its hydrolysis by 
alkali (Table 3). Therefore, in the m etabolic schem e  
proposed for the metabolism of the /V-methyl groups 
in /V,/V-dimethylbenzamide (Fig. 9 ). the first N- 
dem ethylation leads to formaldehyde liberated from  
the degradation of an unstable /V-methylol whereas 
the second /V-demethylation yields a stable /V-meth­
ylol. That the ;Y-(hydroxymethyl)-/V-methyl deriva­
tive is less stable than the /V-(hydroxymethyl) deriva­
tive may be due to the electron-donating effect o f 
the second methyl m oiety which would oppose the 
electron-withdrawing effect o f the carbonyl group.
These workers suggested that the greater stability 
of the /V-(hydroxymethvl) derivative (I) as opposed  
to the /V-(hydroxymethyl)-/V-methvl derivative (II) 
may be due to the fact that the N-hydroxvrnethyl 
group in I can be held in a configuration trans to the 









In the case of II this hydrogen bonding is not 
possible due to the lack o f an amide hydrogen atom , 
and consequently the formation of the cyclic tran­
sition state leading to breakdown o f the m olecule is 
more probable. Another possibility is that lack o f 
the am ide hydrogen atom in II may prevent tauto- 
merism to  the enol form of the m olecule, which 
would prevent the generation o f the transition state 
and subsequent degradation. W hatever the reason, 
it is conceivable that V-methylols o f different sta­
bilities m ay be generated during the successive N- 
dem ethylations of other /V-methyl-containing 
substrates.
Like /V-methvlols produced during successive N- 
dem ethylations of the same substrate. A‘-m ethylols 
generated during the m etabolism  of different types 
of /V-methyl-containing com pound may have varying 
stabilities [15]. Furthermore, different types o f /V- 
m ethylols may undergo degradation by different 
pH -dependent mechanisms. For exam ple, it has been  
shown that /V-methylols derived from .V-methyl- 
m elam ines are more stable in basic rather than acidic 
solution [28]. whereas iV-methylolamides such as 
/V-(hydroxym ethyl)-benzam ide [6. 19] and N- 
(hydroxym ethvl)-nitrosam ines [29] are more stable  
under acidic conditions. This varying stability of 
/V-methylols may have toxicological im plications as 
either the intact .V-methylol [7. 8] or its degradation  
products, form aldehyde [2] and in certain cases the 
/V-des-(hydroxym ethyl) species [30-32]. are capable  
of reacting with biological nucleophiles. It is there­
fore conceivable that particular types of V-methyl 
may be responsible for the antitumour activity 
observed with certain A'-methvl-containing com ­
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pounds, e .g . /V-methylmelamines [33], l-aryl-3,3- 
dim ethyltriazenes [34] and /V-methylformamide [35]. 
Sim ilarly the generation of /V-methylols o f a par­
ticular stability or reactivity may contribute to the 
toxicity and carcinogenicity of other /V-methyl-con­
taining com pounds such as /V,/V-dimethylnitrosa- 
m ine [36], azoxymethane [37] and A/,/V-dimethyl- 
am inoazobenzene [38]. This hypothesis and the 
possible involvement of /V-formyl com pounds pro­
duced during /V-demethylation in the pharmaco­
logical and toxicological effects o f /V-methyl-con- 
taining com pounds are currently under investigation 
in these laboratories.
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LABELLED COMPOUNDS OF INTEREST AS ANTITUMOUR AGENTS I: N-METHYLFORMAMIDE AND
n ,n -q i m e t h y l f o r m a m i o e.
Michael 0 Threadgill and E Nicholas Gate
Cancer Research Campaign Experimental Chemotherapy Research Group 
Department of Pharmacy, University of Aston in Birmingham 
Birmingham B4 7ET, UK.
SUMMARY
Efficient preparations of N-methylformamide (an active antitumour
agent) have been developed in which the compound is labelled with
14 14
C in the formyl group, with C in the methyl group and with
14
deuterium in the methyl group. N.N-Dimethyl- C-formamide has 
also been synthesised.
Key words: Antitumour, Carbon-14, Oeuterium. Dimethylformamide, Methylformamide
INTRODUCTION
N-Methylformamide (1_; NMF) is a compound which shows significant activity
against a number of murine tumours 11-4 J whereas that of i t s  dimethyl analogue
N.N-dimethylformamide 12; DMF) is, at best, marginal. In order to investigate
both the _in vivo distribution and the metabolic fate of the two different one-
14
carbon fragments arising from NMF and DMF, we required NMF labelled with C in
14
each of tne carbon positions separately (3 and 4) and DMF containing a C methyl 
group (5). As it is possible that in vivo oxidation of the methyl group of NMF 
is responsible for furnishing the actual antitumour agent, we sought N-(trideutero 
methyl)-formamide (j5) as a tool to examine any primary Kinetic isotope effect in 
this putative metabolic activation; if such an effect were found, it may 
manifest itself, inter alia, as a decrease in antitumour activity upon deuteration.
0362-4803/83/040447-05$01.00 
©  l983 by John Wiley & Sons, Ltd.
Received October 12, 1982






1: d  = c2= 12c 2: d  =  12C
3: 5: d = l4C
4. d = H : : c 2 = ^
RESULTS
The p y r o l y s i s  o f  am m oniu m  s a l t s  o f  c a r b o x y l i c  a c i d s  h a s  l o n g  b e e n  Known t o
g i v e  c a r b o x a m i d e s ,  a l b e i t  i n f r e q u e n t l y  i n  m o d e s t  y i e l d .  T h e  s y n t h e s i s  o f  N . N -
14 v | |
d i m e t h y l -  C - f o r m a m i d e  ( 5 )  b y  t h i s  r o u t e  h a s  b e e n  d e s c r i b e d  b y  V e r e s  al_  | 5 | ;
h o w e v e r ,  i n  o u r  h a n d s ,  i n  e x p e r i m e n t s  u s i n g  u n l a b e l l e d  m a t e r i a l ,  t h i s  t e c h n i q u e
f a i l e d ,  g i v i n g  a  m i x t u r e  o f  DMF ( 2 )  a n d  d i m e t h y l a m m o n i u m  f o r m a t e .  A
14
m o d i f i c a t i o n  w a s  t h e r e f o r e  e m p l o y e d .  S o d i u m  C - f o r m a t e  w a s  h e a t e d  w i t h  an
e x c e s s  o f  m e t h y l a m i n e  h y d r o c h l o r i d e  i n  t h e  a b s e n c e  o f  s o l v e n t  i n  a n  a p p a r a t u s
d e s i g n e d  t o  p e r m i t  g e n t l e  r e f l u x  b e f o r e  a l l o w i n g  t h e  p r o d u c t  t c  d i s t i l .  T h i s
14
s e r v e d  t o  e n s u r e  t h a t  a l l  t h e  v o l a t i l e  m e t h y l a m m o n i u m  C - f o r m a t e  h a d  b e e n
t h e r m a l l y  c o n v e r t e d  t o  t h e  d e s i r e d  a m i d e  ( 3 ) .  T h e  d i m e t h y l  a n a l o g u e  w a s
14
p r e p a r e d  s i m i l a r l y  f r o m  s o d i u n  C - f o r m a t e  a n d  d i m e t h y l a m i n e  h y d r o c h l o r i d e .
14
T h e m e t h y l - r a d i o l a b e l l e d  c o m p o u n d  ( 4 )  w a s  p r e p a r e d  f r o m  C - m e t h y l a m i n e  
h y d r o c h l o r i d e  a n d  e t h y l  f o r m a t e  i n  t h e  p r e s e n c e  o f  m e t h a n o l i c  b a s e .  C n e m i c a l
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and rad iochem ica l  y ie ld s  o f  compounds ( 2 [ -  ^ )  were h igh.
Pure  anhydrous N -( t r id e u te ro m e th y l) - fo rm am id e  (J5) was prepared  from
tr ideu te ro m eth y lam in e  h y d ro ch lo r id e  and e th y l  fo rm ate  in  moderate y i e l d .  A ll the
l a b e l l e d  NMF d e r i v a t i v e s  (3, 4 ,  jS) a r e  new compounds. D i f f e re n c e s  between th e
i n f r a - r e d  spectrum of (j3) and t h a t  o f  i t s  p ro t io - a n a lo g u e  ( 1 ) p e rm it te d  us to
a s s ig n  c e r t a i n  absorbance bands t o  v i b r a t i o n s  o f  th e  methyl group o f  NMF
~  1 .3 7 ) .  These ass ignm en ts  complement t h e  work o f  Suzuki ( 6 1. who
used o t h e r  d e u te r a te d  NMF d e r i v a t i v e s ,  bu t  c o n f l i c t  w ith  S u t h e r l a n d ' s  | 7 |
- 1  -1p ro p o s a ls  f o r  assignment o f  th e  bands a t  2880 cm and 960 cm in  th e  spectrum 
of  ( 1 ) , which we have shown to  be v ib r a t i o n s  of th e  CH  ^ group (s ee  th e  T a b le ) .
Table . I n f r a - r e d  Spectrum o f  1 and 6
v M) v ( 6 ) v M ) /v  ( 6 ) Assignment
3400 3500-3200 1 NH
3060 3040 1 . 0 1 CH
3060 2230 1.37 CH
2950 2 1 1 0 1.40 ch 3
2880 2080 1.38 CH3
1660 1660 1 . 0 0 Amide I
1550 1520 1 . 0 2 Amide I I
1420 1050 1 .35 CH3
1390 1385 1 . 0 0 CH
1240 1250 0.99 Amide I I I
1150 870 1 .32 CH3
960 700 1.37 “ 3
The outcome o f  the  m e ta b o l ic  and pha rm aco k ine t ic  i n v e s t i g a t i o n s  w i l l  be 
p u b l i sh e d  e lsew here  | 8 | ;  f u r t h e r  s t u d i e s  on t h e  physicochem ica l p r o p e r t i e s  o f 
t h i s  im p ortan t  an ti tum our ag en t  (NMF, _l_) a r e  be ing  a c t i v e l y  pursued .
ACKNOWLEDGEMENTS: This work was suppor ted  by a g r a n t  from th e  Medical
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Experimental
The r a d i o a c t i v i t y  was measured by th e  s c i n t i l l a t i o n  method using a PacKard 
T r ic a rb  2660 in trum ent and rad io chem ica l  p u r i t y  was checked using  t h i n - l a y e r  
chromatography on s i l i c a  g e l  p l a t e s  ( S i l i c a  Gel 60 ^ 5 4 ' M e r c k ) .  In f r a r e d  
s p e c t r a  were o b ta in ed  from t h i n  f i lm s  o f  l i q u id  sample using  a Perk in-E lm er 1310 
sp ec trom e te r .  P roton m agnetic  resonance  s p e c t r a  were o b ta in e d  a t  60 MHz u s in g  a
V/arian EM-360A sp e c t ro m e te r  w i th  t e t r a m e th y l s l l a n e  as  i n t e r n a l  s t a n d a rd .  Radio-
14 14chem icals  ( C-methylamine hy d ro ch lo r id e  and sodium C -form ate) were o b ta in e d
from Amersham I n t e r n a t i o n a l  PLC and tr id eu te ro m e th y lam in e  hy d ro ch lo r ide  (98*0)
from A ldrich  Chemical Co.Ltd.
14N- C-Methylformamide (3)
A s o lu t io n  o f  sodium m ethoxide in  methanol (2.0ml) (p rep a red  from sodium
14m eta l  (69 mg)) was added slow ly  t o  a cooled  s o lu t i o n  o f  C-methylamine hydroch­
l o r i d e  (202.5 mg; 1.0  mCi) in  methanol (1 .0  m l) .  Anhydrous sodium c a rb o n a te  
(318 mg) and e th y l  fo rm ate  (3 .0  ml) were added and th e  m ix tu re  was s t i r r e d  a t
25°C f o r  18 hours .  E thy l fo rm a te  (4 .0  ml) was added and th e  s a l t s  were f i l t e r e d
o f f  using  a co tton-w ool p lu g .  The f i l t r a t e  and e th y l  fo rm ate  washings were
combined and th e  so lv e n ts  evap o ra ted  c a r e f u l l y  under reduced  p re s s u re  to  g iv e  
14N- C-methylformamide (163 mg; 0.92m Ci; chemical y i e l d  92%) a s  a c o l o u r l e s s
l i q u i d .  I t  had chrom atographic  p r o p e r t i e s  i d e n t i c a l  to  a commercial sample o f
u n la b e l le d  N-methylformamide.
14N-Methyl- C-formamide (4)
14Methylamine h yd ro ch lo r id e  (270 mg) and sodium C -form ate  (136 mg; 1.7m Ci)
were p laced in  th e  s ide-arm  o f  a 7cm x 1cm t e s t - t u b e  equipped w ith  10cm x 1cm
side -a rm  and w ith  a r e f lu x  co n den se r .  G en tle  hea t in g  o f  th e  s o l i d s  over a f lam e
f o r  8  minutes caused th e  v o l a t i l e  m a t e r i a l s  to  b o i l  under r e f l u x  w i th in  th e  s i d e -
arm. The m ix tu re  was then  hea ted  more s t ro n g ly  and a p a l e  s t r a w -c o lo u re d  l i q u i d
d i s t i l l e d  in to  th e  main tu b e .  The d i s t i l l a t e  was e x t r a c t e d  w ith  ace ton e  (6x4 ml)
14C a re fu l  evapora t ion  o f  th e  s o lv e n t  f u rn is h e d  N-methyl- C-formamide monohydrate 
(122 mg; 1.35 mCi; chemical y i e l d  79%) a s  a p a le  yellow l i q u i d .  I t  had p r o p e r t i e s  
i d e n t i c a l  tc  an equimolar m ix tu re  o f  a u th e n t i c  N-methylformamide and w a te r .
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N.N-Dimethyl-1 4 C-formamide (5^
This compound was p repa red  using  a te ch n iq u e  s i m i l a r  to  t h a t  used f o r  (£)
14from dimethylamine h yd ro ch lo r id e  (325 mg) and sodium C-formate (135 mg; 870 uCi) 
14N,N-Dimethyl C-formamide monohydrate (120 mg; 560yCi; chemical y ie l d  6 6 *) was 
ob ta ined  as  a p a le  s t raw -co lo u re d  l i q u id  having p r o p e r t i e s  i d e n t i c a l  to  an 
equimolar mix ture  o f  a u t h e n t i c  N.N-dimethylformamide and w a te r .
N -(T r id eu te rom ethy l) -formamide ( 6 )
Sodium (650 mg) was added to  a b s o lu te  e th a n o l  (30 ml) a t  -5°C. When a l l  th e  
metal had d is so lv e d ,  ( t r id e u te ro m e th y l )a m in e  h y d ro c h lo r id e  ( 2 . 0 g) was added,
followed by e th y l  fo rm a te  (25 ml) and anhydrous sodium ca rb o n a te  (1 0 g ) .  The
o cm ix tu re  was s t i r r e d  a t  -5  C f o r  1 hour th en  12 hours  a t  20 C. A c l e a r  s o l u t i o n
was o b ta ined  a f t e r  f i l t r a t i o n  and th e  f i l t r a t e  and e t h y l  fo rm ate  washings were
c o n cen t ra te d  in  vacuo to  10ml. D i s t i l l a t i o n  u s ing  t h e  b u lb - to -b u lb  te c h n iq u e
gave N- (t r id eu te ro m e th y l) - fo rm am id e  (860 mg; 49*) a c o l o u r l e s s  l i q u i d .  BPt^
65-70°C v ( l iq u i d  f i l m ) :  (see  T a b le ) .  6 (C0C1,): 7 .3  (1H) b r  (NH. 8.03)max 3
0 . 1 . )  s CH0 c is - fo rm , 8 .27 (0.9H) s CH0 t r a n s - f o r m ,  m /z :  62 (M ).
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Selective Reactions in the Triazene Series; I. Reduction 
of l-(4-AcetylphenyI)-triazenes
Michael D. Threadgill*. Malcolm F. G. Stevens
Cancer Research Campaign Experimental Chemotherapy Group. D e­
partment o f Pharmacy. University of Aston in Birmingham. Gosta 
Green, Birmingham B4 7ET. U. K.
The l-aryl-3,3-dimethyltriazenes have long been known to 
possess anti-tumour activity', but recent evidence points to 
their being prodrugs2-3. In the case of l-(4-acetylphenyl)-3,3- 
dimethyltriazene (la), H.P.L.C. analysis shows several major 
metabolites to be present in incubation mixtures of la with 
mouse liver preparations4-5. It is likely that some metabolites 
could arise from biological reduction of the acetyl function to 
a I-hydroxyethyl group. Authentic samples of the putative re­
duction products 2 a-d arising from la-d were required and 
their synthesis has been achieved.
The traditional approach to the synthesis of aryl-triazenes. 
that of coupling an arenediazonium salt [here derived from 1- 
(4-aminophenyl)-ethanol] with a primary or secondary ali­
phatic amine, was considered to be inappropriate in this case 
since pentazadienes have been found when primary aliphatic 
amines are treated with arenediazonium salts bearing no other 
electron-withdrawing substituents6.
A more biomimetic approach would involve selective reduc­
tion of the ketone moiety of the triazenes la-d. Triazenes. be­
ing masked diazo-compounds. are very labile to metal/acid 
reducing conditions: indeed, a previous report of such treat­
ment of a triazene showed reduction of the —N = N — 
group while leaving a nitrile unscathed7. The problem en­
countered in the present work was therefore to achieve selec-
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tive reduction o f the the acetyl function o f the triazenes la-d  
without cleavage o f the — N = N — N:^ link. Sodium borohy- 
dride was found to be without effect on acetylphenyltriazene 
la  but use o f  lithium aluminium hydride smoothly and rap­
idly gave the desired 1-hydroxyethyl derivatives 2a-d in the 
cases o f both di- and trisubstituted triazenes.
•v s j C t *






The substrates la-d were prepared in the usual way by cou­
pling 4-acetylbenzenediazonium chloride with the appropriate 
primary or secondary aliphatic amine. Derivatives o f some of 
the triazenes were prepared to aid characterisation. In particu­
lar, the 3,3-dialkyl-triazenes 2a, b were converted to their 4- 
chlorophenylaminocarbonyl derivatives 3a, b by treatment 
with 4-chlorophenyl isocyanate in an aprotic solvent. The 
monoalkyl compounds 2c, d were found to be very unstable 
to purification procedures and to attempted derivatisation; 
however, analysis o f their ’H-N.M.R. spectra indicated that 
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R esolution  o f  the racemic com pounds 2a-d, 3a , b was not attem pted  
sin ce  our b io log ica l interest lies in the effect o f  ch an ge in the eiectron- 
d ensity  in the triazene group rather than in geom etry  rem ote from this  
m oiety.
These results show that a complex hydride agent offers a 
clean and efficient reduction of a substituted phenyltriazene 
while leaving the — N = N — functionality intact. The re­
sults o f metabolic and anti-tumour experiments will be re­
ported elsewhere; it would be expected that metabolicallv- 
generated l-[4-(l-hydroxyethyl)-phenyl]-triazenes (2a-d) 
would be much less stable* than their precursor l-(4-acetyl- 
phenyl)-triazenes (la-d) and perhaps therefore be o f different 
biological activity.
l-(4-A cetylphenyl)-3,3-diinethyltriaze!ie ( la ) ;  T ypical Procedure:
4 '-A m in oacetop h en on e (2.02 g, 15 m m ol) is su sp en d ed  in water (12  
m l) an d  36% hydrochloric acid (7.5 m l) is a d d ed . T he resu lting  slurry is
T ab le. Triazenes 1, 2 , and 3 prepared
Product*  





M olecu lar form u la6
or Lit. m.p. [°CJ
'H -N .M .R . (C D C 1,)  
5 (ppm]
M.S
m/e (M  ' )
la C H , C H , 68 9 2 -9 3 ° 9 1 -9 2 °° 2.55 (s , 3 H ); 3 .35 (br. s .6 H ) :  7.45 ( d .2 H ,7  =  8 H z): 7 .90  (d. 
2 H . 7  =  8 Hz)
191
lb C jH 5 c 2h 5 98 oil — 1.30 (t. 6 H . 7  =  7 Hz): 2.55 (s. 3 H); 3.80 (q, 4 H . 7 = 7  Hzi: 
7.50 (d . 2 H . 7  =  8 Hz): 7.95 (d. 2 H . 7 =  8 Hz)
219
lb sem icarb azon e 79 2 0 6 -2 0 7 ° C „ H joN * 0
(276.3)
1.30 (t, 6 H, 7  =  7 Hz): 2.25 (s. 3H ); 3 .80 (q, 4 H . 7  =  7 H zi: 
6.2 (br. s, 2 H ): 7 .40 (d . 2 H . 7 =  8 H z): 7 .70 (d . 2 H . 7  =  8 
Hz): 7.1 (br. s. I H )c
276
lc C H j H 78 8 9 -9 0 ° 9 0 -9 2 °° 2.25 (s, 3 H ): 3.3 (br. s. 3 H ) . 7 .2 -8 .0  (m. 4 H ):  9 .3  (br. . 
IH )
177
Id C jH , H 78 7 5 -7 7 °
(dec.)
C ,o H i,N ,0
(191.2)
1.30 (t. 3 H . 7  =  7 H z): 2.50 (s. 3 H): 3.75 (q. 2 H . 7  =  7 H z). 
7 .2 -8 .0  (m . 4  H ); 9 .2  (br. s. 1 H)
191
2a d C H , C H , -  100 oil c ,0h 15n , o
(193.2)
1.40 (d . 3 H . 7  =  6  H z): 2.7 (br s. 1 H): 3.30 (s . 6 H ) :  4 .80  (q. 
1H , 7  =  6 H z): 7 .30 ( s .4 H )
193
2b C : H , C ,H , 93 oil C ,; H „ N ,0
(221.3)
1.25 ( t .6 H .  7 = 7  H z): 1.40 (d. 3 H. 7 =  6  Hz); 2.8 (br. s . lH i:  
3.70 (q. 4 H . 7  =  7 Hz): 4.80 (q. IH . 7  =  6 H z): 7 .35  (s . 4 Hi
221
2c C H , H 91 oil — 1.45 (d . 3 H . 7 =  6 Hz): 3.2 (br. s. 1 H): 3.25 (s . 3 H ): 4 .85  <q. 
1 H . 7  =  6 H z): 7.0 (br. s. 1 H): 7.30 (s. 4 H )
179
2d c 2h , H 96 oil 1.25 (t. 3 H. 7  =  7 H z): 1.45 (d . 3 H .7  =  6 Hz): 3 .0  (br s. 1 H): 
3.65 (q . 2 H . 7  =  7 Hz): 4.85 (q. 1 H. 7  =  6 H z): 7 .30  (s . 4 H ):  
8.0 (br. s. 1 H)
193
3a C H , C H , 77 104-105° c , - h „ c i n 4o 2
(346.8)
1.55 (d . 3 H . 7 =  6 Hz): 3.35 (s. 6 H ): 5 90  (q. 1 H . 7  =  6  Hzi: 
7.0 (br. s. 1 H ); 7 .30 (s. 4 H ); 7 40 ( s .4 H )
348. 346
3 b J C ; H , c 2h , 73 oil c |4h 2, c i n 4o 2
(374.9)
1.20 (l. 6 H. 7  =  7 Hz): 1.55 (d. 3 H. 7 =  6 Hz): 3 .75  (q . 4 H .  
7 =  7 H z): 5.90 (q . 1 H. 7  =  6 Hz): 7.0  (br s . 1 H ): 7.25 tv  
4 H ): 7 .40 (s . 4 H )
376. 3~4
'  All com p ou n d s w ere characterised by I.R.. N .M .R .. U .V., and  M.S.
h Satisfactory m icroan alyses were ob ta in ed  for new  com p ou n d s w here sh ow n  (C  ± 0 .3 0 . H ± 0 .2 6 . N ± 0 .3 1 ) . 
c In DM SO-d*.
d Purified by chrom atography (a lum ina, d iethyl ether).
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cooled  to S °C in an ice-bath and a solution of sodium nitrite (1.08 g, 
IS.6 mmol) in water (3 ml) is added at such a rate that the temperature 
does not rise above 10 °C. The resulting solution o f the diazonium salt 
is poured during 5 min into 40% aqueous dimethylamine (30 ml) with 
vigorous stirring. The mixture is immediately extracted with chloro­
form (2 x 30 ml). The combined extracts are washed with water (4 x 30 
ml), dried with sodium sulphate, filtered, and the solvent evaporated 
under reduced pressure. The residue is recrystallised from toluene/cy- 
clohexane giving la as long, pale bufT needles: yield: I.9S g (68%); 
m.p. 92-93 °C.
H4-(l-Hydroxyethyl)-pheiiyl|-3,3-diinethyltriazene (2a); Typical Proce­
dure:
To a solution o f  l-(4-acetylphenyl)-3,3-dimethyltriazene ( la ;  1.91 g, 
10 mmol) in tetrahydrofuran (30 ml) is added lithium aluminium hy­
dride (380 mg, 100 mmol) during S min. The suspension is stirred for a 
further 10 min before addition of water (30 ml) (cautiously at first). 
The mixture is extracted with ethyl acetate (100 ml). This extract is 
washed with water (3 x 80 ml) and saturated brine (SO ml), dried with 
sodium  sulphate, filtered and the solvent evaporated under reduced 
pressure to give 2a as a colourless oil: yield: 1.93 g (100%).
l-(4-ChIorophenylaminocarbonyloxy>-H4-(3,3-dimethyltriazei»-l-yl)- 
phenyil-ethane (3a); Typical Procedure:
A solution o f l-[4-(l-hydroxyethyl)-phenyl)-3,3-dimethyltriazene (2a; 
386 mg, 2 mmol), 4-chlorophenyl isocyanate (307 mg, 2 mmol), and 
trieihylamine (50 mg, 0.5 mmol) in tetrahydrofuran (5 ml) is boiled un­
der reflux for 16 h. Evaporation of the solvent and o f triethyiamine 
under reduced pressure gives a buff solid which, on recrystallisation 
from aqueous methanol, furnishes 3a as pale buff needles: yield: 520 
mg (77%); m.p. 104-105 °C.
C i7H ,9C1N40 2 calc. C 58.88 H 5.52 N 16.15 
(346.8) found 58.75 5.55 15.84
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(± )2,3,-DIHYDROXYPROPYL 
DICHLOROACETATE, AN INHIBITOR OF 
GLYCEROL KINASE
M. J. TISDALE and M. D. THREADGILL
CRC Experimental Chemotherapy Group, Department o f  Pharmacy, University of 
Aston in Birmingham, Birmingham, B4 7ET
Of a range of glycerol analogues, (±)-2,3-dihydroxypropyl dichioroacetate (III) has been shown to be the 
most potent inhibitor of glycerol kinase in vitro. Inhibition is noncompetitive with a Ki valueof 1.8X lO- ’ M. 
The presence of ATP seems essential for effective inhibition of the enzyme, suggesting that the inhibitor is 
phosphoryiated to a glycerol-3-phosphate analogue. In vivo HI causes a decrease in the specific activity of 
liver glycerol kinase and produces a dose-dependent reduction in blood glucose levels. There is a reduction in 
the conversion of [U-|aC| glycerol into glucose after administration of III to CBA/CA mice while 
gluconeogenesis from fructose is increased. This suggests that of the enzymes of gluconeogenesis only 
glycerol kinase Ls inhibited by III. This compound may be useful in reducing the lipid contribution to 
gluconeogenesis in advancing cancer.
INTRODUCTION
Many tumors have an absolute requirement for glucose as an energy supply, either 
because of enzymatic differences (Weinhouse, 1973), or through a low oxygen 
tension(Thom!inson and Gray, 1955) which would prevent oxidation of nutrients by 
molecular oxygen and lead to a dependence on glycolysis to supply the energy 
demands. Thus a tumor behaves as a trap for glucose and acts as a powerful 
hypoglycemic factor imposing a strain on the host’s ability to maintain normal blood 
glucose levels (Shapot, 1972). Despite this tendency towards hypoglycemia normal 
blood glucose concentrations have been observed In most tumor-bearing animals and 
patients. This indicates an increased dependence on gluconeogenesis from non- 
carbohydrate precursors by the host (Gold, 1974). An increased Cori cycle activity is 
present in patients with progressive malignant disease and weight loss (Holroyde etaL, 
1975; Waterhouse, 1974) which could convert the large amounts of lactate produced 
by tumors back into glucose (Gold, 1966; Shapot and Blinov, 1974). There is also an 
enhanced activity of gluconeogenic enzymes in the liver of tumor-bearing animals 
(Gutman, Thilo and Biran, 1969). Since the rate of gluconeogenesis in tumors is low 
(Morris, 1975), all resynthesis of glucose must occur in host tissues, particularly liver 
and kidney.
Gold (1974) has proposed that inhibitors of gluconeogenesis may be tumor growth 
inhibitors. Hydrazine sulfate, an inhibitor o f gluconeogenesis at the phosphoenoly- 
pyruvate carboxykinase reaction, shows antitumor activity (Gold, 1975). The 
antitumor effect of hydrazine sulfate is potentiated by clofibrate, a substance which 
lowers blood triglycerides (Gold, 1978). This combination would be expected to 
inhibit gluconeogenesis from both lactate and amino acids as well as reducing the 
supply of glycerol for conversion to glucose. It has been suggested that there is a 
substantial lipid contribution to gluconeogenesis in advancing cancer (Begg, 1955). 
The glycerol concentration in the plasma from cancer patients has been shown to be
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three times higher than that from control subjects and the glycerol turnover rate has 
also been shown to be significantly higher in cancer patients (Lundholm etaL, 1982). 
However, there is no useful agent which interferes with the conversion of glycerol to 
glucose.
Glycerol passes into the gluconeogenic pathway via phosphorylation to a -  
glycerol-L phosphate mediated by glycerol kinase (ATP): glycerol phosphotrans­
ferase, EC 2.7.1.30) followed by oxidation to dihydroxyacetone phosphate by the 
NAD-dependent glycerophosphate dehydrogenase (syn glycerol-3-phosphate: NAD 
2-oxidoreductase, EC 1.1.1.8). This study reports on the effect of derivatives of 
glycerol on glycerol kinase activity in vitro as well as the effect on glycerol conversion to 
glucose in vivo.
MATERIALS AND METHODS
(U-14C] Glycerol (sp. act. 171 mCi/mmol) and D -[U -14C] fructose (sp. act. 330 mCi/ 
mmol) were obtained from Amersham International PLC., Bucks. E. coli glycerol ki­
nase was purchased from Sigma Chemical Co., Dorset.
(± ) -2,3-Dihydroxypropyl Chloroacetate
Propan-1,2,3-trioI (18.4 g), chloroacetic acid (18.9 g) and 88% phosphoric acid 
(1.0 ml) were suspended in toluene (100 ml). This mixture was boiled under reflux 
with a Dean and Stark water separator until water evolution ceased (3 h) before being 
allowed to stand at ambient temperature for 16 h. Sodium hydrogen carbonate (24 g) 
was added, followed by methanol (300 ml). The suspension was filtered and the 
solvents were removed from the filtrate by evaporation under reduced pressure. The 
residue was distilled at 4 torr and the fraction boiling at 195-200°C was collected as 
2,3-dihydroxypropyl chloroacetate [lit (Merry, 1981) BPto, 130°C]. Yield 24.1 g 
(71.5%). Y™* (liq. film): 3300 (br), 1745 cm"1. 6[(CD3)2S 0 + D ,0 ]:  3.6-3.8 (3H) m 
C(3)H,+C(2)H; 4.15(2H) d (J=7 Hz) C(1)H2; 4.3 (2H)s OCOCH,Cl.
(± ) -2,3-Dihydroxypropyl Dichloroacetate
Prepared as for (±)-2,3-dihydroxypropyl dichloroacetate using propan-1,2,3-triol 
(18.4 g), dichloroacetic acid (25.8 g), 88% phosphoric acid (1.0 ml) and toluene 
(150 ml). Fraction BPt, 220-8°C collected [lit (Merry, 1981) BP^-. 159°CJ. Yield 
31.2 g (77%). yma, (liq. film): 3350 (br), 1760 cm -'. 6[(CD ;)^SO+D,0]: 3.6-3.8  
(3H)m C(3)H,+C(2)H; 4.35 (2H) d (J=7 Hz) C(1)H2; 6.2 (lH )s OCOCHCU.
(±)-l-Chloropropan-2,3-diol was purchased from Aldrich Chemical Co. Ltd., and 
(±)-2,3-dihydroxypropyl acetate from Koch-Light Ltd.
Inhibition o f glycerol kinase activity The incubation mixture consisted of 50 mM 
Tris-HCl, pH 7.0, 2 mM MgCL, 0.5 pmole ATP, glycerol kinase (0.24 U/assay) plus 
or minus the inhibitor. After incubation at 37°C for 10 min the reaction was initiated 
with 25 nmoles of [U 14C]glycerol (sp. act. 0.01 m Ci/mmol) to give a final reaction 
volume of 0.5 ml. After a further 10 min incubation the reaction was terminated with 
0.5 ml of cold 2 M glycerol, followed by thorough mixing. Samples (50 ptl) were 
spotted on DE 81 phosphocellulose discs (Whatman, Maidstone. Kent) and the discs 
were washed extensively in 0.1 M glycerol. Essentially all of the [' C]glycerol-3- 
phosphate was retained by the filters, while the excess radioactive glycerol was
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removed. The discs were eluted with 1 ml of 0.1 N HC1 in scintillation vials and the 
radioactivity determined in PCS scintillation fluid (Hopkin and Williams).
Animal studies In vivo experiments with (±)-2,3-dihydroxypropyl dichloroacetate 
(III) were performed on CBA/CA mice which were starved for 24 h prior to the 
experiments. (±)-2,3-dihydroxypropyl dichloroacetate was dissolved in 10% DMSO 
in arachis oil and administered by i.p. injection. Controls received oil alone. For the 
determination of liver glycerol kinase, livers were removed from mice 2 h after 
injection of drug and homogenized in 3 ml of 150 mMTris-HCl, pH 7.5, containing 5 
mM MgCl2, 25 mM 2-mercaptoethanol and 1 mM EDTA. The supernatant fluid, 
obtained after centrifugation at 18,000Xgfor 30 min, was assayed for glycerol kinase 
as described above. For the determination of glucose blood samples were taken from 
the tail vein at 1 h intervals, and the level of glucose was measured using dextrostix.
Separation o f glucose from fructose and glycerol in blood filtrates Formation of 
glucose from precursors was determined essentially by a method of Friedmann, 
Goodman and Weinhouse (1970). Mice were injected with [U -,4C] glycerol (10 mg, 
2.5 pCi/animal) or D -[U -,4C]fructose (10 mg, 3.2 pCi/animal) 2 h after drug 
injection. Blood samples were taken by heart puncture 30 min after injection of label. 
A protein-free filtrate was prepared from 1 ml blood, 1.5 ml water, 1.5 ml 0.3M 
Ba(OH)2 and 3 ml 5% Z nS04. After centrifugation the supernatant was passed 
through a 9x0.6 cm column of Amberlite MB-3 H C 03~ and the column was washed 
with water to a volume of 10 ml. The filtrate was allowed to stand overnight with 1 mg 
of carrier glucose and 2 mg (20 U) of glucose oxidase and the gluconic acid formed was 
neutralized to a phenolphthalein end-point with 1 mMNaOH. The entire solution was 
passed over a 6X0.6 cm column of Amberlite C G -400,100-200 mesh and the column 
was washed to an eluate volume of 15 ml. Gluconic acid was removed from the resin by 
washing with 15 ml 0. lM NaCl. Radioactivity in the two fractions was determined in 
PCS scintillation fluid.
RESULTS
(±)-2,3-Dihydroxypropyl acetate (I), (±)-2,3-dihydroxypropyl chloroacetate (II) 
and (±)-2,3-dihydroxypropyl dichloroacetate (III) were effective inhibitors of 
glycerol kinase in vitroy the respective ED50 (concentration required for 50% 
inhibition of enzyme activity) being 1.32,0.88 and 0.33 mM respectively. There was 
no inhibition by l-chloro-2,3-propane diol or 2,2,4-trimethyl-4-(phenyl- 
oxymethyl)dihydrodioxole at concentrations up to 25 mM. Maximum inhibition was 
seen with ATP in the inhibition assay; the ED50 for III was increased to 1.11 mMin the 
absence of ATP. This suggests the possibility of phosphorylation of the glycerol ana­
logues, followed by product inhibition of the enzyme, and explains the need for a free 
terminal primary alcohol group. Lineweaver-Burk plots (Figure 1) indicated that III 
inhibited glycerol kinase noncompetitively with an apparent inhibition constant, Kiy of 
1.8x 10-3M. The Km of the purified enzyme towards glycerol was 0.4 mM. In the 
absence of glycerol inhibition of glycerol kinase by III increased with time of 
incubation.
F orm ation o f  a -g ly cero p h o sp h a te  by m ouse liver glycerol k inase  increased linearly  
with reaction tim e and  w as p roportional to  the  p ro tein  co n c en tra tio n  in the assay 
(Figure 2). P re treatm en t o f  mice for 2 h w ith III caused a dec rease  in the specific




FIGURE 1 Double reciprocal plot of the initial velocity of glycerol kinase versus glycerol concentration in 
the absence (V—V) and in the presence of 1.6 (° —°) and 2 mM (° —°) glycerol diacetylchloride.
activity o f the enzym e which increased with increasing concentra tions of the inh ibitor 
(F igure 2). T hese results suggest that III could be an effective inh ib ito r of 
gluconeogenesis from  glycerol in vivo.
T he effect o f III on  precursors for gluconeogenesis is shown in Table I. Increasing 
concentrations o f III caused a reduction in the ratio  of glucose to  glycerol indicating  in ­
hibition o f gluconeogenesis from  glycerol, while the g lucose/fructose ratio  increased , 
except at the highest dose em ployed. A t 625 m g /k g  the g lucose/fructose ratio  was 
significantly elevated  while the  g lucose/glycerol ratio  was unaltered. T hese results 
suggest that of the enzym es o f gluconeogenesis only glycerol kinase is inhibited by III.
TABLE I
Effect of (±)-2,3-dihydroxypropyl dichloroacetate on gluconeogenesis from [L-*C | glycerol and 
D-JU-'^C) fructose in CBA/CA mice
Dose mg/kg |JC glucose/1JC glycerol UC glucose/l4C fructose
0 5.3±0.3 3.7 3 10.6
313 5.3±0.5 3.53x0.5
625 5.5±0.7 6.1 r 0.7
1250 0.4±0.05 5.3 x0.5
2500 0.4 ±0.1 !.: rO.l
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The results in Figure 3 depict the hypoglycemic effect obtained with III in mice 
which had been starved for 24 h after i.p. injections of 250,500, 1000, 2500 or 5000  
mg/kg. A significant decrease in blood glucose between control and treated groups 
was obtained 3 h after treatment. With the two higher doses (1000 and 2500 m g/kg) 
the effect persisted over a 5 h period, while with 5000 mg/kg the mice died. Hence the 
magnitude and duration of the hypoglycemic effect are dose-dependent.
There was no effect of III on UC 0 2 release from D -(U -I4C) glucose by mouse TLX5 
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FIGURE 2 Effect of (±)-2.3-dihydroxypropyl dichloroacetate on mouse liver glycerol kinase. Mice were 
injected i.p. with 625 ( •—•). 1250 ( ' —-)or 2500 m g/kg(V —7 ) of (±)-2.3-dihydroxypropyl dichloroacet­
ate or vehicle alone (x—x) and the activity of liver glycerokinase was assayed 2 h afterwards.
DISCUSSION
Gluconeogenesis from glycerol may be of importance in cancer patients demon­
strating hyperlipemia or in subjects fed a high lipid diet to induce ketosis (Magee etal., 
1979). We have been attempting to reduce the supply of glucose to the tumor either by 
dietary or other means and for this reason analogues of glycerol have been investigated 
as potential inhibitors of glycerol kinase, the first enzyme in the pathway from glycerol 
to glucose. One such analogue, (±)-2,3-dihydroxypropyl dichloroacetate (III), 
proved to be an effective inhibitor of this enzyme, both in vitro and in vivo. Blood 
glucose levels are rapidly reduced after administration of this agent. The decrease 
in blood glucose probably arises from an inhibition of gluconeogenesis from 
glycerol, since gluconeogenesis from D-fructose is increased under such conditions 
and glycolysis is not affected. At 625 m g/kg of III gluconeogenesis from fructose is 
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Time (h)
of (±)-2,3-dihydroxypropyI dichloroacetate on blood glucose levels. Mice were 
vehicle alone (x—x) or with 250 ( • —•). 500 ( ° —°) 1000 (V—V). 2500 (▼—T) or 5000 
)-2.3-dihydroxypropyl dichloroacetate. Samples (50 pi) of blood were taken from the 
ils and the concentration of glucose was determined using dextrosux. Data for each dose 
rom a single animal. The experiment was repeated five times and the results are the data 
lent.
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doses of III cause a rapid decrease in blood glucose and death within 2 h. The toxicity 
of III is probably not due to inhibition of the glycolytic pathway since pharmacological 
concentrations had no effect on l4C 02 release from D-[U-I4C] glucose by TLX5 
mouse lymphoma cells in vitro. It is possible, however, that III could become 
incorporated into membrane lipids.
Recent results (Graziani, Erikson and Erikson, 1983) provide evidence that pp60'rc, 
the Rous sarcoma virus transforming gene product, is associated with glycerol kinase 
activity. Although the physiological significance of this enzyme production has still to 
be elucidated, it seems probable that inhibitors of glycerol kinase activity may directly 
subvert the transformation associated processes.
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The Formation and Metabolism of A-Hydroxymethyl Compounds. Part 6. 
The Synthesis of S'-(Amidomethyl)-, ^-(Ureidomethyl)- and 
iS-( 1,3,5-Triazin-2-ylmethyl)-Glutathione derivatives
S. J. Addison, B. D. M. Cunningham, E. N. Gate, P. Z. Shah and M. D. Threadgill
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y l a m i n o m e t h y l ) - g l u t a t h i o n e  D e r i v a t i v e s
Sally J. Addison, Bernadette D. M . Cunningham, E. Nicholas Gate, Prakash Z. Shah, and 
M ich ae l D. Threadgill *
Cancer Research Campaign Experimental Chemotherapy Group. Department of Pharmaceutical Sciences. 
University of Aston in Birmingham. Gosta Green. Birmingham B4 7ET
Treatment of /V-hydroxymethyl and /V-alkoxymethyl compounds with glutathione or /V-acetylcysteine in 
trifluoroacetic acid affords the corresponding glutathione or /V-acetylcysteine derivatives in high yield. 
Alkoxymethylureas are formed by the condensation of ureas with formaldehyde and alcohols under basic 
conditions; the implications of this observation are discussed with reference to possible biochemical 
mechanisms.
iV-Hydroxymethyl compounds are produced by the metabolism 
o f drugs and other materials containing JV-methyl groups, by 
preparations o f  murine liver.2 It has been reported that, for 
example, the antitumour agents hexamethylmelamine ( l ) 3 and 
A/-methylformamide (2)* and the herbicide Monuron [W-(4- 
chlorophenyl)-jV',jV'-dimethylurea] (3 )5 are hydroxylated by 
this route which involves cytochrome P450. These hepatic 
m etabolites containing the carbinolamine moiety may act as 
electrophiles, either through the intermediacy of a small 
equilibrium concentration o f  the corresponding iminium ion (a 
dehydration product) or through biological derivatisation of  
the alcohol (e.g. sulphation, acetylation) which increases its 
leaving group ability. As electrophiles, they may be predicted to 
be conjugated in vivo (either enzymatically or chemically) to 
glutathione (y-glutamylcysteinylglycine)6 and hence be excreted 
as the glutathione conjugate (4) itself or as the corresponding 
mercapturic acid (5). Any or all of these compounds may be 
electrophiles in their own right (with RS " as a leaving group), 
or may act as transport forms o f formaldehyde and thus be 
present as toxic or carcinogenic metabolites. We sought 
therefore to prepare a range of such S-aminomethyl com­
pounds.
The synthesis o f  one such S-aminomethylglutathione deriv­
ative has been reported recently,7 albeit in low yield, from the 
Mannich-type condensation o f  4-aminoazobenzene with form­
aldehyde and glutathione (6) in an aqueous medium. A 
modification o f this technique enabled us to prepare the N- 
acetylcysteine-melamine adduct (7) in good yield. Glutathione 
is insoluble in the aqueous methanol employed and. not 
surprisingly, failed to react under these conditions. The 
mechanism presumably involves a methylene-iminium ion 
(Scheme 1). It is interesting to note that benzamide did not 
condense with N-acetylcysteine and formaldehyde under these 
conditions, the starting materials being recovered; thus any N- 
hydroxymethylbenzamide formed is not in equilibrium with 
sufficient imine or iminium species to effect condensation.
However, dissolution o f  equimolar amounts o f preformed N- 
hydroxymethyl-/V'.N'„/V',N".Ar '-pentamethylmelamine(8)orN- 
hydroxymethylamides (9) and (10) in ca. 0.7M-solutions o f  
glutathione in anhydrous trifluoroacetic acid (TFA). followed 
immediately by evaporation of the solvent under reduced 
pressure, gave the condensation products in consistently high 
yields. The use o f TFA is apposite in that it acts both as a good 
solvent for the otherwise troublesome glutathione and as an 
acid catalyst o f low nucleophilicity for the generation o f  
iminium ions for capture by the nucleophilic thiol. The 
condensation o f A'-acetylcysteine with W-hydroxymethyl-4-t- 






















generate the methylene-iminium ion under these conditions by 
elimination o f  water in the reverse sense from 4-chloro-A’- 
methylbenzohydroxamic acid s (12) as shown in Scheme 2.
The N-hydroxymethylamides (9) and (10) and N -hydroxy- 
methyl(pentamethyl)melamine (8 g) used above were prepared 
without difficulty in the usual way from the corresponding NH  
compound, formaldehyde, and base in an appropriate solvent 
However, on attempting to prepare the N-hydroxymethylureas
(11). we were unable to repeat the work of Zigeuner et a lq who 
warmed phenylurea (13a) with paraformaldehyde and sodium
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Schem e 1. P rop osed  m echanism  o f  form ation o f  com p ou nd  (7 ) via the 
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Schem e 3. F orm ation  o f  the alkoxym ethylureas (14a— c)
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b; R =  H
( 11 )
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b; R =  Cl
hydroxide in methanol. In our hands, the sole isolable product 
was N-methoxymethyl-AT-phenylurea in very low yield. 
Increasing the reaction time and temperature enabled the three 
representative alkoxymethylureas (1 4 a —c) to be synthesised 
smoothly in the appropriate alcohols, as in Scheme 3. 
Alkoxymethylureas are reported9 to be formed when N- 
hydroxymethylureas are treated with an alcoholic hydrogen 
chloride solution, thus favouring the necessary iminium ion 
formation; nevertheless, a small but significant equilibrium 
concentration o f arylurea methylene-iminium or methylene-
lmtne moieties must be present even under the mildly basic 
conditions of our experiments.
The alkoxymethylureas (1 4 a )  and (1 4 b )  are found to react 
with glutathione, and (1 4 a )  with A'-acetylcysteine, as readily as 
the Af-hydroxymethylamides. Direct ‘H n.m.r. monitoring of 
these reaction mixtures reveals that the condensation is 
complete within 2 min, but that only after 20 min has all the 
methanol or ethanol released been esterified by the tn- 
fiuoroacetic acid; this implies that the rate o f  the reversible 
methylene-iminium ion formation is unaffected by the rate at 
which the alcohol is irreversibly sequestered.
The structural assignment o f the synthetic conjugates is based 
on spectroscopic data. The characteristic feature of the ‘H 
n.m.r. spectrum o f compounds (1 5 )  and (1 6 )  [(C D 3)2SO; 220 
MHz] is the resonance o f the NCH2S moiety which appears as 
two separate sets o f  signals, indicating that the prochiral





A c H N  CO? H 
(15)
a; R = 4-Bu'C6H4CO 
b: R = PhNHCO
( 16)
a; R‘ = H. R2 = CF3C 02 ' 
b; R' = 4-Bu‘C6H*. R2 = picratc' 
c; R' = Ph. R2 = CFjCOj* 
d; R1 = PhNH. R2 =  CFjC02 ‘ 
e; R1 = 4-ClC6H*NH. R2 = CFjCOj'
methylene group is in an asymmetric environment. This effect is 
well illustrated in the 'H n.m.r. spectrum of compound (16b) in 
which the N C H 2S resonances appear at 5 4.46 (1 H. dd, / 1 3  and
6.5 H z) and 4.57 (1 H, dd, J  13 and 6.5 Hz). Treatment with 
deuterium oxide removes the corresponding NH triplet at 6 9.16 
and its 6.5 Hz coupling, leaving the 13 Hz geminal coupling 
typical o f  an asymmetric methylene group; this contrasts with 
the corresponding 2 H singlet in the spectrum of the achiral 
substrate (10a). As expected, the cysteine (3-CH2 is prochiral. 
The coupling constants in the spectrum o f the benzamidomethyl 
glutathione compound (16c) are typical, with geminal coupling 
constants J tUB2 14 Hz, 10.5 Hz, and J t2,a 4 Hz. From a 
simplified Karplus analysis, it can be deduced that the molecule 
adopts one o f the staggered conformations about the Ca- C # 
bond shown in the Figure. As predicted from steric con­
siderations, the benzamidomethylthio group is gauche to one o f  
the peptide links and irons to the other (Figure). The *H n.m.r. 
spectrum o f  the formamide (16a) was more complex, indicating 
approximately equal populations o f two rotamers about the 
formamide carbonyl-nitrogen bond.
T w o main conclusions can be drawn from these results. 
Firstly, since alkoxymethylureas are formed under basic con­
ditions and are stable under such conditions, there must be a 
small but significant equilibrium proportion of the corres­
ponding iminium ions or imines under these very basic 
conditions. It is therefore reasonable to postulate that an equal 
or higher equilibrium proportion o f iminium ions or imines is 
present under the much less basic physiological conditions (pH 
7.4). Hence it is feasible that the methylene-iminium ions 
formed directly from the dehydration o f  ;V-(4-chlorophenyl)-jV'- 
hydroxymethylurea. a known metabolite o f Monuron,5 or from 
jV-hydroxymethyl(pentamethyl)melamine may. as proposed10 
for jV-hydroxymethylamines (in which immium ion formation 
is more favoured), be the actual electrophile responsible for 
biological activity (mutagenic.11 antineoplastic, or antibacter­
ial 10 respectively). Secondly, it is shown here that a rapid, facile
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,C 0G ly .COGly
Figure. Newman projections of the C,-C# bond of the S-benzamido- 
methylglutathione (!6c) conformers established by 'H n.m.r spectro­
scopy (R = PhCONHCH,)
synthesis o f  glutathione conjugates, putative metabolites o f  
some xenobiotic N-methyl compounds, is available. Since 
conjugation to glutathione is a common fate o f hepatically 
generated electrophiles, it is important to have such authentic 
material for chemical and biochemical study. No attempt has 
been made to prepare the free glutathione forms o f the 
glutathione derivatives from the salts, since the former would be 
expected to be released upon dissolution of the salts in the 
buffered aqueous media required for biochemical experiments.
Experim ental
I.r. spectra were determined as Nujol mulls, except where 
otherwise stated. *H N.m.r. spectra were obtained at 60 MHz 
using a Varian EM360A spectrometer and at 220 MHz using a 
Perkin-Elmer R34 instrument and 13C n.m.r. spectra were 
obtained with a Bruker WH-180. using tetramethylsilane as 
internal standard. M.p.s are uncorrected.
N-(4-Chlorophenyl)urea (13b).—This compound was pre­
pared in 81% yield according to the general method o f Fumiss 
ei a/.12 and had m.p. 208— 210 =C (lit.,13 204— 206 °C).
N-(4-Niiropheny[)urea (13c).— 4-Nitrobenzoic acid (8.35 g, 
50 mmol) and phosphorus pentachloride (10.4 g, 50 mmol) were 
heated together at 120 °C until gas evolution ceased. Toluene 
(15 ml) was added and the mixture was heated to 205 °C during 
which process all volatile materials were distilled off (mainly 
toluene and phosphorus oxychloride). On being cooled, the 
crystalline residue was dissolved in acetone (200 ml) and was 
added to sodium azide (10.0 g, 154 mmol) and sodium hydrogen 
carbonate (1.0 g) in water (40 ml). This mixture was stirred for 2 
h before being extracted with dichloromethane (2 x 200 ml). 
The combined organic extracts were dried (Na2SC%), filtered, 
and the solvents evaporated under reduced pressure to give 
almost pure 4-nitrobenzoyl azide as pale yellow prisms (vm„  
2 180, 2 120, and 1 675 cm '1). This azide, in toluene (60 ml), was 
boiled under reflux for 10 min after which a small evaporated 
sample showed v ^  2 250 c m 1, corresponding to 4- 
nitrophenyl isocyanate. The cooled toluene solution was added 
to a large excess o f  ethereal ammonia giving an immediate 
yellow precipitate. Recrystallisation from aqueous methanol 
yielded the urea (13c) (3.30 g, 37%) as lemon yellow needles, 
m.p. 214— 215 °C (lit..14 215 ;C) 6H [60 MHz; C D C lj-fC D j),- 
SO; 1:3] 6.1 (2 H, br, N H 2), 7.65 (2 H. d, J 9 Hz. A rH ). 8.12 (2 H. 
d, J  9 Hz, ArH). and 9.2 (1 H, br. NH).
N'-Ethoxymethyl-N-phenylurea (14a).—Paraformaldehyde (2 
g, 66.7 mmol of HCHO) was added to phenylurea (2.72 g, 20 
mmol) and sodium hydroxide (100 mg, 2.5 mmol) in a mixture 
o f ethanol (50 ml) and water (1 ml). The resulting suspension 
was boiled under reflux for 1.5 h before evaporation o f the 
solvent under reduced pressure. Recrystallisation o f  the residue 
from aqueous ethanol furnished the ethoxymeihylurea (14a) 
(3.41 g, 84%) as white needles, m.p. 105— 107 SC (Found: C. 
61.7; H, 7.1; N. 14.6. C IOH 14N , 0 ,  requires C. 61.85; H. 7.25; N. 
M.4%); v ^  3 250 and 1 660cm  •; 5H (60 MHz; CDC13) 1.12(3
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H, t, 2  7 Hz, CH 2C //3), 3.48 (2 H, q. 2  7 Hz, O C//2CH3X 4.60 (2 
H, d, J  7 Hz, NCHjO), 6 .8 6  (1 H, t, J  7 Hz, CONHCH2X 7.3 (5 
H, m, ArH), and 8.1 (1 H, s, ArNH).
N-(4-ChlorophenytyN ’-methoxymeihylurea (I4b).—Parafor­
maldehyde (3.0 g, 100 mmol of HCHO) and aqueous sodium 
hydroxide (10% w/v; 1.5 ml, 3.75 mmol) were added to N-{4- 
chlorophenyl)urea (15b) (5.12 g, 30 mmol) in methanol (60 ml). 
This suspension was boiled under reflux for 5 h before being 
cooled to 0 °C for 16 h. The solids were isolated by filtration and 
washed with a small volume of cold methanol to give the 
methoxymeihylurea (14b) as white needles (5.08 g, 78%), m.p. 
126— 128 °C (Found: C, 50.35; H, 5.3; N, 12.8. C ,H ,,a N 20 2 
requires C, 50.35; H, 5.15; N, 13.05%); Vmax 3400, 3 300, and 
1 630 cm '1; 8 „ (60 MHz; CDC13) 3.30 (3 H, s, OMeX 4.60 ( 2  H, d, 
J  7 Hz, NCH20), 6.93 (1 H, t, J  7 Hz, NHCH2OX 722(2 H ,d,29 
Hz. AzHX 7=45 <2 H ,d , 7 9  Hz, ArHX and 8.7 <1 H, br, ArNH).
'N-(4-Nitrophenyl)-N'-methoxymethylurea (14c).—Aqueous 
formaldehyde solution (37% w/v; 6.0 ml, 74 mmol) and 
paraformaldehyde (2.7 g, 90 mmol of HCHO) were added to N- 
(4-nitrophenyl)urea (13c) (530 mg, 2.9 mmol) and potassium 
hydroxide (640 mg, 11.4 mmol) in methanol (50 ml). This 
suspension was boiled under reflux for 3 h before evaporation 
o f the solvent under reduced pressure. Recrystallisation of the 
residue from methanol afforded the methoxymeihylurea (14c) 
(310 mg, 44%) as pale yellow needles, m.p. 163.5 °C (decomp.) 
(Found: C, 48.1, H, 5.1; N, 18.5. C ,H MN 30 4  requires C, 48.0; H, 
4.9;N,18.65%XvIIl„  3250andl 6 7 5 an '1;8„[60MHz;CDCl3-  
(CD 3)2SO, 20:1] 3.37 (3 H, s, OMe), 4.70 (2 H, d, 2  7 Hz, 
N CH 2OX 6.9 (1  H, br, NHX 7.70 ( 2  H ,d, 29 Hz, ArH), 820 ( 2  H, 
d, 2  9 Hz, ArHX and 9.1 (1  H, br, NH).
N-Acetyl-SA4-t-buiylbenzamidomeihyT)cysteine (15a).—N- 
Acetyl-L-cysteine (326 mg, 2 mmol) in trifluoroacetic add (3 ml) 
was added to N-hydroxymethyl-4-t-butylbenzamide (10a) 1 
(414 mg, 2 mmol). This mixture was stirred for 5 min at 2 0  °C 
before evaporation of the solvent at 35 °C and 1 Torr. The 
residue, in dichloromethane ( 2 0  ml), was washed with water ( 1 0  
ml). The solution was dried (Na2S 0 4), filtered and the solvent 
evaporated to give a colourless gum. Column chromatography 
(silica gel; CHCI3 with MeOH increasing from 0 to 15%) gave 4- 
t-butylbenzamide (90 mg, 26%) as a white powder identical with 
an authentic sample. 13 Evaporation of the solvents from later 
eluates afforded the cysteine derivative (15a) (413mg, 59%) as a 
white powder which decomposed on gentle heating (Found: C, 
57.6; H, 6.7; N, 7.7. C 17H24N 20 4S requires C, 57.95; H, 6.85; N, 
7.95%); v„„ 3 300, 3 100,1 715, and 1 665 cm"1; 5„ [220 MHz; 
(CD 3)2SO] 1.30 (9 H, s, CMe3), 1.87 (3 H, s, AcX 2.95 (1 H, dd, 2  
7 and 13 Hz),and 3.16 (1 H. dd, 2 4  and 13 Hz) (cysteine CH2), 
3.5(1 H ,b r ,C 0 2H), 4.35(1 H,dt, 2 and 7 Hz, cysteine a-H), 4.48 
(1 H, dd, 2 6  and 13 Hz) and 4.52 (1 H, dd, 2  6  and 13 Hz) 
(NCHjS), 7.56 (2 H, d, 2 8  Hz, ArH), 7.83 (1 H, d, 2  7 Hz, 
AcN/fCys), 7.94 (2 H, d, 2 8  Hz, ArH), and 928 (1 H, t, 2 6  Hz, 
ArCONHCH2); m/z 352 (M+) and 190.
'N-Acetyl-S-(N'-phenylureidomethy[)cysteine (15b).—N'- 
Ethoxymethyl-Af-phenylurea (14a) (970 mg, 5 mmol) was added 
to iV-acetyl-L-cysteine (815 mg, 5 mmol) in trifluoroacetic acid 
( 6  ml). The mixture was stirred at ambient temperature for 15 
min before the solvent was evaporated at 2 Torr. Column 
chromatography of the residue (silica gel; CHC13—MeOH, 7:1) 
gave the cysteine derivative (15b) as a colourless gum (913 mg, 
59%) which could not be crystallised. A satisfactory micro- 
analysis could not be obtained, but the sample appeared to be 
pure by t.l.c and n.m.r. analysis, (liquid film.) 3  150, 1 705, 
and 1 660 cm"1; 5„ [220 MHz; (CD3)2SO] 2.10 (3 H, s, Ac), 2.89 
(1 H, dd, 2 8.5 and 13.5 Hz) and 3.07 (1  H, dd, 2  5 and 13.5 Hz)
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(cysteine CH2X 3.6 (1 H, br, C 0 2H), 4.41 (1 H, d, 2  6.5 Hz) and 
4.42 (1 H, d, 2 6.5 Hz) (NCH2S), 4.51 (1 H, dt, 2 5 and 8.5 Hz, 
cysteine a-H), 6 .8 6  (I H ,t,26.5 Hz,CON//CH2S),6.98(1 H .t,2  
8  Hz, ArHX 7.31 (2 H, t, 2 8  Hz, ArH), 7.48 (2 H, d, 2 8  Hz. ArH), 
8.32 (1 H, d, 28.5 Hz, AcNH), and 8.72 (1 H, s, PhNHCO); m/z 
311 (A/^X 149.
H-Acetyl-S-{N-[4,6-bis(dimethylamino)-1,X5-triazin-2-yf}- 
N-methylaminomethyI)cysteine (7).—A mixture of aqueous 
formaldehyde (37% w/v; 3 ml, 37 mmol), methanol (20 ml), N- 
acctyl-L-cysteine (1.0 g, 6.1 mmol) and 2,4-bis(dimethylamino)- 
6-methylamino-l,3,5-triazine16 (980 mg, 5 mmol) was stirred at 
37 °C for 2 h before being cooled to 0 °C for 1 h. The precipitate 
was filtered off and washed with a small volume of cold 
methanol to give the cysteine derivative (7) as a white powder 
(1.30 g; 70% based on the pentamethyl melamine) which 
decomposed without melting at < 60 °C (Found C, 45.55; H, 
6.9; N, 26.1. C14H 2 3N 70 3S requires C, 4525; H, 6 .8 ; N, 26.4%); 
v ^  3 230, 1 700, and 1 610 cm '1; 5„ [220 MHz; CDC13-  
(CD3)2SO, 2:1] 1.99 (3 H, s, Ac), 3.10 (1 H, dd, 27  and 13.5 Hz, 
cysteine P-H), 3.12 (12 H, s, NMe2), 3.14 (3 H, s, melamine- 
NRCHj), 3.24 (1 H, dd, 24.5 and 13.5 Hz, cysteine p-H), 3.76 (1
H. m, cysteine a-H), 4.88 (1 H. d, 2 14 Hz) and 5.07 (1 H. d, 2  14 
Hz) (NCH2SXand 6.92 (1 H.d,28 Hz, NH);6 C [(CD3)2SO] 22.17, 
32.00,32.44,35.39,40.35,40.79,51.92,164.97,169.06, and 172.10 
p.pjn. m/z 371.1737 (Cl4 H23N70 3S requires 371.1734) (M*),  
209(100%).
S-£N'-{4-Chloropheny[)ureidomethy[]glutathione Trifluoro-
acetate Salt Hydrate (16e).—A^-(4-Chlorophenyl)-Ar'-meth- 
oxymethylurea (14b) (429 mg, 2 mmol) was added to 
glutathione (614 mg, 2 mmol) in trifluoroacetic acid (3 ml). The 
mixture was stirred for 5 min before evaporation of the solvent 
under reduced pressure. The oily residue was triturated with 
diethyl ether to give a white powder. Dissolution of this material 
in acetone followed by reprecipitation on addition of diethyl 
ether and filtration furnished the glutathione derivative (16e) 
(1.09 g, 8 8 %) as a slightly hygroscopic white powder without a 
definite m.p. but which decomposed on gentle heating (Found: 
C, 38.3; H, 4.7; N, 11.0. C 20H27a F 3N jO 10S requires C, 38.6; H, 
4.4; N, 1125%X 3 150, 1 705. and 1 640 c m 1; 5„
• [(CD3)2SO] 207 (2 H. m, glutamyl p-CH2), 239 (2 H. m, 
glutamyl y-CH2), 2.74 (1  H, m, cysteine P-H), 3.05 (1 H, dd, 2
4.5 and 14 Hz, cysteine p-H). 3.83 (2 H, br, glycine CH2), 4.00 (1 
H, m, glutamyl a-H), 4.36 (1 H, dd, 27 and 13 Hz) and 4.44 (1  H, 
dd, 27  and 13 Hz) (NCH 2S), 4.63 (1 H, m, cysteine a-H), 7.35 (2 
H, d, 2 8  Hz, ArH), 7.53 (2 H. d. 2 8  Hz, ArH), and 8.4 (9 H, m, 
NH and OH).
S-Formamidomethylglutathione Trifluoroacetate Salt Dihy­
drate (16a).—This compound was prepared from N-hydroxy- 
methyl formamide17 (9) (150 mg, 2 mmol) and glutathione (614 
mg, 2 mmol) according to the method for (I3e) above, giving the 
glutathione derivative (16a) (966 mg, 94%) as a hygroscopic 
white solid without a definite m.p. (Found: C, 32.4; H, 5.2; N, 
10.6. C l4 H 25F3N40 1 ,S requires C. 32.8; H, 4.9; N. 1 1.0%); v ^ _  
3 200, 1 710, and 1 660 cm '1; 5„ [220 MHz; (CD3)2SO] 2.07 (2 
H, m, glutamyl P-CH2), 2.40 (2 H, m, glutamyl y-CH2), 2.6— 3.1 
(2 H, m, cysteine CH2), 3.85 (2 H, br s, glycine CH2), 4.00 (1 H. m, 
glutamyl a-H), 4.32 (0.5 H.dd.2 6 and 13 Hz) and 4.38 (0.5 H.dd. 
2 6  and 13 Hz) (NCH2S of rotamer AX 4.47 (0.5 H, d, 2 13 Hz, 
NCHS of rotamer B), 4.64 (1.5 H, m, cysteine a-H and NCHS of 
rotamer B), 8.17 (0.5 H. s. formyl HX 8.34 (0.5 H. s. formyl H). 
8.42 (5.5 H, m. NH and OH), 8.75 (0.5 H, ca. t. 2 6  Hz. 
HCONHCH2 of one rotamer), and 9.5 (2 H, br. NH and OH).
S-(4-t-Butylbenzamidomethyl)glutathione Picrate (16b).—N- 
Hydroxymethyl-4-t-butylbenzamide1 (414 mg, 2 mmol) was
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added to glutathione (614 mg, 2  mmol) in trifluoroacetic acid ( 3  
ml). The mixture was stirred at ambient temperature for 10 min 
before the solvent was evaporated at 2 Torr. The gummy 
residue was dissolved in acetone (20 ml) and 2,4,6-trinitrophenol 
(458 mg, 2 mmol) in methanol (4 ml) was added. The solvents 
were evaporated from this mixture under reduced pressure. The 
residue was precipitated from acetone solution by addition of 
diethyl ether to give the glutathione derivative (16b) (1J51 g  
93%) as a slightly hygroscopic bright yellow powder without 
definite m.p. (Found: C, 46.0; H, 5.0; N, 13.3. C28H 35N70 14S 
requires C, 46.35; H, 4.85; N, 13.5%);[>]D23 -21 .7°( c l7.5%w/v 
in dimethyl sulphoxide); v„„ 3 150, 1 705, 1 650, 1 515, and 
1 345 cm '1; 6 „ [(CD 3)2SO] 1.31 (9 H, s, CMe3), 2.05 (2 H, m, 
glutamyl fl-CH2), 2.40 (2 H, m, glutamyl y~CH2), 278 (1 H ,dd,7 
9and 14 Hz) and 3.10(1 H, dd, 7  4 and 9 Hz) (cysteine CH2X 3.7 
(5 H, br, C 0 2H and RN+H3X 3.84 (2 H, d, J  5.5 Hz, glycine 
CH2X 4.00(1 H, t, 7  7 Hz, glutamyl a-HX 4.46 (1 H ,dd,76.5 and
13 Hz) and 4.57 (1  H, dd, J  6.5 and 13 Hz) (NCH2SX 4.68 (1  H, 
dt, J  4 and 9 Hz, cysteine a-H), 7.57 (2 H, d, J  8.5 Hz, benzamide 
ArH), 7.89 (2 H, d, J  8.5 Hz, benzamide ArH), 8.35 (1 H, t, 7  5.5 
Hz, glycine NHX 8.40 (1 H, d, J  9 Hz, cysteine NH), 8.67 (2 H, s, 
picrate ArH), and 9.16 (1 H, t, J  6.5 Hz, ArCONH).
S-Benzamidomethylglutathione Trifluoroacetate Salt Hydrate 
(16c).—W-Hydroxymethylbenzamide1 (302 mg, 2  mmol) and 
glutathione (614 mg, 2 mmol) were treated as for the 
preparation of (16e). This method afforded the glutathione 
derivative (16c) (1.929 g  90%) as a hygroscopic white powder 
without definite m.p. (Found: C, 40.7; H, 4.6; N, 9.2 
C20H 29F 3N4O11S requires C, 40.7; H, 4.95; N, 9.5%); [a] D23
—16.2° (c 39% w/v in water); v  3 200 and 1 690 cm"1; 8 H [220
MHz; (CD3)2SO] 206 (2 H, m, glutamyl £-CH2), 238 (1H, dt, J
14 and 7 Hz), and 243 (1 H, dt, J 14 and 7 Hz) (glutamyl y- 
CH2X 289 (1 H, dd, 710.5 and 14 Hz) and 3.11 (1 H, dd, 74  and 
14 Hz) (cysteine C H 2X 3.83 (2 H, d, 7  7 Hz, glycine CH2), 4.01 (1  
H, m, glutamyl a-H), 4.48 (I H, dd, J  6  and 13.5 Hz) and 4.55 (1 
H ,dd ,76and  13.5 Hz) (NCH2S), 4.69(1 H, ddd ,74 ,6 , and 10.5 
Hz, cysteine a-H), 6.0 (1 H, br, NH or OH), 7.57 (2  H, t, 7 7 Hz, 
ArH), 7.62 (1  H, t, J  7 Hz, ArHX 7.94 ( 2  H, d, J  7 Hz, ArHX 8.38 
( 6  H, m, NH ±  OHX and 9.24 (1  H, t, J  6  Hz, PhCONH).
S-(N'-Phenylureidomethyl)glutathione Trifluoroacetate Salt 
Dihydrate (I6d).—This compound was prepared from N-ethoxy- 
methyl-W'-phenylurea (14a) (388 mg, 2 mmol) and glutathione 
according to the method for (16e) above. The glutathione 
derivative (16d) (1.031 g  90%) was obtained as a slightly 
hygroscopic white powder without a definite m.p. (Found: C, 
39.8; H, 4.7; N, 11.5. C joH ^F jN jO j 3 requires C, 39.65; H, 5.0;
N, 11.55%); [a] D23 — 31.0° (c 25% w/v in water); v 3 150 and
1 685 cm-1; S„ [220 MHz; (CD3)2SO] 2.08 (3 H, m, glutamyl p- 
CH2 and cysteine NH), 2.40 (2 H, m, glutamyl y-CH2), 2.76 (1  
H, dd, J 10 and 14 Hz) and 3.04 (1  H, dd, 74  and 14 Hz) (cysteine 
CHj), 3.81 (2 H, d, 7 7  Hz,glycine CH2), 4.01 (1  H, m, glutamyl 
a-H), 4.37 (I H, dd, 7 7 and 13.5 Hz) and 4.46 (1 H, dd, 7 7 and
13.5 Hz) (NCHjS), 4.46 (1 H, m, cysteine a-H), 6.99 (1 H, t, 7  8  
Hz, ArH), 7.20 (1 H, t, 7 7 Hz, glycine NH or CON//CH2S), 7.31 
(2 H, t, 7  8  Hz, ArH), 7.50 (2 H, d, 7 8  Hz, ArH), 8.4 (5 H, br, NH 
and OH), and 9.02 <1 H, s, PhNH).
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S-{ H-[4,6-Bis(dimethylamino)-1,3£-triazin-2-yl)-H-methyl- 
aminomethyl}glutathione Trifluoroacetate Salt.—This com­
pound was prepared from 24-bis(dimethylamino)-6-(A/-hy- 
droxymethyl-jV-methy lami no)-1,3,5-triazine16 (452 m g 2 
mmol) and glutathione (614 m g 2 mmol) as for (13e) above; the 
glutathione derivative (520 m g 51%) could not be purified 
without decomposition. *H N.m.r. spectroscopy indicated this 
white non-hygroscopic powder to be ca. 85% pure; v~.. 3 300 
and 1 660 cm '1; 8 „ [220 MHz; (CD3)2SO] 206 (2 H, m, 
glutamyl P-CH2), 239 (2 H, m, glutamyl y-CH2), 274 (1 H, m) 
and 3.03 (1  H, m) (cysteine CH2), 3.06 (12 H, s, NMe2), 3.16 (3 
H, br, s, melamine-NRC//3), 3.80 (2 H, br s, glycine CH2), 3.99 
(1 H, m, glutamyl a-H), 4.58 (1 H, m, cysteine a-HX 4.74 (1  H, d, 
713 Hz) and 5.08 (1 H, d, 7 13 Hz) (NCH2S), and 8.4 (7 H, m, 
NH and OH).
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A  series of N-hydroxymethylamides, RCONR'CH 2 O H , and their O m eth y l and O-acetyi derivatives, have 
been studied by UC and 1H magnetic resonance spectroscopy. Signals have been assigned to the E- and 
Z-isomers on the basis of the analysis of the fully coupled spectra, and by comparison of the chemical shifts 
with those of model compounds. The introduction of the hydroxy, alkoxy or acetoxy groups at the a-position  
o f  the N-alkyi moiety causes a significant shift in the equilibrium towards the E-rotamer compared with the 
unsubstituted N-alkyiamide. The predominant effect in determining the E :Z  ratio appears to be the steric 
interaction between the carbonyl oxygen and the o-oxygen  in the alkyl moiety; intramolecular hydrogen 
bonding does not play a significant role in determining the rotamer populations of these molecules.
INTRODUCTION
R otational isomerism (A Z  ^  A E ) in N-alkylam ides 
has been  extensively studied using 13C NM R spectro­
scop y1,2 and, recently, with 1SN natural abundance 
sp ectroscopy .3 In N-m ethylform am ide, the Z -isom er  
is preferreid by a factor o f 9 :1  over the E -isom er . 1 
This present study o f the *H and 13C NM R spectra of 
a series o f  N-hydroxym ethylam ides, and their deriva­
tives, w as undertaken to assess the effect o f the a -  
situated oxygen substituent on the chemical shifts in 
the am ide and on the rotational equilibrium A Z  ^  
A E . T h e  presence o f a hydroxy group in R' introduces 
the additional possibility o f hydrogen bonding, such as 
show n in B , which could exert a significant effect on  
the rotational equilibrium.
\  / R 
C — N








 ^ B \
N-H ydroxym ethylform am ide (H C O N H C H 2OH) 
has acquired special significance as a m etabolite o f the 
anti-tum our agent N-m ethylform am ide (NM F ) .4 In 
structure-activity studies o f a large number o f am ides,
* A uthor to  whom  correspondence should be addressed, 
t  Pan V  in the series T h e  Formation and M etabolism of N- 
Hydroxym ethy! C om pounds.' For Pan IV. see  Ref. 7
N M F was found to be the m ost potent inhibitor of 
tum our growth; small changes in structure, such as 
substitution o f  the methyl with an ethyl group, result 
in loss o f activity .5 N -H ydroxym ethylform am ide (1) 
has been identified as a urinary m etabolite o f NMF* in 
m ice, and although it does not possess the anti-tum our  
efficacy o f  N M F  against murine tumours in vivo , it is 
active against the human mammary tumour xenograft 
(M X -1 ) .7
Som e N-hydroxym ethylam ides (carbinolam ides) can 
be synthesized readily by reaction o f the appropriate  
am ide with form aldehyde ,8 whereas the analogous 
carbinolam ines (R N H C H 2OH) usually revert spon­
taneously to  the com ponent alkylamine and form al­
d eh yd e .9 A m ongst N-hydroxym ethylam ides, there is 
often  considerable variation in stability. For exam ple, 
N-hydroxym ethylbenzam ide (6 ) is a stable crystalline 
substance, readily available from the reaction o f  ben­
zam ide and formaldehyde; however, N -m eth y l-N -  
hydroxym ethylbenzam ide (PhCO NCH 3C H 2O H ) has 
not been synthesized chem ically, although it has been 
generated m etabolicallv from N ,N -d im ethyl- 
benzam ide . 10 T h e  foregoing observations suggest that 
all carbinolam ides of structure R C O N H C H 2O H, 
w here R =  H , alkyl or aryl, are stable; substitution of 
the am ide N H  by alkyl groups has a destabilizing  
effect . 11 It w as o f interest to exam ine the NM R spectra 
o f a series o f  carbinolamides in order to explore  
w hether or not intramolecular hydrogen bonding of 
type B is a significant factor in the geom etry o f these 
m olecules and, hence, influences their stability.
CCC-074SI-15 8 1 /S 5 /0023-0078S 02.50
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EXPERIMENTAL
Spectroscopy
Nuclear magnetic resonance spectra were obtained at 
360 MHz (proton) and 90.8 MHz ( 13C) with a Nicolet 
360 NB spectrometer. The chemical shifts are refer­
enced to TMS.
Materials
N-Methytfonnamide (9). This was purchased from Al­
drich Chemical Co. and redistilled (b.p. 65 °C at 
2 Torr) before use.
N-HydrorymethyKonnamide (1). Obtained by reaction 
of formamide with paraformaldehyde according to the 
method of G rady and Stott. 12 Analysis: found, 
C  31.73, H 6 .84 , N 18.22; calculated for C2H 5NO 2, 
C 32.00, H 6 .71 , N 18.66%.
N-Methoxymethytformamide (2). Aqueous potassium 
hydroxide (40%) (2 ml) was added to  a stirred mixture 
of formamide (45 g) and paraformaldehyde (33 g). 
A fter 0.5 h, methanol (200 ml) and concentrated sul­
phuric acid (3 ml) were added to the clear mixture, 
which was stirred for a further 6  h. A fter filtration to 
remove a white precipitate, dry diethyl ether ( 2 0  ml) 
was added to the filtrate, which was allowed to stand 
over sodium hydrogen carbonate overnight. A fter filt­
ration, the mixture was concentrated under reduced 
pressure and the residue dissolved in water (50 ml) 
and extracted with dichloromethane (5 x 100 ml). The 
combined extracts were washed with water, dried and 
evaporated under reduced pressure to  give an oil 
( 1 2  g), which was distilled under reduced pressure. 
Three fractions were collected: (i) 1.9 g, b.p. 80-90 °C 
at 3 T orr; (ii) 1.7 g, b.p. 90-98 °C at 3 Torr; and (iii)
2.4 g, b.p. 98-110 °C at 3 Ton- (lit. , 13 b.p. 55-58 °C at 
0.1 Torr).
Fractions (i) and (ii) were combined and purified by 
chromatography on a  silica gel (Merck, 70-230 mesh) 
column (60 x 1.5 cm i.d.) with chloroform as the 
eluent. Chloroform fractions were concentrated at 
room tem perature under reduced pressure (2 Torr) to 
afford N-methoxymethylformamide as a colourless liq­
uid (0.7 g). The product gave a single spot with R F
0.5 on TLC using 5%  methanol in chloroform on silica 
gel, developed with iron(III) chloride after conversion 
to the hydroxamic acid . 14 Gas chromatographic 
analysis of the product (l% w /v  solution in acetone), 
injected on to a glass column (1.5 m x 4  mm i.d.) 
packed with 10% w/w PEGA on Chromosorb W AW 
DMCS (100-120 mesh) maintained at 180 °C in a Pye 
Unicam 204 gas chromatograph with the injector and 
detector maintained at 200 and 250 °C, respectively, 
gave a single peak with retention time 4.3 min (carrier 
gas, N2 at a flow-rate of 25 ml m in-1) using flame- 
ionization detection (H2, 45 ml min-1: air,
325 ml min ,).
/V-Hydroxymethyl-N-methytfonnamide (3). This was 
synthesized by the method of Grady and S to tt12 from 
9 and paraformaldehyde.
/V-Acetoxynjethyl-N-methylfonnamide (4). Crude N- 
acetoxymethyl-N-methylformamide was synthesized 
by the method of Ross et al.is The crude product 
(12 g) was dissolved in formamide (50 ml) and ex­
tracted with dichloromethane (3 x 150 ml). The lower 
layer was separated and washed with w ater (75 ml), 
dried and evaporated under reduced pressure to  yield 
the acetate 4 as a pale yellow oil (4.7 g), free from N -  
methylformamide.
N-Hydroxymethylacetamide (5). This was synthesized 
by the method of Milkowski er al.16
N-Hydroxymethyibenzamide (6). A mixture of benz­
amide (20 g), formalin (50 ml) and potassium  carbon­
ate (20 g) in tetrahydrofuran (500 ml) was refluxed 
for 5 h, then left overnight at room tem perature. The 
organic layer was separated from a gummy residue 
and the solvent evaporated under reduced pressure. 
The residual oil solidified slowly and was recrystallized 
from ethyl acetate to give hydroxymethyIbenzamide. 
A further batch was obtained by dissolving the gummy 
residue in water and extracting the resulting dark red 
solution with ethyl acetate. The ethyl acetate  extracts 
were washed, dried and evaporated under reduced 
pressure to afford the second batch of the hydroxy- 
methylbenzamide (total yield 8 . 6  g, 34% ), m.p. 
115-117 °C (lit. , 17 m.p. 104-106 °C).
N-Hydroxymethyl-p- ten -butylbenzamide (8 ) was 
obtained in an analogous manner from p-rerr-butyl- 
benzamide (yield 8 6 % ), m.p. 133-134 °C (lit. , 18 m.p. 
134-135 °C); « w  3230 and 1645 cm "1.
N-Acetoxymethylbe nzamkle (7). N-Hydroxymethyl-
benzamide (5 g) and acetic anhydride (2.4 ml) were 
dissolved in KOH-dried, redistilled pyridine (13.3 ml) 
and stirred for 48 h a t room tem perature. T he clear 
solution was poured over crushed ice (28 g) and left 
in the cold overnight. The mixture was extracted with 
chloroform and the extracts were washed, dried and 
evaporated. The residual liquid was distilled under 
reduced pressure to afford N-acetoxy-methylbenzamide 
(0.53 g), b.p. 150 °C at 4 Torr. (This com pound has 
been reported 19 as the product of the lead  tetraacetate 
oxidation of hippuric acid and, although described 
as a ‘syrup,’ no physical data have been given.)
DISCUSSION
The preparation of N-hydroxymethylform amide (1 ) 
has been described.i: The reaction of form am ide with 
an anhydrous polymer of formaldehyde, preferably 
paraformaldehyde, in the presence of an alkali metal 
hydroxide as catalyst, is reported 12 to give *an almost 
water-white pure product in 98% yield.’ We have 
repeated this procedure, and also obtained a high yield 
of a colourless liquid that gave a C ,H ,N  analysis in
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agreem ent with the formula of hydroxymethyl- 
formam ide, Q H sN O j. H owever, such an analysis 
could also arise from a variety o f mixtures, e.g. (a) a 
1 : 1  mixture o f formamide and formaldehyde, (b) a 
1 : 1  mixture o f m ethylenebisform am ide  
[(H C O N H )2CH2] and bishydroxymethylformamide 
[H C O N (C H 2O H )J  or (c) a mixture containing all o f  
these species in addition to 1. Indeed, the lH NM R  
spectrum of a sample o f 1 prepared by Grady and  
Stott’s m ethod indicates that it is not pure N-hydroxy- 
m ethylform am ide. Further, the 13C spectrum  of this 
material is exceedingly com plex and shows eight sig ­
nals in the carbonyl-carbon region o f the spectrum, ca 
1 6 6 -1 7 2  ppm. Attem pts to  purify the hydroxymethyl- 
formam ide by chromatography or fractional distilla­
tion were unsuccessful. Clearly, spectral analysis o f  
this com plex mixture is not possible without reference 
to  m odel compounds.
N-M ethoxym ethylform am ide (2), which is a suitable 
m odel com pound, was obtained in a pure form by d is­
tillation and chromatography, and a com plete 'H and  
13C N M R  spectral analysis is possible. TTte 'H  NM R  
spectrum of 2  in D 20  clearly shows two rotational 
isom ers. The major rotamer (ca 60% ) is the Z -isom er  
(2Z ), which gives rise to  signals at 8 .32  (1 H , s, formyl 
CH), 4 .7 2  (2 H , d, J  7 .2  H z, C H ^  and 3 .3 6  (3 H , s, 
OM e) ppm. The minor rotamer (2E ) gives proton  
signals at 8 .20 (1 H , d, J  11.5 H z, formyl CH), 4.61  
(2 H , d, J  7 .2  H z, CHz) and 3 .3 2  (3 H , s, O M e) ppm. 
The N H  signals are broadened at ca 6 .0  and 5.7 ppm. 
The major difference between the spectra of the  
rotamers is in the coupling o f the formyl CH  and the
N H  protons. The trans coupling constant o f 11.5 Hz in 
2 E  is c lose  to the expected value for m onosubstituted  
form am ides . 1 The cis coupling constant is invariably 
lower in the Z-isom er (ca 2 .0  Hz in form am ides), and 
the apparent absence o f cis coupling in 2 Z  is probably 
attributable to the electron-withdrawing effect o f the 
— CH 2O C H 3 fragment (Taft a*  + 0 .6 4 ), which is 
trans -coplanar to the formyl proton in 2 Z .
T he 13C  N M R  spectrum of 2  confirms the presence  
o f the rotational isomers 2 Z  and 2 E  in both D 20  and 
CDC13 solutions. In the fully decoupled spectrum  in 
deuteriochloroform  (see Table 1), the m ajor isom er  
2 Z  gives rise to signals at 161.74 ( 0 = 0 ) ,  6 9 .7 2  (C H 2) 
and 5 6 .0 2  (CH 3) ppm. Corresponding signals from the 
m inor E -isom er 2 E a i t  seen at 165 .28 , 7 4 .55  and 
5 4 .7 8  ppm . T he conformations were assigned by com ­
parison o f  l3C -'H  coupling constants, obtained from  
the coupled  spectrum o f 2 in CDC13 (see  Table 2), 
with those reported for the corresponding conform a­
tions o f  N -m ethylform am ide .2 The carbonyl carbon of 
the Z -rotam er (2Z ) is identified by its larger '/(C H )  
value (1 9 5 .2  H z compared with 191.5 H z in 2E )  and 
by the equality o f 2J(C N H ) and 3J(C N C H ) (4 .3  Hz), 
resulting in the doublet o f quartets pattern in the fully 
'H  coupled  spectrum. T he corresponding absorption  
o f the E -rotam er is a doublet o f triplets with the 
2J (C N H ) not resolved. The value o f 6 .6 5  H z for 
3J(C N C H ) in 2E , compared with 3.1 H z in NM F, is an 
effect20 o f  the electronegative m ethoxy substituent on  
the coupled  system . The CH 2 absorptions o f the two 
rotam ers differ mainly in the observation o f an addi­
tional coupling, probably to the N H  proton, in the








R, C H ,_ R ,
E-Isomer
No. R, A R, 0-0 CM,
1 H H OH 167.28 67.25




3 H Me OH 167.26 69.45
4 H Me OAc 167.9 70.7
5 Me H OH 177.2 65.23
6 Ph H OH 168.4 65.04
7 Ph H OAc 167.65 64.54 .
8 p-r-Bu-
c6h«
H OH 168.7 65.32
9 H H H 166.5 26.8
35.9
36.4
A 0-0 CH, R, R» r3 S o lv e n t'
— 168.2 73.1 — — — A
56.02 165.28 74.55 — — 54.8 B
57.99 171.29 77.15 — — 57.2 A
f 22.51




(174.6 j 168.3 76.6 — 31.6 (174.7 jl A





_  _  _  169.75 30.3 — — — A
"Solvent: A  deuterium oxide: B. deuteriochloroform.
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3J( CNCHHCHj) 5.4 •
'JfCHMOy 142.1 141.9
^ /(cocH H ay 5.6 5.4
* Not resolved.
spectrum  of the Z-isomer. The methylene carbon of 
the E -isom er is a triplet of quartets, arising from the 
directly bonded C -H  coupling and the three-bond 
coupling to the O-methyl protons, whereas in the 
spectrum  of 2Z  the methylene carbon is observed as a 
triplet o f quintets. The additional multiplicity presum­
ably arises from coupling to the formyl proton, which 
is suitably situated in a trans -periplanar position in 2Z , 
unlike the  situation in 2E. The signals from the O - 
methyl carbons are quartets of triplets in both isomers.
The 13C spectrum of 2 in D20  is similar to that in 
CDCI3, showing two rotamers but with slightly m od­
ified chemical shifts for each carbon. The trend of the 
chemical shifts is similar in the two solvents; the 
carbonyl and methylene carbons of the Z-isomer ab ­
sorb a t higher field than those of the E-isomer. These 
assignments were used to assign the 13C signals of the 
rotam ers of hydroxymethylformamide (1) and other 
derivatives (Table 1). Hydroxymethylformamide is a 
m ixture o f E -  and Z-isomers with a slight preference 
for the  E-isomer, which has 13C signals at 168.2 
( 0 = 0 )  and 73.1 (CH2) ppm compared with 167.3 and 
67.25 fo r the Z-isomer.
These chemical shifts are remarkably close to  those 
observed in the rotamers of N-methyl-N-hydioxy- 
methylformamide (3Z  and 3E ), which shows a further 
pronounced shift in equilibrium towards the E-isom er 
(approximately 87% based on the relative intensity of 
the carbon signals a t 168.0/76.0 and 167.3/69.5 ppm). 
T he assignment of the signals at 35.9 and 31.1 ppm to 
the N-m ethyl carbons of 3Z  and 3E, respectively, is 
consistent with the general observation that N-methyl 
carbons which are syn to the carbonyl oxygen are 
invariably shielded relative to the anti case.2 The 
assignment of the  signals in the spectrum of 3 was 
confirmed by comparison with the spectrum of the 
O -acetate  derivative (4). which also shows a greater 
than 80%  preference for the E-isomer.
The preference for the E-isomer of the hydroxy- 
methylformamides in D ;0  is not shared by N - 
hydroxymethylacetamide (5). The m ajor form (ca 
90% ) is the Z-isom er with carbon signals at 177.2 
( C = 0 ) ,  65.23 (CH2) and 24.7 (CH3) ppm; the signals 
of the E-isom er appear at 179.6. 71.1 and 23.9 ppm. 
The carbonyl carbon atoms are deshielded relative to 
the formamide analogues, which is consistent with 
reported observations with NM F and acetamide.2 The 
proportion of E - and Z-isomers in 5 is similar to that 
in NM F itself; in the present work, the major (90%)
Z-isom er of NMF (9Z) had carbon signals in D20  at 
166.5 ( 0 = 0 )  and 26.8 (CH3) ppm, compared with the 
published values of 164.8 and 24.7 ppm.2 Compound 
9 E  has carbon signals a t 169.75 and 30.3 ppm (pub­
lished values 168.0 and 28.3 ppm). Significantly, both 
5 and 9  follow the general trend that the N-alkyl 
carbon which is syn to the carbonyl oxygen is shielded 
relative to the anti case.
The shift to the Z-isomer by the introduction of 
bulkier groups at the R  position is completed in the 
case of N-hydroxymethylbenzamide (6), which exists 
exclusively as the Z-isomer in CDC13. The single 
species (6Z ) has a carbonyl carbon which absorbs at
168.4 ppm and a methylene carbon at 65.04 ppm, in 
addition to the four different aromatic signals (Table 
1). The introduction of an electron-donating rert-butyl 
group in the para-position of 6  has no effect on the 
equilibrium; 8 Z  is a single species (Table 1) with 
chemical shifts almost identical with those of 6Z. The 
complete preference of the benzamides (6 and 8) for 
the Z-isom er could be an indication that intra­
molecular hydrogen bonding, of the type shown in B, 
is exerting an effect. However, the acetate derivative 7 
of N-hydroxymethylbenzamide also exists as a single 
species in CDC13; the chemical shifts of the carbonyl 
(167.65 ppm) and methylene (64.54 ppm) carbons 
show that the single species is also the Z-isom er. This 
observation suggests that intramolecular hydrogen 
bonding is not a significant factor in determining the 
equilibrium between E - and Z-isomers of N-hydroxy­
methylbenzamide, and that steric factors are more 
important. The preference of compounds 6, 7 and 8 
for the Z-isom er in CDC13 would thus be a consequ­
ence of steric interaction between the aryl and 
hydroxymethyl groups in the E-isomer.
In order to  determine if a strongly hydrogen- 
bonding solvent could cause a population change in 
the hydroxymethylbenzamides, spectra of 6 and 8 were 
recorded in DM SO-d6. However, these spectra were 
consistent with the presence of a single species, 6 Z  or 
8Z, although small differences in chemical shift were 
observed. For example, hydroxymethylbenzamide (6) 
gave the following chemical shifts in DM SO-d6: 166.2 
(C = 0 ) ,  134.2, 131.3, 128.2, 127.2 (aromatic) and 
62.9 (CH2) ppm.
Table 3 summarizes the results of analysis of the
Table 3. Percentage distribution of E - and Z - 
isomers of N-hydroxymethylamides 
and derivatives from NMR measure-
Compound
ments
Solvent Z<%) E(%) Nucleus
1 0 2 0 43 ± 5 5 7 ± 5 13C
CDC13 5 6± 4 4 4 ± 4 ,3C
2 CDCI3 5 8 ± 5 42 ± 5 ’H
. d 2o 62 38 ’H
3 DjO 13± 6 87 ± 6 ,3C
4 D20 17.6±0.5 82.4 ±0.5 ,3C
5 d2o 90.7 ±3.3 9.3 ±3.3 ,3C
6 CDCI3 1 0 0 — ,3C
7 CDCI3 1 0 0 — ,3C
8 CDCI3 1 0 0 — ,3C
9 D20 90.5±0.5 9.5 ±0.5 ,3C
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NMR spectra to determine the percentage distribution 
of E - and Z-isomers in compounds 1-9. In order to 
test the reliability of such data obtained from the 
relative intensities of signals in the 13C spectra, the 
methoxymethylformamide 2  was analysed by both *H 
and 13C NMR. The results are identical, within the 
limits of experimental error; much of the data in Table 
3 can only be obtained from 13C data, as the proton 
spectra are less well resolved in most cases. The most 
significant observation is the greater preference for the 
E-isom er shown by the hydroxy-, alkoxy- and 
acetoxy-formamides 1-4  compared with the simple N - 
methylformamide (9). This trend is counter to the 
predicted effect of hydrogen bonding (structure B), 
which should favour the Z-isom er. T he percentage of 
the Z -rotam er of N-methylformamide observed in 
this study (90.5%) is close to the reported value 
(92% ).21 Introduction of the O H  group in 1 o r the 
OMe group in 2 shifts the equilibrium towards the 
E-rotam er, so that an almost 1:1 mixture is observed 
in both cases; this observation must reflect an increase 
in steric interaction between the carbonyl oxygen atom 
and the oxygen atom in th e  N-hydroxymethyl o r N - 
methoxymethyl group. Introduction o f a methyl group 
in place of the formyl proton, as in 5, pushes the 
equilibrium back towards the  Z -ro tam er (>90% ); in 5 
the overriding factor appears to be the steric interac­
tion between CMe and NCH2OH groups, which de­
stabilizes the E-rotam er. This trend is completed in 
the hydroxymethylbenzamides (6 ,7 , and 8), where the 
steric interaction with the aryl group is expected to  be
more pronounced and only the Z-rotam er is observed. 
In N-hydroxymethyl-N-methylformamide (3), the  
steric factor again overrides the effect of hydrogen 
bonding; the preferred rotamer is the one with the 
smaller group syn to the carbonyl oxygen.
The effect of introducing the a-oxygen-containing 
substituent into the N-alkyl group of N -m ethyl- 
formamide on the rotamer distribution is significantly 
greater than the change brought about by simply 
increasing the size of the alkyl group.22 T he replace­
ment of the methyl group in NMF by the n -propyl 
group results in a slight shift towards the E -ro tam er 
(8-14% ), whereas the substitution of a methyl group 
by a methoxymethyl group results in a more significant 
shift to ca 40% of the E-rotam er. Evidently, the 
interaction between the methoxymethyl group and the 
carbonyl oxygen in 2 cannot simply be explained by 
the size of the methoxymethyl group, and may involve 
an electronic repulsion not present in simple N-alkyl- 
form amides.
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The ’H n.m.r. spectra of /V/V-dimethyl-2-nitroethenamine. /V-methyl-2-nitroethenamine. and 2- 
nitroethenamine in several solvents have been analysed. In the case of the monomethyl compound, the 
proportions of different rotamers about the C=C and C-N bonds are found to be solvent dependent. An 
X-ray crystallographic study of this compound indicates inter- rather than intra-molecular hydrogen 
bonding in the solid; molecular orbital calculations predict three of the possible four conformers about 
these bonds to be of similar and much lower energy than the fourth.
As part of a continuing study on analogues of the antitumour 
agent N-methylformamide (2b) (NMF), we have prepared a 
short series of 2-nitroethenamines (la—c) for biological evalu­
ation. A previous n.m.r. study undertaken by u s2 has shown 
(2b) to  exhibit restricted rotation about the amide C -N  bond, 
as for most amides, owing to delocalisation of the non-bonding 
pair o f  electrons on nitrogen into the carbonyl 7t-bonding system; 
(2b) shows a ratio of rotamers of ca. 9:1 Z : £  which is almost 
independent of solvent. As NN-dimethylformamide (2a) and 
formamide (2c) can only exist as single ‘rotamers’ about this 
bond, it is interesting to speculate as to whether the ability of 
(2b) to  change conformation has any bearing on the fact that of 
com pounds (2a— c) only (2b) has significant antitumour 
activity in murine models,3 has shown activity against human 
tumour xenografts and is currently in Phase 2 clinical trial. 
In this paper, we present the results of our studies on the 
conformations adopted by the analogous compounds (la—c) 
particularly with reference to the closest analogue of NM F  
(2b), i.e. N-methyl-2-nitroethenamine (lb).
Rajappa * has recently reviewed the current state of know­
ledge concerning the synthesis, utility, and structure of 2- 
nitroenamines, stating that most examples of this class of 
com pounds exist as the enamine tautomer with only two 
examples reported5 to have the 2-nitroimine structure. Our 
results show that all three 2-nitroenamines (la — c) follow the 
general rule in being true enamines in solution in nonacidic 
solvents and (lb) being so in the solid state.
Compounds (la —c) were synthesized generally according to 
known procedures. The dimethylenamine (la) was obtained by 
condensation of dimethylformamide dimethylacetal with nitro- 
methane.6 The methylamino (lb) and amino (lc) compounds 
were prepared by transamination of N-methyl-N-phenyl-2- 
nitroethenamine with methylamine and ammonia, respect­
ively.7 Repeated recrystallisation of (lb) from deuterium oxide 
gave the N -D  species (Id).
T w o main points can be inferred from the 'H n.m.r. spectra 
of (la): geometrical isomerism about the olefinic bond and 
restriction of rotation about the N -C (l) bond. The C(1)H- 
Q 2)H  coupling constant is 11 Hz in both CDC1} and (CD3)2SO  
solution, a value which is of little diagnostic value in 
determining the stereochemistry about that bond, as noted by 
Biichi.8 In (CD3)2SO. the signals due to the methyl groups 
appear as sharp singlets at 5 2.85 and 3.20 indicating the non­
equivalence reported by Biichi8 and by Rajappa9 for this 
compound. Thus, the charge-separated canonical forms (1)—  
(III) of (la) make a contribution, i.e. there is significant 
delocalisation of the non-bonding lone pair at N (l)in to  the n- 
system of the remainder of the molecule. In CDC13, also at
° 2 N ^
NR R
(1)
R1 = R2 = Me 
R1 = Me. R2 =H  
R1 = R2 = H 
R’ = M e. R2 = D
HX....NR R
w
N —  C = C — NMe? 




q . R1 = R2 = Me 
b . R1 = Me, R2 = H 
c  . R1 = R 2 = H
W . -
N — C — C—  NMe-> 
/  H H
*0
( II)
\  ♦ + 
N = C  —  C =  NMe?
/  H H
0
(I II )
29 °C, these resonances are significantly broadened, implying 
that the coalescence temperature is higher in (CD3)2SO than in 
CDC13. (Mannschreck 10 gives a coalescence temperature of 
52 °C in CDBr3.) The origins of this effect are unclear but it 
may arise from the greater viscosity of dimethyl sulphoxide or 
from such factors as the dielectric constant or dipole moment 
of the solvent.
Krowczynski and Kozerski' report a 60:40 Z : £  ratio of 
geometrical isomers about the olefinic bond in (lb) in chloro­
form solution. We observed only one conformer to be present 
in solution in CDC13 at 34 C. The magnitudes of the 
C(1)H-C(2)H coupling constant (5.5 Hz) and of JauH_NH (14.0 
Hz) are consistent with Z and £  configurations respectively 
This arrangement is stabilised by an intramolecular hydrogen 
bond between the NH and the nitro group, which is confirmed 
by the immutability o f the chloroform solution i.r. spectrum 
upon dilution.
A mixture of three rotamers is observed in (CD3)2SO in the 
ratio 23.5:7.7:68.8, as shown in Table 1. Now. three-quarters of 
the total population o f solute adopt an £  conformation about 
C(I)-C(2), reflecting the facility of hydrogen-bonding to 
solvent. However, of these C( 1)—C(2)£ species, the majority 
adopt the Z arrangement about the C( 1)—N bond. Assign-
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Table 1. Relative isomer populations of (lb) in various solvents
Solvent C( 1 )-Q2)Z/Q I )-N £  C(IhC(2)£/Ql)-N£ Q1)-Q2)£/C(1)-NZ (lba) (lbb)
CDCIj 100
(CD j )jSO 23.5 ± 1.0 7.7 + 0.7 68.8 ±  1.7
D jO  63 ± 3 37 + 3
CF3C 0 2H 47.5 ± 0.5 515 ± 0.5
Table 1  'H N.m.r. data for compounds (la—d)
Chemical shift 5
Ql)-C(2) Qlp-N ---------------------- ,
mpound Solvent Stereochemistry Stereochemistry C(!)H C(2)H NH CH,
(1 *) CDC13 £ 8.20 (d. 7 11 Hz) 6.65 (d. 7 11 Hzi 2.90br (s) 
3.25br (s)
(la) (CD3)2SO £ 8.30 (d, 7 11 Hz) 6.80 (d. 7 11 Hz) 285 (s) 
3.20 (s)
(lb) CDCIj Z £ 6.79 (dd, 7 14. 5.5 Hz) 6.54 (d, 7 5.5 Hz) 9.1 br 3.21 (d. 7 5 Hz)
(lb) (CD3)2SO Z £ 122 (dd. 7 15. 6 Hz) 6.48 (d, 7 6 Hzi 9.4br 3.09 (d. 7 6 Hz)
(lb) (CD3)2SO £ £ 8.29 (d, 7 10.5 Hz) 6.80 (d. 7 10.5 Hz) 8.15br 3.03 (d. 7 4.5 Hz)
(lb) (CD3)2SO £ Z 8.24 (dd. 7 7.5.10.5 Hz) 6.82 (d, 7 10.5 Hz) 8.15br 2.74 (d. 7 4.5 Hz)
(lb) d 2o Z 7.55 6.81 (d,7 6 Hz) 3.28 (s)
(lb) d 2o £ 8.51 (d, 7 10.5 Hz) 7.08 (d, 7 10.5 Hz) 2.96 (s)
(lb) CF3C 0 2H Adduct (lba) 5.06 (m) 5.27 (dd. 7 5.5. 16 Hz) 3.10 (t. 7 5.5 Hz)
5.48 (dd, 7 7. 16 Hz)
(lb) c f 3c o 2h Protonated species (lbb) 7.90 (d, 7 15 Hz) 8.2 (m) 8.2br 3.49 (7 5.5 Hz)
(lc) (CD3)2SO Z 7.20 (m) 6.45 (d. 7 6 Hzi 8.1 br
(lc) (CD3)2SO £ 6.80br (d. 7 11 Hz) 8.25 (7 11 Hz) 8.1 br
(Id) (CD3)2SO Z £ 7.20 (m) 6.46 (7 6 Hz) 3.08 (s)
(Id) (CD3)2SO £ £ 8.24 (d, 7 10 Hz) 6.79 (7 10 Hz) 3.02 (s)
(Id) (CD3)2SO £ Z 8.22 (d. -All Hz) 6.83 (d, 7 11 Hz) 2.73 (s)
ments of structure are derived from the coupling constants 
*^ ct i )h .c <2>h an<l -^c <i i h .n h  i ih .c (2)h . 5-5 Hz for the Z and ca. 11
Hz for the £  isomers about Q l)-Q 2); values lower than those 
generally accepted for olefinic cis and trans vicinal coupling, 
owing to reduction o f the double bond character in 2- 
nitroenamines. By analogy, the uncertainty of the stereo­
chemistry of (la) is resolved, the 11 Hz coupling being shown to 
be trans-vicinal J C( i *h .C(2)n h - Similarly, having identified Z  and £  
isomers about C (l}-N  giving chemical shifts of 8 2.74 and 3.03 
for N C H 3 protons, it is possible to assign the resonances due to 
the N(CH3)2 methyl protons in (la) [in (C D 3)2SO solution] as 8 
2.85 for the C H 3 syn to Q 2) and as 8 3.20 anti to C(2). 
Orientation about C(l>-N was also established using coupling 
constant information (7.5 and 15 Hz for Z and £, respectively); 
Fetell and Feuer 11 give . / c <i >.n h  I 4  Hz for an £-C -N  bond in a 
related molecule. Hence, of those molecules of (lb) that are £  
about C(l>-Q2), the E .Z  ratio about C(l>-N is 1:8.9, a 
proportion that is remarkably similar to the 1:9 ratio of E .Z  
rotamers for the archetypal compound in our antitumour 
investigations. jV-methyiformamide (2b). Perhaps the factors 
involved are similar for (lb ) and for (2 b). In D 20 ,  however, 
owing to exchange with the solvent, the Q 1)H -N H  coupling is 
not observed and confident assignment of stereochemistry 
about C (l)-N  is not possible. Two isomers about Q l}-C (2) are 
shown by . /c <i >h .c <2ih  analysis. The proportion of the Z (i.e. 
intramolecularly hydrogen-bonded) isomer is 63%, between the 
amounts present in chloroform and dimethyl sulphoxide. This 
reflects, perhaps, a lesser stabilisation of the £  form (with its 
hydrogen-bonding to solvent) in water (dipole moment p 1.85 
D )12 than in the dipolar aprotic dimethyl sulphoxide (p 3.96 
D).12 Slow hydrolysis is evident in D ,0 ,  a significant amount of 
products tentatively identified as methylamine and nitro- 
acetaldehyde being present after 1 h at 34 °C.
As it was considered, in view of the D 20  spectra, that 
addition of D ,0  to a (C D 3)2SO solution of (lb) might perturb 
the equilibria between isomers, the N -D  derivative was pre-
HO H
NHMe
( l b a )  ( l b b )
HO
\  +
M = r \
-o ' / - & ' !
Nuc
( l a B )  ( l a A )
Figure 1. Proposed structures of products of (lb) and (la) in 
trifiuoroacetic acid, (lba) and (lbb) are shown by n.m.r. in this study 
(laA) and (laB) adapted from ref. 8
pared and its l H n.m.r. spectrum in anhydrous (CD3)2SO was 
examined. Analysis of this spectrum served to confirm our 
assignment of the corresponding (lb ) spectrum.
In trifluoroacetic acid, (lb) forms two distinct species in the 
ratio 47.5:52.5 which we denote as (lba) and (lbb) (Figure 1). 
The spectrum of (lba) contains an ABX system with J9fm of the 
prochiral methylene at C(2) being 16 Hz. The prochirality arises 
from the adjacent asymmetric centre at C(l) in the adduct (lba) 
The N -C H 3 resonates as a triplet coupled now to two protons 
on N(l). Hence we put forward the structure (lba) as 
representing this adduct. The other species appears simply to be 
protonated (lb ) having the structure (lbb) with protonation at 
N (l) followed by tautomerism to give the imine nitronic acid. 
£-Stereochemistry about C(lp-C(2) can be inferred from
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N(3)
0 ( 6 )
Cl2)t
T able 3. A tom  positional param eters (fractional co-ord inates x 10* for 
non-hydrogen  atom s: x 103 for hydrogen atom s) and equivalent iso ­




Figure 2. Structure of (lb) in the crystal with crystallographic 
numbering scheme
^C(i>H.c(2)H 15 Hz, clearly a /raru-coupling constant. Biichi8 
reports the dimethyl compound (la) to be unstable to aqueous 
acid and both he and C olonna13 show that (la ) reacts with 
aromatic carbon nucleophiles under acidic conditions. Two 
intermediates (laA) and (laB), shown in Figure I, are proposed 
in ref. 8 . Whereas we concur in that (lb) does indeed hydrolyse 
very rapidly in wet trifluoroacetic add, in anhydrous trifluoro­
acetic ad d  in the absence of a good nudeophile we observe the 
monomethyl analogue of (laA) [re. (lbb)] but not that of 
(laB). Rather, the nitro tautomer (lba) of the adduct is formed.
The analysis of the i.r. spectra of (lb) and its deuterio- 
analogue (Id) is straightforward. In the solid phase as a KBr 
disc and as Nujol mull, one can observe a hydrogen-bonded 
N -H  stretch band at 3 250 cm-1 which is moved to 2 370 cm-1 
upon deuteriation (wavenumber ratio 137:1). A strong band is 
also observed at 1 615 cm-1, interpretable as having con­
tributions from C=C and C=N bonds. The spectrum in CHC13 
solution was unchanged on dilution confirming the intra- 
molecularly hydrogen-bonded structure determined by *H 
n.m.r. in C D G 3 to be Z  about Q l)-Q 2 ) and £  about C(l)-N . 
The demethyl analogue (lc) is virtually insoluble in chloro­
form; in (C D 3)2SO, the *H n.m.r. spectrum shows it to be a 
mixture of the expected two stereoisomers about C(1)~C(2). 
The Z isomer (^cidh.cijih 6  Hz) comprises 68% of the mixture 
and the £ (y QnH a2IH 11 Hz) represents 32%.
Crystal Structure o f N-Methyl-2-nitroethenamine (lb).—The 
numbering scheme used in the crystallographic determination 
is shown in Figure 2. The crystal was grown from ethyl acetate 
and had dimensions 0.35 x 0.15 x 0.15 mm. The data were 
collected from an Enraf-Nonius CAD4 diffractometer with 
monochromated Mo-K„ radiation, X =  0.710 69 A.
C rystal data. C3H6N 20 2, M  =  102.09, monoclinic, a =  
3.915(3), b =  12.009(7), c =  10.271(7) A, p =  95.46(6)°. V = 
480.7 A 3, Z  =  4, Dm =  1.412(5) g cm'3, Dx = 1.411 g cm '3. 
£(000) =  216.00, p =  0.78 cm '1, space group P lfc . Intensity 
data were collected by the cd-20 scan technique. The 1 829 
reflections were measured for +h ± k  ±1 in the range 
2° <  0 <  24° and were merged to give 760 independent 
reflections of which 384 were deemed observed with F > 3a. 
The structure was determined by the EEES direct methods 
procedure in SHELX . 14 An £-map was produced in which all 
the non-hydrogen atoms were located. After least-squares 
refinement of positions and isotropic temperature factors, a 
difference Fourier synthesis located the hydrogen atoms. 
Further refinement of co-ordinates and anisotropic tempera­
ture factors for non-hydrogen atoms, and co-ordinates and 
isotropic temperature factors for hydrogen atoms, was carried 
out with SHELX, with the methyl C-H, H —  H, and H —  N 
distances constrained by the DFIX procedure in SHELX. In
A tom X y r U .jk '
C (l) 1 565(17) 1 746(5) 2 765(6) 48(2)
Q 2 ) 3 130(16) 1 302(4) 3 881(5) 42(2)
C(4) -8 6 8 (2 1 ) 11(5) 1 868(8) 59(3)
N (3) -2 0 8 (1 3 ) 1 201(4) 1 834(5) 49(2)
N (5) 5 044(14) 1 971(4) 4 764(5) 50(2)
0 (6 ) 6331(13) 1 541(3) 5 805(4) 69(2)
0 (7 ) 5 501(12) 2 974(3) 4 535(3) 66(2)
H (!) 178(11) 250(4) 261(4) 34(13)
H(2) 312(11) 53(3) 417(4) 32(13)
H(3) -1 4 2 (1 8 ) 161(4) 108(5) 100(23)
H(4A) -2 1 0 (1 5 ) -2 0 ( 4 ) 105(4) 83(24)
H(4B) 145(14) -4 4 ( 4 ) 187(5) 98(24)
H(4C) -1 8 8 (1 8 ) - 2 3 ( 5 ) 272(5) 126(29)
T able 4. Bond distances for (lb ) w ith  standard d eviations in parentheses
Bond D istance (A)
C (l>-C (2) 1.356(7)
C (l)-N (3 ) 1.303(7)
C (2)-N (5) 1.378(6)
C (4)-N (3) 1.453(7)
N (5 )-0 (6 ) 1.250(5)
N (5 )-0 (7 ) 1.243(6)
T able 5. Bond angles o f ( lb ) for non-hydrogen  a tom s with standard
d ev ia tion s in parentheses
Bond A ngle (°)
N (3 )-C (l)-C (2 ) 126.1(6)
N(5)—C(2)—C( 1) 120.0(5)
C (4 )-N (3 )-Q 1 ) 124.0(6)
0 (6 > -N (5 H Q 2 ) 118.2(5)
0 (7 ) - N (5 ) -0 (6 ) 120.6(5)
0 (7 ) -N (5 )-C (2 ) 121.3(5)
Table 6. Selected torsion  an gles o f  (lb )
Bonds Torsion an gle (')
N(3>-C( 1 F-C (2)-N(5) 177.4
N (3H T (1)-C (2)-H (2) - 1 . 9
C (2 )-C (l)-N (3 )-C (4 ) 1.8
C (l) -C (2 )-N (5 )-0 (6 ) 177.1
C (l) -C (2 )-N (5 )-0 (7 ) - 3 . 2
C( 1 )-N (3 )-C (4 )-H (4A ) —176.4
C (1)-N (3 )-C (4 )-H (4B ) - 6 4 6
C (D -N (3 )-C (4 )-H (4 C ) 52.1
the final stages of refinement, reflections were weighted 
according to: W  — A'/[a2 (£„) + g  £02] =  1 .5 l64 /[a2 (£„) +
0.000 157 £0*]. The final discrepancy indices were R = 0.0622 
and Rt =  I [M |£ J  -  |£ ,|)2/h-£02]* =  0.0490. No feature on the 
final difference electron density map exceeded ±0.23 eA '3 
The structure and numbering schem e15 are presented in 
Figure 2 and the atomic co-ordinates and equivalent isotropic 
temperature factors are listed in Table 3. Anistropic thermal 
parameters and torsion angles are given in Supplementary 
Publication No. SU P 56125 (3 pp.).* Bond lengths, bond 
angles, and selected torsion angles arc shown in Tables 4— 6.
* For details o f S upplem entary P u b licalion s sec Instructions for 
A uth ors in J. Chem. Soc.. Perkin Trans. 2. 1985. Issue 1
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Table 7. Calculated ground-state energies for conformers of (lb)
QIHQ2) QD-N Electronic Nuclear Energy above lowest
Stereochem. Stereochem. component (a.u.) component (a.u.) Total (a.u.) isomer (kJ m o l1)
£ Z -669.0832 298.4275 -370.6558 10.2
£ £ -665.3905 294.7350 -370.6555 11.0
Z Z -698.2881 327.9118 -370.3763 744.3
Z £ -677.0514 306.3918 -370.6597 0
respectively. Torsion angles show that the molecule is virtually 
planar. Thus the amine nitrogen atom, N(3), is trigonal and 
this is confirmed in that the sum of the H(3>-N(3>-C(4), 
Q 4)-N (3)-C (l), and Q l)-N (3)-H (3) bond angles is 359.7°. 
The nitro and methylamino groups are disposed trans about 
the carbon-carbon double bond, as reported 16 for the solid- 
state conformation of the dimethyl analogue (la). Simple steric 
considerations would predict the stereochemistry about the 
Q l)-N (3 )  bond to be £, but it is found to be Z  in the crystal. 
However, the Q l)-C (2)-H (2) bond angle is 128(2)°, bending 
H(2) slightly towards the nitro group and away from the N- 
methyl. Torsion angles involving the methyl hydrogens show 
that they are also disposed so as to relieve steric strain.
Bond lengths and angles are largely similar to those 
reported16 for the dimethyl analogue (la). Two main ex­
ceptions are evident; in the dimethyl compound the Q l)-N (3) 
bond length is 1.334(4) A and the Q 2)-N (5) distance is 1.394(4) 
A. In (lb), these are significantly shorter at 1.303(7) and
1.378(6) A; moreover, the Q l> -Q 2) bond length is con­
comitantly markedly longer than a simple carbon-carbon 
double bond.17 These data would indicate delocalisation 
throughout the N C C N 0 2 system of (lb) to an even greater 
extent that in (la). Probably there is a contribution from a 
charge-separated canonical form, the so-called ‘push-pull’ 
effect.
Intermolecular hydrogen bonding, as suggested by the solid- 
state i.r. spectra, is found to be present. Molecules in the unit 
cell (Figure 3), related by a screw axis, are linked by inter­
molecular N (3 )-H (3)-* -0 (7 ) bonds with an N(3)-0(7) bond 
distance o f 2.937 A and a N(3)-H(3) • • • 0 (7) bond angle of 164°.
Molecular Orbital Calculations fo r  (lb).— Calculations of 
energies of the four isomers considered (£/Z , £ /£ , Z/Z, and 
Z /£ ) were performed by the GAUSSIAN 70 program using 
STO-3G. The geometry of the £ /Z  form was taken from the X- 
ray crystal structure determination and that of other isomers 
taken to be obtained by altering the appropriate torsion angles 
by 180°. The results are shown in Table 7. Three conformers 
have calculated energies within 11 kJ mol"1 whereas the fourth 
is ca. 744 kJ mol"1 higher. This prediction correlates well with 
the observation that, in n.m.r. experiments, judicious choice of 
solvent can produce these three isomers whereas we have never 
observed the fourth (high energy) isomer.
In two parameters, we can now test the analogy between (lb) 
and the antitumour archetype (2b): populations of the rotamers 
about the C (l)-N  bond and the bond order of that bond with 
respect to the amide or ‘pro-amide’ C (l}-N  bond. First, as 
previously noted, there is observed a 9:1 preference of Z over £  
for both compounds about Q l) -N  as indicated by n.m.r. This 
is corroborated by a calculated energy difference for this 
isomerism of 0.8 kJ m ol'1 in the case of (lb), difference of 1.3 
kJ m ol'1 calculated using STO-3G for (2b).18 Secondly, com­
parison of the C (l)-N  bond lengths determined here for the 
crystal of (lb) and calculated18 for (2b) (1.303 and 1.405 A 
respectively) shows that the double bond character of this 
formal single o-bond is much greater in the nitroethenamine 












Figure 3. The unit cell of a crystal of (lb )
Experimental
■H N.m.r spectra were obtained at 220 MHz using a Perkin- 
Elmer R34 spectrometer and at 60 M Hz using a Varian 
EM360A instrument. M.p.s are uncorrected.
NN-Dimethyl-2-nitroethenamine (la).—This material was 
prepared by the method of Meerwein 6 from nitromethane and 
/V-(dimethoxymethyl)dimethylamine in 75% yield and had m.p. 
104— 105 °C (lit.,6 104 °C). Vra„  (KBr) 3 l00w, 3 030w, 2 920w,
2 820w, and 1 630 cm"1.
N-Methyl-2-nitroethenamine (lb).—Transamination of N- 
methyl-2-nitro-N-phenylethenamine with methylamine accord­
ing to the method of Krowczynski7 gave (lb) in 87% yield. The 
orange-brown crystals had m.p. 121 — 123 °C (lit.,7 114—  
116 °C) (Found: C, 35.0; H. 5.8; N. 27.3. Calc, for C 3H6N 20 2: 
C, 35.3; H, 5.9; N, 27.4%); (KBr) 3 250, 3 100w. 3 040w. and 
1 615 cm"1; v„„  (Nujol) 3 250 and 1 615 cm"1.
2-Nitroethenamine (\ c ) —K-M ethyl-2-nitro-’H-phenylethen- 
amine was transaminated with ammonia as for (lb) above to 
give 2-nitroethenamine (lc) in 88% yield as orange-brown 
needles, m.p. 102— 104 'C (lit..7 101 °C); vm„  (KBr) 3 370.
3 150, and 1 625 cm"1.
N-Deuterio-’N-methyl-2-nitroethenaminc (Id).— .V-Methyl-2- 
nitroethenamine (150 mg, 1.5 mmol) was dissolved in warm 
deuterium oxide (99% + ; Aldrich; 750 pi) followed by evapor­
ation of the solvent under reduced pressure. The process was 
repeated and the residue was recrystallised from deuterium
J. CHEM . SOC. PERKIN TRANS. II 1985 255
oxide to  give the Af-deuterio compound (Id) as brown needles 
(100 mg, 0.97 mmol, 65%), m.p. 119—120 °C; v ^ K B r )  
3 lOOw, 3 050w, 2 370, and 1 620 cm’1; v^JN ujol) 2 370 and 
1 610cm"1.
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THE REACTION OF DIETHANOLAMINE WITH 2-CHL0R0NITR0BENZENE - 
A REINVESTIGATION
Michael D. Threadgill
Cancer Research Campaign Experimental Chemotherapy Group, 
Pharmaceutical Sciences I n s t i t u t e ,
Aston U nivers i ty ,
Aston T riang le ,
Birmingham B4 7ET, U.K.
In a rep o r t  on the  reac tion  of 2-chloronitrobenzene (_1) with  
diethanol amine (2 ) ,  Meltsner £ t  ^1_* claim t h a t  the  expected S^Ar 
product, N-(2-nitrophenyl )di ethanol amine (_3), i s  no t formed; 
ra th e r  th a t  the  products are  2 , 2 '-dichloroazobenzene (_4) ,  2 - n i t r o -  
phenol (5 ) ,  2 -ch lo ro an i l in e  (6) and 4-( 2 -ami nophenyl )morpholine 
(_7)- Similar products in  which the  n i t r o  function i s  reduced a re  
a lso  reported^ f o r  the corresponding re ac t io n  with e thanolamine.
In t h i s  labo ra to ry ,  in  an attempted p repara tion  of 2 ,2 ' - d i c h lo r o -  
azobenzene (_4) f o r  reference  purposes in  photochemical s tu d ie s  on 
the a n t in e o p la s t ic  agent 5 - (3 -az ido-4-ch lo ropheny l) - 6 - e t h y l -  
pyrimidin-2,4-diaraine3, the  expected S^Ar product (3) was obta ined  
along with o th e r  products.
On treatm ent o f  2-chloronitrobenzene (1) w ith  di ethanol ami ne a t  
180*C fo r  3 hours, followed by e x tra c t io n  and chromatography, four
1101
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id e n t i f ia b le  products were i s o la te d  along with a quantity  of  black 
t a r .  2,2 '-Dichloroazobenzene (£) ( t race )  and 2 -ch lo ro an i l in e  {£) 
were formed as reported*, the  l a t t e r  being confirmed a f t e r  
conversion to  2 - c h lo ro a c e ta n i l id e  by treatm ent with a c e t ic  
anhydride. However, the o the r  two claimed* products , 2-nitrophenol 
(j>) and 4-( 2-ami nophenyl )morpho1 ine (_7), were shown by th in  lay e r  
chromatography not to  be p re sen t .  The s tra igh tfo rw ard  nuc leoph ilic  
su b s t i tu t io n  product. N-(2-nitrophenyl )diethanolamine (_3), was 
iso la ted  in f a i r  y ie ld  as an orange o i l .  The remaining major 
product was the  monoalcohol (8) which has been prepared by Kremer^ 
and by Karrer 4  from 2-ami noethanol and 2-chloronitrobenzene. This 
compound has a lready been the  su b je c t  of a s t ru c tu re  re v is io n  in  
Kleb's paper on the  Smiles-type rearrangement of N-(2-hydroxy- 
e thyl ) - 2 -nitrobenzenesulphonamide to  ( 8 ) which was shown^ to  be 
iden tica l  with the "2-(2-nitrophenoxy)ethanamineM of Weddige®. The 
formation of t h i s  material could be r a t io n a l i s e d  in  terms of 
thermal e l im ina tion  of water giving an enamine. Hydrolysis by the 
water so generated would then a f fo rd  the mono-(2 -hydroxyethyl)-  
compound and acetaldehyde which in  tu rn  may be in p a r t  re sp o n s ib le  
fo r  the t a r  formation. In te r e s t in g ly ,  a second e l im in a t io n /  
hydrolysis did not take p lace ,  no 2 - n i t ro a n i l  ine being d e tec ted .
This work shows th a t  s tra ig h tfo rw ard  S^Ar s u b s t i tu t io n  does indeed 
take pTace between dvotfcanolamine and 2 -ch lo ronitrobenzene, 
contrary  t 8  a previous rep o r t* ,  and th a t  th e  morpholtne i s  not 
formed.
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EXPERIMENTAL.
NMR Spectra were obtained 1n CDC^ a t  60 MHz with a Varian EM360A 
spectrometer and IR spec tra  were acquired  using a Perkin Elmer 
1310 instrum ent.  Melting points  a re  uncorrec ted .
Reaction o f  2-Chloronitrobenzene (1) with diethanol amine (2 ) . 
2-Chloronitrobenzene (10.0 g, 63.3 mmol) was heated to  180*C and 
di ethanol amine (43 g, 405 mmol) was added during 30 min a t  t h i s  
temperature. A fte r  being s t i r r e d  a t  180*C fo r  3 h, the mixture was 
cooled to  50*C and poured onto ic e  (150 g ) .  The re su l t in g  dark 
suspension was a c id i f i e d  by the a d d i t io n  of  conc. hydrochloric 
ac id  (100 ml) and ex trac ted  with di chi orome thane (2 x 300 ml). The 
aqueous p o r t ion  was b a s i f ie d  by a d d i t io n  o f  K2 CO3  and ex trac ted  
with fu r th e r  q u a n t i t i e s  o f  di chi oromethane (3 x 250 m l) . Treatment 
with dlatomaceous ea r th  and anhydrous sodium sulphate  followed by 
f i l t r a t i o n  served to  remove suspended t a r  and to  dry the  combined 
e x t r a c t s .  Evaporation of the  so lven ts  under reduced pressure  gave 
a dark o i l .  Column chromatography ( s i l i c a  g e l ,  CHC^ with added 
MeOH in c reas in g  from 0% to  10%) a ffo rded  four  compounds. In order 
o f  increasing  p o l a r i t y ,  the following were obta ined  2 , 2 ' -Diehloro- 
azobenzene (4 ;  50 mg, 0.6%), o range-red  needles MPt 132-133*C 
( l i t . 1, 134*C);6 7 .2 -7 .9  ( 8 H, m, ArH); m/z 254/252/250 (M+). 2- 
C hloroaniline ( 6 ; 3.76g, 46%), co lourless*  l i q u id ,  3470,
3380, 1615 cm"1 ; 6  3 .9  (2H, b r ,  NH2 ) ,  6 .4 5 -7 .3  (4H. m, Ar-H); m/z 
129/127, 102/100, 92; MPt of derived  2 ' - c h lo r o a c e ta n i l id e  8 6 - 8 8 *C 
( l i t . 7 , 87-88*C).
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2-( 2-Ni trophenyl ami no)ethanol ( 8 _); 530mg, 4.6%), orange needles 
MPt 74-75°C ( l i t . 5 , 75*C); vIBax 3400, 3220, 1510, 1340 cm- 1 ; 
6  2.75 (2H, b r ,  OH), 3.50 (2H, q, J  6  Hz, NCH2) ,  3.90 (2H, t ,  J 6  
Hz, CH2 0H), 6.60 (1H, d t ,  J 1 Hz, 8  Hz, 4-H), 6.83 (1H, dd, J 8  
Hz, 1 Hz, 6 -H), 7.49 (1H, d t ,  J 2 Hz, 8  Hz, 5-H), 8.10 (1H, dd, J 
8  Hz, 2 Hz, 3—H), 8 .2  (1H, b r ,  NH); m/z 182 (M+), 151.
N-(2-Ni trophenyl)di ethanolami ne ( 3 ; 1.60g, 11%), orange-brown o i l ,  
Vj^^SSO, 1595, 1510, 1340 cm"*; 6  3 .30 (4H, approx. t ,  J 4 Hz, 
NCH2) ,  3.55 (4H, approx. t ,  J 4 Hz, CH2 0 ) ,  3.60 (2H, b r ,  OH), 6 .9 -  
7 .8 (4H, m, Ar-H); m/z 226 (M+),  195 (100%), 165, 151.
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COMMENTARY
T H E  G E N E R A T IO N  OF P O T E N T IA L L Y  TO X IC. R E A C T IV E  
IM INIUM  IONS FRO M  T H E  O X ID A T IV E  M ETA B O LISM  O F  
X E N O B IO T IC  N -A LKYL C O M P O U N D S
M a r k  O v e r t o n , J o h n  A . H i c k m a n ,*  M i c h a e l  D. T h r e a d g i l l . K e i t h  V a u g h a n *  a n d
A n d r e a s  G e s c h e r
MRC Mechanisms, of Drug Toxicity Group. Department of Pharmaceutical Sciences. University oi 
Aston, Birmingham B4 7ET, U.K.; and ^Department of Chemistry. St. Mary s University. Halifax
Nova Scotia. Canada B3H 3C3
During the past 30 years, a com m on mechanistic 
feature has em anated from the many investigations 
into m echanism s by which chem ically innocuous 
drugs and environmental chem icals exert their 
toxicity. This is that they undergo metabolic acti­
vation to chem ically reactive species capable of caus­
ing toxicity in specific tissues. Reports that the 
m etabolism  of the anaesthetic and psychotropic drug 
phencyclidine gives rise to an electrophilic iminium 
species [1 , 2 ] are amongst a num ber o f recent studies 
which suggest that certain alkylam ines and alkyl- 
am ides may have to be included in the vast array 
o f  such chem icals with hazardous potential. In this 
review , we summarise som e o f  these findings and 
draw attention to  those m olecular features o f alkyl­
am ines and alkylam ides which favour the generation 
o f  potential toxins. Additionally, som e preliminary 
results are presented which suggest that phase 2  
m etabolic reactions o f m etabolites o f alkylamines, 
such as the conjugation o f N-(l-hydroxym ethyl) 
com pounds, may also give rise to  potentially toxic 
species.
The oxidative metabolism o f N-alkylamines ( 1 . 
Fig. 1) to N -(l-hydroxyalkyl) am ines (2) is a ubiqui­
tous m etabolic pathway for m any classes o f xeno- 
biotics bearing an N-alkyl group. This oxidation may 
be the prelude to the formation o f an aldehyde, for 
exam ple form aldehyde from an N -m ethyl compound. 
A lternatively, a relatively stable N -(l-hydroxyalkyl) 
species may be formed. The fate o f  this latter moiety  
is the focus o f  attention o f this review  and, in particu­
lar, the question is addressed o f  which molecular 
feature(s) o f specific xenobiotic N -(l-hydroxyalkyl) 
am ines may dispose them to be in equilibrium with 
the reactive iminium species form ed by loss of 
hydroxide.
/CM, f H f l H  H
R - N   —  R - N     R - N
V  V  V
It) (2) 13)
Fie 1. Metabolism of N-methy! compounds
* Author to whom all correspondence should be 
addressed.
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F ig . 2 . E q u ilib r iu m  b e tw e e n  a ca r b in o la m in c  (2i and im in ­
iu m  ion s (4 ) .
Several exam ples o f the equilibrium between a 
carbinolam ine (2. Fig. 2) and an iminium species (4) 
in biological system s have now been reported. The  
first convincing evidence for the presence of such 
an equilibrium was presented for a m etabolite o f  
nicotine [3]. H ow ever, there are other exam ples o f  
oxidative N-dealkylation reactions where such an 
equilibrium  does not exist, one such being that o f N- 
(hydroxym ethyl)carbazole. a m etabolite o f .V-meth- 
ylcarbazole (34, see Fig. 10). B eke [4] has reviewed  
the chem istry o f the heterocyclic pseudo bases, 
where this equilibrium betw een carbinolamine and 
iminium ion exists. The basicity o f the nitrogen atom  
in the carbinolam ine (2. Fig. 2) naturally depends 
upon its structure; the equilibrium is influenced by 
(a) the electronegativity o f substituents attached to 
the nitrogen (R' and R"). (b) the situation of the 
nitrogen in cyclic or acyclic structures, and (c) the 
arom aticitv o f the ring. Electron-donating sub­
stituents on the nitrogen will tend to facilitate loss 
o f the hydroxide anion. Conversely, electron-w ith­
drawing groups decrease the electron densitx at the 
nitrogen atom  and do not favour iminium ion pro­
duction. This latter effect can lead to the cleavage  
o f  the N— C bond with concom itant loss of the 
aldehyde.
The first experim ents to provide evidence for the 
m etabolic formation of iminium ions from N-alkyl­
am ines were perform ed by Breck and Trager [5] in 
studies o f the m etabolism  o f lidocaine ( F ig . .'). They  
suggested that the formation o f a carbinolamine (6 ) 
and consequently an iminium ion (7) may explain 
the production of a cyclic species ( 8 )  from th e  ox i­
dation o f lidocaine (5). These authors also suggested  
that, if the formation of such a reactive, electrophilic  
interm ediate (7) was a general phenom enon of N- 
dealkvlation . then it might explain the biological 
responses, whether efficacious or toxic, o f various
2055
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3. Metabolism of lidocaine (5)
amine drugs, as the reaction o f such interm ediates 
with nucleophiles at critical enzym e sites [5].
In 1960, Hucker et al. [6 ]. in a study of the m etab­
olism o f nicotine (9). proposed the pathway illus­
trated in Fig. 4. The authors studied the effect of 
m etabolic inhibitors upon this pathway. Cyanide 
inhibited the production o f cotinine ( 11 ) but this 
occurred without inhibition of the consumption of 
nicotine. T he authors suggested that the conversion  
5 ’-hydroxynicotine (10) to cotinine ( 11 ) was cata­
lysed by aldehyde oxidase which had been shown to 
be inhibited by cyanide (7). This suggestion was 
supported by evidence of the accumulation o f an 
interm ediate o f metabolism formed in the presence  
of cyanide, which behaved like the synthetic car­
binolam ine (10). Murphy [3] reinvestigated these  
aspects o f  the metabolism o f nicotine with the aim 
of elucidating the exact enzymatic steps involved 
in the production of cotinine. When nicotine was 
m etabolised in the presence o f cyanide, a novel 
com pound was observed which was characterised as 
5'-cyanonicotine (15. Fig. 5). Murphy proposed two 
pathways to be consistent with the formation o f 5 '- 
cyanonicotine (15). Pathway A (Fig. 5) involved the 
formation o f  nicotine A 1 (5‘) iminium ion (12) from  
hydroxynicotine ( 1 0 ). and it was considered that the 
ion should react readily with cyanide. Pathway B 
involved the formation of the aminoaldehvde tau- 
tomer (13) o f hydroxynicotine. followed by reaction  
with cyanide (14) and ring closure in a manner anal- 
gous to the Strecker reaction. To discriminate 
between these two pathways, the products of the  
incubation o f nicotine with microsomes were treated  
with sodium  borodeuteride. This reduction yielded  
deuterionicotine. in which the single deuterium was 
located at the 5 '-position (16). This observation  
could only be consistent with the existence o f the 
iminium ion (12). In addition, the incubation of 
nicotine with m icrosom es under an lS0 2 atm osphere 
showed that the cotinine (11. Fig. 4) produced did 
not contain lsO . It was thus demonstrated that the 
hydroxyl Qxygen atom in the 5 '-hydroxynicotine m ol­
ecule was not the sam e oxygen as was derived from  
the initial enzym atic hvdroxylation of nicotine, which  
required atm ospheric oxygen. This is consistent with 
a pathway involving the iminium ion (12, Fig. 5).
—  v -
N CH, CH ,
Fig 4. M e ta b o lism  o f  n ico tin e  (9 ) to  c o t in in e  (1 1 )
The iminium salt o f nicotine has been synthesised  
and its structure and stability in aqueous solution  
have been investigated using N M R  spectroscopy {«S]. 
In freshly prepared acid or neutral solution only the 
iminium form ( 1 2 ) was observed, whereas in strongly 
alkaline solutions only the carbinolam ine ( 10 ) was 
observed. It was estim ated that, at phvsioloeical 
pH . 25% or less was present as the carbinolamine 
but exact determ ination was not possible as the im in­
ium ion rapidly dim erised. This finding further sup­
ports Murphy s conclusions [3] that the 5 '-h\droxy- 
nicotine can exist in equilibrium  with an iminium  
ion. The authors [8 ] also dem onstrated that the im in­
ium salt can be readily transform ed into cotinine b> 
m eans o f an enzym e present in the cytosolic fraction 
o f a liver hom ogenate.
A nother route o f nicotine m etabolism  is dem ethyl- 
ation. Nguyen etal. [9. 10] suggested that, if nicotine 
(9) is dem ethvlated via a carbinolam ine (17. Fig. 6 ) 
interm ediate, then an analogous iminium ion (18) 
might be form ed and this may also be trapped by 
cyanide ions. M etabolic incubations were performed 
in the presence of cyanide and tw o m etabolites were 
found; one was 5'-cyanonicotine as shown by Mur­
phy [3 ], the other was determ ined to  be N-(cvano- 
m ethvl)nornicotine (19). This was shown to occur, 
at least in part, without prior nitrogen-carbon bond 
cleavage, im plicating the pathway illustrated in Fig.
6 . Som e .V-(cyanom ethyl)nornicotine appeared to be 
generated by an alternative pathway consisting of 
condensation o f nornicotine (the dem ethvlated  
m etab olite), form aldehyde (generated during 
d em ethvlation ). and cyanide. H ow ever, this route 
appeared to  be quantitatively less important.
Follow ing the studies on n icotine, cyanide has 
been used as a trapping agent for iminium ions in 
m etabolic incubations o f several other agents. The 
tertiary am ine 1-benzylpvrrolidine (20. Fig. ~) 
yielded several cyano adducts (21 . 2 2 .2 3 )  which the 
authors proposed to arise from the nucleophilic 
attack by cyanide ion on a m etabolically generated  
iminium species (24) [11], Attack can occur at posi­
tions 2 and 5 o f the pyrrolidine ring, thereby gen­
erating the dicyano adduct (22). The pyrrolidinone 
(23) is form ed b\ oxidation o f a hydroxylated inter­
m ediate such as (2 5 .2 6 ). The hepatocarcinogenic  
antihistam ine m ethapyrilene (27 . Fig. S) produced 
only one identifiable cyano adduct. .Y-(eyanom eth>!) 
norm ethapyrilene (28) (12]. The experim ental ev i­
dence did not allow the authors to exclude the toi- 
m ation o f another iminium ion (29). how ever, due 
to the chem ical instability o f the corresponding n* 
cyano am ine (30). M ore recently the formation ot 
an iminium ion from the w idely abused drug phen­
cyclidine (31. Fig. 9) has been studied (1 .2 |.  When
Iminium ions in drug metabolism :«57
NaBD,
Pathw ay  A
Path w ay  B
(13) (Ml
Fig. 5. Proposed pathways for the formation of 5'-cyanomcotine (15) from n ico tin e  (9) in m eta b o lic
incubations containing cyanide.
CH,OH
i9: (17) (181 rt9i
Fig. 6. Pathway for the formation of N-(cyanomethyl)nornicotine (19) from nicotine (9) in metabolic
incubations containing cyanide
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tiv e s  an d  o f d ip h en y la m in e  (5~ )
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cyanide was included in microsomal incubation of 
this drug, a cyano adduct was observed (32). Again, 
this was suggested to arise from attack o f cyanide 
ion on an iminium ion (33). The authors also used 
radiolabeled drug to investigate the metabolism- 
dependent covalent binding of phencyclidine to 
microsomal protein. Cyanide, which at the con­
centrations used here, and in all previous experi­
m ents described, does not inhibit significantly micro­
somal m etabolism , was a potent inhibitor of this 
binding, with an ic 5„ of 5 7 /<M. Glutathione also 
inhibited the binding to protein. The results support 
the suggestion that iminium ions may be capable of 
reactions with nucleophilic groups on microsomal 
m acrom olecules and hence other macromoiecules. 
U nequivocal proof of iminium ion production might 
better be obtained for these com pounds by reduction 
using soaium  borodeuteride.
A com pound which at first sight appears to be 
similar to the compounds described above is N- 
(hydroxym ethyl)carbazole (34. Fig. 10). but this 
com pound does not form an iminium ion. Micro­
som al metabolism o f A'-methylcarbazole (3 5 ) under 
an atmosphere o f 180 2 produced N-(hydroxvmethyl)- 
carbazole which contained lsO (13]. Conversely, 
when the metabolism occurred in medium containing 
H 2I80 ,  no incorporation of l80  into the N-(hydroxy- 
m ethyl)carbazole was seen (13. 14]. Thus, no for­
mation o f iminium ions appeared to occur, since 
otherwise an exchange o f the hydroxyl oxygen with 
that o f the water would have taken place. Gorrod 
and Tem ple [15] suggested the stability of the N- 
(hydroxym ethvl)carbazole to be due to the low  
basicity o f the nitrogen. The nitrogen-protonated  
conjugate acid o f yV-methvlcarbazole has a pKa esti­
m ated to be - 8  [16].
The poor basicity of .V-methvlcarbazole at the 
nitrogen atom and the inability o f N-(hvdroxv- 
m ethvl)carbazole to form an iminium ion are pre­
sum ably due to the involvem ent o f the nitrogen lone 
pair in the aromaticity o f the central ring. Pro­
tonation o f  the nitrogen or formation of an iminium 
ion would require the involvem ent o f the nitrogen 
lone pair and would hence destroy this aromaticity. 
From com parison o f the pKa values o f the conjugate 
acids o f carbazole (36. Fig. 10) and diphenylamine 
(37 ). an estim ate o f 42 kJ m o le ' 1 has been made for 
the resonance stabilisation energy derived from the 
central arom atic ring [16].
The proclivity of certain N-( 1-hydroxyalkvl) 
am ines to generate iminium ions appears to be 
dependent not only on the basicity of the nitrogen.
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Fie. 11 Proposed equilibria for myosminc (38) in aqueous 
solution.
as illustrated by N -(hvdroxym ethyl)carbazole. but 
also on the exten t o f  alkvlation of the nitrogen. 
A recent com m unication [17] describes a study by 
nuclear m agnetic resonance spectroscopy o f the 
chemical behaviour in solution o f the tobacco alka­
loid m vosm ine (38. Fig. 11). which exists in equi­
librium with the a-am inoketone (40). Resonances 
from m vosm ine (38) and the y-am inoketone (40) 
were seen in the spectra of acidic solutions of myos- 
m ine. but there was no N M R  evidence for the car­
binolam ine (39) that should , reasonably, be an inter­
m ediate in the reaction m yosm ine (38) := y-amino- 
ketone (40). E vidently the life tim e o f the car­
binolam ine (39) is extrem ely short because o f the 
ease o f dehydration to  m yosm ine. and it is unlikely 
that the im inium  ion (41) plays any role in this 
system . In the n icotine m etabolite hydroxynicotine 
(10, Fig. 5) the presence o f the N-m ethyl substituent 
prevents dehydration, and im inium  ion formation is 
favoured.
M etabolites o f  the fo llow ing three N-m ethyl con­
taining xenobiotics have recently been suggested to 
form iminium ions: jV./V-dim ethviam inoazobenzene 
(D A B ) (42. Fig. 12) [18]. 4-cvano-/V.N-dim ethyl- 
aniline (44. Fig. 12) [19] and hexam ethylm elam ine  
(H M M ) (47. Fig. 13) [20]. A m ajor biliary m etabolite  
of the hepatocarcinogen D A B  (42) in the rat was 
identified as /V -(glutathione-5-m eihylene)-4-am ino- 
azobenzene (43) [18]. and a m ajor urinary m etabolite  
of 4-cyano-/V .N -dim ethylaniline (44) in the rat and 
m ouse was show n to  be .\'-acetyl-5-(4-cyano-anil- 
inom ethyl)cysteine (45) [ 19], In both cases, the thio- 
ether m etabolites were considered to be the products 
of the reaction betw een  glutathione and reactive 
species derived from the N-hydroxym ethvl com ­
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Fig. 13. Structures of hexamethylmclamine (47) and its 
derivatives.
The antineoplastic agent HMM  (47. Fig. 13) is 
m etabolized in vitro  to /V-(hydroxvmethyl)pen- 
tam ethylmelam ine (H M PM M ) (46) [21 J. In vitro 
tests show that HM M  has no cytotoxic activity per 
se but instead requires m etabolic activation: 
HMPMM is cytotoxic and it has been suggested that 
this m olecule might be the active cytotoxic species 
in vivo  [22 ,23]. It is not known, however, if 
HMPMM is active as an intact m oiety or if it is a 
transport form o f cytotoxic form aldehyde. Several 
studies have shown that the addition o f semi- 
carbazide to cell cultures protects them from for­
m aldehyde toxicity [23-25]. The results obtained by 
treating cells with H M PM M  after semicarbazide pre­
treatment are som ew hat equivocal. In som e cell 
lines, cytotoxicity o f  HM PM M  appears to be due to  
form aldehyde, w hereas in others it appears to be 
directly due to the carbinolam ine. Ross et al. [24] 
compared the D N A  dam age caused by HMM (after  
m etabolic activation) with that caused by for­
maldehyde and found only low  levels o f D N A -p ro-  
tein crosslinks with H M M . whereas non-lethal con­
centrations o f form aldehyde caused high levels o f  
D N A -protein  crosslinks. They concluded that the 
cytotoxicity o f HM M  was unlikely to be due to 
formaldehyde. Studies involving [ 14C]ring- and [ UC] 
m ethvl-labelled HM M  in v ivo  have revealed that 
[ l4C]ring-HMM binds to a high degree to cellular  
m acrom olecules, suggesting that it is the whole m ol­
ecule that is bound and not only m etabolites of 
oxidised N-m ethyl groups as would be expected if 
only [ 14C]m ethyl-HM M  was found to be bound [26]. 
A m es et al. [20] studied the binding of the two  
differently labelled com pounds to calf thymus D N A  
in a microsomal incubation and found the two labels 
to be equally bound to the D N A . In contrast, binding 
of [14C]m ethvl-HM M  to protein was greater than the 
binding o f [ 14C]ring-HM M  which may be explained  
by assuming that two species are involved in covalent 
binding: the greater binding o f  the [ ,4C]m ethyl- 
HMM perhaps being due to oxidative metabolism of  
the N-methyl groups to produce formaldehyde which 
consequently reacts with proteins. ( l4C]Ring- 
HMPMM was shown to bind to D N A  and to a lesser  
extent to protein. H ow ever, in this case m etabolic  
activation was not required to obtain binding. On 
the basis o f these results, the form ation of an iminium
Unpublished observation.
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Fig. 14. Equilibria of taurolin (51) in aqueous solution
ion (48, Fig. 13) has been proposed by A m es et al. 
[20] to explain the binding of HM PM M  to cellular  
m acrom olecules, including D N A .
Studies in our own laboratories support this 
hypothesis. Reduction of HM PM M  with cvano- 
borohydride produced a small quantity o f H M M . 
the major product being pentam ethylm elam ine (49) 
from base-catalysed decom position o f HMPMM ."  
The HMM produced can only result from the  
reduction o f the m ethylene iminium ion suggested  
by A m es et al. [20]. Furthermore, incubation of 
pentam ethylm elam ine. form aldehyde and N -acetyl- 
cvsteine y ielded a .V-acetylcvsteine conjugate of 
HMM (50) [27], The mechanism of this reaction is 
not clear, but on e  possibility is an initial reaction  
between form aldehyde and PMM to form the car­
binolam ine H M PM M . which subsequently forms an 
iminium ion which reacts with N -acetylcysteine.
The question as to whether carbinolam ines and 
carbinolam ides exert their toxicity via form aldehyde  
or iminium ions has been investigated recently by 
G idley et al. [28] with respect to the m ode o f action  
of the “m asked” formaldehyde antibacterial agent 
taurolin (51). In aqueous solution the equilibrium  is 
established betw een (51). the carbinolam ine (52 ). 
the thiadiazine (53) and form aldehyde as showm in 
Fig. 14. The am ounts of form aldehyde produced in 
this equilibrium appeared to be insufficient to explain  
the antibacterial activity of taurolin. and the car­
binolam ine (52) was implicated as the active m oiety. 
To test this hypothesis, other carbinolam ines were  
generated in situ by mixing aqueous solutions of 
simple am ines and formaldehyde [28]. The authors 
investigated w hether it was possible to correlate anti­
bacterial activity with the presence o f m ethylene  
iminium ions. Iminium ions were detected by adding  
to the reaction mixture sodium  cvanoborohydride  
which reduces the iminium ion to the corresponding  
N-m ethyl com pound while only slowly reducing for­
m aldehyde to m ethanol. The reaction was fo llow ed  
by NM R spectroscopy. Solutions that dem onstrated  
the presence o f  iminium ions also show-ed anti­
bacterial activity, whereas those mixtures that did 
not generate im inium  ions, even if they could form  
carbinolam ines. show ed only low levels o f  anti­
bacterial activity. In contrast, the antibacterial agent 
noxvthiolin (54 . Fig. 15) decom poses to give only 
form aldehyde and the amide (55) [29|. H ere, treat­
ment with sodium  cvanoborohydride yielded m eth ­
anol with no indication o f the presence o f an im inium  
ion. In addition , for different concentrations and 
aues o f the so lutions, the antibacterial activity o f














Fig 15 Equilibrium  o f  n o x v th io lin  (5 4 ) in aq cu o u s  
so lu tio n
C H ,
noxvthiolin solutions was very similar to that o f the 
amounts o f free tormadehvde present. These results 
suggest that formaldehyde is the active antibacterial 
agent. The authors explained the observations 
obtained with the different “m asked” formaldehyde 
antibacteriais in terms o f the chem ical properties o f  
the N-C H 2-X group. In cases where X  is a reasonably 
good leaving group and the nitrogen possesses a basic 
non-bonding electron pair, form ation o f an iminium  
ion may occur. However, when X  is O H  and it is not 
easily expelled because the nitrogen is not basic, 
then the N -C H r OH m oiety may break down dif­
ferently to give formaldehyde which, in the absence 
o f other nucleophiles, is rapidly hydrated. Inves­
tigations in our own laboratories on a number o f  
N-methyl and N-hydroxymethyl com pounds are in 
accordance with this interpretation. We [30,31] and 
others [32] found relatively stable N-hydroxymethyl 
com pounds as m etabolites o f  N-m ethyl com pounds 
when the nitrogen was in the chem ical environment 
causing low basicity, such as in am ides (56), triazenes
(61) and ureas (60, Fig. 16). N ot surprisingly, the 
loss o f hydroxide from these stable N-hydroxymethyl 
com pounds is not favoured, so  that, for exam ple, 4- 
chloro-N-(hydroxym ethyl)benzam ide (57 , Fig. 16), 
a m etabolite of 4-chloro-N-m ethylbenzam ide (56) 
[31]. did not react with cyanide.* H owever, the 
possibility exists that the generation o f iminium ions 
from N-alkyl com pounds o f low  basicity may com e  
not directly from oxidation o f  the N-alkyl moiety as 
in the case of. for exam ple, nicotine, but instead 
after conjugation of the hydroxyalkylamine or 
hydroxyalkvlamide. Indeed, w e found that the acet­
ate esters o f certain carbinolam ides can react to form  
cyanide adducts. Incubation o f  N -(acetoxym ethyl)- 
benzamide (59) with cyanide produced 4-chloro-N- 
(cyanom ethyl)benzam ide (58).*  An equally striking 
example o f how phase 2 m etabolism  might activate 
an otherwise unreactive N-hydroxym ethyl com -
L n p u b lish ed  o b se rv a tio n .
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Fig. 16. Structures of 4-chloro-.V-methylbenzamide (56). 
its derivatives. .V. V-dimethylphenylurca (6t>) and 
ALV-dimethylaryliriazene (61).
pound is found in the solvolysis reactions o f som e  
recently reported ,V-(hydroxym ethyl)triazene 
derivatives [33]. The ;V-(acetoxym ethyl)triazenes 
(63, Fig. 17) are readily obtained by base catalysed  
acetylation of the .V-(hydroxvm ethyl)triazenes
(62). The acetates (63) undergo solvolysis to the 
jV-(methoxymethyl)triazenes (65) perhaps via the 
intermediate iminium ion (64) in m ethanol, 
whereas the underivatised (unconjugated) N- 
(hydroxym ethyl)triazene (62) does not generate  
iminium ions under the same conditions. T he only  
reaction o f ^-(hydroxym ethyO triazenes in m ethanol 
is the loss o f form aldehyde to produce the m on- 
om ethyltriazene (A r -N = N -N H R ).
In conclusion, in this review we have sum m arised  
the reports which have shown that reactive, e lec ­
trophilic. iminium ions may be generated by the 
m etabolism of a variety o f N -alkvlam ines and N- 
alkylamides. The ability o f these com pounds to form  
such species is dependent upon their basicity. In 
the case o f  hexam ethylm elam ine (47. Fig. 13) the 
generation o f an iminium ion during its m etabolic  N- 
dem ethylation is suggested to lead to a com pound  
capable o f reaction with D N A  [20], This result raises 
the question of whether this and other xenobiotics 
which have the potential to form an im inium  ion may 
therefore be genotoxic. a question presently under 
investigation by us. In addition, such agents may 
prove to be antitum our agents. The biological 
activity o f these com pounds is largely undefined and
CH,OH
! M e O H
C H . O M e
Fig 1“ C h em ica l fo rm a tio n  o f  an .V -(a c e to x y m c th v l) tr ia /e n e  (6 3 )  an d  it '  re .te n o n  w ith  m eth a n o l
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research on them may usefully provide a wealth of 
information in the future on both their hazards and 
utility.
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IDENTIFICATION BY PROTON NMR OF N-(HYDROXYMETHYL)-N-METHYLFORMAMlDE 
AS THE MAJOR URINARY METABOLITE OF N.N-DIMETHYLFORMAMIOE IN MICE*
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(R e c e iv e d  in  f i n a l  fo r a  December 4 ,  1985)
Summary
Urine samples from mice which had. received H.N-dimethylformamide 
were inves t iga ted  by high f i e l d  ^H-NMR spectroscopy. The most 
prominent s ignals  in the N-CH  ^ region had chemical s h i f t s  id en t ica l  
with those of N,N-dimethylTormamide ( 5 2.85, 3.01) and N-
(hydroxymethyl)-H-methyl formamide ( 6  2.91, 3 .05).  Resonances
downfield of 67.5 (from formyl protpns) a lso  coincided with those of 
the re ference  formamides. When [* C]methy 1- la b e l le d  N,N-dimethyl- 
formanide was in jec ted  and urine samples investiga ted  by rad io  th in  
layer chromatography, the major area of r a d io a c t iv i ty  corresponded 
to the  Rf of N-(hydroxymethyl)-N-methylformamide. Dimethyl amine and 
methyl amine were found to  be minor m etabolites of N,N-dimethyl - 
formami de.
The in d u s tr ia l  so lven t  DMF (Fig . 1) which shows some a n t in e o p la s t ic  
e f fe c ts  in mice (2) and i s  an hepatotoxin (3-6), undergoes extensive 
metabolism in laboratory  animals (7) and in workers who are occupationally  
exposed to  i t s  vapor ( 8 ) .  The N-desmethyl analogue NMF (F ig . 1 ) ,  an 
inves t iga t iona l  antitumor drug (9,10) and a potent hepatotoxin (11 ,12),  has 
been considered to  be the  major urinary  metabolite  of DMF (7 ,8 ) .  Recently, 
however, i t  has been suggested (13,14) th a t  the metabolite previously taken to 
be NMF on the basis  of GLC ana lys is  (15) i s  not NMF but HMMF (Fig. 1) which is 
thermally l a b i l e  giving NMF and formaldehyde. Yet, conclusive a n a ly t ica l  
evidence to  support th i s  l a t t e r  contention has h i th e r to  been lack ing . Here we
*Part7 in the s e r ie s :  The formation and metabolism of N-hydroxymethyl
compounds; for p a r t  6  see r e f .  ( 1 ).
+To whom correspondence should be addressed.
Abbreviations: DMF, N,N-dimethylformamide; DN8 S, 2 ,4-d in itrobenzenesu lfon ic
acid ; GLC, gas l iqu id  chromatography; HMMF, N-(hydroxymethy1)-N-methyl- 
formamide; NMF, N-methylformamide; NMR, nuclear magnetic resonance; TLC, th in  
layer chromatography.
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p resen t  unambiguous evidence from h ig h - f i e ld  *H-NMR spectroscopy th a t  HMMF i s  
indeed the major u r inary  m etabolite  of DMF. A dd it iona lly ,  we c h a ra c te r iz e  two 
minor in vivo m etabo li tes  of DMF as dimethyl amine and methylamine, which are  
conceivably enzymatic h ydro lys is  products of DMF and NMF re sp e c t iv e ly .  The 
usefu lness  of h ig h - re so lu t io n  h ig h - f i e ld  NMR spectroscopy in the a n a ly s is  of 
u r ina ry  m etabolites  of drugs has r e c e n t ly  been described for acetaminophen 
(16) .  This r e p o r t  p re se n ts  another example of the important ro le  of NMR 
spectroscopy in  u rinary  m etabo li te  i d e n t i f i c a t i o n .
M ateria ls  and Methods
DMF (Aldrich Chemical Co, Gillingham, Dorset, UK), ^Hy-OMF (Sigma 
Chemical Co, Poole, UK) or [* cjmethyl-DMF (a g i f t  from C. S te f fen ,  Marburg, 
W. Germany; 96* pure) were given in t r a p e r i to n e a l ly  (400 mg/kg in 0 .2  ml 
s a l in e )  to  CBA/CA mice (20-25 g). Animals were kept in metabolism cages for 
24 hr and u r in e  samples were c o l le c te d  and kep t  a t  -20 °C un t i l  a n a ly s is .  
Spectra of u r in e  samples and re fe ren ce  compounds in DoO a t  concen tra t ions  <1% 
were obtained using a Bruker WH400 instrum ent. Sodium 3 - ( t r im e th y l s i ly l  )- 
p ro p an - l- su lfo n a te  was used as in te rn a l  marker. Suppression of the H2 O signa l 
in  the v i c i n i t y  of 6  4 .8  was achieved by s e le c t iv e  p re sa tu ra t io n  (1 .5 s )  
followed by c o l le c t io n  of f re e  induction decay, with 4 preliminary dummy 
scans. Water suppression a f fe c ted  resonance s igna ls  caused by N-hydroxymethyl 
methylene protons in  HMMF which could th e re fo re  not be observed in u r in e .  HMMF 
was prepared by E N Gate according to  Grady and S t o t t  (17). Signals  observed 
u p f ie ld  of 6 4 .0  and downfield of $7.0 were su i ta b le  for an a ly t ic a l  d iagnosis  
and were compared w ith  s ig n a ls  in  sp ec tra  of re fe rence  compounds. The ur ine  
s ig n a ls  recorded in t a b le  1, column 5, were obtained from a spectrum of a 
sample of pooled u r ine  of 4 female mice. Urine of DMF-treated male mice 
afforded  an almost id e n t ic a l  spectrum.
For TLC a n a ly s is  u r in e  samples were placed on s i l i c a  gel 60 F254 p la te s  
(Merck AG, Darmstadt, W. Germany) of e i t h e r  0.2 or 2 mm coat th ick n ess ,  which 
were developed in  chloroformrmethanol 4:1 (v /v ) .  Location and sem iquanti­
t a t i v e  TLC autoradiography of r a d io la b e l le d  m etabolites  were performed by 
methods described  p rev iously  fo r  [^C]NMF (18). The spray reag en t  fo r  the 
d e tec t ion  of formaldehyde p recu rso rs  was a mixture of phenyl hydrazine and iron 
( I I I )  c h lo r id e  (19). Treatment of urine  samples w ith  DN3S and q u a n t i ta t io n  of 
u r ina ry  alkylamines by HPLC as t h e i r  2 , 4-dinitrophenyl d e r iv a t iv e s  was 
performed according to  Saba e t  al (20) w ith  m odifications (18). Under these  
cond it ions  apprec iab le  evapora tion  of amines did not occur.
Results
^H-NMR an a ly s is  of u r in e  samples from mice whicn had rece ived  DMF 
afforded several s ig n a ls  which were absen t from the spectra  of con tro l urine  
or of the u r ine  of mice t r e a te d  with 2^-DMF (Table 1). The most prominent 
s ig n a ls  from the u r ine  of DMF-treated mice had chemical s h i f t s  id e n t ic a l  to 
those of the  methyl protons of DMF and HMMF. The in teg ra l  r a t i o  of s ig n a ls  a t  
62.85 and $3.01 i s  1 : 1  corresponding to the resonances from the methyl groups 
o f  re fe ren ce  DMF, which are  t r a n s  ( Jfonnyi h CH ° * 5  92  ^ and 
( J formylH,CH3  0Hz> r e s p e c t iv e ly .  ’ 3
The two s ig n a ls  for  the  methyl protons of HMMF a t  6 2 . 9 1  and 63.05 have an 
in te g ra l  r a t i o  of c a .  5:1 and a r i s e  from E_ and 2 rotamers r e s p e c t iv e ly .  We 
have p rev iously  ( 2 1 ) determined a r a t i o  of 87±6:13±6 for t h i s  compound 
using NMR spectroscopy. Assignment of rotamers was made from the spectrum 
of au th en t ic  HMMF in D?0 w ith  transo id  4-Dond couplings (formyl H. to  D^OD or 
CH3 ) being observed and c i s o id  couplings absen t .  The major (E^ rotamer gave
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^formylH,CH2  3 -°  Hz and the mi' nor sp e c ie s  gave -.formylH,CH3  ° * 5  Hz*
0  CH-d (d)
^  /  JC - N/  v
0 ^  W a , 0 ,  w
C - N  f - H ,/  \
( O N  CH3 (bi  10 H H
W 2
( g ) H  VCH3 (f)
D M F  H MM F  N M F
FIG. 1
S tructures  o f  DMF, HMMF and NMF.
TABLE 1
Chemical s h i f t s  of major ^H-NMR s i g n a l s  in the spectra of contro l urine and ur ine  o f  
mice a f t e r  a d m in istra tion  of DMF or ZH^ -DMF (400 mg/kg).
Regi on o re fe ren c e  compounds* 6 control urine a f t e r 5 urine  a f t e r
with r a t i o s  of ur i ne zh7- dmf DMF**
r e la t iv e  in te g r a t io n ( i n te g r a t io n )
52.5 - 63.5 2 .60  [CH3NH3+] 
2 .72  C( CHo^NHp]
2 .6 0 2.60 2 .60 (5)
2 .72 2.72 2.72 (26)
2 .7 6  (h)
2 .85  (b) 2.85 (19)
/ 2.86 (8)
1:1 2 .89
\ v 2 . 9 1  ( d ) . 2.91 (64)
' 3 . 0 1  ( a ) \ 3.01 (20)
\  5:1 3 .02 3.02
3:1 V  
\  3 . 05  ( f K  \




67.5 - 68.5 \  7 . 93  ( c ) '








8 .45 8.45 8.45 (3)
* for  proton assignment see  F ig . 1.
** In ad d it ion  there  were minor s i g n a l s  a t  a l l  chemical s h i f t s  o f  the control u r in e  
resonance freq u en cies  and a t  6 2 .7 5 .
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HOD
i;x //■1------1------!----- i----- !-----W/---- - ---- J----- - ---- :----- '—/--- - ---- i----- - ---- :--------
8-4 8*2 8-0 5*0 4*8 4-6 3-2 3-0 2-8
p p m
FIG. 2
^H-NMR spectrum of  the m e ta b o l i t e  i s o la t e d  by TLC. For assignment of  
s ig n a l s  t o  protons see  F ig .  1.
Resonances downfield  o f  6  7 .5  arose  from the formyl p ro to n s .  Assignment 
of th e s e  s i g n a l s  to the var iou s  formamides presen t was made on th e  b a s is  o f  
comparison of chemical s h i f t s  w ith  r e fe r e n c e  compounds and on in t e g r a t io n  
v i s - a- v i s  the  N-CH3  S1 9 na l s .  Only a very small peak was observed in the  
spectrum o f  u r in e  from DMF-treated mice a t 6  2 .7 5  (correspond!*ng to  the major 1 
rotamer o f  NMF) confirm ing t h a t  NMF i s  but a minor m eta b o lit e  o f  DMF.
R a d io a c t iv i ty  d e tected  on radio-TLC a n a ly s i s  o f  urine samples of mice 
which had r e c e iv e d  [ 1 4 C]methyl -DMF was con cen tra ted  in one area (Rf 0 .6 5 )  
rep resen t in g  45% o f  the d o se .  R a d io a c t iv i ty  was a l s o  p resen t  a t  Rf 0 .0 2  (7% 
of the d o s e ) ,  which co-chromatographed w ith  d im ethyl-  and methyl amine, and Rf
0 .8 5  (1% o f  the  d o s e ) ,  which was the  Rf va lue  o f  [ 1 4 C]DMF. The major meta­
b o l i t e  gave a p o s i t i v e  co lo u r  r e a c t io n  for  formaldehyde. The p la t e  material  
in  the v i c i n i t y  o f  Rf 0 .6 5  was e lu t e d  w ith  w ater .  On GLC a n a l y s i s  under the  
c o n d it io n s  d escr ib ed  p r e v io u s ly  (13 )  the e lu t e d  m ateria l l i k e  a u th e n t ic  HMMF 
afforded a peak id e n t ic a l  to  th a t  produced by NMF. NMR a n a ly s i s  o f  a f r e e z e -  
dried e x t r a c t  y i e l d e d  a spectrum c o n ta in in g  s i g n a l s  id e n t ic a l  to  those o f  
a u th en t ic  HMMF (F ig .  2 ) .
NMR sp e c tr a  of urine samples con ta in ed  two resonance fr e q u e n c ie s  w ith  
chemical s h i f t s  id e n t ic a l  to  th ose  o f  the  methyl protons o f  dimethyl amine 
h ydrochlor ide  ( 62 -72) and methylamine hydroch lor ide  ( o 2 . 6 0 ) .  These protons  
were p r e se n t  in  con tro l  urine  and urine o f  ^Hy-DMF-treated mice but were
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m arkedly augmented in  the u r in e  of DM F-treated mice, which in d ic a te s  th a t  both 
amines a re  DMF m e ta b o lite s .  HPLC a n a ly s is  of u r in a ry  a lk y lam in es a f t e r  
d e r iv a t iz a t i o n  .witn DNBS a ls o  showed a s ig n i f ic a n t  in c re a se  o f dim ethylam tne 
and m ethyl amine ex c re te d  a f t e r  DMF a d m in is t ra t io n .  In the  ca se  o f d im e th y l- 
am ine, th e  amount ex c re ted  exceeded th e  c o n tro l level by a f a c to r  o f 4 and 
re p re s e n te d  3.9±1.9% (n=3) o f the  d o se . The amount o f m ethylam ine e x c re te d  
a f t e r  DMF a d m in is tra tio n  in c re ase d  by a f a c to r  o f 5 over th e  c o n tro l  le v e l and 
c o n s t i tu t e d  4.1±0.7% of the  dose.
D iscussion
I t  has been suggested  th a t  tne major u rin a ry  m e ta b o lite  o f DMF which has 
been c h a r a c te r is e d  as NMF on GLC a n a ly s is  o f u rin e  sam ples of an im als (7 ) o r 
humans (8 ) exposed to  DMF i s  r e a l ly  HMMF and n o t NMF (1 3 ,1 4 ) . T his h y p o th e s is  
has so f a r  been based on two ambiguous p ie c e s  of ev idence . The u r in e  o f  DMF- 
t r e a te d  mice has been shown to  c o n ta in  a s ta b le  form aldehyde p re c u rs o r  (1 3 ) , 
bu t i t s  chem ical id e n t i ty  was no t c h a ra c te r iz e d  f u r th e r .  R e c e n tly , ev idence 
has been p re se n ted  (22) which shows t h a t  among the c o n s t i tu e n ts  in  th e  u r in e  
o f r a t s  t r e a te d  w ith  DMF was one which a ffo rd e d  the  fragm ents o f a u th e n tic  
HMMF on mass sp e c tro m e tric  a n a ly s is  a f t e r  se p a ra tio n  by GLC. However, th e  
d e f in i t i v e  in te r p r e ta t io n  o f the mass s p e c tra  of small m o lecu la r w eig h t 
c o n s t i tu e n ts  in  u r in e  s u f fe r s  from th e  s c a r c i ty  of u n ique ly  c h a r a c t e r i s t i c  
mass, fra g m en ts . The r e s u l t s  p rese n ted  h ere  show unequ ivoca lly  t h a t  th e  m ajor 
u r in a ry  m e ta b o lite  of DMF in  mice i s  indeed HMMF and n o t NMF.
Whereas DMF i s  m etabolized  only  to  a minor e x te n t when in c u b a te d  w ith  
l i v e r  p re p a ra tio n s  (1 3 ,1 5 ,2 3 ), i t  undergoes ex ten siv e  m etabolism  in  v ivo  
( 7 ,8 ,1 3 ,1 4 ) .  In mice 55% of a dose of 400 mgAg was e x c re te d  as w hat we have 
now shown’ to  be HMMF w ith in  24 h r a f t e r  a d m in is tra t io n , and on ly  5% as  
unchanged DMF (1 3 ). • Dimethyl amine and methylamine a re  a l s o ,  a l b e i t  m inor,
m e ta b o l i te s  o f DMF in  m ice.
A ccording to  the  r e s a l t s  p re se n ted  h e re , i t  i s  u n lik e ly  t h a t  NMF i s  
r e s p o n s ib le  fo r  th e  h e p a ta to x ic  p o te n t ia l  o f DMF. However, HMMF m ight be 
r e s p o n s ib le .  The b io lo g ic a l p r o p e r t ie s  of HMMF a re  n o t known and i t  i s  
c o n c e iv ab le  t h a t  i t  i s  h e p a to to x ic . C e rta in  alkylam ines a re  m e tab o lized  to  
ca rb in o lam in es  w hich, by lo s s  of h y d ro x id e , can e x i s t  in  e q u i l ib r iu m  w ith  
r e a c t iv e ,  p o te n t ia l ly  *toxic a lk y len e  iminium io n s  (24 ). However, on the  b a s is  
o f  ex p erim en ts  which showed th e  lack of p r o c l iv i ty  of N -(hydroxym ethyl) -am ides 
such a s  N-(hydroxymethyl )-benzam ide and N-(hydroxymethy 1 )-form am ide to  form 
m ethylene iminium ions (unpub lished  d a ta ) we co n sid er i t  u n l ik e ly  t h a t  HMMF i s  
th e  p re c u rso r  of a to x ic  iminium s p e c ie s .
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Structural Studies on Bioactive Compounds. 4.1 A Structure-Antitumor Activity 
Study on Analogues of jV-Methylformamide
E. Nicholas Gate, Michael D. Threadgill,* Malcolm F. G. Stevens, David Chubb, Lisa M. Vickers,
Simon P. Langdon, John A. Hickman, and Andreas Gescher
Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University,
Aston Triangle, Birmingham B4 7ET, U.K. Received July 11, 1985
A series of derivatives of N-methylformamide (NMF), an experimental antitumor agent, has been prepared, having 
the general formula R^QQNR'R2 where R1 = H, CH3, CD3, CH2CF3, CH2CH2C1, cydopropyl, CjHj, CHjOH, CH2OR, 
CH2N(CH3)2; R2 = H, CH3; R3 = H, CF3, CC13, CH3, Ph, NHCH3, N(CH3)2; and X = 0 , S, NH. A further short 
series of “push-pull" olefins of the general formula R1R2C=CHNR3R4 has been synthesized where R l = H, CH3 
and R2 = H, N 02, CN, CHO, CH3 and R3 = H and R4 = H, CH3, morpholino. These compounds have been tested 
for activity against the M5076 ovarian sarcoma and the TLX5 lymphoma in mice. NMF was by far the most potent 
agent of both series with activity against both tumors. Some other compounds showed weak activity, but there 
is a rigorous structural requirement for activity and most analogues were inactive. Certain members of the series 
exist as equilibrium mixtures of rotamers about the amide or pro-amide bonds as shown by NMR.
The antitumor activity of N-methylformamide (NMF; 
NSC 3051: 1) in experimental use was first described2 in 
1953. A subsequent clinical trial3 in five patients was 
terminated when indications of hepatotoxicity intervened. 
We have shown that the hepatotoxicity of NMF toward 
mice can be minimized if the drug is scheduled in divided 
doses;4 moreover, optimum antitumor activity is elicited 
if the drug is administered in a chronic schedule.4 On the 
basis of these preclinical studies, a new phase 1 trial was 
conducted, and the dose-limiting toxicities were hyper­
bilirubinemia, nausea, and malaise. Remarkably the agent 
has no myelosuppressive activity in rodents or in man.5 
Beneficial effects of 1 in combination with conventional 
(myelosuppressive) antitumor agents have been demon­
strated against rodent experimental tumors.6 The drug 
is now in phase 2 trial particularly against lung and colon 
tumors since the compound is very active against the NCI 
lung (LX-1), colon (CX-1), and mammary (MX-1) human 
tumor xenografts implanted in mice.7
Earlier studies on analogues of NMF tested against the 
Ehrlich ascites8 and sarcoma 180 tumors2 revealed that 
only the simplest amides, NMF, and formamide 2 had 
antitumor activity. We have screened a range of form- 
amides, thioformamides, acetamides, benzamides, ureas, 
thioureas, guanidines, enamines, and vinylogous amides
3-35 and some related compounds 36-39 against either the 
TLX5 lymphoma or the M5076 reticulum cell sarcoma (or 
both). These tumors are sensitive to a range of agents that 
have an N-alkyl group bearing an electron-withdrawing 
substituent, The TLX5 lymphoma is especially sensitive 
to nitrosoureas,9 triazenfes,10 and the recently discovered 
imidazotetrazines11 whereas the M5076 tumor is addi­
tionally responsive to the 1,3,5-triazine series based on 
hexamethylmelamine.12 Structure-activity studies in the 
aforementioned agents have confirmed a requirement for 
either an N-methyl or N-(2-haloethyl) fragment for opti­
mum antitumor activity. It was of interest, therefore, to 
investigate whether or not there are similar structural
( 1 ) Presented in part at the 25th Annual Conference of the British 
Association for Cancer Research, Manchester, U.K., 1984. For 
the previous paper in this series, see: Griffin, R. J.; Schwalbe,
C. H.; Stevens, M. F. G.; Wong, K. P. J. Chem. Soc., Perkin 
Trans. 1 1985, 2267.
(2 ) Clarke, D. A.; Philips, F. S.; Sternberg, S. S.; Barclay, R. K.; 
Stock, C. C. Proc. Soc. Exp. Biol. Med. 1953, 84, 203.
(3) Myers, W. P. L.; Karnofsky, D. A.; Burchenal, J. H. Cancer 
1956, 9, 949.
(4) Langdon, S. P.; Chubb, D.; Hickman, J. A.; Stevens, M. F. G. 
Toxicology 1985, 34, 173.
(5) McVie, J. G.; Ten Bokkel Huinink, W. W.; Sim onetti, G.; 
Dubbelman, R. Cancer Treat. Rep. 1984, 68, 607.
(6 ) Langdon, S. P.; Hickman, J. A.; Gescher, A.; Stevens, M. F. G.; 
Chubb, D.; Vickers, L. M. Eur. J. Cancer 1985, 21, 745.
(7) Lomax, N. R., Narayanan, V. L. In Chemical Structures of 
Interest to  the Division of Cancer Treatment-, Drug Synthesis 
and Chemistry Branch, Developmental Therapeutics Program, 
National Cancer Institute: Bethesda, M D, 1981.
(8 ) Furst, A.; Cutting, W. C.; Gross, H. Cancer Res. 1955,15, 294.
(9) Gibson, N. W.; Hickman, J. A. Biochem. Pharmacol. 1982.31, 
2795.
(10) Gescher, A.; Hickman, J. A.; Simm onds, R. J.; Stevens. M. F. 
G.; Vaughan, K. Biochem. Pharmacol. 1981, 30, 89.
( 1 1 ) Langdon, S. P.; Chubb, D.; Vickers, L. M.; Stone, R.; Stevens, 
M. F. G.; Baig, G. U.; Gibson, N. W.; Hickman, J. A.; Lunt, E.; 
Newton, C. G.; Warren, P. J.; Smith, C. Br. J. Cancer 1985,52, 
437.
(12) Langdon. S. P.; Gescher, A.; Hickman, J. A.; Stevens, M. F. G. 
Eur. J. Cancer 1984, 20, 699.
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req u irem en ts in a series o f  analogues o f  N M F . 
C h e m is tr y
P reparation  o f the sim ple N -alkylform am ides 3 -6  and  
N -h y d ro x y -N -m eth y lfo rm a m id e  (15) was ach ieved  by  
form ylation  o f  the appropriate am ine by a lcoholic  ethy l  
form ate in th e  presence o f  an inorganic base. H owever  
2,2 ,2 -trifluoroeth ylam ine proved to  be in su ffic ien tly  nu- 
cleophilic toward this agent, and a more vigorous m ethod, 
previously  u sed  by  u s13 for th e  syn thesis o f  N -m eth y l-  
[MC ]form am ide involving controlled  fusion o f  sodium  
[14C ]form ate w ith  the am ine hydrochloride, was em ployed  
for th e  sy n th e sis  o f  7. T h e isom eric N -m ethyltrifluoro- 
acetam ide (18) was prepared d irectly  from  m eth ylam in e  
and trifluoroacetic anhydride. A ttem pts to alkylate N M F  
1 or form am ide 2 at nitrogen using a variety o f  conditions, 
inclu d ing  th e  use o f the a lum ina-supported potassium  
fluoride ca ta ly st reported by Y am aw aki,14 were unsuc­
cessfu l.
H y d roxym eth y la tion  o f  form am ide and N M F  w ith  
form aldehyde in the presence o f a catalytic am ount o f base 
gave th e  carb inolam ides 9 and 12, respectively; these  
co lorless o ils  were therm ally  unstab le  and could  n o t be  
purified by  distillation . In contrast, the carbinolam ide 22 
could be crystallized to  purity.15 T h e major contam inant 
in 12 (show n b y  N M R ) was 5% o f  the starting N M F  
whereas th e  N M R  spectrum  (!H and l3C) o f N -(h ydroxy- 
m eth yl)form am ide (9) show ed num erous im purities in ­
cluding, probab ly , N ,N -b is(h yd roxym eth y l)form am id e
(40). T h e  in v o lv em en t16 o f 40 in the H C O N H 2/H C H O /  
H C O N H C H 2O H  system  is also  ind icated  in th e  reaction  
o f 9 w ith  benzoyl chloride in which both th e  expected
(13) Threadgill, M. D.; Gate, E. N. J. Labelled Compd Radiop- 
harm. 1983, 20, 447.
(14) Yamawaki, J.; Ando, T. Chem. Lett. 1979, 755.
(15) Gate, E. N.; Hooper, D. L.; Stevens, M. F. G.; Threadgill, M.
D.; Vaughan, K. Magn. Reson. Chem. 1985, 23. 78.
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m onoester 41 and bis[(benzoyloxy)m ethyl]form am ide (42) 
are form ed. Two pathways are possible for the production  
o f  42 (Schem e I): the preform ed N ,N -b is(h y d ro x y -
m eth y l) form am ide (40) m ight be esterified  by benzoyl 
chloride: alternatively , the interm ediate m onoester  41 
could be hyd roxym ethylated  by form aldehyde and  su b ­
seq u en tly  benzoylated . E sterification  o f N -(h yd roxy-  
m eth yl)-N -m eth ylform am id e (12) proceeded stra ightfor­
wardly to  give 13 and 14. T h e  ether 10 was prepared from  
N -(h ydroxym eth yl)form am id e (9) in acid ic e th an o l, th e  
m ech an ism  presum ably involving trapping o f th e  in ter ­
m ediate17 N -form ylm ethyleneim inium  ion (43) by  ethanol 
(Schem e I).
T he am inal 11 was synthesized by the E inhom  reaction18 
from  d im ethylam in e, form aldehyde, and form am ide. In 
th is  case, the im in ium  ion in term ediate  a r ises19 from  
condensation  o f form aldehyde w ith  the secondary am ine  
rather than with form am ide. T h e  am inal was qu atem ized  
to  afford the trim ethylam m onium  iodide 44 in order to  
enhance th e  leaving-group ab ility  o f  the am ino group. A 
variety  o f  basic con d ition s was exam ined  in an e ffo r t to 
e ffec t condensation  o f  th e  sa lt w ith  N -acetyl-L -cysteine: 
N M R  analysis o f the products confirm ed the presence of 
N -acety l-S -(form am id om eth y l) cy stein e  (45), bu t a pure 
sam p le  cou ld  not be iso lated  from  the m ixtures.
N JJ-Dim ethy\g\ycine  (37) was prepared in tw o effic ien t 
steps: substitu tion o f brom ide in m ethyl brom oacetate by 
dim ethylam ine was followed by acid hydrolysis o f  th e  ester 
to  give th e  hydrochloride sa lt o f  37 in 76% overall y ield .
S y n th esis  o f the “pu sh -pull"  o lefins and v inylogous  
am ides 2 9 -3 5  involved cond en sation  o f the appropriate  
activated  m ethyl and m eth ylen ic  substrates w ith  a dialk- 
oxy m eth y l electroph ile . S y n th e tic  and conform ation al 
stu d ies on nitro enam ines 2 9 -31  have been describ ed  by
(17) Review: Overton, M.; Hickman, J. A.; Threadgill, M. D.; 
Vaughan, K.; Gescher, A. Biochem. Pharmacol. 1985, 34, 2055.
(18) Einhorn, A. Liebigs Ann. Chem. 1905, 343, 207.
(19) Zaugg, H. E.; Martin, W. B. Org. React. 1965. 14, 52.
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u s previously.20 T he morpholine analogue 32 was prepared 
in  a three-com ponent condensation  (n itrom ethan e, m or­
ph olin e, and triethyl orthoform ate). T h e  lH N M R  sp ec­
trum  o f  th is  com pound confirm s E  geom etry  abou t the  
C = C  bond in so lution  in d im ethyl su lfox id e  (c/ c ih .czh  =  
11 Hz); th is  coupling constan t is d iagn ostic  o f  trans cou­
p ling  in 30  and 3 1.20 T reatm ent o f  preform ed 2-cyano-3- 
e th oxyp rop en en itr ile  w ith  m eth ylam in e in a conjugate  
a d d itio n -e lim in a tio n  reaction afforded the m onom ethyl 
d icyan o  enam ine 33 w hereas use o f m alonon itrile  as th e  
activ a ted  m eth y len ic  reactant in cond en sation  w ith  di- 
m ethylform am ide dim ethyl acetal furnished the d im ethyl 
analogue 34. A ttem pts to  prepare 2 -n itro-3-(sub stitu ted  
am ino) propenenitriles through co n d en sation  using the  
relatively unstable nitroacetonitrile (46) were unsuccessful.
T h e  vinylogous am ide 35 was form ed in good yield from  
trea tm en t o f  3-m eth oxy-2-m eth ylp rop en al w ith  m eth y l­
am ine again via a conjugate addition -elim ination  reaction. 
P roton N M R  spectroscopy o f 35 in chloroform showed the  
E  conform ation  about th e  pro-am ide C -N  bond ( J C3H .nh  
=  14 Hz). A lso, com pound 33 is shown to  be a 5:1 m ixture 
o f  rotam ers in d im ethyl su lfox id e w ith  th e  E  conform er  
(«/vinyiCHjjh =  15 H z) about the pro-am ide bond predom ­
in atin g  over th e  Z  form (</vinyicH.NH = 9  H z).
A n t itu m o r  A c t iv ity
O f the range o f am ides screened a ga in st the T L X 5  
lym phom a (T able II), only N M F  (1) (optim um  T /C  191% 
a t  800 mg k g '1), its CD3 analogue 3 (T /C  142% at 400 mg 
kg-1 day-1), and the N -e th y l hom ologue 4 (T /C  137% at 
800 mg kg-1 day-1) display activity. T he M 5076 tum or was 
co m p lete ly  inh ib ited  by N M F  a t a dose o f  200 m g kg-1 
d a y -1 for 17 d ays (T able III), but, o f th e  o ther congeners 
o f  N M F  tested , only form am ide (2), N ^N -dim ethylform - 
a m id e (D M F, 8), N -(h ydroxym eth yl)form am id e (9), and  
N -m eth y lb en zam id e (21) show ed m arginal activ ity . P ar­
ticu la r ly  notew orthy  is th e  in a ctiv ity  o f  N -(2-ch loro- 
ethyl)form am ide (5) against the T L X 5  lym phom a, which  
contrasts w ith  th e  m arked a ctiv ity  e lic ited  by the 2- 
chloroethyl derivatives in the nitrosourea,9 triazene,10 and  
im idazotetrazine11 series and suggests that the formam ides 
m ay operate by  a nonalkylating m echanism .
(20) Gate, E. N.; Meek, M. A.; Schwalbe, C. H.; Stevens. M. F. G.; 




r5 / C v- nr'r2
R, Rj R3 X
1 Me H H 0
2 H H H O
3 c d 3 H H O
4 Et H H O
5 c h 3c h 2c i H H O
6 cyclopropyl H H O
7 CHjCF3 H H O
8 Me Me H O
9 CHjOH H H O
1C CH2OEt H H O
11 CHjNMej H H 0
12 CH2OH Me H 0
13 CH2OAc Me H 0
14 CH20 2CPh Me H 0
15 Me OH H O
16 Me Me H s
17 Me H Me 0
18 Me H c f 3 0
19 Me Me Me 0
20 CH2OH H CC13 0
21 Me H Ph 0
22 CH2OH H Ph 0
23 OH H NH2 0
24 Me H NHMe 0
25 Me Me NMe, 0
26 Me H NHMe s
27 Me Me NMe2 s
28 Me Me NMe2 NH
29 H H H c h n o 2
30 Me H H c h n o 2
31 Me Me H c h n o 2
32 -CH2CH2OCH2CH2- H c h n o 2
33 Me H H C(CN)2
34 Me Me H C(CN)2
35 Me H H C(Me)CHO
M any N -a lk y l xenobiotics are m etabolized to  the cor­
responding a-hydroxy derivatives, som e of which give rise 
to  electrophiles.16 T hus, the possibility21 that N M F  m ight 
require in vivo  m etab olic  activation  to N -(h yd roxy-  
m eth y l)form am id e  (9), or a conjugate thereof, was given  
in itia l credence w hen the carb inolam ide was show n to 
possess p o ten t inh ib itory activity against the T L X 5  lym ­
phom a in vitro: how ever, th is e ffec t m ay have been m e­
d iated21 by traces o f cytotoxic form aldehyde that contam ­
inated th e  sam p le o f 9. A ttem pts to  purify the sam ple of 
9 by fractional d istilla tion  led to  fragm entation o f  the  
carbinolam ide in to  starting m aterials, form aldehyde, and  
form am ide. Four N -hydroxym ethyl com pounds 9 (a m e­
ta b o lite  o f  N M F  in m ice),22 12 (th e  major m etab o lite  o f  
dim ethylform am ide in rodents),23 and the carbinolam ides 
20 and 22, derived from trichloroacetamide and benzam ide, 
respectively, were all devoid o f activ ity  against the T L X 5  
lym phom a in v ivo  (T able II). N evertheless, com pound 9 
show ed m arginal activity against the M 5076 tum or (T able  
III), a lb e it a t a very high dose (1600 mg kg-1 daily  x  17). 
T h e d isa p p o in tin g  in vivo results w ith  these com poun ds  
m ay reflect an inh eren t lack o f  a ctiv ity  o f JV-hydroxy- 
m eth y l am ides per se, a lthough N -h ydroxym eth yl co m ­
pounds o f  the m elam ine2* and triazene10 series are at least
(21) Cooksey, P. G.; Gate, E. N.; Gescher, A.; Hickman, J. A., 
Langdon, S. P.; Stevens, M. F. G. Biochem. Pharmacol. 1983, 
32. 3037.
(22) Kestell, P.; Gescher, A.; Slack, J. A. Drug. Metab. Dispos. 1985. 
13 587
(23) Kestell, P.; Gill, M. H.; Threadgill. M. D.; Gescher. A.: Ho- 
warth, O. W.; Curzon. E. H. Life Sci. 1986, 38. 719.
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Table II. Antitumor Activity of N-Methylformamide and Its Active Analogues® against the TLX5 Lymphoma6 in Mice
dose range tested, mg kg' 1 day'
optimal dose/ 










































° Analogues 5, 7-15, 17, 20, 22, 23, 29, 30, 32-39 were found to be inactive against this tumor. The data for these compounds are presented 
in the supplementary material (see below). 6 The TLX5 lymphoma was passaged at 7-day intervals by ip injection of 2 x  10s cells into 
female CBA/ca mice (18-23 g). For antitumor tests 2 x  10s cells were injected subcutaneously into the inguinal region of female CBA/ca 
mice (18-23 g). Drugs were dissolved in physiological saline or Me^O/arachis oil (1:9) and administered daily for 5 days by ip injection 
commencing 72 h after tumor implantation. The mean day of death of groups of five animals were recorded and survival times of treated 
animals (T) compared with untreated controls (C). A value of T /C  (X100%) of >125 is considered significant antitumor activity. 'Except 
for compound 1 where a range of doses is described. * Value at optimal dose. 'T /C  X 100% for NMF (1) at this dose was 139 in this 
experiment.
Table III. Antitumor Activity of N-Methylformamide and Its Active Analogues® against the M5076 Reticulum Cell Sarcoma6 in Mice
dose range 
tested, mg kg' 1 
day' 1
LD10,e mg 
kg' 1 day' 1
optimal 
dose* mg













































1.0 (0 .2) 
0.8 (0 . 1) 























“Analogues 4, 6 , 12, 16-19, 24-28 were found to be inactive against this tumor. The data for these compounds are presented in the 
supplementary material (see below). 6 Fragments of tumor were obtained from donor BDF, mice (18-23 g). These were pooled, homogen­
ized, and diluted with saline to produce a suspension of 107 cells mL~l. Cells (10s in 0.1 mL) were injected intramuscularly into the left hind 
legs of groups of five female BDF! mice (18-23 g). Drugs were administered daily for 17 days by ip injection commencing 24 h after tumor 
implantation. Mean tumor volumes (in cm3) were determined 24 days after tumor implantation. Tumor diameters were measured by 
calipers and the volumes calculated according to the following formula: volume = (/ X w2) /2 where I is the longest tumor diameter and w the 
diameter perpendicular to the long axis. The volume of the leg without tumor is 0.1-0.2 cm3 when measured in this manner. Tumors 
smaller than 0.2 cm3 are “nonmeasurable” (NM). The mean tumor volumes of test animals (T) was compared to those of controls (C). A 
value of T /C  X 100% of <42% is considered significant antitumor activity.6 'Lethal dose values were estimated on day 24 from the number 
of survivors in the drug-treated groups. * Except for compound I where a range of doses is described.
as active  as their  N -m eth y l analogues. A lternatively, the  
in a ctiv ity  o f th e  N ’-hydroxym ethyl derivatives in the for­
m am ide ser ies m ay be due to pharm acokinetic problem s 
asso cia ted  w ith  their  h igh polarity. Su ccessfu l chem ical 
effo r ts  to  prepare lip oph ilic  prodrug-m od ification s o f  
AL(hydroxym ethyl)form am ide (9) did not lead to biological 
activ ity . T h u s, /V -(ethoxym ethyl)form am ide (10), N- 
{(d im eth y lam in o)m eth y l]form am id e (11), and 1,3,5-tri- 
form ylhexahydro-l,3,5-triazine (39) were all inactive in vivo 
aga in st the T L X 5  lym phom a as were the acetyl (13) and  
b e n zo y l (14) d e r iv a tiv es  o f  N -(h y d r o x y m eth y l)-N -  
m eth y lform am id e (12).
P o ssib ly , m etab o lic  hyd roxylation  o f N M F  represents  
a bioinactivation as far as antitum or activity is concerned,21 
bu t its in v o lv em en t in  th e  h ep a to tox ic ity  o f the drug 
cannot be excluded . M etabolic N -hydroxylation was also 
considered , bu t th e  possib le  product o f  such  a pathway, 
N -hydroxy-N -m ethylform am ide (15), a known teratogen,25 
proved in active  a ga in st th e  T L X 5  lym phom a as did an­
other N -h yd roxy  com pound, the clin ically  used hydroxy­
urea 23.
It has been show n recen tly22 th a t the form yl carbon o f  
N M F  is ex ten siv e ly  m etabolized , being excreted by mice  
as carbon dioxide. T he inactivity o f  a series o f com pounds
(24) Rutty, C. J.; Abel, G. Chem.-Biol. Interact. 1980. 29. 235.
(25) von Kreybig, T.; Preussmann, R.; Schmidt. W. Arzneim.-
Forsch. 1968. 18. 645.
where th e  formyl hydrogen is replaced by m eth yl or su b ­
stitu ted  m ethyl groups (17-20) or am ino and su b stitu ted  
am ino groups (23-28) and the corresponding inactiv ity  of 
derivatives where th e  form yl oxygen is replaced by sulfur 
(16, 2 6 -2 7 ) a ttests  to  the critical influence o f  th e  form yl 
group in m ediating the activ ity  o f  N M F. C om pounds 21 
and 38 do, however, possess marginal activ ity  against the  
M 5076 sarcom a. R ep lacem ent o f the form yl group by 
su bstitu ted  ethenyl residues to afford “p u sh -p u ll” olefins  
29-34  and the v inylogous N M F  35 led to  lo ss o f activ ity , 
except in the case o f  N ,N -d im eth y l-2 -n itroeth an eam in e
(31), which inhibited both tumors, although not m arkedly  
w ith T /C  x  100% =  139 on T L X 5 and T /C  x  100% = 
35 on M 5076 experim ents. Interestingly, the corresponding 
m onom ethyl com pound 30, arguably a closer analogue of 
N M F  (w ith  a 9:1 Z /E  ratio o f rotam ers abou t the  
M eN H -C  bond),20 is inactive against the T L X 5  lym phom a  
(T able II).
In conclusion , N M F  (1) is the only com poun d  in the  
series reported w ith  good inhibitory activ ity  aga inst both  
the T L X 5  lym phom a and M 5076 reticu lum  cell sarcom a  
in vivo; any structural m odification  has a dyschem other- 
apeutic effect. T hese results are consistent w ith an earlier 
stu d y8 on the e ffec ts  o f form am ides aga in st th e  Ehrlich  
ascites tumor, which dem onstrated that there is a rigorous 
structural requirem ent for antitum or activ ity . O ther tu ­
mors do  respond to  certain  of the agents descr ib ed  here: 
worthy o f m ention is the inhibitory activity o f  N M F  ( l ) ,26
1050 Journal of Medicinal Chemistry, 1986, Vol. 29, No. 6
N-(hydroxymethyl)formamide (9),21 N-(acetoxymethyl)- 
N-methylformamide (13), and carecamide 08)26 against 
the MX-1 mammary xenograft Moreover, recent interest 
in NMF stems from the recognition that it is a prototype 
of a new class of low molecular weight antitumor agent 
capable of inducing terminal differentiation of human 
tumor cell lines such as the human promyelocytic leukemia 
HL60,27 a property that it shares with a number of the 
congeners described in this paper. Results of these studies 
will be described in a future paper.28
Experimental Section
Unless otherwise stated, NMR spectra were obtained at 60 MHz 
with Varian EM360A and Varian A60A spectrometers. Other 
NMR spectra were acquired at 80 MHz and 220 MHz with Bruker 
WP80 and Perkin-Elmer R34 instruments, respectively. IR 
spectra were recorded with Pye Unicam SP2 0 0  and Perkin Elmer 
1310 spectrometers. Melting points are uncorrected.
N-(Hydroxymethyl)-2,2^2-trichloroacetamide (20) was a kind 
gift of Professor Bundgaard (Copenhagen, Denmark) and N,0- 
bis-(iV-methylcarbamoyl)acetohydroxamic add (38, carecamide) 
was donated by the Drug Resources Branch of the National Cancer 
Institute. iV-(Trideuteriomethyl)formamide (3) ,13 N-(acetoxy- 
methyl)-N-methylformamide (13),15 N-(hydroxymethyl)benzamide
(22) , 15 2-nitroethenamine (29),20 N-methyl-2-nitroethenamine 
(30),20 and N.N-dimethyl-2-nitroethenamine (31)20 were prepared 
as previously described by us.
AT-Ethylformamide (4). Ethyl formate (74.0 g, 1 .0  mol) was 
added to 70% aqueous ethylamine with cooling, and the mixture 
was stirred a t ambient temperature for 2 h. Distillation gave 
N-ethylformamide (70.0 g, 96%) as a colorless liquid, bp 195-198 
°C (lit.29 bp 197-199 °C).
Ar-(2-Chloroethyl) formamide (5). Sodium (2.30 g, 100 mmol) 
was dissolved in anhydrous ethanol (100 mL). Ethyl formate (25 
mL), anhydrous Na2C0 3  (20 g), and 2-chloroethylamine hydro­
chloride (8.15 g, 70 mmol) were added at -5 °C during 30 min. 
Stirring was continued a t ambient temperature for 20 h before 
the mixture was filtered. Distillation of the filtrate afforded the 
formamide (5.50 g, 51%) as a colorless liquid: bp 98-100 °C (2  
mm) (lit30 bp 79-95 °C (2 mm)); IR (liquid film) 3290,1670, and 
1520 cm"1; NMR (CDCI3) 3 3.5-3.7 (m, 4 H, CH2CH2), 7.5 (br, 
1 H, NH), and 8.0-8.3 (m, 1 H, CHO); MS, m/z 109/107 (M+).
fV-Cyclopropylformamide (6 ). Cyclopropylamine (11.4 g, 
200 mmol) was added to a mixture of ethyl formate (50 mL), 
anhydrous Na2C03 (30 g), and anhydrous ethanol (50 mL) at -5 
°C, and the mixture was stirred at ambient temperature for 20 
h. N-Cyclopropylformamide was isolated as for 5 above as a 
colorless liquid (10.0 g, 59%), bp 8 6 - 8 8  °C (3 mm); IR (liquid film) 
3260 and 1670 cm '1; NMR (220 MHz, CDC13) 3 0.9-1.1 (m, 4 H, 
CH2CH2), 2.6-2.85 (m, 1 H, cydopropyl 1-H), 8.18 (s, 0.6 H, CHO 
of Z rotamer), and 8.29 (d, J  -  12 Hz, 0.4 H, CHO (£)); MS, m /z  
85 (M+). Anal. (C<H7NO) C, H, N.
lV-(2^2-Trifluoroethyl)formamide (7). A mixture of sodium 
formate (680 mg, 10  mmol) and 2 ,2 ,2 -trifluoroethylamine hy­
drochloride (1.35 g, 10 mmol) was heated gently under reflux for 
2 0  min in the apparatus described previously18 and then distilled. 
This product was redistilled (Kugelrohr) to give N-(2 ,2 ,2 -tri- 
fluoroethyl) formamide (1.05 g, 83%) as a colorless liquid: bp 70-80 
°C (3 mm); IR (liquid film) 3310,1680, and 1540 cm’1; NMR (220 
MHz, CDCI3) 6 3.96 (dq, J  = 6.5 and 10 Hz, 1 .8  H, CH2CF3 of 
Z  rotamer), 8 .1 1  (d, J  = 11.5 Hz, 0.1 H, CHO (E)). 8.23 (s, 0.9 
H, CHO (Z)), and 8.75 (br, 1 H, NH); MS, m /z  127 (M+). Anal. 
(C3H4F3NO) C, H, N.
(26) Lomax, N- R.; Narayanan, V. L. In Chemical Structures of 
Interest to the Division of Cancer Treatment; Drug Synthesis 
and Chemistry Branch, Developmental Therapeutics Program, 
National Cancer Institute: Bethesda, MD. 1984; Vol. 4.
(27) Collins. S. J.; Ruscetti, F. W.; Gallagher, R. E.; Callow, R. C. 
Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 2458-
(28) Langdon, S. P.; Hickman, J. A. Br. J. Cancer 1985, 51. 601.
(29) W east. R. C. In “CRC Handbook of Chemistry and Physics', 
58th ed., CRC Press: Cleveland; OH, 1979.
(30) Franco, F.; Muchowski, J. M. J. Heterocycl. Chem. 1980, 17, 
1613.
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JV-(Ethoxymethyl)formamide (10). A mixture of 40% 
aqueous KOH (2 mL, 14 mmol), formamide (45 g, 1 mol), and 
paraformaldehyde (33 g, 1 .1  mol HCHO) was stirred for 30 min 
before ethanol (200 mL) and concentrated H ^ I^  (3 mL) were 
added. The reaction mixture was stirred for a further 6  h and 
filtered. Anhydrous diethyl ether (25 mL) was added to the 
filtrate. The whole was allowed to stand over NaHC03 for 20 h, 
filtered, and concentrated under reduced pressure. The residue, 
in water (50 mL), was extracted with dichloromethane (5 x 1 0 0  
mL). The combined extracts were washed with water and dried 
(Na^O*) and the solvents evaporated under reduced pressure. 
Distillation gave N- (ethoxymethyl) formamide (22.0 g, 21%) as 
a colorless liquid: bp 108-120 °C (1  mm) (lit.31 bp 71-82 °C 
(0.01-0.1 mm)); ER (liquid film) 3450 and 1670 cm-1; NMR (CDCI3) 
5 1.16 (3 H, t, J  = 7 Hz, CH3), 3.53 (m, 2 H, C //2CH3), 4.7 (m, 
2  H, NCH20), 7.1 (br, 1 H, NH), and 8.27 (m, 1 H, CHO); MS, 
m /z 103 (M*).
Af-(Dimethylaminomethyl)formamide (II). Aqueous 
formaldehyde (37%, 112 g) was added dropwise to a mixture of 
formamide (45 gv 1 mol) and 40% aqueous dimethylamine (70 
g) at 0 °C. The whole was stirred a t ambient temperature for 
20 h. Distillation furnished N-(dimethylaminomethyI)formamide 
(68*1  g, 67%) as a colorless oik bp 10 0  °C (3 mm) (lit.32 bp 62-65 
°C (0.05 mm)); IR (liquid film) 3300 and 1650 cm-1; NMR (CDCI3) 
5 2.25 (m, 6  H, NfCHa)^, 4.0 (m, 2 H, NCH2N), 7.1 (br, 1 H, NH), 
and 8 .2  (m, 1 H, CHO); MS, m /z 1 0 2  (M+).
jV-(Hydroxymethyl)-N-methylformamide (12) was pre­
pared by the method of Grady and Stott.33 :H NMR showed 
the product to contain 5% Af-methylformamide (1). The former 
decomposed on attempted distillation. N-(Hydroxymethyl)for- 
amide (9) was similarly prepared .33
JV-[(B«nzoyloxy)methyl]-lV-methylformamide (14). N- 
(Hydroxymethyl)-iV-methylformamide (11; 95%; 9.0 g, 96 mmol) 
and benzoyl chloride (11.5 mL) were stirred together in 5% 
aqueous NaOH (120 mL) at 0 °C for 30 min. The oily lower layer 
was washed with aqueous NaHC03. Distillation furnished the 
ester (5.2 g, 29%) as a colorless oil: bp 154 °C (3 mm) (lit.34 bp 
111-123 °C (0.02 mm)); ER (liquid film) 1720 and 1690 cm-1; NMR 
(220 MHz; (CDsJjSO) b 2.94 (s, 2.55 H, NCH3 of Z  rotamer), 3.14 
(s, 0.45 H, NCH3 (£)), 5.64 (s, 0.3 H, NCH2 (£)), 5.72 (s, 1.7 H, 
NCH2 (Z)), 7.66 (m, 3 H, Ar 3-, 4-, and 5-H), 8.08 (m, 2 H, Ar 2- 
and 6 -H), 8.29 (s, 0.15 H, CHO (£)), and 8.70 (m, 0.85 H, CHO 
(Z)).
AT-Hydroxy-Ar-methylformamide (15). To N-methyl- 
hydroxylamine hydrochloride (835 mg, 10 mmol), in methanol 
(20 mL), was added sodium methoxide (540 mg, 10 mmol), fol­
lowed by ethyl formate (20 mL). The whole was stirred for 16 
h before being filtered through diatomaceous earth. The solvents 
were evaporated from the combined filtrate and methanol 
washings. Distillation of the residue gave the hydroxamic acid 
(610 mg, 81%) as a colorless oil: bp 140-147 °C (1 mm) (lit.35 
bp 60 °C (0.005 mm)); IR (liquid film) 2300 (br) and 1670 cm'1; 
NMR (CDCI3) b 3.20 (br s, 3 H, CH3), 7.8-8.2 (m, 1 H, CHO). and 
9.73 (s, 1 H, OH).
JV-MethyI-2,2,2-trifluoroacetamide (18). Excess methyl- 
amine was passed through a solution of trifluoroacetic anhydride 
(12.6 g, 60 mmol) in diethyl ether (400 mL) during 2 h. The 
mixture was filtered and the filtrate was concentrated under 
reduced pressure. The residue was distilled at 3 torr to give 
/V-methyl-2,2,2-trifluoroacetamide (4.44 g, 58%) as a white solid: 
mp 45 °C (lit36 bp 80 °C (3 mm), mp 48-49.5 °C); IR (Nujol mull) 
3320, 1700, and 1560 cm-1; NMR (CDC13) b 2.95 (d, 3 H, J  = 5 
Hz, NCH3) and 7.2 (br, 1 H, NH).
N-(2-Nitroethenyl)m orpholine (32). A mixture of tri- 
methoxymethane (29.6 g, 279 mmol), morpholine (8.7 g, 100 
mmol), nitromethane (30.5 g, 500 mmol), and toluene-4-sulfonic 
acid (500 mg) was boiled under reflux for 1 h. Evaporation of
(31) Finkelstein, M.; Ross, S. D. Tetrahedron 1972. 29, 4497.
(32) Bohme, H.; Fuchs. G. Chem. Ber. 1970, 103. 2775.
(33) British Patent 1092632.
(34) Ross, S. D.; Finkelstein, M.; Petersen, R. C. U.S. Patent 
3411997, 1968.
(35) Walter, W.; Schaumann, E. Liebigs Ann. Chem. 1971, 743,154.
(36) Pailer, M.; Huebsch, W. J. Monatsh. Chem. 1966, 97, 1541.
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excess reagents under reduced pressure and passage of the residue 
through a short column of silica gel in CH2C12 followed by re- 
crystallization from EtOH afforded N-(2-nitroethenyI)morpholine 
(10.4 g, 73%) as yellow needles: mp 142.5 °C (lit.37 mp 140-141 
°C); IR (KBr) 1625 cm"1; NMR ((CD^jSO) b 3.63 (m, 8  H. CHj),
7.00 (d, 1 H, J  = 1 1  Hz, 2 -H), and 8.30 (d, 1 H, J  = 11 Hz, 1-H).
2-Cyano-3-(methylamino)propenenitrile (33). Excess me- 
thylamine was passed into a suspension of 2-cyano-3-ethoxy- 
propenenitrile (1.22 g, 10 mmol) in diethyl ether (50 mL) at 0 °C 
and the whole was stirred a t ambient temperature for 2 0  h. 
Evaporation of the solvent and excess methylamine under reduced 
pressure and recrystallization of the residue from anhydrous EtOH 
yielded 2-cyano-3-(xnethylamino)propenenitrile (770 mg, 72%) 
as orange microcrystals: mp 191-194 °C (lit.38 mp 191-192 °C); 
IR (KBr) 3250, 2220, 2200, and 1640 cm"1; NMR ((CD^jSO) 6 
2.97 (d, J  = 4 Hz, 2.5 H, NCH3 of £  rotamer about vinyl-N bond),
3.07 (m, 0.5 H, NCH3 (Z)), 7.53 (d, J  = 9 Hz, 0.17 H, CH (Z)), 
7.83 (d, J  = 15 Hz, 0.83 H, CH (£)), and 8 .8  (br. 1 H, NH); MS, 
m/z 107 (M+).
2-C yano-3-(dim ethylam ino)propenenitrile (34). Di- 
methylformamide dimethyl acetal (4.76 g, 40 mmol) and pro- 
panedinitrile (2.64 g, 40 mmol) were stirred together for 5 h and 
then concentrated under reduced pressure to give a yellow solid. 
Chromatography (silica gel, ethyl acetate) furnished the amino 
nitrile (1.0 g, 21%) as a white solid: mp 80.5-82 °C (lit39 mp 82-83 
°C); IR (KBr) 2220, 2210, and 1650 cm-1; NMR (CDCI3) b 3.23 
(s, 3 H, NCHa), 3.37 (s, 3 H, NCH^, and 7.1 (s, 1 H, CH); MS, 
m /z 1 2 1  (M+).
2-M ethyl-3-(methylamino)propenal (35). Ethanolic me­
thylamine (33%, 12.5 mL, 135 mmol) was added dropwise to
3-ethoxy-2-methylpropenal (11.4 g, 10  mmol) at 0 °C and the whole 
was stirred a t ambient temperature for 20 h. Distillation gave 
a yellow oil (bp 114-118 °C (2 mm)), which was redistilled to afford 
2-methyl-3-(methylamino)propenal (5.7 g, 58%): bp 114-116 °C 
(1  mm); mp 55 °C; IR 3260,1660, and 1580 cm"1; NMR (80 MHz, 
CDCla) 6 1.65 (s, 3 H, CCHa), 3.07 (d, J  = 3 Hz, 3 H, NCHj), 6.54 
(br, 1 H, NH), 6 .8 6  (d, J  = 14 Hz, 1 H, NCH), and 8.84 (s, 1 H, 
CHO); MS, m /z 99 (M+). AnaL (CsH9NO) C, H, N.
N'^V-Dimethylglycine (37). Dimethylamine hydrochloride 
(50 g) was dissolved in HjO (100 mL) and diethyl ether (400 mL) 
was added at 0 °C followed by sufficient anhydrous K2C03 to dry 
the organic phase. Filtration gave an ethereal solution of di­
methylamine to which was added methyl bromoacetate (15.3 g, 
1 0 0  mmol), and the mixture was allowed to stand a t ambient 
temperature for 20 h. The precipitated dimethylamine hydro­
bromide was removed by filtration and the filtrate was concen­
trated at atmospheric pressure. Distillation of the residue gave 
methyl (dimethylamino)acetate (9.13 g, 77%) as a colorless liquid: 
bp 45-51 °C (20 mm) (lit40 bp 50-54 °C (30 mm)); ER (liquid film) 
1740 cm-1. The above ester (9.13 g, 77 mmol) was boiled under 
reflux in 11 M hydrochloric acid for 24 h before evaporation of 
the excess reagent and drying at 1 0  torr in the presence of sodium 
hydroxide pellets gave NJ\f-dimethylglycine hydrochloride (10.70 
g, 99%) as a white powder mp 187-189 °C (lit41 mp 186-189 
°C); IR (liquid film) 2930 (br) and 1740 cm-1; NMR (CDC13) 6
2.9 (s, 6  H. N(CH3)2), 4.3 (s, 2 H, NCH2), and 7.4 (br, 2 H, NH 
and OH).
l,3,5-Triform ylhexahydro-l,3,5-triazine (39). Acetic an­
hydride (21.4 g) was added during 20 min to formic acid (9.7 g, 
2 1 1  mmol) at -5 °C. Hexamethylenetetramine (6.7 g, 48 mmol) 
was added during 1.5 h such that the temperature remained below 
1 0  °C, and then the mixture was stirred at ambient temperature 
for 2 h. Water (1 1  mL) was added and the mixture was neutralized 
by addition of K2C 03. After evaporation of the solvents under 
reduced pressure, the residue was extracted with CHC13. Drying 
(Na2S04) and evaporation of the solvent furnished a white solid 
which was recrystallized from anhydrous EtOH to yield the 
hexahydrotriazine (2.4 g, 22%) as an hygroscopic white solid: mp
(37) Falques, M.; Rene, L.; Royer, R. Synthesis 1982, 261.
(38) Trofim enko, S. J. Org. Chem. 1963, 28, 2755.
(39) Meerwein, H.; Florian, W.; Schon, N.; Stopp, G. Liebigs Ann. 
Chem. 1961. 641, 1.
(40) Terakawa, T . </. Pharm. Soc. Jpn. 1954, 74, 287.
(41) Taylor, W. I.; Uyeo, S.; Yajima, H .J. Chem. Soc. 1955, 2962.
170.5-171.5 °C (lit.42 mp 171-172 °C); IR 1710 and 1675 cm '1; 
NMR (CDCla) 6 5.2 (s. 6  H, NCH2N) and a25 (s, 3 H, CHO); NMR 
(CF3C02H) b 5.5 (s, 6  H, NCH2N) and 8.46 (m, 3 H, CHO); MS, 
m /z  171 (M+). Anal. (C6H9N30 3) C, H, N.
W -[(Benzoyloxy)methyl]formamide (41) and N JV -Bis- 
[(benzoyloxy)m ethyl]form am ide (42). To Af-(hydroxy- 
methyl)formamide (4; 10.0 g, 133 mmol) and triethylamine (20 
mL) in THF (100 mL) at 0 °C was added dropwise benzoyl 
chloride (17 mL). The mixture was stirred for 1 h at 0 °C, then 
filtered and concentrated under reduced pressure. The residue, 
in CHC13, was washed with NaHC03 and water and dried 
(Na2S 04), and the solvents were evaporated under reduced 
pressure. Chromatography (silica gel, chloroform) gave N- 
[(benzoyloxy)methyl]formamide (240 mg, 1%): mp 8 6 - 8 8  °C from 
aqueous MeOH; IR (KBr) 3250,3150,1710, and 1690 cm"1; NMR 
(220 MHz, CDCy b 5.52 (d, J  = 8.5 Hz, 0.67 H, CH2 of E  rotamer), 
5.58 (d, J  = 8.5 Hz, 1.33 H, CH2 (Z)), 6.94 (br, 0.33 H, NH (£)),
7.07 (br, 0.67 H, NH (Z)), 7.52 (m, 2  H, Ar 3- and 5-H), 7.66 (m, 
1 H, Ar 4-H), 8.11 (m, 2 H, Ar 2- and 6 -H), 8.35 (s, 0.67 H, CHO 
(Z)), and 8.48 (0.33 H, d, J  = 11  Hz, CHO (£)); MS, m /z  180 (M 
+ 1). AnaL (C9HgN02) C, H, N. Evaporation of the solvents 
from earlier eluates afforded N^V-bis[(benzoyloxy)methyl]form- 
amide ( 1 0 0  mg, 0 .2 %) as a colorless oil: ER (liquid film) 1720 and 
1710 cm"1; NMR (CDCy b 5.75 and 5.8 (2  x s, 4 H, CHj), 7.3 (m, 
6  H, 3-, 4-, and 5-H), 7.75 (m, 4 H, 2- and 6 -H), 8.63 (s, 1 H, CHO). 
Anal. (C17Hl5N0 5 ) C, H, N.
N-(Formamidomethyl)trimethylammonium Iodide (44). 
A mixture of iodomethane (10 mL) and N-[(dimethylamino)- 
methyl] formamide (9; 5.1 g, 50 mmol) was stirred in diethyl ether 
at 0 °C for 2 h. The evaporation residue was recrystallized from 
EtOH to give N-(formamidomethyl)trimethylammonium iodide 
(5.9 g, 58%) as a white solid: mp 149-151 °C Git.43 mp 151-156 
°C dec); IR (KBr) 3300 and 1695 cm*1; NMR ((CD^jSO) 5 3.1 
(9 H, s, NtCHala), 4.75 (d, J  = 7 Hz, 1.6 H, NCH2N of Z rotamer),
5.00 (d, J  -  7 Hz, 0.4 H, NCH2N (£)), 8.45 (s, 0.8 H, CHO (Z)), 
8.57 (m, 0 .2  H, CHO (£)), and 9.4 (br, 1 H, NH).
N itroacetonitrile (46). Freshly distilled thionyl chloride (4.3 
mL) was added dropwise to a solution of 2 -nitroacetaldoxime44 
(6.0 g, 58 mmol) in boiling anhydrous diethyl ether (40 mL) during 
5 min, and the mixture was boiled under reflux for a further 1 
h. Filtration and concentration under reduced pressure gave a 
yellow oil which, in diethyl ether, was washed with water and dried 
(CaCy, and the solvents were evaporated to give nitroacetonitrile 
(2.9 g, 58%) as a brown oil: IR (liquid film) 1560 and 1350 cm-1; 
NMR (CDC13 + (CD^jSO; 3:1) b 5.85 (s, 2 H, CH2); MS, m /z  120 
(M+).
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A r e n e d i a z o n i u m  S a l t s  w i t h  F o r m a m i d e
M ichael D. Threadgill * and Adrian P. Gledhill
Cancer Research Campaign Experimental Chemotherapy Group. Pharmaceutical Sciences Institute. Aston 
University. Aston Triangle. Birmingham B4 7ET
Treatment of preformed arenediazonium tetrafiuoroborates or arenediazonium trifluoroacetates (formed 
in situ) with formamide and base effects reduction to the corresponding arene in moderate to good yield 
in cases where an electron-withdrawing substituent is present on the aromatic ring. Other functionalities 
remain unaffected. The mechanism of the protodediazoniation is shown to involve transfer of the formyl 
hydrogen atom to the substrate and may proceed via a 1 -aryl-3-formyltriazene.
It has recently been shown that many jV-methyl-containing 
compounds are metabolised by a preparation of murine liver to 
the corresponding W-hydroxymethyl derivatives2 and, in the 
case o f /V-methylbenzamide, oxidised further to the N-C H O  
compound, jV-formylbenzamide.3 l-Aryl-3,3-dimethyltriazenes 
are known antitumour agents but require prior oxidative 
metabolism for activity,* 3-(hydroxymethyl)triazenes being 
implicated as intermediates. In order to be able to test the 
hypothesis that these latter triazenes could be further meta­
bolised, like the benzamides, to Af-formyl analogues, a synthetic 
programme towards the preparation of l-aryl-3-formyltri- 
azenes was initiated. However, during this programme, the sole 
identifiable product (in moderate yield) from treatment of
r2iT S nh2
(1 )
a; R 1 =  R 2 =  R4 =  H . R J =  C O ,M e
b; R ' =  R 2 =  R4 =  H . R 3 =  C O ,E l
c; R ' =  R 2 =  R4 =  H . R 3 =  N O ,
d; R ‘ =  R 3 =  H . R 2 =  2.4-diam ino-6-ethylpyrim idin-5-yl. R4 = Cl
e; R ' =  R J =  H. R 2 =  N O ,.  R4 =  M e
f; R ' =  C N . R 2 =  R 3 =  R4 =  H
g. R 1 =  O M c. R 2 =  R4 =  H. R 3 =  N O ,
h; R ’ =  R 2 =  R4 =  H . R1 =  Ac
i; R 1 =  Ac, R 2 =  R J =  R4 =  H
j; R ' =  C O ,M e . R 2 =  R 3 =  R4 =  H
k; R ' =  M e. R 2 =  R 3 =  R4 =  H
t  R ' =  M e. R2 =  R4 =  H . R 3 =  N O ,
m; R ‘ =  R 2 =  R4 =  H . R 3 =  O M e
a. R ' =  R 2 =  R4 =  H . R 3 =  M e
o: R 1 =  R 2 =  R4 =  Br. R 2 =  H
p; R 1 =  R 2 =  R4 =  H . R 3 =  Br
4-methoxycarbonylbenzenediazonium tetrafluoroborate (2a) 
with formamide and base was methyl benzoate (3a). Several 
agents have been reported to reduce arene diazonium salts to
R1
R2( f V 2+ .
( 2 )
R '.R 2R3R4 as (1)
a— f; X =  B F .
g - p ;  X =  C F ,C O ,
the corresponding arene, including tetrahydrofuran,5 form­
aldehyde,6 hypophosphorous acid.7 AW-dimethylformamide8 
(DM F), and alcohols,9 although problems have been en­
countered with each method. For example, biphenyls have been 
observed9 as important by-products in the ethanol reduction. 
Formamide has once been claimed 8 to reduce a diazonium salt 
but the yield was reported to be markedly inferior to that 
achieved when the substrate was treated with DM F.
(3 )
Cl
a; R' = R2 = R4 = H. R3 = CO,Me
b; R' = R2 = R4 = H. R3 = CO,Et
c  R' = R2 = R* = H. R3 = NO,
d: R 1 =  R 3 =  H . R 2 =  2 .4-d iam ino-6-ethylpyrim id in-5-yl. R4
e: R 1 =  R 3 =  H . R 2 =  N O ,.  R4 =  M e
f; R ' =  C N . R 2 =  R 3 =  R4 =  H 
g; R ' =  O M e. R 2 =  R4 =  H. R 3 =  N O ,
h. R ' =  R 2 =  R4 =  H . R 3 =  A c
i; R' =  M e. R 2 =  R4 =  H . R 3 =  N O ,  
j R ‘ =  R 3 =  R4 =  Br. R 2 =  H
k ; R ‘ =  R 2 =  R4 =  H . R 3 =  Br
In order to investigate the generality of the reduction of (la) 
by formamide, nitroaniline ( lc ) and 5-(3-amino-4-chloro- 
phenyl)-6-ethylpyrimidine-2,4-diamine (id) were diazotised in 
the usual way with sodium nitrite in aqueous tetrafluoroboric 
acid. The diazonium salts were isolated and dried before being 
dissolved in anhydrous formamide and treated with triethyl- 
amine. In both cases, good yields of the protodediazoniatcd 
product (3c,d) were obtained.
The method can be made into a true ‘one-pot' synthetic 
reaction by carrying out the diazotisation with the formamide 
as solvent. Trifluoroacetic acid serves as the acid catalyst 
required. The intermediate diazonium trifluoroacetates were 
not isolated but the success of the sodium nitrite diazotisation 
step was indicated routinely by the formation of a bright 
orange-red azo-dye on treatment of a withdrawn aliquot with
2-naphthol and aqueous potassium carbonate. Addition at this 
stage of a large excess of triethylamine caused the rapid 
evolution of nitrogen gas characteristic of the reaction. Many 
arylamines were found to be deaminated by this facile process, 
as shown in the Table.
Substrates bearing only electron-donating substituents in the 
paro-position. such as methoxy and methyl as in (lm ) and (In).
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did not give the expected arene, only tarry materials resulting. 
However, where an electron-withdrawing substituent was 
present in substrate (lg ) along with an electron-withdrawing 
moiety, protodediazoniation was achieved.
When 2-methylaniline (Ik) was diazotised and treated with 
formamide and triethylamine according to the general one-pot 
procedure, the expected reduction product, toluene, was not 
observed by t.l.c. analysis of the reaction mixture. Here the 
isolated products were 2-methylphenol (4) and a trace of 
indazoie (5). As with the diazonium salts (2iimi), 2-methyl- 
benzenediazonium (2k) is insufficiently electrophilic to be 
reduced by the formamide but undergoes base-catalysed cydis- 





h c o n h 2
CF3c0 2H 












Schem e I. D iazo tisa tion  o f  2-m ethylaniline in form am ide. fo llow ed  by 
reaction w ith triethylam ine gives products o f  sub stitu tion  and cyclis- 
ation , not reduction
water to give the phenol. Indazoie formation has been widely 
reported to be the outcome of attempted protodediazoniation 
of 2-methylbenzenediazonium salts; for example, the treatment 
of 2-methylanilines with pentyl nitrite and dioxane or tetra- 
hydrofuran has been reported5 to give indazoles as the sole 
products. When a powerful electron-withdrawing moiety, such 
as nitro, is present attached to the aromatic ring as in the cases 
of (le) and (II), we find indazoie and phenol formation to be 
suppressed and good yields of the reduction products are
obtained. This is consistent with Marx's observation10 that 
5-nitroindazole is not a product of the interaction of 2-methyl- 
4-nitrobenzenediazonium tetrafluoroborate with dimethyl- 
formamide.
Steric hindrance in the form of one orr/io-substituent, as in 
the cases of the salts (2b,e— g,ij,I) does not interfere with the 
progress of the reaction as shown by the moderate to good  
yields using these substrates or intermediates. However, where 
two bulky (bromo) substituents are present ortho to the 
diazonium function in salt (2o), the yield drops to 16%.
Mechanistic Studies.—The hydrogen atom which replaces the 
diazonium group on the arene could, at first sight, be derived 
from any of a number o f sources including the formyl and N H 2 
protons of the formamide, the triethylamine, or water. Water 
has been shown not to be the hydrogen source in a deuterium 
labelling study by Doyle et al.6 in which 2,4,6-trichIoroaniline 
was diazotised with t-butyl nitrite and then reduced by 
HCO NM e2 in the presence of one equivalent of D 20 .  However, 
the tertiary amines tribenzylamine and iViV-dimethylbenzyl- 
amine have been reported n to be the hydrogen source when 
2,4,6-trichlorobenzenediazonium tetrafluoroborate was treated 
with the amines. In considering the formamide, Doyle et a l}  
also suggest that, since AWWA^-tetramethylurea is as effective 
a reducing agent towards arenediazonium salts as is NN- 
dimethylformamide, then the formyl group is not the hydrogen 
source. This proposal is, however, weakened by their com ­
parative study using AW-dimethylacetamide which was totally 
ineffective in reducing 4-nitrobenzenediazonium tetrafluoro­
borate (2c), whereas DM F gave a good yield of nitrobenzene.
In the present work, a sample of formamide deuteriated in the 
formyl group but not at the N H 2 function was prepared in a 
straightforward manner from 99 atom% methyl deuterioform- 
ate (D C 0 2Me) and ammonia in anhydrous methanol. In­
sufficiently rigorous exclusion of moisture was found to lead to 
extensive hydrolysis of the starting ester. Treatment of the 
diazonium salt (2c) with this regiospecificaily labelled form­
amide (6) and triethylamine furnished 4-deuterionitrobenzene 
(7) in which no pentaprotio compound could be detected by ‘H 
n.m.r. or mass spectroscopy. Hence, the formyl group is the sole 
hydrogen source under the conditions employed here (Scheme 
2). This method using a relatively simply prepared isotopomer
BFt '
0->N
N 2 +  DCONH2 ( 6 )
Et->N 0->N
(2C) ( 7 )
Schem e 2. R eaction  o f  d iazon iu m  salt (2c) w ith  deuterioform am ide
of formamide may prove to be a useful method for the regio- 
specific labelling of aromatic compounds.
The question now arises as to whether the reduction process 
involves intermolecular hydride or H’ transfer from formamide 
to arene or, alternatively, is the originally sought l-aryl-3- 
formyltriazene formed in situ as an intermediate followed by 
intramolecular hydride transfer (Scheme 3). In their com ­
parative study of aryl diazocyanides and aryl diazoisocyanides, 
Ignasiak et al.12 prepared l-aryl-3-formyltriazenes in low yield 
by treatment of solid arene diazonium chlorides and formamide 
in ether with aqueous sodium hydrogen carbonate. In the 
present study, the tetrafluoroborate (2c) was subjected to 
similar treatment, giving, in low yield, 3-formyl-l-(4-nitro- 
phenyl)triazene (8) accompanied by a quantity of the reduction
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product, nitrobenzene (3c). Interestingly, Ignasiak reports the 
crude formyl triazenes to be oily solids; perhaps the liquid 
components were the corresponding reduction products. Re­
action of (8) with triethylamine effected reduction smoothly to 
give (3c), thus implying that compound (8) is an intermediate
Table. Methods and yields of protodediazoniation products
( 8 )
in the protodediazoniation reaction and that hydride 
transfer is intramolecular (Scheme 3). The absence of biphenyl 
derivatives from the products of these reactions is indicative 
that radical processes {e.g. H’ transfer) are not involved, 
unlike in cases where hypophosphorous acid 13 and alcohols14 
are the reductants.
r rr< V N^ N " N'
T  
0
■cr" N <  / NH
CHO
Scheme 3. Proposed pathway of the reduction reaction
The identities of co-products arising from the reducing agent 
formamide have not been established. Consideration of the 
proposed reaction pathway would suggest that isocyanate 
(" NC O ) should be formed. However, attempts to trap it as 4- 
chlorophenylurea 15 by treatment of the mixture arising from 
(2c), formamide, and triethylamine with an excess of acetic 
acid and 4-chloroaniline were unsuccessful. Furthermore, the 
cyclic trimer, cyanuric acid (2,4,6-trihydroxy-1.3,5-triazine) was 
shown by t.l.c. to be absent.
In conclusion, a method for the efficient protodediazoni­
ation of arenediazonium salts bearing electron-withdrawing 
substituents has been developed. The facility of this reaction 
may explain why Af-formyltriazenes have not been reported as 
metabolites of the antitumour A-methyltriazenes in marked 
contrast to the situation in the benzamide series.3
Experim ental
The following methods are illustrative. M.p.s are uncorrected. 
N.m.r. spectra were obtained at 60 MHz using a Varian 
EM360A spectrometer and a Perkin-Elmer 1310 instrument 
furnished the i.r. data.
M ethod A: Nitrobenzene (3c) from  A-Nitrobenzenediazomum 
Tetrafluoroborate (2c).—Triethylamine (375 mg, 3.7 mmol) was 
added to 4-nitrobenzenediazonium tetrafluoroborate (474 mg,
2.0 mmol) in formamide (2.0 ml). After the evolution of nitrogen 
had ceased (5 min), the red mixture was stirred at ambient 
temperature for a further 30 min. An ethyl acetate extract (20 
ml) of the mixture was washed with water (4 x 25 ml), 2m- 
hydrochloric acid (2 x 20 ml), saturated aqueous sodium 
hydrogen carbonate (20 ml), and saturated brine (15 ml) before 
being dried (N a2SO,*), filtered, and the solvent evaporated to
Substrate Method Product* Yield (°
(2 a) A (3a) 58*
(2 b) A (3b) 21'
(2 c) A (3c) 82*
(2 d) A (3d) 64*
(2 e) A (3e) 78'
(2f) A (3f) 35'
(lg) B (3g) 67
(lh) B (3b) 25
(H) B (3h) 29
(Ik) B (3a) 73.5
dj) B (4)‘ 2 0
(5)' Trace
(ID B (3i) 53
(lm ) B 0
(In) B e 0
(lo) B (3j) 16
(lp) C (3k) 60.5
* Products were characterised by n.m.r. and mass spectroscopy and 
had m.p.s or b.p.s consistent with reported values (‘CRC Handbook of 
Chemistry and Physics', ed. R. C. Weast. CRC Press, Cleveland. Ohio, 
U.S.A_ 1979, 58th edn.; P. B. Russell and G. H. Hitchings, J. Am 
Chem. Soc.. 1951. 73. 3763; P. H. Griffiths, W. A. Walkcy, and H. B. 
Watson. J. Chem. Soc.. 1934, 631). ‘ Yield based on isolated 
arenediazonium tetrafluoroborate. ' Yield based on starting aniline. 
‘ Toluene shown by t.l.c. to be absent. 'Starting material (In) (79%) 
recovered.
give a dark oil. Preparative layer chromatography (silica gel. 
diethyl ether) furnished nitrobenzene (202 mg, 82%) as a very 
pale yellow oil.
M ethod B: Z-Methoxynitrobenzene (3g) from  2-Methoxy-4- 
nitroaniline (lg ).—Trifluoroacetic acid (2.0 g, 17.5 mmol) was 
added to 2-methoxy-4-nitroaniline (1.68 g, 10 mmol) in form­
amide (20 ml), followed by sodium nitrite (700 mg, 10 mmol) in 
water (1.3 ml) and the pale brown solution was stirred at 
ambient temperature for 20 min. Triethylamine (3.0 g, 30 mmol) 
was added and the deep red effervescing mixture was stirred for 
a further 20 min before being partitioned between ethyl acetate 
(100 ml) and water (50 ml). The organic portion was washed 
with 2M-hydrochloric acid (70 ml), water (4 x 50 ml), and 
saturated brine (50 ml), and then dried (N a2SO*) and filtered. 
The solvent was carefully evaporated to give a dark red oil 
which was chromatographed [silica gel, toluene-redistilled 
light petroleum (b.p. 60— 80 °C); 1:1] to give 3-methoxynitro- 
benzene (1.03 g, 67%) as pale yellow crystals.
M ethod C: Bromobenzene (3k) from  Bromoaniline (lp ).— 4- 
Bromaniline (1.72 g, 10 mmol) was treated as in Method B 
except that the crude product was distilled (Kugelrohr) to afford 
bromobenzene (950 mg, 60.5%) as a colourless liquid.
Deuterioformamide (6).— Anhydrous methanol (15 ml) 
(freshly distilled from magnesium methoxide) was saturated 
with ammonia at 0 °C. Methyl deuterioformate (99 atom %; 
Aldrich Chemical Co. Ltd.; 1.22 g, 20 mmol) was added and 
the mixture was stirred at ambient temperature in a tightly 
stoppered vessel for 16 h before careful evaporation of the 
solvent and excess ammonia gave deuterioformamide (890 mg, 
97%) as a colourless liquid, b.p. 215 °C (lit.,16 b.p. 111 °C at 20 
mmHg for protio compound) v ^  (liquid film) 3 300. 2 150 
(C-D stretch), and 1 650 cm '^ SfD jO ) 5.2 (HOD); m/z 46 (A/*).
4- Deuterionitrobenzene (7).—4- N i t robenzenediazoniu m
tetrafluoroborate (2c) (237 mg, 1 mmol) was treated as for
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Method A above except that deuterioformamide (6 ) (0.8 mi) 
and triethylamine (190 mg. 1.9 mmol) were employed. 4- 
Deuterionitrobenzene (96 mg. 77%) was obtained as a pale 
yellow liquid, v„,„ 2 950 (C-H stretch). 2 150 (C-D stretch), 
1 520, and 1 330 cm '1; 8(CDC13) 7.6 (2 H. ca. d, J  8  Hz. Ar 3- 
and 5-H).and 8.3 (2 H ,d .78  Hz, Ar 2- and 6 -H); m/z 124 ( M * ).
3-Formyl- 1 -(A~niirophenyl)iriazene (8 ).—4-Nitrobenzenedi- 
azonium tetrafluoroborate (2c) (1.19 g, 5 mmol), formamide 
(900 mg, 20 mmol), water (10 ml), and diethyl ether (20 ml) were 
heated to reflux. Aqueous sodium hydrogen carbonate (8.4% 
w/v; 2 .0  ml, 2  mmol) was added and the whole stirred under 
reflux for 15 min. The ether layer was removed and replaced by 
fresh ether (20 ml) and the NaHCOj addition/ether replace­
ment cycle was repeated 5 times. The combined ethereal 
extracts were washed with water, dried, and the solvent 
evaporated to give an oily solid. This solid was triturated with 
light petroleum (b.p. 60—80 °C). The light petroleum super­
natant was separated and the solvent was evaporated to give 
nitrobenzene (230 mg, 37%). The pale brown solid residue was 
characterised as 3-formyl-l-(4-nitrophenyl)triazene (280 mg, 
29%) which decomposed when gently heated and failed to give a 
satisfactory CHN analysis although it appeared to be pure by 
t.l.c. (silica gel, toluene, and silica gel, light petroleum-dichloro-
methane; 2:1) v (Nujol) 3 250, I 710, 1 520, and 1 340 cm-1;
5[(CDj)2SO] 6.2 (1 H. br, NH). 7.8 (2 H. ca. d, J  8  Hz) and 8.3 
(2 H, d, J  8  Hz) (ArH), and 8.5 (1 H, br. CHO); m/z 194, 138, 
and 123.
Nitrobenzene (3c) from 5-Formyl-1 -(4-nitrophenyi)triazene 
(8 ).—3-Formyl-l-(4-nitrophenyl)triazene(8) (194 mg. 1 mmol), 
was treated with triethylamine ( 2  ml) at ambient temperature 
for 4 h. Careful evaporation of the excess of reagent gave a dark 
residue which, on preparative layer chromatography (silica gel, 
diethyl ether) afforded nitrobenzene (81 mg. 6 6 %) as a pale 
yellow oil.
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The Oxidative D ecarboxylation of iV-Aroylglycines to 
iV-(Acetoxym ethyl)benzam ides and iV-Formylbenzamides w ith  Lead(IV)
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Treatment of N-aroylglycines that do not bear a strong electron-withdrawing substituent with lead (IV) acetate 
in acetic add/acetic anhydride mixtures at 60-100 °C rapidly gives the corresponding N-(acetoxymethyI)benzamides 
and N-formylbenzamides in moderate yields after chromatography. These compounds are of interest in the study 
of the metabolism of xenobiotic N-methylbenzamides. V-(4-Nitrobenzoyl)glycine gives only N-(acetoxy- 
methyl)-4-nitrobenzamide. 4-Chloro-N-methylbenzamide, N-aroylproline, and esters of Af-aroylglycines are 
unaffected. Deuterium incorporation and other studies are consistent with a mechanism involving initial ligand 
exchange at lead followed by N-acetoxylation. Decarboxylation and elimination then ensue; final readdition 
of acetic acid to /V-aroylimines leads to the observed products.
M any N -m ethyl-containing drugs and other com pounds 
are m etabolized  to the corresponding /V -hydroxym ethyl 
analogue by preparations of murine liver.2 T h e antitum or  
agent hexam eth y lm elam in e,3 th e  herb icide M onuron  
[N -(4-chlorophenyl)-A r/^ V-dimethylurea],'* and  th e  co m ­
mon industrial so lv en t N ^V -dim ethylform am ide1 have  
been show n to  be C -hydroxylated m etab olica lly  in v itro  
or in w hole anim als. T he generated N -h y d ro x y m eth y l  
m oieties are then  either excreted as such or undergo fur­
ther enzym ic m etabolism  or intracellular chem ical reaction. 
T h e relatively  labile  N ’-hydroxym ethylam ines m ay h y ­
drolyze to  give form aldehyde, a m utagen; w h ile  N - 
hydroxym ethylbenzam ide is su ffic ien tly  stab le  to  be a 
substrate for further oxidation  by cytoso lic  en zym es to  
N-form ylbenzam ide.5 H epatic m etabolites containing the  
carbinolam ine group m ay also act as electroph iles, e ith er  
through the interm ediacy o f a sm all equilibrium  co n cen ­
tration of the corresponding im inium  ion or im ine (recently  
review ed6) or through biological derivatization  o f  th e  a l­
cohol (e.g., acetylation ) which enhances its leaving group  
ability . W e therefore sought a general preparation  o f  
N -(acetoxym ethyl)benzam ides and N -form ylb en zam ides
(1) P art 8 o f  the series “T h e  Form ation and M etab olism  o f  N- 
H ydroxym ethyl C om pounds’ . For Part 7, see: K estell, P.; G ill, M . H.; 
T hreadgill, M. D.; G escher, A.; Howarth. O. W.; Curzon, E. H. Life Sci. 
1986, 38, 719.
(2) G escher, A.; H ickm an, J. A.; S teven s, M. F. G. Biochem. Phar­
macol. 1979, 28, 3235.
(3) B on n . P.; M ingels, M.-J.; Hulshoff, A : Franzhuizen-Sierevogel, A ;  
N oordhoek, J. Life Sci. 1983, 33, 2113.
(4) Ross, D.; Farmer, P. B.; Gescher, A.; H ickm an, J. A.; T h read gill, 
M. D. Biochem. Pharmacol. 1982, 31, 3621.
(5) R oss, D.; Farmer, P. B.; Gescher, A.; Hickm an. J. A.; T h read gill, 
M. D. Biochem. Pharmacol. 1983, 32, 1773.
(6) O verton, M.; H ickm an, J. A.; T hreadgill. M. D.; V aughan, K.;
Gescher, A. Biochem. Pharmacol. 1985, 34, 2055.
S c h e m e  I . T h e  O x id a t iv e  D e c a r b o x y la t io n  o f  N - A r y l  
A m in o  A c id s 0







■ (i) Pb(0Ac)4/A c0H /A c,0.
as reference com pounds for m etabolic work and for stu dy  
o f their chem ical reactiv ity  in order to  predict their b io ­
chem ical reactions w ith  cellu lar nucleoph iles. A lthough  
N -(acetoxym ethyl)benzam id e (2a) has been prepared by  
acetylation  o f  N -d iyd roxym ethyD benzam id e7 and benz- 
am ide can be N -form ylated  w ith  d ifficu lty ,5 th e  p resen t 
m ethod furnishes both desired products from one reaction  
on one substrate. T h e  ox idative  decarboxylation  o f  N - 
benzoylglycine ( la )  by treatm ent w ith lead(IV) acetate to  
N -(acetoxym ethyl)benzam ide has been briefly reported by  
Sus and R osenberger,8 although the product was not well 
characterized, th is paper now describes the results o f  our 
investigation into th is reaction as regards synthetic utility, 
scope, lim ita tion s, and m ech an istic  pathway.
(7) G ate, E. N.; H ooper, D. L.; S teven s. M. F. G ; T h readgill, M. D.; 
Vaughan, K. Magn. Reson. Chem. 1985, 23, 78.
(8) Sus, 0 .;  Rosenberger. S. Justus Liebigs Ann. Chem. 1949,564, 137.
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T he O xidative Decarboxylation o f Af-Aroylglycines 
Table I
I R 1 R 2 R 3 y ie ld  o f  2 , % y ie ld  o f  3 , %
la H H H 10 22
lb Cl H H 39“ 28“
lc Me H H 2.5° 11“
Id n o 2 H H 72“ 0
le OMe H H 21“ 12“
If Cl Me H 0 0
lg Cl H Me 0 21“
lh Cl CH2CH2CH2 0 0
“ S a t is fa c to r y  a n a ly t ic a l d a ta  (± 0 .4 %  for C, H , N ) w ere  re p o r te d  
fo r  a ll  n ew  c o m p o u n d s  l i s t e d  in  th e  ta b le  a n d  fo r  2 d .
A r y l-su b stitu ted  iV -benzoylg lycines l a - c  an d  N -4- 
chlorob en zoyl am in o  ac id s l f - h  were prepared by  con­
v en tion a l S ch o tten -B a u m a n n  tech n iques9 by a d d ition  o f  
th e  aroyl chloride to  th e  am ino  acid  in aqueous sod iu m  
hydroxide so lu tion  a t am b ien t tem perature w ith  vigorous 
stirring, ac id ifica tion  an d  co llection  o f th e  iV-aryl am ino  
acid by filtration follow ed by recrystallization, usually from  
a q u eo u s eth an o l. iV -(4-C hlorobenzoyl)sarcosine ( lb )  
proved  d ifficu lt to  recrysta llize  b u t was purified  after  
conversion to  its d iisopropylam ine s a l t  T h e  free acid  was 
released  by p recip ita tio n  w ith  hydrochloric acid  from  
a q u eou s so lu tion  before o x id a tio n  was a ttem p ted .
N -(4-C hlorobenzoyl)glycine ( lb )  was the substrate used  
in prelim inar exp erim en ts designed  to  optim ize th e  reac­
tio n  con d ition s so  as to  give acceptab le  y ie ld s o f  both  
products 2b and 3b  in th e  sam e preparative run (Schem e  
I). T h e  b est y ie ld s  w ere ob ta ined  by  carrying o u t the  
reaction a t 60 °C  w ith  reaction tim es betw een 30 m in  and  
2 h  in a  so lven t m ixture com prising ca. 10% acetic  a n h y­
dride and  90% a cetic  acid  and b y  use o f betw een  1 and  
2 equiv o f  lead(IV) acetate. H igher tem peratures, su ch  as 
th e  100 °C  em p loyed  by  S u s8 or boiling under reflux, 
sp eed ed  the already con v en ien tly  rapid reaction b u t also  
facilitated  side reactions; significantly lower yields o f  both  
produ cts were iso la ted . T h e  reaction  d id  not proceed  at 
a m easurable rate a t  a m b ien t tem perature. As sh ow n in  
T able  I, su b stitu tion  a t various position s in the su bstrate  
hippuric acids has a profound effect on the outcom e o f  the  
reaction. Su bstitu tion  in  the para position  o f the benzoyl 
m o iety  w ith  groups th a t  are n o t strongly  e lectron -w ith ­
drawing as in l a - c ,e  gave m oderate to  good yields o f  both  
o xid ized  products 2 a - c ,e  and 3 a -c ,e .  H ow ever, w h en  a 
strong electron-w ithdraw ing group is present on th e  aro­
m atic ring, as in th e  n itro group o f  substrate Id , on ly  the  
a cetoxym ethyl com poun d  2d could be isolated . In terest­
ingly, the m axim um  yield  (72% ) o f  2d  was obtained using  
2 equiv o f lead(IV) acetate. H ence, it  can be seen th a t the  
product distribution is m arkedly affected by the electronic  
nature o f  the para su b stitu en t; further oxidation  tak ing  
place w hen a m eth oxy  group (H am m ett su b stitu en t con ­
sta n t a =  -0 .2 7 )10 is p resen t on th e  arom atic ring b u t not 
w ith  th e  nitro d er iva tive  (a =  + 0 .7 8 ) .10
Substitution at nitrogen, in the case o f substrate I f , leads 
to  a reaction  m ixture in w h ich  neither N -(a ceto x y -  
m eth y l)-4 -ch loro-N -m eth y lb en zam id e  (2f) nor 4-chloro- 
JV -form yl-iV-m ethylbenzam ide (3f) could be id en tified . 
T L C  analysis show ed th a t  I f  w as very largely un affected  
by th e  oxidant. T h e  presence o f  a m eth yl group a t the  
a-carbon  o f the g lycin e  m o iety  (in substrate lg ) ,  o n  the  
other hand, did not prevent oxidative decarboxylation. In 
th is case, the sole isolated material was the doubly oxidized  
product N -acetyl-4-chlorobenzam ide (3g) in m odest yield.
(9) Furniss, B. S.; H annaford, A. J.; Rogers, V.; Sm ith , P . W . G.; 
T atch ell, A. R. Vogel's Textbook of Practical Organic Chemistry, 
Longm ans: London, 1978.
(10) R itchie, C. D.; Sager, W. F. Prog. Phys. Org. Chem. 1964, 2 , 323.
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S c h e m e  I I . P o s s ib le  M e c h a n i s t i c  P a t h w a y s  f o r  t h e  
O x id a t iv e  D e c a r b o x y la t io n  o f  H ip p u r ic  A c id s  1 to  
A T -(A c e to x y m e t h y l)b e n z a m id e s  2""*
o(i) n
"  A r ' '  ' ' N ' ^ O A c  
H
“ P a th s  w ith  -X—-  h a v e  b een  sh o w n  b y  ex p e r im e n t n o t  t o  tak e  
p la ce . 6 ( i ) - C 0 2; (ii) P b (O A c)4; ( ii2 ) -A c O H ; (iv) + A c O H . “A r =  
4 -R 1C 6H 4 (R 1 a s in  T a b le  I).
It m ay be th a t th e  1-acetoxy e th y l com pound 2 g  was 
form ed during the reaction but was unstable. N o  oxidized  
p rod u cts were ob ta ined  from  l h  w h ich has su b stitu tio n  
a t b o th  nitrogen and  a lip hatic  carbon by ann u lation .
A n attem pt to  extend the scope o f  the synthetic reaction  
by se lec tio n  o f a d ifferen t lead(IV ) carboxylate w as un­
su ccessfu l. N eith er  o f the ex p ected  ox idative  decarb ox­
y la tio n  products [4-chloro-Ar-(trifluoroacetoxym eth yl)-  
b enzam ide and 3b] were o b ta in ed  from trea tm en t o f  
substrate lb  w ith a solution o f lead(IV) oxide in a m ixture  
o f  trifluoroacetic acid and trifluoroacetic anhydride. T he  
form er ester  m ay be hydrolyzed during the m ild ly  basic  
a q u eo u s w orkup, b u t th e  correspon ding  a lcoh o l, 4- 
chloro-iV-hydroxym ethylbenzam ide, was also not obtained  
as a produ ct o f  th e  reaction.
M e c h a n is t ic  S tu d ie s . As shown in Schem e II, the first 
in term ed ia tes on  th e  path  from  starting  hippuric acid  1 
to  th e  first iso la ted  ox idation  p rodu ct 2 m ay arise e ith er  
from  in itia l decarb oxylation  (in th e  case o f th e  N - 
m ethylbenzam ide 4) or from acetoxylation (to give 5 or 6). 
H ow ever, the interm ediacy o f 4 can be d iscounted  on the  
fo llow in g  grounds. F irst, no trace o f the corresponding  
iV -m ethylbenzam ide 4 is ev id en t on  TLC exam in ation  
(com pared w ith  a u th en tic  m ateria ls5-11) o f any o f th e  re­
a ctio n  m ixtures involving lead (IV ) acetate  ox id ative  of 
h ip p u ric  acids 1. Second , a lthough  there are several re­
p o r ts12 o f  ox idation  o f iV-alkyl com pounds a  to  n itrogen
(11) Auerbach, J.; Zamore, M cF.; W einreb, S. M. J. Org. Chem. 1976, 
41, 725.
(12) G alliani, G.; R indone, B.; S colastico , C. Tetrahedron Lett. 1975, 
1285.
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S c h e m e  I I I . C o n d e n s a t io D  o f  4 -C h lo r o b e n z a m id e  w i t h  
G l y o x y l ic  A c id ”
t
- „ C r " C0,H
111
Schem e V. P artia l M ass Fragm entation o f 2a
1®
CH,OAc














*(i) DjO; (ii) Pb(0A c)4/C H 3C 0 2D/Ac20 ; (iii) H20 /N a H C 0 3.
by acetates o f  m eta ls in high oxidation  states, no co n ­
sum ption o f 4-ch loro-N -m ethylbenzam ide (4b) w as o b ­
served under th e  general conditions em ployed . H ence  
oxidation precedes rather than succeeds decarboxylation.
Several ex p erim en ts w ere conducted  to  in v estig a te  
whether oxidation  occurs a t carbon, converting 1 directly  
to  the 2-acetoxyhippuric acid  6, or a t nitrogen, giving the  
N -a cetoxyh ip p u ric  acid  5. In th e  first, N -(4 -ch loro-  
benzoyl)-2-hydroxyglycine 11 was prepared in ex ce llen t  
yield by treatm ent o f 4-chlorobenzam ide 10 with glyoxylic  
acid hydrate (Schem e III). All a ttem p ts to  acety la te  11 
to  give the proposed interm ediate 2-acetoxy-N -(4-chloro- 
benzoyD glycine (6b) by usin g  acetic  anhydride or acety l  
chloride in the presence o f  inorganic or organic base were  
unsuccessful, intractab le m ixtures being obtained. W ith  
6b thus n o t availab le as an iso lated  characterizable m a­
terial for further investigation , a m ore indirect approach  
was sou gh t Esterification o f  11 to  give 6b m ight well take  
place in the warm  acetic  a c id /a c e tic  anhydride m edium  
o f the principal ox idative  decarboxylation experim ents. 
T reatm ent o f 11 w ith  such  A c^O /A cO H  m ixtures in th e  
presence or absen ce o f lead(II) aceta te  (added to  m im ic  
th e  m ain reaction  co n d itio n s m ore c losely) gave th e  
acetoxym ethyl com pound 2b. R ep lacem ent o f  the no­
noxidizing lead(II) aceta te  by lead(IV ) acetate  led to  
markedly decreased yields o f  2b. H ence, it is highly likely, 
but not com p lete ly  rigorously proven, that at lea st som e  







Schem e VI. Proposed S im ultaneous  






arises through the in term ediacy o f 6.
T h e  m ost usefu l ev idence for contrib utions (or other­
w ise) o f  pathways to  the overall reaction sequence com es 
from  the deuterium  incorporation experim en ts show n in  
S ch em e IV. For ease o f  interpretation  o f  th e  m ass 
sp ectroscop ic  an a lysis o f  products, the u n su b stitu ted  
benzoyl series ( la ,  etc.) was em ployed  for th ese  experi­
m en ts. T h e  carboxylic acid and am ine N H  protons of  
hippuric acid ( la )  were exchanged for deuterium  to  an 
e x te n t  greater than  95%  (judged by lH N M R  in CDC13) 
by repeated recrystallization from deuterium  oxide. T he  
oxidative decarboxylation was then carried out under the  
standard conditions using lead (IV) acetate (free from acetic 
acid ), m onodeuterioacetic  acid (CH 3C 0 2D; 98 atom  %), 
and  acetic  anhydride [(C H 3C 0 )20 ] ,  follow ed by norm al 
aq u eou s workup. O f the N - (acetoxym ethyl)benzam id e  
formed, 60-80%  (varying between experim ents) was found  
by m ass spectrom etry not to contain deuterium  (m /z  193, 
150), i.e ., to  be P h C O N H C H 2OAc. A corresponding  
20-40%  o f  the m aterial contained  one d euteriu m  atom  
(P hC O N H C H D O A c). E xam ination o f  the m ass spectral 
fragm entation  pattern confirm ed the location o f the deu- 
teron in th e  m ethylene group (Schem e V). As expected , 
no ions corresponding to th e  d id eu ter io  com pound, 
P hC O N H C D 2OAc, were observed, and control experim ents 
sh ow ed  th a t deuterium  is neither gained nor lo st by ex ­
change o f  hydrogens o f product 2a w ith  so lven t. T h ese  
data  are co n sisten t on ly  w ith the in itia l form ation o f  the  
iV-acetoxyhippuric acid 5, followed by a m ixed mechanism . 
T h e  major proportion of 5 then undergoes a sim ultaneous  
elim ination/decarboxylation , giving 8 (Schem e VI). W ith  
th e  m inor part, elim ination  o f acetic acid gives the im ine  
carboxylic acid 9, w hich could then either add acetic  acid 
(giving 6) or decarboxylate (giving 8). E vidence for the  
in vo lvem en t o f 6 is presented  below in that it appears to
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Schem e V II. A P ossib le  M echanism  of N -A cetoxylation  o f  
H ip p u r ic  A cids by Lead(IV) A cetate
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be the in term ed ia te  w hich is further oxidized, giving 3 as 
the final p rodu ct.
A related  reaction  has b een  rep orted13 in tr iazene  
chem istry in th a t 3-hydroxy-3-m ethyl-l-phenyltriazene has 
been converted  to  3 -(acetoxym eth y l)-3 -acety l-l-p h en y l-  
triazene by trea tm en t w ith  acetic  anhydride via e lim ina­
tio n /a d d itio n . H owever, no iV-(acetoxym ethyl)-4-chloro­
benzam ide (2b) was form ed w hen 4-chloro-N-hydroxy-iV- 
m ethylbenzam ide was heated  w ith m ixtures of acetic  acid  
and acetic anhydride in the presence or absence o f lead(II) 
acetate, th u s ruling ou t 7 as an interm ediate. T h is  ob ­
servation is co n siste n t w ith  our previous report th a t th is  
N -m eth y lh yd roxam ic  acid  d oes not elim inate water to  
generate an im in ium  ion on treatm ent with trifluoroacetic  
acid .14 A s sh ow n in T ab le  I, N -(4-chlorobenzoyl)g lycine  
( lb )  is readily converted  to  acetoxym ethyl com pound 2b, 
whereas all a ttem p ts  to  carry ou t the sam e conversion on  
the JV-blocked analogue, N -(4-chlorobenzoyl)-A r-m ethyl- 
glycine (If) , to  give 2 f  faded. T hus, direct C-acetoxylation  
of 1 to 6 does n o t occur. Additionally, none of the expected  
further ox id ation  product, 3 f, could be isolated from th is  
reaction. H ence, it would appear that the N H  is im portant 
for the reaction  to  take place; a deduction  th at supports  
the form ation o f th e  C -acetoxy com pound 6 via an e lim ­
in a tio n /a d d it io n  rearrangem ent from  the N -acetoxy  
species 5.
It would app ear  th a t th e  carboxylic acid m oiety  is e s ­
sential for th e  reaction to  take place since no oxidation  o f  
m ethyl [(4-chlorobenzoyl)am ino]acetate could be detected  
under the u su a l reaction  cond itions. A rationalization  
could be th a t  th e  in itia l s tep  o f the N -acetoxylation  is 
carboxylate “ligand” exchange a t lead (Schem e VTI). T h is  
would be fo llow ed  by an e ssen tia lly  intram olecular o x i­
dation a t n itrogen .
T he reaction pathw ays leading to  the further oxidation  
products 3 are m uch m ore com plex, involving step s o f  
oxidation, e lim in ation , add ition , and, perhaps, decarbox­
ylation, cu lm in atin g  in hyd rolysis on workup. T h e  first 
question (Schem e VIII) is w hether the isolable product o f  
the first oxidation , 2, is itse lf acetoxylated  or whether one  
o f the other in term ed ia tes in Schem e II is the su bstrate  
for lead(IV) a ceta te , lead ing u ltim ately  to the N -form yl- 
benzam ide 3. A pure sam p le o f  2b was subjected  to
(13) Foster. K.; H ess, F.; G rozinger, K. Justus Liebigs Ann. Chem. 
1973, 811.
(14) A ddison. S . J.; C unningham . B. D. M.; Gate, E. N.: S hah , P. Z.; 
Threadgill. M. D . J. Chem. Soc.. Perkin Trans. 1 1985, 75.
Schem e V III. P ossib le  P ath w ays to TV-Formylbenzamides0-4
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a P a th s  w ith  X -  h ave b een  show n  by e x p er im en t n o t  to  ta k e  
p lace . 4 (i) Pb(O A c)«; (ii) -A cO H ; (iii) + A cO H ; (iv ) - C 0 2; (v) h y ­
d ro ly t ic  w ork up .
treatm ent w ith  lead(IV) acetate under the standard con ­
d itions. N o conversion to  3b was observed, and th e  sole  
effect o f higher tem peratures an d /or  longer reaction tim es 
led  to  d ecom position  o f th e  starting iV -(acetoxym ethyl)- 
4-chlorobenzam ide to unidentifiable products. T h is result 
show s th at com pounds 2 are indeed su bject to  ox idation  
by lead(IV) acetate  but th at this oxidation is degradative. 
T h u s 2 d oes n o t lie on th e  pathw ay from  1 to 3. T h is  
finding is further supported by the total lack o f deuterium  
incorporation in to  product 3a w hen th e  overall reaction  
is carried o u t in P b (0 A c )4/C H 3C 0 2D/Ac^O  m ixture.
T h e  in vo lvem en t o f  6 in the form ation o f 3 is also  in ­
d icated  by th e  su ccessfu l experim ental conversion o f  the  
glyoxylic acid  add uct 11 to  3b under the standard exper­
im ental conditions. One m ay therefore speculate that the  
C -acetoxy com poun d 6 is the in term ediate  actually  o x i­
d ized . As in the first stage ox idation  o f 1 above, acet- 
oxylation  eith er  at carbon or a t nitrogen is conceivable. 
H ow ever, th e  C ,C -d iacetoxy com pound 16 (Schem e VII) 
is n o t an in term ed iate  since decarboxylation  o f 16 in the  
deuterate m edium  would lead, after subsequent hydrolysis, 
to  P hC O N H C D O  rather than the sole oberved m oiety  
PhC O N H C H O  (3a). Clearly, interm ediates o f  type 16 are 
im possib le  in th e  observed conversion o f l g  to  3g. T h e  
excellent yield (72% ) o f  2d under the standard conditions 
together w ith  th e  com plete absence o f th e  N -form yl com ­
pou nd  3d in th e  p-n itro  series also  lends w eight to the  
proposal th a t 6 is d irectly  N -acetoxylated to give 15. T h e  
nitro  group w ou ld  have the e ffec t o f m arkedly reducing  
th e  electron  d en s ity  a t  th e  am ide nitrogen atom , thu s  
disfavoring o x id ation  by an electroph ilic  oxidant. It is 
tem pting to speculate that a sim ultaneous elim ination and  
oxidation  step  is involved , which is sim ilar to that show n  
in S chem e VI for the other series o f products.
In conclusion, it can be seen that a useful sim ultaneous  
synthetic route to the N- (acetoxym ethyl) benzam ides 2 and  
N -form ylb en zam id es 3 has been developed . T h ese  com ­
pounds are lik ely  to be o f  biological and toxicological in­
terest as weak electrophiles. T he characterization o f  their
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chem ical and  biochemical electrophiiic reactivity is in 
progress an d  will be presented in a fu ture paper . 15 T he 
m echanism  of the oxidative decarboxylation of hippuric 
acids has been shown to  involve two sim ultaneous routes 
to  th e  f irs t isolated oxidation products 2 , b u t only one 
in term ediate  is fu rther oxidized leading to compounds 3.
Experimental Section
General. IR spectra were determined as Nujol mulls. NMR 
spectra were obtained a t 60 MHz with a Varian EM 360A 
spectrometer using tetramethylsQane as internal standard. Mass 
spectrometric studies were carried out with a VG Micromass 12  
instrument in electron-impact mode at 70 eV. Melting points are 
uncorrected.
AT-(4'Chiorobenzoyl)-jV-methylglycine Diisopropylamine 
Salt (If). A mixture of 4-chlorobenzoyl chloride (8.75 g; 50 mmol), 
JV-methylglycine (4.45; 50 mmol), KOH (5.6 g, 1 0 0  mmol), and 
water (100 mL) was stirred at ambient temperature for 3 h before 
being acidified by addition of 1 0  M hydrochloric acid. The re­
sulting suspension was extracted with CH2C12. This extract was 
dried (NazSOJ and filtered and the solvent evaporated under 
reduced pressure to give the acylsarcosine I f  as a slightly gummy 
solid, mp 119-121 °C (lit16 mp 133-134 #C). The melting point 
could not be raised by recxystallization from aqueous ethanoL The 
solid, in ethanol (100 mL), was treated with diisopropylamine (2 0  
mL), and the volatile materials were again evaporated. Recrys­
tallization of the residue from propan-2 -ol gave the diiso­
propylamine salt of N-(4-chlorobenzoyl)-N-methylglydne (10.9 
g; 6 6 %) as white needles: mp 129-130 °C; IR 2700, 2450,1630, 
1560 cm’1; NMR (CDClj) 8 1.30 (1 2  H, d, J  = 7 Hz, (Ctf3)2CH),
3.10 (3 H, s, NCH3), 3.27 ( 2  H, septet J  = 7 Hz. (CH^CH), 3.75 
(2 H, s, NCHa), 7.2-7.6 (6  H, m, Ar H, N*H2). Anal. Calcd for 
C16H2SC1N20 3: C, 58.45; H, 7.65; N, 8.5. Found: C, 58.15; H, 7.65; 
N, 8.35.
JV-(4-Chlorobenzoyl)-L-alanine (lg). 4-Chlorobenzoyl 
chloride (5.25 g, 30 mmol) was added to L-alanine (2.67 g; 30 mmol) 
and KOH (3.9 g, 70 mmol) in water (50 mL). After being stirred 
vigorously for 13 h, the mixture was acidified by addition of 10 
M hydrochloric add and extracted with ethyl acetate. The extract 
was washed with saturated aqueous NaCl and dried (Na^OJ and 
the solvent evaporated under reduced pressure to afford, after 
recrystallization from aqueous propan-2-ol, the N-acylalanine lg  
(5.05 g, 74%) as white needles: mp 161-163 °C; IR 3290, 2750, 
1710,1640,1600,1550 cm"1; NMR (2:1  CDC13/(CD3)2S0 ) { 1.45 
(3 H, d, J  = 7 Hz, CHCH3), 4.52 (1  H, quintet, J  = 7 Hz, alanine 
H), 5.4 (1  H, br, C 02H), 7.43 (2 H, d, J  = 8  Hz) and 7.92 (2 H, 
d, J  = 8  Hz) (Ar H], 8.45 ( 1  H, d, J  = 7 Hz, NH). Anal. Calcd 
for C10Hl0ClNO3: C, 52.75; H, 4.45; N, 6.15. Found: C. 52.5; H, 
4.35; N, 6.05.
JV-(Acetoxymethyl)-4-chlorobenzamide (2 b) and 4- 
Chloro-N-formylbenzamide (3b). N-(4-Chlorobenzoyl)glycine 
(lb) (6.27 g, 30 mmol) and Pb(OAc)< (13.29 g, 30 mmol) were 
stirred at 60 °C for 10 min in acetic acid (80 mL) and acetic 
anhydride (8  mL) before evaporation of the solvents under reduced 
pressure. The residue, in CH2C12, was washed twice with water, 
twice with saturated aqueous NaHC03, and once with saturated 
aqueous NaCl before being dried (NajSOJ and filtered. Evap­
oration of the solvent under reduced pressure gave a viscous yellow 
oil, which, on chromatography [silica gel; 1:4 ethyl acetate-re­
distilled light petroleum (bp 60-80 °C)], furnished, as the faster 
running fraction, 4-chloro-JV-formylbenzamide (3b) (1.53 g, 28%) 
as a pale yellow solid: mp 95-96 °C; IR 3280, 1730, 1685 cm-1; 
NMR (CDCI3) 8 2.00 (3 H, s, Ac), 5.40 (2  H, d, J  = 7 Hz, NCH20), 
7.40 (2 H, d, J  = 9 Hz) and 7.85 (2 H, d, J  = 9 Hz) [Ar H], 8.25 
(1  H, br t, J  = 7 Hz, NH); mass spectrum m /z  185/183 (M+). The 
slower fraction, after evaporation of the eluant under reduced 
pressure, comprised N-(acetoxymethyl)-4-chlorobenzamide (2b) 
(2.69 g, 39%) as an off-white powder: mp 163-165 °C; IR 3320, 
1730,1650 cm"1; NMR (CDCI3) 8 7.55 (2 H, d, J  = 8  Hz) and 8.10 
(2 H, d. J  * 8  Hz) [Ar H], 9.50 (1 H, d. J  = 10 Hz, CHO), 10.7
(15) Overton, M.; Threadgill, M. D.; Chipman, J. K.; Gescher, A.; 
Hickman, J. A. Biochem. Pharmacol., in press.
(16) Boyd, G. V.; Wright, P. H. J. Chem. Soc.. Perkin. Trans. 1 1972, 
909.
(1  H, br, NH); mass spectrum, m /z  229/227 (M+).
N-(Acetoxymethyl)benzamide (2a) and N-Formylbenz- 
amide (3a). N-Benzoylglycine (la) (4.5 g, 25 mmol) was treated 
with Pb(OAc)4 (20.5 g, 50 mmol), and the products were isolated 
as for the preparation of 2b and 3b above. N-Formylbenzamide 
(3a) (80 mg, 22%) was obtained as a pale yellow solid: mp 109-110 
°C (lit. 17 mp 112-113 °C); IR 3280,1730,1685 cm’1; NMR (CDClj) 
6 7.5-8.3 (5 H, m, Ar H), 9.45 (1  H, d, J  = 10 Hz, CHO), 10.5 (1  
H, br, NH); mass spectrum, m/z 193 (M+), 150,122,121,105 (100). 
N~ (Acetoxymethyl) benzamide (2a) (480 mg, 10%) was isolated 
as a colorless viscous oil identical with a sample previously pre­
pared by us by another route.7
JV-(Acetoxymethyl)-4-methylbenzamide (2c) and N -  
Formyl-4-methylbenzamide (3c). N-(4-Methylbenzoyl)glycine 
(lc) (9.65 g, 50 mmol) was treated with Pb(OAc)4 (41.0 g, 92.5 
mmol), and the products were isolated as for the reaction of lb  
above. N-Formyl-4-methylbenzamide (3c) (920 mg; 11%) was 
obtained as a white solid: mp 104 °C; IR 3320,1745,1690 cm-1; 
NMR (CDCla) 8 2.40 (3 H, s, AxCHa), 7.25 (2 H, d, J  = 8  Hz) and 
7.90 (2 H, d, J  * 8  Hz) [ArH], 9.35 (1  H, d, J  = 9 Hz, CHO), 10.45 
(1  H, ca. d, J  -  9 Hz, NH); mass spectrum, m/z 163 (M+), 135, 
119 (100), 91. N-(acetoxymethyl)-4-methylbenzamide (2c) (260 
mg, 2.5%) was obtained as a white solid: mp 49 °C; IR 3320,1760, 
1670 cm-1; NMR (CDClj) 8 2.00 (3 H, s, C0CH3), 2.35 (3 H, s, 
ArCHa), 5.40 (2  H, d, J  = 7 Hz, NCH20), 7.15 (2 H, d, J  = 8  Hz) 
and 7.75 (2 H, d, J  = 8  Hz) [Ar H], 8.30 (1  H, t, J  = 7 Hz, NH); 
mass spectrum, m /z  207 (M+), 164, 148, 119 (100).
JV-(Acetoxymethyl)-4-nitrobenzamide (2d). N-(4-Nitro- 
benzoyl)glycine (Id) (5.60 g, 25 mmol) was treated with Pb(OAc)4 
(22.15 g, 50 mmol) as for the preparation of 2b above except that 
chromatography was replaced by recrystallization from ethyl 
acetate/light petroleum (bp 60-80 °C). The acetoxymethyl- 
benzamide 2d (4.28 g, 72%) was obtained as a very pale greenish 
yellow solid: mp 94 °C (lit. 18 mp 1 2 0  °C); IR 3370, 1760, 1670 
cm"1; NMR (CDC13) 8 2.10 (3 H, s, COCH3), 5.45 (2  H, d, J  = 7 
Hz, NCH20), 7.90 (1  H, ca. t, J  = 7 Hz, NH), 8.05 (2 H, d, J  = 
8  Hz) and 8.35 (2 H, d, J  = 8  Hz) [Ar HJ.
JV-(Acetoxymethyl)-4-methoxybenzamide (2e) and N - 
Formyl-4-methoxybenzamide (3e). N-(4-Methoxybenzoyl)- 
glycine (le) (2.99 g, 10 mmol) was treated with Pb(OAc)4 (8 .8 6 g; 
29 mmol) as for the preparation of 2b and 3b above. N- 
Formyl-4-methoxybenzamide (3e) (215 mg, 1 2 %) was obtained 
as a white solid: mp 42-46 °C dec; NMR (CDC13) 8 3.60 (3 H, 
s, OCH3), 6.95 (2 H, d, J  = 8  Hz) and 7.85 (2 H, d, J  = 8  Hz) [Ar 
H], 9.30 (1  H, d, J  = 9 Hz, CHO), 10.0 (1  H. br, NH); mass 
spectrum, m /z  179 (M+). 7V-(Acetoxymethyl)-4-methoxybenz- 
amide (2e) (470 mg, 21%) was a white waxy solid of indefinite 
low mp: NMR (CDCI3) 8 2.00 (3 H, s, COCH3), 3.55 (3 H, s, 
OCHa), 5.35 (2 H, d, J  = 7 Hz, NCH20), 7.00 (2 H, d, J  = 8  Hz) 
and 7.75 (2 H, d, J  = 8  Hz) (Ar H), 8.60 (1  H, br. NH); mass 
spectrum, m /z 223 (M+).
N-Acetyl-4-chlorobenzamide (3g). Ar-(4-ChlorobenzoyI)-L- 
alanine (lg) (910 mg, 4 mmol) was treated with Pb(OAc)4 (2.22 
g, 5 mmol) as for the preparation of 2b and 3b above. N- 
Acetyl-4-chlorobenzamide (3g) (166 mg, 21%) was obtained as 
a colorless oil: IR 3370, 1700,1650 cm"1; NMR (CDC13) 8 2.60 
(3 H, s, COCH3), 7.50 (2 H, d, J  = 8  Hz) and 7.80 (2 H, d, J  = 
8  Hz) [Ar H], 9.6 (1 H, br, NH); mass spectrum m/z 199/197 (M*).
Ar-(4-Chlorobenzoyl)-2-hydroxyglycine (1 1 ). 4-Chloro- 
benzamide (3.3 g; 20 mmol) was stirred with glyoxylic acid hydrate 
(1.84 g; 20 mmol) in 1,4-dioxane (50 mL) at 60 °C for 1 h. 
Evaporation of the solvent under reduced pressure afforded the 
adduct 11 (4.1 g; 89%) as white crystals: mp 150 °C dec; IR 3300, 
2750,1720,1665 cm '1; NMR (1:1 CDCla/fCDaJjSO) 8 5.75 (1 H, 
d, J  = 8  Hz, NCHO), 7.50 (2 H, d, J  = 8  Hz) and 7.90 (2 H, d, 
J  = 8  Hz) [Ar H], 8.0 (1  H, br, C02H), 8.20 (I H, brs, CHOtf), 
8.95 (1H, d, J  = 8  Hz, NH).
Reaction of N-(4-Chlorobenzoyl)-2-hydroxyglycine (10 
w ith Acetic Acid and Acetic A nhydride A solution of 11 (500 
mg, 2.2 mmol) in acetic acid (4.0 mL) and acetic anhydride (2.0 
mL) was stirred at 60 °C for 4 h in the presence of Pb(OAc)2 (800 
mg, 2 mmol). Evaporation of the solvents under reduced pressure 
gave a pale yellow gum, which, on column chromatography [silica
(17) Thompson, Q. E. J. Am. Chem. Soc. 1951, 73. 5914.
(18) Zawadowska, I.; Zawadowski, T. Acta Pol. Pharm. 1969, 26, 409.
gel; 1:4 ethyl acetate-redistilled light petroleum (bp 60-80 °C)I, 
afforded A/-(acetoxymethyl)-4-chlorobenzamide (2b) (80 mg; 12%) 
with physical properties identical with those of the sample de­
scribed above.
Reaction of Ar-(4-Chlorobenzoyl)-2-hydroxyglycine (1 1 ) 
w ith  Lead(IV) Acetate. Glyoxylic acid adduct 11 (500 mg, 2.2 
mmol) was treated with Pb(OAc)4 (1.8 g, 4.06 mmol) according
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to the general method for the preparation of 2b and 3b above to 
furnish 4-chloro-Af-formylbenzamide (3b) (110 g, 27%) with 
physical properties identical with those of the sample described 
above.
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N-Methylformamide (NMF, NSC 3051) i s  an a n tin e o p la s tic  agent in  m ic e [ l,2 ) . In c l in ic a l  
t r i a l s  in  which the p o te n tia l of NMF fo r  th e  therapy of human cancers was eva lua ted , 
m anifestations of l iv e r  damage were o b se rv e d [3 ,4 ,5 ] . The mouse appears to be p a r t ic u la r ly  
sen sitiv e  to  the hepato tox ic p ro p ertie s  of NMF[6,7] and r e s u lts  of m echanistic s tu d ies  in  
mice suggest th a t  a re a c tiv e  m etabolite o f N-1F i s  resp o n sib le  fo r i t s  hep a to to x ic1' t y [ 7 ,8 ] . 
Whereas NMF is  m etabolised v itro  only to  a very minor ex ten t by l iv e r  f ra c tio n s  or 
iso la ted  mouse hepatocy tes, i t  undergoes ex ten siv e  metabolism in vivo in  ro d en ts[9 ] . Carbon 
dioxide, methylamine and N-hydroxymethylformamide have been id e n tif ie d  as major m etabo lites 
of WF[10]. In th a t s tu d y , a fu rth e r  m etab o lite  was detec ted  but no t character!'sed . We now 
repo rt the id e n tif ic a tio n  of a new u rinary  m etabo lite  of NMF and suggest th a t  i t s  
precursor(s) may well be responsib le  fo r  th e  h ep a to to x ic ity  and/or th e  an ti tumour a c t iv i ty  
of NMF.
MATERIAL AND METHODS
Chemicals. The la b e lle d  isotopomers of fNF, N -m ethyl-[^C]fom am ide and N-[1^C]- 
raethylformamide, were prepared as p rev iously  d e s c r ib e d [ ll] .  S-(N-Methylcarbamoyl)-N- 
acety lcyste ine  was prepared as follow s: Methyl isocyanate  (2 .0  g, 35 mmol) was added to  N- 
acety l-L -cyste ine  (4.1 g , 25 mmol) in  anhydrous py rid in e  a t  0*C and th e  m ixture was s t i r r e d  
a t th is  temperature fo r  4 days with th e  exc lusion  of m oisture. The so lv en t was evaporated 
under reduced p ressu re . The residue was d isso lv ed  in  dichioromethane and ex trac ted  w ith 
water. The aqueous e x tra c t  was f in a l ly  f re e z e -d rie d  to  fu rn ish  S-(N-methylcarbamoyl)-N- 
ace ty lcyste ine  (3.7 g, 67%) as a very hygroscopic w hite s o l id ,  MPt 65JC.
Drug adm inistra tion  and m etabolite  i s o la t io n  and id e n t if ic a t io n .  D eta ils  of the i . p .  
adm inistration  of NMF o r  [^C J-W F (fiv e  d a ily  doses o f 400 mg/kg) to  male CBA/CA mice (18- 
25 g) and male W istar r a ts  (300-350 g) and of the subsequent u rin e  c o lle c tio n  have been 
described p rev iously [10 ,12]. Human u rine  samples were obtained from seven p a tie n ts  who 
received NMF ( i .v .  or p .o . ,  dose range 300 mg/m^ to  1200 mg/ra^) as a s in g le  dose. Urine 
samples were co llec te d  every 6 hr during a 24 h r period  a f t e r  drug adm in tstra 'tion . D e ta ils  
of the patien ts*  age, sex and m alignancies and o f the form ulation of NMF have been reported  
previously[4 ] . Urine samples were frozen a f t e r  c o l le c tio n  and pooled p r io r  to  a n a ly s is .  
A fter add ition  of 1M HC1 to achieve pHl, samples were f re e z e -d rie d . The residues were 
suspended in  methanol and sub jected  to  TLC a n a ly s is  usinq s i l i c a  gel 60 coated p la te s  (0 .2  
mm o r 2 mm th ickness, Merck AG, Darmstadt, W. Germany). P la tes  were developed in  bu tan-1- 
o l:w a te r :« th a n o l (8 :2 :1  v /v ) . T h ioesters  were d e tec ted  by spraying th e  p la te s  e i th e r  w ith 
. aqueous NaOH followed by Ellm an's reagen t[13] o r  w ith c h lo ro p la tin a te  reagen t[14]. I / T ] -  
Labelled m etabolites were detec ted  as describ ed  by K estell e t  al_.[10]. On p rep a ra tiv e  TLC, 
the area of s i l ic a  a t  the  Rf value of the m ateria l whicfT^jave a rea c tio n  w ith E llm an's 
reagent a f te r  a lk a lin e  hydro lysis was removed from th e  p la te  and e lu te d  with methanol. The 
solvent was evaporated a t  room tem perature. The l ig h t  brown residue was fre e z e -d rie d  to  
t r a ces of b u ta n - l-o l.  The m etabo lite  is o la te d  as described above o r au th en tic  S-(N- 
®ethyl carbamoyl )-N -acetyl cy s te in e  were d isso lv ed  in  methanol (5 m l). HC1 gas was bubbled 
rough the  so lu tions fo r  30 min. The so lu tio n s  were l e f t  standing  overn igh t a t  room
2283
2284 Rapid communication
tem perature, a f te r  which the so lven t was evaporated under reduced p ressure . The m aterial 
was p u r if ie d  by HPLC with methanolrwater {3:1 v /v ) as e lu an t, and a FRAC-100 fra c tio n  
c o l le c to r  (LKB, Croydon, U .K.). The e lu a te  was concentra ted  under reduced pressu re  at 
40*C. HPLC an a ly sis  was performed using a H aters trim odular system (Waters A ssociates, 
Northwich, U .K .), a Waters RCM-100 rad ia l compression u n it  and a Cj« 5 *«m reverse-phase 
column. R ad ioactiv ity  in the  column e lu a te  was detec ted  by an hPLC ESI-Panax 506C 
ra d io a c tiv ity  monitor (Rotherol and M itchell L td . ,  R u is lip , U.K.); u .v . d e tec tio n  was 
achieved with a Waters Am x 480 LC spectrophotom eter s e t  a t  205 nm. The e lu an t (e ith e r
0.01M octy l amine in  w ater ad ju sted  to  pH6  w ith concentra ted  HC1 :methanol, 3:1 v /v ; or 
w ater:m ethanol, 3:1 v /v ) was pumped through th e  column a t  a flow ra te  of 1 ml/min- H-NMR 
sp ec tra  were obtained a t  400 MHz using a Broker WH400 spectrom eter w ith OjO o r borate  buffer 
PH8 /D2 O as so lv e n ts . Mass sp e c tra  were determined on a VG 7070 mass spectrom eter in  the 
chemical io n iz a tio n  mode, using 2-methyl propane as reagen t gas. Spectra were run a t  a scan 
ra te  o f 1 sec/decade and were processed on a YG 2035 data system.
RESULTS
TLC an a ly s is  of samples obtained by freeze-d ry ing  pooled u rine  of mice o r r a ts  which had 
received IMF o r  t^ C -IM F  o r  o f p a tie n ts  who had been trea ted  with IMF afforded  a 
chrom atographic band (Rf 0.30) which gave a p o s it iv e  reac tion  w ith the c h lo ro p la tin a te  
reagent and with Ellm an's reagen t subsequent to  a lk a lin e  hydro lysis . This m aterial was 
absent in  con tro l u rin e  samples. On HPLC an a ly s is  the  m ateria l ex trac ted  from the  TLC p la te  
afforded one predominant peak detected  by e i th e r  i t s  uv absorbance or monitoring of i t s  
rad io a c tiv e  la b e l .  The re te n tio n  time of the m e tab o lite  was in d is tingu ishab le  from th a t  of 
au th en tic  S-(N -m ethylcarbam oyl)-N -acetylcysteine.
The 400 MHz *H-NMR spectra  of S-(N-methylcarbamoyl )-N -ace ty lcyste ine  a t  pH8  and of the
m etabo lite  is o la te d  from p a t ie n t s ’ urine are showr. in  F ig . 1. In the spectrum of th e
reference  compound the  protons of the  acetyl group resona te  as a 3H s in g le t a t  52.01 ppm and 
the N-methyl moiety gives r i s e  to  a 3H s in g le t a t  5 2.78 ppm. The remaining protons of th e  
m olecule, the  cy s te in e  a-CH and tf-CHg, form an ABX system . The magnetic inequivalence of the  
0 -methylene protons a r is e s  from the p ro c h ira l ity  o f the  CH2  th e  presence of a c h ira l
c e n tre . The a-H appears as 54 .40 ppm {1H, dd, J 7 .6  Hz and 4.2 Hz), 0-H as 53.16 ppm (1H,
dd, J_ 14.3 Hz and 7.6 Hz), 0 -H as 53.43 ppm (1H, dd, J_ 14.3 Hz and 4.2 Hz). The geminal 
coupling co n s tan t of 14.3Hz and the  two v ic in a l coupling constan ts (7.6 Hz and 4.2 Hz) a re  
s im ila r  to  the  corresponding J  values prev iously  rep o rted  by us for o th e r  m ercapturic 
ac id s[1 5 ]. At th is  a lk a lin e  pH, slow degradation to  u n id e n tif ie d  products was observed. In 
the  *H-NMR spectrum of the m etabo lite  (Fig. 1), th e  general p a tte rn  i s  very s im ila r  and th e  
coupling co n stan ts  a re  id e n tic a l to  those of th e  s y n th e tic  m a te ria l.
Both is o la te d  m etabolite and au th en tic  reference compound were tre a te d  with m ethanolic HC1 
and thus converted to  a d e riv a tiv e  which m igrated to  Rf 0 .70 on TLC an a ly s is . The chemical 
io n is a tio n  mass sp ec tra  of th e  e s te r i f ie d  products a re  shown in  F ig . 2 and show e x c e lle n t 
cong ru ity . Each spectrum has p rincipal ions a t  m/z 235, 178, 136 and 60 which are  due to  
(M+H) ions of the complete methyl e s te r  m olecule, N -ace ty lcyste ine  methyl e s te r  ( lo ss  o f  
MeNCO), cy s te in e  methyl e s te r  (subsequent lo ss  of ketene) and acetamide re sp e c tiv e ly . 
Although the  sp ec tra  presented in  F igs. 1 and 2 were ob tained with samples is o la te d  from 
p a t ie n t s ' u r in e , the  m ateria l iso la te d  from the  u rin e  of mice and ra ts  afforded  sp ec tra  
almost id e n tic a l to  those shown in the  f ig u re s .
DISCUSSION
Studies of the  mechanism by which NMF causes h e p a to to x ic ity  in mice have accrued s tro n g  
evidence f o r  the conten tion  th a t  i t  is  m etabolised to  a reac tiv e  species responsib le  fo r  
to x ic i ty [2 ,7 ,8 ,9 ,1 6 ] .  However the id e n tif ic a tio n  of carbon d ioxide, methylamine and th e  
pharm acologically innocuous N-(hydroxymethyl)formamide[17] as m etabolites of NMF in  v ivo [ 10] 
gives but l i t t l e  in d ic a tio n  as to  the  nature o f t h i s  sp e c ie s . IMF i t s e l f  i s  no t hydrolysed 
to  methylamine and formic acid  by l iv e r  f ra c tio n s  in  v i t r o .  One might sp ecu la te  th a t  






Fig. 1 Salient features of the 
spectra with 020 of S-(li­
me thy 1 carbamoyl )-N-acetyl- 
cysteine (top panel) and the 
metabolite which was isolated by 
preparative TLC from the urine 
of patients who received NMF 
(bottom panel). The presence of 
alkaline buffer in the solution 
of authentic sample caused some 
degradation as shown by the 
signals near 6 2.92, 3.23, 4.28 
and 4.48 ppm. The chemical 
shifts of the synthetic mercap- 
turic acid were found to be 
markedly sensitive to changes in 
pH in aaueous solution. It may 
be that the borate buffer used 
to mimic the pH of the solution 
of the isolated metabolite was 
not of precisely the same pH or 
ionic strength thus causing the 
small discrepancies in chemical 
shifts. The ^H-NMR spectrum of 
an extract of control urine 
obtained by preparative TLC in 
the same way in which the 
metabolite was isolated showed 
resonances at 62.17, 3.24, 3.27 
and 3.29 ppm which can also be 
















Fig. 2 Mass spectra of the 
methyl esters of (A) authentic
S-(N-methylcarbamoyl)N-acetyl 
cysteine and (B) the metabolite 
isolated from the urine of 
patients who had received NMF.
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methyl Isocyanate (MeNCO) are  the immediate precursors of the observed methylamine. 
A lte rn a tiv e ly , these  or o th e r ox idation  products of WF would be ab le to  form con ju g ates . 
In th i s  re p o r t, the id e n t if ic a t io n  of such a conjugate, S-(N-methylcarbamoyl )-N -ace ty l. 
c y s te in e , as a m etabo lite  of NMF in  the u rine  of mice, r a ts  and men i s  described . Hydrolysis 
of N -m ethylthiocarbam ates, such as th is  m etabo lite , indeed leads to  methylamine and carbon 
diox ide. I t  i s  highly l ik e ly  th a t  the  m ercapturic acid c h a ra c te r ise d  in  th is  study  re su lts  
from m etabolic m odification  of th e  corresponding S-(N -m ethylcarbam oylIglutathione generated 
in  the  l iv e r .  The formation of t h i s  l a t t e r  compound from NMF form ally involves an ox idation  
a t  the  formyl carbon of NMF, b u t th e  m echanistic rou te fo r th i s  novel m etabolic s te p  i s  yet 
an enigma. I t  i s  noteworthy th a t  N-alkylmonothiocarbamate compounds are  e le c tro p h i le s  and 
carbamoyl a tin g  agents and S -(N -alkylcarbam oyl)cysteines, compounds s tru c tu ra lly  r e la te d  to 
the novel m etabo lite  of NMF described  here, have been reported  to  be po ten tly  c y to to x ic [18].
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Abstract—The electrophilic properties of 4-chloro-N-(hydroxymethyl)benzamide as a model compound 
of carbinolamides formed during the metabolic oxidation of N-methylamides were investigated. 
4-Chloro-N-(hydroxymethyl)benzamide did not react with nucleophiles such as cyanide or glutathione 
under physiological conditions. In contrast, AL(acetoxymethyl)-4-chlorobenzamide yielded the cyano- 
methylamide with KCN and 5'(4-chlorobenzamidomethyl)glutathione with glutathione. Under non- 
aqueous conditions, N-(acetoxymethyl)-4-chlorobenzamide reacted avidly with ethanethiol, with meth­
anol and with diethylamine in the presence of base, whereas 4-chloro-AL(hydroxymethyl)benzamide did 
not afford products under these conditions. These results show dearly that N-(acetoxymethyl)-4- 
chlorobenzamide is the precursor of reactive electrophilic methyleneimines. 4-ChIoro-N-(hydroxy- 
methyl)benzamide was not biotransformed to such electrophilic spedes when incubated with mouse 
hepatic microsomes or a microsomal supernatant with acetyl-CoA or a PAPS generating system. Neither
4-chloro-N-(hydroxymethyl)benzamide nor its acetate ester were mutagenic in the short term bacterial 
assay using Salmonella typhimurium. Nevertheless, esters of carbinolamides, such as N-(acetoxymethyl)-
4-chlorobenzamide, might possess toxic or carrinogenic properties.
Compounds having N-methyl moieties are prone to 
oxidative metabolism to the corresponding N- 
hydroxymethyl analogues. Frequently, the latter 
compounds decompose to formaldehyde and the 
N -H  derivative. However, in some xenobiotics, low 
electron density at nitrogen confers chemical stability 
on these N-hydroxymethyl metabolites [2]. Thus, for 
example, the N-hydroxymethyl metabolites of N- 
methylamides can either be excreted unchanged or 
undergo further oxidative metabolism [3].
We have recently reviewed the evidence which 
shows that metabolically generated carbinolamines 
and carbinolamides can be the precursors o f elec- 
trophilic methyleneiminium or methyleneimine 
species, metabolites which may be toxins [4]. The 
formation of these species might be the consequence 
of the loss o f hydroxide or the elimination of water, 
respectively. Alternatively, iminium ions o r imines 
derived from N-methyl compounds may be the prod­
ucts of metabolically generated esters of the N- 
hydroxymethyl compounds rather than the N- 
hydroxymethyl compounds themselves [4]. In this 
report, work is described in which these hypotheses 
have been investigated. 4-Chloro-N-(hydroxy- 
methyl)benzamide and its acetate ester, N- 
(acetoxymethyl)-4-chlorobenzamide, were syn­
thesised as model compounds from which for-
$ Author to whom correspondence should be addressed. 
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m aldehyde is not readily released [3]. In addition to 
a com parison of their ability to form reactive species, 
their genotoxic potential was investigated as 
m easured by the Salmonella m utation assay. In this 
study, the acetate ester of 4-chloro-N-(hydroxy- 
methyl)benzamide (a possible albeit unlikely metab­
olite) was chosen as a model ester for the sulphate 
analogue which is a difficult synthetic target. The 
results o f these investigations help to  explain certain 
toxic properties of N-methyl compounds such as 
the anticancer drug hexamethylmelamine [5], the 
herbicide M onuron [6 ] and some N-methylaniline 
derivatives [7, 8 ] which require metabolism to exert 
their toxicity and which are known or strongly sus­
pected to undergo metabolism to their N-hydroxy- 
methyl derivatives.
MATERIALS AND METHODS
Chemicals. The following substances were pre­
pared generally according to published methods: 4- 
chloro-N-(hydroxymethyl)benzamide [2, 9], N- 
(acetoxymethyl)-4-chlorobenzamide [1], 4-chloro-N- 
(cyanomethyl)benzamide [ID] and S-(4-chloroben- 
zam idom ethyl)glutathione [11]. The latter com­
pound is novel and was characterised by NMR 
spectroscopy: <5 [400 MHz; (C D 3) 2SO| 2.1 (2H, m. 
glutamyl /?-CH2), 2.35 (2H, m, glutamvl y-CH2), 
2.72 ( IH , dd, /  13.5 and 10.0 Hz) and 3.07 (1H. dd. 
J  13.5 and 4.4 Hz) (cysteine 0-C H 2), 3.77 (2H, d, J
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5.9 Hz, glycine CH2), 3.9 (1H, m, glutamyl ar-CH), 
4.38 (1H, dd, J  13.7 and 2.2 Hz) and 4.48 (1H, dd, 
J  13.7 and 4.0 Hz) (NCH2S), 4.61 (1H, m, cysteine 
or-H), 7.55 (2H, d, J  8.6 Hz) and 7.91 (2H, d, J  
8.6 Hz) (ArH), 8.7 (7H, br, NH and OH) and 9.37 
(1H, t, J  ca  6 Hz, glycine NH).
Kl4CN was purchased from Amersham Interna­
tional (Amersham, U.K., specific activity: 59mCi/ 
mmol). The following materials were obtained from 
Sigma Chemical Co. (Poole, U.K.): acetyl-CoA, 
ATP, glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, NADP. The benzamide derivatives 
were added to the incubation mixtures dissolved in 
DMSO or acetonitrile (25 pi).
A n im a ls . Male BALB/c mice (19-24 g) were used 
for all metabolism experiments. In the bacterial 
mutagenicity tests, 9000 g  supernatant fractions of 
livers from male Wistar rats (approximately 250 g) 
which had received Aroclor were used.
Stu d ies o f  ch em ica l reactivity. To investigate the 
reactivity of N-(acetoxymethyl)-4-chlorobenzamide 
with nucleophiles, the following chemical experi­
ments were conducted. N-(Acetoxymethyl)-4- 
chlorobenzamide (341 mg, 1.5 mmol) was dissolved 
in methanol (5 ml). TLC analysis (silica gel, diethyl 
ether) showed no change after 15 min at ambient 
temperature or 5 min at 64°. Triethylamine (202 mg, 
2 mmol) was added to the cooled mixture whereupon 
TLC showed quantitative conversion. Dichloro- 
methane (20 ml) was added and the mixture was 
washed with aqueous toluene-4-sulphonic acid, 
water and saturated brine before being dried 
(Na2S 04). The solvents were evaporated under 
reduced pressure to give 4-ch loro-H -  
(m e th o x ym eth y l)b en za m id e  (7 7 % ) as white crystals; 
NMR <5 (60 MHz; CDCI3) 3.35 (3H, s, OCH3), 4.85 
(2H, d, /  6 Hz, NCH20 ), 7.40 (2H, d, J  8 Hz) and 
7.85 (2H, d, /  8 Hz) (ArH) and 8.0 (1H, br, NH). 
Treatment of a solution of N-(acetoxymethyI)-4- 
chlorobenzamide in dichloromethane with excess 
ethanethiol and N,N-diisopropylethylamine, fol­
lowed by washing with water, drying (Na2S 0 4) and 
evaporation of the solvent under reduced pressure 
afforded 4 -ch lo ro -N -(e th ylth iom eth yl)ben zam ide  
(85%) as a white powder; NMR <5 (60 MHz; CDC13) 
1.30 (3H, l ,  J  7 H z , CH3), 2.70 (2H, q, J  7 Hz, 
CH2CH3), 4.50 (2H, d, /  6 Hz, NCH,0), 7.45 (2H, 
d, J  8 Hz) and 7.85 (2H, d, /  8 Hz) (ArH) and 8.65 
(1H, t, J  6 Hz, NH). Similarly, N-(acetoxymethyl)-
4-chlorobenzamide was allowed to react at ambient 
temperature with excess diethylamine in dichloro­
methane to give 4-ch loro-N ~(diethylam ino- 
m eth y l)b en za m id e  (86%) as an off-white solid; 
NMR <5 (60 MHz; CDC13) 1.10 (6H, t, J  7 Hz, 
CH3), 2.58 (4H, q, J  7 Hz, CH2CH3), 4.35 (2H, 
d, J  6 Hz, NCH2N), 7.2 (1H, br, NH), 7.30 (2H, 
d, J  8 Hz) and 7.75 (2H, d, J  8 Hz) (ArH).
Ar-(Acetoxymethyl)-4-chlorobenzamide (0.5 mM) 
was incubated in Earl’s buffer, pH 7.4, (2.5 ml) with 
KUCN (1 mM, specific activity 3.2 mCi/mmol) at 37° 
for 1 hr under shaking. Incubations of N-(acet- 
oxymethyl)-4-chlorobenzamide (ImM) with glu­
tathione (10 mM) were performed in buffer con­
taining 3-(N-morpholino)propanesulphonic acid 
(MOPS, 0.4 M, pH 7.4).
In vitro m eta b o lism  o f  4 -ch lo ro -(N -h ydroxy-
m eth yI)b en za m id e . Livers were excised and a hom- 
ogenate (25%) was prepared in sucrose solution 
(2.5 M, pH 7.4). Microsomes were obtained in 
the standard way involving centrifugation of the 
homogenate at 9000 g  for 20 min and centrifugation 
of the 9000# supernatant at 100,000 g  for 1 hr. 4- 
Chloro-N-(hydroxymethyl)benzamide (1 mM) was 
incubated either with microsomes or microsomal 
supernatant equivalent to 0.3 g liver. Microsomal 
incubations were carried out for 1 hr in Earl’s buffer 
(2.5 ml) containing MgCl2 (5 mM) and a NADPH 
generating system (NADP, 1 mM, glucose-6-phos- 
phate 4.5 mM, glucose-6-phosphate dehydrogenase 
1.5 units). Incubations with microsomal supernatant 
were performed in MOPS buffer (0.4 M). These 
incubates also contained either K14CN (1 mM, 
specific activity 3.2 mCi/mmol) or glutathione 
(10 mM). In some experiments, a system which gen­
erated 3 '-phosphoadenosine-5'-phosphosulphate 
(PAPS; K2S 0 4 2.4 mM, ATP, 8mM, mercapto- 
ethanol, 2.4 mM) or acetyl-CoA (2.5 mM) with ATP 
(5mM) was added to the incubation. Incubations 
were terminated either by placing incubates on ice, 
or by precipitation of proteins via addition of 20% 
aqueous zinc sulphate (0.6 ml) followed by saturated 
aqueous barium hydroxide (0.6 ml). For the analysis 
of 4-chloro-Ar-(cyanomethyI)benzamide the incu­
bation mixtures were passed through Cl8 Sep-Pak 
cartridges (Waters Associates, Northwich, U.K.), 
which were washed with water (5 ml) and eluted 
with methanol (5 ml). The methanol extract was 
evaporated to dryness under partial vacuum in a 
Savants Speed-vac concentrator. For the analysis of
5-(4-chlorobenzamidomethyl)glutathione, the incu­
bates were centrifuged after denaturation of proteins 
and aliquots of the supernatant were used immedi­
ately for analysis.
H P L C  analysis. Separation of metabolites was 
performed using an Altex 100A pump (Anachem 
Ltd., Luton, U.K.) linked to a Pye LC-UU detector 
(A = 254 nm) (Pye Unicam, Cambridge, U.K.) or a 
Waters trimodular system both fitted with Waters 
RCM-100 radial compression units and C18 5-m 
reverse phase columns. For the analysis of the 
cyanomethylamide, the mobile phase was 60% 
methanol-40% 0.05 M sodium acetate in water 
(adjusted to pH 5); for the analysis of S-(4- 
chlorobenzamidomethyl)glutathione: 50% meth- 
anol-50% 0.05 M aqueous sodium acetate or 60% 
methanol-40% (1% trifluoroacetic acid in water). 
The flow rate was 1 ml/min.
B acteria l m u tagen ic ity  tests. The benzamide 
derivatives were evaluated using the plate incor­
poration assay as described by Maron and Ames [12] 
with S alm on ella  ryph im uriu m  strains TA 98 and TA 
100. Some tests of 4-chloro-N-(hydroxymethyl)- 
benzamide involved preincubation of the compound 
with a liver 9000g  supernatant (10%) obtained from 
rats treated with Aroclor with or without K2S 0 4 
(2.4 mM) and ATP (8 mM) or acetyl-CoA (2.5 mM) 
and ATP (5 mM) preceding the addition of the bac­
teria. The inclusion of acetyl-CoA was prompted by 
the observation that the mutagenicity of metabolites 
of the herbicide Monuron, a N-methyl compound 
related to the N-methylbenzamides, was increased 
in the presence of this cofactor [6].
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RESULTS ( a )
U nder physiological conditions, 4-chloro-W- 
(hydroxym ethyl)benzam ide did not react either with 
cyanide to afford the cyanom ethylam ide (F ig. 1) or  
with glutathione to yield the S-am idom ethyl g lu­
tathione derivative (Fig. 2). In contrast, the acetate  
ester reacted with both cyanide (Fig. 1) and glu­
tathione (Fig. 2). T he product o f the reaction  
betw een N -(acetoxym ethyl)-4-chlorobenzam ide and 
glutathione was isolated by HPLC. High-field proton  
N M R  showed this material to be 5-(4-chloro- 
benzam idom ethyl)glutathione consistent with the  
spectrum  o f a sam ple o f the com pound prepared by  
the general m ethod previously reported [11]. Under  
the incubation conditions used, 3% o f the N -ace- 
toxym ethyl com pound reacted with cyanide to give  
the cyanom ethylam ide, whereas the reaction with  
glutathione was alm ost quantitative.
In order to  investigate the m echanism s whereby  
jV-(acetoxym ethyl)-4-chlorobenzam ide reacts with  
nucleophiles, several experim ents were conducted. 
Firstly, the pH  dependence of the rate o f  hydrolysis 
of this com pound to 4-chloro-N-(hydroxy- 
m ethyl)benzam ide in 0.02 M phosphate buffer 
was determ ined at 37° by HPLC analysis. The tlf2 
o f hydrolysis was 13.2 min at pH 3, 16.9 min at 
pH  7 and less than 1 min at pH 9, which shows 
that the reaction was base-catalysed. Secondly, the  
substrate, in m ethanol, was treated with triethyl- 
am ine. N o reaction was observed by T L C  during 
10 m in in the absence o f  base. Addition o f successive  
aliquots o f triethylam ine caused very rapid m ethan- 
olysis involving stoichiom etric consum ption o f base. 
The isolated product was 4-chloro-N -(m ethoxy- 
m ethyl)benzam ide (see  Fig. 4) in virtually quanti­
tative yield, hence the electrophilic reactivity o f  the  
starting ester is at the m ethylene carbon exclusively  
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Fig. 1. High pressure liquid chromatogram of (a) reference 
compounds 4-chioro-iV-(hydroxymethyl)benzamide (i) and 
4-chioro-iV-(cyanomethyl)benzamide (ii); (b) a sample of 
the incubate of /V-(acetoxvmethyl)-4-chlorobenzamide with 
KUCN; and (c) a sample of the incubate of 4-chIoro-jV- 
(hydroxymethyl)benzamide with KUCN. Detection by u.v. 
spectrophotometry (a) or radioactivity counting (b and c).
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Fig. 2. High pressure liquid chromatogram of (a) a sample 
of the incubate of W-facetoxymethyO^-chlorobenzamide 
with glutathione; (b) a sample of the incubate of 4-chloro- 
A/-(hydroxymethyl)benzamide with a 9000 g supernatant 
and glutathione. Peak (i) co-elutes with 5-(4-chloro- 
benzamidomethyl)glutathione and peak (ii) with 4-chloro- 
iV-(hydroxymethyl)benzamide. A chromatographic trace 
very similar to the one shown in (b) was observed when 
the 9000 g supernatant was fortified with a PAPS generating 
system.
stoichiom etric in base, rather than catalytic. A  
similar reaction o f Af-(acetoxym ethyl)-4-chloro- 
benzam ide was observed with diethylam ine and with 
ethanethiol in the presence o f the non-nucleophilic  
base A^/V-diiropropylethylamine, giving the 
diethylam inom ethyl- and ethylthiom ethyl- 
benzam ides, respectively. U nder th ese  experimental 
conditions, 4-chloro-A/-(hydroxym ethyl)benzam ide  
did not react with m ethanol, ethanethiol or 
diethylam ine.
W hen 4-chloro-A^-(hydroxymethyl)benzamide was 
incubated with either m ouse hepatic m icrosom es or 
m icrosom al supernatant with or w ithout addition of 
acetyl Co A  or a PAPS generating system , m etab­
olism  to  precursors of m ethylene iminium ions or 
im ines did not occur as indicated by the lack o f  
evidence for the formation o f a cyanom ethylam ide  
in the presence o f  cyanide or a glutathionyl derivative 
in the presence o f  glutathione (results not shown).
W hether )V-(acetoxym ethyl)-4-chlorobenzam ide  
reacts with glutathione in v ivo  is unclear. The urine 
o f mice which had received jV-(acetoxymethyl)-4-
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Fig. 3. Lack of mutagenicity of N-(acetoxymethyl)-4-chlo- 
robenzamide to Salmonella typhimurium TA 100. Results 
are the mean ± SD of three plates.
chlorobenzam ide or 4-chloro-N-(hydroxym ethyl)- 
benzam ide contained 4-chlorohippuric acid and 
the HPLC chrom atogram s showed a peak which 
was possibly due to 5-(4-chlorobenzam ido- 
methyl)-./V-acetylcysteine (results not show n). 
T he small am ount o f this material formed and its 
chrom atographic properties rendered its identi­
fication im possible.
Neither 4-chloro-Ar-(hydroxym ethyl)benzam ide  
nor its acetyl ester w ere genotoxic in the Salmonella 
assay (T A  100 strain) in the presence or absence  
o f  a 9000 g  supernatant fraction obtained from rat 
(Table 1, Fig. 3). N -(A cetoxym ethyl)-4-chloro- 
benzam ide w as, how ever, much more toxic towards 
the bacteria than was 4-chloro-N-(hydroxym ethyl)- 
benzam ide. A t a concentration of 0.316 mg per 
plate of the acetate ester, 50% of the bacteria 
were killed whereas a concentration o f 5 mg per 
plate 4-chloro-N-(hydroxym ethyl)benzam ide did not 
cause toxicity to  the bacteria. Results obtained with
Fig. 4. Mechanism of the base-catalysed reaction between 
jV-(acetoxymethyl)-4-chlorobenzamide and nucleophiles 
(Nu =  C N ', glutathione, MeO. EtS, Et2N).
the T A  98 strain w ere very similar to those observed  
with T A  100, with the rate o f  spontaneous reversion  
similar to that reported  previously [12].
DISCUSSION
T he results o f  this study dem onstrate unequivo­
cally that 4-chloro-AL (hydroxym ethyl)benzam ide  
d oes not form  a m ethyleneim inium  or m ethy- 
leneim ine under physiological conditions. This is not 
unexpected  since the hydroxide group is a poor leav­
ing group. H o w ever , the situation is very different 
in a m olecu le in w hich the N-hydroxym ethyl group  
is esterified. In the m odel com pound, N -(acet- 
oxym ethyl)-4-ch lorobenzam ide, the acetoxy group is 
a good  leaving group. This renders the m olecu le  
capable o f form ing an im ine under physiological 
conditions. Such sp ecies can react with cyanide to 
yield the cyanom ethylam ide or with glutathione to 
afford 5-(4-ch lorobenzam idom ethyl)glutathione. In 
the presence o f  cyanide, the elim ination-addition  
reaction with the electroph ilic  m ethylene was not the 
only reaction occurring, in that cyanide appeared
Table 1. Lack of mutagenicity of 4-chloro-N-(hydroxymethyl)benzamide to Salmonella ryphi-
murium strain TA 100
Number of revertant colonies above background, 
in the presence of
9000 g fraction 9000 g fraction
Dose and PAPS and acetvl-CoA
(ug/plate) 9000 g fraction generating system and ATP
50 -9* 3 16
100 - 9  ± 22 -2 9  r  25 -11
500 -1 8  r  16 -3 0 -21
1000 20 i  6 -2 9  * 18 -4 2
5000 -1 2  -  33 -21 — 5
■Acetylaminofluorene
50 ug/plate 2073 z  219
* Values are the mean of two or the mean r  SD of 3-5 tests. Background levels were: 
123 -  3 (9000g supernatant). 98 z: 18 (9000 g fraction and PAPS generating system). 81 * 18 
(9000 g fraction and acetyl-CoA).
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also to catalyse hydrolysis by acting as a base as 
well as a nucleophile. Therefore, the amount of the 
cyanomethylamide formed in the presence of cyanide 
was much less than the amount of the glutathionyl 
derivative generated during the reaction of the ester 
with glutathione. The pH dependence and the stoi­
chiometry of base consumption of these substitution 
reactions suggests a mechanism implicating the 
methyleneimine rather than the methyleneiminium, 
as outlined in Fig. 4.
The results indicate that the metabolic conjugation 
of 4-chloro-//-(hydroxymethyl)benzamide with acet- 
yl-CoA, activated sulphate or UDP-glucuronic acid 
is not a biochemical reaction in vitro. Reaction prod­
ucts of the /V-hydroxymethyl compound with cyanide 
or glutathione could not be detected in incubations 
of liver fractions supplemented with either acetyl- 
CoA or a PAPS generating system. Furthermore, 
the presence of small amounts of a mercapturate 
derived from 4-chloro-/V-(hydroxymethyl)benz- 
amide was suspected in the urine of mice which 
had received this carbinolamide, but unequivocal 
identification was not possible. These observations 
are in accordance with our failure to detect either 
S - (N-(2,4,6- bis(dimethylamino)-1,3,5 -triazin-5-y 1)- 
A/-methylaminomethyl)glutathione as a metabolite 
of Af-(hydroxymethyl)pentamethylmelamine in vitro 
in liver preparations or Af-acetyl-S-(7V-(2,4,6-bis- 
(dimethylamino)-l,3,5-triazin-5-yl)-W-methylamino- 
methyl)cysteine as an in vivo metabolite of this com­
pound in the urine of mice.*
Two recent reports describe the identification of 
NCH2S conjugates of Af-methyl compounds in vivo. 
A major biliary metabolite of the hepatocarcinogen 
4-dimethylaminoazobenzene in the rat was shown to 
be S-((4-phenylazo)phenylaminomethyl)glutathione
[7] and a major urinary metabolite of 4-cyano-N, N- 
dimethylaniline has been identified as jV-acetyl-S- 
((4-cyanophenyl)aminomethyl)cysteine in rodents
[8]. In both cases, the thioester metabolites were 
considered to be the products of the reaction between 
glutathione and either methyleneiminium ions or 
imines derived from the AMiydroxymethyl inter­
mediates. As the hydroxymethyl moiety in the ani­
line derivatives is located in an environment of 
greater electron density than in the /'/-(hydroxy­
methyl )benzamide molecule, it is reasonable to 
assume that they undergo facile elimination of water, 
as do the aliphatic /V-(hydroxymethyl)amines [13]. 
Alternatively, one could suggest that, in analogy to 
the results reported in this paper, metabolic esteri- 
fication increases the leaving group ability of the 
hydroxy group in these /V-(hydroxymethyl)aniIine 
derivatives.
4-Chloro-/V-(hydroxymethyl)benzamide was not a 
mutagen in the Salmonella mutation assay. This is
* D. Ross. A. Gescher and M. D. Threadgill. unpub­
lished results.
not surprising in the light of its inability to form 
electrophilic species. It is. however, puzzling that N- 
(acetoxymethyl)-4-chlorobenzamide, which we have 
now shown unequivocally to be a precursor of elec­
trophilic species, is not mutagenic. Two explanations 
can be tendered: either the methyleneimine formed 
by elimination of acetate is intrinsically unreactive 
with DNA to cause deleterious lesions or, more 
likely, the Salmonella test is incapable of detecting 
the potential mutagenicity of this kind of soft elec- 
trophile. It has been shown recently that N- 
(hydroxymethyl)chloroacetamide, an amide related 
to 4-chloro-/V-(hydroxymethyl)benzamide, was with­
out genotoxic properties in Salmonella [14]. 
However, it was shown to be clastogenic in a human 
lymphocyte cytogenic assay, both in the presence 
and absence of rodent liver 9000 g homogenate. It 
remains to be investigated whether or not Af-(acet- 
oxymethyl)-4-chlorobenzamide or, indeed, 4-chloro- 
//-(hydroxymethyl)benzamide are clastogenic in this 
genotoxicity test.
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In order to clarify the role of oxidative processes in cytotoxicity we have studied the 
metabolism and toxicity of 2-methyl-l,4-naphthoquinone (menadione) and its 2,3 di­
methyl (DMNQ) and 2,3 diethyl (DENQ) analogs in isolated rat hepatocytes. The two 
analogs, unlike menadione, cannot alkylate nucleophiles directly and were considerably 
less toxic than menadione. This decreased toxicity was consistent with the inability of 
DMNQ and DENQ to alkylate but we also found them to undergo lower rates of redox 
cycling in hepatocytes and a higher ratio of two electron as opposed to one electron 
reduction relative to menadione. Thus, facile analysis of the respective roles of alkylation 
and oxidation in cytotoxicity was not possible using these compounds. In hepatocytes 
pretreated with bischloroethyl-nitrosourea (BCNU) to inhibit glutathione reductase, all 
three naphthoquinones caused a potentiation of reduced glutathione (GSH) removal/ 
oxidized glutathione (GSSG) generation and cytotoxicity relative to that observed in 
control cells. These data show that inhibition of hepatocyte glutathione reductase by 
BCNU results in enhanced naphthoquinone-induced oxidative challenge and subsequent 
cellular toxicity. That DMNQ and DENQ are cytotoxic, albeit at high concentrations, 
and that this cytotoxicity is potentiated by BCNU pretreatment suggest that oxidative 
processes alone can be a determinant of cytotoxicity, e 1986 Academic press, inc.
The metabolism and toxicity of mena­
dione,2 2-methyl-l,4-naphthoquinone, have 
been extensively studied in isolated hepa­
tocytes (1-5) which constitutes a useful 
model system for investigations of mech-
1 To whom correspondence should be addressed.
2 Abbreviations used: Menadione, 2-methyl-l,4- 
naphthoquinone; DMNQ, 2,3-dimethyl-l,4-naphtho- 
quinone; DENQ, 2,3-diethyi-1.4-naphthoquinone: 
DT-diaphorase, NAD(P)H: (quinone acceptor) oxi- 
doreductase; SOD. superoxide dismutase; BCNU, 1,3- 
bis-(2-chloroethyl)-l-nitrosourea; Hepes, 4-(2-hy- 
droxyethyO-l-piperazineethanesulfonic acid; DMSO, 
dimethvlsulfoxide.
an isms of hepatotoxicity in vitro. Mena­
dione-induced toxicity in hepatocytes is 
thought to involve depletion of cellular 
thiols such as glutathione (GSH), and thiol 
groups contained in proteins (4, 5). Recent 
evidence has implicated removal of cellular 
thiol groups to be the mechanism whereby 
menadione-induced perturbations in in­
tracellular calcium ion homeostasis may 
occur (5, 6). These changes may lead to in­
creases in cytosolic free calcium concen­
tration, cytoskeletal alterations, and sub­
sequent cell death (I, 2).
The removal of cellular thiols in cells by 
menadione is a consequence of two major
0003-9861/86 $3.00
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processes, alkylation and oxidation. Men­
adione is an electrophile and as such can 
react with nucleophiles directly, generating 
a menadione-GSH conjugate and alkylated 
protein in the case of GSH and protein SH 
groups, respectively (4, 7). Menadione is 
also a substrate for various one-electron 
reductases in both the mitochondrial and 
endoplasmic reticular compartments of the 
cell (1). These enzymes catalyze the pro­
duction of semiquinone radicals derived 
from menadione whose subsequent reoxi­
dation by molecular oxygen generates the 
parent quinone and superoxide anion rad­
ical (0$) (1). Dismutation of O2  produces 
hydrogen peroxide (H20 2), and further re­
actions of these species can lead to the pro­
duction of hydroxyl radical (OH) and sin­
glet oxygen ( ^ 2) (7,8). Thus, an assortment 
of oxidizing species can be produced in the 
cell as a consequence of one-electron re­
duction of menadione, and such species will 
readily oxidize reduced thiols.
In an attempt to clarify the role of the 
generation of oxidizing species in quinone- 
induced cytotoxicity, we have studied the 
metabolism of menadione and two of its 
analogs which cannot alkylate nucleophilic 
sites directly. In this study we have com­
pared the metabolism and toxicity of men­
adione, 2,3-dimethyl-l,4-naphthoquinone 
(DMNQ) and 2,3-diethyl-l,4-naphthoqui­
none (DENQ), in isolated rat hepatocytes. 
Furthermore, we have also investigated the 
role of oxidative processes in the cytotox­
icity of these three naphthoquinones by 
using bis-chloroethylnitrosourea (BCNU) 
to inhibit cellular glutathione reductase 
(9). This enzyme, which utilizes NADPH 
as a cofactor, reduces GSSG to GSH, thus 
ensuring a high intracellular ratio of re­
duced to oxidized thiol. Inhibition of glu­
tathione reductase severely limits the ef­
ficient functioning of glutathione peroxi­
dase, an enzyme which removes peroxides 
such as H2O2 at the expense of the conver­
sion of GSH to GSSG. Thus H2O2  produced, 
for example, from the dismutation of O2 , 
can only be removed by this enzyme until 
the initial supply of GSH is exhausted, as 
the catalytic cycle regenerating GSH via 
glutathione reductase is blocked. We have 
compared the toxicity of menadione,
DMNQ, and DENQ to both control and 
BCNU pretreated hepatocytes and mea­
sured the effects of the quinones on cellular 
thiol homeostasis.
MATERIALS AND METHODS
1,4-Naphthoquinone was purchased from Aldrich. 
GSH, GSSG, dicoumarol, and menadione were ob­
tained from Sigma, while collagenase (grade II), 
NADPH, and superoxide dismutase (SOD) were pur­
chased from Boehringer-Mannheim. All other chem­
icals were of a t least reagent grade and were pur­
chased locally.
2,3-Dimethyl-l,4-naphthoquinone (DMNQ) and 2,3- 
diethyl-1,4-naphthoquinone (DENQ) were prepared as 
follows: a mixture of 1,4-naphthoquinone (1.58 g), 
propanoic acid (6.0 g), sulpholane (20 ml), w ater (25 
ml), and silver nitrate (0.5 g) was heated to 80eC. Po­
tassium peroxydisulfate (5.5 g) in water (25 ml) was 
added during 20 min a t 80°C. A fter a further 15 min 
a t th is temperature, the mixture was poured onto ice 
(100 g). The w ater was decanted off and the residue 
dissolved in acetonitrile (50 ml), filtered, and evapo­
rated to dryness. The residue was chromatographed 
on Silica gel, with petroleum ether (BPt 60-80°C)/ 
ethyl acetate (9/1) giving 2,3-diethyl-l,4-naphthoqui­
none (1.61 g; 75%; MPt 67-68°C, l i t  MPt 68.5-69.50C 
(10)). An analogous preparation was used for 2,3-di- 
methyl-1,4-naphthoquinone, using 1,4-naphthoqui­
none and acetic acid, in 79% yield (MPt 124-125°C; 
l i t  M Pt 125-126°C (11)). TLC was used to check the 
purity  of these compounds (Silica plates; petroleum 
ether/e thy l acetate 3/1) DMNQ-one spot Rf -  0.85; 
DENQ-one spot Rf -  0.90. NMR analysis was totally 
consistent with the proposed structures.
Male Sprague-Dawley rats (200-250 g) were used 
in all experiments. Hepatocytes were isolated as in 
(12) and cell incubations were performed in rotating 
round-bottomed flasks (10s cells/ml) under an atm o­
sphere of 95% O2 5% C02. Glutathione reductase was 
inhibited by treatm ent of the cells with l,3-bis-(2- 
chloroethyl)-l-nitrosourea essentially as previously 
described (13), except th a t Eagles minimal essential 
medium supplemented with 1 mu methionine was used 
for cell treatm ent and cell recovery. This treatm ent 
produces a t least 90% inhibition of GSSG reductase 
w ithout affecting cellular GSH content (13) and this 
was verified in these studies. Incubations were per­
formed in Krebs-Henseleit buffer, pH 7.4, containing
12.5 m u Hepes a t  37°C, and substrates were added in 
dimethylsulfoxide (0.4% of final volume except for 
toxicity curves of DMNQ and DENQ 0.6 mM (0.8%) 
and 1 mM (2%)). Control experiments showed th a t 
concentrations of up to 2% DMSO were not cytotoxic 
and had no effect on menadione-induced toxicity. Cell 
viability was determined by trypan blue exclusion. 
GSH and GSSG were determined by HPLC after de-
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rivatization as described by Reed et aL (14). OJ was 
detected by SOD-sensitive reduction of acetylated cy­
tochrome c, prepared as in (15) using the wavelength 
pair 550-540 nm (16). Dialyzed whole liver homogenate 
was prepared by homogenization of the liver in 0.25 
M sucrose (20% w /v), centrifugation at 2000p for 10 
min, followed by overnight diaiysis of the supernatant 
against 0.15 M KC1, pH 7.4 (21). Aliquots of super­
natant (0.05 ml) were mixed with 0.15 M Tris-HCl 
buffer, pH 7.4 (I ml), containing acetylated cytochrome 
c (1 m g/m l) and NADPH, 1 mM. In all experiments 
dicoumarol was used at a concentration of 30 fiM and 
SOD at 0.1 mg/ml. SOD-sensitive reduction of ferri- 
cytochrome derivatives cannot be used as an absolute 
measure of 0 £ production due to other competing re­
actions of Oj, such as enzymatic and nonenzymatic 
dismutation. Protein was determined according to the 
method of Lowry et aL (17).
RESULTS
Alkylation reactions of quinones gener­
ally proceed a t the ortho position to the 
quinone moiety. Thus both the 2,3-dialkyl- 
ated derivatives (DMNQ and DENQ) would 
not be expected to directly alkylate biolog­
ical nucleophiles. This was verified exper­
im entally using GSH as a model nucleo­
phile. If conjugate formation between qui­
none and GSH did not occur then full 
recovery of thiol equivalents in term s of 
GSH rem aining and GSSG formed should 
be possible. T hat this was the case during 
reaction of DMNQ and DENQ with GSH 
is shown in Table I.
The toxicity of menadione and its two 
alkylated analogs, DMNQ and DENQ, in 
isolated ra t  hepatocytes is shown in Fig. 1 
(A-C). The results show that both of the
TABLE I
R e c o v e r y  o f  T h i o l  E q u i v a l e n t s  a f t e r  R e a c t io n  
OF DMNQ o r  DENQ (0.2 mM) w i t h  GSH 










quinone 170 31 201
DMNQ 143 66 209
DENQ 138 66 204





Fig. 1. Toxicity of 2,3-dimethyl-l,4-naphthoquinone 
(A). 2,3-diethyl-l,4-naphthoquinone (B), and mena­
dione (C) in isolated hepatocytes. (Quinone concen­
trations were: • ,  0.1 mM; A, 0.2 mM; O, 0.6 mM, □ ,  1 
mM). One experiment typical of three.
substitu ted  analogs were markedly less 
toxic than menadione. The lack of toxicity 
of DMNQ and DENQ could reflect their in ­
ability to alkylate cellular nucleophiles but 
may also be a consequence of diminished 
one-electron reduction by m itochondrial 
and microsomal reductases relative to 
menadione. This would in tu rn  lead to a 
decreased generation of semiquinone rad ­
ical, and active oxygen species such as 0 2 
and H 20 2- Alternatively, the diminished 
toxicity of DMNQ and DENQ may be due 
to th e ir higher affinity for the enzyme DT- 
diaphorase [NADPH (quinone acceptor) 
oxidoreductase], a two-electron reductase 
which catalyzes the reduction of quinones 
to hydroquinones without the generation 
of semiquinone radical interm ediates (18). 
Thus, it has been proposed th a t this enzyme 
plays a protective role in quinone-induced 
toxicity (1, 19). A dialyzed whole liver ho­
mogenate, devoid of soluble cellular thiols 
(which may interact with quinones directly 
to generate 0 2 (4, 20)), was used to inves­
tigate these possibilities. A decreased ca­
pacity of DMNQ and DENQ relative to 
menadione to generate species which 
caused acetylated cytochrome c reduction 
was evident using the dialyzed whole liver 
homogenate preparation (Fig. 2A). Reduc­
tion of the cytochrome can reflect genera­
tion of either hydroquinone3 or 0 2, as both
3 We have found that the hydroquinone of mena­
dione, synthesized according to L. Feiser [(1940) J. 
Biol Chem. 133, 391-396], readily reduces acetylated 
cytochrome cl
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F ig. 2. NADPH-dependent reduction of acetylated 
cytochrome c induced by 1,4-naphthoquinones in di­
alyzed whole liver homogenate. (Menadione (□); 2,3- 
dimethyl-l,4-naphthoquinone (O); and 2,3-diethyl-l,4- 
naphthoquinone (•)) . (A) Concentration dependence 
of NADPH-(1 mM) dependent acetylated cytochrome 
c reduction in dialyzed whole liver homogenate. (B) 
Effects of SOD (0.2 mg/ml, open bar), and dicoumarol 
(0.03 mM, solid bar) on NADPH-dependent reduction 
of acetylated cytochrome c in dialyzed whole liver ho­
mogenate. (a) Menadione, 0.2 mM; (b) 2.3-dimethyl- 
1,4-naphthoquinone, 0.2 mM; (c) 2,3-diethyl-l,4-naph- 
thoquinone. 0.2 mM. Means ± standard deviation of 
three experiments.
are capable of transferring  electrons to 
acetylated cytochrome c. (1). With m ena­
dione, however, 50% of the reduction was 
SOD sensitive, suggesting the involvement 
of O2 , whereas SOD had no significant ef­
fect on DMNQ- and DENQ-induced acet­
ylated cytochrome c reduction (Fig. 2B). 
Conversely, dicoumarol, an inhibitor of DT- 
diaphorase (19), alm ost totally inhibited 
the NADPH-dependent reduction of the 
cytochrome by DMNQ and DENQ, whereas 
menadione-induced reduction was still 35% 
of the control value (Fig. 2B). These ex­
perim ents dem onstrate th a t the alkyl-sub­
stitu ted  analogs of menadione have a 
higher ratio of two- as opposed to one-elec­
tron reduction relative to menadione itself. 
In agreem ent with previous studies (1, 21) 
and the protective role of DT-diaphorase, 
p re treatm ent of hepatocytes with dicou­
marol (0.03 m M ) markedly exacerbated the 
toxicity of all three quinones to hepatocytes 
(data not shown).
In an attem pt to clarify the role of oxi­
dative processes in naphthoquinone-in­
duced toxicity we have used cells pretreated 
with BCNU, an inhibitor of glutathione re ­
ductase. This trea tm ent exacerbates in­
tracellular oxidative challenge, as any 
GSSG generated in the cell cannot be re­
duced back to GSH. Both DMNQ and 
DENQ caused some loss in hepatocyte GSH 
content (Figs. 3B-C) relative to controls 
(Fig. 3A). There was, however, a potentia­
tion of GSH removal of GSSG generation 
in BCNU-pretreated cells relative to con­
tro l cells in the case of all three naphtho­
quinones (Figs. 3A-D). Furtherm ore, the 
three naphthoquinones were significantly 
more toxic to BCNU-pretreated cells than 
to control cells (Figs. 4A-D), dem onstrat­
ing th a t enhanced oxidative challenge can 
result in enhanced cellular toxicity.
DISCUSSION
In this study we have investigated the 
metabolism and toxicity of alkyl-substi­
tuted analogs of menadione which cannot 
alkylate cellular nucleophiles directly in 
order to determ ine the role of oxidative 
processes in cytotoxicity. The alkyl-sub­
stitu ted  analogs of menadione, DMNQ and 
DENQ, were markedly less toxic to isolated 
hepatocytes than  the paren t compound. 
High concentrations of DMNQ and DENQ 
were required to induce significant cyto­
toxicity in hepatocytes. These data do not 
allow us to conclude, however, th a t oxi­
dative processes are  unim portant in m en­
adione-induced cytotoxicity and th a t al- 
kylation reactions represent the only de­
term inants of the toxicity observed. An 
alternative explanation for the decreased 
toxicity of DMNQ and DENQ relative to 
menadione may be their low ability to gen­
erate oxidizing species w ithin the cell—ei­
ther because of low affinity for one-electron 
reductases or because of higher affinity for 
alternative pathw ays of metabolism such 
as DT-diaphorase-catalyzed two-electron 
reduction. Using dialyzed liver homogenate 
we found th a t SOD could substantially  in­
hibit menadione-induced acetylated cyto­
chrome c reduction, whereas it had m ini­
mal inhibitory effect on DMNQ- and 
DENQ-mediated reduction (Fig. 2). This 
suggests tha t O2  generated by redox cycling 
reactions is responsible for a substantial 
proportion of the observed reduction of
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Fig. 3. GSH depletion (a) and GSSG generation (b) 
during metabolism of 2,3-dimethyl-l,4-naphthoqui- 
none 0.2 mM (B), 2,3-diethyl-l,4-naphthoquinone 0.2 
mM (C), and menadione 0.05 mM (D), in control (O) 
and BCNU-pretreated cells ( • ) .  The thiol status of 
control (O) and BCNU-pretreated ( • )  cells in the ab­
sence of quinone but in the presence of the solvent 
vehicle (DMS0) is shown in (A). One experiment typ­
ical of three.
acetylated cytochrome c only with m ena­
dione. Furtherm ore, data  obtained using 
dicoumarol, an inhibitor of DT-diaphorase, 
showed th a t two-electron reduction was 
involved in the metabolism of all three 
naphthoquinones, but th a t th is metabolic 
pathway was more active with DMNQ and 
DENQ. The alkylated analogs, therefore,
undergo a higher ratio of two- as opposed 
to one-electron reduction relative to men­
adione and thus this represents a possible 
explanation of the decreased toxicity of 
DMNQ and DENQ relative to menadione.
W hether a particular quinone is m etab­
olized by one- or two-electron reductases 
depends on a number of factors such as 
steric considerations, lipophilicity, and 
one-electron reduction potential. The de­
pendence of the ra te  of O2  production by 
isolated ra t hepatocytes on the one-elec­
tron reduction potential of quinones has 
been studied previously by Powis et aL (22). 
These workers showed th a t in isolated he­
patocytes maximal quinone-induced O2  
formation occurs a t a quinone one-electron 
reduction potential of —70 mV (22). From 
their data one can also predict th a t a more 
negative one-electron reduction potential






C (D EN Q  0 .2 m M )
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Fig. 4. Toxicity of 2,3-dimethyl-l,4-naphthoquinone 
0.2 mM (B), 2.3-diethyl-1.4-naphthoquinone0.2 mM (C). 
and menadione 0.05 mM (D). in control (O) and BCNU- 
pretreated cells ( • ) .  The toxicity of the solvent vehicle 
to control (O) and BCNU-pretreated ( • )  cells is shown 
in (A). One experiment typical of five.
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than that of menadione (—200 mV) would 
lead to a marked decrease in the rate of 
superoxide formation. As alkyl substitu­
tion of the naphthoquinone nucleus would 
be expected to cause donation of electrons 
into the ring system, the one-electron re­
duction potentials of DMNQ and DENQ 
would be predicted to be more negative 
than menadione itself. Thus, on the basis 
of one-electron reduction potential alone, 
the alkyl-substituted derivatives of men­
adione would be expected to induce the 
generation of fewer oxygen-derived radi­
cals.
The observation that DMNQ and DENQ 
were cytotoxic, albeit at high concentra­
tions, suggests that oxidative processes 
alone can cause cytotoxicity. To investigate 
this we used cells preincubated with BCNU, 
which inhibits cellular glutathione reduc­
tase. In control cells, all three naphtho­
quinones induced some GSH loss and 
GSSG formation, but these changes were 
markedly exacerbated by BCNU pretreat­
ment (Fig. 3), showing that the alterations 
in GSH homeostasis observed occur, at 
least in part, by means of oxidative mech­
anisms. Although DMNQ and DENQ did 
not induce significant formation of O2  in 
dialyzed liver homogenate (Fig. 2), naph­
thoquinones can still induce an oxidative 
challenge including O2 and H2O2 genera­
tion, via chemical reactions (23), and this 
may represent the route whereby DMNQ 
and DENQ induce oxidative stress.
As well as a potentiation of naphtho­
quinone-induced GSH loss and GSSG for­
mation in BCNU-pretreated cells relative 
to control cells, marked potentiation of 
toxicity in the nitrosourea-treated cells 
was also observed. It seems probable that 
the potentiation of oxidative challenge ob­
served in BCNU-pretreated cells contrib­
utes to the increased toxicity of the naph­
thoquinones, although our data is not con­
clusive proof of this. It is clear from the 
data shown in Figs. 3D and 4D that GSH 
loss alone does not necessarily result in 
cytotoxicity, thus confirming previous 
work (5).
When both alkylation and oxidation can 
play a role in quinone-induced cytotoxicity, 
for example in the case of 1,4-naphthoqui-
none (21) and menadione (5), the dissection 
of the relative importance of each process 
for the eventual cytotoxic effect observed 
is not a simple exercise. Indeed, as the al­
kylation of thiols by menadione (4,20) and
1,4-naphthoquinone (G. Cohen, personal 
communication) produces active oxygen 
species, then the two processes are not mu­
tually exclusive. In addition naphthoqui­
nones may induce cytotoxicity by other 
undefined processes. Thus, it seems obvious 
that in the case of menadione and 1,4- 
naphthoquinone more than one mechanism 
contributes to cytotoxicity.
In this study we have shown that deriv­
atives of menadione which cannot directly 
alkylate nucleophiles are still cytotoxic, 
albeit at high concentrations, in isolated 
hepatocytes. We have also investigated the 
toxicity of naphthoquinones in BCNU-pre­
treated cells. Increased quinone-induced 
changes in soluble thiol oxidation were ob­
served in BCNU-pretreated cells and these 
changes were associated with exacerbated 
cytotoxicity. These data suggest that oxi­
dative processes alone can function as a 
determinant of the cytotoxicity of naph­
thoquinones.
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In order to clarify the role of oxidative processes in cytotoxicity we have studied the 
metabolism and toxicity of 2-methyl-l,4-naphthoquinone (menadione) and its 2,3 di­
methyl (DMNQ) and 2,3 diethyl (DENQ) analogs in isolated rat hepatocytes. The two 
analogs, unlike menadione, cannot alkylate nucleophiles directly and were considerably 
less toxic than menadione. This decreased toxicity was consistent with the inability of 
DMNQ and DENQ to alkylate but we also found them to undergo lower rates of redox 
cycling in hepatocytes and a higher ratio of two electron as opposed to one electron 
reduction relative to menadione. Thus, facile analysis of the respective roles of alkylation 
and oxidation in cytotoxicity was not possible using these compounds. In hepatocytes 
pretreated with bischloroethyl-nitrosourea (BCNU) to inhibit glutathione reductase, all 
three naphthoquinones caused a potentiation of reduced glutathione (GSH) removal/ 
oxidized glutathione (GSSG) generation and cytotoxicity relative to that observed in 
control cells. These data show that inhibition of hepatocyte glutathione reductase by 
BCNU results in enhanced naphthoquinone-induced oxidative challenge and subsequent 
cellular toxicity. That DMNQ and DENQ are cytotoxic, albeit at high concentrations, 
and that this cytotoxicity is potentiated by BCNU pretreatment suggest that oxidative 
processes alone can be a determinant of cytotoxicity, c  1986 Academic Press, inc.
The metabolism and toxicity of mena­
dione,2 2-methyl-l,4-naphthoquinone, have 
been extensively studied in isolated hepa­
tocytes (1-5) which constitutes a useful 
model system for investigations of mech­
1 To whom correspondence should be addressed.
2 Abbreviations used: Menadione, 2-methyl-l,4- 
naphthoquinone; DMNQ, 2,3-dimethyl-l,4-naphtho- 
quinone; DENQ, 2.3-diethyl-l,4-naphthoquinone; 
DT-diaphorase. NAD(P)H: (quinone acceptor) oxi- 
doreductase; SOD. superoxide dismutase; BCNU, 1,3- 
bis-(2-chloroethyl)-l-nitrosourea; Hepes, 4-{2-hy- 
droxyethyl)-l-piperazineethanesulfonic acid; DMSO, 
dimethvlsulfoxide.
anisms of hepatotoxicity in vitro. Mena­
dione-induced toxicity in hepatocytes is 
thought to involve depletion of cellular 
thiols such as glutathione (GSH), and thiol 
groups contained in proteins (4,5). Recent 
evidence has implicated removal of cellular 
thiol groups to be the mechanism whereby 
menadione-induced perturbations in in­
tracellular calcium ion homeostasis may 
occur (5, 6). These changes may lead to in­
creases in cytosolic free calcium concen­
tration, cytoskeletal alterations, and sub­
sequent cell death (1, 2).
The removal of cellular thiols in cells by 
menadione is a consequence of two major
460
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processes, alkylation and oxidation. Men­
adione is an electrophile and as such can 
react with nucleophiles directly, generating 
a menadione-GSH conjugate and alkylated 
protein in the case of GSH and protein SH 
groups, respectively (4, 7). Menadione is 
also a substrate for various one-electron 
reductases in both the mitochondrial and 
endoplasmic reticular compartments of the 
cell (1). These enzymes catalyze the pro­
duction of semiquinone radicals derived 
from menadione whose subsequent reoxi­
dation by molecular oxygen generates the 
parent quinone and superoxide anion rad­
ical (02) (1). Dismutation of 0 2 produces 
hydrogen peroxide (H20 2), and further re­
actions of these species can lead to the pro­
duction of hydroxyl radical (OH) and sin­
glet oxygen (10 2) (7,8). Thus, an assortment 
of oxidizing species can be produced in the 
cell as a consequence of one-electron re­
duction of menadione, and such species will 
readily oxidize reduced thiols.
In an attempt to clarify the role of the 
generation of oxidizing species in quinone- 
induced cytotoxicity, we have studied the 
metabolism of menadione and two of its 
analogs which cannot alkylate nucleophilic 
sites directly. In this study we have com­
pared the metabolism and toxicity of men­
adione, 2,3-dimethyl-l,4-naphthoquinone 
(DMNQ) and 2,3-diethyI-l,4-naphthoqui- 
none (DENQ), in isolated rat hepatocytes. 
Furthermore, we have also investigated the 
role of oxidative processes in the cytotox­
icity of these three naphthoquinones by 
using bis-chloroethylnitrosourea (BCNU) 
to inhibit cellular glutathione reductase 
(9). This enzyme, which utilizes NADPH 
as a cofactor, reduces GSSG to GSH, thus 
ensuring a high intracellular ratio of re­
duced to oxidized thiol. Inhibition of glu­
tathione reductase severely limits the ef­
ficient functioning of glutathione peroxi­
dase, an enzyme which removes peroxides 
such as H20 2 at the expense of the conver­
sion of GSH to GSSG. Thus H20 2 produced, 
for example, from the dismutation of 0 2, 
can only be removed by this enzyme until 
the initial supply of GSH is exhausted, as 
the catalytic cycle regenerating GSH via 
glutathione reductase is blocked. We have 
compared the toxicity of menadione,
DMNQ, and DENQ to both control and 
BCNU pretreated hepatocytes and mea­
sured the effects of the quinones on cellular 
thiol homeostasis.
MATERIALS AND METHODS
1,4-Naphthoquinone was purchased from Aldrich. 
GSH, GSSG, dicoumarol, and menadione were ob­
tained from Sigma, while collagenase (grade II), 
NADPH, and superoxide dismutase (SOD) were pur­
chased from Boehringer-Mannheim. All other chem­
icals were of a t  least reagent grade and were pur­
chased locally.
2,3-Dimethyl-l,4-naphthoquinone (DMNQ) and 2,3- 
diethvl-1,4-naphthoquinone (DENQ) were prepared as 
follows: a mixture of 1,4-naphthoquinone (1.58 g), 
propanoic acid (6.0 g), sulpholane (20 ml), w ater (25 
ml), and silver n itrate (0.5 g) was heated to 80“C. Po­
tassium peroxydisulfate (5.5 g) in water (25 ml) was 
added during 20 min a t 80°C. After a further 15 min 
a t  th is temperature, the mixture was poured onto ice 
(100 g). The w ater was decanted off and the residue 
dissolved in acetonitrile (50 ml), filtered, and evapo­
rated to dryness. The residue was chromatographed 
on Silica gel, with petroleum ether (BPt 60-80°C)/ 
ethyl acetate (9/1) giving 2,3-diethyl-l,4-naphthoqui- 
none (1.61 gr, 75%;MPt 67-68°C, lit. MPt 68-5-69.5°C 
(10)). An analogous preparation was used for 2,3-di­
methyl-l,4-naphthoquinone, using 1,4-naphthoqui­
none and acetic acid, in 79% yield (MPt 124-125° C; 
lit. M Pt 125-126°C (11)). TLC was used to check the 
purity of these compounds (Silica plates; petroleum 
ether/ethyl acetate 3/1) DMNQ-one spot Rf — 0.85; 
DENQ-one spot Rf = 0.90. NMR analysis was to tally  
consistent with the proposed structures.
Male Sprague-Dawley ra ts  (200-250 g) were used 
in all experiments. Hepatocytes were isolated as in 
(12) and cell incubations were performed in ro ta ting  
round-bottomed flasks (10* cells/ml) under an atm o­
sphere of 95% 02 5% C02. Glutathione reductase was 
inhibited by treatm ent of the cells with l,3-bis-(2- 
chloroethyl)-l-nitrosourea essentially as previously 
described (13), except th a t Eagles minimal essential 
medium supplemented with 1 mM methionine w as used 
for cell treatm ent and cell recovery. This trea tm en t 
produces a t least 90% inhibition of GSSG reductase 
w ithout affecting cellular GSH content (13) and th is 
was verified in these studies. Incubations were per­
formed in K rebs-Henseleit buffer, pH 7.4, containing
12.5 mM Hepes a t 37°C, and substrates were added in 
dimethylsulfoxide (0.4% of final volume except for 
toxicity curves of DMNQ and DENQ 0.6 mM (0.8%) 
and 1 mM (2%)). Control experiments showed th a t 
concentrations of up to 2% DMSO were not cytotoxic 
and had no effect on menadione-induced toxicity. Cell 
viability was determined by trypan blue exclusion. 
GSH and GSSG were determined by HPLC a fte r  de-
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rivatization as described by Reed el aL (14). OJ was 
detected by SOD-sensitive reduction of acetylated cy­
tochrome c, prepared as in (15) using the wavelength 
pair 550-540 nm (16). Dialyzed whole liver homogenate 
was prepared by homogenization of the liver in 0.25 
M sucrose (20% w/v), centrifugation at 2000p for 10 
min, followed by overnight dialysis of the supernatant 
against 0.15 M KC1, pH 7.4 (21). Aliquots of super­
natant (0.05 ml) were mixed with 0.15 M Tris-HCl 
buffer, pH 7.4 (1 ml), containing acetylated cytochrome 
c  (1 m g/m l) and NADPH, 1 mM. In all experiments 
dicoumarol was used at a concentration of 30 mM and 
SOD at 0.1 mg/ml. SOD-sensitive reduction of ferri- 
cytochrome derivatives cannot be used as an absolute 
measure of 0 £ production due to other competing re­
actions of Oj, such as enzymatic and nonenzymatic 
dismutation. Protein was determined according to the 
method of Lowry et aL (17).
RESULTS
Alkylation reactions of quinones gener­
ally proceed a t the ortho position to the 
quinone moiety. Thus both the 2,3-dialkyl- 
ated derivatives (DMNQ and DENQ) would 
not be expected to directly alkylate biolog­
ical nucleophiles. This was verified exper­
imentally using GSH as a model nucleo­
phile. If conjugate form ation between qui­
none and GSH did not occur then full 
recovery of thiol equivalents in term s of 
GSH rem aining and GSSG formed should 
be possible. That this was the case during 
reaction of DMNQ and DENQ with GSH 
is shown in Table I.
The toxicity of menadione and its two 
alkylated analogs, DMNQ and DENQ, in 
isolated ra t hepatocytes is shown in Fig. 1 
(A-C). The results show th a t  both of the
TABLE I
R e c o v e r y  o f  T h i o l  E q u i v a l e n t s  a f t e r  R e a c t io n  
o f  DMNQ o r  DENQ (0.2 mM ) w i t h  GSH 










quinone 170 31 201
DMNQ 143 66 209




* In Krebs-Henseleit buffer, pH = 7.4.
Fig. 1. Toxicity of 2,3-dimethyl-l,4-naphthoquinone 
(A), 2,3-diethyl-l,4-naphthoquinone (B), and mena­
dione (C) in isolated hepatocytes. (Quinone concen­
trations were: • ,  0.1 mM; A, 0.2 mM; O , 0.6 mM, □ ,  1 
mM). One experiment typical of three.
substituted analogs were markedly less 
toxic than menadione. The lack of toxicity 
of DMNQ and DENQ could reflect their in­
ability to alkylate cellular nucleophiles but 
may also be a consequence of diminished 
one-electron reduction by m itochondrial 
and microsomal reductases relative to 
menadione. This would in tu rn  lead to a 
decreased generation of semiquinone rad ­
ical, and active oxygen species such as 0 2 
and H20 2- Alternatively, the diminished 
toxicity of DMNQ and DENQ may be due 
to th e ir higher affinity for the enzyme DT- 
diaphorase [NADPH (quinone acceptor) 
oxidoreductase], a two-electron reductase 
which catalyzes the reduction of quinones 
to hydroquinones without the generation 
of semiquinone radical interm ediates (18). 
Thus, it has been proposed th a t this enzyme 
plays a protective role in quinone-induced 
toxicity (1,19). A dialyzed whole liver ho­
mogenate, devoid of soluble cellular thiols 
(which may interact with quinones directly 
to generate 0 2 (4, 20)), was used to inves­
tigate these possibilities. A decreased ca­
pacity of DMNQ and DENQ relative to 
menadione to generate species which 
caused acetylated cytochrome c reduction 
was evident using the dialyzed whole liver 
homogenate preparation (Fig. 2A). Reduc­
tion of the cytochrome can reflect genera­
tion of either hydroquinone3 or 0 2, as both
3 We have found that the hydroquinone of mena­
dione, synthesized according to L. Feiser [(1940) J. 
BioL CheirL 133, 391-3961 readily reduces acetylated 
cytochrome c






Fig. 2. NADPH-dependent reduction of acetylated 
cytochrome c induced by 1,4-naphthoquinones in di­
alyzed whole liver homogenate. (Menadione (□); 2,3- 
dimethvl-1,4-naphthoquinone (O); and 2,3-diethyl-l,4- 
naphthoquinone (•)) . (A) Concentration dependence 
of NADPH-(1 mM) dependent acetylated cytochrome 
c reduction in dialyzed whole liver homogenate. (B) 
Effects of SOD (02  m g/m l, open bar), and dicoumarol 
(0.03 mM, solid bar) on NADPH-dependent reduction 
of acetylated cytochrome c in dialyzed whole liver ho­
mogenate. (a) Menadione, 0.2 mM; (b) 2.3-dimethyl- 
1,4-naphthoquinone, 0.2 mM; (c) 2,3-diethvl-l,4-naph- 
thoquinone, 0.2 mM. Means ± standard deviation of 
three experiments.
are capable of transferring  electrons to 
acetylated cytochrome c. (1). With m ena­
dione, however, 50% of the reduction was 
SOD sensitive, suggesting the involvement 
of O2 , whereas SOD had no significant ef­
fect on DMNQ- and DENQ-induced acet­
ylated cytochrome c reduction (Fig. 2B). 
Conversely, dicoumarol, an inhibitor of DT- 
diaphorase (19), alm ost totally inhibited 
the NADPH-dependent reduction of the 
cytochrome by DMNQ and DENQ, whereas 
menadione-induced reduction was still 35% 
of the control value (Fig. 2B). These ex­
periments dem onstrate th a t the alkyl-sub- 
stituted analogs of menadione have a 
higher ratio  of two- as opposed to one-elec­
tron reduction relative to menadione itself. 
In agreem ent with previous studies (1, 21) 
and the protective role of DT-diaphorase, 
pretreatm ent of hepatocytes with dicou­
marol (0.03 m M ) m arkedly exacerbated the 
toxicity of all three quinones to hepatocytes 
(data not shown).
In an a ttem pt to clarify the role of oxi­
dative processes in naphthoquinone-in­
duced toxicity we have used cells pretreated 
with BCNU, an inhibitor of glutathione re­
ductase. This treatm ent exacerbates in­
tracellular oxidative challenge, as any 
GSSG generated in the cell cannot be re­
duced back to GSH. Both DMNQ and 
DENQ caused some loss in hepatocyte GSH 
content (Figs. 3B-C) relative to controls 
(Fig. 3A). There was, however, a potentia­
tion of GSH removal of GSSG generation 
in BCNU-pretreated cells relative to con­
trol cells in the case of all three naphtho­
quinones (Figs. 3A-D). Furtherm ore, the 
three naphthoquinones were significantly 
more toxic to BCNU-pretreated cells than  
to control cells (Figs. 4A-D), dem onstrat­
ing tha t enhanced oxidative challenge can 
result in enhanced cellular toxicity.
DISCUSSION
In this study we have investigated the 
metabolism and toxicity of alkyl-substi- 
tuted analogs of menadione which cannot 
alkylate cellular nucleophiles directly in 
order to determ ine the role of oxidative 
processes in cytotoxicity. The alkyl-sub­
stituted analogs of menadione, DMNQ and 
DENQ, were markedly less toxic to isolated 
hepatocytes than the paren t compound. 
High concentrations of DMNQ and DENQ 
were required to induce significant cyto­
toxicity in hepatocytes. These data do not 
allow us to conclude, however, th a t oxi­
dative processes are unim portant in m en­
adione-induced cytotoxicity and th a t  al- 
kylation reactions represent the only de­
term inants of the toxicity observed. An 
alternative explanation for the decreased 
toxicity of DMNQ and DENQ relative to 
menadione may be th e ir low ability to gen­
erate oxidizing species w ithin the cell—ei­
ther because of low affinity for one-electron 
reductases or because of higher affinity for 
alternative pathways of metabolism such 
as DT-diaphorase-catalyzed two-electron 
reduction. Using dialyzed liver homogenate 
we found th a t SOD could substantially  in­
hibit menadione-induced acetylated cyto­
chrome c reduction, whereas it had m ini­
mal inhibitory effect on DMNQ- and 
DENQ-mediated reduction (Fig. 2). This 
suggests th a t O2 generated by redox cycling 
reactions is responsible for a substan tial 
proportion of the observed reduction of
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undergo a higher ratio of two- as opposed 
to one-electron reduction relative to men­
adione and thus this represents a possible 
explanation of the decreased toxicity of 
DMNQ and DENQ relative to menadione.
Whether a particular quinone is m etab­
olized by one- or two-electron reductases 
depends on a number of factors such as 
steric considerations, lipophilicity, and 
one-electron reduction potential. The de­
pendence of the rate of O2 production by 
isolated ra t hepatocytes on the one-elec­
tron reduction potential of quinones has 
been studied previously by Powis et a l (22). 
These workers showed th a t in isolated he­
patocytes maximal quinone-induced O2  
formation occurs a t a quinone one-electron 
reduction potential of -7 0  mV (22). From 
their data one can also predict th a t a more 
negative one-electron reduction potential
A (c o n t r o l) B (D M N Q  0 .2 m M )
Tim* (min)
Fig. 3. GSH depletion (a) and GSSG generation (b) 
during metabolism of 2,3-dimethyl-l,4-naphthoqui- 
none 0.2 mM (B), 2,3-diethyl-l,4-naphthoquinone 0.2 
m M  (C), and menadione 0.05 m M  (D), in control (O) 
and BCNU-pretreated cells ( • ) .  The thiol status of 
control (O) and BCNU-pretreated ( • )  cells in the ab­
sence of quinone but in the presence of the solvent 
vehicle (DMSO) is shown in (A). One experiment typ­
ical of three.
acetylated cytochrome c only w ith m ena­
dione. Furtherm ore, da ta  obtained using 
dicoumarol, an inhibitor of DT-diaphorase, 
showed th a t two-electron reduction was 
involved in the metabolism of all th ree  
naphthoquinones, but th a t  th is metabolic 
pathway was more active w ith DMNQ and 
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Fig. 4. Toxicity of 2.3-dimethyl-l,4-naphthoquinone 
0.2 mM  (B), 2,3-diethyl-l,4-naphthoquinone0.2 mM (C). 
and menadione 0.05 mM (D), in control (O) and BCNU- 
pretreated cells ( • ) .  The toxicity of the solvent vehicle 
to control (O) and BCNU-pretreated ( • )  cells is shown 
in (A). One experiment typical of five.
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than that of menadione (—200 mV) would 
lead to a marked decrease in the rate of 
superoxide formation. As alkyl substitu­
tion of the naphthoquinone nucleus would 
be expected to cause donation of electrons 
into the ring system, the one-electron re­
duction potentials of DMNQ and DENQ 
would be predicted to be more negative 
than menadione itself. Thus, on the basis 
of one-electron reduction potential alone, 
the alkyl-substituted derivatives of men­
adione would be expected to induce the 
generation of fewer oxygen-derived radi­
cals.
The observation that DMNQ and DENQ 
were cytotoxic, albeit at high concentra­
tions, suggests that oxidative processes 
alone can cause cytotoxicity. To investigate 
this we used cells preincubated with BCNU, 
which inhibits cellular glutathione reduc­
tase. In control cells, all three naphtho­
quinones induced some GSH loss and 
GSSG formation, but these changes were 
markedly exacerbated by BCNU pretreat­
ment (Fig. 3), showing that the alterations 
in GSH homeostasis observed occur, at 
least in part, by means of oxidative mech­
anisms. Although DMNQ and DENQ did 
not induce significant formation of 0£ in 
dialyzed liver homogenate (Fig. 2), naph­
thoquinones can still induce an oxidative 
challenge including 0 2 and H20 2 genera­
tion, via chemical reactions (23), and this 
may represent the route whereby DMNQ 
and DENQ induce oxidative stress.
As well as a potentiation of naphtho­
quinone-induced GSH loss and GSSG for­
mation in BCNU-pretreated cells relative 
to control cells, marked potentiation of 
toxicity in the nitrosourea-treated cells 
was also observed. It seems probable that 
the potentiation of oxidative challenge ob­
served in BCNU-pretreated cells contrib­
utes to the increased toxicity of the naph­
thoquinones, although our data is not con­
clusive proof of this. It is clear from the 
data shown in Figs. 3D and 4D that GSH 
loss alone does not necessarily result in 
cytotoxicity, thus confirming previous 
work (5).
When both alkylation and oxidation can 
play a role in quinone-induced cytotoxicity, 
for example in the case of 1,4-naphthoqui­
none (21) and menadione (5), the dissection 
of the relative importance of each process 
for the eventual cytotoxic effect observed 
is not a simple exercise. Indeed, as the al­
kylation of thiols by menadione (4,20) and
1,4-naphthoquinone (G. Cohen, personal 
communication) produces active oxygen 
species, then the two processes are not mu­
tually exclusive. In addition naphthoqui­
nones may induce cytotoxicity by other 
undefined processes. Thus, it seems obvious 
that in the case of menadione and 1,4- 
naphthoquinone more than one mechanism 
contributes to cytotoxicity.
In this study we have shown that deriv­
atives of menadione which cannot directly 
alkylate nucleophiles are still cytotoxic, 
albeit at high concentrations, in isolated 
hepatocytes. We have also investigated the 
toxicity of naphthoquinones in BCNU-pre­
treated cells. Increased quinone-induced 
changes in soluble thiol oxidation were ob­
served in BCNU-pretreated cells and these 
changes were associated with exacerbated 
cytotoxicity. These data suggest that oxi­
dative processes alone can function as a 
determinant of the cytotoxicity of naph­
thoquinones.
ACKNOWLEDGMENTS
This study was supported by funds from the Uni­
versity of Colorado, the Royal Society of Great Britain, 
the Swedish Medical Research Council, the Swedish 
Council for Planning and Coordination of Research, 
the Swedish Cancer Society, the Karolinska Institute, 
and the National Foundation for Cancer Research.
REFERENCES
1. Thor, H., Smith, M. T„ H artzell, P., Bellomo,
G., J e w e l l ,  S. A., a n d  O r r e n iu s ,  S. (1982) J.
Biol Chem. 257,12,419-12,425.
2. J e w e l l ,  S. A., B e l lo m o ,  G., T h o r ,  H., O r r e n iu s ,
S., and Smith, M. T. (1982) Science 217, 1257-
1259.
3. B e l lo m o , G., J e w e l l ,  S. A., T h o r ,  H., a n d  O r ­
r e n iu s ,  S. (1982) Proc. Nail Acad. ScL USA 79,
6842-6846.
4. Di M o n te , D., R o s s ,  D„ B e l lo m o ,  G., E k lo w ,  l .,
a n d  O r r e n iu s ,  S. (1984) Arch. Biochem. Bio­
phys. 235, 334-342.
5. Di M o n te , D., B e l lo m o ,  G., T h o r ,  H., N i c o t e r a ,
P ., a n d  O r r e n iu s ,  S. (1984) Arch Biochem.
Biophys. 235,343-350.
6. N icotera , P ., Mo o r e , M ., M ir a b e l l i, F ., B ello m o ,
466 ROSS ET AL.
G., a n d  O r r e n iu s , S. (1 9 8 5 ) FEBS Lett 181, 
149-153.
7. N ic k e r s o n ,  W . J ., F a j lc o n e , G., a n d  S t r a u s s ,  G.
(1963) Biochemistry 2,537-543.
8. W e f e r s ,  H., a n d  S ie s ,  H. (1983) Eur. J. Biochem.
1 3 7 ,2 9 -3 6 .
9. B ab son , J . R., A b e l l ,  W . S., a n d  R e ed , D . J . (1981)
Biochem. PharmacoL 39, 2229-2304.
10. A r a k a w a , S. (1977) J. Org. Chem 42, 3800-3805.
11. J a c o b s e n , N., a n d T o r s s e l l ,  K. (1972) Liebigs Ann.
Chem 763,135-147.
12. M o ld e u s , P., H o g b e r g , J ., a n d  O r r e n iu s ,  S. (1978)
In Methods in Enzymology (Fleischer, S., and 
Packer, L., eds.). Vol. 52, pp. 60-71, Academic 
Press, New York.
13. E k lo w , L., M o ld e u s ,  P., a n d  O r r e n iu s ,  S. (1984)
Eur. J. Biochem 138,459-463.
14. R e ed , D . J., B a b so n , J. R., B e a t t y ,  P. W ., B r o d ie ,
A . E ., E l l i s ,  W . W ., a n d  P o t t e r ,  D . W . (1980) 
AnaL Biochem 106, 5 5 -6 2 .
15. A zz i, A .. M o n te c u c c o ,  C., a n d  R ic h t e r ,  C. (1975)
Biochem Biophys. Res. Ccrmmun. 65,597-607.
16. T h a y e r ,  W. S. (1977) Chem BioL Interact 19,265-
275.
17. L o w r y , 0 .  H., R o s e b r o u g h , N. J., F a r r ,  A . L.,
a n d  R a n d a l l ,  R. J. (1951) J. BioL Chem 193, 
263-275.
18. Iyan aG I, T., a n d  Y a m a za k i, I. (1970) Biochim
Biophys. Acta 216, 286-294.
19. L in d , C., H o c h s t e in ,  P., a n d  E r n s t e r ,  L. (1982)
Arch Biochem Biophys. 216,178-185.
20. W e f e r s ,  H., a n d  S ie s ,  H. (1983) Arch Biochem
Biophys. 224,568-578.
21. D ’A r c y  D o h e r t y ,  M„ C o h e n , G. M., a n d  S m ith ,
M. T. (1984) Biochem PharmacoL 33, 543-549.
22. Powis, G.. S v in g e n . B. A., a n d  A p p e l, P. (1981)
MoL PharmacoL 20, 387-394.
23. Ross, D.. T h o r ,  H., M o ld e u s ,  P., a n d  O r r e n iu s ,
S. (1985) Chem BioL Interact 55,177-184.
PUBLICATION 21
Hepatotoxicity of iV-Methylformamide in Mice. II. Covalent Binding of Metabolites of 
[14C]-Labelled iV-Methylformamide to Hepatic Proteins
P. G. Pearson, A. Gescher, E. S. Harpur and M. D. Threadgill
Biochemical Pharmacology, 1987, 36, 385-390.
Biochemical Pharmacology. Vol. 36. No. 3. pp. 385-390. 1987. 
Primed in Great Britain.
0006-2953/87 S3.00 t- 0.00 
©  1987 Pergamon Journals Ltd.
HEPATOTOXICITY OF N-METHYLFORMAMIDE IN
MICE—II
COVALENT BINDING OF METABOLITES OF [14C]-LABELLED N- 
METHYLFORMAMIDE TO HEPATIC PROTEINS
Pau l  G . Pe a r so n ,* A n d r e a s  G esc h er ,t  E rnest S. H ar pu r  and M ichael D .
T h rea dg ill
MRC Mechanisms of Drug Toxicity Group and CRC Experimental Chemotheraphy Group, 
Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, U.K.
(Received. 8 July 1986; accepted 4 September 1986)
Abstract—Incubation of the hepatotoxin IV-methylformamide (NMF) labelled either in the methyl 
group (OHCNH,4CH3) or the formyl group (O H 14CNHCH3) with mouse hepatic microsomes in the 
presence of NADPH, but not in its absence, led to covalent binding of metabolites to microsomal 
proteins. When [14C]NMF was injected into BALB/c mice radioactivity was found to be associated with 
liver and, to a much lesser extent, with kidney proteins. Association of radioactivity derived from 
OHCNHi4CH3 with hepatic proteins was higher in BALB/c mice than in CBA/CA mice and in these 
it was higher than in BDFj mice. Association of label derived from either isotopomer was significantly 
reduced but not abolished by pretreatment of mice with cydoheximide suggesting both covalent binding 
and metabolic incorporation of NMF metabolites. Depletion of hepatic glutathione by pretreatment of 
mice with buthionine sulfoximine or diethyl maleate prior to administration of OHI4CNHCH3 enhanced 
the assodation of label with hepatic proteins measured 1 hr after drug injection. Covalent binding of 
[I4C]NMF to hepatic microsomes in vitro was abolished in the presence of glutathione. It is argued that 
the generation of the toxic lesion and the association of NMF metabolites with hepatic proteins may be 
causally related even though certain mechanistic and enzymatic details of this link remain obscure.
The biotransfonnation of relatively inert chemicals 
to reactive metabolites, commonly referred to as 
“metabolic activation”, is now considered to be an 
obligatory initial event in a number of toxidties 
induced by chemicals [1]. The experimental anti­
tumour drug N-methylformamide (NMF) [2,3] is 
known to be hepatotoxic [4,5]. In an accompanying 
paper [6], compelling evidence is presented for the 
contention that NMF undergoes metabolic activation 
to a hepatotoxic metabolite. Reactive metabolites 
generated from such chemicals can bind covalently 
to cellular macromolecules, thus modifying their bio­
logical properties, possibly in a detrimental way [7]. 
The objectives of the work described in this paper 
were to provide a better understanding of the mech­
anism by which NMF causes hepatotoxidty, and, 
more specifically, to test the hypothesis that like 
other hepatotoxic drugs, NMF is metabolised to 
species which can bind covalently to hepatic 
macromolecules.
MATERIALS AND METHODS
Chemicals and animals. Materials were purchased 
in the purest commercially available forms: Glu­
tathione, NADP, glucose-6-phosphate, glucose-6- 
phosphate dehydrogenase, phenobarbital and cyclo- 
heximide (Sigma Chemical Co., Poole, U.K.);
* Present address: Department of Medicinal Chemistry, 
School of Pharmacy, University of Washington, Seattle, 
WA 98185, U.S.A. 
t To whom correspondence should be addressed.
diethyl maleate and NMF (Aldrich Chemical Co., 
Gillingham, U.K.). NMF was distilled before use. 
(±)-Buthionine sulfoximine was prepared as 
described previously [8] and [14C]-labelled NMF with 
the label either in the methyl group, OHCNH14CH3, 
or in the formyl group, OH14CNHCH3, was also 
synthesized according to a published method [9].
Experiments were conducted using male BALB/ 
c, CBA/CA or BDFX mice (18-25 g, supplier: Bantin 
and Kingman, Hull, U.K.). Animals were housed 
on wire mesh and allowed free access to tap water 
and food (Heygate 13 breeding diet, Pilsbury’s Ltd., 
Birmingham, U.K.) in rooms with a daily light cycle 
from 6 a.m. to 6 p.m. All chemicals were injected i.p. 
after dissolution in isotonic saline (injection volume: 
0.2 ml) except diethyl maleate which was injected as 
a solution in arachis oil (0.2 ml). Chemicals were 
administered at the following doses (unless otherwise 
stated) which were based on the references quoted: 
NMF, 400 mg/kg [3], cydoheximide, 2 mg/kg 45 min 
before NMF or leudne, and [3H] leudne, 20 mg/kg 
with 2 juCi/mouse [10]; (±)-buthionine sulfoximine, 
1600mg/kg 4 hr before NMF [11]; diethyl maleate, 
0.3 ml/kg 1 hr before NMF [12]. In the in vivo bind­
ing studies 5 pCi [14C] NMF was administered 
together with the amount of NMF to make up the 
desired dose.
Determination of association of label with liver and 
kidney macromolecules in vivo. Tissues were excised, 
weighed and frozen until analysis. After thawing 
a 25% (w/v) homogenate in water was prepared. 
Proteins were predpitated with 3 vol. of acetone. 
The predpitate was exhaustively washed with water
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Table 1. Covalent binding of metabolites of [MC]NMF to hepatic microsomal proteins
Covalent binding 
(ng NMF equivalents/mg protein, mean ± SD)
Experimental conditions* OHCNH14CHj O H MCNHCH3
Microsomes 14.6 ± 2.0 (7)t 14.4 ±  6.1 (4)
Heat-inactivated
microsomes with NADPH 32.4 2: 5.1 (3) 13.8 ±  2.6 (3)
Microsomes with NADPH 123.6 ± 13.2 (9)* 60.7 ±  9.8 (5)$
Microsomes, NADPH and
glutathione (10 mM) 10.0 ±  3.5 (3)§ 13.9 ± 6.2 (3)||
* [WC]NMF (7 mM) was incubated with microsomes obtained from BALB/c mice 
for 2 hr as described under Materials and Methods, 
t Number of experiments in brackets.
I  Significantly different from microsomes alone (P <  0.001).
§|| Significantly different from microsomes with NADPH (§P <  0.001, ||P <  0.01).
(10 times) and water: methanol (1:1) (5 times), after 
which no farther non-covalently bound radioactivity 
could be removed. The tissue pellet was solubilized 
in 2 ml of soluene 350 (Packard United Technologies, 
Reading, U.K.). The amount of protein which had 
been precipitated was determined according to 
Lowry et al. [13], protein loss during the washing 
procedure was less than 5%. The results were cal­
culated as ng NMF equivalents bound to lmg 
protein, unless described otherwise, and are either 
presented as such or as percent of control binding. 
Radioactivity bound to DNA and RNA was deter­
mined as summarized by Pohl and Branchflower [14].
Determination of covalent binding to metabolites 
of [I4C]NAfF to liver microsomes in vitro. Livers 
were excised from BALB/c mice at 9 a.m. and a 
homogenate (20% w/v) was prepared in phosphate 
buffer (50 mM, pH 7.4). Microsomes were prepared 
in the standard way involving centrifugation of the 
homogenate at 9000 g for 20 min and centrifugation 
of the 9000 g supernatant at 100,000 g for 60 min. 
The microsomal pellet was resuspended in phosphate 
buffer and aliquots (equivalent to 200 mg liver) were 
incubated in open beakers with [14C]NMF (7 mM, 
specific activity 71 jrCi/mol). This concentration 
equals the peak concentration of NMF in the blood 
of mice which received 400 mg/kg NMF [15]. The 
final incubation volume measured 2 ml and, when 
appropriate, contained also NADP (1 mM), glucose- 
6-phosphate (5 mM), glucose-6-phosphate dehydro­
genase (2 units/ml) as NADPH generating system 
and MgC  ^ (5mM). The metabolic viability of the 
microsomes was assessed in control incubations with 
aminopyrine. Aminopyrine metabolism to formal­
dehyde was determined according to Nash [16]. 
Under the conditions of the covalent binding assay 
aminopyrine (5 mM) was metabolized to 
5.5 ± Q.8 nmoles HCHO/mg protein/min (mean ± 
SD, N = 3) in the presence of NADPH and to 
0.9 ± 0.2 nmoles HCHO/mg protein/min without 
NADPH. Covalent binding experiments were car­
ried out in duplicate. Incubations were performed 
with shaking at 37° for 2 hr. Microsomal proteins 
were precipitated with acetone (4 ml). TTie pre­
cipitate was washed as described for the in vivo 
experiments and the pellet obtained was dissolved in
1M NaOH (2 ml). Aliquots of the solute were used 
for protein determination (50 [A) and for scintillation 
counting (1 ml).
Measurement of radioactivity Aqueous samples 
(1 ml) were mixed with Fisofluor mpc scintiilant 
(10ml, Fisons Ltd., Loughborough, U.K.), tissue 
protein samples dissolved in soluene 350 (1 ml) were 
mixed with Beckman Readysolve (10 ml; Beckman 
Instruments Ltd., High Wycombe, U.K.) and the 
dissolved microsomal proteins in aqueous NaOH 
(1 ml) were mixed with Dimilume 30 (10 ml; Packard 
United Technologies). Radioactivity was counted in 
a Packard Tricarb 2660 scintillation counter using 
the external standardization mode. For all samples 
the counting efficiency was > 80%.
Statistical analysis. Results were compared using 
Student’s r-test.
RESULTS
On incubation with hepatic microsomes and an 
NADPH generating system, [14C]NMF was metab­
olised to compounds which bound covalently to 
microsomal protein (Table 1). Approximately twice 
as much radioactivity derived from OHCNH14CH3 
was bound than activity derived from 
OH14CNHCH3. When [14C]NMF was administered 
to BALB/c mice it bound to hepatic proteins in a 
dose dependent manner (Fig. 1). Injection of 20 mg/ 
kg led to only negligible binding. At the dose of 
400 mg/kg approximately twice as much radioactivity 
was associated with proteins when OHCNH14CH3 
(Fig. 1A) was injected as compared to 
OH14CNHCH3 (Fig. IB) which parallels the results 
obtained in the in vitro experiments (Table 1). When 
calculated as percentage of the 400 mg/kg dose, 
2.4 ± 0.2% in the case of OHCNH14CH3 and 
0.8 ± 0.3% in the case of OH14CNHCH3 were found 
bound to liver macromolecules 8 hr after drug 
administration. Activity was not associated with 
nucleic adds. Therefore, we assume that metabolites 
were assodated mainly, if not exclusively, with 
proteins.
In the kidneys, an organ to which NMF does not 
appear to be toxic, label derived from OHCNH14CH3 
was also bound to a much greater extent than label
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Fig. 1. Relationship to dose of the association of label derived from OHCNHMCH3 (A) and
OH14CNHCH3 (B) with hepatic proteins in BA L B /c mice; x  x 20 mg/kg, □ ------- □  100 mg/kg,
O O  400 mg/kg. Association of activity with proteins was measured as described under Material
and Methods. Values are the mean ±  SD of 3 mice.
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Fig. 2. Association of label derived from 400 mg/kg OHCNH14CH3 ( • )  or OH,4CNHCH3 (■) with 
kidney proteins in BALB/c mice. Activity associated with proteins was determined as described under 
Material and Methods. Values are the mean i  SD of 3 mice.
derived from O H 14C N H C H 3 (Fig. 2). The radio­
activity found in the kidneys 8 hr after administration  
of 400 m g/kg  [14C]N M F was only 36%  o f that associ­
ated with liver proteins in the case o f O H C N H 14C H 3 
and 25%  after injection o f O H 14C N H C H 3. R adio­
activity associated with other tissues (e .g . lungs, 
spleen, heart) was less than a quarter o f that 
measured in the liver (results not show n). In these  
tissues NM F does not appear to cause toxicity [17].
There was a marked difference betw een strains o f  
m ouse in the extent to which m etabolites o f  
[14C ]N M F were bound to or incorporated into  
proteins. Figure 3 show s that association o f  radio­
activity was highest in B A L B /c  m ice, both in the  
liver and the kidneys. In the case o f  O H C N H 14C H 3, 
the am ount o f label associated with hepatic proteins 
in C B A /C A  mice was significantly lower than that 
m easured in B A L B /c  mice but significantly higher 
than that m easured in BD Fj mice (Fig. 3).
In order to distinguish betw een covalent binding 
and incorporation o f  [14C]NM F m etabolites, bound  
radioactivity was determ ined in livers o f m ice which  
had been  pretreated with cydohexim id e, an inhibitor  
o f  protein synthesis, prior to drug adm inistration. 
The decrease in association of label from [14C ]N M F  
with liver proteins caused by cydohexim id e was 
greater than (1 hr after NM F injection) or sim ilar to 
(8 hr after NM F administration) the effect which  
cydohexim ide exerted  on the incorporation o f  [14C] 
leu d n e (Fig. 4 ), indicating that m etabolites o f  NM F  
were incorporated to som e exten t into proteins via 
precursors o f endogenous substrates. H ow ever, this 
result has to be interpreted with caution as the possi­
bility cannot be excluded that cyd ohexim id e affects 
the enzym es involved in the m etabolism  o f  N M F  to 
the reactive sp ed es.
With the view o f  studying the role of glutathione  
in the processes leading to the association o f NM F
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Fig. 3. Association of label derived from 400 mg/kg 
OHCNHwCH3 (hatched bars) or OH,4CNHCH3 (stippled 
bars) with proteins in the liver (A ) and the kidneys (B) of 
BALB/c, CBA/CA and BDF, mice. Values are the mean ± 
SD of 3 mice; *bsignificant difference compared to BALB/ 
c mice (*P <  0.001, bP <  0 .0 1 ),e significant difference com­
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Fig. 4. Effect of cydoheximide (2 mg/kg) on the assodation
of label derived from OHCNH,4CH3 (O O) or
OH14CNHCH3 (A  A ) with hepatic proteins, or on
the incorporation of [3H] leudne ( x  x )  into hepatic
proteins in BALB/c mice. Cydoheximide (2 mg/kg) was 
administered 45 min prior to either 400 mg/kg [14C]NMF 
or 2 MCi|3H] leucine. Results are expressed as percentage 
of values measured in mice which were not pretreated 
with cydoheximide (controls), on the basis of ng NMF 
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Fig. 5. Influence of pretreatment with buthionine sul­
foximine (1600 mg/kg) on the association of label derived 
from OHCNH14CH3 (hatched bars) or OH,4CNHCH3 
(stippled bars) with hepatic proteins in BALB/c mice. 
Buthionine sulfoximine (1600 mg/kg) was injected 4 hr 
prior to [14C]NMF (400 mg/kg) and label was measured 
1 hr and 4 hr after NMF administration. Assodation is 
expressed as percent of binding observed in animals which 
were not pretreated with buthionine sulfoximine (controls), 
calculated on the basis of the amount of metabolites associ­
ated with the whole liver rather than with a mg of protein. 
As in these animals necrosis occurred and blood proteins 
accumulated in the livers within 4 hr of NMF adminis­
tration, this representation was considered to reflect 
changes in assodation appropriately (20). Values are the 
mean ± SD of 3 mice; stars indicate significant difference 
with controls, *P <  0.05, **P <  0.005.
m etabolites with hepatic proteins, hepatic glu­
tathione was depleted by adm inistration o f  buthion­
ine sulfoxim ine, an inhibitor o f glutathione synthesis, 
prior to administration o f [14C]N M F. T his pre­
treatm ent led to a decrease in hepatic glutathione to  
19% o f control levels at the tim e o f  [14C ]N M F injec­
tion [6]. W hereas pretreatm ent with buthionine sul­
foxim ine inhibited the association o f  label derived  
from O H C N H 14C H 3 to a m oderate exten t, it mark­
edly enhanced the association in the case o f  
O H 14C N H C H 3 when covalently bound label was 
determ ined 1 hr after NM F adm inistration (F ig . 5). 
H ow ever, 4 hr after adm inistration, radioactivity  
derived from either radioisotopom er was associated  
with liver proteins to an extent similar to  that 
observed in control m ice. A t this tim e livers o f  m ice  
which had received NM F after buthionine sul­
foxim ine exhibited severe haem orrhagic lesion s and 
som e animals w ere clearly m oribund. T herefore, 
the interpretation of the am ount o f radioactivity  
associated with hepatic proteins at this stage m ay not 
be meaningful. N evertheless, such hepatic dam age  
was not apparent on m acroscopic inspection o f  livers
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1 hr after administration of NMF. Pretreatment of 
mice with diethyl maleate, a compound which deple­
tes hepatic glutathione by avid electrophilic attack, 
also raised the level of activity associated with pro­
teins 1 hr after administration of OH14CNHCH3 to 
218 ± 20% (mean ± SD, N = 3) of control, whereas 
the association of label derived from OHCNH14CH3 
was only 33 ± 9% (N = 3) of that observed in control 
mice. Thus, removal of hepatic glutathione appears 
to increase the propensity of liver proteins towards 
association with metabolites of the formyl moiety of 
the NMF molecule, a finding congruent with the 
observation that the covalent binding from both iso- 
topomers of [14C]NMF to hepatic microsomes in 
vitro was completely abolished in the presence of 
10 mM glutathione (Table 1).
DISCUSSION
It is shown here for the first time that metabolites 
of NMF bind covalently to hepatic macromolecules, 
and there are three pieces of evidence which suggest 
that the generation of the toxic lesion caused by 
NMF and the covalent binding of it metabolites are 
causally related.
(i) The binding observed in vivo was appreciably 
higher in the organ in which toxicity is expressed 
than in other tissues.
(ii) The rank order of association of metabolites 
of [14C]NMF with liver macromolecules in three 
strains of mouse in vivo (Fig. 3) paralleled dif­
ferences between the sensitivity of these strains 
towards NMF-induced hepatotoxicity and hepatic 
glutathione depletion [6].
(iii) Modulation of the hepatic glutathione status 
prior to NMF administration affected both the sever­
ity of the hepatic damage and the binding in a fashion 
which suggests the involvement of a reactive, toxic 
intermediate. Depletion of hepatic glutathione 
exacerbated toxicity and increased binding of metab­
olites of the NMF formyl moiety in vivo (Fig. 5). 
Conversely, pretreatment of mice with thiol com­
pounds protected the livers against toxicity and, like­
wise, the presence of glutathione in the incubation 
medium totally abolished covalent binding measured 
in vitro (Table 1).
The radioactivity found to be associated with the 
hepatic proteins in vivo was at least partially due 
to incorporation into proteins of metabolites which 
were precursors of endogenous substrates. This con­
clusion is based on the finding that inhibition of 
protein synthesis markedly decreased the associ­
ation. What percentage of the overall association 
was due to covalent adduct formation is difficult to 
establish. However, since covalent binding occurred 
in vitro, it is likely that it also contributed to overall 
association with tissue macromolecules in vivo.
There was a difference between the two [14C]NMF 
isotopomers with regard to both the extent of binding 
in vitro and in vivo and the relationship between 
dose and their binding in vivo. This suggests that 
metabolic rupture of the amide bond in the NMF 
molecule precedes binding or incorporation of at 
least a portion of the dose of [14C]NMF injected. 
The end products of NMF metabolism have recently
been identified [18]. Carbon dioxide and methyl- 
amine are the major metabolites of NMF and both, 
or their immediate precursors, could conceivably 
contribute to incorporation of label into protein, as 
they are substrates of endogenous metabolic path­
ways. On the basis of the recent finding that S- 
(A/-methylcarbamoyl)-/V-acetylcysteine is a urinary 
metabolite of NMF in rodents and man [19], a num­
ber of chemically plausible electrophilic metabolic 
intermediates of NMF can be proposed. The for­
mation of these intermediates could explain both 
the hepatic necrosis [4,5] and the hepatic covalent 
binding which NMF causes in mice. Which enzyme 
system is responsible for the activation of NMF is 
still unclear.
Pretreatment of mice with buthionine sulfoximine 
exacerbated NMF toxicity [6] and it increased the 
association of label derived from OH14CNHCH3 with 
liver proteins in vivo. Assuming that the binding 
characterised in this study is indeed linked to the 
genesis of the toxic lesion one could conclude that 
the metabolic fate of the NMF formyl moiety is more 
crucial for the development of toxicity than that of 
the methyl moiety. It is, however, difficult to recon­
cile this conclusion with the difference between the 
two isotopomers in the'relationship of the binding 
to dose. The amount of radioactivity derived from 
OH14CNHCH3 which was found in the liver after 
administration of the toxic dose of 400 mg/kg was 
only approximately twice the amount bound after 
the innocuous dose of 100 mg/kg, whereas in the 
case of OHCNH14CH3 the level of association after 
400 mg/kg was approximately four times that 
observed after 100 mg/kg (Fig. 1). This would indi­
cate that the extent of binding of the 14CH3-labelled 
isotopomer reflects more convincingly the dose 
threshold for toxicity than does the binding of the 
14CHO-labelled isotopomer. This interpretation 
would be in accordance with the postulate that events 
leading to the association of metabolites of the NMF 
formyl moiety are less important for toxicity than 
those causing the binding of metabolites of the 
methyl group.
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ABSTRACT
The hepatotoxicity and metabolism of the following dose analogs 
of the hepatotoxic ant/tumor agent N-methytformamkje (NMF) 
were investigated in CBA/CA mice: N-ethytformamide (NEF). 
dimethytformamide (DMF). formamide and N-methytacetamide 
(NMA). Apart from NMF only NEF was potently hepatotoxic as 
measured by the elevation of plasma activities of the enzymes 
sorbitol dehydrogenase and alanine and aspartate aminotrans­
ferases 24 hr after drug administration. In freeze-dried urine 
samples of mice which had received NEF or NMF, but not in the 
case of DMF, formamide or NMA. thioesters were detected by 
thin-iayer chromatography. Evidence based on high-pressure 
liquid chromatography analysis and 400 MHz ’H-NMR and mass 
spectrometry suggests that the thioester metabolite of NEF is
S-(N-ethylcarbamoyl)-N-acetylcysteine. It has been shown pre­
viously that NMF is metabolized to  S-(N-methy1carbamoyl)-N-
acetylcysteine. NEF also underwent extensive metabolism to 
ethytamine; similarly NMF was biotransformed to methytamine. 
In contrast, the urine of mice which had received DMF contained 
only very small amounts of dimethytamine and methytamine could 
not be detected as a  metabolite of NMA. Instead, the major 
metabolite of NMA was identified by 400 MHz ’H-NMR spec­
trometry as N-(hydroxymethyt)acetamide. DMF is known to 
undergo extensive metabolism to its N-hydroxymethyt derivative. 
The results suggest that two metabolic pathways of N-alkytfor- 
mamides can be distinguished: Hydroxytation at the cr-carbon of 
the N-alkyl group and oxidation of the formyl moiety. The former 
pathway presumably constitutes a detoxification route, and the 
latter may wen be associated with hepatotoxicity, and affords a 
glutathione conjugate, excreted in the urine as a mercapturate.
N-Alkylformamides are important industrial chemicals as 
starting materials for chemical syntheses and  as solvents. Their 
solvent properties are related to their high dipole m om ent and 
to  their extensive miscibility with both aqueous and  organic 
media. Among the N -alkylformamides, DM F is th e  compound 
used most frequently as a solvent I t has been found to be 
hepatotoxic in rodents (Dexter et aL, 1982; Lundberg et aL, 
1981; Massmann, 1956; Mathew et aL, 1980) and  in  workers 
after occupational exposure to high concentrations o f the  vapor 
(Chivers, 1978; Finzel, 1972; Potter, 1973; Reinl and  Urban, 
1965; Tolot et aL, 1969; von Klavis, 1970). N M F shows an ti­
neoplastic activity in mice (Clarke et aL, 1953, Furst et aL, 
1955; Gescher et aL, 1982; Gate et aL, 1986) and  its  preliminary 
clinical investigation as an antitumor drug (Laird Myers et aL, 
1956; McVie et al~, 1984; Ettinger et aL, 1985) as well as
Received for publication June 23.1386.
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experiments in mice (Langdon et aL, 1985; Whitby et al., 1984) 
have shown it  to  be a hepatoxin. The mechanisms by which 
DMF and  NMF cause toxicity are poorly understood. N M F has 
been proposed as proximate or ultimate toxic metabolite 
through which DMF exerts its hepatotoxicity (Lundberg et al., 
1981). However, th is is unlikely, as i t  has been dem onstrated 
recently th a t NM F is not a  major urinary metabolite o f D M F 
in rodents (Brindley et aL, 1983; Scailteur and Lauwerys, 1984; 
Kestell et aL, 1986a). As far as the mechanism of toxicity of 
NM F is concerned, evidence has emanated from our laborato­
ries which suggests th a t NMF is metabolized to a chemically 
reactive, potentially toxic, compound which is able to  bind 
covalently to  hepatic macromolecules (Pearson et aL, 1986a) 
and causes the depletion of hepatic glutathione stores (Gescher 
et aL, 1982). The major urinary metabolites of NMF are m eth- 
ylamine (Kestell et aL, 1985) and S-(N-methylcarbamoyl)-N- 
acetylcysteine (Kestell et aL, 1986b). T he identification o f the 
latter metabolite has prompted the postulate tha t its formation, 
which involves oxidation a t the formyl carbon, is a  biotransfor­
AB8REVIAT10NS: DMF. N.N-dimethytformamide; NMF. N-methytformamkje; NEF. N-ethytformamide; F. formamide; NMA. N-methytacetamide; SDH. 
sorbitol dehydrogenase; AST. aspartate aminotransferase: ALT. alanine aminotransferase; HPLC. high-pressure Squid chromatography; TLC. thin- 
layer chromatography; 6LC. gas-liquid chromatography.____________________________________________
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mation route which leads via the hepatotoxic intermediate. In 
the present paper, this hypothesis is being tested further. The 
hepatotoxic potential in the mouse of four close analogs of 
NMF has been investigated, namely of DMF, NEF, F and 
NMA (for structures see table 1). The hepatotoxic potencies of 
these compounds are compared with their proclivity to undergo 
oxidative and conjugative metabolism giving S-(N-carba- 
moyDmercapturates via a pathway analogous to that which 
affords S-(N-methylcarbamoyl)-N-acetylcysteine in case of 
NMF (Kestell et aL, 1986b). The results presented in this paper 
demonstrate that, among the amides examined, only NEF and 
NMF are hepatotoxins in the mouse and also only NEF and 
NMF are metabolized to thiocarbamates.
Materials and Methods
T h e am id es N M F, N E F, D M F. F and N M A  were purchased from  
Aldrich C hem ical Co. (Poole, U .K .). S -(N -m eth ylcarb am oyl)-N -acety l-  
cysteine w as prepared as described by K este ll et aL (1986b) and the  
synth esis  o f  th e  following thiocarbam ates w ill be reported elsewhere: 
S-( N -ethylcarbam oyl) - N -acetylcysteine, S -(N ,N -d im eth y lcarb am oyl) - 
N -acety lcyste in e and S -(caib am oyl)-N -acetylcystein e. N -(H ydroxy- 
m ethyD acetam ide was made as described by Chwala (1948) and (WC] 
m ethylene-labeled  N E T  (O H C N H 'X H jC H ,) was synth esized  accord­
ing to  a m ethod  published previously for [>4C ]m ethyl-labeled  N M F  
(O H C N H ,4C H j) (ThreadgiU and Gate, 1983).
A m ides w ere d issolved in saline so lu tion  and adm inistered via th e  
Lp. route to  m ale C B A /C A  mice (18 -25  g). T h e  injection  volum e was 
0.2 m l and, in  th e  m etabolism  experim ents, th e  dose w as 400 rag/kg.
In order to  measure the extent o f  h epatotoxicity , th e activ ities in 
plasm a o f  th e follow ing three enzym es w ere assayed 24 hr after drug 
adm inistration . S D H , a s  described by R ose and  H enderson (1975), and  
A S T  and A L T  as  described by K achm ar and M oss (1976).
For th e d etection  o f  S -(N -alkylcaxb am oyl)-N -acetylcyste in es as m e­
tabolites o f  form am ides. urine sam ples w ere freeze-dned a fter acid ifi­
cation  w ith  9 M  HC1 to  achieve pH  1. In  a d d ic  m edia th ese S-(N - 
carbam oyb-m ercapturates are o f  su fficient stab ility  to  a llow  d etection . 
T h e residues w ere suspended in m ethanol an d  analyzed b oth  by H P L C  
and T L C . For th e  H PLC  analysis, a W aters trim odular system  (W aters  
A ssociates. N orthw ich , U JC ) fitted  w ith  a  W aters R C M -100 radial 
com pression  u n it and a  Cu 5 pm reverse p hase colum n w as used, U V  
detection  w as achieved w ith a W aters _ 4 8 0  LC spectrophotom eter set 
a t 205 nm . T h e  eluan t (0.01 M octylam ine hydrochloride in  water, pH  
6.0: m eth an ol. 3:1 v /v )  was pumped through th e  colum n a t  a flow  rate 
o f  1 m l/m in . T L C  analysis was conducted o n  silica  gel 60-coated  plates  
(0.2 mm th ick n ess, M erck, A G .. D arm stadt, W . G erm any). P la tes  were 
developed in  butan-l-ol-w ater-m ethanol (8^2:1 v /v ) . T h e m ercapturates  
were detected  b y  spraying the p lates w ith  eith er  1 M  aqueous N aO H  
followed by E llm an's reagent (Glaser et aL, 1970) or w ith  cfaloroplatin- 
ate reagent (B arn sley  et aL, 1964). S -(N -E th y lcarb am oyl)-N -acety lcys-  
teine was id en tified  a s an  N E F m etabolite a fter  isolation b y  preparative 
TLC  and esterifica tion  w ith  m ethanolic hydrogen chloride a s  described
TABLE 1









Amide R, R, R,
F H H H
NMF CH, H H
NEF H H
DMF CH3 CH, H
NMA CH, H CH,
previously for S -(N -m eth ylcarb am oy!)-N -acety lcysteine (K e ste ll et al., 
1986b).
'H -N M R  and mass spectra of the m eth yl es ters  o f  m eta b o lite  and  
au thentic  thiocarbam ate were obtained, resp ectively , a t  400  M H z  using  
a Bruker W H  400 spectrom eter w ith  D jO  as so lv en t, a n d  u sin g  a VG 
7070 m ass spectrom eter (with a VG 2035 d ata  sy stem ) in  th e  ch em ica l 
ion ization  m ode, using 2-m ethylpropane a s  reagen t gas, run a t a  scan  
rate o f  1 sec/decade. 400 M Hz ‘H -N M R  spectra  o f  u rin e sam ples  
involved  suppression o f  the HjO signal b y  se le c tiv e  p resa tu ra tion  (1.5  
sec) follow ed by collection o f  free induction  d ecay, w ith  4 prelim in ary  
dum m y scan s. Unchanged am ides in  th e  urine w ere q u a n tita te d  by 
GLC as described previously by G escher et aL (1982 ). N -(h yd roxy  
m eth y l)-acetam ide w as identified a s a  m etab olite  o f  N M A  by 4 0 0  M H z  
'H -N M R  analysis after separation o f  th e c o n s titu en ts  o f  freeze-dried  
urine sam ples by preparative TLC using b en zen e -a ce to n e -a ce tic  acid  
(3:2:2 v /v )  a s so lvent and pbenylh ydrazin e-fem c ch lor id e  reagen t (pre­
pared according to N air and Francis (1980)] a s d e tectin g  sp ray . After  
elu tion  o f  th e  m aterial from the TLC p late residual a ce tic  ac id  and  
w ater w ere removed by freeze drying. N -(h y d roxym eth y l)acetam id e  
w as quan titated  by GLC analysis under co n d itio n s u sed  for th e  m eas­
urem ent o f  N M A . On the GLC colum n, th is  carb inolam id e d ecom p oses  
quan tita tively  to acetam ide. Q uantitative a n a ly sis  w as fea sib le  a s  ‘H- 
N M R  spectra o f  urine obtained after N M A  ad m in istra tion  sh o w ed  th at  
there w as no appreciable excretion o f  acetam id e gen erated  m etab oli-  
ca lly  from N M A .
A lip h atic  am ines in th e urine were d etected  by H P L C  a fter  deriva- 
tization  w ith  dinitrobenzenesulfonic acid  an d  ex trac tion  in to  e th er  as  
described previously (K estell et al., 1985). M eth y lam in e a n d  eth y la m in e  
were q uantitated  by counting o f  rad ioactiv ity  a fter T L C  sep aration  
(K este ll et aL, 1985) o f  urinary con stitu en ts  ob ta in ed  from  m ice  w hich  
had received OHCNH'TIH* or O H C N H ,<C H 2C H J.
Results
In order to investigate the hepatotoxic potential o f four close 
analogs of NMF, different doses of these amides were admin­
istered to mice and, after 24 hr, the plasma activities o f  three 
marker enzymes of hepatic damage, SDH, AST and ALT, were 
measured. In accordance with observations published previ­
ously (Langdon et aL, 1985), NMF was hepatotoxic at doses 
exceeding 200 mg/kg (3.4 mmol/kg) (fig. 1). Likewise, NEF  
exerted marked liver toxicity at 600 mg/kg (8.2 m m ol/kg). 
However, none of the other three amides at doses o f up to  3 g/ 
kg caused plasma activities of the marker enzymes to increase 
as dramatically as seen after NMF. Nevertheless, even though 
F, DMF and NMA exhibited low hepatotoxic potential, at this 
dose they caused the mice to lose weight (table 2).
To study the formation of S-(N-alkylcarbamoyl)-mercaptur- 
ates as urinary metabolites of the amides under test, freeze- 
dried urine samples from mice which had received either NMF, 
NEF, F or DMF were analyzed by TLC. The appropriate 
authentic mercapturates were prepared as reference com­
pounds. Only the two monoalkylformamides NM F and NEF, 
but not DMF or F, gave rise to the appearance o f  thiocarba­
mates in the urine, as shown by TLC and HPLC analysis. The 
mercapturates arising from metabolism o f NM F and N E F  had 
R*s identical to those of the respective synthetic materials, S- 
(N-methylcarbamoyl)-N-acetylcysteine (0 .3 0 )  and S-(N -ethyl- 
carbamoyl)-N-acetylcysteine (0 .3 7 ) .  Both metabolites gave a 
positive reaction with Ellman’s reagent after treatm ent with 
aqueous base as described under “Materials and Methods," 
indicating the presence of thioesters/thiocarbamates. T he limit 
of detection by HPLC for unlabeled S-(N-alkylcarbamoyl)- 
mercapturates in the urine was near 10 /unol/mL Therefore we 
cannot exclude the possibility that small amounts o f DM F or
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h‘ s .
O (4Jfc C CH?CH?
C i  6 
h c^^ n^ co.ch:H
6.8 6.7 5.5 5.4 4.8 4.7 3.8 3.7 3.4
ppm
Fig. 3 . Prominent signals in the 400  MHz ’H-NMR spectra  of S-(N - 
ethylcart>amoyO-N-acetyfcysteine methyl ester (A) and o f a  urinary m e­
tabolite o f NEF after reaction with methanoHc hydrogen chloride (8). 
Details of th e m etabolite isolation are described under "Materials and  
Methods."
TABLE 3
Amounts of unchanged amides and of metabofically generated 
alkylamines excreted in the urine of mice which received NMF,
NEF, DMF or NMA (400 mg/kg)
Amort Exacted Amort Exacted
Amide Administered Uctanged Amine Detected* as Amine
(% o< dose ± SJD.) (% of dose ±  S OJ
NMF 26.4 ±  1.9 (5)* CHjNHj 15.0 ±  1.9 (3)
NEF 4 .8  ± 1 .9  (5) CjHjNHj 42.1 ±  2 .0  (4)
DMF 4 .9  ±  1.4 (Sf HN(CH3)j 3.9 ± 1 .9 "
CHsNHj 4.1 ±  0 .8"
NMA 2.0 ± 2 .0  (6) N.D .*
K-C,
HO-tpC
8.0 7X1 6.0 S.0 4.0 3.0 2.0 IX) 0.0
ppm
— /
8.0 7.0 6.0 S.0 4.0 3.0 2.0 1.0
•Urine was coAected for 24 hr and amides and amines were detected and 
quantitated as described under 'Materials and Methds "
* Numbers in parentheses, number o< animals.
c As reported by Brindtey ef al. (1983).
* As reported by Kestel et al. (1986a).
* NX)., methytamine not detected.
spectrum of urine samples of mice which had received NM A is 
dominated by the acetyl proton resonance frequency o f  its 
major urinary metabolite (2.01 ppm). This metabolite was 
separated from other urine constituents by TLC. Figure 4B  
shows its ’H-NMR spectrum which is a virtually identical with 
that o f synthetic N-hydroxymethylacetamide (fig. 4A). 
Whereas 54 ±  10% (mean ±  S_D_, n =  5) of the dose o f NM A  
was metabolized to N-hydroxymethylacetamide, only 2% was 
excreted as unchanged NMA (table 3).
Discussion
Among the formamides, NMF is the most effective antineo­
plastic agent in mice (Gate e£ aL, 1986). According to the results
ppm
F ig. 4 . ’H-NMR spectra  of N -hydroxym ethytacetam iPe (A) and the major 
urinary m etabolite of NMA (B) in DjO. D etails o f  th e synth esis o f N- 
(hydroxym ethyl)acetam ide and of the m etabolite isolation are d escribed  
under "Materials and M ethods."
presented in this paper, the monoalkylformamides NMF and 
NEF appear also to be more potently hepatotoxic than other 
formamides. The amides investigated here seem to exert tox- 
icities also in targets other than the liver, as the derivatives 
which lacked marked hepatotoxic potential caused marked 
weight loss at high doses (3 g/kg).
Little is known about the mechanism by which NMF causes 
toxicity. Studies of the effect of NM F on glutathione status 
and of the effects o f manipulation o f glutathione status on 
hepatotoxicity and covalent binding o f metabolic products of 
radiolabeled NMF suggest that NMF undergoes metabolic ac­
tivation to a reactive, potentially toxic, metabolite (Whitby et 
oL., 1984; Pearson et aL, I987a,b). The analytical chemical work 
described here demonstrates that the two bepatotoxins among 
the five amides tested in this study are also the ones which 
underwent metabolism to S-(N-alkylcarbamoyl)-mercaptur- 
ates. This result is good evidence for the contention that the 
biotransformation route (fig. 5A) which yields thiocarbamates 
is linked closely with the formamide-induced generation of the 
hepatotoxic lesion. The formation of the N-alkylthiocarba-
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Fig. 5 . Major m etabolic loxification (A) and detoxification (8 ) pathw ays  
of N-aJkytformamides and NMA.
mates from N-alkylformamides involves the oxidation of the 
formyl moiety and one could postulate a number o f conceivable 
metabolic precursors, among them alkylisocyanates (alkyl- 
N = C = 0 ). The formation of such a powerful electrophile would 
explain the fulminant hepatic necrosis observed in mice which 
had received NMF (Whitby et aL, 1984). It would appear (fig. 
1) that NM F is slightly more toxic, on a molar basis, than is 
NEF and that this difference might correlate with the greater 
amount of mercapturic acid found in the urine, although this 
association probably does not indicate causality. It is worth 
noting that NM F and NEF are also the derivatives among the 
amides which gave rise to large amounts of metabolically pro­
duced alkylamines in the urine. The way in which the alkylam- 
ines are formed from the formamides is unclear. It is unlikely 
that direct hydrolysis o f the formamide molecule occurs, as 
NMF and DM F are both resistant to hydrolysis catalyzed by 
liver or plasma enzymes (C. Brindley and D. Ross, unpublished 
observation). Indeed, the observation of a large primary H /D  
kinetic isotope effect on the metabolism of NMF to methyla- 
mine when ODCNHCHj and OHCNHCDj are coadministered 
[fe(formyl—H)/fe(formyl—D) =  5.5. ±  0.2] shows that NMF is 
not hydrolyzed to methylamine in vivo but rather that cleavage 
of the formyl C-H bond is involved (M. D. Threadgill, P. Kestell 
and A. Gescher, unpublished observation). It is therefore likely
that the product o f alkylformamide oxidation or, indeed, its  
conjugation product S-(N-alkylcarbam oyl)glutathione or its 
cysteinylglycine, cysteine or mercapturic acid derivatives are 
the im mediate precursors of th e  alkylam ines found in  the urine.
Among the amides studied here, NMA is the only one inca­
pable, in principle, of undergoing oxidation or dehydrogenation 
in its carbonyl moiety. It was metabolized predominantly to its 
hydroxymethyl amide. The major metabolic pathway o f DMF 
in rodents is also N-methyl C-hydroxylation (Kestell et al., 
1986a; Scailteur and Lauwerys, 1984). This is remarkable in 
view of the fact that DMF possesses a formyl group which 
could be oxidized. However, oxidation at the formyl carbon 
does not appear to occur in DMF. On the basis of the dem on­
stration of the very low toxicity in vivo o f a related carbinolam- 
ide, N-(hydroxymethyl)formamide (Cooksey et aL, 1983), which 
has been found to be a minor urinary metabolite o f NM F  
(Kestell et aL, 1985), we suggest that metabolic N-methyl C- 
hydroxylation (fig. 5B) is a detoxification pathway in tb j<; 
series. Therefore, the results o f  the study described here lead 
to the proposition that two metabolic pathways of N-alkylfor­
mamides can be distinguished (fig. 5): either hydroxylation at 
the a-carbon of the N-alkyl group, which probably constitutes 
a detoxification reaction, or metabolic oxidation of the formyl 
moiety, which is a prelude to the generation of the hepatotoxic 
lesion.
In antitumor tests in mice o f a large number of amides, only 
NMF possessed highly significant activity in several murine 
tumors (Gate et aL, 1986). Both NEF and DMF were only 
marginally inhibitory of tumor growth, each in one mouse 
tumor model. F and NMA lacked completely antitumor activity. 
Because, as shown in this paper, NM F and NEF (amongst the 
compounds examined) both exhibit hepatotoxicity and are me­
tabolized significantly to S-(N-alkylcarbamoyl)-mercapturic 
acid but only NMF is an effective antitumor agent in mice, it 
would appear that the biochemical mechanisms of hepatotoxic­
ity and antitumor activity are different.
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ABSTRACT
S-^N-MethylcarbamoyQglutathione has been identified by cesium 
ion liquid secondary ion mass spectrometry as a  biliary metabo­
lite in mice of the experimental antitumor agent and hepatotoxin 
N-methylformamide. Metabolism of N-methylformamide to uri­
nary methytamine, urinary N-acetyl-S-{N-methylcarbamoy!)- 
cysteine and biliary S-(N-methy!cart)amoyl)glutathione was found 
to be subject to large intermolecuiar primary kinetic isotope 
effects when hydrogen was replaced by deuterium in the formyl 
group (kH/kD — 5.5 ±  02., 4.5 ± 1 .0  and 7 ±  2, respectively), as 
shown by mass spectrometry of derivatives of these metabolites. 
These values indicate the existence of a common metabolic 
precursor for each of these metabolites. In particular, methyia-
mine is shown not to arise from simple enzymatic hydrolysis of 
N-methytfonmamide but is associated with an oxidative process. 
Therefore, it is highly likely that N-methylformamide is oxidized 
and conjugated to form S-(N-methylcarbamoyl)glutathione which 
is metabolized further to N-acetyl-S-{/V-methylcarbamoyl) cys­
teine. Either of these thiocarbamates could be hydrolyzed to give 
the parent thiol and the observed metabolic end products, meth- 
ylamine and carbon dioxide. The presence of deuterium in the 
formyl moiety of N-methylformamide reduced markedly the hep­
atotoxicity of the compound, as shown by measurements of the 
activities of appropriate hepatic enzymes in plasma.
N M F (OHCNHCH 3; NSC 3051; fig. 1) is a powerful solvent 
with antineoplastic activity against implanted rodent tumors 
(Clarke et aL, 1953; Gescher et aL, 1982). Of a large series of 
analogs tested in these murine systems, only NMF showed 
consistent activity (Gate et aL., 1986). NM F has been the subject 
of clinical evaluation (Laird Myers et al., 1956; McVie et al., 
1984; Eisenhauer et aL, 1986) and has shown hepatotoxicity 
both in humans (Laird Myers et al., 1956) and in rodents 
(W hitby et al., 1984; Langdon et aL, 1985). It is likely that this 
toxicity is mediated via one or more metabolites of NM F  
(Pearson et aL, 1987; Whitby et aL, 1984). It has also been 
suggested that the hepatotoxicity o f the important industrial
Received for publication December 18,1986.
1 This work was supported by the Cancer Research Campaign of Great Britain, 
by NATO and by National Institutes of Health Grants AM30699 and RR01614. 
Preliminary accounts of parts of this work were presented at the 27th Annual 
Meeting of the British Association for Cancer Research. Bristol, U.K. and at the 
9th International Symposium on Medicinal Chemistry, Berlin, Federal Republic 
of Germany.
solvent (DMF) may be associated with its metabolism to NMF 
(Kimmerle and Eben, 1975a,b; Lundberg et al., 1981), although 
a recent study has shown that the latter secondary amide is at 
most a very minor metabolic product when high doses of DMF 
are adm inistered to mice (Kestell et al., 1986a). NMF is metab­
olized extensively in m am m als and the following urinary me­
tabolites have been identified: N-(hydroxymethyl)formamide 
(mouse) (Kestell et al., 1985b), methylamine (mouse and rat) 
(Kestell et al., 1985a,b) and N-acetyl-S-(N-methylcarba- 
moyl)cysteine (mouse, rat and humans) (Kestell et al., 1986b; 
Tulip et al., 1986). Additionally, WC 0 2 was found in the breath 
of mice which had received [14C]NM F (Kestell et al., 1985b) 
and some 26% o f the parent amide is excreted unchanged in 
this species (Brindley et al., 1982).
In a limited structure-toxicity study, we have reported re­
cently (Kestell et al., 1987) the observation of a qualitative 
relationship between the hepatotoxic potential of formamides 
and the presence o f an S-(N-alkylcarbamoyl)mercapturic acid 
as a urinary metabolite. Therefore, the metabolic pathway of
ABBREVIATIONS: NMF. N-methytformamide; OMF. N.N-dimethylformamide: El. electron impact; BPt, boiling point; HPLC, high-pressure liquid 
chromatography; LSIMS, liquid secondary ion mass spectrometry: TLC, thin-layer chromatography; Cl. chemical ionization; SDH. sorbitol dehydro- 
genase; AST, aspartate aminotransferase; ALT. alanine aminotransferase. ________________________
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Fig. 1. Structures of synthetic compounds and isotopomers used in this 
study.
NMF which leads to the mercapturic acid appears to be the 
prime candidate for the route which generates the hepatotoxic 
intermediate. The chemical identity of this material and other 
details of the sequence of metabolic events leading from NMF 
to the mercapturic acid are unknown and difficult to establish 
directly as the reactive intermediate is likely to be a very short­
lived species. Experiments are reported here which are designed 
to elucidate these details with the use of deuterated analogs of 
NMF. In particular, the following three hypotheses have been 
tested: 1 ) S-(N-methylcarbamoyl)glutathione is a precursor of 
the urinary mercapturic acid and is itself excreted in the bile; 
2) the metabolic cleavage of the C-H bond in the formyl group 
of NMF is the rate-determining step in the metabolism of NMF 
to the thiocarbamates and to methylamine; and 3) the metabolic 
removal of the formyl hydrogen is involved in the genesis of 
the hepatotoxic lesions caused by NMF. Overall, it was hoped 
that this work may contribute to an understanding of the 
mechanisms of toxicity and of antitumor activity of NMF and 
perhaps to the design of a therapeutic analog in which these 
activities are separated.
Methods
M aterials. The radiochemical starting material (HuC 02", Na+) was 
purchased from Amersham International P.L.C. (Amersham, U.K.). 
Deuterated starting materials and other chemicals were purchased from 
Aldrich Chemical Company Ltd. (Gillingham, Dorset, U.K.) or from 
Aldrich Chemical Company (Milwaukee, WI). N-[methyl-uC]form- 
amide (OHuCNHCHs) and N-(trideuteromethyl)formamide 
(OCHNHCD3) were prepared as described previously (Threadgill and 
Gate, 1983) and the latter was found by El mass spectrometry to be >  
98% labeled in the methyl group. N-(trideuteromethyl)- 
deuteroformamide (ODCNHCD3) was prepared as follows; sodium (161 
mg, 7 mmol) was dissolved in anhydrous methanol (15 ml; freshly 
distilled from magnesium methoxide) and the solution of sodium meth- 
oxide was cooled to 0*C. Trideuteromethylamine hydrochloride 
(CD3NH3* Cl'; 492 mg, 7 mmol) was added, followed after 2 0  min by 
methyl deuteroformate ( 1  ml). The reaction mixture was stirred for 16
hr before being filtered. Distillation (Kugelrohr) gave the product as a 
colorless liquid (70 mg, 2 2 %) with BPt7«> 183-187°C (literature BPt76o 
180-185*C for protio compound (Weast, 1977)]. This material was 
found by El mass spectrometry to consist of a mixture of 55% 
C^H^sNO and 45% C2HD4NO. High field proton NMR analysis of 
this material indicated that the trideutero species corresponded to 
OHCNHCD3 whereas the tetradeutero molecules were labeled at both 
the methyl and the formyl positions. N-Methyldeuteroformamide 
(ODCNHCH3 ) was synthesized thus: methyl deuteroformate
(ODCOCH3) was added to anhydrous methanol (20 ml) which had been 
saturated with gaseous methylamine (CH3NH2) at 0°C. This mixture 
was stirred for 16 hr. Distillation (Kugelrohr) furnished N-methyldeu- 
teroformamide (1 . 0 2  g, 75%) as a colorless liquid BPtrro 191-194°. El 
mass spectrometry showed the material to be >  98% ODCNHCH3. 
Infrared spectrum (liquid film) 3300, 2950, 2150 and 1650 cm-1.
HPLC. HPLC purification of the N-ethoxycarbonylglutathione con­
jugate of NMF isolated from bile was performed using a Beckman 
model 342 instrument, equipped with a reverse phase 5 mM Ultrasphere 
ODS column (15 cm x 4.6 mm internal diameter, Rainin Instruments, 
Berkeley, CA). The mobile phase consisted of a linear 20 m in  gradient 
from 20 to 70% methanol in water, with 1% acetic acid throughout. 
The mobile phase was maintained at 70% methanol for a further 10 
min. The flow rate was held at 1 . 0  ml min- 1  and 1 -min fractions were 
collected. Under these conditions the ethoxycarbonyl-, ethoxycarbonyl 
methyl ester- and ethoxycarbonyl dimethyl ester derivatives of the 
NMF conjugate eluted in fractions 5 to 6 , 8  to 9 and 10 to 1 1 , 
respectively. The recovery of radioactivity in the HPLC eluate was >  
95% of that applied to the column. Detection was carried out by liquid 
scintillation counting using a Beckman LS-7500 counter. HPLC equip­
ment and conditions for the analysis of the urinary metabolites were 
as described previously by us (Kestell et al. 1986b) except that the 
mobile phase for the purification of N-methyl-2,4-dinitro-aniline was 
methanol-water (2:1 v/v) and UV absorption detection was carried out 
at 346 nm.
M ass spectrom etry. LSIMS of the derivatized glutathione conju­
gates was performed on a Kratos MS-50S mass spectrometer, equipped 
with a 23-kG magnet and a postacceleration detector which was oper­
ated at —10 kV. Samples were dissolved in a glycerol matrix containing 
HC1 and NaCl (to increase the intensity of [M + HP and [M + Na]° 
species) and ionization was achieved by bombardment with a l.O-^A 
primary beam of Cs* ions (Falick et al., 1986). Chemical ionization 
mass spectrometry was carried out on a VG70-70 instrument as de­
scribed previously (Kestell et al., 1986b). El mass spectrometry of 
deuterated analogs of N-methyl-2-4-dinitroaniline was carried out us­
ing a VG Micromass 12B instrument operating at an electron energy 
of 70 eV with a probe temperature of 250°C. The exact isotopic 
composition of the mixtures of the deuterated analogs which were 
administered to mice was determined by El mass spectrometry using 
either a VG Micromass 1 2 B or a VG 70-70H instrument.
Anim als and treatm ent procedures. NMF or its deuterated or 
uC-analogs (6 . 8  mmol kg' 1 in 200 pi of saline) were administered to 
male BALB/c mice (20-25 g) i.p. The total dose corresponds to the 
optimum antitumor dose (Gate et al., 1986). Animals were sacrificed 
by cervical dislocation.
Identification of the biliary  glutathione conjugate and deter­
m ination o f  the primary k inetic  isotope effect on its formation. 
Mice received NMF or its deuterated analogs together with 
OH14CNHCH3 as tracer (final specific activity, 30 mCi mmol'1). In 
experiments designed to elucidate the position of the link of the NMF- 
derived moiety to glutathione, separate groups of four mice received 
either OHCNHCH3 or ODCNHCH3. In order to determine the mag­
nitude of the primary kinetic isotope effect on the formation of this 
conjugate, a further group of mice received a mixture comprising 
OHCNHCH3 (59%), OHCNHCD3 (22.8%) (a byproduct of the synthe­
sis of ODCNHCDs) and ODCNHCD3 (18.2%). Mice were sacrificed 4 
hr after administration of NMF and bile was then collected via puncture 
of the gall bladder with a syringe.
Aliquots of bile (50 pi) were treated with a solution of ethyl chloro-
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formate (100 #d) in 0-1 M phosphate buffer (pH 9.0, 3.0 ml). Excess 
ethyl chloroformate was removed by extraction with dichloromethane 
(5 ml) and the residual aqueous portion was acidified (to pH <  2) and 
applied to a prewashed Cl 8  Sep-Pak cartridge (Waters Associates, 
Milford, MA). The cartridge was rinsed with water and the ethoxycar­
bonyl derivatives were eluted with methanol and evaporated to dryness 
under a stream of nitrogen. The residues were subjected to analysis by 
HPLC. Fractions 5 to 7 (which contained the majority of the radioac­
tivity) were pooled and processed, as described above, on a second Sep- 
Pak cartridge. The purified conjugates thus obtained were then treated 
with anhydrous methanolic hydrogen chloride at ambient temperature 
for 2 hr. The resulting methyl esters were purified further by HPLC, 
as described above, and fraction 1 0  was collected for mass spectrometric 
analysis. The precise isotopic composition of the fully derivatized 
NMF-glutathione conjugates, isolated from each of the separate studies, 
was determined under LSIMS conditions by sweeping the accelerating 
potential of the spectrometer repetitively to bring into focus the mass 
range 485 to 495. The duration of each limited mass scan was 10 sec 
and measurements of deuterium content were based on the 
[M + NaJ* cluster (at m /z  487 in the spectrum of the unlabeled 
conjugate) using the mean of 1 0  scans across this peak.
Study on the m etabolism  o f NMF to N -acetyl-S-(N -m ethyl- 
carbam oyl)cysteine. Collections of urine (24 hr) were made from 
three mice which had been given a mixture of OHCNHCD3 (50%) and 
ODCNHCH3 (50%). Each sample of urine was freeze-dried and the 
residues were subjected to preparative TLC as described previously 
(Kestell et aL, 1986b). The isolated mercapturic acid from each sample 
was esterified using methanolic hydrogen chloride (Kestell et al., 1986b) 
and the resulting mixtures of isotopomers of N-acetyl-S-(N-methylcar- 
bamoybcysteine methyl ester were subjected to Cl mass spectrometry 
in order to determine the isotopic composition of the N-methyl groups. 
Averages of five spectra were taken for each sample.
Study on the m etabolism  o f NMF to methylam ine. Urine was 
collected from each of three male mice for 24-hr periods both before 
and after administration of a mixture of OHCNHCD3 (47%) and 
ODCNHCH3 (53%). To each urine sample (ca. 1 ml) was added 2  M 
ethanolic 2,4-dinitrofluorobenzene (2 ml) and the mixtures were al­
lowed to stand for 1  hr at ambient temperature before addition of 
saturated aqueous sodium chloride ( 1  ml). Each sample was then 
extracted with diethyl ether ( 2 x 5  ml). The organic extracts were 
washed with 2.5 M aqueous sodium hydroxide ( 2 x 2  ml) and with 
saturated aqueous sodium chloride ( 2  ml) before being dried with 
anhydrous sodium sulfate and filtered. The solvent was then evaporated 
from each filtrate under reduced pressure. An aliquot of the residue 
from each sample was then assayed for total N-methyl-2,4-dinitroani- 
line by HPLC to determine the contribution of endogenous CH3NH2 
to the total methylamine in the urine samples from animals after 
administration of NMF. The N-methyl-2,4-dinitroaniline from the 
urine of each treated animal was purified by preparative TLC [ 2  mm 
thick silica gel 60 plates, Merck, Darmstadt, FRG, dichloromethane- 
methanol, 9:1 (v/v)], followed by HPLC. Evaporation of the eluent 
from appropriate fractions gave the pure mixtures of isotopic analogs 
as yellow solids, the compositions of which were then determined by 
El mass spectrometry.
Studies on the effects of deuteration on hepatotoxicity of 
NMF. Single doses of OHCNHCH3 and OHCNHCD3 ( 1 0 0  and 2 0 0  mg 
kg-1) and of ODCNHCH3 (100,200 and 300 mg kg-1) were administered 
i.v. in saline ( 2 0 0  id) and control mice received saline ( 2 0 0  >d) alone. 
Twenty four hours after administration of the dose, the animals were 
anesthetized with diethyl ether and exsanguinated by cardiac puncture 
into syringes containing aqueous sodium heparin (2500 U ml-1; 50 jd). 
Plasma was obtained from each sample by centrifugation. The activity 
of SDH was determined by the method of Rose and Henderson (1975) 
and those of AST and ALT were determined by the method of Kachmar 
and Moss (1976). Statistical comparison was effected using the Mann- 
Whitney U test.
Results
The bile obtained from mice which had received 
OHuCNHCH3 contained a radioactive metabolite which was 
derivatized by treatment with ethyl chloroformate and the 
products were analyzed by HPLC. The exemplary chromato­
gram (fig. 2A) shows that a single radioactive component was 
present (fraction 5). This material was collected, esterified and 
analyzed in the same HPLC system (fig. 2B). One major, less 
polar, radioactive product (fraction 1 0 ) was observed, together 
with two minor components arising from incomplete esterifi- 
cation of the sample. The major product was isolated and 
subjected to structural analysis by Cs+ ion LSIMS. The result­
ing mass spectrum (fig. 3) contained three prominent ions 
which correspond to the [M + H]+ (m/z 465), [M + Na]+ (m/ 
z 487) and [M + K]+ (m/z 503) species of a compound of MW 
464. This molecular weight corresponds to the sum of those of 
NMF (59) and N-(ethoxycarbonyl)glutathione dimethyl ester 
(407) minus two hydrogens.
In order to determine to which position in the NMF moiety 
the glutathione was attached, the conjugate excreted in the bile 
of mice which had received ODCNHCH3 was derivatized, pur­
ified and analyzed, similarly. The partial mass spectra repro­
duced in figure 4 are representative of those arising from the 
fully derivatized glutathione conjugates from OHCNHCH3 and 
ODCNHCH3  (fig. 4, A and B, respectively). The strong simi-
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Fig. 2. A, reverse-phase high-pressure liquid chromatogram of bile of 
mice given OH14CNHCH3. After treatment of a  sample of bile with ethyl 
chloroformate, metabolites were extracted and analyzed by HPLC as 
described under "Methods." Fractions (1 ml) were collected for radioac­
tivity measurements. B, high-pressure liquid chromatograms of pooled 
fractions 4 -6  from A, after treatment with methanolic hydrogen chloride.








Fig. 3. Molecular ion region of the LSIMS spec­
trum of the fully derivatized NMF-glutathione 
conjugate as isolated by HPLC (fraction 10. fig. 
2B).
T T
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Fig. 4. A. the [M +  Na]* region of the LSIMS spectra of the fully derivatized NMF-glutathione conjugates isolated from the bile of mice which had 
received OHCNHCH3 (A) or ODCNHCH3 (B).
larity in relative intensities of the [M + Na]* ions at m/z 487 
and m/z 488 in the spectra of the two conjugates is indicative 
of the total loss of deuterium from the ODCNHCH3  during the 
metabolic process to give the glutathione conjugate. Thus, the 
NMF moiety must be linked exclusively through the formyl 
group to glutathione. The structure of the fully derivatized 
conjugate, as determined in this study, is shown in figure 5.
The magnitude of the apparent primary kinetic deuterium 
isotope effect associated with formation of S-(N-methylcarba- 
moyl)glutathione from NMF labeled with deuterium at the 
formyl position was estimated by administering a known mix­
ture of OHCNHCH3, OCHNHCD3 and ODCNHCD3 to mice. 
Bile was collected from the animals, as before, and the conju­
gate was converted to its ethoxycarbonyl dimethyl ester deriv-
CH3CHjOv ^ N .
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Fig. 5. Structure of the N-(ethoxycart>onyl) dimethyl ester derivative of 
the glutathione conjugate derived from NMF.
ative. Based on the relative intensities of the ions at m/z 487 
and m/z 490 in the LSIMS spectrum of this derivatized conju­
gate, corresponding to [M + Na]* ions for the —SCONHNCH3 
and —SCONHCD3 species, respectively (fig. 6), and taking into 
account the GSCONHCD3 generated from the impurity
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Fig. 6. The [M + Na]* region of the LSIMS spectrum of fully derivatized 
S^N-methylcartjamoyOglutathione isolated from the bile of mice which 
had received a mixture of OHCNHCH3 and ODCNHCD3.
OHCNHCD3, it could be calculated that the apparent kinetic 
isotope effect associated with this metabolic process in vivo 
(kH/k D) is 7 ± 2 (n = 3) as referred to the formyl carbon- 
hydrogen bond. In this experiment, the presence of a 
—SCONHCH3 group in the conjugate reports on the metabo­
lism of OHCNHCH3 and the —SCONHCD3 reports on the 
metabolism of the ODCNHCD3 and OHCNHCD3.
The primary kinetic deuterium isotope effect on the metab­
olism of NMF to N-acetyl-S-(N-methylcarbamoyl)cysteine was 
evaluated by administration of a known mixture of 
ODCNHCH3 and OHCNHCD3  to mice. The mixtures of deu­
terated analogs of the mercapturic acid were isolated from urine 
from each mouse and were esterified by treatment with meth­
anolic hydrogen chloride before Cl mass spectrometric analysis 
(fig. 7). Comparison of the intensities of the ions at m/z 235 
and m/z 238, corresponding to the molecular ions of N-acetyl- 
S-(N-methylcarbamoyl)cysteine methyl ester and N-acetyl-S- 
[N-(trideuteromethyl)carbamoyl]cysteine methyl ester, respec­
tively, indicated the magnitude of the apparent primary kinetic 
isotope effect (kH/k D) for this metabolic process to be 4.5 ± 1.0 
(n = 3). In this experiment, the mercapturic acid bearing the 
SCONHCD3  reports on the metabolism of OHCNHCD3 and 
that bearing the SCONHCH3 group reports on the metabolism 
of ODCNHCH3 .
To evaluate the corresponding apparent primary kinetic iso­
tope effect for the metabolism of NMF to methylamine, a 
similar mixture to that used for the N-acetylcysteine conjugate 
experiment was administered. Twenty four-hour urine collec­
tions were made both before and after the dose. Derivatization 
of the urinary methylamine was effected by treatment of the 
urine samples with ethanolic 2,4-dinitrofluorobenzene under 
neutral conditions. HPLC assay showed that endogenous meth­
ylamine (CH3NH2) in the control samples comprised < 5% of 
the total methylamine (CH3 NH2 + CD3NH2) found in the urine 
after treatment of the animals; the contribution of endogenous 
methylamine to the total was therefore regarded as negligible.
The N-methyl-2,4-dinitroaniline from the samples of urine 
after administration of NMF was purified by extraction into 
diethyl ether, followed by preparative TLC and HPLC. Based 
on the intensities of the ions in the El mass spectra at m/z 197 
and m/z 2 0 0 , being the molecular ions for N-methyl-2,4-dini- 
troaniline and N-(trideuteromethyl)-2,4-dinitroaniline, respec­
tively, an apparent kinetic isotope effect (kH/k D) of 5.5 ± 0.2 
(n = 3 ) was observed for the metabolism of NMF to methylam­
ine, depending on the presence of a C—H or a C—D bond in 
the formyl group of the substrate. Again, the —NCD3 group 
reports on the metabolism of OHCNHCD3 and the —NCH3 
group reports the production of methylamine from 
ODCNHCH3.
The elevations of the activities of the hepatocellular enzymes 
SDH, AST and ALT in the plasma of mice which had received 
NMF or its isotopic analogs (fig. 8 ) indicate that the threshold 
dose of OHCNHCH3 and OHCNHCD3 for hepatotoxicity lies 
between 1 0 0  and 2 0 0  mg kg-1, whereas that of 0 DCNHCH3 is 
markedly higher and falls between 200 and 300 mg kg-1.
Discussion
There is little doubt that the hepatotoxicity of NMF is 
associated with its metabolism (Whitby et al., 1984; Pearson et 
al., 1987). However, the structure of the hepatotoxic metabolite 
has hitherto eluded characterization. We have reported previ­
ously that NMF is metabolized (inter alia) to methylamine and 
N-acetyl-S-(N-methylcarbamoyl)cysteine (Kestell et al., 1985b, 
1986b). In this paper, the excretion of S-(N-methylcarba- 
moyDglutathione as a biliary metabolite of NMF is demon­
strated unambiguously. That the “NMF” moiety is linked 
through the formyl carbon to glutathione was shown by the 
complete loss of deuterium from ODCNHCH3  during metabolic 
conjugation. Thus, the S-substitution is the same as that in the 
mercapturic acid derived from NMF and consequently it would 
appear that the glutathione conjugate characterized here is a 
metabolic precursor of the latter urinary conjugate in vivo (fig.
9).
In order to assess the importance of the metabolic cleavage 
of the formyl carbon-hydrogen bond on the metabolism and 
toxicity of NMF, the effect of replacement of C—H by C—D 
was studied. Carbon-deuterium bonds have a higher activation 
energy for cleavage than do carbon-hydrogen bonds, owing to 
the lower zero-point energy of the former (Alder et al., 1971). 
If a carbon-hydrogen bond is cleaved during the rate-determin­
ing step of a multistep process, then substitution of deuterium 
for hydrogen will have the effect of slowing the rate of formation 
of all products (metabolites) downstream of this step. The 
formation of the glutathione conjugate of NMF was found to 
be subject to such an apparent intermolecular primary kinetic 
deuterium isotope effect in that it was slowed by a factor of 7 
± 2 when hydrogen in the formyl group of NMF was replaced 
by deuterium. A similarly significant kinetic isotope effect was 
observed for the formation of the mercapturic acid. These 
results confirm that both the S-substituted glutathione and the 
mercapturic acid lie downstream of the rate-limiting step in 
this metabolic pathway. Also implied is the conclusion that the 
formyl C—H bond is broken in this step. Interestingly, the 
formation of urinary methylamine is subject to an apparent 
kinetic isotope effect of the same magnitude when formyl-H is 
replaced by formyl-D in the substrate NMF. Hence, this amine 
is not the product of any biological hydrolysis of NMF as such














Fig. 7. Example of a Cl mass spectrum of the methyl esters of N-acetyl-S-(N-methylcarbamoyl)cysteine isolated from the urine of mice which had 
received a 50:50 mixture of ODCNHCH3 and OHCNHCD3.
reactions necessarily would not involve cleavage of this formyl 
C—H bond and thus an hepatic formamidase similar to that 
reported by Shinohara and Ishiguro (1979) or to the bacterial 
N,N-dimethylformamidase described by Schar et al. (1986) is 
not involved in the metabolism of NMF. Therefore we propose 
that, in the metabolic sequence, NMF is first oxidized at the 
formyl group to give a short-lived reactive intermediate in 
which the formyl-H bond has already been broken (represented 
as ? in fig. 9) and that this compound is conjugated with 
glutathione either chemically or catalytically by a glutathione 
S-transferase. It is, of course, possible that the oxidation and 
conjugation steps are concerted, Le., that glutathione is a co- 
factor of the oxidizing enzyme and that there is no discrete 
intermediate (?). This glutathione conjugate would then be 
converted to the mercapturic acid in the usual way, presumably 
through the intermediacy of the cysteinylglycine and cysteine 
conjugates which are, as yet, undetected. The facile base- 
catalyzed chemical hydrolysis in vivo of any or all of these 
metabolites, including the postulated initial reactive interme­
diate, may well be responsible for the generation of the meth­
ylamine, as shown in figure 9. The 1 4C0 2  which is a metabolite 
of OH1 4CNHCH3 (Kestell et al., 1985b) would be, in part, the 
by-product of this hydrolysis.
The observation and mechanistic significance of primary 
kinetic deuterium isotope effects occurring in biological systems 
has been recently reviewed briefly by Van Langenhove (1986) 
and, more extensively, by Pohl and Gillette (1985) and by 
Foster (1985). It has been shown that the intermolecular kinetic 
isotope effects on the oxidative demethylation catalyzed by 
cytochrome P-450, in rodent microsomes, of several substrates 
is low, with kH/kD frequently equal to unity (Miwa et al., 1980). 
The corresponding intramolecular kinetic isotope effects (rep­
resenting more closely the intrinsic effect) have been reported
to lie in the range kH/k D = 1.45 to 3.9 (Miwa et al., 1980; 
Hjelmeland et al., 1977; Heimbrook et al., 1984) and the intra­
molecular effect using a model porphyrin system is similar (Nee 
and Bruice, 1982). Whether cytochrome P-450 enzymes can 
catalyze the oxidation of N-formyl groups remains to be estab­
lished. The mechanism of yeast formate dehydrogenase has 
been shown to involve hydride transfer from formate ion to 
NAD"' in a process which is subject to a (necessarily intermo­
lecular) kinetic deuterium isotope effect (kH/k D = 2.3) on 
replacement of substrate HC02~ by DC02" (Blanchard and 
Cleland, 1980; Hermes et al., 1984). 10-Methylacridinium ion 
has been claimed to be a useful model for this enzymic reaction 
in that it also oxidizes formate to carbon dioxide through a 
hydride transfer mechanism with a similar retardation when 
the substrate is deuterated at carbon {kJkD = 2.7) (Hutchins 
et al., 1986). However, NMF was not oxidized by this chemical 
hydride acceptor (M. D. Threadgill, unpublished observations), 
despite the apparent structural similarity of the formamide to 
formate. In view of the large intermolecular deuterium kinetic 
isotope effects demonstrated for the metabolism of NMF, it is 
unlikely that cytochrome P-450-containing enzymes catalyze 
the oxidation of the N-formyl group, although an isoenzyme 
not examined in previous kinetic isotope effect studies may be 
involved. Conversely, it may be that NMF is metabolized by 
another enzyme system related to formate dehydrogenase, such 
as monoamine oxidase or xanthine oxidase. The results of 
studies in vitro to determine the enzyme responsible for this 
oxidation will be presented later.
Primary kinetic isotope effects on toxicity also have been 
described. Deuterochloroform (CDC13) was reported to be some 
50 to 70% less cytotoxic in rodents than protiochloroform 
(CHCI3 ) (Branchflower et al., 1984), indicating that metabolic 
cleavage of the carbon-hydrogen bond is involved in the for-
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Fig. 8. Activities of SDH, AST and ALT in the plasma of mice 24 hr after 
doses of OHCNHCH3i OHCNHCD3 or ODCHNCH3. Values are the mean 
±  SO. Significantly different from control at P <  .005 (*) and P <  .002 
(**) (Mann-Whitney U Test). Significantly different from results from mice 
receiving 200 mg kg”’ OHCNHCH3 at P <  .005 (f) and P <  .002 (tt)-
mation of the ultimate toxic derivative. Conversely, tetradeu- 
tero-l,2 -dibromoethane (BrCD2 CD2 Br) has been shown to be 
more genotoxic than the protio analog (BrCH2 CH2 Br) (White 
e t al., 1983), showing retardation of a competing detoxification 
pathway. In the present study, we have shown that the hepa­
totoxicity of NMF is reduced upon deuteration of the NMF in 
the formyl group. No such effect was in evidence for the 
trideuteromethyl analog. There appears to be a relationship 
between the hepatotoxicity of formamides and the metabolic 
generation of the corresponding N-acetyl-S-(N-alkylcarba- 
moyDcysteine (Kestell e t al., 1987). These two pieces of evi­
dence suggest strongly that either a S-(N-methylcarba- 
moyl)peptide or amino-acid metabolite or the (as yet) unknown 
reactive intermediate arising from oxidation of the formyl group 
of NMF (possibly methyl isocyanate) may be the hepatotoxic 
entity. It is unlikely that methylamine is responsible for the 
damage to the liver, inasmuch as this amine is present in 
untreated animals, albeit in small amounts. Further pharma­
cological studies will show whether replacement of the formyl 
hydrogen by deuterium will lead to loss of antineoplastic po­
tency similar to the diminution of hepatotoxicity caused by 
ODCNHCH3 .
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Fig. 9. Proposed pathway for the metabolism of NMF in mice.
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SUMMARY
The specific activity of the enzyme serine hydroxymethyltransferase (EC 
2.1.2.1) was determined in various murine, ra t and human tumour cell lines. 
The activities of the enzyme were also investigated in tissues of non-tumour 
bearing DBA/2 mice and BALB/c mice bearing the PC6 ascites tumour. The 
highest enzyme activity in the murine tissues was found in the liver and 
then the kidneys. The enzyme was present in all the tissues assayed. The 
activities of enzyme found in the tumours varied considerably, with the PC6 
ascites, Walker 256 and Lewis lung cells, being the highest.
INTRODUCTION
The enzyme serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) cataly­
ses the interconversion of L-serine and glycine, in the presence of dl-L- 
tetrahydrofolic acid (FH4), generating a one carbon unit in the form of 
N5,N10-methylenetetrahydrofolate (CH2-FH 4). This one carbon unit may be 
used for the biosynthesis of purines, pyrimidines and, as Ns-methyltetrahy- 
drofolate, methionine [7]. SHMT has been found in several tumour cells [9]. 
Recently Snell and Weber have investigated the enzymes of L-serine meta­
bolism in rat hepatomas [10]. Unlike the other enzymes of L-serine 
catabolism, only SHMT was present in the hepatomas. They suggest 
that this imbalance of enzymes is due to L-serine being biosynthesised pref­
erentially for formation of nucleosides in the tumour cells. This has been
* Present address: D ivision  o f  P hysica l B iochem istry , N a tio n a l In stitu te  for M edical Research, 
T he Ridgeway, M ill H ill. London NW7 1AA, U .K .
A ddress correspondence to: S au l J .B . Tendler.
0304-3835/87/$03.50 .<* 1987 E lsev ier Scien tific  P ub lishers Ireland Ltd.
Published and Printed in Ireland
66
confirmed by Burkin and Draudin-Krylenko who found a relationship be­
tween the activities of SHMT in Friend mouse leukaemia and Pliss’ rat 
lymphosarcoma with the rate of development of the tumour [1]. These re­
sults suggest that SHMT may be a good target for cancer chemotherapy.
In an attempt to determine whether the activities of enzyme found in vari­
ous tumour cells are elevated when compared to normal cells and whether 
the enzyme activity can be related to the tumour type, the activity of SHMT 
in various malignant and normal tissues has been investigated.
MATERIALS AND METHODS
All reagents were of Analar grade and were purchased from BDH Chemi­
cals (Atherstone, Warwickshire, U.K.) or Sigma (Poole, Dorset, U.K.). L-[3- 
l4C] Serine (53 mCi mmol" l) was obtained from Amersham International 
(Amersham, Buckinghamshire, U.K.). Ascites tumours were removed from 
the peritoneal cavity of mice or rats, washed with 0.9% sodium chloride and 
resuspended in erythrocyte cell lysis buffer (ammonium chloride 7.5 g l-1 in 
0.16 M Tris-HCl pH 7.2). The suspension was sedimented at 2000 x g  for 
10 min, washed twice with 0.9% sodium chloride, and the cells were dis­
rupted as below. Internal organs and solid tumours were freshly removed, 
homogenised and treated as for ascitic fluid. Murine bone marrow was re­
moved by the method of Oliver and Goldstein [5].
The cells were disrupted in a minimum volume of 100 mM Tris-HCl buffer 
at pH 7.1 at 10 kHz for 3 x 10 s using a MSE sonic oscillator. The suspen­
sion was sedimented at 3000 x g for 1 h and the pellet was discarded. The 
SHMT activity was assayed using the method of Taylor and Weissbach us­
ing L-[3-l4C] serine as the substrate for the enzyme and measuring the rate of 
formation of [14C] formaldehyde. The number of counts per minute was 
recorded on a Beckman LS-230 scintillation counter. Protein was deter­
mined by the method of Lowry et al [4], using bovine serum albumin as 
standard.
The TLX5 lymphoma and PC6 plasmacytoma ascitic fluid were obtained 
from CBA and BALB/c mice respectively, supplied by Mr. D. Chubb, Aston 
University. The Lewis lung carcinoma solid tumour was obtained from 
C57BL/6 mice, the Walker 256 ascites and solid tumour were obtained from 
Wistar rats, and the sarcoma 180 solid tumour was obtained from CRH 
mice, all supplied by Dr. R. Fenton, Glaxo Group Research, Greenford, U.K. 
HT29 human colon carcinoma cells and Colon 26 cells were obtained from 
Dr. A. Baxter, Glaxo Group Research. The murine L1210 leukaemia cells 
derive from Flow Laboratories and the L1210 MTX, originally obtained from 
Flow Laboratories, were made resistant to methotrexate. 0 6-Alkyl- 
(methyl)guanine-DNA-methyltransferase (0 6-MeGMT) proficient and defi­
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Fig. 1 . The relative rate of formation of [ UC] formaldehyde by tumour cells.
RESULTS
The production of [14C] formaldehyde from l-[3-14C]serine proceeded lin­
early for 20 min, with enzyme concentrations up to G»3'mg of protein per in­
cubation. The SHMT activity for the tum our cells investigated was 
determined by m easuring the ra te  of form ation of [ 14C] formaldehyde over a 
20-min period. Enzyme activity of the tissues was measured by determ ining 
the quantity  of [ 14C] formaldehyde produced during a 10-min incubation. Du­
plicate determ inations agreed w ithin 5%.
The relative rates of formation of [ l4C] formaldehyde by tum our cells is 
presented in the form of a histogram  in Fig. 1 (th e  enzyme activity  is the 
linear regressed value for nmole [ 14C] formaldehyde per mg protein in 
10 min). The levels of SHMT activ ity  for the different tissues of non-tumour- 
bearing DBA/2 and of BALB/c (bearing PC6 ascites) mice are shown in the 
form of histograms in Fig. 2.
DISCUSSION
SHMT is present in all of the tum our cells assayed in this study. Sim ilar 
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Fig. 2. The relative rate of formation of [ MC] formaldehyde by murine tissues.
exception of the PC6 ascites. W alker 256 and Lewis lung cells, which have 
elevated levels of activity. L ittle difference in activity was observed from 
the m ethotrexate-sensitive and -resistant L1210 cell lines. The presence or 
absence of 0 6-MeGMT also does no t appear to influence the activity  of the 
enzyme.
The activity of SHMT found in the different organs of the BALB/c bear­
ing PC6 ascites and the non-tum our-bearing DBA/2 mice are sim ilar to 
those previously reported [8,13]. The highest activities of the enzyme are 
found in the liver, followed by the kidneys. SHMT was found to be present 
in all the tissues assayed. The levels of activity of SHMT found in the 
m urine liver appears to be higher th an  the levels found in many of the tu ­
mour cells assayed, whereas the o th er murine tissues have levels compara­
ble to the majority of the tum our cell lines. The high activ ity  of SHMT in 
the kidneys is to be expected as the ra t kidney has been shown to have sig­
nificant levels of the enzyme in the proximal segment of the nephron [3], 
allowing the independent synthesis of L-serine from glycine [ 6].
No strong trend could be observed in the levels of activ ity  of SHMT in 
the cell types surveyed. However, the presence of enzyme activ ity  in all the 
tum our cell lines, together with the role of the enzyme in supplying C, units 
for biosynthesis of nucleosides during, for example, cell proliferation, sug­
gests th a t SHMT mav be an apposite target for anticancer therapy. The
69
results of a programme of synthesis and evaluation of compounds designed 
to inhibit SHMT will be reported elsewhere [12].
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Structural S tud ies on Bio-active Compounds. Part 6.1 Determination of the 
Sites of Protonation on Three 2,4-Diaminopyrimidines of Pharmaceutical 
Im portance by Proton-coupled 13C and 1H Nuclear Magnetic Resonance 
Spectroscopy
Michael D. Threadgill,* Roger J. Griffin, Malcolm F. G. Stevens, and Sang K. Wong
Pharmaceutical Sciences Institute. Department of Pharmaceutical Sciences. Aston University. Aston 
Triangle. Birmingham B4 7ET
The protonation of three 2,4-diaminopyrimidines of interest as antitumour agents has been studied by 
proton-coupled 13C n.m.r. and by 7H n.m.r. spectroscopy in solution in dimethyl sulphoxide. Assignment 
of 13C resonances was achieved through chemical-shift considerations and through 13C-’H coupling 
patterns, supported in one case by a DEPT experiment and by heteronuclear decoupling by selective 
irradiation in the proton spectrum. In each case, first protonation occurs at pyrimidine N-1 with the 
second, much weaker, basic site of 2,4-diamino-5-(3-amino-4-chlorophenyl)-6-ethylpyrimidine being 
at the aniline amino group. The observations are consistent with current hypotheses of structural 
requirements for inhibitory activity against dihydrofolate reductase.
The 2,4-diaminopyrimidines, and particularly 2,4-diamino-5- 
(4-chlorophenyl)-6-ethylpyrimidine (pyrimethamine) (1), are 
important in the control of infectious disease through their 
potent inhibition of dihydrofolate reductase (DHFR).2 
Inhibition of the corresponding mammalian enzyme with the 
folate analogue methotrexate has also proved a successful 
strategy in the chemotherapy of neoplastic disease.3 Recently,
2.4-diamino-5-(3-azido-4-chlorophenyl)-6-ethylpyrimidine 
(MZP) (2) has entered clinical trial as an antitumour agent as its 
monoethanesulphonate salt (MZPES). Protonation at the ring 
nitrogen N-1 at physiological pH (pH 7.4) has been suggested to 
be of considerable importance in the inhibitory binding of 2,4- 
diaminopyrimidines to the active site of DHFR,*-5 although the 
site of protonation of the pyrimidines in solution has hitherto 
been inferred from solid-state crystallographic techniques.6 It 
was therefore of interest to determine the sites of protonation of
2.4-diaminopyrimidines in solution through study of the l3C 
n.m.r. spectra of these compounds in protonated and unproton- 
ated forms.
The pyrimidines studied were two compounds of therapeutic 
importance (1) and (2) and 2,4-diamino-5-(3-amino-4-chloro- 
phenyl)-6-ethylpyrimidine (3) which is a metabolite, photo­
product, and thermal degradation product7 of compound (2). 
Chemical-shift data from l3C n.m.r. experiments are potentially 
more useful than ‘H data for this study owing to the lack of 
protons bonded directly to pyrimidine ring carbons. Thus, lH 
n.m.r. spectroscopy can only report protonation of the 
pyrimidine ring at long range in these compounds. Confident 
assignment of the 13C resonances is essential; hence proton- 
coupled 13C spectra were obtained and, in one case, selective 
heteronuclear decoupling was employed. Dimethyl sulphoxide 
(DMSO) was used as spectroscopic solvent in most experi­
ments, owing to the very poor solubility of the free bases of 
compounds (I)— (3) in water.
The proton-coupled |3C n.m.r. spectral data of (I), the 
simplest of the three pyrimidines studied, is listed in Table 1 
(numbering scheme shown in Figure 1). Assignment of the 
resonances corresponding to C-l" and C-2", the carbon atoms 
of the ethyl group attached to C-6 of the pyrimidine, was carried 
out in a straightforward manner from chemical-shift consider­
ations with C -T  resonating at 8 27.32 and C-2" at 5 13.76. 
Confirmation was achieved by consideration of carbon-proton 
coupling. The signal from C-l" is found to be a triplet of 
quartets with a one bond C-H coupling constant ( 'J  126.7
5'
Figure I. Numbering scheme for carbon atoms in pyrimidines (1: 
R = H). (2: R = N ,). and (3; R =  N H 2) and in ethanesulphonatc 
anion
Hz) typical for an sp3-hybridised carbon atom; the two-bond 
coupling constant corresponding to coupling of the methyl 
protons with C -l' (2J  4.5 Hz) is also consistent with 
reported values for related systems.* The lJ  and 2J  values 
for the quartet of triplets from the methyl carbon (C-2") are 
very similar to those of C-l".
Assignment of the 13C resonances from the benzene ring of (1) 
was carried out in the opposite order, i.e. consideration of 
multiplicity allowed the four resonances between 5 110 and 5 
145 (the usual aromatic range) to be separated into groups of 
tertiary carbons (with coupling >  150 Hz) and quaternary 
carbon (all C-H coupling <  10 Hz). Careful comparison of 
chemical shifts with accepted typical values* then enabled 
individual assignment of l3C resonances as in Table 1. The one- 
bond C-H coupling constants ( lJ  161.0 and 165.4 Hz) 
correspond with the usual values for sp2-hybridised carbon 
atoms. Longer range couplings (2/4 .7  Hz and V  7.5, 7 Hz) are 
also of typical magnitude for an aromatic ring, although 
2J c - 2 \ i  - h  7.1 Hz is unusually large* (Figure 2). Little has been 
published on the 13C n.m.r. spectra of 2,4-diaminopyrimidines 
and, as no protons are bonded directly to the carbon atoms of 
the pyrimidine ring in compound (I), use was made of the longer 
range C-H couplings observed. Clearly, the three carbon atoms 
(C-2, -4, and -6) adjacent to ring nitrogens (some bearing amino 
groups) should experience considerable deshielding and the 
resonances of all three appear in the range 5C 162— 167. C-6 Is 
identifiable as giving rise to the resonance at 5C 166.56, the signal 
at lowest field in the spectrum of pyrimethamine (1), which is a 
quartet (V  5 Hz) owing to three-bond C-H  coupling through to 
the exocyclic C-2" methyl protons. C-2 and C-4 are far from 
coupling protons and appear as singlets at 8C 162.06 and 162.19, 
although differentiation between these two is not possible in this
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Table 1 . Proton-coupled ,JC n.m.r. spectral data of pyrimethamine (1 ) in (CD3)2SO
Free base Salt (1 x EtSOjH)
Carbon 8 c Mult. J (Hz)' 8 c Mult. J (Hz)' AS*
2 162.06 s 154.88 s -7.18/
162.19c s -7.31
4 162.06/ s 164.20 s -2.14,
162.19' s + 2 .0 1
5 105.32 m d 107.26 m d + 1.94
6 166.56 q 5 154.58 m d -11.98
1 ' 135.11 t 7.5 133.70 tt 10.8, 3 —1.41
2 /6 ' 132.64 dd 161.0, 7.1 132.63 dd 162.5, 7.0 - 0 . 0 1
3'/5' 128.97 dd 165.4, 4.7 129.56 dd 166.3, 4.4 +0.59
4' 131.87 t 7 130.22 t 8 .1 -1.65
r 27.52 tq 126.7, 4.5 23.66 tq 131.0,4 -3.86
2 " 13.76 qt 126.9, 4.5 12.71 qt 128.8, 4.1 -1.05r 45.37 tq 132.9, 4.6
2 ” 9.79 qt 127.4,4.1
- Coupling constants shown to the nearest integer were estimated graphically, others were taken from the numerical listing generated by the 
spectrometer. *6(1 x EtS03 H) — 6  (free base).' Assignment uncertain between the resonances indicated. “ J < 10 Hz but poorly resolved.
(1)
Figure 2. Illustrative 13C -‘H long-range coupling systems observed 
for the free base of (1) and the monoprotonated form of MZP (2). 
Numbers are coupling constants in Hz. * represents poorly resolved 
coupling with 4 Hz < J < 8  Hz. lJ Couplings are omitted for clarity
spectrum. The C-5 atom, which is not adjacent to nitrogen, gives 
a resonance at 5C 105.32 as a narrow multiplet owing to 3-bond 
C -H  coupling with the protons bonded to C-l", -2', and -6 '.
When the spectrum of the monoethanesulphonate salt of 
compound ( 1 ) was examined, the same methods of assignment 
were used (Table 1 ). In this spectrum, however, not only has the 
coupling from C -l' to 3', 5'-H been increased to 3J  10.8 Hz but 
the usually very small two-bond aromatic coupling between this 
carbon and 2'-, 6 '-H has been resolved (2J  3 Hz). The effects of 
monoprotonation of pyrimethamine ( 1 ) on the chemical shifts 
of pyrimidine ring carbons are profound, with a lesser effect on 
the ethyl group and, as expected owing to the local lack of basic 
centres, absent in the carbocyclic ring. In the pyrimidine moiety, 
C-2 and C - 6  experience large upheld shifts (ca. 7 and ca. 12 
p.p.m. respectively). These shifts are similar in sign and 
magnitude to the changes on protonation in the chemical shifts 
of the ipso carbon atoms of anilines, as recently reported 
by Faure et al:,9 there is also good agreement with the A5 
on protonation observed by Smal et a l.10 using specific 
, 3 C-labelled trimethoprim [2,4-diamino-5-(3,4,5-trimethoxy-
benzyl)pyrimidine]. Thus, it can be inferred that N-1 of the 
pyrimidine has been protonated, since C-2 and C - 6  are both 
directly bonded to this nitrogen. That protonation has occurred 
exclusively at N-1 and not at N-3 is shown by the observation 
that the signal for C-4 does not experience this upfield shift but 
rather moves slightly downfield.
The 13C n.m.r. spectrum of the free base of the other 
therapeutic pyrimidine in the study (2 ) is similar to that of 
pyrimethamine (I), with the only exceptions arising in the 
benzene ring as a result of the additional (azido) substituent at 
C-3' (Table 2). Again, no differentiation is possible between the 
singlet resonances at 5C 162.01 and 162.30 for C-2 and C-4 in the 
free base; similarly, the doublets with 3J  coupling at 8 C 136.86 
and 136.92 are assigned to C -l' and C-3', not necessarily 
respectively. The contribution of the azido group to the ,3C 
chemical shifts in benzene rings has hitherto not been reported 
for many compounds. In this case, comparing spectra of 
compounds (1) and (2), the effects are approximately +  7 p.p.m. 
(ipso carbon; C-3'), —5 p.p.m. (ortho carbons; C-2' and C-4'), 
+  2 p.p.m. (meta carbons; C -l' and C-5'), and —10 p.p.m. (para 
carbon; C-6 '). These general values reflect well the nature of the 
azido group as a pseudohalogen similar to bromine in electronic 
character and steric factors but are at some quantitative 
variance with one report11 for the azido group. When 
protonated by one equivalent of ethanesulphonic acid, the 
carbon chemical shifts in the spectrum of MZP (2) (Table 2) 
change very much as do those of pyrimethamine (1 ), again 
indicating exclusive protonation at N-1. Interestingly, C -l' 
experiences a greater upfield shift (some 5 p.p.m.) upon 
protonation in compound (2) than in the case with (I) (ca. 1.4 
p.p.m.).
The analysis and implications of the I3C n.m.r. spectra of the 
amino analogue (3) are more complex, since a basic site 
attached to the benzene ring can be identified in addition to 
those on the 2,4-diaminopyrimidine moiety. It is not absolutely 
clear, a priori, whether N-1 or the 3'-amino group would be the 
site of first protonation, although comparison of the measured 
p o f  the conjugate acid of pyrimethamine (I) (reported as 
7 .301 and 7.345) with that reported for 2-chloroanilinium ion 
(2.65),12 as model compounds for the constituent parts of the 
amine (3), would tend to predict initial protonation at N-1. N o  
prediction is available to select 3'-N H 2 or N-3 (or, indeed, 
2-N H 2 or 4-N H 2) as the site of the second protonation.
The spectroscopic data for the free base of compound (3) with
J CH EM . SOC. PERK IN  TRANS. I 1987 2231
Table 2. Proton-coupled l iC n.m.r. spectral data of MZP (2) in (CD3)2SO
Free base Salt (1 x EtS03H)
Carbon Sc Mult. J (Hz)* Sc Mult. J (  Hz)' AS*
2 162.01/ s 154.88 s -7 .13/
162.30 ‘ s -7.42
4 162.01/ s 164.05 s + 2.04
162.30 ‘ s + 1.75
5 104.80 m d 106.67 m d + 1.87
6 166.70 m d 154.7* m d - 1 2 . 0
r 136.86/ d 8 . 0 131.77 d 9.1 -5 .09 /
136.92 ‘ d 6 -5 .15
2 ' 128.74 dd 164.2, 7.1 128.41 dd 165.3. 7.2 -0.33
3' 136.86/ d 8 . 0 137.60 d 7.6 + 0.74/
136.92 ‘ d 6 . 0 + 0 . 6 8
4' 1 2 2 . 2 2 m d 124.0' m d - 1 .8
5' 130.86 d 166.6 131.31 d 167.7 +0.45
6 ' 122.75 dd 161.2, 7.4 123.01 dd 162.9, 7.2 +0.26
1 ' 25.27 tq 127.2,4.1 23.70 tq 133.1. d -3 .87
2" 13.17 qt 126.8, 4.8 12.62 qt 128.4. 5.3 -0.55
1 " 45.31 tq 133.3, 4.7
2~ 9.70 qt 127.4, 3.9
‘ Coupling constants shown to the nearest integer were estimated graphically, others were taken from the numerical listing generated by the 
spectrometer. *5(1  x EtS03 H) — S (free base). ‘ Assignment uncertain between the resonances indicated. 4 J < 10 Hz but poorly resolved. 
' Estimated graphically.
Table 3. Proton-coupled 13C n.m.r. spectral data of compound (3) in (CD3)2SO
Free base Salt (1 x EtS03 H)
Carbon 5C Mult. J (Hz)* Sc Mult. J (Hz)' A8 , V
2 161.96/ s 154.92 s -7 .04 /
162.17* s -7.25
4 161.96/ s 164.14 s +  2.18/
162.17‘ s +  1.97
5 106.29 m d 107.96 m + 1.67
6 166.42 q 4.6 154.40 m d - 1 2 . 0 2
r 135.59 d 6 .8 130.62 d 9.0' -4 .97
2 ' 117.28 dm 167.1. d 116.92 dm 157.0/ d -0.31
3' 145.04 d 8 . 6 145.42 d 6.0' +0.38
4' 116.65 m d 117.75 m d + 1 . 1 0
5' 129.57 d 162.8 130.03 d 163.4' +  0.46
6 ’ 119.19 dd 170.3. 7.7 118.55 dd 160.3/ 7.2 -0 .64
r 27.60 tq 127.5, 3.9 23.69 tq 131.1. 4 -3.91
2" 13.53 qt 127.1. 5.0 1 2 . 8 8 qt 128.7.4 -0.65
r 45.35 tq 132.4. 4.6
2 " 9.72 qt 128.3.4
“ Coupling constants shown to the nearest integer were estimated graphically, others were taken from the numerical listing generated by the 
spectrometer. * 6  (1 x EtS03 H) — 6  (free base). ‘ Assignment uncertain between the resonances indicated. “ J < 10 Hz but poorly resolved. 
‘ Decoupled by irradiation of proton resonance centred at 5„ 7.273 (5'-H). '  J reduced by ca. 10 Hz by irradiation as in (e).
one equivalent of ethanesulphonic acid are given in Table 3. In 
the case o f the spectrum of the free base, initial assignments were 
confirmed by a *H broadband-decoupled DEPT experiment; C- 
2', -5', -6 ', and -2" appearing as positive peaks, C-l" as a negative 
peak, and the remaining (quaternary) carbons giving no signal. 
Supporting evidence for assignment of the spectrum of the 
monoethanesulphonate came from selective heteronuclear 
decoupling. Irradiation at the centre o f the 5'-H signal (SH 7.273) 
in the proton spectrum removed the two three-bond couplings 
of this proton ( V  9.9 Hz to C -l' and 3J  6.0 Hz to C-3 ) and, 
surprisingly in view of the low decoupler power involved, 
removed the * / 163.4 Hz coupling to C-5'. Accidental 
irradiation of the two other aromatic protons was negligible, 
resulting only in slight reductions in the magnitudes of lJ  for 
C-2' and C-6 '. Yet again, the C-2 and C-4 resonances occur as
two very close singlets (6 C 161.96 and 162.17) in the free base. 
The changes in chemical shift, in the presence of one equivalent 
of acid, for compound (3) parallel closely those observed for 
M ZP (2) and also correlate well with the AS for protonation 
of pyrimethamine (1). Hence, it can be deduced that the initial 
protonation of the amine (3) occurs exclusively at N-1. 
However, when the experiment was carried out in the presence 
of two equivalents of ethanesulphonic acid, i.e. when the 
crystalline bis(ethanesulphonate) sa lt1 of compound (3) is 
dissolved in DMSO, the resulting l3C n.m.r. spectrum (Table 4) 
shows only minor to moderate differences from that of the 
monoethanesulphonate. The maximum deviation in chemical 
shift o f pyrimidine and 6 -ethyl carbons betwen the 1 x E tS 0 3H 
and 2 x E tS 0 3H spectra is merely 0.23 p.p.m.. showing that no 
change in protonation status has occurred in the pyrimidine
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Table 4. Proton-coupled 13C n.m.r. spectral data of compound (3) in (CD,),SO
Salt (2 x EtSO,H)
Free base ,--------------- -------------------,





- 0 . 1 0
4 161.96/
162.17'
164.15 s + 2.19/ 
+ 1.98
+ 0 . 0 1
5 106.29 107.73 m d + 1.44 1 O to
6 166.42 154.29 m d -12.13 - 0 . 1 1
1 ' 135.59 130.69 d 8 . 6 -4.90 +0.07
2 ' 117.28 118.63 dd 160.5, 5 + 1.35 + 1 .6 6
3' 145.04 143.06 m d + 1.98 -2.36
4' 116.65 119.35 m d + 2.70 + 1.60
5' 129.57 130.27 d 164.4 +0.70 + 0.24
6 ' 119.19 118.55 dd 169.7, 5 + 1.53 + 2.17
r 27.60 23.60 tq 132.7, d -4.00 -0.09
2" 13.53 12.79 qt 127.0, 5.0 -0.74 -0.09
1 " 45.38 tq 128.8, 4.6 +0.03
2 ” 9.54 qt 128.2, 4.2 -0.18
* Coupling constants shown to the nearest integer were estimated graphically, others were taken from the numerical listing generated by the 
spectrometer. * AS2_o'. 8  ( 2  x EtSO,H salt) — 5 (free base), A52_,: 8(2 x EtSO,H salt) -  5(1 x EtSO,H salt). ' Assignment uncertain between 
the resonances indicated. d J < 10 Hz but poorly resolved.
Table 5. Proton-coupled ,3C n.m.r. spectral data of compound (3) in CF3C 0 2D compared with that of free base in (CD3)2SO
MZP (2) CF3C 0 2D
Free base ----------- A----------
Carbon 5C 5C Mult. J (Hz)* A5tFad_o6 A5tfad-i b
2 161.96/ 152.12 s -9.84/ -2.80
162.17' -10.05
4 161.96/ 160.08 s - 1.8 8 / -4.06
162.17' -2.09
5 106.29 107.36 m d + 1.07 -0.60
6 166.42 159.76 m d - 6 . 6 6 + 5.36
r 135.59 127.90/ m d -7.69/ — 2.72/
128.43' br d 8 . 0 -7 .16 -2.19
2’ 117.28 127.25 dd 164.0. 8.0 +10.67 +10.98
3' 145.04 127.90/ m d -17.14/ -17.52/
128.43' br d 8 . 0 -16.61 -16.99
4' 116.65 131.80 m d + 15.15 +14.05
5' 129.57 133.72 d 171.9 +4.15 + 3.69
6 ' 119.19 134.24 dd 165.6. 7.4 + 15.05 + 15.69
r 27.60 24.78 tq 1315, 5.0 -2.82 + 1.09
2 " 13.53 10.55 qt 130.6, 5.1 -2.98 -2.33
* Coupling constants shown to the nearest integer were estimated graphically, others were taken from the numerical listing generated by the 
spectrometer. * A8 XFad_0: 5(CF3C 0 2 D) -  6  [free base/(CD,)2SO]. A8 TFad.,: S(CF3C 0 2 D) -  [1 x EtSO,H salt/(CD3 )2SO]. 'Assignment 
uncertain between the resonances indicated. * J <  10 Hz but poorly resolved.
ring. Changes in chemical shift of the benzene ring carbons vary 
from —2.36 p.p.m. for C-3' to +2 .17  p.p.m. for C-6 '. Con­
sideration of the signs and relative magnitudes of these A8 2_,, 
shown in Table 4, and comparison with reported shifts on 
protonation of aniline in DM SO solution suggest that a small 
amount of protonation remains at the 3'-N H 2 in solution in an 
equilibrium which is rapid on the n.m.r. time-scale. When the 
changes in chemical shift observed here on partial protonation 
of the 3'-NH 2 ( — 2.36 p.p.m. for the ipso C-3', +1.66 p.p.m. for 
the ortho carbons, +0.07 and +0 .24  p.p.m. for the meta 
carbons, and +2 .17  p.p.m. for the para  carbon) are compared 
with those reported 9  for full protonation of aniline in the same 
solvent {ipso — 16.7 p.p.m., ortho +  9.4 p.p.m., meta +  1.0 p.p.m., 
and para +12.3 p.p.m.), it can be inferred that the 3'-amino 
group is ca. 16% protonated. Hence, the 3'-ammonium function 
which is present in the solid state dissociates to the extent of ca. 
84% upon dissolution in DMSO.
Since compound (3) is largely only monoprotonated in the
presence of two equivalents of ethanesulphonic acid, it was 
necessary to make use of much higher acid concentrations to 
examine the spectra of multiprotonated species from compound 
(3). The proton-coupled 13C n.m.r. spectral data of amine (3) in 
neat deuteriotrifluoroacetic acid are listed in Table 5. This 
spectrum, although slightly less well resolved than the others, is 
still capable of full assignment except that the resonances for C- 
1 ' and C-3' could not be distinguished between signals at 8 C 
127.90 and 128.43. Clearly, the 3'-amino group is fully ionised in 
this medium and corresponding characteristic chemical-shift 
differences between the spectrum of the free base o f (3) in 
DM SO  (and, incidentally, the monoethanesulphonate) and that 
in C F jC 0 2D solution are observed. The A8 tfad_, values for the 
benzene-ring protons are: ipso carbon (C-3') ca. —17 p.p.m., 
ortho carbon (C-2') +  10.98 p.p.m., ortho carbon (C-4') +  14.05 
p.p.m., meta  carbon (C -l') ca. — 2.5 p.p.m., meta carbon (C-5') 
+  3.69 p.p.m., para carbon (C-6 ') +  15.69 p.p.m. These data are 
in good agreement with the changes in chemical shift on
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Table 6. 1H N.m r. spectral data of compound (3) cihancsuiphonatc salts in (CD3)2SO. Only C-H signals arc shown
Salt (I x EtSOjH) Salt (2 x EtSQ3H)
Proton Oil Mult. J (Hz) o„ Mult. y(Hz)
2-H 6.65 d 2.0 6.69 d 2.0
S'-H 7.27 d 8.1 7.32 d 8.1
6-H 6.40 dd 8.1. 2.0 6.47 dd 8.1. 2.0
r - H , 2.23 br q 7.6 2.22 br q 7.6
2--h ; 1.05 br t 7.6 1.04 t 7.6
i ~-h 2 2.57 q 7.4 2.53 q 7.4
2”-H3 1.12 t 7.4 1.09 t 7.4
Table 7. ‘H N.m.r. spectral data of compound (3) in (CD3)2SO and in CF3C 0 2D. Only C-H signals are shown





r -H , 2.18 q
2'-H 3 1.00 t
° Estimated graphically.
J (Hz) &H Mult. J (Hz)
1.5 7.84 br d 1.5*
8.0 7.93 d 8.3
8.0, 1.5 7.61 dd 8.3. 1.5
7.5 2.60 q 7.5
7.5 1.29 t 7.5
protonation of aniline reported9 by Faure et al. (see above), 
subject to the effects of change of solvent (predicted to be <  3 
p.p.m . ) . 9  Examination of the resonances from the pyrimidine 
carbons in C F 3 C 0 2D (Table 5) and comparison with the mono- 
(N-l)-protonated species shows some additional protonation 
on this heterocycle or its amino substituents. More detailed 
examination of chemical-shift differences between amine (3) in 
its monoprotonated form in DMSO and in trifluoroacetic 
acid (TFA) shows upheld shifts for C-2 and C-4 and a downfield 
shift for C - 6  (Table 5), indicative of protonation at N-3. The 
magnitudes of the AS values involved, when compared with the 
magnitudes o f the effects o f protonation at N -1. suggest however 
that this protonation is incomplete even in this highly acidic 
medium.
Proton n.m.r. spectra were also recorded for the solutions of 
amine (3) and acids as detailed above for the 13C n.m.r. spectra; 
the data are recorded in Tables 6  and 7. The resonances for the 
C -H  protons are very similar in the spectra of amine in DMSO  
in the presence of 0 , 1 , and 2  equiv. of ethanesulphonic acid, 
confirming that only slight protonation of the 3'-NH 2 group 
occurs under these conditions. In neat TFA. full protonation at 
3'-N H 2 is reported by downfield shifts of ca. 1.1 p.p.rt. for 2'-H 
and 6 '-H (ortho and para  respectively to the amino group) and 
of 0.66 p.p.m. for 5'-H {meta).
In conclusion, it can be seen from the above data that the first 
protonation of all three 2,4-diaminopyrimidines studied takes 
place on N -l in D M SO  solution, as predicted by X-rzy  
crystallographic work . 6  This protonation is complete in the 
presence of only I equiv. of ethanesulphonic acid, indicating a 
relatively high basicity o f N -l in these molecules, which is 
consistent with values for the overall values of p o f  the 
conjugate acids determined by conventional techniques [7.3 for
( l ) , 1 - 5 7.2 for (2 ) , 1 and 7.5 for (3 )13]. The second protonation of 
amine (3) has been shown to take place extensively only at very 
high acid strengths and then at 3 -NH,. This conclusion allows 
the rationalisation of the observation that amine (3) is an 
inhibitor of DH FR [although weaker than ( 1 ) or (2)] 1 according 
to the classical requirements for protonation at N -l, but at no 
other sites, at physiological pH for binding to the active site of 
the enzyme.
Experimental
Spectroscopy.— N.m.r. spectra were obtained at 100.8 MHz 
( 1 3 C) and at 400 MHz ( 1 H) with a Bruker WH400 spectrometer. 
l3C Spectra were recorded at natural abundance without 
decoupling from protons except that selective irradiation of the 
proton resonance at SH 7.273 was used in one l3C experiment 
using the monoethanesulphonate of compound (3) in order to 
confirm assignment of certain ,3C resonances. All chemical 
shifts are referenced to tetramethylsilane as interna! standard. 
Spectra were recorded at 300 ± 2  K at ca. 10?; w/v 
concentration.
M aterials.— Pyrimethamine (1) was a kind gift of The 
Wellcome Foundation Ltd., Dartford, Kent. The amino 
analogue (3) was prepared by nitration (H N 0 3 -H 2S 0 J  and 
subsequent reduction (SnCl2) of compound ( 1 ); diazotisation 
(aq. H C I-N a N 0 2) and treatment with sodium azide furnished 
the free base of compound (2) as previously reported. 1 The 
crystalline monoethanesulphonate salts of compounds ( 1 ) and
(2) and bis(ethanesulphonate) salt of compound (3) were 
prepared by treatment of the free bases with aqueous 
ethanesulphonic acid followed by recrystallisation. 1 The 
spectroscopic sample for the monoethanesulphonate salt of 
compound (3 ) was prepared by dissolution of equimolar 
amounts of compound (3 ) (free base) and ethanesulphonic acid 
in (C D 3 )2 SO: correct proportions were checked by integration 
of the proton n.m.r. spectrum.
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Structural S tu d ies on B ioactive Com pounds. Part 7 .1 The D esign and 
S yn th esis o f a-S u b stitu ted  Serines as Prospective Inhibitors o f Serine  
H ydroxym ethyltransf erase
S aul J .  B. T e n d le r ,t  M ich ae l D. T hreadgill,*  and  M ichae l J . T isda le
Pharmaceutical Sciences Institute. Department of Pharmaceutical Sciences. Aston University. 
Birmingham B4 7ET
A short series of a-substituted analogues of serine, designed as enzyme-activated, irreversible inhibitors 
of serine hydroxymethyltransferase, has been prepared. (± )-a-A lly l- and (± )-a-prop-2-ynyl-serine 
were synthesised by appropriate alkylation of the anion derived from ethyl acetamidocyanoacetate, 
followed by selective reduction of the ester function and hydrolysis of protecting groups. 
Acetoxymethylation of the anion derived from methyl 2-(benzylideneam ino)but-2-enoate gave (± ) -a -  
vinylserine after deprotection. These novel analogues of serine were largely inactive as inhibitors of the 
enzyme, except that ( ±  )-a-vinylserine showed weak competitive inhibition.
Serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) catalyses 
the conversion of L -serine  (4) to g ly c in e  (5) in the presence of 
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the form of Af5,W 10-methylenetetrahydrofolate (FH4-CH2) 
(2).2 This one-carbon unit may then be used either for the 
biosynthesis of purines and pyrimidines or for other anabolic 
processes. The enzyme is a tetramer with each subunit having a 
coenzyme, pyridoxal phosphate (PLP) (3).3 The enzyme SHMT 
appears to have an essential role in rapidly proliferating tumour 
cells which have a high requirement for L-serine.1* In these cells, 
it has elevated activity in channelling one-carbon units into 
denovo nucleoside synthesis.5 If SHMT could be inhibited, then 
it may be possible to inhibit the growth of these cells as a 
strategy for cancer chemotherapy.
t  Present address: Division of Physical Biochemistry, National 
Institute for Medical Research, Mill Hill, London.
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Scheme 1. Probable mechanism of serine hydroxymethyltransferase: 
i, Transimination; ii, delocalisation of negative charge. R = CHzO- 
POjH "
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L-Serine (4) binds to the active site of the enzyme by 
a transimination reaction, as shown in Scheme 1, and is 
cleaved by a reverse-aldol reaction to a stabilised carbanion. 
Protonation of the carbanion followed by a reversal of the 
initial transimination produces glycine (5) and FH 4 -C H 2 (2). 
D-Fluoroalanine (6 ) (a product analogue) has been shown 6  to
H
H2N ^ ^ C 0 2H
(6 )
be an enzyme-activated irreversible inhibitor o f this enzyme. 
The aim of the present work was to prepare a more effective 
inhibitor of this type. a-Vinylserine (7) was designed as an 
irreversible inhibitor with a proposed mechanism of action, 
shown in Scheme 2, analogous to the mechanism of inhibition of
HO
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Scheme 2. Designed mechanism for the inhibition of serine hydroxy­
methyltransferase by (7): i, binding to the active site of the enzyme: ii, 
reverse aldol reaction; iii, conjugate addition. R = CH20 P 0 3H '
the PLP-dependent enzymes by *,{i-unsaturated amino acids. 
The reverse aldol product (8 ) may be reprotonated at the 
terminal carbon giving an electrophilic a, ()-unsaturated acid (9 ) 
as a soft centre to react with the th io l7 at the active site, 
irreversibly inhibiting the enzyme. a-Vinyl amino acids have 
previously been found to be effective inhibitors o f a range of 
PLP dependent enzymes.® Two other serine analogues, a- 
allylserine ( 1 0 ) and a-prop-2 -ynylserine ( 1 1 ), with unsaturated 
substituents may also be proposed as irreversible inhibitors of 
SHMT. #-(Dichloroacetyl)serine (12) has been reported to be 
an active agent against experimental rodent tumours9 , 1 0  and 
was also evaluated in this study.
HO
H2N3C
C = C H
C 02H




H C 02H 
( 12)
Initial approaches to the introduction of substituents at the a- 
carbon of serine involved the use o f diethyl acetamidomalonate 
(14) as a synthon for the serine a-anion (13) (Scheme 3). In a 
model sequence, the sodium derivative of (14) was cleanly 
alkylated in ethanolic solution using bromoethane to give the 
diester (IS). The maionate (14) also reacted with aqueous 
formaldehyde in the presence o f sodium hydroxide to afford the 
hydroxymethyl compound (16). All attempts to prepare the 
2-bromoethyl compound (17), for possible subsequent elimin­
ation of hydrogen bromide to give a vinyl compound, were 
unsuccessful. Similarly, diethyl acetamidomalonate did not 
react with acetaldehyde to give the 1 -hydroxyethyl derivative
(18). Heyashi has reported 11 the attachment of a vinyl group to 
dimethyl maionate by treatment of the anion of the diester with 
ethylene in the presence of a stoichiometric amount of the 
square planar complex bis(acetonitrile)palladium(n) chloride
(19). The synthetic scope of this potentially useful reaction is 
extended by our observation that ethylene reacts with diethyl 
acetamidosodiomalonate in the presence of (19) to afford the a- 
vinyl compound (20) after work-up in air. This material was, 
however, found to be unstable and thus to be unsuitable for the 
proposed synthetic route to a-vinylserine (7).
One ester group of the model maionate diester (15) was 
hydrolysed selectively with ethanolic potassium hydroxide, to 
give the monoester (21). Selective reduction of either the 
remaining ester or of the carboxylic acid should then give a 
protected a-ethylserine. The selective reduction of the ester 
group in ethyl acetamidocyanoacetate has been reported1 2  to 
be effected by sodium borohydride but this reagent was without 
effect on the substrate (2 1 ), possibly owing to prior ionisation 
o f the carboxylic acid. Likewise, the selective reduction of 
the carboxylic acid of (2 1 ) by sodium borohydride was un­
successful after activation with oxalyl chloride-#,#-dim ethyl- 
formamide. 13
Scheme 4 shows the route employed for the synthesis of (7). 
( ±  )-Threonine (22), a readily available starting material with 
most of the required carbon skeleton, was converted to its 
methyl ester hydrochloride (23) in the usual way by treatment 
with boiling methanolic hydrogen chloride. Elimination of the 
hydroxy group could not be achieved directly, so phosphorus 
pentachloride was used to replace the hydroxy group, giving the
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Scheme 3. Attempted syntheses of a-substituted serines using (14) as a synthon for (13): i. MeCHO-base; ii, BrCH2CH2Br-base; iii, HCHO- 
aq.NaOH; iv, EtBr-NaOEt-EtOH; v, KOH-EtOH; vi, NaH-THF-C2H4-(19); vii, oxalyl chloride-DMF; viii, NaBH*
chloro compound (24) in which azirane formation is suppressed 
by protonation o f the primary amine. Concomitant activation 
of the a-proton and protection was most conveniently effected 
by condensation of (24) with benzaldehyde to give the imine 
(25).
l,5-Diazabicyclo[5.4.0]undec-7-ene (DBU ), a non-nucleo- 
philic bicyclic amidine base, was used to eliminate hydrogen 
chloride to give methyl 2 -(benzylideneamino)but-2 -enoate (26). 
This dehydroamino acid represents the carbon framework for 
the synthesis of a-vinyl substituted amino acids by alkylation 
of the a-carbon. 1 4  The lithiated compound was prepared using 
lithium hexamethyldisilazide and this anion was smoothly 
acetoxymethylated with chloromethyl acetate (27) in the 
presence of hexamethylphosphoric triamide, providing a con­
venient method of introducing a protected hydroxymethyl 
group into the compound. Direct hydroxymethylation with 
formaldehyde was not possible in the non-aqueous environment 
required to prepare the anion; chloromethyl acetate was 
selected as a suitable synthon consistent with the required 
conditions. The chloromethyl acetate (27) had been previously 
prepared from acetyl chloride and paraformaldehyde. 1 5  The 
protecting groups were then removed from (28) in two stages 
by hydrolysis with aqueous acid and the ( ±  )-*-vinylserine (7) 
was isolated after neutralisation with aqueous ammonia.
Selective reductions were, however, employed in the syn­
theses of oc-allyl- and a-prop-2 -ynyl-serine (1 0 ) and (1 1 ), as
shown in Scheme 5. The sodium derivative of ethyl acetamido- 
cyanoacetate (29) reacted sm oothly with allyl bromide to give 
the substituted ethyl pentenoate (30). In this case, reduction 
with the more active lithium borohydride proved to be more 
successful than the attempts using the sodium analogue (vide 
supra). However, the immediate reduction product (31) could 
not be isolated from the resulting borate complexes, so it was 
hydrolysed with 6 M-hydrochloric acid. Neutralisation with 
aqueous ammonia gave a-allylserine ( 1 0 ) in moderate yield. 
Ethyl acetamido(cyano)sodioacetate, prepared in absolute 
ethanol, failed to react with prop-2-ynyl bromide. However, the 
use of toluene, a less solvating solvent, facilitated the alkylation. 
The resulting substituted ethyl pentynoate (32) was then 
similarly reduced with lithium borohydride and the intermediate 
(33) was hydrolysed with 6 M-hydrochloric acid to give a-prop- 
2 -ynylserine (II) after cation exchange column chromatography 
using Dowex 50-X8.
The novel a-substituted serine analogues (7), (10), and (11) 
and the /V-dichloroacetyl compound (12) were initially tested 
against K.562 human erythroid leukaemia total cell SHMT 
using the assay method of Taylor and Weissbach . 1 6  The pro­
duction of [ 1 4 C]formaldehyde from L-[3-l 4 C]serine proceeded 
in a linear manner for 2 0  min, with total protein concentrations 
of up to 0.3 mg protein per 0.2 ml incubation. The activity of 
SHMT for the K.562 total cell enzyme was determined by 
measuring the rate of formation of [ , 4 C]formaldehyde during
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Scheme 4. Synthesis of (7). i. MeOH-HCl; ii, PC1S-C H 2CI2; 
iii. PhCHO-MgS04-CH2CI2-E ti N; iv, DBU-CH2C12; v. 
Li"-N(SiMe3)2- a C H 2OAc (27)-THF-HMPA; vi. aq. HCI
20 min. Duplicate determinations were consistent within 5%. 
All four compounds had little inhibitory effect on the enzyme 
activity, at concentrations of 0.25— 4 mmol I"‘.
To establish whether or not the substituted serines (7), and 
(10)— (12) are effective inhibitors of total cell SHMT. and to 
classify the type of any inhibition, the kinetics of the effects 
of each compound were evalulated. The rate of reaction was 
determined in the presence of serine (0.25— 3 m M ) and the test 
amino acid (2.5— 10 mM ). Only a-vinylserine deviated from the 
control in this assay. Lineweaver-Burk plots (Figure) show  
this compound to be a competitive inhibitor of total K.562 cell 
SHMT (Afj 15.2 mmol I"1). To investigate the effects of the 
a-substituted serine analogues on whole cells, the growth 
inhibitory effects of these compounds against the GM0621 and 
K562 leukaemia cell lines was determined. At concentrations 
< 10 m M , the serine analogues showed no toxicity. The 
activation of the amino acids (7). (10). and (11) as inhibitors 
of SHMT depends on thq capability of the enzyme to accept 
substrate analogues with substituents on the a-carbon of serine. 
While it is known 1 7  that the enzyme will accept (3-subslituted 
serines, the ability of the enzyme to catalyse the removal o f the 
C H 2OH group from a-substituted serines has yet to be fully 
explored. However.it has been reported 18 that L-a-methylserine 
and a-hydroxymethylserine (34) are substrates, although the 
latter, (34). has Km 20 mol l' 1 (the Km for the natural substrate, 
serine, is 4.3 mol I'1). This suggests that the active site o f the
C02Et
AcHN ^ X n  
(2 9 )
/  X
HC =  C — v C02Et 
AcHN
(3 2 )

















Scheme 5. Synthesis of (10) and (11): i. HCCCH2Br-NaH-PhMe; ii. 
H2CCHCH2Br NaOEt EtOH: iii. LiBH*-THF: iv. aq. HCI
30 --
o
2 0 - -
10 -
[Ser in e^  (mM_1)
Figure. Lineweaver-Burk plots for the kinetics of inhibition of serine 
hydroxymethyltransferase by (7). Concentrations of (7): +10: x 5: 
A  2.5 mol I '1; ■  Control (0 mmol I 1)
enzyme should be able to accept a-substituted serines of similar 
steric bulk. The longer chain unsaturated analogues (10) and 
(11) caused no inhibition of the enzyme from the K562 cells.
HO— V s'- OH 
H2 N ^ ^ C 0 2H 
(3 4 )
This may suggest that either these compounds have substituents 
that are too bulky for the enzyme to accept or that removal of 
the (3 -proton by the enzyme, a prerequisite for the activation of
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these compounds as irreversible inhibitors, does not occur. ( ±  )- 
x-Vinylserine was shown to be an inhibitor (Kx 15.2 mol l"1). 
This inhibition was, however, shown to be reversible, in contrast 
to the designed mechanism. The nature of the binding of (7) to 
the enzyme is not clear, although it appears to compete with 
serine for the binding site. Further investigations with partially 
purified enzymes will be conducted to reveal the true nature of 
this interaction.
Experimental
I.r. spectra were recorded on Pye-Unicam SP200 or Perkin- 
Elmer 1310 spectrometer as potassium bromide discs unless 
otherwise stated. l H N.m.r. spectra were recorded at 60 MHz 
using a Varian EM360A spectrometer and at 200 MHz with a 
Bruker AM200 instrument and are referenced to tetramethyl- 
silane as the internal standard. Mass spectra were obtained 
using aV G  Micromass 12B single focussing mass spectrometer 
in the electron-impact mode. M.p.s are uncorrected. Compounds 
are racemic unless otherwise stated.
Ethyl 2-Acetamido-2-(ethoxycarbonyl)but-3-enoate (20).— 
Dry tetrahydrofuran (38.5 ml), containing bis(acetonitriIe)- 
palladium(n) dichloride (19) (500 mg, 1.9 mmol) was saturated 
with ethylene at — 70 °C. Triethylamine (0.54 ml, 3.8 mmol) 
was added, followed after 15 min by diethyl acetamido(sodio)- 
maionate (1.9 mmol) in dry tetrahydrofuran (10 ml). The 
mixture was stirred at — 5 °C for 1 h and warmed to ambient 
temperature during 70 min. After the palladium(o) had been 
removed by filtration, rapid chromatography of the evaporation 
residue (silica gel, ethyl acetate) yielded ethyl 2-acetamido-2- 
(ethoxycarbonyl)but-3-enoate (290 mg, 62%) as an unstable 
colourless oil, vmax 1 520, 1 640, and 1 740 cm-1; 8(CDCI3) 1.25 
(6 H, t, J 7 Hz, CH2Me), 2.10 (3 H, s, COMe),4.30 (4 H, q, J 7 Hz 
C tf2Me), 5.25(1 H ,d ,7  17 Hz, 4-H), 5.30(1 H, d, /1 0  Hz, 4-H), 
6.55 (1 H, dd, J  17, 10 Hz, 3-H), and 7.1 (1 H, s, NH).
Chloromethyl Acetate (27).—Acetyl chloride (25.9 g, 33 
mmol), paraformaldehyde (9.0 g, 33 mmol HCHO) and 
anhydrous zinc chloride (ca. 100 mg) were warmed together to 
50 JC. After a short induction period, the heat of reaction caused 
the solution to boil gently for 3 h. The mixture was filtered 
through basic alumina to give a yellow liquid (33.0 g). N.m.r. 
spectroscopy revealed this to comprise 92% chloromethyl 
acetate and 8% bis(chloromethyl) ether (yield of ester 85%). 
This material was used for later experiments without further 
purification and had v ^  1 760 cm-1; 8(CDC13) 2.10 (3 H. s. 
Me) and 5.60 (2 H, s. CH2). The contaminating ether had 
8(CDC13) 5.55 (s, 2 x CH2).
Methyl 2-Amino-Z-chlorobutanoate Hydrochloride (24).— 
Phosphorus pentachloride (6.35 g, 30 mmol) was added to a 
suspension of threonine methyl ester hydrochloride (23) (5.0 g, 
29 mmol) in dichloromethane (260 ml) during 1 h and the 
resulting solution was stirred at ambient temperature for 3 h 
then cooled to 0 °C for 16 h. The white crystals were collected by 
filtration, washed with diethyl ether and light petroleum (b.p. 
60— 80 'C), and recrystallised from acetonitrile to afford methyl 
2-amino-3-chlorobutanoate hydrochloride (3.7 g, 68%) as white 
crystals, m.p. 169— 171 °C (lit.,19 169— 172 °C), v ^  1 500,
1 600,1 740, and 2 500— 3 000cm-1;8(D 2O) 1.65 (3 H ,d ,/7  Hz, 
4-H3), 3.95 (3 H, s, OMe), 4.60 (1 H, d, J  3 Hz, 2-H), and 4.8 (4 H, 
m, N *H 3 and 3-H).
Methyl 2-(Benzylideneamino)but-2-enoate (26).— Benz-
aldehyde (4.5 g, 44 mmol) was added to a well-stirred slurry of 
methyl 2-amino-3-chlorobutanoate hydrochloride (24) (8.3 g, 
44 mmol) in dichloromethane (80 ml) at 5 °C, followed by
triethylamine (6.15 ml, 44 mmol) and dried magnesium sulphate 
(4.0 g). The resulting suspension was stirred at ambient temper­
ature for 21 h before water (100 ml) was added. The aqueous 
layer was extracted with dichloromethane (3 x 50 ml) and 
the organic solutions were combined, washed with saturated 
aqueous sodium chloride, and dried (MgSO*). Evaporation of 
the solvent under reduced pressure afforded crude methyl 2- 
(benzylideneamino)-3-chlorobutanoate (11.1 g), 8(CDC13) 1.55 
(3 H, d, /  7 Hz, 4-H3), 3.75 (3 H, s, OMe), 4.10 (1 H, d, /  7 Hz, 
2-H), 4.65 (1 H, quintet, J  7 Hz, 3-H), 7.3— 7.9 (5 H, m, ArH), 
and 8.35 (1 H, s, PhCH). l,5-Diazabicyclo[5.4.0]undec-5-ene 
(6.5 ml) was added dropwise during 5 min to the above ester in 
dichloromethane (80 ml) at 5 °C. After 3 h, water (100 ml) was 
added and the organic layer was separated and dried (M gSOJ. 
Evaporation of the solvent under reduced pressure gave an oil 
which, in hexane-diethyl ether (10:1), was filtered through 
neutral alumina (20 g) to give, after evaporation of the solvents, 
methyl 2-(benzyIideneamino)but-2-enoate (8.4 g, 94%) as a 
colourless oil, vmax (liquid film) 1 580, 1 600, 1 640, and 1 715 
cm-1; 8(CDC13) 1.90 [2.1 H, d , / 7  Hz, 4-H3 (£ )], 2.05 [0.9 H, d, 
J  7 Hz, 4-H3 (Z)], 3.70 [2.1 H, s, OMe (£ )], 3.75 [0.9 H, s, OMe 
(Z)], 5.85 [0.3 H, q, 77 Hz, 3-H (Z)], 6.50 [0.7 H, q, /  7 Hz, 3-H 
(£ )], 7.4 (3 H, m) and 7.8 (2 H, m) (Ar-H), 8.25 [0.3 H, s, ArCH  
(Z)], and 8.45 [0.7 H, s, A tC H  (£)]; m/z 203 (M+) and 143 
(100%).
2-Amino-2-(hydroxymethyl)but-3-enoic Acid (a- Vinylserine)
(7).— Lithium hexamethyldisilazide was prepared by the 
addition of butyl-lithium (8.0 ml, 12.3 mmol; 1.55m in hexane) to 
hexamethyldisilazane (2.0 g, 12.3 mmol) in tetrahydrofuran 
(freshly distilled from calcium hydride; 5 ml) at —70 °C under 
nitrogen. Hexamethylphosphoric triamide (7 ml) and methyl 2- 
(benzylideneamino)but-2-enoate (26) (2.3 g, 11.2 mmol) were 
then added, followed by chloromethyl acetate (27) (1.35 g, 12.3 
mmol) in dry tetrahydrofuran (10 ml). The mixture was stirred 
for 1 h at — 70 °C and for 2 h at ambient temperature before 
being diluted with saturated aqueous ammonium chloride and 
extracted with diethyl ether (3 x 50 ml). The combined organic 
extracts were washed with water (2 x 50 ml) and with saturated 
aqueous sodium chloride (20 ml) and dried (MgSO*). Evapor­
ation of the solvent under reduced pressure gave a yellow oil 
which was treated with hydrochloric acid (2m; 40 ml) for 2 min. 
The resulting solution was washed with diethyl ether (2 x 50 
ml) and with chloroform (2 x 50 ml). Hydrochloric acid (6 m ; 
20 ml) was added and the whole was boiled under reflux for 2 h 
before being washed with dichloromethane (2 x 10 ml) and 
treated with activated charcoal (100 mg). The filtered solution 
was concentrated to 10 ml under reduced pressure and 
neutralised by the addition of aqueous ammonia. Hot ethanol 
(25 ml) was added and, upon cooling, white crystals were 
deposited. Recrystallisation of these from aqueous ethanol 
yielded 2-amino-2-(hydroxymethyl)but-3-enoic acid (170 mg,
11.6%) as fine white needles m.p. 173— 175 °C (decomp.) 
(Found: C, 45.5; H, 7.1; N, 10.8. CsH9N 0 3 requires C, 45.8; H, 
6.9; N, 10.7%); Vmax (Nujol) 1 510, 1 590, 1 610, and 1 640 cm-1; 
8(D20 )  3.80 (1 H, d, J  12 Hz) and 4.00 (1 H, d, J  12 Hz) 
(CH2OH), 5.35 (1 H, d, /1 8  Hz, 4-H), 5.44 (1 H, d, J 12 Hz, 4-H), 
and 6.02 (1 H, dd, J  12, 18 Hz, 3-H); m/z 100 (AT -  CH2OH) 
and 54 (100%).
Ethyl2-Acetamido-2-cyanopent-4-enoate (30).—Sodium (1.15 
g, 50 mmol) was dissolved in dry ethanol (30 ml) and ethyl 
acetamidocyanoacetate (29) (8.5 g, 50 mmol) and 3-bromo- 
propene (6.5 g, 50 mmol) were added. The mixture was boiled 
under reflux for 16 h before the solvent was evaporated under 
reduced pressure. The residue was washed with water (30 ml) 
and recrystallised from aqueous ethanol to give ethyl 2- 
acetamido-2-cyanopent-4-enoate (4.1 g, 39%) as a white solid,
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m.p. 83—85 °C (lit.,20 86—88.5 ’C). vm„. 1 515,1 650, and 1 740 
cm -1; 5(CDCIj) 1.35 (3 H. t. /  7 Hz, CH2Me), 2.05 (3 H, s, 
COMe), 2.80 (2 H, d, J  6 Hz, 3-H2). 4.30 (2 H, q, /  7 Hz, 
CH2Me), 5.2— 5.9 (3 H. m,4-H and 5-H2), and 7.5 (1 H, s, NH); 
m /z  211 (M *  +  1) and 95 (100%).
2-Amino-2-(hydroxymethyl)pent-4-enoic Acid (x-allylserine) 
(10).—Lithium borohydride (360 mg, 16 mmol) in dry tetra­
hydrofuran (10 ml) was added dropwise during 5 min to a 
suspension of ethyl 2-acetamido-2-cyanopent-4-enoate (30) (3.5 
g, 16 mmol) in dry tetrahydrofuran (50 ml) and the mixture was 
boiled under reflux for 3 h before being diluted with methanol 
(50 ml) and acidified with hydrochloric acid (6 m ; 2 ml). 
Evaporation o f the solvents under reduced pressure gave a 
yellow gum which, in hydrochloric acid (6 m ; 20 mi), was boiled 
under reflux for 2 h. Evaporation of the solvent and the excess of 
reagent under reduced pressure followed by neutralisation with 
aqueous ammonia gave a white powder from which 2-amino-2- 
(hydroxym ethyl)pent-4-enoic acid  (460 mg, 20%) was isolated 
by recrystallisation from aqueous ethanoL The white crystals 
had m.p. 215— 220 °C (decomp.) (Found: C, 49.6; H, 7.7; N, 9.7. 
C6H , ,N 0 3 requires C, 49.6; H, 7.6; N, 9.6%); vN I 1 510,1 610,
1 640, 2 500—3 200, and 3 450 cm '1; 5(D20 )  2.40 (1 H, dd, J  
14.6,9.3 Hz) and 2.60 (1 H,dd, J  14.6,6.3 Hz)(3-H2), 3.71 (I H, 
dd, J 11.2 Hz) and 3.95 (1 H, dd, J 11.2 Hz) (C //2OH), 5.27 (1 H, 
d, J  112 Hz, 5-H), 5.28 (1 H, d ,J  15.1 Hz, 5-H), and 5.7 (1 H, m, 
4-H); m /z  126 {M + -  CH2OH) and 114 (100%).
Ethyl 2-A celamido-2-cyanopeni-A-ynoale (32).—Ethyl aceta- 
midocyanoacetate (29) (17.0 g, 100 mmol) was added to a 
suspension of sodium hydride (50% in oil; 4.8 g, 100 mmol) in 
dry toluene (100 ml), followed by 3-bromopropyne (70% in 
toluene, 14.8 g, 180 mmol) and the mixture was boiled under 
reflux for 3 h. Ethyl acetate (20 ml) was added, followed by 
water (50 ml) and diethyl ether (50 ml). The combined organic 
solutions were concentrated under reduced pressure and, when 
allowed to stand, deposited light brown crystals. Recrystallis­
ation of these from ethanol-light petroleum (b.p. 60—80 *C) 
furnished ethyl 2-aceiamido-2-cyanopent-A-ynoate (5.2 g, 25%) 
as very pale buff crystals m.p. 87—88 °C; v  1 660,1 760, and
2 500—3 500 cm -1; 5(CDC13) 1.40 (3 H, t , /  7 Hz, CH2A/e), 2.15 
(3 H, s, COMe), 2.24 (1 H, t, /  2 Hz, 5-HX 3.10 (1 H, dd, J  13, 2 
Hz) and 3.44 (1 H, dd, J  13, 2 Hz) (3-H2X 4.41 (2 H, q, /  7 Hz, 
CH2Me),and 7.63 (I H, s, NH) (Found: M *, 208.0858. Calc, for 
C l0H 12N 2O3: M, 208.0848); m/z 179, 166, 135, and 93 (100%).
2-Amino-2-{hydroxymethyl)pent-A-ynoic Acid (x-Propargvl- 
serine) (11).— Ethyl 2-amino-2-(hydroxymethyl)pent-4-ynoate 
(32) was reduced using lithium borohydride and the inter­
mediate was hydrolysed as described above for the synthesis of 
(10). Neutralisation with 2M-aqueous ammonia yielded a tar 
which, in water (5 ml), was adsorbed onto a column of Dowex 
50 X8 (2 x 10 cm) (H + form). The column was washed with 
water until the eluates were neutral and the amino acid was 
eluted from the column using aqueous ammonia (2m; 100 m l). 
The evaporation residue was recrystallised from aqueous 
ethanol to give 2-amino-2-{hydroxymelhyl)pentA-ynoic acid  
(390 mg, 17%) as a white solid, m.p. 157— 160 °C (Found: C, 
50.0; H, 6.2; N, 9.7. C6H9N 0 3 requires C, 50.3; H, 6.3: N. 9.8%);
1 590,1 620, and 2 500—3 400 cm”1; S(D20 )  2.57 (1 H, dd, 
J  1.9, 2.4 Hz, 5-H), 2.75 (1 H. dd, J  17.6, 1.9 Hz) and 2.82 (1 H, 
dd, J  17.6, 2.4 Hz) (3-H2), and 3.80 (1 H, d, /  11.2 Hz) and 3.95 
(1 H ,d ,7  l l .2 H z ) (C / /2OH);m/r 112(A/* -  CH2OH, 100%).
Assay fo r A ctiv ity  o f  SH M T .—Cells were washed once with 
0.9% aqueous sodium chloride and disrupted in the minium 
volume of 100mM Tris-HCI buffer at pH 7.1 using a sonicator
probe at 10 KHz for 3 x 10 s. The suspension was then 
centrifuged at 3 000 x g  for 1 h at 4 °C. Each assay contained 
the test compound, L-[3-,4C]serine (0.1 jimol), pyridoxal 
phosphate (0.1 pmol), tetrahydrofolic acid (0.8 pmol), 2- 
mercaptoethanol (2 pmol), and potassium phosphate buffer 
(pH 7.4; 30 pmol), and the supernatant from the disrupted cell 
preparation in a total volume of 0.2 ml. Reactions were initiated 
by the addition of the supernatant and were terminated by 
addition of sodium acetate buffer (1m; pH 4.5; 0.3 ml), aqueous 
formaldehyde (0.1m; 0.2 ml) and 5,5-dimethylcyclohexane-l,3- 
dione (0.4m  in 50% aqueous ethanol; 0.3 ml). The mixture was 
heated for 5 min then cooled to 0 °C. Scintillation grade toluene 
(5 ml) was added and the bis(4,4-dimethyl-2,6-dioxocycIohexyl)- 
[ ‘^Cjmethane was extracted into the toluene by vigorous 
shaking for 1 min. Following centrifugation, the radioactivity 
was determined by mixing a sample of the upper layer (3 ml) 
with Beckman E.P. scintillation fluid (10 ml) and counting by 
the liquid scintillation method on a Beckman LS-230 counter.
Growth Inhibition Assays.—The growth inhibitory effects of 
the compounds were determined against GM0621 and K562 
cells, plated out into duplicate 1-ml wells of a 24-well plastics 
plate at a density of 5 x 10* cells ml"1. R.P.M.I. 1 640 medium 
supplemented with 10% foetal calf serum was used as the culture 
medium with solutions of the compounds in the culture medium 
being added as appropriate. The cells were maintained under an 
atmosphere of 10% C 0 2 in air at 37 °C. The cells were 
enumerated using a Coulter-counter during a 5 day incubation 
period and the percentage inhibition of growth was determined 
over the linear part of the growth curve.
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1. INTRODUCTION
1 -Aryl-3,3-dialkyltriazenes (I, Fig. 1) are carcinogens (Preussman et al., 1969; Druckrey, 
1973) and the dimethyl analogs (I; R', R" =  CH3) show potent antineoplastic activity 
against rodent tumors (Clarke et al., 1955; Burchenal et al., 1956). Use of these potently 
biologically active compounds has also been claimed for such diverse applications as 
herbicides (Mazza et al., 1974), reagents for the determination of heavy metals (Popescu 
and Danet, 1983) and agents to render grain unpalatable to pests (Adams and Wright, 
1964). Structure-antitumor activity studies on 1-aryl-3,3-dialkyltriazenes have shown that 
at least one N-methyl group is necessary for activity and that substitution in the phenyl 
ring has little effect on activity against the TLX5 lymphoma in mice (Audette et al., 1973; 
Connors et al., 1976). Various attempts have been made to attach the 3,3-dimethyltriazen- 
1-ylphenyl ‘warhead’ to ‘delivery’ moieties such as 2,4-diaminopyrimidines (Bliss et al., 
1987) and peptides (Ionescu et al., 1981). During the last 20 yr, the role of metabolism 
in the mechanisms of the carcinogenicity and cytotoxicity of aryldialkyltriazenes has 
been studied extensively. However, many important aspects of these mechanisms 
remain enigmatic. One heteroaryldimethyltriazene, 5-(3,3-dime thy ltriazen-1-yl)-imidazole-
4-carboxamide (dacarbazine, DTIC; II, Fig. I), is o f moderate clinical usefulness in the 
treatment of disseminated melanoma, cancer of the colon and Hodgkin’s disease which is 
resistant to therapy with MOPP (a combination of mechloroethamine, vincristine, 
procarabazine and prednisone) (Spassova and Golovinsky, 1985). Curiously, most studies 
of the metabolism and mechanism of the antineoplastic action of dimethyltriazenes have 
been carried out using substituted phenyldimethyltriazenes rather than dacarbazine itself.
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Fig. I. Structures of triazenes and related therapeutic agents. 
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Fig. 2. Mechanism of acid-catalyzed chemical degradation of l-aryl-3.3-dialkyltriazenes.
Very recently, a number of cyclic arylmonoalkyltriazenes, the 3-alkyl-8-carbamoyl- 
imidazo[5,l-*f]-l,2,3,5-tetrazin-4(3H)-ones (III, Fig. 1), have been designed as potential 
therapeutic alternatives to dacarbazine (Stevens et al., 1984). They exhibit potent 
antineoplastic properties (Hickman et al., 1985; Fodstad et al., 1985) and two such 
compounds, mitozolomide [8-carbamoyl-3-(2-chloroethyl)imidazo[5,1 -d ]-1,2,3,5-tetrazin- 
4(3H)-one; III, R = CH2CH2C1] and temozolomide [8-carbamoyl-3-methylimidazo[5,l-rf]- 
l,2,3,5-tetrazin-4(3H)-one; III, R =  CH3] are currently under clinical evaluation.
The chemical properties and therapeutic aspects of 1-aryl-3,3-dialkyltriazenes have 
recently been reviewed extensively (Kolar, 1984; Spassova and Golovinsky, 1985). Hence, 
this review is principally confined to aspects of their metabolism.
In aqueous solution at physiological or mildly basic pH, 1-aryl-3,3-dialkyltriazenes are 
moderately stable. In contrast, acidic environments cause rapid reversal of the usual 
synthetic reaction (Gescher et al., 1981) giving the arenediazonium salt (IV, Fig. 2) and 
the protonated secondary amine (V). This degradation yields potently electrophilic species 
and therefore this pathway could be considered to be the source of biologically reactive 
entities. However, no firm evidence has been put forward to support the contention that 
this reaction occurs at a significant rate under physiological condition.
The oxidative metabolism of 1-aryl-3,3-dialkyltriazenes by hepatic microsomes in vitro 
was first reported in 1969 (Preussman and von Hodenberg, 1969) and this study and 
subsequent investigations (e.g. Kolar and Schlesiger, 1976a; Kolar and Wildschutte, 1982) 
have left little doubt that oxidative V-dealkylation is a metabolic pathway pivotal for the 
biological properties of these compounds.
2. OXIDATIVE METABOLISM OF 3,3-DIALKYL-l-ARYLTRIAZENES IN
THE ALKYL GROUPS
In the original study (Preussman and von Hodenberg. 1969) 3,3-dimethyl-1- 
phenyltriazene (VI, Fig. 3) was incubated with rat liver microsomes and NADPH. 
Formaldehyde was reported to be a metabolite and the authors suggested that the other 
product of this oxidation was 3-methyl-1-phenyltriazene (VII, Fig. 3). Monoalkyltriazenes 
such as this are powerful directly acting alkylating agents (VIII, Fig. 4) and are known 
to be carcinogens (Vaughan and Stevens, 1978). They react spontaneously with nucleo­
philes giving the corresponding arylamine (IX), molecular nitrogen and the alkylated
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Fig. 3. Metabolism of 3,3-dimethyl-1-phenyltriazene by rodent hepatic microsomes in vitro, (a) 
Preussmann and von Hodenberg, 1969. (b) Kleihues et al., 1976. (c) Pool. 1979b.
NuCH,
X II  XI
Fig. 4. Mechanism of methylation of nucleophiles by l-aryl-3-methyltriazenes. Nu = H:0 .  
nucleophilic sites on DNA, proteins etc.
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nucleophile (X). It can be assumed that it is this reaction mechanism which is operative 
in biological alkylations involving monoalkyltriazenes rather than a reaction which has 
been claimed to invoke the ‘methyl carbonium ion’ (XI), as the latter is rather unlikely 
to occur in biological media. Also, deuterium labeling studies have shown that diazo- 
alkanes (XII) are unlikely to be involved as intermediates (Lown and Singh, 1981) in these 
alkylations. There is good evidence that the reaction between monomethyltriazenes and 
bionucleophiles such as nucleic acids can occur in vivo (Preussmann and von Hodenberg, 
1969; Kleihues et al., 1979; Margison et al., 1979). Therefore the oxidative metabolic 
pathway (Fig. 3) has been postulated to be responsible for the generation of the ultimate 
cytotoxin which is responsible for the carcinogenicity and, possibly, the antitumor activity 
of aryldiaikyltriazenes.
Most of the studies of the metabolism of aryldiaikyltriazenes which have been conducted 
in the wake of the original report by Preussmann and von Hodenberg (1969) used the 
colorimetric determination of the aldehyde generated by hydroxylation of the //-alkyl 
group mediated by cytochrome P450 enzymes and subsequent hydrolysis/elimination. In 
that study, some 20 to 80% of the alkyl groups (based on the assumption that complete 
removal of one of the two alkyl groups equals 100%) were oxidized to aldehydes, 
depending upon the chemical nature of the alkyl moieties. In a later study, incubation of 
four (haloaryl)-dimethyltriazenes and the unsubstituted 3,3-dimethyl-1-phenyltriazene 
with microsomes led to the loss of between 35 and 122% of the methyl groups as 
formaldehyde (Poole 1979a). 3,3-Dimethyl-1-phenyltriazene yielded the lowest and 
2,4,6-trichlorophenyl-3,3-dimethyltriazene (XIII, Fig. 5) gave the highest extent of 
oxidation at N-CH3. These results imply some partial oxidation of the second methyl 
substituent. The ultimate fate of some 40% of the radioactivity administered as
3,3-di['4C]methyl-l-phenyltriazene to rats was reported to be exhalation as MC 0 2 by 
KJeihues et al. (1976) who also observed the formation o f 7-[14C]methylguanine and other 
methylated DNA and RNA base residues. A study using chemical biomimetic oxidation 
of related triazenes in which the two alkyl groups are part o f a heteroalicyclic ring has also 
shown facile oxidation alpha to nitrogen, although the chemical products were devoid of 
antitumor activity (Stevens et al., 1979).
Unambiguous and direct identification of a monoalkyltriazene as a metabolite 
of a 1-aryl-3,3-dimethyltriazene has been reported only once; l-(4-acetylphenyl)- 
3-methyltriazene (XIV, Fig. 6), together with 4-aminoacetophenone (XV), was found as 
a metabolite of l-(4-acetylphenyl)-3,3-dimethyltriazene (XVI) both in the plasma of mice 
in vivo and in 9000 x g fractions of mouse liver homogenate in vitro (Farina et al., 1982). 
A more indirect observation of a monomethyltriazene as a metabolite of a dimethyltriazene 
has been made in that one of the metabolites found in incubations of rodent hepatic 
microsomes with 1-phenyl-3,3-dimethyltriazene was 3-acetyl-3-methyl-1-phenyltriazene 
(XVII, Fig. 3) (Pool, 1979b). Presumably, the formation of this //-acyltriazene involves 
the monomethyltriazene (VII) as a metabolic intermediate which is subsequently 
acetylated.
Some doubt has been cast on the contention that an electrophile as indiscriminate and 
nonselective as a monomethyltriazene could account for the antineoplastic activity of 
dimethyltriazenes (Gescher et al., 1981). This doubt was based on experiments in which 
the cytotoxicity of a monomethyltriazene was tested in a bioassay against a mouse TLX5
ci
XIII
F ig . 5. Structure of 3.3-dimethyl-l-(2,4,6-trichlorophenyl)tnazene.
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F i g .  6. Metabolism of 1 -(4~acetylphenyl)triazenes. (a) Farina et al., 1982. (b) Farina et al., 1983.
(c) Farina et al.. 1986.
lymphoma cell line which had acquired resistance to dimethyltriazenes in vivo. The 
monomethyltriazene was found to be nonselectively toxic to both the sensitive and the 
resistant lines, whereas incubation of the dimethyltriazene with a liver homogenate 
produced metabolites which were more toxic to the sensitive than to the resistant 
lymphoma cells (Gescher et al., 1981). However, cytotoxic metabolites of dimethyltriazenes 
which are more selective than the monomethyltriazenes have yet to be isolated or 
characterized. The immediate metabolic precursors of 1-aryl-3-methyltriazenes, the
3-(hydroxymethyl)-3-methyltriazenes (XVIII, Fig. 7), have been synthesized (Gescher et 
al., 1978; Juillard et al., 1980) and were found to be equally as cytotoxic as their 
decomposition products, the monomethyltriazenes (Vaughan et al., 1984; Kohlsmith et al., 
1984). Consequently, it has been suggested by some workers that the TV-(hydroxymethyl) 
compounds may be the ultimate or proximate cytotoxic metabolites of dimethyltriazenes 
(Vaughan et al., 1984). However, such carbinolamines have not yet been identified 
unambiguously as metabolites of aryldimethyltriazenes. At first sight, it is difficult to
C H j O H
N .  .N . CH,
XVI11
F ig .  7. Synthetic N -(hydroxymethyl)triazenes (Gescher et al., 1978; Juillard et al., 1980). 
R = CO,Me, CO,Et. COMe. CONHj. Cl. Br. CN. N 0 2.
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Fig. 8. (A) Lack of equilibrium between /V-(hydroxymethyl)triazenes and the corresponding 
iminium ions. Z = CH, N. (B) Electrophilicity of a iV-(acyloxymethyl)triazene.
envisage how such carbinolamines could be more selectively cytotoxic than their decom­
position products, the monomethyltriazenes. Certain V-(hydroxymethyl)-amines and 
-amides related to Af-(hydroxymethyl)-N-methyltriazenes have the ability to form, or can 
be in equilibrium with, electrophilic, potentially toxic imines or iminium ions, either 
themselves or after conjugation, and the chemical features which predispose N- 
(hydroxymethyl) compounds to undergo such reactions under physiological conditions 
have recently been reviewed (Overton et al., 1985). Such an elimination reaction (Fig. 8A) 
could, on paper, be a mechanism by which hydroxymethyltriazenes exert toxicity in a 
manner different from that which renders monomethyltriazenes cytotoxic (Hemens et al., 
1984; Solway et al., 1983). However, a chemical and kinetic study of the reactions of
3-(hydroxymethyl)-3-methyl-l-(pyridin-3-yl)triazene with amine bases to give 3-methyl- 
l-(pyridin-3-yl)triazene as the sole product (Cheng et al., 1985) and the failure of the 
treatment of 3-(hydroxymethyl)-3-methyltriazenes with sodium cyanoborohydride, an 
iminium trapping agent, to yield 3,3-dimethyltriazenes (Threadgill, unpublished results) 
suggest that this is not an electrophilic reaction pathway open to V-(hydroxymethyl)- 
triazenes under physiological conditions. Nevertheless, it has been shown that such a 
reactive moiety is formed during chemical reactions of acetate and benzoate esters of 
^-(hydroxymethyOtriazenes (XIX and XX respectively, Fig. 8B); presumably the en­
hanced leaving-group ability of the carboxylate leads to this increased electrophilicity 
(Hemens et al., 1984). However, such acylation of a W-(hydroxymethyl)triazene has 
yet to be shown in biochemical experiments. The rather unstable nature of N- 
(hydroxymethyl)-A^-methyltriazenes (Vaughan et al., 1984) has also been claimed to 
mitigate against their role as the ultimate antineoplastic species derived from dimeth­
yltriazenes. Nevertheless, the possibility that they are important as precursors of mono­
methyltriazenes with a transport function cannot be excluded, particularly if they are 
stabilized as the corresponding glucuronide acetal conjugate. It is pertinent in this context 
to note that Kolar and Carubelli (1979) identified 1-([3-methyl-1-(2,4,6-trichlorophenyl)- 
triazen-l-yl]methyl)-/?-D-glucuronic acid (XXI, Fig. 9) as a metabolite in the urine of 
mice which had received 3,3-dimethyl-1-(2,4,6-trichlorophenyl)triazene and the authors
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XXI
Fig. 9. Metabolic oxidation/conjugation of 3,3-dimethyl-l-(2,4,6-trichlorophenyl)triazene in the
mouse.
suggested that this species may, indeed, carry the monomethyltriazene to the target tissue. 
Conjugation of triazenes to glutathione and to sulfate has yet to be reported.
Monomethyltriazenes and 3-(hydroxymethyl)-3-methyltriazenes generated as metabo­
lites of dimethyltriazenes could be considered as substrates for further oxidative metabo­
lism. V-(Hydroxymethyl)benzamides are subject to further metabolic oxidation at the 
carbinolamide methylene group yielding the corresponding V-formylbenzamide which is 
excreted by the mouse in the urine (Ross et al., 1983). W-(Hydroxymethyl)triazenes, 
however, have not been reported to undergo this oxidation to afford the corresponding 
V-formyltriazenes which are highly reactive entities (Ignasiak et al., 1975; Threadgill and 
Gledhill, 1986). Evidence for a second biological oxidation has, nevertheless, been obtained 
in experiments in which the fate of l-(4-acetylphenyl)-3-methyltriazene (XIV, Fig. 6) in 
suspensions of murine hepatocytes was investigated (Farina et al., 1983). The mono­
methyltriazene was consumed in this medium at a rate significantly more rapid than in 
suspensions of nonviable cells. The chemical nature of the products of this metabolic 
reaction and their toxic properties are completely unknown. Oxidation at the nitrogen 
atoms of the triazene group of an arylmonoalkyltriazene has not been reported as a 
metabolic reaction, although V-hydroxy-V-methyltriazenes are relatively stable chemical 
entities (Freter et al., 1973).
3. METABOLISM REMOTE FROM THE TRIAZENE MOIETY
It is, o f course, not surprising that I-aryl-3,3-dialkyltriazenes undergo metabolism also 
at sites remote from the triazene moiety, i.e. in the aryl part of the molecule or involving 
transformation of functional groups attached thereto. Kolar and Schlesiger (1976b) 
reported indirect evidence for such metabolites in that the major urinary metabolite 
derived from 3,3-dimethyl-1-phenyltriazene in rats was found to be 4-hydroxyaniline 
(XXII) with smaller amounts of the 2-hydroxy and 3-hydroxy isomers (XXIII and XXIV 
respectively, Fig. 10). These authors also characterized ring-hydroxylated triazenes as 
metabolites of this substrate, but only after chemical coupling with 1 -(ethylamino)- 
naphthalene to give the azo dyes l-(ethylamino)-4-(4-hydroxybenzeneazo)naphthalene 
(XXV) and l-(ethylamino)-4-(2-hydroxybenzeneazo)naphthalene (XXVI). This derivatiz- 
ation method involves the loss of nitrogen-3 of the triazene (with its attached groups) and 
thus the urinary triazenes XXVII and XXVIII may have been 3,3-dimethyl, 3-methyl or 
even 3-(hydroxymethyl)-3-methyl compounds. A more direct example of metabolism 
remote from the triazene moiety with confirmed retention of the N-3 substituents is that 
the ketone carbonyl group of l-(4-acetylphenyl)-3,3-dimethyltriazene was reduced by 
preparations of murine hepatic tissue in vitro to give l-[4-(l-hydroxyethyl)phenyl]-
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F ig .  10. Aryl-hydroxylated metabolites of 3,3-dimethyl-1-phenyltriazene in the mouse. R = C H 3;
R' = H. CHjOH. CHj.
3,3-dimethyltriazene (XXIX, Fig. 6). Interestingly, this material retained an antitumor 
activity similar to that of the parent drug (Farina et al., 1983).
4. METABOLIC FATE OF l-(IMIDAZOL-5-YL)-3-ALKYLTRIAZENES
The major urinary metabolite of dacarbazine (II) in man is 5-aminoimidazole-
4-carboxamide (AIC: XXX, Fig. 11) (Householder and Loo, 1969; Skibba et al., 1970a,b; 
Breithaupt et al., 1982). AIC has also been identified as a product of metabolism of 
dacarbazine in vitro in incubations with mouse liver microsomes (Hill, 1975) and with 
human and animal tumor tissue (Gerulath and Loo, 1972; Mizuno and Humphrey, 1972). 
From the mechanistic point of view, it is difficult to envisage how AIC could be formed 
by a metabolic pathway other than one implicating the intermediate formation of
5-(3-methyltriazen-l-yl)imidazole-4-carboxamide (MTIC: XXXI), followed by the tautom- 
erism noted by, amongst others, Hooper and Vaughan (1981) and subsequent hydrolysis. 
Metabolism has been reported many times to be required for activity of dacarbazine 
(Skibba et al., 1969; Skibba and Bryan, 1971; Preussmann and von Hodenberg, 1969). The
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metabolic precursor of MTIC, 5-[3-(hydroxymethyl)-3-methyltriazen-1-yljimidazole-
4-carboxamide (HMTIC, XXXII, Fig. 11) has been characterized as a urinary metabolite 
of dacarbazine in rats (Kolar et al., 1980). Surprisingly, this compound was reported to 
be more stable than MTIC in polar solvents. This observation led to the suggestion that 
HMTIC may act as a transport form of MTIC which is the postulated ultimate 
antineoplastic species derived from dacarbazine. After the manner of 3-methyl- 
1-phenyltriazene, MTIC decomposed spontaneously in aqueous media to form AIC 
(XXX) and was capable of alkylating biological nucleophiles such as DNA (Mizuno and 
Decker, 1976).
The pharmacokinetic studies published so far on dacarbazine (Householder and Loo, 
1971; Loo et al., 1968; Skibba et al., 1969; Breithaupt et al., 1982) have not provided 
information on plasma or tissue concentrations of metabolically generated HMTIC or 
MTIC. Therefore, the pharmacokinetic data available on dacarbazine is of limited value 
in helping to relate the efficacy or toxicity of this drug with concentrations of cytotoxic 
or biologically inactive metabolites in body fluids and tissues. The major shortcoming of 
most of the pharmacokinetic data reported in the literature is the analytical procedure 
employed, a colorometric method which determines the total amount of compounds with 
intact triazene linkages and therefore does not discriminate between dacarbazine, HMTIC 
or MTIC. The plasma elimination half-life of such species after i.v. administration of 
dacarbazine to patients was 35 min (Loo et al., 1968). Measurement of plasma concen­
trations of dacarbazine using a HPLC method yielded a biphasic elimination profile with 
a terminal half-life of 41.4 min (Breithaupt et al., 1982). In this study, the plasma decay 
of metabolically generated AIC was monoexponential with a half-life of 43-116 min. The 
urinary recovery was 46-52% for dacarbazine and 9-18% for AIC. These pharmacokinetic 
data are in broad agreement with those obtained earlier from studies using inferior 
analytical methods (Householder and Loo, 1969, 1971; Loo et al., 1968, 1976; Skibba et
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Fig. 11. Metabolism of dacarbazine. Nu = H20 ,  nucleophilic sites on DNA, protein, etc.
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Fig. 12. Photodecomposition and subsequent chemical degradation of dacarbazine.
al., 1969). On the basis of a preliminary pharmacokinetic study of dacarbazine and its 
metabolite MTIC in rodents and patients, Rutty (1983) suggested that the relative lack of 
activity of dacarbazine in man compared to rodents may be related to differences in the 
rate of hydroxylation at the N-methyl group of dacarbazine which is slow in man and fast 
in mice. It is, however, interesting to note that murine Sarcoma 180 tumor cells themselves 
are capable of metabolizing dacarbazine (Mizuno and Humphrey, 1972).
Dacarbazine is photolabile and reverts in light to its synthetic precursor
5-diazoimidazole-4-carboxamide (XXXIII, Fig. 12) (Horton and Stevens, 1981). This 
diazo compound (XXXIII) and its decomposition products, 2-azahypoxanthine (XXXIV) 
and 4-carbamoylimidazolium-5-olate (XXXV) have not been found as metabolites of 
dacarbazine in vivo, although the former has been implicated in the antibacterial action 
of the parent drug (Saunders and Schultz, 1972).
The metabolic fate of the imidazotetrazinones remains to be fully elucidated. Unlike the 
open-chain dacarbazine, which does not decompose under physiological conditions, the 
cyclic mitozolomide (XXXVI) undergoes rapid hydrolytic ring-opening to give
5-[3-(2-chloroethyl)triazen-l-yl]imidazole-4-carboxamide (MCTIC, XXXVII, Fig. 13) 
(Stevens et al., 1984) which may well be the ultimate antineoplastic metabonate of the 
parent drug (Horgan and Tisdale, 1984). There is some evidence to suggest that 
metabolism is an important determinant of the rate of deactivation of this drug. Workman 
and Lee (1984) have shown that pretreatment of mice with phenobarbital reduces the 
activity of mitozolomide against the KHT sarcoma. In accordance with this finding, the 
area under the plasma concentration of mitozolomide vs time curve, determined in mice 
which had been pretreated with phenobarbital, was also significantly smaller than that in 
control animals (Brindley et al., 1986). Furthermore, microsomes fortified with NADPH 
appeared to detoxify mitozolomide when they were added to incubation mixtures of the 
drug with murine TLX5 lymphoma cells (Horspool, Gescher and Stevens, unpublished).
The highly reactive and unstable mono-(2-chloroethyl)triazene MCTIC (XXXVII) 
which is thought to be the metabonate responsible for the antineoplastic action of 
mitozolomide, has a /I/2 of only 5.5 min at pH 7.5 (Horgan, 1985). Interestingly, this is the 
same compound as would be speculated to be formed by metabolic oxidative dealkylation 
of 5-[3,3-bis(2-chloroethyl)triazen-l-yl]imidazole-4-carboxamide (XXXVIII) a dialkyl-














Fig. 13. Hydrolytic ring-opening of mitozolomide. Structure of 5-[3,3-bis(2-chloroethyl>- 
triazen-1 -yl]imidazole-4-carboxamide.
triazene with activity against tumors in the brain (Shealy et al., 1968; Levin et al., 1975). 
The instability and, hence, great reactivity o f 3-(2-chloroethyl)triazenes (XXXIX, Fig. 14) 
is thought to be due to their facile cyclization to 1,2,3-triazolines (XL) or 1,2,3-triazolinium 
species (XLI), (Abraham et al., 1969; Lown and Singh, 1981).
XXXIX
A rI
( /,” XL '—N
Fig. 14. Cyclization of /V-(2-chloroethyl)triazenes.
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5. THE ROLE OF METABOLISM IN THE MECHANISM OF ANTITUMOR
ACTIVITY OF TRIAZENES
Many crucial mechanistic details which link the metabolism of dimethyltriazenes with 
their antineoplastic activity remain obscure. Answers to the following three questions 
appear pivotal in the elucidation of this link and require further work:
(i) How can the aggressively reactive monomethyltriazene generated by metabolism of 
a dimethyltriazene cause selective cytotoxicity?
(ii) Is the metabolic route which leads to the antineoplastic species identical with that 
which generates the carcinogenic metabolite?
(iii) Are differences in the metabolism between dimethyltriazenes and dialkyltriazines 
with alkyl groups other than methyl responsible for the marked difference in 
antineoplastic activity observed in some murine tumors (Connors et al., 1976; 
Gescher et al., 1981)?
Even though the evidence for the involvement of metabolism in the mechanism of 
antitumor activity of dimethyltriazenes is overwhelming, the possibility that, under certain 
circumstances, some dimethyltriazenes are themselves cytotoxic without metabolic activa­
tion cannot be dismissed. Dacarbazine has been used in local therapy in patients with 
advanced malignant melanoma and soft tissue sarcoma of the extremities and tumor 
regression has been observed (Aigner et al., 1983). Furthermore, l-(4-carboxyphenyl)-
3,3-dimethyltriazene (I; R = 4-COOH, Fig. 1) did not undergo marked oxidative de- 
methylation in vitro (Sava et al., 1982), yet it possessed antimetastatic properties in mice 
bearing Lewis lung carcinoma (Giraldi et al., 1981). This drug also increased the survival 
of mice bearing the TLX5 lymphoma or the P388 leukaemia without exerting marked 
cytotoxicity (Sava et al., 1982).
The third question posed above has been addressed in a recent comparison of the 
antitumor activities and toxicities of l-(4-acetylphenyl)-3,3-dimethyltriazene (XVI, Fig. 6) 
and l-(4-acetylphenyl)-3,3-diethyltriazene (XLII, Fig. 6) (Farina et al., 1986). The diethyl- 
triazene was inactive against three murine tumors which were highly sensitive to the 
dimethyltriazene. However, the diethyltriazene was much more toxic to the host than was 
the dimethyltriazene. Both drugs were rapidly metabolized in vivo and in vitro and the 
monoalkyltriazenes (XIV and XLIII respectively) and 4-aminoacetophenone (XV) were 
identified as metabolites of these compounds. However, the extent to which the drugs were 
//-dealkylated differed markedly. The amount of monoethyltriazene generated was only 
a third of the amount of the monomethyl derivative found (Farina et al., 1986). This result 
suggests that the difference in activities between different dialkyltriazenes may indeed by 
due to differences in metabolism.
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c o m p l e x * t i o n  w i t h  Cu ? p e r m i t t i n g  h y d r o x y m e t h y l a t i o n  a t  t h e  a -
e
c a r b o n  b y  f o r m a l d e h y d e  i n  a q u e o u s  b a s i c  s o l u t i o n  . A f t e r
d e m e t a l l a t i o n  u s i n g  a c a t i o n  e x c h a n g e  r e s i n ,  a n  a d e q u a t e  y i e l d  o f
a - ( b e n z y l o x y m e t h y l ) s e r i n e  ( 2 )  w a s  o b t a i n e d  a s  s h o w n  i n  t h e  S c h e m e .
T h e  r e q u i r e d  s u b s t r a t e  (4. )  f o r  t h e  d i m e t h y l a m i n o s u l p h u r  t n f l u o r i d e
r e a c t i o n ,  w i t h  p r o t e c t e d  a m i n o  a n d  c a r b o x y l i c  a c i d  g r o u p s  b u t  w i t h
a f r e e  p r i m a r y  h y d r o x y l ,  w a s  e a s i l y  s e t  u p  i n  t w o  s t e p s .  T r e a t m e n t
o f  (2> w i t h  a c e t i c  a n h y d r i d e  i n  p y r i d i n e  a t  a m b i e n t  t e m p e r a t u r e
g a v e .  a s  e x p e c t e d .  a c e t y l a t i o n  a t  b o t h  n i t r o g e n  a n d  h y d r o x y l
0
o x y g e n .  R a i s i n g  t h e  r e a c t i o n  t e m p e r a t u r e  t o  100  C c a u s e d  
c y c l i s a t i o n  t o  o c c u r ,  g i v i n g  t h e  o x a z o l - 5 - o n e  ( 2 ) .  T r e a t m e n t  w i t h  
m e t h a n o l i c  s o d i u m  m e t h o x i d e  r e m o v e d  t h e  u n w a n t e d  a c e t a t e  e s t e r  by  
t r a n s e s t e n f i c a t i o n  w i t h  s i m u l t a n e o u s  a t t a c k  o f  m e t h o x i d e  a t  C - 5  o f  
t h e  o x a z o l o n e  t o  g i v e  ( 4 . )  . C o m p o u n d  ( 2*  w a s  f o u n d  t o  b e  v e r y  
l a b i l e  t o  n u c l e o p h i l i c  r i n g - o p e n i n g . i n  com m on w i t h  r e l a t e d
9
o x a z o l - 5 - o n e s  a n d .  f o r  e l e m e n t a l  a n a l y s i s ,  w a s  c h a r a c t e r i s e d  a s
t h e  p r o d u c t  o f  a t m o s p h e r i c  h y d r o l y s i s  ( 2 )  . T r e a t m e n t  o f  (4.) w i t h
0
d i m e t h y l a m i n o s u l p h u r  t n f l u o r i d e  a t  - 4 5  C g a v e  t h e  d i h y d r o o x a z o l e
( 6 )  a s  t h e  p r o d u c t  o f  c y c l o d e h y d r a t i o n , r a t h e r  t h a n  t h e  e x p e c t e d
s u b s t i t u t i v e  f l u o r i n a t i o n . C l e a r l y .  t h e  i n t r a m o l e c u l a r  c a r b o n y l
o x y g e n  i s  a b e t t e r  c o m p e t i n g  n u c l e o p h i l e  t h a n  t h e  e x o g e n o u s
f l u o r i d e  i o n  i n  d i s p l a c i n g  t h e  a c t i v a t e d  h y d r o x y  l e a v i n g  g r o u p .
10
I n t e r e s t i n g l y ,  o n e  p r e v i o u s  r e p o r t  c o n c e r n s  t h e
d e h y d r a t i o n / e l i m i n a t i o n  o f  a n  e s t e r  o f  N - ( b e n z y l o x y -  
c a r b o n y l ) t h r e o n i n e . a n o t h e r  R - h y d r o x y a m i n o  a c i d ,  t o  g i v e  t h e  2 . 3 -  
d e h y d r o  a m i n o  a c i d  d e r i v a t i v e ,  w i t h o u t  c y c l o d e h y d r a t i o n .
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SCHEME
T h i s  o b s e r v a t i o n  s h o u l d .  t h e r e f o r e .  b e  a d d e d  t o .  t h e  s m a l l
1 1 1 2c o l l e c t i o n  o f  c i r c u m s t a n c e s  i n  w h i c h  d i a l k y l s u l p h u r
t n f l u o r i d e s  c a n n o t  b e  u s e d  f o r  c o n v e r s i o n  o f  Oh t o  F by  s i m p l e  
s u b s t i t u t i o n .
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EXPERIMENTAL
M e l t i n g  p o i n t s  a r e  u n c o r r e c t e d .  NMR s p e c t r a  w e r e  r e c o r d e d  u s i n g  a 
B r o k e r  AC3 0 0  s p e c t r o m e t e r .  M a s s  s p e c t r a  w e r e  o b t a i n e d  u s i n g  a VG 
ZAB- E i n s t r u m e n t  a n d  i n f r a  r e d  s p e c t r a  w e r e  a c q u i r e d  u s i n g  a 
P e r k m - E l m e r  13 10 s p e c t r o m e t e r .  A l l  c o m p o u n d s  w e r e  r a c e m i c .
2 - A m i n o - 2 - ( b e n z v l o x v m e t h v l ) - 3 - h v d r o x v o r o D a n o i c  a c i d  ( 2 ) •  1M A q u e o u s
c o p p e r  ( I I )  s u l p h a t e  ( 2 . 5  m l )  w a s  a d d e d  t o  0 - b e n z y l s e r i n e  ( J . :  5 . 0
g .  25  mmo l )  i n  0 . 2  M a q u e o u s  CO^ ( 5 0 0  m l ) ,  f o l l o w e d  by a q u e o u s
f o r m a l d e h y d e  (3 8 Z . 1 5 . 1  m l ) .  T h e  m i x t u r e  w a s  b o i l e d  f o r  25  m i n
t h e n  r e d u c e d  t o  100  ml  b y  e v a p o r a t i o n .  T h e  c a t i o n s  i n  t h e  r e s i d u e
w e r e  a d s o r b e d  o n t o  a c o l u m n  o f  D ow ex 50 - W X8 ( m e s h  s i z e  2 0 0 - 4 0 0 .  2
x 10 c m;  H f o r m ) .  The  r e s i n  w a s  w a s h e d  w i t h  w a t e r  u n t i l  n e u t r a l
a n d  t h e  a m m o - a c i d  w a s  e l u t e d  w i t h  2M a q u e o u s  NH^ ( 1 0 0  m l ) .  The
0
e l u a t e s  w e r e  e v a p o r a t e d  t o  5 m l  a n d  c o o l e d  t o  0 C.  T h e  p r e c i p i t a t e
w a s  r e c r y s t a l l i s e d  f r o m  e t h a n o l  t o  g i v e  t h e  a m i n o - a c i d  ( £ ;  1 . 1 6  g .
0
2 8 Z ) .  w h i t e  n e e d l e s  MPt  1 6 4 - 7  C;  ( F o u n d :  C.  5 8 . 7 ;  H.  6 . 7 :  N.  6 . 2 .
C1 1 M1 S N0 4 r e Qu l r e s  C - 5 8 . 7 ;  H.  6 . 7 ;  N.  6 . 2 Z ) :  v  ^  ( N u ^ o l )  1 6 4 0 .  
- 1
1 5 9 0 .  1 4 6 0  cm : 6 ( C F ^ C C ^ D)  3 . 9 5  ( 1 H . d .  J  12 Hz )  a n d  4 . 1 0  ( 1 H .  d .  
J 12 Hz )  CH^OH.  4 . 3 0  ( 1 H .  d .  J  13 Hz )  a n d  4 . 4 3  ( 1 H.  d .  J  13 Hz )
Cfl OCH P h .  4 . 6 6  ( 2 H.  s .  P h C ^ O ) .  7 . 2 5 - 7 . 6 0  ( 5H.  m.  A r H ) .
4 - ( A c e t o x y m e t h y l ) -  4 - ( b e n z v l o x y m e t h y l ) - 2 - m e t h y l - 4 . 5 - d i h y d r o - 1 . 3 - 
o x a z o l - 5 - o n e  ( 2 ) -  2 - A m i n o  - 2 - ( b e n z y l o x y m e t h y l ) - 3 - h y d r o x y p r o p a n o i c
a c i d  ( £ ;  6 2 8  mg.  2 . 8  m m o l )  w a s  h e a t e d  w i t h  a c e t i c  a n h y d r i d e  ( 4 . 5
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0
m l )  a n d  p y r i d i n e  ( 3  m l )  f o r  i h  a t  100  C b e f o r e  t h e  m i x t u r e  w a s
e v a p o r a t e d  t o  d r y n e s s  a t  20  t o r r .  T h e  r e s i d u e ,  i n  c h l o r o f o r m ,  w a s
w a s h e d  r a p i d l y  w i t h  l h  h y d r o c h l o r i c  a c i d  a n d  d r i e d  ( a n h y d r o u s
Na^SO^ ) . E v a p o r a t i o n  o f  t h e  s o l v e n t  g a v e  t h e  o x a z o l o n e  ( 2 :  519  mg .
6 4 2 ) .  w h i t e  s o l i d  MPt  1 2 i - 5 ° C :  v  ( l i q u i d  f i l m )  1 8 2 5 .  1 7 4 0 .ma x
1 6 9 0  c m ' 1 ; 6 ( C0 C1 3 I 2 . 0 3  ( 3 H.  s .  O ^ C ^ ) .  2 . 2 7  ( 3 H.  s .  2 - C H3 ) .
3 . 7 0  ( 2 H.  s .  CJi2 0CH? P h ) . 4 . 1 3  ( I H .  d .  J 1 1 H z )  a n d  4 . 3 8  ( I H .  d .  J
11HZ)  CJtl^OAc. 4 . 5 3  ( 2 H.  s .  Ph^CH 0 ) .  7 . 2 7  ( 5H.  s .  A r H ) . A s m a l l
s a m p l e  w a s  a l l o w e d  t o  s t a n d  i n  a m o i s t  a t m o s p h e r e  f o r  l d a y  t o  g i v e
2 - a c e t a m i d o - 3 - a c e t o x v - ? - ( b e n ? v 1 o x v me  t h v l l o r o o a n o i c  a c i d  ( 2 )
( F o u n d :  C.  5 7 . 8 :  H.  6 . 2 :  N.  4 . 3 .  C, S H2 0 N°6 r e<>u i r e s  c - 5 8 . 2 :  H.
6 . 2 ;  N.  4 . 5  Z ) ; m / z  3 1 0 . 1  30 7 ( h » H ) ‘ (C H NO r e q u i r e s  3 1 0 . 1 2 9 1 ) .
1 5 2 0 6
P g t H y l  2 - A c y t ? m i d o - 2 -  {ly g n ^ y lg jn tfn g A H Y ll - ? .- .n x g rg .> (Y g rg fi? n ? .Ve <i.» *»>•
f o r e g o i n g  o x a z o l - 5 - o n e  ( 2 :  4 0 1 mg.  1 . 4  mmo l )  w a s  s t i r r e d  w i t h  
s o d i u m  m e t h o x i d e  ( 4 . 3 5  mmo l )  i n  m e t h a n o l  ( 2 0  m l )  f o r  40  m i n  b e f o r e  
t h e  s o l v e n t  w a s  e v a p o r a t e d .  The  r e s i d u e .  i n  w a t e r  ( 1 0 m l )  w a s  
a c i d i f i e d  by  a d d i t i o n  o f  4 K h y d r o c h l o r i c  a c i d  a n d  e x t r a c t e d  w i t h  
d i c h l o r o m e t h a n e . The  e x t r a c t  wa s  d r i e d  ( a n h y d r o u s  N a ^ S O ^ )  a n d  t h e  
s o l v e n t  w a s  e v a p o r a t e d  t o  a f f o r d  t h e  e s t e r  (4. ;  301 mg .  7 8 Z ) .  w h i t e  
s o l i d  MPt  118°  C ; v ma>< ( N u ^ o l )  3 3 3 0 .  2 8 5 0 .  1 7 2 0  c m ' 1 ; 6 ( 0 0 0 ^ )  2 . 0 8
( 3 H .  s .  02 CCH3 ».  3 . 7 7  ( 3 H.  s .  O C ^ ) .  3 . 7 7  ( I H .  d d . J 1 1 . 6  Hz .  7 . 0  
Hz .  CHHOH) .  3 . 8 1  ( I H .  d .  J 9 . 3  Hz )  a n d  3 . 8 7  ( i h . d .  J 9 . 3  Hz )  
CM^OCH^Ph.  4 . 0 1  ( I H .  d d .  J 1 1 . 6  Hz .  5 . 4  Hz .  CHHOH) .  4 . 5 0  ( I H .  d .  J 
1 2 . 1  Hz )  a n d  4 . 5 2  ( I H .  d .  J 1 2 . 1  Hz )  P h C ^ O .  4 . 6 3  ( I H ,  d d . J 7 . 0
Hz .  5 . 4  Hz .  OH) .  6 . 5 9  ( I H .  b r .  NH) .  7 . 2 6  ( 5 H.  s .  A r H ) .  The  NMR
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s p i n  s y s t e m s  w e r e  c o n f i r m e d  u s i n g  a COSY e x p e r i m e n t .  m / z  2 8 2 . 1 3 5 8
( M. H) *  (C H NO,  r e q u i r e s  2 8 2 . 1 3 4 1 ) .
1 4 2 0 5
nethvl_______ 4- ( BenzvlQKvmethyl) -2-methyl-4 . 5-di.hvdro-1. 3-ox^zols-4 -
c a r b o x v l a t e  ( £ )  . The  f o r e g o i n g  e s t e r  (A: 144  mg.  0 . 5  m m o l)  i n
d i c h l o r o m e t h a n e  ( 5  m l )  w a s  a d d e d  t o  d i m e t h y l a m i n o s u l p h u r
0
t n f l u o r i d e  ( 7 0  mg ,  0 . 5 3  mmo l )  i n  d i c h l o r o m e t h a n e  (3 m l )  a t  - 4 5  C.
0
Th e  m i x t u r e  w a s  s t i r r e d  a t  - 4 5  C f o r  3 0  m i n  a n d  a l l o w e d  t o  w a r m  t o  
2 0 °  C b e f o r e  b e i n g  w a s h e d  ( s a t u r a t e d  a q u e o u s  Na HC03 a n d  w a t e r )  a n d  
d r i e d  ( a n h y d r o u s  N a ^ S O ^ ) .  P r e p a r a t i v e  l a y e r  c h r o m a t o g r a p h y  ( s i l i c a  
g e l .  e t h y l  a c e t a t e )  f u r n i s h e d  t h e  o x a z o l e  ( £ :  80 mg .  6 1 Z ) .  o i l :
v ma x  C l i q m d  f i l m )  1 7 2 0  . 1 6 4 0  c m ' 1 ; 6 ( C 0 C 1 3 ) 2 . 0 0  ( 3 H.  s .  2 - C H 3 ) .
3 . 5 4  ( I H .  d .  J 9 . 2  Hz .  CHHOCH^ P h ) . 3 . 7 7  ( 3 H ,  s .  0CH3 ) .  3 . 8 4  ( I H .  d .  
J 9 . 2  Hz .  CHH OCH^ P h ) .  4 . 3 1  ( I H .  d .  J  8 . 9  Hz .  5 - H ) ,  4 . 5 5  ( 2 H .  s .  
PhCH^ 0 ) .  4 . 7 1  ( I H .  d .  J 8 . 9  Hz .  5 - H ) .  7 . 2 6  ( 5H,  s .  A r H ) ;  m / z
( C h e m i c a l  i o n i s a t i o n )  2 6 4 . 1 2 3 9  ( M*H)  (C H NO r e q u i r e s
13 18 4
2 6 4 .  1 2 3 6  ) .
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Applications of Tandem Mass Spectrometry to the Characterization of Derivatized 
Glutathione Conjugates. Studies with £-(A-Methylcarbamoyl)glutathione, 
a Metabolite of the Antineoplastic Agent A-Methylformamide
P. G. Pearson, M. D. Threadgill, W. N. Howald and T. A. Baillie
Biomedical and Environmental Mass Spectrometry, 1988, 16, 51-56.
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Applications of Tandem Mass Spectrometry to the 
Characterization of Derivatized Glutathione 
Conjugates. Studies with A-(A^ -Methylcarbamoyl)- 
glutathione, a Metabolite of the Antineoplastic 
Agent iV-Methylformamide
Paul G. Pearson, Michael D. Threadgill,t William N. Howald and Thomas A. BaiIIie£
Department of Medicinal Chemistry, School of Pharmacy, University of Washington. Seattle. Washington 98195, USA
Daughter ion spectra are reported for [M + Hp ions generated by fast atom bombardment mass spectrometry of
S-^A-methylcarbamoyl^ lutathiooe (1) and a series of alkoxycarbonyl methyl ester derivatives thereof. Structurally 
informative, even-electroo fragment ions, which serve to define the nature of both the xenobtotic and peptide 
components of tbe conjugate, are observed in tbe collisionafly activated dissociation (CAD) spectra of 1 and its 
ethoxy- and benzyloxycarbonyl methyl esters. Studies with tbe /-butyloxycarbooyl (rBOC) methyl ester derivative, 
on the other hand, indicated that the rBOC group exerts a powerful directing influence on tbe CAD process, and 
that the major daughter ions in this case are associated with cleavage of the rBOC functionality itself and are of 
little diagnostic value. Of tbe derivatives examined, tbe benzyloxycarbonyl congener, which may be generated 
readily from 1 in aqueous media, is judged to be tbe most useful from the standpoints of ease of formation, 
desirable high-performance liquid chromatographic properties, and informative mass spectral fragmentation char­
acteristics under CAD conditions.
INTRODUCTION
Conjugates of the endogenous tripeptide glutathione (y- 
L-glutamyl-L-cysteinylglycine, GSH) represent an 
important class of metabolites since they are formed 
from -a wide_variety of biological electrophiles.1-3 In 
many cases, such elecTrophilic intermediates, which 
typically are generated as short-lived metabolites of 
drugs or other foreign compounds, have been impli­
cated as causative agents in various xenobiotic-induced 
toxicities. Consequently, the development of methods to 
isolate and characterize GSH adducts has become an 
important goal in biochemical toxicology, since knowl­
edge of the structure of a given conjugate provides a 
unique insight into the nature of the reactive metabolite 
from which it derives.4"
Mass spectrometric analyses of GSH conjugates, 
however, have been hampered by the high polarity, 
thermal instability and. in certain instances, the chemi­
cal reactivity of these compounds, which have combined 
to preclude study of all but the simplest examples by 
traditional electron impact (El) or chemical ionization 
(Cl) techniques.6 On the other hand, ‘soft* ionization 
methods, e.g. field desorption7' 12 and, more recently, 
fast atom bombardment (FAB) or liquid secondary ion 
(LSI) mass spectrometry13"22 and liquid 
chromatography/thermospray mass spectrometry23-24
t Present address: Medical Research Council Radiobiology Unit. 
Chilton. Didcot. Oxfordshire 0X11 ORD. UK.
J Author to whom correspondence should be addressed.
0887-6134/88/240051 -06 505.00 
<£) 1988 by John Wiley & Sons. Ltd.
have provided highly effective means of examining GSH 
conjugates as intact species, and have been applied suc­
cessfully to the mass spectrometric analysis of numerous 
members of this structural class.25 However, although 
abundant [M +  H ]+ and [M + Na] + ions normally 
are produced under such conditions, few fragment ions 
are observed from which details of molecular structure 
may be inferred. Very recently, collisionally activated 
dissociation (CAD) methods, employed in conjunction 
with tandem mass spectrometry (MS/MS), have been 
used to overcome this problem, and have been applied 
to the characterization of selected GSH conjugates of 
synthetic or biological origin.26-30
A complementary approach to the analysis of thio- 
ether adducts, which has proven to be of considerable 
value in studies performed in our laboratories,31'32 
involves conversion of the conjugates (in aqueous 
media, e.g. bile) into the corresponding alkoxycarbonyl 
derivatives in order to facilitate their initial isolation 
from biological matrices, and to assist in their sub­
sequent purification prior to mass spectrometric 
analysis. By this procedure, derivatized drug-GSH con­
jugates, such as that of the analgesic agent acetamino­
phen, were readily isolated in pure form and yielded 
both protonated molecular species and a limited 
number of daughter ions when analysed by field desorp­
tion mass spectrometry or by LSI mass spectrometry 
with Cs4- ion bombardment.33
The objective of the present investigation was to 
extend the above derivatization approach to a study of 
the behavior of functionalized GSH conjugates upon 
CAD, in an attempt to extract detailed structural infor­
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mation from their FAB spectra through tandem mass 
spectrometric analysis of the family of daughter ions 
produced. As a model compound for these experiments, 
we chose S-(A/-methylcarbamoyl)glutathione (I), the 
G SH  conjugate of the experimental anti-tumor agent 
N-methylformamide (2) (Fig. I).34 In addition to pro­
viding a means of assessing the influence of alkoxycarb­
onyl formation on the pathways of collision-induced 
fragmentation of the GSH moiety, selection of this 
model compound afforded an opportunity to compare 
the C A D  spectra reported recently30 for S-alkyl and
S-aryl G SH  conjugates with that o f the novel S- 
carbamoyl-GSH structure o f I. Moreover, since 1 had 
to be generated biochemically for these studies by 
metabolism  of 2 in isolated rat hepatocytes, it was pos­
sible in this investigation to make a realistic assessment 
of the practical value of the combined aqueous-phase 
derivatization and FAB mass spectrometry (or FAB 




N-M ethylformamide (N M F) (2), ethylchloroformate, 
benzylchloroformate and reagents for synthetic and 
analytical work were purchased from the Aldrich 
Chemical Co. (Milwaukee, Wisconsin). [ I3C 2.15N ]N M F  
(3), with an isotopic purity o f 90 atom% excess l3C 2 
and 95 atom% excess 15N , was obtained from MSD  
Isotopes (St Louis, MissouriX while N - [14C-methyl]- 
formamide (specific activity 1 mCi m m ol" \  radiochemi­
cal purity 97%) was synthesized by treatment of 
[ 14C]m ethylam ine hydrochloride (ICN, Irvine, 
California) with excess ethyl formate, as described pre­
viously.35 CoHagenase (grade II) was obtained from 
W orthington Biochemical (Freehold, New Jersey). A 
sample o f the r-butyloxycarbonyl (rBOC) methyl ester 
derivative 7 was prepared by total synthesis, full details 
of which will be reported elsewhere.36
Biological experiments
H epatocytes were isolated from male Sprague-Dawley 
rats (200-250 g; Charles River Laboratories, Wilming­
ton, Massachusetts) by a collagenase perfusion tech­
nique.37 Cell viability, determined by Trypan Blue 
exclusion, was typically between 85 and 90%. Incu­
bations (2 x 106 cells m l-1 ), with 2 or 3 as substrate (5 




C H 3- N H - C - S G  C H j - N H - C  - H  C H j -  N H  -  C -  H
1  2 3
F ig u r e  1 . S tru ctu res o f th e  G SH  co n ju g a te  o f N M F (1 ) .  and of 
u n la b e led  (2 )  a n d  ’ 3C , . ,5 N -la b e le d  N M F (3 ) .
final volume 20 ml) under an atmosphere of 0 2/C 0 2 
(95/5). (UQ N M F  (diluted for metabolic experiments, 
with 2 or 3, to a specific activity of 18.4 pCi m m o l'') 
was added to hepatocytes at the outset, and incubations 
were performed for 4 h at 37 °C in an orbital incubator. 
Metabolism was terminated by the addition of two 
volumes of ice-cold acetone, and the precipitated 
protein was removed by brief centrifugation (500 x g). 
Acetone was removed from the supernatant under 
reduced pressure, and the residual aqueous phase, 
which contained 1 (or its l3C 2 ,15N-labeled analog), was 
treated as outlined previously34 with excess ethyl- or 
benzylchloroformate, and extracted using a Sep-Pak 
cartridge (Waters Associates).34 Samples of these deri­
vatized extracts were taken directly for analysis by high- 
performance liquid chromatography (HPLC).
HPLC
Purification of alkoxycarbonyl derivatives was per­
formed using a Beckman model 342 dual pump instru­
ment, equipped with a reverse-phase Novapak ODS  
column (15 cm x 4.6 mm i.d., 4 pm; Waters Associates, 
Milford, Massachusetts) and fixed-wavelength ( /  =  254 
nm) Beckman model 160 ultraviolet (UV) detector. The 
mobile phase consisted of a linear 20 min gradient from 
20% to 70% methanol in water with 1% acetic acid 
throughout. The flow rate was 1.0 ml m in '1 and 1 min 
fractions were collected and evaporated to dryness. 
Under these conditions, the ethoxy- and benzyl­
oxycarbonyl derivatives of 1 eluted in fractions 5-6  and
11-12, respectively. The recovery of radioactivity in the 
HPLC eluent was >95%  of that applied to the column, 
based on counting of fractions on a Beckman LS-7500 
liquid scintillation spectrophotometer. The purified con­
jugates thus obtained were treated with anhydrous 
methanolic HC1 at room temperature for 2 h, and the 
resulting alkoxycarbonyl methyl esters were subjected 
to HPLC purification using the above system. The frac­
tions eluting from the column between 10-11 and 15-16 
min (which contained 4 and 5, respectively) were col­
lected, evaporated to dryness, and taken for mass spec­
trometric analysis.
Mass spectrometry
Mass spectrometric analyses were performed using a 
VG 70 SEQ hybrid tandem instrument of EBQQ 
geometry (VG Analytical Ltd, Manchester, UK), 
equipped with an Ion Tech fast atom gun and VG 
11/250 data system. Samples (5-10 pg) were dissolved in 
methanol (3 pi) and added to glycerol (3 pi) containing 
0.1 m HC1 (1 pi) on an FAB target. Ionization was 
achieved following bombardment with xenon (6 keV) as 
the primary beam, and conventional FAB spectra were 
recorded, at an accelerating potential of 8 kV, via the 
data system.
CAD was performed in the first (rf-only) quadrupole 
region, using helium as the collision gas with collision 
energies of 38-40  eV. The pressure in the quadrupole 
analyser housing was maintained at 1 x 10" 6 Torr, and 
daughter ion spectra were obtained by selection of the 
appropriate [M  +  H] + parent ion through adjustment
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of the magnetic field, and scanning the quadrupole mass 
analyser from m/z 600 to 50 over a period of 10 s. 
Daughter ion spectra were recorded using an oscillo­
graphic recorder.
RESULTS AND DISCUSSION
Preparation of alkoxycarbonyl derivatives
Reaction of metabolite 1 with ethyl- or benzyl­
chloroformate in buffered aqueous solution afforded the 
respective ethoxy- and benzyloxycarbonyl derivatives in 
essentially quantitative yields. The benzyloxycarbonyl 
derivative of i was, as expected, appreciably more lipo­
philic than its ethoxy counterpart. This property, 
coupled with the introduction of a chromophore which 
permitted detection of the conjugate by UV absorbance, 
favored the benzyloxycarbonyl derivative for use in the 
purification of the NMF conjugate by reverse-phase 
HPLC techniques.
FAB mass spectrometry
Conventional FAB mass spectrometric analysis of the 
native conjugate 1, and of derivatives 4-7, afforded 
spectra with prominent [M + H]* ions, similar to 
those reported for 5-alkyl and S-aryl GSH conju­
gates.13“22-30 In some cases, structurally informative 
fragmentation was noted, e.g. compound 1 exhibited 
even-electron daughter ions resulting from cleavage of 
the y-glutamyl-cysteinyl peptide bond with charge 
retention on the residual drug conjugate (ion e, Scheme 
1), and from elimination of the elements of methyl- 
isocyanate (CHjNCO) from the NMF moiety (ion i. 
Scheme 1). Modification of the conjugate by formation 
of alkoxycarbonyl methyl ester derivatives, on the other 
hand, led to preferred cleavage of the cysteinyl-glycine 
linkage to yield ion a (Scheme 1). Similar changes in
f











S c h e m e  1 . P a th w ays o f  fragm en tation  of g lu ta th io n e  c o n ju g a tes
fo llo w in g  co llis ion a l a c tiva tion . The id en tities o f su b stitu en ts  R ,.
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fragmentation following derivative formation were 
observed under CAD conditions (see below). The rBOC 
methyl ester 7 was unique among the compounds exam­
ined in this study in that abundant daughter ions 
resulting from cleavages involving the alkoxycarbonyl 
group were evident in the FAB mass spectrum; 
these ions corresponded to the [M + H -  C4H8] + and 
[M + H — C 02C4H8] + species typically observed in 
the FAB spectra of rBOC-protected peptides.38
Despite the appearance of daughter ions in the con­
ventional FAB spectra of 1 and its derivatives, these 
fragments generally were of low abundance and fre­
quently were obscured by interfering components of the 
sample matrix. The spectrum reproduced in Fig. 2(a), 
which was obtained by FAB analysis of the benzoxy- 
carbonyl methyl ester derivative 5 isolated from rat 
hepatocytes, may be taken as a representative example.
FAB MS/MS
When the [M -t- H] * ions from the native and deriva­
tized GSH conjugates were subjected to CAD, a series 
of even-electron daughter ion spectra were generated 
whose salient features are summarized in Table 1. The 
proposed origins of fragments a-k are depicted in 
Scheme 1, which is adapted from recent work by 
Gaskell and co-workers30 and employs the same nota­
tions for ion structures. Shifts in the m/z values of 
daughters produced either by changes in the alkoxy­
carbonyl substituent or by isotopic labeling of the NMF 
moiety served to support these proposed assignments.
In the case of the underivatized conjugate (1), loss of 
the y-glutamyl moiety (129 u) to give ion e represented 
the major route of fragmentation, and was accompanied 
by further elimination of the elements of water to yield 
the prominent [e -  H20 ] + ion at m/z 218. These cleav­
ages have been described for many other native GSH 
conjugates analysed by ‘soft’ ionization methods, with 
and without CAD, and appear to be characteristic of 
this structural class.10-26-29-30'33 Other significant 
daughter ions in the CAD spectrum of 1 resulted, from 
expulsion of the elements of methylisocyanate 
(CH3NCO), either directly from the [M + H]* (to give 
0 or from the above e fragment (to yield m/z 179), both 
of which served to confirm the composition of the xeno- 
biotic moiety attached directly to sulfur. Interestingly, 
this pathway of ion decomposition is absent in the CAD 
spectra of both 5-alkyl and 5-aryl GSH conjugates,30 
and may therefore have some diagnostic importance for 
the ‘H—Y—CO—SG' partial structure (where ‘Y* is a 
heteroatom). Indeed, preliminary CAD studies on a 
derivative of N-ethylcarbamoylcysteine (which elimi­
nates the elements of ethylisocyanate) and on an A/JV-  
dimethylcarbamoylcysteine conjugate (which does not 
fragment by such a pathway) serve to support this con­
tention (data not shown). Thus, daughter ions indicative 
of the structure of both drug and tripeptide elements of 
the GSH conjugate 1 were clearly evident in the CAD 
spectrum of its [M + H]* parent.
Conversion of I to its methyl ester ethoxy- (or 
benzyloxy)carbonyl derivative induced a pronounced 
change in the relative abundances of several of the ions 
a-k, most notably in the intensity of fragment a
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(elimination of the elements of glycine methyl ester) 
which dominated the CAD spectra of compounds 4-6 
(Table 1). (Similar changes have been reported to 
accompany A/-acetylation of model GSH conjugates, 
e.g. S-octylglutathione.30 However, loss of the y- 
glutamyl residue (to give e) remained an important 
route of fragmentation of these derivatives, as did expul­
sion of methylisocyanate (57 u) from the respective 
[M + H] + ions. In addition, losses of small neutral 
molecules from the [M + H]* parent proved to be a 
characteristic feature of the CAD spectra of compounds
4-6, and were ascribed to reactions involving the methyl 
ester (—MeOH) or alkoxycarbonyl functionalities 
(—EtOH, — PhCH2OH, —C 0 2). The daughter ion 
spectra of the ethoxy- and benzyloxycarbonyl deriv­
atives, therefore, reflected the nature of the drug residue, 
the GSH moiety, and the functionalized amino and car­
boxyl groups of the conjugate. These features are illus­
trated in the CAD spectrum of the benzyloxycarbonyl 
methyl ester 5, which is shown in Fig. 2(b). In striking 
contrast to the spectra of daughter ions produced from
the ethoxy- and benzyloxycarbonyl methyl esters of 1, 
that recorded from the rBOC methyl ester 7 was domi­
nated by two ions which resulted from fragmentation of 
the rBOC group itself, viz. m/z 437 ([M + H — C4H8] +) 
and m/z 393 ([M + H -  C 0 2C4H8] + ). These species, 
which also were evident in the conventional FAB spec­
trum of 7 (see above), may be regarded as characteristic 
products of collisional activation of peptide rBOC 
derivatives38 and convey little information on molecu­
lar structure. Only ions a and e provided any such 
information in this case, although their low relative 
abundances would limit the potential utility of this 
rBOC derivative for analytical purposes.
CONCLUSIONS
The results of these FAB mass spectrometric and FAB 
tandem mass spectrometric studies with the GSH con­
jugate of NMF indicate that adducts with the novel S-
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carbamoylglutathionc structure behave in a generally 
similar fashion to their more widely encountered S-alkyl 
and S-aryl counterparts. However, fragmentation 
involving loss of the xenobiotic moiety with accom­
panying hydrogen transfer to the charged species (ion i) 
appears to be unique to this group of metabolites, 
where it should prove to be of diagnostic utility.
Formation of alkoxycarbonyl methyl ester derivatives 
of 1 had a marked directing influence on the CAD 
spectra of the [M + H ]+ ion, a feature which should 
prove to be of value in the design of experiments to 
detect specific GSH conjugates in biological samples by 
FAB mass spectrometric techniques. Thus, by analogy 
with the proposed use of constant neutral loss scanning 
for 129 u (formation of ion e) as a means of screening 
complex mixtures for native GSH adducts,26,30 neutral 
loss scans for elimination of both the derivatized gly- 
cinyl and y-glutamyl residues (formation of ions a and e, 
respectively) in the CAD spectra of alkoxycarbonyl 
methyl esters should, in principle, provide an increased 
degree of specificity for the detection of such conjugates.
Finally, this work has confirmed and extended the 
findings of others26,29,30 who have reported on the 
value of tandem mass spectrometric techniques for the 
characterization of GSH conjugates, and further indi­
cates that the combination of aqueous phase derivatiza- 
tion procedures33 and contemporary mass 
spectrometric methods represents a powerful approach 
to the study of this toxicologically important class of 
xenobiotic conjugates.
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A B o te  on
NMR AS AN AID IN STUDYING A-ALKYLFORMAMIDES 
AND METABOLITES t
Michael D. Threadgill4 and Andreas Gescher
Cancer Research Campaign Experimental Chemotherapy Group 
Pharmaceutical Sciences Institute, Aston University 
Aston Triangle, Birmingham B4 7ET, U.K.
The common industrial and laboratory solvent DMF^and its close 
analogue NMF share the ability to cause hepatotoxicity in man. They 
differ, however, in their biological properties towards rodents. 
NMF is a hepatotoxin towards rats and mice and shows significant 
activity against tumours of murine [1] and human [2] origin grown 
in mice. DMF shows neither strong therapeutic nor hepatotoxic activity 
in mice, whereas NEF in mice shows hepatoxicity only {1, 3]. The 
explanation for these comparisons and contrasts may be connected 
with the nature and quantity of the metabolites formed from different 
A-alkylformamides in the various species. The characterization of 
the urinary metabolites by conventional techniques such as MS and 
UV spectrometry is hampered by their lability and lack of a suitable 
chromophore.
NMR spectroscopy was used to overcome these problems in two 
ways. Firstly, 1H-NMR spectra were obtained using a Bruker WH400 
spectrometer at 400 MHz on 0.5 ml samples of urine from mice to which 
DMF, NMF or other analogues had been administered at -7.0 mmol/Kg. 
No other manipulation such as derivatization was involved, but 0.05 ml 
D20 was added so as to provide a lock signal for the spectrometer. 
Sodium 3-(trimethylsilyl)propan-l-sulphonate was also added, as 
an internal chemical shift standard. Suppression of the H20 signal 
(6 4.80) was achieved by selective presaturation (1.5 sec) and was 
followed by collection of the free induction decay after 4 dummy
"•■See also J.K. Nicholson et al. , art. #D-1 in Vol. 16, this series.- Ed. 
*
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f A b b rev ia tio n s .- Formamide derivs.: A,A-dimethyl, DMF; A-methyl, 
NMF; A-ethyl, NEF; see  over fo r HMMF. A-acetyl-S-(A-methylcarba*n- 
oy1)cysteine, AMCC; if Et, not Me: AECC.
390 .M/D- Threadqill & A- Gescher I#NC(F)-6
scans. This technique permitted satisfactory *H spectra to be recorded 
for the 6 ranges tr-A and 6—11 and so resonances* arising from most 
of the protons of the various metabolites of the formamides could 
be resolved, with the exception of those of NCH20K groups which have 
chemical shifts in the 6 range A.3-5 [A].
By comparison of the chemical shifts of the CHO protons(S 8.03 
for rotamer, 7.93 for E) and NCH3 protons (6 3.05 and 2.91 E) 
in synthetic M-(hydroxymethyl)-tf-methylformamide (HMMF) with those 
of signals in the urine of mice which had been treated with DMF, 
it was possible to show [A] that the major urinary metabolite of 
DMF in rodents is HMMF. This product is degraded to NMF under GC 
and MS conditions, leading to previous reports [5, 6] of NMF as the 
major metabolite of DMF; this demonstrates the value of the non-destruc­
tive nature of direct NMR analysis.
Similarly, A’-(hydroxymethyl)acetamide was shown to be the almost 
exclusive urinary metabolite of ff-methylacetamide in mice [3]. The 
corresponding direct ^-NMR spectra of urine of mice which had received 
NMF and NEF indicated the presence of the parent compound and the 
corresponding amine (methylamine and ethylamine respectively). 
Additionally fcf. observations by J.K. Nicholson et al. (p. 331 in 
Vol. 16)- Ed.], signals corresponding to the SCONHalkyl and NC0CH3 
protons of the corresponding mercapturic acids (AMCC and AECC) were 
observed in thse direct urine spectra, as shown in Fig. 1.
The two principal drawbacks encountered by us with the above 
straightforward direct method were insufficient sensitivity and over­
lapping of signals of metabolites with those of endogenous compounds. 
The latter problem led to difficulties in full characterization of 
the above mercapturic acids and, in some cases, in relative quantita­
tion. These could be obviated in some respects by the second applica­
tion of NMR spectroscopy. In this, the metabolites were isolated 
from urine by TLC or HPLC and the resulting pure or partially pure 
metabolite was analyzed by 1H-NMR at A00 MHz in an appropriate solvent 
[usually CDC13, (CD3)2S0 or D20j. Thus, metabolites present in lower 
concentration could be characterized, although >300 pg of material 
was still required. The mercapturic acids AMCC and AECC were fully 
identified by this less direct approach by comparison of the NMR 
spectra of the isolated metabolites with those of synthetic material 
[3, 7].
*H-NMR clearly has an important role in the identification of 
abundant labile metabolites of non-chromophoric compounds such 
as formamides or acetamides, but is limited by the relative insensitivity 
of the technique and could not be applied to urinary metabolites 
arising from lower doses of the formamides in rodents or in human 
studies.
#NC)F)-6] Alkylformamides studied by NMR 3 9 1









Fig. 1. Partial ^-NMR spectrum (400 MHz) of 24 h collections of 
urine from control mice (A) ,  mice receiving 400 mg/kg NEF (B), 
and mice receiving 400 mg/kg NMF (C).
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( +  )-a-Vinylserirte has previously been found to be a com petitive inhibitor of serine hydroxymethyl- 
transferase, an important target in anti-tum our chem otherapy. The crystal structure of ( ± )-a-vinylserine 
w as determ ined by X-ray diffraction techniques, and m olecular modelling w as used to  build the am ino 
acid pyridoxal 5 '-m onophosphate Schiff's base. M olecular-m echanics calculations indicate that the 
reacting conformation for the cleavage of the  a~P bond of the com pound w hen bound to 
pyridoxal 5 '-m onophosphate is achievable. However, th is com pound, w hen incubated with 
hom ogeneous rabbit-liver serine hydroxymethyltransferase, w as not dehydroxymethylated under any 
conditions, nor could any quinonoid interm ediates be detected . Circular dichroism spectroscopy 
indicates that this molecule is not an effective enzym e inhibitor because it is not forming an imine base 
w ith the pyridoxal phosphate at the active site of the  enzyme.
Serine hydroxymethyltransferase (EC 2.1.2.1), an enzyme which 
requires pyridoxal 5'-monophosphate (1), catalyses the inter­
conversion of L-serine (2) and glycine (3) in the presence of 
tetrahydrofolate, generating a one-carbon unit in the form of 
/V5,Afl0-methylenetetrahydrofolate.2 This one-carbon unit is 
used in the biosynthesis of purines, pyrimidines, and 
methionine. The enzyme has been shown by many workers to be 
an apposite target for anticancer therapy.3 While effective 
inhibitors for many other pyridoxalphosphate-requiring 
enzymes have been developed by a combination of serendipity 
and rational synthesis, few have been found for this enzyme. D- 
Fluoroalanine4 (4) is a weak inhibitor with a K, of 10-60 mmol
hoh2c \ .  h 
+ X
HjN ^ C 0 2
(2 )
HV 'CH/
h, n ^ ^ co;
(4)
H. H 
H3N ^  ^ C 0 "  
(3)
hoh2c c = ch2
+ / X .
HjN ^ C 0 2
(5)
dm-3. L-a-Vinylserine (5) was rationally designed to be an 
enzyme-activated irreversible inhibitor of serine hydroxymethyl­
transferase, based on the knowledge that the enzyme is capable 
of dehydroxymethylating z-substituted serine analogues.5 
However, ( ±  )-a-vinylserine was found to be a competitive 
inhibitor 5 with K, 15.2 mmol dm"3. The weakness of inhibition 
and the lack o f time dependence may be attributable to one of 
three possible events occurring at the active site of the enzyme, 
(a) The compound may compete with L-serine for the active site 
but fail to bind via formation of an external aldimine. (b) The 
compound may bind to the active site pyridoxal phosphate 
without undergoing dehydroxymethylation. (c) The compound 
may bind and be dehydroxymethylated, but the product may be 
a Michael acceptor which reacts with other nucleophiles before 
it can react with the enzyme (or is unreactive). In order to 
distinguish between these hypotheses, the crystal structure of 
( ±  )-*-vinylserine has been determined, its mode of interaction 
with the enzyme has been predicted by molecular modelling, 
and the extent of the reaction with the enzyme has been 
investigated by biochemical techniques.
The likelihood of dehydroxymethylation was considered first. 
Dunathan6 predicted that if an amino acid, bound to 
pyridoxal phosphate as an external aldimine, is to lose a group 
from its a-carbon, enhancement of the delocalisation energy of 
the system must occur. The greatest drop in energy will be 
achieved when the bond to be broken is in a plane perpendicular 
to the delocalised system, giving an overlap of the a  bond 
orbitals of the *~P bond and the n orbitals of the imine function.
Molecular modelling was used to construct the serine pyri­
doxal phosphate SchifTs base, as shown in Figure 1, starting 
from the crystal structure of pyridoxal 5 -phosphate as derived 
by Fujiwara. 7 When the serine N(6)-C(2) bond is rotated in 
increments of 10°, two relative energy minima appear (Figure 2). 
The conformation corresponding to one of these mimima (0
t  Present address: Department of Pharmaceutical Sciences. University 
of Nottingham. University Park. Nottingham NG7 2RD
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Figure 1. The modelled L-serine-pyridoxal phosphate  SchifTs base.
Table 1. Fractional co-ordinates with estimated standard deviations in
parentheses.
Atom X y
C(l) 0.775 3(6) 0.257 2(6) 0.669 2(6)
C(2) 0.725 8(5) 0.241 1(6) 0.777 1(6)
C(3) 0.713 3(6) 0.370 8(7) 0.835 2(7)
C(4) 0.602 0(6) 0.179 2(8) 0.705 5(8)
C(5) 0.568 8(7) 0.069 5(9) 0.726 2(10)
N(6) 0.810 7(5) 0.158 6(4) 0.893 9(5)
0(7) 0.853 4(4) 0.180 5(4) 0.673 3(4)
0 (8) 0.726 8(5) 0.344 9(5) 0.584 1(5)
0(9) 0.824 3(5) 0.440 0(4) 0.887 9(5)
C(l') 0.124 6(5) 0.209 1(6) 0.115 9(6)
C(2') 0.182 3(5) 0.243 8(6) 0.270 7(6)
C(3') 0.1704(6) 0.130 6(6) 0.354 4(6)
C(4') 0.314 2(6) 0.275 3(7) 0.323 2(7)
C(5') 0.374 3(7) 0.364 9(7) 0.408 3(8)
N(6') 0.112 3(5) 0.355 7(5) 0.288 8(5)
0(7') 0.038 0(4) 0.276 4(4) 0.034 5(4)
0 (8') 0.169 7(4) 0.116 8(4) 0.080 9(4)
0(9') 0.049 0(4) 0.093 6(4) 0.312 5(5)
H(l) 0.917 0.204 0.962
H(2) 0.818 0.067 0.861
H(3) 0.772 0.155 0.975
H(4) 0.663 0.371 0.904
H(5) 0.659 0.405 0.758
H(6) 0.559 0.239 0.623
H(7) 0.494 0.062 0.640
H(8) 0.638 0.028 0.833
H(9) 0.854 0.455 0.968
H(I') 0.021 0.337 0.199
H(2) 0.142 0.350 0.401
H(3) 0.117 0.444 0.247
H(4') 0.217 0.053 0.356
H(5') 0.210 0.156 0.438
H(6 ) 0.367 0.216 0.261
H(7') 0.469 0.371 0.443
H(8 ) 0.338 0.426 0.459
H(9) 0.015 0.136 0.362
36 72 106 1U 180 216 256 288 324 360
Torsionf C(8 ) —  N(6)---- C(2)-----H
Figure 2. Effect of the rotation of the N(6)-C(2) bond of the modelled l -  
serine-pyridoxalphosphate SchifTs base on the potential energy of the 
model.
Figure 3. p l l t o  draw ing of the tw o structurally  independent molecules 
o f x-vinylsenne in the asym m etric unit.
320°) has the scissile bond nearly perpendicular to the n system 
and is very similar to the preferred reacting conformation for the 
cleavage of the a-|3 bond.6 Other bonds were kept fixed in this 
study. 31P N.m.r. studies have shown that no change in the 
environment of the phosphate group occurs when pyridoxal 
phosphate binds L-serine.8 The fixed phosphate position is 
responsible for the apparent high-energy interaction when the 
torsion angle is ca. 130°. but this is irrelevant to the successful 
construction of a model with low energy as well as favourable 
geometry for dehydroxymethylation.
The A'-ray diffraction crystal structure of ( ±  )-»-vinylserine 
was determined by direct methods and refined by the full-matrix 
least-squares method. The presented data for the zwittcrionic
compound confirm the inferences from spectroscopic data,5
with bond angles and lengths being essentially as predicted. The 
study reveals two structurally independent but nearly 
superimposable molecules as shown in Figure 3. Both have the 
carboxy group and C(2}-N(6) bond in the same plane, with one
hydrogen atom of the ammonium group being in a near-eclipsed 
conformation that favours intramolecular hydrogen bonding 
(Table 5). Corresponding bond distances in the two molecules 
do not differ significantly (A <  1.7a) from each other.
Differences from those in ( ± )-serine, which was refined from
neutron-diffraction data by Frey et a l9 starting with the co­
ordinates proposed by Shoemaker et al..10 are slight. The
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Table 2. Bond lengths/A for non-hydrogen atoms in ( + )-a-vinylserine 










Table 3. Bond angles/® for non-hydrogen atoms in (+ >-a-vinylserinc
with estimated standard deviations given in parentheses.
Unprimed Primed
C(2)-C(l)-0(7) 117.8(5) 117.6(5)
C(2K (1K >(8) 114.5(4) 117.1(5)
0(7)-C (l)-0(8) 127.7(6) 125.3(6)
C(D-C(2>-C(3) 110.9(5) 109.7(5)
C( 1 )-C(2>-C(4) 108.3(4) 110.9(5)






Table 4. Torsion angles/® for all non-hydrogen atoms in (+  )-a-vinyl-
serine.
Unprimed Primed
0(7)-C( 1 )-C(2)-C(3) 137.7 119.15
0(7)-C( I )-C(2)-N(6) 17.4 12
0 (8 K ( 1 K ( 2 K ( 4 ) 74.4 58.6
C( 1 )-C(2)-C(4)-C(5) 114.1 139.8
Q3>-c (2h :(4h :(5) -125.3 -99.4




N(6>-C(2)-C(4)-C(5) -5 .6 19.6
The estimated standard deviations range from 0.7-1.0®.
Table 5. Hydrogen bonds present in the unit cell ol‘ a-vinylserine.
Distance (A)
Bond ,-------------- »----- --------- > Angle (®)
a-b • • • c a-b b-c a —  c a-b-c
N(6)-H( 1) • • • 0(7'') 1.27 1.54 1806 172
N(6)-H(2) - - • 0(8 ") 1.04 2.00 2.888 141
N(6)-H(3) —  0(8) 1.16 1.51 2.677 177
N(6>H(I') • • • 0(7"') 1.13 1.96 2.888 136
N(6')-H(2') —  0(8') 1.10 1.84 2.910 164
N(6>H(3 ) • - - 0(9*v) 1.04 2.25 3.182 149
0(9>-H(9) - - - 0 (7V) 0.79 2.63 3.189 130
0(9)-H(9) • - • 0(7'*) 0.79 2.77 2.935 94
0(9>H (9') - - • 0(7'v) 0.92 1.97 2.803 149
Symmetry code: (I) 1 + .v.y. 1 + r; (II) 1 -  .v. - r . I -  .-.(III) -1  + jr.
\ -  j r .-  { + r, (IV) 1 -  ,v. 1 y. 1 -  (V) v. 5 -  >•< i + --
fractional co-ordinates for ( +  )-a-vinylserine are given in Table
1. and the bond lengths and angles in Tables 2 and 3 
respectively. Torsion angles are given in Table 4.
Similar conformational calculations were then carried out for 
the modelled L-a-vinylserine-pyridoxal 5'-phosphate imine 
(Figure 4). The C(2)-C(4) and N(6)-C(2) bonds were rotated
simultaneously and the potential energy was calculated. The 
data are presented in the form of a contour plot in Figure 5. 
Relative minima of I kcal mol-1 above the global minimum are 
observed at conformations (300°, 330°) and (70°. 20°). The 
former corresponds to the required conformation for cleavage 
of the a-p bond.6 This indicates that, for a modelled system, 
there are no conformational energy restrictions which inhibit 
the dehydroxymethylation of L-a-vinylserine. It is unknown 
whether this conformation can occur in the active site of the 
enzyme. Although calculations suggest that both serine and a- 
vinylserine would be able to be dehydroxymethylated by serine 
hydroxymethyltransferase the crystallographic packing of these 
two racemic compounds differs markedly. Four pairs of isomers 
of ( +  )-a-vinylserine are found in the unit cell, with the 
enantiomers bound together by hydrogen bonds of which four 
have a H • • • O distance <2.3 A, as shown in Table 5. In the 
crystalline state, ( ±  )-a-vinylserine is orientated such that the 
polar carboxylate, alcohol and ammonium groups point 
towards the edge of the unit cell. The vinyl groups are directed 
towards the centre of the unit cell, creating alternate polar and 
non-polar planes extending throughout the crystal. This 
packing is different to that found in ( ±  )-serine,9 10 where the 
unit cell was found to contain sheets o f serine stacked parallel to 
the [ 100] face.
In order to investigate whether ( +  )-a-vinylserine is 
dehydroxymethylated by the enzyme, the compound (20  mmol 
dm'3) was incubated with homogeneous rabbit-liver cytosolic 
serine hydroxymethyltransferase and tetrahydrofolate over a 
period of 1 h. No production of methylenetetrahydrofolate 
could be detected under any conditions, suggesting that no 
cleavage of the a- 0  bond was occurring with this compound. 
This hypothesis was then further investigated using u.v. 
spectroscopy. The u.v. absorption spectrum of the enzyme has 
been studied and the intermediates produced on de­
hydroxymethylation have been characterised." It is known 
that the quinonoid intermediate produced upon a-P bond 
cleavage has a characteristic absorption at 500 nm; 12 this can be 
amplified by the addition of tetrahydrofolate, which inhibits the 
re-protonation of the quinonoid. 13 When (±)-*-vinylserine (20 
mmol dm-3) was incubated with the rabbit-liver enzyme, no 
change in the u.v. absorption spectrum occurred and no 
quinonoid intermediate was detected. The effect of incubating 
the enzyme with glycine (5 mmol dm"3) and tetrahydrofolate 
(0.7 mmol dm '3) is shown in Figure 6 .
Thus a-vinylserine is not bio-activated. This failure may 
imply that the compound binds to the active site of the enzyme 
without cleavage of the a-P bond, or the compound may not 
even bind to the active site. Circular dichroism (c.d.) 
spectroscopy was used to investigate these alternative 
explanations. Although pyridoxal phosphate is achiral, it has an 
induced optical activity when bound in the asymmetric environ­
ment of an enzyme.14 In pyridoxal-phosphate-dependent 
enzymes a strong positive Cotton effect is observed due to 
n—»jt* transitions in the aldimine chromophore.14 The c.d. 
spectra of cystosolic rabbit-liver enzyme 8 and the Escherichia coli 
enzyme 15 have this absorption band present. Conversion of the 
internal aldimine into the external aldimine induces a change in 
the 320-500 nm region of the c.d. spectrum. 15 The effect of 
50 mmol dm-3 ( ±  )-a-vinylserine on the c.d. spectrum is shown 
in Figure 7. Similar results were obtained for the buffer control. 
The drop in the is due to a dilution effect and indicates that 
no new aldimine bond is being formed by this compound, i.e. 
that the compound does not bind covalently to the pyridoxal 
phosphate in the active site of the enzyme. This is unlike the 
effect of the addition of 50 mmol dm ' 3 glycine, a positive 
control. This amino acid is forming a new aldimine bond and 
therefore changes the c.d. spectrum. The finding that ( ±  l-a- 
vinylserine is not a substrate due to the inability of the
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Torsion/* C(8)— N(6 )— CC2)— C(4)
Figure S. Effect of the simultaneous rotation of the C(2)-C(4) and 
N(6>-C(2) bonds of the modelled a-vinylserine-pyridoxal phosphate on 
the potential energy of the model (contours in kcal mol'1).
compound to bind covalently to the pyridoxal phosphate at the 
active site of the enzyme is unexpected. It is known that other *- 
vinylamino acids are enzyme-activated irreversible inhibitors of 
pyridoxal phosphate-dependent enzymes, e.g. a-vinyldopa 
inhibits dopa decarboxylase. 16 The mechanism of transimin- 
ation is well known 17 and there is no apparent reason why it 
should not occur with a-vinylserine. especially as it is known 
that serine hydroxymethyltransferase can dehydroxymethylate 
a-substituted serines such as s-methyl-. a-ethyl-, and a- 
hydroxymethylserine. ' 8 These amino acids have a-substituents 
that are approximately isosteric with the vinyl group. The 
reasons for the lack of binding of this compound is unknown.
This work suggests that the design and synthesis of new *- 
substituted serine analogues as potential inhibitors of serine 
hydroxymethyltransferase may not yield effective inhibitors of 
this enzyme. It is, however, noted that a-fluoromethylserine with 
its small a-substituent may be an active inhibitor and routes to 
the synthesis of this compound are being investigated in this 
laboratory.
Experim ental
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Figure 6. Effect of the addition  of glycine 5 mmol dm"5 (-  -  -  -)  and 
then te trahydrofolate (0.7 mmol dm "1) ( -  • -  - )  on the absorp tion  of 
purified rabbit-liver serine hydroxym ethyltransferase (------ ).
methylbut-2-enoic A cid ].— ( +  )-*-Vinylserine was prepared as 
previously described.5 The compound (100 mg) was dissolved in 
water (10 cm 3) and warmed gently. Hot ethanol (20 cm 3) was 
added and the solution was allowed to stand for 14 days at 
ambient temperature. The crystalline florets of needles were 
separated by sonicating the suspension for 2 x 5 s. The suspen­
sion was then filtered and the crystals dried in vacuo for 3 days. A 
specimen 0.7 x 0.07 x 0.055 mm was mounted about the needle 
axis on a glass fibre for collection of Af-ray diffraction data.
Crystal Data.— C sH9N 0 3. M =  131.1. monoclinic. a = 
12.346(3). b =  10.442(4), <■ =  10.763(5) A. p = 116.70(3), V =
1 239.7 A3 (by least squares analysis of setting angles of 25 
reflections. X = 0.710 69 A), space group P2XU\ Z  = 8.





Figure 7. Effect of the addition of amino acids on the c.d. absorp­
tion spectrum of purified rabbit-liver serine hydroxymethyltransferase:
(--------) enzyme alone; (------ ) effect of addition of buffer alone or a-
vinylserine (50 mmol dm'1); (- —  -) effect of the addition of glycine 
(50 mmol dm'3).
Dm =  1.41 g cm '3, Dx =  1.42 g cm*3, p(Mo-K,) =  0.75 cm '1, 
F(000) =  560.
D ata Collection and Processing.— Enraf-Nonius four circle 
CAD-4 diffractometer, co/20 scans, co scan width (1.0 +  0.35 
tan0)°, co scan speed of 0.5-5° min' 1 depending on intensity, 
graphite monochromated Mo-K,), 4 612 reflections measured 
(2 <  0 <  25°), 2 177 unique (merging R 0.0561). 1 037 
Reflections deemed observed with |/"0| >  SaflFJ). Standard 
deviations were calculated on the basis o f counting statistics and 
instrument instability. Intensity and orientation monitor 
reflections indicated no need to correct for time-dependent 
instability. Maximum (sin0)/X reached was 0.63 with range h , k ,  
/, 0 -12 , — 14 to 14, and — 12 to 12 respectively. No correction 
was made for absorption.
Structure Analysis and Refinement.— The crystal structure 
was solved by direct methods using the shelx-76 program; 19 
hydrogen atoms were located in difference electron density 
maps. Non-hydrogen atom positions and anisotropic thermal 
parameters together with group isotropic temperature factors 
for the hydrogen atoms were refined by the full-matrix least- 
squares technique based on the stored scattering factors (using 
the same temperature factors for structurally equivalent 
hydrogen atoms in the two independent molecules comprising 
the asymmetric unit).* The weighting scheme it =  (a 2(|F0|) +
0.008|To|2)-' gave satisfactory agreement analyses. The final R 
and values are 0.0648 and 0.0693 respectively, with a 
goodness-of-fit ratio of 5  = 1.35. Molecular drawings were 
obtained using the p lu to  program developed by Motherwell 
and Clegg .20
Molecular Calculations.— Molecular-mechanics conform- 
ational-energy calculations were performed using the Glaxo 
Group Research molecular modelling system. The structure of 
L-serine was taken from fragments constructed from the internal
• Supplementary data (see section 5.6.3 of Instructions for Authors, in 
the January issue). Thermal parameters have been deposited at the 
Cambridge Crystallographic Data Centre.
database of the system. The crystal structure of pyridoxal 5'- 
phosphate derived by Fujiwara7 was obtained from the 
Cambridge Crystallographic Database.21 Conformational- 
energy calculations were performed by the summation of the 
individual components for the non-bonded and torsional 
energies.22
Enzyme Purification and Activity Assays.—The cytosolic 
rabbit-liver serine hydroxymethyltransferase was purified as 
previously described.23 The purity of the enzyme was deter­
mined by sodium dodecyl sulphate polyacrylamide gel electro­
phoresis and the enzyme found to be a single band with the same 
Rf value as that previously obtained.23 The determination of 
enzyme activity and the detection of the dehydroxymethylation 
of ( ±  )-x-vinylscrine utilised a coupled assay involving /V5^ 10- 
methylenetetrahydrofolate dehydrogenase as described by 
Schirch et al.2A
The absorption spectra were recorded on a Cary 210 
spectrophotometer, using degassed solvents, with the cuvette 
temperature maintained at 30 °C. The spectrum of hom o­
geneous rabbit-liver enzyme (2 mg ml"1) in 50 mmol dm "3 
potassium phosphate pH 7.3 was recorded between 300-530 nm 
against buffer alone. The amino acid under test dissolved in the 
buffer was then added and the absorption spectrum of the 
enzyme was re-recorded during 1 h.
In order to amplify the production of the stabilised quinonoid 
intermediate, 0.7 mmol dm"3 tetrahydrofolate and 30 mmol 
dm"3 2-mercaptoethanol was added and the cuvette was sealed. 
The absorption spectrum between 460-530 nm was re-recorded 
over a time period of 30 min.
C.d. spectra were recorded on a Jasco J-500C spectropolari- 
meter. A 1 cm pathlength ceil was used with all buffers degassed 
prior to use. The c.d. spectrum of homogeneous cytosolic 
rabbit-liver enzyme (3.1 mg cm"3) in 50 mmol dm-3 potassium  
phoshate pH 7.3 was recorded between 300-530 nm at a scan 
rate of 50 nm min-1. The amino acid under test (5 mmol dm -3 in 
buffer) was added to the cell and the spectrum was re-recorded.
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Butylation of 2-Methylnaphthalene-2,4-dione (Menadione) by Solvent Sulpholane 
During Radical Methylation and Ethylation
M. D. Threadgill
Synthetic Communications, 1989,1 9 ,167-172.
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B U T Y L A T I O N  OF  2 - M E  T H Y L N A P H T  H A L E N E  -  1 . <> -  D I ONE  
( ME NA 0  I O N E ) B Y  S O L V E N T  S U L P H O L A N E  D U R I N G  R A D I C A L  
M E T H Y L A T I O N  A N D  E T H Y L A T I O N
M i c h a e l  D .  T h r e a d g i l l *
P n a r m a c e u t i c a l  S c i e n c e s  I n s t i t u t e .  A s t o n  U n i v e r s i t y .  
A s t o n  T r i a n g l e .  B i r m i n g h a m  B 4 7 E T .  U . K .
A B S T R A C T :  T r e a t m e n t  o f  2 - m e t h y I n  a p h t h a l e n e -  1 . 4 - d i o n e
w i t h  p o t a s s i u m  p e r o x y d i s u l p h a t e , s i l v e r  n i t r a t e  a n d  
a c e t i c  o r  p r o p a n o i c  a c i d s  i n  a q u e o u s  s u l p h o l a n e  g a v e  
3 - D u t y l - 2 - m e t h y l n a p n t h a l e n e - l . 4 - d i o n e  i n  a d d i t i o n  t o  
t h e  e x p e c t e d  3 - a l k y l - 2 - m e t h y l n a p h t h a l e n e - 1 . 4 - d i o n e s .
A s e r i e s  o f  3  -  a l k y 1 - 2 - m e t h y l n a p h t h a l e n e -  1 . 4 - d i o n e s
( n a p h t h o q u i n o n e s )  r e l a t e d  t o  m e n a d i o n e  ( J . )  w a s
1 2
r e q u i r e d  f o r  s t u d i e s  ' o n  t h e  m e c h a n i s m s  o f
m e t a b o l i s m  a n d  t o x i c i t y  o f  t h e s e  c o m p o u n d s  i n  m a m m a l s  
a n d  f o r  f u r t h e r  s i m i l a r  i n v e s t i g a t i o n s .
M e n a d i o n e  w a s  t r e a t e d  w i t h  p o t a s s i u m  p e r o x y d i s u l p h a t e . 
s i l v e r  n i t r a t e  a n d  a c e t i c  o r  p r o p a n o i c  a c i d s  i n
* T o  w h o m  c o r r e s p o n d e n c e  s h o u l d  b e  a d d r e s s e d  a t  
MRC R a d i o b i o l o g y  U n i t .  C h i l t o n ,  D i d c o t  . O x f o r d s h i r e .  
0 X 1 1  O R D . U . K .
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a a u e o u s  s u l p h o l a n e  ( t e t r a h y d r o t h i o p h e n e - S  . S - d i o x i d e ) 
a c c o r d i n g  t o  t n e  g e n e r a l  m e t n o d  o f  J a c o b s e n  a n d  
T o r s s e l l . ' 3 T h e  m a g o r  p r o d u c t s  ( i s o l a t e d  b y  c o l u m n  
c h r o m a t o g r a p h y )  w e r e  2 . 3  -  d i m e t h y I n a p h t h a l e n e -  1 . i - d l o n e  
( 2 ) a n d  3 - e t h y 1 - 2 - m e t h y I n a p h t n a  1 e n e -  1 . i - d i o n e  ( 2 *
r e s p e c t i v e l y .  a r i s i n g  f r o m  a l k y l a t i o n  b y  m e t h y l  a n d  
e t h y l  r a d i c a l s  f o r m e d  b y  o x i d a t i v e  d e c a r b o x y l a t i o n  o f  
t h e  s i l v e r  c a r b o x y l a t e s  f o r m e d  i n  s i t u . H o w e v e r ,  
d u r i n g  t h e  e t h y l a t i o n  r e a c t i o n  w h i c h  g a v e  ( 3 . )  i n  6 8  I. 
y i e l d ,  a t r a c e  o f  a  l e s s  p o l a r  b y - p r o d u c t  w a s  o b s e r v e d  
b y  t . l . c .  T h e  s a m e  c o m p o u n d  w a s  o b t a i n e d  i n  1 7. y i e l d
w h e n  ( j _)  w a s  t r e a t e d  w i t h  M e C O  2 H /  K 2 S 2 0 8 /  A g N O  3 i n  
a q u e o u s  s u l p h o l a n e  a n d .  a f t e r  i s o l a t i o n  b y  c o l u m n  
c h r o m a t o g r a p h y .  w a s  c h a r a c t e r i s e d  a s  3 - b u t y l - 2 -  
m e t h y l n a p h t h a l e n e - 1 . a - d i o n e  ( O  . S i n c e  t h i s  m a t e r i a l  
w a s  n o t  f o u n d  w h e n  s u l p h o l a n e  w a s  r e p l a c e d  b y  
a c e t o n i t n l e  a s  t h e  c o - s o l v e n t ,  a c c o r d i n g  t o  a w i d e l y -  
u s e d  m o d i f i c a t i o n 4 6 o f  t h e  o r i g i n a l  p r o c e d u r e .  i t  
i s  h i g h l y  l i k e l y  t h a t  t h e  C * u n i t  i s  d e r i v e d  f r o m  
t h e  s u l p h o l a n e .
T h e  g e n e r a t i o n  o f  m e t h y l  a n d  m e t h y I s u l p h 1 n y 1  r a d i c a l s  
f r o m  d i m e t h y l s u l p h o x i d e  ( D M S O )  h a s  b e e n  r e p o r t e d  b y
B e r t i l s s o n  e t  a l _7 w h o  i d e n t i f i e d  ( £ . )  a n d  2 -
m e t h y l s u l p h o n y I n a p h t h a l e n e -  1 . 1 - d i o l  a s  p r o d u c t s  o f  t h e
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t r e a t m e n t  o f  n a p h t h a l e n e - 1 , 4 - d i o n e  ' w i t h  F e n t o n ' s  
R e a g e n t  I H 2 0 2 / F e 2 * )  i n  t h a t  s o l v e n t .  I n t e r e s t i n g l y .  
r e p l a c e m e n t 7 o f  D MS O  b y  t e t r a h y d r o t h l o p h e n e - S - o x i d e
g a v e  ( 5 . )  a s  t h e  p r o d u c t  a r i s i n g  f r o m  h o m o  l y s i s  o f  t h e  
h e t e r o c y c l e ;  ( O  w a s  n o t  r e p o r t e d 7 a s  a  p r o d u c t .  I t
i s .  t h e r e f o r e ,  l i k e l y  t h a t  t h e  b u t y l  g r o u p  o f  ( O  d o e s  
i n d e e d  a r i s e  f r o m  t h e  s u l p h o l a n e .  r a t h e r  t h a n  f r o m  a n y  
t r a c e  t e t r a h y d r o t h i o p h e n e - S - o x i d e  p r e s e n t  a s  i m p u r i t y  
i n  t h e  s o l v e n t .  A p r o p o s e d  m e c h a n i s m  f o r  t h i s
u n e x p e c t e d  a n d  n o v e l  b u t y l a t i o n  i s  s h o w n  i n  t h e  
S c h e m e .
a s  b u t y l n a p h t h o q u i n o n e s  o f t e n  r e q u i r e  v e r y  c a r e f u l  
c h r o m a t o g r a p h y  f o r  s e p a r a t i o n  f r o m  l o w e r  a l k y l  
n o m o l o g u e s . t h e s e  o b s e r v a t i o n s  i d e n t i f y  t h e  s o u r c e  o f  
t h e s e  c o n t a m i n a n t s  i n  t h e  d e s i r e d  p r o d u c t s  o f  r a d i c a l  
a l k y l a t i o n  o f  n a p h t h o q u i n o n e s .  S u l p h o l a n e  i s .
t h e r e f o r e ,  i n d i c a t e d  a s  a n  i n a p p r o p r i a t e  s o l v e n t  f o r  
t h e s e  s y n t h e t i c  p r o c e d u r e s .
E X P E R I  M E N T A L
NMR s p e c t r a  w e r e  o b t a i n e d  i n  C D C I t a t  6 0  m h :  u s i n g  a 
v a n a n  E M 3 6 0 A  s p e c t r o m e t e r  a n d  a VG M i c r o m a s s  1 2 B  
i n s t r u m e n t  f u r n i s h e d  t h e  m a s s  s p e c t r a .  M e l t i n g  p o i n t s  
a r e  c o r r e c t e d .
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2 . 3 - D i m e t h y l n a p h t h a l e n e - 1 . 4 - d i o n e  ( 2 ) a n d  3 - b u t v l - ? -
m e t h v l n a p h t h a l e n e - 1 t - d i o n e ________ ( 4 ) . 2 -
M e t h y l n a p h t h a l e n e - i  . t - d i o n e  I J , :  6 . 8 8  g .  4 0  m m o l ) ,
a c e t i c  a c i d  ( 3 . 0  g .  5 0  m m o l )  a n d  s i l v e r  n i t r a t e  ( 2 . O g .
1 1 . 8  m m o l )  w e r e  h e a t e d  t o  8 0 ° C  i n  a m i x t u r e  o f  
t e t r a h y d r o t h i o p h e n e - S . S - d i o x i d e  ( s u l p h o l a n e :  8 0 m l )  a n d
w a t e r  ( 1 2 0  m l ) .  P o t a s s i u m  p e r o x y d i s u l p h a t e  ( 2 2 . 0 g .
8 1 . 5  m m o l )  w a s  a d d e d  d u r i n g  4 0  m i n  a t  8 0 ° C .  T h e
m i x t u r e  w a s  p o u r e d  o n t o  i c e  ( 4 4 0  g )  a n d  t h e  y e l l o w  g u m  
w a s  c o l l e c t e d  a n d  c h r o m a t o g r a p h e d  ( s i l i c a  g e l :  e t h y l
a c e t a t e :  h e x a n e  1 : 4 )  t o  g i v e  3 - b u t y l - 2 -
m e  t  h y  I n  a p h  t  h a l e n e  -  1 . 4 -  d i  o n e  ( 4 . :  8 0  m g .  1 Z )  f r o m  t h e  
f a s t e r  r u n n i n g  f r a c t i o n .  y e l l o w  n e e d l e s  M P t  6 7 - 8 ° C  
( l i t . 6 M P t  6 8 -  9 0 C ) . 6  0 . 9 5  ( 3 H  . t .  J  7 H z .
A r  C H 2 C H 2 C H 2 C H.3 ) . 1 . 4  ( 4 H .  m .  A r  C H 2 C H.2 C H 2 C H 3 ) . 2 . 2 5
( 3 H  . S .  A r C H  3 ) . 2 . 6 0  ( 2 H .  m .  A r  C H 2 C H 2 C H 2 C H 3 ) . 7 . 6 - 7 . 9
( 4  H . m.  A r H ) ; m / z  2 2 8  ( M * ) .  F r o m  s l i g h t l y  l a t e r
r u n n i n g  f r a c t i o n s  w a s  o b t a i n e d  2 . 3 -
d i m e t h y l n a p h t h a l e n e - 1 . 4 -  d i o n e  ( 2 . :  2 . 1 0  g ,  2 8  Z )
i d e n t i c a l  w i t h  m a t e r i a l  p r e v i o u s l y  r e p o r t e d 1 f r o m  t h e  
r a d i c a l  d i m e t h y l a t i o n  o f  n a p h t h a l e n e * 1 . 4 - d i o n e  .
A C K N O W L E D G E M E N T
T h e  a u t h o r  t h a n k s  M r s .  K . C .  F a r r o w  ( A s t o n  U n i v e r s i t y )  
f o r  t h e  m a s s  s p e c t r a .
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Synthesis of Peptides Containing iS,-(A/-Alkylcarbamoyl)cysteine Residues, 
Metabolites of iV-Alkylformamides in Rodents and in Man
M. D. Threadgill and A. P. Gledhill
Journal of Organic Chemistry, 1989, 54,2940-2949.
Synthesis of Peptides Containing S'-(Ar-Alkylcarbamoyl)cysteine Residues, 
Metabolites of N -A lkylform am ides in Rodents and in Humans
Michael D. Threadgill*-1 and Adrian P. Gledhill
Cancer Research Campaign Experimental Chemotherapy Group, Pharmaceutical Sciences Institute. Aston 
University, Aston Triangle. Birmingham 34 7ET, U.K.
Received August 24, 1988
Hydrochloride salts of S-(N-methylcarbamoyl), S-(A/-ethvlcarbamoyl), and S-(N,A'-dimethylcarbainoyH de­
rivatives of cysteine, A'-acetylcysteine, and cysteinylglydne have been prepared. S-(A:-Methyicarbamovl)glutathione 
hydrochloride has also been synthesized. Protecting groups for amino and carboxylic acid functions were selected 
for their ability to solubilize the peptides in dichloromethane in which solvent the thiols were treated with alkyl 
isocyanates and with NJV-dimethylcarbamoyl chloride. Removal of S-(amidomethyl) protecting groups using 
mercury(II) acetate was found to cause some loss of N-(ferf-butoxycarbonyl) groups. Elimination of disulfide 
was evident during coupling of disulfide derivatives of cysteine using mixed anhydride methods but not with 
a carbodiimide coupling agent. Mixed disulfide protections were reductively cleaved by propane- 1.3-dithiol. Many 
of the deprotected S-carbamoyl amino adds and peptides are metabolites of the corresponding A'-alkvlformamides 
in rodents and in humans.
TV-Substituted formamides have a variety of biological 
activities, both beneficial and adverse. N-Methylform- 
amide (NMF; la) has been found to be an antitumor agent 
in experimental systems2 and also to be an hepatotoxin,3-* 
whereas TV-ethylformamide (lb) has little or no anticancer 
activity2 but is also toxic to the liver.5 N^V-Dimethyl- 
formamide (DMF; lc), however, displays both of these 
effects only weakly in rodents.25-7 We have recently shown
(1) Author to whom correspondence should be addressed at: Medical 
Research Council Radiobiology Unit, Chilton, Didcot, Oxfordshire 0X11 
ORD. U.K.
(2) Gate. E. N.; Threadgill, M. D.; Stevens, M. F. G.; Chubb. D.: 
Vickers, L. M.; Langdon. S. P.; Hickman. J. A.; Gescher. A. J. Med. Chem. 
1986. 23, 1046.
(3) Laird Myers, W. P.; Karaofsky. D. A.: Burchenal, J. H. Cancer 
1956. 9, 949.
(4) Langdon. S. P.; Chubb. D.; Hickman. J. A.: Stevens. M. F. G. 
Toxicology 1985. 34, 173.
(5) Kestell. P.; Threadgill, M. D.; Gescher, A.: Gledhill. A. P.; Shaw. 
A. J.; Farmer, P. B. J. Pharmacol. Exp. Ther. 1987. 240, 265.
(6) Barnes, J. R_; Ranta. K. E. Toxicol. AppL Pharmacol. 1972,23. 271.
that the two secondary amides are metabolized to the 
corresponding mercapturic acids 5a.b in mice5 and that 
this metabolic pathway (Scheme I) is implicated5-8-9 in the 
hepatotoxicitv of la.b. A mass spectrometric study9 has 
also enabled the characterization of the glutathione de­
rivative 2a as a metabolite of la in mice. /V-Acetvl-S-(A'- 
methvlcarbamoy 1 )cysteine (5a) has also been detected7 in 
the urine of mice and humans exposed to lc, with an 
apparent parallel between the amount excreted and the 
extent of hepatotoxicitv. Selective oxidation of the formyl 
group of A’-methylformamide has been reported rarely in
(7) Kimmerlc. G.: Eben. A. Int. Arch. Arbeitsmed. 1975. 34. 109.
(8) Kestell. P.: Gledhill. A. P.: Threadgill. M. D.: Gescher. A. Biochem. 
Pharmacol. 1986. 35. 22S3.
(9) Threadgill. M. D.: Axworthy. D. B.: Bailiie. T. A.: Farmer. P. B.. 
Farrow. K. C.: Gescher. A.: Kestell. P.: Pearson. P. G.: Shaw. A. J. J  
Pharmacol. Exp. Ther. 19S7. 242. 312.
(10) Mraz. J.: Cross. H.: Threadgill. M. D.: Gescher. A.: Flek. J. Tox­
icol. Appl. Pharmacol., in press.
(11) Mraz. J.: Turecek. F. J. Chromatocr. 1987. 414. 399
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Scheme I. Partial Proposed Routes of Metabolism of 
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‘ Compounds 2a and 5a,b have been shown to be metabolites.
the chemical literature, oxidants being limited to transition 
metal ions,12 ketones (under drastic conditions in the 
Leukart reaction),13 and elemental selenium;14 the latter 
gives a carbamoylating intermediate possibly analogous 
to that formed in vivo. The synthesis of the proposed 
metabolic intermediates and the N,N-dimethyl analogues 
2-5 was therefore of importance for the study of their 
chemical, biochemical, and toxicological properties.
The preparation of S- (N-ethylcarbamoyl)cysteine (4 b) 
has been reported by Guttmann15 who used it as an S- 
protected cysteine during syntheses of glutathione (21) and 
oxytocin. In our laboratory, however, neither cysteine nor 
its N-acetylated analogue 6 reacted smoothly with methyl 
isocyanate in DMF according to this method.15 Treatment 
of N-acetylcysteine (6) with methyl isocyanate or with 
ethyl isocyanate in anhydrous pyridine at 0 °C gave 5a,b, 
respectively, in good yield.8 Higher temperatures (>15 °C) 
led to exclusive formation of the corresponding N- 
methylamide 7 from 6 and methyl isocyanate. A route of 
the type shown in Scheme II is likely to be involved, al­
though direct formation of N-substituted amides by 
treatment of carboxylic acids with isocyanates has been 
reported.16
Owing to the reactivity of isocyanates and dimethyl- 
carbamoyl chloride with polar solvents, protecting groups 
for amino and carboxyl functions of 6 and cysteine were 
sought, which would confer good solubility in the less polar 
and nonnucleophilic organic solvents. Facile removal upon 
mild treatment with add was also required in view of the 
lability of thiocarbamates to base.845 A suitably protected 
cysteine derivative 9 was prepared in high yield by the 
selective tert-butoxycarbonylation of cysteine methyl ester 
8 with di-tert-butyl dicarbonate in dichloromethane in the 
presence of a tertiary amine base (Scheme III). No re­
action of the thiol was observed under these conditions.
(12) Ahmed. F.; Basweni. V. S. Polyhedron 1984. 3. 977.
(13) Brewer. E.; Melumad. D. J. Ort . Chem. 1972. 37. 3939.
(14) Kondo, K.; Sonoda, N.; Sakurai, H. J. Chem. Soc., Chem. Com- 
mun. 1974, 160.
(15) Guttmann. S. Helv. Chim. Acta 1966. 49, 83.
(16) Blagbrough, I. S.; Mackenzie, N. E-: Ortiz. C.; Scott, A. I. Tetra­
hedron Lett. 1986. 27. 1251.
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®(i) RNCO/pyridine/O °C: (ii) MeNCO/pyridine/25 °C.
Scheme III. Syntheses of S-(N-Alkylcarbamoyl)cysteines 4 
and the Af-Acetyl Analogue 5c‘
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*(i) (Bu‘OCO),0/EtJN/CH,C1,; (ii) RNCO/(Pr*1NEt or EtjN)/ 
CHjCl,; (iii) Me,NCOC1/pyridine/CHjCljj (iv) NaOH/MeOH; (v) 
H*; (vi) 9 M aqueous HC1; (vii) Ac,0/pyridine (4c only).
The resulting N-protected ester 9 could be hydrolyzed 
smoothly with methanolic sodium hydroxide to N-(tert- 
butoxycarbonyl)cysteine (10). Now suitably protected and 
solubilized, 9 was carbamoylated smoothly by using the 
appropriate isocyanate or dimethylcarbamoyl chloride in 
dichloromethane. Deprotection of the resulting S-carba- 
moyl compounds lla,b and 12 to the desired cysteine 
derivatives 4 was effected by dissolution in concentrated 
hydrochloric acid for a prolonged period, a procedure to 
which the thiocarbamate proved largely inert. Subsequent 
acetylation of the N,N-dimethyl compound 4c with acetic
2942 J. Org. Chem., Vol. 54, No. 12, 1989 Threadgill and Gledhill
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*(i) PhCHjOCOCl/KOH/HjO; (ii) dicydohexylcarbodiimide/ 
CHjClj; (iii) GlyOCHjPh-HOTs/Pr'jNEt/CHjClj; (iv) Hg(OAc)2/  
HOAc/HjO/60 °C; (v) MeNCO/P^jNEt/CH,^; (vi) HBr/HOAc; 
(vii) (Bu*OCO)sO/NaOH/EtjO/HiO; (viii) Bu‘OCOCl/EtaN /  
CHjCl,; (ix) GlyOMe-HCl/EtaN/CHjC12; (x) Hg(0Ac), / various 
conditions.
anhydride in pyridine gave the mercapturic acid 5c.
For the syntheses of the dipeptide series of compounds 
3, initial approaches to a suitable amino- andcarboxy- 
protected and solubilized cysteinylglycine centered on the 
preparation of the N-(benzyloxycarbonyl)cysteinylglycine 
esters 16 and 17. Protection of the thiol moiety with an 
amidomethyl group was an attractive proposition as such 
groups are reported17 to be labile to mild acid in the 
presence of mercuric or cadmium ions, conditions to which 
N- (benzyloxycarbonyl) groups and carboxylic esters are 
stable. An intramolecular version of an S-(amido- 
methyl)-protected cysteine is available via acylation of 
l,3-thiazolidine-4-carboxylic add (thiaproline; 13) (Scheme 
IV). Both N-(benzyloxycarbonyl)thiazolidinecarboxylic 
add 14 and the N-(tert-butoxycarbonyl) analogue 18 
proved to be excellent substrates for the carbodiimide 
method of peptide coupling; N-[[N-(benzyloxy­
carbonyl)- i,3-thiazolidin-4-yl]carbonyl]glydne benzyl ester 
(15) and the methyl ester 19 of the corresponding N- 
(£er£-butoxycarbonyl) dipeptide were prepared in high 
yield. Treatment of the benzyl compound 15 with mer- 
cury(II) ions in warm aqueous acetic add caused depro­
tection at sulfur to give the thiol 16, whereas the N- 
(£er£-butoxycarbonyl) group of 19 was not stable to any
(17) Veber. D. F.; Milkowski, J. D.; Varga. S. L.; Denkewalter, R. G.: 
Hirschmann. R. J. Am. Chem. Soc. 1972. 94. 5456.
*(i) 4-tert-Butyl-N-(hydroxymethyl)benzamide/CF3C01H;18 (ii) 
(ButOCO)jO/Et3N/EtsO/H,0; (iii) CH*N2/Et,0; (iv) Hg(OAc)j/ 
MeOH or H0Ac/H,0.
similar conditions which would hydrolyze the “S-amido- 
methyl" function; thus 20 is unavailable by this route 
(Scheme IV). The dibenzyl compound 16 reacted with 
methyl isocyanate to give the S-(JV-methylcarbamoyl)- 
protected dipeptide 17 (Scheme IV). However, the S- 
carbamoyl moiety was found not to be stable to hydrogen 
bromide in acetic add in this case, in contrast to the 
analogous deprotections reported to be useful by Gutt­
mann.15 Only traces of the correct S-(N-methyl- 
carbamoyl)cysteinylglydne (3a) could be detected by mass 
spectrometry (cesium ion liquid secondary ionization MS) 
in the crude product mixtures. In the tripeptide series, 
a sample18 of the S-protected glutathione 22 was £er£-bu- 
tyloxycarbonylated at nitrogen, giving 23, and the dimethyl 
ester 24 was formed (Scheme V). Again, no conditions 
could be found in which the N-BOC function outlasted the 
S-amidomethyl group. Alternative methods of removal of 
amidomethyl protecting groups either destroyed the N- 
BOC group (Cd2+/acetic acid) or were considered to be 
inappropriate.19-20
A conceptually different form of temporary inactivation 
of thiols as irreversible nucleophiles is to form either 
symmetrical or mixed disulfides from which the thiol can 
be unmasked by reduction. Owing to some difficulties in 
separating the coformed N^'-dicydohexylurea from the 
products from the carbodiimide couplings above, a cleaner 
coupling system was investigated for the reactions of the 
symmetrical disulfides, N^V-bis(£er£-butoxycarbonyl)- 
cystine (26b) and N,N-bis(benzyloxycarbonyl)cystine 
(26c), and the unsymmetrical disulfide N-(£er£-butoxy-
(18) Addison. S. J.; Cunningham. B. D. M.; Gate. E  N.; Shah, P. Z.; 
Threadgill. M. D. J. Chem. Soc.. Perkin. Trans. 1 1985. 75.
(19) Moroder. L.; Marchiori. F.; Borin. G.; Schoffone. E. Biopolymers 
1973. 12, 493.
(20) Fontana. A. J. Chem. Soc.. Chem. Commun. 1975. 976.
(21) Anderson. G. W.; Zimmerman. J. E.; Callaghan. F. M. J. Am. 
Chem. Soc. 1966. 88. 133S.
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Scheme VI. Preparation of S-(AT-AlkylcarbamoyI)cyateinyIglycines 3 and Elimination of RSS~ during Mixed-Anhydride
Coupling*
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(vii) 9 M aqueous HC1.
carbonyl)-S-(£ert-butylthio)cysteine (26a) (Scheme VI). 
The “mixed-anhydride" method has been widely used to 
form amide bonds and mixed carboxylic-carbonic anhy­
drides derived from isobutyl chloroformate have been re­
ported13 to be particularly effective. In the present case, 
NJV'-di-BOC-cystine 26b was treated with isobutyl chlo­
roformate and glycine methyl ester at ambient tempera­
ture. The sole isolable product (in moderate yield) was 
characterized as the protected dehydroalanylglycine 28a. 
This elimination also took place to a minor extent (giving 
28b) during the coupling of the unsymmetrical disulfide 
26a with glycine tert-butyl ester, as shown by NMR of the 
crude product. Unwanted elimination of an activated 
sulfur group from a cysteinyl peptide has been reported22 
to occur, for example, when the S-(dimethylthiono- 
phosphino) protecting group is employed. However, the 
elimination of an apparently unactivated disulfide during 
a mixed-anhydride coupling procedure is undocumented. 
The mechanism of the process is unclear. Also formed 
during the reaction of 26a with glycine tert-butyl ester, 
isobutyl chloroformate, and tertiary amine base were the 
expected product 29b and a low yield of an unstable oily 
material tentatively characterized as the S-(tert-butylthio) 
thioester 27. This compound has similar, but distinct, 
spectroscopic properties from the analogous tert-butyl 
thioester 32 prepared from the 4-nitrophenyl ester 30 (see 
below). Thioester 27 may well result from acylation of 
tert-butyl disulfide anion by the mixed anhydride, and its 
formation implies that the elimination of ButSS” is taking 
place while the anhydride is still unreacted with the glycine 
ester and possibly before the amino acid ester is added. 
In contrast, the coupling of 26a and NJJ  -bis(benzyloxy- 
carbonyl)cystine (26c) with glycine methyl ester by this 
mixed-anhydride method gave only the protected di­
peptides 29a,c. During some experiments, however, the 
crude products were shown by NMR to be contaminated
(22) Ueki, M.; Shinazaki, K. Bull. Chem. Soc. Jpn. 1983. 56. 1187.
with the corresponding 2-methylprop-l-yl esters. Com­
pound 29c had properties identical with those described 
by Zahn and Schmidt23 and by Zervas et aLu  but not to 
those claimed by Dadic et al.25 for this material. A more 
reliable synthesis of the potentially useful 29a, with N-, 
S-, and O-protecting groups separately removable under 
conditions of anhydrous add, reduction, and aqueous base, 
was therefore sought.
N-BOC-S-(£er£-butylthio)cysteine (26a) was coupled in 
good yield with 4-nitrophenol by the carbodiimide method 
to give the “active" ester 30 (Scheme VI). This ester re­
acted smoothly with 2-methylpropane-2-thiol to give the 
thioester 32 alluded to above. The reaction with glycine 
esters was similarly rapid and facile, affording the pro­
tected dipeptide methyl and tert-butyl esters 29a,b in 
almost quantitative yield. Of these dipeptide esters, 29a 
is the more synthetically useful, being the precursor of 
S-substituted cysteinylglycines and, after further elabo­
ration, of S-(N-methylcarbamoyl)glutathione (2a).
In the approach to 3a,b, selective reduction of the un­
symmetrical disulfide moiety of 29a was required. The 
reductive removal of mixed disulfide protecting groups 
during peptide synthesis has been reported to be effected 
by sodium borohydride (although no details of yield or 
method were given)26 and by treatment with thiophenoL27 
In the present work, reduction of 29a by treatment with 
ethanolic sodium borohydride was not successful and 
proceeded only very poorly with thiophenol. A dithiol, 
such as propane-l,3-dithiol, should be a more effective 
reagent for this purpose. After initial intermolecular di-
(23) Zahn. H.; Schmidt. G. Justus Liebigs Ann. Chem. 1970, 731, 91.
(24) Zervas. L.; Photaki, L; Ghelis. N. J. Am. Chem. Soc. 1963, 85. 
1337.
(25) Dadic, M.; Flee, D.; Markovic-Prpic, A. Croat. Chim. Acta 1961, 
33. 73.
(26) Wunsch. E.; S pangen berg. R. In Peptides 1969: Scoffone, E.. Ed.; 
North Holland, 1971.
(27) Inukai. N.; Nakano. K.; Murakami, M. Bull. Chem. Soc. Jpn. 
1967. 40. 2913.
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CFjC02H; (iii) base; (iv) PrijNEt/4-(dimethylamino)pyridine/ 
tetrahydrofuran; (v) Pr’jNEt/tetrahydrofuran; (vi) 
HSCHjCHjCHISH/PrijNEt/tetrahydrofuran; (vii) MeNCO/ 
Et,N/CHjClj; (viii) 9 M aqueous HC1.
sulfide exchange (with exogenous thiolate presumably 
attacking the less sterically hindered cysteinyl sulfur rather 
than that adjacent to the tert-butyl group), a subsequent 
intramolecular disulfide exchange would lead to the re­
quired N-BOC-cysteinylglycine with a free thiol for further 
reaction with carbamoylating agents. T his process was, 
indeed, found to be satisfactory, in that treatm ent of the  
protected dipeptide 29a with an excess o f propane-1,3- 
dithiol in tetrahydrofuran gave the dipeptide thiol 20  in 
good yield. The rate of the process was considerably en­
hanced by addition of a hindered tertiary amine to aid 
intermediate formation of the appropriate thiolate anions. 
T he byproduct, 1,2-dithiacyclopentane, has been report­
ed28"30 to  be unstable and to give rise to intractable in­
soluble polymers, but no such degradation was evident 
during any of these reductive deprotection steps. The  
dipeptide thiol 20 reacted with m ethyl and ethyl iso­
cyanates in the presence of catalytic tertiary amine base 
to  give the thiocarbamates 31a,b, respectively. Depro­
tection o f the N- and C-terminals of these dipeptides was 
achieved in a “one-pot" process involving dissolution o f 31 
in concentrated aqueous hydrochloric acid. Rapid evolu­
tion of gaseous carbon dioxide and 2-m ethylpropene in­
dicated that the removal of the (erf-butoxycarbonyl group 
was com plete within 5 min, whereas hydrolysis of the  
methyl ester took several hours (as shown by proton NM R  
monitoring of an experiment with 35% deuterium chloride 
in deuterium oxide as the hydrolytic medium). Evapora­
(28) Affleck, J. G.; Doughertv. G. J. Org. Chem. 1950, 75. 865.
(29) Calvin, M.; Barltrop. J. A. J. Am. Chem. Soc. 1952, 74. 6153.
(30) Barltrop. J. A.; Hayes. P. M.; Calvin. M. J. Am. Chem. Soc. 1954. 
76. 4348.
tion of the reagents gave the unprotected S-(A;-alkyl- 
carbamoyl)cysteinvlglycines (3a,b) as the hydrochloride 
salts.
The selective deprotection (using trifluoroacetic acidi 
of the amino function of 29a was exploited in the successful 
synthetic approach to the glutathione derivative 2 a 
(Scheme VII). T he evaporation residue comprised the  
trifluoroacetate salt of the amine 36 from which the free 
nucleophile could be liberated for reaction with an ap­
propriate N - and a-carboxyl-protected glutam ic acid 
bearing an activated 7 -carboxvl function. Following the  
success of the corresponding protection and activation  
strategies in the dipeptide series, the novel N -(te r t-but- 
oxycarbonyl)glutamic acid a-m ethyl 7 -(4 -nitrophenyl) 
diester 34 was the chosen electrophile for the coupling  
reaction and was synthesized as follows. N-BOC-glutamic 
acid a-methyl ester dicyclohexylammonium salt (33) was 
prepared generally by the method of Schroder and 
Klieger.31 The 7 -carboxylic acid moiety was then coupled 
with 4-nitrophenol by the dicyclohexylcarbodiimide m e­
thod, giving the diester 34 in excellent yield after chro­
matography. T he correct regioisomeric identity o f 34 as 
being the o-m ethyl 7 -(4 -nitrophenvl) diester was con­
firmed, after satisfactory elemental and spectroscopic  
analyses, by the significant difference between the melting 
point of this material and the reported32 melting point of 
N-(terf-butyloxycarbonyl)glutamic acid a-(4-nitrophenyl) 
7 -methyl diester. The reaction of the “active ester" 34 with 
35 was efficient but was markedly slower than the acylation 
of glycine esters by the protected cysteine 4-nitrophenyl 
ester 30, probably owing to the bulky nature o f the d i­
peptide nucleophile. Catalysis by 4-(dim ethylam ino)- 
pyridine was required, since its absence led to lower yields 
of 36 and formation of the diketopiperazine 38. Reductive 
deprotection of this tripeptide 36 with propane-1,3-dithiol 
was again effective, and the thiol 25 was obtained in good 
yield. As in the case of protected cysteine 9 and the  
protected cysteinylglycine 20 , treatment with m ethyl iso­
cyanate in dichloromethane in the presence o f NJf - di -  
isopropylethylamine gave high yields of the corresponding 
/V-BOC-S-(N-methylcarbamoyl)glutathione dimethyl ester
37. Deprotection of the amino group and the carboxylic 
acids was again carried out in high yield with aqueous acid. 
Using deuterated solvent and reagent, the reaction of the  
S- (TV-methylcarbamov 1) - protected glutathione 37 with acid 
was monitored by lH NMR spectroscopy, revealing that, 
as expected, the tert-butyl and N-carboxy groups were 
eliminated immediately upon dissolution. The hydrolyses 
of the m ethyl esters were seen to be almost com plete in 
20 min and 20 h, respectively, although it is not clear which 
ester of the intermediate protonated S-substituted gluta­
thione diester is the more labile.
Optical rotations were measured for 12 representative  
compounds. In no case was complete racemization o b ­
served during the various chemical transformations. S ig­
nificant partial loss of stereochemical integrity is also 
unlikely, as there was no evidence of other diastereoisomers 
in the NM R spectra of the substituted glutathiones 2a, 25, 
and 36.
Evaluation of the biochemical and biological properties 
of the synthetic S-(Ar-alkylcarbamoyl)cysteines and pep­
tides is in progress and will be described elsewhere. In­
terestingly, the free base of S-(N-ethylcarbamoyl)cysteine 
together with the analogous S-[N-(2-chloroethyl)carba- 
m oyljcysteine have been reported to have antitum or ,33
(31) Schroder. E.; Kliecer, E. Justus Liebigs Ann. Chem. 1964. 673.
196.
(32) Levy, D.; Carpenter. F. H. Biochemistry 1967. 6. 3559.
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antimicrobial,34 and cytotoxic33 properties. In addition to 
the preparation of the thiocarbamates 2a, 3a,b, 4, and 5, 
the successful synthetic route described above involves the 
preparation, in good yield, o f the glutathione derivative 
40, with separately removable protecting groups for amino, 
thiol, and carboxyl functions, and furnishes a potentially 
highly useful intermediate in the chemical synthesis of of 
S-substituted glutathiones. These compounds are in- 
volved35-38 in the metabolic activation or detoxification of 
many xenobiotic organic compounds.
Experimental Section
IR spectra were recorded as liquid films (except where noted) 
with Perkin-Elmer 1310 or Philips PU9516 spectrometers. NMR 
spectra were obtained (in CDC13 except where noted otherwise) 
at 60 MHz with Varian EM360A or JEOL PMX60SI spectrom­
eters, at 300 MHz with Varian XL300 or Broker AC300 spec­
trometers, and at 400 MHz with a Broker WH400 instrument. 
Optical rotations were measured with an Optical Activity Ltd. 
AA-10 polarimeter. Electron impact mass spectra were furnished 
by VG Micromass 12B and ZAB-E instruments. Cesium ion 
promoted liquid matrix secondary ionization mass spectra 
(LSIMS) were obtained with a Kratos MS-50S mass spectrometer 
equipped with a 23-kG magnet and a postacceleration detector 
operating at -10 kV. Samples were dissolved in a glycerol matrix 
containing HC1 (to increase the intensity of MH+ species), and 
ionization was achieved by bombardment with a 1.0-j*A primary 
beam of Cs+ ions.® Melting points are corrected. Reactions were 
carried out at ambient temperature except where indicated oth­
erwise. Organic solutions were dried by treatment with anhydrous 
Na^O* and filtration. Solvents were evaporated under reduced 
pressure. All chiral amino acids were of the L configuration. THF 
refers to tetrahydrofuran.
S-(N-Methylcarbamoyl)glutathione Hydrochloride (2a). 
Compound 25 (435 mg, 1 mmol) was stirred for 3 days with methyl 
isocyanate (285 mg, 5 mmol) and iVJV-diisopropylethylamine (129 
mg, 1 mmol) in CH2C12 (10 mL). The solution was washed with 
ice-cold aqueous H2S 0 4 (1 M), H20 , and saturated aqueous NaCl 
before being dried. Evaporation of the solvent afforded 37 (400 
mg, 81%) as a colorless gum; DR 3300,1720,1700,1680 cm'1; NMR 
b 1.43 [9 H, s, C(CHj)3], 1.0-2.5 (4 H, m, Glu 0-CH2 and Glu 
7 -CHj), 2.83 (3 H, d. J  = 5 Hz. NCHj), 3.3 (2 H, m, Cys 0-CH2),
3.74 (6 H, s, 2 OCH3), 4.00 (2 H, d, J  = 5 Hz, Gly CH2), 4.24 (1 
H, m, Glu a-H), 4.75 (1 H, m, Cys a-H), 5.75 (1 H, d, J  = 7 Hz, 
Glu NH or Cys NH), 7.3-7.7 (2 H, m, 2 NH), and 8.41 (1 H, ca. 
q, J  = ca. 5 Hz, NHCH3); mass spectrum, m/z 335 [(M -  C4Hg 
-  C02 -  MeNCOn, 304 {(M -  C4H8 -  C02 -  NHCH2C02CH3)+), 
247, 57 (100%). This material (246 mg, 0.5 mmol) was treated 
with 35% DC1 in D20  (2 mL) at ambient temperature for 4 days 
before excess reagent was evaporated. H20  (5 mL) was added. 
The gummy evaporation residue was triturated with acetone and 
then with anhydrous THF to afford 2a (160 mg, 65%) as a very 
hygroscopic pale buff solid of indefinite melting point (dec) which 
did not give a satisfactory microanalysis but was shown to be 
>95% pure by NMR; IR (Nujol) 2900-2600, 1710, 1690 cm'1; 
NMR (DjO) b 2.10 (2 H, m, Glu d-CHj), 2.45 (2 H, m, Glu y-CH2),
2.75 (3 H, s, NCHj), 3.15 (1 H. dd, J = 14 Hz, J  = 7 Hz) and 3.40 
(1 H. dd, J = 14 Hz, J  = 4 Hz) (Cys /S-CH2), 3.75 (1 H, t, J = 7 
Hz, Glu a-H), 3.95 (2 H, s. Gly CH2), and 4.50 (1 H. m, Cys a-H).
(33) Nemeth. L.; Somfai-Relle. S.; Kellner. B.; Sugar, J.; Bognar. R.; 
Farkas. J.; Balint, J.; Palyi. I.; Toth. K.; Szentmimay, Z.; Somosy. Z.; 
Pokomy, E. Arzneim.-Forsch. 1978. 28, 1119.
(34) Ross. D. L: Skinner. C. G.; Shive, W. J. Med. Pharm. Chem. 1961. 
3 ,  519.
(35) Glutathione S-Transferases and Carcinogenesis: Mantle, T. J.; 
Pickett, C. B.; Hayes. J. D.. Eds.; Taylor and Francis: London. 19S7.
(36) Drug Metabolism—from Molecules to Man; Benford. D. J.: 
Bridges, J. W.; Gibson. G. G.. Eds.; Taylor and Francis: London. 19S7.
(37) Chasseaud. L. F. In Glutathione: Metabolism and Function 
Arios, I. M.. Jakoby. W. B.. Elds.; Raven Press: New York, 1976.
(38) Ketterer. B. Drug Metab. Rev. 1982. 13. 161.
(39) Falick. A. M.; Wang. G. H.; Walls. F. C. Anal. Chem. 1986. 58. 
1308.
(40) Barber. M.; Jones, J. H. Int. J. Pept. Prot. Res. 1977. 9, 269.
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AT-[S-(N-M ethylcarbamoyl)cysteinyl]glycine Hydro­
chloride (3a). Compound 31a (200 mg, 573 nmol) was treated 
with aqueous HC1 (9 M) for 1 week. Trituration of the gummy 
evaporation residue with acetone afforded 3a (143 mg, 92%) as 
an hygroscopic white powder which decomposed on heating at 
>70 °C: NMR (DjO) o 170 (3 H. s, NCH3), 3.2-3.35 (2 H. m. Cys 
/?-CH2), 4.00 (2 H, s, Gly CH2), and 4.15 (1 H, m, Cys a-H); mass 
spectrum (FAB), m/z  236 ((M + H)*]. Anal. Calcd for 
C7H14C1N30 4S: C, 30.95: H, 5.2; N, 17.45. Found: C, 30.65; H. 
5.5; N, 17.25.
N -(S-(A f-E thylcarbam oyl)cysteinyl]glycine H ydro­
chloride (3b). Compound 31b was treated with aqueous HC1. 
as for the preparation of 3a above, to give 3b (83%) as an hy­
groscopic white powder which decomposed on heating at >70 °C: 
NMR (D20) o 1.15 (3 H. t, J  = 7 Hz, CH2CH3). 2.90 (2 H. q, J  
= 7 Hz, NCH2CH3), 3.2-3.4 (2 H, m, Cys 0-CHj), 4.00 (2 H. s. Gly 
CH2), and 4.20 (1 H, m. Cys a-H); mass spectrum (FAB), m /z  
250 ((M + H)+]. Anal. Calcd for C8H16C1N30 4S: C, 33.65; H. 
5.65; N, 14.7. Found: C. 33.35; H, 5.9; N, 14.5.
S-(./V-Methylcarbamoyl)cysteine Hydrochloride (4a). 
Ester I la  (1.20 g, 4.1 mmol) was treated with aqueous HC1 (9 M; 
25 mL) for 1 week The gummy evaporation residue was triturated 
with propan-2-ol (30 mL) to give a white solid (100 mg, 15%), 
which was identified as cysteine hydrochloride. The solvent was 
evaporated from the supernatant solution to give a gum. Trit­
uration with acetone gave 4a (730 mg, 83%) as a white powder: 
mp 186-189 °C dec; IR (Nujol) 3325, 2750 br, 1720, 1660, 1565 
cm'1; NMR (400 MHz; D,0) b 2.70 (3 H, s, NCH3), 3.33 (1 H, dd. 
J = 15.4 Hz, J  = 6.4 Hz) and 3.50 (1 H, dd, J = 15.4 Hz, J  = 4.0 
Hz) (CHCtfjS), 4.24 (1 H. dd, J  = 6.4 Hz. J  = 4.0 Hz, CtfCH2), 
and 4.75 (5 H, br s, HOD); mass spectrum (LSIMS), m/z  179 [(M 
+ H)-]. AnaL Calcd for CjHuClNAS: C. 28.0; H, 5.15; N, 13.05. 
Found: C, 27.7; H, 5.2; N, 12.75.
S-(iV-Ethylcarbamoyl)cysteine Hydrochloride (4b). Ester 
11b was hydrolyzed with aqueous HC1, as for the preparation of 
4a above, to give 4b (81%) as a white powder: mp 177-180 °C 
dec; optical rotation (c = 354 mM in H20) [a]21^  -56.2°, [a]21578 
-58.2°; DR (Nujol) 3300,2750 br, 1725,1665 cm'1; NMR (60 MHz; 
D20) 6 1.10 (3 H, t, J = 7 Hz, CH ^tfj), 3.25 (2 H, q, J = 7 Hz, 
NCH2), 3.45 (1 H, d. J  = 6 Hz) and 3.50 (1 H, d. J  = 4 Hz) 
(CHCffjS), 4.35 (1 H. dd, J = 6 Hz, J  = 4 Hz, CHCHj), 4.9 (5 
H, br s, HOD); NMR (300 MHz; (CD^jSO] b 1.04 (3 H, t, J = 
7.4 Hz, CHjCHj), 3.15 (2 H, dq, J  = 6.4 Hz. J = 7.4 Hz, NCH2), 
3.27 (1 H, dd. J  = 14.8 Hz. J = 5.6 Hz) and 3.37 (1 H, dd. J =
14.8 Hz, J = 4.6 Hz) (CHCtfjS), 4.10 (1 H, ca. t, J = ca. 5 Hz, 
CHCHj), 8.39 (1 H, ca. t, J  = ca. 6 Hz, NHCH2), 8.5 (3 H. br. 
CHN-Hj); mass spectrum (LSIMS), m/z 193 (100%) [(M + H)+). 
AnaL Calcd for CeHuClNjOjS: C, 31.5; H, 5.75; N, 12.25. Found: 
C. 31.2; H, 5.4; N, 12.0.
S-(iV^Y-Dimethylcarbamoy 1 )cysteine Hydrochloride (4c). 
Compound 12 was hydrolyzed with aqueous HC1, as for the 
preparation of 4a above, to give 4c a white powder mp 146-150 
°C dec; NMR (D20 ) 3.00 (6 H, s, N(CH3)2], 3.2-3.4 (2 H, m. 
CHCHjS), 3.50 (1 H. dd. J = 6 Hz. J  = 4 Hz, CHCH2), and 4.7 
(5 H, br s, HOD); mass spectrum (LSIMS), m/z 193 (1007c) [(M 
+ H H . AnaL Calcd for C^HnClNjOjS: C. 31.5; H, 5.75; N. 12.25. 
Found: C, 31.5; H, 5.45; N, 11.95.
N -A cetyl-S -(iV ,A r-dim ethylcarbam oyl)cysteine (5). 
Compound 4c (228 mg, 1 mmol) was treated with acetic anhydride 
(2 mL) and pyridine (100 mg, 1.3 mmol) for 4 h. Evaporation 
of the excess reagents gave a gum which, after preparative TLC 
(silica gel; CHCl3/MeOH. 7:1). afforded 5 (140 mg, 607c) as a 
colorless gum: IR 3300. 2700 br, 1730. 1680, 1660 cm'1; NMR 
[(CDaljSO) b 2.00 (3 H. s. C0CH3). 3.05 [6 H. s. N(CH3)2], 3.2 
(2 H, m, CHCHjS), 4.30 (1 H. m, CHCH2). 7.1 (1 H, br d, J = 
6 Hz, NH); mass spectrum, m/z 234 (M*). Anal. Calcd for 
C8H14N20 4S: C. 41.0; H. 6.0; N. 11.95. Found: C. 40.85; H, 6.25; 
N, 11.65.
N-Acetyl-S-fN-m ethylcarbam oyDcysteine N-M ethyl- 
amide (7). N-Acetylcysteine (6) (4.1 g. 25 mmol) was stined with 
methyl isocyanate (2.0 g, 35 mmol) in pyridine at 25 °C for 2 days 
before evaporation of the volatile materials. Trituration with ether 
gave 7 (4.31 g. 747c) as a white solid: mp 195 °C; optical rotation 
(c = 45.1 mM in H20) (a)21* , -23.8°, [a)21578-24 .r . [a]21^  -33.3°. 
l« !21<36 -53.4°; IR 3300. 3220. 3080, 1675, 1640 cm'1; NMR 
((C D ^ O ] o 1.90 (3 H. s. COCHj). 2.60 (3 H. d. J  = 6 Hz. NCH3)
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(becomes s on decoupling at b 7.8), 2.68 (3 H, d, J  = 6 Hz, NCHJ 
(becomes s on decoupling at o 7.8), 3.06 (1 H, d, J  = 8 Hz) and 
3.12 (1 H, s. J  = 5 Hz) (CHCHjS), 4.30 (1 H. dt, J  = 5 Hz. J  =
8 Hz, CHCHJ (becomes d, J  = 8 Hz on decoupling at b 3.1), 7.8 
(3 H, br m, NH); mass spectrum, m/z  234 (M*). Anal. Calcd 
for CgH^NaOjS: C. 41.2; H. 6.5; N. 18.0. Found: C; 41.15; H, 
6.25; N, 17.6.
N-(tert-Butoxycarbonyl)cysteine Methyl Ester (9). EtjN 
(1.01 g, 10 mmol) was added to a well stirred slurry of cysteine 
methyl ester hydrochloride (8) (1.72 g, 10 mmol) in CH2C12 (20 
mL), followed after 10 min by di-tert-butyl dicarbonate (2.18 g, 
10 mmol). The mixture was stirred for 16 h, washed with H20, 
and dried. Evaporation of the solvent gave 9 (2.29 g, 97%) as 
a colorless oil: optical rotation (c = 318 mM in CHC13) [a]21589 
+28.5°, [a]21^  +29.6°, [a]21^  +33.2°, [a]21** +57.6°; IR 3360, 
2560. 1745, 1710 cm'1; NMR b 1.45 [9 H, s, C(CH3)3], 1.55 (1 H. 
br, SH). 2.85 (1 H, d, J  = 4 Hz) and 3.00 (1 H, d. J  = 4 Hz) 
(CHCtfjS), 3.75 (3 H, s, OCH3), 4.55 (1 H, dt, J  = 8 Hz, J  = 4 
Hz, CHCH2, 5.60 (1 H, d, J  -  8 Hz, NH); mass spectrum, m/z  
235 (M T Anal. Calcd for C^HnNO.S: C, 45.95; H, 7.3; N, 5.95. 
Found: C, 46.1; H, 7.3; N, 6.0.
N -(ter t -Butoxycarbonyl)cysteine (10). Ester 9 (235 mg,
1 mmol) and NaOH (100 mg, 2.5 mmol) were stirred in MeOH 
(5 mL) under N2 for 16 h before evaporation of the solvent. 
Aqueous HC1 (1 M; 2.5 mL) was added to the residue to give a 
solution with Final pH = 6.0, which was extracted twice with 
EtOAc. The combined extracts were washed with saturated 
aqueous NaCl and were dried. Evaporation of the solvent fur­
nished 10 (150 mg, 68%) as a colorless gum, which was shown 
to be >97% pure by NMR but would not give a satisfactory 
microanalysis: IR 3340, 2900-2600, 1710 cm-1; NMR 5 1.40 (9 
H, s, C(CHJ3], 1.50 (1 H, br, SH), 2.9 (2 H, m, CHCtfjS), 4.55 
(1 H, dt, J  = 8 Hz, J  = 4 Hz, CtfCHJ, 5.60 (1 H. d, J  = 8 Hz, 
NH), 8.0 (1 H, br, C O ^ ; mass spectrum, m /z  221 (M+). A small 
sample was oxidized with I2 to given N rAr'-bis(£err-butoxy- 
carbonyl)cystine as a white solid: mp 141-143 °C, identical with 
a commercial sample.
N -(tert -Butoxy car bonyl)-S-(N-methylcarbamoyl)cys te- 
ine Methyl Ester (11a). Compound 19 (2J2Q g, 9.4 mmol), methyl 
isocyanate (4 mL), and N,N-diisopropylethylamine (Oh mL) were 
stirred together in CH2C12 (20 mL) for 3 days after which time 
the solvent and excess reagents were evaporated. The residue, 
in CH2C12, was washed with H20  and with saturated aqueous NaCl 
and was dried. The solvent was evaporated to furnish 11a (2.35 
g, 96%) as white needles: mp 45-46 °C; IR 3350,1735,1700,1665 
ea-h NMR b 1.45 [9 H,s, C(CH3)3], 2.95 (3 H, d, J  = 7 Hz, NCHJ, 
3.35 (2 H, d, J  = 6 Hz, CHCtfjS), 3.70 (3 H, s. OCHJ. 4.45 (1 
H, ca. q. J  = ca. 6 Hz, CHCHJ, 5.85 (1 H, d, J  = 7 Hz, OCONH),
6.20 (1 H, br q, J  = 7 Hz, MeNH); mass spectrum, m /z 292 (M+). 
Anal. Calcd for CnH^NjOsS: C, 45.15; H, 6.9; N, 9.65. Found: 
C. 45.45; N, 7.0; N, 9.4.
N-(tert -Butoxycarbonyl)-S-(N-ethylcarbamoyl)cysteine 
Methyl Ester ( l ib ) . Compound 9 was treated with ethyl iso­
cyanate and E^N in CH2C12 as for the preparation of 11a above, 
to yield l ib  (91%) as a colorless oil: IR 3300, 1735, 1700, and 
1670 cm'1; NMR b 1.15 (3 H, t, J  = 7 Hz, CH2CHJ. 1.45 (9 H, 
s, C(CH3)3], 3.30 (2 H. quintet, J  = 1 Hz, NHCtf2CHJ, 3.35 (2 
H, d. J  = ca. 6 Hz, CHCHjS), 3.70 (3 H, s. OCH3), 4.45 (1 H. ca. 
q, J = 6 ca. Hz, CHCHJ, 5.55 (1 H ,d ,J  = 7 Hz, OCONH), and
6.00 (1 H, br t, J  = 7 Hz, EtNH); mass spectrum, m /z 306 (M+). 
Anal. Calcd for C12H22N20 5S: C, 47.05; H, 7.25; N, 9.15. Found: 
C, 47.1; H, 7.05; N, 9.0.
N-(ter£-Butoxycarbonyl)-S-(N JV-dimethylcarbamoyl)- 
cysteine M ethyl Ester (12). Ester 9 (7.05 g, 30 mmol), di- 
methylcarbamoyl chloride (3.3 g, 30.7 mmol), and pyridine (5.0 
g, 63.3 mmol) were stirred together in CH2C12 (120 mL) for 3 days 
before the mixture was washed with aqueous H^O* (1 M) and 
H20. The solution was dried, and the solvent was evaporated 
to give 12 (2.94 g, 96%) as a colorless oil: optical rotation (c = 
251 mM in CHC1J [a]21^  +10.9°; IR 3350,1740,1705,1680 on’1; 
NMR 1.40 [9 H. s, C(CH3)3], 3.05’ (3 H, s) and 3.15 (3 H, s) 
[C0N(CHJ2], 3.1 (2 H. m, CHCtfjS), 3.73 (3 H. s, OCH3), 4.5 (1 
H, m, CHCHJ, 5.50 (1 H, d, J  = 7 Hz, NH); mass spectrum, m /z 
306 (M+). Anal. Calcd for C ^ H ^ N ^ S : C, 47.05; H, 7.25; N, 
9.15. Found: C, 47.2; H, 7.1; N. 9.25.
N-(Benzyloxycarbonyl)-lh-thiazolidine-4-carboxyIic Acid 
(14). Benzyl chloroformate (3.4 g, 20 mmol) was added in one 
portion to l,3-thiazolidine-4-carboxylic acid (13) (2.66 g. 20 mmol) 
and KOH (2.55 g, 45.5 mmol) in H20  (30 mL), and the whole was 
stirred vigorously for 16 h. The solution was washed with CH2C1: 
and acidified with aqueous HC1 (9 M) before being extracted twice 
with CH2C12. The combined extracts were dried. The solvent 
was evaporated to give 14 (4.81 g, 90%); as a colorless gum: NMR 
o 3.20 (2 H, d, J  = 5 Hz. CHCtfjS). 4.45 (1 H. d, J  = 9 Hz) and
4.55 (1 H, d, J  = 9 Hz) (NCHjS), 4.85 (1 H, m, NCHRC02H).
5.20 (2 H, s, OCH2Ph). 7.30 (5 H, s. ArH), and 9.65 (1 H, s, C02H); 
mass spectrum, m /z  267 (M*), 221, 91 (100%). A sample was 
converted to the diisopropviarnine salt: NMR b 1.20 (12 H. d.
J  = 7 Hz. 2 CH(Ctf J 2], 3.17 (2 H. septet, -J = 7 Hz, 2 CH(CH3)2],
3.25 (2 H, m, thiazolidine 5-CH2), 4.40 (1 H, d, J  = 8 Hz) and 4.65 
(1 H, d, J  = 8 Hz) (thiazolidine 2-CHJ, 4.75 (1 H, m, thiazolidine 
4-H), 5.10 (2 H, s, PhCHJ, 7.25 (5 H, s, ArH), 8.1 (2 H, br, N-HJ. 
Anal. Calcd for CisHjcN^S: C, 58.65; H, 7.65; N, 7.6. Found:
C, 58.9; H, 7.6; N, 7.65.
N -[[N -(B e n z y lo x y ca r b o n y l)- l,3 -th ia z o lid in -4 -y l]-  
carbonyl]glycine Benzyl Ester (15). Acid 14 (1.33 g, 5 mmol) 
was added to NJV'-dicyclohexylcarbodiimide (1.03 g, 5 mmol) in 
CH2C12 (20 mL). After 10 min, a mixture of glycine benzyl ester 
4-methylbenzenesulfonic acid salt (1.68 g, 5 mmol). NJN-diiso- 
propylethylamine (650 mg. 5 mmol), and CH2C12 (20 mL) was 
added, and the whole was stirred for 4 days. The evaporation 
residue was extracted with Et^O (2 X 50 mL). The combined 
extracts were washed with H20  (50 mL), aqueous HC1 (2 M; 2 
X 50 mL), and saturated aqueous NaHC03 (2 X 50 mL) before 
being dried. The filtrate was cooled to 4 °C for 3 days and filtered 
again. Evaporation of the solvent afforded 15 (1.78 g, 86%) as 
a colorless oil: IR 3360. 1735, 1680 cm"1; NMR b 3.30 (1 H, dd.
J = 12 Hz, J  = 6 Hz) and 3.40 (1 H, dd, J = 12 Hz, J  = 4 Hz) 
(thiazolidine 5-CHJ, 4.00 (2 H, d. J = 5.5 Hz. Gly CH2), 4.40 (1 
H, d, J  = 9 Hz) and 4.60 (1 H. d, J = 9 Hz) (thiazolidine 2-CHJ.
4.75 (1 H, dd, J = 6 Hz, J = 4 Hz, thiazolidine 4-H), 5.15 (4 H, 
s, 2 PhCH20), 6.7 (1 H. br. NH) and 7.15 (10 H, s. ArH); mass 
spectrum, m /z  414.1256 (M*) (C ^ H ^ N ^ S  requires 414.1249). 
413, 279,220,91 (100%).
Af-{N-(Benzyloxycarbonyl)cysteinyl]glycine Benzyl Ester 
(16). Compound 15 (1.0 g, 2.4 mmol) was stirred with Hg(OAc)2 
(1.0 g, 3.1 mmol) in AcOH (30 mL) and H20  (12 mL) at 60 °C 
for 2 h before being cooled to ambient temperature. A steady 
stream of H ^  was passed through the solution for 20 min, and 
the black precipitate of HgS was removed by Filtration through 
diatomaceous earth. Evaporation of the filtrate and AcOH 
washings gave 16 (903 mg, 94%) as a colorless gum: NMR (400 
MHz) b 1.65 (1 H, dd, J  = 7.5 Hz, J  = 10.7 Hz, SH). 2.71 (1 H, 
ddd, J = 6.1 Hz, J  = 10.7 Hz, J  = 14.0 Hz) and 3.13 (1 H. ddd, 
J  = 4.2 Hz, J  = 7.5 Hz. J  = 14.0 Hz) (Cys 0-CH2), 4.08 (2 H, d. 
J  = 5 Hz, Gly CHJ, 4.4S (1 H. m, Cys o-H), 5.12 (2 H, s. OCtf2Ph), 
5.17 (2 H, s, OCHjPh). 5.80 (1 H. br d. J  = 7.8 Hz, Cys NH). 6.83 
(1 H, br t, J  = 5 Hz, Glv NH). 7.35 (10 H, s, ArH); mass spectrum, 
m/z 402.1246 (CjoHeNjOsS requires 402.1210), 91 (100%).
iV -[N -(B enzyloxycarbonyl)-S-(A r-m etbylcarbam oyl)- 
cysteinyl]glycine Benzyl Ester (17). Methyl isocyanate (2.0 
mL) and NJV-diisopropylethvlamine (1 mL) were added to 16 
(470 mg, 1.17 mmol) in CH2C12 (10 mL), and the whole was stirred 
for 16 h. The evaporation residue, in CH2C12, was washed with 
aqueous HC1 (2 M) and H20  before being dried. Evaporation of 
the solvent afforded 17 (470 mg, 88%) as a colorless gum: IR 3350, 
1725, 1660, 1535 cm'1: NMR (400 MHz) o 2.83 (3 H. d, J  = 4.9 
Hz, NCHJ, 3.22 (1 H. dd. J  = 14.8 Hz, J  = 8.6 Hz) and 3.36 (1 
H, dd, J  = 14.8 Hz, J = 4.1 Hz) (Cys (3-CHJ, 4.05 (1 H. br d. -J 
= 4.7 Hz) and 4.08 (1 H. br d. J  = 5.6 Hz) (Gly CHJ. 4.42 (1 H. 
m, Cys a-H). 5.11 (1 H. d. J  = 12.3 Hz) and 5.13 ( lH .d  , J  = 12.3 
Hz) (OCHJPh), 5.17 (2 H. s. OCtf2Ph), 5.47 (1 H, br, NH). 6.21 
(1 H, br d. J  = ca. 6 Hz, Cys-NH). 7.02 (1 H, br, NH). 7.35 (10 
H, m, ArH); mats spectrum, m /z  311 [(M -  PhCH2 -  MeNCO)'1’!, 
294, 267, 91 (100%). Anal. Calcd for C ^H ^N A S: C. 57.5; H. 
5.5; N, 9.15. Found: C. 57.2; H, 5.7; N, 8.85.
N - [ [ N - ( t e r t  -B utoxycarbonyl) -l,3 -th ia zo lid in -4 -y l]-  
carbonylJglycine Methyl Ester (19). EtsN (520 mg. 5.15 mmol) 
was added to 18“  (1.16 g. 5.0 mmol) in CH2C12 (20 mL), followed 
after 20 min by isobutvl chloroformate (680 mg, 5.0 mmol), and 
the mixture was stirred for 1 h. A mixture of glycine methyl ester
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hydrochloride (650 mg. 5.2 mmol), EtjN (540 mg, 5.35 mmol), and 
CH2C12 (20 mL) was then added, causing vigorous effervescence. 
After a further 2 h, the mixture was washed with H20 , aqueous 
H^O* (2 M), aqueous K2C03 (2 M). and H20  and was dried. The 
solvent was evaporated to afford 19 (1.46 g, 96%) as a colorless 
oil: optical rotation (c = 43.6 mM in CHCl3) [a]21^  -120.8°. 
[a )2l578 -126.9°, [«]2,j4$ -145.0°; NMR 6 1.50 (9 H. s, C(CH3)3],
3.30 (1 H. dd. J  = 12 Hz. J  = 6 Hi) and 3.40 (1 H. dd. J  = 12 
Hz, J  = 4 Hi) (thiazolidine 5-CH2), 3.70 (3 H, s. OCH3), 4.05 (2 
H, d, J  = 5.5 Hz, Gly CH2), 4.40 (1 H. d. J  = 9 Hz) and 4.65 (1 
H, d, J = 9 Hz) (thiazolidine 2-CH2), 4.70 (1 H, dd, J = 6 Hz, J  
= 4 Hz, thiazolidine 4-H), 6.9 (1 H, br. NH); mass spectrum, m/z  
304 (M*). Anal. Calcd for C ^ H ^ A S : C. 47.35; H. 6.6: N. 8.95. 
Found: C, 47.5; H, 6 .6; N, 8.95.
N -[N - ( te r t -Butoxycarbonyl)cysteinyl]glycine Methyl 
Ester (20). Compound 29a (810 mg, 2.13 mmol) was boiled under 
reflux with propane-1,3-dithiol (1.6 g. 23 mmol) and N./V-diiso- 
propylethylamine (700 mg, 5.4 mmol) in anhydrous THF (20 mL) 
for 2 days. The evaporation residue, in CH2C12, was washed twice 
with ice-cold aqueous H2SO< (1 M) and with saturated aqueous 
NaCl and was dried. Column chromatography of the evaporation 
residue (silica gel; CHCI3) afforded 20 (590 mg, 95%) as a colorless 
oil with a distinctive odon IR 3320,2560,1745,1700,1660 cm'1; 
NMR b 1.45 [9 H, s, CfCH^], 1.72 (1 H, t. J = 8 Hz, SH), 2.7-3.1 
(2 H. m, Cys /3-CH2), 3.72 (3 H, s, OCH3), 4.02 (2 H, d. J  = 5 Hz, 
Gly CH2), 4.45 (1 H. ddd. J = 8 Hz. J  = 7 Hz, J  = 5 Hz. Cvs a-H). 
5.80 (1 H. d, J  = 8 Hz, Cys NH). and 7.37 (1 H, t, J  = 5 Hz, Gly 
NH); mass spectrum, m/z  236 ((M -  C^ Hg)""] and 220. AnaL Calcd 
for CuHjoNAS: C, 45.2; H, 6.9; N, 9.6. Found: C. 45.5; H, 7.2; 
N, 9.3.
Experiment to determine the relative lability of S-(amido- 
methyl)- and N-(tert-butoxycarbonyl) protecting groups. Di- 
tert-butyl dicarbonate (1.09 g, 5 mmol) in Et^O (10 mL) was added 
to S-[(4-ter£-butylbenzamido)methyl]glutathione trifluoroacetate 
salt18 (22) (610 mg, 1 mmol) and Et3N (1 mL) in HjO (5 mL), and 
the whole was stirred vigorously for 3 days. The resulting aqueous 
solution was washed twice with CH2C12, and the solvent and excess 
reagents were removed by freeze-drying to give crude 23 (600 mg) 
as a gummy white solid: NMR [400 MHz; (CD^jSO] 5 1.30 [9
H. s, AtC(CH3)3], 1.39 [9 H, s. OC(CHj)3], Z10 (1 H. m) and 2.18 
(1 H. m) (Glu /3-CH2), 2.36 (2 H, m, Glu y-CH2), 2.86 (1 H, dd. 
J = 14.7 Hz, J = 7.3 Hz) and 3.15 (1 H. dd, J  = 14.7 Hz, J = 3.6 
Hz) (Cys 0-CH2), 3.81 (1 H, d, J = 3.7 Hz) and 3.82 (1 H, d. J  
= 4.4 Hz) (Gly CH2), 4.13 (1 H, ca. q, J  = ca. 6 Hz, Glu a-CH), 
4.59 (1 H, dd, J = 13.5 Hz. J  = 6.2 Hz) and 4.66 (1 H, dd, J =
13.5 Hz, J  = 6.0 Hz) (NCHjS), 4.65 (1 H, m, Cys a-CH), 5.61 (1 
H, d. J = 6.9 Hz, Glu NH or Cys NH). 7.32 (1 H. ca. t, J = ca. 
4 Hz, Gly NH), 7.38 (1 H, d, J = 6.8 Hz, Cys NH or Glu NH), 
7.44 (2 H, d, J  = 8.4 Hz) and 7.88 (2 H, d, J  = 8.4 Hz) (ArH), 
8.50 (1 H, ca. t. J  = ca. 6 Hz, SCH2NH ) .  This material (500 mg) 
was treated with excess CH2N2 in EtjO for 24 h. Careful evap­
oration of the solvent and excess reagent furnished 24 (500 mg) 
as a colorless oil of sufficient purity for the next stage: NMR [400 
MHz. (CD3)jSO] b 1.31 [9 H, s, ArC(CH3)3], 1.42 [9 H, s, OC- 
(CHj)3], 2.10-2.20 (2 H, m, Glu 0-CHj), 2.35 (2 H. m, Glu y-CH2), 
2.85 (1 H. dd, J  = 14.5 Hz, J  = 7.5 Hz) and 3.15 (1 H, dd. J  =
14.5 Hz, J  = 3.3 Hz) (Cys d-CH2), 3.75 (3 H, s, OCH3), 3.78 (3 
H, s, OCH3). 3.83 (1 H, d, J  = 3.8 Hz) and 3.84 (1 H, d. J = 4.3 
Hz) (Gly CH2), 4.15 (1 H. ca. q, J  = ca. 6 Hz, Glu a-H), 4.60 (1 
H, dd, J = 13.5 Hz, J = 6.2 Hz) and 4.66 (1 H. dd. J  = 13.5 Hz, 
J  = 6.0 Hz) (NCHjS), 4.68 (1 H. m, Cvs a-H). 5.73 (1 H, br, NH),
7.31 (1 H. br, NH), 7.39 (1 H, br, NH). 7.45 (2 H, d, J = 8.6 Hz) 
and 7.91 (2 H, d. J  = 8.6 Hz) (ArH). and 8.60 (1 H. ca. t, J  = ca. 
6 Hz, SCH2Nff). Treatment of a sample (100 mg) of this material 
with Hg(OAc)2 in 50% aqueous AcOH at 25 °C was without effect 
during 1 h, but warming to 45 °C for 10 min gave material which 
had lost the BOC protecting group (primary amine shown by color 
reaction with indan-l,2,3-trione) whereas no thiol was evident by 
TLC (comparison with authentic 25).
N-(ferr-Butoxycarbonyl)glutathione Dimethyl Ester (25). 
Compound 36 (800 mg, 1.53 mmol) was boiled under reflux with 
propane-1,3-dithiol (1.2 g. 8.0 mmol) and N.N-diisopropyl- 
ethylamine (400 mg, 3.1 mmol) in anhydrous THF (10 mL) under 
N2 for 2 days. The evaporation residue, in CH2C12, was washed 
with ice-cold aqueous H^O* (2 M) and H20  and was dried. 
Chromatography (silica gel; CHCl3/MeOH. 50:1) of the yellow
oily evaporation residue gave unreacted disulfide 36 (260 mg. 32%) 
and 25 (330 mg, 50%) as a white solid: mp 94-95 °C; NMR (400 
MHz) 5 1.43 (9 H. s, OC(CH3)3], 1.82 (1 H, dd. J  = 10.0 Hz. J  
= 7.9 Hz, SH). 1.96 (1 H. ca. dq. J  = ca. 14 Hz, J  = 7 Hz) and
2.21 (1 H, ca. dq, J  = 14 Hz, J  = 7 Hz) (Glu 0-CH2), 2.37 (2 H. 
t. J  = 7.2 Hz, Glu y-CH2), 2.78 (1 H, m) and 3.13 (1 H. ddd. J 
= 14.0 Hz, J  = 7.9 Hz. J  = 4.6 Hz) (Cys 0-CH2), 3.74 (3 H. s, 
OCH3), 3.75 (3 H. s. OCH3), 4.00 (1 H, dd, J  = 18.1 Hz. J  = 5.4 
Hz) and 4.08 (1 H, dd. J  = 18.1 Hz, J  = 5.8 Hz) (Gly CH2). 4.34 
(1 H, m, Glu a-H), 4.68 (1 H. ddd. J  = 8.5 Hz, J  = 6.0 Hz. J  = 
4.6 Hz. Cys a-H), 5.29 (1 H, d. J  = 8.5 Hz, Cys NH), 6.86 (1 H, 
d. J  = 7.0 Hz, Glu NH). 6.97 (1 H, ca. t. J  = ca. 5.5 Hz, Gly NH); 
mass spectrum, m/ z  435 (M*). 335, 144, 84 (100%), 57. Anal. 
Calcd for C^H ^NAS: C. 46.9; H. 6.7; N, 9.65. Found: C, 46.6;
H, 6.5; N, 9.4.
Attempted Coupling of N - ( t e r t -Butoxycarbonyl)-S- 
(tert-butylthio)cysteine (26a) with Glycine tert-Butyl Ester 
by the Mixed-Anhydride Method. Compound 26a (309 mg,
1 mmol) was stirred with EtsN (120 mg, 1.2 mmol) and isobutyl 
chloroformate (137 mg, 1 mmol) in CH2C12 (10 mL) for 20 min 
before addition of a mixture of CH2C12 (5 mL), Et^N (110 mg,
I.1 mmol), and glycine tert-butyl ester hydrochloride (170 mg,
1 mmol). After a further 15 min, the mixture was washed with 
H20 , aqueous H^O* (2 M), and H20  and was dried. Chroma­
tography of the evaporation residue (silica gel; CHC13) yielded 
27 (60 mg, 14%) as an unstable colorless gum, which did not give 
a satisfactory microanalysis but appeared to be >95% pure by 
NMR; IR 3350,1700,1680 cm'1; NMR b 1.30 [9 H, s, SC(CH3)3], 
1.33 [9 H, s, SC(CHj)3], 1.47 (9 H, s, OC(CH3)3], 3.10 (2 H. br d.
J  = 6 Hz, CHjS), 4.70 (1 H, ca. q, J  = ca. 6 Hz, CH), 5.40 (1 H. 
br d, J -  ca. 7 Hz, NH). From later running fractions was obtained 
a colorless gum (230 mg), which was shown by NMR to comprise 
85 mol % 29b, identical with the material described below and 
15 mol % 28b: NMR b 1.45 (18 H, s, 2 C(CHj)3], 3.95 (2 H, d. 
J  = 5 Hz, Gly CH2), 5.20 (1 H. m) and 6.00 (1 H, d, J  = 1.5 Hz> 
(propenoyl 3-CH2), 6.5 (1 H, br. Gly NH), 7.2 (1 H, ca. d, J  = ca.
2 Hz, NH).
Attempted Coupling of N^V-Bis(tert-butoxycarbonyl)- 
cystine (26b) w ith Glycine Methyl Ester by the Mixed- 
Ajahydride Method. Compound 26b (1.76 g, 4 mmol) was treated 
with Et^N (810 mg, 8 mmol) and isobutyl chloroformate (1.09 g,
8 mmol) in CH2C12 (10 mL) for 20 min before addition of EtjN 
(810 mg, 8 mmol) and glycine methyl ester hydrochloride (1.0 g,
8 mmol) in CH2C12 (20 mL). After a further 45 min, the mixture 
was washed with H20  and aqueous H2S 0 4 (2 M) and was dried. 
Chromatography of the evaporation residue (silica gel; CHC13) 
yield N-[2-[(£er£-butoxycarbonyl)amino]propenoyl]glycine methyl 
ester (28a) (490 mg, 24%) as an unstable colorless gum: ER 3300, 
1720,1690 cm'1; NMR (400 MHz) b 1.46 (9 H, s, C(CH3)3], 4.10 
(2 H, d, J  = 6 Hz, Gly CH2), 5.13 (1 H, t, J  = 1.7 Hz becomes 
d, J  = 1.7 Hz on decoupling at 6 7.3) and 6.04 (1 H, d, J  = 1.7 
Hz) (propenoyl 3-CH2), 7.3 (1 H, ca. d, J  = ca. 2 Hz, NH); mass 
spectrum, m/z  258.1215 (M-*) (CuH18N2Os requires 258.1216), 
202, 185, 57 (100%).
Af-[lV-(Benzyloxycarbonyl)cysteinyl]glycine Methyl 
Ester Disulfide (29c). AfJV/-Bis(benzyloxycarbonyl)cystine (26c) 
(508 mg, 1 mmol) was treated with isobutyl chloroformate, EtjN, 
and glycine methyl ester hydrochloride, as for the reaction of 26b 
above, to give a gum comprising mixed methyl and 2-methyl- 
prop-l-yl esters of N-(N-(benzyloxycarbonyl)cysteinyl]glycine 
disulfide as determined by NMR. This mixture was stirred for 
2 days with MeOH (30 mL) and EtjN (1 mL). Chromatography 
(silica gel; CHCI3) furnished 29c (430 mg, 66%) as a white powder, 
mp 168-171 °C (lit." mp 170-171 °C); NMR b 3.2 (4 H. m. 2 Cys 
d-CHj), 3.70 (6 H. s. 2 OCH3), 4.00 (4 H. d. J  = 6 Hz. 2 Gly CH2),
4.55 (2 H, m, 2 Cys a-H), 5.10 (4 H. s. 2 PhCH2), 5.8 (4 H. br. 
4 NH), 7.30 (10 H, ArH).
N-[N -(  t e r t -Butoxycarbonyl)-S - ( te r t -butylthio)cystci- 
°yl]glycine Methyl Ester (29a). Compound 30 (320 mg, 0.74 
mmol) was stirred with glycine methyl ester hydrochloride (251 
mg, 2 mmol) and N//-diisopropylethylamine (600 mg, 4.5 mmol) 
in CH2C12 (6 mL) for 4 h. The mixture was washed with aqueous 
NaOH (2 M), H20  (thrice), aqueous (2 M: twice), and H20
and was dried. Evaporation of the solvent afforded 29a (270 mg, 
96%) as a white solid: mp 105-107 °C: optical rotation (c = 279 
mM in CHC13) [a]21^  -56.7°. [a)21STe -59-4°. (a]2‘s46 “68 0°; IR
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3350,1725.1685 a ir 1; NMR (300 MHz) b 1.24 (9 H. s. SCICH^],
1.46 (9 H, s, OaCHjJj). 3.08 (2 H, m, Cys 0-CH2), 3.75 (3 H. s. 
OCHj), 4.03 ( 1  H. dd, J  = 18.3 Hz, J  = 5J2 Hz) and 4.08 ( 1  H, 
dd. J  = 18.3 Hz, J  = 5.2 Hz) (Gly CH2), 4.43 (1 H. ca. q. J  = ca 
6  Hz, Cys a-CH), 5.29 ( 1  H, d, J  = 7 Hz, Cys NH). 6.82 ( 1  H, br 
t, J  = ca. 5 Hz. Gly NH); mass spectrum, m/z 381.1512 [(M + 
H)+] (CjsHmNjOjSj requires 381.1518), 380.1431 (M+) 
(QsHjgNASz requires 380.1440), 325,268,224.57 (100%). Anal. 
Calcd for CuHaNASj: C. 47.35; H, 7.4; N, 7.35. Found: C.47.5; 
H, 7.7; N, 7.4. A sample (30 mg) was treated with 357c DC1 in 
D20  for 4 days to give a solution of JV-{S-(tert-butylthio)cyste- 
inyljglycine deuteriochloride: NMR (DC1/D20) b 1.40 [9 H, s, 
SC(CH3)3], 3.40 ( 2  H, d, J  = 6  Hz, cys 0 -CH2), 4.20 (2 H. s, Gly 
CH2), 4.62 ( 1  H, t, J  = 6  Hz. Cys a-H).
N -[N -(te r t  -Butoxycarbonyl)-S-(tert -butylthio)cystei- 
nyl]glycine Methyl Ester (29a) by the Mixed-Anhydride 
Method. Compound 26a was treated with isobutyl chloroformate, 
EtjN, and glycine methyl ester hydrochloride, as for the reaction 
of 26b above, to give, after chromatography, 29a (44 %) as a white 
solid identical with the material described above.
N -[N -(te r t  -Butoxycarbonyl)-S-(tert-butylthio)cystei- 
nyljglycine te r t -Butyl Ester (29b). Ester 30 was treated with 
glycine tert-butyl ester hydrochloride and AMV-diisopropyl- 
ethylamine, as for the preparation of 29a above, to furnish 29b 
(240 mg, 95%>) as a colorless gum: optical rotation (c = 57.0 mM 
in CHCI3) [a]21*;, - 1 1 .6 °; IR 3320,1730.1670 cm'1; NMR b 1.28 
[9 H. s. SC(CHj)3], 1.41 (18 H, s, 2 OC(CH3)3], 3.04 (2 H, ca. d, 
J  = ca. 6  Hz, becomes s on decoupling at 0 4.40, Cys 0-CH2), 3.86 
(2 H, d, J  -  5 Hz, Gly CH^, 4.40 ( 1  H, ca. q, J  = ca. 7 Hz, becomes 
ca. t ,«/ = ca. 6  Hz on decoupling at b 5.60, becomes d, J  = 7 Hz 
on decoupling at b 3.04, Cys a-H), 5.60 ( 1  H, d, J  = 7 Hz, Cys 
NH), and 6.99 ( 1  H, ca. t, J  = ca. 5 Hz, becomes s on decoupling 
at b 3.86, Gly NH). Anal. Calcd for CwH^NsOsSj: C, 51.15; H, 
8 .1 ; N, 6.65. Found: C, 51.05; H, 8 .0 ; N, 6.5.
N -(tert -Butoxycar bony 1 )-S -(tert -b utyIthio)cysteine 4- 
Nitrophenyl Ester (30). N-(terf-Butoxycarbonyl)-S-(tert-bu- 
tylthio)cysteine (26a) (309 mg, 1  mmol) was stirred with di- 
cyclohexylcarbodiimide (206 mg, 1 mmol) and 4-nitrophenol (139 
mg, 1 mmol) in CH2C12 (5 mL) for 2 h before being filtered. 
Chromatography of the evaporation residue (silica gel; CHC13) 
afforded 30 (330 mg, 77%) as white needles: mp 102-103 °C; 
optical rotation (c = 146 mM in CHClj) (a]21^  +25.2°, (a] 21S78 
+27-3°, [a p s *  +31.1°; IR 1750, 1690,1510, 1330 cm'1; NMR b 
1 25  (9 H, s, SCtCHjJJ, 1.48 (9 H, s, OC(CH,),]. 3.28 (2 H, d. J  
= 6  Hz, /5-CHj), 4.78 ( 1  H. m, a-CH), 5.65 ( 1  H, d, J  = 8  Hz, NH).
7.30 (2 H, d, J  = 9 Hz, Ar 2,6-H), and 8.20 (2 H. d. J  = 9 Hz, Ar
3,5-H); mass spectrum, m /z 318 [(M -  2 ^H gT], 301, 274, 208, 
57(100%). AnaL Calcd for C ^H ^N A S,: C, 50.25; H, 6 .1 ; N,
6.5. Found: C, 50.55; H, 6.05; N, 6.25.
N -[N -(te r t-Butoxy carbonyH-S-fN-methylcarbamoyl)- 
cysteinyljglycine Methyl Ester (31a). Compound 2 0  (270 mg, 
0.92 mmol) was stirred with methyl isocyanate (570 mg, 10 mmol) 
and NJV-diisopropylethylamine (300 mg, 2.3 mmol) in CH2C12 
(12 mL) for 3 days before the mixture was washed twice with 
ice-cold aqueous HjS04 ( 1  M), with H20  and with saturated 
aqueous NaCL The solution was dried, and the solvent and excess 
isocyanate were evaporated to furnish 31a (244 mg, 70%) as an 
unstable colorless oil, which did not give a satisfactory micro­
analysis but was shown to be >977c pure by NMR: IR 3350,1735, 
1665 cm*1; NMR b 1.43 (9 H, s, C(CH,),]. 2.95 (3 H, d, <7 = 5 Hz, 
NCH3), 3.2 ( 2  H, m, Cys 0-CH2), 3.72 (3 H, s, OCH3). 4.05 ( 2  H, 
d, J  = 5 Hz, Gly CH2), 4.35 ( 1  H, m. Cys a-H), 6.08 ( 1  H, d. J  
= 7 Hz, Cys NH), 6.90 ( 1  H, t, J  = 5 Hz, Gly NH), and 7.20 (1  
H, q, J  = 5 Hz, NHCH3); mass spectrum, m /z 236 [(M -  C«Hg 
-  MeNCOH and 192.
N -[N -(tert  -Butoxy carbony 1) -S-(N-ethylcarbamoyl)cys - 
teinyljglycine Methyl Ester (31b). Compound 2 0  (270 mg, 0.92 
mmol) was treated with ethyl isocyanate (600 mg, 8 . 5  mmol), as 
for the preparation of 31a above, to give 31b (235 mg, 70%) as 
an unstable colorless gum: NMR b 1.14 (3 H, t, J  = 7 Hz. 
CH2CH J, 1.43 (9 H, s. C tC H ^.'S.l-S^ (4 H. m, Cys 0-CH: + 
NCHjCHJ, 3.71 (3 H, s, OCHj), 4.02 (2 H, d, J  =  5 Hz. Gly CH2), 
4.3 ( 1  H, m. Cys a-H), 5.98 (1  H, d, J  = 7 Hz, Cys NH). 6.73 ( 1  
H, t, J  = 5 Hz. NHEt or Gly NH), and 7.39 (1 H, t. J  = 5 Hz, 
Gly NH or NHEt); mass spectrum, m /z  236 ((M -  C4H8 -  
EtNCOH and 192.
Threadgill and Gledhill
N -(te r t  -B utoxycarbonyl)-S - ( te r t  -butylthio)cysteine  
tert -Butyl Thioester (32). Ester 30 (430 mg, 1 mmol) was stirred 
with N,N-diisopropylethylamine (516 mg, 4 mmol) in 2- 
methylpropane-2 -thiol (5 mL) for 16 h under reflux. Evaporation 
of excess reagent gave an oil which, in CH2C12, was washed with 
ice-cold aqueous H2S 0 4 (1 M) and with saturated aqueous NaCl 
and was dried. Chromatography of the evaporation residue (silica 
gel; EtOAc/hexane, 1:4) afforded 32 (156 mg, 41%) as a colorless 
gum, which would not give a satisfactory microanaiysis but ap­
peared by NMR and TLC to be >96% pure: NMR b 1.35 (18 
H, s, 2 SC(CH3)3), 1.45 (9 H, s, OC(CHj)3], 3.25 (2 H, d, J  = 6  
Hz. d-CH2). 4.68 (1 H, m, a-H), and 6.10 (1 H, br, NH).
N -(ter t  -Butoxycarbonyl)glutam ic Acid a-Methyl y-(4- 
Nitrophenyl) Diester (34). N-(tert-Butoxycarbonyl)glutamic 
acid a-methyl ester dicyclohexylammonium salt31 (33) (optical 
rotation (c = 53.5 mM  in CHClj) [a]21^  -2.0°) (2.87 g, 6.5 mmol), 
in CH2C12 (80 mL), was washed with aqueous HjS04 ( 2  M; 2  X 
50 mL) at 0 °C and was dried. The solution was then stirred with 
dicyclohexylcarbodiimide (1.34 g, 6.5 mmol) and 4-nitrophenol 
(904 mg, 6.5 mmol) for 24 h before being filtered. Chromatography 
of the evaporation residue (silica gel; EtOAc/hexane, 1:4) gave 
34 (1.93 g, 78%) as a white solid: mp 53-54 °C; IR (Nujol) 3380, 
1760,1735,1680,1520,1350 cm-1; NMR (300 MHz) 8 1.43 [9 H. 
s,  C(CH3)3], 2.01 ( 1  H, ca. dq, J  = 15 Hz, J = 7 Hz) and 2.32 (1  
H, ca. dq, J  = 15 Hz, J  = 7 Hz) (/S-CH2), 2.69 (1  H, dt, J  = 17.2 
Hz, J  = 6 . 8  Hz) and 2.72 ( 1  H. dt, J  = 17.2 Hz. J  = 7.5 Hz) 
(•y-CHj), 3.76 (3 H, s, OCHj), 4.45 (1 H, ca. q, J  = ca. 7 Hz, a-H),
5.14 (1 H, d. J  = 7.8 Hz, NH), 7.29 (2 H, d, J  = 9.2 Hz, Ar 2,6-H),
8.26 (2 H. d. J  = 9.2 Hz, Ar 3,5-H); mass spectrum, m/z 382 (M+), 
325,309,139,57 (100%). Anal. Calcd for C^H ^N A: C. 53.4;
H, 5.8; N, 7.35. Found: C, 53.5; H. 5.85; N, 7.4.
N-( tert -B utoxy carbony 1) -S -( ter t  -buty lthio )gl utathione 
Bis(methyl ester) (36). Compound 29a (1.14 g, 3 mmol) was 
stirred with CF3C 02H (10 mL) for 16 h before CH2C12 (30 mL) 
was added. This solution was washed with saturated aqueous 
NaHC03 and dried. Evaporation of the solvent gave crude 35 
(800 mg, 95%) as a colorless oil: NMR b 1.30 (9 H, s, SCfCHjjj], 
255 (2 H, br, NHj), 270 ( 1  H, dd, J  = 12 Hz, J  = 9 Hz) and 3.30 
( 1  H, dd, J  = 12 Hz, J  = 3 Hz) (Cys 0-CH2), 3.67 ( 1  H. dd, J  =
9 Hz, J  = 3 Hz, Cys a-H), 3.70 (3 H. s, OCH3), 4.02 ( 2  H, d, J  
= 5 Hz, Gly CHj), and 7.9 ( 1  H. ca. t, J  = ca. 5 Hz, NH). This 
amine was boiled under reflux with 34 (764 mg, 2 mmol), NJ4- 
diisopropylethylamine (400 mg, 3.1 mmol), and 4-(dimethyl- 
amino)pyridine (20 mg) in anhydrous THF (20 mL) for 30 h. The 
evaporation residue, in CH2C12, was washed with H20  (twice), 
aqueous H^O* (2 M) (twice), 2 M aqueous NaOH (twice), and 
H20 . The solution was dried, and the solvent was evaporated 
to afford 36 (878 mg, 84%) as a colorless gum: optical rotation 
(c = 24.3 mM in CHC13) [a]21^  -47.2°. (a] 21S78 -50.4°, [a]21** 
-56.7°, la]21^  -103-9°; IR 3320 (br), 1750,1710-1640 (br) cm’1; 
NMR (400 MHz) b 122 [9 H, s, SaCHaJJ, 1.42 {9 H, s, OCXCH^],
I.93 ( 1  H, dq, J  = 15 Hz, J  = 7.5 Hz) and 217 ( 1  H, J  = 15 Hz, 
J  = 7.5 Hz) (Glu -r-CH2), 2.36 (2 H, m, Glu 0 -CH2), 3.09 ( 1  H, 
dd. J  = 14.0 Hz, J  = 6 . 1  Hz) and 3.13 ( 1  H, dd, J  = 14.0 Hz, J  
= 6.9 Hz) (Cys CH2), 3.728 (3 H, s, OCH3), 3.734 (3 H, s, 0CH3), 
4.00 ( 1  H, dd, J  = 18.1 Hz, J  = 5.3 Hz) and 4.05 ( 1  H, dd, J  =
18.1 Hz, J  = 5.6 Hz) (Gly CH2), 4.37 ( 1  H, m, Glu a-H), 4.73 ( 1  
H, ca. q, J  = ca. 7 Hz, Cys a-H), 5.35 ( 1  H, d. J  = 7.3 Hz, Cys 
NH or Glu NH), 6.80 ( 1  H. d, J  = 7.2 Hz, Glu NH or Cys NH), 
and 7.09 ( 1  H, ca  t, J  = ca. 5.5 Hz, Gly NH); mass spectrum, m/z 
523 (M+), 467, 450. 434,367 (100%), 224, 90, 57,136.72 (M*: 367 
— 224). Anal. Calcd for C2 1HT7N30 8S2: C, 48.15; H, 7.1; N, 8.0. 
Found: C. 47.85; H, 7.1; N, 7.7. From one experimental run in 
the absence of 4-(dimethylamino)pyridine, a gum was obtained 
which was subjected to column chromatography (silica gel; CHClj). 
From the slowest running fraction was isolated 3 -[[(tert-butyl- 
sulfenyl)thio)methyl]-2,5-dioxopiperazine (38) (6 %) as a white 
solid: mp 210-214 °C dec; IR (Nujol) 3200,3050,1660 cm’1; NMR 
[CDC13 /(CD3)jSO; 1 :1 ] 8 1.35 [9 H, s. SC(CH3)3], 3.22 ( 2  H, d. 
J = 5 Hz, SCtfjCH), 3.84 ( 2  H. m. NHCH2C0), 4.14 ( 1  H, dt, J  
= 2 Hz, J  = 5 Hz, NHCHCHj) (becomes t, J  = 5 Hz on decoupling 
at 8 8.10), and 8 . 1  (2 H. br. 2 NH). From other fractions were 
obtained 36 (59%) and 35 (14%).
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Differences between Rodents and Humans in the Metabolic Toxification of A'..V-DimethyI- 
formamide. M ra z .  J., C ro ss , H„ G e s c h e r ,  A., T h r e a d g i l l ,  M. D.. a n d  Flek. J. (1989). 
Toxicol. Appl. Pharmacol. 98,507-516. The widely used industrial solvent N. .V-dimethylform - 
amide (DMF) causes liver damage in occupationally exposed persons and is suspected of in­
volvement in the generation of certain occupational malignancies. Here the extent of the bio- 
transformation of DMF to three urinary metabolites has been compared in humans and rodents. 
The metabolites, which were quantified by gas chromatography (GC) are A/-(hydroxymethyl)- 
Af-methylformamide (HMMF), which yielded Ar-methylformamide on GC analysis, a species 
which decomposed to formamide on GC analysis, and Af-acetyl-S-fW-methylcarbamoylJcysteine 
(AMCC), measured after derivatization with ethanol to give ethyl jV-methylcarbamate. Ten vol­
unteers who absorbed between 28 and 60 pmol/kg DMF during an 8 -hr exposure to DMF in 
the air at 60 mg/m3 excreted in the urine within 72 hr between 16.1 and 48.7% of the dose as 
HMMF, between 8.3 and 23.9% as formamide, and between 9.7 and 22.8% as AMCC. AMCC, 
together with HMMF, was also detected in the urine o f workers after occupational exposure to 
DMF. The portion of the dose (0.1,0.7, or 7.0 mmol/kg given ip) which was metabolized in 
mice, rats, or hamsters to HMMF varied between 8.4 and 47.3% of the dose; between 7.9 and 
37.5% were excreted as formamide and only between 1. 1 and 5.2%, as AMCC. The results sug­
gest that there is a quantitative difference between the metabolic pathway of DMF to AMCC in 
humans and rodents. It is argued that the hepatotoxic potential of DMF may be linked to the 
extent of its metabolic conversion to AMCC, © 1989 Academic Press. Inc.
The physical properties of M/V-dimethyl- 
formamide (DMF)4 (Fig. I) make this chemi­
cal exceptionally useful as a solvent in the
1 This work was supported by grants from the Health 
and Safety Executive, the Cancer Research Campaign, 
and the Medical Research Council of Great Britain. The 
British Council and Nuffield Foundation provided a 
travel grant.
2 To whom correspondence should be addressed.
3 Present address: Medical Research Council Radiobi­
ology Unit. Chilton. Didcot. Oxon OX 11 ORE. En­
gland.
4 Abbreviations used: DMF. A'.A'-dimethvlform- 
amide: NMF. A-meihylformamide: F. formamide:
HMMF, AKhydroxymethyl)-A/,-methylfoimamide: HMF.
chemical laboratory and in industrial pro­
cesses, especially for the manufacture o f poly­
mers such as polyvinylchloride, polyacryloni- 
trile, and polyurethanes (Eberling, 1980). 
World production of DMF is approximately 
2 X 105 tons per year (Eberling, 1980). Occu­
pational exposure to DMF causes pancreatic 
disorders, hepatic damage, and intolerance to 
alcohol. Recently, carcinomas of the testes 
have been detected in several individuals in
A/-(hydroxymethyl)formamide: bisHMF. A/.A/-bis(hy- 
droxymethyl)formamidc: AMCC. A’-acetyl-S-(N-meth- 
ylcarbamoyl)cysieinc: GC. gas chromatography.
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two populations working with DMF in 
different industrial settings (Ducatman et a i. 
1986; Levin et a i, 1987). In rodents the toxic 
potential of DMF seems to be low (for review 
see Kennedy, 1986; Scailteur and Lauwerys, 
1987). There has been one report, as yet un­
corroborated, that DMF is carcinogenic in 
the rat (Kommineni, 1972).
The mechanisms by which DMF causes 
toxicity are unclear. DMF has been claimed 
to undergo metabolism to A'-methyl formam­
ide (NMF) (Fig. 1) (Barnes and Ranta, 1972; 
Kimmerfe and Eben, I975a,b). This bio­
transformation was thought to be responsible 
for the liver-damaging properties o f DMF 
(Barnes and Ranta, 1972; Kimmerle and 
Eben. 1975a) as NMF is a powerful hepato- 
toxicant in rodents (Whitby et a i.  1984; 
Langdon et a i. 1985) and in patients, in 
whom it has been tested for antineoplastic ac­
tivity (MeVie et a i. 1984; Ettinger et a i. 
1985; Eisenhauer el a i, 1986). However, the 
urinary metabolite o f DMF which had been 
identified as NMF on the basis o f gas chro­
matographic analysis has recently been 
shown to be V-(hydroxymethyl)-7/-methyl- 
formamide (HMMF) (Fig. 1), which is stable 
in aqueous solution but is thermally degraded 
to NMF on the gas chromatography column 
(Brindley et al., 1983; Scailteur and Lau­
werys, 1984a; Kestell etal., 1986a). Although 
the biological properties and metabolic fate 
o f HMMF are presently unknown, studies 
on its analog Af-(hydroxymethyl)formamide 
(HMF)(Fig. 1) (Cooksey etal., 1983) suggest 
that it is not hepatotoxic.
The hepatotoxicity o f monoalkylformam- 
ides, such as NMF, in mice appears to be 
linked to the metabolism of these compounds 
(Pearson et a i. 1987a,b) and, in particular, to 
a metabolic pathway which leads to the uri­
nary excretion of V-acetyl-S-(V-alkylcarba- 
moyl)cysteines (AMCC) (Kestell et a i. 1987). 
AMCC (Fig. 1) has been identified as a major 
metabolite of NMF in patients, rats, and mice 
(Kestell e ta i.  1986b; Tulip et a i. 1986). Very 
recently, AMCC has also been identified un­
equivocally in the urine after exposure of a
human to DMF (Mraz and Turecek, 1987). 
This finding raises the possibility that the 
mechanisms by which DMF and monoal- 
kylformamides cause hepatic toxicity in hu­
mans are related and involve the same reac­
tive intermediate. This paper focuses on the 
metabolic pathway of DMF which termi­
nates with the excretion o f AMCC as it ap­
pears to be pivotal for the understanding of 
the mechanism by which DMF causes toxic­
ity. In particular, the hypothesis has been 
tested that DM F is biotransformed to AMCC 
not only in humans (Mraz and Turecek, 
1987) but also in rodents. Rodents are most 
frequently used in investigations of the mech­
anisms by which solvents such as DMF cause 
toxicity. Therefore it seems appropriate to es­
tablish whether the metabolism of DMF in 
rodents is qualitatively or quantitatively sim­
ilar to that observed in humans. To this end, 
DMF was administered to mice, rats, and 
hamsters and urine samples were analyzed 
for the presence o f AMCC and other DMF 
metabolites. The amounts of metabolites 
found were compared with those determined 
in the urine o f 10 human volunteers after in­
halation or ingestion o f DMF. Furthermore, 
in order to determine if AMCC is detectable 
also under conditions o f occupational expo­
sure to DMF, its metabolites were measured 
in urine samples obtained from 12 workers 
who were exposed to DMF in their working 
environment.
METHODS
Chemicals. DMF. NMF. and formamide (F) were pur­
chased from Aldrich Chemical Co. Ltd. (UK). .V-Acetyl-
5-(/v'-methylcarbamoyl)cysteine was prepared as de­
scribed by Kestell et al. (1986b). [,',C]Methyl-labeled 
DMF was synthesized by the general method described 
by Threadgill and Gate (1983).
Animat experiments. DMF was dissolved in saline so­
lution and administered (0.1.0.7. or 7 mmol/kg) via the 
ip route to male BALB/c mice (19-26 g). male Sprague- 
Dawley rats (235-270 g). or male Syrian hamsters (100— 
114 g). The volume of injection was 0 .1 ml in mice and 
0.5 ml in rats and hamsters. Animals were housed indi­
vidually in metabolic cages. Urine samples were col-
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Fig. I. Proposed metabolic pathway o f DMF. So far, o f the compounds shown, only HMMF (Kestell et 
al 1986a) and AMCC (Mraz and Turecek, 1987) have been unequivocally identified as DMF metabolites. 
In addition to the metabolites shown, methylamine and dimethylamine are minor DMF metabolites in 
the mouse (Kestell et al.. 1986a).
lected for 72 hr at 12-hr intervals. To ensure quantitative 
collection of excreted metabolites, cages were rinsed with 
small volumes of water at each collection.
Exposure of humans. After giving informed consent, 
10 healthy volunteers (5 male, 5 female) aged between 26 
and 56 years (mean: 41 years) and of 52-94 kg body wt 
(mean: 70 kg) were exposed for 8  hr to 60 mg/m3 DMF 
(20 ppm) in the air. The temperature of the exposure 
chamber was 25 ± 2‘C. The exposure was conducted at 
the Institute of Hygiene and Epidemiology, Prague. The 
exposure chamber, designed as described by Sedivec ei 
al. (1974), allowed for the measurement o f airborne con­
centrations of DMF by GC at 5-min intervals and the 
maintenance of a constant DMF concentration. The 
dose absorbed via inhalation was calculated as the prod­
uct o f DMF vapor concentration, total lung ventilation 
(measured usinga Wright respirometer) during the expo­
sure period, and lung retention of DMF measured by GC 
analysis of the DMF content in the expired air. DMF ab­
sorption via the skin was not taken into account. In a 
separate study, one of the male volunteers (26 years old) 
ingested aliquots of DMF (0.02 or 0 . 1 mmol/kg) dis­
solved in water ( 1 0  ml) at half-hour intervals for 8  hr. 
Urine was collected at 2- to 8 -hr intervals for 4 to 5 days 
and frozen until analysis by GC.
Early morning urine samples were obtained in the 
middle of a working week from 1 2  workers who were oc­
cupationally exposed to DMF in a plastics factory in 
Eastern Bohemia (Czechoslovakia) in which DMF is 
used to wash polyurethanes off molds. Owing to the pre­
liminary nature of this part of the study, the concentra­
tion o f DMF vapor at the workplace was not determined.
Analysis o f  DMF metabolites. Preparation of samples 
and GC analysis of formamides and AMCC were con­
ducted essentially as described by Mraz et al. (1987) and 
Mraz (1988) using either a Pye Unicam Series 204 or a 
Chrom 5 (Laboratomi pristroje. Prague) chromatograph, 
both fitted with nitrogen-sensitive detectors. The method 
involves derivatization of AMCC with ethanol under al­
kaline conditions to form ethyl jV-methylcarbamate 
prior to GC analysis. The recover)' of AMCC as ethyl N- 
methylcarbamaie was between 60 and 70% depending on 
the dilution o f the urine sample. Rat urine contained a 
constituent which cochromatographed with ethyl N-
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TABLE I
A c c u r a c y  a n d  R e p r o d u c i b i l i t y  o f  M e a s u r e ­
m e n t  o f  AMCC i n  U r i n e  S a m p l e s  f o l l o w i n g  E x ­
t r a c t i o n  w i t h  E t h y l  a c e t a t e ®
Coefficient of variation (%)h
AMCC Variation Within-
concentration on repeated day Between-
(mm ) injection variation days variation
2 0 6 . 1 8.3 3.8
1 0 0 0.9 2 . 8 6 . 6
® For details of analytical determination see Methods. 
* Sample size in each case: 6 .
methylcarbamate. To eliminate the interference of such 
endogenous urine constituents and to increase the sensi­
tivity o f the method, it was necessary in some cases to 
extract further and concentrate the ethyl /V-methylcarba- 
mate. To this end. ethanolic urine extract containing the 
internal standard was evaporated and the residue was 
taken up into 1 ml water and extracted into ethyl acetate 
( 1  ml) which was analyzed by GC. The limit of quantita­
tion for AMCC was 1 nmol/ml. The method is character­
ized by the coefficient of variation values shown in Table 
1 for six samples prepared with two concentrations of 
AMCC. It should be noted that this method determines 
total ALmethylcarbamoylating species; previous studies 
(Mraz and Turecek, 1987; Kestell et al.. 1986a) suggest
that this is exclusively AMCC in the urine after adminis­
tration o f DMF or NMF.
On the basis of previous work (Brindley el al.. 1983; 
Scailteurand Lauwerys. 1984a; Kestell e ia l. 1986a). we 
conclude that the metabolite which was detected as NMF 
by GC was HMMF which decomposes on the GC col­
umn. This metabolite is labeled “NMF' in the following. 
HMMF itself cannot be detected by HPLC with the re­
quired sensitivity. Metabolites of [l4C]DMF, of which 
0.7 or 7 mmol/kg was given ip. were separated and mea­
sured in the urine of six mice by thin-layer chromatogra­
phy followed by counting of radioactivity as outlined be­
fore for metabolites of [ ,4C]NMF (Kestell et al.. 1985).
RESULTS
AMCC has never before been described as 
a metabolite of DMF in rodents. Here we re­
port that AMCC together with “ N M F ’ and 
DMF were detected and measured in the 
urine of mice, rats, and hamsters which had 
received DMF, 0.1, 0.7. or 7 mmol/kg. The 
am ount o f DMF excreted as AMCC consti­
tutes between 1.1 and 5.2% of the adminis­
tered dose (Table 2). Figures 2 to 4 show  the 
time course o f excretion of the two DMF me­
tabolites, “ N M F ’ and AMCC. In mice (Fig. 
2) these metabolites were excreted rapidly so 
that they could not be detected beyond 24 hr
TABLE 2
A m o u n t s  o f  M e t a b o l i t e s  o f  DMF in  t h e  U r i n e  o f  M ic e ,  R a t s ,  a n d  H a m s t e r s  E x p r e s s e d  a s  a  





Amount excreted in the urine® 
(% o f dose ± SD)
DMF “NMF'' "F" AMCC
Mouse 7.0 1.2 ± 0 .7 45.5 ±  14.3 16.3 ± 7.7 1 .1  ±0.3
0.7 0 . 1  ± 0 . 1 18.2 ±  4.8 27.6 ± 4.9 1.3 ±0.4
0 . 1 0 8.4 ± 3.5 26.0 ± 4.9 1.6 ±0.4
Rat 7.0 5.5 ± 1.3 44.6 ± 6.1 8.3 ± 2.1 1.7 ±0.2
0.7 1.0 ±0 .3 43.2 ± 6 . 8 15.5 ± 2.8 2.7 ±0.8
0 . 1 0 36.8 ±  2.6 37.5 ± 3.5 5.2 ± 1.0
Hamster 7.0 2 . 2  ± 0 . 6 47.3 ±  8.0 7.9 ± 2.7 1+ o u
0.7 0.3 ±0.1 44.9 ± 18.9 24.0 ± 10.7 2 . 8  ± 1 . 0
0 . 1 0 29.0 ±  6.9 22.9 ± 4.5 1.9 ±0.4
" Values were obtained in six or seven animals. Measurable amounts o f metabolites were detected in mice up to 24 
hr. in rats up to 60 hr. and in hamsters up to 36 hr after dosing.
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Fig. 2. Time course of excretion of the metabolite 
which gave NMF on GC analysis and is presumably 
HMMF (A) and of AMCC (B) in the urine of BALB/c 
mice after ip administration of 0.7 ( a ) or 7 mmol/kg 
DMF (□). Values are the mean ± SD of six animals.
after drug administration. In rats which re­
ceived 7 mmol/kg DMF the excretion of the 
DMF metabolites was delayed. AMCC was 
not detectable before 24 hr had elapsed after 
DMF administration (Fig. 3). In hamsters 
(Fig. 4) “N M F ’ was excreted rapidly, and the 
excretion of AMCC after the high dose of 
DMF was slightly delayed. In accordance 
with previous reports (Brindley et al.. 1983: 
Scailteur and Lauwerys, 1984a; Kestell ei al.. 
1986a), “ NMF,” which was most Iikelv
HMMF which decomposes to NMF on GC 
analysis, was found to be the major or one of 
the major products of the biotransformation 
of DMF in all three species. A metabolite 
which gave F on GC analysis and which is la­
beled “ F ’ in the tables was also a major excre­
tion product. The experiments in mice were 
repeated using [l4C]methyl-labeled DMF. 
The proportion of the injected radioactivity 
which was recovered in the urine of six mice 
was 55 ± 8% after a lew (0.7 mmol/kg) and 
75 ± 7% after a high dose (7 mmol/kg). The 
amounts of metabolites measured by count­
ing of radioactivity (results not shown) were 
very similar to those determined by GC, ex­
cept in the case of the species which cochro­
matographed with F. Only 18.3 ± 2.0% of the 
low and 8.2 ± 1.2% (n = 6) of the high dose 
produced this metabolite. The exact chemical 
nature of this product of biotransformation 
of DMF is currently under investigation and 
preliminary evidence suggests that it is a mix­
ture containing HM F (see Fig. 1) as the major 
component. HM F would decompose to F 
during gas chromatographic analysis.
In order to find out how  the amount of me­
tabolites of DMF generated in rodents com­
pares with those formed in humans, samples 
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TIME AFTER ADMINISTRATION (HR)
Fig. 3. Time course of excretion of the metabolite which gave NMF in GC analysis (A) and of AMCC 
(B) in the urine o f Sprague-Dawley rats after ip administration of 0.7 ( a ) or 7 mmol/kg DMF (□). Values 
arc the mean * SD of six rats.
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TIME AFTER ADMINISTRATION (HR)
Fig. 4. Time course of excretion of the metabolite which gave NMF on GC analysis (A) and of AMCC 
(B) in the urine o f Syrian hamsters after ip administration of 0.7 ( a ) or 7 mmol/kg DMF (□). Values are 
the mean ±  SD of six animals.
exposure to airborne DMF at 60 mg/m3 
which is twice the threshold limit value as de­
fined in a number of countries including the 
United States. The mean of the amount of 
DMF absorbed via the lung was 49.3 /zmol/ 
kg, which is half of the lowest dose adminis­
tered to rodents. The results o f the analysis 
(Table 3) show that, in accordance with a pre­
vious report (Kimmerle and Eben, 1975b), 
only a very small proportion of the dose was 
excreted unchanged. “NMF,” “ F,” and 
AMCC were three major DMF metabolites 
excreted by the volunteers. In a separate 
study, one of the volunteers ingested rather 
than inhaled DMF, either 0.02 or 0.1 mmol/ 
kg. The time course of excretion of metaboli- 
cally generated “N M F ’ and AMCC after oral 
ingestion of DMF is shown in Fig. 5. “N M F ’ 
was detected almost immediately after the 
start of the period of DMF administration. 
The volunteer excreted 17.7% of the lower 
and 17.0% of the higher oral dose as “N M F ' 
compared to 25.6% after exposure to DMF 
vapor. Most of this metabolite was excreted 
within 12 hr with peak amounts occurring at 
the end of the period of ingestion. In contrast, 
excretion of AMCC did not start until the end 
of the oral administration and peak concen­
trations were reached 24 hr later (Fig. 5B). 
AMCC was detectable in the urine for 5 days 
and the volunteer excreted 8.5% of the lower 
and 9.1% of the higher oral dose as AMCC
compared to 15.8% after exposure to air­
borne DMF. The characteristics of the meta­
bolic profile obtained after exposure of the 
volunteers to DMF vapor (results not shown) 
were identical to those shown in Fig. 5.
In a preliminary experiment, it was investi­
gated whether AMCC is also detectable in the 
urine of workers occupationally exposed to 
DMF. AMCC was indeed discovered in each 
urine sample obtained from 12 workers who 
had been exposed regularly to DMF in their 
working environment. The concentrations 
varied between 10 and 590 /zM (mean: 109 
/xM). The concentrations of “N M F ' found in 
these urine samples fluctuated between 14 
and 112 /zM (mean: 45 /zm) and the mean 
± SD of the ratios of concentrations of 
AMCC to “ N M F ’ in individual workers was 
2.3 ± 1.5. These findings are comparable 
with those ofM alonovaand Bardodej (1983). 
They reported an increase in urinary concen­
trations of constituents which decomposed to 
thiols on alkaline hydrolysis in workers who 
had been occupationally exposed to DMF.
DISCUSSION
This is the first time that a quantitative 
difference has been observed in the metabo­
lism of DMF between humans and rodents. 
The formation of AMCC is only a minor
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t a b l e  3
A m o u n t s  o f  M eta bo lites o f  D M F in  t h e  U r in e  
o f  10 Vo l u n t e e r s  Ex pr essed  as a Pe r c e n t a g e  o f  
t h e  Do se  a b s o r b e d ®
Metabolite
Amount excreted in the urine (% of dose)
Mean ± SD Highest value Lowest value
DMF 0.7 ± 0.4 1.5 0.4
“NMF” 25.9 ± 8.5 48.7 16.1
“F” 14.2 ±5.2 23.9 8.3
AMCC 14.5 ± 3.6 22.8 9.7
® The volunteers were exposed for 8 hr to 60 mg/m3 
DMF in the air and absorbed between 28 and 60 Mmol/ 
kg DMF. The mean ± SD of the amount of DMF ab­
sorbed was 49.3 ± 11.6 Mmol/kg. Metabolites were de­
tected in the urine up to 120 hr after the start of exposure. 
Further details on the volunteers and measurements are 
under Methods.
metabolic pathway of DMF in rodents but it 
is a major route o f biotransformation in hu­
mans. Whereas in humans 14.5% of the dose 
absorbed on inhalation o f DMF was found as 
AMCC, the amount measured in mice, rats, 
or hamsters after ip administration o f DMF 
was only a third or less of this percentage. 
One could argue that this difference may be 
partly due to the difference in dose adminis­
tered. However, this is unlikely because the 
metabolism of DMF to AMCC in mice or 
hamsters was not dose-dependent and in rats 
the percentage o f DMF excreted as AMCC 
increased only threefold on decreasing the 
dose from 7.0 to 0.1 mmol/kg. It cannot be 
excluded that the yield of DMF metabolites 
was to some extent influenced by the route 
of administration. Indeed, the volunteer who 
ingested DMF excreted 5% less as AMCC af­
ter oral administration than when he inhaled 
DMF. Absorption of DMF through the skin 
was not taken into consideration when the 
dose absorbed on inhalation was determined 
and therefore the percentages shown in Table 
3 may be a slight overestimation. On balance, 
however, the evidence presented here leaves 
little doubt that a larger percentage of a dose 
o f DMF is excreted as AMCC in humans
than in mice, rats, or hamsters. The results 
have considerable implications for the assess­
ment o f the occupational risk associated with 
DMF. We have previously demonstrated in 
mice that there is a mechanistic link between 
the generation o f alkylformamide-induced 
hepatotoxicity and the urinary excretion of 
N -acetyl - S - ( N -alkvlcarbamoyljcysteines 
(Kestell et al.. 1987). In BALB/c mice in 
which the hepatotoxic threshold dose of 
NMF was 3.4 mmol/kg (Kestell et al., 1987).
15% of the dose was excreted as AMCC (Kes­
tell et al., 1985). NMF is also a hepatotoxi- 
cant in humans (McVie et al.. 1984; Ettinger 
et al., 1985; Eisenhauer et al.. 1986) and un­
dergoes metabolism to AMCC in this species 
(Kestell et al.. 1986b). For example, an oral 
dose of 14 mmol/m2 (approximately 0.36 
mmol/kg) given three times per week for 4 
weeks elicited hepatotoxicity during 11 out of 
a total o f 29 courses o f treatment (Eisenhauer 
et al.. 1986). Although AMCC has been iden­
tified unequivocally as a metabolite o f NMF 
in the urine of patients (Kestell et al.. 1986b), 
the amount was not measured. In a prelimi­
nary experiment, one o f the above volunteers 
ingested NMF (0.1 mmol/kg). Analysis of the 
urine showed that 17% o f the dose was ex­
creted as AMCC (unpublished result), a pro­
portion which is remarkably similar to that 
produced by mice. In contrast, doses of up to 
41 mmol/kg DMF did not cause hepatotoxic­
ity in BALB/c mice (Kestell et al., 1987), and. 
according to the results presented here, DMF 
is metabolized to AMCC only to a small ex­
tent in this species. Similarly, Sprague-Daw- 
ley rats are not very susceptible to the hepato­
toxic potential of DMF. A single dose of 14 
mmol/kg did not result in liver damage 
(Scailteur et al.. 1981) and, again, the meta­
bolic pathway o f DMF leading to the mer- 
capturate was found here to be only o f little 
importance in this species. A single dose of 
only 6.7 mmol/kg DMF has been claimed to 
cause the elevation o f serum activities o f he­
patic enzymes in Sprague-Dawley rats. This 
would suggest damage to the liver (Lundberg 
et al.. 1981). The reason for this dichotomy is
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Fig. 5. Time course o f excretion of the metabolite which gave NMF on GC analysis (A) and of AMCC 
(B) in the urine of a volunteer after ingestion of 0.02 ( a ) or 0.1 mmol/kg DMF (□).
unclear. If, as seems likely, the metabolic 
route from DMF to AMCC involves the ulti­
mate hepatotoxic entity as a metabolic inter­
mediate, it is logical to suggest that the rela­
tive insensitivity of rodents to DMF-induced 
hepatotoxicity is related to their poor ability 
to metabolize DMF via this route. DMF has 
caused liver damage in exposed workers 
(Kennedy, 1986; Scailteur and Lauwerys, 
1987) and has recently been implicated in the 
etiology of some occupational testicular can­
cers (Ducatman et al.. 1986; Levin et al.. 
1987) even though an epidemiological study 
on 2530 workers did not corroborate an in­
creased cancer incidence linked to DMF ex­
posure (Chen et al.. 1988). The findings pre­
sented here suggest that the biotransforma­
tion of DMF to AMCC is an important 
pathway in humans but not in rodents. The 
results cast doubt on the role of rodents as the 
most appropriate animals to be used in stud­
ies designed to help assess the occupational 
risk associated with exposure to DMF. It re­
mains to be determined whether or not toxic 
effects of DMF other than hepatic damage are 
caused by its metabolites. Also, the structures 
of the ultimate hepatotoxicants formed as 
metabolites of DMF and of monoalkylform- 
amides are currently unknown.
We have recently postulated that methyl 
isocyanate (CH,NCO) or a reactive ester 
of /V-methylcarbamic acid (for example, 
CH3NHCOOPO^_) may be toxic metabolites
of NMF and precursors of the AMCC found 
in the urine (Kestell et al.. 1987). These reac­
tive species may also be responsible for the 
toxicity of DMF. Furthermore, thiocarba- 
mates related to AMCC are themselves cyto­
toxic in vitro and in vivo (Nemeth et al..
1978), presumably owing to their carbamoyl- 
ating properties. Hence, S-(jV-methylcarba- 
moyl)glutathione or other precursors of 
AMCC (Threadgill et al.. 1987) may cause, or 
contribute to, the toxicity elicited by DM F or 
by monoalkylformamides. Currently, the de­
termination of urinary levels of “N M F ’ is 
routinely used to assess occupational expo­
sure to DMF. Further studies of the mecha­
nism by which formamides cause toxicity to­
gether with the results presented here might 
suggest that AMCC is a more appropriate 
biomonitor of exposure to DMF as it is likely 
to be the product of the metabolic pathway of 
DMF responsible for toxicity.
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C onform ation of Aryl-substituted 1 -(2-Hydroxyphenyl)-3-phenylpropane-1,3- 
diones in the  Solid Phase and in Solution
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The tautomerism of a series of aryl-substituted 1 -(2-hydroxyphenyl)-3-phenylpropane-1i.3-diones has 
been studied in deuteriochloroform solution by 'H n.m.r. techniques and, in the case of 1- (2-  
hydroxy-4-methoxyphenyl)-3-phenylpropane-1,3-dione and 1 -(2-hydroxy-4,6-dimethoxyphenyl)-3- 
phenylpropane-1,3-dione, in the solid state by X-ray crystallography. Of these compounds, most 
exist between 80 and 95% in the enolised form in solution and 1 -(2-hydroxy-4-methoxyphenyl)-3- 
phenylpropane-1,3-dione adopts this tautomer in the crystal. However, 1 -(2-hydroxy-4,6-dimethoxy- 
phenyl)-3-phenylpropane-1,3-dione is present as the diketone in the solid phase and enolises very 
slowly in solution. 1-(6-Benzoyloxy-2-hydroxyphenyl)-3-hydroxy-3-phenylprop-2-en-1-one is 
shown by ’H n.m.r. spectroscopy possibly to adopt a 'coiled' conformation in solution in 
deuteriochloroform.
During the preparation of a series of flavones as potential 
enzyme inhibitors, variously substituted l-(2-hydroxyphenyl)-
3-phenylpropane-l,3-diones (5) were required as intermediates. 
The enolisation of 1,3-dicarbonyl compounds and the structure 
of the enol have been the subject of many studies2-3 by 
spectroscopic and other methods. Recently, Bassetti et al.* have 
inferred from *H n.m.r. data on simple 1,3-dialkyl- and 13- 
diaryl-propane-13-diones that the six-membered hydrogen- 
bonded ring system in the enol form of these compounds is best 
described as ‘pseudo-aromatic’. It was therefore o f interest to 
study the extent of tautomerism of the 13-diphenylpropane-l,3- 
diones when a potentially hydrogen-bonding ortho phenolic 
hydroxy group is present on one of the phenyl rings and to study 
the structure of the enols formed.
The synthesis of the required diones was generally straight­
forward and is shown in Scheme 1. Appropriately substituted 
2-hydroxyacetophenones (2) were commercially available or 
were prepared by a Friedel-Crafts-type acetylation of 3- 
methoxyphenol (la) or 3,5-dimethoxyphenol (lb) using the 
modification described by Piccolo et al.5 using boron tri­
chloride as a catalyst. In this procedure, an initial complex or 
borate ester is formed between the phenolic oxygen and the 
Lewis acid in dichloromethane solution at —10 °C. Addition of 
acetyl chloride leads to complexation of its carbonyl oxygen to 
the boron, ensuring that acylation takes place exclusively at 
the carbon ortho to the phenolic hydroxy group. The results 
presented here show that there is no interference caused by the 
potentially complexing methoxy group to the regioselectivity of 
the acylation. This process obviates the need for the harsh 
conditions of the classical ortho acylation of phenol by 
esterification and subsequent Fries rearrangement at elevated 
temperature in the presence of aluminium chloride. Phenols (2) 
were then acyiated with a benzoyl chloride (3) in pyridine with 
or without catalysis by 4-(dimethylamino)pyridine to give the 
esters (4). Migration of the acyl group from oxygen to carbon 
was then achieved under base catalysis either by the method of 
Fumiss et al* with powdered potassium hydroxide in pyridine 
or, in the cases of the more labile or recalcitrant esters, under
t  Present address Medical Research Council Radiobiology Unit. 
Chilton. Didcot. Oxfordshire OXl I ORD.
anhydrous and non-nucleophilic conditions using lithium hexa- 
methyldisilazide as the base.
The 400 MHz 'H n.m.r. spectrum of the prototype 
unsubstituted I-(2-hydroxyphenyl)-3-phenylpropane-1,3-dione 
(5c) shows the presence of both keto and enol tautomers 
(Scheme 2) in solution in deuteriochloroform at ambient 
temperature in the ratio 7:93 respectively. The methylene 
protons of the keto form resonate as a singlet at 5 4.63; the 
corresponding vinylic proton of the enol appears as a singlet 
at 5 6.84. The resonances arising from the OH protons were 
observed in the downfield portion of the spectrum, as expected 
for hydroxy groups in strongly hydrogen-bonded environments. 
Sharp singlets were observed at 6 11.93, 12.19. and 15.94. 
corresponding to the phenolic OH of the keto and enol 
tautomers and to the ‘enol’ respectively. It has been reported by 
Burdett and Rogers3 that 1.3-diphenylpropane-1.3-dione is 
fully enolised in solution in carbon tetrachloride, whereas 
Bassetti et al.* observed both keto and enol forms in 
deuteriochloroform. In the solid state, Weast records the 
existence of crystals of each tautomer.
The majority of the l-(2-hydroxyphenyl)-3-phenylpropane-
1,3-diones (5a, c-k) showed greater than 80% enolisation in 
deuteriochloroform as revealed by their 1H n.m.r. spectra. The 
dimethoxy compound (5b). however, was shown to exist 
initially as the keto tautomer in solution in this solvent. 
Progressive enolisation was observed on increasing the 
temperature from 295 to 325 K. in steps of 5 K. This was not 
reversed on cooling and the final solution contained 38?£ enol 
and 62% keto forms of (5b). To investigate whether the 
enolisation of (5) was an effect of dissolution or. alternatively, 
the enol form was present in the solid state, a determination of 
the crystal structure of an example of a l-(2-hydroxyaryl)-3- 
ary 1 propane-1,3-dione was carried out by A'-ray diffraction 
techniques. Similarly, the solid state structure of the anomalous 
(5b), which is very slowly enolised in solution, was investigated. 
The monomethoxy analogue (5a) was selected as a typical 
‘enolisable’ propane-1.3-dione on two grounds. Firstly, 'H 
n.m.r. spectroscopy of its deuteriochloroform solution showed 
it to be ca. 92% enolised. Secondly, whereas careful re- 
crystallisation of (5c-k) from a variety of solvents furnished only 
powders, (5a) formed large transparent brown crystals from
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Scheme 2. Keto-enol tautomerism of (5) (R',R2 .R\R* as Scheme 1); 
(5aA) and (5bB) are limiting structures of the enol of (5a) (R1 = OMe. 
R2 = R3 = R* = H).
(5)
Scheme I. Synthesis of 1.3-Diarylpropane-1.3-diones (5). Reagents: i. 
BC13-A cO -C H 2C12; ii, pyridine ± 4-(dimethylamino)pyridine; iii, 
KOH-pyridine or Li* 'N(SiMe,)2.
methanol. Similarly, the dimethoxy compound (5b) formed 
elegant hexagonal plates from the same solvent.
C rystal Structure o f  \-{2-Hydroxy-A-methoxyphenyl)-3- 
phenylpropane-\,3-dione (5a).— The numbering scheme used in 
the crystallographic determination is shown in Figure 1(a).
C rystal data. 1 -(2-Hydroxy-A-methoxyphenyl)-3-phenyipro- 
pane-\,3-dione  (5a).—C 1 6 H ,*0*, M  =  270.3. Monoclinic, 
o =  10.622(2), b = 12.795(5), r =  10.748(3) A, p =  111.77(1)°,
V =  1 356.6(6) A3 (by least-squares refinement on diffracto­
meter angles for 25 automatically centred reflections X =  
0.710 69 A), space group P2xja, Z  =  4, Dx =  1.321 g cm '3, 
crystal dimensions =  0.6 x  0.55 x  0.325 mm, p(Mo-KJ =  
0.57 c m '1.
C rystal Structure o f  1 -(2-Hydroxy-4,6-dimethoxyphenyl )-3- 
phenylpropane-\,3-dione (5b).—The numbering scheme used in 
the crystallographic determination is shown in Figure 2(a).
C rystal data. 1 -(4,6- Dimethoxy phenyl-2-hydroxy )-3-phenyl- 
propaneA,3-dione (5b).—C17H16b 5, M  =  300.3. Monoclinic. 
a = 9.503(2). b = 9.924(2), c = 16.125(3) A. P = 1 0 2 .2 2 (2 )°.
V =  1 486.3 A 3 (by least-squares refinement on diffractometer
Figure l.(a) Numbering scheme for atoms in (5a). (b) Stereo plots of (5a).
angles for 25 automatically centred reflections, X =  0.710 69 A), 
space group P 2x/c, Z  =  4, D x = 1.439 g cm '3. Crystal 
dimensions =  0.80 x 0.48 x 0.64 mm, p(M o-/(,) =  0.64 cm '1.
Collection and Processing o f  Data.— Enraf-Nonius CAD4 
diffractometer, o>-20 mode with scan width =  1.0 +  0.35 
tan 0, scan speed 0.9-3.30  min'1. graphite monochromated 
Mo-/f„ radiation; for compound (5a) 2 671 unique reflections 
(merging R =  0.093) were measured between 2° ^  0 <  26° 
for + h , ± k , ±1  giving 1 939 with |F0| > 3c(F0); for com ­
pound (5b), 2 970 unique reflections (merging R =  0.025) 
were measured between 2° ^ 6  <  26° giving 2 442 with 
|F0| >  3a(F0). N o decomposition or movement of the crystal 
was detected during data collection and refinement. No 
correction was made for absorption or extinction.
Analysis and Refinement o f  Structures.—The structure of
Hf°(27] o(i) h[0 Q»















Figure 2. (a) N umbering scheme for atoms in (5b). (Z>) Stereo plots of (5b).
Table 1. Positional parameters (fractional co-ordinates x 10*) for (5a) 
with estimated standard deviation (esd) in parentheses.
Atom X V r
C(l) 2 766(3) 1 296(2) 3 899(3)
C(2) 2 278(3) 1 960(2) 2 747(3)
C(3) 2 902(3) 2027(2) 1 862(3)
CO') 2 424(3) 2 654(2) 621(3)
C(2') 2 981(4) 2 483(3) -353(3)
a  3') 2 516(4) 3 033(3) - 1  536(4)
C(4') 1 533(4) 3 765(3) -1  761(4)
C(5') 1 001(4) 3 965(3) -796(4)
Q 6 ') 1 443(3) 3 411(3) 388(3)
C(l') 2 050(3) 1 199(2) 4 821(3)
C(2) 2 440(3) 445(2) 5 853(3)
C(3) 1 743(4) 340(3) 6  704(3)
C(4') 660(4) 958(3) 6  567(3)
C[0(4')] 311(6) 184(5) 8  437(5)
C(5) 255(4) 1 713(3) 5 573(4)
C(6 ') 937(4) 1 824(3) 4 727(3)
0 ( 1 ) 3 831(2) 756(2) 4 114(2)
0(3) 4 048(2) 1 499(2) 2 035(2)
0 (2 ') 3 498(2) -206(2) 6  049(2)
0 (4 ) 96(2) 912(2) 7 350(2)
H(2") 3 614(28) 1 945(21) -186(26)
H(3") 2 813(39) 2 858(28) - 2  192(38)
H(4') 1 057(35) 4 129(26) - 2  623(36)
H(5') 212(35) 4 422(27) 950(35)
H(6 ") 1 065(28) 3 574(21) 1 028(28)
H(2) 1 423(30) 2  261(21) 2 595(26)
H[0(3)] 4 209(35) 1 068(26) 2 803(35)
H(6 ') 669(46) 2 481(33) 4 045(42)
H(5) -437(40) 2 081(29) 5 472(39)
H(3) 2 112(32) -98(24) 7 348(32)
H[0(2')] 3 959(42) 73(32) 5 427(40)
H[0(4')]A 1 250(40) 404(26) 8  983(35)
H[0(4')]B -501(44) 231(31) 8  849(40)
H[0(4')]C 342(51) -581(40) 8  067(48)
1 -(2-hydroxy~4-methoxyphenyl )-3-phenylpropane-1,3-dione 
(5a) was solved by the use of s h e l x .8 All hydrogen atoms were 
located by difference electron density synthesis. Final full- 
matrix least-squares refinement of co-ordinates and anisotropic




q i K x n 1.272(3)
C(2)-C(3) 1.349(4)




























C(6 > H ( 6 ) 1.08(4)
0(3)-H [0(3)] 0.95(4)
0 (2>H [0(2 ')] 1.03(4)
Table 3. Interatomic angles for (5a) with esds in parentheses.
Atoms Bond angle,^
C(l')-C(l)-C(2) 121.7(3)
0 (  1 )-C( 1 >-C(2) 119.5(2)














C (6>C (r)-C (i) 122.7(3)
C(6')-C(l'>-C(2) 116.2(2)
C(3>C(2')-C(1') 120.9(3)
0 (2 > C (2 > C (r ) 121.9(2)
0 (2 > C (2 > C (3 ) 117.2(3)
C (4> c (3'h :(2') 120.9(3)
C(5)-C(4')-C(3) 119.8(3)
0(4)-C(4')-C(3') 125.3(3)
0(4>C (4>C (5') 114.9(3)
C(6)-C(5')-C(4j 119.8(3)
C (5>C (6)-C (D 122.4(3)
C[0(4')]-0(4')—C(4) 117.7(3)
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Table 4. Selected torsion angles for (5a).
Atoms Angle/ 0
C( 1 ">-C( 1 )-C(2)-C(3) -177.5
0 (  I >-C( 1 )-C(2)-C(3) 0 . 8
C(2)-C(l>-C(r>-C(2') 171.8
C(2)-C(l)-C(r>-C(6') -7.1
cxd- q d - c o t -c q ) -6 .5
0 (IK (IK (I')-C (6 ') 174.6
C( 1 )-C(2)-C(3)-C(r) 176.9




0 ( 3 K ( 3 K d 'K ( 6 ' ) -166.4
C(3)-C(r)-C(2')-C(3') 177.7








C (iK (i'K (2 'H H 2 ') 1.1
C (6 'K d K (2 'K (3 ') 0.4
C(6')-C( I ')-C(2')-0(2') -180.0
C(l)-C(r)-C(6')-C(5) 178.5
C(2'}-C( I '}-C(6')-C(5') -0.4
CX2>C(2')-C(3')-C(4') -179.4
C(2')-C(3')-C(4')-C(5') - 0 . 8
C(2')-C(3')-C(4'KX4) 179.7
C(3')-C(4')-C(5')-C(6') 0 . 8
0(4')-C(4')-C(5')-Q6') -179.7
C (3 K (4 'H )(4 ')-q o (4 ')] 2.5
C (5 'K (4'K )(4 'K tO (4’)] -176.9
Q4')-C(5')-C(6')-C( 1') - 0 .1
thermal parameters for non-hydrogen atoms, and co-ordinates 
and isotropic temperature factors for hydrogen atoms reduced 
R =  I ||F 0| -  |Fc||/E|F0| and =  Iw *||F 0l -  |Fc||/r|w*|F0| to 
0.056 and 0.057 respectively. In the final stages of refinement, 
reflections were weighted according to W  =  k /a2(F0) where k 
converged at 2.3867 and a(F0) was obtained from counting 
statistics and an allowance for the instability of the instrument. 
Refinement was terminated when no positional parameter 
shifted by more than 0.006 esd. at which point a difference 
electron density map showed no feature greater than 
±0.19 e A"3.
The structure of l-(2-hydroxy-4,6-dimethoxyphenyl)-3- 
phenylpropane-l,3-dione (5b) was solved by the use of 
the MULTAN78 direct methods package9  and subsequently re­
fined using s h e l x.8 Again, all hydrogen atoms were located by 
difference electron density synthesis. Final full-matrix least- 
squares refinement, as for (5a). reduced R and /?.. to 0.042 and
0.041 respectively and reflections in the final stages were 
weighted according to w =  k io 2(F0) where k  converged at 
3.195. The refinement was terminated when no positional 
parameter shifted by more than 0 . 0 0 2  esd. at which point a 
difference electron density map showed no feature greater than 
±0.27 e A '3.
Positional parameters for the structure of (5a) are shown in 
Table 1 , with bond lengths in Table 2. bond angles in Table 3,
* Supplementary data: (see section 5.6.3 of Instructions for A uthors, in 
the January  issue). Full lists o f bond lengths and angles 
and of therm al param eters have been deposited at the C am bridge 
C rystallographic D ata Centre.
Table 5. Positional parameters 
with esds in parentheses.
(fractional co-ordinates x 10*) of (5b)
Atom X y z
C(6 ) 5 031(2) 2921(1) 5 792(1)
as*) 4 117(2) 2418(2) 6  266(1)
C<4) 3 137(2) 1411(1) 5 934(1)
C(3)' 3 047(2) 912(2) 5 127(1)
C(2) 3 978(2) 1 424(1) 4 649(1)
an 5 003(2) 2 442(1) 4 953(1)
C(l) 5 964(2) 2902(2) 4 420(1)
C(2) 7 085(2) 3 977(2) 4 690(1)
C(3) 8  313(2) 3 508(2) 5 386(1)
an 9 195(2) 4514(1) 5 957(1)
C(2') 10 356(2) 4 064(2) 6  566(1)
C(3') It 148(2) 4 966(2) 7 135(1)
C(4") 10 789(2) 6  307(2) 7 100(1)
C(5') 9 657(2) 6  763(2) 6  498(1)
C(6 ') 8  870(2) 5 884(2) 5 922(1)
0 (6 ) 5 984(1) 3 923(1) 6  075(1)
C[0(6')] 6  081(3) 4 428(2) 6917(1)
0 (4 ) 2 306(1) 996(1) 6  472(1)
C[0<4')] 1 224(2) 5(2) 6  185(1)
0 (2 ) 3 587(1) 902(1) 3 866(1)
0 ( 1 ) 5 878(1) 2414(1) 3 697(1)
0(3) 8  587(1) 2 314(1) 5461(1)
H(5) 4 161(17) 2 728(16) 6810(11)
H(3') 2 402(19) 237(17) 4 880(11)
H[0(6')]A 5 152(24) 4 790(19) 6  973(13)
HfO(6 ')]B 6400(21) 3 667(19) 7 332(12)
H[0(6')JC 6  808(20) 5 101(18) 6  987(11)
H[0(4')]A 478(23) 382(20) 5 747(14)
H[0(4')]B 1 646(22) -802(21) 6040(13)
H[0(4)]C 771(25) -139(21) 6  713(16)
H(2)A 6641(17) 4 785(16) 4 844(10)
H(2)B 7 487(18) 4 193(16) 4 207(11)
H[0(2')] 4 545(27) I 358(23) 3 659(14)
H(2') 10 587(20) 3 118(18) 6591(11)
H(3') 11 898(22) 4 629(18) 7 530(13)
H(4') 11 323(22) 6  922(20) 7 536(14)
H(5') 9 385(22) 7 736(21) 6  470(12)
H(6 ') 8  095(20) 6  228(18) 5 474(11)
and selected torsion angles in Table 4. The corresponding data 
for the dimethoxy analogue (5b) are reported in Tables 5-8 
respectively.*
The crystal structures confirm that (5a) exists in the enol form 
in the solid state and that (5b) exists in the keto form. As 
expected, the enol system in (5a) is planar. However, unlike the 
situation for enols of simple l.3-diarylpropane-1.3-diones, 3 this 
six-membered hydrogen-bonded ring is not symmetrical in terms 
of bond lengths and thus the enol can be described as tending 
towards either structure (5aA) or structure (5aB) (Scheme 2). 
The distinction between these two limiting structures is revealed 
by the differences between the lengths of the two carbon-oxygen 
bonds, with C (l)-0 (1 )  being 1.273 A and C (3)-0(3) being 1.343 
A. The former is slightly longer than expected for a ketonic 
carbonyl group ; 1 0  this may be attributable to a reduction in 
bond order through hydrogen-bonding both from the phenolic 
and the enolic OH. The length of C (3)-0(3) is comparable to 
that of a shortened C -O  single bond (e.g. in a carboxylic acid) 
(ca. 1.36 A ).10 That the solid state structure of the enol of (5a) 
tends to the limit (5aA) is confirmed by comparison of the 
lengths of C (l)-C (2 ) (1.431 A) and C(2>-C(3) (1.349 A), 
indicating approach to single and double bond character 
respectively. Indeed, the phenvl-carbonyl bond [C(T>-C(1)] 
also has bond order slightly higher than unity with length 1.461 
A compared with the normal alkane C-C bond length of ca. 
1.541 A .10 The shortening of C( 1 >—C( 1 ) and C( 1 )—C(2 ) reflects
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Q D -C (2) 1.417(2)
C(2'>-0(2') 1.348(2)
Cd')-C(I) 1.453(2)





























the extensive conjugation in this system resulting in co­
planarity of the phenyl ring bearing the OH substituent and the 
enol system. It is interesting to note, however, that the phenyl 
ring attached to C(3) is not co-planar with the enol system but is 
at an angle of 14°. While it might initially be thought that there 
would be further conjugation of the Jt-bonds of the enol system 
with the jt system of the phenyl ring, consideration of the 
interatomic distance between the vinyl proton and the 
aromatic proton ortho to the enol system explains this effect. 
Even at an angle of 14°, the contact distance between H(2) (the 
vinyl proton) and H(6 ') (one of the ortho protons) is 2.308 A. If 
the phenyl ring were co-planar with the enol system, then these 
protons would virtually be in contact.
In contrast to the enol system seen in (5a), the crystal 
structure of (5 b ) shows no such tautomerism, although the 
carbonyl oxygen [ 0 ( 1 )] is hydrogen-bonded to the ortho 
phenolic OH. The C-C single bond lengths of the propane-1,3- 
dione system are similar to the single bonds in (5a), although 
they are not identical (Tables 2 and 6 ).
The ‘H n.m.r. spectrum o f (5 b ) showed a marked difference in 
chemical shift of the two 0-methyI groups. This A8  is surprising 
when compared with the corresponding value for the precursor 
benzoate ester (4 b ) (Table 9). It appears that one of the O- 
methyl groups is being unusually shielded. Consideration of the 
crystal structure and data supplies a reasonable explanation for 
this effect. Since this compound exists as the diketone, the 
molecule is not constrained to planarity about the propane-1,3-






















o (3h :(3k :(i') 120.8(1)
C(2*)-C(r)-C(3) 118.8(1)
C(6')-C(r>-C(3) 1226(1)
Q 6 'K (1 K (2 -) 118.6(2)






C[0(4' )]-0(4' )-C(4') 118.6(1)
dione system. In the crystal, the 0-methyl group in the 6 '- 
position lies very close to the phenyl ring attached to C(3) of the 
propane- 1,3-dione. If this structure were maintained in solution, 
there would be a contact distance of ca. 2.97 A between one of 
the protons of the O-methyl group [H O (6 ')] and C(6 '), placing 
this methyl group within the anisotropic shielding region of the 
phenyl ring. The shielding is also notable in the ‘H n.m.r. 
spectrum of the 4'-nitro analogue (5d) (keto form) with 
resonances for the methoxy groups at 5 3.53 and 3.82.
A trend is notable in the chemical shifts of the phenolic OH in 
the enol forms of (5a, c-k) as shown in Table 10. The enols of 
compounds (5c, h-k) with no substituent in the phenolic ring 
give 5Pbcno|<)H in the range 11.92-12.10, whereas (5a, e, f) 
with one electron-donating oxygen substituent give resonances 
for this proton in the range 8  12.36-12.50 and the dimethoxy 
compound (5d) shows 5OH 13.33. The chemical shift of the enol 
OH proton varied from 8  15.20 to 15.85 with 4"-electron- 
withdrawing substituents causing the upheld shift and vice 
versa. Introduction of a 4'-methoxy substituent also resulted in 
a slight upheld shift of this proton. In contrast, the reported 4  
chemical shift for this proton in 3-hydroxy-l,3-diphenylprop-2- 
en-l-one is 8  16.80. Little variation is seen in the chemical shifts of 
the vinyl proton in the enol forms of (5a, c, e, f, h-k) in that they 
lie in the range 8  6.62-6.90. consistent with the corresponding 
value ( 8  6 .82)3 for 3-hydroxy-1 ,3-diphenylprop-2-en- 1 -one. The 
exceptions are (5b, d), with 8 Vtn . H 7.32 and 7.41, respectively, 
resulting from the electronic or steric effects of the introduction 
of the 6 '-methoxy function.
In an attempt to prepare 5-hydroxyflavone, 2-acetyIbenzene-
1,3-diol (2d) was benzoylated to give the diester (4g) which was 
rearranged to furnish the propane- 1,3-dione (5g). No hydrolysis 
of the remaining benzoate ester was evident under the 
conditions of the rearrangement (hot potassium hydroxidc- 
pyridine). The chemical shifts of the ArH protons of the enol
1280
Table 8. Selected torsion angles for (5b).
Atoms A n g ler
C( 1 ')-C(6 ')-C( 5')-C(4') 0.4
C(6 ')-C(6 '>-C( 5'>-C(4') 178.4
C(2')-C(l')-C(6')-C(5') 0 . 0
C( 1)—C( 1 ')-C(6')-C(5') -178.3
0(6')-C(6')-C(r)-C(2') -178.2
0(6')-C(6')-C( 1')—C( I ) 3.5
C(5')-C(6')-C(6')-q;0(6')] 3.0






C(3')-C(4')-0(4')-C[0(4')] - 1 1
C (4 'K (3 K (2 'K (r ) - 0 . 6
C(4')-C(3\H:(r)-0(2') 179.7
C(6')-C(r>-C(2')-C(3') 0 . 2
C( 1 )-C( 1 ')-C(2')-C(3') 178.5
0(2'KX2>-C(r)-C(l) -179.9









C(3>-C(r)-C(2')-C(3') -1 7 6 .5
C(6')-C(r)-C(2>C(3-) 1.3
C(3)-C(r)-C(6>C(5') 175.6
C(2')-C(r>-C(6x:(5') - 2 .1
C(D-C(2'>-C(3'K:(4') 0 . 0
C(2')-C(3')-C(4')-C(5') - 0 . 6
C(3')-C(4')-C(5')-C(6') 0.1
C(4>C(5')-C(6'>-C(r) 1.5
Table 9. Chemical shifts of methoxy groups in compounds (4b). (5b). and 
(5d).
Compound 6 „ of OMe groups
(4b) 3.73 3.75
(5b) 3.43 3.79
(54) (keto) 3.53 3.82
Table 10. Chemical shifts of phenol OH. vinyl H. and enol OH of enol 
forms of compounds (5a. c-k).
Compound Substituents Ophcnol Oil *^in*l II C^IK>l Oil
(5a) 4-OMe 12.50 6.62 15.40
(5c) unsubstituted 1 1 1 0 6.84 15.54
(5d) 4'.6'-(OMe),.4'-NO; 13.33 7.41 15.26
(5e) 4-OMe. 4'-NO, 12.44 6.78 15.20
(5f) 4-0,C Ph 12.36 6.80 15.45
(Sg) 6 -OXPh 11.91 6.87 15.73
(5h) 3-.4--C1, 11.95 6.78 15.43
(5i) 3".4"-(OMe), 12.09 6.75 15.85
(5j) 4--C1 11.95 6.70 15.5
(5k) 4 'N 0 2 11.92 6.90 15.30
form of (5g) were anomalous in the 'H n.m.r. spectrum, with 
resonances of the ‘benzoyl’ groups spread over the range S 7.16— 
8.26. Despite the apparent similarity of environment o f these 
two phenyl rings, the chemical shifts of the two pairs o f ortho 
protons were widely different at 6  7.40 and 8.26. A two- 
dimensional technique (COSY 45 ) grouped the former with the
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(5gC) (5gD)
meta proton resonances at 6  7.16 and the para proton resonance 
at 8  7.37. Similarly, the signals at 8  7.52 and 7.68 were shown to 
arise from the same phenyl ring as downfield ortho proton 
resonances. The chemical shift of the ‘downfield’ set of signals is 
unremarkable but that of the ‘upheld’ set is unusual. The 
orientation of the phenyl rings in the molecule should explain 
the shielding of one of the rings seen in the spectrum. There are a 
number of potential orientations of the two phenyl rings and 
these are shown in Figure 3.
The first conformation (5gC) shows the xj.\v\r,z# ring to be 
at a steep angle to the enol system and so the z~.' protons may be 
shielded by loss of conjugation. The second orientation (5gD) 
shows the aja'JbJb\c phenyl ring at a steep angle to the carbonyl 
group, shielding the a#' protons. The third possible orientation 
(5gE) shows the benzoate ester to be positioned so that the 
phenyl ring lies over the enol system in a ‘coiled’ molecular 
conformation. In this last orientation, the a,a' protons would be 
shielded by interaction with the n-orbitals of the enol system.
In order to verify which, if any. of these possibilities is correct, 
a number of n.m.r. experiments were performed. If the z ~  
phenyl ring is in plane with the enol system [as in (5gD)], then 
the z,z‘ protons would be expected to experience a nuclear 
Overhauser effect (n.O.e.) from the vinylic proton. Irradiation of 
the proton at 8  6.87 did indeed produce an n.O.e.. however both 
sets of protons ortho to the carbonyl groups showed an 
enhancement, although there was a fivefold enhancement of the 
resonances at 8  7.4 compared with that at 8  8.3. This suggests 
that the protons generating the upfield signal are closer in space 
to the vinyl protons than the protons generating the downfield 
signal, although these protons are also close enough to the vinyl 
proton to experience some small n.O.e. This experiment rules 
out one of the potential orientations of the phenyl rings (5gD). If 
the aja' phenyl ring were normal to the carboxylate system then 
no n.O.e. would be experienced by the a.a protons when the 
vinyl proton was irradiated.
If the r,r‘ phenyl ring were at right angles to the carbonyl 
system [as in (5gC)], then no n.O.e. would be expected. If. 
however, this phenyl ring were co-planar with the enol system 
then a large n.O.e. should be seen but this does not explain why
(SgE)
Figure 3. Possible conformations of (5g).
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these protons would be shielded. Consideration of the crystal 
structure of l-(2-hydroxy-4-methoxyphenyl)-3-phenylpropane-
1,3-dione shows that the phenyl ring attached to the 3-carbon in 
(5a) is out o f plane by 14°, so this may explain why an n.Ox. is 
seen at both the z,z and the ap' protons.
To determine if the ajbjc phenyl ring is orientated in such a 
way that it lies over the top of the enol system [as in (5gE)], 
another n .0 .e. difference experiment was carried out. This time 
the enolic O H, at 5 15.S, was irradiated. This, too, produced an 
ambiguous result, in that saturation transfer to the phenolic OH  
caused enhancement of the resonance due to the ortho proton. 
However, by far the largest n.0.e. enhancement observed was 
again at the ortho doublet of the upheld set of protons, although 
the downfield ortho protons also appeared to be stimulated but 
to a much smaller extent. Although none of these spectroscopic 
data are completely conclusive, the balance of evidence would 
tend to support the ‘coiled’ conformation (5gE) as representing 
the structure o f the enol form of (5g).
The results o f  the spectroscopic experiments described above 
show that extensive enolisation of the majority of the 
substituted l-(2-hydroxyphenyl)-3-phenylpropane-l,3-diones 
(5) is facile in solution in deuteriochloroform. Crystallographic 
evidence on (5a, b) illustrates that, depending on substitution 
patterns, these compounds can crystallise either in the keto or 
enol form.
Experimental
I.r. spectra were recorded on a Perkin-Elmer 1310 spectrometer. 
*H N.m.r. spectra were recorded at 60 MHz using a Varian 
EM360A instrument, at 300 MHz using a Bruker AC300 
instrument, and at 400 MHz with a Bruker WH400 
spectrometer, samples were dissolved in CDClj and tetra- 
methylsilane was used as an internal standard. Mass spectra 
were obtained using a VG Micromass 12B single focussing mass 
spectrometer in the electron-impact mode. Light petroleum 
refers to the fraction b.p. 60-80 °C.
1 - Acetyl-4, B-dimethoxy-2-hydroxybenzene (2b).— 3,5-Di- 
m ethoxyphenol (lb) (7.7 g, 50 mmol) in dichloromethane 
(50 cm 3) was added to boron trichloride in dichloromethane 
( 1  mol dm-3; 50 cm3) under nitrogen at —10 °C. The mixture 
was stirred for 5 min and acetyl chloride (3.9 g, 50 mmol) was 
added. The reaction mixture was then heated to reflux for 3 h 
before being carefully quenched by addition of an excess of 
hydrochloric acid (1 mol dm"3). After 1 h at ambient tempera­
ture, the organic phase was separated and the solvent was 
evaporated under reduced pressure. The residue, in dichloro­
methane (50 cm 3), was filtered through a silica plug. Removal of 
the solvent from the filtrate under reduced pressure afforded
1-acetyl-2-hydroxy-4,6-dimethoxybenzene (7.7 g, 78%) as a 
white solid, m.p. 82 °C(lit.,u  82-83 °C); 6H(60 MHz) 2.56(3 H, s, 
COM e), 3.78 (3 H, s, OMe), 3.80 (3 H, s, OMe), 5.85 (1 H, d, J 
2 Hz, A rH ),6.00(1 H ,d ,/2  Hz, ArH),6.00(1 H ,d ,/2 H z , ArH), 
and 13.9(1 H ,s, OH).
1 -Acetyl-2-hydroxy-4-methoxybenzene (2a).— 3-Methoxy-
phenol (la ) was treated with boron trichloride and acetyl 
chloride, as for the preparation of (2 b) above, to afford 1 -acetyl-
2-hydroxy-4-methoxybenzene (78%) as white crystals, m.p. 
50 °C (lit. , 12 48 °C); 6„(60 MHz) 2.50(3 H. s, COMe), 3.75 (3 H,s, 
OM e), 6.30(1 H, d, /  2 Hz, 6 -H). 6.37 ( 1  H, dd, J  9, 2 Hz, 4-H), 
7.54(1 H, d, 7  9 Hz, 3-H). and 12.72(1 H.S.OH).
2-Acetyl-2>,5-dimethoxyphenyl Benzoate (4b).— 2-Acetyl-3,5- 
dimethoxyphenol (2b) (2.94 g. 15 mmol) was treated with 
benzoyl chloride (3a) (2.8 g. 20 mmol), and 4-(dimethyl- 
amino)pyridine (366 mg. 3 mmol) in pyridine (15 cm 3) at ambient
temperature for 10 min. The mixture was poured onto an excess 
of hydrochloric acid (1 mol dm"3) and crushed ice. The solid was 
collected by filtration and recrystallised from chloroform-light 
petroleum to furnish 2-ace tyl-Z,5-dime thoxyphenyl benzoate 
(3.16 g, 70%) as white crystals, m.p. 92-93 °C (Found C, 67.7;
H, 5.4. C 17H 1 6 O s requires C, 68.0; H, 5.35%); vra„(Nujol) 1 735 
and 1 680 cm"1; 5„(60 MHz) 2.41 (3 H, s, COMe), 3.73 (3 H, s, 
OMe), 3.75 (3 H, s, OMe), 6.32 (2 H, s, 4,6-H), 7.3-7.7 (3 H. m, 
3\4',5'-H), and 8.05 (2 H, dd, J  7, 2 Hz, 2\6'-H); m/z 300 (A/ %, 
285,105 (100%), and 77.
2-Acelylphenyl Benzoate (4c).—2-Acetylpheno! (2c) was 
treated with benzoyl chloride (3a) as for the preparation of (4b) 
above, except that the dimethylaminopyridine was omitted and 
the solvent for recrystallisation was methanol, to afford 2 - 
acetylphenyl benzoate (78%) as a white solid, m.p. 89-90 °C 
(lit. , 6  87-88 °C); 5„(60 MHz) 2.4 (3 H, s, COMe), 7.0-7.6 ( 6  H. 
m, 3',4,4',5,5',6-H), 7.70 (1 H, dd, J  8 , 2 Hz, 3-H), and 8.15 (2 H. 
dd, 7  6 ,2  Hz, 2',6'-H).
2-Acetyl-5-melhoxyphenyl Benzoate (4a).— l-Acetyl-2-
hydroxy-4-methoxybenzene (2a) was treated with benzoyl 
chloride (3a) as for the preparation of (4b) above, with the 
exception o f recrystallisation, to give 2-acetyl-5-methoxvphenyl 
benzoate (84%) as a pale yellow oil; vm„  (liquid film) 1 735 and
1 680 cm"1; 6H(60 MHz) 145 (3 H, s, COMe), 3.78 (3 H, s. Me). 
6.70 (1 H, d, y  2 Hz, 6 -H), 6.75 (1 H, dd, J  8 ,2  Hz, 4-H), 7.53 (3 H . 
m, 3',4',5'-H), 7.81 (1 H, d J  8  Hz, 3-H), and 8.15 (2 H, dd. J 9.
2 Hz, 2\6'-H); m/z 270.0891 (A T ) (CI6 H 1 40 4  requires 
270.0892), 105 (100%), and 77.
2- Acetyl-5,5-dimethoxyphenyl 4-Nitrobenzoate (4d).— 1-
Acetyl-4,6-dimethoxy-2-hydroxybenzene (2b) was treated with
4-nitrobenzoyI chloride (3b) as for the preparation of (4b) 
above, except that ethyl acetate-light petroleum was used as the 
solvent for recrystallisation, to give 2-acetyl-3,5-dimethoxy- 
phenyl 4-nitrobenzoate (67%) as pale yellow crystals, m.p. 159- 
160°C (Found C, 59.15; H, 4.35; N, 4.05. C i 7 H i 5 N O ? requires 
C, 59.15; H, 4.35; N, 4.05%); 5„(60 MHz) 145 (3 H, s, COMe). 
3.80(3 H, s, OMe), 3.86 (3 H ,s, OMe), 6.31 (1 H ,d ,y 2  Hz, 6 -H), 
6.38 (1 H, d, y  2 Hz, 4-H), and 8.26 (4 H, s, 2\3',5\6'-H); m /z 345 
(A T ), 330 (100%), 314, 286, 256, 150, 137, 104, and 76.
2-Acetyl-5-methoxyphenyl 4-Nitrobenzoate (4e).— 2-Acetyl-
1-hydroxy-5-methoxybenzene (2a) was treated with 4-nitro- 
benzoyl chloride (3b) as for the preparation of (4b) above to 
afford 2-acetyl-5-methoxyphenyi 4-nitrobenzoate (6 8 %) as a 
pale yellow solid, m.p. 141 °C (lit. , 1 3  135-137 °C); 6H(60 MHz) 
2.45 (3 H, s, COMe), 3.83 (3 H, s, OMe), 6 . 6 6  (1 H, d, J  2 Hz,
6 -H), 6.76 (1 H, dd. J  9 ,2  Hz, 4-H), 7.80 (1 H. d, J  9 Hz, 3-H). and 
8.28 (4 H, s, 2\3\5',6'-H).
1 -Acetyl-2,4-bis(benzoyloxy)benzene ( 4 f ).— 1 -Acetylbenzene-
2,4-diol (2d) (7.6 g, 50 mmol) was treated with benzoyl chloride 
(3a) (16.8 g, 120 mmol) in pyridine (20 cm 3) for 1 h and the 
mixture was poured onto an excess of hydrochloric acid 
(1 mol dm-3) and ice. The solid was collected by filtration 
and recrystallised from methanol to furnish \-acetyl-2A-bts- 
(benzoyloxy)benzene (14.94 g, 83%) as a white solid, m.p. 85 °C 
(Found: C, 73.25; H.4.45. C 22H l 6 O s requires C. 73.3; H. 4.45%); 
5„(60 MHz) 2.53 (3 H ,s, COMe), 7.18 (1 H. d .y  2 Hz. 6 -H). 7 .3 7  
(1 H, dd, y  8 , 2 Hz, 4-H), 7.40-7.63 ( 6  H. m. 3',4\5'.3'.4',5'-H). 
7.90 (1 H, d, y  8  Hz. 3-H), and 8.06-8.26 (4 H. m. 2'.6'.2'.6‘-H); 
m /z 360 (A/%, 105 (100%). 77. 52, and 43.
2-A cetyl-1,3-bis(benzoyloxy)benzene (4g).—2-Acetylbenzene-
I.3-diol (2e) was treated with benzoyl chloride (3a) as for the 
preparation of (4e) above to afford 2-acetyl-1.3-bis(benzoyloxy)-
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benzene (63%) as a white solid, m.p. 108 °C (Found: C, 73.3; 
H, 4.6. C 22H i6 O s requires C, 73.3; H, 4.45%); 6H(60 MHz) 2.45 
(3 H, s, COMe), 7.1-7.7 (9 H, m, 4,5,6,3\4',5',3',4',5'-H), and
8.14 (4 H, m, 2\2", 6 \ 6 '-H); m/z 360 (M  + ), 105 (100%), 77, 52, 
and 43.
2-Acelylphenyl 3,4-Dichlorobenzoale (4h).— 2-Acetylphenol 
(2c) was treated with 3,4-dichlorobenzoyl chloride (3c) as for 
the preparation of (4e) above to afford 2-aceiylphenyl 3,4- 
dichlorobenzoaie (78%) as a white solid, m.p. 84 °C (Found: 
C, 58.1; H, 3.25. C 1 5 H 1 0 Cl2 O3 requires C, 58.25; H, 3.25%); 
5„(60 MHz) Z52 (3 H, s, COMe), 7.15 (1 H, dd, J 8 , 2 Hz, 6  -H), 
7.30-7.50 (2 H, m, 4,5-H), 7.56 (1 H, d, J  8  Hz, 5'-H), 7.83 (1 H, 
dd, J  8 , 2 Hz, 3-H), 7.92 (1 H, dd, J  8 ,2  Hz, 6 -H), and 8.26 (1 H, 
d, J  2 Hz, 2'-H); m /z 308/310/312 (A T ), 173/175/177 (100%), 
145/145/149, and 75.
2-Acetylphenyl 3,4-Dimethoxybenzoate (4i).— 2-Acetylphenol 
(2c) was treated with 3,4-dimethoxybenzoyl chloride (3d) as for 
the preparation of (4e) above to afford 2-acetylphenyI 3,4-di- 
methoxybenzoate (84%) as a white solid, m.p. 126-127 °C (lit. , 14  
129 °C) (Found: C, 68.0; H, 5.4. C 1 7 H 1 6 O s requires C, 68.0; 
H, 5.35%); 5„(60 MHz) 1 5  (3 H, s, COMe), 3.92 ( 6  H, s, 
2 x OMe), and 6.8-7.9 (7 H, m, ArH).
2-Acetylphenyl 4-Chlorobenzoate (4j).— 2-Acetyiphenol (2c) 
was treated with 4-chlorobenzoyi chloride (3e) as for the 
preparation of (4e) above to yield 2-acetylphenyl 4-chloro- 
benzoate (75%) as a white solid, m.p. 94 °C (lit. , 1 5  92-93 °C) 
(Found: C, 65.65; H, 4 .1  C ,sH ,,C 1 0 3 requires C, 65.6;
H. 4.05%); 5h(60 MHz) 2.50 (1 H, s, COMe), 7.1-7.4 (3 H, m,
4.5.6-H), 7.42 (2 H, d, J  8  Hz, 3',5'-H), 7.80 (1 H, dd, J  7 and
I.5 Hz, 3-H), and 8.08 (2 H, d, J  8  Hz, 2\6'-H).
2-Acetylphenyl 4-Nitrobenzoate (4k).— 2-Acetylphenol (2c) 
was treated with 4-nitrobenzoyl chloride (4b) as for the prepar­
ation of (4e) above to yield 2-acetylphenyl 4-nitrobenzoate 
(65%) as a pale yellow solid, m.p. 90 °C (lit. , 1 6  99-100 °C); 
5„(60 MHz) 2.50 (3 H, s, COMe), 7.10-7.67 (3 H, m, 4,5,6-H). 
7.88 (1 H, dd, J  6 ,2  Hz, 3-H), and 8.36 (4 H, s, 2',3\5',6'-H).
1 -(2-Hydroxy-4,6-dimethoxyphenyl)-3-phenylpropane-l,3- 
dione (5b).— Butyl-lithium (1.44 mol dm ' 3 in hexane; 14 cm3. 
2 0  mmol) was added to hexamethyldisilazane (2.82 g, 2 0  mmol) 
in anhydrous tetrahydrofuran (30 cm 3) at - 7 8 ° C  under 
nitrogen. 2-Acetyl-3,5-dimethoxyphenyl benzoate (4b) (2.25 g, 
1 0  mmol) in anhydrous tetrahydrofuran (2 0 cm 3) was then added 
during 15 min. The mixture was allowed to warm to 20 °C and 
was quenched with an excess of hydrochloric acid ( 1  mol dm '3). 
The solid was collected by filtration and washed with water 
before being recrystallised from methanol to yield l - ( 2 -hydroxy-
4.6-dimethoxyphenyl)-3-phenylpropane-\,3-dione (1.42 g. 63%) 
as a yellow solid, m.p. 151 °C (Found: C, 67.95; H, 5.30. 
C, ,H i 6 O s requires C, 68.0; H, 5.35%); v ^ N u j o l )  2 700 br and 
1 600 cm '1; 8„(300 MHz) 3.43 (3 H. s, OMe), 3.78 (3 H, s, OMe). 
4.51 (2 H, s, COCH>CO), 5.78 ( I H .d .7 2  Hz, 3'-H),6.02 (1 H,d. 
J  2 Hz, 5'-H), 7.4-‘7.6 (3 H, m. 3",4',5"-H), 7.8-8.0 (2 H. m. 
2 ".6 "-H), and 13.67(1 H ,s ,O H );m /r300(A r ) .283 ,269 .181. 105 
(100%), and 77.
1 -{2-Hydroxy-4-methoxyphenyl )-3-(4-mtrophenyl )propane-
1,3-dione (5e).— 2-Acetyl-5-methoxyphenyi 4-nitrobenzoate 
(4e) was treated with lithium hexamethyldisilazide as for the 
synthesis of (5b) above to give 1 -{2-hydroxy-4-melhoxvphen\i )-
3-(4-nitrophenyl)propane-\,3-dione (48%) as yellow hexagonal 
crystals, m.p.' 200 °C (Found: C. 60.7; H, 4.15; N. ~4.45. 
C , 6 H , 3 N 0 6 requires C, 60.95; H. 4.15; N, 4.45%); 5H(300 M Hz) 
3.81 (3 H, s, O C H ,). 4.61 (0.16 H. s. CO CH 2CO), 6.48 (1 H. d.
J 2.4 Hz, 3'-H), 6.51 ( I H, dd, J 8 .9,14 Hz, 5-H ), 6.78 (0.92 H, s, 
vinyl-H), 7.70 (1 H, d, J  8.9 Hz, 6 '-H), 8.08 (2 H, d, J  8 . 8  Hz, 
2",6'-H), 8.33 (2 H, d, J  8 . 8  Hz, 3',5'-H), 1120 [0.08 H, s, 
phenolic OH (keto form)], 12.44 [0.92 H, s, phenolic OH (enol 
form)], and 15.20 (0.92 H, s, enol OH); m/z 315 (A T ), 298, 285, 
193, 150(100%), 104. and 76.
1 -{2-Hydroxy-4-methoxyphenyl )-3-phenylpropane-1,3-dione 
(5a).—2-Acetyl-5-methoxyphenyl benzoate (4a) was treated 
with lithium hexamethyldisilazide as for the synthesis of (5b) 
above to give 1 -(2-hydroxy-4-methoxyphenyl)-3-phenylpropane-
1.3-dione (37%) as brown transparent crystals, m.p. 138°C  
(Found: C, 71.1; H, 4.95. C 1 6 HI4 0 4  requires C, 71.1; H, 5.2%); 
v,»„(Nujol) 2 700 br, 1 680, and 1 580 cm '1; 8„(300 MHz) 3.76 
(3 H, s, OMe), 4.5 (0.16 H, brs, COCH2 CO), 6.42 (2 H, dd. J  9, 
2 Hz, 5'-H), 6.53 (1 H, d, J 2 Hz, 3 -H), 6.62 (0.88 H, s, vinyl-H).
7.4-7.6 (3 H, m, 3',4'.5"-H). 7.60 (1 H, d, J  9 Hz, 6 -H), 7.7-7.9 
(2 H, m, 2',6'-H), 12.50 ( 1  H, s. phenolic OH), and 15.40 (0.88 H, 
s, enol O H );m /z 300(A/% . 283, 269,181,105 (100%). and 77.
1 -(2-HydroxyA,6-dimethoxyphenyl )-3-(4-nitrophenyl )- 
propane- 1,3-dione (5d).—2-Acetyl-3,5-dimethoxyphenyl 4-nitro- 
benzoate (4d) was treated with lithium hexamethyldisilazide 
as for the synthesis of (5b) above to give 1 -(2-hvdroxy-4.6- 
dimethoxyphenyl)-3-{4-nitrophenyl)propane-1,3-dione (53%) as 
a bright yellow solid, m.p. 192 °C (Found: C, 59.05; H, 4.4; N, 
3.85. C I7 H 1 5 N 0 7 requires C. 59.15; H, 4.35; N. 4.05%); 
vm»(Nujol) 2 700-3 100 br. 1 575. 1 515, and 1 340 cm '1; 8H(300 
MHz) 3.53 [0.6 H, s, OMe (keto)]. 3.82 [0.6 H, s, OMe (keto)]. 
3.85 [2.4 H, s, OMe (enol)], 3.94 [2.4 H, s, OMe (enol)], 4.59 (0.4 
H, s, COCH 2CO), 5.87 [0.2 H. d.7  2.4 Hz, 5'-H (keto)], 6.06 [0.8 
H, d, J, 2.4 Hz, 5'-H (enol)], 6 .11 [0.2 H, d, J 2.4 Hz, 3 -H (keto)], 
6.13 [0.8 H, d, J  2.4 Hz, 3 -H (enol)], 7.41 (0.8 H, s, vinyl-H), 8.03 
[ 1. 6  H, d, 78.9 Hz, 2',6'-H  (enol)], 8.13 [0.4 H, d, J 8.9 Hz. 2',6 '- 
H (keto)], 8.32 [1.6 H, d, J  8.9 Hz, 3',5'-H (enol)], 8.36 [0.4 H,
H, d, J  8.9 Hz, 3",5'-H (keto)]. 13.33 [0.8 H, s, phenolic OH  
(enol)], 13.55 [0.2 H, s, phenolic OH (keto)], and 15.26 (0.8 H, s, 
enol OH).
1 -(2-Hydroxyphenyl)-3-phenylpropane-1,3-dione (5c).—
Finely powdered potassium hydroxide (1.7 g, 30 mmol) was 
added to 2-acetylphenyl benzoate (4c) (4.8 g, 20 mmol) in 
pyridine (50 cm3) at 50 °C. The mixture was stirred for 20 min 
before being poured into a slight excess of hydrochloric acid 
(1 mol dm '3). The solid was collected by filtration and was 
recrystallised from methanol to give l-(2-hydroxyphenyl)-3- 
phenylpropane-1,3-dione (1.07 a, 63%) as a yellow solid, m.p. 
124 °C (lit. , 1 7  1I7-120°C): 8H(400 MHz) 4.63 (0.13 H, s, 
COCHjCO), 6.84 (0.94 H, s. vinyl-H), 6.92 (1 H. ddd. J  8.0. 7.0.
I.1 Hz. 5-H ), 7.00(1 H, dd. J  8.3. 1.1 Hz, 3 -H). 7.46 (1 H. ddd.
78.3,7.0,1.1 Hz, 4'-H), 7.48(2 H.dd, 78.0.7.3 Hz. 3 \5 '-H ). 7.56 
(1 H, tt, 7 7.3, 1.6 Hz, 4*-H). 7.79 ( 1  H, dd. 7 8.0. 1.6 Hz. 6  -H).
7.94 (2 H. dd, 7 8.0, 1.6 Hz. 2 \6 ’-H). 11.93 [0.06 H. s. phenolic 
OH (keto)]. 12.10 [0.94 H. s. phenolic OH (enol)]. and 15.54 
(0.94 H .s. enol OH).
I -(4-Ben:oyloxy-2-hydroxyphenvl )-3-phenylpropanc-1,3- 
dione (5f).— l-Acetyl-2,4-bis(benzoyloxy)benzene (4f) was 
treated with potassium hydroxide in pyridine as for the 
preparation of (5c) above to give l-(4-benzoyloxv-2-hydroxy- 
phenyI)-3-phenylpropane-1,3-dione (52%) as yellow crystals, 
m.p. 171 °C (lit. , 1 8  167 °C): 6H(400 MHz) 4.63 (0 . 2  H. s. 
COCH,CO). 6.80 (0.9 H ,s. vinvl-H).6.84 ( 1  H . d d . 7  8.9. 2.3 Hz. 
5 -H). 6.89 (1 H, d, 7 2.3 Hz. 3 -H). 7.5 [5 H. m. 3%T. (4'-H or 
4"‘-H). 5",5'"-H], 7.66 (1 H. tl. 7 7.4. 1.3 Hz. 4 ’-H o r  4"- 
H). 7.85 (1 H. d, 7  8.9 Hz. 6  -H). 7.94 [2 H. d d .  7 8.4. 1.3 Hz. 
(2*.6"-H) o r  (2”',6"'-H)], 8.19 [2  H. dd. 7 8.4. 1.2 Hz. (2\6~-
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H) or (2'”,6“*-H)], 12.16 [0.1 H. s, phenolic OH (keto)], 
12.36 [0.9 H, s, phenolic OH (enol)] and 15.45 (0.9 H, s, enol OH).
1 -(6-Benzoyloxy-2-hydroxyphenyl )-3-phenylpropane-1 ,3- 
dione (5g).—2-Acetyl- l,3-bis(benzoyloxy)benzene (4g) was 
treated with potassium hydroxide in pyridine as for the 
preparation of (5c) above to give 1 -(6-benzoyloxy-2-hydroxy- 
phenyl)-3-phenylpropane-1 ,3-dione (64%) as yellow crystals, 
m.p. 184 °C (Found: C, 73.4; H.4.5. C2 2 H 1 6O s requires C, 73.3;
H, 4.45%); 8„(400 MHz) 6.75 (1 H,dd, J 7.8,0.9 Hz, 3 -H or 5'-H), 
6.87 (1 H, s, vinyl-H), 6.95 (1 H, dd, J  8.5,0.9 Hz, 3 -H or 5'-H), 
7 .16(2  H, dd, 78.1, 7.6 Hz, 3"\5~-H), 7.37(1 H, 11,77.3, 1.2 Hz, 
4~-H ), 7.40 (2 H, dd, J  7.3, 1.2 Hz, 2~,6~-H), 7.45 (I H, t, J  8.2 
Hz, 4'-H), 7.52 (2 H, dd, J  7.9,7.6 Hz, 3',5'-H), 7.68 (1 H, tt, J  7.4,
I.2 Hz, 4'-H), 8.26 (2 H, d d ,/8 .3 ,1.2 Hz, 2',6'-H). 11.91 fl H, s, 
phenolic OH), and 15.73 ( 1  H, s, enol OH); m/z 260 (A O , 238, 
105(100%), and 77.
1 -(3,4- Dichlorop'nenyl )-3>-(2-hydroxyphenyl )propane-1,3- 
dione (5h).— 2-Acetylphenyl 3,4-dichlorobenzoate (4h) was 
treated with potassium hydroxide in pyridine as for the 
preparation of (5c) above to give 1 -{3,4-dichlorophenyl)-3-(2- 
hydroxyphenyl)propane-1,3-dione (47%) as a yellow solid, m.p. 
155-157°C (Found: C, 58.1; H, 3.2. C lsH 1 0 Cl2 O 3 requires C, 
58.25; H, 3.25%); 5„(400 MHz) 4.59 (0.14 H, s, COCH 2CO), 6.78 
(0.93 H, s, vinyl-H), 6.93 (1 H, ddd, J 8.16,7.1,1.0 Hz, 5 -H), 7.00 
(1 H, dd, J  8.4, 1.0 Hz, 3'-H), 7.48 (1 H, ddd, J  8.4, 7.0, 1.5 Hz, 
4 -H), 7.56 (1 H, d, J  8.5 Hz, 5'-H), 7.75 (1 H, dd, J  8.5. 2.1 Hz, 
6 '-H ), 7.77 ( 1  H, dd, J  8.2,1.5 Hz, 6  -H), 8.00 (1 H, d, J  2.1 Hz, 
2'-H ), 11.80 [0.07 H, s, phenolic OH (keto)], 11.95 [0.93 H, s, 
phenolic OH (enol)], and 15.43 (0.93 H, s, enol OH); m /z 
308/310/312 (A/"), 173/175/177 (100%), and 121.
1 -(3,‘4- Dimethoxy,phenyl )-3-(2-hydroxyphenyl )propane-1 ,3- 
dione (Si).—2-Acetylphenyl 3,4-dimethoxybenzoate (4i) was 
treated with potassium hydroxide in pyridine as for the 
preparation of (5c) above to give l-(3,4-dimethoxyphenyl)-3-(2- 
hydroxyphenyI)propane-1,3-dione (62%) as a yellow solid, m.p.
115 °C Oil- , 1 9  115 °C); 5„(400 MHz) 3.90 [0.63 H, s, OMe 
(keto)], 3.94 [0.63 H, s, OMe (keto)], 3.95 [2.37 H, s, OM e 
(enol)], 3.96 [2.37 H, s, OMe (enol)], 4.58 (0.42 H, s, 
C O C H 2 CO), 6.75 (0.79 H, s, vinyl-H), 6.90 [0.79 H, ddd, J  8 . 1 ,
7.0,1.0 Hz, 5'-H (enol)], 6.91 [0.21 H, ddd, J  8 .0 ,7 .0 ,1.0Hz,5'-H  
(keto)], 6.91 [0.21 H, d, J  8.5 Hz, 5'-H (keto)], 6.92 [0.79 H, d, J
8.5 Hz, 5-H (enol)], 6.97 (0.21 H, dd. J  8 .6 , 1.0 Hz, 3 -H (keto)], 
6.98 (0.79 H, dd, J  8.4, 1.0 Hz, 3'-H (enol)], 7.43 (0.79 H, ddd, J
8.4, 7.0, 1.5 Hz, 4 -H (enol)], 7.44 ( 1  H, d. J  2.1 Hz, 2'-H), 7.47 
(0.21 H. ddd, J  8 .6 , 7.0, 1.6 Hz, 4'-H (keto)], 7.56 [0.79 H, dd. J
8.5, 2.1 Hz, 6 ”-H (enol)], 7.63 [0.21 H. dd, J  8.3, 2.0 Hz. 6 '-H  
(keto)], 7.75 [0.79 H, dd, J  8.1,1.5 Hz. 6  -H (enol)], 7.80 [0.21 H, 
dd, J  8.0, 1.6 Hz, 6  -H (keto)], 11.96 [0.21 H, s, phenolic OH  
(keto)], 12.09 [0.79 H, s, phenolic OH (enol)], and 15.85 (0.79 H. 
s, enol OH).
1 -(4-Chlorophenyl)-3-{2-hydro.xyphenvt )propane-1 ,3-dione 
(5j).— 2-Acetylphenyl 4-chlorobenzoate (4j) was treated with 
potassium hydroxide in pyridine as for the preparation of (5 c) 
above to give !-(2-hydroxyphenyI)-3-(4-chlorophenyI)propane-
1.3-dione (43%) as yellow crystals, m.p. 120 °C (lit. . 1 s 122.4 °C); 
5„(60 MHz) 6.70 (1 H. s, vinyl-H). 6.80-7.40 (3 H, m. 3 .4\5'-H).
7.37 (2 H, d, J  8  Hz, 3'-H), 7.66 (1 H, dd, J  7, 1 Hz, 6 '-H), 7.79 
(2 H ,d ,/8 H z ,2 '-H ),I1 .9 5 (l H. s, phenolic OH), and 15.5(1 H, 
brs, enol OH).
1 -(2- Hydroxyphenyl )-3-(4-nitrophenyl )propane-1,3-dione 
(5k).— 2-Acetylphenyl 4-nitrobenzoate (4k) was treated with 
potassium hydroxide in pyridine as for the preparation of (5c) 
above to give l-(2-hydroxyphenyl)-3-(4-nitrophenyl)propanc-
I ,3-dione (58%) as a yellow  solid, m.p. 195 °C (lit . , 1 6  198- 
201 °C);5„(400 MHz) 6.90(1 H, s. vinyl-H), 6.95 (1 H ,d d d ,/8 .1 ,
7.1, 1.0 Hz, 5'-H), 7.03(1 H ,d d ,/8 .5 , 1.0 Hz, 3 -H), 7.51 (1 H, 
ddd, J  8.5, 7.1, 1.6 Hz,4'-H), 7.79(1 H ,d d ,/8 .1 , 1.6 Hz, 6  -H), 
8.09 (2 H, d, J  8.9 Hz, 2',6'-H), 8.33 (2 H, d, J 8.9 Hz, 3'.5'-H),
II.92(1 H, s, phenolic OH), and 15.30(1 H, s, enol OH).
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Labelled Compounds of Interest as Antitumour Agents. Part II. Synthesis of 
2H and 3H Isotopomers of RSU 1069 and Ro 03-8799 (Pimonidazole)
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LABELLED COMPOUNDS OF INTEREST AS ANTITUMOUR AGENTS. PART II (1). SYNTHESIS OF 
*H AND JH ISOTOPOMERS OF RSU 1069 AND Ro 03-8799 (PIMONIDAZOLE).
PAUL WEBB and MICHAEL D. THREADGILL*
Medical Research Council Radiobiology Unit. Chilton, Didcot, Oxfordshire
0X11 ORD, U.K.
SUMMARY
*H- and ^-Labelled RSU 1069 and Ro 03*8799 (pimonidazole) have been synthesised 
by reduction of l-(3-chloro*2-oxopropyl)-2*nitroimidazole with the appropriately 
labelled sodium borohydride, followed by ring-closure of the chlorohydrins and 
treatment of the resulting epoxides with aziridine or piperidine. In both cases, 
the specific activities were 200 mCi mmol*1 and the radiochemical yields were 
86 X. The parent compounds are radiosensitisers of hypoxic tumour cells.
Key words: Radiosensitiser, Pimonidazole. [*H]-Ro 03*8799, [3H]-Ro 03-8799,
[*H]-RSU 1069, [3H]-RSU 1069.
RSU 1069 (1) (2*4) and pimonidazole (Ro 03-8799. 2) (5,6) are members of the
second generation of electron-affinic radiosensitisers based on 2-nitroimidazole
and have shown some useful additional activity and/or lower toxicity when
compared with the archetype misonidazole (2) (Figure 1). The aziridine 1 also
exhibits much greater selective toxicity towards hypoxic cells than does
•misonidazole (7-9). this selectivity arising from the ability of the compound to
act as a bifunctional electrophile under hypoxia (10*12). [M C]*RSU 1069,
prepared from 2*[M C]*2*nitroimidazole. has been shown to react with DNA j_Q
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v j t r o  ( 1 1 ) .  A s t u d y  ( 1 3 )  o f  t h e  p h a r m a c o k i n e t i c s  and  m e t a b o l i s m  o f  1 ,  u s i n g  
u n l a b e l l e d  m a t e r i a l ,  h a s  r e v e a l e d  s e v e r a l  m e t a b o l i t e s  o f  l ow m o l e c u l a r  w e i g h t ,  
a l t h o u g h  t h i s  t e c h n i q u e  d o e s  n o t  g i v e  i n f o r m a t i o n  on t h e  n a t u r e  and  l o c a t i o n  o f  
c h e m i c a l  and  m e t a b o l i c  p r o c e s s e s  i n v o l v i n g  p e r s i s t e n t  c o v a l e n t  b i n d i n g  t o  
b i o l o g i c a l  m a c r o m o l e c u l e s .  I t  was  t h e r e f o r e  o f  i n t e r e s t  t o  p r e p a r e  a t r i t i u m  
l a b e l l e d  i s o t o p o m e r  o f  1  a t  m o d e r a t e  s p e c i f i c  a c t i v i t y  t o  e n a b l e  t h e  e x t e n s i o n  
o f  t h e s e  s t u d i e s  i n  v i t r o  and  i n  v i v o . The  s y n t h e t i c  r o u t e  e m p l o y e d  a l s o  
f a c i l i t a t e d  t h e  p r e p a r a t i o n  o f  a r a d i o l a b e l l e d  i s o t o p o m e r  o f  2  f o r  a n a l o g o u s  
s t u d i e s ,  a l t h o u g h  e l e c t r o p h i 1 i c  r e a c t i o n  o f  t h i s  a g e n t  w i t h  m a c r o m o l e c u l e s  w o u l d  
n o t  b e  e x p e c t e d  i n  t h e  a b s e n c e  o f  b i o r e d u c t i o n .
1 :  R = a z i r i d i n - l - y l  
£ :  R = p i p e r i d i n - l - y l  
2 :  R = OMe
[ JH ] - M i s o n i d a z o l e  h a s  b e e n  r e p o r t e d  ( 1 4 , 1 5 )  t o  b e  f o r m e d  by t h e  r e d u c t i o n  o f  t h e  
c o r r e s p o n d i n g  k e t o n e  ( 1 - ( 3 - m e t h o x y - 2 ~ o x o p r o p y 1 ) - 2 * n i t r o i m i d a z o l e ) . T h i s  m o s t  
d i r e c t  i n c o r p o r a t i o n  o f  t r i t i u m  i n t o  RSU 1 0 5 9  by r e d u c t i o n  o f  t h e  c o r r e s p o n d i n g  
a z i r i d i n y l m e t h y l k e t o n e  c o u l d  n o t .  h o w e v e r ,  b e  a c h i e v e d  s i n c e  a t t e m p t s  t o  o x i d i s e  
t h e  s e c o n d a r y  a l c o h o l  f u n c t i o n  Of  1  r e s u l t e d  i n  c o n c o m i t a n t  d e s t r u c t i o n  o f  t h e  
h i g h l y  l a b i l e  a z i r i d i n e  m o i e t y .  H o w e v e r ,  o x i d a t i o n  o f  t h e  c h l o r o h y d r i n  4 ( 1 5 )
w i t h  c h r o m i u m  t r i o x i d e  i n  a c i d i c  a c e t o n e  f u r n i s h e d  t h e  k e t o n e  5  i n m o d e s t  y i e l d  
( S c h e me  1) i n  a r e a c t i o n  s i m i l a r  t o  t h a t  r e p o r t e d  ( 1 6 )  f o r  t h e  o x i d a t i o n  o f  3 
T r e a t m e n t  o f  £  w i t h  0 . 2 9  m o l a r  e q u i v a l e n t s  o f  s o d i u m  b o r o [ zH ] h y d r i d e  g a v e  
c o m p l e t e  r e d u c t i o n  a s  shown by t h i n  l a y e r  c h r o m a t o g r a p h y  ( T L C ) .  i n d i c a t i n g  t h a t  
a l l  f o u r  h y d r o g e n s  Of t h e  b o r o h y d r i d e  a r e  a v a i l a b l e  f o r  r e a c t i o n  W i t h  t h i s  
h i g h l y  e l e c t r o p h i 1 i c  c a r b o n y l  g r o u p .  The  i n t e r m e d i a t e  [ 2H ] - c h 1o r o h v d r i n  was
n o t  i s o l a t e d  o w i n g  t o  i t s  p o o r  s o l u b i l i t y  i n  o r g a n i c  s o l v e n t s  b u t  wa s  c y c l i s e d  
i n  t h e  p r e s e n c e  o f  a q u e o u s  b a s e  t o  g i v e  t h e  r e a d i l y  i s o i a b l e  [ * H ] - e p o x i d e  1&.
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I n  o r d e r  t o  i n v e s t i g a t e  w h e t h e r  p r i m a r y  k i n e t i c  i s o t o p e  e f f e c t s  may c a u s e  
s i g n i f i c a n t  p r e f e r e n t i a l  i n c o r p o r a t i o n  o f  r a t h e r  t h a n  3H f r o m  s o d i u m
b o r o [ JH ] h y d r i d e ,  5  was  t r e a t e d  w i t h  a n  e x c e s s  o f  a m i x t u r e  o f  NaB1H4 and  NaB*Ha . 
S u b s e q u e n t  c y c l i s a t i o n  g a v e  a m i x t u r e  o f  t h e  [ l H ] -  a n d  [ * H ] - e p o x i d e s .  Fr om t h e  
i n t e g r a l  o f  t h e  m u l t i p l e t  c e n t r e d  a t  6 3 . 4 4  i n  t h e  *H NMR s p e c t r u m  ( f r o m  t h e  2 -H 
o f  t h e  s i d e - c h a i n ) ,  i t  was  e s t i m a t e d  t h a t  k [ * H ] / k [ * H ]  = 1 . 5  f o r  t h e  r e d u c t i o n  
s t e p .  T h e r e f o r e ,  t o  a v o i d  p o o r  i n c o r p o r a t i o n  d u e  t o  a s i g n i f i c a n t  v a l u e  o f  
k [ l H ] / k [ J H ] ,  an  e x c e s s  o f  5  w a s  t r e a t e d  w i t h  s o d i u m  b o r o [ JH ] h y d r i d e  o f  h i g h  
s p e c i f i c  a c t i v i t y ,  f o l l o w e d  a f t e r  a s h o r t  p e r i o d  by a n  e x c e s s  o f  NaB! H4 t o  
c o m p l e t e  t h e  r e d u c t i o n .  A g a i n ,  t h e  c h l o r o h y d r i n  wa s  n o t  i s o l a t e d  b u t
c o n v e r t e d  t o  t h e  [ 3H ] - e p o x i d e  7& i n  n e a r  q u a n t i t a t i v e  c h e m i c a l  a n d  
r a d i o c h e m i c a l  y i e l d .  Thus  t h i s  ' c o l d  c h a s e r '  p r o c e d u r e  o f f e r s  an a d v a n t a g e  i n  
i n c o r p o r a t i o n  o f  r a d i o l a b e l  when c o m p a r e d  w i t h  t h e  l o w e r  l a b e l l i n g  r e p o r t e d  by
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S e t i a b a u d i  e t  a l  ( 1 7 )  f o r  t h e  a n a l o g o u s  s t o i c h i o m e t r i c  r e d u c t i o n / c y d i s a t i o n  o f  
p h e n a c y l  b r o m i d e s  t o  p h e n y l e p o x i d e s .
The  e p o x i d e s  7 a . b  w e r e  c o n v e r t e d  i n  e s s e n t i a l l y  q u a n t i t a t i v e  c h e m i c a l  and  
r a d i o c h e m i c a l  y i e l d s  t o  t h e  r e q u i r e d  a z i r i d i n e s  8 a . b  r e s p e c t i v e l y  by b r i e f  
t r e a t m e n t  w i t h  a z i r i d i n e  i n  r e f l u x i n g  e t h a n o l  ( S c h e m e  1 ) .  The p r e s e n c e  o f  a 
t e r t i a r y  a m i n e  b a s e  was  n e c e s s a r y  t o  i n h i b i t  t h e  a c i d - c a t a l y s e d  p o l y m e r i s a t i o n  
known  t o  o c c u r  f o r  t h e  u n l a b e l l e d  a n a l o g u e .  C a r e f u l  m o n i t o r i n g  o f  t h e  p r o g r e s s  
o f  t h e  a d d i t i o n  r e a c t i o n  by TIC was  a l s o  n e e d e d  f o r  o p t i m u m  y i e l d ,  The  l a b e l l e d  
e p o x i d e s  r e a c t e d  s m o o t h l y  w i t h  e x c e s s  p i p e r i d i n e  g i v i n g  t h e  r e q u i r e d  i s o t o p o m e r s  
o f  p i m o n i d a z o l e  ( 9 a . b ) . a g a i n  i n  v e r y  h i g h  y i e l d s .
The  u s e  o f  t h e  a b o v e  s y n t h e s e s  a l l o w e d  [ JH] -RSU 1069  a n d  [ 3H ] - p i m o m d a z o l e  t o  be  
p r e p a r e d  i n  s u f f i c i e n t l y  h i g h  s p e c i f i c  a c t i v i t y  f o r  u s e  i n  e x p e r i m e n t s  d e s i g n e d  
t o  e x a m i n e  t h e  s e l e c t i v i t y  o f  c o v a l e n t  b i n d i n g  w i t h  DNA a n d  o t h e r  m a c r o m o i e c u l e s  
o f  c e l l s  i n  v i t r o  i n  h y p o x i a  a n d  i n  t h e  p r e s e n c e  o f  o x y g e n .  S i m i l a r l y ,  
a s s e s s m e n t  o f  t h e  e x t e n t  a n d  s e l e c t i v i t y  o f  r e t e n t i o n  o f  t h e s e  r a d i o s e n s i t i s e r s  
a n d  b i o r e d u c t i v e l y - a c t i v a t e d  c y t o t o x i n s  i n  t u m o u r s  a n d  i n  v a r i o u s  n o r m a l  t i s s u e s  
by  a u t o r a d i o g r a p h y  i s  f a c i l i t a t e d .  The  r e s u l t s  o f  t h e s e  b i o l o g i c a l  s t u d ' e s  w i l l  
b e  r e p o r t e d  e l s e w h e r e .
FXPFRIMFNTA1
S o l u t i o n s  w e r e  d r i e d  o v e r  a n h y d r o u s  s o d i u m  s u l p h a t e  a n d  w e r e  f i l t e r e d  o ^ i o r  t o  
e v a p o r a t i o n  o f  t h e  s o l v e n t s  u n d e r  r e d u c e d  p r e s s u r e .  M e l t i n g  p o - t s  w e r e  
u n c o r r e c t e d .  NMR s p e c t r a  w e r e  o b t a i n e d  u s i n g  a J e o i  PMX60SI s o e c : - c ~ e t e - '  w i t h  
t e t r a m e t h y l s i  l a n e  a s  i n t e r n a l  s t a n d a r d .  IR s p e c t r a  w e r e  r e c o r d e d  on \ u ; : '  m u l l s  
u s i n g  a P h i l i p s  PU9510 i n s t r u m e n t .  D e t e r m i n a t i o n  o f  r a d i o a c t i v i t y  was  c a r r i e d  
o u t  by  l i q u i d  s c i n t i l l a t i o n  c o u n t i n g  u s i n g  B eckman  I S 2 8 0 0  a n d  Beckman _ S5000CE
i n s t r u m e n t s .  R a d i o c h e m i c a l  p u r i t i e s  w e r e  e s t i m a t e d  b y  s c i n t i l l a t i o n  c o u n t i n g  o f
a p p r o p r i a t e  p o r t i o n s  o f  S i l i c a  s c r a p e d  f r o m  TLC a n a l y s e s .  S o d i u m  b c r o [  -’ ^ I h v d r i d e  
was  O b t a i n e d  f r o m  A l d r i c h  C h e m i c a l  Co.  a n d  s o d i u m  b o r o [ l H ] h y d r < o e  was r e t a i n e d
f r o m  Ame r s h am I n t e r n a t i o n a l  P l C .
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I - ( 3 - C h l p r o - 2 - o x o o r o D v l ) - 2 ~ n i t r o i m i d a z o l e  ( 5 ) . -  1 - ( 3 - C h l o r o - 2 - h y d r o x y - p r o o y 1 ) - 2 -  
n i t r o i m i d a z o l e  ( 4 ;  2 . 0 6  g ,  10 mmol )  ( p r e p a r e d  f r o m  2 - n i t r o i m i d a z o l e  and  3-
c h l o r o - 1 , 2 - e p o x y p r o p a n e  by t h e  m e t h o d  o f  Beaman e t  a l  ( 1 6 ) )  wa s  s t i r r e d  w i t h  
Ch r o mi u m t r i o x i d e  ( 1 . 0  g ,  10 mmol )  a nd  S u l p h u r i c  a c i d  ( 2  m l )  i n  a c e t o n e  ( 4 0  ml )  
f o r  3 d a y s .  S o d i u m h y d r o g e n  c a r b o n a t e  ( 8  g )  was  a d d e d  a n d  t h e  m i x t u r e  was
f i l t e r e d .  The  s o l v e n t  was  e v a p o r a t e d  f r o m  t h e  f i l t r a t e  a n d  t h e  r e s i d u e ,  m  e t h y l
a c e t a t e ,  wa s  w a s h e d  w i t h  w a t e r  a n d  w i t h  s a t u r a t e d  a q u e o u s  s o d i u m  h y d r o g e n
c a r b o n a t e  b e f o r e  b e i n g  d r i e d .  The  e v a p o r a t i o n  r e s i d u e  w a s  r e c r y s t a l  1 i s e d  f r om 
e t h y l  a c e t a t e  t o  a f f o r d  5  ( 9 3 6  mg.  46  %) a s  w h i t e  c r y s t a l s  m . p .  9 3 - 9 4 ° C :  v max 
17 5 0  c m - * ;  6 ( C0 C 1 3 : (CD3 ) 2S 0 ,  3 : 1 )  4 . 4 8  ( 2  H,  s ,  CH? C 1 ) .  5 . 7 7  (2 H.  s .
i m i d a z o l e - C H 2 ) ,  7 . 1 2  (1 H. b r s .  i m i d a z o l e - H ) . 7 . 3 5  (1  H.  b r s .  i m i d a z o ’ e - H ) .
1-  ( 2 . 3 - E D o x v - 2 - | ' ?H ] o r o o y l ) - 2 - n i  t r o  i m i d a z o l e  ( 7 a ) . - The  c h  l o r o m e t h y l  k e t o n e  £  
( 2 0 3  mg.  1 . 0  n m o l )  was  s t i r r e d  w i t h  NaB*Ha ( 9 8  a t o m  %; 1 2 . 2  mg.  0 . 2 9  mmol)  i n
a b s o l u t e  e t h a n o l  ( 1 5  ml )  f o r  20  m i n .  A c e t o n e  ( 3  m l )  wa s  t h e n  a d d e d  a n d  t h e
m i x t u r e  was  s t i r r e d  f o r  1 h b e f o r e  e v a p o r a t i o n  o f  t h e  s o l v e n t s .  The  r e s i d u e  was
s t i r r e d  v i g o r o u s l y  w i t h  a q u e o u s  s o d i u m  h y d r o x i d e  ( 1 0  %. 2 . 0  m l .  5 . 0  mmol)  f o r
30 m i n .  The  s u s p e n s i o n  was d i l u t e d  w i t h  w a t e r  ( 5  m l )  a n d  was  e x t r a c t e d  w i t h  
c h l o r o f o r m  ( 3  x 15 m l ) .  The c o m b i n e d  e x t r a c t s  w e r e  d r i e d  a nd  t h e  s o l v e n t  was  
e v a p o r a t e d  t o  g i v e  Z a  ( 1 3 0  mg.  76 %) a s  an o f f - w h i t e  c r y s t a l l i n e  s o l i d  m . p .  
5 3 - 5 5 ° C ;  6 ( CDC13 ) 2 . 5 5  (1 H, d ,  J  « 4 . 5  Hz)  and  2 . 9 0  (1 H. d .  J  = 4 . 5  Hz.
e p o x i d e - C H 2 , 4 . 2 5  (1  H. d ,  J  * 1 4 . 5  Hz)  and 4 . 9 5  (1  h . d ,  J  = 1 4 . 5  Hz) N O : ? .
7 . 0 8  (1  H. s ,  i m i d a z o l e - H ) .  7 . 2 0  (1 H. s ,  i m i d a z o l e - H ) .
E x p e r i m e n t  t o  d e t e r m i n e  k f 1H l / k f ? Hl  f o r  t h e  r e d u c t i o n  o f  5 - A s o l u t i o n  0*'
N a B ^  ( 3 7 . 5  mg,  0 . 9 8 /  mmol)  a n d  Na8*H4 ( 9 8  a to m %: 4 1 0  mg.  0 . 9 7 6  mmp1 ) m
e t h a n o l  ( 2 5  m l )  was  a d d e d  t o  k e t o n e  5  (-*07 mg.  2 . 0  mmol )  a nd  t h e  r e s u l t i n g  
s o l u t i o n  was  s t i r r e d  f o r  15 m i n .  A c e t o n e  (5 m l )  wa s  a d d e d  a n d  t h e  m i x t u r e  
was  s t i r r e d  f o r  16 h b e f o r e  e v a p o r a t i o n  o f  t h e  s o l v e n t s .  The  r e s i d u e  was  t r ea*.ed 
w i t h  a q u e o u s  s o d i u m  h y d r o x i d e  a s  a b o v e  t o  a f f o r d  a p a l e  y e l l o w  c r y s t a l l i n e  s o 1 ’ d 
( 3 2 0  mg,  94 %) w h i c h  was  Shown by NMR t o  c o m p r i s e  a m i x t u r e  o f  i SOt  Ppnme*'S ?■
1 * ( 2 .  3 * e p O x y p r o p y  1 ) - 2 * n  i t  r o  im i d d Z O 1 e I n t e g r a t i o n  o f  t h e  m u l t i p l e t  c e n t r e d  a*.
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6 3 . 4 4  s h o we d  t h a t  t h e  m i x t u r e  c o n t a i n e d  t h e  [ ' H j - e p o x i d e  ( 6 1  X) an d  t h e
[ * H ] - e p o x i d e  ( 3 9  X) .  From t h e s e  d a t a  i t  was  c a l c u l a t e d  t h a t  k [ l H ] / k [ * H ]  = 1 . 5
f o r  t h e  r e d u c t i o n  s t e p .
1 - ( 2 . 3 - E o o x v - ? - \ * H l n r o o v l  l - ? - n i t r o i m i d a z o l e  f 7b 1 . -  S o d i u m  b o r o h y d r i d e  (1  mg,  
0 . 0 2 6  mmol)  was  a d d e d  t o  k e t o n e  5  ( 2 0 3  mg,  1 . 0  mmol )  i n  e t h a n o l  ( 1 0  m l ) ,
f o l l o w e d  a f t e r  5 mi n  b., s o d i u m  b o r o [ 5H ] h y d r i d e  ( 1 . 8  mg;  0 . 0 4 8  mmol ,  220  mCi )  i n  
e t h a n o l  (1  m l )  and  w a t e r  ( 0 . 5  m l ) .  A f t e r  a f u r t h e r  20  m i n ,  s o d i u m  b o r o h y d r i d e  
( 4 0  mg,  1 . 0 5  mmol )  was  a d d e d  a n d  t h e  m i x t u r e  was  s t i r r e d  f o r  30  m i n .  A c e t o n e  
( 3  m l )  was  t h e n  a d d e d  and t h e  m i x t u r e  wa s  s t i r r e d  f o r  16 h b e f o r e  e v a p o r a t i o n  o f  
t h e  s o l v e n t s .  The r e s i d u e  was  s t i r r e d  v i g o r o u s l y  w i t h  10 % a a u e o u s  s o d i u m  
h y d r o x i d e  ( 4 . 0  m l .  10 mmol)  f o r  35 m i n .  The  S u s p e n s i o n  was  d i l u t e d  w i t h  w a t e r  
( 1 0  ml )  a n d  was  e x t r a c t e d  w i t h  c h l o r o f o r m  ( 3  x 5 0  m l ) .  T h e  c o m b i n e d  e x t r a c t s  
w e r e  d r i e d  a n d  t h e  s o l v e n t  was  e v a p o r a t e d  t o  g i v e  7£  ( 1 6 0  mg.  9 5  % c h e m i c a l
y i e l d ;  189 mC i ,  86  X r a d i o c h e m i c a l  y i e l d )  w h i c h  c o - c h r o m a t o g r a p h e d  (TLC,  s i l i c a ,  
C H C l 3 /MeOH, 9 : 1 ,  Rf 0 . 6 )  w i t h  a u t h e n t i c  u n l a b e l l e d  m a t e r i a l .  T h e  r a d i o c h e m i c a l  
p u r i t y  was  > 9 6  X a n d  t h e  s p e c i f i c  a c t i v i t y  was  200  mCi m m o l ' 1 .
l i 3 : . ( A z i r i d i n - l - y 1  l - 2 - h v d r o x v - 2 - r ?H l o r o o v l  ) - ? - m  t r o  i m i d a z o l e  ( 8a  1 . - The  [ * H ] -  
e p o x i d e  Z& ( 1 2 0  mg,  0 . 7  mmol)  was  b o i l e d  u n d e r  r e f l u x  i n  e t h a n o l  ( 2  m l )  w i t h  
a z i r i d i n e  ( 0 . 0 9  m l ;  75 mg,  1 . 7  mmol )  a n d  t r i e t h y l a m i n e  ( 0 . 0 3  ml )  f o r  15 m i n .  
E v a p o r a t i o n  o f  t h e  s o l v e n t s  a n d  e x c e s s  r e a g e n t  g a v e  a s o l i d  w h i c h  wa s  t r i t u r a t e d  
w i t h  c o l d  a c e t o n e  t o  a f f o r d  f ta ( 1 4 0  mg,  94  %) a s  a p a l e  y e l l o w  s o l i d  m . p .  11 6 -  
1 1 8 ° C ;  6 (CDjOD) 1 . 4  (2  H,  m) a n d  1 . 8  ( 2  H. m) a z i r i d i n e - H .  2 . 2 5  (1  H.  d .
J  = 12 Hz) a n d  2 . 4 5  (1 H,  d ,  J  = 12 Hz)  a z i r i d i n e - C t i 2CD(0H)  - .  4 . 3 0  ( 1  H.  d .
J  = 14 Hz) a n d  4 . 6 8  (1 H, d , J  * 14 Hz )  i m i d a z o l e - C H ? C D ( 0 H ) - .  4 . 7 5  ( 1  H, S,  OH) .
7 . 0 3  (1  H. d ,  J  = 2 Hz.  i m i d a z o l e - H ) ,  7 . 3 7  (1 H.  d .  J  = 2 Hz ,  i m i d a z o l e _H ) .
1 - ( 3 - (Az i r  i d i n - 1 - y 1 1 - 2 - h y d r o x y - 2 - f  3H~loropy 1 ) - 2 - ni  t  r o  im i d a z o  1 e  ( 8 b l  . - E p o x i d e  
( 1 0 0  mg,  0 . 5 9  mmol ;  118 mCi)  was  b o i l e d  u n d e r  r e f l u x  i n  e t h a n o l  ( 5  ml )  w i t h  
a z i r i d i n e  ( 0 . 3 5  m l )  and  t r i e t h y l a m i n e  ( 0 . 1  ml )  f o r  20 m i n .  E v a p o r a t i o n  o f  t h e
[:H. fH]RSU 1069 and Ro 03-8799
s o l v e n t s  a n d  e x c e s s  r e a g e n t  g a v e  f i t  ( 1 2 5  mg,  q u a n t . ;  118  mCi .  q u a n t . )  w h i c h  c o ­
c h r o m a t o g r a p h e d  (TLC,  s i l i c a .  CHCl 3 /MeOH. 9 : 1 .  Rf 0 . 1 5 )  w i t h  a u t h e n t i c  
u n l a b e l l e d  m a t e r i a l  The  r a d i o c h e m i c a l  p u r i t y  was  > 96  % a n d  t h e  s p e c i f i c
a c t i v i t y  wa s  200 rnCi m m o l ' 1 .
1 - ( 2 - H v d r o x y - 3 - f p i p e r i d i n - 1 - y l ) - 2 - r ?H l p r o p y l 1 - 2 - n i t r o i m i d a z o l e  C S i l - * The  [ * H ] -
e p o x i d e  Z t  ( 2 4 0  mg,  1 . 4  mmol )  was  b o i l e d  u n d e r  r e f l u x  i n  e t h a n o l  ( 2 0  ml )  w i t h  
p i p e r i d i n e  ( 2 6 0  mg,  3 . 1  mmol )  f o r  15 m i n .  E v a p o r a t i o n  o f  t h e  s o l v e n t  and  e x c e s s
r e a g e n t  g a v e  fia ( 3 6 0  mg,  9 9  %) a s  p a l e  y e l l o w  c r y s t a l s  m . p .  1 0 7 - 1 0 8 ° C ; v max
( N u j o l  m u l l )  3320  b r ,  2 1 6 0  c m ' 1 ; 6 ( CDC13 ) 1 . 5  ( 6  H,  b r .  p i p e r i d i n e  3 . 4 , 5 - C H ? ) .
2 . 1 - 2 . 8  ( 6  H. m. CDCHZN + p i p e r i d i n e  2 . 6 - C H ; .  4 . 2 2  (1 H,  d . J  = 14 Hz)  and 4 . 6 4  
( 1  H. d ,  J  * 14 Hz) i m i d a z o l e - C H ? C D ( 0 H ) - .  4 . 2 8  (1 H.  s .  OH) .  6 . 9 8  (1 H. b r s .  
i m i d a z o l e - H ) . 7 . 2 5  (1  H, b r s .  i m i d a z o l e - H ) .
1 - ( 2 - H v d r o x v - 3 - ( o i p e r i d i n - l - v n  - 2 - r 3H l p r o o v n  - 2 - m t r o i m i d a z o l e  ( 9 b )  ■ - E p o x i d e  I t  
( 3 0  mg,  0 . 1 8  mmol ;  35 mCi )  w a s  b o i l e d  u n d e r  r e f l u x  i n  e t h a n o l  ( 1 . 5  ml )  w i t h
p i p e r i d i n e  ( 1 5  mg,  0 . 5 3 4  mmol )  f o r  5 m i n .  E v a p o r a t i o n  o f  t h e  s o l v e n t s  a n d  e x c e s s
r e a g e n t  g a v e  f i t  ( 4 5  mg.  q u a n t . ;  35 mCi .  q u a n t . )  w h i c h  c o - c h r o m a t o g r a p h e d  ( T I C .  
s i l i c a .  CHCl j /MeOH.  9 : 1 ,  Rf  0 . 2 )  w i t h  a u t h e n t i c  u n l a b e l l e d  m a t e r i a l  The
r a d i o c h e m i c a l  p u r i t y  was  > 9 6  % a n d  t h e  s p e c i f i c  a c t i v i t y  was  2 0 0  mCi m m o l ' 1
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SUMMARY
C h e m i c a l l y  a n d  r a d i o c h e m i c a l l y  e f f i c i e n t  s y n t h e s e s  o f  N - ( 2 - h y d r o x y - 2 - [ ?H ] e t h y l ) -
2 - ( 2 - n i t r o i m i d a z o l - 1 - y l ) a c e t a m i d e  a n d  N - ( 2 - h y d r o x y - 2 - [ J H ] e t h y 1 ) - 2 - ( 2 - n i t r o -  
i m i d a z o l - 1 - y l ) a c e t a m i d e ,  i s o t o p o m e r s  o f  t h e  h y p o x i c  c e l l  r a d i o s e n s i t i s e r  
e t a n i d a z o l e  (SR 2 5 0 8 ) ,  h a v e  b e e n  a c h i e v e d  by r e d u c t i o n  o f  t h e  c o r r e s p o n d i n g  
a l d e h y d e  w i t h  i s o t o p i c a l l y  l a b e l l e d  s o d i u m  b o r o h y d r i d e .  The  p r i m a r y  k i n e t i c  
d e u t e r i u m  i s o t o p e  e f f e c t  f o r  t h e  p r o c e s s  i s  1 . 5 .
Key w o r d s :  [ * H ] - E t a n i d a z o l e .  [  JH ] - E t a n i d a z d e .  E t a n i d a z o l e .  SR 2 5 0 8 .
INTRODUCTION
E t a n i d a z o l e  (SR 2 5 0 8 ;  1 ;  F i g u r e  1)  ( 2 , 3 )  i s  a me mb e r  o f  t h e  s e c o n d  g e n e r a t i o n  o f  
e l e c t r o n - a f f i n i c  c o mp o un ds  b a s e d  on  2 - n i t r o i m i d a z o l e .  d e s i g n e d  f o r  t h e  
s e n s i t i s a t i o n  o f  h y p o x i c  t u m o u r  c e l l s  t o  r a d i a t i o n .  P a r t i c u l a r l y ,  i t  e l i c i t s  
l e s s  n e u r o t o x i c i t y  t h a n  t h e  a r c h e t y p e  m i s o n i d a z o l e  ( £ ) .  I t  i s  a l s o  s i g n i f i c a n t l y  
m o r e  p o l a r  t h a n  t h e  l a t t e r .  I t  wa s  t h e r e f o r e  o f  i n t e r e s t  t o  a s s e s s  t h e  
s e l e c t i v i t y  o f  u p t a k e  a nd  c o v a l e n t  r e t e n t i o n  o f  1  i n  h y p o x i c  a n d  o x i c  r e g i o n s  o f  
t u m o u r s  a n d  i n  n o r m a l  t i s s u e s ,  i n c l u d i n g  b r a m .  R a d i o l  a b e l  l e d  m a t e r i a l  was  
r e q u i r e d  f o r  t h i s  p u r p o s e  .
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OMe
NO,
We h a v e  r e p o r t e d  ( 1 )  t h e  e f f i c i e n t  a n d  r a p i d  i n c o r p o r a t i o n  o f  ?h and  3H by t h e  
r e d u c t i o n  o f  a d o u b l y  a c t i v a t e d  k e t o n e  by  t h e  a p p r o p r i a t e  i s o t o p ’ c a l l y  l a b e l l e d  
s o d i u m  b o r o h y d r i d e .  I t  was  t h e r e f o r e  c o n s i d e r e d  h i g h l y  l i k e l y  t h a t  t h e  a n a l o g o u s  
r e d u c t i o n  o f  t h e  a c t i v a t e d  a l d e h y d e  2  w o u l d  be  s u c c e s s f u l  i n  p r o v i d i n g  t h e  
r e q u i r e d  i s o t o p i c a l l y  l a b e l l e d  m a t e r i a l s .
S y n t h e s i s  o f  7 was  a c h i e v e d  i n  f o u r  s t e p s  a s  s h o wn  i n  Sc he me  1. 2 - N i t r o i m i d a z o l e
( 2 )  was  a l k y l a t e d  w i t h  i - b u t y l  b r o m o a c e t a t e  u n d e r  b a s i c  c o n d i t i o n s  i n  r e f l u x i n g  
d i m e t h y l f o r m a m i d e  and  t h e  i m i d a z o l e a c e t i c  a c i d  2  w a s  f o r m e d  by t r e a t m e n t  o f  t h e  
i n t e r m e d i a t e  i - b u t y l  e s t e r  4 w i t h  a n h y d r o u s  t r i f l u o r o a c e t i c  a c i d .  T h i s  r o u t e  was  
f o u n d  t o  a v o i d  many o f  t h e  p r e v i o u s l y  r e p o r t e d  p r o b l e m s  ( 4 )  o f  i s o l a t i o n  and 
p u r i f i c a t i o n  a s s o c i a t e d  w i t h  t h e  g r e a t  a q u e o u s  s o l u b i l i t y  an d  a c i d  s t r e n g t h  o f  
S .  The  a c i d  c h l o r i d e  o f  2  p r o v e d  t o  b e  d i f f i c u l t  t o  f o r m  a n d  t o  be  u n s t a b l e ,  s o  
a c a r b o d i i m i d e  m e t h o d  was  u s e d  t o  c o u p l e  t h i s  a c i d  w i t h  2 . 2 - d i m e t h o x y e t h y l a m i n e .  
a l b e i t  i n  m o d e s t  y i e l d .  H y d r o l y s i s  o f  t h e  a c e t a l  f u n c t i o n  o f  2  a c h i e v e d  
u s i n g  an i o n - e x c h a n g e  r e s i n  a s  c a t a l y s t .  The r e s u l t a n t  a l d e h y d e  7 was f o u n d  t o  
be  h i g h l y  e l e c t r o p h i 1 i c .  b e i n g  e x t e n s i v e l y  h y d r a t e d  i n  w a t e r  a nd  f o r m i n g  f u l l y  
t h e  c o r r e s p o n d i n g  h e m i a c e t a l  1 2  wh e n  a n  a t t e m p t  wa s  ma de  t o  r e c o r d  t h e  J H NMR 
s p e c t r u m  i n  s o l u t i o n  i n  [ ] m e t h a n o  1 . The  d i n i t r o p h e n y 1n y d r a ; o n e  1 1  was 
p r e p a r e d  f o r  c h a r a c t e r i s a t i o n .
F-or t h e  p u r p o s e  Of t h e  r e d u c t i o n s  w i t h  s o d i u m  b o r o [  * H ' hy{ j r -  d e .  2  wa s  n o t
i s o l a t e d  b u t  was  u s e d  a s  t h e  n e u t r a l  a q u e o u s  s o l u t i o n  g i v e n  r e m o v a l  o f  t h e
c a t a l y t i c  r e s i n  by f i l t r a t i o n ;  t h e  [ 2H ] - p r i m a r y  a l c o h o l  3 “ 3S O b t a i n e d  i n  good
y i e l d .  To d e t e r m i n e  t h e  k i n e t i c  i s o t o p e  e f f e c t  f o r  t h i s  r e r ; : c ? i . ? «  s t e p ,  t h e  
a q u e o u s  s o l u t i o n  o f  2  wa s  r e d u c e d  w i t h  an  e x c e s s  o f  an e o u i m o ' a r  m i x t u r e  o f
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NaB*H4 -and NaBJ H4 . A n a l y s i s  o f  t h e  r e s u l t i n g  m i x t u r e  o f  i s o t o p o m e r s  by NMR w a s  
f a c i l i t a t e d  by  a c e t y l a t i o n .  t h u s  r e m o v i n g  t h e  o v e r l a p p i n g  o f  t h e  NCJ H2 C l H2H0H 
an d  NC1H? C 1H2H0H r e s o n a n c e s  i n  t h e  s p e c t r u m  o f  £ .  C o m p a r i s o n  c*‘ t h e  i n t e g r a l s  o f  
s i g n a l s  a t  6 3 . 4 5  (C0NC' H? ) .  and  6 4 . 1 0  ( C l H*H0Ac ♦ C ; h , 0 A c ) e n a b l e d  t h e
e s t i m a t i o n  k [ * H ] / k [ * H ]  = 1 . 5  f o r  t h e  r e d u c t i o n  s t e p  To a v o i d  p o s s i b l e  p o o r  
i n c o r p o r a t i o n  o f  J H f r o m  s o d i u m  b o r o [ J H ] h y d r i d e  t h r o u g h  u n f a v o u r a b l e  c o m p e t i t i o n
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w i t h  l H,  t h e  c o l d  c h a s e r '  t e c h n i q u e  ( 1 )  w a s  u s e d  a n d  t h e  r a d i o c h e m i c a l  y i e l d  o f  
2  was  e x c e l l e n t .  I n t e r e s t i n g l y ,  C o l e m a n  e t  a l  ( 5 )  r e p o r t  t h a t  t h e  c o r r e s p o n d i n g  
u n l a b e l l e d  a c e t a t e  e s t e r  i s  a g o o d  p r o d r u g  f o r  1 .
The d e v e l o p m e n t  o f  t h i s  f a c i l e  a n d  h i g h - y i e l d i n g  p r e p a r a t i o n  o f  r a d i o l a b e l l e d  
e t a n i d a z o l e  p e r m i t s  s t u d i e s  o f  s e l e c t i v i t y  i n  u p t a k e  a nd  r e t e n t i o n  o f  t h e  d r u g  
a nd  i t s  m e t a b o l i t e s  i n  n o r m a l  t i s s u e s  a n d  i n  t u m o u r s .  The  r e s u l t s  o f  t h e s e  
e x p e r i m e n t s  w i l l  be  p u b l i s h e d  e l s e w h e r e .
FXPFRIMFNTAI
DMF r e f e r s  t o  d i m e t h y l f o r m a m i d e .  T e t r a h y d r o f u r a n  (THF)  was  d i s t i l l e d  f r om 
c a l c i u m  h y d r i d e  b e f o r e  u s e .  S o l u t i o n s  w e r e  d r i e d  w i t h  a n h y d r o u s  s o d i u m  s u l p h a t e  
a n d  w e r e  f i l t e r e d  p r i o r  t o  e v a p o r a t i o n  o f  t h e  s o l v e n t s  u n d e r  r e d u c e d  p r e s s u r e  
M e l t i n g  p o i n t s  a r e  u n c o r r e c t e d .  NMR s p e c t r a  w e r e  o b t a i n e d  u s i n g  a J e o l  PMX60SI 
s p e c t r o m e t e r  w i t h  t e t r a m e t h y 1s i 1a n e  a s  i n t e r n a l  s t a n d a r d .  IR s p e c t r a  w e r e  
r e c o r d e d  u s i n g  a P h i l i p s  P U9510  i n s t r u m e n t .  D e t e r m i n a t i o n s  o f  t h e  r a d i o a c t i v i t y  
w e r e  c a r r i e d  o u t  by t h e  l i q u i d  s c i n t i l l a t i o n  m e t h o d  u s i n g  Beckman L S 2800  and 
Beckman  LS5000CE i n s t r u m e n t s .  T h e  r a d i o c h e m i c a l  p u r i t y  o f  2  c h e c k e d  by
s c r a p i n g  a p p r o p r i a t e  p o r t i o n s  o f  an  a n a l y t i c a l  t h i n  l a y e r  c h r o m a t o g r a p h y  p l a t e  
( s i l i c a  g e l :  CHC13 : MeOH. 4 : 1 )  a n d  a s s a y i n g  r a d i o a c t i v i t y  by  l i q u i d
s c i n t i l l a t i o n  c o u n t i n g .  S o d i u m  b o r o [ * H ] h y d r i d e  was  o b t a i n e d  f r o m  A l d r i c h  
C h e m i c a l  Co.  and  s o d i u m  b o r o [ 3H ] h y d r i d e  w a s  o b t a i n e d  f r o m  Ame rs ham I n t e r n a t i o n a l  
PLC.
t - B u t v l  2 - ( 2 - n i t r o i m i d a z o l - l - y l l a c e t a t e  ( 4 1 . -  2 - N i t r o i m i d a z o l e  ( 2 :  4 . 5 7  g.
4 0 . 4  mmol)  was  S t i r r e d  a t  r e f l u x  i n  DMF ( 4 0  m l )  w i t h  p o t a s s i u m  i ' b u t o x i d e  
( 4 . 8 5  g ,  4 3 . 3  mmol)  f o r  5 m i n  b e f o r e  b e i n g  c o o l e d  t o  120 ° C .  i - B u t y l  b r o m o a c e t a t e
( 7 . 9 0  g .  4 0 . 5  mmol )  was  a d d e d  a n d  t h e  w h o l e  w a s  s t i r r e d  a t  r e f l u x  f o r  a f u r t h e r
5 m i n .  The  c o o l e d  m i x t u r e ,  i n  e t h a n o l  ( 1 0 0  m l )  wa s  f i l t e r e d  and  t h e  s o l v e n t s  
w e r e  e v a p o r a t e d  a t  1 t o r r .  The  r e s i d u e ,  i n  d i c h l o r o m e t h a n e .  was  w a s h e d  w i t h  
w a t e r  (4  x)  a n d  s a t u r a t e d  a q u e o u s  s o d i u m  c h l o r i d e  b e f o r e  b e i n g  d r i e d .  The
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s o l v e n t  was e v a p o r a t e d  t o  g i v e  4 ( 6 . 3 8  g ,  70 %) as  a p a l e  y e l l o w  o i l ;  6 ( CDC1 3 ) 
1 . 4 5  (9 H, S, C ( C H j ) j ) .  5 . 0 2  (2 H. s ,  CH2 ) .  7 .1  (2 H, b r .  2 X i m i d a z o l e - H ) .
2 - ( 2 - N i t r o i m i d a z o W - y l ) a c e t i c  f i £i d L i l - - T h e  i - b u t y l  e s t e r  4 ( 6 . 2 9  g .
2 7 . 7  mmol) was s t i r r e d  w i t h  t r i f l u o r o a c e t i c  a c i d  ( 4 0  ml)  f o r  16 h b e f o r e  
e v a p o r a t i o n  o f  t h e  r e a g e n t .  The r e s i d u a l  s o l i d  was  washed w i t h  a m i x t u r e  of  
d i e t h y l  e t h e r  and hex a n e  ( 1 : 1 )  t o  a f f o r d  £  ( 4 . 7 4  g ,  q u a n t . )  as  a p a l e  y e l l o w  
s o l i d  m . p .  145-146°c  ( l i t .  ( 4 )  m.p .  1 5 9 - 160°C ( e x p l . ) ) ;  6 (C0C13 ) 5 . 2 0  ( 2  H, s .  
CH2 ) .  7 . 5 2  (1  H,  d ,  J  = 1 . 5  Hz .  i m i d a z o l e - H ) .  7 . 5 8  ( 1  H.  d .  J  = 1 . 5  Hz.  
i m i d a z o l e - H ) .
N - ( 2 . 2 - 0 i m e t h o x v e t h v l ) - 2 - ( 2 - m t r o i m i d a z o l - I - y l ) a c e t a m i d e  ( 6 ) . -  The c a r b o x y l i c  
a c i d  5  ( 5 1 0  mg,  3 mmol )  was  S t i r r e d  w i t h  N . N ' - d i c y c l o h e x y l c a r b o d i i m i d e  ( 6 3 0  mg.  
3 mmol )  a n d  2 , 2 - d i m e t h o x y e t h y l a m i n e  ( 3 6 0  mg.  3 mmol )  i n  THF ( 1 3  ml )  f o r  3 d a y s  
b e f o r e  t h e  m i x t u r e  wa s  f i l t e r e d  a n d  t h e  s o l v e n t  wa s  e v a p o r a t e d .  C e n t r i f u g a l l y -  
a c c e l e r a t e d  p r e p a r a t i v e  l a y e r  c h r o m a t o g r a p h y  ( s i l i c a  g e l ,  e t h y l  a c e t a t e r h e x a n e .  
1 : 1 .  f o l l o w e d  by e t h y l  a c e t a t e )  g a v e  a c r u d e  s o l i d  w h i c h  was  r e c r y s t a l l i s e d  f r o m  
e t h y l  a c e t a t e r h e x a n e  t o  a f f o r d  6  a s  an  o f f - w h i t e  s o l i d  m . p .  1 1 6 - 1 1 7 ° C ;  6 ( CDC1 3 : 
( C D j ) 2C0.  1 : 2 )  3 . 3 0  ( 6  H, s ,  2 x 0CH3 ) .  3 . 3 5  ( 2  H.  t .  J. = 5 Hz.  NCH2CH).  4 . 3 5
(1 H,  t .  J  = 5 Hz .  NCHjCH).  5 . 1 5  ( 2  H.  s .  i m i d a z o l e - C H 2 ) .  7 . 0 7  (1 H, d ,  J = 1 . 5
Hz .  i m i d a z o l e - H ) ,  7 . 1 7  (1  H, d .  J  = 1 . 5  Hz,  i m i d a z o l e - H ) .  7 . 5 5  (1 H. b r .  NH).
N - ( 2 - H v d r o x y - 2 - r ?H l e t h y l ) - 2 - ( 2 - n i t r o i m i d d z o l - l - y l l a c e t a m i d e  ( 8 )  and  N- jLZ*
A c e t o x v - 2 - r a H l e t h y l 1 - 2 - ( 2 - n i t r o i n n d a z o l - l - v l l a c e t a m i d e  ( 1 0 ) . -  The a c e t a l  6  
( 2 5 8  mg.  1 mmol )  wa s  b o i l e d  u n d e r  r e f l u x  w i t h  Dowex 50X4 (H* f o r m ;  300  mg) i n  
THF ( 5  ml )  a n d  w a t e r  ( 3  m l )  f o r  1 h b e f o r e  t h e  s u s p e n s i o n  wa s  f i l t e r e d  t o  g i v e  a 
s o l u t i o n  Of t h e  a l d e h y d e  2 -  S o d i u m  b o r o [ zH ] h y d r i d e  (NaBzHa ; 42 mg.  1 m m o l ) ,  i n
w a t e r  ( 2  m l )  was  a d d e d  t o  t h e  c o o l e d  f i l t r a t e  a n d  t h e  m i x t u r e  was  s t i r r e d  f o r
5 m i n  b e f o r e  a d d i t i o n  o f  a c e t o n e  ( 3  m l ) .  A f t e r  a f u r t h e r  16 h .  t h e  s o l v e n t s  w e r e  
e v a p o r a t e d  a n d  t h e  r e s i d u e ,  i n  w a t e r  ( 5  m l ) ,  was  a p p l i e d  t o  a s h o r t  c o l u m n  o f  
A m b e r l i t e  I RA- 4 0 0  ( ‘ 0 h f o r m :  1 . 0  g )  a n d  was  e l u t e d  w i t h  a w a t e r  ( 1 0  m l ) .  T h i s
270 P. Webb and M. D. Threadgill
e l u a t e  was  t h e n  p a s s e d  t h r o u g h  a s h o r t  c o l u m n  o f  Dowex 50X4 (H* f o r m ;  1 . 0  g )  and  
t h e  w a t e r  was  e v a p o r a t e d  f r o m  t h e  f i n a l  e l u a t e  t o  g i v e  fi ( 1 5 0  mg,  74 %) a s  an 
o f f - w h i t e  s o l i d  m . p .  1 3 3 - 1 3 6 ° C ; v max ( N u j o l  m u l l )  3 4 0 0 .  3 3 00 ,  212 0  , 1665  cm- 1 ;
6 ( CDC1 3 ♦ ( C0 3 ) 2S 0 ;  1 : 1 )  3 . 2 - 3 . 6  ( 3  H,  m, NCH2CHD), 5 . 1 5  (3  H, b r s ,  i m i d a z o l e -
CH2 + OH) ,  7 . 1 0  (1 H, b r s ,  i m i d a z o l e - H ) ,  7 . 4 5  (1 H, b r  i m i d a z o l e - H )  a n d  8 . 2 0
(1  H,  b r t ,  J  = 6 Hz ,  NH).  A s m a l l  s a m p l e  was  t r e a t e d  w i t h  a c e t i c  a n h y d r i d e  and  
p y r i d i n e  t o  a f f o r d  I D  a s  a p a l e  y e l l o w  s o l i d  2 . 0 2  (3  H.  s ,  C0CH3 ) ,  3 . 4 5  ( 2  H, t .
J  = 7 Hz ( b e c o me s  d ,  J  = 7 Hz on  d e c o u p l i n g  a t  6 8 . 3 2 ) ,  C0NCH2 ) .  4 . 1 0  (1  H,
b r t ,  J  = 7 Hz ,  CHD),  5 . 1 5  ( 2  H,  s ,  i m i d a z o l e - C H 2 ) ,  7 . 1 3  (1 H. b r s .  i m i d a z o l e - H ) ,
7 . 4 3  (1 H,  b r s ,  i m i d a z o l e - H )  a n d  8 . 3 0  (1  H, b r t ,  J  = 6 Hz .  NH).
N j _ ( 2 : H y l c o x Y - 2 - [ 3H3e t h y i  ) . - 2 - C 2 - n i t r Q i m i d a 2Qi - i - y i ) a c e t g n i i de  t i l - -  A c e t a i  6
( 1 3 6  mg,  0 . 5 1  mmol)  was  h y d r o l y s e d  w i t h  Dowex 50X4 i n  a q u e o u s  THF and  t h e  r e s i n  
w a s  r e m o v e d  by f i l t r a t i o n  a s  d e s c r i b e d  a b o v e .  S o d i u m  b o r o h y d r i d e  (1 mg,  0 . 0 2 6  
mmol )  wa s  a d d e d ,  f o l l o w e d  a f t e r  5 mi n  by  a n  a q u e o u s  s o l u t i o n  o f  s o d i u m
b o r o [ J H ] h y d r i d e  ( 0 . 0 0 0 5  mmol ,  2 . 5  m C i ; 0 . 5  m l ) .  A f t e r  a  f u r t h e r  5 m i n ,  s o d i u m
b o r o h y d r i d e  ( 1 9  mg,  0 . 5  mmol )  wa s  a d d e d  a n d  t h e  m i x t u r e  wa s  s t i r r e d  f o r  15 mi n  
b e f o r e  a d d i t i o n  o f  a c e t o n e  ( 2  m l ) .  A f t e r  a f u r t h e r  16 h ,  t h e  s o l v e n t s  w e r e  
e v a p o r a t e d  a n d  t h e  r e s i d u e ,  i n  w a t e r  (5  m l ) ,  w a s  a p p l i e d  t o  a s h o r t  c o l u m n  o f  
A m b e r l i t e  I RA- 400  ("OH f o r m ;  0 . 7  g )  a n d  w a s  e l u t e d  w i t h  a w a t e r  (7  m l ) .  T h i s  
e l u a t e  wa s  t h e n  p a s s e d  t h r o u g h  a s h o r t  c o l u m n  o f  Dowex 50X4 (H* f o r m ;  1 . 0  g )  and  
t h e  w a t e r  was  e v a p o r a t e d  f r o m  t h e  f i n a l  e l u a t e  t o  g i v e  2  ( 9 5  mg.  2 . 0  mCi .  
c h e m i c a l  y i e l d  87 %, r a d i o c h e m i c a l  y i e l d  80  %) w i t h  TLC p r o p e r t i e s  i d e n t i c a l  t o  
t h o s e  o f  an  a u t h e n t i c  s a m p l e  o f  1  ( s i l i c a  g e l ,  C H C^ r Me OH,  4 : 1 .  Rf 0 . 2 ) .  The 
r a d i o c h e m i c a l  p u r i t y  wa s  > 97  % a n d  t h e  s p e c i f i c  a c t i v i t y  was  4 . 5  mCi m m o l ' 1 .
N - ( 2 - . 0 x o e t h v l ) - 2 - ( 2 - n i t r o i m i d a z o l - 1 - v l l a c e t a m i d e  2 . 4 - D i n i t r o p h e n y l h y d r d z o n e
( 1 1 ) . -  A s o l u t i o n  o f  t h e  a l d e h y d e  7 ( 0 . 7  mmol )  wa s  p r e p a r e d  by h y d r o l y s i s  o f  6
w i t h  Dowex 50X4 i n  a q u e o u s  THF a s  d e s c r i b e d  a b o v e .  T r e a t m e n t  w i t h  2 . 4 -
d i n i t r o p h e n y l h y d r a z i n e  ( 1 5 0  mg.  0 . 7 5  mmol )  i n  e t h a n o l  f o r  5 mi n  a f f o r d e d ,  a f t e r  
r e c r y s t a l  1 i s a t i o n  f r o m  w a t e r .  JU a s  b r i g h t  y e l l o w - o r a n g e  c r y s t a l s  m . p .  2 3 9 -
2 4 2 ° C ;  6 ( ( C D j ) 2S0)  4 . 0 5  ( 2  H, d d .  J  = 5 Hz.  J  = 3 . 5  Hz ( b e c o m e s  d .  J  = 5 Hz on
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d e c o u p l i n g  a t  6 8 . 0 0 ;  be co m e s  d .  J  = 3 . 5  Hz on  d e c o u p l i n g  a t  6 8 . * 5 ) ,  NCH2CHN) . 
5 . 2 5  (2  H, s ,  i m i d a z o l e * C H ? ) .  5 . 7  ( 1  H.  b r .  A r N H ) . 7 . 2 5  (1 H, d .  J  = 1 Hz.
i m i d a z o l e - H ) ,  7 . 7 0  (1 H. d ,  J  = 1 H z ,  i m i d a z o l e - H ) ,  7 . 9 5  (1 H.  c .  J  = 9 Hz,  Ar
6 - H ) ,  8 . 0 0  ( 1  H,  m ( b e c o m e s  s on  d e c o u p l i n g  a t  6 4 . 0 5 ) ,  NCH2CHN).  5 . 4 0  (1 H, d d ,  
il = 9 Hz,  J  = 2 Hz,  Ar 5 - H ) , 8 . 7 5  ( 1  H,  t .  J  = 5 Hz ( b e c o m e s  s on d e c o u p l i n g  a t  
6 4 . 0 5 ) ,  C0NHCH? ) ,  8 . 8 5  (1  H,  d ,  J  * 2 Hz ,  Ar  3 - H ) .
E x p e r i m e n t  t o  d e t e r m i n e  k f I H ~ | / k [ ?H] f o r  t h e  r e d u c t i o n  n f  A c e t a l  6  was  
h y d r o l y s e d  w i t h  Dowex 50X4 i n  a q u e o u s  THF, r e d u c e d  a n d  t r e a t e d  w i t h  a c e t i c  
a n h y d r i d e  i n  p y r i d i n e  a s  a b o v e ,  e x c e p t  t h a t  t h e  r e d u c t a n t  was  a -  e x c e s s  o f  an  
e q u i m o l a r  m i x t u r e  o f  N a 8 , H4 a n d  NaB*H4 ( 9 8  a t o m  %).  The r e s i d u e  was shown py nmr 
t o  c o m p r i s e  a m i x t u r e  o f  i s o t o p o m e r s  o f  N - ( 2 - a c e t o x y e t h y 1 ) - 2 - ( 2 - n - - - o i m i d a z o l - 1  - 
y l ) a c e t a m i d e .  I n t e g r a t i o n  o f  t h e  t r i p l e t  c e n t r e d  a t  6 4 . 1 0  s howed  t h a t  t h e
m i x t u r e  c o n t a i n e d  65 % o f  t h e  ^ - c o m p o u n d  a n d  35 % o f  t h e  *H- compound .  Fr om
t h e s e  d a t a  i t  was  c a l c u l a t e d  t h a t  k [ J H ] / k [ * H ]  = 1 . 5  f o r  t h e  r e d u c t i o n  s t e p
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Synthesis and Evaluation of Novel Electrophilic Nitrofuran Carboxamides and 
Carboxylates as Radiosensitizers and Bioreductively Activated Cytotoxins
Matthew A. Naylor,* Miriam A. Stephens, Shirley Cole, Michael D. Threadgill, 1 Ian J. Stratford, Peter O’Neill, 
E- Martin Fielden, and Gerald E. Adams
Medical Research Council Radiobiology Unit, Chilton, Didcot, Oxon 0X 11 ORD, U.K. Received January 22, 1990
A  series of 5-nitrofuran-2- and 3-carboxamides bearing alkylating side-chains has been synthesized and tested for 
their ability to radiosensitize selectively hypoxic Chinese hamster cells (V79) to the lethal effects of ionizing radiation 
and also for their ability to act directly and selectively as cytotoxic drugs on hypoxic V79 cells. The compounds 
were extremely efficient radiosensitizers of such cells in vitro and were more efficient than known nitroimidazoles 
of similar type. Their efficiencies as radiosensitizers correlated with their high electron affinity (£ 7) as measured 
by pulse-radiolysis. However the compounds showed little radiosensitizing activity towards KHT sarcomas in C3H 
mice. The compounds in this series of nitrofurans were generally more toxic towards hypoxic cells than towards 
oxic cells in vitro but were less effective upon the basis of a differential effect than were similar nitroimidazoles 
reported previously.
Nitroheterocyclic compounds can act as radiosensitizers 
of hypoxic cells and as bioreductively activated cytotoxins. 1 
Radiosensitization is a fast, free-radical process, and a 
correlation has been observed between the one-electron 
reduction potentials (£ 7 ) of a large number of chemically 
diverse nitroheterocycles and their ability to act as ra­
diosensitizers of hypoxic cells. 2 -3  Nitro compounds can 
be reductively metabolized to form highly potent cyto­
toxins. Since bioreductive activation occurs more readily 
in hypoxic tissue, there is a sound basis for a high degree 
of specificity in poorly oxygenated solid tumors.
Both the bioreductive activity and radiosensitizing ef­
ficiency of 2 -nitroimidazoles can be greatly increased by 
incorporating monofunctional alkylating groups into the 
molecule. One of the first examples of such a compound 
was a- ( 1  -aziridiny lmethyl)-2 -nitro- 1H- imidazole- 1  -ethanol 
(RSU-1069, l ) , 4 -5  a 2 -nitroimidazole bearing an aziridine 
(Figure 1 ). This compound is about 5-10-fold more ef­
ficient than misonidazole (a related nitroimidazole not 
containing an alkylating group) as a radiation sensitizer 
of experimental tumors and shows considerably more cy­
totoxicity when reductively metabolized under hypoxic 
conditions. Preliminary clinical investigation of RSU-1069 
has revealed gastrointestinal toxicity which restricts doses 
to levels not likely to produce significant radiosensitiza­
tion . 6  Various analogues have been synthesized and 
evaluated in attempts to reduce toxicity towards normal 
tissues without a corresponding reduction in radiosensi­
tization of tumors. Examples include compounds in which 
the aziridine group is deactivated by substitution . 7  Lower 
toxicity can also be achieved by using a prodrug of RSU- 
1069 such as the new and recently reported compound 
a-[[(2 -bromoethyl)amino]methyl]-2 -nitro-lH-imidazole-
1-ethanol hydrobromide (RB-6145, 2 ) . 8
Increasing therapeutic benefit can also be achieved by 
increasing radiosensitizing potency. One possible way of 
obtaining this is to raise the redox potential of the nitro-
f Present address: School of Pharmacy, University of Bath. 
Bath, BA2 7AY, U.K.
heterocycle. For example 5-nitrofurans are generally more 
electron affinic than 2-nitroimidazoles and both 5-nitro-
2-furaldehyde semicarbazone (nitrofurazone, 3) and 5- 
nitro-2-furaldoxime (nifuroxime, 4) have been found to be 
very effective radiosensitizers of hypoxic cells in tissue 
culture systems. 9 - 1 0  We have investigated nitrofurans 
bearing alkylating side-chains, and with E\ values of be­
tween -210 and -350 mV (ie; both higher and lower E\ 
than the known nonalkylating sensitizer nitrofurazone, 3) 
by altering the patterns of substitution. Of particular 
importance is the position of the nitro group on the furan 
ring and possible conjugation with electron withdrawing 
substituents. Changes in the nature of the substituents 
likely to have an effect on electron affinity have also been 
investigated. This paper describes studies with the ni­
trofurans having the highest (most positive) electron af­
finities of those synthesized, namely the 5-nitrofuran 
carboxamides and propenamides bearing side chains of 
varying electrophilic reactivity.
(1 ) Collected papers in Biochem. Pharmacol. 1986,35,1-122 (Eds.
Alexander, P., Gielen, J., Sartorelli, A  C.).
(2) Adams, G. E.; Clarke, E. D.; Flockhart, I. R.; Jacobs, R. S.;
Sehmi, D. S.; Stratford, I. J.; Wardman, P.; Watts, M. E.;
Parrick, J.; Wallace. R. G.; Smithen, C. E. Int. J. Radiat. Biol.
1979, 35, 133.
(3) Adams, G. E.; Flockhart, I. R.; Smithen, C. E.; Stratford, I. J.;
Wardman, P.; Watts, M. E. Radiat. Res. 1976, 67, 9.
(4) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. Br.
J. Cancer 1984. 49, 571.
(5) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. Int.
J. Radiat. Oncol. Biol. Phys. 1984, 10, 1653.
(6 ) Horwich, A.; Holliday, S. B.; Deacon, J. M.; Peckham, M. J. Br.
J. Radiol. 1986. 59, 1238.
(7) Ahmed, I.; Jenkins, T. C.; Walling, J. M.; Stratford. 1. J.;
Sheldon, P. W.; Adams. G. E.; Fielden. E. M. Int. J. Radiat.
Oncol. Biol. Phys. 1986. 12, 1079.
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Chemistry
The common starting material for the series of 5-nitro- 
furan-2-carboxamides 15-23 (of which, 15 has been re­
ported previously11) was 5-nitro-2-furoyl chloride, prepared 
from commercially available 5-nitro-2-furoic acid (5) by 
treatment with refluxing thionyl chloride in the presence 
of a catalytic amount of dimethylformamide (DMF). 
Subsequent amides or esters were then prepared directly 
from this intermediate with the appropriate alcohol or 
amine (Scheme I).
Compounds 24-28 were prepared from the common 
starting material 5-nitro-2-furylacrylic acid (9), prepared
( 1 1 ) Gumennyi, V. I.; Levchenko, A. I.: Panasenko, B. F. Tr. Vses. 
Nauchn. Konf. Khim. Tekhnol. Furanovykh. Soedin. [Tezisy 
Dokl. 1 1978, 3. 107; Chem. Abstr. 1980, 92. 180901a.
by Perkin condensation from 5 -nitro-2 -furaldehyde (7) 
with acetic anhydride/sodium acetate or directly by ni­
tration of 2-furylacrylic acid (8 ). Corresponding propen- 
amides (of which, 24 has been reported previously as an 
antibacterial agent12) were then prepared from the acyl 
chloride (Scheme II).
Compounds 29 and 30 were prepared by nitration of
2-methyl-3-furoic acid (11) according to the procedure of 
Gilman et al. , 1 3  followed by coupling to allylamine by a 
mixed anhydride method. This coupling was used owing 
to the instability of 2-methyl-5-nitrofuran-3-carboxylic acid 
(12) in the presence of thionyl chloride. The 3-nitro 
analogue 31 was prepared from 2-methyl-5-furoic acid by 
nitration of the methyl ester (13) according to the method 
of Rinkes, 14 followed by direct coupling of the hydrolyzed 
ester (14) with allylamine (Scheme III).
Oxiranes 16, 20, 25, and 30 were generally synthesized 
from the allyl amide or ester by treatment with 3-chloro- 
perbenzoic acid (MCPBA). With the exception of 30, 
which was broken down to unidentified products in re- 
fluxing aziridines under a variety of conditions, treatment 
of these oxiranes with the appropriate aziridines in boiling 
THF gave the N-substituted aziridines (21, 22. 26, and 27,
(12) Ohyama, A. Bull. Inst. Chem. Res.. Kyoto L'niv. 1956. 34. 25.
(13) Gilman. H.; Burtner, R. R.; Smith, E. W. Reel. Trau. Chim.
Pays-Bas 1932, 51. 407.
(14) Rinkes. I. J. Reel. Trav. Chim. Pays-Bas 1930. 49. 1118.
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Scheme III®
2 9  3 0
13 14 31
0 Reagents: (i) NaOH/HjO/EtOH; (ii) AcjO/HNO* (iii) ethyl 
chloroformate/aUylamine/EtaN/CHjCl^ (iv) MCPBA/CH2Cl2; (v) 
NaOH/EtOH then allylamine/DCC/THF.
Schemes I and II). Treatment of the oxiranes with un­
substituted aziridine was unsuccessful due to the instability 
of the products. Treatment of the ester 16 with 2,2-di- 
methylaziridine gave only the N-acyl aziridine 17 by re­
action at the carbonyl center of the molecule rather than 
at the oxirane (Scheme I). 2,2-Dimethylaziridine and 
stereochemically pure c£s-2,3-dimethylaziridine were pre­
pared from the appropriately substituted 2 -aminoethanols 
by O-sulfation and elimination with potassium hydroxide, 
according to the methods of Dickey et al. 1 5  The poten­
tially bifunctionally alkylating analogue 28 was prepared 
by reaction of 25 with cis-2,3-dimethylaziridine in the 
presence of MCPBA and triethylamine (EtjN). Compound 
18, with a nonalkylating hydroxyethyl substituent was 
prepared from the corresponding acyl chloride and the 
appropriate amine as described. The ring-opened analogue 
23 was prepared by treatment of 21 with HBr by methods 
similar to those we have described elsewhere for a series 
of 2 -nitroimidazoles . 8
Results and Discussion
The 5-nitrofurans investigated show high radiosensi­
tizing activity in vitro with C1 6  values of as low as 8  mM 
for compounds 25 and 26, 5-nitro-2-furanpropenamides 
with oxiranyl and 2 ,2 -dimethylaziridinyl substituents, re­
spectively (Table I). Generally C1 6  values of 10-50 /iM 
were found for this series of nitrofurans. These radios­
ensitizing efficiencies compare favorably with that of 
compound 3 and all compounds are more efficient ra­
diosensitizers than the nitroimidazoles such as miso- 
nidazole and RSU-1069 (I ) , 4 -5  as would be expected for 
such highly electron affinic compounds. The less oxidizing 
3-nitro analogue, 31, is considerably less effective as a 
radiosensitizer. With the exception of compounds 25 and 
26, which were considerably more potent sensitizers than 
their nonalkylating analogues, there appears to be little 
benefit in terms of radiosensitizing efficiency when bi­
functional character is introduced in this series of com­
pounds. This is in contrast to the trends observed with 
nitroimidazoles.
The 5-nitrofurans in this study showed some selective 
activity in the assay used for direct bioreductive cytotox­
icity. The highest ratios of air to nitrogen toxicity (Cso* 
(air)/C 5 o(N2)) are displayed by those compounds having 
aziridinyl or (bromoethyl)amino substituents, but these 
ratios are lower than those observed in our previous studies
(15) Dickey, F. H.; Fickett. W.; Lucas. H. J. J. Am. Chem. Soc. 
1952, 74, 944.
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Table I. Physicochemical and in Vitro Biological Data of 









n 2 d toxc
misonidazole 389* 0.3* 45.0 4.0 11.3
I 389* 0 .1' 0.3 0.0045 6 6 . 6
2 nd™ 0 .1* 2.3* 0.09* 25.6*
3 257' 0 J » 1.7 0 . 2 8.5
15 2 1 1 * 0.05 0 . 1 0.025 4.0
16 268* 0.025 0 . 2 0.075 2.7
17 nd 0 . 1 0.18 0.18 1 . 0
18 2 2 0 * 0.05 0.25 0 . 1 2 2 . 1
19 nd 0.05 0.08 0.045 1 . 8
2 0 241* 0 . 0 2 0.05 0.05 1 . 0
2 1 nd 0.04 0.15 0.075 2 . 0
2 2 219* 0.05 0.06 0 . 0 2 3.0
23 nd 0.03 0.14 0.025 5.6
24 nd 0.03 0.06 0.025 2.4
25 252* 0.008 0.03 0 . 0 1 3.0
26 nd 0.008 0.045 0 . 0 1 4.5
27 231* 0.035 0.07 0.04 1 . 8
28 335* 0.025 0 . 0 1 2 0 . 0 1 2 1 . 0
29 325* 0.075 0.35 0 . 8 0.4
30 327* 0.04 0 . 1 0 . 1 1 . 0
31 >600* nd1 0.015 0.03 0.5
* Cl 6 = molar concentration of the compound required to give a 
sensitizer enhancement ratio (ER) of 1.6. Hence the lower the 
value of Ci.6 the greater is the sensitizing efficiency. * Cx  (Air or 
N2) = concentration required to reduce optical density by 50% in 
the MTT assay (proportional to cell killing) . 20 ed tox = differen­
tial toxicity; Cx  (airJ/Cjo (Nj) (mean of at least three experi­
ments). dData taken from ref 3. 'Data taken from ref 21. 'Data 
taken from ref 7. *Data taken from ref 8 . * These values are con­
centrations required to reduce cell survival to 1 %.* 'Data taken 
from ref 2 2 . 1 Data taken from ref 2 . * Referred to the normal hy­
drogen electrode (NHE) using benzyl viologen as redox couple; 
[BV^/BV**] = -3 5 4  mV. ' Not determined due to toxicity. ER = 
1.4 at 0.02 mM. m nd = not determined.
with nitroimidazoles. For example, compounds bearing 
the 2,2-dimethylaziridine substituent (21 and 26) are 5-10 
times less effective as hypoxia-selective cytotoxins than 
is the corresponding nitroimidazole analogue a-((2 ,2 -di- 
methyl- 1  -aziridinyl) methyl)-2-nitro- IH- imidazole- 1  -ethanol 
(RSU-1150).7 The most potent compound showing direct 
hypoxia-selective cytotoxic properties is the (2 -bromo-
l,l-dimethylethyl)amino compound 23, with a differential 
toxicity ratio of 6 . This is a comparable differential to that 
found for the known nitrofuran, nitrofurazone 3, but the 
oxic and hypoxic toxicities are 10 times higher. With the 
exception of 25, differential cytotoxicity was not shown by 
the corresponding oxiranes.
The toxicities of these compounds towards oxic cells are 
at least 1  order of magnitude greater than are the toxicities 
of similar nitroimidazoles, a property which could account 
for the poor differentials observed. High oxic toxicities 
could be related to high one-electron reduction potentials, 2  
coupled with alkylating moieties. However, a number of 
compounds (15,18,19, and 24) have higher toxicities than 
3 despite comparable electron-affinities and similarly do 
not possess alkylating moieties. It therefore appears that 
other factors are contributing towards toxicity in this series 
of furans. One-electron reduction potentials (E \ ) measured 
at pH 7 for a selection of the 5-nitrofuran-2-carboxamides 
and propenamides using a pulse-radiolytic method were 
found to be between -210 and -270 mV, ie; 100-150 mV 
more positive than the nitroimidazoles (Table I). There 
is some variation in E) with changes in the side chain at 
the 2 -position. The compounds bearing aziridinyl groups 
are more electron affinic than their oxiranyl analogues, but 
sensitizing efficiency was unaffected by these changes. In 
view of the high oxic toxicity and poor hypoxia selectivity 
that appears to be related to highly positive E\, the re-
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duction potential was lowered to below -300 mV by the 
synthesis of analogues bearing the functionalized side chain 
at the 3-position and a methyl group at the 2-position 
(compounds 29 and 30). These analogues were less toxic 
than the corresponding 2 -carboxamides but showed no 
improvement in differential toxicity. Compound 28, in 
which the conjugation between the furan ring and pro- 
penamide side chain (present in compounds 24-27) was 
removed by epoxidation, had a greatly lowered E \ o f-335 
mV. This analogue, however, showed a slight increase in 
both aerobic and anaerobic toxicity over 24-27, probably 
due to the presence of two potential alkylating moieties 
and showed no hypoxia selectivity. The only 3-nitro 
analogue synthesized, 31, showed no differential cytotox­
icity towards hypoxic cells and in fact displayed slightly 
higher oxic toxicity. The E \ was measured for this com­
pound and found to be <-600 mV. Further 3-nitro ana­
logues of this type were therefore not investigated in view 
of probable similarly low electron affinities.
Despite promising in vitro radiosensitization results with 
this series of nitrofurans, and some improvement over 
nitrofurazone(3), they were ineffective as radiosensitizers 
of murine KHT tumors in vivo (Figure 2), and no greater 
killing of cells could be achieved than was apparent with 
radiation alone. Indeed, slight radioprotection appeared 
to occur 5-15 min after administration of 18, 20, and 25, 
possibly as a consequence of unknown physiological effects 
of these agents. Only 16 showed a consistent but small 
radiosensitizing effect. Together with possible poor dis­
tribution and tumor uptake, the ineffectiveness of the 
compounds as radiosensitizers in vivo could be a conse­
quence of rapid metabolism and/or interactions of the 
compounds with noncritical targets in the animals, as has 
been postulated previously with some other nitrofurans. 1 6 *17  
This could involve, for example, the reaction of metabo­
lized nitrofurans with cellular thiol groups, although in 
culture medium we have not found these compounds to 
be reactive towards the thiols glutathione and N-acetyl- 
cysteine.
In conclusion, these nitrofurans show little promise as 
mixed-function radiosensitizers of clinical potential unless 
the high oxic toxicity can be overcome and significant 
radiosensitizing activity in vivo can be demonstrated. It
is pertinent to note, however, that the doses of the nitro­
furans which could be administered to mice were relatively 
low compared to doses used for similar nitroimidazoles, 
even with those compounds which were not limited by poor 
solubility. The relatively high toxicity of these compounds 
toward oxic cells in vitro may lead to dose-limiting toxicity 
towards normal tissues in vivo. The design of nitrofurans 
and other nitroheteroarenes with lower (more negative) E\ 
values may reduce oxic toxicity and could lead to greater 
hypoxia selectivity. This approach is currently being in­
vestigated in this laboratory.
Experim ental Section
Chemical Synthesis. NMR Spectra were obtained at 60 MHz 
with a Jeol PMX60SI spectrometer with SiMe< as internal 
standard. Mass spectra were carried out on a Finnigan 4500 
instrument in the electron-impact mode. Melting points are 
corrected. CH2CI2 was purified by passing through basic alumina, 
drying over CaCl2, and distilling prior to use. Tetrahydrofuran 
(THF) was distilled from CaH2; other solvents were unpurified 
commercial grades unless stated otherwise. Commercially 
available 3-chloroperbenzoic add (MCPBA) was further purified 
by washing with phosphate buffer (pH 7) and drying the residue 
at reduced pressure in the presence of P2O5 . Elemental analyses 
were determined by Elemental Microanalysis Ltd., Okehampton, 
UK. Solutions in organic solvents were dried by treatment with 
anhydrous Na^O* and filtration. Solvents were removed by 
evaporation under reduced pressure. All compounds were racemic. 
The one-electron reduction potentials (E\) of selected compounds 
(Table I) were determined by using pulse-radiolysis techniques 
as previously described . 18
Prop-2-enyl 5-Nitrofuran-2-carboxylate (15). 5-Nitro-2- 
furoyl chloride (0.5 g, 2.85 mmol) in CH2C12 (3 mL) was added 
to allyi alcohol (1.4 g, 24 mmol) and E^N (3 mL) in CH2C12  (5 
mL) at 0 °C under N* The solution was stirred at 0 °C for 1  h, 
poured onto ice (50 g), and extracted with CH2C12 (50 mL). The  
organic layer was washed with 5% aqueous NaHC03 and H20  
and dried. The solvent was evaporated, and the residue was 
recrystallized from EtOH to give 15 (0.35 g, 62%) as pale yellow  
prisms: mp 71-71.5 °C; NMR (CDCI3) b 4.8 (d, J  = 6  Hz, 2 H, 
allylic CHz), 5.2-6.2 (m, 3 H, olefinic-H), 7.25 (s, 2 H, furan-H). 
Anal. (CgHvNOs) C, H, N.
O xiranylm ethyl 5-Nitrofuran-2-carboxylate (16). Dried
3-chloroperbenzoic acid (7.3 g, 42 mmol) in CH2C12 (75 mL) was 
added to 15 (3.5 g, 17.7 mmol) in CH2C12 (30 mL). The solution 
was heated under gentle reflux for 15 h before being washed with 
10% aqueous Na^C^ (100 mL), 5% aqueous NaHC03 (twice), 
H20 , and saturated aqueous NaCl. The organic layer was then  
dried, and the solvent was evaporated. The residue was recrys­
tallized from EtOH to give 16 (2.3 g, 61%) as a colorless solid: 
mp 98-99 °C; NMR (CDCfj) b 2.7 (dd, J  = 4.5 and 3 Hz, 1 H) 
and 2.9 (t, J  = 4 5  Hz, 1  H), oxiranyl 3-CH2, 3.25 (m, 1  H, oxiranyl
2-H), 4.2 (dd, J  = 12 and 6  Hz, 1 H), and 4.7 (dd, J  = 12 and 3 
Hz, 1 H), C 0 2CH2, 7.25 (s, 2 H, furan-H). Anal. (CgH-jNOs) C, 
H, N.
2,2-D im ethyl-l-(5-nitro-2-furoyl)aziridine (17). Epoxide 
ester 16 ( 1 . 0  g, 5 mmol) was stirred at 2 0  °C with 2,2-di­
methylaziridine (4.0 g, 56.3 mmol) for 5 h. Excess aziridine was 
then evaporated, and the residue was recrystallized from EtOH  
to give 17 (0 . 6  g, 57%) as a pale yellow solid: mp 104-106 °C dec, 
NMR (CDCla) b 1.5 (s, 6  H, azmdmMCHj)*), 2.45 (s, 2 H, aziridine 
CH2), 7.2 (d, J  = 3.5 Hz, 1 H, furan-H), 7.3 (d, J  = 3.5 Hz. 1 H, 
furan-H). Anal. (C^HjoNjOJ C, H. N.
fV-(l,l-Dim ethyl-2-hydroxyethyl)-5-nitrofuran-2-carbox- 
amide (18). 5-Nitro-2-furoyl chloride (1.5 g, 8 . 6  mmol) in CH2C12 
(10 mL) was added to 2 -amino-2 -methylpropan-l-ol ( 1 0  mL, ca. 
100 mmol) and Et^N (10 mL) in CH2C12 (30 mL). The mixture 
was stirred at 25 °C for 0.5 h and was then washed with H20  and 
dried. The solvent was evaporated, and the residue was recrys- 
taliized twice from CH2C12 to afford 18 (1.35 g, 69%) as a colorless 
solid: mp 1 1 0 - 1 1 2  °C; NMR (CDC13) b 1.4 (s, 6  H. (CH3)2), 3.65
(16) Agnew. D. A.; Skarsgard. L. D. Radiat. Res. 1974, 57, 246.
(17) Sutherland. R. M.; Durand, R. E. Int. J. Radiat. Biol. 1972. 22.
613.
(18) Wardman, P.; Clarke, E. D. J. Chem. Soc., Faraday Trans. 1 
1976, 72, 1377.
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(s, 2  H, Ctf2OH), 6.5 (br, 1 H, NH), 7.2 (d, J  = 3.5 Hz, 1 H, 
furan-H), 7.3 (d, J  = 3.5 Hz, 1 H, furan-H). Anal. (CjHmNjOs) 
C, H, N.
5-Nitro-AT-(prop-2-enyl)furan-2-carboxamide (19). 5- 
Nitro-2-furoyl chloride (5.0 g, 28.5 mmol) in CHjClj (50 mL) was 
added dropwise to allylamine (12 mL, 276 mmol) and EtjN (30 
mL) in CH2Cl2 (50 mL) at 0  °C under N2, and the solution was 
stirred at 0 °C for a further 0.75 h. The mixture was washed with 
5% aqueous NaHC03 and saturated aqueous NaCl and was dried. 
Evaporation of the solvent and recrystallization from EtOH gave 
19 (3.3 g, 59%) 5 as pale yellow needles: mp 64-65.5 °C; NMR  
(CDCI3) 8  4.1 (br t, J  =  6  Hz, 2  H, allylic CHj), 5.2 (br d, J  = 13 
Hz, 1 H) and 5.3 (br d, J  = 17 Hz, 1  H) olefinic CH2, 5.6-6.2 (m,
1 H, allylic 2-H), 7.0 (br, 1 H, NH), 755 (d, J  = 3.5 Hz, furan-H),
7.35 (d, J  -  3.5 Hz, furan-H). AnaL (CgHgNA) C, H, N.
JV-(OxiranyImethyI)-5-nitrofuran-2-carboxamide (2 0 ). 
Epoxidation of 19 was carried out as described for the preparation 
of 16. The product was recrystallized from EtOH to afford 2 0  
(1.14 g, 53%) as colorless prisms: mp 1 1 0 - 1 1 2  °C; NMR (CDC13) 
8 2.6-4.1 (m, 5 H, oxirane-CH2 and oxiranvl-H), 6.9 (br, 1  H, NH),
7.2 (d, J  = 3.5 Hz, furan-H), 7.3 (d, J  =  3.5 Hz, furan-H). Anal. 
(CgHaNjOj) C, H, N.
7V -(3-(25-D im ethyl-l-aziridinyI)-2-hydroxypropyl)-5- 
nitrofuran-2-carboxamide (21). Epoxide 20 (05 g, 0.94 mmol) 
was heated under reflux with 2 ,2 -dimethylaziridine (0 . 2  g, 2 . 8  
mmol) and EtjN (0.03 mL) in THF (3 mL) for 5 h. The solvent 
was then evaporated, and the residue was purified by chroma­
tography (silica gel (75 g); EtOH/EtjN (99:1, v/v)). Recrystal­
lization from EtOH/EtaN (99:1) afforded 21 (0.07 g, 26%) as a 
pale yellow solid: mp 94-95 °C; NMR (CDCI3) 8 1.2-1.3 (m, 7 
H, aziridine-(CH3 ) 2  and aziridine-H), 1.85 (d, J  = 3 Hz, 1  H, 
aziridine-H), 2.3-2.6 (m, 2 H, CHCH2  aziridine), 3.6-3.9 (m, 4 H, 
NHCH 2CHOH), 7.20 (d, J  = 3.5 Hz, furan-H), 7.25 (d, J  = 3.5 
Hz, furan-H), 7.8 (br, 1 H, NH). AnaL (C12H 17N30 s) C, H, N.
N -(3 -(c is  -2,3-Dimet hy 1- 1  -aziridinyl )-2-hydroxy p ro p y l) - 
5-nitrofuran-2-carboxamide (2 2 ). Epoxide 20 was treated with 
c£s-2,3-dimethylaziridine as for the preparation of 2 1  above to 
give 22 (0.32 g. 32%) as a pale yellow solid: mp 87-89 °C; NMR  
(CDCls) 8 1 . 2  (d, J  = 6  Hz, 6  H, 2  x  aziridine-CHa), 1.5 (m, 2  H,
2 x  aziridine-H), 2.3 (dd, J  = 13 and 5 Hz, 1  H), and 2.45 (dd, 
J  = 13 and 5 Hz, 1  H) CHCH2 aziridine, 3.6-4.0 (m, 4 H, 
NHCH2CHOH), 7.15 (d, J  = 3.5 Hz, furan-H), 7.25 (d, J  = 3.5 
Hz, furan-H), 7.7 (br, 1  H  NH); MS, m / z  284 (M + H ) \  266,240, 
139,84 (100). AnaL (C ^H nN ^s) C, H, N.
7V -(3-((2-B rom o-l,l-dim ethylethyl)am ino)-2-hydroxy- 
propyl)-5-nitrofuran-2-carboxam ide Hydrobrom ide (23). 
Aziridine 21 (0.1 g, 0.35 mmol) was treated with 48% aqueous 
HBr (2 mL) at 25 °C for 10 min, and the excess reagent was 
evaporated under reduced pressure at 40 °C. H20  ( 2  mL) was 
added and was evaporated; this operation was repeated. A small 
volume of EtOH was added to the residue,-and the product was 
precipitated with Et^O and recrystallized from aqueous acetone 
to afford 23 (0.05 g, 40%) as a yellow solid: mp 115-117 °C; NMR  
(CDCla) 8 1 . 8  (s, 6  H, (CH ^), 3.4 (m, 2 H, CHCH2+NH2), 3.8-4.5 
(m, 4 H, NHCH2CtfOH), 4.2 (s, 2 H. CHjBr), 7.6 (s, 2  H, furan-H). 
AnaL (C12H I9 N 3OsBr2-0.5H2O) C, H, N.
3-(5-Nitrofuran-2-yl)-N-(prop-2-enyl)propenamide (24). 
5-Nitro-2-furaldehyde (5.4 g, 40 mmol) and dry powdered NaOAc 
(2.0 g, 40 mmol) were added to acetic anhydride (10 mL), and 
the mixture heated was at 140-150 °C for 2.5 h. The dark solution 
was then cooled to 80 °C, and H20  (100 mL) was added, together 
with decolorizing charcoal, and the solution was boiled under reflux 
for 10 min. The hot solution was filtered and acidified with 2  
M aqueous HC1. Cooling afforded 3-(5-nitrofuran-2-yl)propenoic 
acid (4.2 g, 57%) as a pale brown solid: mp 228-230 °C, (lit . 19 
mp 235-236 °C). This material (1.83 g, 1 0  mmol) was boiled under 
reflux in S0C12 (3 mL) and dimethylformamide (0.1 mL) for 3.5 
h. The S0C12 was evaporated, and the resulting acyl chloride, 
in CH2C12 (20 mL), was added dropwise under N 2 to allylamine 
(5 mL, ca. 70 mmol) and E^N (12 mL) in CH2C12 (20 mL) at 0  
°C. The solution was stirred at 0  °C for 1.5 h before being washed 
with H20 , 5% aqueous NaHC03, and saturated aqueous NaCl 
and dried. The solvent was removed, and the residue was twice
(19) Gilman, H.; Wright, G. F. J. Am. Chem. Soc. 1930, 52, 2550.
N a ylo r  et al.
recrystallized from CHjClj to give 24 (1.1 g, 50%) as pale yellow 
needles: mp 168-169 °C; NMR (CDCy 5 4.1 (dt, J  = 7 and 1 
Hz, 2 H, allylic CH2), 5.20 (br d, J  = 13 Hz, 1  H). and 5.25 (br 
d, J  =  18 Hz, 1 H), and 5.6-6.2 (m, 1 H), CH =C H 2, 6.2 (br t, J  
= 7 Hz, 1  H, NH). 6.7 (d, J  = 16 Hz, 1 H, furan-CH=CH), 6.7 
(d, J  = 3.5 Hz, 1 H, furan 3-H), 7.3 (d, J  = 3.5 Hz, 1 H, furan
4-H), 7.4 (d, J  = 16 Hz, 1 H, furan-CH=CH). AnaL (C10H 10N2OJ 
C, H, N.
!V-(O xiranylm ethyI)-3-(5-nitrofuran-2-yl)propenam ide
(25). Epoxidation of 24 (1.0 g, 4.5 mmol) was carried out as 
described for compounds 16 and 2 0  but with an extended reaction 
time of 2 5  h and purification by column chromatography (silica 
gel; CH jC y to afford, after recrystallization from EtOH, 25 (0.5 
g, 47%) as yellow needles: mp 175-177 °C; H NMR (CDC13) b 
2.65 (dd, J  = 5 and 3 Hz, 1 H) and 2.85 (t, J  = 5 Hz, 1 H), and
3.2 (m, 1  H) 3  x  oxirane-H, 3.3-4.1 (m, 2 H, NCHj), 6.3 (br. 1 
H, NH), 6.65 (d, J  = 16 Hz, 1 H, furan-CH=CH), 6.7 (d, J  = 3.5 
Hz, 1  H, furan 3-H), 7.3 (d, J  = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, 
J  = 16 Hz, 1 H, furan-CH=CH); MS, m /z 239 (M +  H )+, 192, 
166 (100), 134. Anal. (C10H 10N 2Os) C, H, N. 
AT-(3-(2»2-Dimethyl-l-aziridinyl)-2-hydroxypropyl)-3-(5-
nitrofuran-2 -yl) propen amide (26). 25 (0.2 g, 0.84 mmol) was 
heated with 25-dimethylaziridine (0.2 g, 2.8 mmol) and E ^N (0.03 
mL) in THF (3 mL) under reflux for 6  h. The solvent was then 
removed, and the residue was purified by centrifugally accelerated 
layer chromatography (silica gel; EtOH/Et,N (99:1 v/v)) to give 
26 (0.15 g, 58%) as a pale yellow solid: mp 149-150 °C; NMR 
(CDCI3) 8 15-1 .5  (m, 7 H, C tC H ^ and aziridine-H), 1.85 (d, J  
= 3 Hz, 1  H, aziridine-H), 2.3-2.6 (m, 2  H, CHCH2-aziridine), 
3.8-4.2 (m, 4 H, NHCH2CH0H), 6.65 (d, J  = 16 Hz, 1  H, fu- 
ran-CH=CH), 6.7 (d, J  =  3.5 Hz, 1 H, furan 3-H), 7.3 (d, J  = 3.5 
Hz, 1 H, furan 4-H), 7.4 (d, J  = 16 Hz, 1 H, furan-CH=CH); MS 
m /z 310 (M +  H)+ (100), 85,70,56. Anal. (C14Hl9 N 30 5 <).3 3 H20 ) 
C, H, N.
7V-(3-(cis-25-D im ethyl-l-aziridinyl)-2-hydroxypropy!)-
3-(5-nitrofuran-2-yl)propenamide (27). Epoxide 25 was treated 
with cis-2 5 -dimethylaziridine as for the preparatin of 26 above 
to afford, after recrystallization from EtOH, 27 (0.15 g, 48%) as 
a  yellow solid: mp 145-146 °C; NMR (CDCy 6 1.2 (d, J  = 6  Hz, 
6  H, 2 X aziridine-CH^, 1.6 (m, 2 H, 2 X aziridine-H), 2.5 (m, 
2  H, CHCHz-aziridine), 3.1-3.8 (m, 4 H, NHCH2CHOH), 6.65 (d, 
J  = 16 Hz, 1  H, furan-CH=€tf), 6.7 (d, J  = 3.5 Hz, 1 H, furan
3-H), 7 5  (d, J  = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, J  = 16 Hz, 1 H, 
furan-CH=CH) 7.5 (br, 1 H, NH). Anal. (C14H19N 3Or0.33H20) 
C, H, N.
7V -(3-(cis-25-D im ethyl-l-azirid inyl)-2-hydroxypropyl)-
2,3-epoxy-3-(5-nitrofuran-2-yl)propenam ide (28). A crude 
sample of 25 (0.5 g, ca. 2.4 mmol) and 3-chloroperbenzoic acid 
(0.5 g, 2.9 mmol) was boiled under reflux with Et^N (0.24 mL) 
and cis-2 5 -dimethylaziridine (0.4 mL, ca. 8  mmol) in THF ( 6  mL) 
for 6  h. The solvent and excess aziridine were then evaporated 
The residue was subjected to column chromatography (silica gel; 
EtOAc/EtjN (99:1, v/v)) and recrystallization from EtOH to give 
28 (0.25 g, 34%) as a yellow solid: mp 74-75 °C; NM R (CDC13) 
5 1.2 (d, J  = 6  Hz, 6  H, 2  x  aziridine-CH3), 1.6 (m, 2  H, 2  x 
aziridine-H), 25-2 .6  (m, 2 H, CHCHraziridine), 2.7-4.0 (m, 6  H, 
NHCH2CHOH and 2  x oxirane-H). 6.5 (d, J  = 3.5 Hz, 1 H, furan
3-H), 7.05 (br, 1 H, NH), 7.25 (d, J  = 3.5 Hz, 1 H, furan 4-H). 
Anal. C14H 19N 30 6  C. H, N.
2-M ethyI-5-nitro-Ar-(prop-2-enyl)furan-3-carboxam ide
(29). 2-Methyl-5-nitrofuran-3-carboxylic acid (prepared according 
to the methods of Gilman et al.13) (2.0 g, 11.7 mmol) was stirred 
for 1.5 h at 0  °C with ethyl chloroformate (1.26 g, 11.7 mmol) and 
EtsN ( 1  mL) in CH2C12 (20 mL). Allylamine (2.0 g, 35.1 mmol) 
was then added and stirring continued for 1 h at 0  °C. The 
solution was then poured onto ice (50 g), stirred for 0.5 h, and 
extracted with Et^O (2 x  50 mL). The combined organic extracts 
were washed with 10% aqueous NaHC03 (twice) and H20  and 
dried, and the solvent was removed. The residue was twice 
recrystallized from EtOH to give 29 (1.5 g, 61%) as colorless 
needles: mp 100-101 °C; NMR (CDC13) 8 2.8 (s, 3 H, furan-CH3). 
4.1 (br t, J  = 6.5 Hz, 2 H, allylic-CH2), 5.05-6.3 (m. 3 H, C H =  
CH2), 6.35 (br, 1 H, NH). 7.45 (s. 1 H, furan 4-H). Anal. (C9- 
H10N 2O4) C, H, N.
7V-(O xirany lm ethyl )-2-m ethyl-5-nitrof u ran -3 -carb ox­
amide (30). Oxirane 30 was prepared as described for compounds
2513










16 1 . 0 0.12 (25 mg kg*') solubility
18 0.5 0.44 (100 mg kg'1) toxicity
2 0 0.5 0.24 (50 mg kg’1) toxicity4
25 1 . 0 0.11 (25 mg kg'1) solubility
° Injected as suspensions. 6No acute, severe, or persistent phys­
ical or behavorial effects were apparent in C3H/He mice with any 
of the doses shown in the table. However, following injection of 18, 
piloerection, an increased respiration rate, and decreased locomo­
tor activity were observed in the mice for approximately 1 h after 
injection. After higher doses of any of the drugs limited by toxic­
ity severe tremors and convulsions occurred, from which the mice 
did not recover. e Injected ip.
16 and 20 from 0.5 g (2.5 mmol) of 29. Recrystallization from 
EtOH gave 30 (0.3 g, 53%) as colorless needles: mp 129-130 °C; 
NMR (CDC13) b 2.8 (s, 3 H, furan-CHa), U b -A .l  (m, 5 H, NCH2 
and 3 x  oxirane-H), 6.5 (br, 1 H, NH), 7.45 (s, 1 H, furan 4-H). 
Anal. (C,H 10N 2O5 ) C, H, N.
2-M ethyl-3-nitro-A r-(prop-2-enyl)furan-5-carboxam ide  
(31). 2-Methyl-3-nitrofuran-5-carboxylate (prepared by the 
method of Rinkes14) (0.25 g, 1.4 mmol) was stirred with allylamine 
(3 mL, 69 mmol) and dicyclohexylcarbodiimide (2.1 g, 10 mmol) 
in T H F (7 mL) at 25 °C for 12 h. Excess amine was then 
evaporated after filtration and the residue was purified by 
chromatography (silica gel; EtOAc/CHCl3 (1 :1 , v/v)) to give 31 
(0.1 g, 35%) as pale yellow prisms: mp 55-56 °C; NMR ((C D ^ O )  
b 2.6 (s, 3 H, furan-CHa), 4.0 (m, 2  H, allylic CH2), 5.2-5.8 (m, 
3 H, C H =C H 2), 7.6 (s, 1  H, furan 4-H), 8.5 (br t, J  = 7 Hz, 1 H,
NH). Anal. (C ^ H ^ O ,) C. H, N.
B iological Methods. The radiosensitization studies in vitro 
were carried out as described previously with use of Chinese 
hamster V79-379A cells.8 The methods for determining selective 
toxicity to hypoxic V79-379A cells using the MTT assay are also 
described elsewhere. 20
On the basis of results from experiments in vitro, compounds 
16, 18,20, and 25 were selected for evaluation in vivo in C3H/He 
mice. The compounds were injected as suspensions or solutions 
in phosphate-buffered saline (pH 7.3). TLC analyses were carried 
out to show that the compounds were unchanged at the time of 
injection. Initial studies were carried out to determine the 
maximum doses of compounds which could be administered 
(Table II). Subsequently, the maximum single doses of each 
compound which could be administered (according to toxicity or 
solubility) were injected at various times (5-90 min) before local 
irradiation of subcutaneous KHT sarcomas with a 10-Gy dose of 
X-rays. Tumors were excised 24 h later and clonogenic assays 
performed in vitro to determine the survival of tumor cells .8
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Synthesis and Evaluation of 
a-[[(2-Haloethyl)am ino]m ethyl]-2-nitro-liI-im idazole-l-ethanols as Prodrugs of 
a-[(l-A ziridinyl)m ethyl]-2-nitro-liI-im idazole-l-ethanol (RSU-1069) and Its 
Analogues W hich Are Radiosensitizers and Bioreductively Activated Cytotoxins
Terence C. Jenkins/ Matthew A. Naylor, Peter O’Neill,* Michael D. Threadgill, 1 Shirley Cole, Ian J. Stratford, 
Gerald E. Adams, E. Martin Fielden, Mark J. Suto,* and Michael A. Stier5
M edical Research Council Radiobiology Unit, Chilton, Didcot, Oxfordshire 0X 11 ORD, U.K., and Parke-Davis Pharmaceutical 
Research Division, Warner-Lambert Company, 2800 Plym outh Road, Ann Arbor, Michigan 48105. Received January 16, 1990
ar-[(l-Aziridinyl)methyl]-2 -nitro-lf/-imidazole-l-ethanols, of general formula ImCH2CH(OH)CH2NCR1R2CR3R<, 
where Im = 2-nitroimidazole and Rl, R2, R3, R4 = H, Me, are radiosensitizers and selective bioreductively activated 
cytotoxins toward hypoxic tumor cells in vitro and in vivo. Treatment of the aziridines with hydrogen halide in 
acetone or aqueous acetone gave the corresponding 2-haloethylamines of general formula lmCH2CH(OH)CH2+- 
N H j C R W R ^ X  X", where Rl, R2, R3, R4  = H, Me, and X = F, Cl, Br, I. These 2 -haloethylamines were evaluated 
as prodrugs of the parent aziridines. The rates of ring closure in aqueous solution at pH ~ 6  were found to increase 
with increasing methyl substitution and to depend on the nature of the leaving group (I ~  Br > C l»  F). A competing 
reaction of ImCHjCHlOHJCH^NHjC^CHjX X- (X  = Cl, Br) with aqueous HC03' ions gives 3-{2-hyroxy-3-(2- 
nitro-l//-imidazol-l-yl)propyl]-2 -oxazolidmone The activities of these prodrugs as radiosensitizers or as bioreductively 
activated cytotoxins were consistent with the proportion converted to the parent aziridine during the course of the 
experiment. a-[[(2 -Bromoethyl)amino]methyl]-2 -nitro-lf/-imidazole-l-ethanol (RB 6145, 1 0 ), the prodrug of a- 
[(l-aziridinyl)methyl]-2-nitro-l/f-imidazole-l-ethanol (RSU-1069,3), is identified as the most useful compound in 
terms of biological activity and rate of ring closure under physiological conditions.
In troduction
It is generally known that many solid tumors contain 
areas of diminished oxygen supply. While the underlying 
reasons for this hypoxia can vary depending upon the type 
and environment of the tumor, this phenomenon provides 
a potential basis for selectivity of cancer chemotherapeutic 
agents towards tumors. Compounds which are anaerobi­
cally reduced to a cytotoxin should be more cytotoxic to 
hypoxic tumor cells than to oxygenated normal tissues. 1 
Many nitroheterocyclic compounds, such as the 2-nitro­
imidazoles, owe their selective cytotoxicity toward hypoxic 
cells within tumors to their bioreductive properties. 2  They 
are activated in vivo by anaerobic, enzymatic reduction to 
form metabolites which are considerably more cytotoxic 
than the parent compound from which they were derived.
Nitroimidazoles also act as hypoxic cell radiosensitizers, 
acting primarily by fast free-radical mechanisms. 3  The 
agents increase the sensitivity to radiation of the normally 
radiation-resistant hypoxic cells but have little or no effect 
on the response of well-oxygenated cells to radiation. The 
ability of these compounds to act as radiosensitizers4  and 
hypoxic cell cytotoxins is related to their reduction po­
tentials, although the mechanisms of the two effects are 
different.
Misonidazole ( l ) 5  has undergone extensive clinical 
evaluation as a radiosensitizer, but cumulative neurotox­
icity severely limits the dosage which may be administered. 
An equally potent but less toxic analogue, etanidazole (2) , 6  
is in phase III trials. An alternative approach has been 
to develop compounds with greater potency than 1  or 2  
(Chart I). An example is the dual functional agent a-  
((l-aziridinyl)methy 1] -2-nitro- lff-imidazole- 1 -ethanol (3), 
which combines the 2 -nitroimidazole ring with an alkyla­
ting moiety, resulting in a powerful hypoxic cell radios­
ensitizer and bioreductively activated cytotoxic agent both 
in vitro and in vivo. 7 " 9  This aziridine 3 was selected from
T Present address: Cancer Research Campaign Biomolecular 
Structure Unit, Institute of Cancer Research, Sutton, Surrey SM 2  
5NG, UK.
1 Present address: School of Pharmacy, University of Bath, 
Bath BA2 7AY, UK.
‘ Warner-Lambert Co.
Chart I. Structures of the Hypoxic Cell Radiosensitizers 
Misonidazole (I) and Etanidazole (2)
/ = \\  ° H 
NO,
OMe
a series of compounds based upon its partition coefficient 
and activity in model tumors. The ability of 3 to sensitize 
hypoxic tumor cells to the lethal effects of radiation at 
1 0 - 1 2  times less than the dose of 1  or 2  in experimental 
animal models led to its investigation clinically. Unfor­
tunately, in early phase I trials, gastric toxicity (emesis) 
was observed. 1 0  TTie maximum tolerated dose achievable 
in humans was considered to be too low to achieve a 
usefully high degree of radiosensitization. This led to a 
search for equally active but less toxic analogues.
This study describes the synthesis, stability, and de­
velopment of a series of [(haloethyl)amino]propyl-2 - 
nitroimidazoles derived from 3 and its analogues. Pre­
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Scheme I. Synthesis of 2-Haloethylamines 9-18, 




1 2  R*H. X=F 
1 9  R=Me. X=OH
21 R=X=H
2 2  R‘ H, Z=CK
Scheme II. Synthetic Approaches to 
2,2,3,3-Tetramethylaziridine
3  R 's R ^ R ’ sR -sH
4  R ’ =R J»M e, RJ =R‘ =H
5  R ‘ =RJ =*te, KJ » R ' =H


















Rl =RJ sR'*=R*=H, X=C1 
R U R 'x R  s R '- H ,  X=Br 
r'iR'sR^R'^H, X-l 
R 'sR ’ s R ^ R 's H .  X=F CIC1 s a l t )  
Rl =R‘ -J1e, R '= R ‘ *H . X=C1 
R’ s R ^ l f e ,  R ^ R '^ H ,  X=Br 
R 's R ' f l e .  R ’ =R '= H , X=C1 
Rl =RJ =»te, RJ * R ' =H, X=Br 
R>.RJ *R ! =R '=M e. X < 1  
Rl =R, =R: *R '= M e. X=Br
CF,CO,
ensitizers are also provided.
Chemistry
Compounds 3-6 were prepared as described previously 
by us8 *1 1 *1 2  from oxirane 7 and the corresponding aziridine 
(Scheme I). The overall yield of 4 was increased consid­
erably with stereochemically pure cis-2,3-dimethylaziridine 
prepared from cis-2 ,3-epoxybutane by the method of 
Dickey et al . 1 3  Alternative procedures for the synthesis 
of 2,2,3,3-tetramethylaziridine, used in the preparation of 
6 , were explored, in order to avoid the use of the expensive, 
noxious, and unreliable nitrosyl chloride. 1 4 ,1 5
The cyclization of 2 -amino alcohols via the O-sulfates 
fails for the more substituted examples. The insertion of 
[(2,4-[dinitrophenyl)sulfenyl]nitrene, generated from 2,4- 
dinitro benzenesulfonamide and lead tetraacetate , 1 6 into 
the double bond of 2,3-dimethylbut-2-ene gave l-[2,4-di- 
nitrophenyl)thio]-2,2,3,3-tetramethylaziridine (8 ) in high 
yield (Scheme II). However, reductive cleavage of the S-N 
bond could not be achieved in preparatively useful pro­
cedures. Addition of iodine azide, formed in situ from 
sodium azide and iodine monochloride, across the double 
bond of 2,3-dimethylbut-2-ene, reduction of the resultant 
azide, and concomitant ring closure furnished the aziridine 
in acceptable yield1 7  (Scheme I).
The 2-haloethylamines 9-18 were obtained from the 
corresponding aziridines 3-6 by acid-catalyzed nucleophilic
(11) Adams, G. E.; Ahmed, I.; Gibson, D.; Stratford, I. J. U.K. 
Patent GB 2123816A, Feb 8 , 1984.
(12) Ahmed, I.; Jenkins. T. C.; Walling, J. M.; Stratford, I. J.; 
Sheldon, P. W.; Adams, G. E.; Fielden, E. M. Int. J. Radiat. 
Oncol. Biol. Phys. 1986, 12, 1079.
(13) Dickey, F. H.; Fickett, W.; Lucas, H. J. J. Am. Chem. Soc. 
1952, 74, 944.
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ring opening with the appropriate hydrogen halide, as 
shown in Scheme II. The yields were generally greater if 
anhydrous conditions were employed, thus avoiding the 
possibility of nucleophilic attack by water leading to the 
corresponding 2 -hydroxyethylamines.
Compounds 13 and 14 have the threo relative stereo­
chemistry in the haloalkylamine moiety but were isolated 
as mixtures of diastereoisomers with respect to the chiral 
center adjacent to the hydroxy group. Proton NMR at 300 
MHz and HPLC analysis revealed that 13 consisted of such 
diastereoisomers in the approximate 1 : 1  ratio, indicating 
that the electrophilic centers in protonated 4, which are 
prochiral, are roughly equivalent in reactivity and/or steric 
crowding in the reacting conformation. HPLC analysis of 
14 also indicated the presence of both the analogous dia- 
stereomers in similar quantities. Ring-closure of 13 and 
14 in the presence of aqueous base gave exclusively cis-
2,3-dimethylaziridine 4, showing that both ring-opening 
and ring-closing reactions proceed with complete inversion 
at the reacting center.
The correct regioisomeric structures of 15 and 16 as
l,l-dimethyl-2 -haloethylamines which are products of 
attack a t CH2, rather than isomeric 2 -halo-2 -methyl- 
propylamines resulting from alternative attack at CMe2, 
were also confirmed by two pieces of evidence from JH 
NMR spectra. Firstly, the CMe2 CH2Cl protons of 15, in 
solution in 1 0 % deuterotrifluoroacetic acid in deuterium 
oxide, resonate as a sharp singlet at 8 3.90. In comparison, 
the spectrum of 19, in the same solvent, shows a corre­
sponding singlet a t 8 3.80 for the CMe2 C//2OD protons 
whereas that of isomeric alcohol 2 0 , prepared in situ from 
3 by hydrolytic ring opening in the NMR solvent, contains 
a singlet for the +ND2 CH2 CMe2OD protons at 5 3.40. 
Secondly, when the spectra were recorded of solutions of 
these materials in anhydrous protiotrifluoroacetic acid, 
coupling was evident between the +NH2  protons and the 
adjacent CH2CMe2  in 20 but was absent from the 
+NH2 CMe2 C/f2OH signal of 19. The corresponding signal 
of 15 also showed no coupling to the +NH2 protons. These 
observed regioselectivities of acid-catalyzed ring opening 
of 2 ,2 -dimethylaziridines with the weak nucleophilic water 
and the strong nucleophile chloride are consistent with the 
reported1 8  corresponding reactions of simple N-unsub- 
stituted aziridines. The attack of chloride proceeds via a 
SN2 -type mechanism involving the less hindered CH 2 
center; whereas water can only trap the more stable ter­
tiary carbonium ion in a SNl-like process.
The diastereotropic nature of the NC(CH3 ) 2 and C1C- 
(CH3 ) 2  groups of protons of 17 was revealed by proton 
NMR at 250 MHz in solution in (CT^j^O. The A8 for the 
pairs of methyl groups were 0 . 0 2  and 0 . 0 1  ppm, respec-
(18) Schatz. V. B.; Clapp. L. B. J. Am. Chem. Soc. 1955. 77. 5113.
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Scheme III. “One-Pot" Conversion of 2-Hydroxyethylamines 2 2  
and 19 to 2-Bromoethyiamines 1 0  and 16
Table I. Half-Life of the Agents in PBS Aqueous Solution at 
pH 5.5-6.0 Together with the Major Product Formed at 23 °C
R1 R2
2 2  (R *R - H)
19 (R’-R^Me)'
10 (R1 * R2= H)*
16 (R’-R^Mel*
'R eagents; Me2SBr2 ‘R eagents; NBS/Ph3P
tively, indicating their remoteness from the *CHOH chiral 
center. Resolution of the corresponding NCH2 CH2CI 
prochiral methylene protons was not possible. However, 
in the 250- and 300-MHz spectra of 12, 13, and 17, the 
+NH 2  protons were found to be significantly inequivalent, 
with A6 ranging from 0.14 to 0.13 ppm, possibly indicating 
conformations involving one, but not the other, NH proton 
in an intramolecular hydrogen bond.
Direct reaction of oxirane 7 with 2-fluoroethylamine or 
with ethylamine in ethanol provided compounds 1 2  and 
2 1 , respectively, as shown in Scheme I. However, this 
method cannot be used to prepare the more reactive ha- 
loethylamino compounds 9-11 and 13-18, since unavoid­
able cyclization and/or polymerization of the starting 
(substituted) 2 -haloethylamine occurs.
Attempts to replace directly the primary hydroxyl 
groups of 19 and 22 by bromine, thus avoiding the rela­
tively toxic and unstable aziridines 3 and 5, met with some 
limited success (Scheme III). Treatment of diol 2 2  with 
bromodimethylsulfonium bromide by the general proce­
dure of Furukawa et al . , 1 9  followed by chromatographic 
isolation and addition of hydrogen bromide, gave bromo 
compound 1 0  in 18% yield. The corresponding reaction 
of diol 19 with triphenylphosphine and N-bromosuccin- 
imide according to the method of Ponpipom and Hanes- 
sian2 0  similarly afforded 16 in 27% yield. However, in view 
of the extremely rapid cyclization of the free bases of 1 0  
and 16 noted below, it is possible that the materials eluted 
from the chromatography columns were not these free 
bases. These “brominating agents” may have effected 
cyclization of the hydroxyethylamines to the corresponding 
aziridines 3 and 5 and treatment of these chromato- 
graphically purified intermediates with hydrogen bromide 
may have caused ring-opening as above. Triphenyl­
phosphine dibromide2 1  and triphenylphosphine/carbon 
tetrachloride2 2  are known to effect such cyclizations.
S tab ility  of Compounds and Biological Studies “in 
V itro”
The first half-lives for the reaction of a series of 2 - 
haloethylamino compounds in phosphate-buffered saline 
solution (PBS) were determined from the dependence of 
their rate of loss with time and are shown in Table I for 
the conditions indicated. With increasing methyl-sub- 
stitution of the analogues, it was necessary to investigate 
their degradation at a lower temperature, e.g. 4 °C. Even 
at this temperature, the tetramethyl analogues 17 and 18 
are consumed within the time required for preparation of 
solutions. The compounds become more stable when the 
solution pH «  pKt of the amino group, the pKt of which 
is estimated to be ~7.2 for compounds 9-11. The major 






9 »300  (~280)° 3 1 0
1 0 30 3 1 0
1 1 80 3 1 0
13 1 2 0 4 13.75
14 30* 4 1 0
15 766 5 25
16 <56 5 25
17 « 2 b 6 1 0
18 « 2 * 6 1 0
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Figure 1 . The dependence of hypoxic radiosensitization of V79 
cells in vitro on the concentration of 3 ( • ) ,  9 ( a ) ,  and 10 (O). The 
dashed line shows the dependence of 1 for comparison.
product of ring-closure, as shown in Table I. For com­
pound 1 0 , it was confirmed that the rate of release of 
bromide is the same as that for the loss of 1 0 , indicating 
that the rate-determining step involves ring closure. These 
findings are consistent with the degradation occurring 
predominantly via the free base. From the half-lives given 
in Table I, it is apparent that the rate of ring closure is 
influenced by (i) the leaving-group ability of the halide and 
(ii) the pattern of methyl substitution. The aqueous sta­
bility of these agents is in agreement with previous ob­
servations with simple substituted haloethylamino com­
pounds . 2 3
From assessment of the dependence of hypoxic radios­
ensitization in vitro for 9 and 10 on concentration, as shown 
in Figure 1 , it is apparent that the active agent in the 
biological response to 1 0  is ring-closed aziridine 3. In 
contrast, the radiosensitizing efficiency of 9 is less than 
that of 1 0  and similar to that of 1 , a conventional 2 - 
nitroimidazole radiosensitizer whose redox potential ( £ 7  
= -389 mV ) 2 4  is similar to that of 3. These findings are 
consistent with the observation that, at pH 7, 10 but not 
9  is cyclized to the aziridine 3 in PBS within a time con­
siderably less than the preirradiation contact period used
(19) Furukawa, N.; Inoue, T.; Aida, T.; Oae, S. J. Chem. Soc., 
Chem. Commun. 1973, 212.
(20) Ponpipom, M. M.; Hanessian. S. Carbohydr. Res. 1971, 18, 342.
(21) Freeman. J. P.; Mondron, P. J. Synthesis 1974, 894.
(22) Appel. R.; Kleinstuck, R. Chem. Ber. 1974, 107, 5.
(23) Dermer, O. C.; Hern. G. E. In Ethyleneimine and Other 
Aziridines, Chemistry and Applications', Academic Press: 
New York, 1969.
(24) Wardman, P.; Clarke. E. D. J. Chem. Soc., Faraday Trans. 1 
1976, 72. 1377.
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Table II. Concentration of Agent Required To Reduce Cell 
Survival to 1% following Incubation (3 h) with V79 Mammalian 
Cells under Aerobic (C ,^) or Hypoxic (C^j) Conditions
substance C Jm M  C^/mM C^,/CN;
9 5 0.35 14.3
1 0 2.3 0.09 25.5
11 2.4 0.08 30.0
1 2 35 2.5 14.0
3 0.3 0.003 1 0 0 . 0
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F igu re 2 . The in vitro cytotoxicity of 1 0  following exposure (3 
h) under hypoxic (O) and aerobic ( • )  conditions. The dashed 
line represents the cytotoxicity exhibited by 3 under both gassing 
conditions.
in the radiosensitization studies in vitro. Further, the 
similarity of radiosensitizing efficiency of 9 and 1 is con­
sistent with the determined stability of 9 under these 
conditions. The abilities of the other agents listed in Table 
I to act in vitro as radiosensitizers was not determined, 
owing to their rapid conversion in solution at pH 7 to the 
corresponding aziridine.
The cytotoxicity of these agents was determined in vitro 
in V79 cells held in cell culture growth medium at pH 7.4 
instead of the PBS used for the radiosensitization studies. 
In contrast to the similarity of the radiosensitizing effi­
ciency of 10 with that of the corresponding aziridine 3, it 
is apparent that the haloethylamines tested (9-12) are far 
less cytotoxic, under both aerobic and hypoxic conditions, 
than the corresponding aziridine 3 as shown in Table II 
and in Figure 2 . The cytotoxicity of the hydroxyethyl- 
amine 2 2  is shown in Table II for comparison. The other 
haloethylamines were not tested since their stabilities in 
solution at pH 7 will result in their conversion within a very 
short period compared with the contact period of 3 h. 
From these differences in biological response of 9-12 
compared with that of 3, it is inferred that the reactive 
haloethylamines undergo additional chemical transfor­
mations in cell-culture medium to yield not only 3 but also 
a compound which is less cytotoxic than 3.
It was established, from testing several of the individual 
components of the medium, that 9-11 interact with hy­
drogen carbonate ion. With a concentration of hydrogen 
carbonate (24 mM) in PBS equivalent to that in cell- 
culture medium, it was found that an additional product 
is formed in competition with formation of the aziridine 
in the ratios shown in Table III. Increasing the concen­
tration of hydrogen carbonate (24-107 mM) increases the 
importance of the pathway leading to the product as shown 
in Scheme IV. This product was identified, by coelution 
with authentic compound , 2 5  to be the corresponding oxa-
(25) Suto. M. U.S. Patent 07/274.209. Nov. 25. 1988.
Jenkins et al.
Table III. Ratio of Oxazolidinone to Aziridine Formed upon 
Treatment of the Agents with PBS Aqueous Solution Containing 







Scheme IV. Competing Reactions of Prodrug 10 in 
Phosphate-Buffered Saline Solution Containing Hydrogen 
Carbonate Ions
zolidin-2-one 23. Formation of oxazolidin-2-ones has 
previously been shown to occur upon interaction of hy­
drogen carbonate with simple 2 -haloethylamines . 2 6  
Scheme IV shows the various pathways with 1 0  as an ex­
ample. For the methylated analogues 13-18, the rates of 
cyclization to aziridines were so great as to preclude the 
formation of detectable quantities of the corresponding 
oxazolidinones. Thus, whereas methyl substitution en­
hances substantially the rate of formation of the 3-mem- 
bered ring owing to the relief of steric crowding in the 
approach to the transition state, such steric relief is not 
available in the transition state for formation of the 5- 
membered cyclic analogue.
Since the cytotoxicity experiments are performed at 37 
°C, the effect of temperature (20-37 °C) upon the degra­
dation of 1 0  in PBS containing hydrogen carbonate (24 
mM) was determined. The formation of 23 is favored with 
increasing temperature (step a, Scheme IV). Assuming 
that 23 shows minimal cytotoxicity over the concentration 
range of 1 0  employed, the observed cytotoxicity of 1 0  in 
Table II is in reasonable agreement with that resulting 
from the yield of 3 formed under these biological condi­
tions. Further, the formation of 23 may reduce the cyto­
toxicity of 3 under hypoxic conditions as has previously 
been shown for 3 coincubated with l . 2 7
Biological Assessment of the Compounds in Mice
The maximum tolerated doses (MTD) determined for 
the compounds administered intraperitoneally (ip) to 
C3H/He mice are presented in Table IV. The dose-lim­
iting factor for the agents is their toxicities (Table IV) with 
the exception of 14, 16, and 18, which are limited by their 
solubilities. Since compounds 13-18 will be converted to 
the aziridines (see above) within the period required for 
preparation of the solution and prior to administration, 
the MTD values for those compounds limited by toxicity 
are consistent with those determined for the corresponding
(26) Rauen, H. M.; Norpoth. K.; Kramer, K.-P. Arzneim. For- 
sckung 1965, 15, 1048.
(27) Stratford, I. J.; Walling. J. M.; Silver, A. R. J. Br. J. Cancer 
1986, 53, 339.
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Table IV. MTD Determined for a Series of Haloethyiamine 










1 0 1 . 0 toxicity
13 3.0 toxicity
14 1 . 0 solubility
15 0 . 8 toxicity
16 1 . 0 solubility
17 1.3 toxicity
18 0.7 solubility
2 1 3.9 toxicity
* Administered as a suspension in arachis oil.
aziridines 4-6 (Table IV). In contrast, the MTD values 
of 9 and 10, which were administered as the haloethyl­
amines, as verified with HPLC, are ~2.5 and 4 times 
greater than th a t of the corresponding aziridine 3 but less 
than the corresponding ethylamino compound 21. The 
latter compound is stable to ring closure but has a pKa 
value which is about 2 pK  units greater than that of 9, a 
property that has previously been shown to modify uptake 
of drugs of this type.28 Such comparatively high values 
of MTD of compounds 9 and 10 are compatible with their 
partial conversion to a less toxic product as well as to 3 
in vivo.
From the chemical studies, it is evident that only 9 and 
10, of the haloethylamines reported in Table IV, were 
sufficiently stable in aqueous solution for direct assessment 
of their ability to act as radiosensitizers of the KHT sar­
coma. The properties in vivo of the other compounds are 
consistent with their conversion to the corresponding 
aziridine prior to administration.29 The dependences of 
the surviving fraction of clonogenic tumor cells upon ip 
dose of 9 or 10 are shown in Figure 3 for administration 
45 min prior to irradiation of the tumor with X-rays (10 
Gy). This dose of radiation kills most of the oxic tumor 
cells and hence the responses reflect predominantly the 
modification of the survival of residual clonogenic, hypoxic 
cells. It is apparent that 10 is slightly less effective than 
3 as a radiosensitizer but is about 1 order of magnitude 
more effective than 9 for an equal dose. From other 
studies, the effectiveness of 9 to act as a  radiosensitizer 
has been shown to be similar to that of 21 for equivalent 
administered doses.29 For compounds 3 and 10, the cell 
survival falls to a constant value at the highest adminis­
tered doses used. This value is equivalent to that corre­
sponding to the maximum radiosensitizing effect of oxy­
gen.30 At the highest tolerated dose of 9, the reduction 
of cell survival is about 1 order of magnitude less than that 
observed at the MTD of 3 and 10.
The differences in the effectiveness of 9 and 10 as ra­
diosensitizers could be explained if 23, formed to a greater 
extent from 9 than from 10 in the presence of hydrogen 
carbonate (Table III), is a relatively ineffective radiosen­
sitizer in vivo a t these concentrations. The ability of 23 
to act as a radiosensitizer of hypoxic tumor cells was in­
vestigated. Compound 23 was produced from 9 in PBS
(28) Adams, G. E.; Ahmed, L; Clarke, E. D.; O'Neill. P.; Parrick, J.; 
Stratford, I. J.; Wallace, R. G.; Wardman, P.; Watts. M. E. Int. 
J. Radiat. Biol. 1980, 38, 613.
(29) Cole, S.; Stratford. I. J.; Adams. G. E.; Fielden. E. M.; Jenkins. 
T. C. Radiat. Res. 1990, in press.
(30) Stratford, I. J.; Adams, G. E.; Godden, J.; Howells, N. Int. J.





A dm inistered dose / mmol/kg
Figure 3. Comparison of the radiosensitization of the KHT  
sarcoma by various concentrations of 3 (O), 9 (□), 10 (•) and 23 
(■) administered ip 45 min before a 1 0  Gy dose of X-rays.
containing hydrogen carbonate; greater than 95% con­
version to 23 was verified by HPLC prior to its adminis­
tration. As shown in Figure 3, 23 produces little or no 
radiosensitization at the concentration used and is far less 
effective than 10 (or 3).
Conclusions
Treatment of aziridines 3-6 with hydrogen halides under 
mild conditions provides an efficient route to 2-halo- 
ethylamine salts 9-18. With the exception of fluoro com­
pound 12, the corresponding free bases revert to the parent 
aziridine at rates depending on the nature of the leaving 
halide and on substitution in the 2-haloethyl moiety. 
Compounds 9-11 and 13-18 can therefore be considered 
as prodrugs of 3-6. As the conversions of 13-18 to the 
parent aziridines are extremely rapid in neutral or slightly 
acidic aqueous media, the soluble haloethyiamine salts may 
be useful in the formulation of solutions of 4-6 for clinical 
use. However, the corresponding conversions of 9 and 10 
to 3 are sufficiently slow at pH 5 to enable direct assess­
ment of their biological activities in vivo. Studies with the 
murine KHT tumor demonstrate tha t the efficiency of 9 
to act as a radiosensitizer is similar to that of 21, reflecting 
its relative resistance to ring closure under the experi­
mental conditions. In contrast, 10, which converted in 
significant yield to 3 under the experimental conditions, 
shows an efficiency of radiosensitization comparable to that 
of 3 but is less toxic. Of the compounds tested for bio­
logical activity, 10, acting as a prodrug of 3, may show 
considerable promise as a radiosensitizer with an increased 
therapeutic ratio. The ability of this series of compounds 
to act as bioreductively activated cytotoxins in vivo is 
reported elsewhere.29
Experim ental Section
Synthetic Chemistry. Unless otherwise stated, NMR spectra 
were obtained at 60 MHz with a JEOL PMX60SI spectrometer 
using SiM e4 as internal standard. Other NMR spectra were 
obtained at 300 MHz (Bruker AC300) and at 250 MHz (Bruker 
AM250). A Philips PU9516 instrument furnished the IR spectra. 
Melting points are uncorrected. Elemental microanalyses were 
carried out by Butterworths Laboratories Ltd., Middlesex, UK, 
and Elemental Microanalysis Ltd., Okehampton, UK. NJ4-Di- 
methylformamide (DMF) was distilled under reduced pressure 
from molecular sieves before use. Ether refers to diethyl ether. 
Solvents were evaporated under reduced pressure. a-[((2- 
Hydroxyethyl)amino]raethyI]-2-nitro-lH-imidazole-l-ethanol (22) 
was prepared as described previously .31
(31) Silver. A. R. J.; McNeil, S. S.; O'Neill. P.; Jenkins. T. C.; 
Ahmed, I. Biochem. Pharmacol. 1986, 35, 3923.
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a - [ ( c is -2,3-D im ethy I-1 -azirid iny I )m e th y l]-2 -n itn - li /-  
im id azole-l-ethan ol (4). Oxirane 7 was treated withm -2,3- 
dimethyl aziridine13 in boiling ethanol by the general method of 
Adams et aLW U 2  to afford 4 (54%) as an off-white solid: mp84-85 
°C (lit . 12 mp 84-85 °C); NMR (300 MHz; CDC13) b 1 . 1 0  Id, J  =
5.5 Hz, 3 H, CH3), 1 . 1 1  (d, J  = 5.5 Hz, 3 H, CH3), 1.53 (dq, J  =
6 . 6  Hz, J  = 5.5 Hz, 1 H, aziridine-H), 1.58 (dq, J  = 6 . 6  Hz, J  =  
5.5 Hz, 1 H, aziridine-H). 1 . 8  (br, 1 H, OH). 2.32 (dd, «/= 12.0 
Hz, J  = 4.1 Hz, 1 H), and 2.49 (dd, J  = 12.0 Hz, J  = 7.7 Hz, 1 
H) (aziridine-CH2), 4.06 (ddt, J  = 4.1 Hz, J  = 2.7 Hz, <7 =  8  Hz,
1 H, CHOH), 4.29 (dd, J  = 13.8 Hz, J  = 8.0 Hz, 1 H) and 4.67 
(dd, J  = 13.8 Hz, J  = 2.7 Hz, 1 H) (imidazole-CH2), and7J2 (d, 
J  = 1.0 Hz, 1 H) and 7.24 (d, J  = 1.0 Hz, 1 H) (imidazole 4J5-H).
2-Nitro-er-[(2,2,3,3-tetram ethyl-l-aziridinyI)m ethyI]-l£f- 
im idazole-l -ethanol (6 ). 2,2,3,3-Tetramethylaziridine14 [bp 
102-103 °C (lit . 14 bp 104-104.5 °C); NMR (CDCl^ b -1.28 (s, 1 
H, NH) and 1.25 (s, 1 2  H, 4  x  CH^] was treated with 7, ly  the 
method previously described, 12 to give 6  (64%) as a pale yellow 
solid: mp 131-132 °C ( l i t 12 mp 131-132 °C); NMR [CDC13 +  
(CD^jSO; 1 :1 ) b 1.05 (s, 1 2  H, 4  x  CH3), 2.30 (d, J  = 5 Hz, 2 H, 
aziridine-CH2), 3.8 (br, 1 H, OH), 4.1-5.1 (m, 3 H, iraidazole- 
C H £H ), and 7.05 (br s, 1  i i )  and 7.50 (br s, 1 H) (imidazole4£-H).
l-(O xiranylm ethyl)-2-nitroim idazole (7). Alkylalion of
2 -nitroimidazole with l-chloro-2 ,3-epoxypropane, followed by 
base-catalyzed ring closure, generally according to the method 
of Beaman et al. , 32 gave 7 (96%) as white needles: mp 553-56  
°C ( l it 32 mp 53.5-55 °C); NMR (CDClj) b 2.55 (dd, *7 = 5 Hz, J  
= 3 Hz, 1 H) and 2.90 ( t  J  = 5 Hz, 1 H) (CH20 ) , 3.45 (ddt J  = 
6  Hz, J  = 5 Hz, J  = 3 Hz, 1  H, CHO), 4.30 (dd, J  -  14 Hz, J  = 
6  Hz, 1 H) and 5.08 (dd, J  = 14 Hz, J  = 3 Hz, 1 H) (imidazole- 
CH2), and 7.10 (s, 1 H) and 7.25 (s, 1 H) (imidazole 43-H).
l-[(2 ,4-D initrophenyl)th io]-2^3,3-tetram ethylazirid ine
(8 ). Pb(OAc) 4 (85%; 1.0 g, ca. 2 mmol) was added during 10 min 
to 2,4-dinitrobenzenesulfenamide16 [mp 118-119 °C ( lit 13 mp 
119-120 °C)] (430 mg, 2  mmol) and 2,3-dimethylbut-2-ene (840 
mg, 10 mmol) in CH2C12 (3 mL). After a further 20 min, the 
solution was diluted with CH2C12 (10 mL) and was washed with 
saturated aqueous NaHC03. The organic phase was dried 
(Na2S 0 4) and filtered and the solvent was evaporated to afford 
8  (550 mg, 93%) as an orange solid: mp 148-149 °C; ER (Nujol) 
1590,1510, and 1300 cm'1; NMR (CDCI3) b 1.40 (s, 1 2  H, 4  x  CHj),
8.35 (dd, J  = 9 Hz, J  = 2 Hz, 1 H, 5-H), 8.45 (dd, J  =  9H z, J  
= 0.5 Hz, 1  H, 6 -H), and 9.06 (dd, J  = 2 Hz, J  = 0.5 Hz, 1  H.3-H). 
Anal. (C u H xsN ^ S ) C, H, N.
ar-[[(2-Chloroethyl)amino]methyl]-2-nitro-lJ?-mudazoIe- 
1-ethanol H ydrochloride (9). Method A. A solution of a- 
(aziridinylmethyl)-2-nitro- 1 H-imidazole- 1 -ethanol8*11-12 (3; 2.12 g, 
10 mmol) in acetone (20 mL) at 40 °C was cooled rapidly to 5-10 
°C and was treated with a saturated solution of HC1 in acetone 
(20 mL). After 2 min, decolorizing charcoal (300 mg) was added 
and the mixture was filtered while still warm from the exothermic 
reaction. On cooling of the filtrate, there was obtained 9 (2.66 
g, 93%) as very pale yellow crystals: mp 153-154 °C dec. An 
analytical sample was recrystallized from aqueous acetone to give 
pale yellow prisms: mp 153-154 °C dec; ER (KBr) 3450 (br), 3345 
(br), 3146,3090,1593,1542,1509, and 1495 cm'1; NMR [(CDjljSO] 
b 3.1 (m, 2 H, CHCtf2-N H 2), 3.4 [m (becomes t, J  = 7 Hz, on 
decoupling at b 9.35), 2 H, +NH2CH2CH2C1), 3.95 (t, J  = 7 Hz,
2  H, CH2C1), 4.2-4.7 (m, 4 H, imidazole-CH2CHOH), 7.15 (d, J  
= 1 Hz, 1 H) and 7.65 (d, J  = 1 Hz, 1 H) (imidazole 4,5-H), and
9.35 (br, 1 H, +NH2). Anal. (C8H 14C12N40 3) C, H, Cl, N.
a-[[(2-Chloroethyl)amino]methyl]-2-nitro-ljEf-imidazole-
1 -ethanol Hydrochloride (9). M ethod B. Aqueous HCI (10.5 
M; 2  mL, 21 mmol) was added in one portion to a fine suspension 
of 3 (2.12 g, 10 mmol) in acetone (20 mL) at 0-5 °C. The solution 
was stirred for 5 min then treated with decolorizing charcoal (300 
mg) and filtered. The filtrate was chilled to afford 9 (1 . 8 8  g, 6 6 %) 
as pale yellow microcrystals: mp 152.5-153.5 °C dec, identical 
(mixed melting point, IR, analysis) with the material prepared 
by method A above.
or-[[(2-Brom oethyl)am ino]m ethyl]-2-nitro-lf7-im idazole- 
1 -ethanol Hydrobromide ( 1 0 ). Treatment of 3 with anhydrous
(32) Beaman. A. G.; Tautz, W.; Duschinsky, R. Antimicrob. Agents 
Chemother. 1986. 520.
Jenkins et al.
HBr, according to method A for the preparation of 9 above, gave 
1 0  (96%) as very pale yellow crystals: mp 150.5-151.5 °C dec. 
Alternatively, treatment of 3 with 2 equiv of aqueous HBr (5.9 
M), according to method B for the preparation of 9 above, except 
that the charcoal was omitted and the recrystallization solvent 
was aqueous acetone, gave 10 (74%) as pale yellow prisms: mp 
150-151 °C dec; IR (KBr) 3450 (br), 3345 (br), 3160, 3140, 3087, 
1590,1539,1507, and 1493 cm'1; NMR [250 MHz; (CE^jSO) 2.94 
[m (+D 20  becomes dd, J  = 12.6 Hz, J  = 9.8 Hz), 1 H) and 3.15 
[m (+D 20  becomes dd, J  = 12.6 Hz, J  = 2.7 Hz), 1 H] 
(CHC772+NH2), 3.46 [m (+D20  becomes t, J  = 6.5 Hz, 2  H, 
♦NH^tf^HzBr], 3.68 (t, J  = 6.5 Hz, 2 H, CHjBr), 4.21 [m, (+D20  
becomes dddd, J  = 9.8 Hz, J  = 8.0 Hz, J  = 3.9 Hz, J  = 2.7 Hz),
1 H, C7/OH], 4.31 (dd, J  = 13.4 Hz, J  = 8.0 Hz, 1 H) and 4.53 
(dd, J  = 13.4 Hz, J  = 3.9 Hz, 1 H) (imidazole-CH^, 5.95 (br d, 
J  = 5 Hz, 1 H, OH), 7.22 (s, 1 H) and 7.60 (s, 1 H) (imidazole 
4,5-H), and 8.72 (br, 2 H, NH2). Anal. (C8 H 14Br2 N40 3). From 
some preparations of 1 0  according to this method, a crystalline 
monohydrate (mp 161-162 °C) was obtained.
a-[[(2-Brom oethyl )am ino]m ethyl]-2-nitro-1 H-imidazole- 
1-ethanol Hydrobromide (10). Method C. In a modification 
of the general procedure of Furukawa et aL, 19 2 2 31 (2^0 g, 10 mmol) 
and dimethylbromosulfonium bromide19 (2 . 2 2  g, 1 0  mmol) were 
stirred at 50 °C for 1 2  h in dry DMF (20 mL) before the solvent 
was evaporated. The residue, in ethanol (10 mL), was chroma­
tographed (silica gel; CHC13, MeOH; 9:1). Treatment of the 
appropriate fraction of eluate with ethereal HBr gave 10 (680 mg, 
18%) as a yellow solid: mp 148.5-150.5 °C dec, identical (mixed 
melting point, IR, analysis) with the material described above.
a-[[ (2-Iodoethy I )am ino]methy 1 ]-2-nitro-1 H -im idazole-1 - 
ethanol Hydriodide (11). Treatment of 3 with 2 equiv of aqueous 
HI, according to method B for the preparation of 9 above, except 
that the recrystallization solvent was H20 , gave 1 1  (51%) as yellow 
crystals: mp 172-173 °C dec; IR (KBr) 3460 (br), 3310 (br), 3135, 
3106, 3092, 1539, 1509, and 1492 cm’1; NMR [(CD^jSO] b 3.12 
(m, 2 H, CHCtf2+NH2), 3.36 (s, 4 H), NCH2CH2I), 4.1-4.6 (m, 3 
H, imidazole-CH2CH), 5.8 (br, 1 H, OH), 7.16 (d, J  = 1 Hz, 1 H) 
and 7.59 (d, J  = 1 Hz, 1 H) (imidazole 4,5-H), and 8 . 6  (br, 2 H, 
+NH2). Anal. (C8H 14I2N 40 3) H, N; C: calcd, 20.53; found 21.02; 
I: calcd, 54.23; found 53.76.
a-[[(2-Fluoroethyl)am ino]m ethyl]-2-nitro-lH -im idazole- 
1-ethanol H ydrochloride (12). According to method B for the 
preparation of 9 above, 3 was treated with 2 equiv of aqueous HF 
(24 M; CAUTION). The reaction mixture was then stirred with 
ethanolic NaOH (5% w /w , 1.0 mol equiv) and decolorizing 
charcoal for 15 min. Treatment of the filtrate with a small excess 
of ethereal HCI gave 1 2  (41%) as a pale yellow solid: mp 177-179 
°C dec, identical with the material described below.
a-[[(2-Fluoroethyl)am ino]m ethyl]-2-nitro-lfl'-im idazole- 
1 -ethanol H ydrochloride (12). M ethod D. Oxirane 7 (4.0 g,
23.7 mmol), (2-fluoroethyl)ammonium chloride (5.0 g, 50.2 mmol), 
and NaOH (2.0 g, 50 mmol) were stirred at 15 °C for 30 min in 
ethanol (60 mL) and heated to reflux for 3 h. The mixture was 
then treated with decolorizing charcoal (500 mg) and filtered. The 
evaporation residue, in ethanol (20 mL), was treated with a small 
excess of ethereal HCI to furnish, after recrystallization from 
aqueous ethanol, 12 (4.38 g, 69%) as pale yellow crystals: mp 
178-179 °C dec; IR (KBr) 3450 (br), 3280 (br), 3140, 3090,1580, 
1531, and 1487 cm'1; NMR [250 MHz; (CD^jSO] b 2.92 (m, (+D20  
becomes dd, J  = 12.5 Hz, J  = 9.9 Hz), 1 H] and 3.13 [m (+ D 20  
becomes dd, J  = 12.5 Hz, J  =  2 Hz). 1 H] (CHCH2+NH2), 3.33 
[br d, J  = 27.9 Hz (+D20  becomes dt, J  = 27.9 Hz, J  = 6.5 Hz),
2  H, +NH 2CH2CH2F], 4.25 (m, 1 H. CtfOH), 4.39 (dd, J  = 13.6 
Hz, J  = 7.8 Hz, 1 H) and 4.58 (dd, J  = 13.4 Hz. J  = 4.0 Hz, 1 
H) (imidazole-CHz), 4.76 (dt, J  = 47.1 Hz, J  = 4.4 Hz, 2 H. CH2F),
6.04 (br, 1 H, OH), 7.20 (s, 1 H) and 7.66 (s. 1 H) (imidazole 4,5-H). 
and 9.14 (br, 1 H) and 9.28 (br 1 H) NH2. Anal. (C8 HUCIFN40 3) 
C, H, Cl. F, N.
or-[[(f/ire0 -2 -C h loro-l-m ethylpropyl)am ino]raethyI]-2 - 
nitro-1 -imidazole- 1 -ethanol Hydrochloride (13). Compound 
4 was treated with aqueous HCI generally according to method 
B for the preparation of 9 above, except that the charcoal was 
omitted and the recrystallization solvent was ethanol, to give 13 
(8 8 %) as a very pale yellow solid: mp 138.5-139 °C dec; NMR 
(300 MHz; (CD^jSO) b 1.30 (d. J  = 6 . 6  Hz. 1.5 H. NCHCH3  of 
one diastereoisomer). 1.31 (d. J  = 6.7 Hz. 1.5 H, NCHCH3 of other
/ m idazo lee th an o ls as Prodrugs
diastereoisomer), 1.52 (d, J  = 6.7 Hz, 3 H, CICHCtfj), 2.96 (m,
1 H) and 3.16 (m, 1 H) and 3.52 (m, 0.5 H) and 3.52 (m, 0.5 H) 
(CH2*NH 2CH), 4.27 (m, 1 H) and 4.39 (m, 1 H) and 4.57 (m, 3 
H) (imidazole-CH2CHOH and C1CH), 7.19 (br s, 1 H) and 7.65 
(br s, 1 H) (imidazole 4,5-H), and 8.70 (br, 0.5 H) and 8.84 (br, 
0.5 H) and 9.02 (br, 0.5 H) and 9.38 (br, 0.5 H) CNHj). Anal. 
(C10H l8Cl2N 4O3) C, H, Cl, N.
a - [ [ \ th re o  -2-B romo-1-methyl propyl )am ino]m ethyl ]-2- 
nitro-1 /7-im idazole-1 -ethanol Hydrobromide (14). Aziridine 
4 was treated with aqueous HBr generally according to method 
B for the preparation of 9 above, except that the charcoal was 
omitted, to give 14 (83%) as a pale yellow powder, mp 165-166 
°C dec; NMR [D20  +  CFjC02D (8 :1 )) b 1.50 (d, J  = 7 Hz, (be­
comes s on decoupling at b 3.65), 3 H, NCHC/f3], 1.85 (d, J  = 6  
Hz, (becomes s on decoupling at b 4.4), 3 H, BrCHC/fJ, 3.5 (m,
2 H, Ctfj-ND j), 3.65 (m, 1 H, NCHCH3), 4.3-4.8 (m. 4 H, imid- 
azole-CH2CH and BrCH), and 7.30 (br s, 1 H) and 7.55 (br s, 1 
H) (imidazole 4,5-H). Anal. (C10H l8Br2N«O3) C, H, N.
a-[[(2-Chloro-l,l-dim ethylethyl)am ino]m ethylJ-2-nitro- 
1 i f -imidazole- 1-ethanol H ydrochloride (15). ar-[(2,2-Di- 
methyl- 1  -aziridine)methyl)-2 -nitro- 1 H-imidazole- 1 -ethanol8-11 1 2
(5) was treated with aqueous HCI, generally according to method 
B for the preparation of 9  above, except that the reaction was 
carried out at 40 °C and the recrystallization solvent was aqueous 
acetone containing a trace of HCI, to yield 15 (78%) as colorless 
prisms: mp 196.5-198 °C dec; NMR [D20  +  CF3C 02D (8 :1 )] b 
1.60 (s, 6  H, 2  x  CHa), 3.35 (dd, J  = 13 Hz, J  = 2 Hz, 1 H) and 
3.42 (dd, J  = 13 Hz, J  = 4 Hz, 1 H) (CH ^ND^, 3.92 (s, 2 H, 
CH2C1), 4.4-5.0 (m, 3 H, imidazole-CH2CH), and 7.30 (br s, 1 H) 
and 7.53 (br s, 1  H) (imidazole 4,5-H). Anal. (C10H,8C12N<03) 
C, H, Cl, N.
a-[[(2-Brom o-1 , l-dim ethylethyl )am ino]m ethy 1 ]-2 -nitro- 
l-ff-imidazole-l-ethanol Hydrobromide (16). Aziridine 58 -11-12 
was treated with aqueous HBr generally according to method B 
for the preparation of 9 above, except that the reaction was carried 
out at 40 °C, to yield 16 (82%) as very pale yellow prisms: mp 
186-197 °C  dec; NMR [(CDjJjSO) b 1.42 (s, 6  H, 2  x  CH3), 3.1 
(m, 2 H, C tf2+NH2), 3.80 (s, 2 H, CH2Br), 4.1-4.6 (m, 3 H, im- 
idazole-CH2CH), 5.5 (br, 1  H, OH), 7.12 (d, J  = 1 Hz, 1 H) and 
7.53 (d, J  = 1  Hz, 1 H) (imidazole 4,5-H), and 8 . 6  (br, 2 H, ♦NH2). 
Anal. (C10H 18Br2N 4O3) C, H, N; B r  calcd, 39.75; found 39.23.
a-[[(2-Brom o-l,l-dim ethylethyl)am ino]m ethyl]-2-nitro- 
lff-im idazole-l-ethanol Hydrobromide (16). Method EL In 
a modification of the method of Ponpipom and Hanessian,20 19 
(2.58 g, 1 0  mmol), N-bromosuccinimide (NBS; 2.67 g, 15 mmol), 
and triphenylphosphine (333 g, 15 mmol) were stirred in dry DMF 
(50 mL) at 50 °C for 1.5 h. The solvent was evaporated and the 
residue was extracted with ethanol (20 mL). This solution was 
filtered. Column chromatography (silica gel; CHC13, MeOH; 9:1) 
and treatment of the appropriate fraction of eluate with a small 
excess of ethereal HBr gave 16 (1.09 g, 27%) as a yellow solid: 
mp 181-184 °C dec. AnaL ((^oHnjBr^Oa) C, H, N; Br: calcd 
39.75; found 38.91. TLC analysis indicated the presence of a very 
slight trace of triphenylphosphine oxide.
<*-[[(2-Chloro-l,2,2-trim ethylpropyI)am ino]m ethyl]-2- 
nitro-lff-im idazole-l-ethanol Hydrochloride (17). Aziridine 
6  was treated with aqueous HCI generally according to method 
B for the preparation of 9 above, except that the charcoal was 
omitted and the reaction was carried out at 2 0  °C, to give 17 (8 8 %) 
as colorless microcrystals: mp 183-184 °C dec; NMR [250 MHz; 
(CDaljSO) b 1.42 (s, 3 H) and 1.44 (s, 3 H) (NC(CH3)2). 1.73 (s,
3 H) and 1.74 (s, 3 H) [C(CH3 )2C1], 3.11 [m. (+D20  becomes dd. 
J  = 12.5 Hz, J  = 9.9 Hz), 1 H) and 3.33 [m, CDjO becomes brd. 
J  =  1 2  Hz), 1 H] (+NH 2CH2), 4.32 [m. (+D20  becomes ddd, J  = 
9.9 Hz, J  = 8 . 1  Hz, J  = 3.7 Hz), 1 H CHOH], 4.42 (dd, J  = 13.3 
Hz, J  = 8 . 1  Hz, 1 H) and 4.61 (dd, J  = 13.3 Hz, J  = 3.7 Hz, 1 
H) (imidazole-CH2), 6.25 (br, 1 H. OH). 7.21 (d, J  = 0.8 Hz, 1 H) 
and 7.66 (d, J  = 0.8 Hz, 1 H) (imidazole 4,5-H), and 7.97 (br 
quintet, J  =  7 Hz, 1 H) and 9.10 (br. 1 H) (+NH2). Anal. 
(C ^ H aC l^ O a) C, H, N.
a-[[(2-B rom o-l,2 ,2-trim ethylpropyl)am ino]m ethyl]-2- 
nitro-Iff-im idazole-1 -ethanol Hydrobromide (18). Aziridine 
6  (810 mg, 3 mmol), in acetone (10 mL), was treated with aqueous 
HBr ( 6  M; 1.2 mL, 7.2 mmol) at reflux for 10 min before being 
cooled. Recrystallization of the evaporation residue from aqueous 
acetone afforded 18 (950 mg, 73%) as pale yellow crystals: mp
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163-164 °C dec; NMR ((CD^jSO) b 1.45 (s, 6  H. 2  x CH3). 1.50 
(s, 6  H, 2  x CH3), 3.2 (m, 2 H, -NHjC/fj), 4.2-4.7 (m, 3 H, 
imidazole-CffjC/fOH), 5.2 (br, 1 H, OH), 7.15 (br s, 1 H) and 7.65 
(br s, 1 H) (imidazole 4,5-H), and 8 . 1  (br, 1 H) and 8.7 (br, 1 H) 
r N H 2). Anal. (C ^ H a B r^ O ^  C, H, Br, N.
a -[[(2 -H y d ro x y -l,l-d im e th y le th y l)a m in o ]m e th y l]-2 -  
nitro-1 //-im idazole-1 -ethanol (19). Oxirane 7 (4.0 g, 23.7 mmol) 
and 2 -amino-2 -methylpropanol ( 1 0 . 0  g, 1 1 2  mmol) were boiled 
under reflux in ethanol (100 mL) for 45 min. The solvent was 
evaporated and the residue was extracted with hot ether (75 mL). 
The extract was cooled to 0  °C and the precipitated solid was 
recrystallized from ethanol to furnish 19 (4.94 g, 81%) as almost 
colorless prisms: mp 114.5-115.5 °C; NMR [D20  + CF3C 02D 
(8:1)] b 1.55 (s, 6  H, 2  x  CH3), 3.2 (dd, J  = 13 Hz. J  = 2 Hz, 1 
H) and 3.55 (dd, J  = 13 Hz, J  = 4 Hz, 1 H) r N D 2C /f2), 3.85 (s,
2 H, CH20 ), 4.3-5.0 (m, 3 H, imidazole-Ctf2Ctf), and 7.40 (d, J  
= 1 Hz, 1 H) and 7.65 (d, J  = 1 Hz, 1 H), (imidazole 4,5-H). Anal.
(C10H 18N<0<) C, H, N.
a-[(Ethylam ino)m ethyl]-2-nitro-117-im idazole-1 -ethanol 
H ydrochloride (2 1 ). Oxirane 7 (507 mg, 3 mmol) was boiled 
under reflux with 70% aqueous EtNH2 (2 mL) in ethanol ( 8  mL) 
for 1 h. The solvents and excess reagent were evaporated. Dry 
ethanol (20 mL) was added and was subsequently evaporated. 
The residue, in dry ethanol (4 mL), was treated with ethereal HCI 
( 1  M, 4.5 mL, 4.5 mmol). The precipitate recrystallized from 
ethanol to furnish 21 (650 mg, 87%) as pale yellow crystals: mp 
196-197 °C; ER (Nujol) 3300 (br), 1540,1505, and 1495 cm '1; NMR 
((CD^^O) b 1.20 [t, J  = 7 Hz (becomes s on decoupling at b 3.00),
3 H, CH3], 3 .7-3 . 1  (m, 4 H, Ctf2+NH2CH2), 4.2-4.6 (m, 3 H, 
imidazole-CH2Cfl), 5.9 (br, 1 H, OH), 7.10 (d, J  = 1 Hz, 1 H) and 
7.58 (d, J  -  1 Hz, 1 H) (imidazole 4,5-H), and 8 . 8  (br, 2 H, +NH2). 
Anal. (C8H 15C1N40 3) C, H, Cl, N.
HPLC A nalysis for Stab ility  of Drugs. The stability of 
compounds 9-11 and 13-18 was determined at 4 °C and at 23 
°C by incubation of the agents (0.2-0.5 mM) in aqueous solution 
containing phosphate-buffered saline (PBS, Oxoid) and in the 
presence or absence of sodium hydrogen carbonate (24-107 mM) 
at pH 5-8. In all cases, the pH of the solutions was adjusted 
immediately following their preparation. At given times, aliquots 
were assayed for degradation of the compounds with HPLC. A 
Waters HPLC system with a UV-vis detector set at 313 nm 
(Model 440) was used to perform isocratic elutions with a CN 
column (Waters Resolve CN, 10 pm or a Nova-Pak CNHP, 4 pm). 
The mobile phase (flow rate 2  mL min'1) contained 10-25% 
methanol in aqueous KH2P 0 4 (10 mM) at pH 3.0 (see Table I). 
The rate of release of Br' from 10 in PBS solution was determined 
with a bromide ion selective electrode (Radiometer Fl022Br) in 
conjunction with a pH meter (Radiometer PHM64).
B iological S tu d ies. In Vitro. Chinese hamster V79-379A 
cells, maintained in suspension culture, were plated onto 6  cm 
diameter glass Petri dishes in MEM (modified essential medium) 
containing 1 0 % fetal calf serum and allowed to attach for 2  h. 
For radiosensitization studies, the medium was then replaced with 
2  mL of a freshly prepared solution of the agent in PBS at pH 
7.4, and the Petri dishes were placed into gas-tight dural vessels. 
Hypoxia was induced by purging the vessels with N2 (<10 ppm 
0 2) for 1 h prior to irradiation at 22 °C with ®Co 7 -rays at a dose 
rate of 8  Gy m in'1. The solution of drug was removed after 
irradiation and replaced with fresh medium. The cells were 
incubated at 37 °C for 7 days before assaying for formation of 
colonies. Sensitizer enhancement ratios were determined from 
the ratio of slopes of survival curves for hypoxic conditions in the 
presence and absence of the agent. For cytotoxicity assays, cells 
were plated into 100-mL glass bottles (1.5 x  1 0 6 cells/bottle), 
allowed to grow to confluency over 48 h and exposed to various 
concentrations of the agents for 3 h in growth medium under either 
hypoxic or aerobic conditions at 37 °C. Cultures were then 
trypsinized, diluted, and plated to assay formation of colonies.
B iological S tu d ies. Id Vivo. C3H/He mice were bred at 
the Radiobiology Unit to provide U.K. specified pathogen free, 
category IV, 8-12 week old female mice for experiments. The 
KHT sarcoma33 was provided by Dr. P. Twentyman, MRC
(33) Kallm an. R. F.: S ilin i. G.; van Putten . L. M. J. N a t l .  Cancer  
Inst .  1967. 39. 539
2 6 1 0
Cambridge, U.K., in 1983 and maintained by intramuscular in­
oculation of a tumor brei for up to 1 2  consecutive passages and 
then reestablished from frozen stocks. For experimentation, 2-4 
x 1 0 s viable tumor cells were injected subcutaneously in the 
middorsal pelvic region of the mice. Treatments were initiated 
10-14 days later when tumors reached a maximum diameter of 
6 ~ 8  mm.
Prior to injection, compounds were usually dissolved at 20 °C 
in PBS at pH 7.0 by means of sonication for up to 5 min. Com­
pounds 9 and 1 0  were dissolved in phosphate buffer at pH 5 to 
minimize cyclization to 3. All solutions were administered within 
1 0  min of preparation. Solutions were administered by the in- 
traperitoneal route in a volume of 0.5 mL per 25 g of mouse body 
weight, with the exception of 14,16, and 18, which were admin­
istered in a volume of 1 mL per 25 g owing to their dose-limiting 
solubility. Escalating doses o f each of the test compounds were 
administered to groups of two or three tumor-bearing mice to 
establish the maximum tolerated dose (MTD). The MTD is 
defined as the highest single dose which does not produce severe 
or persistent clinical signs or death of the animals within 24 h.
The responses of KHT sarcomas to therapy administered in 
vivo were measured by means of a soft agar clonogenic assay in 
vitro ,34 as described recently . 35 Tumors were excised 18-24 h 
after treatment and each was assayed individually. Surviving 
fractions were calculated as thp ratios of the numbers of colonies 
scored to the number of viable cells plated, relative to the plating 
efficiency of a control tumor processed at the same time. The 
mean plating efficiency of cells from 6 6  untreated tumors was 49.5
(34) Thomson, S. E.; Rauth, A. M. Radiat. Res. 1974, 58, 262.
(35) Stratford, I. J.; Adams, G. E.; Godden, J.; Nolan, J.; Howells,
N. Br. J. Cancer 1988, 58, 122.
±  1 .8 % (mean ±  SE) and the yield of cells ranged between 8.9 
X 10® and 7.6 X 107 cells g*1 of tumor tissue. A Pantac X-ray set 
was used to produce 250 kV X-rays (15 mA) at a dose rate of 3.8 
Gy min- 1  with a half-value layer (HVL) equivalent to 1.33 mm 
Cu. Radiation doses were monitored with an air chamber cor­
rected for ambient temperature and pressure. Unanesthetized 
mice were restrained in polyvinyl jigs with Pb shielding and a 
cutaway section to allow local irradiation of tumor by the unilateral 
beam. 36 A dose of 10 Gy of X-rays was used to test the efficiency 
of each compound as a hypoxic cell radiosensitizer. Each ex­
periment included mice exposed to a 1 0  Gy dose of X-rays without 
drug and mice treated with drug without radiation. There is a 
minimum of three tumors in each group; most points were de­
termined from the geometric mean of surviving fractions from 
at least four to six tumors from two separate experiments. Ini­
tially, the optimum time of administration before irradiation for 
m ax im u m  radiosensitization was determined for each of the 
compounds by administering the MTD. Subsequently a range 
of single doses of the compounds were administered at the op­
timum time (45-60 min in each case) before exposure to X-rays 
to obtain a drug dose/response curve for radiosensitization. Where 
appropriate, direct comparisons of radiosensitization by equimolar 
doses of chemically related compounds were made in a single 
experiment.
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SELECTIVE REDUCTIONS OF l-(CARBONYL)SUBSTITUTED 2-NITRO­
IMIDAZOLES WITH ALKALI METAL BOROHYDRIDES AND WITH 
BORANE.TETRAHYDROFURAN
Michael D. ThreadgilT and Paul Webb
Medical Research Council Radiobiology Unit,
Chilton, Didcot, Oxfordshire 0X11 ORD
Abstract: Sodium borohydride, lithium borohydride and borane.THF reduce carbonyl groups 
(esters, amide) in 1 -substituted 2 -nitroimidazoles in high yield without reduction of the 
nitroheterocycle.
1-Substituted 2-nitroimidazoles sensitise1-4 hypoxic cells to killing by ionising radiation by 
acting as electron-affinic mimics of dioxygen and are reduced readily by biological systems5  to 
substances which can be selectively retained and be cytotoxic towards cells deficient in 
dioxygen6. During our programme of synthesis of substituted 2-nitroimidazoles, selective 
reductions of various types of carbonyl group have been required while retaining the 
nitroheterocycle (E! 7  = ca. -380 mV)7. We have already demonstrated reductions of ketones and 
aldehydes attached to nitroimidazoles by sodium borohydride under very mild conditions8*9; the 
reductions addressed here are of esters to the corresponding alcohols and of a primary amide to a 
primary amine.
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Reagents: (i) 1-BOCpiperazine/Dicyclohexylcarbodiimide/THF; (ii) CF3C02H; (iii) Glutamic 
acid a-methyl ester 7-(4-nitrophenyl) ester C5)/diisopropylethylamine/THF; (iv) LiBH^/THF.
of substituted 2 -nitroimidazoles with different physico-chemical and pharmacokinetic parameters 
for therapeutic and diagnostic applications, particularly facilitating isotopic labelling.
FYPFR TMF.NT AL
IR, NMR and mass spectra were obtained using Philips PU9516, Jeol PMX60SI and VG7070 
spectrometers, respectively. Melting points are uncorrected. Tetrahydrofuran (THF) was distilled 
from CaH2  before use. Radial PLC refers to centrifugally accelerated preparative layer 
chromatography performed using a Chiomatotron (TC Research). Solvents were evaporated 
under reduced pressure.
2 -Nitroimidazole-l-ethanoI (20-- Methyl 2-nitroimidazole-l-acetate14 (1) (580 mg, 3.14 mmol) 
was stirred with NaBH4  (630 mg, 16.6 mmol) in EtOH (20 mL) for 1.5 h. Aqueous HCI (9 M, 
2 mL) was added carefully. The suspension was filtered and the solvents were evaporated from 
the combined filtrate and MeOH washings. Column chromatography (silica gel, CHCl3 :MeOH, 
9:1) afforded (2) (440 mg, 89%) as an off-white solid: mp 113.5-115°C (lit. 19 mp 116°Q. 5 
(CDC13  + CD3OD, 2:1) 3.95 (2 H, t, J 5 Hz, CH2 OD), 4.65 (2 H, t, /  5 Hz, imidazole-CHj), 
7.15 (s, 1 H, imidazole 4-H), 7.45 (s, 1 H, imidazole 5-H).
l-(/-Butoxycarbonyl)-4-(2-nitroimidazol-l-ylacetyl)piperazine (4).- 2-Nitroimidazole-l-acetic 
acid Q ) 3  (513 mg, 3 mmol) was stirred with dicyclohexylcarbodiimide (700 mg, 3.4 mmol) and 
l-(t-butoxycarbonyl)piperazinen (558 mg, 3 mmol) in THF (13 mL) for 24 h. The suspension 
was filtered and the solvents were evaporated from the combined filtrate and Et20  washings. 
Radial PLC (silica gel, CHjCl^ gave (4) (848 mg, 83%) as a glass: 5  (CDCI3) 1.45 (9 H, s, BuO, 
3.55 ( 8  H, s, piperazine-H), 5.30 (2 H, s, imidazole-CH^; 7.10 (2 H, s, imidazole 4,5-H); rrdz 
(El) 339.1533 (A/+) (C14H2 1N5 0 5  requires 339.1543).
l-(S-4-(f-Butoxycarbonylamino)-5-methoxy-5-oxopentanoyl)-4-(2-nitroimidazol-l-ylace- 
tyl)piperazlne (6 ).- Protected piperazine (4) (848 mg, 2.5 mmol) was stirred with trifluoroacetic
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M olecular formula: C4H9NO
M olecular weight: 87.12
Properties:
boiling point: 166 .1°C
melting point: -2 0 °C
flash point: 70°C (158°F)
vapor pressure: 0 .27 kPa (2 mmHg) at 25°C
vapor density (air = 1.00): 2.97
specific gravity (liquid density): 0.9366 (25°C/4°C)
refractive index: 1.4375 at 20°C (sodium D line)
conversion factors (at 25°C): 1 p.p.m. = 3.563 mg/m3
1 mg/m 3 = 0.2806 p.p.m. 
solubility: miscible with ethanol, ether, acetone, water, chloroform, benzene, 
methanol
E ihd  Browning’s Toxicity and M etabolism  of Industrial Solvents. 2nd edition. 
Vol. 2: Nitrogen and Phosphorus Solvents. D.R. Buhlcr and  D .J. Reed, editors
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ECONOMY, SOURCES AND USES 
PRODUCTION
Dimethylacetamide has been produced by the reaction of acetic acid with dime- 
thylamine (Siegle, 1980).
INDUSTRIAL USES
Dimethylacetamide is a powerful industrial solvent, the uses of which are very 
similar to those of dimethylformamide (Siegle, 1980). Its strong solvent action 
renders it particularly useful in the manufacture of films and fibers and as a solvent 
for polyacrylonitrile, polyvinyl chloride, polyamides, cellulose derivatives and 
polystyrenes and in coatings and adhesive formulations. Dimethylacetamide dis­
solves many inorganic salts.
BIOCHEMISTRY
ESTIMATION
Gas chromatography seems to be the method of choice for the analytical determi­
nation of dimethylacetamide.
METABOLISM
Gas chromatographic analysis of the urine of rats which had received dimethyl­
acetamide by the subcutaneous route indicated the presence of N-methyl-acet- 
amide and acetamide (Bames and Ranta, 1972). Both metabolites were also found 
by the same authors in incubation mixtures of dimethylacetamide with rat liver 
homogenate. N -Methylacetamide was detected in the urine of human volunteers 
who had inhaled dimethylacetamide or absorbed dimethylacetamide vapor through 
the skin (Maxfield et al 1975). Measurement of the amount of the metabolite 
/V-methylacetamide excreted by individuals exposed to dimethylacetamide vapors 
with or without face masks which allowed the inhalation of air free of dimethyl­
acetamide indicated that more dimethylacetamide was absorbed through the lungs 
than through the skin. Interestingly, in this study, only 2-10% of the amount of 
dimethylacetamide inhaled was recovered in the urine in the form of N-methyl- 
acetamide. It has been suggested that the major urinary metabolite of the 
analogous dimethylformamide is N-(hydroxymethyl)-N-methylformamide and not 
N-methylformamide, since the carbinolamide decomposes on the gas chroma-
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tography column (to A/-methylformamide) but is relatively stable in aqueous 
solution (Kestell et al 1986). In analogy, it would be logical to assume that the 
N-methylacetamide found in the urine after exposure to dimethylacetamide really 
arose from chemical breakdown of /V-(hydroxymethyl)-N-methylacetamide during 
the analytical process. This contention, however, remains to be proven.
TOXICOLOGY
Dimethylacetamide is an agent of only moderate toxic potential. Its major target 
organ of toxicity appears to be the liver. Dimethylacetamide is also embryotoxic.
ANIMAL TOXICITY
Acute
Lethal dose. The LD50 of a single dose of dimethylacetamide ranged between 2 
and 5 g/kg in rats and mice, depending on the route of administration (Bartsch et al 
1976; Caujolle et al 1970; Davis and Jenner, 1959; Ochia, 1980; Smyth et al 1962; 
Thiersch, 1962; Wiles and Narcisse, 1971). The oral LD50 in male and female rats 
was found to be similar, at 5.8 and 4.9 g/kg respectively (Kennedy and Sherman, 
1986). The 1 hour LCjq by inhalation in this species was 2475 p.p.m. (Kennedy 
and Sherman, 1986).
Chronic
Repeated administration of 0.5 g/kg orally to rats daily for 1 month did not cause 
pathological lesions detectable by microscopy (Auclair and Hameau, 1964). At 1.9 
g/kg applied dermally to rats daily on 10 consecutive days, death occurred 
between the sixth and tenth dose (Stula and Kraus, 1977); in this study, severe 
inflammation and irritation of the stomach and the lungs was recorded. Cutaneous 
application of dimethylacetamide at 4 g/kg/day for 5 days/week for 6 weeks killed 
dogs after they had experienced weakness, ataxia, diarrhea, loss of weight and 
jaundice (Horn, 1961). Hepatic damage was indicated by increases in the bromo- 
sulphothalein retention time and the activity of serum alkaline phosphatase and 
was confirmed by histopathology. In contrast, the dogs survived this treatment for 
6 months when the dose was only 1 g/kg and toxicity was not observed except for 
pale coloration and fatty degeneration in the livers. The central nervous system of 
rabbits which received 0.25 to 2 g/kg given by different routes for 21 days or 
longer was affected as evidenced by variable electroencephalographic changes, 
dysrhythmias and electrographic seizures at the higher doses (Steiner and
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Himwich 1964). In this species, dimethylacetamide caused mild irritation when 
applied undiluted to the belly (Smyth et al 1962).
Hepatotoxicity
One month after intraperitoneal administration of a near lethal dose of dimethyl­
acetamide to mice, damage to hepatocytes was observed together with necrotic 
pancreatitis and severe necrosis of splenic lymphocytes (Caujolle et al 1970). In 
this study, testicular atrophy was also seen four days post treatment. Post mortem 
examination of rats which had received the LD50 of dimethylacetamide via the oral 
route revealed generalized hemorrhage in several organs and necrosis in the liver 
and kidneys (Kafyan 1971). Dermal doses of 2 g/kg caused death of rabbits from 
acute hepatic necrosis (Kennedy and Sherman 1986).
Reproductive toxicity
Dimethylacetamide was embryotoxic in rats when a single dose of 2 g/kg was 
administered via the intraperitoneal route on days 4 and 14 of gestation. This dose 
produced the resorption of all litters (Thiersch 1962). Daily oral administration of 
dimethylacetamide (0.4 g/kg) to rats from day 6 to day 19 of gestation caused fetal 
malformations accompanied by toxicity to the maternal organism (Johanssen et al 
1985). Reproduction in rats was not influenced by repeated exposure to dimethyl­
acetamide vapors up to 300 p.p.m. (Ferenz and Kennedy 1986). In rabbits, daily 
oral doses of 0.09 g/kg from day 6 to 19 of gestation had no adverse effect; at 0.29 
g/kg fetal resorption was observed, together with weight loss in the mothers. 
Repeated administration of 0.47 g/kg was very toxic to the mothers and caused 
total resorption in the surviving animals (Merkle and Zeller, 1980).
HUMAN TOXICITY
A study of 41 workers who had been exposed to dimethylacetamide from 2 to 10 
years revealed the occurrence of disorders reflecting liver damage (Corsi, 1971). 
Retention of bromosulfophthalein was increased in 9 of 10 workers who had been 
exposed to dimethylacetamide for 7 to 10 years, and in 10 of 20 workers who had 
been exposed to dimethylacetamide for 2 to 7 years. Other parameters of hepatic 
function which were altered in the exposed individuals include proteinemia, 
cholesterolemia, activities of hepatic transaminases and alkaline phosphatase in 
serum, and bilirubinemia. Hepatomegaly was diagnosed in 14 workers.
In a clinical trial, dimethylacetamide was administered to patients with ad­
vanced malignancies and caused abnormal mental states (Weiss et al 1962a, b). 
This effect was observed at a dose of 400 mg/kg given daily for 3 or more days.
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The symptoms were not seen at 300 mg/kg or lower. The second or third dose 
caused depression, lethargy, Occasional confusion or disorientation. The fourth or 
fifth dose produced striking hallucinations, perceptual distortions and delusions in 
all nine patients. All patients reverted to normal several days after discontinuation 
of treatment with dimethylacetamide.
GENETIC TOXICITY
Dimethylacetamide was not mutagenic in a number of tests in vitro (Kennedy 
1986; McGregor 1980). Nor was there an increase in the incidence of tumors when 
dimethylacetamide was given orally to rats at either 0.1, 3, 10 or 30 mg/kg 
(Hadidian et al 1968).
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M olecular formula: C3H7NO
M olecular weight: 73.10
Properties:
boiling point: 1204-206°C  
melting point: 28°C 
flash point: 108°C
vapor pressure: 12.3 Pa (0.92 mmHg) at 25°C  
vapor density: (air = 1.00): 2.49 
specific gravity  (liquid density): 0.9571 at 25°C/4°C  
refractive index: 1.4301 at 20°C (sodium D line) 
conversion factors  (at 25°C): 1 p.p.m. = 0.3345 mg/m 3
1 m g/m 3 = 2 .990 p.p.m  
solubility: miscible with ethanol, ether, acetone, water, chloroform, benzene
Ethel Browning's Toxicity and M etabolism o f  Industrial Solvents. 2nd edition. 
Vol. 2: Nitrogen and Phosphorus Solvents. D .R . Buhier and  D .J . Reed, editors
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ECONOMY, SOURCES AND USES 
PRODUCTION
N-Methylacetamide has been prepared by reaction of methylamine with hot acetic 
acid (D’Alelio and Reid, 1937) and with acetic anhydride (Mauger and Soper, 
1946). Other methods include heating N.AT-dimethylurea with acetic acid (US 
Patent, 1936) and reduction/hydrogenation of A/-(hydroxymethyl)acetamide (US 
Patent, L944).
INDUSTRIAL USES
Even though N-methylacetamide shares many general physical and chemical 
properties with dimethylacetamide, it has not found the extensive industrial 
applications of the latter. N-methylacetamide dissolves many inorganic salts.
BIOCHEMISTRY
ESTIMATION
The method of choice for the detection and estimation of N-methylacetamide 
appears to be gas chromatography (Barnes and Henry, 1974).
METABOLISM
In a recent comparative toxicity and metabolism study on four formamides and on 
N-methylacetamide, the sole metabolite of N-methylacetamide in the urine of 
mice was identified as N-(hydroxymethyl)acetamide (Kestell et al 1987). There 
was no evidence of induction of hepatic drug metabolizing enzymes in rats 
following treatment with N-methylacetamide (Ackerman and Leibman, 1977). 
N-Mcthylacetamide influenced neither the sleeping time induced by hexobarbital 
nor the metabolism of hexobarbital or aniline.
TOXICOLOGY





Lethal dose. The LDjq values for N-methylacetamide are between 5 and 7 g/kg in 
the rat after intraperitoneal, subcutaneous or oral administration (Caujolle et al 
1970; Peters et al 1966; Thiersch, 1962) and 6.1 g/kg after intraperitoneal 
administration in the mouse (Caujolle et al 1970).
Diabetogenicity and other toxicities
Repeated oral dose of 0.8 g/kg per day for an unspecified period caused weight 
loss in rats and an increase in fasted blood sugar concentrations whereas glucose 
tolerance was decreased (Peters et al 1966). There was also evidence of pathologi­
cal change in pancreatic tissue. A single subcutaneous dose of 10 g/kg impaired 
metabolism of carbohydrates in rats which led to an increased elimination of 
glucose (Sitt et al 1966). The same workers observed an increase in the secretion 
of glucorticoids and epinephrine and a decrease in inactivation of glucocorticoids, 
an increase in glomerular filtration rate and an enhanced secretion of insulin 
following intravenous administration of N-methylacetamide. Furthermore, the 
efficacy of endogenous or exogenous insulin was reduced. N-Methylacetamide is 
diabetogenic in the rat (Guidoux and Peters, 1965; Guidoux, 1969). An oral dose 
of 3.5 g/kg was diabetogenic in all animals, lower doses causing reversible 
hyperglycemia which lasted for several days. At 0.8 g/kg or less administered 
orally, N-methylacetamide showed no toxicity or diabetogenicity.
Reproductive toxicity
The embryOtoxicity of N-methylacetamide was shown in rats after intraperitoneal 
administration of a single dose of or exceeding 1 g/kg which caused resorption of all 
fetuses (Thiersch, 1962). Repeated dermal application of N-methylacetamide (0.6 
g/kg) to rabbits on days 9-11 or J :1 and 12 or 12 and 13 of gestation produced only a 
slight increase in the fetal resorption (Stula and Kraus, 1977). The repeated daily 
oral administration of 0.24 g/kg on gestation days 6 through 18 produced fetal 
malformations as well as maternal toxicity in this species (Merkle and Zeller, 1980). 
When 0.05 g/kg was administered in this study, five malformed kits were observed 
from three litters without maternal toxicity; 0.01 g/kg was without adverse effects.
GENETIC TOXICITY
N-Methylacetamide caused a small but consistent increase in the number of
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revertants in a bacterial mutagenicity test using E. coli at 10, 20 or 50 mg/plate 
(Hemmerly and Demerec, 1955).
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6 The chemistry of azolotetrazinones
M. D. THREADGILL
6.1 Introduction
In I97S, it was believed1-2 that the 1,2,3,5-tetrazine ring was inherently 
unstable, despite claims3 of the preparation of this system. Indeed, there is only 
one confident report4 of a [2,5-dihydro]-1,2,3,5-tetrazine without fusion to an 
azole. In 1979, Ege5 published the first report of pyrazolo[5,1 -d]-1,2,3,5- 
tetrazin-4(3H)-ones. There followed comprehensive reports6' 8 by the Aston 
group of the synthesis and antitumour activity of 3-alkyl and 3-aryl-S- 
substitutedimidazo[5,l-d]-1,2,3,5-tetrazin-4{3f/)-ones and an indazolotetra- 
zinone. 6-Alkylimidazotetrazinones and pyrazolotetrazinones have also been 
prepared by this group9. A group from the University of Kansas and from 
Warner Lam bert/Parke-Davis have described10 a further two pyrazolo[5,l- 
d]-l ,2,3,5-tetrazin-4(3//)-ones closely analogous to the active lead compounds 
of Stevens e i a l?  The Heidelberg group followed up their first report of the ring 
system with an extensive study11 of the synthesis of some forty pyrazolo[5,l- 
d ] - 1 ^ 3,5-tetrazin-4(3/f)-ones, together with some 3-aryltriazolotetrazinoncs, 
by three distinct routes. Pyrrolo- and tetrazolo-tetrazinones remain unknown. 
The ring structures and numbering system (according to the IUPAC 
convention) of the two series of azolotetrazinones (1, 2) are shown in 
Figure 6.1.
Extensive studies have been carried out on the antitumour and other 
biological activities of the imidazotetrazinones. 8-Carbamoyl-3-(2-chloro- 
ethyl)imidazo-[5,ld]-l,2,3,5-tetrazin-4(3/f)-one (3, mitozolomide, CCRG 
81010, M & B 39565, NSC 353451) was the first azolotetrazinone to show good 
antitumour activity1213 in a murine screen, although results against cultures 
of human cancer cells have been mixed14. It has been the subject of Phase 113 
and Phase 2 clinical trials and, despite displaying some activity, the further use 
of Mitozolomide may be limited by severe delayed toxicity16. It shows curative 
activity17 towards the L1210 and P388 murine leukaemias and is highly 
potent against the TLX5 lymphoma, B16 melanoma, M5076 sarcoma, 
ADJ/PC6A plasmacytoma and the Colon 26 and Colon 38 tumours. 
Subsequent structure-activity studies8'9 have shown a requirement for a 3- 
(2-chloroethyl) group for curative activity in murine tumour screeens. A 3- 
methyl group, as in temozolomide (4, CCRG 81045), confers less but definite 
activity, including the differentiation of K562 cells to a less malignant 
phenotype18. Other 3-substituents lead to the abolition of antitumour activity








3: R = CHjCHjCl 
4: R = CH j
F ig u re  6.1 Numbering schemes of imidazotetrazinones and pyrazolotetrazmones Structures of 
mitozolomide (3) and temozolomide (4).
in vivo. A small alkyl group is tolerated at the 6-position, whereas there is a 
requirement for the 8-substituent to be electron-withdrawing (carbonyl or 
sulphonyl) and. preferably, to bear a hydrogen-bonding N-H  moiety. In the 
pyrazolo series, only 3-(2-chloroethyl)pyrazolotetrazinone-8-carboxamide 
inhibited the growth of the P388, L1210 and M5076 tumours10.
6.2 Synthesis
Most published syntheses of pyrazolo[5,l-J]-l,2,3,5-tetrazin-4(3tf )-ones5 9 
and ail ofimidazo[5,l-<f]-l,2,3,5-tetrazin-4(3/f)-ones6 7 9 have involved treat­
ment of the corresponding diazoazole (5, Scheme 6.1) with an alkyl or aryl 
isocyanate (6) at ambient temperature in a non-hydroxylic organic solvent, 
often for prolonged reaction times9. Systems with two liquid phases can be 
used for the more water-soluble diazopyrazoles and diazotriazoles11. Higher 
temperatures result in degradation of the diazoazole, particularly in the case of 
5-diazoimidazole-4-carboxamide (7) which gives 2-azahypoxanthine (8) 
(Scheme 6.2). The cycloaddition of 5-diazoimidazole-4-carboxamide proceeds
R N C O
RT/non-hydroxy1ic  
so lv e n t
- - N
5 1.2
Scheme 6.1 Synthesis of azolotetrazinones from diazoazolcs and isocyanates.
THE CHEMISTRY OF AZOLOTETRAZINONES 189
N ^ N
 * M
0  =  C N© 0  =  C .N
\  -O fJ/ N '/-  N— N
H
, I
- n  4
a>
7 «X
Scheme 6.2 Side reactions of 4-diazoimidazoleo-carboxamidc
smoothly in heterogeneous reactions with a wide range of isocyanates but fails 
with cyclohexyl isocyanate and with reri-butvl isocyanate19, presumably 
owing to steric interactions. The corresponding bis(pyrazolotetrazinones) are 
formed if a, cu-di isocyanates are used11. Radiolabelled isotopomers of some 
imidazotetrazinones have been prepared with **C in the 3-substituent20 or at 
C-421. Synthesis of 3-unsubstiluted azolotetrazinones (I, 2: R = H) by direct 
or indirect routes remains to be achieved. Treatment of 5-diazoimidazole-4- 
carboxamide with other heterocumulenes fisothiocyanates and car- 
bodiimides) also failed19 to furnish bicycles.
1,3-Dipolar cycloadditions have been studied extensively as routes to 
heterocycles22-25. The mechanism of the cycloaddition between diazoazoles 
and isocyanates to form azolotetrazinones has yet to be determined satis­
factorily. Both concerted and stepwise pathways are conceivable. The fully 
concerted [4 +  2] route11, shown as A in Scheme 6.3A, is unlikely owing to 
the considerable increase in reaction rate in the presence of hexamethyl- 
phosphoric triamide26. Gilchrist and Storr2 have also generally discounted 
concerted mechanisms where heterocumulenes are involved as dipolarophiles. 
In the stepwise ionic pathway (Scheme 6.3B). there is an initial nucleophilic 
attack at the isocyanate carbon, followed by ring closure. More attractive is 
mechanism C in which an initial [3 + 2] concerted cycloaddition is followed 
by a [1,5] sigmatropic rearrangement, this compares closely with the 
mechanism28 of the reaction between diazopyrazole (9) and 1,1 -dimethoxyeth- 
ene (10) to give the pyrazolo-L2,4-triazine (II) (Scheme 6.3D).
Stepwise synthetic assembly of the tetrazinone ring in two distinct senses 
has been reported11 for the pyrazolotetrazinones. In the first, involving 
insertion of N-2 (Scheme 6.4A), diazotisation/ring closure of carbamoylpv- 
razole (12) is effected by a nitrosating agent to give the pyrazolotctrazinone 
(13). Insertion of the carbonyl group by phosgene or its equivalent is also 
possible11, converting the pyrazolyltriazene (14) to the bicycle (13) (Scheme 
6.4B).
The infrared spectra5 7'9 1 1 of the azolotetrazinones show that the tetra­
zinone carbonyl is in a relatively electron deficient environment (t,miI 1725— 
1790cm"1). The electronic absorption maximum of the 8-carba- 
moylimidazo[5,l-d]-l,2,3,5-tetrazin-4(3H)-ones occurs in the ultraviolet 
region between 325 nm and 338 nm and is largely independent of the nature of
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Scheme 6 3  Proposed mechanisms for the reaction of diazoimidazolcs with isocyanates. (A) 
Concerted mechanism: (B) stepwise ionic mechanism; (C) stepwise 1.3-dipolar cycloaddition 
followed by 1,5 shift.
the 3-substituent (aryl or alkyl). The corresponding 8-carbamoylpyrazolote- 
trazinones absorb10 at shorter wavelengths (310-314 nm). In the NM R  
spectra of the 6-unsubstituted imidazotetrazinones, the principal character­
istic signal arises from the 6-proton which resonates7 919 29 between <5 8.60 
and <5 9.05 ppm. The 3-CH3 protons of temozolomide (4) give rise to a sharp 
singlet at <5 3.90; this strong deshielding again reflects the electron-deficient 
and electrophilic nature of the l,2,3,5-tetrazin-4-one ring. In the mass spectra,
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Scheme 6.4 AUcrnative synthetic approaches to p> razolotcirazinoncs.
the factor determining the fragmentation pathway is the nature of the 3- 
substituent. 3-Arylimidazotetrazinones do not give a molecular ion19 but only 
ions corresponding to the products of retrocyclisation. In contrast, the 3-alkyl 
imidazotetrazinones and pyrazolotetrazinones show abundant molecular 
ions10-19. Interestingly, a major ion (often the base peak) in the mass spectra of 
3-{2-chloroethyl)azolotetrazinones is the 3-methyleneiminium ion10'21*30. X- 
ray crystal structure determinations have been reported for mitozolomide 
(3)30, for the analogous 3-{2-methoxyethyl) compound31 and for tem- 
ozolomide (4)31. The two rings of each compound lie effectively in one plane 
which also contains the atoms of the carboxamide moiety.
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6.3 R eaction s involving opening o f  the tctrazinone ring
Comprehensive studies have been carried out on the reactivity of the 
imidazotetrazinones. However, study of the chemistry of the pyrazolotetrazi- 
nones has been limited. Pyrazolotetrazinonesare generally1019 stable to light; 
whereas the imidazo compounds are moderately photolabile19, giving rise to 
red pigments, presumably azoimidazoles. Thermolysis of azolotetrazinones 
leads to retrocyclisation7.
Treatment of azolotetrazinones with nucleophiles results in opening of the 
tetrazinone ring, whereas acidic or electrophilic reagents usually permit this 
structure to be retained. Stone19 determined the half-lives of 8-carbamoylim- 
idazotetrazinones in aqueous phosphate buffer (pH 7.4) in the dark and found 
them to be in the range 2.9 min to 155 min. These data compare well with the 
rates of hydrolysis of mitozolomide in plasma32 and with the observed great 
sensitivity to pH of the rate of hydrolysis of mitozolomide33 (f!/2 =  2.1 h at pH 
7.0 and 0.9 h at pH 7.5). Baig and Stevens34 reported that mitozolomide (3) and 
temozolomide (4) both decomposed rapidly in boiling water to give 5- 
aminoimidazole-4-carboxamide (15, Scheme 6.5) as the major product, 
together with azahypoxanthine (8) and the imidazolylazoimidazole (16). The 
minor products arise from initial thermal 6r. electrocyclic ring opening giving 
5-diazoimidazole-4-carboxamide. The tentative identification of the inter-
H.NOC NH.  '  *r )
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Scheme 6.5 Decomposition of mitozolomide (3) and temozolomide (4) in water.
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Scheme 6.6 Hydrolysis of imidazoieirazmones in aqueous base
mediate carbamate salt (17) in the hydrolysis of temozolomide in cold aqueous 
sodium carbonate shows that the formation of triazene (20) involves initial 
nucieophilic attack of water (or hydroxide) at the carbonyl group a! the 4- 
posiiion of the tetrazinone ring (Scheme 6.5).- The main products of such base- 
catalysed hydrolysis** of the 3-alkyl-8-carbamoylimidazotetraztnones (3. 4, 
18) were the corresponding triazenes (19-21). The ester (22) and the carboxylic 
acid (23) both gave.the triazene carboxylic acid (24). Base-catalysed hydrolysis 
of pyrazolotetrazinones proceeds similarly11. The 2-chloroethyltriazene 
(MCTIC, 19) arising from hydrolysis of mitozolomide is itself labile33 to 
hydrolysis at pH 7.4 giving a mixture of 2-chloroethanol and (15) with the 
evolution of nitrogen35.
The imidazotetrazinones react in a similar manner with alcohols, although 
the reported rates of reaction vary from worker to worker (Scheme 6.7). The
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Scheme 6.7 Alcoholvsis of imidazoictrazinones.
products from the treatment of mitozolomidc with cold methanol were 
reported by Stone19 to be 2-azahypoxanthine (8) and methyl N-(2- 
chloroethyl) carbamate (25); in boiling methanol, a small trace of methyl 5- 
aminoimidazole-4-carboxylate (26) was observed7. However. Baig34 reported 
the 3-methyl and 3-ethyl imidazotetrazinones (4, 18) to be very stable to
boiling methanol. The rate of reaction with alcohols is greatly enhanced by
addition of a trace of ammonia19-29. Under these base-catalysed conditions, 
the main product from the 3-methyl and 3-ethyl imidazotetrazinones was still 
2-azahypoxanthine but the alkoxycarbonylimidazoles (27, 28) were also 
formed3,4. The characterisation of these products of alcoholysis was com ­
plicated owing to conflicting identifications36-37 of the products of alkoxy-
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carbonylation of 5-aminoimidazole-4-carboxamide (15). Mitozolomide gave 
exclusively 2-azahypoxanthine, the product of cleavage of the 4.5 bond of the 
tetrahedral intermediate. It is interesting to note the lengths30-31 of the 3, 4 
(1.374 + 0.003 A) and 4,5 (1.392 +  0.003 A) bonds of the imidazotetrazi­
nones in this context as indicators of bond order and bond energy and that 
corresponding lengths are not appreciably different between analogues.
The reactivity of the 3-{halo)alkylimidazotetrazinones with a representative 
nitrogen nucleophile, hydrazine34, parallels that with the oxygen nucleophiles 
detailed above. The four 3-alkyl compounds (4,18,29,30) react slowly to form 
the carbohydrazide (31) through cleavage of the 3,4 bond (Scheme 6.8). In 
contrast, hydrazine caused fission of the 4,5 bond of mitozolomide (3), the Hnal 
isolated product being 4-azidoimidazole-5-carboxamide (32). presumably via 
one of the tetrazenes (33. 34). This mechanistic proposal is supported by the
H,NOC
tR /C H .C K .C
.CONHNH.
NH CO NH NH .
H,NOC H,NOC H,NOC
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Scheme 6.8 Hydrazinolysis of imidazotetrazinones
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Figure 6.2 Sicreoelecironic requirements for intramolecular nucleophilic catalysis in the reaction 
of 3-(2-chloroethvl) imidazotetrazinones with oxygen and nitrogen nucleophiles. Steric 
interaction between the methyl group (Me) and the nudeophiles (Nu) preclude this anchimeric 
assistance in 3-{2-methoxyethyl) analogues.
ready synthesis of this azide from 5-diazoimidazole-4-carboxamide (7) and 
hydrazine'8. An explanation for the apparently greater lability of the 4,5 bond 
in mitozolomide, when compared with the 4,5 bond in the 3-alkylimidazotra- 
zinones, during reaction with alcohols and hydrazine may be that the chlorine 
atom in the tetrahedral intermediate can, owing to geometric constraints, only 
provide an intramolecular nucleophilic catalysis (anchimeric assistance) for 
cleavage of this bond (Figure 6.2). Clearly, this bond-weakening effect is not 
possible when the 3-substituent does not bear a heteroatom. The ethereal 
oxygen atom in the 2-methoxyethyl sidechain may be unable to perform this 
assistance owing to steric interactions from the methyl group in the 
stereoelectronically required reacting conformation. In the pyrazolotetrazi- 
none series, however, the 4,5 bond is intrinsically weaker than the 3,4 bond1 *.
Sandmeyer-type products (4-haloimidazole-5-carboxamides) are obtained 
when mitozolomide is treated with bromide or iodide ions in hot acetic acid3-1. 
It has been suggested this represents reaction of the thermal cycloreversion 
product, 5-diazoimidazole-4-carboxamide, rather than direct reaction of the 
tetrazinone although this is not completely clear. Products arising from the 
formal trapping of 5-diazoimidazole-4-carboxamide, generated from mitozo­
lomide, by carbon nucleophiles have also been observed34 during reactions in 
hot acetic acid and in boiling pyridine (Scheme 6.9). The regioselectivity of the 
subsequent cyclisations to form imidazotriazines (35-41) is determined by the 
acidic or basic catalysis provided by the solvents and by the nature of the 
substituents attached to the active methylene function.
The effect of powerful oxidants on azolotetrazinone rings has not been
THE CHEMISTRY OF AZOLOTETRa ZINONES
CONH. CONH.
^ " • N H NH
CONH, H CONH, H CONH.
CM* N H , O
CfY f j fr  /yV"
r v
CONH, CONH, C O N H , H
35: R =  C 0 2Mc 3S: R =  CN 40: R = CN
36:R = COjEt 39:R =  C0,Et 41:R = Ac
37: R = Ac
Scheme 6.9 Reactions of mitozolomide (3) with carbon nucleophiles.
reported. Similarly, the efTect of reducing agents is unknown but simple 
triazenes are unaffected by complex hydrides39.
In summary, the chemistry of the imidazotetrazinones with nucleophiles is 
characterised by opening of the tetrazinone ring. The immediate products are 
frequently subject to further transformation under the reaction conditions.
6 .4  R eactions involving retention o f  the tetrazinone ring
Acidic or electrophilic reagents usually permit the imidazotetrazinone ring 
structure to be retained. Indeed, mitozolomide (3) has been recovered 
unchanged from warm concentrated sulphuric acid, in striking contrast to the 
considerable acid-lability of the open-chain triazenes40. Presumably, this 
reflects the basicity of the N = N -N  group in the different systems.
Some useful chemical transformations of functional groups attached to 
azolotetrazinones have, however, been accomplished using acidic and 
electrophilic reagents29. Treatment of mitozolomide with concentrated ‘nit-
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Scheme 6.10 Reactions of mitozolomide (3) with electrophiles. R * 3-l2-chlc*rocihylH- 
oxoim idazo[5.1 -4 ]-1 .2 .3 .5-tetrazin-8-yl.
rating mixture’ gave only the A'-nitroamide (42) (Scheme 6.10). This com­
pound was found to be stable to mild hydrolytic conditions and to attempted 
rearrangement32. Nitrosation at carboxamide nitrogen affords a convenient 
synthesis of the carboxylic acid (43); this hydrolysis can also be effected by 
aqueous sodium hypochlorite. The chemistry of this carboxylic acid is 
straightforward, provided that aqueous basic conditions are avoided. The acid 
chloride (44), formed by treatment with thionyl chloride, reacts vigorously'2
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with the appropriate nucleophiles to give amides, esters and thioestcrs (45-47).
Metabolic oxidation of the N-methyl groups of the N,N- 
dimethylcarboxamide analogue of mitozolomide by cytochrome P4S0 re­
quiring enzymes of rodent systems has been described recently by Hors pool40. 
The characterised products are the 7V-methylamide and mitozolomide 
presumably arising via /V-(hydroxymethyi) intermediates in analogy with 
other aromatic amides41.
Efficient deprotection of N -{4-methoxy benzyl) protected
imidazotetrazinone-8-carboxamides and -8-sulphonamides by a standard43 
method of acid-catalysed nucleophilic substitution has been reported29. When 
the protecting group is attached directly to the tetrazinone ring, as in 3-(4- 
methoxybenzyl)imidazotetrazinones, this method appears to fail and the 3- 
unsubstituted imidazotetrazinone is not formed29.
In summary, the chemistry of the azolotetrazinones with electrophiles and 
with acids is confined to interactions with peripheral functional groups.
6.5 Relationship of the chemistry of the azolotetrazinones to their 
biochemistry
The potent cytotoxicity of the lead compound, mitozolomide (3), has been 
attributed to interstrand cross-linking of DNA44-45. Tisdale46 has recently 
extended this study to a wider range of cell lines and to the active antitumour 
agent temozolomide (4). and to the 3-ethyl analogue (18) which is cytotoxic in 
vitro but is not an antitumour agent in vivo. Discussions of the relationship of 
the chemistry to the (bio)chemical modes of action of the imidazotetrazinones 
must therefore take account of these observations and of the structure/ 
antitumour activity relationship.
Of the two types of electrophilic biochemical reactivity (carbamoylation 
and alkylation) considered by Horgan and Tisdale47, the former was 
discounted on the grounds that mitozolomide does not inhibit glutathione 
reductase, chymotrypsin and y-glutamyltranspeptidase under conditions 
where these enzymes are inhibited by carbamoylating agents. The partial 
inhibition of an esterase of EMT6 cells by mitozolomide may, however, 
indicate some carbamoylation by the reagent48. The most likely reactive 
antitumour metabolite or metabonate of mitozolomide (3) is the N-(2- 
chloroethyl)triazene (MCTIC, 29), the known product of aqueous hydrolysis. 
The cytotoxic activity'of mitozolomide has then been explained47 in terms of 
the reaction of this potent alkylating electrophile with nucleophilic sites on 
DNA, in particular with O6 of guanine bases, with subsequent cross-linking of 
the two strands of the macromolecule. The differential sensitivity of the cell 
lines VA13 (sensitive, Mer”) and IMR90 (more resistant, Mer+) to mitozolo­
mide is then consistent with the ability of the latter to repair the 0 6-(2- 
chloroethyl) lesion prior to the cross-linking reaction. Temozolomide (4) is 
thought to exert its cytotoxicity through a similar mechanism involving the
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monomethyltriazene (20); although cross-linking is precluded. The 3-ethyl 
analogue (18), is an alkylating agent towards RNA, DNA and proteins and is a 
cytoloxin in vitro\ however, alkylation of the O6 position of guanine is not 
involved20*46.
True enzymic metabolism of the imidazotetrazinones, as distinct from 
chemical change in physiological media, has been reported to result either in 
activation of the substrate as an antitumour agent or in deactivation, 
depending on the precise nature of the peripheral functional croups49-51.
6.6 Concluding remarks
The azolotetrazinones represent a highly reactive series of heterocycles, both 
chemically and biologically. Suitably substituted, they show both electrophilic 
and nucleophilic character, with opening or retention of the ring system, 
respectively. Both the antitumour efficacy of some members of the class and 
their toxicity towards cells and organisms result from potently alkylating 
electrophiles generated by hydrolytic chemical reactions in vico. Further 
detailed analysis of the interactions of azolotetrazinones and their metabo- 
nates with DNA may be necessary to explain satisfactorily the observed 
structure-activity relationship at a molecular level and to permit the design of 
a more selective and, therefore, more therapeutically useful agent.
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syn-Selectivity in the  Epoxidation of 1-(Cyclohex-2-enyl)-2-nitroimidazole mediated by 
Hydrogen Bonding
Michael D. Threadgill* and Paul Webb
Medical Research Council Radiobiology Unit, Chilton, Didcot, Oxfordshire 0X11 ORD, UK
Epoxidation of 1-(cyclohex-2-enyl)-2-nitroimidazole with 3-chloroperoxybenzoic acid occurs exclusively syn to the 
nitroimidazole in the absence of water; amines react only with the syn epoxide.
The stereochemistry of epoxidation by peroxy acids of many 
cydohexenes bearing bulky 3-substituents is generally gov­
erned by steric factors, the geometrical isomer with the 
epoxide oxygen anti to the 3-substituent being the major or 
exclusive product when the substituent is non-polar or a 
hydrogen-bond acceptor. 1*4 Hydrogen bonding is, however, 
involved in the exclusive syn-epoxidation of cyclohexen-3- 
ol;4-6 similar control may be taking place in the syn-aziridina- 
tion of this substrate.7 One exception to this rule is the 
dependence on solvent of the epoxidation of 3-(rm-butyl- 
dimethylsilyloxy)cydohexene by peroxytrifluoroacetic acid.8 
As part of a continuing programme of design, synthesis and 
evaluation of new radiosensitisers and bioreductively acti­
vated cytotoxins based on nitro-heterocycles and, in parti­
cular, study of conformationally controlled analogues of the 
lead compound RSU 1069 [a-(aziridin-l-ylmethyl)-2-nitro- 
imidazole-l-ethanol],9 we required the diastereoisomers of 
1 -(3-aziridinyl-2-hydroxycyclohexyl )-2-nitroimidazole and
expected that those with aziridine trans to the hydroxy group 
could be formed from the appropriate epoxide.
l-(Cyclohex-2-enyl)-2-nitroimidazole 2t was prepared by 
alkylation of the potassium salt of 2-nitroimidazole 1 under 
phase-transfer conditions, + in a modification of the general
* Present address, to which correspondence should be addressed: 
School of Pharmacy and Pharmacology. University of Bath, Claver- 
ton Down, Bath BA2 7AY, UK.
t  New compounds were chromatographically homogeneous and gave 
satisfactory lH NMR and accurate mass spectra. All compounds were 
racemic.
X Salt 1 was stirred with 18-crown-6 and 3-bromocydohexene in 
acetonitrile for 24 h, giving, after work-up. 2 (31%) as a gum; 
>H NMR (CDCI3) 6  1 .5-2.4 ( 6  H. m, 4.5.6-H). 5.70 (1 H, m) and 5.80 
(1 H. m) (1,2-H). 6.20 (1 H. ddd. J 8 .4 . and 3 Hz. 3-H). 7.10 (1 H, s. 
imidazole 4-H) and 7.25 (1 H, s. imidazole 5-H).
method of Parrick et al.10 (Scheme 1). Treatment of cyclo- 
alkene 2 with the commercial grade of 3-chloroperoxybenzoic 
acid (MCPBA) (containing ca. 35% water) in boiling di- 
chloromethane gave§ a mixture of epoxides 3a and 3b in ratios 
between 2:1 and 3:1. When the epoxidation was carried out 
using dried samples of the peroxyacid, the sole epoxide 
formed was 3a. Mixtures of 3a and 3b could be separated 
analytically but not preparatively by chromatography. Assign­
ment of the diastereoisomeric identities of the major and 
minor components of the product mixture was made by 
nuclear Overhauser enhancement (NOE) measurements in 
the 270 MHz 'H NMR spectra (Fig. 1), which confirmed the 
assignments of the resonances due to the cyclohexane 1-H,
2-H and 3-H. Particularly diagnostic are the values of the 
NOEs between the 1-H and 2-H in 3a,b; the value for the 
syn-isomer 3a is nearly three-fold larger than the correspond­
ing value for the anti-isomer 3b. These data are consistent with 
the distance between 1-H and 2-H in the cu-arrangement in 3a 
being much shorter than the 1-H to 2-H (trans) distance in 3b 
in the geometry required by the pseudochair conformation. 
Treatment of mixtures of 3a and 3b with aziridine (CAUTION) 
or with the less sterically demanding nucleophile methylamine 
in boiling ethanol resulted in the consumption exclusively of
§ Typical experiment. Compound 2  was boiled under reflux in 
dichloromethane with MCPBA [commercial sample: MCPBA (55% 
w/w), 3-chlorobenzoic acid (10%) and water (35%)] (3 equiv.) for 20 h 
to give, after aqueous work-up. a mixture of 3a and 3b (48%) in the 
ratio ca. 3 :1 .3a: »H NMR (CDCI3) 6  1.5-2.2 ( 6  H, m, 4.5.6-H), 3.43 
(2 H. br s, 2,3-H), 5.56 (1 H, m. 1-H), 7.17 ( 1  H, s. imidazole 4-H), 
and 7.57 (1  H, s. imidazole 5-H). 3b: >H NMR (CDC13) 6  1.45-1.65 (3
H. m. 5 <zx.5 « 7,6 ax-H), 1.95 (1 H. ddt. 4ax-H). 2.12 (1 H, m, 6 eg-H). 
2.22 (1 H. ddt, 4eq-H). 3.25 (1 H. d, 2-H), 3.43 (I H, m. 3-H), 5.27 (1
H. dd, 1-H), 7.22 (1 H, d. imidazole 4-H) and 7.24 (1 H, br s. 
imidazole 5-H).
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5 R = N*H2Me
S ch em e 1 Synthesis and re a a io n s  o f epoxide s tereo isom ers 3a,b. 
E poxide  3b is only form ed in the  presence o f w ater. Reagents: i.
3 -brom ocyclohexene-18-crow n-6-aceton itrile : ii, 3 -ch lo roperoxyben­








Fig. 1 N O E s for epoxides 3 a ,b . T he values of the N O E s are show n as 
percen tages on  the  dashed lines join ing  pairs of hydrogens.
the major isomeric epoxide, giving 4+ and 5+ in 81 and 52% 
yields respectively (based on the content of jyn-isomer 3a in 
the starting mixture of 3a and 3b). lH NMR spectral; 
demonstrated that the addition products 4 and 5 have the 
structures and conformations shown in Scheme 1. In par­
ticular, the 2-D carbon-proton chemical shift correlation 
study on 5 showed inter alia that the proton resonances at 
6 3.26. 4.19 and 5.33 are due to C-H, whereas that at 6 5.89 is 
not and can be assigned to O-H. Irradiation of the signal at 
6 4.19 causes collapse of couplings at 6 5.89 and 5.33; thus, 
these protons comprise a CH-CH-OH system. The resonance 
at 6 5.33 is assigned to 1-H by chemical shift analogy with 
open-chain analogues (e.g. RSU 1069) and by observation of a 
trans diaxial coupling to 6ax-H. Therefore, the OH group is at
1i 4: ‘H  N M R  [(C D 3)2SO) 6 1.12 (1 H , dd , azirid ine-H  syn to 
N -cy d o h e x an e  b o nd), 1.16 (1 H , dd , aziridine-H  syn to  N -cyclohex- 
ane b o nd), 1 .45-1 .90  (7 H , m , 2 x  aziridine-H  anti to N -cy d o h ex an e  
bond  +  4ax,4eq,5ax,5eq,6eq-H), 2.17 (1 H . dq, 6ax-H ), 3.34 (1 H , m.
3 -H ), 3.91 (1 H , m , 2-H ), 5.11 (1 H , d. O H ). 5.49 (1 H , d ca. t. 1-H). 
7.15 (1 H , d , im idazole 4 -H ), and  7.67 (1 H , d . im idazole 5-H ). 5: 
‘H  N M R  [(C D 3)2SO] 6 1 .6 -1 .9  (5 H . m . 4ax.AeqSaxJeq.6eq-H ). 2.19 
(1 H , b r q ,  6ox-H ), 2.63 (1 H , b r s, N C H 3). 3 .26(1  H , m , 3-H ). 4.19 (1 
H , m . 2-H ). 5.33 (1 H , 1-H), 5.89 (1 H . d . O H ), 7 .2 0 (1 H . s, im idazole
4 -H ). 7.72 (1 H . s, im idazole 5 -H ), and  9.20 (1 H . b r) and 9.35 (1 H . 
b r) (* N H 2).
jpro
6 ;  . .  h
'':o
y s
Fig. 2 G eneral transition  sta te  fo r epox ida tion  o f a lkenes by peroxy 
acids
N * -0 ” O
F ig . 3  Stereocon tro l by hydrogen  bonding in the  reacting  com plex 
b e tw een  cycloalkene 2 and  M C P B A
C-2 and 5 has the structure shown; other regio- and 
stereo-isomers are not consistent with these observations. 
Both compounds have approximately the conformations 
indicated in Scheme 1, with nitroimidazole in the equatorial 
arrangement and hydroxy and nitrogen functions axial; this 
contrasts with the conformation reported by Lier et al. 1 for the 
analogous r-3-amino-c-2-phenoxycyclohexan-r-l-ol.
The mechanism of the epoxidation of alkenes is considered 
to involve the peroxy acid in the conformation with an 
intramolecular hydrogen bond, with rates of reaction being 
lower in hydrogen-bond accepting solvents.11 There is also 
general consensus on the structure of the transition state being 
similar to that shown in Fig. 2, although 1,3-dipolar cycloaddi- 
tion has also been proposed.12 The specificity of epoxidation 
of 2 by MCPBA in the anhydrous reaction can be rationalised 
in terms of control through the hydrogen-bonded complex 
shown in Fig. 3. Examination of models of this structure 
reveals that the peroxide oxygen is appositely located for the 
epoxidation process shown in Fig. 2. The presence of trace 
amounts of water in the reaction mixture, occasioned by the 
use of undried commercial MCPBA, would tend to disrupt 
this controlling hydrogen bond, relatively disfavouring epoxi­
dation syn to the nitroimidazole.
Thus, stereocontrol is possible through hydrogen bonding 
of the weak acid MCPBA to an appropriately located 
hydrogen-bond acceptor, such as the nitro group. This 
contrasts with the reported8 lack of such control with MCPBA 
but good control with the stronger acid peroxytrifluoroacetic 
acid in the epoxidation of 3-(/err-butyldimethylsilyloxy)cyclo- 
hexene; this selectivity is abolished when a hydrogen-bond 
acceptor, such as tetrahydrofuran, is used as the solvent. The 
demonstration of syn-stereospecificity in the epoxidation of 2 
with MCPBA suggests either that the nitro group is a more 
powerful hydrogen-bond acceptor than is a silyl alkyl ether or 
that the geometry of the intermediate complex is more 
appropriate for reaction. Further studies on the generality and 
mechanism of this stereospecificity are being pursued.
The complete lack of reactivity of the amine nucleophiles 
with isomer 3b, compared with ready addition to isomer 3a, is 
consistent with a preference for ring-opening to give a 
rrans-diaxial product in analogy with precedents for opening 
of other epoxides3-413 with nucleophiles. The corresponding 
rra/u-diaxial reaction of nucleophiles with the arch-isomer 3b
27! J. CHt.M. SO C .,  CIII-M. C O M M U N ..  I 9 9 I
would require approach to C-2: this is precluded on steric 
grounds.
The epoxidation of cyctohexene 2 with MCPBA in the 
presence or absence of small amounts of water represents a 
new opportunity for exploitation of hydrogen bonding of this 
readily handled perqxy acid in stereocontroiled synthesis.
The authors thank Mr R. R. Hartell (University of Bath) for 
measuring some of the 270 MHz lH NMR spectra and Dr S. K. 
Branch (University of Bath) for helpful discussions. Financial 
support from the National Cancer Institute (USA) under 
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Herstellung des Arzneimittels Hexamethylmelamin mit deuteriertem Seitenstiick
M . D. T h rea d g ill*)
A s to n  U n iv e rs ity .  P h a rm a c e u tic a l  S c ien ces  In s t i tu te .  C R C  E x p e r im e n ta l  C h e m o th e ra p >  R ese a rch  G ro u p .  A s to n  T r ia n g le .  
B irm in g h a m  B 4 7 E T . G ro B b rita n n ie n
Bei der L m se tzu n g  von N .X .M '.N '.X~-Pentum cihy/-1  J J - tr ia z in -2.4,6-triam in  m it B u n /lith iu m  unci Trideutero/odm ethan cu ts relit in 
grower A u sheu te  N ,N ,h r ,N" .S '-P e n ta m e th y l-S ” - 1  tr id eu te ro m e th y lj- l J.5-triazin -2 .4 ,6 -triam in . das A rzneim irtel H exam ethylm elum in  
m it deuteriertem  Seitenstuck.
Trea tm ent o f  .V..V,N '.N '.S '" • Pentam ethy I - l ,3.5- triazin-2.4,6-triam ine with h u ty /lith ium  and  trideuteroiodom elhttne gives .Y..V..V..Y'..V“- 
P en tu m eth y l-S " - ( trideuterom ethyl> -l.3 .5 'triazin-2.4.6-trium ine. a d eu tera ted  analogue o f the anticancer drug hexam ethx Im elam m e. 
in high yield.
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Threadgill'. A rz n e im itte l  H e x a m e th y la m in
Hexamethylmelamin (HMM; 1) ist ein Arzneimittel mit Wirksam- 
keit gegen verschiedene maligne Erkrankungen besonders Eier- 
stockcarzinom [1]. Die metabolische Hydroxylierung von /V-CH3 
Gruppen ist unentbehrlich fur diese Aktivitat [2]. Um Versuche uber 
den Mcchanismus der metabolischen Oxidation von Hexamethyl­
melamin in der Saugetierleber durchzufiihren und die metabolische 
Veranderung an den Kohlenstoffatomen nachst StickstofTatomen 
zu studieren [3 — 6], waren deuterierte Derivate erforderlich. Solche 
Derivate von Verbindung 1 sind noch nicht beschrieben worden. 
obwohl die Herstellung von beiden moglichen [l4C]-markierten 
Derivaten nach der klassischen Methode die auf der Reaktion von 
2,4,6-Trichloro-l,3,5-triazin mit Dimethylamin beruht, in mittlerer 
Ausbeute in der Literatur beschrieben ist [7, 8].
In der vorliegenden Arbeit wurde die isotopisch markierte Gruppe 
in der letzten Herstellungsstufe mit dem Restmolekiil verbunden. 
In zwei vorherbeschriebenen Stufen wurde Pentamethylmelamin (2) 
aus 2,4,6-Trichloro-l,3,5-triazin hergestellt, (i) durch Umsetzung 
mit Dimethylamin bei Raumtemperatur; (ii) durch Reaktion des 
Zwischenprodukts Ar,A',.V,A,’-Tetramethyl- l,3,5-triazin-2,4,6-tri-
amin mit Methylamin unter Erhitzen. Umsetzung der Verbindung 
2 mit Butyllithium entwickelt das Anion 3. Dieses Anion reagiert 
schnell und ruhig mit Trideuterojodomethan bei Raumtemperatur 
(siehe Schema) und die Reinigung des Ar,N,V’,N',Af"-pentamethyl-
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V"-(trideuteromethyl)-l,3,5-triazin-2,4.6-triamins (4) war einfach. 
Diese Beobachtung widerspricht dem Vorschlag von Honda et al.
[9], demzufolge Natriumamid und Dimethylsulphat als hartes Elec- 




l,3,5-triazin-2,4.6-triamin (4). -  Zueincr Losung von N ,N .N \N \N “- 
Pentamethyl-l,3,5-triazin-2,4,6-triamin [10] (570 mg, 2.91 mmol) in 
wasserfreicm Tetrahydrofuran (aus Calciumhydrid frisch destilliert; 
10 mL) wurde Butyllithium (2.0 mL; 1.5 M in Hexan; 3.0 mmol) bei 
Raumtemperatur zugetropft. Nach 30 Min wurde Trideuterojodo­
methan (99atom% ; Aldrich Chemical Co.: 500 mg, 3.45 mmol) 
zugesetzt. Das Reaktionsgemisch wurde bei Raumtemperatur fiir 
18 Std. geriihrt. Das Losungsmittei wurde unter vermindertem 
Druck abgedampft. Der Riickstand wurde in Dichloromethan 
aufgelost, mit Wasser geschiittelt und mit wasserfreiem Na2S 0 4 
getrocknet. Der Abdampfriickstand wurde saulenchromatogra- 
phisch (S i0 2; Hexan: Diethylester; 1:1) vereinigt: N,N,N\N',N"- 
pentamethyl-A/"'-(trideuteromethyl)-l,3,5-triazin-2,4,6-triamin (4) 
(470 mg, 75%); weiBe Kristalle; Schmp. 166 C (lit. [11] 171 -1 7 2  °C 
fiir die unmarkierte Substanz); IR (Nujol) v 2800 (NCH3), 2045 
(NCD3) cm - 1 ; lH NMR (CDC13) 3.10 (s, 5 x C H 3); MS (El) m /z 
213 (100%) (M + ). Diese Substanz war diinnschichtchromatogra- 
phisch identisch mit der unmarkierten Substanz (1), die durch 
Reaktion von 2,4,6-Trichloro-l,3,5-triazin mit Dimethylamin her­
gestellt wurde.
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Aziridinyl nitropyrroles and nitropyrazoles as 
hypoxia-selective cytotoxins and 
radiosensitizers
M.A. Naylor1, M.A. Stephens1,1.J. Stratford1, A. Keohane2, 
P.O’Neill1, M.D. Threadgill3, P. Webb1, E.M. Fielden1 &
G.E. Adams'
lM RC Radiobiology Unit. Chilton. Didcot. Oxon. OXIIORD. UK, 2Biological 
Research Unit. Cancer Institute, 481 Little Lonsdale Street, Melbourne. Victoria 3000. 
Australia and 3School o f Pharmacy and Pharmacology. University o f  Bath, Claverton 
Down. Bath. BA2 7A Y. UK
Summary: A series of 1- and 2-subsiituied 4- and 5-nitropyrroles and 3- and 4- 
nitropyrazoles has been prepared and evaluated in vitro as radiosensiiizers of hypoxic 
cells and as bioreductively-activated cytotoxins. Both the nitropyrroles and the nitropyr­
azoles were considerably less effective, based upon the differential between hypoxic and 
aerobic toxicity, than were similar 2-nitroimidazoles bearing alkylating moieties. The 
trends in radiosensitizing efficiency observed for both classes of drugs corresponded with 
their one-electron reduction potentials (E1,) as measured by pulse radiolysis, although 
they were generally more effective than predicted from previous correlations of £ \  with 
sensitizing efficacy and reactivities. Furthermore, the enhancement of sensitizing ef­
ficiency by the incorporation of alkylating groups is considerably greater than has been 
observed for nitroimidazoles. a-[(l-Aziridinyl)methyI]-3-nitropyrazole-1-ethanol (10, 
£ \  = -456mV) and methyl 5-nitro-I-(cyclopropylcarbonyl)pyrrole-2-carboxylate (25. 
E1,= -326mV) were the most effective radiosensitizers in vitro. Only 3-((cis-2.3- 
dimethyl-1 -aziridinyl) methyl)-l-oxo-3,4-dihydro-6-nitro-l-H-pyrrolo [2.1-c] oxazine 
(22) and methyl 5-nitro-l-(cyclopropylcarbonyl)pyrrole-2-carboxyIate (25) showed sig­
nificant bioreductively-activated cytotoxicity, with differentials of 3.5. Although these 
differential toxicities were coupled with significantly lower aerobic toxicity compared 
with similar 2-nitroimidazoles. this series was not deemed effective enough to warrant 
further evaluation. The electron affinity and radiosensitization could be manipulated by 
chemical design but hypoxia-selectivity was not clearly related to these properties.
The development of nitroheterocyclic drugs in the field of radiosensitization and bioreduct­
ively-activated cytotoxic drugs in cancer chemotherapy is dominated by the nitroimidazoles 
(Adams et al.. 1984; Coleman et al., 1984; Ahmed etal.. 1986; Chaplin et al.. 1986; Newman 
et al., 1986; Roberts et al.. 1986; Jenkins, 1989; Jenkins et al.. 1990). These compounds act 
as sensitizers o f normally radiation-resistant hypoxic cells with little or no effect on normal 
well oxygenated cells. The ability of the drugs to act in this way is known to be related to 
their reduction potentials (Adams et al., 1976. 1979). 2-Nitroimidazoles have the further 
advantage of selective cytotoxicity, by being anaerobically reduced to toxic metabolites in 
hypoxic tumour cells, with little effect on normal cells (Alexander et al.. 1986; O'Neill et a l. 
1987; Jenkins. 1989).
Misonidazole ( 1) (Figure 1) has undergone extensive clinical evaluation as a radiosensit-
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izer. but has failed clinically due to neurotoxicity (Adams & Stratford. 1988; Dische, 1988). 
The equally potent but less toxic compound, etanidazole (2) (Coleman et al., 1984), is in 
phase III trials. Our approach has been to develop more potent compounds by introducing 
alkylating moieties, and has led to the nitroimidazoles ot-[(l-aziridinyl)methyI]-2 -nitroimi- 
dazole-1-ethanol (RSU-1069. 3) (Adams et al., 1984; Ahmed et al., 1986) and a pro-drug 
designed to reduce the observed gastrointestinal toxicity of 3 (Horwich et al., 1986), a[[(2- 
bromoethyl)amino]methyl]-2-nitroimidazole-1 -ethanol (RB-6145. 4) (Jenkins et al., 1990). 
A large number of nitroheterocycles, both azoles and other ring systems, remain uneva­
luated as dual-functional radiosensitizers. We have reported recently on our investigations 
into compounds with higher electron affinities in nitrofurans. 5 (Naylor et al.. 1990) and 
compounds with similar electron affinities to these nitropyrazoles (nitrotriazoles, 6 ) have 
been reported by this laboratory (Jenkins et al.. 1989). These studies clarified further the 
relationship between electron affinity, electrophilic reactivity and dual function radiosensit- 
ization but met with only limited success in the search for compounds of equal or greater 
efficacy than 3 whilst lowering the toxicity of this compound. Highly electron affinic 5- 
nitrofurans ( -  £ \  = 250-350 mV) were found to be highly efficient radiosensitizers in vitro 
but were shown to have high aerobic toxicity and little hypoxia-selectivity as cytotoxins. 3- 
Nitrotriazoles showed similar or improved radiosensitizing efficiency, in accord with their 
redox behaviour and significantly lower aerobic toxicity compared with the corresponding
2-nitroimidazoles but with little or no hypoxia-selective cytotoxicity. No study to date has 
addressed the synthesis and evaluation of the closely related aziridinyl nitroazoles with 1 or 
2 nitrogen atoms, which, in their simplest, unsubstituted forms, would be expected to be of 
lower electron affinity than corresponding 2-nitroimidazoles, although some simple mono­
functional nitropyrazoles (Asquith et al., 1974). nitropyrazole hydroxamic acids (Mulcahy 
et al.. 1986), and nitropyrroles (Ruddock & Greenstock, 1977) have been studied.
Nitropyrroles are expected to have poor electron-affinities (Ruddock & Greenstock, 
1977). and correspondingly low £% values; however the redox properties of the nitropyr­
roles can be altered. Substitution with electron withdrawing groups and alterations to the 
patterns of substitution can be achieved without major synthetic difficulties, to give a series 
of compounds with varied £% values. We have sought to investigate nitropyrroles closely 
related to the parent hypoxia selective agent 3. and as such have synthesized both C-
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substituted and N-substituted 4- and 5-nitropyrroles bearing the potentially alkylating 
aziridinyl, substituted aziridinyl, oxiranyl and cyclopropyl groups.
We also chose to investigate the nitropyrazoles closely related to 3 which are the only 
other nitrogen heterocycles of this type that have not been evaluated as dual-function 
hypoxia-selective agents to date, although some acetohydroxamic acid derivatives have 
been studied (Mulcahy et al., 1986). The one-electron reduction potentials of 3- and 4- 
nitropyrazoles were unknown prior to this study (Wardman, 1989), although half-wave 
reduction potentials for 1- and 2-nitropyrazole have been reported (Ruddock & Green­
stock, 1977). Polarographic measurements on 4-nitropyrazole have been carried out 
(Rowley et al., 1979), and recent studies have shown that this compound forms a 
comparatively stable one-electron radical which may be important in any biological effects 
(Edwards & Tocher, 1990).
Chemistry
Nitration of pyrazole with acetyl nitrate in acetic acid (Huttel and Buchele. 1955) affords N- 
nitropyrazole in 6 8 % yield. Treatment of this compound with c.H ,S04 affords 4-nitropyra­
zole, whereas heating in a high boiling solvent yields 3-nitropyrazole via a thermally 
induced 1,5-sigmatropic rearrangement (Janssen et al., 1976). Treatment of these isomeric 
pyrazoles with refluxing epichlorohydrin affords the oxiranyl synthons 7 and 9 (Scheme I). 
In the case of the 4-nitro derivative, the chlorohydrin was isolated and required treatment 
with base. Treatment of these expoxides with aziridine in refluxing ethanol gave the target 
aziridinyl derivatives 8  and 10.
L  J  9 10
Scheme I (i) AcOH Ac.O H N O :. (ii) (a) c .H ,S 0 4 (b) epichlorohydrin. (iii) (a) 140‘C 
lOh (b) epichlorohydrin. (iv) 10% NaOH(aq). (v) aziridine Et,N/EtOH
Derivatives of nitropyrroles which are close analogues of 3, although expected to be 
less electron affinic. were considered important targets in this study. Pyrrole can be nitrated 
to give predominantly 2 -nitropyrrole although small quantities of the 3 -nitropyrrole can be 
isolated by column chromatography (Morgan & Morrey, 1966). The 2- and 3-nitropyrroles 
were efficiently .V-alkylated with allyl bromide via their sodium salts and subsequently 
converted to the oxiranes with MCPBA to afford pyrroles 11 and 14 (Scheme II). Reaction 
of these oxiranes with appropriate aziridines in refluxing methanol or ethanol gave the 
target aziridines 12. 13 and 15.
Introduction of a carboxamide moiety onto the heterocyclic ring is expected to influence 
the electron affinity markedly, as we have observed with a series of nitrofurans (Naylor et 
al.. 1990). Compounds of this type are available from l-methylpyrrole-2-carboxylic acid, 
which was efficiently nitrated with A c,0 /H N 0, and the resulting 4- and 5-nitro derivatives 
separated as their methyl esters on silica essentially as described by Bailer et al. (1978).




Schem e [I (i) (a) NaH, DMF/allylbromide. (b) MCPBA/CH;Cl;. (ii) aziridine. Et.N 
EtOH. (iii) d.v-2.3-dimethylaziridine/Et;N/EtOH
These esters were then hydrolysed and converted into their corresponding acyl chlorides 
with SOCK.THF (tetrahvdrofuran). Reaction with allylamine then furnished the allyl 
amides which were epoxidized with MCPBA (3-chloroperbenzoic acid) (55-65% yield) to 
give the oxiranes 16 and 18 (Scheme III). Reaction of these derivatives with unsubstituted 
aziridine was unsuccesful but could be achieved with c/5-2 ,3-dimethylaziridine to give
Scheme III (i) (a) SOC1 THE. (b) allylamine CH .Cl. Et,N (c) MCPBA CH.CK, (ii) cis-2. 
.'-dimcthylaziridmc E iN  TH F.(iii)(a)SO C K  TH F(b) l-(2-aminocthyl)pipcridinc THF
NITROPYRROLES & NITROPYRAZOLES AS RADIOSENSITIZERS 155
compounds 17 and 19. A compound containing a basic rather than an alkylating side- 
chain. as present in the known nitroimidazole. pimonidazole. which shows selective uptake 
into tumours (Dische et al., 1986), was synthesized by condensation of l-(2-aminoethyl) 
piperidine with l-methyl-4-nitropyrrole-2-carboxylic acid to give 20.
A series of compounds bearing the functionalized side chain on the pyrrole nitrogen and 
further substitutions on the ring carbon atoms were synthesized from the common 
precursor pyrrole-2-carboxylic acid (Morgan & Morrey. 1971). Nitration again gives a 
mixture of 4- and 5-nitropyrroles separated by silica gel chromatography. Generation of 
the oxiranylmethyl derivatives 21 and 23 (Scheme IV) was then achieved by conversion to 
the sodium salt in DMF and reaction with glycidyl tosylate. Reaction of 23 with os-2,3- 
dimethylaziridine with concurrent transesterification gave the aziridinyl analogue 24. 
Reaction of 21 with cis-2, 3-dimethylaziridine resulted in the bicyclic fused pyrrole 22.
The cyclopropyl carbonyl derivative 25 was synthesized by condensation of the corres­
ponding 5-nitropyrrole-2-carboxylic ester with cyclopropyl carbonyl chloride (Scheme IV).
Synthetic chemistry
N.m.r. spectra were obtained at 60 MHz with a Jeol PMX60SI spectrometer with SiMe4 as 
internal standard. Mass spectra were carried out on a Finnigan 4500 instrument in the 
electron-impact mode. Melting points are uncorrected. Tetrahydrofuran (THF) was 
distilled from CaH, and dimethylformamide was distilled at reduced pressure and stored 
over 4A sieves. Commercially available 3-chloroperbenzoic acid (MCPBA) was purified by 
washing with phosphate buffer (pH 7) and drying at reduced pressure over P:Os. C/5-2 ,3- 
dimethylaziridine was prepared as described by Dickey et al. (1952) and l(H)-aziridine was 
purchased from Serva Fine Biochemicals Ltd. Elemental analyses were determined by 
Elemental Microanalysis Ltd. Okehampton. UK and Butterworth Laboratories. Tedd- 
ington, UK. Where elemental analyses are indicated by symbols, analytical results obtained




(iii) C O ,C H ,
NO
25
C O ,C H ,
.OCH.
23 24
Scheme IV' (i) NaH'DM F glycidyl tosylate. (ii) a'.v-2J-dimetlnlaziridinc Et,N F.tOH. 
(iii) cyclopropylcarbonyl chloride
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for these elements are within ±0.4% of the theoretical values. Solutions in organic solvents 
were dried by treatment with anhydrous Na2S 0 4 and filtration. Solvents were removed by 
evaporation under reduced pressure. All compounds were racemic. The one-electron 
reduction potentials (£%) of all target compounds were determined as previously described 
(Wardman & Clarke, 1976).
a -/ (1-Aziridinyl)methyl}-4-niiropyrazole- l-ethariol (8)
Pyrazole was converted to the /V-nitro derivative with Ac20 /H N 0 3 in AcOH (Huttel & 
Buchele, 1955) in 87.5% yield (m.p. =  90-92®.Lit.92-93°C). 1-Nitropyrazole (5.72 g, 
0.05 mmol) was added slowly to c.H2S 0 4 (20 ml) and stirred for 20 h at ambient tempera­
ture, poured onto ice (150 g), filtered, and the filtrate extracted with Et20  (3 x 200 ml). The 
combined extracts were dried and evaporated to afford 4.63 g (81%) of 4-nitropyrazole as a 
colourless solid (m.p.= 149-150°C). 'H-n.m.r. (CDCl3/(CD3)2SO 6  8.2 (s,2H) ppm.
4-Nitropyrazole (2.26 g, 0.02 mol) and Na2C 0 3 (0.21 g, 2.0 mmol) were heated under 
reflux in epichlorohydrin (20 ml) for 1 h. The hot solution was then filtered and washed 
with hot EtOH, cooled and evaporated. The residue was taken up in EtOAc (250 ml). 
washed with H ,0  (3 x 200 ml). sat.NaCl(aq) (200 ml), dried and evaporated. The residue 
was purified on silica (150g) eluting with CHCl3/MeOH (9:1) to afford 0.35g (10.4%) 
l-oxiranylmethyl-4-nitropyrazole (7) as a pale yellow oil.
'H-n.m.r. (CDC13) 5 2.55 (dd. J = 2.5 and 4 Hz, 1H) and 2.9 (t, J =  4.5 Hz, 1H), oxiranyl 
3-CH,, 3.4 (m, 1H, oxiranyl 2-H), 3.95 (dd, J =  6  and 14.5 Hz, IH) and 4.6 (dd, J = 3.6 
and 14.5 Hz, IH), arom-CH,. 8.0 (s. 1H, pyrazole-H), 8.2 (s, 1H, pyrazole-H) ppm.
Further elution of the column afforded 1.87 g (45.5%) l-(2-hydroxy-3-chloropropyl)-4- 
nitropyrazole as a pale yellow solid (m.p. =  59-6 TC). 'H-n.m.r. (CDCl3/(CD,),SO) 6 3.55 
(dd, J=  1.5 and 4.8 Hz, IH. C//.C1), 4.1-4.4 (m, 3H, arom-Ctf,C//(OH)), 4.8 (s', IH, Off),
8.0 (s, IH, pyrazole-H), 8.35 (s, IH. pyrazole-H) ppm.
This material was converted to the oxiranyl synthon by treatment with 100 ml 10% 
NaOH(aq) for lh  at 5°C. diluting with H ,0  (150ml) and extracting with CHC1, 
(3 x 100 ml). The combined extracts were dried and evaporated to give a further 0.8 s (65%) 
of 7.
7 (0.8 g. 4.7 mmol) was dissolved in EtOH/Et,N (99:1) (25 ml) and heated under reflux 
with aziridine (2.0g. 46.5 mmol) for 30min. Half the solution was then evaporated and. 
upon cooling 0.38 g (39%) of 8  was obtained as a pale yellow solid, recrvstallized from 
EtOH/Et.N (99:1) (m.p. = 144 145°C).
'H-n.m.r. (CDCl./(CDj,SO) 6 1.2 and 1.7 (2  x dd. J = 2 and 4  Hz. 2 x 2H. N(CH,),). 2.3 
(2 x dd, J = 4 and 7.5 Hz. 2H. C//,-aziridine). 4.0-4.5 (m, 3H, arom-C//,C//(OH).'8.0 (s. 
IH, pyrazole-H). 8.5 (s, IH. pvrazole-H) ppm.
Anal.QH^NjO. C. H. N.
ql-[ ( I-Aziridinyl) methyl J ~3-niiropyruzole-1 -ethanol (10)
1-Nitropy'razole (5.68 g. 0.05 mol) was dissolved in xylene (100 ml) and heated at 130- 
I40°C for 10 h. The solvent was evaporated to dryness to afford 3-nitropyrazole (3.81 g. 
67.5%) as a colourless solid (m.p. = 166-I67°C) which was used without further purifica­
tion.
'H-n.m.r. (CDCl./(CD:):SO) 6  7.0 (d. J = 3 Hz. IH), 7.8 (d, J = 3 Hz. IH) ppm.
This material was treated with epichlorohydrin as described above for 7 to afford 2.3 g 
(40%) l-oxiranylmethyl-3-nitropyrazole (9). None of the corresponding chlorohydrin was 
isolated in this sample.
'H-n.m.r. (CDCI;) 6  2.6 (dd. J = 3 and 5 Hz, IH) and 3.0 (t, J = 5 Hz. IH). oxiranyl 3-
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CH,. 3.45 (m, 1H, oxiranyl 2-H), 4.0 (dd. J = 6  and 14.5 Hz. lH)and 4.6 (dd, J = 3.6 and 
14.5* Hz, IH). arom-Ctf,, 7.0 (d, J = 3 Hz, 1H, pyrazole-H), 7.6 (d. J = 3 Hz. 1H. pyrazole- 
H) ppm.
Conversion to the target aziridine was carried out as described above for 8  to give 1.08 g 
(48.4%) of 10 as a pale yellow solid, recrystallized from Et,0 (m.p.= 120— 121 ®C).
'H-n.m.r. (CDCl,/(CD3),SO) 6 1.25and 1.7 (2 x dd, J = 2*and 4 Hz. 2 * 2H,N(CH),), 2.3 
(dd, J =  4 and 7.5 Hz, 2H, C //:-aziridine), 4.1-4.5 (m, 3H. arom-C//:C//(OH)). 6 .8  (d* J = 3 
Hz, IH, pyrazole-H), 7.7 (d, j  = 3 Hz, IH, pyrazole-H) ppm.
Anal.C8H,2N40 3 C, H, N.
a -[( l-Aziridinyl)methyl]-5-nitropyrrole-l-ethanol (12)
Pyrrole (10 g, 0.15 mol) was dissolved in A c ,0  (60 ml) and cooled to -20°C. HNO? 
(70%, 8  ml) in A c,0 (38 ml) was then added slowly, maintaining the temperature at -  20°C 
for 30 min. The reaction mixture was then poured onto ice (250 g), stirred for 30 min and 
extracted with Et,0 (3 x 250 ml). The solvent was then dried and evaporated and the 
residue purified on silica (250 g) eluting with hexane/CH:Cl, ( 1:1, v/v) to give 3.8 g (23%) 2- 
nitropyrrole as pale yellow needles (m.p. =  60-61 *C, lit. (Morgan & Morrey, 1966) 65- 
66.5°C). Further elution yielded 0.5 g (3%) of 3-nitropyrrole (m.p. = 98--99°C, lit. 101 °C).
2-Nitropyrrole, (1.0 g, 8.9 mmol), was dissolved in 5 ml DMF and NaH (0.47 g, 
9.8 mmol) added with stirring. The solution was stirred for 30 min at room temperature 
and then allyl bromide (1.2 ml, ca.lOmmol) added with stirring. After 2 h the DMF was 
removed and the residue redissolved in EtOAc (75 ml) and washed with H ,0  (3 x 100 ml) 
and sat.NaCl (100 ml), dried and evaporated. The residue was purified on silica (100 g) 
eluting with CH,CI, to give 1.2 g (8 8 %) o f 2-nitro-l-(prop-2-enyl)pyrrole. as a yellow oil.
T.l.c.(CHClj) * ,=  0.75.
'H-n.m.r. (CDClj) 5 4.8 (brd, J = 6.5 Hz, 2H, allylic-CH;). 5.1 (m. 2H) and 5.7-6.0 (m, 
IH). olefinic, 6.2 (dd, J=  1.5 and 3 Hz, IH, pyrrole-H), 6 .8  (t. J=  1.5 Hz, IH, pyrrole-H). 
7.1 (dd, J=  1.5 and 3 Hz, IH, pyrrole-H) ppm.
This material was epoxidized as described for 16 with MCPBA and final purification on 
silica, eluting with hexane/CH,Cl: (1:1, v/v) to afford the oxirane 11 in 37% yield as a pale 
yellow gum.
'H-n.m.r. (CDC1,) 6  2.5 (dd, J = 2.4and 4.8 Hz, IH), and 3.0 (t. J = 3.6 Hz. IH). oxiranyl 
3-CH,. 3.5 (m, IH, oxiranyl 2-H ),4.3 (dd, J = 6  and 12 Hz. IH), 5.1 (dd. J =  2 .4and 4.8 Hz, 
IH)arom-CH,, 6.3 (dd, J=  1.5 and 3 Hz, IH, pyrrole-H). 7.0(t, J = 1.5 Hz, IH. pyrrole-H).
7.3 (dd, J = 1.5 and 3 Hz, IH, pyrrole-H) ppm.
The oxiranyl synthon 11 was used immediately and without further purification; 0.15 g 
(0.9 mmol) was dissolved in 2 ml EtOH (1% Et?N) together with 0.2 g (4.6 mmol) 1(H)- 
aziridine. The solution was heated under reflux for 15 min. cooled and evaporated. The 
residual material was twice recrystallized from EtOH/Et,N (99:1) to afford 55 mg (29%) 12 
as a pale yellow solid (m.p. = 108-109°C).
T.l.c. (EtOH/EtjN, 99:1) * f=0.3.
'H-n.m.r. (CDCI3 5) 1.1 and 1.8 (2xd d , J = 2 and 4 Hz. 2x2H . N(CH,);), 2.2-2.5 
(2 x dd. J = 4 and 7.5 Hz, 2H, CH,-aziridine), 3.9-4.5 (m, 3H, arom-C//,Ctf(OH)). 6 .1 (dd, 
J= 1.5 and 3 Hz, IH, pyrrole-H),'6.8  (t, J =  1.5 Hz. IH. pyrrole-H). 7.i (dd, J= 1.5 and 3 
Hz. 1H, pyrrole-H) ppm.
Anal.C9H„N.O, C, H, N.
i ' [  < cis-2 .3-Dimethyl-I-aziridinyl) methyl ]-5-nitropyrrole- / -ethanol (131
11. 0.2 g (1.2 mmol) was dissolved in 2.5 ml MeOH(l% Et,N) together with 0.2 ml 
(ca.4 mmol) <7.?-2.3-dimethylaziridine and the solution heated under reflux for 45 min. The
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solution was cooled and evaporated and the residue recrystallized from EtOH to afford 
0.21 g (73%) of 13 as a pale yellow solid (m.p. =  87-88.5*C).
T.I.c. (EtOAc/Et,N. 99:1) £,. = 0.35.
'H-n.m.r. (CDC1,) 8  1.1 (d, J = 6 Hz, 6 H, 2 x aziridine-CH3), 1.5 (m. 2H, 2 x aziridine-H),
2.5 (dd, J = 2.4 and 4.8 hz, 2H, CH,-aziridine), 4.2-4.8 (m, 4H, arom -C//,C /f(0//)), 6.2 
(dd, J=  1.5 and 3.0 Hz, 1H, pyrrole-H), 7.0 (t, J =  1.5 Hz, IH, pyrrole-H), 7.2 (dd, J=  1.5 
and 3 Hz, IH, pyrrole-H) ppm.
Anal.C,,H,7NjO3.0.25 H ,0  C, H. N.
a-/ (1 - Aziridinyl )me thyl I-4-niiropyrr ole-1-ethanol (15)
l-Oxiranylmethyl-4-nitropyrrole (14) was prepared in 33% yield (as a similar high boiling 
oil) by the same route as that used for 11 using the 4-nitropyrrole available as the minor 
product from the nitration of pyrrole described above.
T.l.c.(hexane/CH,CU 1:1) £ f= 0 . 12.
'H-n.m.r. (CDCljj 8  2.55 (dd. J = 2.4 and 4.8 Hz, IH) and 2.8 (t. J = 3.6 Hz. IH), oxiranyl 
3-CH,. 3.3 (m, IH, oxiranyl 2-H). 3.9 (dd, J =  4.8 and 14 Hz, IH), and 4.4 (dd, J = 3 and 14 
Hz, IH), arom-CH,, 6 .6  (m, 2H. 2 x pyrrole-H), 7.6 (t, J =  1.5 Hz. IH. pyrrole-H) ppm.
14,0.15 g (0.9 mmol), was converted to the aziridine 15 as described for 12 to afford, after 
recrystallization from EtOH/Et.N (99:1), 57 mg (30%) 15 (m.p. = 124-125.5#C). 
T.l.c.(EtOH/Et,N, 99:1) £ f=0.25
'H-n.m.r. (CDCU) 8  1.1 and 1.8 (2 *dd. J«=2 and 4 Hz, 2 x 2H. N-(CH,),), 2.2-2.5 
(2  x dd, J = 4 and 7.5 Hz. 2 H. CH,-aziridine). 3.9-4.6 (m. 4H, arom-CH:CH(0~H)l 6.7 (m. 
2H. 2 x pyrrole-H). 7.6 (t. J = 1.5 Hz. IH. pyrrole-H) ppm.
Anal.C9Hl3N.O, C. H. N.
N -f3-fc\s-2. 3-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-I-methyl-5-nitropyrrole-2- 
carhoxaniide <17)
JV-Methyl-5-nitropyrrole-2-carboxylic acid (0.5 g, 2.94 mmol) was dissolved in 2.5 ml THF 
together with 1.5 ml SOCI, and the solution heated under gentle reflux for 10 min, cooled 
and evaporated. The residue was redissolved in 5 ml CH,C1, and added dropwise to a 
solution of allylamine (l.Og. 17.5 mmol) in CH,C1, (5 ml) containing 3 ml Et3N. The 
solution was stirred at 0*C for 30 min. 20 ml H ,0  added and the organic layer washed with 
5% NaHCO, (50 ml). H ,0 (25 ml). dried and evaporated. The residue was recrystallized 
from ethanol to afford 0.5 g (82%) of l-methyl-5-nitro-Ar-(prop-2-enyl)pyrrole-2-carboxa- 
mide as a pale yellow solid (m.p. = 9I-92°C).
'H-n.m.r. (CDC1,) 8  4.0 (brt. J = 4.8 Hz, 2H. allylic CH,), 4.2 (s, 3H. N-CH,), 5.1-6.0 (m. 
3H. olefinic). 6.2 (brs. IH. NH). 6.4 (d, J= 4 .5  Hz, IH, pyrrole-H). 7.1 (d. J = 4.5 Hz, IH. 
pyrrole-H) ppm.
0.5 g (2.4 mmol) of the above material was dissolved in 5 ml CH.Cl, together with l.Og 
(5.8 mmol) MCPBA and the solution heated under gentle reflux for 30 min; 10% Na,SO, 
(25 ml) was then added and the organic layer washed with the same solution followed by 
5% NaHCO, (2x25  ml) and H ,0 (25%ml). The solution was dried, evaporated and 
purified on silica (lOOg) eluting with CHC1, to afford, after recrystallization from ethanol. 
0.3 t: (56%) of 16 as a white solid (m.p. =94-95°C).
T l.c. (CHC1,) £, = 0 .2 .
'H-n.m.r. (CDCI.) 8  2.7 (dd. J = 2.4 and 4.8 Hz. 1H,) and 2.9 (t. J = 3.6 Hz, IH), oxiranyl 
3-CH.. 3.3 (m. IH. oxiranyl 2-H). 3.65 (dd, J = 4.8 and 12 Hz. IH) and 3.9 (dd, J = 4 and 
12 Hz* IH). CONHC//.. 4.3 (s. 3H. N-CH,). 6.4 (d. J = 4.5 Hz. IH. pyrrole), 7.1 (d,J = 4.5 
Hz. IH. pyrrole-H) ppm.
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A nal.C ,H „N,04 C, H, N.
The oxiranyl synthon 16 above (0.25 g, 1.13 mmol) was dissolved in 4 ml dry THF (1 % 
Et,N) together with 0.2 g (2.8 mmol) as-2,3-dimethylaziridine and heated under reflux for
2.5 h, cooled, evaporated and the residue recrystallized from CHUCK to afford 0.175g 
(6 8 %) o f 17 as a pale yellow solid (m.p. =  10l-102°C).
'H-n.m.r. (CDCl3) 8 1.2 (d. J = 6  Hz, 6 H, 2 x aziridine-CH3), 1.4 (m, 2H, 2 x aziridine-H).
2.3 (dd, J =  5 and 13 Hz. 1H) and 2.5 (dd, J = 5 and 13 Hz, 1H), CHC//,-aziridine. 2.7 (brs, 
1H, C H (0//)), 3.4-3 .8 (m, 3H, NHCtf,C//(OH)), 4.2 (s,3H,N-CH3), 6.5 (d, J =4.5 Hz. 1H. 
pyrrole-H), 7.1 (d, J = 4.5 Hz, IH, pyrrole-H) ppm.
Anal.CI3H20NJO4 C, H, N.
N -( 3-( cis-2.3-Dimethyl-1-aziridinyl) -2-hydroxypropyl ) -1-methyl-4 
nitropyrrole-2-carboxamide (19)
The corresponding 4-nitro oxiranyl synthon 18 was prepared as described for the above 5- 
nitropyrroles from l-methyl-4-nitropyrrole-2-carboxylic acid in 37% overall yield 
(m.p. =  167-168*C).
T.l.c. (EtOAc) Rf=0A.
'H-n.m.r. ((CD,),SO) 8 2.6 (dd, J = 2.4 and 4.8 Hz. IH) and 2 .8  (t. J = 3.6 Hz, IH). 
oxiranyl 3-CH,. 3.2 (dd. J = 4.8 and 12 Hz. IH) and 3.5 (dd, J = 4 and 12 Hz, IH). 
CO NH C//,, 4.0 (s, 3H, N-CH,). 7.5 (d, J=  1.5 Hz IH, pyrrole-H), 7.8 (d. J= 1.5 Hz, IH. 
pyrrole-H), 8.5 (brs, IH, NH) ppm.
This material was then converted to the m-2,3-dimethylaziridinyl analogue 19 in 39% 
yield as described above for 17 (m.p. = 139-140#C).
'H-n.m.r. (CDC1,) 8 1.2 (d. J = 6  Hz, 6 H, 2 x aziridine-CH3), 1.5 (m, 2 H. 2 x aziridine-H). 
2.35 (dd, J =  4.8 and 12 Hz. lH)and 2.7 (dd,J = 4.8and 12 Hz, IH), CH,-aziridine. 3.0-3.8 
(m. 4H. N H C //,C tf(0 //)). 3.95 (s. 3H, N-CH,). 7.0 (d, J= 1.5 Hz, IH, pyrrole-H). 7.4 (d. 
J =  1.5 Hz, IH. pyrrole-H) ppm.
Anal.C,,H,0N4O4 C. H. N.
l-Melhvl-4-nitro-N-(2-(piperidin-l-yl)ethyl)pyrrole-2-carboxamide hydrochloride (20)
l-Methyl-4-nitropyrole-2-carbonyl chloride (2.0 g, 11 mmol, prepared as described above), 
was dissolved in 20 ml dry CH,C1, and added to a solution of l-(2 -aminoethyl)piperidine 
(2.0 g. 14 mmol) in CH,C1, (10 ml) and Et,N (10 ml) at 0°C. After 15 min the solution was 
washed with sat.NaHCO, (2 x 50 ml) and H ,0  (50 ml), dried and evaporated. The residue 
was redissolved in 10 ml CH,C1, and 5 ml o f a solution of 1.0 m HC1 in Et,0 added dropwise 
at 0#C. The resulting solid was filtered off and washed with Et,0 to afford 20  ( 1.9 g. 80%) as 
a white solid (m.p. = 246-247°C (dec.)).
'H-n.m.r. (D ,0) 8  1.8- 1.9 (m. 6 H, NCH,(C//,),CH,N). 3.4—3.8 (m. 8 H. NH C//,Ctf,N- 
and piperidine CH:NCH,). 3.9 (s. 3H.N-CH,). 7.2 (d,'j = 1.5 Hz, IH, pyrrole-H). 7.85 (d. 
J=  1.5 Hz, IH. pyrrole-H) pp.
Anal.CnH,,N40 3Cl.H,0 C. H. N.
3-( (cis-2.3- Dimethyl-1-aziridinyl) methyl)-1-oxo-3,4-dihydro-6-nitro-1 - H-pvrrolo[ 2.1-cJ 
oxazine (22)
Methyl 5-nitropyrrole-2-carboxylate (l.Og. 5.9mmol) was dissolved in 10ml DMF and 
0.2 g (6.5 mmol) NaH (80% in oil) added with stirring. The solution was stirred at 20#C for 
30 min and glycidyl tosylate (prepared according to Klunder et al., 1986) added (1.5 g,
6 .6  mmol) and stirring continued for 15 h. The solvent was then removed and the residue
160 M.A. NAYLOR c t al.
redissolved in 50 ml CHC1, and washed with H ,0  (3 x 150 ml), dried and evaporated. The 
residue was purified on silica (200 g) eluting with CH,C1, to afford, after recrystallizing 
from ethanol, 0.56 g (42%) methyl l-(oxiranyImethyl)-5-nitropyrrole-2-carboxylate (21) as 
pale yellow needles (m.p. = 56-57°).
T.l.c. (CH,CL) * f= 0.3.
'H-n.m.r. (CDC1,) 5 2.45 (dd, J = 2.4 and 4.8 Hz, 1H) and 2.8 (t, J = 3.6 Hz, 1H), oxiranyl
3-CH,, 3.3 (m, IH, oxiranyl 2-H), 3.9 (s, 3H, N-CH}), 5.2 (d, J = 4 Hz, 2H, arom-CH2), 6.9 
(d, J = 4.5 Hz. IH, pyrrole-H), 7.1 (d, J =  4.5 Hz, IH, pyrrole-H) ppm.
Anal.C,Hl0N:O5 C, H, N.
The oxiranyl synthon 21 above (0.1 g, 0.44 mmol) was dissolved in 2.5 ml MeOH- 
(1% Et,N) together with 0.1 g (1.4 mmol) ay-2,3-dimethylaziridine. The solution was then 
heated under reflux for 1.5 h. cooled and evaporated. The residue was recrystallized twice 
from ethanol (1% Et,N) to give 0.85 g (73%) of 22 as a pale yellow solid (m.p. -  109- 
110°C).
T.l.c. (EtOAc/EtjN, 99:1) * f=0.58.
'H-n.m.r. (CDCU) 5 1.1 (d, J = 6  Hz, 6 H, 2 x aziridine-CHj), 1.4 (m, 2H, 2 x aziridine- 
H). 2.6 (dd. J = 2.4 and 4.8 Hz, CHCtf,-aziridine), 4.2-4.9 (m, 4H, arom-C/7,C//(0//)), 6.9 
(d. J = 4.5 Hz. IH. pyrrole-H). 7.1 (d, J = 4.5 Hz, IH. pyrrole-H) ppm.
MS, m/z 266 (M + H)'(100).I 10, 85.
AnaI.Cl2H15N,O4.0.25 H ,0  C, H, N.
Ethyl l-(3 -(cis-2. 3-dimethyl-1-aziridinyl) -2-hydroxypropyl) -4-nitropyrrole-2- 
car boxy late (24)
The oxiranylmethyl synthon 23 was prepared in 45% yield as described for 21 but using 
methyl 4-nitropyrrole-2-carboxvlate as starting material (m.p. = 85-86°C).
T.l.c. (CH,CL,) *,=0.24.
'H-n.m.r. (CDC1.J 6 2.5 (dd. J = 2.4 and 4.8 Hz. IH) and 2.9 (t, J =  3.6 Hz. IH). oxiranyl
3-CH„ 3.4 (m. IH. oxiranyl 2 -H). 2.9 (s. 3H, CO,CH,).  4.2 (dd, J = 6  and 14 Hz. IH) and
5.0 (dd. J = 2.5 and 14 Hz. IH). arom-CH:. 7.4'(d, J=1.5 Hz. IH. pyrrole-H). 7.65 (d. 
J=  1.5 Hz. IH. pyrrole-H) ppm.
This oxiranyl intermediate 0.5 g (2 .2  mmol) was dissolved in 10 ml ethanol ( 1% Et.N) 
together with 0.5 g (7 mmol) cis -2.3-dimethylaziridine and the solution heated under reflux 
for 2 h. cooled and evaporated. The residue was recrystallized from ethanol (1% Et;N) to 
afford 0.4 g (59%) of 24 as a pale yellow solid (m.p. = 74~75°C).
T.l.c. (EtOAc Et.N. 99:1) *,. = 0.5.
'H-n.m.r. (CDCl.) 6  1.1 (dd. J = 6  Hz, 6 H, 2 x aziridine-CH,). 1.4 (t, J = 6.5 Hz. 3H. 
CO,CH.). 1.5 (m. 2H. 2 x aziridine-H) 2.4 (dd, J = 2.4 and 4.8 Hz, 2H, CH,-aziridine). 3.6 
(brs. IH. CH (OH)). 4.1 (m. I H. C //(O H )), 4.3 (q. J = 6.5 Hz, 2H, CO,Ctf,CH,). 4.35 (dd. 
J = 4.8 and 12 Hz. IH)and 4.5 (dd. J = 7.5 and 12 Hz. IH), arom-CH,. 7.4 (d. J = 1.5 Hz. 
IH. pyrrole-H). 7.8 (d. J=  1.5 Hz. IH. pyrrole-H) ppm.
Anal.Cl4H:iN A -0.25 H.O C. H. N.
Methyl 5-nitro-1-(cyclopropylcarhonyl)pyrrole-2-eurboxylate (25)
Methyl 5-nitropyrrole-2-carboxylate. 0.4 g (2.35 mmol), was dissolved in 3 ml CH.Cl. 
containing 2 ml Et.N. The solution was cooled to 0°C and cyclopropylcarhonyl chloride 
(0.25 g, 2.5 mmol) added with stirring. After 15 h at room temperature 20 ml CH.Cl. was 
added and the solution washed with 25 ml 10% NaHCO. 25 ml H ,0. dried and evaporated. 
The residue was purified on silica, eluting with CH.Cl, to give, after recrystaliization from 
EtOH. 0.175 g (31%) of 25 as a pale yellow solid (m.p. = 67-68°C).
T.l.c. (CH.CL.) *, = 0.8.
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'H-n.m.r. (CDCI-) 6 1.5 (m, 5H, 5 * cyclopropyl-H). 4.0 (s. 3H. CO;CH;). 6 .8  (d. J =4.5 
Hz, IH, pyrrolc-H). 7.1 (d, J=4.5 Hz, IH. pyrrole-H) ppm.
Anal.Cl(IHI0N,O< C. H. N.
Biological methods
The in vitro radiosensitization studies were carried out as described previously with use of 
Chinese hamster V79-379 A cells (Adams et al., 1976). Briefly, cells maintained in 
suspension culture were plated onto 6  cm glass Petri dishes in Eagles” minimal essential 
medium (MEM) containing 10% fetal calf serum and allowed to attach for 2h. The 
medium was then replaced with 2  ml of a solution of the agent in phosphate-buffered saline 
(PBS) at pH 7.4 and the Petri dishes placed into gas-tight dural vessels. Hypoxia was 
induced by purging the vessels with N, (<  10 ppm 0 :) for I h prior to irradiation with ^Co 
y-rays at a dose rate of 8 Gy/min. The drug solution was removed after irradiation and 
replaced with fresh medium. The cells were incubated at 37°C for 7 days before assaying for 
colony formation (Adams et al., 1976), the plating efficiency achieved for untreated cells 
was routinely >90%. In these experiments, the maximum concentrations of agents tested 
were such that the plating efficiency of unirradiated cells was reduced by no more than 50% 
after a contact time of 2 h in hypoxia at room temperature. Values of enhancement ratio. 
ER (ratio o f survival curve slope, drug treated versus control) were obtained from single 
survival points (usually between 2 * 1 0"- and 1 0~1) obtained by appropriate choice of 
radiation dose and by assuming an unchanged extrapolation number (Adams et al.. 1979). 
The term C, 6. which is the concentration o f agent required to give an ER o f 1.6. is used as 
the measure o f sensitizing efficiency.
The determination of toxicity o f agents to aerobic and hypoxic V79-379 A cells was 
carried out by using a modification of the MTT assay (Stratford & Stephens, 1989). The 
basis of this assay is the ability of viable cells to convert MTT into a water insoluble 
formazan product. Following addition to DMSO the optical density o f the coloured 
product can be read on a multiwell spectrophotometer. Optical density is proportional to 
the number of surviving, metabolizing cells. In order to compare the cytotoxic efficiency of 
any drug we have chosen the concentration required to reduce OD to 50% of the control 
value from an untreated cell population. Cells were treated with drugs for 3 h at 370C under 
hypoxic or aerobic conditions, then following removal of drug the cells were allowed to 
proliferate for 3 days, prior to MTT assay. This method for measuring bioreductive drug 
activity gives very similar results to those obtained using conventional clonogenic assays 
(Stratford & Stephens. 1989; Stratford et al.. 1990).
Results and discussion
A wide range o f one-electron reduction potential (£',) was observed (Table I) within this 
series of compounds, the most electron-affinic compounds being the 5-nitropyrroIes (-E': 
= 326-590 mV) and the least electron-affinic compounds the 4-nitropyrroles (-£'?= 584- 
657 mV). Within these two classes of compounds, those bearing carbonyl substituents had 
the highest £'- values. The two nitropyrazoles 8  and 10 had different electron affinities, and 
reflects the influence of the position of the nitro group in these compounds.
These trends in redox behaviour were generally reflected in the observed radiosensitizing 
efficiencies although there were some exceptions. A comparison of the regression lines 
obtained for these compounds and the relationship between £ '. and C1(, established by 
Adams et al. (1976. 1979) is shown in Figure 2. The figure shows that all compounds
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Figure 2 Dependence o f sensitizing efficiency (C ,J  on the one-electron reduction 
potential (£'.) of nitropyrazoles and nitropyrroles (■ )  compared with data from some 
monofunctional nitrohetcroarenes (Adams et al.. 1976. 1979) ( . ). Compound 13 ( • )  
was omitted from the regression
evaluated were displaced to the left relative to the established regression line, signifying 
enhancem ent in excess o f  that due to electron affinity. A change in the slope also indicates 
tha t  large changes in within this series have a lesser effect on their sensitizing efficiencies 
than  expected for monofunctional nitroheteroarenes. Only com pound 13 was exceptional 
in its biological properties, indicating tha t substitution o f  the aziridine in the simpler 
pyrrole  examples may have a larger influence on sensitization. All com pounds  except 13 
and  24 are more efficient than both  misonidazole (1) and etanidazole (2) and the sensitizing 
efficiencies o f  this series o f  nitropyrroles are generally com parable with those of  similar 
nitrotriazoles reported previously (Jenkins et al.. 1989). despite their £% values being 
generally some 200 mV lower. Furtherm ore,  the presence o f  an alkylating function has a 
grea ter  effect on sensitization by nitropyrroles than has previously been observed with 2- 
nitroimidazoles. For example the aziridinyl 5-nitropyrrole 12 is four-fold more efficient as a 
radiosensitizer than is the less reactive alkylating agent, the m-2,3-dim ethylazir id inyl 
ana logue 13. This is in contrast to the differences that were observed between the 
corresponding nitroimidazoles. in which a 1.25-fold increase in activity is apparen t  with the 
substituted aziridine (Ahmed et al.. 1986). A comparison between com pound  19 an d  its 
piperidinyl analogue 20. reveals that the alkylating com pound 19 is the more po ten t  
sensitizer (as shown by an ER  o f  1.6 over an ER  o f  1.4 at equal concentra tions) despite 
previous studies (Jenkins et al.. 1989) showing basic substituents to give enhanced  
sensitizing efficiencies. The influence o f  alkylating reactivity, and consequently also the 
toxicity, upon sensitizing efficiency is therefore much greater in this series o f  com pounds ,  
a l though  the unexpectedly high aerobic toxicity o f  the oxiranes 16 and 21 indicate that 
o th e r  structural features lead to general toxicity in pyrroles o f  this type. N itropvrazole 10
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( £ ‘7 = -4 5 6  mV) was three-fold more efficient than I despite a 67 mV difference in their £'. 
values, and the pyrazoles in this study were also at least ten-fold more efficient than were 
some monofunctional nitropyrazoles reported previously (Asquith et al., 1974). Incorpora­
tion o f alkylating groups into these compounds is expected to increase to some extent their 
sensitizing efficiencies (Ahmed et al., 1986; Jenkins et al., 1989). These levels of sensitiza­
tion, however, indicate that the relationships between radiosensitization and redox 
behaviour observed for nitroimidazoles are not broad principles that can be applied as 
accurately to the nitropyrroles and nitropyrazoles. This applies in particular to compounds 
containing unsubstituted aziridines such as 10 and 12.
Large changes in electron affinity were achieved with the introduction of electron 
withdrawing groups into the pyrrole ring and in particular the N-acylated derivative 25 is 
significantly more oxidizing. This compound is approaching the efficacy o f 3 but with an £'- 
some 50 mV more positive. The presence o f the carboxyl group in the W-functionalized 
pyrroles produced a 120mV increase in £ ‘7 (compounds 13 and 22) and at least 6 -fold 
increases in efficiencies of radiosensitization, but with little effect upon their bioreductively- 
activated cytotoxicity.
All 4- and 5-nitropyrroles have lower aerobic cytotoxicities than 3. There were no 
obvious relationships between aerobic toxicity and £ ‘- value within this series of agents 
although they were generally considerably more toxic than were some monfunctional 
nitroaromatic compounds with £', values o f between -  450 and — 500 mV that have been 
investigated previously (Adams et al., 1980). This further illustrates the extraordinary 
influence of the alkylating functions within these series. The closest analogues o f 3 (17, and 
19) had similar aerobic cytotoxicities, but showed little difference in their anaerobic 
toxicities. It therefore appears that, as with nitrotriazoles, both nitropyrazoles and 
nitropyrroles are either not metabolized in a bioreductive manner or that the bioreduction 
products are not toxic in the same way as nitroimidazole metabolites. The aerobic 
toxicities. with the exception of the oxiranes. generally corresponded with the expected 
alkylating reactivities of the side-chain and what little additional bioreductive toxicity was 
present resulted in differential toxicities o f up to 3.5, which is comparable to similar 
nitrotriazoles reported previously. The jV-acylated derivative 25, was one o f the better dual­
functioning compounds despite its weakly alkylating side-chain, and this may be attribut­
able to its acylating potential, although we have not studied its reactivity or stability in 
solution.
Despite pyrroles 22 and 25 showing some hypoxia selectivity in their cytotoxic action and 
up to a two-fold lower aerobic toxicity than 3 there seems to be little potential for the 
development of nitroazoles similar to those reported here as bioreductively-activated 
cytotoxins. In contrast, for radiosensitization there is more promise, and we have shown 
that effective radiosensitization in vitro can be achieved with compounds of much lower 
(more negative) £ ' 7 than previously anticipated.
We have demonstrated the effective manipulation of the electron-affinity of an otherwise 
poorly oxidizing nitroazole. namely nitropyrrole. resulting in the ability to produce 
‘tailored’ compounds of the desired £ ' 7 range which can be effective radiosensitizers in vitro. 
This could be adapted to the development o f compounds which have also demonstrated 
hypoxia-selectivity such as nitroimidazoles and some nitrofurans.
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Synthesis of a Series of Nitrothiophenes with Basic or Electrophilic Substituents 
and Evaluation as Radiosensitizers and as Bioreductively Activated Cytotoxins
Michael D. Threadgill,* Paul Webb, Peter O'Neill, Matthew A. Naylor, Miriam A. Stephens, Ian J. Stratford, 
Shirley Cole, Gerald E. Adams, and E. Martin Fielden
Medical Research Council Radiobiology Unit, Chilton, Didcot, Oxfordshire 0X11 ORD, U.K. Received November 14,1990
A series of 2- and 3-nitrothiophene-5-carboxamides bearing iV-(<i>-aminoalkyl) side chains has been prepared by 
treatment of the thiophenecarbonyl chloride with the appropriate (protected) waminoalkylaxnine. Analogous 
N-(oxiranylmethyl)nitrothiophene*5-carboxamides have been synthesized by epoxidation of the corresponding 
N-allylamide. Compounds in both classes were evaluated in vitro both as radiosensitizers of hypoxic mammalian 
cells and as selective bioreductively activated cytotoxins. The most potent radiosensitizers were those agents with 
strong tertiary amine bases or oxiranes in the side chain. Studies in vivo showed that 2-methyl-iV-[2-(dimethyl- 
amino)ethyl]-3-nitrothiophene-5-carboxamide caused slight radiosensitization of the KHT sarcoma in mice given 
0.34 mmol kg'1. However, administration of this and related tertiary amines at higher doses was precluded by systemic 
toxicity.
The relative resistance of cells in hypoxic regions of solid 
tumors to killing by ionizing radiation remains an im­
portant reason for failure of local control of cancer by 
radiotherapy since molecular oxygen is required as an 
electron acceptor for the manifestation of damage to DNA. 
Electron-affinic nitroheterocycles can, however, act as
mimics of molecular oxygen in this process and thus can 
be effective as radiosensitizers of hypoxic cells.1,2 Indeed, 
a correlation between the one-electron reduction potential 
(E1^ ) of such compounds and their efficiency as sensitizers 
of hypoxic cells in vitro to ionizing radiation has been 
reported.3,4
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School of Pharmacy and Pharmacology, University of Bath, 
Claverton Down, Bath BA2 7AY, U.K.
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C hart I. Structures of 2-Nitroimidazole Radiosensitizers 
Misonidazoie (1), Etanidazole (2), Pimonidazole (3), RSU 1069








The first such electron-affinic radiosensitizer to receive 
extensive clinical study was misonidazoie (1, Chart I); 
however, owing to neurotoxicity, it was found5 not to be 
possible to administer a sufficient dose of this compound 
to achieve radiosensitization of tumors. The second gen­
eration of agents to be the subjects of clinical trials were 
also l-sub8tituted-2-nitroimidazole8. Etanidazole 
(SR 2058, 2)6’7 was designed to avoid the neurotoxicity by 
being highly polar and thus less able to cross the “blood- 
brain barrier". Pimonidazole (Ro 03-8799; 3) 8,9 which 
bears a basic tertiary amine, was designed to be selectively 
taken up into acidic regions of tumor tissue. RSU 1069 
(4 ) ,10-12 a “dual-function" agent with electrophilic and 
electron-affinic groups, is more potent as a radiosensitizer 
in experimental systems but elicited dose-limiting gastro­
intestinal toxicity in the clinic. RB 6145 (5),13,14 a prodrug 
of 4, has recently been developed in an attempt to alleviate 
this problem.
Many of the 1-substituted-2-nitroimidazoles are also 
selectively toxic toward hypoxic cells.15 The basis of this
(3) Adams, G. E.; Clarke, E. D.; Flockhart, I. R.; Jacobs, R. S.; 
Sehmi, D. S.; Stratford, I. J.; Wardman, P.; Watts, M. E. Int. 
J. Radiat. Biol. 1979, 35, 133.
(4) Adams, G. E.; Flockhart, I. R.; Smithen, C. E.; Stratford, I. J.; 
Wardman, P.; Watts, M. E. Radiat. Res. 1976, 67, 9.
(5) Wasserman, T. H.; Philips, T. L.; van Raalte, G.; Urtasun, R. 
C.; Partington, J.; Koziol, D.; Schwade, J.; Gangji, D.; Strong, 
J. M. Br. J. Radiol. 1980, 53,172.
(6) Coleman, C. N.; Urtasun, R. C.; Wasserman, T. H.; Hancock, 
S.; Harris, J. W.; Halsey, J.; Hirst, V. K. Int. J. Radiat. Oncol. 
Biol. Phys. 1984, 10, 1749.
(7) Beaman, A. G.; Tautz, W.; Duschinsky, R. Antimicrob. Agents. 
Chemother. 1967, 5020.
(8) Roberts, J. T.; Bleehen, N. M.; Workman, P.; Watson, M. L 
Int. J. Radiat. Oncol. Biol. Phys. 1984, 10,1755.
(9) Saunders, M. I.; Anderson, P. J.; Bennett, M. H.; Dische, S.; 
Minchington, A.; Stratford, M. R. L.; Tothill, M. Int. J. Ra­
diat. Oncol. Biol. Phys. 1984, 10, 1759.
(10) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. Br. 
J. Cancer 1984, 49, 571.
(11) O'Neill, P.; Jenkins, T. C.; Stratford, I. J.; Silver, A. R. J.; 
Ahmed, I.; McNeil, S. S.; Fielden, E. M.; Adams, G. E. Anti- 
Cancer Drug Des. 1987, 1, 271.
(12) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. Int. 
«I. Radiat. Oncol. Biol. Phys. 1984, 10, 1653.
(13) Jenkins, T. C.; Naylor, M. A.; O'Neill, P.; Threadgill, M. D.; 
Cole, S.; Stratford, I. J.; Adams, G. E.; Fielden, E. M.; Suto, 
M. J.; Stier, M. A. J. Med. Chem. 1990, 33, 2508.
(14) Cole, S.; Stratford, I. J.; Adams, G. E.; Fielden, E. M.; Jenkins,
T. C. Radiat. Res., in press.
selective cytotoxicity is that the 2-nitroimidazole is 
bioreduced in these cells to an electrophile. The nature 
of this electrophile is still the subject of investigation, 
although the corresponding 2-nitrosoimidazoles and 2- 
(hydroxylamino)imidazoles have been implicated.16-18 For 
example, 1 has been reported19 to be 11 times more toxic 
toward V79 cells incubated under nitrogen than toward 
those incubated under air. Aziridinyl compound 4 is even 
more potent in this differential toxicity, the corresponding 
ratio19 being 67. This potentiation is due to conversion 
from a monofunctional to a bifunctional electrophile upon 
bioreduction, which is capable20 of cross-linking and 
cleaving the strands of DNA.
Recently, we have reported the synthesis and biological 
activity of two other series of nitroheterocycles (nitro­
triazoles21 and 2-nitrofuran-5-carboxamides19) augmented 
with basic and/or electrophilic (alkylating) side chains. In 
this paper, the extension of this program of drug devel­
opment through the synthesis and biological evaluation 
of a series of 2-nitrothiophene-5-carboxamides and 2- 
methyl-3-nitrothiophene-5-carboxamides with electrophilic 
and with basic side chains is presented.
Chemical Synthesis
For the preparation of the series of nitrothiophene-2- 
carboxamides with the nitro group in the /3-position of the 
heterocyclic ring, it was necessary to direct the nitration 
by blocking with an alkyl group the remaining a-position 
of a thiophene-2-carboxylic acid synthon. To this end,
2-methylthiophene-5-carboxylic acid (6) was prepared from
2-methylthiophene by Friedel-Crafts acetylation and 
subsequent haloform reaction, generally according to the 
method of Hartough.22 Nitration with nitric acid/acetic 
anhydride at low temperature then gave the central in­
termediate 7 (Scheme I).
For the preparation of nitroheterocycles with basic am­
ino groups in the side chains, it was necessary to couple 
a range of (protected) w-aminoalkylamines with the ap­
propriate nitroheterocyclecarboxylic acids. Formation of 
acid chloride 8 and subsequent treatment with the corre­
sponding amines furnished u>-(tertiary)aminoalkylamides 
9-13 in moderate to good yields after separation from 
highly colored byproducts and conversion to the hydro­
chloride salts (Scheme I). The deep colorations may be 
due to a small amount of nucleophilic ring opening of the 
nitrothiophene analogous to those reported by Dell’Erba 
et al.23-24 u>-(Primary)alkylamino amide 19 was synthesized 
from Na-BOC-lysine (14) in five steps. Protection of the 
eamine as the FMOC derivative was achieved with 
fluoren-9-ylmethyl chloroformate, giving 15, and the car- 
boxylic acid was blocked as the methyl ester to give the
(15) Jenkins, T. C. In The Chemistry of Antitumour Agents; Wil- 
man, D. E. V., Ed.; Blackie: Glasgow, 1990.
(16) Noss, M.; Rauth, A. M.; Panicucci, R.; McClelland, R. A. Bio- 
chem. Pharmacol. 1988, 37, 2585.
(17) McClelland, R. A.; Panicucci, R.; Rauth, A. M. J. Am. Chem. 
Soc. 1985, 107, 1762.
(18) McClelland, R. A.; Panicucci, R.; Rauth, A. M. J. Am. Chem. 
Soc. 1987, 109, 4308.
(19) Naylor, M. A.; Stephens, M. A.; Cole, S.; Threadgill, M. D.; 
Stratford, I. J.; O’Neill, P.; Fielden, E. M.; Adams, G. E. J. 
Med. Chem. 1990, 33, 2603.
(20) O’Neill, P.; McNeil, S. S.; Jenkins, T. C. Biochem. Pharmacol. 
1987, 36, 1787.
(21) Jenkins, T. C.; Stratford, I. J.; Stephens, M. A. Anti-Cancer 
Drug. Des. 1989, 4, 145.
(22) Hartough, H.; Kosak, A. J. Am. Chem. Soc. 1947, 69, 3093.
(23) Dell’Erba, C.; Spinella, D.; Leandri, G. J. Chem. Soc., Chem. 
Commun. 1969, 549.
(24) Guanti, G.; Dell’Erba, C.; Leandi, G.; Thea, S. J. Chem. Soc., 
Perkin Trans. 1 1974, 2357.
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•Reagents: (i) HN0,/A<*0; (ii) SOC1* (iii) RCHjCHjNHj/EtjO; (iv) NajCOj/CHjCl*; (v) FMOCCl/NaHCOs/dioxane/H ,0; (vi) 
CHjNj/EtjO, (vii) CFjCOjH; (viii) piperidine; (ix) HC1. BOC = tert-butoxy carbonyl. FMOC = (fluoren-9-yhnethoxy)carbonyL
Scheme II.a Synthesis of Basic Nitrofuran 23
• —  r v„ - Q - ON COKHCH£HIN
Scheme III.0 Synthesis of 3-Nitrothiophene 21 with an 
Electrophilic Side Chain
J  V COkH
•Reagents: (i) l-(2 -aminoethyl)piperidine/EtjN/CH2Cl2.
fully orthogonally protected amino acid 16. Deprotection 
of the a-amino group with trifluoroacetic acid rapidly 
afforded the salt of amine 17, which was coupled with 8 
under mildly basic conditions, giving 18. The required 
w-aminoalkylamide 19 was then obtained by facile de­
protection of the terminal amine effected by the secondary 
amine piperidine. In a similar manner to the general 
coupling, 2-nitrofuran-5-carbonyl chloride (22), prepared 
as described previously,19 was treated with N-(2-amino- 
ethyl)piperidine to yield the required nitrofuran with a 
basic side chain (23) (Scheme II).
Synthesis of nitrothiophenecarboxamides with electro­
philic oxirane side chains was achieved through the cor­






•Reagents: (i) SOCla, (ii) allylamine/EtjO, (ii) 3-chloroperoxy- 
benzoic acid/CHjClj.
IV. Reaction of acid chloride 8 with allylamine gave 
3-nitro amide 20 in excellent yield, without the attendant 
discoloration noted during the syntheses of the free bases
«
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Schem e IV.8 Synthesis of N-(Oxiranylmethyl)-2-nitrothiophenainide8 27 and 30
8 Reagents: (i) AgNOj/HjO; (ii) SOC1* (iii) allylamine/CH2Cl2; (iv) 3-chloroperoxybenzoic atid/CHjCl* (v) malonic add/pyridine.
of the tertiary amine amides 9-13. Epoxidation was ef­
fected using 3-chloroperoxybenzoic acid, giving oxiranyl- 
methylamide 23 (Scheme III). In the 2-nitro series, the 
commercially available 2-nitrothiophene-5-carboxaldehyde 
24 was oxidized smoothly to the corresponding carboxylic 
acid 25 with silver (I) nitrate (Scheme IV). Treatment of 
24 with potassium permanganate under a variety of con­
ditions gave 25 in only trace amounts, in contrast to the 
reported25 synthesis of 25 from 5-methyl-2-nitrothiophene 
with this reagent. Reaction of the corresponding acid 
chloride with allylamine and subsequent epoxidation with 
the same peroxyacid yielded allylamide 26 and oxiranyl- 
methylamide 27, respectively. Nitrothiophenepropenoic 
acid 28 was formed in moderate yield by Doebner con­
densation of aldehyde 24 with malonic acid in hot pyridine 
in a modification of the procedure of Tirouflet et al.26 
Again, the acid chloride reacted smoothly with allylamine 
(forming 29). As expected, epoxidation under acidic con­
ditions occurred only at the relatively electron-rich ter­
minal olefin, affording the V-oxiranylmethyl unsaturated 
amide 30.
The coupling of an appropriately functionalized three- 
carbon side chain to a nitrothiophene could be accom­
plished via conjugate addition of a Grignard reagent to an 
appropriate substrate and oxidative rearomatization of the 
intermediate addition product. Ballini et al.27 have re­
cently reported on the addition of a variety of alkyl- 
magnesium halides to unsubstituted 2-nitrothiophene, 
noting that the products of 2,3- and 2,5-addition were both 
formed in each case and were separated only with great 
difficulty, if at all. The yields were reported to be modest.
On the basis of this information, we predicted that addition 
of allylmagnesium bromide to 3-methyl-2-nitrothiophene
(32) may be governed, at least in part, by steric factors
(25) Rinkes, I. J. Reel. Trav. Chim. Pays-Bas 1932, 51, 1134.
(26) Tirouflet. J.; Foumari, P. C. R. Seances Acad. Sci. 1956, 243, 
61.
(27) Ballini, R.; Bartoli, G.; Bosco, M.; Dalpozzo, R.; Marcantoni, 
E. Tetrahedron 1988, 44, 6435.
(28) Wardman. P. J. Phys. Chem. Ref. Data 1989, 18, 1637.
(29) Ahmed, I.; Jenkins, T. C.; Walling, J. M.; Stratford, I. J.; 
Sheldon, P. W.; Adams, G. E.; Fielden, E. M. Int. J. Radiat. 
Oncol. Biol. Phys. 1986, 12, 1079.
Scheme V.8 Conjugate 2,3-Addition of a Grignard Reagent to 
Nitrothiophene 32
8 Reagents: (i) HNOj/A^O; (ii) allylmagnesium bromide/THF; 
(iii) 5,6-dichloro-2,3-dicyanobenzoquinone/THF; (iv) BFj-EtjO/ 
THF; (v) 3-chloroperoxybenzoic acid/CH2Cl2. THF = tetrahydro- 
furan.
tending to favor formation of the product (33) of 2,5-ad- 
dition, rather than isomer 34. Furthermore, isolation of 
the required 2,3,5-trisubstituted thiophene 35 was facili­
tated by the inability of 34 to be oxidatively rearomatized 
with dichlorodicyanobenzoquinone (DDQ), owing to the 
presence of a quartemary carbon atom at C-3 (Scheme V). 
The :H NMR spectrum of the crude product mixture 
showed the presence of dihydrothiophene 34 and aromatic 
thiophene 35. The latter compound was isolated easily 
from this mixture by chromatography in modest overall 
yield. Interestingly, the oxidative rearomatization was 
effected with equal efficiency by air in the presence of 
catalytic Lewis acid (boron trifluoride diethyl etherate),
2116 Journal of Medicinal Chemistry, 1991, Vol. 34, No. 7 Threadgill et al.
Schem e VI.° Conjugate 2,5-Addition of a Grignard Reagent to 
Nitrothiophene 36
OMc
Table I. Radiosensitization by, and Redox Potentials of, 
Nitrothiophenes 9-13, 19, 21, 23, 26, 27, 30, 36, and 40 and 
Nitrofuran 23 in Vitro (Data for nitroimidazoles 1, 4, and 5 are 
shown for comparison.)
OUtm
■Reagents: (i) MeOH/HCl; (ii) allylmagnesium bromide/THF; 
(iii) 5,6-dichloro-2,3-dicyanobenzoquinone/THF. THF = tetra- 
hydrofuran.
obviating the need to remove the organic byproduct di- 
chlorodicyanohydroquinone. Epoxidation with peroxyacid 
furnished oxiranylmethylnitrothiophene 36. The useful­
ness of addition of appropriate Grignard reagents into 
substituted 2-nitrothiophenes was demonstrated in the 
synthesis of compound 40 (Scheme VI), which requires 
selective addition in the 2,3-mode, rather than in the
2,5-mode as above. Protection of the aldehyde function 
of 24 was carried out by formation of dimethyl acetal 37. 
In this substrate, the dimethoxymethyl group should have 
a large steric requirement and direct addition toward the
2,3-mode. Addition of allylmagnesium bromide to 37 gave 
a mixture of dihydrothiophenes 38 and 39. Of these, only 
38 could be rearomatized with DDQ, giving 40 as the only 
thiophene product, albeit in poor yield. Attempted ep­
oxidation of 40 failed owing to acid-catalyzed degradation 
of the acetal function.
Although strict analogues of lead compound 4, bearing 
an aziridinyl group, were sought, treatment of oxiranes 21, 
27, 30, and 36 with aziridine gave only complex, highly 
colored mixtures. Similarly, reaction of these oxiranes with 
substituted aziridines 2,2-dimethylaziridine and cis-2,3- 
dimethylaziridine, which gave more stable adducts in the 
nitrofuran series,19 also failed to furnish identifiable, stable 
products.
The one-electron reduction potentials (E \) were mea­
sured, according to the method previously described by 
us,11 for compounds 9-11,13,23,26,27, 30, and 36. Amides 
of 2-methyl-3-nitrothiophene-5-car boxy lie acid (7) are some 
200-250 mV less oxidizing than those of 2-nitro- 
thiophene-5-carboxylic acid (25); this trend is similar to 
that observed for related nitrofurans.19 Interestingly, 






1 0.6* 2.6 (10)' -389*
4 0.1/ 3.1 (0.5)* -389*
5 0.1* 3.1 (0.5)*
9 0.1 2.0 (0.5) -499
10 1.0 1.6 (1.0) -537
11 0.07 3.2 (1.0) -537
12 0.07 2.2 (0.2)
13 0.03 2.5 (0.5) -519
19 0.05 1.6 (0.05)
21 0.2 1.6 (0.2)
23 0.01 1.9 (0.05) -242
26 0.08 1.6 (0.08) -272
27 0.05 1.9 (0.1) -271
30 0.05 1.6 (0.05)* -274
36 0.06 2.7 (0.1) -481
40 1.3 (0.005)
® Concentration of compound required to give enhancement ratio 
= 1.6. b Enhancement ratio at maximum concentrations of com­
pounds (in parentheses). This maximum concentration was the 
highest concentration which did not cause significant cytotoxicity 
to the cells. 'Referred to the normal hydrogen electrode (NHE), 
using methyl viologen, benzyl viologen, and triquat as redox cou­
ples (£ 17[Vi+/V*+] = -448, -370, and -549 mV, respectively).28 
‘'Data taken from ref 13. 'Data taken from ref 4. 'Data taken 
from ref 29. 'Data taken from ref 11. *Concentration limited by 
solubility.
potential for 5-nitrothiophenes, which are in broad 
agreement with those reported in this study. However, the 
value reported30 for a close analogue of 7 (a 4-nitro- 
thiophene) is at variance with those determined here for 
a range of 4-nitrothiophenes.
Biological Evaluation in Vitro
Nitrothiophenes 9-13, 19, 21,26, 27, 30, 36, and 40 and 
nitrofuran 23 were assayed for their ability to sensitize 
hypoxic V79 cells in vitro to 7 -radiation, as described 
previously.13,19 The results are expressed in Table I as ER 
max, the maximum factor (enhancement ratio) by which 
the cells were sensitized to radiation when compared to 
control cells without added nitroheterocycles, and Cl£, the 
concentration of nitroheterocycle required to give an en­
hancement ratio of 1.6.
The 2-methyl-3-nitrothiophene-5-carboxamides with 
primary or tertiary amine bases in the side chains, com­
pounds 9,11-13, and 19, all have values of C16 in the range 
0.03-0.1 mM. The exception is morpholinyl analogue 10, 
which would be expected31 to be markedly less basic than
9,11-13, and 19, owing to the presence of the heterocyclic 
oxygen; this compound gives Cl>6 = 1.0 mM. The struc­
turally analogous N-oxiranylmethylcarboxamide 23, with 
a potentially electrophilic rather than a basic side chain, 
is intermediate in potency.
For the strong tertiary amine bases 9 and 11-13, sig­
nificant toxicity toward the experimental cells was not 
observed at concentrations equal to C16 and higher values 
of the enhancement ratio (up to 3.2 for 11) were achieved 
at concentrations up to 1 order of magnitude higher than 
C16. The remaining, less potent compounds, 10 and 21, 
together with primary amine 19, elicited significant killing 
of cells through toxicity at concentrations equal to C1-6. 
Thus 2-methyl-3-nitrothiophene-5-carboxamides 9 and
11-13 are markedly more potent than is misonidazoie (1)
(30) Breccia, A.; Busi, F.; Gattavecchia, E.; Tamba, M. Radiat. (31) CRC Handbook of Chemistry and Physics, 58th ed.; Weaat, R.
Environ. Biophys. 1990, 29, 153. C., Ed.; CRC Press: Cleveland, 1978; p D-147.
Nitrothiophenes with Basic or Electrophilic Substituents
Table II. Selective Toxicity of Nitrothiophenes 10- 12, 19, 21, _ 
26, 27, and 30 and Nitrofuran 23 to Hypoxic V79 Cells in Vitro' 






1 45.0* ^O' 11'
4 0.3* 0.0045' 67'
5 2.3d 0.09* 26d
10 2.5 2.5 1.0
11 1.8 0.8 2.3
12 0.5 0.25 2.0
19 0.35 0.35 1.0
21 0.35 0.4 0.9
23 0.05 0.016 3.0
26 0.30 0.11 2.5
27 0.15 0.15 1.0
30 0.08 0.08 1.0
36 0.065 0.045 1.3
' Cao(AIR) and Cgo(N^  are the concentrations of compounds re­
quired to reduce the optical density by 50% compared to controls 
when the incubations in the MTT assay are performed under air 
or under nitrogen, respectively^1 optical density is proportional to 
the number of viable cells present at the end of the period of in­
cubation. ‘Ratio = CW(AIR)/Cb^Nj). 'Data taken from ref 19. 
d These data are the concentrations required to reduce the survival 
of cells to 1% in a donogenic assay and are taken from ref 13.
and, indeed, equal or greater in potency than is the leading
2-nitroimidazole with an electrophilic side chain, com­
pound 4, despite having redox potentials (El7) some 100 
mV more negative (less oxidizing) than those of the 2- 
nitroimidazoles. These data are in apparent contrast to 
the relationship3,4 between increasing radiosensitizing 
potency in vitro and more positive redox potential found 
for a wide range of nitro(hetero)aromatic agents. An ap­
parent enhancement of radiosensitizing potency has, 
however, been reported32"34 for electron-affinic compounds 
with strong organic bases in the side chain. This phe­
nomenon has been ascribed35-38 to enhanced uptake of 
these bases by cells in culture, leading to higher effective 
concentrations within the cell compared to those in the 
external medium. In addition, weak bases analogous to 
those described here are reported39,40 to be able to con­
centrate adjacent to DNA through electrostatic interac­
tions between the negatively charged DNA phosphate 
backbone and the positively charged conjugate adds of the 
amino groups on the sensitizers. This effect may well be 
operating for 9,11-13, and 19 but not for the less basic 
morpholine 10. To investigate whether this method of 
increasing potency could be applied to a nitroheterocycle 
of more positive redox potential, 2-nitrofuran-5-carbox- 
amide 23 was evaluated for radiosensitizing effidency and
(32) Wardman, P.; Clarke, E. D. J. Chem. Soc., Faraday Trans. 
1976, 72,1377.
(33) Anderson, R  F.; Patel, K. B.; Smithen, C. E. Int. J. Radiat. 
Biol. 1977,32, 471.
(34) Smithen, C. E.; Clarke, E. D.; Dale, J. A.; Jacobs, R  S.; 
Wardman, P.; Watts, M. E. In Radiation Sensitizers: Their 
Use in the Clinical Management of Cancer, Brady, L. W., Ed.; 
Masson Press: New York, 1980.
(35) Walling, J. M.; Stratford, I. J.; Adams, G. E.; Silver, A. R. J.; 
Ahmed, I.; Jenkins, T. C.; Fielden, E. M. Int. J. Radiat. OncoL 
Biol. Phys. 1986,12,1083.
(36) Walling, J.; Stratford, L J.; Adams, G. E.; Stephens, M. A. Int. 
J. Radiat. Biol. 1988, 53, 641.
(37) Dennis, M. F.; Stratford, M. R L.; Wardman, P.; Watts, M. E. 
Int. J. Radiat. Biol. 1985, 47, 629.
(38) Watts, M. E.; Jones, N. R  Int. J. Radiat. Biol. 1985,47,645.
(39) Stratford, M. R; Dennis, M. F.; Watts, M. E.; Watfa, R R Br. 
J. Radiol. 1988,61, 860.
(40) Smoluk, G. S.; Fahey, R C.; Ward, J. F. Radiat. Res. 1988,114,
3.
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Table III. Maximum Tolerated Ip Doses of Nitrothiophenes 
9-11, 13 and 19 and Nitrofuran 23 in C3H/He Mice (Data for 






1 4.00* 11 <0.34
4 0.38* 13 0.24
5 1.00' 19 0.34
9 0.34 23 0.17
10 0.34
‘ Compounds were dissolved in 0.1 M phosphate-buffered saline 
solution at pH 7.4 immediately before use and were injected in a 
total volume equivalent to 0.02 mL per g mouse body weight 
‘The maximum tolerated dose (MTD) is the highest single dose 
which did not produce severe or persistent clinical signs or death 
of the adult non-tumor-bearing mice within 24 h. 'Data taken 
from ref 14.
Table IV. Radiosensitization by Nitrothiophene 9 and 
Nitrofuran 23 of KHT Tumors in Vivo (Data for nitroimidazole 4 





mmol kg-1 surviving fraction'
none 2.8 x l(r2 (3.1-2.4 x ldr2)
4 60 0.38 8.3 X 10-4 (7.2-9.5 X 10-4)
9* 30 0.34 5.0 x 10-* (2.9-8^ x 1(T*)
23d 60 0.17 2.2 x HT* (1.9—2.7 x 10-*)
' Optimum time interval between injection of the compound and 
irradiation of the tumor. ‘Compounds were administered ip as in 
Table HI, footnote a. 'Surviving fraction of donogenic cells (mean 
± SE) after treatment with compound and X-rays (10 Gy). 
d Compounds 9 and 23 had no effect on the survival of donogenic 
cells when irradiation was omitted.
was found to be 7-fold more potent than its analogue 11 
in terms of CL6 (Table I). This fur an has E 17 = -242 mV 
and, like other nitrofurancarboxamides,19 is up to 270 mV 
more electron-affinic than the 2-methyl-3-nitro- 
thiophene-5-carboxamides. Analogous 2-nitrofuran-5- 
carboxamides with potentially electrophilic or unreactive 
side chains have values of Cu  in the range 0.02-0.1 mM,u  
compared with C16 = 0.01 mM for 23.
In contrast with die considerable potency of many of the 
compounds tested as radiosensitizers of hypoxic cells in 
vitro, no useful selective toxicity toward hypoxic V79 cells 
was shown by 3-nitrothiophenes 10-12,19, and 21, nitro­
furan 23, and 2-nitrothiophenes 26,27, and 30 (Table II). 
Although the values of CeofAIR), the concentration re­
quired to kill 50% of the aerobic cells under the conditions 
of the assay, range from 0.05 mM for the highly oxidizing 
nitrofuran 23 to 2.5 mM for nitrothiophene 10, little ad­
ditional toxicity as a result of bioreduction is evident. 
Ratios of Cgo(AIR)/Cgo(N2) range from 0.9 to 3.0 with no 
apparent structure-activity relationship. Similar results 
have been reported by us21 with a series of nitrotriazoles 
and the lack of differential toxicity toward hypoxic cells 
was attributed either to lack of bioreduction or to lack of 
chemical reactivity of the reduced products leading to lack 
of toxic effects. For comparison, even the monofunctional
2-nitroimidazole lead compound misonidazoie (1) gives a 
corresponding ratio of 11, whereas "dual function” agents 
4 and 5 show even higher selectivities in cytotoxicity to­
ward hypoxic cells.
Biological Evaluation in Vivo
Selected compounds (nitrothiophenes 9-11,13, and 19 
and nitrofuran 23) were administered in escalating doses 
to mice by the ip route. The maximum single, nontoxic 
doses (MTD) were determined, initially to provide a basis 
for subsequent experiments on radiosensitization in vivo. 
The values of MTD are shown in Table III. The nitro-
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thiophenes were generally not well-tolerated and at the 
MTD doses (0.24-0.34 mmol kg"1) caused rapid respiration 
and bizarre stretching activity in the mice, which persisted 
from about 2 to 90 min after injection. At higher doses, 
immobility, tremors, and spasms were noted, and the mice 
did not recover. Nitrofuran 23 was also toxic, leading to 
convulsions and death after doses greater than 0.17 mmol 
kg"1. Effects on the central nervous system are known to 
be caused by some tertiary amines. For example, valproic 
acid (2-propylbutanoic acid) is an anticonvulsant thera­
peutic drug42 whereas the corresponding A/-[2-(dimethyl- 
amino)ethyl]amide causes convulsions;43 this amide has 
some structural analogy to 9 and 11-13.
As the compounds had been shown to have little selec­
tive toxicity toward hypoxic cells in culture, they were not 
evaluated as bioreductively activated cytotoxins in vivo. 
The radiosensitizing potencies of 9 and 23 were investi­
gated and are compared with the effect of 4 in Table IV. 
The compounds were administered at their MTD to mice 
bearing the subcutaneous KHT sarcoma at various times 
before local irradiation of the tumors with 240 KV X-rays 
(10 Gy). The tumors were excised after 24 h and the 
survival of tumor cells was determined in a donogenic 
assay.14 In this experimental system, 4 reduced the sur­
viving fraction of cells after irradiation to a value which 
would be expected if all the tumor cells were aerobic;14 Le. 
sensitization was equivalent to that of oxygen. Compound 
9 was much less effective, producing no radiosensitization 
when administered 15 or 60 min before irradiation and 
only a small reduction in surviving fraction when the 
highest possible dose was administered 30 min before the 
dose of X-rays. In contrast, the highly electron-affinic 
nitrofuran 23 does show some radiosensitizing properties 
in vivo. However, even when administered at its MTD, 
it is markedly less effective than is the lead compound 4 
when given at an equitoxic dose. Other nitrothiophenes 
were excluded from evaluation as radiosensitizers in vivo 
as they elicited equal or greater toxicity (measured by 
MTD) than did 9.
Conclusions
A series of nitrothiophenecarboxamides has been syn­
thesized; those compounds (9,11-13,19) which have strong 
amine bases in the side chain are potent sensitizers of 
hypoxic cells to the effects of 7 -radiation in vitro, as is 
nitrofuran 23. Indeed, these compounds are markedly 
more potent as radiosensitizers in vitro than would be 
predicted3*4 from their relatively negative one-electron 
redox potentials. However, systemic toxicity precludes the 
translation of these potencies into useful antitumor ra­
diosensitization in vivo. Similarly, general toxicity prevents 
the demonstration of selective bioreductively activated 
cytotoxicity toward hypoxic V79 cells in vitro. Although 
the compounds were cytotoxic to hypoxic V79 cells at 
concentrations equal to or 1 order of magnitude lower than 
for misonidazoie (1), despite much more negative values 
of E \  strong nonselective (aerobic) toxicity was manifest 
also at similar concentrations.
It is concluded that despite the undoubted intrinsic 
potency of 2-methyl-3-nitrothiophene-5-carboxamides and 
related compounds as radiosensitizers of hypoxic cells, 
development of a clinically useful agent of this type will 
depend on the understanding of the mechanisms of general
(41) Stratford, I. J.; Stephens, M. A. Int. J. Radiat. Oncol. Biol. 
Phys. 1989, 16, 973.
(42) Carraz, C. L. Aggressologie 1967, 8 ,13.
(43) Carraz, G.; Boucherle, A.; Lebreton, S.; Benoit-Guyot, J. L.; 
Boitard, M. Therapie 1964,19, 917.
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toxicity and design of suitable analogues to circumvent this 
problem.
Experim ental Section
NMR spectra were obtained at 60 MHz with JEOL PMX60SI 
and at 270 MHz with JEOL GX270 spectrometers, using SiMe4 
as internal standard. A Philips PU9516 instrument furnished 
the IR spectra, which were obtained with Nujol mulls except where 
indicated. Mass spectra were obtained with a VG 7070 spec­
trometer in either the electron impact (El) mode at 70 eV or in 
the chemical ionization mode (with 2-methylpropane). Melting 
points are uncorrected. Tetrahydrofuran (THF) was distilled from 
CaH2. Brine refers to saturated aqueous NaCl. Elemental 
analyses were determined by Elemental Microanalysis Ltd., 
Okehampton, U.K. The one-electron reduction potentials CEli) 
of selected compounds (Table I) were determined as previously 
described.11 Solutions in organic solvents were dried by treatment 
with anhydrous Na^C^ and filtration. Solvents were removed 
by evaporation under reduced pressure. Radial PLC refers to 
centrifugally accelerated preparative-layer chromatography using 
a Chromatotrori (TC Research, Norwich, U.K.). All chroma­
tography was performed with silica gel as stationary phase. 2- 
Methyl-3-nitrothiophene-5-carboxylic acid (7),22,44 (£)-3-(3- 
nitrothiophen-5-yl)propenoic acid (28),45 and 3-methyl-2-nitro- 
thiophene (32J46 were prepared by literature methods.
2-Methyl-jV-[2-(dimethylamino)ethyl]-3-nitrothiophene- 
5-carboxamide Hydrochloride (9). Carboxylic acid 7 was 
treated with SOCl2 and with 2-(dimethylamino)ethylamine as for 
the preparation of 12 below to afford 9 (43%) as off-white crystals: 
mp 156-157 °C; IR *w  3330,1635,1560,1550 cm'1; NMR (free 
base; CDCI3) 6 2.30 (2, 6 H, NfCHslj), 2.50 (t, J  = 6 Hz, 2 H, 
MejNCHj), 2.80 (s, 3 H, thiophene CH*), 3.50 (q, J  *  6 Hz, 2 H, 
NHCH2), 7.05 (br, 1 H, NH), 7.90 (s, 1 H, thiophene H). Anal 
C, H, N.
2-MethyI-JV-(2-morpholin-4-ylethyl)-3-nitrothiophene-5- 
carboxamide Hydrochloride (10). Carboxylic add 7 was treated 
with SOCl2 and with 4-(2-aminoethyl)morpholine as for the 
preparation of 12 below to afford 10 (60%) as off-white crystals: 
mp 259-261 °C; IR j w  3200, 3110 (w), 2600-2450, 1635,1540 
cm'1; NMR (D20) 5 2.80 (s, 3 H, CH3), 3.4-4.2 (m, 12 H, mor­
pholine 2,3,5,6-H + NCH2CH2N), 8.10 (s, 1 H, thiophene H); MS 
(El) m fz  213 (M -  C4H8NO), 170 (M -  morpholine CH2CH2NH), 
100 (100) (morpholine CH ;^ MS (CD m fz  300 (M + 1), 270,100 
(100) (morpholine CH2). Anal. C, H, N.
2-Methyl-3-nitro-N-(2-piperidin-l-ylethyl)thiophene-5- 
carboxamide Hydrochloride (11). Carboxylic add 7 was treated 
with SOCl2 and with l-(2-aminoethyl)piperidine as for the 
preparation of 12 below, except that the crude material was 
purified by radial PLC (Et^ O then CHCl3/MeOH (9:1)) to furnish 
11 (40%) as buff crystals: mp 237-238 °C; IR *'aMI 3290,3090 (w), 
2700-2550, 1670,1550 cm’1; NMR (D20) 8 1.6-2.1 (m, 6 H, pi­
peridine 3,4,5-H), 2.75 (s, 3 H, CH3), 2.9-3.3 (m, 4 H, piperidine
2,6-H), 3.4-3.9 (m, 4 H, NCH2CH2N), 8.05 (s, 1 H, thiophene H); 
MS (El) m/z 214 (M -  piperidine CH^, 98 (100) (piperidine CH ;^ 
MS (Cl) m /z  298 (M + H), 268 (M -  NO), 98 (100) (piperidine 
CH2).
JV-[2-[JVJV-Bis(l-methylethyl)amino]ethyl]-2-methyl-3- 
nitrothiophene-5-carboxamide Hydrochloride (12). Car­
boxylic add 7 (380 mg, 2 mmol) was boiled under reflux in SOCl2 
(3 mL) for 10 min and the excess reagent was evaporated. (2- 
Aminoethyl)bis(l-methylethyl)amine (0.75 mL) was added to the 
residue in EtjO (20 mL). After 10 min, the suspension was poured 
into CH2C12, was washed twice with saturated aqueous NaHCOj, 
with H20, and with brine, and was dried. The evaporation residue, 
in propan-2-ol (100 mL), was treated with aqueous HC1 (10 M, 
0.6 mL). Recrystallization of the evaporation residue from pro- 
pan-2-ol gave 12 (420 mg, 59%) as off-white crystals: mp 216-218 
°C dec; IR 3250,2680,1665,1545 cm'1; NMR (D20) 6 1.35 
(d, J  = 6 Hz, 12 H, 2 x C(CH3)2), 2.75 (s, 3 H, thiophene CHj),
(44) Snyder, H. R.; Carpino, L. A; Zack, J. F. Jr.; Mills, J. F. J. Am. 
Chem. Soc. 1957, 79, 2556.
(45) Carrara, G.; Ettore, R.; Fava, F.; Rolland, G.; Testa, E.; Vecchi, 
A. J. Am. Chem. Soc. 1954, 76, 4391.
(46) Rinkes, I. J. Reel. Trav. Chim. Pays-Bas 1933, 52.1052.
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3.05 (septet, J  = 6 Hz, 2 H, 2 x CHMe2), 3.3-3.8 (m, 4 H, 
NCHjCHjN), 8.10 (s, 1 H, thiophene H). Anal. C, H, N.
2-Methyl-3-nitro-AT-(3-pyrrolidin-l-ylpropyl)thiophene- 
5-carboxamide Hydrochloride (13). Carboxylic acid 7 was 
treated with SOClj and with l-(3-aminopropyl)pyrrolidine as for 
the preparation of 12 above to afford 13 (31%) as off-white 
crystals: mp 214-215 °C dec; IR ^  3240,2580,2500,1650,1540 
cm-1; NMR (D20) 6 1.2-1.7 (m, 6 H, pyrrolidine 3,4-H + 
NCH2Cff2CH2N), 2.70 (s, 3 H, CH3), 3.0-3.5 (m, 4 H, 
NCtf2CH2CH2N), 8.05 (s, 1 H, thiophene H). Anal. C, H, N.
jVa-(tei?-Butoxycarbonyl)-JV(-[(fluoren-9-ylmethoxy)- 
carbonyl]lysine Methyl Ester (16). Fluoren-9-ylmethyl 
chloroformate (2.585 g, 10 mmol), in 1,4-dioxane (60 mL), was 
added to Na- (t er£-butoxycarbonyl) lysine (14) (2.46 g, 10 mmol) 
and NaHCOj (2.1 g, 25 mmol) in H20  (60 mL) and the mixture 
was stirred for 16 h before being partitioned between CH2C12 (400 
mL) and aqueous H2SO4 (1.0 M, 150 mL). The organic phase was 
washed with H20  and was dried. The solvent was evaporated to 
give N m- (fert-butoxycarbonyD-N,- ((fluoren-9-ylmethoxy)- 
carbonyl]Iysine (15) (4.34 g, 93%) as a gum: NMR (CDClj) 6 1.45 
(8 + m, 15 H, C(CHj)3 + lysine /3,y,3-H), 3.20 (br q, J  = 6 Hz, 
2 H, lysine <-H), 4.0-4.5 (m, 4 H, fluroene 9-H + fluorene CH2 
+ lysine a-H), 5.2-5.8 (br, 2 H, 2 x NH), 7.2-7 A (m, 8 H, fluorene
1- 8-H). This add (2.17 g, 4.64 mmol) in E^O (100 mL) was 
treated with excess C H ^  in E^O (30 mL) for 10 min until 
evolution of N2 ceased. A solution of AcOH in E^O (10%) was 
then added until no more N2 was evolved and the yellow color 
was discharged. The solvent was evaporated to give 16 (2.235 g, 
quant) as a white solid: mp 103-105 °C; NMR (CDCls) b 1.45 
(8 +  m, 15 H, C(CHs)3 + lysine 0,7 ,3-H), 3.20 (br q, J  = 6 Hz, 
2 H, lysine c-H), 3.70 (s, 3 H, OCHs), 4.1-4.6 (m, 4 H, fluorene 
9-H + fluorene CH2 + lysine a-H), 4.7-5.3 (br, 2 H, 2 x  NH),
7.2-7.8 (m, 8 H, fluorene 1- 8-H). AnaL C, H, N.
JV.-[ (2-Methy l-3-nitrothiophene-5-y 1 )carbony 1 ]lysine 
Methyl Ester Hydrochloride (19). Protected amino add 16 
(1.45 g, 3 mmol) was treated with CFsCOsH (10 mL) for 20 min 
before the excess reagent was evaporated. The residue (Nt- 
[(fluoren-9-ylmethoxy)carbonyl]lysine methyl ester 17), in CH2C12 
(100 mL), was washed with saturated aqueous NaHCOs and was 
dried. Anhydrous Na2C03 (4 g) was added, followed by 2- 
methyl-3-rutxothiophene-5-carbonyl chloride (8 as described above; 
2 mmol). The mixture was stirred for 30 min, was washed with 
H20  (twice), aqueous (0.5 M), and H20, and was dried. 
Purification of the evaporation residue by radial PLC (CHCls) 
gave N<-((fluoren-9-ylmethoxy)carbonyl}-Na-l(2-methyl-3-nitro- 
thiophene-5-yl)carbonyl]ly8ine methyl ester (18) (670 mg, 60%) 
as a gum: NMR (CDCI3) b 1.2-2.0 (m, 6 H, lysine (3,y,b-H), 2.70 
(s, 3 H, thiophene CHs), 3.15 (br q, J  = 6 Hz, 2 H, lysine e-H),
3.75 (s, 3 H, OCHs), 4.1-4.55 (m, 4 H, fluorene 9-H + fluorene 
CH2 + lysine Na-H), 4.70 (br q, J  -  6 Hz, 1 H, lysine a-H), 5.40 
(t, J  -  6 Hz, 1 H, lysine Nt-H), 7.3-7.9 (m, 8 H, fluorene 1- 8-H),
8.20 (s, 1 H, thiophene H). This material (670 mg, 1.2 mmol) in 
THF (20 mL) was treated with piperidine (5 mL) for 10 min. The 
evaporation residue was purified by radial PLC (silica gel, 
CHCl3/MeOH (9:1)) and was treated with aqueous HC1 (10 M, 
0.2 mL) in propan-2-ol (20 mL). The solvent was evaporated to 
obtain 19 (160 mg, 36%) as a white solid: mp 83-84 °C; NMR 
(D20) 5 1.5-2.1 (m, 6 H, lysine /3,y,3-H), 2.80 (s, 3 H, thiophene 
CHj), 3.15 (br t, J  »  7 Hz, 2 H, lysine t-H), 3.85 (s, 3 H, OCHg), 
4.60 (m, 1 H, lysine a-H), 8.20 (s, 3 H, thiophene H).
2-Methyl-3-nitro-jV-prop'2-enylthiophene-5-carboxamide 
(20). Compound 7 was treated with SOCl2 and with allylamine 
as for the synthesis of 12 above, except that the treatment with 
HC1 was omitted, to give 20 (81%) as a pale buff solid: mp 84£-86 
•C; IR ^  3320,1625,1535 cm"1; NMR (CDC13) b 2.80 (s, 3 H, 
CHa), 4.05 (tt, J  -  6 and 1 Hz, 2 H, NCHa), 5.15 (br d, J  * 11 
Hz, 1 H) and 5.25 (br d, J  = 16 Hz, 1 H) (OCHs), 5.90 (ddt, 
J  = 16,11 and 6 Hz, 1 H, CH=CHj), 6.6 (br, 1 H, NH), 7.90 (s, 
1 H, thiophene H). AnaL C, H, N.
2-MethyI-3-nitro-JV-(oxiranylmethyl)thiophene-5- 
carboxamide (21). Amide 20 (1.89 g, 836 mmol) was boiled under 
reflux with 3-chloroperoxybenzoic acid (50%, 6.48 g, 18.8 mmol) 
in CHaCla (100 mL) for 8 h. The solution was washed three times 
with aqueous NasSOs (10%), twice with saturated aqueous 
NaHC03, with H20, and with brine and was dried. Column 
chromatography of the evaporation residue gave 21 (650 mg, 32%)
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as a pale buff solid: mp 92-93 °C; IR v„„ 3350, 3110 (w), 1625, 
1535 cm"1; NMR (CDC13/CD30D) b 2.70 (dd, J  = 4 and 2 Hz, 1 
H) and 2.80 (m, 1 H) (oxirane 3-Ha), 2.80 (s, 3 H, thiophene CHs),
3.2-3.9 (m, 3 H, NCH2CH), 8.07 (s, 1H, thiophene H); MS (El) 
m/z 242.0314 (M) (C^H^NAS requires 242.0361), 224,211,199, 
170 (100) (M -  oxiranylmethyl); MS (Cl) m/z 243 (100) (M + H), 
170.
2-Nitro-jV-(2-piperidin-l-ylethyl)furan-5-carboxamide 
Hydrochloride (23). 2-Nitrofuran-5-carbonyl chloride19 (22) (1.50 
g, 10 mmol) in CH2C12 (15 mL) was added to AT-(2-amino- 
ethyl)piperidine (1.0 mL, 7.5 mmol) and EtjN (7.5 mL) in CHaCla 
(50 mL) at 0 °C. Stirring continued at this temperature for a 
further 30 min before the solution was washed twice with saturated 
aqueous NaHC03 and with H20  and was dried. The evaporation 
residue, in THF (10 mL), was treated with ethereal HC1 (1.0 M, 
5.0 mL). The solid was collected and was washed with EtaO to 
afford 23 (1.93 g, 85%) as a white solid: mp 256-258 °C dec; NMR 
(D20) b 1.6-1.9 (m, 6 H, piperidine 3,4,5-H), 3.4-3.8 (m, 8 H, 
piperidine 2,6-H + NCH2CH2N), 7.20 (d, J  = 3.5 Hz, 1 H, furan
4-H), 7.30 (d, J  = 3.5 Hz, 1 H, furan 3-H). AnaL C, H, N.
2-Nitrothiophene-5-carboxylic Acid (25). 2-Nitro- 
thiophene-5-carboxaldehyde (24) (3.14 g, 20 mmol) was stirred 
with AgN03 (6.8 g, 40 mmol) and NaOH (3.27 g, 82 mmol) in HaO 
at 5 °C for 20 min. The solution was filtered, acidified by addition 
of aqueous HC1, and extracted three times with E^O. The 
combined extracts were washed with H20  and with brine and were 
dried. Recrystallization of the evaporation residue from Et^O/ 
hexane furnished 25 (1.88 g, 54%) as white crystals: mp 155-157 
°C (lit.26 mp 157-158 °C); NMR (CDClj/tCD^O 2:1) b 7.60 (d, 
<7=5 Hz, 1 H, thiophene 4-H), 7.80 (d, J  ~ 5 Hz, 1 H, thiophene
3-H), 9.75 (br, 1 H, C02H).
2-Nitro-N-prop-2-enylthiophene-5-carboxamide (26). 
Carboxylic acid 25 (690 mg, 4 mmol) was boiled under reflux in 
SOC12 (3 mL) until no acid remained (TLC of sample quenched 
in MeOH). Excess reagent was removed by distillation and the 
residue was treated with allylamine (2 mL) in CH2C12 (20 mL) 
for 1 H. The solution was washed twice with saturated aqueous 
NaHC03, with H20, and with brine and was dried. Purification 
of the evaporation residue by radial PLC (CH2Cl2) and recrys­
tallization from CH2Cl2/hexane afforded 26 (520 mg, 62%), as 
white crystals: mp 110-111 °C; IR >».. 3310,1630,1555 cm"1; 
NMR (CDC13/CD30D) 6 4.00 (dt, <7=6 and 1 Hz, 2 H. NCHj),
5.15 (br d, J  = 11 Hz, 1 H) and 5.25 (br d, J  -  15 Hz, 1 H) 
(CsssOH2), 5.75 (ddt, J  = 15,11, and 6 Hz, 1 H, CH=CU^, 7.45 
(d, J  =* 4 Hz, 1 H, thiophene 4-H), 7.75 (d, J  = 4 Hz, thiophene
3-H); MS (El) mfz 212.0208 (M) (C^IgNAS requires 212.0256, 
197,166,156 (100) (M -  CjHeN), 110; MS (Cl) m/z 213 (100) (M 
+ H).
2-Nitro-AT-(oxiranylmethyl)thiophene-5-carboxamide (27). 
Amide 26 (1.16 g, 5.5 mmol) was boiled under reflux with 3- 
chloroperoxybenzoic acid (85%; 2.04 g, 10 mmol) in CH2C12 (50 
mL) for 6 h. The solution was washed with aqueous NajSOs (10%) 
(twice), H20, saturated aqueous NaHCOs (twice), H20, and brine 
and was dried. The evaporation residue was purified by column 
chromatography (CH2Cl2/MeOH 19:1) then by radial PLC 
(CHCy to furnish 27 (540 mg, 43%) as a white solid: mp 113-114 
°C dec; NMR (CDC13/CD30D) b 2.65 (dd, J  = 4 and 2 Hz, 1 H) 
and 2.85 (t, J = 4 Hz, 1 H) (oxirane 3-Hj), 3.25 (m, 1 H, oxirane
2-H), 3.4-4.0 (m, 2 H, NCHs) 7.55 (d, J  = 4 Hz, 1 H, thiophene
4-H), 7.85 (d, J  = 4 Hz, 1 H, thiophene 3-H); MS (El) mfz 
228.0197 (M) (C8H8N20 4S requires 228.0205).
(2?)-3-(2-Nitrothiophene-5-yl)-iV-(oxiranylmethyl)- 
propenamide (30). Carboxylic acid 28 (500 mg, 2.5 mmol) was 
boiled under reflux in SOCI2 (2.5 mL) for 15 min. Allylamine (1.0 
mL) was added to the evaporation residue in CH2C12 (10 mL) at 
0 °C and the mixture was stirred for 30 min. The solution was 
washed with saturated aqueous NaHC03 and with brine before 
being dried. The evaporation residue was recrystallized from 
CH2C12/hexane to give (£)-3-(2-nitrothiophen-5-yl)-N-(prop-2- 
enyl)propenamide (29) (520 mg, 87%) as an off-white solid: mp 
153-154 °C; NMR ((CDjljSO/CDaOD) b 4.05 (dt, J  = 6 and 1 
Hz, 2 H, NCHj), 5.18 (br d, J  = 11 Hz, 1 H) and 5.30 (br d, J  ~ 
16 Hz, 1 H) (C=CH2), 5.75 (ddt, J  = 16, 11 and 6 Hz, 1 H, 
C77=CH2), 6.80 (d, J  * 15 Hz, 1 H) and 7.70 (d, J  = 15 Hz, 1 
H) (thiophene CH=€H), 7.50 (d, J  = 4 Hz, 1 H, thiophene 4-H),
8.15 (d, J  = 4 Hz, 1 H, thiophene 3-H). This amide (460 mg, 1.93
2120
mmol) was boiled under reflux with 3-chloroperoxybenzoic acid 
(85%; 1.44 g, 7 mmol) in CH2C12 (50 mL) for 8 h. The solution 
was washed with aqueous Na2S0 3 (twice), saturated aqueous 
NaHC03 (twice), H20, and brine and was dried. The evaporation 
residue was purified by column chromatography (CHCl3) to 
furnish 30 (240 mg, 33%) as a white solid: mp 120 °C dec; IR 
3270, 2800-2550, 1650, 1620, 1560 cm’1; NMR (CDC13/  
(CDaJjSO) 5 2.60 (dd. J  = 4 and 2 Hz, 1 H) and 2.75 (t, J  = 4 Hz, 
1 H) (oxirane 3-Hj), 3.0-3.9 (m, 3 H, NCH2CH), 6.65 (d, J  = 16 
Hz, 1 H) and 7.50 (d, J  = 16 Hz, 1 H) (propenamide 2,3-H), 7.20 
(d, J  -  4 Hz, 1 H, thiophene 4-H), 7.85 (d, J  — 4 Hz, 1 H, 
thiophene 3-H). 8.3 (br, 1 H, NH); MS (El) m/z 254.0366 (M) 
(CioHioN20 4S requires 254.0361).
3-Methyl-2-nitro-5-prop-2-enylthiophene (35). Method A. 
Allylmagnesium bromide (1.0 M in THF; 5 mL, 5 mmol) was 
added to 32 (710 mg, 5 mmol) in THF (20 mL) during 15 min 
at -50 °C. Stirring continued for a further 15 min at -50 °C.
5,6-Dichloro-2,3-dicyanobenzoquinone (1.7 g, 7.5 mmol) in THF 
(25 mL) was added and the solution was stirred at ambient 
temperature for 3 h before being poured into aqueous NH4CI and 
extracted three times with E^O. The combined extracts were 
dried. The evaporation residue was purified by column chro­
matography (EtOAc/hexane 1:4) and by radial PLC (EtOAc/ 
hexane 1:5) to afford 35 (170 mg, 19%) as a colorless glass: NMR 
(CDCls) b 2.55 (s, 3 H, CHj), 3.50 (br d, J  = 6 Hz, 2 H, thiophene 
CH ,^ 5.0-6.2 (m, 3 H, CH^CH^, 6.60 (br s, 1 H, thiophene 4-H).
Method B. Compound 32 (720 mg, 5 mmol) in THF (20 mL) 
was added during 30 min to allylmagnesium bromide in THF (1.0 
M, 6 mL, 6 mmol) at -65 °C. After a further 30 min at this 
temperature, BFj-Et^ O (1.0 mL) was added and the mixture was 
stirred at ambient temperature for 16 h before being poured onto 
aqueous NH4CL The mixture was stirred for 1 h and was extracted 
four times with EtjO. The combined extracts were dried. The 
evaporation residue was purified by column chromatography 
(CH2Cl2) to give 35 (220 mg, 24%) identical with the material 
described above. These materials were used for the preparation 
of 36 without further purification.
3-Methyl-2-nitro-5-(oxiranylmethyl)thiophene (36). Ni­
trothiophene 35 (250 mg. 1.4 mmol) was boiled under reflux with
3-chloroperoxybenzoic acid (55%; 2.52 g, 8 mmol) in CHsC  ^(40 
mL) for 12 h. The mixture was washed with saturated aqueous 
Na2S0 3 (three times), saturated aqueous NaHC03 (twice), and
brine before being dried. The evaporation residue was purified 
by radial PLC (CH2C12) to give 36 (110 mg, 41%) as a colorless
gum: IR (liquid film) v 1555 (w) cm-1; NMR (270 MHz; CDCI3)
b 2.58 (s, 3 H, CH3), 2.60 (dd. J  = 4.8 and 2.6 Hz, 1 H) and 2.87 
(dd, J  = 4.5 and 3.5 Hz. 1 H) (oxirane 3-Hj), 2.95 (dd, J  = 15.8 
and 6.0 Hz, 1H) and 3.08 (dd, J  = 15.8 and 4.0 Hz, 1 H) (thiophene 
CH2), 3.19 (ddt, J  = 6.0,2.6, and 4.0 Hz, 1 H, oxirane 2-H), 6.76 
(s, 1 H, thiophene 4-H); MS (El) m/z 199.0297 (100) (M) 
(CgHsNOaS requires 199.0303), 182, 156,126, 110.
5-(Dimethoxymethyl)-2-nitro-3-(prop-2-enyI)thiophene
(40). 2-Nitrothiophene-5-carboxaldehyde (24) (314 mg, 2 mmol) 
was boiled under reflux with MeOH (5 mL) and ethereal HC1 (1.0 
M, 4 mL) for 45 min. The solvent and excess reagent were 
evaporated to give 5-(dimethoxymethyl)-2-nitrothiophene (37) 
(406 mg, quant.) as a colorless gum: NMR (CDCls) b 3.40 (s, 6 
H, 2 x OCHs), 5.60 (s, 1 H, C/ftOMeJa), 7.00 (d, J  = 4 Hz, 1 H, 
thiophene 4-H), 7.80 (d, J  -  4 Hz, 1 H, thiophene 3-H). This acetal 
was treated with allylmagnesium bromide according to method
A above to afford 40 (15%) as a colorless oil: IR (liquid Him) v__
2950,1500,1330 cm '1; NMR (CDC13) 3.35 (s, 6 H, 2 X OCH^,
3.75 (br d, J  -  6 Hz, 2 H, thiophene CHs), 5.05 (br d, J  = 16 Hz, 
1 H) and 5.10 (br d, J  = 11 Hz, 1 H) (C^CHj), 5.50 (s, 1 H, 
CfflOMeJa), 5.80 (ddd, J  = 16,11 and 6 Hz, 1 H, CH==CH2), 6.85 
(s, 1 H, thiophene 4-H).
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The reaction of 2-hydrazino-4-(4'-substitutedphenyI)thiazoles with 1,1,1-trifluoropentane-
2,4-dione (1) gives the isomeric 5(3 }-trifluoromethyl-3(5)-methyl-1 -[4'-{4"-substituted phenyl )thiazol- 
2'-yI)]pyrazoles (3 and 4). A similar reaction of 2-hydrazinobenzothiazoles with ethyl 2,4-dioxovale­
rate (2) furnishes the isomeric-l-{6'-H/methylbenzothiazol-2'-yl)-5(3)-ethoxycarbonyl-3(5)-methyl- 
pyrazoles (8 and 10). However, the reaction of 2-hydrazinobenzothiazoles with 1 gives l-{6'-substit- 
utedbenzothiazol-2'-yl)-5-trifluoromethyl-3-methylpyrazoles (5) as the sole products. The intermedi­
ate 5-hydroxy-2-pyrazolines (6 ) have been isolated and characterised. The structure of the isomeric 
pyrazoles have been established on the basis of their NMR (*H and 13C) spectra.
We have recently described1 the products of the 
reaction of several hetarylhydrazines with 1,3- 
diketones as having pyrazole structure instead of 
isomeric diazepines or triazepines as reported by 
earlier investigators2. During the course of present 
investigation, it was noted that the methyl groups 
located at positions-3 and 5 of pyrazole moiety 
resonated around d 2.3 and 2.7, respectively. The 
deshielding of C5-C H 3 may be due to the lone 
pair effect, hydrogen bonding or ring current3.
In continuation of our work on the reaction of 
hetarylhydrazines with 1,3-diketones, we thought 
it of interest to study the structures of the reac­
tion products between hetarylhydrazines and un- 
symmetrical 1,3-diketones to explore the general­
ity of this observation in distinguishing the isom­
eric pairs and also to determine the isomer ratio 
when electron withdrawing substituents such as a 
trifluoromethyl and ethoxycarbonyl are present. 
In this paper, we report the results of the reaction 
of hetarylhydrazines with 1,1,1-trifluoropentane-
2,4-dione (1) and ethyl 2,4-dioxovalerate (2).
Condensation of 2-hydrazino-4-(4,-tolyl)thiazole 
with 1 furnished a mixture of two isomeric pro­
ducts 3b and 4b in the ratio 4:1 (Scheme 1) 
which were separated by column chromatography. 
The isomer whose ‘H NMR exhibited the two 
methyl signals around <5 2.30, was identified as 
3b. The other isomer (4b), obviously, has the me­
thyl group located at position-5, which resonated 
characteristically at 6 2.85.
The isomers 3b and 4b could also be readily 
distinguished using 13C NMR spectroscopy. The 
signals at <5 150.65, 111.70 and 132.20 were attri­
buted to C-3, C-4 and C-5 carbons, respectively 
of the pyrazole moiety in 3b, whereas these car­
bons resonated at 6 145.70, 106.54 and 142.67 in 
4 b. Shielding of such a magnitude is in agreement 
with the observation that the replacement of me­
thyl by a trifluoromethyl group causes an upheld 
shift of about 6 ppm in benzene derivatives4. In 
the case of 3b, the CF3 carbon signal appeared as 
a quartet around <5 119.52. However, the CF3 sig­
nal could not be located in the spectra of 4b, per­
haps due to the lack of sufficient concentration of 
the compound. The complete assignment of all 
other carbon atoms was made by DEPT techni­
que (vide experimental).
The other isomers (3a, 3c and 4a, 4c) were 
obtained by a similar reaction of 2-hydrazino-4- 
(4'-substitutedphenyl)thiazoles with 1 and showed 
similar NMR characteristics. The characterization 
data of these compounds are given in Table 1.
However, when 2-hydrazinobenzothiazoles were 
treated with 1, only one of the two isomeric pro­
ducts (indicated by *H NMR of crude solid) could 
be obtained having the methyl group at position- 
3. The C3-C H 3 protons in all these compounds 
(5a-d) resonated at <5 2.35. The proton decoupled 
13C NMR spectrum of 5d showed that carbon at­
oms C-3, C-4 and C-5 of the pyrazole moiety res-
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Table 1 -  Characterization data of the various compounds pre­
pared
Compd m.p. Yield Mol. formula N (%)
*C (%)
Found Calc.
3a 104 53 C UH 10F3N3S 13.2 13.6
3c 121 38 CmH9C1F,N,S 12.0 12.2
4a 115 05 C i«H10F3N3S 13.4 13.6
4c 144 44 C i4H,CIF,NjS 12.0 12.2
Sa 155 71 C12HgF3N3S 12.9 13.2
Sb 137 74 C ijH 10F3N jS 13.8 14.1
5c 138 77 C ijH i0FjN3OS 13.1 13.4
8a 110 60 c uh i3n 3o 2s 14.3 14.6
9a 218(d) 25 C uH^NjO jS 16.0 16.2
12a 125 58 C|7H]7N3O j 14.3 14.2
13a 216(d) 28 c 15h 13n 3o : 15.6 15.7
12b 121 56 c „ h I6c in 3o 2 12.7 12.8
13b 228(d) 25 c 15h 12c in 3o 2 13.6 14.0
onated at <3 151.69, 112.97 and 133.13 respect­
ively, as observed in the case of 3b. Complete as­
signment of other carbon atoms was made on the 
basis of DEPT technique (vide experimental).
These observations reflect the difference in the 
reactivity of thiazolylhydrazines and benzothiazo- 
lylhydrazines. It has already been established that
1 exists in 97% enol form at the COCF3 group in 
nonpolar solvents5-6. Presuming that the pyrazole 
formation involves nucleophilic attack of the 
terminal nitrogen on the carbonyl carbon of the 
/kiiketone, it appears likely that the thiazolylhyd- 
razine react rather slowly in comparison to the 
benzothiazolylhydrazine. However, the present
data do not permit us to reach to a definite con­
clusion on reactivity.
In an attempt to isolate the intermediate of the 
reaction, 6 -chloro-2-hydrazinobenzothiazole was 
treated with 1 in abs. ethanol at room tempera­
ture to give a crystalline solid which appeared to 
be 5-hydroxy-2-pyrazoline derivative (6d) rather 
than the isomeric hydrazone (7). The structure 7 
for the intermediate was ruled out as the *H 
NMR spectrum displayed a broad signal (2H) at 
<5 3.32, a methyl singlet at <3 2.10 and no signal 
for the olefinic proton around <3 6.05. Formation 
of 6d was further supported by recent reports in 
which similar types of intermediates were isolat­
ed7,8. As expected, treatment of 6d in ethanolic 
HC1 gave 5d.
The reaction of hetarylhydrazines with ethyl
2,4-dioxovalerate (2) was also investigated. Treat­
ment of 2-hydrazino-6-methyIbenzothiazole with 
2 in ethanolic HC1 afforded a solid whose ‘H 
NMR spectrum indicated the formation of two 
products (Scheme 2). Chromatographic separation 
provided firstly, a compound (8b; m.p. 135°) 
whose NMR spectrum exhibited two methyl 
signals at <3 2.45 (C6-C H , of benzothiazole 
moiety) and 2.81 (C5- C H 3 of pyrazole moiety) 
besides signals for ethoxycarbonyl and aromatic 
protons. The other compound (9b; m.p. 245°) 
exhibited the presence of a carboxyl group in the 
IR spectrum. The ‘H NMR spectrum revealed it 
to be a pyrazole derivative with a methyl substitu­
ent at position-3 (<5 2.33). The compound could 
readily be converted into its ethyl ester (10b) 
which was found to be isomeric with 8b on the 
basis of 'H NMR spectral characteristics.
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Scheme 2
The structural assignments were further con­
firmed by an inspection of ,3C NMR spectra of 
8 b and 9b. The carbon atoms C-3, C-4 and C-5 
of pyrazole- moiety in 8b resonated at <5 145.56,
111.10 and 143.13 and in 9b at <5 151.59, 112.97 
and 136.91, respectively. These values suggest 
that replacement of methyl by COOC2H5 or 
COOH group causes shielding of that carbon by 
5-6 ppm4-9. Complete assignment of other carbon 
atoms are given in the experimental section.
However, when the reaction of 2-hydrazino-6- 
methylbenzothiazole with 2 was carried out in 
ethanolic acetic acid, a mixture of two isomeric 
products (8b and 10b) in 3:1 ratio was obtained 
as indicated by the *H NMR spectrum of the 
crude solid. This observation is in agreement with 
an earlier report10 describing the formation of two 
isomeric products by treatment of 2 with phenyl- 
hydrazine in acetic acid. It is thus clear that while 
using HCI instead of acetic acid, the ethoxycarbo- 
nyl group at position-5 gets preferentially hydro­
lyzed in the reaction medium. Furthermore, treat­
ment of 2 with 2-hydrazino-6-methylbenzothia- 
zole in abs. ethanol produced a mixture of 8 b and
5-hydroxy-2-pyrazoline derivative (11) as revealed 




Similarly, quinolylhydrazines on condensation 
with 2 in ethanolic HCI afforded two products 
having Cs -C O O H  and C3-C O O C 2H 5 groups. 
This mixture was resolved either by column 
chromatography or by using sodium bicarbonate.
The characterization data of these compounds are 
given in Table 1.
Experimental Procedure
Melting points are taken in open capillaries and 
are uncorrected. IR and ‘H NMR spectra were 
recorded on Beckman IR-20 spectrometer and 
R-32 Perkin-Elmer (90 MHz) instruments, re­
spectively, I3C NMR spectra on Bruker WH-90 
and JEOL GX 270 spectrometers and mass 
spectra on a Kratos MS-50 instrument at 70 eV.
5 - Trifluoromethyl- 3 - methyl-1 -{4'-{4"-tolyl)thiazol- 
2'-y [[pyrazole (3b) and 3 - trifluoromethyl- 5 - me thy l-
l-[4'-(4"-tolyl)thiazol-2'-y[)\pyrazole {4b)
A mixture of 2-hydrazino-4-(4-tolyl)thiazole11 
(2.05 g, 0.01 mole) and 1 (1.54 g, 0.01 mole) in 
ethanol containing a few drops of acetic acid or 
HCI was refluxed for 3 hr. The reaction mixture 
was concentrated and left overnight at room tem­
perature. The solid, which separated out indicated 
the formation of isomeric products 3b and 4b in 
4:1 ratio as determined by *H NMR spectrum. 
Column chromatographic separation using pet. 
ether-benzene (60:40) as eluant afforded 3b, m.p. 
124°, yield 62%, >H NMR (CDC13): 6 2.33 (s, 3H,
3-CHj), 2.36 (s, 3H, 4"-CH3), 6.64 (s, IH, H-4),
7.12-7.32 (m, 3H, H-3", H-5" and thiazole H-5'), 
7.66 (d, 2H, J = 8.3 Hz, H-2" and H-6"): 13C 
NMR (CDC13): 6 13.29 (3-CH3), 21.14 (4"-CH3), 
109.01 (C-5'), 111.70 (d, 3Jc _f = 4 Hz, C-4), 
119.52 (q, 1 Jc _F = 271 Hz, CF3), 125.78 (C-2" and 
C-6"), 129.31 (C-3" and C-5"), 131.03 (C-l"),
132.20 (q, 2Jc - f = 40 H z ,  C-5), 138.10 (C-4"),
150.65 (C-3), 152.57 (C-4'), 158.60 (C-2'); MS: 
m/z 323 ( M \  100%), 322 (9), 278 (8 ), 254 (15), 
161 (14), 148 (23), 147 (28). 115 (15) (Found: N,
12.9. C 15H ,,F ,N 3S requires N. 13.0% ).
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Further elution of the column with pet. ether- 
benzene (60:40) afforded 4b, m.p. 150°, yield 
16%; *H NMR (CDCl3): 6 2.39 (s, 3H, 4"-CH3), 
2.85 (s, 3H, 5-CH3), 6.47 (s, 1H, H-4), 7.26 (s, 
1H, thiazole H-5') 7.24 (d, 2H, J = 7.5 Hz, H-3" 
and H-5"), 7.77 (d, 2H, J = 8.3 Hz, H-2" and 
H-6"); ,3C NMR (CDCl3): 6 13.84 (5-CH3), 21.17 
(4"-CH3), 106.54 (C-4), 109.33 (05'), 125.78 (O  
2" and 06"), 129.38 (03" and 05"), 131.03 (O  
1"), 138.26 (04"), 142.67 (05), 145.70 (03),
152.66 (04'), 160.80 (02 ') (However the CF3 
signal could not be located, perhaps due to the 
lack of sufficient concentration of the compound); 
MS: m/z 323 (M-*, 100%), 322 (8), 278 (7), 254 
(14), 161 (12), 148 (28), 147 (30), 115 (15) 
(Found: N, 12.9. C15H12F3N3S requires N, 13.0%).
The characterization data of other compounds 
(3a, 3c, 4a and 4c) which were similarly pre­
pared are given in Table 1.
1 -(6'- Chlorobenzothiazot-l'-yty 5- trifluoromethyb
3-methylpyrazole (5d)
A mixture of 6-chloro-2-hydrazinobenzothia- 
zole12 (998 mg, 5 mmoles) and 1 (770 mg, 5 
mmoles) in ethanol (25 ml) containing a few 
drops of conc. HC1 was refluxed for 3 hr. The 
reaction mixture was concentrated and kept at 
room temperature overnight The solid thus sepa­
rated was filtered, dried and crystallised from eth­
anol, m.p. 170°, yield 75%; ‘H NMR (CDC13):<5 
2.35 (s, 3H, 3-CH,), 6.68 (s. 1H, H-4), 7.31 (dd, 
1H, J=8.8 and 1.8 Hz, H-50,7.64 (d, 1H, J = 8.8 Hz, 
H-4'), 7.69 (d, 1H, J = 1.8 Hz, H-7'); 13C NMR 
(CDC13): <5 13.34 (3-CH3), 112.97 (d, 3Jc - f = 3  
Hz, C-4), 119.29 (q, 1JC_F=269 Hz, CF3), 120.95 
(C-7'), 124.11 (C-4'), 127.29 (C-5') 131.10 (C-6'),
133.13 (q, 2Jc - f = 42 Hz, C-5), 134.66 (C-7'a),
149.59 (C-3'a), 151.69 (C-3), 158.70 (C-2'); MS: 
m/z 317/319 [M+, 100 (37%)], 282 (4), 249 (4), 
248 (22), 221 (8), 169 (9), 133 (9) (Found: N,
12.9. C12H7C1F3N3S requires N, 13.2%).
The characterization data of other members 
(5a-c) prepared similarly are given in Table 1.
1 -6'- Chlorobenzothiazol-2’-yl)r5-triflu.oromethyt- 
5-hydroxy-3-methylpyrazole{6d)
6-Chloro-2-hydrazinobenzothiazole12 (798 mg, 
4 mmoles) and 1 (616 mg, 4 mmoles) were dis­
solved in ethanol by warming and the solution left 
overnight at room temperature. The crystalline 
solid thus obtained was filtered, dried and crystal­
lized from little ethanol, m.p. 115°, yield 85%; ER 
(nujol): 3250 cm’ 1 (OH); lH NMR (CDC13): <3
2.10 (s, 3H, 3-CH3), 3.32 (bs, 2H, 4-CH2), 7.28 
(dd, 1H, J = 8.2 and 1.8 Hz, H-5'), 7.53 (d, 1H.
J = 8.2 Hz, H-4'), 7.65 (d, 1H, J=  1.8 Hz, H-7').
The other 5-hydroxy-2-pyrazoIine derivative 
(6c) was prepared similarly and crystallised from 
ethanol, m.p. 118°, yield 80%; IR (nujol): 3250 
c m '1 (OH); *H NMR (CDC13): <5 2.16 (s, 3H,
3-CH3), 3.26 (bs, 2H, 4-CH2) 3.78 (s, 3H, 6'- 
OCH3), 6.87 (dd, 1H, J = 8.8 and 1.8 Hz, H-5'),
7.13 (d, 1H, J -  1.8 Hz, H-7'), 7.46 (d, 1H, J -  8.8 
Hz, H-4').
\-{6’-Methylbenzothiazol-2'-yl)r3-ethoxycarbonyl- 
5-methylpyrazole (8b) and 1 -(6'-methylbenzothia- 
zol-2’-yt)-5-carboxy-3-methy[pyrazole (9b) and its 
ethyl ester {10b)
A mixture of 2-hydrazino-6-methylbenzothia- 
zole (895 mg, 5 mmoles) and ethyl 2,4-dioxoval- 
erate (2, 790 mg, 5 mmoles) in ethanol (30 ml) 
containing few drops of HQ was refluxed for 2.5 
hr. The reaction mixture was concentrated and 
left at room temperature for 4-5 hr and the sepa­
rated solid filtered and dried. TLC and lH NMR 
spectrum of the crude solid showed the formation 
of two compounds (3:1). Column chromatogra­
phic separation using benzene and then benzene- 
chloroform (50:50) as eluant afforded 8b which 
crystallised from ethanol, m.p. 135°, yield 58%; 
IR (nujol): 1730 c m '1 (C = 0); lH NMR (CDC13): 
<5 1.41 (t, 3H, -COOCH 2C//3), 2.45 (s, 3H, 6'- 
CH3), 2.81 (s, 3H, 5-CH3), 4.40 (q, 2H, 
-COOCH2CH3), 6.70 (s, 1H, H-4), 7.25 (d, 1H, 
J = 8.8 and 1.8 Hz, H-5'), 7.61 (d, 1H, J=  1.8 Hz, 
H-7'), 7.78 (d, 1H, J = 8.8 Hz, H-4'); 13C NMR 
(CDC13): 6 13.80 (5-CH3) 14.12 ( -  CH3), 21.30 
(6'-CH3), 61.15 ( —OCH2- ), 111.10 (C-4),
121.09 (C-7'), 122.39 (C-4'), 127.81 (C-5'), 
133.39 (C-7’a), 135.36 (C-6'), 143.13 (C-5), 
145.56 (C-3), 149.10 (C-3'a), 159.98 (C-2'),
161.59 (CO); MS: m/z 301 (M*, 100%), 229 (9), 
228 (17), 227 (25), 225 (20), 202 (5), 201 (20), 
188 (32), 187 (6), 149 (15), 148 (5), 122 (3), 121 
(8) (Found: N, 13.7. C,5H 1SN30 2S requires N, 
14.0%).
Further elution of the column with benzene- 
chloroform (50:50) afforded 9b which crystallised 
from ethanol, m.p. 245°, yield 21%; IR (nujol): 
1730 cm"1 (C = 0); *H NMR (DMSO-d6): <5 2.33 
(s, 3H, 3-CH3), 2.50 (s, 3H, 6'-CH3) 6.85 (s, 1H, 
H-4), 7.40 (dd, 1H, J = 8.8 and 1.8 Hz, H-5'), 
7.83) d, 1H, 1 = 8.8 Hz, H-4'), 7.89 (bs, 1H, H-7'); 
13C NMR (DMSO-d6): 6 12.94 (3-CH3), 20.93 
(6'-CH3), 112.97 (C-4), 121.88 (C-7'), 122.01 (C- 
4'), 128.17 (C-5'), 133.26 (C-7'a), 135.32 (C-6'), 
136.91 (C-5), 147.59 (C-3'a), 151.59 (C-3),
158.09 (C-2'), 160.30 (CO); MS: m/z 273 (M \ 
48%), 229 (19), 228 (5), 188 (100), 187 (7), 149 
(6), 148 (11), 122(5), 121 (13) (Found: N, 15.3. 
C,3H uN30 2S requires N, 15.4%).
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The mixture was also separated by making so­
dium salt of the acid and then extracting the ester 
with chloroform. The acid was then regenerated 
by adding HC1 to the sodium salt The acid 9b 
(500 mg) was converted to its ethyl ester (10b) by 
refluxing it in abs. ethanol with a drop of HC1, 
m.p. 115°, yield 90%; IR (nujol): 1725 cm-1 
(C = 0); ‘H NMR (CDC13): <5 1.31 (t, 3H, 
-COOCH2C //3), 2.36 (s, 3H, 3-CH3), 2.47 (s, 
3H, 6'-CH3), 4.37 (q, 2H, -  COOCtf2CH3), 6.69 
(s, 1H, H-4), 7.26 (dd, 1H, J = 8.8 and 1.8 Hz, 
H-5'), 7.64 (bs, 1H, H-7'), 7.79 (d, 1H, J -8 .8  Hz, 
H-4').
When 2-hydrazino-6-methylbenzothiazole and 
2 were treated with ethanol containing a few 
drops of acetic acid, two isomeric esters (8b and 
10b) obtained in 3:1 ratio. The characterization 
data of other compounds (8a, 9a, 12 and 13) 
prepared using 2-hydrazinobenzothiazole and 
quinolines13 are given in Table 1.
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Synthesis of Carborane-contaimng Nitroimidazole Compounds via Mild 1,3-DipoIar 
Cycloaddition
Martin Scobie and Michael D. Threadgill*
School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK
Nitroimidazole-iinked carboranes are synthesised  in good yield from w-alkenyl- and  u)-alkynyl-2-nitroimidazoles and a 
carborane nitrile oxide by 1,3-dipolar cycloaddition under mild conditions.
Boron neutron capture therapy (BNCT) is of increasing 
interest as a strategy for treatment of various cancers1 and is 
based on the 10B(n,a)7Li reaction of the 10B isotope. Early 
studies of BNCT using non-targeted boron compounds gave 
mixed results.2 Failures were attributed to inadequate concen­
trations of 10B in the tumour tissue or lack of selectivity of 
disposition of 10B, leading to damage to normal tissue. 
Recently, carboranes have been linked to nucleosides3 and to 
porphyrins4 in attempts to target boron to tumours. 2-Nitro- 
imidazoles are selectively retained in poorly vascularised 
hypoxic tumour tissue by reductive metabolism to electro- 
philes.5 As an extension of a programme of synthesis and 
evaluation of nitroimidazoles in the treatment of cancer,6-7 we
propose that a compound containing 10-12 boron atoms 
linked to 2-nitroimidazole would form a useful method of 
concentrating boron in solid tumours. Nitroimidazoles bear­
ing boron are hitherto unreported.
Simple and complex boranes are widely used as reducing 
agents but l-substituted-2-nitroimidazoles are themselves 
readily reduced ( £ l7 = -389 mV);7 thus assembly of a 
molecule containing both moieties must be achieved under 
mild conditions. Alkylation of 2-nitroimidazole 1 requires 
vigorous conditions and the c/oso-l,2-dicarbadodecarboranes 
are prepared8 by reaction of alkynes and decarborane(14) 
(Bl0Hi4) in the presence of boiling Lewis bases for long 
reaction times. 1,3-Dipolar cycloadditions of nitrile oxides to







2a; R = (CH2)4CH=CH 
b; R = (CH2)2C=CH
Scheme 1 Reagents and conditions: i, KOBu'. DMF, 100 °C; ii. 
BrCH2CH2CH2CH2CH=CH2 or TsOCH2CH2O C H . DMF. 130 °C
j C t ° —
10^ 10
5; R = 4 -^dihydrodrthioJ-2-yl — . -■ 
6; R = CHO -= {






Scheme 2 Reagents and conditions: i, HSCH2CH2SH. BF3 Et20 ;  ii. 
B10Hi4, MeCN, reflux 3 days; iii. Hg(Cl04)2-3H20 .  THF. 5 min; iv, 
NH2OHHCl. Na2C 0 3, EtOH; v. NaOCl. H20 .  CH2Cl2; vi. 2a. vii. 
2b; viii, PhMe, reflux
alkenes and alkynes proceed9 under mild conditions; hence 
this method was chosen to link appropriate nitroimidazoles 
and carboranes for the final assembly step.
The potassium salt of 2-nitroimidazole 1 was alkylated with
6-bromohex-l-ene and with but-3-ynyl tosylate10 in hot DMF
(dimethylformamide) to give the alkene 2a7 (78%) and the 
alkyne 2b+ (59%), respectively (Scheme 1). As predicted, 
treatment of 2b with B10H |4 gave only polar degradation 
products.
4-(3-Prop-l-ynyloxy)benzaldehyde 3“ was chosen as the 
bifunctional compound for elaboration to form a carborane 
and a nitrile oxide. Both aldehyde 3 and the 4,5-dihydro-1,3- 
dioxole protected form were unstable to Bi0H l4. However, 
protection of the aldehyde as the 4,5-dihydro-1,3-dithiole 4+ 
was achieved in 80% yield (Scheme 2). This protecting group 
resisted prolonged treatment with BioH14 in refluxing aceto- 
nitrile, which furnished carborane 5t (51%). The aldehyde 
was unmasked cleanly under very mild conditions using 
Hg(C104)2, giving carboranylmethoxybenzaldehyde 6 t (90%) 
in a much shorter sequence than that reported4 for the 
synthesis of the meta isomer. Oxidation of the corresponding 
oxime 7t to give nitrile oxide 8t and 1,3-dipolar cycloaddition 
with 2a and 2b were e£fected§ as one-pot procedures, 
affording the required dihydroisoxazole 9 tf  and the isoxazole 
10t|| in which both nitroimidazole and carborane moieties are 
present. Yields were essentially quantitative based on dipolar- 
ophile and nitrile oxide consumed.
Formation of the intermediate nitrile oxide 8 was very rapid 
but prolonged reaction times at ambient temperature were 
required for acceptable conversion into heterocycles. Even 
after several days, no boron-containing compounds other than 
8,9  or 10 were evident and it was possible to isolate unreacted 
8 from the reaction mixtures by chromatography. This nitrile 
oxide is remarkably stable, with little decomposition after 
several weeks at ambient temperature; in contrast, the q of 
most aromatic nitrile oxides is reported9 to be only a few 
hours. Conversion into the dimer, 1,2,5-oxadiazole 2-oxide 
11,+** was effected only on heating in boiling toluene.
The mild conditions of the 1,3-dipolar cycloaddition de­
scribed here permit the joining of sensitive 2-nitroimidazole 
and boron cage moieties within one molecule. This strategy 
represents an opportunity for incorporating chemically sensi­
tive pharmacophores and targeting groups into drug mol­
ecules while generating a heterocycle which is itself capable 
of further elaboration. Compounds 9 and 10 are highly
+ New compounds were characterised by *H NMR and MS and. for 
target compounds, microanalysis or high resolution MS.
t  Spectroscopic data 8; IR vmix/crn_1 2600 (B-H) and 2320 (C=N*- 
O -); NMR (CDClj) 6 1.2-3.1 (10 H. br m. B10-H,0). 3.97 (1 H. s. 
carborane 2-H), 4.38 (2 H. s, carborane-CH2), 6.82 (2 H. d. Ar
3.5-H2) and 7.40 (2 H. d. Ar 2.6-H2).
§ Typical experiment: oxime 7 (1 mmol) and alkyne 2b (1 mmol) in 
CH2C12 (20 ml) were treated with aqueous NaOCl for 18 h. 
Chromatography (silica gel; CH2C12) of the evaporation residue gave 
isoxazole 10.
H 9; NMR (CDCh) 6 1.3-3.3 (10 H. br m. B10-H10). 1.5-2.0 (6 H. m. 
imidazole-CH2C //2C//2C //2). 2.93 (1 H. dd) and 3.40 (1 H. dd) 
isoxazole 4-H2, 4.09 (1 H, br, carborane 2-H), 4.45 (4 H. m. 
imidazole-CH-. + carborane-CH-.). 4.73 (1 H. ddt, isoxazole 5-H). 
6.87 (2 H. d. Ar 3.5-H,) 7.11 (1*H. s) and 7.15 (1 H. s) imidazole
4.5-H2. and 7.61 (2 H, d. Ar 2.6-H:).
II 10: NMR (CDClj) 6 1.3-3.3 (10 H. br m. Bt0-H10), 3.42 (2 H. t. 
isoxazole-CH2), 4.09 (1 H. br. carborane 2-H), 4.46 (2 H. s. 
carborane-CH2). 4.82 (2 H. t. imidazo!e-CH->), 6.26 (1 H. s. isoxazole 
4-H). 6.92 (2 H, d. Ar 3,S-H2). 6.% (1 H. s) and 7.09 (1 H. s) 
imidazole 4,5-H2, and 7.70 (2 H, d. Ar 2,6-H2).
** 11: NMR (CDClj) 6 1.3-3.3 (20 H. br. m. 2 x B I0-H|0). 4.07 (2 H. 
br. 2 x carborane 2-H), 4.46 (2 H. s. carborane-CH2). 4.47 (2 H. s. 
carborane-CH2), 6.92 (4 H, d, Ar 3.5-H, + Ar' 3,5-H^). 7.47 (2 H. d. 
Ar 2.6-H,). and 7.49 (2 H, d. Ar' 2.6-H%).
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lipophilic; the development of more water-soluble analogues 
for biological evaluation will be reported elsewhere.
We thank the Cancer Research Campaign for generous 
financial support and the SERC and Dr J. A. Ballantine 
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FAB mass spectrum of compound 9.
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Synthesis and biological evaluation of a series 
of flavones designed as inhibitors of protein 
tyrosine kinases
Bernadette D.M. Cunningham1, Michael D. Threadgill2, Paul W. 
Groundwater3, Ian L. Dale4 & John A. Hickman5
1 Oncogene Science Incorporated, 106 Charles Lindbergh Boulevard, Uniondale, 
N Y 11553, USA, 2School o f Pharmacy and Pharmacology, University o f Bath, 
Claverton Down, Bath BA2 7A Y, 3School o f Chemistry and Applied Chemistry, 
University o f Wales College o f Cardiff, Cardiff CF1 3TB, 4Xenova Limited, 240 
Bath Road, Slough SL1 4EF and 5 Department o f Physiological Sciences, University 
o f Manchester, Manchester Ml3 9PT, UK
Summary: A series of flavones has been prepared, which are variously substituted in 
the 3,3',4',5 and 7 positions with halo-, alkoxy-, nitro-, amino-, hydroxy-, acyloxy- and 
azido-groups, for evaluation of their cytotoxicity to ANN-1 cells (3T3 murine fibro­
blasts transformed with the Abelson murine leukaemia virus) which contain a tyrosine 
kinase. This cytotoxicity was compared to their non-transformed 3T3 counterparts. 3'- 
Amino-4'-methoxyflavonc was the most cytotoxic compound (IC50 = 1.6 p-M) and was 
less inhibitory to the non-transformed parent 3T3 cell line (IC50 = 8  p .M ). The 
compound was inactive at 50 jam in assays of the inhibition of the cell-associated 
Abelson protein tyrosine kinase but inhibited an epidermal growth factor (EGF) 
protein tyrosine kinase by 42% at 50 |am . Quercetin (3,3',4',5,7-pentahydroxyflavone) 
was the most potent inhibitor of the Abelson protein tyrosine kinase but showed no 
selective inhibition of the growth of ANN-1 cells compared to the parent 3T3 cell line. 
Different structure-activity relationships were observed between the results of the 
cytotoxicity assays and inhibition of protein tyrosine kinases. Inhibitors of the Abelson 
protein tyrosine kinase which were competitive with respect to ATP showed different 
potencies for inhibition of the EGF receptor kinase.
Key words: Abelson kinase/ANN-1 cells/flavone/protein tyrosine kinase/synthesis
Introduction
In the search for new and more selective agents for the treatment of cancer, the 
modulation of biochemistry associated with the cell membrane, which acts to undermine 
the normal regulation of proliferation and differentiation (Heldin ei al., 1987), presents 
itself as an attractive pharmacological strategy (Tritton & Hickman, 1990; Powis, 1991). 
It is at this cellular locus that the products of oncogenes are expressed in such a way as to 
subvert growth regulatory processes. The protein tyrosine kinases encoded by oncogenes 
(Yarden & Ullrich, 1988) have become targets for the medicinal chemist.
Several natural and synthetic compounds inhibit these kinases, including the isoflavone 
genistein (I; Chart I) (Akiyama et al., 1987), the diuretic amiloride (2) (Davis & Czech, 
1985) and the alkaloid staurosporine (3) (Nakano et al., 1987). The disadvantage
Correspondence: M.D. Threadgill 
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Chart I Structures of known inhibitors of protein tyrosine kinases and analogous 
flavones; I: genistein; 2: amiloride; 3: staurosporine; 4: erbstatin; 5: tvrphostins; 
6: BOCtyrosylaminomalonic acid; 7: quercctin; 8: 4'-amino-6-hydroxyflavonc; 
9: flavonc-8-acetic acid
common to all these compounds is their poor selectivity towards inhibition of purified 
tyrosine kinases when compared to inhibition of the serine and threonine kinases. 
Synthetic multisubstrate analogues, incorporating features of the [ATP—Tyr]$ transition 
state, inhibit both the transforming Abelson viral tyrosine kinase p60‘ and the Ser/ 
Thr specific phosphorylase kinase (Kruse et al., 1988). Erbstatin (4) and synthetic 
benzylidenemalononitrile analogues have been described as selective competitive sub­
strate. inhibitors of the epidermal growth factor (EGF) receptor tyrosine kinase (Yaish et 
al., 1988). The activities of these ‘tyrphostins’ (5) were demonstrated (Gazit et al.. 1987) 
to show IC50 <  100 jam as competitive reversible inhibitors of the insulin receptor 
tyrosine kinase and were minimally cytotoxic at 100 p.M towards A431 cells, but were 
cytostatic. A recent study has, however, suggested that their role in growth inhibition 
may not only involve inhibition of cellular EGF receptor tyrosine kinase activity 
(Faaland et al.. 1991). BOCtyrosylaminomalonic acid (6) has been reported to be a
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competitive inhibitor of the tyrosine kinase activity of the insulin receptor (Schechter et 
al., 1989), but phosphonic acid analogues of phosphotyrosine are largely inactive (Burke 
etal., 1991).
For our study, quercetin (7) was chosen as a lead compound. This flavone inhibits the 
tyrosine kinase activity of the Rous sarcoma viral kinase pp60‘"src (Graziani et al., 1983). 
The selectivity of the flavones and isoflavones is notable since quercetin is a competitive 
inhibitor at the ATP binding site of many enzymes, a region of considerable homology 
amongst kinases (Hanks et al., 1988). The polyhydroxylated flavones have been 
described as having a promiscuous pharmacology (Havsteen, 1983), although consider­
able specificity can be achieved against kinases. Cushman et al. (1991) disclosed recently 
that a wide range of flavone-3-carboxylates are inactive against the protein tyrosine 
kinase activity of p56/fA\  whereas potency 10-fold greater than that of quercetin was 
shown by 4'-amino-6-hydroxyflavone (8).
One of our goals was to synthesize flavones which have greater selectivity when 
compared with quercetin whilst retaining or increasing potency. The effects of these 
novel compounds on the proliferation of normal 3T3 murine fibroblasts were compared 
with the effects on ANN-1 cells (3T3 fibroblasts transformed by the Abelson murine 
leukaemia virus) (Scher & Siegler. 1975). Such a comparison would facilitate the identi­
fication of those compounds exerting their effects specifically through inhibition of the 
Abelson kinase from those exhibiting a non-selective cytotoxicity. Selected compounds 
were assayed against the tyrosine kinase activities of either a recombinant protein, 
ptablSO, from the Abelson virus or on extracts from the ANN-1 cells. Additionally, the 
effects of the most active of our compounds on the activities of the EGF receptor protein 




Benzoate esters were synthesized by Methods A, B and C, propane-2,4-diones were 
synthesized by Methods D and E. and flavones were synthesized by Methods F-O. 
below. NMR spectra at 60, 300 and 400 MHz were obtained using Varian EM360A. 
Bruker AC300 and Bruker WH400 spectrometers, respectively. Electron-impact mass 
spectra were obtained using VG Micromass 12B and ZAB-E instruments. Compounds 
11, 12, 30, 33, 35, 37, 43-45, 49, 52, 54, 56 and 62-64 were prepared as previously 
described (Cunningham et al., 1989).
Method A. The substituted benzoyl chloride (35 mmol) was stirred with the substituted 
2-acetylphenol (25 mmol) in pyridine (20 ml) for 30 min. The mixture was added to an 
excess of hydrochloric acid (1 m) at 0°C. The solid was recrystallized from methanol to 
give the benzoate ester.
Method B. The substituted benzoyl chloride (40 mmol) was stirred with the substituted 
2-acetylphenol (30 mmol) and 4-(dimethylamino)pyridine (3 mmol) in pyridine (15 ml) 
for 10 min. The ester was isolated as for Method A.
Method C. The substituted benzoyl chloride (60 mmol) was stirred with the substituted
2-acetylphenol (25 mmol) in pyridine (20 ml) for 30 min. The ester was isolated as for 
Method A.
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Method D. Powdered potassium hydroxide (30 mmol) was added to the substituted 
benzoate ester (20 mmol) in pyridine (50 ml) at 50°C. The mixture was stirred at 50°C for 
20 min, then added to an excess of hydrochloric acid (1 m ). The solid was recrystallized 
from methanol to give the substituted propane-1,3-dione.
Method E. Butyl lithium (20 mmol; 1.5 m in hexanes) was added to hexamethyldisilazane 
(20 mmol) in dry tetrahydrofuran (50 ml) at —78°C under N2 and the mixture was stirred 
for 30 min. The benzoate ester (10 mmol) in dry tetrahydrofuran (20 ml) was added 
during 15 min at —78°C. The mixture was warmed to 20°C during 2 h and an excess of 
hydrochloric acid (1 m) was added. Recrystallization of the solid (methanol) gave the 
substituted propane-1,3-dione.
Method F. The substituted propane-1,3-dione (10 mmol) was boiled under reflux with 
concentrated sulphuric acid (1 ml) in acetic acid (30 ml) for 1 h. The mixture was added 
to ice. The solid was recrystallized to give the substituted flavone.
Method G. Boron tribromide (6 mmol) was stirred with the methoxyflavone (2 mmol) 
in dichloromethane (50 ml) for 16 h. The reaction was quenched with aqueous sodium 
hydroxide (10%), acidified with hydrochloric acid (9 m) and extracted with dichloro­
methane. The organic solvent was evaporated to a small volume and the hydroxyflavone 
was collected.
Method H. The methoxyflavone (2 mmol) was boiled under reflux for 7 days with 
hydrogen bromide in acetic acid (15% w/w; 20 ml). The cooled mixture was quenched 
with aqueous sodium hydroxide (10%), acidifed with hydrochloric acid (1 m) and ex­
tracted with dichloromethane. Recrystallization of the evaporation residue gave the 
hydroxyflavone.
Method /. The chloroflavone (2.5 mmol) was boiled under reflux with aqueous 
dimethylamine (40% w/w; 50 ml) for 2 h. The mixture was poured onto ice and 
hydrochloric acid. Neutralization with aqueous sodium hydroxide gave a solid which 
was recrystallized to give the dimethylaminoflavone.
Method J. The nitroflavone (1.5 mmol) was boiled under reflux with tin (II) chloride 
(7.5 mmol) in hydrochloric acid (9 m ; 20 ml) for 1 h. then cooled to 0°C. Recrystallization 
of the solid gave the aminoflavone.
Method K. The nitroflavone (0.5 mmol) was boiled under reflux with tin (II) chloride 
(7.5 mmol) and hydrochloric acid (9 m ; 1 ml) in ethanol (20 ml) for 1 h. The cooled 
mixture was basified with excess aqueous sodium hydroxide (10 m ) and was extracted 
with dichloromethane. Drying (anhydrous sodium sulphate) and evaporation of the 
solvent under reduced pressure gave the diaminofiavone as an oil which darkened on 
exposure to air.
Method L. Sodium nitrite (2.7 mmol) in water (15 ml) was added during 15 min to the 
aminoflavone (2.5 mmol) in hydrochloric acid (5 m; 5 ml) at 0°C. After a further 15 min 
at 0°C. sodium azide (10 mmol) (CAUTION!) was added during 30 min. After a further 
30 min, the mixture was poured onto ice and was basified with aqueous ammonia. The 
solid was washed with water and recrystallized to give the azidoflavone.
Method M. The flavone ester (2 mmol) was stirred with aqueous potassium hydroxide
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(20%; 20 ml) for 1 h at 60°C, then poured onto an excess of hydrochloric acid (1 m ) at 
0°C. The solid was suspended in aqueous sodium hydrogen carbonate for 30 min at 50°C, 
then collected. Recrystallization gave the hydroxyflavone.
Method N. Butyl lithium (1.6 m in hexanes; 6.25 ml) was added to diisopropylamine (10 
mmol) in dry tetrahydrofuran (20 ml) at —78°C, followed, after 15 min, by the flavone 
(10 mmol). After a further 15 min at -78°C, trimethyl borate (10 mmol) was added and 
the mixture was stirred for 30 min. Acetic acid (15 mmol) and hydrogen peroxide (30% 
in water; 1.2 ml) were then added during 15 min. The mixture was extracted with ethyl 
acetate and the extract was washed with aqueous sodium hydrogen carbonate. The 
evaporation residue was recrystallized to give the 3-hydroxyflavone.
Method O. Sulphuryl chloride (11 mmol) was stirred with flavone (10 mmol) in tetra- 
chloromethane (30 ml) for 24 h. Chromatography (silica gel; chloroform) gave the 3- 
chloroflavone and the trichlorodihydroflavone.
Cytotoxicity assays and biochemical methods
Cytotoxicity assays. 3T3 cells and ANN-1 cells (Scher & Siegler, 1975), kind gifts of Dr 
Gordon Foulkes, were grown in Dulbecco’s modified Eagles medium, supplemented 
with 10% fetal calf serum. Both had a doubling time of 18 h. ANN-1 cells grew in 
suspension culture, whereas the 3T3 cell line grew as a monolayer. Cells (2 x 104) were 
treated with a range of concentrations of test compounds. Compounds were dissolved in 
dimethylformamide (DMF) or dimethylsulphoxide (DMSO) such that the final concen­
trations of these solvents did not exceed 0.5% v/v. The cells were incubated for 3 days in 
the presence of each agent prior to assay of cell numbers. Following aspiration to 
disperse clumps, ANN-1 cells were counted using a Coulter Counter model ZM. 3T3 
cells were washed with Ca2+-free and Mg2+-free phosphate-buffered saline solution and 
were treated with 0.2% trypsin in saline solution until the cells detached from the 
substratum. Fresh medium (I ml) was added and the cells were aspirated to disperse 
clumps prior to counting. The inhibition of cell growth was calculated as the percentage 
change in the increase in cell number in the treated cells compared to that of the controls 
which had received DMF or DMSO alone.
Assays o f protein tyrosine kinase activity. The activity of the Abelson protein tyrosine 
kinase was assayed by the use of either a purified, cloned fragment of the kinase 
(ptfl£/50) (a kind gift of Dr Gordon Foulkes) or by the use of a cellular lysate from ANN-1 
cells. For assays with the purified enzyme, a sample (10 n-1) of the plablSO kinase (0.165 
mg/ml) was diluted 1:100 with enzyme buffer containing EDTA (0.1 m M ), Brij 35 
(0.05%), dithiothreitol (1.0 m M ) and bovine serum albumin (BSA) (0.1 mg/ml) in PIPES 
buffer (50 m M ) at pH 7.5. To this were added 10 j j l I  of a solution of angiotensin I (3 mg/ 
ml) in the assay buffer which contained EDTA (0.1 m M ) and Brij 35 (0.05%) in PIPES 
(50 m M ) buffer at pH 7.5. The solution of the test compound or solvent (5 jxl) was added 
(see above) and the reaction was initiated by the addition of 0.3 m M  y-['2P]ATP (specific 
activity 600-1000 c.p.m./pmol; 10 jxl). The mixture was incubated at 30°C for 30 min 
before being quenched with aqueous phosphoric acid (10% v/v; 100 p.1). A portion of the 
reaction mixture (100 p.1) was spotted onto Whatman p81 phosphocellulose paper which 
was washed extensively with 6% aqueous acetic acid and once with acetone, and dried. 
The radioactivity was counted using a Packard Tricarb CA2000 scintillation counter.
When the cell lysate was used, 107 ANN-1 cells were lysed for 10 min at 37°C in a
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buffer containing EDTA (0.2 m M ), sodium vanadate (100 jjlm), Triton X-100 (1%) and 
dithiothreitol (1.0 m M ) in PIPES buffer (50 mM ) at pH 7.5. The suspension was centrifu­
ged at 600 g for 5 min. The supernatant was diluted 1:10 with enzyme buffer and was 
used as for ptabl5Q above, except that the reaction was quenched with 5% aqueous 
trichloroacetic acid. For assays of EGF receptor tyrosine kinase activity, membranes 
were prepared from 108 A431 cells/ml by the method of Pike (1987) and were stored at 
—20°C in a buffer comprising NaCl (100 mM) and NP-40 detergent (0.1%) in HEPES 
buffer (20 m M ) at pH 7.5. The same buffer was used to prepare stock solutions of EGF 
(0.4 p.M), RR-SRC peptide (Casnellie et al., 1982) (4.0 mM ) and an ATP cocktail of 
y-[32P]ATP (400 p.M; 125 nCi/ml), supplemented with MnCl2 (16 m M ), Zn(OAc)2 
(40 jj.m) and sodium vanadate (400 (jlm). The A431 membrane preparation (4 j j l I ) ,  the 
EGF stock solution (4 p.1), the solution of RR-SRC peptide (4 |xl) and the test compound 
or solvent (DMF or DMSO) were preincubated for 5 min before the reaction was 
initiated by addition of the ATP solution (4 p.1). Incubation continued for a further 
5 min. Non-specific phosphorylation was assayed in incubations in the absence of either 
the EGF or the RR-SRC peptide. The reaction was stopped by adding 3.5% aqueous 
trichloroacetic acid (184 pi) at 0°C. The mixture was centrifuged at 13 500 g for 2 min. A 
sample (100 pi) of the supernatant was spotted onto Whatman p81 phosphocellulose 
paper and was washed with aqueous phosphoric acid (75 mM; 5 ml). The content of 32P 
was measured as above. Phosphorylation of the RR-SRC peptide by the crude membrane 
preparation was found to be linear with time. Phosphorylation by unstimulated membranes 
remained <15% of the levels observed during stimulation.
Chemistry
A series of flavones variously substituted in the 3,3',4',5 and 7 positions was sought, 
these positions corresponding to the positions of the potentially hydrogen-bonding 
hydroxy groups in quercetin (7). These flavones were generally more hydrophobic than 
7. The method of Baker (1933), involving acid-catalysed cyclodehydration of substituted 
l-(2-hydroxyphenyl)-3-phenylpropane-l,3-diones, has been the most widely employed 
and was selected for the synthesis of many of the flavones (2-phenylbenzo-4H-pyran-4- 
ones) in this study. 2-Acetylphenol (10) was esterified by benzoyl chloride (14). Baker- 
Venkataraman rearrangement of the resulting ester (29) was effected using powdered 
potassium hydroxide in pyridine. The final cyclodehydration was carried out with catalytic 
sulphuric acid in hot acetic acid to give flavone (66). In some cases, the base-catalysed 
rearrangement did not proceed satisfactorily with "OH, but O to C migration of the acyl 
group in esters 42-44 using lithium hexamethyldisilazide as base enabled the synthesis 
of the propane-1,3-diones 61-63. Flavones 66-79, bearing 3' and/or 4' substituents 
which are stable to the various sets of reaction conditions, were easily approached using 
suitably substituted benzoyl chlorides 15-27 through esters 29-41 and through propane- 
1,3-diones 48-60 (Scheme I). Yields, analyses and spectroscopic data are given in Tables 
I-IV.
The introduction of the more labile 3' and 4' substituents was carried out using several 
methods. Flavone 86 substituted with a hydroxy group at position 3' was prepared by 
demethylation of the corresponding methyl ether using hydrogen bromide in acetic acid 
(Scheme II). The rate of demethylation was considerably enhanced by the use of boron 
tribromide, enabling the relatively rapid formation of 3',4'-dihydroxyflavone (85) and 
hydroxynitroflavones 87 and 88 from methoxy precursors 68, 77 and 78. Treatment of 4'- 
ch!oro-3'-nitroflavone (76) with boiling aqueous dimethylamine furnished the dimethyl- 
amino compound 89 (Scheme III). The (primary amino)flavones 90-94 were generated 
efficiently by the reduction of nitroflavones 71, 72, 76, 77 and 78 with tin (II) chloride
OH
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C (%) H(%) N(%)
14 10 28 A 78 89-90*
15 10 29 A 74 65 69.76 4.29 calc’d
69.58 4.33 found
17 10 31 A 85 116b
18 10 32 A 53 52 71.10 5.22 calc’d
71.11 5.22 found
20 10 34 A 75 94c
22 10 36 A 73 94d
24e 10 38 A 55 99-100 56.35 3.15 calc’d
56.36 3.16 found
25f 10 39 A 86 139-140 60.95 4.15 4.44 calc’d
60.83 4.20 4.46 found
26* 10 40 A 86 108-109 60.95 4.15 4.44 calc’d
60.78 4.13 4.49 found
27 10 41 A 81 84 65.58 4.03 calc’d
65.68 4.05 found
19 12 42 B 68 141h
18 13 46 C 81 67-68* 67.79 5.00 calc’d1
67.68 5.00 found*
“ lit. (Furniss er a/. 1981) m.p. 87-88°C  
b lit. (B aker & Glockling, 1950) m .p. 113-114°C 
'  lit. (V irkar. 1942) m.p. 99-100°C 
d lit. (B aker et al.. 1952) m.p. 92-93°C  
e Al-Jallo & Jalhoom (1972)
1 W u & H erbst (1952)
« Liss (1952)
h lit. (W adodkar & Marathey. 1972) m .p. 135-137°C 
1 M ono-methanol solvate
(Scheme IV). Reduction of the nitro function of 89 gave the diamine 95 which autoxi- 
dized too rapidly to permit meaningful biological evaluation. Diazotization of amines 90 
and 91, and subsequent treatment with sodium azide, gave the azidofiavones 96 and 97 in 
good yields.
Preparation of flavones substituted at positions 7 and 5 required ring-substituted 
phenols. Attempted Fries rearrangement of 3-nitrophenyl acetate to 2-acetyl-4- 
nitrophenol with aluminium trichloride (leading towards 7-aminoflavones) failed owing 
to deactivation of the benzene ring. As reported previously (Cunningham et al., 1989), 
Lewis acids caused degradation of the electron-rich mono- and di-methoxyphenyl 
acetates, hence the direct acetylation of 3-methoxyphenol and 3,5-dimethoxyphenol 
ortho to the hydroxy group was effected using boron trichloride generally by the method 
of Piccolo et al. (1986). Introduction of hydroxy groups at position 7 of flavones was 
achieved through the diacylation of l-acetylbenzene-2,4-diol (13) by appropriate benzoyl 
chlorides 14 and 18, giving the diesters 45 and 46 (Scheme I). The esters of propane-1,3- 
diones 64 and 65 were stable to the conditions of base-catalysed rearrangement 
(potassium hydroxide in hot pyridine), probably owing to the exclusive presence of the
3-ketoenolates. Cyclization to the acyloxyflavones 83 and 84 was effected under the
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28 47 D 63 124*
31 50 D 66 l l l b
42 51 D 70 84-88 71.10 5.22 calc’d
70.74 5.26 found
34 53 D 72 150°
36 55 D 42 142 56.45 3.47 calc'd
56.75 3.54 found
38 57 D 54 196d
39 58 D 95 171 60.95 4.15 calc'd
61.09 4.28 found
40 59 D 54 188-189 calc'd
60.95 4.15 found
60.55 4.21
41 60 D 56 117—118c
42 61 E 48 200 60.95 4.15 calc'd
60.71 4.13 found
* lit. (Fumiss et al., 1981) m.p. 121°C 
b lit. (W heeler, 1963) m .p. 111°C
e lit. (V irkar, 1942) m .p. 157°C 
d lit. (Jucker & Vogel, 1963) m.p. 189-190°C
• lit. (Netherlands Patent. 1965) m.p. 115°C
usual acid-catalysed conditions. Subsequent basic hydrolysis of 84 furnished the 7- 
hydroxy-3'-methoxyflavone (98) (Scheme V).
Functionalization of flavones at the 3-position was investigated. Costa et al. (1985) 
reported lithiation of the 3-position of flavone (66) with lithium diisopropylamide. 
Treatment of this anion with trimethyl borate, followed by oxidation with hydrogen 
peroxide, gave the required 3-hydroxyflavone (99) (Scheme VI). The general appli­
cability of this method is limited by the acidity of the 3-proton. Anions were not formed 
from methoxyflavones 69 and 70, as shown by quench either with trimethyl borate or 
with deuteroacetic acid. The corresponding nitroflavones were very poorly soluble in 
solvents appropriate for lithiation reactions. Since a chlorine atom is approximately 
isosteric with a hydroxy group, the synthesis of 3-chloroflavone (100) was of interest. 
Treatment of 66 with sulphuryl chloride in tetrachloromethane (Scheme VII) not only 
gave the required substitution product 100 but also a low yield of the subsequent addition 
product 2,3,3-trichloroflavanone (101).
Cytotoxicity and enzyme inhibition
The ANN-1 cell line (Scher & Siegler, 1975) was used for an initial screen of inhibition of 
growth. Compounds were incubated for 3 days with the test flavones (50 i x m ) .  Those 
flavones which caused >50% inhibition of growth of ANN-1 cells at this concentration 
were tested for inhibition of growth of the parent cell line 3T3. This arbitrary initial test 
concentration was chosen to select those flavones showing potency in the same range as 
the tyrphostins (Gazit et al., 1989). Compounds 77, 78 and 89 were insufficiently soluble 
to be assayed at 50 pM and were shown to have no growth inhibitory effects at







47 66 F hexane 70
48" 67 F hexane 72
49 68 F EtOAc 73
50 69 F hexane 64
51 70 F EtOAc 60
52 71 F EtOAc 72
53 72 F EtO CH 2CH2OH/
water
71
54 73 F EtOAc 73
55 74 F hexane 71
56 75 F hexane 63
57 76 F hexane 59
58 77 F EtOAc 95
59 78 F hexane 82
60 79 F hexane 64
61 80 F CTICV
hexane
64
62 81 F hexane 63
63 82 F hexane 62
64 83 F hexane 73
68 85 G _ 61
70 86 H EtOAc 60
77 87 G - 53
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229 64.64 3.72 4.71 calc’d
64.58 3.73 4.89 found
241 64.64 3.72 4.71 calc'd
128'
64.61 3.59 4.74 found
218 64.64 3.72 4.71 cale'd
151'"
110"














76 89 I EtO CH 2CH2OH/
water
62
71 90 J EtOAc 56
72 91 J EtOAc 62
76 92 J EtOAc 62
77 93 J EtOAc 47
78 94 J EtOAc 75
89 95 K 85
90 96 L MeOII 63
91 97 L McOII 76
84' 98 M . EtOII 76
66 99 N EtOAc 86
66 too O - 83
66 101 O - 1.5
219-220 65.8 4.5 9.0 calc’d
224s
65.7 4.4 8.6 found
237 75.93 4.67 5.90 calc’d
231-232'
75.65 4.62 5.95 found
181 71.89 4.90 5.24 calc'd
71.91 5.04 5.53 found





143 68.42 3.44 15.96 calc’d
68.13 3.40 16.06 found











“ lit. (Fu rn iss et al . ,  1981) m .p . 98°C 
'* C ru d e  niiilcriiil p rep ared  by M ethod  D 
1 lit. (C h en  e ta! . ,  1962) m .p . 101-102“C* 
lit. (Cuvill et al. ,  1954) m .p . I55°C 
tf lit. (L o o k e r & H an n em an , 1962) m .p . I5 6 -I5 7 °C  
1 (L o o k er & H an n em an , 1962) m .p . 130— 131 ° ( '
8 lit. (D oy le  et al . ,  1948) m .p . 244-246°C  
h lit. (R e ich c l & H cm p cl. 1959) m .p . 2(JI-202°C  
‘ lit. (B ak e r et al. .  1952) m .p . I88 -189°C  
» lit. (L in  et al. .  1963) m .p . I78°C 
k lit. (Ju ck e r & V ogel, 1963) m .p . 227°C 
1 C o m p o u n d  rep o rted  by Lin et al. (1963) but no m .p . given 
lit. (Ja in  et til.. 1965) m .p . I53°C
" lit. (A sh ihara el al. ,  1977) m .p . I0 7 -I0 8 °C
” lit. (Jain  et al. ,  1965) m .p . 243°C
•’ lit. (L ooker & H ann cm an , 1962) m .p . 209°C
■* m / z  283.0485 (M +) (100% ) (C „ H .,N O , requ ires 283.1479)
r m / z  283.0490 (M «) (100% ) (C l5HvN O , requ ires 283.1479)
'  lit. (G ow an & W heeler, 1950) m .p . 233°C 
1 lit. (Jucker & V ogel, 1963) m .p . 225°C 
" m / z  280.1211 (M ‘ ) ( C ^ H 9N 0 5 requ ires 280.1211) 
v C rude m aterial p rep ared  from  46 by M ethod  D and  M ethod  F 
* lit. (Sim pson & B eton , 1954) m .p . 238-240°C  
'  lit. (M ann eta! . ,  1979) m .p. I69°C 
> lit. (M ann e tui . ,  1979) m .p. I2 2 -I2 4 °C  





























71: R '.R l.R ’ =H :R * = NOJ 
72: R1. RJ = H: R* *  NO> R* = H 
76: R'. R2 = H; R1 = NO j  R* = Cl 
77: R1.R 1 = H ;R ,  = N O fR 4 = OMe 
78: R1. R1 = H: R1 = OMe: R4 * N O , 
89: R‘. R1 = H; R> = NO,: R4 = NM e,
90: R '.R ,.R 5 = H :R4 = NH j 
91: R‘.R j - H ;R 5 = N H *R 4» H  
92: R1. RJ *  H: R5 = NH* R4 = Cl 
93: R‘.R l « H :R ,  = NHI:R 4 = OMe 
94: R‘.R J * H ;R ,  = O M e;R 4 = N Hj 





96: R5 = H: R* * N,
97: R* = Nj: R4 = H
Scheme IV Reduction of nitroflavones 71, 72, 76-78 and 89 to give aminoflavones 
90-95, and formation of azidofiavones 96 and 97. Reagents: (i) SnCl->/HC!/EtOH; (ii) 
NaNO:/HCI aq.; (iii) NaNj
OM«
MeO
Scheme V Hydrolysis of ester 84 to give 7-hvdroxy-3'-methoxyflavone (98). Reagent: 
(i) KOH aq
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B(OMe)
99
Scheme VI Synthesis of 3-hydroxyflavone (99). Reagents: (i) LiNPr'->/tetrahydro- 
furan; (ii) (MeO),B; (iii) H 20 2/H 0 A c
7-methoxyfiavone (82) were inhibitory to the Abelson kinase, both with kinetics which 
showed competition with ATP (data not shown). Interestingly, the antitumour agent 
flavone-8-acetic acid (9; Chart I) was a weak competitive inhibitor of this kinase. The 
other compounds tested, flavones 93 and 100, showed no inhibition at concentrations 
< 200 jam. The activity of the five inhibitors of the Abelson kinase was also measured 
against bovine brain cAMP-dependent protein kinase. No inhibition of the latter enzyme 
was observed at concentrations up to 200 j a m ;  thus, inhibition of the tyrosine kinase is 
selective as defined by Graziani et al. (1983) in their studies of pp60,' i'r . The abilities of 
the flavones to inhibit autophosphorylation were not studied.
Clearly, the inhibition of growth of Abelson-transformed ANN-1 cells appears not to 
result from an inhibition of the oncogene tyrosine kinase abl\ for example, the most 
potent and selectively cytotoxic compound, 93, was devoid of activity against the enzyme 
(Table VI). However, when the inhibitors of the Abelson kinase, together with com­
pound 93, were assayed against another protein tyrosine kinase— the EGF receptor- 
associated protein tyrosine kinase— 93 was found to inhibit its activity with a potency 
similar to that of quercetin (7) (Table VII). The existence of a relationship between 
inhibition of the EGF receptor protein tyrosine kinase and inhibition of growth of cells is









Scheme VII Chlorination of flavone (6 6 ). Reagent: (i) S 0 2 C12 /CC14
Table V Activities of flavones and analogous compounds as cytotoxic agents in vitro, 






ICjc versus ANN-1 cells 
(range in \lm)
IC$0 versus 3T3 cells 
(range in \lM)
I genistein 9-15 17-31
7 quercetin 22-43 29-50
6 6 flavone 100-140 22-35
67 3'-fluoroflavone 25-40 n.d.b
6 8 3' ,4'-dimethoxyflavone 23-35 23-36
70 3'-methoxyflavone 18-30 n.d.b
75 3',4'-dichloroflavone 5-20 58
81 5,7-dimethoxyflavone 22-30 2 2
82 7-methoxyflavone 45 n.d.b
85 3'.4'-dihydroxyflavone 8-16 19-26
8 6 3'-hydroxyflavone 14-35 21-37
90 4'-aminoflavone 1 0 - 2 0 18
91 3 -aminoflavone 24-32 2 0
92 3'-amino-4'-chioroflavone 8-27 12-25
93 3'-amino-4'-methoxyflavone 0 .8 - 2 .5 8
94 4'-amino-3'-methoxyflavone 20-35 38-54
99 3-hydroxyflavone 8-15 7-17
* Flavones 9, 69, 71-74, 79, 83, 87, 88 , 96 , 97 and 100 were not toxic to ANN-1 cells at 50 m-M and/or were 
not soluble at this concentration 
6 n.d. = not determined
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Table VI Activities of flavones against the tyrosine kinase activity of pt<zb/50; competition with 









7 quercetin 10 91 3.67
9 flavone-8-acetic acid 150 50 145
82 7-methoxyflavone 100 67 58
93 3 '■-am ino-4 '-methoxyflavone 500 _a 'JL
99 3-hydroxyflavone 150 87 39
100 3-chloroflavone 360 _a
* No activity observed at this concentration
Table VII Inhibition of the protein tyrosine kinase activity of EGF receptor derived from 
A431 cells by flavones
Compound Compound Concentration of Percent
number name flavone (fiM) inhibition
7 quercetin 50 25 ± 16
9 flavone-8-acetic acid 150 -5  ± 9
93 3'-am i no-4'-methoxyflavo ne 50 42+11
99 3-hydroxyflavone 150 43 ± 11
100 3-chloroflavone 150 32 + 9
being investigated. Cushman et al. (1991) reported that a series of 4'-aminoflavones 
inhibited the activity of the protein tyrosine kinase p56/c* and it may be that our com­
pounds inhibit growth via inhibition of some other protein tyrosine kinase. The findings 
from the above experiments suggest that a panel of tyrosine kinases might usefully be used 
to detect activity of candidate inhibitors, despite our use of the kinase responsible for the 
transformation of the primary screen, the ANN-1 cell line. It is clear that the assessment 
of the biological activity of tyrosine kinase inhibitors may be difficult. Faaland et al. 
(1991) showed that a tyrphostin could inhibit EGF-induced cytostasis in A431 cells, yet 
did this by a mechanism which appeared to be other than inhibition of the EGF- 
stimulated protein tyrosine kinase. We are pursuing the mechanism of action whereby 
the compounds which demonstrate antiproliferative effects might exert their activity.
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2-Nitroimidazole Dual-Function Bioreductive Drugs: Studies on the Effects of 
Regioisomerism and Side-Ch&in S truc tu ra l Modifications on D ifferential 
Cytotoxicity and Radiosensitization by Aziridinyl and Oxiranyl Derivatives
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A series o f 2-nitroimidazoles bearing side chniwa terminating in or containing aziridinyl and oxiranyl groups has 
been prepared, and the compounds were evaluated in vitro as hypoxia-selective bioreductively-aetivated cytotoxins 
and selected compounds tested for their radiosensitizing properties toward hypoxic mammalian cells. Compounds 
were either the regioisomers of analogues of the potent dual-functional 2-nitroimidiazole a-[(l-aziridinyl)- 
methyl]-2-nitro-li/-im idazole-l-ethanol (RSU-1069,1) with additional methyl groups of related oxiranes of varying 
side-chain length and type. Oxiranyl derivatives showed little differential toxicity, and those tested were less effective 
as radiosensitizers, and although these properties were influenced by side-chain length, differences were not great 
Aziridinyl compounds related to 1 but with increased side-chain lengths were unstable. Methylation of 1 in various 
regions had little effect on radiosensitization and no clear advantages over 1 as differential cytotoxic drugs. Progressive 
methylation at C-3 was found to increase toxicity but decrease hypoxia selectivity. Incorporation of a cydohexane 
side chain in l£-cis-23-trans-3-aziridin-l-yl-2-hydroxy-l-(2-mtroimidazol-l-yl)cyclohexane (26) abolished hypox­
ia-selective toxicity and unexpectedly reduced radiosensitizing efficiency. Of the aziridines, l- (2-nitro-l- 
imidazolyl)-2-methyl-3-(l-aziridinyl)-2-propanol (20) was comparable in efficacy to 1 as a bioreductively-aetivated 
cytotoxin with slightly lower aerobic toxicity; however, the prodrugs of 1 remain as preferred candidates for clinical 
evaluation.
Introduction
a- [ (1 -Aziridinyl)methyl] -2-nitro- lif-imidazole- 1-ethanol 
(RSU-1069,1) is the most effective of a large number of 
nitroheterocyclic compounds that have been synthesized 
and evaluated as radiosensitizers and bioreductively-ac- 
tivated cytotoxins. 1-3 Compounds of this type owe their 
selective cytotoxicity toward hypoxic cells within tumors 
to their bioreductive properties. Activation in vivo is by 
anaerobic enzymatic reduction to toxic metabolites. 4 The 
radiosensitizing activity of 2 -nitroimidazoles is via fast 
free-radical mechanisms and is related to their one-electron 
reduction potentials. 5
Compound (1) is an alkylating analogue of misonidazole
(2 )—a drug which failed clinically due to neurotoxicity. 6,7 
Preliminary clinical investigation of 1 has, however, re­
vealed gastrointestinal toxicity, which is severely dose- 
limiting.8 A large number of other nitroheterocyclic 
moieties have been evaluated as carriers of aziridinyl and 
other alkylating functionalities; however, these have failed 
to produce comparable efficacy to the 2 -nitroimidazoles 
as hypoxia-selective cytotoxins and any increase in ra­
diosensitizing potency has generally been accompanied by 
higher toxicity.9-12 Other approaches have been to reduce 
the observed toxicity of 1 , and this has been achieved most 
effectively with the prodrug a-[[(2 -bromoethyl)amino]- 
methyl]-2-nitro-lH-imidazole-l-ethanol (RB6145, 3), 
which is the current candidate for Hminal evaluation. 13’14 
With the exception of substitution of the aziridine ring, 
which results in lower toxicity, but also a reduction in 
selective bioreductive differential toxicity, there have been 
no reports of 2 -nitroimidazoles closely related to 1  or its 
substituted analogues such as a- [ (2 -methylaziridinyl) - 
methyl]-2 -nitro-lH-imidazole- 1 -ethanol (RSU-1131, 4) . 2 
We therefore present here the synthesis and evaluation of 
two classes of potentially alkylating 2 -nitroimidazoles. (i) 
Aziridines: Regioisomers of 4 in which methyl substitution 
of the propyl side chain has been carried out are of interest 
to evaluate the steric influence of methyl substitution, 
which might be expected to influence reductase enzyme 
recognition and/or DNA binding. Such substituents may

















also be expected to influence the and consequent 
reactivity of the aziridine moiety. A close analogue of 1
(1) Adams, G. E.;Ahmed, L; Sheldon, P. W.; Stratford, L J. Ra­
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“Reagents: (i) ethenyloxirane/DMF, (ii) MCPBA/CH2C12, (Hi) 
4-butenyloxirane, (iv) MCPBA/CHC13.
in which the l-aziridinyl and 2 -hydroxy groups are fixed 
in an antiperiplanar (trans-diaxial) conformation has also 
been synthesized by utilizing a cyclohexyl side chain in 
order to gain further information on structure-activity 
within this series, in particular steric and conformational 
effects, (ii) Oxiranes: One further way of moderating the 
toxicity of such alkylating 2 -nitroimidazoles is to introduce
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“Relative stereochemistry only is shown. Reagents: (i)
MCPBA/CH2C12, (ii) aziridine/EtOH/EtgN.
Scheme IV0
T  ! K Me OH a
NO,
20
NOj Me Me 
23
“Reagents: (i) MCPBA/CH2C12, (ii) aziridine/EtOH/EtgN.
a somewhat less reactive alkylating function. There have 
been no data published to date on differential toxicities 
of corresponding oxiranes although some radiosensitization 
data is available, 1 5  and we have therefore synthesized and 
evaluated a number of closely related and previously un­
reported oxiranyl analogues of varying side-chain lengths, 
and including the desoxy derivatives, which have been 
studied in view of recent reports that a hydroxyl group /3 
to the imidazole is not required for activity in this class 
of bioreductive agent . 1 6 ' 1 7
Synthetic Chemistry
All compounds were synthesized from the common 
precursor 2 -nitroimidazole (azomycin), which was available 
commercially in bulk quantity. This material was best 
utilized as its potassium salt in DMF, often in the presence 
of a crown ether. The alkenylnitroimidazoles 6  and 8  were 
thus synthesized from appropriate bromoalkenes in DMF 
with 18-crown-€ (Scheme I), whereas the 2 -hydroxyalkenyl 
derivatives 11 and 13 were synthesized from 2-nitro­
imidazole and the appropriate epoxyalkene in refluxing 
DMF (Scheme II).
Reaction of oxirane 7 with refluxing aziridine in ethanol 
proceeded to give the chain-extended version of 1 , but this 
compound (1 0 ) was too unstable to isolate in a satisfac­
torily pure form for biological evaluation. Oxiranes 9,12, 
and 14 gave only complex darkened mixtures under these
(15) Stratford, L J. Mechanisms of hypoxic cell radiosensitization 
and the development of new sensitizers. Int. J. Radiat. Oncol. 
Biol. Phys. 1982, 8, 391-398.
(16) Suto, M. J.; Stier, M. A.; Werbel, L. M. Dual-function radios­
ensitizers. a- [ [ (2-Bromoethyl)amino] methyl] - 2-nitro- 1H- 
imidazole- 1-ethamol and related compounds: preparation via 
an aziridine equivalent J. Med. Chem. 1991, 34, 1207-1209.
(17) Sebolt-Leopold, J.; Arundel-Suto, C. M.; Elliott, W. E.; Leo­
pold, W. R.; Werbel, L. M.; Suto, M. J. Preclinical evaluation 
of PD 130908, a desoxy analogue of RSU-1069 with superior 
potency and reduced toxicities. Radiation Research Society, 
Annual Meeting, New Orleans, LA, 1990, Abstract CV-14.
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Scheme V“
“Reagents: (i) aziridine/EtOH/EtjN.
and a variety of other conditions in the presence of azir­
idine.
Regioisomers of 4 and derivatives with further methyl 
substitutions in the hydroxypropyl side chain were syn­
thesized via appropriately substituted oxiranes, which were 
themselves target compounds. Thus, as for the above 
compounds, appropriately substituted bromoalkenes were 
treated with potassium 2-nitroimidazole in DMF, and the 
resulting alkenes epoxidized with MCPBA to give the 
oxiranes 16, 19, and 22 (Schemes HI and IV). Oxirane 
16 was shown by NMR to be a mixture of isomers (ap­
proximately 1 0 : 1  transrds) corresponding to the isomeric 
content of the starting material. Oxiranyl synthons 16,19, 
and 2 2  reacted cleanly with aziridine in refluxing ethanol 
containing 1% triethylamine to afford aziridines 17, 20, 
and 23. Some selectivity was evident in the reaction of 
aziridine with the 2,3-disubstituted oxirane 16 in that 17 
comprised an inseparable mixture of erythro and threo 
diastereoisomers in the ratio 4.5:1, as shown by XH NM R 
Assignments and connectivity were established by a COSY 
experiment; the spectroscopic dispersion was sufficient at 
250 MHz to permit measurement of most coupling con­
stants for both stereoisomers. Karplus analysis of these 
data suggested that, in the predominant conformation for 
both erythro-17 and threo-17, the aziridinyl group was 
gauche to the OH, in contrast to the conformation of 
compound 26 below.
The correct regioisomeric identity of compound 23 was 
established by the observation of a 6.2-Hz doublet for the 
OH proton in the 270-MHz NMR spectrum. This shows 
that the alcohol is secondary rather than tertiary and that 
the structure is as shown in Scheme IV rather than the 
regioisomer. Thus, it is demonstrated that the aziridine 
nucleophile has attacked the oxirane 2 2  at the more sub­
stituted carbon atom under basic conditions, in contrast 
to the regioselectivity usually observed for nucleophilic 
attack on substituted oxiranes. This regioselectivity may 
be the result of an electronic effect of the neighboring 
2 -nitroimidazole moiety, favoring ring opening at the distal 
epoxide carbon. The (2,3-epoxycyclohexyl)-2-nitro- 
imidazoles 24 and 25 were synthesized as previously de­
scribed. 1 8  The diastereoisomer 24 could be isolated in pure 
form for biological evaluation by virtue of its unreactivity 
toward nucleophilic attack by aziridine. Epoxide 25 reacts 
to give the corresponding aziridinyl derivative 26 (Scheme 
V).
Biological Evaluation in Vitro
Selective toxicity to hypoxic V79-379A cells was deter­
mined for all compounds using the MTT assay as has been
(18) Threadgill, M. D.; Webb, P. syrc-Selectivity in the epoxidation 
of l-(cyclohex-2-enyl)-2-nitroimidazole mediated by hydrogen 
bonding. J. Chem. Soc., Chem. Commun. 1991, 4, 269-271.
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5 0.25* 0.55 0.27 2.0
7 ndr 0.5 0.25 2.0
9 nd 1.2 0.7 1.7
12 0.2 1J2 0.36 3.3
14 0.4 0.6 0.4 1.5
16 nd 10.0 3.3 3.0
19 nd 0.2 0.2 1.0
24 nd 0.28 0.18 1.5
“Concentration required to give enhancement ratio = 1.6. 
6 Concentration required to kill 50% of aerobic cells. 
“Concentration required to kill 50% of cells under N*. rfCso(air)/ 
CsqCN .^ “Data taken from ref 15. f Not determined.









1 0.1 0.3 0.015 20.0
4 0.08 0.79 0.065 12.2
17 0.12 02 0.01 20.0
20 nd* 0.55 0.02 27.5
23 0.07 0.1 0.008 12J>
26 0.45 0.35 0.35 1.0
“Concentration required to give enhancement ratio = 1.6. 
6 Concentration required to kill 50% of aerobic cells. 
“Concentration required to kill 50% of cells under N* d Cso(air)/  
CsoOSj). “Not determined.
described elsewhere. 1 2 *1 9  These results are presented in 
Tables I and IX, where C ^air), the concentration required 
to kill 50% of the aerobic cells under the conditions of the 
assay, are divided by ^ ( N ^  values, concentrations re­
quired to kill hypoxic cells, to give differential toxicity 
ratios, which enable quantitative comparisons of biore­
ductive activities of drugs.
The oxiranyl derivatives 5, 7, 9, 12, 14, 16, 19, and 24 
showed only small additional toxicities as a result of 
bioreduction, and were indeed less effective than 2. The 
high aerobic toxicity of oxiranes has also limited the 
bioreductive potential of other nitroheterocyclic com­
pounds such as pyrroles and furans. 1 0 -1 2  Those compounds 
that do not show high aerobic toxicity, such as 1 2  and 16, 
are therefore likely to be limited in hypoxia selectivity by 
the reduced alkylating potential of the oxirane ring com­
pared to the aziridine ring of their close analogues 1  and 
17, under similar conditions. Of the oxiranes most closely 
related to 1 , the four-carbon side chain of 1 2  resulted in 
greater differential cytotoxicity than a six-carbon side 
chain (14), although both differential values were low. A 
gfmilflT comparison be made between compounds 7 and 
9. A side-chain length study of aziridinyl derivatives was 
not possible due to the instability of chain-extended ver­
sions of 1 , but these results indicate that elongation of the 
side chain does not improve the bioreductive potential. In 
contrast, studies on 2-nitroimidazoles with varying N-l 
side-chain lengths terminating in morpholine, piperidine, 
and pyrrolidine showed that changes in sensitizing effi­
ciency and, in some cases, cytotoxicity can occur. 2 0
Aziridinylnitroimidazoles 17,20, and 23 displayed dif­
ferential cytotoxicities in the range 15-25; these figures are 
considered insignificantly different from values obtained
(19) Stratford, I. J.; Stephens, M. A. The differential hypoxic cy­
totoxicity of bioreductive agents determined in vitro by the 
MTT assay. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16, 
973-976.
(20) Adams, G. R; Ahmed, L; Fielden, E. M.; O’Neill, P.; Stratford,
I. J. The development of some nitroimidazoles as hypoxic cell 
sensitizers. Cancer Clin. Trials 1980, 3, 37-42.
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for 1 . Methyl substitution of the hydroxypropyl side chain 
therefore has little influence on bioreductive activity. Only 
23 shows a more significant drop in activity, but more 
notable is the increase in aerobic toxicity in this example. 
Indeed the results for 1,17, and 23 indicate progressive 
methylation at C-3 of the side chain increases toxicity in 
air and decreases hypoxia selectivity as a result This could 
be due to progressive increases in the aziridine pKt and 
hence increases in its reactivity to impractical levels. 
Consequently compound 23 has similar differential toxicity 
to the derivative containing a substituted aziridine (4), 
although this compound is known to contain a less potent 
alkylating group. All bioreductive activity was abolished 
when the side-chain stereochemistry was fixed in the 
trans-diaxial conformation of a cyclohexane substituent 
in compound 26. Aerobic toxicity was at a level attrib­
utable to the aziridine ring, with no additional toxicity 
under hypoxic conditions. Stereochemical and steric 
constraints on reductase enzyme recognition and binding 
are therefore in evidence and a cyclohexane skeleton will 
not be tolerated.
Aziridinyl-2-nitroimidazoles 1,4,17,23, and 26, together 
with oxiranyl derivatives 12 and 14, were assayed for their 
ability to sensitize hypoxic V79 cells in vitro to 7 -radiation, 
carried out as described previously. 12,13 The results are 
expressed in Tables I and II as CL 6 values, the concen­
tration of nitroimidazole required to give an enhancement 
ratio of 1 .6 .
The two oxiranyl derivatives evaluated were the com­
pounds most closely related to 1 and containing a /8-hy­
droxy substituent on the side chain. There was a 2-fold 
difference in these compounds fipngftiwng efficiencies, with 
12, containing a 4-carbon side chain, being the more ef­
fective. This indicates that the chain length for maximum 
potency as a dual-function sensitizer may be quite small 
(four or five carbon atoms).
There was little effect on sensitizing efficiency within 
the series of aziridinyl derivatives upon methyl substitution 
of either the side chain or aziridine ring, although a similar 
small enhancement in sensitization was observed with 
compounds 4 and 23. Increases in aziridine piC, as a result 
of these substitutions therefore may not be significant 
enough to improve tumor uptake, as has been observed 
with the more basic 2 -nitroimidazoles including those 
bearing more substituted aziridines. 21 In contrast, the 
cyclohexyl derivative 26 was markedly less potent than its 
acyclic analogues. The contribution of the aziridine 
function toward radiosensitization has therefore been much 
reduced in 26 and its potency is even lower than that of 
non-alkylating nitroimidazoles such as 2. This is unex­
pected in view of the normal contribution the aziridine 
moiety exhibits toward aerobic toxicity in the bioreductive 
assay. The activity of 23 indicates that steric crowding at 
C-3 of the side chain is tolerated; hence the inactivity of 
26 must be conformational in origin, not steric.
Conclusions
Although reduction of the alkylating potency of 1 by 
methyl substitution of the aziridine retains significant 
bioreductively-aetivated cytotoxicity, this is not the case 
for corresponding oxiranes. These derivatives do not have 
the alkylating potential required for bifunctional electro- 
philirity under hypoxic conditions and show little promise 
for further development.
(21) Walling, J.; Stratford, L J.; Adams, G. E.; Stephens, M. A. 
Dual-function radiation sensitizers and bioreductive drugs: 
factors affecting cellular uptake and sensitizing efficiency in 
analogues of RSU-1069. Int. J. Radiat. Biol. 1988,53,641-649.
N aylor e t al.
Single methyl substitutions of the hydroxypropyl side 
chain of 1 has little effect on its activity, although aerobic 
toxicity was influenced by progressive C-3 methylations. 
No obvious advantages over 1 were apparent with these 
derivatives although 2 0  was slightly less toxic to aerobic 
cells and may be worthy of further study in vivo. Major 
structural modification of the side chain, for example with 
the cyclohexane ring of 26, abolishes activity, presumably 
by inhibiting bioreducibility. The prodrug 3 remains the 
candidate of this series of 2-nitroimidazoles for Phase I 
clinical evaluation.
Experimental Section
NMR spectra were obtained at 60 MHz with JEOL PMX60SI 
and at 270 MHz with JEOL GX270 spectrometers, using SiMe« 
as internal standard. Mass spectra were obtained with a VG 7070 
spectrometer in either the electron impact (El) mode at 70 eV  
or in the chemical ionizatioin mode (Cl) with 2-methylpropane. 
M elting points are uncorrected. Elemental analyses were de­
termined by Butterworth Laboratories Ltd., Teddington, Mid­
dlesex, UJC Solutions in organic solvents were dried by treatment 
with Na^O* and filtration. Solvents were removed by evaporation 
under reduced pressure. Dichloromethane (CH2CI2) was dried 
over calcium chloride and passed through neutral alumina prior 
to use. Dimethylformamide (DMF) and acetonitrile (CH3CN) 
were anhydrous commercial grades. Silica gel radial chroma­
tography was carried out on a Chromatotron (TC Research, 
Norwich, UJC). 3-Chloroperbenzoic add (MCPBA) either was 
the commercial grade (55%) or was purified by treatment with 
phosphate buffer (pH 7.0) and dried over P20 5 to obtain material 
of approximate 85% purity. 1-Potassio-2-nitroimidazole was 
obtained by treatment of azomydn with 1.1 equiv of potassium  
tert-butoxide (t-BuOK) in refluxing DMF, the mixture cooled, 
and the solid salt washed with CH2CI2. Oxirane 5 was synthesized 
as described previously.22 Compounds were racemic »nlwa 
otherwise stated. Where elemental analyses and/or accurate mass 
spectra are not given due to compound form, instability, or lack 
of molecular ion, other mass spectral and NMR data were sat­
isfactory and compounds were chromatographically homogeneous.
l-(3,4-E poxybutyl)-2-nitroim idazole (7). l-Potassio-2- 
nitroimidazole (3.03 g, 20 mmol) in dry CH3CN (50 mL) was 
stirred with 4-bromo-l-butene (10 mL, 985 mmol) in the presence 
of 18-crown-6 (0.12 g, 0.45 mmol) for 16 days. The suspension 
was evaporated to dryness, redissolved in CHC13 (200 mL), and 
washed with H20  (3 x 200 mL). The solution was then evaporated 
to dryness to afford 3.32 g (99%) of 6 as a pale yellow oil: NMR 
(CDCla) 5 2.55 (q, 2 H, J  «  7.5 Hz, Im-CH2Cff2CH=CH2), 4.5 
(t, 2 H, J  = 7.5 Hz, Im-Cff2CH2CHsasCH2), 5.3 (m, 3 H, 3 x 
olefinic-H), 7.1 (s, 1 H, Im-H), 7.25 (s, 1 H, Im-H). This material 
(352 g, 19J9 mmol) was dissolved in CH2G 2 (100 mL) and MCPBA 
(55%, 7.3 g, 23.3 mol) added. The solution was heated under 
gentle reflux for 6 h, cooled, diluted with CH2C12 (100 mL), and 
washed with 10% Na^C^aq) (3 x 150 mL), H20  (2 x 150 mL) 
and saturated NaHC0^(aq) (2 x 150 mL). The solution was dried 
and evaporated, and the residue was purified on silica gel eluting 
with CHC13, to give 1.63 g (44.8%) of l-(3,4-epoxybutyl)-2- 
nitroimidazole (7): mp 37-39 °C; NMR (CDCI5) 6 2.0 (q, 2 H, 
J  =  7.5 Hz, Im-CH^H^, 2.4 (dd, 1 H, J  = 3 and 4.5 Hz) and 2.9 
(t, 1 H, J  = 4.5 Hz) oxiranyl CH* 3.1 (m, 1 H, oxiranyl-H), 4.5 
(t, 2 H, J  = 75  Hz, Im-CHz), 7.1 (s, 1 H, Im-H), 72 (s, 1 H, Im-H). 
AnaL (C^HgNaOj) C, H, N.
l-(5,6-E poxyhexyl)-2-nitroim idazole (9). l-Potassio-2- 
nitroimidazole (1.51 g, 10 mmol) in dry CH3CN (50 mL) was 
stirred with 6-bromo-l-hexene (1.9 mL, 14 mmol) for 8 h in the 
presence of 18-crown-6 (0.1 g, 0.38 mmol). The solution was then 
heated under reflux for 12 h, cooled, and evaporated to dryness. 
The residue was redissolved in EtOAc (250 mL) and washed with 
H20  (3 x  150 mL) and saturated NaCl(aq) (150 mL), dried, and 
evaporated to give 1.76 g (90%) of l-(5-hexenyl)-2-nitroimidazole 
(8) as a yellow oil: NMR (CDClj) 5 1.8 (m, 6 H, Im -CH ^CH ^,
(22) Beaman, A. G.; Tautz, W.; Duschinsky, R. Studies in the ni­
troimidazole series, m . 2-Nitroimidazoles substituted in the 
1-position. Antimicrob. Agents Chemother. 1968, 520-530.
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4.5 (t, 2 H, J  = 3.6 Hz, Im-CH2), 5.25 (m, 3 H, CH=CH2), 7.2 
(br, 2 H, 2 x  Im-H). This material (1.76 g, 9.0 mmol) was dissolved 
in CH2C12 (100 mL) and stirred with MCPBA (55%, 4.14 g, 13.2 
mmol) at 25 °C for 6 h. A further 1.7 g (5.4 mmol) of MCPBA 
was then added and stirring continued for 16 h. The solution was 
diluted with CH2C12 (150 mL) and washed with 10% Na2S 03(aq) 
(3 x  150 mL), H ^  (2 x  150 mL), and saturated NaHC03(aq) (2 
x  150 mL), dried, and evaporated The residue was purified on 
silica, eluting with EtOAc, to afford 1.5 g (79%) of 9 as a pale 
yellow so lid  recrystallized from aqueous ethanol: mp 29-31 °C; 
NMR (CDC13) 6 1.8 (m, 6 H, Im-CH^CH^j), 2 8  (dd, 1 H, J  =
3.6 and 4.8 Hz) and 2.9 (t, 1 H, J  -  4.8 Hz), oxiranyl 6-CH* 3.1 
(m, 1 H, oxiranyl 5-CH), 4.6 (t, 2 H, J  = 7.5 Hz, Im-CH^, 7.2 (s,
1 H  Im-H), 7.3 (s, 1 H, Im-H). AnaL (C»HI3N30 3-0.25H20 ) C,
H, N.
l-(2-H ydroxy-3,4-epoxybutyl)-2-nitroim idazole (12). 2- 
Nitxoimidazole (3.0 g, 268 mmol) was dissolved in 10 mL of DMF 
and refluxed with 10 g (142 mmol) of butadiene monoxide and 
0.2 g (1.4 mmol) o f K^CV After 20 min the DMF was removed 
and the residue redissolved in H ^  (100 mL) and extracted with 
EtjO (3 X 100 mL). The combined ether extracts were evaporated 
and the residue was recrystallized from EtOAc/CHCl3 to afford 
28  g (52%) of l-(2-bydrt^-3-butenyi)-2-mtroiinidazole (11): mp 
92-93 °C (lit.23 mp 90-92 °C). This material (0.5 g, 2.7 mmol) 
was dissolved in 10 mL of dry C H ^ s together with L0 g (85%, 
4.9 mmol) of MCPBA and the solution heated under reflux for
I.5 h. The solution was then cooled and evaporated and the 
residue was purified on silica (eluting with EtOAc) to give 0.35 
g (65%) of 12 as a pale yellow so lid  recrystallized from EtOH: 
mp 131-132 °C (lit23 mp 134-136 #C); NMR ((C H ^ O ) 5 2.1 
(t, 1 H, J  *  2.4 Hz) and 2.7 (dd 1 H, J  = 2.4 and 4& Hz), oxiranyl 
4-CH2, 3.0 (m, 1 H, oxiranyl 3-CH), 3 8  (m, 2 H, CHOH), 4.8 (dd
2 H ,J  = 3.6 and 7.5 Hz, Im-CHj), 7.0 (s, 1 H, Im-H), 7.3 (s, 1 H, 
Im-H).
l-(2-H ydroxy-5,6-epoxyhexyl)-2-nitroim idazole (14). 2- 
Nitroimidazaole (3.46 g, 30.6 mmol) and Na2Q03 (0.72 g, 68  mmol) 
were heated under reflux in DMF (35 mL) with L2-epoxy-5-hexene 
(3.75 mL, 332 mmol) for 15 min with stirring. The solution was 
then poured into EtOH (100 mL) and filtered, and the solid 
material was washed with EtOH (150 mL). The filtrate was 
evaporated to dryness and the residue redissolved in EtOAc (250 
mL) and washed with H20  (4 x  200 mL) and saturated NaCl(aq) 
(200 mL), dried and evaporated The residue was purified on 
silica, eluting with EtOAc, to afford 2.42 g (37.5%) of l-(2- 
hydraxy-5-hexenyl)-3-nitroimidazole as a yellow solid (13): mp 
81-83 °C; NMR (CDClj) 1 1 8  (dt, 2 H, J  *  1 8  and 7 8  Hz, 
CH2=CHCH2CH2), 2.4 (dt, 2 H, J  = 2.4 and 7.5 Hz, C H j=  
CHCH2CH2), 4 2  (br, 2 H, J  -  ca. 10 Hz, Im-CHj), 4.35 (m, 2 H, 
CHOH), 5.7 (m, 3 H, CH*=CH), 7.0 (s, 1 H, Im-H), 7.2 (s, 1 H, 
Im-H).
The above material (1.06 g, 5.3 mmol) was dissolved in CHC13 
(100 mL) and 55% MCPBA (3.6 g, 11.5 mmol) added. The 
solution was stirred for 1 h at 25 °C and then heated under reflux 
for 1.5 h, cooled and evaporated The residue was purified on 
silica, eluting with EtOAc, to afford 083 g (73%) of l-(2- 
hydroxy-5,6-epoxyhexyl)-2-nitroimidazole (14): mp 76-78 °C; 
NMR (CDClj) 5 1.8 (m, 4 H, CH2CHrOxirane), 2.5 (dd, 1 U ,J  
= 2.4 and 4.8 Hz) and 2.8 (t, 1 H, J  -  4.8 Hz), oxirane 6-CH2,
3.0 (m, 1 H, oxirane 5-CH), 485 (m, 4 H, Im-CH2CH(OH)), 7.0 
(s, 1 H, Im-H), 7.2 (s, 1 H, Im-H); CIMS, m /z = 228 (M +  H).
ery th ro -l-(3 -A zir id in -l-y l-2 -h y d ro xy b u ty l)-2 -n itro - 
im idazole (17). l-Potassio-2-nitroimidazole (2.26 g, 15 mmol) 
and l-bromo-2-butene (2 mL, 19.4 mmol) were refluxed in 20 mL 
of DMF for 5 min. cooled, poured into EtOH (100 mL), and 
filtered The solid material was washed with hot EtOH (100 mL) 
and the filtrate evaporated, dried and redissolved in CH2C12 (200 
mL) and washed with H20  (4 x  250 mL) and saturated NaCl(aq) 
(250 mL). The solution was dried and evaporated and the residue 
was treated with activated charcoal (MeOH, reflux, 5 min), filtered 
and evaporated to dryness to give 2.05 g (61.4%) of l-but-2- 
enyl-2-nitro imidazole (15) as a yellow oil, which was used without
(23) Ahmed, I.; Stratford I. J-; Jenkins, I. J. Radiosensitizers of 
hypoxic mammalian cells. Arzneim.-Forsch.fDrug Res. 1985, 
35,1763-1768.
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further purification: NMR (CDC13) 5 1.8 (d  3 H, J  = 3.6 Hz, 
CH=CHCHa), 5.1 (br d, 2 H, J  = 4.8 Hz, Im-CHJ, 5.8 (m, 2 H, 
CH =C H ), 7.15 (s, 1 H, Im-H), 7.2 (s, 1 H, Im-H).
The alkene 15 (0.84 g, 5.0 mmol) was dissolved in CHjC^ (50 
mL) and MCPBA (55%, 1.7 g, 58  mmol) added The solution 
was heated under reflux for 6 h, cooled and diluted with CHjClj 
(100 mL). The organic material was washed with 10% NajSO^aq) 
(2 x 100 mL), saturated NaHC03(aq) (2 X 150 mL), H20  (2 x 
150 mL), and saturated NaCl(aq) (200 mL), dried and evaporated 
The residue was purified by silica gel radial chromatography, 
eluting with CH2C12, to give 0.47 g (51.1%) of l-(2,3-epoxy- 
butyi)-2-mtroimidazole (16) as a pale yellow gum: NMR (CDClj) 
S 18  (d  3 H, J  = 4.8 Hz, oxirane 3-CH3), 2.8 (dd, 1 H, «7 = 2.4 
and 4 8  Hz, oxirane 3-CH), 81 (m, 1 H, oxirane, 2-CH), 4.2 (dd  
1 H, J =  7 8  and 14.4 Hz), and 48  (dd  1 H ,« /= 8 6  and 14.4 Hz), 
Im-CH* 7.1 (s, 1 H, Im-H), 7.15 (s, 1 H, Im-H); EIMS 183.0635 
(calcd for C,UJi30 3 183.0644).
The oxiranyl synthon 16 (0.46 g, 2.5 mmol) was dissolved in 
E tO H /1% EtgN (20 mL) and heated under reflux with 1H- 
aziridine (CAUTION!) (80  g, 468 mmol) for 8 h. The solution 
was evaporated and the residue purified on silica (eluting with 
CHCl^/MeOH/Et^N, 98:1:1) to give, after recrystallization from 
EtOH (1% E^N ), 0.46 g (81%) of 17 as an off-white solid: mp 
118-114 °C; NMR (CDClaACDsJSO) 6 L3 (s, 3 H, CH{CHJ), 185 
(d d  2 H,«7 = 2 and 4 Hz, aziridine-CH^, 18  (dd  2 H, J  = 2 and 
4 Hz, aziridine-CH^, 8 6  (m, 1 H, CH{CH£), 4.0 (m, 1 H, CH- 
(OH)), 4.4 (d d  1 H ,«/ = 9.6 and 19.2 Hz) and 4.8 (dd  1 H, J  =
2.4 and 12 Hz), Im-CH* 7.1 (s, 1 H, Im-H), 7 8  (s, 1 H, Im-H). 
erythro-17: NMR (CDC13, 250 MHz) 5 1.17 ( d , 3 H , J = 7  Hz, 
CH3), 181 (ca. q, 1 H ,«/ = ca  4 Hz) and L37 (ca, q, 1 H, J  = ca  
4 Hz), 1.67 (ca. q, 1 H, J  = ca  4 Hz) and 1.69 (ca, q, 1 H, J  = 
c a  4 Hz), aziridine-H*, 184 (dq, 1 H, J  = 3 and 7 Hz, CHCH3),
3.7 (br 1 H, OH), 4.03 (dd, 1 H, /  = 3 and 10 Hz, CHOH), 4.08 
(d d  1 H, J  -  10 and 13 Hz) and 4.72 (d, 1 H, J  = 13 Hz), 
imidazole-CH2, 7.14 (s, 1 H, Im-4-H), 7.29 (s, 1 H, Im-5-H). 
threo-17: NMR 2 L22 (d  3 H, J  = 7 Hz, CHj), 187 (m, 1 H) and 
1.40 (m, 1 H) and 1.90 (ca  q, 1 H, J  — ca  4 Hz) and 1.92 (ca q,
1 H, *7 = c a  4 Hz), aziridine-H<, 1.66 (dq, 1 H, J  = 6 and 7 Hz, 
CHCHa), 3.6 (br, OH), 3.91 (ddd, 1 H , J  -  2 8  and 6 and 10 Hz, 
CHOH), 4.26 (dd  1 H ,«/ = 10 and 14 Hz) and 4.87 (d d  1 H, J  
— 2 8  and 14 Hz), imidazole-CH2, 7.13 (br s, 1 H, Im-4-H), 7.27 
(br s, 1 H, Im-5-H); CIMS m/z = 227 (M +  H), 197,180. AnaL 
(C9H14N40 34)85H20 ) C, H, N.
l-(2 -N itro -l-im id a zo iy I)-2 -m eth yI-3 -(l-azirid in y l)-2 - 
propanol (20). To l-potassio-2-nitroimidazole (5.72 g, 378 mmoi) 
in 50 mL o f DMF was added sodium iodide (0.1 g, 0.67 mmol) 
followed by 0-methaDyl chloride (10 mL, 101 mol) and the solution 
heated under reflux for 0.25 h. The solution was then cooled, 
poured into EtOH (100 mL), and filtered and the solid material 
was washed with warm EtOH (150 mL). The combined filtrates 
were evaporated and the residue was redissolved in CHC13 (250 
mL), washed with H20  (4 x 200 mL) and saturated NaCl(aq) (200 
mL), dried, and evaporated to afford 6.95 g (822% ) of l-(2- 
methyiprop-2-enyl)-2-nitroim irfazole (18) as a pale yellow ofl, which 
was used without further purification: NMR (CDCI3) 6 1.8 (s, 
3 H, CH2C(CH3)), 4.6 (bs, 1 H) and 5.0 (bs, 1 H), C{CRJ=CHJ,
5.0 (s, 2 H, Im-CHj), 7.2 (s, 2 H, 2 X Ln-H). This material (3.42 
g, 208 mmol) was dissolved in CH2Q 2 (100 mL) and heated under 
reflux with MCPBA (55%, 1214 g, 388 mmol) for 3 h. The cooled 
solution was diluted with CHG3 (150 mL) and washed with 10% 
NasS03(aq) (3 X 200 mL), saturated NaHC03(aq) (2 x 200 mL), 
H20  (2 X 200 mL), and saturated NaCl(aq) (200 mL). The 
solution was dried and evaporated and the residue purified on 
silica, eluting with EtOAc, to give 1.89 g (50.4%) of l-(2- 
methyl-28-epoxypropyl)-2-nitroimidazole (19) as a yellow solid: 
mp 70-71 °C; NMR (CDCy 6 1.4 (s, 3 H, oxirane 2-CHs), 27 (dd,
2 H, J  = 3.6 and 14.5 Hz, oxiranyl 3-CH^, 4.7 (dd, J  =  14.5 and 
33 Hz, Im-CHz), 7.2 (s, 1 H, Im-H), 7.25 (s, 1 H, Im-H). Anal. 
(CjH^NsOs) C, H, N. The oxirane 19 (126 g, 69  mmol) was heated 
under reflux in EtOH (1% EtjN, 30 mL) with LH-aziridine (20  
g, 46.5 mmol) for 0.75 h. The solvent was then evaporated and 
the residue recrystallized from EtOH (1% EtjN) to afford 0.93 
g (59.8%) of 20 as a pale yellow solid: mp 108-110 °C; NMR 
(CDC13/(C D )3S0 ) 5 1.2 (s, 3 H. C(OH)CHj), 1.25 (dd, 2 H, J  = 
2 and 4 Hz, aziridine CH^, 1.8 (dd, 2 H, J  = 2 and 4 Hz, aziridine 
CHj), 2 3  (dd. 2 H. J  = 12 and 22 Hz, CH2-aziridine), 4.7 (s, 2
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H, Im-CHj), 7.05 (s, 1 H, Im-H), 7.3 (s, 1 H, Im-H). AnaL 
(CsHwN^Oj) C, H, N.
l-(2-N itro-l-im idazolyl)-3,3-d im ethyl-3-(l-azirid inyl)-2- 
propanol (23). l-Potassio-2-nitroimidazole (3.05 g, 20.2 mmol) 
in dry CH3CN (50 mL) was stirred with 4-bromo-2-methylbut-
2-ene (4.75 g, 31.8 mmol) and 18-crown-6 (0.26 g, 0.98 mmol) for 
24 h. The suspension was evaporated and redissolved in CHC13 
(200 mL) and washed with H20  (4 x  75 mL) and saturated NaCl 
(75 mL) and then dried and evaporated to dryness. The residue 
was purified on silica gel eluting with CHCI3 to afford 0.8 g (22%) 
of l-(3-methylbutenyl)-2-nitroimidazole (21) as a pale yellow oib 
NMR (CDCI3) 6 L8 (bs, 6 H, C H ^ C H ^ , 5.1 (bd, 2 H, Im-CHJ,
5.4 (m, 1 H, CH=C(CHJJ, 7.1 (s, 1 H, Im-H), 7.15 (s, 1 H, Im-H).
The above alkene (2.7 g, 14.9 mmol) was dissolved in  CH2C12 
(100 mL) and heated under reflux with MCPBA (6.29 g, 20.1 
mmol) for 1 h, cooled, diluted with CH2C12 (100 mL), and washed 
with 10% N a^C^aq) (3 x  150 mL), HjO (2 x  150 mL), and 
saturated NaHC03(aq) (2 x  150 mL). The solution was dried 
(Na^O*) and evaporated, and the residue was purified on 3ilica, 
eluting with EtOAc, to  give 1.8 g (8L7%) of l-(3,3-dim ethyl- 
2,3-epoxybutyl)-2-nitroimidazole (22) as a pale yellow oil: NMR 
(CDCI3) 51.4 (s, 3 H, oxirane 3-CH3), 1.45 (s, 3 H, oxirane 3-CH3), 
3.2 (dd, 1 H, J  = 3.6 and 8.4 Hz, oxirane 2-CH), 4.3 (dd, 1 H, J  
= 8.4 and 133 Hz), and 5.1 (dd, 1 H ,« /= 3.6 and 14.4 Hz), Im-CH^ 
7.15 (s, 1 H, Im-H), 7 3  (s, 1 H , Im-H).
The oxiranyl synthon 22 (1.09 g, 5.5 mmol) was dissolved in 
EtOH (1% EtjN) (30 mL) and heated under reflux with 1H- 
aziridine (2.0 g, 46.5 mmol) for 10 h. Further aziridine (5 mL, 
116 mmol) was then added, and heating was continued for another 
4 h. The solution was then evaporated and the residue purified 
on silica (eluting with CHC13/M eO H /E^N (90:9:1)) to  afford, 
after recrystallization from EtOH (1% EtsN), 0.32 g (32.8%) of 
23 as a pale yellow solid: mp 127-128 °C; NMR ((C D j^O ) 6 0.78 
(s, 3 H, CtCHs)), 0.83 (s, 3 H, C(CHj)), 1.4 (m, 4 H, 2 x  aziridine 
CHz), 4.25 (dd, 1 H, J  =  10.7 and 13.5 Hz) and 4.92 (dd, 1 H, J
= 1.5 and 13.5 H z), Im-CH2, 5.07 (d, 1 H, J  = 6.2 Hz, OH), 7.14 
(s, 1 H, Im-H), 7.59 (s, 1 H, Im-H); NMR (CDCI3) & 0.92 (s, 3 H, 
CfCHg)), 0.98 (s, 3 H, CfCHa)), 1^  (m, 2 H) and 1^3 (m, 1 H) 
and 1.61 (m, 1 H ), 2 X aziridine CHj, 3.66 (dd, 1 H, J  -  1.7 and 
10.1 Hz, CHOH), 4.10 (dd, 1 H, J  «  10^ and 13.5 Hz) and 4.9 
(dd, 1 H, J  = 1.7 and 13.5 Hz), Im-CH2, 4.2 (br, 1 H, OH), 7.08 
(d, 1 H, </ = 1.1 Hz, Im-H), 7J27 (d, 1 H ,«/ = 1.1 Hz, Im-H). AnaL 
(C10H16N4O3) C, H, N .
l^ -cis-2 ,3 -rran s-3 -A zirid in -l-y l-2 -h yd rory-l-(2 -n itro - 
im id azol-l-y l)cycloh exan e (26). l-Cydohex-2-enyl-2-mtro- 
imidazole was prepared and epoxidized with MCPBA as described 
previously.18 The anti-isomer 24 was isolated as unreacted starting 
material when a mixture of isomers was used for the following 
reaction. The syn-isomer 25 reacts with aziridine, but could be 
obtained in pure form when the above epoxidation was carried 
out with dried peroxy add as described previously.18
The oxiranyl synthon 25 (0.5 g, 2.4 mmol) was refluxed in 40 
mL of EtOH (1% EtjN) with lH-aziridine (2.0 g, 463> mmol) for
1.5 h. The solution was evaporated to dryness and the residue 
purified on silica, eluting with CHCl3/M eO H /Et3N (903:1), to  
give 0.15 g (26%) of 26 as a pale yellow solid, recrystallized from 
acetone: mp 204-206 °C; NMR ((01)3)280) 6 LI2 (dd, 1 H, J  —
6.0 and 3 3  Hz, aziridine-H syn to N-cyoohexane bond), L16 (dd, 
1 H, J  = 6.0 and 3.4 Hz, aziridine-H syn to IV-cyclohexane band),
1.45-130 (m, 7 H, 2 x aziridine-H anti to H -cydohexane bond 
+  4ax,4eq,5ax3eq,6eq-H), 2.17 (dq, 1 H, J  = 11.4 and 3.4 Hz, 
6ax-H), 3.34 (m, 1 H, 3-H), 3.91 (m, 1 H, 2-H), 5.11 (d, 1 H, J  =
5.6 Hz, OH), 5.49 ( d c a . t , l H , J =  11.9 and 3 Hz, 1-H), 7.15 (d, 
1 H, *7 = 0.7 Hz, bn-4H), 7.67 (d, 1 H, 0.7Hz,Im-5H);EIM S 
252.1222 (calcd for CuHuNtQ, 252.1240).
Acknowledgment. Financial support from the British 
Technology Group is gratefully acknowledged. This work 
was also funded by the National Cancer Institute under 
Grant No. 5 ROl CA44126.
PUBLICATION 52
Analysis of Cocaine, Benzoylecgonine, Ecgonine Methyl Ester, Ethylcocaine and 
Norcocaine in Human Urine using HPLC with Post-Column Ion-Pair Extraction
and Fluorescence Detection
I. M. Roy, T. M. Jefferies, M. D. Threadgill and G. H. Dewar
Journal o f Pharmaceutical and Biomedical Analysis, 1992,10, 943-948.
Journal of I’hunnactruticul fiiiim cdn  ul Analysis 
V ol. 10. N os 10-12 . pp . <W.1-<J4X. IW 2 
P rim ed  in G rea t B ritain
U7.t| -70X5/V2 S5 (K) + 0.0(1 
©  IW 3 Pergam on Press I.ttl
Analysis of cocaine, benzoylecgonine, ecgonine 
methyl ester, ethylcocaine and norcocaine in human 
urine using HPLC with post-column ion-pair 
extraction and fluorescence detection*
I.M. ROY, T.M. JEFFERIES,t M.D. THREADGILL and G.H. DEWAR
School of Pharmacy and Pharmacology, University of Bath. Claverton Down. Bath BA2 7AY, UK
Abstract: The measurement of cocaine and its major metabolites has been achieved by an HPLC method that 
compensates for their different solubilities and detection properties. Although ecgonine methyl ester is a major 
metabolite it is generally not measured by HPLC because it is poorly detectable by L'V. and its water solubility makes 
recovery from urine difficult. Using modified solid-phase extraction procedures recoveries of 85% for ecgonine methyl 
ester. 97% for cocaine. 106% for benzoylecgonine and 80% for ethylcocaine have been obtained from urine. Increased 
chromatographic retention and detection sensitivity has been obtained by formation of the /-butvldimethylsilyl derivative 
of ecgonine methyl ester which was found to be stable in the HPLC mobile phase for at least 1 week. Alkylation of 
norcocaine and benzoylecgonine has improved their detection sensitivity and also chromatographic resolution. All 
calibrations were linear over the range 200-1000 ng ml-1 in urine with correlation coefficients >0.99.
Keywords: Cocaine; benzoylecgonine: ecgonine methyl ester; ethylcocaine; post-column high-performance liquid 
chromatography; silylation; alkylation.
Introduction
The development of improved analytical pro­
cedures for drugs of abuse continues to be an 
active area of research because of the increas­
ing availability of drugs world-wide. In this 
laboratory, sensitive and selective methods 
have been developed using pre-column deriv- 
atization [ 1 |, detection at 205 nm [2] and post­
column ion-pair extraction [3] for drugs of 
abuse. Cocaine is widely abused for its CNS 
stimulant properties. In humans cocaine is 
metabolized and excreted in the urine mainly 
as benzoylecgonine (BE) and ecgonine methyl 
ester (EME). Typical values for cocaine 
excretion are BE 46%; EME 41%; cocaine 3% 
and the other metabolites about 10% [4]. In 
cases where cocaine is concurrently abused 
with ethanol an additional metabolite, ethyl- 
cocain.e is produced [5]. Metabolism of cocaine 
by liver esterases forms EME and the resulting 
loss of the benzoyl group means that the 
metabolite has lost its important chromophore, 
has become more water soluble and is difficult 
to recover from urine using procedures suit­
able for cocaine or benzoylecgonine.
Numerous HPLC methods have been 
described for the measurement of cocaine and 
its metabolites {6 . 7] but usually EME is not 
included, even in recent methods [8 ]. How­
ever, as a major metabolite of cocaine [9] EME 
is important in both drug metabolism studies 
and in forensic investigations since, with BE, it 
is an indication of when the cocaine was 
ingested. Examples of methods that measure 
EME include that by Miller and DeVane [10] 
who used an RP-HPLC procedure to measure 
C and BE by UV detection at 230 nm and also 
C and EME by electrochemical detection, with 
the two detectors arranged in series. A mobile 
phase of pH 8 . 8  was required to detect EME so 
that a polymeric column was required. Ethyl­
cocaine was selected as internal standard, and 
the analytes measured in sheep plasma in the 
calibration range of 100-2400 ng ml-1. GC 
with a nitrogen phosphorous detector has been 
used [11] to measure C, BE and EME in urine 
following SPE extraction and derivatization of 
BE and EME. Detection limits were 100 ng 
ml- 1  for C and BE and 250 ng ml" 1 for EME. 
Unfortunately, BE was dcrivatized to its ethyl 
ester, ethylcocaine and the percentage re-
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covcry of EME was only 41%. GC-MS has 
been described [12] to measure C. BE, EME 
and EC in hair collected from cocaine users, 
and the presence of ethylcocaine found to be a 
particularly useful indication of cocaine use, 
since cocaine could conceivably contaminate 
the hair externally. In this work an HPLC 
method is reported for the simultaneous 
measurement of cocaine, benzoylecgonine, 
ecgonine methyl ester and ethylcocaine from 
urine by suitable modification of solid-phase 
extraction procedures, derivatizations to im­
prove chromatography and extractions, 




Cocaine HC1 was obtained from the dis­
pensary of the School of Pharmacy and Phar­
macology. University of Bath. Benzoylecgo­
nine was synthesized following the procedure 
of Lampert and Stewart [6 ]. Ecgonine methyl 
ester was prepared from ecgonine following 
the procedure of Findlay [13]. Ecgonine was 
prepared by acid hydrolysis of cocaine. Ethyl­
cocaine was prepared from ecgonine by treat­
ing it with iodoethane in the presence of 
potassium carbonate in acetone. Norcocaine 
was prepared following the proced.ure of Borne 
[14]. The structures of all the metabolites was 
confirmed by IR and lH NMR. The purity of 
the samples was confirmed by HPLC and for 
EME by GC. No extraneous peaks were 
observed.
Acetonitrile, methanol, ammonia, dichloro- 
ethane, dichloromethane. 9,10 dimethoxy 
anthracene sulphonate sodium salt (DAS) 
were HPLC grade and were obtained from 
Fisons (Loughborough, UK). Buffer com­
ponents (analytical grade) were also obtained 
from Fisons. Iodoethane, iodobutane and 
iodohexane were synthesis grade (99% purity) 
and obtained from Aldrich Chemical Company 
(Gillingham, Dorset. UK). MTBSTFA (N- 
methyl-A/{fer/-butyldimethylsilyl}trifluoroacet- 
amide) was obtained from Pierce Warriner 
Ltd (Cheshire, UK). Urine was Lyphocheck 
'Screen Control Negative” from Bio-Rad Labs 
(Hemel Hempstead, UK). Water was distilled 
from an all glass still. Solid-phase extraction 
was carried out using a Vac Elut SP24 unit with 
Bond-Elut ‘Certify’ (300 mg) cartridges from 
Jones Chromatography (Hengoed, UK).
Instrumentation
Chromatography was performed using an 
SSI (State College. PA. USA) HPLC system 
consisting of a gradient system Model 402 with 
a microbore head that was modified to carry 
out gradients at low flow rates. Commercial 
low pressure gradient systems are designed to 
carry out gradient elution at flow rates of
1.0 ml min" 1 or more with 4.6 mm i.d. 
columns. The volume of the mobile phase in 
the system, i.e. the gradient controller, the 
pump and the associated tubing before the 
column is about 5 ml and causes a delay in the 
time before the gradient reaches the column of 
about 5 min. If the same system is used at flow 
rates of 0 .2 - 0 .4 ml min”1, as required for 
columns of 2 . 1  mm i.d., the delay time be­
comes 25-12.5 min. This delay also causes 
problems with the gradient pattern and so 
modifications are required to minimize this 
effect. This was achieved by using short
0 . 8  mm i.d. tubing to connect the pump to the 
gradient controller instead of the usual 2 . 0  mm
1.d. tubing and using short narrow bore tubing 
(0 . 2  mm i.d.) between the column and the 
purge valve of the pump. These modifications 
reduced the delay time of 12.5 min to 4.0 min 
at 0.4 ml min”1.
A Rheodyne 7125 model with a 50 jil loop in 
a model 505 oven and maintained at 40°C was 
connected to a 250 x 2.1 mm i.d. Supelco pKb 
100 column, 5 p.m particle size (Supelco. Belie- 
fonte, PA, USA). The column was attached to 
the post-column ion-pair extraction detector as 
shown in Fig. 1 . consisting of two model 350 
pumps with either a Guardian pulse dampener 
or Model LP Lo-Pulse dampener (SSI). Ad­
ditional pulse dampening was provided with 
100 x 4.6 mm i.d. columns containing 10 |xm 
Partisil silica (aqueous phase) and 10 |xm CPS- 
Hypersil (organic phase). The addition of the 
aqueous reagent to the HPLC eluent and the 
segmentation of aqueous phase with organic 
phase was achieved using Tee-connectors. 
1/16 x 0.015 inch (SSI). An Uptight pre­
column. 20 x 2 mm i.d. (Anachem) packed 
with 75 p.m glass Ballotini beads was used as 
mixing column. The extraction coil was 
1.5 m x 0.8 mm i.d. s/s tubing. The phase 
separator, which has been described elsewhere
[3] was connected to a Perkin-Elmer Model 
204S Spectrofluorometer fitted with a 1 0 0  jj.1 
flow cell (Perkin-Elmer-Hitachi) and con­
nected to a Servoger 120 chart recorder.
The mobile phase used an acetonitrile step
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Figure 1
Schematic diagram of HPLC post-column system. 1.6 and 
9 = in-line columns: 2 = injection valve; 3 = analytical 
column: 4 = oven: 5 and 8 = Tee connectors; 7 = mixing 
column; 10 = extraction coil; 11 = phase separator; and 
12 = microneedle valves.
g r a d ie n t  fr o m  11 to  3 0 %  v /v  a c e to n it r i le  in
0 .0 5  M  p h o sp h a te  b u ffe r  ( p H  4 .0 )  a t  0 .4  m l 
m in -1 a t 7 .0  m in  a f te r  in j e c t io n ,  a n d  r e tu r n e d  
to  11%  at 25  m in . 9 .1 0 - d im e th o x y a n th r a c e n e  
s u lp h o n a te  so d iu m  sa lt  ( D A S .  3 4  m g  I" 1) w a s  
a d d e d  to  th e  e lu e n t  f lo w  p o s t - c o lu m n  a t a flow  
r a te  o f  0 .5  m l m in - 1 . D ic h lo r o e t h a n e  w a s  u s e d  
to  s e g m e n t  an d  e x tr a c t  th e  d r u g - D A S  io n -  
p a ir s  a t  a f lo w  ra te  o f  0 .6  m l m in " 1. F lu o r ­
e s c e n c e  d e te c t io n  w a s  a c h ie v e d  u s in g  an  
e x c it a t io n  w a v e le n g th  o f  3 8 3  n m  a n d  e m is s io n  
w a v e le n g th  o f  46 5  n m .
Extraction procedure
A n  a p p r o p r ia te  a m o u n t  o f  a n  a c e to n it r i le  
s t o c k  s o lu t io n  o f  th e  v a r io u s  s t a n d a r d s  w a s  
p ip e t t e d  in to  g la ss  tu b e s ,  e v a p o r a t e d  to  d r y ­
n e s s  u s in g  n itr o g e n  a n d  1 .0  m l o f  B io -R a d  
u r in e ,  p r e p a r e d  a c c o r d in g  to  th e  m a n u fa c ­
t u r e r ’s in s tr u c t io n , w a s  a d d e d  to  th e  d r ie d  
r e s id u e .  T h e  sa m p le  w a s  v o r te x e d  fo r  1 m in  
a n d  4 .0  m l o f  p h o s p h a te  b u ffe r  (p H  6 .0 )  
a d d e d .
B o n d -E lu t  'C e r t ify ’ L R C  c o lu m n s  w e r e  in ­
s e r te d  in to  a S P 2 4  v a c u u m  m a n ifo ld  a n d  
c o n d i t io n e d  w ith  6 .0  m l m e t h a n o l  a n d  6 .0  m l 
p h o s p h a te  b u ffe r  (p H  6 .0 ) .  T h e  c o lu m n s  w e r e
p r e v e n te d  fro m  d r y in g  o u t  a t  th is  s t a g e  by  
tu r n in g  th e  v a c u u m  o f f .  T h e  s a m p le s  p r e p a r e d  
a b o v e  w e r e  p o u r e d  in to  th e  p r e p a r e d  
c a r tr id g e s  a n d  g e n t ly  p u lle d  th r o u g h . A f t e r  th is  
th e  c a r tr id g e s  w e r e  w a s h e d  w ith  6 .0  m l o f  
w a te r  a n d  a ir -d r ie d  fo r  5 m in  at 15 m m  H g . 
T h e y  w e r e  th e n  w a s h e d  w ith  9 .0  m l o f  0 .1  N  
HC1 fo llo w e d  b y  7 m l m e th a n o l  a n d  3 m l 
a c e to n it r i le .  E lu t io n  o f  th e  s a m p le s  w a s  p e r ­
fo r m e d  w ith  6 .0  m l o f  1 .5 %  N H 4O H  in d i- 
c h lo r o m e t h a n e - is o p r o p a n o l  (8 0 :2 0 % , v /v ) .
T h e  s a m p le s  w e r e  tr a n s fe r r e d  to  R e a c t i -v ia ls  
(P ie r c e ,  W a r r in g to n , C h e s h ir e ,  U K )  an d  
e v a p o r a te d  to  d r y n e s s  u s in g  a g e n t le  s tr e a m  o f  
N 2 a n d  d e r iv a t iz e d .
Derivatization procedures
(a )  T h e  a lk y la t io n  p r o c e d u r e  w a s  a m o d if i ­
c a t io n  o f  th a t d e s c r ib e d  b y  O r tu n o  et al. [11] 
fo r  th e  d e r iv a t iz a t io n  o f  b e n z o y le c g o n in e  an d  
n o r c o c a in e .  T o  th e  d r ie d  r e s id u e  o f  s ta n d a r d s ,  
180 p.1 o f  a c e to n it r i le ,  3 0  jjlI o f  io d o b u ta n e .
1 0 .0  m g  o f  K 2C 0 3 a n d  2 0  p.1 o f  0 .2 0  m g  m l" 1 
18 C r o w n  6  e t h e r  in  a c e to n it r i le  w a s  a d d e d .  
T h e  R e a c t i -v ia l  w a s c lo s e d ,  v o r te x e d  fo r  3 0  s .  
a n d  th e n  h e a te d  at 8 5 °C  fo r  1 h . A f t e r  th e  
s a m p le s  w e r e  a l lo w e d  to  c o o l  th e y  w e r e  
e v a p o r a te d  to  d r y n e s s  u n d e r  N 2.
(b )  S i ly la t io n  o f  E M E . A c e t o n i t r i l e  (1 0 0  p.1) 
a n d  M T B S T F A  (5 0  p.1) w e r e  a d d e d  to  th e  
d r ie d  r e s id u e  fr o m  (a )  a n d  th e  v ia ls  h e a te d  at 
6 0 °C  fo r  3 0  m in . T h e  s a m p le s  w e r e  th e n  
a l lo w e d  to  c o o l  an d  e v a p o r a te d  to  d r y n e s s  
u n d e r  a g e n t le  s tr e a m  o f  N : . T o  th e  d r ied  
r e s id u e ,  in te r n a l s ta n d a r d  (5 0  y.1). m o b ile  
p h a s e  (3 5 0  p.1) an d  8 .5 %  p h o s p h o r ic  a c id  
(1 0 0  |x l) w e r e  a d d e d  a n d  v o r te x e d  fo r  3 0  s . T h e  
s a m p le  w a s  in je c te d  in to  th e  H P L C  s y s t e m .  
P e a k  h e ig h t  r a t io s  w e r e  m e a s u r e d  a n d  p lo t te d  
a g a in s t  c o n c e n tr a t io n  o f  s ta n d a r d s . T h e  
r e c o v e r ie s  o f  s a m p le s  fr o m  u r in e  w e r e  c a lc u ­
la te d  b y  c o m p a r is o n  w ith  n o n -e x tr a c te d  
s ta n d a r d s .
Results and Discussion
In it ia l a t te m p ts  w ith  B o n d -E lu t  'C e r t ify '  
c a r tr id g e s  (1 3 0  m g ) f o l lo w in g  th e  m a n u f a c ­
tu r e r 's  in s tr u c t io n s  s h o w e d  th a t r e c o v e r y  o f  
E M E  fr o m  s p ik e d  u r in e  w a s  a r o u n d  4 0 % .  
S u b s e q u e n t  e x a m in a t io n  o f  th e  p r o c e s s  s h o w e d  
th a t E M E  w a s  b e in g  lo s t  d u r in g  th e  first 
w a s h in g  p r o c e d u r e . T o  im p r o v e  r e c o v e r ie s  o f  
E M E  th e  c a p a c ity  o f  th e  c a r tr id g e  w a s  in ­
c r e a s e d  to  3 0 0  m g . a n d  th is  r a is e d  r e c o v e r ie s  to
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7 0 - 8 0 % .  H o w e v e r  th is  c a r tr id g e  s iz e  a lso  
r e ta in e d  a d d it io n a l e n d o g e n o u s  c o m p o n e n t s  
fr o m  th e  u r in e . T o  c le a n  th e  u r in e  e x tr a c t  m o r e  
th o r o u g h ly  th e  v o lu m e  o f  w a s h  s o lv e n t s  an d  
e lu t in g  s o lv e n ts  w a s  a lso  in c r e a s e d .  In it ia lly  as 
r e c o m m e n d e d  b y  th e  m a n u fa c tu r e r  m e th a n o l  
a lo n e  w as u sed  a s  th e  w a sh  s o lv e n t  b u t th is  
lo w e r e d  th e  r e c o v e r ie s  o f  E M E  a n d  e t h y l ­
c o c a in e .  R e p la c in g  m e th a n o l  w ith  a c e to n it r i le  
g a v e  a le s s  c le a n  b la n k  c h r o m a to g r a m . A  
c o m b in a t io n  o f  7 .0  m l o f  m e th a n o l  a n d  3 .0  m l 
o f  a c e to n itr i le  w a s  fo u n d  to  g iv e  th e  b e st  
c o m p r o m is e  in te r m s  o f  r e c o v e r ie s  a n d  c le a n  
b la n k s .
A n  a d d it io n a l c o m p l ic a t io n  w a s  th a t s o m e  
e x tr a  p e a k s  w e r e  fo u n d  to  o r ig in a t e  fr o m  th e  
c a r tr id g e  m a te r ia l i t s e l f  a n d  r e p e a t e d  w a s h in g  
o f  th e  c a r tr id g es  w ith  m e th a n o l  o r  e lu t in g  
s o lv e n t s  fa ile d  to  r e m o v e  th e m . T h e  p e a k s  
w e r e  fo u n d  to  b e  p r o p o r t io n a l  to  th e  p e r ­
c e n t a g e  o f  a m m o n ia  in th e  e lu t in g  s o lv e n t ,  a s  
s h o w n  in F ig . 2 , a n d  is p r o b a b ly  c a u s e d  b y  
a m m o n ia  a t ta c k in g  th e  s i l ic a -b a s e d  p a c k in g  





Effect of the percentage ammonia present in the Uichloro- 
methanc-isopropyl alcohol elution step on Bond-Elut 
Certify' cartridges. No standards or urine was added to the 
cartridges Methadone was added after the elution step as 
a marker The cartridge residues were derivatized and 
alkylated as for the cocaine analysis. A = 2% ammonia: 
B = 1% ammonia: and C = 0.5% ammonia.
a m m o n ia .  D e c r e a s in g  th e  p e r c e n ta g e  o f  
a m m o n ia  in th e  e lu t in g  s o lv e n t  a ls o  lo w e r e d  
th e  r e c o v e r ie s  o f  B E ,  w h ic h  is th e  m o s t  b a s ic  
m e ta b o l i t e  (p K a v a lu e  11 c o m p a r e d  to  8 .5  fo r  
th e  o t h e r  m e ta b o l i t e s ) .  A s  a c o m p r o m is e  1 .5%  
(v /v )  a m m o n ia  in th e  e lu t in g  s o lv e n t  w a s  th e  
le a s t  th a t  c o u ld  b e  u se d  fo r  g o o d  r e c o v e r y  
v a lu e s .
In th is  a p p lic a t io n  th e  d e r iv a t iz a t io n  p r o ­
c e d u r e s  to  in c r e a se  th e  h y d r o p h o b ic ity  o f  B E ,  
N C  a n d  E M E  h a v e  tw o  m a jo r  b e n e f i t s .  F irstly  
th e ir  c h r o m a to g r a p h ic  r e t e n t io n  t im e s  a re  in ­
c r e a s e d ,  w h ic h  m o v e s  th e m  fu r th e r  a w a y  fro m  
th e  e n d o g e n o u s  p e a k s  e x t r a c te d  fr o m  u r in e ,  
a n d  s e c o n d ly  it im p r o v e s  th e  e x tr a c t io n  o f  th e  
io n -p a ir  c o m p le x e s  in to  th e  o r g a n ic  p h a s e  an d  
s o  in c r e a s e s  s e n s it iv ity .
F o r  b e n z o y le c g o n in e  a n d  n o r c o c a in e .  a lk y l­
a t io n  is  a p p r o p r ia te  b u t n o t  th e  e th y l  d e r iv ­
a t iv e s  b e c a u s e  c o c a in e  is m e ta b o l iz e d  to  e t h y l ­
c o c a in e  b y  th o s e  p e r s o n s  w h o  a ls o  a b u se  
a lc o h o l .  In it ia lly  th e  p r o c e d u r e  o f  O r tu n o  et al. 
[1 1 ] w a s  u s e d  w ith  io d o b u ta n e  r e p la c in g  io d o ­
e t h a n e .  D e r iv a t iz a t io n  w a s  sa t is fa c to r y  an d  
r e p r o d u c ib le ,  b u t r e q u ir e d  3 h at 6 0 °C . S in c e  
c r o w n  e t h e r s  h a v e  b e e n  u s e d  a s c a ta ly s t s  fo r  
a lk y l h a lid e  d e r iv a t iz a t io n s  [1 5 ] ,  18 C r o w n  6  
e th e r  w a s  s e le c t e d  in  th is  s tu d y  to  s p e e d  u p  th e  
r e a c t io n .  A c e t o n itr i le  w a s  u s e d  a s  th e  s o lv e n t  
in s te a d  o f  a c e to n e  s o  th a t th e  r e a c t io n  t e m ­
p e r a tu r e  c o u ld  b e  r a ise d  to  8 5 °C  a n d  th e  v ia l 
c a p s  r e m a in  s e c u r e . A c e t o n i t r i l e  is a ls o  m o r e  
c o m p a t ib le  w ith  th e  s i ly la t io n  s t e p .
18 C r o w n  6  e th e r  is s o lu b le  in  d ic h lo r o -  
e th a n e  a n d  p r o d u c e s  a la r g e  p e a k  n e a r  th e  
s o lv e n t  fr o n t , a n d  s o  to  m in im iz e  e x tr a c t io n  
in to  th e  p o s t - c o lu m n  s y s t e m  a m in im u m  
a m o u n t  o f  c r o w n  e t h e r  w a s  u s e d .  D e c r e a s in g  
th e  a m o u n t  o f  c r o w n  e t h e r  fr o m  2 .0  to  0 .0 3  m g  
m l" 1 d id  n o t  m a k e  a n y  d i f f e r e n c e  to  th e  
d e r iv a t iz a t io n  y ie ld  o r  t im e  r e q u ir e d .
S i ly la t io n  is w id e ly  u s e d  in  G C  to  fo rm  
tr ia lk y ls ily l  e th e r s  fo r  c o m p o u n d s  w h ic h  c o n ­
ta in  h y d r o x y l g r o u p s . M o s t  o f  th e  s i ly la t in g  
a g e n ts  a re  v e r y  s e n s i t iv e  to  m o is tu r e  an d  
c a n n o t  b e  u s e d  for  R P -H P L C . T e r t ia r y  b u ty l-  
d im e th y ls i lo x y l  g r o u p s  ( T B D M S )  a re  104 t im e s  
m o r e  s ta b le  th a n  te r tia r y  m e th y l  s i lo x y l  g r o u p s  
[1 6 .  17], M T B S T F A  w a s  fo u n d  to  fo rm  a s ta b le  
r -b u ty ld im e th ls i ly l  e c g o n in e  m e th y l  e s t e r  d e r iv ­
a t iv e  w h ic h  is r e s is ta n t to  h y d r o ly s is  fo r  m o r e  
th a n  1 w e e k  at r o o m  te m p e r a tu r e .  It is im ­
p o r ta n t  to  e x c lu d e  a n y  m o is tu r e  d u r in g  th e  
d e r iv a t iz a t io n  p r o c e d u r e  in  o r d e r  to  o b ta in  a 
s u c c e s s f u l ,  a n d  r e p r o d u c ib le  d e r iv a t iz a t io n .
I.C ASSAY OF-COCA IN I; A N D  MEiTAHOUTES IN URINE
T h e  S u p e lc o  p K b  1 (K) c o lu m n  is  m a r k e te d  
fo r  th e  c h r o m a to g r a p h y  o f  b a s ic  c o m p o u n d s  
a n d  g a v e  s y m m e tr ic a l  n a r r o w  p e a k s  fo r  a ll th e  
m e ta b o l i t e s  in th is  a p p lic a t io n .  T h e  c o lu m n  h a s  
b e e n  u se d  fo r  o v e r  a y e a r  w ith o u t  a n y  m a jo r  
d e te r io r a t io n  in its p e r fo r m a n c e .  A  2 .1  m m
i .d .  c o lu m n  w a s  p r e fe r r e d  fo r  th is  a p p lic a t io n  
in o r d e r  to  in c r e a se  s e n s i t iv i ty  a n d  r e d u c e  
s o lv e n t  c o n s u m p t io n  a n d  w ith  c a r e  c a n  b e  u s e d  
u n d e r  g r a d ie n t c o n d it io n s  w ith  l it t le  b a c k ­
g r o u n d  n o is e .
W ith o u t  d e r iv a t iz a t io n ,  n o r c o c a in e  
a p p e a r e d  ju s t  a f te r  c o c a in e  a n d  t h e s e  c o m ­
p o u n d s  w e r e  d iff ic u lt  to  s e p a r a te  u n d e r  
g r a d ie n t  c o n d it io n s .  C h a n g in g  th e  m o b i le  
p h a s e  p H  o r  th e  o r g a n ic  m o d i f ie r  d id  n o t  
im p r o v e  th e  s i tu a t io n .  A  s t e p  g r a d ie n t  w a s  
u s e d  to  sh o r te n  th e  a n a ly s is  t im e .  F ig u r e  3 
s h o w s  a  c h r o m a to g r a m  o f  a m ix tu r e  o f  d e r iv -  
a t iz e d  s ta n d a r d s . N o r c o c a in e  a s  its  b u ty l  d e r iv ­
a t iv e  is w e ll  s e p a r a te d  fr o m  c o c a in e  a n d  
a p p e a r s  a f te r  e t h y lc o c a in e .  N o r c o c a in e  w a s  n o t  
u s e d  in s p ik e d  u r in e  s a m p le s  a s  th e r e  w a s  s o m e  
in te r fe r e n c e s  from  th e  c a r tr id g e s  a t  its  r e t e n ­
t io n  t im e . F o r tu n a te ly ,  n o r c o c a in e  is a v e r y  
m in o r  m e ta b o l it e  in h u m a n s .
In  th e  p r e se n t  a p p lic a t io n  m e t h a d o n e  h a s  
b e e n  u s e d  a s an  in te r n a l s ta n d a r d . H o w e v e r ,  
m e th a d o n e  ca n  a ls o  b e  p r e s e n t  in th e  u r in e  o f
s o m e  c o c a in e  u sers  a s  it is p r e s c r ib e d  fo r  th e  
t r e a tm e n t  o f  c o c a in e  a d d ic ts . In th a t c a s e  
h e x y lb c n z o y le c g o n in e  can  be u s e d  a s  a n  in ­
te r n a l s ta n d a r d  an d  th e  m e th o d  c a n  th e n  a ls o  
b e  u s e d  to  m e a s u r e  m e th a d o n e  (F ig .  3 ) .
T h e  c a l ib r a t io n  c u r v e s  fo r  a ll th e  s t a n d a r d s  
s p ik e d  in to  u r in e  w e r e  lin e a r  fr o m  2 0 0  to  
1000 n g  m l * 1 w ith  c o r r e la t io n  c o e f f i c i e n t s  
> 0 . 9 9  (F ig .  4 ) .  T h e  e q u a t io n s  o f  th e  c a l i ­
b r a t io n s  w ith  s ta n d a r d  d e v ia t io n s  s h o w n  in 
b r a c k e ts  w e r e  a s  fo llo w s :  fo r  c o c a in e ,  y  =  0 .9 1 3  
( ± 0 . 1 2 4 ) * +  0 .0 1 1  ( ± 0 . 0 8 1 ) , *  =  4  . r =  0 .9 9 9 ,  
l im it  o f  d e t e c t io n  ( L O D )  =  0 .0 5 9  pig m l * 1; fo r  
e t h y l - c o c a in e ,  y  =  2 .6 8  ( ± 0 . 7 1 2 ) *  +  0 .0 9 7  
( ± 0 . 3 9 5 ) ,  n =  4 ,  r =  0 .9 9 5 .  L O D  =  0 .0 9 5  p.g 
m l- 1 ; fo r  b e n z o y le c g o n in e ,  y  =  1.61  
( ± 0 . 1 6 5 ) *  -  0 .1 2 6  ( ± 0 . 1 1 4 ) ,  n =  4 .  r =  
0 .9 9 9 .  L O D  =  0 .0 4 6  p g  m l* 1; fo r  e c g o n in e  
m e th y l  e s t e r ,  y  =  0 .9 8 3  ( ± 0 . 1 5 6 ) *  -  0 .0 2 1  
( ± 0 . 1 2 3 ) ,  n = 4 .  r =  0 .9 9 8 .  L O D  =  0 .0 8 1  pig 
m l* 1. W ith in -d a y  p r e c is io n  (n =  4 )  fo r  c o c a in e  
w a s  0 .7 8  ±  0 .0 5 6 ,  r e c o v e r y  1 0 0 % ; fo r  e t h y l ­
c o c a in e  0 .9 6  ±  0 .0 4 7 .  r e c o v e r y  8 0 % ; fo r  
b e n z o y le c g o n in e  0 .9 6  ±  0 .0 4 5 .  r e c o v e r y  9 1 % ;  
fo r  e c g o n in e  m e th y l e s te r  0 .5 6 5  ±  0 .0 3 7 ,  
r e c o v e r y  9 8 % . M u ch  lo w e r  l im its  o f  d e t e c t io n  
a r e  p o s s ib le  if  th e  in te r fe r in g  p e a k s  fr o m  th e  
c a r tr id g e s  c a n  b e  e l im in a te d . T h e  p r o b le m  o f  
in te r fe r in g  p e a k s  w a s  a lso  o b s e r v e d  fr o m  th e
3
30 25 20 15 10
m inutes
Figure 3
Chromatogram of standards de rival ized at 65°C for 3 h {ref. 111 dissolved in mobile phase 1 = cocaine 0 .6  ng ml '. 2 = 
ethylcocaine 0.-14 ng m l 1; 3 = .V-hutylnorcocaine 0.4 ng m l 1, 4 = hutylhcnzoylccgonine 0.5 ng ml 5 = m ethadone 
0.3 ng m l'1: 6 = r-butyldimethylsilyl ecgonine methyl ester 0.6 ng ml 1; and 7 = hex v I be n zoy lecgon i ne 2 ng ml 
Chromatographic conditions as in Experimental
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Figure 4
Chromatogram of standards in urine derivatized at 85®C 
for 1 h in the presence of 18 Crown 6 ether, as in 
Experimental. A = cocaine and metabolites in urine; B = 
urine with internal standard. 1 = cocaine 0.23 p.g m l'1; 
2 = ethylcocaine 0.16 jig ml*'; 3 = butylbenzoylecgonine 
0.20 ng ml-1; 4 = methadone 0.75 M-g ml"1 (internal 
standard); 5 = r-butyldimethylsilyl ecgonine methyl ester 
0.2 fLg m l'1. Chromatographic conditions as in 
Experimental.
c a r tr id g e s  o f  o t h e r  m a n u fa c tu r e r s , n a m e ly  J .T .  
B a k e r  ‘N a r c  2' a n d  W o r ld -w id e  M o n ito r in g  
‘C le a n  S c r e e n  D A U \  T h is  is b e c a u s e  th e  
c a r tr id g e  m a te r ia ls  a n d  p r o c e d u r e s  fo r  c o c a in e  
a n d  m e ta b o l i t e s  r e c o m m e n d e d  b y  t h e s e  m a n u ­
fa c tu r e r s  are  s im ila r . I f th e  in te r fe r in g  p e a k s  
a r e  d u e  to  th e  r e a c t io n  o f  a m m o n ia  o n  th e  
s i l ic a  o f  th e  p a c k in g  m a te r ia l th e n  a c a r tr id g e  
u s in g  a p o ly m e r ic  m a te r ia l w o u ld  b e  a b e t te r  
a lte r n a t iv e .  T h is  is c u r r e n t ly  u n d e r  
in v e s t ig a t io n .
T h r o u g h o u t  th e  e n tir e  s tu d y  th e  p h a se  
se p a r a to r  w a s  o p e r a te d  at a s e p a r a t io n  e f ­
f ic ie n c y  o f  0 . 8 - 0 . 9  w ith o u t  a n y  p r o b le m s  a n d  
d id  n o t r e q u ir e  a n y  m a jo r  a d ju s tm e n t s  a p a r t  
fr o m  r o u t in e  m a in te n a n c e  su c h  a s  c le a n in g  th e  
n e e d le  v a lv e  o u t le t  tu b in g s  w ith  a c e t o n e  a n d  
b lo w in g  air th r o u g h  th e m .
Conclusions
T h e  m e th o d  d e s c r ib e d  p e r m its  th e  s im u l­
ta n e o u s  m e a s u r e m e n t  o f  c o c a in e ,  its  m a jo r
m e t a b o l i t e s  E M E  an d  B E , a n d  a l s o  e t h y l ­
c o c a in e  in  u r in e . T h e  m e th o d  c o u ld  a d d it io n ­
a lly  m e a s u r e  m e th a d o n e  b y  u s in g  h e x y l-  
b e n z o y le c g o n in e  as in te rn a l s t a n d a r d . T h e  
r e c o v e r y  o f  E M E  from  u r in e  h a s b e e n  in ­
c r e a s e d  fr o m  ty p ic a lly  40 %  to  at l e a s t  8 0 %  by  
th e  u s e  o f  la rg e r  c a p a c ity  c a r tr id g e s . T h e  s ily l  
r e a g e n t  M T B S T F A  p r o d u c e d  a s t a b le  f -b u ty l-  
d im e th y ls i ly l -E M E  d e r iv a t iv e  fo r  th is  L C  
a p p lic a t io n .  L o w  p r e ss u r e  g r a d ie n t  s y s t e m s  ca n  
b e  u s e d  at lo w  f lo w -r a te s ,  su c h  a s  0 .4  m l 
m in - 1 , w ith  2 m m  i .d .  c o lu m n s ,  p r o v id e d  th a t  
th e  in te r n a l  v o lu m e  o f  th e  g r a d ie n t  s y s t e m  is 
r e d u c e d .
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Synthesis o f a deuterated isotopomer of the anticancer drug hexamethyl­
melamine and kinetic isotope effect during biomimetic oxidation
Michael D. Threadgill
School of Pharmacy & Pharmacology, University of Bath, Bath BA2 7AY, United Kingdom
Abstract
Biomimetic oxidation of D3-hexamethylmelamine (A^N,NyvyV"-pentamethyl-N"-(tri- 
deuteromethyl)-l,3,5-triazine-2,4,6 -triamine), an isotopomer of the antineoplastic drug 
HMM, with chloro-5,10,15,20-tetraphenylporphyrinato-iron(III) /  iodosobenzene gives 
pentamethylmelamine with primary deuterium kinetic isotope effect jfcH /  *d = 3-2 ± 0.4. A 




Hexamethylmelamine (HMM; 1, Scheme) is a drug with activity against ovarian cancer. 
Metabolic hydroxylation, catalysed by a cytochrome P-450, of two or more A-methyl groups 
in the molecule is required for this chemotherapeutic activity [ 1 ]. Pentamethylmelamine 
(PMM; 3, Scheme 2) is a major metabolite resulting from degradation of an intermediate 
N-CH2OH compound. The mechanism of this oxidative process is unknown but the
mechanisms of metabolic oxidation of 
several other N-methylalkylamines and N- 
methylarylamines by P-450 have been 
studied [2,3]- Primary kinetic deuterium 
isotope effects have been used [4] to 
indicate whether the rate-determining step 
is transfer of an electron (Path A in 
Scheme 1) or transfer of hydrogen (as H or 
as H-) (Path B). Tetraarylporphyrinato- 
iron (III) / iodosobenzene systems are 
good models for oxidation by cytochromes 
P-450 [5], both in terms of chemoselectivity 
and mechanism of oxidation. As pan of a 
programme of study of metabolism at 
carbon alpha to nitrogen [6,7], the 
oxidative demethylation of HMM (1) by 











Schem e 1. A lternative rate-determ ining steps 
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Figure 1. A: E.I. mass spectrum of synthetic unlabelled PMM (3) at 70 eV ionisation energy; 
B: EL m.s. of synthetic unlabelled PMM (3) at lower ionisation energy; C: Low ionisation 
energy E.L m.s. of PMM (3) formed from unlabelled HMM (1) by oxidation with TPPFeCl / 
PhIO; D: Low ionisation energy E.I. m.s. of mixture of isotopomers of PMM (3+ 4) formed 
by oxidation of D,-HMM (2) with FeTPPCl /  PhIO.
The ratio of isotopomers of PMM (3 and 4) in the product was measured by low 
ionisation energy E.I. m.s.; a spectrum from a typical run is shown in Figure ID. The ratio 
of 3 to 4 in the product mixture was determined from the ratio of abundance of molecular 
ions at mlz 196 and mlz 199, respectively. After correction for statistical factors (principally 
the 5:1 ratio of CH3  to CD3  in 2), the intramolecular primary kinetic deuterium isotope 
effect was calculated to be £H /  £D = 3.2 ± 0.4 (n = 5 experiments).
4. CONCLUSIONS
This value of intramolecular kinetic deuterium isotope effect (kH /  kD = 3.2) is 
consistent with a mechanism of oxidation involving cleavage of the carbon-hydrogen bond 
in the N-methyl group during the rate-determining step in the formation of the 
corresponding N-(hydroxymethyl) moiety. This latter compound is unstable under the 
reaction conditions and decomposes to the N-H derivative (PMM) in a step not involving 
cleavage of C-H or C-D bonds. Thus, the biomimetic oxidative process is suggested to 
proceed via initial transfer of H' or H- from the substrate to the intermediate 
oxoporphyrinato-iron, in analogy with the proposed mechanisms of oxidation of the
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2. CHEMICAL SYNTHESIS
Unlabelled hexamethylmelamine (1) was prepared from 2,4,6-trichloro-l,3,5-triazine by 
treatment with boiling aqueous dimethylamine; unlabclled pentamethylmelamine (3) was 
prepared from 6-chloro-NA,N7V'*tetramethyl-l,3,5-triazine-2,4-diamine, according to the 
method of Borkovec and DeMilo [8 ]. The trideutero isotopomer 2 was synthesised in 75% 
yield by (i) treatment of PMM (3) with /2-butyl lithium and (ii) reaction of the anion with 
trideuteroiodomethane, as previously described [9]. Isotopic purity was >99% as judged by 
mass spectrometry. Chlorination of iodobenzene and subsequent hydrolysis of the 
intermediate PhICl2  with aqueous NaOH furnished the oxidant, iodosobenzene [10].
3. BIOMIMETIC OXIDATION
To minimise artifacts from isotope effects on fragmentation in the mass spectrometer, 
spectra of synthetic unlabelled PMM (3) were obtained under various spectroscopic 
conditions. Electron impact (E.I.) mass spectra using the standard ionisation energy (70 eV) 
contained many peaks due to daughter ions (Figure 1A); however, lowering the ionisation 
energy gave spectra exemplified by Figure IB, in which the molecular ions (m/z 196 
(1 2 C9 H1 8 N6) and mlz 197 (1 2 C8 1 3 C!H1 8 N6)) account for >95% of the total ion current.
Treatment of unlabelled hexamethylmelamine (I) with iodosobenzene (PhIO) and a 
catalytic amount of chloro-tetraphenylporphyrinato-iron (III) (TPPFeCl) in CH2 C12  gave 
pentamethylmelamine (PMM; 3) which was characterised by comparison with synthetic 
material using thin layer chromatography (silica gel, various solvents) and electron-impact 
mass spectrometry. An example of a mass spectrum of PMM formed by such an oxidative 
demethylation is shown in Figure 1C. The rate of reaction was found to be sensitive to the 
state of division of the sparingly soluble PhIO and all quantitative experiments were 
performed using one batch of Finely powdered material; the substrate and metal complex 
were soluble. Addition of large excesses of PhIO caused destruction of the catalyst.
For the measurement of the isotope effect, D3-HMM (2) was treated with TPPFeCl and 
PhIO (ca. 15 mol%) so as to allow conversion of 10% of the substrate, thus artifacts due to 
selective depletion of the substrate and due to consumption of the product are minimised.
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electron-poor N-methylamides [11] and form amides [7] by cytochrome P-450 but in contrast 
to the initial transfer of an electron from the relatively electron-rich N-methylanilines and 
N-methylalkylamines to the cytochrome [3].
5. EXPERIMENTAL
5.1. Chemical synthesis
DyHMM (A /^'///'Ar',Ar-pentamethyl-Ar-(trideuteroniethyl)-1,3,5-triazine-2,4,6-triamine; 
2) was synthesised in 75% yield and 99% isotopic purity by alkylation of the lithium salt of 
pentamethylmelamine (W,N,NyV7V"-pentamethyl-l,3,5-triazine-2,4,6-triamine; 3 [8 ]) with 
CD3 I (Aldrich Chemical Co., Gillingham, U.K.) in dry THF, as previously described [9].
5.2. Biomimetic oxidation / kinetic isotope effect
Typical experiment: D3 -HMM (2 ) (40.0 mg, 0.188 mmol) was dissolved in CH2 C12  
(2.5 ml) and chloro-tetraphenylporphyrinato-iron (III) (14.0 mg, 0.020 mmol) was added, 
followed by iodosobenzene (6 . 6  mg, 0.030 mmol). The mixture was stirred for 30 min at 
ambient temperature. The mixture of isotopomers of pentamethylmelamine (3 + 4) was 
isolated from the evaporation residue by centrifugally accelerated preparative layer 
chromatography (silica gel, chloroform/methanol 19:1; twice), giving off-white crystals 
(3.8 mg, 10% based on 2). The ratio of isotopomers was determined by mass spectrometry 
using a VG 7070 instrument in the E.I. mode.
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Summary. The intra-cellular uptake of the weakly basic 
radiosensitiser pimonidazole (PIMO) was determined as a 
function of the pigmentation of Nal 1+ human melanotic 
melanoma cells in vitro. Two experimental conditions 
were considered: exponentially growing cells (Exp.) and 
plateau-phase cells (PI.). The melanin content of Nal 14- 
cells ranged from 500 jig/g cell weight in exponentially 
growing ceils to 6000 jig/g in heavily pigmented plateau- 
phase cells. Cells were exposed to PIMO (medium dose. 
0.2 mmol/dm3; 58.2 pg/ml). The intra-cellular concentra­
tion ranged from 163 pg/g in Exp. to 900 jig/g in pig­
mented PI.: the latter being equivalent to an intra- to extra­
cellular concentration ratio (Ci/Ce) of 17. However, this 
increase in the cellular uptake of PIMO was not accom­
panied by an increase in radiosensidsing efficiency. In 
comparison, the Ci/Ce for etanidazole (ETA), a radiosensi­
tiser that is uncharged at physiological pH. remained ap­
proximately constant at 1 for all values of melanin con­
tents. Treatment of Nal 1+ tumours in vivo with [3 H]- 
PIMO resulted in a tumour, blood ratio of about 3 at 
30-60 min after administration. However, at 24 h a grain 
count of label derived from [3H]-PIMO showed that pic- 
notic areas of tumours contained levels that were some 40 
times greater than the background value. This high level of 
label was coincident with areas of highest apparent 
melanin content. In conclusion. PIMO accumulates in very 
heavily pigmented melanoma cells present in necrotic 
zones with picnosis. As these cells are probably non-clono- 
genic. PIMO is not suitable for use in melanoma radio­
therapy.
Introduction
Most rodent and human xenografted tumours contain hy­
poxic cells [12. 25. 28], and a few clinical studies have
* This work was supported in pan by the Ligue Nationale Franqause 
Contrc le Cancer (Comitc des Hauts-de-Seine)
Correspondence to: M. Guichard
suggested that radiotherapy might be improved by the use 
of agents such as nitroimidazoles that increase the radio- 
sensitivity of these hypoxic cells [6 ]. The first agents eval­
uated were metronidazole and misonidazole, but neurotox­
icity has limited their use in radiotherapy. A second gener­
ation of hypoxic cell sensitisers have been developed, 
among which pimonidazole (PIMO) is particularly inter­
esting since it is preferentially accumulated by tumour cells 
in vitro [4]. PIMO also accumulates in rodent tumours as 
indicated by tumour: blood ratios of >1 [15,20,21,24.33, 
37. 44-46] and. similarly, in human tumour xenografts 
[21, 35] and in human tumours in patients [1,8,26], with 
the uptake being highest in melanomas as compared with 
other tumours (1 , 5, 8 . 20. 21, 26]. The high tumour-cell 
concentration of PIMO that can be obtained suggests that 
the radiosensidsing effect of PIMO should also be high, 
and the results obtained using non-melanotic cells growing 
exponentially in vitro support this hypothesis [30. 40]. In 
addition. PIMO has generally been found to be effective in 
non-pigmented rodent tumours in vivo [15. 16. 32. 44]. 
However, using human tumour xenografts and clinically 
relevant drug doses, a radiosensidsing effect has been de­
tected in rectal adenocarcinoma HRT18 but not in melano­
ma Nal 1+. although the accumulation of PIMO in the 
melanoma was particularly high [21, 35]. We report the 
results of some studies that may explain the basis for the 
lack of effect of PIMO on the Nal 1+ melanoma.
Tumours are very heterogeneous, especially with re­
spect to the cell-proliferation kinetics (exponentially grow­
ing cells, plateau-phase cells) and to the presence of necrot­
ic zones. This heterogeneity suggests that the average 
intra-tumour concentration may not necessarily reflect the 
concentration of the drug in the clonogenic hypoxic cells, 
which are the cells essential for rumour radiosensitivity. In 
vitro radiosensitisation and drug uptake have previously 
been investigated in exponentially growing cells [30. 
38-41]. Therefore, the aim of the present work was, 
firstly, to measure the uptake of PIMO into exponentially 
growing and plateau-phase melanotic melanoma cells in 
vitro and determine whether this might be related to their 
melanin content and secondly, to determine whether the
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inter- and intra-cellular distribution of (3 H]-PIMO in 
Na 1 1 + tumours might explain the lack of radiosensitisation 
observed for PIMO in this tumour type.
M aterials and methods
Compounds. Eianidazolc (ETA. Ar-(2-hydroxyethyl)-2-mtroimidazoiyl 
acetamide: Chemistry Branch. Division of Cancer Treatment. National 
Cancer Institute. USA| and pimonidazole {PIMO. a-((2-nitro-l-imida- 
zolyl)meihyl!-!-piperidine-ethanol hydrochloride: Hoffman-La Roche. 
Switzerland} were dissolved in minimum essential medium (MEM) 
supplemented with 20 mw HEPES (pH 7.2) at a concentration of 
0.2 mmol/dm-5 (42.8 ug/ml for ETA and 582 pg/ml for PIMO). f :H1- 
PIMO (42) dissolved in absolute ethanol had a specific activity of 
5.5 x  107 Bq/ml. {-'H)-PlMO (10 pi for scintillation or 100 pi for auto­
radiography) was mixed with non-radioactive PIMO dissolved in Dul- 
becco's phosphate-buffeted saline (PBS). The total amount of PIMO 
injected i. v. into mice via the retro-orbital sinus in a volume of 0.3 mi 
was 200 mg/g body weight. Control mice were given PBS alone.
Tumour-cell system. The melanotic melanoma Nal 1 + originated from a 
human melanoma. The characteristics and maintenance of this cell line 
have been described elsewhere [14|. Congenitally athymic nude mice 
were bred and maintained in a defined flora- and pathogen-free colony. 
Details of the mouse breeding and tumour production have been publish - 
ed elsewhere (13. 14], Tumours were obtained by injecting 3 x  I06 cells 
into both flanks of mice that had been whole-body-irradiared with 5 Gy 
,37Cs y-rays to increase tumour uptake.
In vitro studies. Plateau-phase cells were obtained 7 days after 5 x  10s 
cells had been seeded in glass petri dishes (unpublished data). A few 
experiments were performed using exponentially growing cells obtained 
2 days after the cells had been seeded. For the aerobic study, cells were 
placed in an incubator (37* C. 5% CO;. 45 min). For hypoxia, open 
dishes were placed in aluminium chambers and gassed with a humidified 
mixture of 95% N2 and 5% CO2 (<3 ppm O;) for 45 min. A filtered 
solution of dithionite-sodium carbonate was placed in the center of the 
chambers to remove traces of oxygen (18). After undergoing incubation 
with PIMO or ETA and/or irradiation, the cells were trypsinised and the 
surviving fraction was assessed by an in vitro colony assay. Colonies 
were fixed and stained with crystal violet (0.25%. w/v. in 80% methanol 
containing 10% formaldehyde).
Cellular uptake and drug concentration in the medium was measured 
by high-performance liquid chromatography (HPLC) (21. 23). Briefly, 
the medium was analysed directly and cells were collected with a rubber 
policeman and stored at -80' C. On the day of analysis, the cells were 
sonicated in water and ETA and PIMO were extracted with acetonitrile- 
water (1:1. v/v). The extraction was repeated and the supernatants were 
pooled and evaporated to dryness. The residue was diluted in eluent B 
containing an appropriate amount of internal standard (Ro 03-1902). and 
cellular uptake was analysed using a Varian model 5000 chromato­
graph equipped with a 5-pm Nudeosil column connected to a Van- 
chrom UV-visible detector at 326 nm. The elution flow rate was 
2 ml/min (eluent A. 75% acetonitrile and 25% water, eluent B. 4 mM 
heptane suiphonic acid. 5 m M  dibutylamine and 50 m M  glycine adjusted 
to pH 3): the gradient was: 0 min. 8% eluent A: 10 min. 45% eluent A: 
10 -11 min. 45%-8% eluent A.
In vivo studies. Tumours were used when they had reached a mean 
diameter of 9 -11  mm. Animals were anaesthetised at various times alter 
drug injection and blood was collected by cardiac puncture into he- 
parinised tubes immediately before tumour excision and frozen in liquid 
nitrogen. Tumours were removed and immediately frozen in liquid nitro­
gen. Subsequently, tissue samples were weighed and 100- 300 mg was 
suspended in Optisolve (LKB). Tissues were digested by incubation at 
55* C for 16 h. 15 ml liquid scintillation fluid (Optiphase. Hisafe-TM: 
LKB) was added and samples were counted on a Packard Tricard liquid 

















INTRACELLULAR CONC OF MELANIN (p g /g  )
Fig. 1. Intra-cellular concentrauons of ETA ( A. &) and PIMO ( ■ . G) 
as a function of melanin content. Closed symbols, piateau-phase cells: 
open symbols, exponentially growing cells
calibration. These were prepared by adding a known acuvitv of tritiated 
water to a set of eight samples containing between 0 and 0.2 ml whole 
blood digested as described above. Any very highly coloured samples 
were bleached by incubation at 60* C for 2 h with benzoyl peroxide 
(0.4 mL 5% (w/v) in toluene] prior to the addition of scintillanu
Histology, autoradiography and melanin determination. Tumours were 
removed at 24 h after (3H]-PIMO administration and were immediately 
fixed in ethanol: acetic acid (3:1. v/vj. The tissues were dehydrated and 
embedded in paraffin and sections (3 pm) were cut and mounted on 
microscope slides. For autoradiography the slides were dipped in Ilford 
K2 emulsion and exposed for 2 months. The slides were then developed 
in Kodak D19b and stained with hemalum and erythrosin. The amount of 
radioactivity in the tumour was determined by grain counting using an 
ocular grid. The percentage of cellular areas was identified under a 
microscope and oudined on photographs of the sections. The areas were 
weighed and cellular areas were expressed as a percentage of the total 
areas. Melanin was localized by the method of Fontana-Masson (17],
For melanin determination, the quantitative colourimetric method of 
Foster et al. (9. 10] as adapted to normal and cultured retinal pigment 
cells by Whittaker (43) was used, with a few modifications. Cells were 
sonicated in water, and non-melanic substances that interfered with the 
assay were removed by three extractions with 5% trichloroacetic acid, 
two extractions with cold ether-alcohol (1:3. v/v) and one extraction 
with absolute ether. The dried residue extracted from 50-100 mg cells 
was dissolved in I ml 1 A' KOH and .then heated to 100* C for 30 min. It 
was cooled to room temperature and the opdcal density was measured at 
400 nm (Varian spectrophotometer). A standard curve was constructed 
using synthetic melanin (Sigma) dissolved in 1 yV KOH (1 -  100 pg/ml). 
Absorbance at 400 nm increased linearly with melanin concentration up 
to 100 ug/ml.
Results
A preliminary experiment showed that the melanin content 
was very homogeneous in exponentially growing cells but 
varied greatly in plateau-phase cells. The melanin content 
of plateau-phase cells obtained at 7 days after seeding in­
creased by a factor of > 6  within 1 2  h (results not shown). 
The uptake of PIMO into hypoxic plateau-phase N all + 
cells in vitro was compared with that of ETA. Figure I 
shows that the intra-cellular concentration of PIMO in­
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Fig. 2 a, b. Surviving fractions of Na 11 + Exp. (open symbols) and Na 11+ 
PI. (closed symbols) after the delivery of a radiation dose of 10 Gy under 
hypoxic conditions in the presence or absence of PIMO. a As a function 
of intra-cellular melanin concentration: (O. • ) .  in the absence of PIMO: 
(□ . ■ ). in the presence of PIMO. The intra<ellular PIMO concentration 
is shown (in pg/g of cells) in parentheses, b As a functioa of intra-cellu­
lar PIMO concentration. The shaded area represents the 95% confidence 
intenal of cell survival in nitrogen without PIMO. Data points represent 
mean values for 2 experiments: error bars indicate 95** confidence inter­
vals
in the plating efficiency was detected as a function of either 
the pigmentation or the intra-cellular PIMO concentration. 
In Fig. 2b. these results expressed as intra-cellular concen­
tration (Ci) are compared with those obtained for radiosen­
sitisation of exponentially growing cells (melanin content. 
<500 iig/g). The extra-cellular concentration (Ce) re­
mained constant (58.2 |ig/mi) in plateau-phase cells, 
whereas it varied from 29.1 to 174.6 jig/g in exponentially 
growing cells. Clearly, in exponential N a ll+  cells, 
radiosensitisation by PIMO increases as a function of Ci. In 
contrast, no similar increase in radiosensitisation was ob­
served in plateau-phase cells. Furthermore, the maximal Ci 
value obtained in exponential cells (437 pg/g) was limited 
by toxicity, whereas in plateau-phase cells a Ci value of 
628 pg/g was achieved with no loss in plating efficiency.
Liquid scintillation studies
[3H]-PIMO radioactivity in the blood and in the tumour is 
shown in Fig. 3. The radioactivity in the blood decreased 
with time after administration, whereas that in the tumour 
increased to a plateau. The tumour/blood ratio was rela­
tively constant (2 -3 ) at between 30 and 60 min.
function of melanin content. At the lowest melanin content 
(500 pg/g), the Ci/Ce ratio for PIMO was between 3 and 4, 
which is very similar to that found for exponentially grow­
ing Nal 1+ cells. However, in plateau-phase cells in which 
the melanin content increased, the Ci/Ce value also in­
creased to >17. In contrast, the intra-cellular concentration 
of ETA remained fairly constant, with Ci/Ce values being 
close to I.
The radiosensidsing effect of 58.2 pg PIMO/ml in hy­
poxic Nal 1+ cells was determined as a function of cellular 
pigmentation. Figure 2 shows that there was no significant 
change in the radiosensitivity with pigmentation in 
plateau-phase cells following a radiation dose of 10 Gy in 
the presence of PIMO (Fig. 2a). although the intra-cellular 
PEMO concentration measured in the more pigmented cells 
was at least 3-fold that determined in the less pigmented 
cells (Fig. 1). In these experiments, no significant change
Histology studies
The cellular zone represented only 51% of the tumour. 
Figure 4 shows the melanin content, with the highest con­
centrations of melanin being found in the zones of tumour 
in which picnotic cells form the largest proportion of cells 
(Fig. 4b). The radioactivity derived from [3H]-PIMO was 
not evenly distributed throughout the tumour. The results 
of grain counts from two experiments are given in Table 1: 
it is apparent that the necrotic zones containing numerous 
picnoses were most highly labeled, showing values some 
40 times greater than the background level. In contrast, 
viable zones of tumour and necrotic regions containing no 
identifiable cell fragments or picnotic cells showed sub­
stantially lower grain counts. Only one-fifth of the total 
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Fig. 4 a, b. Histological sections of Nal 1+ 
tumours showing melanin a in the cellular 
zones and b in necrotic zones where 
picnotic cells are found. Bar = 40 pm
Table 1. Distribution of radioactivity derived from [3H]-PIMO in tumours and percentage of total radioactivity








With picnotic cells 





With picnotic cells 





Mean number of grains (MNG) 156(20) 621 (86) 209 (21) 140(7) 533 (30) 81 (13)
% Total area (TA) 52 35 13 44 43 13
% Total radioactivity0 25 67 8 20 76 4
Numbers in parentheses represent standard errors; 8 -4 0  fields were 
studied per zone (background value = 15)
1 See Fig. 4 a for the histology of the cellular zone 
b See Fig. 4 b for the histology of the necrotic zone with picnotic cells 
and cell fragments
c % Total radioactivity: MNGczx% TAcz+M NGnzp x  % TAnzH- 
M N G nz x  % TA nz = 100%
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melanin content and the radioactivity derived from [3 H]- 
PIMO were not identified on the same slide, it is clear that 
the highest activity and the highest staining of melanin 
were found in the same zones.
Discussion
It has been suggested that weak bases can concentrate in 
melanin-containing cells [3.20-22.31.35.36]. The intra­
cellular concentrations of weak bases such as PIMO [4], 
RSU 1069 and RSU 1164 [37] are increased at elevated 
extra-cellular pH. and their much higher uptake into 
melanotic as compared with non-melanotic cells led to the 
suggestion that the intra-cellular pH of melanotic melano­
ma cells is lower than the pH of non-pigmented cells. 
However, other mechanisms are likely to be involved in the 
concentration of weak bases in melanotic melanomas. The 
present in vitro results show that the pigmentation is higher 
in plateau-phase cells relative to exponentially growing 
Nal 1+ cells: furthermore, when the cells reach the plateau 
phase, a continuous and rapid increase in pigmentation is 
observed. For plateau-phase melanotic cells, the results 
clearly show that the intra-cellular concentration of PIMO 
depends strongly on die intra-cellular concentration of 
melanin: the higher the melanin content, the higher the 
PIMO concentration (Fig. 1 ). PIMO had no greater 
radiosensidsing effect on these cells than it had on ex­
ponentially growing cells, despite the observation that the 
intra-cellular concentration of PIMO was higher and the 
plating efficiency was not modified. An association be­
tween PIMO and melanin could explain these results, espe­
cially if the melanin is remote from the DNA [34], thus 
spatially preventing PIMO from exerting its radiosensitis- 
ing effect
The data for melanoma transplanted into nude mice 
show that at a short time after its administration. PIMO 
accumulates in tumours (Fig. 3). Histological data derived 
from tumours excised at 24 h after the administration of 
[3 H]-PIMO show the presence of label to be coincident 
with areas of high melanin content, which would be consis­
tent with the in vitro results. It is unlikely that this localisa­
tion would be a consequence of passive sequestration onto 
or association with melanin: rather, it is probably due to 
selective hypoxia-induced binding in these areas. In non- 
melanotic tumours it has been claimed that [14C]-miso- 
nidazole [2, 11] and PIMO [19, 29] accumulate in viable 
hypoxic tumour cells, whereas other investigators have 
reported that uptake is lower in necrotic tumours [7.27] or 
that there is no link between accumulation and necrosis 
[21. 26]. On the basis of our results, it is difficult to deter­
mine the influence of the necrotic areas on PIMO accumu­
lation, as these regions were also those in which the 
melanin content was the highest. It must be emphasised 
that although it was not possible to evaluate the melanin 
content in the necrotic zones, these dying cells probably 
contained much more melanin than did the plateau-phase 
cells we studied; indeed, the plateau obtained in the present 
studies is not a perfect one, since 1 \% of the cells remained 
in the S phase (unpublished results).
On the basis of the above-mentioned observations, it is 
possible to provide an explanation for our previous results, 
which indicated an inability of PIMO to sensitise Nal 1 + 
tumours [35]. The accumulation of PIMO in the tumour 
(liquid scintillation studies) may well have resulted from 
the accumulation of PIMO in necrotic zones containing 
picnotic cells of very high melanin content. Its accumula­
tion in these regions cannot influence radiosensitivity; only 
the PIMO in areas of clonogenic hypoxic cells is important.
In conclusion, the present results obtained both in vitro 
and in vivo indicate that PIMO accumulates in very heavily 
pigmented melanoma cells. The in vivo results also show 
that the accumulation of label derived from PIMO is higher 
in the necrotic zones with picnosis than in the cellular 
areas. The latter findings could explain why the intra-cellu­
lar accumulation of PIMO is not linked with a radiosensi- 
tising effect in melanotic melanoma. To explain the lack of 
efficiency of PIMO in vitro, a mechanism such as the 
localisation of PIMO far from the DNA close to the 
melanin content or a very low sub-cellular pH must be 
supposed. As far as melanotic melanomas are concerned. 
PIMO is probably not the compound to be used in clinical 
radiotherapy.
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Dimethylformamide (DMF) is an industrial solvent with hepatotoxic properties. The toxicity 
o f DM F has been associated with its metabolism to S-(iV-methylcarbamoyl) glutathione (SMG). 
T he major urinary metabolite of DMF is N-(hydroxymethyl)-N-methylformamide (HMMF). 
H M M F undergoes oxidation in the formyl moiety, possibly via the intermediacy of its hydrolysis 
product N-methylformamide (NMF), and the reactive intermediate thus generated reacts with 
glutathione to yield SMG. Experiments were conducted to elucidate enzymatic details of the 
metabolism of DMF. Generation of HMMF from DMF in microsomes from rats which had 
received acetone, an inducer of cytochrome P450 2E1, was increased by 175 % over that observed 
in control microsomes. In liver microsomes from 4 humans the metabolism of DMF to HMMF 
was inhibited by a monospecific antibody against  ra t liver P450 2 E 1 , and the metabolic rates 
were correlated with those of NM F to SMG, a process known to be mediated via P450 2E1. 
D M F was also metabolized by purified ra t liver P450 2E1. The kinetic parameters which 
characterize the metabolism of DMF or its deuterated isotopomers to the respective HMMF 
isotopomers, of HMMF to SMG and of NMF to SMG in liver microsomes, were computed horn 
Eadie-Hofstee plots. The affinity of DMF for the metabolizing enzyme in ra t liver microsomes 
is considerably higher (apparent K m = 0.20 mM) than th a t of NMF (Km =  4.28 mM) or of 
H M M F (Ka = 2.52 mM). The respective values observed with human microsomes are very 
similar. The apparent K m values for the N-methyl oxidation of NJV-dimethyldeuteriof ormamide 
([2 Hi]DM F) and N’rN-bis(trideuteriomethyl)formamide ([2 H$]DMF) in ra t microsomes are 0.14 
and  0.21 mM, respectively. The apparent V -.. for the oxidation of [2H JD M F is similar to that 
com puted for DMF, and the V—. for [2Hg]DMF is less than half of that computed for DMF. 
T he kinetic deuterium isotope effect (KDEE) on DMF metabolism was determined in incubations 
w ith ra t microsomes in three ways: (i) the noncompetitive intermolecular KDIE by the ratio 
of VjojoJKu for DMF to V— /K -  for [2H6 ]DMF, (ii) the competitive intermolecular KDIE as 
the quotient of metabolic products HMMF to N-(hydroxydideuteriomethyl)-Af-(trideuterio- 
methyl)formamide in incubations of DMF together with [2 He]DMF, and (iii) the intramolecular 
K D IE  as the quotient of the ratio of N- (hydroxymethyl)-N- (trideuteriomethyl) formamide to 
N-(hydroxydideuteriomethyl)-//-methylfonnamide generated from N-(trideuteriomethyl)-AT- 
methylformamide ([2H3 ]DMF). The respective values were found to be (i) 2.4, (ii) 5.0, and (iii)
5.2. DMF inhibited the oxidation of NMF or HMMF to SMG. Deuterium substitution of the 
DM F methyl hydrogens did not affect the apparent K t for the inhibition of the oxidation of 
N M F to SMG. Among a series of 8  formamides and acetamides structurally related to DMF 
only NJV-diethylformamide and NJV-dimethylacetamide were equally effective with DMF as 
inhibitors. The results suggest that (i) hepatic P450 2 E 1  is an important catalyst of the metabolism 
of DM F and related low-molecular-weight amides, (ii) DMF inhibits its own metabolic toxification, 
and  (iii) there is a marked KDIE on the metabolic oxidation of DMF.
In troduction
N ,N-Dimethylformamide [DMF, 1 (CHshNCHO] is a 
polar solvent used widely in a variety of industrial 
processes, among them the manufacture of synthetic fibers,
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leathers, films, and surface coatings. Worldwide produc­
tion of DMF annually has been estimated to be 2 x  103 
tons (2 ). Gastric irritation and hepatotoxicity are the major 
untoward effects which have been reported in workers 
exposed to DMF (for review see ref 3). For example, an 
elevation in biochemical indices of hepatotoxicity has been 
described recently in workers occupationally exposed to 
DMF under conditions of poor industrial hygiene (4,5). 
These reports have been considered of sufficient gravity
© 1993 American Chemical Society






F igure 3. HPLC separation of HMMF (retention tim e 3.9 min) 
from NMF (retention time 3.4 min) (top trace) and formaldehyde 
(bottom trace). Formaldehyde content in the fractions of the 
HPLC eluate was determined using the colorimetric method of 
Nash (24). Values on the y-axis are arbitrary.
E xperim ental Procedures
C hem icals. DMF, NMF, NJV-dimethylformamide, NJ4- 
dibutylformamide, N-ethylformamide, N^N-dimethylacetamide, 
N,N-diethylacetamide, N-methyLacetamide, formamide, aceta- 
mide, and diethyldithiocarbamate (DEDTC) were bought from 
Aldrich Chemical Co. (Poole, U.K.). DMF and NM F were 
purified by distillation to >99 % purity (GLC) prior to use. PH J - 
DMF was prepared from pHJdimethylamine hydrochloride 
(Sigma Chemical Co. Ltd., Poole, UJC) and ethylformate 
essentially according to the method described for the synthesis 
of N-(trideuteriomethyl)formamide (PH3]NMF) (22). In analogy 
PH JDM F was prepared from dimethylamine hydrochloride and 
PHJmethylformate (Aldrich) and PH JDM F from ethylformate 
and N-(trideuteriomethyl)-N-methylamine hydrochloride, which 
was kindly provided by Dr. R. P. Hanzlik (University o f  Kansas). 
The purity o f the synthesized isotopomers was verified by GLC 
and lH-NM R spectroscopy. Biochemicals (glucose 6-phosphate, 
glucose-6-phosphate dehydrogenase, GSH, NADP) were obtained 
from Sigma. HMMF was prepared according to Gate et aL (23). 
The crude product of the synthesis contained 6-8% NMF as 
determined by HPLC analysis (vide infra) and a similar amount 
of formaldehyde as determined colorimetrically according to Nash
(24). The product was purified by semipreparative HPLC to 
furnish HMM F of suitable purity for in vitro metabolism studies. 
The HPLC system  used for this purpose consisted o f a Waters 
510 pump, a Waters WISP 710 autoinjector, a Shimadzu SPD- 
6A UV detector (set at X = 233 nm). and a Waters Maxima 820 
workstation. Separation was achieved on a Lichrospher 100 RP- 
18 column (250 x  4 mm. 5-^m particle size) through which 10 
mM phosphate buffer (pH7.4) was pumped at a flow rate of 1.0 
mL/min. Under these conditions the contaminants in 20-nL 
samples containing 10% HMMF were sufficiently separated from 
the carbinolamide. Figure 3 demonstrates the,separation by 
HPLC of H M M F, NMF. and formaldehyde in a typical sample 
of crude product. The HMMF content in the collected eluate 
was measured by GLC as NMF (vide infra); residual NMF was 
determined by HPLC as described above. SMG was synthesized
by Drs. D. H. Han and P. G. Pearson, University of Washington, 
Seattle, as described previously (25). Propyl N- methylcarb am a te 
was prepared from AMCC and 1-propanol using the procedure 
for derivatizationof AMCC in preparation for GLC analysis (26). 
All other chemicals and reagents were available in the laboratory.
A nim als and Source o f Human Microsomes. Male Spra- 
gue-Dawley rats (170-200 g) were purchased from Bantin and 
Kingmans Ltd. (Hull, U.K.). In some experiments rats were 
used which had been given acetone as a 50% solution in saline 
(5 mL kg-1) by single oral gavage 24 h prior to preparation of 
microsomes (27). Control animals received saline. Excess 
samples of healthy human liver tissue were obtained after graft 
reduction of donor liver from the Liver Transplant Unit at the 
Queen Elizabeth Hospital (Birmingham, U.K.). Tissues origi­
nated from four organ donors, two females and two males, aged 
between 10 and 55 years. Homogenate (25%) of human or rodent 
liver was prepared in Tris-buffered (50 mM, pH 7.4) KClsolution 
(154 mM). Human liver microsomes, which were prepared within 
3 h after liver became available, were stored in liquid nitrogen 
for up to 12 months before use. P450 2E1 was purified from 
streptozotodn-treated rats as described previously (20).
Preparation  o f L iver M icrosomes and M icrosom al In­
cubations. Microsomes were obtained in the usual way by 
differential centrifugation of homogenate first at (9 x  lO3)# for 
20 min, and then at HPg for 1 h in a Beckman L8-60M 
ultracentrifuge. The microsomal pellet was suspended in Tris 
buffer (50 mM, pH 7.4), recentrifuged at HPg for 1 h, and 
resuspended in phosphate buffer (50 mM, pH 7.4). The rat liver 
microsomes used in each experiment were pooled from 2-4 
animals.
All incubations were carried out, with duplicate samples, in
5-mL glass vials under shaking at 37 °C. Incubates contained 
microsomes (1—2.5 mg of protein-mL*1), a NADPH generating 
system [glucose 6-phosphate (20 mM), NADP (10 mM), glucose-
6-phosphate dehydrogenase (4 IU)J, GSH (10 mM), phosphate 
buffer (50 mM, pH 7.4), and substrate with or without inhibitor 
at the concentrations decribed below in a final volume of 2 mL. 
The GSH in the mixture converted metabolically generated 
N-methylcarbamoylating species to SMG (18). Reactions were 
initiated by addition of substrate after a 3-min preincubation 
period at 37 °C and terminated after incubation for 30 min. 
Preliminary experiments established that the metabolic gener­
ation of HMMF from DM F and that of SMG from NM F or 
HMMF were linear with time during this time period.
The monospecific antibody against rat liver P450 2 E l was 
prepared and purified as described recently (20).
Preparation  o f Sam p les and Quantitation o f  M etabolites. 
In preparation for analysis by GLC samples of the incubate were 
processed as described by Mraz (26) and Mraz et aL (28). This 
procedure involves derivatization of metabolically produced SMG 
with ethanol in alkali to furnish ethyl N-methylcarbamate and, 
at the same time, conversion to HMMF to NMF. Likewise 
metabolically generated N-(hydroxydideuteriomethyl)-N-(tri- 
deuteriomethyDdeuterioformamide (pHJHM M F) is converted 
to N-(trideuteriomethyl)deuterioformamide (PH JN M F), N- 
(hydroxydideuteriomethyb-Af-(trideuteriomethyl)formamidd pH J - 
HMMF) and N-(hydroxymethyl)-N-(trideuteriomethyl)forma- 
mide (P H 3]H M M F) to N-(trideuteriom ethyl)form am ide  
(pH J  NMF), N-(hydroxydideuteriomethyl)-N-methylformamide 
(pH 2]HMMF) to NMF, and N-(hydrorymethyl)-N-methyldeu- 
terioformamide (pH ,]H M M F) to :V-methyldeuterioformamide 
(pH JNM F). Metabolic incubations were terminated by transfer 
of a sample (1.5 mL) of the incubate into a tube containing ethanol 
(3 mL) with propyl N-methylcarbamate (10 >xM). which served 
as internal standard. For the determination of ethyl N-meth- 
ylcarbamate (the analytical derivative of SMG) an additional 
extraction step with ethyl acetate was included (11). Gas 
chromatographicdetermination of ethyl :V-methylcarbamate and 
of NMF isotopomers was performed using a HP-5890A gas 
chromatograph with a nitrogen-selective detector, attached to a 
fused silica capillary HP-20M column (25 m x  0.32 mm i.d.; 
0.32-jxm  film thickness). The column oven temperature was 130
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[nm fl HMMF~| mg prot. x m in jF ig u re  6. Correlation of apparent of metabolism of NMF 
with that of DMF in microsomes from 4 human livers. The 
values used are the ones which describe the enzyme with high 
affinity for NMF and DMF. For details of incubation and analysis 
of metabolites see the Experimental Procedures. Standard linear 
regression analysis gave a correlation coefficient of r = 0.99.
100
I  20
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F ig u re  7. Effect of anti-rat P450 2E1 IgG (closed circles) or 
preimmune IgG (open squares) on the metabolism of DMF (10 
mM) in human liver microsomes. Values, which are expressed 
as percentage of the rate o f metabolic production of HMMF 
from DMF in incubations without IgG, are the mean of two 
individual microsomal preparations, each conducted in duplicate. 
Details of incubation conditions and metabolite analysis are 
described under Experimental Procedures.
metabolism of DMF was studied in incubates with 
microsomes in the presence of DEDTC which is a relatively 
specific inhibitor of P450 2E1 at concentrations in the 
lO^-lCH M range (34). DEDTC indeed inhibited DMF 
oxidation potently (Figure 5B). Third, the rate of me­
tabolism of DMF was compared with that of NMF, a P450 
2E1 substrate (20), in liver microsomes from four different 
humans. The plot obtained (Figure 6) shows a good 
correlation between rates. Fourth, a monospecific anti­
body against rat P450 2E1 inhibited DMF metabolism in 
incubations with human liver microsomes substantially 
(Figure 7). Microsomal N-demethylation of aminopyrine 
was not affected by the presence of this antibody (result 
not shown). Fifth, in a preliminary experiment, HMMF 
was also detected in incubates of DMF (10 mM) with 
purified rat liver P450 2E1 after reconstitution with 
cytochrome P450 reductase and cytochrome 6S. The 
mixture was incubated for 1 h in order to maximize 
metabolite formation. The amount of HMMF generated, 
110 nmol-(nmol of cytochrome P450)-1, was 5 times that 
which was found under identical incubation conditions in 
microsomes from livers of streptozotocin-treated rats, 
which served as the source of the purified enzyme. The
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F igu re  8. Eadie-Hofstee plot of generation of HMMF from 
DM F in incubates of rat liver microsomes. The individual values 
are the mean of 2 incubations. They were obtained with substrate 
concentrations ranging from 0.02 to 100 mM. The plot shown 
is representative of 4 experiments. Symbols “v" and “s" represent 
the reaction rate and substrate concentration, respectively. For 
details of incubation and metabolite analysis see the Experimental 









F ig u re  9. Eadie-Hofstee plot of metabolic generation of SMG 
from NMF in incubations of rat liver microsomes. The individual 
values are the mean of 2 incubations. They were obtained with 
substrate concentrations ranging from 0.2 to 200 m M  The plot 
shown is representative of 9 experiments. Symbols and ~s~ 
represent the reaction rate and substrate concentration, respec­
tively. For details o f incubation and metabolite analysis see the 
Experimental Procedures. For the mean apparent K a and VMi 
values see Table I.
difference in HMMF production between purified enzyme 
and microsomes mirrors the contribution of P450 2E1, as 
determined by p-nitrophenol oxidation, to the overall 
microsomal cytochrome P450 (result not shown).
Kinetic Analysis of Formamide Metabolism. In this 
series of experiments we wished to elucidate the discrep­
ancy in the metabolic generation of N-methylcarbamic 
acid thioester from DMF between humans or animals in 
vivo and microsomal incubations in vitro, that is, to 
ascertain why the microsomal metabolism of DMF yields 
only HMMF but not SMG (18). To that end, DMF, NMF, 
and HMMF were incubated with rat and human liver 
microsomes. The rates of the enzyme-catalyzed reactions 
(i) DMF — HMMF, (ii) NMF -  SMG, and (iii) HMMF 
— SMG were determined and used to construct Eadie- 
Hofstee plots. The plots for reactions i and ii are shown 
in Figures 8 and 9. They consist of two linear segments, 
which relate to low and high substrate concentrations and 
describe catalytic reactions of, respectively, high and low 
affinity for the enzyme. The apparent Km and values 
calculated from the high-affinity sections of the plots are 
shown in Table I. In the case of the metabolic formation 
of HMMF from DMF in rat liver microsomes (Figure 8) 
the high-affinity segment of the Eadie-Hofstee plot is
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Table III. Intermolecular Kinetic Isotope Effect on DMF 
N-Methyl Oxidation
substrate concn (mM) substrate concn (mM)
DMF PHjDMF KDIE* DMF [*H<]DMF' KDIE8
25 2.5 5.8 ±0.6  1 4 5.2 ±0.1
0.5 0.5 4.6 ±  0.2 0.2 0.8 43 ± 0.2
* Ratio of formation of HMMF to pH$]HMMF. Details of 
metabolite analysis are described under Experimental Procedures. 
Each value is the mean ±  SD of 4 separate experiments. Mean KDIE 
± SD of the mean values shown is 5.0 ± 0.7.
Table IV. Intramolecular Kinetic Isotope Effect on DMF 
__________________ fV-Methyl Oxidation__________________
PHjJDMF PH3]DMF
concn (mM) KDIE* concn (mM) KDIE*
5 5.7 ±0.4 0.2 4.9 ±0.2
1 5.0 ±0.5
* Ratio of formation of PHJHMMF to pHJHMMF. Details of 
metabolite analysis are described under Experimental Procedures. 
Elach value is the mean ±SD of4 separate experiments. Mean KD EE 
± SD of the mean values shown is 5.2 ±  0.4.
PHJDM F. The ratios of for DMF to
for either PH^JDMF or pHilDMF gave 2.36 ± 0.74 (mean 
±  SD, n = 4) and 0.82 ±  0.33 (n = 5), respectively. The 
difference between these values is significant (P < 0 .0 1 ). 
In order to measure the competitive intermolecular KDIE, 
mixtures of DMF and PHJDM F were subjected to 
incubation with rat liver microsomes. Each isotopomer 
was used a t four different concentrations, and they were 
mixed at two concentration ratios (1:1 and 1:4). The 
quotient of the rates of production of HMMF, the 
metabolite of DMF, and of PHslHMMF, the metabolite 
of pHdDMF, at the different substrate concentrations 
ranged from 4.3 to 5.8, with a mean ±  SD of 5.0 ± 0.7 
(Table HI).
For the determination of the intramolecular KDIE on 
the generation of HMMF from DMF, PI^IDMF was 
synthesized and incubated with liver microsomes at three 
substrate concentrations. P H J HMMF and PHJHMMF 
were analyzed by GLC in the incubate as products of the 
oxidation of the N-CH3  and the N-CD3  groups, respectively 
(see Figure 2B). The KDIE calculated from the ratios of 
the isotopomeric metabolites gave 5.2 ±  0.4 as the mean 
±  SD (Table IV). It has to be stressed that we were able 
to conduct this study without the use of a mass spec­
trometer only because of the interesting finding that the 
GLC method allowed the separation of NMF and [2Hsl- 
NMF (Figure 4), the products of hydrolysis either of 
HMMF and PHslHMMF, respectively, in the intermo­
lecular competitive KDIE determination, or of P H J- 
HMMF and PH3JHMMF, respectively, in the intramo­
lecular KDIE measurement.
Effect of DMF, [ ^ D M F ,  and Related Amides on 
Metabolic Formyl Oxidation. The retarded excretion 
of AMCC as urinary metabolite of DMF (22,16) and the 
lack of generation of measurable SMG from DMF in vitro 
(28) suggest that metabolic formyl oxidation is inhibited 
by DMF or one of its products. This hypothesis was tested 
by the determination of metabolic production of SMG 
from NMF or HMMF in incubations with microsomes 
fortified with GSH and in the presence of varying 
concentrations of DMF. It is pertinent to reiterate that 
these experiments were possible only because DMF 
incubated on its own with microsomes did not yield 
detectable amounts of SMG (28). DMF did indeed inhibit 
the generation of SMG from NMF and HMMF. Figure
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Figure 11. Eadie-Hofstee plot of metabolic generation of SMG 
from NMF in the absence (closed circles) and presence of DMF 
(open squares) in incubations of rat liver microsomes. The 
individual values are the mean of 2 incubations. They were 
obtained with substrate (NMF) concentration ranging from 0.4 
to 10 mM and inhibitor (DMF) concentrations of 0.1 mM. The 
plot shown is representative of 3 experiments. Symbols “i>" and 
“s' represent the reaction rate and substrate concentration, 
respectively. For details of incubation and metabolite analysis 
see the Experimental Procedures. The apparent if; value for the 
inhibition of NMF oxidation by DMF computed from this 
experiment is 0.08 mM.
Table V. Inhibition of Metabolic Generation of SMG from 
NMF in Rat Liver Microsomes by Low-Molecular-Weight 
Amides
inhibitor RiR2NC(0 )R3
Ri r 2 . R3 app K,  (mM)* n>
H H H 44 ±  7 4
c ,h 5 H H 0.34 ±0.09 3
CH3 c h 3 H 0.11 ±  0.02 9
C2Hs C2H5 H 0.054 ±  0.027 4
C4H9 c«h9 H 0.56 ±  0.14 4
H H c h 3 158 ± 11 3
CH3 H c h 3 6.52 ±  1.16 3
CH3 CH3 CH3 0.25 ±  0.04 3
CjH5 C2H5 CHi 251 ±  0.33 3
* Details of metabolite analysis and calculation of apparent K-, 
values are described under Experimental Procedures. Values are 
the mean ±  SD. * Number'of separate experiments, each of which 
consisted of 6-6 individual incubations.
1 1  demonstrates that the inhibition of the oxidation of 
NMF by DMF was almost fully competitive. In  all three 
repeat experiments the plot of the inhibited reaction 
provided apparent Vm*x values which were consistently 
slightly below the apparent V ^ o f  the uninhibited reac­
tion. Therefore, the possibility cannot be excluded that 
a minor noncompetitive component contributes to the 
overall mechanism of inhibition. The apparent K\ values 
calculated for DMF are 0.11 mM in rat liver microsomes 
(Table V) and 0.16 ±  0.06 mM in human liver microsomes 
(mean ±  SD of the following individual values: 0.24,0.09,
0.17, 0.15 mM). The apparent K\ values describing the 
ability of DMF to inh ib it  the metabolic formyl oxidation 
of HMMF are 0.48 ±  0.18 mM (mean ±  SD, n -  3) in rat 
liver microsomes and 0.064 mM in microsomes from a 
human liver. These inhibition constants are thus similar 
to the apparent Km values determined for the metabolic 
N -methyl oxidation of DMF, 0.20 and 0.12 mM, in rat and 
human microsomes, respectively (Table I).
Next we wanted to test the hypothesis that the ability 
of DMF to inhibit metabolic formyl oxidation and thus 
the generation of SMG from NMF is subject to a KDIE. 
To that end, (2 He]DMF at several concentrations was 
added to incubates of NMF with rat liver microsomes. 
The Kx value obtained was 0.16 ± 0 . 0 2  mM (mean ± SD
Microsomal Metabolism of NJ4-Dime thy I formamide
to DMF in the work environment (38-41). It is unlikely 
that DMF itself acts like disulfiram, as it does not inhibit 
alcohol or aldehyde dehydrogenase enzymes in vitro (42, 
43). Instead, a DMF metabolite might inhibit acetalde- 
hyde dehydrogenases. In this context it is instructive to 
consider the structural similarity between disulfiram 
[(CzHshNClSlSSCfSMCsHsJd or its analog dioxiram 
[(C2 Hs)2NC(0 )SSC(0 )N(C2Hs)2] and the DMF metab­
olites SMG and AMCC. Both disulfiram and dioxiram at 
concentrations as low as 2  nM  were shown to decrease 
potently the activity of sheep liver cytoplasmic aldehyde 
dehydrogenase in vitro (44). In view of their structural 
resemblance with disulfiram and dioxiram SMG and 
AMCC might likewise inhibit aldehyde detoxification and 
thus beTesponsible for the alcohol incompatibility caused 
by DMF. Alternatively, the interaction responsible for 
the DMF-alcohol incompatibility reaction might occur 
directly a t the level of hepatic P450 2E1. P450 2 E1  was 
recently shown to catalyze the oxidation of acetaldehyde 
with a K m of about 30 pM (45). Thus DMF itself might 
increase hepatic levels of acetaldehyde via inhibition of 
P450 2E1, even though the contribution of this enzyme to 
the overall metabolism of acetaldehyde in vivo is probably 
small. These speculations and their relevance to the 
mechanism of the adverse effects of DMF need further 
experimental verification.
The ability of DMF to inhibit the P450 2 El-mediated 
metabolism of its own metabolites is consistent with the 
observation that DMF blocks the N-demethylation of NJN- 
dimethylnitrosamine, another P450 2 E 1  substrate (21). 
The K\ value reported in that paper, 0.07 mM, is close to 
that reported here for the inhibition by DMF of NMF 
formyl oxidation (0.11 mM). It is remarkable that the 
inhibitory potential of DMF on the metabolism of sub­
strates of P450 2 E l was first discovered thirty years ago. 
Heath showed then that DMF retards the exhalation in 
rats of l«C02  derived from [14C]-labeled N^V-dimethylni- 
trosamine (46). His astute deduction that both DMF and
A^ rA^dimethylnitrr>fiflmim»<nfe>rflrt nrith the sams nridmng 
enzymes because they share structural similarity has been 
prophetic in view of the conclusion proffered here that 
both molecules are substrates of P450 2E1. The microso­
mal hydroxylation of DMF, like that of NJV-dimethylni- 
trosamine, is characterized by both a high- and a low- 
affinity component The low-affinity segment of the 
oxidation of N^V-dimethylnitrosamine has been attributed 
to P450 LM2  (19). The findings described above of the 
influence of substitution of hydrogen in the DMF molecule 
by deuterium are somewhat at variance with the effect of 
deuterium substitution on the metabolic N-demethylation 
of N^N-dimethylnitrosamine. Deuteration of the methyl 
moieties in N’^ V’-dimethylnitr os amine increased the ap­
parent Ka by a factor of 5, but did not change the apparent 
Vm.T of the reaction (47), whereas in our experiments 
deuteration of the DMF methyl moieties affected the Vmtx 
but not the Km.
The intriguing inhibition by DMF of metabolic formyl 
oxidation explains why the start of the urinary excretion 
of AMCC after exposure to DMF in vivo is delayed (11, 
16). This explanation hints at the possibility that man­
ifestations of detrimental effects of DMF on the health of 
workers after overexposure may develop well beyond the 
end of the work shift. Inhibition of the metabolism of 
NMF by DMF also rationalizes the observation that DMF 
decreased the severity, and postponed the onset, of NMF-
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induced hepatotoxicity as measured by elevated serum 
sorbitol dehydrogenase levels in rats (17).
Another vexing question associated with the link 
between DMF toxicity and its metabolic conversion to 
IV-methylcarbamic acid thioesters has been whether 
HMMF is a substrate for the formyl-oxidizing microsomal 
enzyme, or if production of SMG, the progenitor of the 
ultimate metabolite AMCC, from DMF (10,11) requires 
the intermediacy of NMF. NMF is only a quantitatively 
minute urinary metabolite of DMF, whereas its relatively 
stable N-(hydroxymethyl) precursor HMMF is the major 
biotransformation product of DMF in the urine (7-9). In 
view of this fact, it has been impossible to decide whether 
NMF and not HMMF is the immediate metabolic pre­
cursor of SMG and AMCC in vivo. The interpretation of 
previous studies on the metabolism of HMMF in mi­
crosomes in vitro (18) has been severely confounded by 
the fact that the product of chemical synthesis of HMMF 
from NMF and formaldehyde always contained at least 
5% NMF, so that it has never been clear whether SMG 
formation reflected the metabolism of HMMF or that of 
its contaminant NMF. In contrast, in the investigations 
described above we have been able to use authentic HMMF 
which contained only up to 0.5% NMF. The generation 
of SMG proceeded a t a rate much inferior to that observed 
with NMF as substrate; for example, in the case of rat 
liver microsomes the rate was only 5% of that discerned 
with NMF. The knowledge of the kinetic parameters 
which characterize these metabolic processes (Table I) 
allows calculation according to which the rate of SMG 
production from HMMF was approximately 3 times as 
fast as that expected if the 0.5% contaminant NMF was 
the exclusive substrate of microsomal metabolism. The 
possibility cannot be completely excluded that microsomes 
catalyze the breakdown of HMMF to NMF. The HPLC 
method used here for the simultaneous measurement for 
NMF and HMMF did not clarify tins matter conclusively 
as components of the microsomal incubate interfered with 
the determination of NMF. However, the finding that 
the plot of v against s for the biotransformation HMMF 
— SMG observed saturation kinetics (result not shown) 
renders the possibility unlikely that NMF generated by 
degradation of HMMF, rather than HMMF itself, was 
responsible for the production of SMG. The kinetic 
parameters help also to explain why the formation of SMG 
has never been observed in incubations of liver microsomes 
with DMF. Under the conditions of incubation adopted 
in the study reported here 10 mM DMF would generate 
not more than 20 /iM HMMF within 30 min. Assuming 
an (obviously fictitious) constant presence of 1 0  pM 
HMMF during the whole of the incubation period the 
final concentration of SMG generated from DMF via 
HMMF would be 3 nM. As the limit of detection of the 
assay used is about 0 . 1  mM, it is not surprising that SMG 
was not found in these incubations, even without taking 
the ability of DMF to inhibit SMG formation into 
consideration.
In enzymic systems, isotope effects can be measured 
using several different experimental designs, which furnish 
intermolecular or intramolecular KDIE values. For the 
measurement of the intermolecular KDIE one can adopt 
a noncompetitive and a competitive approach. The 
noncompetitive design requires separate determinations 
of and Ka for both labeled and unlabeled substrate. 
In the competitive strategy, a known mixture of labeled
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ABSTRACT
The deuterium isotope effect on gas chromatographic retention of a series of N,N-dimethylformamide. N-methylformamide and 
formamide isotopomers was studied on methyl and phenyl methyl polysiloxane and polyethylene glycol stationary phases. The 
deuterium isotope effect was substantially affected by the position of deuterium in the molecule. Whereas methyl-deuterated 
(C2Hj)zNCHO and C2H3NHCHO eluted, as expected, earlier than their non-Iabelled analogues, elution of formyl-deuterated 
(CH3)2NC2HO, CH,NHC2HO and NH2C2HO was always delayed. The presence of chemically inequivalent deuterium atoms in 
(C2Hj)2NC2HO and C2H3NHC2HO resulted in final deuterium isotope effects to which the contributions of the individual groups 
were additive. The elution order of the individual isotopomers was not affected by the polarity of the stationary phase. 
Interpretation of the deuterium isotope effect observed is provided by the theory of vapour pressure isotope effects.
INTRODUCTION
Changes in the chromatographic retention of 
molecules with different isotopic composition 
have often been noted. Perhaps most reports 
deal with the effect of replacing ‘H by 2H 
(deuterium) (for review, see ref. 1). The great 
majority of reported gas chromatographic (G C)
* Corresponding author.
separations result in earlier elution of heavier 
:H-labelled compounds, which is referred to  as 
the inverse isotope effect [lj. Accordingly, in a 
series of isotopomers differing by a num ber of 
deuterium atoms within some structural unit, 
e.g. in an alkyl group [2.3] or on an arom atic 
ring [4], the compounds are eluted in the o rder 
of decreasing number of deuterium atom s. The 
normal isotope effect, i.e. later elution o f heavier 
species, is observed mainly in absorption G C 
(GSC), for example on alkali-etched glass capil­
lary columns [5,6]. Examples of normal isotope
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Fig. 1. Structures of DMF. MF and F isotopomers.
effects in partition GC (GLC) are very scarce 
[3,5]-
In this paper we report on an unusual observa­
tion, namely that the deuterium isotope effect on 
GC retention may be substantially affected by 
the position of deuterium atoms in the molecule. 
The observation is discussed in terms o f the 
theory of vapour pressure isotope effects.
EXPERIMENTAL
Chemicals
Unlabelled N,N-dimethylformamide (d0- 
D M F), N-methylformamide (d0 -MF) and form ­
amide (d 0 -F) were bought from Aldrich (Gilling­
ham , U K ), d7-DM F was bought from Sigma 
(Poole, UK). Compounds d 6-DMF, d 3-DM F 
and d 3-MF were prepared from d 6 -di- 
methylamine hydrochloride (Sigma), d 3 -di- 
methylamine hydrochloride (a gift from D r. R.P. 
Hanzlik, University of Kansas) and d 3 -methyl- 
amine hydrochloride (Sigma), respectively, and 
ethyl formate [7]. By analogy. d r DMF, d ,-M F
195
and d ,-F  were prepared from the respective 
am ine hydrochlorides and d,-methyl formate 
(Aldrich). Compound d4-MF was prepared from 
d 3-methylamine hydrochloride and d,-methyl 
form ate. N,N-Dimethylacetamide (DM A) was 
bought from Aldrich; propyl-N-methylcarbamate 
was prepared as described previously [8 ]. For 
structures of DMF, MF and F isotopomers see 
Fig. 1.
GC analysis
Retention times were measured on an HP- 
5890 A gas chromatograph with 3394 A inte­
grator. The fused-silica capillary columns used 
were HP-20M (polyethylene glycol 20M), 25 m 
x 0 .3 2  mm I.D ., 0.3 /xm film thickness, and 
HP-50 + (cross-linked 50% phenyl methyl 
silicone gum), 15 m x 0.53 mm I.D ., 1.0 /im  film 
thickness, both from Hewlett-Packard, and DB-1 
(cross-linked 1 0 0 % methyl silicone gum), 15 m x
0.53 mm I.D ., 3.0 ^tm film thickness, from J & 
W Scientific. The injector was in a split mode 
with a 1:30 splitting ratio, and the nitrogen- 
selective detector was used. Helium was em ­
ployed as carrier gas. Experimental conditions of 
the m easurem ents and informative values of 
dead and retention times are shown in Table I.
A typical sample was a solution of a single 
isotopomer (1 m M )  and an internal standard (1 
mM) in acetone (1 jul). The internal standards 
were DM A for DMF, propyl-N-methylcarba­
mate (on HP-20M) or DMA (on HP-50 + and 
DB-1) for MF, and MF for F.
TABLE I






















t ,"  
(min)
DMF 90 0.9 1.9 7.3 75 2.1 1.4 5.1 75 2.3 1.2 4.8
MF 130 0.7 2.0 7.7 75 2.1 1.4 5.0 75 2.3 1.2 4.3
F 130 0.7 2.0 12.1 75 2.1 1.4 3.5 Not measured'”
" tR of the non-deuterated isotopomer.
* Not measured because of the strong tailing and dose dependence of the retention time.
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Calculations 
In this study, the deuterium isotope effect on 
chromatographic retention is expressed using 
relative retention, r J2, between a deuterated 
compound and its non-deuterated analogue: 
r n  = ^(deu tera ted) / /^(non-deuterated). Here 
tR = /R - t M, where tR is retention time, / R is 
corrected retention time and rM is dead time. In 
the most straightforward way, r 12 can be mea­
sured upon injection of both compounds 
together. This could not be applied here since in 
some cases peaks of isotopomers could not be 
resolved sufficiently. Thus, separate injection of 
each compound was necessary. The absolute 
values of retention time, however, may be affect­
ed by the drift or fluctuations in experimental 
conditions during measurement. On the other 
hand, accuracy of the retention parameters de­
termined should be very high. Therefore, a 
retention of each isotopomer (i) including the 
non-deuterated compound was related to the 
retention of an internal standard (I.S.), which 
was added for this purpose to the sample. 
Auxiliary relative retentions r I2aux were calcu­
lated as r 12aux = ^r(1)/^r(I-S.) and, finally, the r 12 
value for each deuteromer was obtained:
r l2 = r 12aux(deuterated)/r12aux(non-deuterated).
RESULTS AND DISCUSSION
The deuterium isotope effect on the GC reten­
tion of a series of deuteromers of DMF, MF and 
F was studied on three fused-silica capillary 
columns of different polarity. As an index of the 
deuterium isotope effect, values of the relative 
retention r l2 of a pair of deuterated/non-deuter­
ated isotopomers were measured. The results 
(Table II) are consistent for DMF, MF and F, 
and can be summarized as follows.
(a) The presence of deuterium in the methyl 
position of formamides results in lower reten­
tion.
(b) The presence of deuterium in the formyl 
position of formamides results in higher reten­
tion. The formyl-related deuterium isotope effect 
is more pronounced than the methyl-related 
deuterium isotope effect: the corresponding val-
TABLE II
DEUTERIUM ISOTOPE EFFECT ON THE RETENTION 
OF N,N-DIMETHYLFORMAMIDE, N-METHYLFORM­
AM IDE, AND FORMAMIDE ISOTOPOMERS
Compound ri!
HP-20M HP-50+ DB-1
d0-DMF 1.000 1.000 1.000
d,-DM F 1.023 1.013 1.009
dj-DMF 0.998 0.989 0.990
d6-DMF 0.995 0.979 0.982
d7-DMF 1.017 0.991 0.989
d0-MF 1.000 1.000 1.000
d,-MF 1.017 1.014 1.010
dj-MF 0.982 0.977 0.980
d4-MF 1.000 - -
d0-F 1.000 1.000
b
d,-F 1.019 1.024 b
'T h e  values are mean of at least eight measurements; S.D.
was less than 0.001 in most cases.
‘ Not measured because of the strong tailing and dose 
dependence of retention time.
ues of an index (r12 -  1)/ND (where ND is 
number of deuterium atoms in the molecule) 
were 0.009 to 0.024 and -0.001 to -0 .008 , 
respectively. The separation of MF isotopomers 
is shown in Fig. 2.
(c) The presence of chemically inequivalent 
deuterium atoms results in the final deuterium  
isotope effect, to which the contributions of 
individual deuterium atoms are additive. Thus, 
r ,2 of d 7-DMF or d 4-MF is consistent with that
i u in
t  IminJ 7060
Fig. 2. Resolution of C'H,NHCHO (I), CH,NHCHO (II) 
and CH,NHC:HO (III) on fused-silica capillary column HP- 
20M 25 m x  0.32 mm I.D.. 0.3 *xm film thickness; column 
temperature 70°C; carrier gas helium. 1.0 ml/min
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estimated from the individual r 12 values of par­
tially deuterated analogues' d 6-DM F and d ,- 
DM F, o r d 3-MF and d,-M F, respectively.
(d) The observations described under (a) to
(c) are similar on strongly polar (HP-20M), 
slightly polar (HP-50+), and low polar (DB-1) 
columns.
Numerous reports on GC of isotopomers are 
consistent in that the deuterium isotope effect 
related to deuterium in methyl o r methylene 
groups is regularly the inverse effect [1 ,9 , 1 0 ]. 
This has been interpreted to be a consequence of 
shorter C -2H intemuclear distances as compared 
with C -H  bonds, resulting in lower molar vol­
umes and thus weaker dispersion forces. The 
effect on dispersion forces is thus responsible for 
the inverse deuterium isotope effect related to 
C 2 H 3 groups in DMF and MF (even when the 
contribution of these forces to overall interaction 
does not have to be prevailing). Dispersion 
forces seem to predominate in the interaction of 
formamides with non-polar stationary phases 
such as DB-1, as judged from the elution in the 
order o f F, MF and DMF, i.e. with increasing 
m olar volume. In contrast, these compounds are 
eluted in the opposite order where polar interac­
tions (dipole-dipole, dipole-induced dipole, 
etc.) prevail, as in the case of elution from polar 
HP-20M column. The increasing role of polar 
interactions in the order of DMF to F is con­
sistent with the order of boiling points: DMF, 
153°C; M F, 185°C; F, 195°C.
Unlike methyl-deuterated compounds, the 
normal D IE  as observed with formyl-deuterated 
formamides seems to be surprising and difficult 
to account for by simple considerations. The key 
to understanding this phenomenon is provided 
by the theory of isotope effects, especially va­
pour pressure isotope effects, supported by 
numerous experimental data (for review, see ref. 
11). All available reports show that deuterium at 
saturated carbon displays inverse vapour pres­
sure isotope effect, whereas substitution in 
groups that form hydrogen bonds and associate 
often results in normal vapour pressure isotope 
effect. There is an intrinsic relationship between 
isotope effect and molecular motion; normal 
isotope effects correlate with blue and inverse 
isotope effects with red frequency shifts.
Good examples to study the vapour pressure
isotope effect related to deuterium in different 
groups of the same compound are methyl- 
acetylenes and alkylamines [12-14]. H ere, 
deuterium in the methyl group results in an 
inverse vapour pressure isotope effect, whereas 
C H 3 CC 2 H, C H 3 N 2 H 2  and (C H 3 ) 2 N 2H exhibit a 
normal vapour pressure isotope effect. The 
above effects were interpreted with the aid of 
Bigeleisen theory [15]. In a most simplified way, 
the vapour pressure isotope effect is calculated 
using the equation In P ’lP  =  A I T 2 -  B IT , where 
P ' and P  are the vapour pressures of the heavier 
and lighter isotopomers, respectively, A  (lattice 
term) and B  (zero-point energy term) represent 
external and internal frequency modes, respec­
tively, and T  is temperature. In this model, 
replacement of H by 2H in the methyl group 
affects only the A  term, which is always positive 
so that inverse vapour pressure isotope effects 
occur. On the other hand, the location ^of 
deuterium in methynic or amino groups affects 
both A  and B  terms, the latter being responsible 
for the normal vapour pressure isotope effect 
observed. Analysis of the shape of an ex­
perimental plot of In P ’lP  vs. T  for CH 3 CC 2 H, 
C H 3 N 2 H 2  and (C H 3 ) 2 N 2H revealed tem- 
perature-dependency of B, which is indicative of 
molecular association in condensed phases [1 2 -  
14]. This view was further reinforced by finding 
that the vapour pressure isotope effect as m ea­
sured for C H 3N H , or (C H 3 ) 2 N2H in solution 
with hexane changed from a normal to inverse 
effect at high dilution [13,14], in which the 
association was negligible.
The data on formamides presented here are 
obviously in good agreement with those on 
methylacetylenes and amines. Thus, the normal 
isotope effect related to GC retention o f formyl- 
deuterated formamides is likely to reflect 
stronger interaction of those compounds, via the 
formyl group (compared with their non-labelled 
counterparts), with each other as well as with 
o ther molecules such as GC stationary phases. 
Owing to the polar nature of those interactions 
one can expect that the magnitude of the 
deuterium  isotope effect on GC retention of 
formyl-deuterated formamides will increase with 
polarity of the stationary phase. This was in fact 
the case, except for F (Table II). Another 
similarity was observed between the sets of
198 J. Mraz et al. I J. Chromatogr. 641 (1993) 194-198
methylacetylene, methyl- and dimethyiamine 
and formamide isotopomers, namely that the 
presence of chemically inequivalent deuterium 
atom s resulted in a final deuterium isotope effect 
to which contributions of individual deuterium 
atoms were additive.
In conclusion, the deuterium isotope effect on 
GC retention o f formamides reported here, 
despite its unusual character, complies well with 
the general theory of isotope effects.
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SYNTHESIS OF THE ENANTIOMERS OF THE 
BIOREDUCTIVELY-ACTIVATED CYTOTOXIN 
RSU-1069 AND ITS PRODRUG RB6145 AND LACK 
OF STEREOSELECTIVITY IN THEIR 
CYTOTOXICITY AND RADIOSENSITIZATION
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The R(+>- and S(—)-enantiomers of the radiosensitizer and bioreductively-activated cytotoxin RSU-1069 
and their prodrugs have been synthesised. The parent drugs were evaluated as radiosensitizers and 
bioreductively-activated cytotoxins in vitro. No stereoselectivity in the activities in vitro of the two 
enantiomers was evident and both compounds were potent hypoxia-selective agents.
KEY WORDS: Bioreductive, cytotoxin, radiosensitizer, RSU-1069, RB6145, enantiomers
INTRODUCTION
The dual-function radiosensitizer and bioreductively-activated cytotoxin a-[[(2- 
bromoethyi)amino]methyl]-2-nitro-l/f-imidazole-l-ethanol hydrobromide (1, RB6145) 
is the lead compound that has arisen from a programme of development of 
2-nitroimidazole derivatives as agents for cancer chemotherapy . 1 ,2  Selective toxicity 
towards hypoxic cells within tumours is due to anaerobic, enzymatic reduction of 
the drugs to toxic metabolites. In contrast, the radiosensitizing action of these 
compounds is through radiation-induced fast free-radical mechanisms occurring 
within normally radiation resistant hypoxic cells.
RB6145 (1) is a prodrug of RSU-1069 (2)3,4—the most effective of a series of 
dual-function compounds related to misonidazole, a drug withdrawn from clinical 
evaluation owing to cumulative neurotoxicity . 5 A number of regioisomers of 2 have 
been evaluated6  but the prodrug 1 remains the lead compound and has now progressed 
to the status of a candidate for clinical evaluation. However, to date stereoisomerism
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has not been addressed, and all biological evaluation of the drug both in vitro and 
in vivo has been carried out using the racemic mixture of the R( —) and 
S( + )-enantiomeric forms.
A possible clinical future for 1 means that it has become necessary to evaluate 
thoroughly the separate enantiomers for their individual cytotoxic properties. In view 
of the enzymatic nature of the bioreductive activation, differences in their rates of 
reduction by the cellular reductases involved could not be discounted. Similarly 
differences in reactivity of the enantiomeric forms of various metabolites towards 
cellular targets such as DNA are possible.
We therefore report here on the synthesis of the respective enantiomers of 2 and 
their prodrugs, and a preliminary study comparing the efficacies of the parent drugs 
as bioreductively-activated cytotoxins and as radiosensitizers in vitro.
CHEMISTRY
Two routes to the enantiomers 7 and 8 were evaluated. The first (A) makes use of the 
chiral forms of epichlorohydrin. Reaction with 2-nitroimidazole (azomycin) affords 
the chiral chlorohydrins 3 and 4 which, upon treatment with aqueous base give the 
oxiranyl synthons 5 and 6. These compounds were then converted into the 
corresponding aziridine derivatives 7 and 8 essentially as described by us earlier.2
The second route (B) utilises the respective enantiomers of oxiranyl methyl tosylate, 
which react preferentially with the anion of 2-nitroimidazole by nucleophilic 
displacement of the tosylate rather than by epoxide ring-opening. This was confirmed 
from the resulting aziridines which were identical to those obtained by Route A. The 
aziridines 7 and 8 were converted into their respective ring-opened hydrobromides 
with HBr/Me2CO to afford the hydrobromides 9 and 10. These chiral prodrug forms 
of 2 were used in the determination of enantiomeric purity by chiral HPLC. Compounds 
9 and 10 were found to be 99.3 and 97.1% enantiomerically pure respectively.
EXPERIMENTAL SECTION 
Synthetic Chemistry
NMR spectra were obtained at 60 MHz with a Jeol PMX60SI spectrometer using 
SiMe4 as internal standard. Elemental microanalyses were carried out by Butterworth
B IOREDUCTIVELY-ACTIVATED C Y TO TO X IN  RSU-1069
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Scheme I Svnthciic routes to enantiomers of 1.
Laboratories Ltd., Middlesex, U.K. HPLC experiments were carried out with a 
Diacel AS column (5 //, 0.46 x 25 cm) precooled and maintained at 10CC with a mobile 
phase of EtOH/Hexane (1:9, v/v). Detection was at 315 nm. Optical rotations were 
determined on an Optical Activity Ltd AA10 automatic polarimeter.
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( R ) (  — )-a-(I-aziridinylmethyl)-2-nitro-l-H-imidazole-I-ethanol (7)
Route A: A mixture of powdered 2-nitroimidazole (0.42 g, 3.7 mmol), 5 mL of (2SX + ) 
epichlorohydrin and anhydrous K2 C 0 3  (0.085 g, 0.062 mmol) was stirred under reflux 
for 1 0  m in, filtered while hot and any insoluble material washed with a little hot 
EtOH. From the refrigerated filtrate and concentrated remainder (2S)-a-(chloromethyl)- 
2 -nitro - 1 //-imidazole- 1 -ethanol (3) (0.56 g, 6 6 %) was obtained after recrystallization 
from EtOH as pale yellow crystals: mp 153-154°C. This material was stirred vigorously 
at 20°C for 0.5 h in aqueous NaOH (10%, 3 mL). Cold water (5 mL) was then added, 
and the solution was extracted with CHC13  (3 x 10 mL). The combined extracts were 
dried and evaporated and the residue was recrystallized from water and dried to give 
(2S)-2-nitro- 1 -(2-oxiranylmethyl)-1 tf-imidazole (5) (0.3 g, 73%) as a white solid: mp 
54-55°C. The above material (0.3 g, 1.8 mmol) was dissolved in EtOH (3.5 mL, 
containing 1% Et3 N) and aziridine (0.24 g, 5.4 mmol) was added (CAUTION). The 
solution was heated under gentle reflux for 1 0  min. and then cooled and evaporated. 
The residue was recrystallized from EtOH (1% Et3 N) to afford (RX—}-a-(l- 
aziridinylmethyl)-2-nitro-1 H-imidazole- 1 -ethanol (7) (0.22 g, 57%) as white crystals: 
mp 119.5-121°C. NMR (CDC13) <5 1.3 (dd, 2H, J = 2  and 4 Hz, aziridine CH2), 1 . 8  
(dd, 2H, J =  2 and 4 Hz, aziridine CH2), 2.4 dd, 2H, J = 4  and 7.5 Hz, CH 2 -aziridine), 
4.2 (m, 2H, CHOH),  4.3 (dd, 1H, J =  7.2 and 16.8 Hz) and 4.7 (dd, 1 H, J =  2 and
9.6 Hz) Im-CH2, 7.1 (s, 1H, Im-H), and 7.2 (s, 1H, Im-H) ppm. AnaL Calc, for 
C 8 H 1 2 N 4 0 3: C, 45.28; H, 5.66; N, 26.42%. Found: C, 45.51; H, 5.76; N, 26.04%.
[ a ] ^ =  — 23.5°(c =  1.15, CHC13).
Route B: l-Potassio-2-nitroimidazole was prepared by treatment of 2 -nitroimidazole 
with one equivalent of potassium tert-butoxide in DM F, heating at 110°C for 0.5 h, 
cooling and washing the resulting solid with dry CH 2 C12 . 1 -Potassio 2 -nitroimidazole 
(0.75 g, 5 mmol) was dissolved in anhydrous DM F (10 mL) together with (2RX —) 
glycidyl tosylate (1.6 g, 7 mmol) and the solution stirred for 12 h at ambient 
temperature. The solvent was removed under reduced pressure at 35°C and the 
residue redissolved in 100 mL CHC13, washed with water, dried and evaporated. The 
residue was purified by flash chromatography on silica (200 g), eluting with CH 2 C12  
to give (5) (0.58 g, 55%) identical to that obtained by Route A. This material was 
trreated with l(H)-aziridine as described above to obtain material identical to 7 above.
( R )-<*-[[ (2-Bromoethyl) amino ] methylJ-2-nitro-l H-imidazole-1-ethanol 
hydrobromide (9)
Compound 7 was treated with aqueous HBr in acetone as described previously, 2  to 
give the hydrobromide 9 in 74% yield: mp 149-150.5°C (Lit.2(± )  150-151°C), 99.3% 
optically pure by HPLC (tr =  27.4 min.).
( S ) (  + )-a.-( 1 -AziridinylmethyI)-2-nitro-lH-imidazole-l-ethanol (8 )
This enantiomer was prepared exactly as described above from either (2RX —) 
epichlorohydrin or (2SX +  ) glycidyl tosylate to give 8 : mp 118.5-120°C. The NMR 
spectra was identical to that obtained for 7 at 60 MHz. Anal. Calcd. for C 8 H 1 2 N 4 0 3: 
C, 45.28; H, 5.66; N, 26.42%. Found: C, 45.53; H, 5.81; N, 26.26%.
[a ]s4 = +21.4°(c=0.98, CHC13).
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( S )-a -[[  (2-Bromoelhyl)amino]methylJ-2-nilro-1 H-imidazole-1 -ethanol (1 0 )
T h e  p r o d r u g  (10) w a s  p r e p a r e d  in  th e  sa m e  m a n n e r  a s  9  a n d  a s d e scr ib e d  p r e v io u s ly :2 
m p  1 4 8 -1 4 9 ° C (L it .2( ± )  1 5 0 -1 5 1  ° C ) ,97 .1  % o p tic a lly  p u re  b y  H P L C ( t r =  2 3 .0 5  m in .).
Biological Studies
In vitro e v a lu a tio n  o f  th e  c o m p o u n d s  a s  b io r e d u c t iv e ly -a c t iv a te d  c y t o t o x in s  a n d  a s  
r a d io se n s it iz e r s  w a s  ca rr ied  o u t  a s  d e scr ib e d  p r e v io u s ly  u s in g  V 7 9 -3 7 9 A  c e l l s .6 -7,8 
S e le c t iv e  to x ic ity  to  th e se  c e l ls  u n d e r  h y p o x ic  c o n d it io n s  w a s d e te r m in e d  u s in g  th e  
M T T  a s s a y .7 T h e se  re su lts  a r e  p r e se n te d  in  F ig u re  1. C y to to x ic ity  to w a r d s  c e l ls  is 
p r e se n te d  a s  a  red u c tio n  in  o p t ic a l  d e n s ity , w h ich  is  p r o p o r t io n a l  to  th e  n u m b e r  o f  
v ia b le  c e l ls  in  th is  a s sa y , p lo t t e d  a g a in s t  d r u g  c o n c e n tr a t io n . T h e  c o n c e n t r a t io n  
req u ired  t o  k ill 50 %  o f  th e  a e r o b ic  c e l ls  (C 50(air)) u n d e r  th e  c o n d it io n s  o f  th e  a s s a y ,  
d iv id e d  b y  th e  c o n c e n tr a t io n  req u ir e d  to  k ill h y p o x ic  c e l ls  (C 50( N 2)), w a s  th u s  2 0  fo r  
b o th  e n a n tio m e r s  7  a n d  8  a n d  fo r  th e  r a c em a te  2.
T h e se  c o m p o u n d s  w ere  a l s o  a s s a y e d  fo r  th eir  a b il ity  to  s e n s it iz e  h y p o x ic  V 7 9  c e l ls  
in vitro to  y -r a d ia t io n  (60C o )  c a r r ie d  o u t  a s  d e scr ib e d  p r e v io u s ly .8 T h e  s u r v iv in g  
fr a c t io n  o f  th e se  c e lls  is  p lo t te d  a s  a  fu n tio n  o f  d o s e  (G y ) fo r  v a r io u s  c o n c e n t r a t io n s  
o f  th e  d r u g s  a n d  c o m p a r e d  w ith  th e  e ffec ts  o f  r a d ia tio n  a lo n e  u n d er  h y p o x ic  c o n d i t io n s .  
E n h a n c e m e n t ra t io s  a re  th e n  d e te r m in e d  (ra tio  o f  su r v iv a l c u rv e  s lo p e , d r u g  tr e a te d  
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Figure 1 The in vitro cytotoxicity of compounds 2 (# ) , 7 (A) and 8 (■ ) under hypoxic (closed symbols) 
and aerobic (open symbols) conditions.
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Figure 2 Dependence of hypoxic radiosensitization of V79 cells in vitro on the concentration of 2 (Ok 
7 (A) and 8 (□).
was no difference in radiosensitizing efficiency between the two enantiomers 7 and 8 
and results for both compounds were comparable to those of the racemic drug.
CONCLUSIONS
Stereospecific synthesis of the R( + ) and S( —) enantiomers of the 2-nitroimidazole 
aziridine RSU-1069 (2) has been achieved by two different routes from stereoisomeric 
precursors. No racemisation occurs during these synthetic routes and ring-opened 
prodrug forms of the two aziridinyl compounds were greater than 97% enantiomerically 
pure by chiral HPLC analysis. The two enantiomers do not show any differences in 
their hypoxia-selective cytotoxicity in vitro, nor do they exhibit any significant 
differences in their radiosensitizing efficiencies. A similar lack of stereoselectivity in 
the pharmacokinetics and metabolism in vivo cannot be assumed, although this is 
the case with the related developmental hypoxic cell radiosensitizer pimonidazole 9 
Full studies in vivo using the prodrugs 9 and 10 are to be reported elsewhere.
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The reaction of l,l,l,5,5,5-hexafluoropentane-2,4-dione with 
hydrazines: a re-investigation
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Abstract
The reaction of l,l,l,5,5,5-hexafluoropentane-2,4-dione with hydrazine (N2H4) in boiling ethanol gives 3,5- 
bis(trifluoromethyl)pyrazole but reaction with N-aryl or A^-aroyl hydrazines gives the 1-aryl- or l-aroyl-3,5- 
bis(trifluoromethyI)-4,5-dihydro-5-hydroxypyrazoles, as shown by NM R and mass spectra, in contrast to a previous 
report.
Introduction
During a programme of synthesis of (trifluorome- 
thyl)heterocydes for medicinal and pH sensor appli­
cations [1], 3,5-bis(trifluoromethyl)pyrazole (4a) and its
1-substituted analogues were required. Preparation of 
the parent compound 4a has been reported to have 
been carried out by reaction of 1,1,1,5,5,5-hexafiuo- 
ropentane-2,4-dione (1) with hydrazine (2a) under var­
ious conditions [2-4] and by dipolar cycloaddition of
2-diazo-l,l,l-trifluoroethane with 3,3,3-trifluoropropyne 
[5]. Synthesis of 1 -aiyl and l-aroyl-3,5-bis(trifluoro- 
methyl)pyrazoles 4b-e has hitherto only been claimed 
by Claire et al. [2] by reaction of substituted hydrazines 
2b-e with diketone 1 in boiling ethanol. Since it is 
difficult to rationalise the spectroscopic data reported 
[2 ] with the aromatic pyrazole claimed, and in view of 
our observations [1 ] that treatment of heteroarylhy- 
drazines with l,l,l-trifluoropentane-2,4-dione some­
times affords only the partial condensation products,
i.e. the 5-hydroxy-4,5-dihydropyrazoles, a re-investiga­




( 1 ) with an equimolar amount of hydrazine hydrate in 
refluxing ethanol gave, as predicted, 3,5-bis(trifluoro- 
methyl)pyrazole (4a) as volatile white crystals with a 
distinctive odour. The ‘H NMR spectrum was consistent
•To whom all correspondence should be addressed.
with an aromatic pyrazole structure. The 4-H atom 
gives a resonance at 8 6.95, which is slightly broadened 
by coupling to 19F. Only one ,9F NMR signal was 
evident for 4a, owing to rapid site exchange of the NH 
proton. The electron-impact mass spectrum of this 
pyrazole showed an abundant molecular ion at mfz 204, 
with no evidence of ions at higher mass (e.g. mtz 218 
for the hydroxydihydropyrazole structure).
However, the *H NMR spectra of the heterocycles 
formed from 1  and the substituted hydrazines 2 b-e 
showed no signal in the region expected for the 4-H 
atom of an aromatic pyrazole ( 6  5 .8-512) [1,6 ]. Claire 
et al. [2] also report no signals in this region but claim 
that 4-H resonates at £~3.6; no integral or multiplicity 
data were given. The extensive study by Tensmeyer 
and Ainsworth [6 ] of substituent effects on the chemical 
shifts in pyrazoles does not support this assignment. 
In our work, the signals in the region 8 3-8  4 comprised 
two doublets, the integral of each doublet corresponding 
to one proton. The coupling constants between these 
doublets were >14 Hz, typical values for geminal 
coupling. Thus these signals can be assigned to a 
prochiral CH2  group in an asymmetric environment. 
Broad resonances due to OH were also observed. On 
the basis of these data, the hydroxydihydropyrazole 
structures 3b-e are proposed, rather than the pyrazoles 
4b-e claimed [2 ].
The electron-impact (El) mass spectra of the 5- 
hydroxydihydropyrazoles 3c-e at 70 eV ionisation energy 
revealed abundant molecular ions. The molecular ion 
of 3b was present in the El spectrum only at 1% 
abundance, but abundant ions were observed at mtz 
326 (M) in the chemical ionisation (Cl) spectrum and 
at mtz 327 (M + H) in the positive ion fast atom bom-
0022-1139/93/S6.00 © 1993 -  Elsevier Sequoia. All rights reserved








0 :  R = H C: R = 4-(N08)C6H4 6 :  R = QF}
b: R = PhCO d : R = 2.4-(NO,),C;H,
Scheme 1. Reaction of hydrazines with l,l,l,5,5,5-hexafluoropentane-2,4-dione in boiling ethanol.
bardment (FAB) spectrum. Dehydration was not fa­
voured (giving M-18) but loss of CF3 gave highly 
abundant peaks at (M -69) in all cases. The reported 
interpretation [2] of similar data, representing the ions 
at highest mass as molecular clusters of (pyrazole + 
H20), should be regarded as unlikely under El con­
ditions.
Experimental
lH NMR spectra were obtained at 270 MHz and 
400 MHz using JEOL GX270 and JEOL EX400 spec­
trometers, respectively (solvent, CDG3; internal stan­
dard, SiMe4). The 19F  NMR spectrum was obtained 
at 84.25 MHz using a JEOL FX90Q spectrometer 
(solvent, HzO/phosphate buffer pH 73; external stan­
dard, NaPF6 in phosphate buffer pH 73). Low-resolution 
El, Cl (isobutane) and FAB and high-resolution El 
mass spectra were furnished by a VG 7070 spectrometer, 
whereas a ZAB-E instrument gave the high-resolution 
FAB spectrum. Solvents were evaporated under reduced 
pressure, except where noted.
3,5-Bis(trifiuoromethyl)pyrazole (4a)
l,l,1333-Hexafluoropentane-2,4-dione (1) (4.16 g, 
20 mmol) was added to hydrazine hydrate (2a) (1.2 g, 
24 mmol) in ethanol (50 ml). The mixture was boiled 
under reflux for 18 h and allowed to cool. The solvent 
was distilled off carefully at atmospheric pressure. The 
residue was distilled at atmospheric pressure. The dis­
tillate, in dichloromethane, was dried (anhydrous 
MgS04) and filtered and the solvent evaporated to give 
4a (1.04 g, 25%) as white crystals, m.p. 69-70 °C (lit.
[2] m.p. 71-72 °C). ’H NMR (270 MHz) 5: 6.95 (br 
s, 1H, 4-H); 11.97 (br, 1H, NH) ppm. 19F NMR 8: 




l,l,1333-Hexafluoropentane-2,4-dione (1) (300 mg,
1.44 mmol) was added to benzoyl hydrazide (2b) (136 
mg, 1 mmol) in ethanol (50 ml). 7116 mixture was boiled 
under reflux for 5 h and allowed to cool. The solvent 
was evaporated to give 3b (315 mg, 96%) as a white 
solid, m.p. 82-84 °C (lit. [2] m.p. 84-85 °C claimed for 
pyrazole 4b). ’H NMR (270 MHz) 8: 3.38 (d septet, 
1H, 7H-h = 1 9 3  H z, 13 Hz, pyrazole 4-H); 3.56 
(br d, 1H, 7h-h = 193 Hz, pyrazole 4-H); 6.43 (br s, 
1H, OH); 7.47 (c. t, 2H, 7 = 7 3  Hz, Ar 33-H2); 7.59 
(tt, 1H, 7=7.5 Hz, 7= 13 Hz, Ar 4-H); 7.86 (c. d, 2H, 
7 = 7 3  Hz, Ar 2,6-H2) ppm. MS (El) mlz: 326 (M, 1%); 
105 (PhCO, 100%). MS (Cl) mtz: 326 (M). MS (FAB; 




The dione 1 (300 mg, 1.44 mmol) was added to 4- 
nitrophenylhydrazine (2c) (200 mg, 1.3 mmol) in ethanol 
(50 ml). The mixture was boiled under reflux for 3 h 
and allowed to cool. The solvent was evaporated to 
give 3c (410 mg, 92%) as a yellow solid, m.p. 105-106 
°C (lit. [2] m.p. 105-108 °C claimed for pyrazole 4c). 
JH NMR (270 MHz) 8: 3.42 (d septet, 1H, 7„_„= 19.6 
Hz, 7„_F= 13 Hz, pyrazole 4-H); 3.74 (br d, 1H, 7„_„ =
19.6 Hz, pyrazole 4-H); 5.75 (br, 1H, OH); 7.60 (d, 
2H, 7=9.4 Hz, Ar 2,6-H2); 8.12 (d, 2H, 7=9.4 Hz, Ar 
33-H2) ppm. MS (El) mlz: 343 (M); 274 (100%); 228. 
Analysis: Found: C, 38.70; H, 2.03; N, 12.50%. 
Cn H7F6N30 3 requires: C, 38.48; H, 2.06; N, 12.25%.
3.5-Bis(trifluoromethyl)-4,5-dihydro-1-(2,4-dinitrophenyl) - 
5-hydroxypyrazole (3d)
The dione 1 (208 mg, 1.0 mmol) was added to 2,4- 
dinitrophenylhydrazine (2d) (260 mg, 1.3 mmol) in 
ethanol (60 ml). The mixture was boiled under reflux 
for 5 h and allowed to cool. Evaporation of the solvent 
gave a gum which was extracted with methanol. Evap­
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oration of the methanol gave 3d (300 mg, 77%) as a 
viscous orange oil which crystallised on standing to an 
orange-yellow solid, m.p. 81-83 °C (lit- [2] m.p. 82-83 
°C claimed for pyrazole 4d) *H NMR (400 MHz) 8:
3.06 (d, 1H, 7 =  14.6 Hz, pyrazole 4-H); 3.18 (d, 1H, 
7= 14.6 Hz, pyrazole 4-H); 5.1 (br, 1H, OH); 8.04 (d, 
1H, 7=9.5 Hz, Ar 6-H); 8.40 (dd, 1H, 7=9.5 Hz, 7=2.4 
Hz, Ar 5-H); 9.14 (d, 1H, 7=2.4 Hz, Ar-3-H) ppm. 
MS, (El) mlz: 388.0179 (M) ( C ^ H ^ R A  requires: 




The dione 1 (300 mg, 1.44 mmol) was added to 
pentafluorophenylhydrazine (2e) (198 mg, 1.0 mmol) 
in ethanol (50 ml). The mixture was boiled under reflux 
for 5 h and allowed to cool. The solvent was evaporated 
to give 3e (355 mg, 91%) as colourless prisms, m.p. 
61-62 °C (lit. [2] m.p. 60-62 °C claimed for pyrazole 
4e). *H NMR (400 MHz) 8: 332 (br d, 1H, 7=18.9 
Hz, pyrazole 4-H); 3.59 (dq, 1H,7„.„ = 18.9 Hz,7„_F= 1.5 
Hz, pyrazole 4-H); 6.13 (br s, 1H, OH) ppm. MS (El) 
mlz: 388.0099 (M) (Q ,H 3Fn N20  requires: 388.0070); 
319 (100%); 299.
Conclusions
Whereas condensation of hydrazine (2a) with
l,l,1333-hexafluoropentane-2,4-dione (1) in boiling 
ethanol gives the aromatic pyrazole 4a, treatment of
this dione with more hindered and less nucleophilic 
aryl- and acyl-hydrazines gives only the partial con­
densation products, the 4,5-dihydro-5-hydroxypyrazoles 
3b-e. A previous report [2] of the formation of the 1- 
substituted pyrazoles 4b-e must be regarded as erro­
neous. The conditions required to effect the dehydration 
3b-e-»4b-e are under investigation.
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THE LANCET
Poly(ADP-ribosylation) as target for 
cancer chemotherapy
T h e enzym e poly(ADP-ribose) polymerase (ADPRP), 
which is abundant in all cell nuclei, is an important 
regulatory enzym e. Stimulated by D N A  strand breaks it 
links poly(A D P-ribose) chains to nuclear proteins, and to 
D N A  repair enzym es including A D P R P  itself. Inhibition 
o f  this enzym e im pedes D N A  repair and probably 
interferes w ith  the vital processes o f  differentiation, gene 
expression, D N A  replication, and genetic recombination.1-2 
T h e high levels o f  A D P R P  observed in certain tumour cells 
suggest th is enzym e as a target for chemotherapy,3 and it 
has been argued that inhibition o f  A D P R P  could have a role 
in the treatment o f  retroviral infection by affecting 
processes such as integration o f  viral sequences into D N A  
and reverse transcription.4 H ow ever, the main focus o f  
interest in A D P R P  inhibitors has been in exploiting their 
ability to  inhib it D N A  repair, in combination with D N A -  
damaging treatments such as radiotherapy and alkylating 
agents.
Early attem pts focused on analogues o f  N A D  + , from  
which the p oly  (A D  P-ribose) derives. M olecular mimics o f  
adenosine w ould  not be much use because they would also 
bind to A D P  and A T P  requiring enzymes. However, 
nicotinamide m im ics should show  selectivity, and
3-am inobenzam ide (3-AB) was identified in 1980 as an 
A D PR P inhibitor5 and became a standard laboratory tool 
for inhibition o f  D N A  repair. Inhibition o f  A DPRP m ight
also exert a more direct antitumour effect. For example, 
some inhibitors (1,2-benzopyrone [coumarin], benzamide, 
hexamethylene bisacetamide) inhibit ray-activated cells in 
vitro and suppress their tumorigenicity in vivo.6 T h ese  
agents seem to bind to the D N A  interactive site on the 
enzyme.
Modulation or inhibition o f  D N A  repair may explain the 
efficacy o f drugs used in combination with dsp latin , 
including 5-fluorouradl, cytarabine, and hydroxyurea.7 
Refinement o f  the structural requirements for potent 
inhibition of A D PR P opens up the realistic prospect o f  
clinically useful chemosensitising or radiosensitising drugs 
acting via inhibition o f  D N A  repair.*-9 Hitherto, the 
chemists’ approach has been limited to substrate analogues 
acting as competitive inhibitors; now effort should be 
directed towards the design o f  more potent agents, 
induding the so-called “ su id d e” (irreversible) inhibitors. 
Selectivity for target should be feasible too for we already 
know that several A D P R P  inhibitors are orders o f  
magnitude less inhibitory towards the m ono(A D P- 
ribosyl)ation involved in the control o f other enzym es.9 
Whether such drugs will display selectivity for cancer cells 
is less certain, but one approach to increase selectivity is to 
exploit the lower oxygen concentration in the core o f  solid  
tumours by designing pro-drugs which will be 
metabolically activated to inhibitors o f  A DPRP in th is 
environment. Prospects for enhancing the efficacy o f  
chemotherapy and radiotherapy via inhibition o f  A D P R P , 
and hence D N A  repair, look excellent but much remains to 
be done.
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Tumour-targetted Boranes. Part 2.1 Coupling of c/oso-Carboranes to Substituted  
2-Nitroimidazoles via 1,3-Dipolar Cycloaddition
Martin Scobie.*  Mary F. M ah on 6 and Michael D. Threadgill*
* School o f Pharmacy & Pharmacology. University of Bath. Claverton Down. Bath BA2 7A Y. UK 
b School of Chemistry. University of Bath. Claverton Down. Bath BA2 7A Y. UK
Carboranes targetted to specific tumour tissues are important for boron neutron capture therapy of 
cancer. Direct syntheses of carboranes linked to 2-nitroimidazole were unsuccessful. A mild 
procedure for 1.3-dipolar cycloaddition of 4-(carboranylmethoxy)benzonitrile /V-oxide 32 with a 
nitroimidazolyl-alkene 27 and with nitroimidazolyl-alkynes 3 and 30 has been developed, using a 
series of model reactions, yielding a dihydroisoxazole 28 and the isoxazoles 29 and 31. respectively. 
The nitrile oxide 32 is unusually stable. Dithioacetals are show n to be suitable protecting groups for 
aromatic aldehydes under the vigorous reductive and Lewis acidic-basic conditions of carborane 
formation. 6-Methoxy-4/Y-[1 ]benzopyrano[4.3-c]isoxazole 16 has been synthesised by intra­
molecular 1.3-dipolar cycloaddition. The structure of the isoxazole derivative 29 has been confirmed 
by an X-ray crystal structure analysis.
Boron neutron capture therapy (BNCT) is o f  increasing interest 
as a strategy for treatment of various cancers, notably gliomas 
and m elanom as.2 When the 10B isotope is irradiated with slow 
(‘thermal’) neutrons, an [n.a] reaction ensues, giving mainly 7Li 
and *He nuclei, along with kinetic energy (2.31 MeV). With this 
energy, the *He has a range o f ca. 9 pm in tissue (ca. 1 cell 
diam.). Thus, damage is limited to the cell containing the boron 
and to adjacent cells. Early studies o f  BNCT gave mixed 
results.3 Failures were attributed to inadequate concentrations 
o f 10B in the tumour tissue or to lack o f  selectivity o f disposition 
o f 10B, leading to damage to normal tissue. Recently, 
carboranes have been linked to nucleosides,4 to amino acids5 
and to porphyrins6 in attempts to target boron to tumours.
1-Substituted 2-nitroimidazoles are known to be selectively 
retained in poorly vascularised hypoxic tumour tissue by 
reductive metabolism to electrophiles.7 As part o f  a programme 
o f synthesis and evaluation of nitroimidazoles in the treatment 
o f cancer,1-8' 10, we propose that compounds containing 10-12 
boron atom s linked to 2-nitroimidazole would form a useful 
method o f  concentrating boron in solid tumours. Derivatives 
o f l,2-dicarba-c/oso-dodecaborane(12)11 (‘carborane’, I, Fig. 
1) were selected for linkage to 2-nitroimidazole in view of 
their good chemical stability relative to other boron clusters and 
their predicted metabolic inertness. Before our preliminary 
com m unication,1 no report of nitroimidazoles bearing boron 
had been made in the journal literature.
In most cases, carboranes are readily formed 11 by reaction of 
alkynes and decaborane( 14) (B ,0H ,4) in the presence o f boiling 
Lewis bases for long reaction times. Consequently, the nitro- 
imidazolylalkyne 3 was prepared by alkylation o f 2-nitroim- 
idazoie 2 with but-3-ynyl tosylate. However, treatment of 3 with 
decaborane( 14) under the standard reaction conditions (accto- 
nitrile, heat) gave only an inseparable mixture o f materials 
probably arising from reduction o f the nitroimidazolc. Such 
reduction is unsurprising, smce simple and complex boranes are 
widely used as reducing agents but 1-substituted 2-nitroimi­
dazoles are themselves known to be readily reduced (£%  = 
-  389 m V )10 Thus, the carborane must be formed before the 
nitroimidazolc is introduced into the molecule.
2-Nitroimidazolc reacts under basic conditions with oxiranes 
to give substituted nitroimidazolylcthanols8 and the anion of 2 
can be a lkylated10 at elevated temperatures (>  130°C) by a 
variety o f  halogenoalkancs and alkyl tosylates. Carboranes 
bearing both types of clectrophilc were assembled for invcstig-
r = \
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Scheme I Syntheses o f substituted nitroimidazole 3 and substituted 
carboranes 4. 5 and 8. precursors for attempts at 'direct' routes to 
nitroimidazole-carboranes: i. H C sC C H .C H .O T s-K O B u1: ii. BuLi: iii. 
epichlorohydrin: iv. N aH -H C sC C H  ,Br: \ .  B |0H U McCN
CH
BH
Fig. I Representations o f the structure o f  
borane(!2) (‘carborane ) 1
ation o f their reaction with 2. Treatment o f phenylcthync with 
dccaborane(I4) gave the known 11 monosubstilutcd carborane 
4 and treatment o f  the corresponding anion with epichloro- 
hydrin gave the carboranylmethyloxiranc 5 in good yield. 1 he
1.2-dicarba-t7//.r<7-dodcca-
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chloro alcohol 6 was alkylated using the reactive electrophilc 
prop-2*ynyl bromide, giving the chloroalkyne 7. The cor­
responding carborane 8 was formed in satisfactory yield. 
Neither 5 nor 8 reacted with 2-nitroimidazole. Similarly, the 
lithio derivative o f 4 did not react with 2-nitro-l-(oxiranyl- 
methyl)imidazolc.8
Clearly, the conditions required for the formation o f  nitro- 
imidazolylcarboranes by these ‘direct’ methods were too harsh 
to permit the co-existence o f the nitroimidazole and the 
carborane. 1,3-Dipolar cycloadditions of nitrile oxides with 
alkenes and alkynes proceed 12 under mild conditions; this 
method o f  carbon-carbon bond formation was investigated as 
a route to the target compounds. Nitrile oxides are most 
conveniently formed by oxidation o f the corresponding 
aldoximes. The series o f  model reactions shown in Schemes 2 
and 3 were studied to check the compatibility o f  these oxidative 
conditions (aqueous sodium hypochlorite) with carboranes and 
the stability o f  the precursor oximes and synthons thereof to 
decaborane(14). Treatment o f 3,4,5-trimethoxybenzaldehyde 
oxime 9 with aqueous sodium hypochlorite gave the nitrile 
oxide which reacted in situ with alkenylcarborane 10 (prepared 
by alkylation o f  the anion o f 4) to give the dihydroisoxazole 11. 
Thus, the stability o f carboranes to sodium hypochlorite is 
demonstrated.
To study the effects o f  the carborane formation conditions on 
aldehyde and oxime groups and their synthetic equivalents,
3-methoxy-2-prop-2-ynyloxybenzaldehyde 12 was converted 
into its oxime 14, as shown in Scheme 3. However, both 
aldehyde and oxime functions were found to be degraded by 
decaborane(14), preventing the synthesis o f  the model car-
boranyl aldehyde 13 and the model carboranyl oxime 15 by 
these direct routes. Interestingly, the intramolecular 1,3-dipolar 
cycloaddition o f  the nitrile oxide derived from 14 was successful 
in giving the 4//-[l]bcnzopyrano[4,3-c]isoxazolc 16. The yield 
was modest, presumably owing to the usually unfavourable 






  4 R = H
 10 R = (CH2)«CH = C H 2
OMe
9




Scheme 2 Model reactions to demonstrate the compatibility of 
carborane with the conditions required for 1.3-dipolar cvdoaddition 
i. BuLi: ii, HjC=CH(CH2)*Br: 111. NaOCl-HjO-CHjCl,
■ B 1 0 H 1 0
Scheme 3 Model reactions to investigate the stability of aldehydes and their protected forms to B10H ,a and svnthests of 
methoxybenzopyranoisoxazole 16: i. B10H ,,-M eC N : ii. HOCH,CH,OH-TsOH: iii. HONH,-HC! Na.CO,: iv. H SCH,CH,SH-BF,-EtjO: 
v. NaOCl
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o f the nitrile oxide; this heterocyclic system has hitherto been 
reported only once.13 The cyclic acetal 17, formed from 12 by 
treatment with ethane-1,2-diol under acidic conditions, was 
also not stable to decaborane(14). Protection o f  the aldehyde as 
the cyclic dithioacetal 19 by Lewis acid-catalysed reaction with 
ethane-1,2-dithiol was, however, effective in permitting the 
synthesis o f  the carborane 20. Hence, aldehydes can be 
protected as dithioacetals during formation o f carboranes. 
Assembly o f nitroimidazolylcarboranes was, therefore, expected 
to be feasible by a route involving an appropriate 1,3-dipolar 
cycloaddition.
To provide the central framework to support carborane and 
oxime groups, 4-hydroxybenzaldehyde 21 was prop-2-ynylated 
by the method o f Matolcsy et a /.,14 giving the alkynealdehyde 
22 (Scheme 4). Protection o f the aldehyde as the cyclic dithio-
a x - a x
21 22
B10H,0
24 R = S(CH2)2S C H -
. p - OHCC«H4 
26 HON = CH —
Scheme 4 Synthesis of the carborane-aldoxime 26, a precursor of a 
carborane-nitrile oxide: i, NaH-HCsCCH2Br; ii, HSCH2CH2SH- 
BFj-EtjO; iii. B)0HI4-MeCN; iv, Hg(C10j2; v. HONH2-HCI- 
Na2C 03
acetal 23 was achieved in 80% yield. As predicted by the model 
experiments, this protecting group resisted prolonged treat­
ment with decarborane(14) in boiling acetonitrile, which 
furnished the carborane 24. Deprotection was effected 
virtually quantitatively within 5 min using mercury(n) 
perchlorate to give the carboranyl aldehyde 25 which was 
converted into the carboranyl oxime 26. This oxime 
represents the precursor to the nitrile oxide 32 for 1,3-dipolar 
cycloaddition with the range of nitroimidazolyl-alkenes and 
-alkynes (Scheme 5). The polyether-linked nitroimidazole 30 
was synthesised by reaction of the potassium salt of 2- 
nitroimidazole with the alkyne 7 under the usual vigorous 
conditions required fof alkylation o f this weak nucleophile 
(dimethylformamide, !30°C).
Oxidation/elimination o f  the carboranyl oxime 26 using 
aqueous sodium hypochlorite to give the intermediate nitrile 
oxide 32 was very rapid as shown by TLC but prolonged 
reaction times at ambient temperature were required for 
cycloaddition in siiu with nitroimidazolylalkenc 27'° and 
nitroimidazolylalkynes 3 and 30. The dihydroisoxazolc-linkcd 
compound 28 and the isoxazole-linked compounds 29 and 31, 
respectively, in which both 2-nitroimidazole and carborane 
moieties are present, were formed in excellent yields based on 
consumption o f starting materials (Scheme 5).
HOv 
H '  "Ar
'N
» A 28

















Scheme 5 Dipolar cycloaddition reactions of carborane-nitrile oxide 
3 2  and synthesis of nitroimidazole-carboranes 28. 2 9  and 31. i. NaOCl; 
ii, l-hex-5-enyl-2-nitroimidazole 27; iii. nitroimidazole-alkyne 3: iv. 
KOBu'-alkyne 7; v, nitroimidazole-alkyne 30; vi, toluene, reflux
In each case, even after reaction for several days, no boron- 
containing compounds other than 26. 28. 29, 31 and 32 were 
evident in the reaction mixtures and it was possible to isolate 
the unchanged nitrile oxide 32 by chromatography. This nitrile 
oxide is remarkably stable, with little decomposition on storage 
for several weeks at ambient temperature. In contrast, the half- 
life of most aromatic nitrile oxides is reported 12 to be only a few 
hours. It did not react with cyclohexene. a weak dipolaro- 
phile,12 at reflux temperature and was converted into its dimer, 
the 1.2.5-oxadiazole 2-oxide 33. only when heated in boiling 
toluene.
Additional evidence for the structure o f target com pound 29 
was provided by a determination o f the crystal structure by X- 
ray diffraction methods. Recrvstallisation o f a sample o f  
compound 29 from benzene afforded a crystal which was not o f  
high quality but which diffracted strongly and was. therefore, 
adequate for this determination. Other solvents gave only 
microcrystalline material. The crystal had approximate dim en­
sions 0.4 x 0.4 x 0.2 mm.
Crystal Dat a. — M  = 495.5. tn- 
clinic. a = 7.320(2). h = 11.275(3). r = 16.359(4) A.  x = 
94.86(4). ft =92.83(3). y = 100.78(4). U = 1318.6 A \  space 
group P\ ,  7. =  2. Dc = 1.25 g cm \  /((M o-K,) = 0.47 cm '. 
/^OOO) = 514. Data were measured at ambient temperature on 
a Hilger and Watts Y290 four-circle diffractometer in the range 
2 $  0 ^ 22°. 3444 Reflections were collected, o f  which 1430 
were unique with / ^  3a(/). Data were corrected for Lorcnt/ 
and polarisation effects but not for absorption. The structure
O -N
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was solved by direct methods and was refined using the 
SH E L X 15 suite o f  programmes. In the final least-squares 
cycles, all the atoms were allowed to vibrate anisotropically. 
The half portion o f benzene solvent molecule which 
accompanies the structure is proximate to a centre of symmetry. 
This generates the remaining atoms to complete the benzene 
ring. Hydrogen atoms were included at calculated positions 
where appropriate, except in the solvent species. In the later 
stages o f  refinement, the molecule and associated solvent of 
recrystallisation were treated as separate blocks. Final residuals 
after eight cycles o f least squares were R =  /?„ =  0.1218. 
Maximum final shift/esd was 0.009. The maximum and mini­
mum residual densities were 0.12 and -0 .1 0  eA \  respectively.
Table I gives selected bond lengths. Table 2 gives selected 
bond angles and Table 3 gives selected torsion angles for the 
structure o f  the substituted nitroimidazoiyl-carborane 29. Full 
tables o f  final fractional coordinates and isothermal parameters, 
bond distances, bond angles, torsion angles and anisotropic







0(1>-N(3) 1.20(3) 0(2)-N(3) 1.24(2)
<X3)-N(4) 148(2) 0(3)-C(6) 129(2)
0(4)-C(12) 1.42(2) CX4)-C(15) 1.35(3)
N(3)-C(l) 1.42(2) N(l)-C(l) 1.38(2)
N(2)-C(l) 1.30(3) N(l)-C(3) 1.28(2)
N(2)-C(2) 1.37(2) C(2)-C(3) 1.44(3)
C( 15)—C( 16) 1.63(3) C( 16)—C( 17) 1.61(3)
C( 16)-B( 1) 172(3) C(I6)-B(2) 1.51(3)
C(16)-B(3) 1.62(3) C( 16)—B(4) 1-73(3)
C(17)-B(l) 1.67(3) C(17)-B(2) 167(3)
C( 17)-B(5) 1.66(3) C(17)-B<6) 1.66(3)
B( 1 >-B(4) 1.85(3) B(l)-B(5) 1.80(3)
B(l)-B(9) 185(4) B(2)-B(3) 175(3)
B(2)-B(6) 1.81(3) B(2)-B(7) 1.79(4)
B(3)-B(4) 1.61(3) B(3)-B(7) 185(3)
B(3>-B(8) 1.78(3) B(4)-B(8) 166(4)
B(4)-B(9) 1-85(3) B(5>-B(6) 1.59(4)
B(5)-B(9) 1.72(3) B(5)-BO0) 165(4)
B(6)-B(7) 1.91(4) B(6>-B(10) 1.69(4)
B(7)-B(8) 1.86(3) B(7)-B(10 1.95(3)
B(8)-B(9) 1.63(4) B(8)—B( 10) 1.66(3)
B(9)-B(10) 1.57(3)
Table 2 Selected bond angles for the crystal structure of the 
nitroimidazole-carborane 29
Bond Bond
Atoms angle (°) Atoms angle (°)
N(3)-C(l)-N(l) 123(2) N(3)-C(l)-N(2) 125(2)
N( 1 >-C(l)-N(2) 112(1) C(l)-N(3)-0(l) 121(2)
C( 1 )-N(3>-0(2) 114(2) CKD-N(3>-0(2) 124(2)
C( 1 )-N( 1)—C(4) 129(1) C(3)-N(l)-C(4) 124(1)
C(5)-C(4)-N(l) 107(1) C(4) C(5)-C(6) 105(1)
C(5)-C(6)-0(3) 06(1) C(5)-C(6)-C(7) 130(1)
C(8)-C(9)-C(10) 117(1) C00)-C(9)-C(14) 122(2)
C(11)—C( 12)—C( 13) 126(2) 0(4)-C(15>-C(I6) 111(1)
C(I5)-C(16)-C(17) 113(2) C(15V-C06)-B0) 111(1)
C(15)-C(16)-B(2) 117(1) C(15hC(l6>-B(3) 122(1)
C(15)-C(I6)-B(4) 122(1)
Fig. 2 Asymmetric unit of the crystal structure of the nitroimidazole- 
carborane 29 with the labelling scheme used for the crystallographic 
structure determination
temperature factors have been deposited with the Cambridge 
Crystallographic Data Centre.* The asymmetric unit is shown 
in Fig. 2, along with the labelling scheme used. In the crystal, 
the compound adopts an extended conformation, with torsion 
angles of the two flexible units linking the nitroiraidazole to the 
isoxazole and the benzene to the carborane [N (l)-C (4 )-C (5)-  
C(6) and C(12)-0(4)-C(15>-C(l6), respectively] being close to 
180°. The tilt angle between the two adjacent aromatic rings, 
the benzene and the isoxazole, is 11.4°, Le. the two rings diverge 
only slightly from coplanarity. The carborane forms a slightly 
distorted icosahedron, as reported by the bond lengths and 
bond angles to C( 16) and C(17). Hence, this carborane 
corresponds to the usual icosahedral shape for such C 2B 10 
structures (e.g. ref. 16), rather than the ‘basket handle" structure 
proposed by Zakharkin et  al . 1'
The oxidising character o f 2-nitroimidazoles and the 
potential reductant activity o f boron hydrides preclude the 
formation o f  linked nitroimidazolyl-carboranes by the vigorous 
conditions required for ‘direct" methods, such as treatment o f a 
nitroimidazolyl-alkyne with decaborane(I4) or alkvlation of 
the anion o f  2-nitroimidazole with electrophiles linked to 
carboranes. Model reactions have demonstrated that both
2-nitroimidazole and carborane moieties are stable to the 
conditions o f the generation o f nitrile oxides and their 1.3- 
dipolar cycloaddition to alkenes and alkynes. These model 
studies have also shown the utility and importance ol 
dithioacetal protection for aromatic aldehydes under the 
conditions o f formation of carboranes. On the basis o f  these 
studies, the unusually stable carboranylmethoxyphcnyl nitrile
* For details see Insiructions for Authors. J. Chem. Sot . Perkin 
Tram. I. 1994. Issue 1
Table 3 Selected torsion angles for the crystal structure of nitroimidazole-carborane 29
Atoms Torsion angle (°) Atoms Torsion angle (°)
0 ( I )-N(3)-C( I )-N( I) 10.5
N(4)-C(8)-C(9) C( 14) 114
N( I) -C(4)-C(5)-C(6) 174.9
CO2) 0(4) C(l5) C( 16) 171.4
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oxide 32 was synthesised and was shown to react efficiently with 
nitroimidazolyl-alkenes and -alkynes to give the required 
linked nitroimidazoie-carboranes 28,29 and 31.
1,3-Dipolar cycloaddition of nitrile oxides is, therefore, 
demonstrated to be a mild process which has great potential in 
medicinal chemistry for joining chemically sensitive targeting 
moieties to pharmacophores. A new carbon-carbon bond is 
formed and the linking (dihydro)isoxazole gives opportunity 
for further elaboration. Unfortunately, the target compounds 
28,29 and 31 were found to be insufficiently soluble in water to 
permit satisfactory biological evaluation. The contruction of 
alternative, more polar links between nitroimidazole and 
carborane is under active investigation.
Experimental
JEOL GX270 and EX400 instruments furnished the NMR 
spectra. CDC13 was the solvent for NMR spectroscopy unless 
otherwise noted. The external reference for 11B NMR was 
boron trifluoride-diethyl ether complex. 7 Values are recorded 
in Hz. Solutions in organic solvents were dried with anhydrous 
magnesium sulfate. Solvents were evaporated under reduced 
pressure. The chromatographic stationary phase was silica gel. 
Distillation was carried out using a Buchi Kugelrohr apparatus; 
b.p.s refer to the temperature of the oven. l-(Hex-5-enyl)-
2-nitroimidazole 27 was prepared as described previously by 
us.10 DMF refers to dimethylformamide; THF refers to 
tetrahydrofuran. M.p.s are uncorrected.
1 -But-3-ynyl-2-nitroimidazole 3.—2-Nitroimidazole 2 (340 
mg, 3 mmol) in dry DMF (10 cm3) was treated with potassium 
/er/-butoxide (340 mg, 3 mmol) at 130 °C until it dissolved and 
then for a further 10 min. The mixture was cooled to 80 °C, but-
3-ynyl-4-methyIbenzenesulfonate18 (670 mg, 3 mmol) and 
sodium iodide (10 mg) were added to it and the whole heated at 
130 eC for 10 min. Evaporation of the solvent from the mixture 
left a residue which was dissolved in water (S cm3) and the 
solution was filtered and extracted with chloroform. The extract 
was evaporated to give a yellow semi-solid which was recrystal- 
lised from pentane-benzene (CAUTION) to afford the title 
compound 3 (290 mg, 59%) as pale yellow crystals, m.p. 
71-72 °C (Found: C, 50.8; H, 4.2; N, 25.8. C7H7N30 2 requires 
C, 50.9; H, 4.25; N, 25.45%); S 2.08 (1 H, t, J  2.5, C=CH), 2.81 
(2 H, dt, J  2.5 and 6.4, CH2CsC), 4.58 (2 H, t, J  6.4, imidazole- 
CH2) and 7.17 (1 H, br s) and 7.24 (1 H, br s) (imidazole 4,5-H).
[(2 -Phenyl-1,2-dicarba<\oso-dodecaboran( 12)-1 -yl )methyl']- 
oxirane 5.—Butyllithium (1.6 mol dm-3 in hexanes; 3.1 cm3, 5 
mmol) was added to 1-phenyl-1,2-dicarba-c/oso-dodecabor- 
ane(12) 4‘1 (880 mg, 4 mmol) in dry THF (20 cm3) at — 78 °C. 
The mixture was stirred at — 78 °C for 30 min after which 
chloromethyloxirane (460 mg, 5 mmol) was added to it. The 
mixture was then allowed to warm to 20 °C during 16 h after 
which it was partitioned between water and dichloromethane. 
The organic phase was separated and evaporated and the 
residue was chromatographed (pentane-dichioromethane, 1:1) 
to give the title compound5 (850 mg, 62%) as a white solid, m.p. 
63-65 °C (Found: C, 47.7; H, 7.35. CmH20BioO requires C, 
47.8; H, 7 .3% );1.7-3.1 (10H.brm,B10HI0), 1-90(1 H,dd,7 
15.4 and 5.9) and 2.08 (1 H, dd. J  15.4 and 6.1) (carborane- 
CH2). 2.17(1 H,dd. 74.9 and 2.4) and 2.71 (1 H,dd, 74.6 and 
4.1) (oxirane 2-H2), 2.97 (1 H, m. oxirane 1-H) and 7.45-7.65 (5 
H, m. Ph-Hs);5# -  15.5 to -12.5 (8 B, br) and -7.04 (2 B, d. 
7bh 150).
3-{2-[2-(2-Chloroetho.xy)eihoxv']ethoxy}prop-2-yne 7.—2-
[2-(2-Chloroethoxy)ethoxy]ethanol 6 (6.74 g, 40 mmol) was 
added to sodium hydride (oil-free; 960 mg. 40 mmol) in dry
THF (50 cm3) at -20°C. After 15 min at — 78 °C, 3- 
bromopropyne (4.76 g, 40 mmol) was added to the mixture 
which was then boiled under reflux for I h. The mixture was 
evaporated and the residue was treated with water (50 cm3) and 
extracted with dichloromethane. The extract was dried and 
evaporated and the residue was distilled to give the title 
compound 7 (5.83 g, 71%) as a colourless oil, b.p. 160 °C at 0.1 
mmHg; f j a n ' 1 2120w; <5 2.44(1 H, t, 7 2.4, CeCH), 3.6-3.8 
(12 H, m, 5 x OCH2 + C1CH2) and 4.21 (2 H, d, 7 2.4, 
CH2CaC); m/z (Cl) 207.0788 (M + H) (C,H1635C103 requires 
207.0788).
1 -({2-{2-(2-Chloroethoxy)ethoxy "]ethoxy}methyl)-1,2-di- 
carba-doso-dodecaborane( 12) 8.—Decaborane(14) (B10H14.) 
(1.22 g, 10 mmol) was stirred with acetonitrile (20 cm3) for 3 h 
before addition of the alkyne 7 (2.07 g, 10 mmol). The mixture 
was boiled under reflux for 3 d and then evaporated. Chro­
matography (pentane-dichioromethane 1:1) of the residue 
gave the title compound 8 (2.10 g, 65%) as a pale yellow oil; 
vnoJaa~1 2590;<51.3-3.1 (10 H, br m, Bl0Hl0), 3.6-3.8 (12 H, 
m, 5 x OCH2 + C1CH2), 3.96 (2 H, s, carborane-CH2), and
4.07 (1 H, br s, carborane 2-H); m/z (Cl) 10B/UB 35C1/37C1 
cluster centred at 326 (M); m/z (FAB, positive ion) 325.2587 
(M + H)(C9H2610B2IlB835ClO3 requires 325.2574).
2-Hex-5-enyl-1 -phenyl-1,2-dicarba<loso-dodecaborane{ 12)
10.—Butyllithium (1.6 mol dm'3 in hexanes; 2.76 cm3, 4.4 
mmol) was added to I -phenyl- 1,2-dicarba-c/oso-dodecabor- 
ane(12) 412 (720 mg, 3.3 mmol) in dry THF (10 cm3) under 
nitrogen and the mixture was stirred for 30 min. l-Bromohex-5- 
ene (720 mg, 4.4 mmol) was added to the mixture which was 
then stirred for 18 h. It was then washed with water and 
extracted with diethyl ether. The extract was evaporated and 
the residue chromatographed (pentane) to give the title
compound 10 (800 mg, 81%) as a colourless oil; v /cm'1 3080,
2580 and 1640; S 1.08 (2 H, quintet, 7 7.3, CH2C//2CH2),
1.2-3.3(10 H,brm,B10H10), 1.34(2H,m,CH2Ctf2CH2), 1.68 
(2 H, m, CH2C//2CH2), 1.80 (2 H, qt, 77.5 and 1, CH2OC),
4.81 (2 H, m, C=CH2), 5.55 (1 H, m, OCH) and 7.25-7.57 (5 H, 
m, Ph-H5); m/z (El) 303.3010 (M) (C,*H2610BllB9 requires 
303.3001), 302.3014 (M) (C,*H26I0B2n B8 requires 302.3034); 
m/z  (Cl) l0B/“ B cluster centred at 605 (2M + H), 10B/UB 
cluster centred at 302 (M).
4,5-Dihydro-4-[4-(2-phenyl-1,2-dicarba-c\oso-dodecaboran- 
(12)-\-yl)butyl~\-3-(3A5-trimethoxyphenyl)isoxazole 11.—3.-
4.5-Trimethoxybenzaldehyde oxime 9 19 (210 mg, 1 mmol) and 
the carborane 10 (300 mg. 1 mmol) in dichloromethane (20 
cm3) were stirred vigorously with aqueous sodium hypochlorite 
(8% available chlorine; 1.5 cm3) for 16 h; further aqueous 
sodium hypochlorite (1.5 cm3) was then added to the mixture. 
After 30 min, the mixture was diluted with water and extracted 
with dichloromethane. The extract was evaporated and the 
residue was chromatographed (pentane-dichioromethane. 3:1. 
then dichloromethane-ethyl acetate. 10:1. and then ethyl 
acetate). The starting carborane 10 (37%) and oxime 9 (29%) 
were isolated from the first and last portions of eluatc, 
respectively. Evaporation of the solvent from the second 
portion of eluate gave the title compound 11 (300 mg, 59%) as a 
colourless oil; <5„ 1.0-3.2 (10 H. br m. B,0HI0). 1.26 (2 H. m, 
CHj). 1.47 (4 H, m. 2 x CH2). 1.79(2 H. m. CH,). 2.85 (1 H, 
dd. 7 16.5 and 7.2) and 3.33(1 H, dd.7 16.5 and 10.3) (isoxazole 
4-Hj), 3.87 (9 H, s, 3 x OCH,). 4.61 (I H. m. isoxazole 5-H),
6.85 (2 H.s, Ar-H2)and 7.35-7.64(5 H. m, Ph-Hs);<5c 24.7,29.6,
34.7. 34.8, 40.0, 56.1, 56.1. 60.9. 80.7. 80.8. 82.1. 83.5. 103.8. 
125.0, 128.9, 130.6, 131.0. 153.3 and 156.1: m/z (FAB, positive 
ion) ,0B/MB cluster centred at 512 (M + H): m/z (FAB.
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negative ion) 510.3657 (M -  H) (C24H36loB2MB8N04 
requires 510.3648).
3-Methoxy-2-prop~2-ynyloxybenzaldehyde Oxime 14.—3- 
Methoxy-2-prop-2-ynyIoxybenzaldehyde 1220 (1.16 g, 6.1 
mmol) was stirred, with sodium carbonate (640 mg, 6 mmol) 
and hydroxylamine hydrochloride (830 mg, 12 mmol) in 
ethanol (50 cm3) for 16 h. The mixture was evaporated and the 
residue was dissolved in dichloromethane and the solution 
washed with water, dried and evaporated to give the title 
compound 14 (890 mg, 71%) as a white solid, m.p. 76-78 °C; 
»'m.x/cm‘1 3270; S 2.48 (I H, t, J  2.4, C=CH), 3.88 (3 H, s, 
OCH3), 4.77 (2 H, d, J  2.4, CH2GsQ, 6.95 (1 H, dd, 7 8.2 and
1.5, Ar4-H), 7.10(1 H, t, 78.1, ArS-H), 7.38(1 H,dd,78.0 and
1.5, Ar 6-H), 8.21 (1 H, s, C//NOH) and 8.60 (1 H, s, OH). This 
material was used without further purification.
(y-Melhoxy-AW-\_ 1 ']benzopyrano[4,3-c]isoxazole 16.—The 
oxime 14 (150 mg, 0.75 mmol) in dichloromethane (10 cm3) 
was stirred with aqueous sodium hypochlorite (8% available 
chlorine; 2 cm3) for 48 h. The mixture was extracted with 
dichloromethane and the extract was washed with water and 
evaporated. Chromatography (dichloromethane-pentane, 1:1) 
of the residue gave the title compound 16 (20 mg, 13%) as a white 
solid, m.p. 126-128 °C; 6 3.92 (3 H, s, OCH3), 5.33 (2 H, d, 71.1, 
pyran-H2), 6.99 (I H, dd, 7 8.1 and 1.8, ArH), 7.04 (1 H, t, 7 8, 
ArH), 7.50 (1 H, dd, 7 7.5 and 1.8, ArH) and 8.23 (1 H, t, 71.1, 
isoxazole-H); m/z (El) 203.1606 (M) (CMH9N 0 3 requires 
203.1582).
2-{3-Methoxy-2-prop-2-ynyloxyphenyl)-A,5-dihydro-1,3-7/- 
oxole 17.—The aldehyde 12 (1.90 g, 10 mmol) was stirred at 
reflux with ethane-1,2-dioI (680 mg, 11 mmol) and 4-methyl- 
benzenesulfonic add hydrate (10 mg) in toluene (25 cm3) with 
azeotropic removal of water for 24 h. The mixture was 
evaporated and the residue chromatographed (dichloro­
methane-pentane, 1:1) to give the title compound 17 (2.11 g, 
90%) as a white solid, m.p. 93-94 °C (Found: C, 66.55; H, 5.95. 
C, 3H140 4 requires C, 66.65; H, 6.00%); 7 2.49 (1 H, br, CsCH), 
3.87 (3 H, s, OCH3), 4.00-4.20 (4 H, m, CH2CH2), 4.77 (2 H, d,
71.5, CH2C=C), 6.23 (1 H, s, dioxole 2-H) and 6.95-7.15 (3 H. 
m, Ar-H3); m/z (El) 234.0876 (M) (Cl3H140 4 requires 
234.0892).
2-(3-Methoxy-2-prop-2-ynyloxyphenyl)-A,5-dihydro-1,3-7/- 
thiole 19.—The aldehyde 12 (950 mg, 5 mmol) and ethane-1,2- 
dithiol (940 mg, 10 mmol) in dry dichloromethane (10 cm3) 
were treated dropwise with boron trifluoride-diethyl ether 
complex (710 mg, 5 mmol). The mixture was stirred for 24 h 
after which it was diluted with water (10 cm3) and extracted 
with chloroform. The extract was evaporated and the residue 
chromatographed (pentane-dichioromethane, 4:1) to give the 
title compound 19 (700 mg, 53%) as a colourless oil; 6 2.49 (1 H. 
t, 7 2.4, CaCH), 3.30-3.54 (4 H, m. CH2CH2). 3.85 (3 H. s. 
OCH3), 4.79 (2 H, d, 72.4, CH2CsC), 6.21 (1 H, s, dithiole 2-H) 
and 6.81-7.35 (3 H, m, Ar-H3).
2-[2-( 1,2-Dicarba<\oso-dodecaboran( 12)-1 -yl )methoxy-3- 
meihoxyphenyl~\-A,S‘dihydro-13-dithiole 20.—Decaborane( 14) 
(BI0H14) (120 mg, 1 mmol) was stirred in dry acetonitrile (10 
cm3) for 2 h after which the dithiole 19 (270 mg, 1 mmol) was 
added to it and the mixture boiled under reflux for 3 d. 
Evaporation of the mixture gave a residue which was 
chromatographed (pcntanc-dichloromcthanc. 10: 1) and the 
resulting product recrystalliscd from hexane-benzene (CAU­
TION) to furnish the title compound 20 (200 mg. 52%) as white 
crystals, m.p. 132-133 °C (Found: C. 40.6; H, 6.35. 
C13H24Bl0O2S2 requires C. 40.6; H, 6.25%); v^/cm '1 2540; <:>
1.0-3.2 (10 H, br m, BI0H10), 3.41 (4 H, m, CH2CH2), 3.83 (3 H, 
s,OCH3),4.31 (1 H,brs, carborane 2-H), 4.44 (2 H,s,carborane- 
CH2), 5.89 (1 H, s, dithiole 2-H) and 6.81-7.33 (3 H, m, Ar-H3); 
m/z (FAB, positive ion) 10B/UB cluster centred at 385 
(M +H).
A-Prop-2-ynyloxybenzaldehyde 22.—4-Hydroxybenzaldc- 
hyde 21 (6.1 g, 50 mmol) was added to sodium cthoxide (50 
mmol) in dry ethanol (100 cm3), followed by 3-bromopropyne 
(6.55 g, 55 mmol). The mixture was boiled under reflux for 3 h 
and then evaporated. The residue was dissolved in dichloro­
methane and the solution washed with water, dried and 
evaporated to afford the title compound 22 (5.08 g, 64%) as a 
buff solid, m.p. 70-72 °C (lit.,21 m.p. 79-80 °C);<5 2.58 (1 H, l, 7
2.5, CsCH), 4.79 (2 H, d, 7 2.5, CH2C=C), 7.10 (2 H, d, 7 8.8, Ar
3.5-H2), 7.86 (2 H, d, 78.8, A 2,6-H2) and 9.91 (1 H, s, CHO).
2-(4-Prop-2~ynyloxyphenyl)-A,5-dihydro-1,3-dithiole 23.— 
Boron trifluoride-diethyl ether complex (4.26 g, 30 mmol) 
was added to the aldehyde 22 (4.8 g, 30 mmol) and ethane-1,2- 
dithiol (5.64 g, 60 mmol) in dichloromethane (150 cm2) at 0 °C 
and the mixture was stirred at ambient temperature for 16 h. It 
was then washed with water and evaporated. Chromatography 
(pentane-dichioromethane, 4:1) of the residue gave the title 
compound 23 (5.68 g, 80%) as a colourless oil; S 2.52 (1 H, t, 7
2.5, CsCH), 3.33 (2 H, m) and 3.47 (2 H, m) (CH2CH2), 4.65 (2 
H, d, 72.5, CH2C=C), 5.63 (1 H, s, dithiole 2-H), 6.91 (2 H, d, 7
8.8, Ar 3,5-H2) and 7.46 (2 H, d, 78.8, Ar 2,6-H2). This material 
was used directly without further purification.
1 -[4-(4,5-Dihydro-1,3-dithioI-2-yI)phenoxymethyiy 1,2-7/- 
carba-closo-dodecaborane(l2) 24.—Decaborane(14) (B10H,J 
(2.44 g, 20 mmol) was stirred with acetonitrile (200 cm3) for 3 h 
after which the dithiole 23 (4.72 g, 20 mmol) was added to the 
mixture. After being boiled under reflux for 3 d the mixture was 
evaporated and the residue chromatographed (pentane-di­
chioromethane, 4:1) to yield the title compound24 (3.62 g, 51 %) 
as a white solid, m.p. 123-125 °C (Found: C, 40.9; H, 6.2. 
C12H22BloOS2 requires C, 40.7; H, 6.3%); v^Jcm '1 2590; SH
1.5-3.0 (10 H, br m, Bt0HI0), 3.34 (2 H, m) and 3.49 (2 H, m) 
(CH2CH2), 4.08 (1 H, br s, carborane 2-H), 4.39 (2 H, s, 
carborane-CH2), 5.60 (1 H, s, dithiole 2-H), 6.77 (2 H, d, 7 8.8. 
Ar 3,5-H2) and 7.46 (2 H, d, 78.8, Ar 2,6-H2);<5B (H-decoupled) 
-15.0 (4 B), -13.5 (2 B), -10.7 (2 B), -6.5 (1 B) and -4.5 
(1 B); m/z (El) ,0B/llB cluster centred at 354 (M), l0BllB 
isotope cluster centred at 326 (M — C2H J.
1 -(4- Formylphenoxymethyl)-1,2-dicarba-closo-dodecabor- 
ane{ 12) 25.—The dithiole 24 (356 mg, 1 mmol) was stirred with 
mercury(n) perchlorate trihydrate (1.00 g, 2.2 mmol) in THF 
(8 cm3) for 5 min. The suspension was then filtered and the 
filtrate evaporated to afford a residue which was dissolved in 
dichloromethane and the solution washed twice with aqueous 
sodium carbonate (10%). dried and evaporated to give the title 
compound 25 (250 mg, 90%) as white crystals, m.p. 148-151 °C 
(Found: C, 42.8; H. 6.5. Ci0H18B10O2 requires C. 40.7: H. 
6.3%); v^cm-' 2580and 1690; J 1.3-3.4(10H, brm. B10H10).
4.07 (1 H, br s, carborane 2-H), 4.51 (2 H. s. carborane-CH2), 
6.97 (2 H. d, 7 8.8, Ar 2.6-H2), 7.87 (2 H. d. 7 8.8. Ar 3.5-H2) and 
9.92 (1 H, s, CHO); m/z (El) 10B/‘1B cluster centred at 278 (M).
1 -\A-(Hydroxyiminomethyl)phenoxymethyl'\ 1.2 -dicurba- 
c\oso-dodecaborane( 12) 26.—The aldehyde 25 (1.39 g. 5 mmol) 
was stirred with hydroxylamine hydrochloride (1.74 g. 25 
mmol) and sodium carbonate (1.33 g. 12.5 mmol) in dry ethanol 
(50 cm3) for 2 d after which the mixture was evaporated. The 
residue was dissolved in ethyl acetate and the solution washed 
with water and dried. Chromatography (dichloromethane) gave 
the title compound 26 (830 mg. 71 %) as a white solid, m.p. 174- 
176 °C; u./cm ’1 3300 and 2600; <J[(CD,)2CO] 1.3-3.4(10 H.
J. CHEM. SOC. PERKIN TRANS. I 1994 209
br m, BI0HI0), 4.70 (2 H, s, carborane-CH2), 5.00 (1 H, br s, 
carborane 2-H), 7.02 (2 H, <1,79.1, Ar 2,6-H2), 7.57 (2 H, d, J 
9.1, Ar 3,5-H2), 8.08(1 H, s, C/fNOH) and 10.19(1 H,s,OH); 
m/z (El) 295.2388 (M) (CloH „n B10NO2 requires 295.2346), 
294.2420 (M) (CloHI910Bn B9NO2 requires 294.2381), 
293.2449 (M) (C,oHl9,0B2n B8N02 requires 293.2419) and 
292.2454 (M) (CloH19IOB3n B7N 02 requires 292.2455).
1 -(4- {3-[4-( 1,2-Dicarba-c\oso-dodecaboran( 12)-1 -ylmeth- 
oxy)phenyT]-A,S-dihydroisoxazol~S-yl \bulyl )-2-nitroimidazole 
28 and 4-( 1,2-Dicarba-c\oso-dodecaboran( 12)-1 -ylmethoxy)- 
benzonitrile N-Oxide 32.—The oxime 26 (290 mg, 1 mmol) and
l-hex-5-enyl-2-nitroimidazole 27’ (200 mg, 1 mmol) in 
dichloromethane (8 cm3) were stirred vigorously with aqueous 
sodium hypochlorite (8% available chlorine; 2 cm3) for 18 h. 
Further aqueous sodium hypochlorite (6 cm3) was added to the 
mixture which was then stirred for a further 1.5 h. It was then 
washed with water and evaporated and the residue chromato­
graphed (pentane-dichioromethane, 1:1, then dichloro­
methane, then ethyl acetate) to give the title compound 32 (110 
mg, 38%) (from the first fraction) as a white solid, m.p. 212- 
216 °C (decomp.); v ^ cm ' 1 2600 and 2310 cm'1; 6 1.0-3.2 (10
H, br m, BI0H10), 3.97 (1 H, br s, carborane 2-H), 4.38(2 H, s, 
carborane-CH2), 6.82 (2 H, d, J 9.0, Ar 3,5-H2) and 7.40 
(2 H, d, J  9.0, Ar 2,6-H2); m/z (El) 291.2262 (M) 
(Cl0H17loB2l 1B8N 0 2 requires 291.2262), 10B/UB duster 
centred on 291 (M), and l0B/ 1 lB isotope cluster centred on 275 
(100%) (M — O). From the third fraction was obtained the title 
compounds (280 mg, 57%) as a gummy solid; v /cm~l 2600; S
I.3-3.3 (10 H, br m, B10H10), 1.5-2.0 (6 H, m, imidazole- 
CH2CH2CH2CH2), 2.93 (1 H, dd, J  16.5 and 7.9) and 3.40 (1 
H, dd, J 16.5 and 10.4) (isoxazole 4-H2), 4.09 (1 H, br s, 
carborane 2-H), 4.45 (4 H, m, carborane-CH2 + imidazole- 
CH2), 4.73 (1 H, ddt, J 10,8  and 7. isoxazole 5-H), 6.87 (2 H, d, 
J 9.0, Ar 3,5-H2), 7.11 (1 H, s) and 7.15 (1 H, s) (imidazole
4,5-H2) and 7.61 (2 H, s, J  9.0, Ar 2,6-H2); m/z (FAB, positive 
ion) 487.3296 (M + H) (C19H3l ,0B2n B8N4O4 requires 
487.3348).
I -(2-{3-[4-( 1,2-Dicarbac\oso-dodecaboran( 12)-1 -ylmelh- 
oxy)phenyl]isoxazol-S-yl }ethyl)-2-nitroimidazole 29.—The 
oxime 261 and the nitroimidazolealkyne 3 were treated with 
sodium hypochlorite, as for the synthesis of compound 28 
above. Chromatography (pentane-dichioromethane, 1: 1, 
then dichloromethane, then dichloromethane-diethyl ether, 
2:1) gave the /V-oxide 32 (38%) (from the first fraction) and 
then the title compound 29 (57%) (from the third fraction) as 
a white solid, m.p. 151-154 °C: w /c m ' 1 2590; 6 1.3-3.3 (10 
H, br m, B10H10), 3.42 (2 H, t. J 6.7. imidazole-CH 2C//2),
4.09 (1 H, br s, carborane 2-H). 4.46 (2 H, s, carborane-CH2),
4.82 (2 H, t, J 6.7, imidazole-CH,). 6.26 (I H, s, isoxazole 4- 
H), 6.92 (2 H, d, J 8.8, Ar 3.5-H’,). 6.96 (1 H, s) and 7.09 (1 
H, s) (imidazole 4,5-H2) and 7.70* (2 H. s, J 9.0, Ar 2,6-H2); 
m/s (El) 458.2786 (M) (CI7H,4UBION40 4 requires 458.2728), 
457.2798 (M) (C17H24,0BMB9N4O4 requires 457.2764). 
456.2827 (M) (C,7H2410B,n B8N4O4 requires 456.2801), 
455.2865 (M) (Cl7H2410B3l ‘B7N,iO4 requires 455.2837) and 
454.2886 (M) (C,7H24IOB4"B6N40 4 requires 454.2873).
2-Nitro-]-{2-[2-(2-prop-2-yny/o.xyetho.xy)ethoxy]ethy{}imid- 
azole 30.—2-Nitroimidazolc 2 (460 mg, 4 mmol) was stirred at 
130 °C in DMF (10 cm3) with potassium rer/-butoxide (440 
mg, 4 mmol) for 30 min. Potassium iodide (20 mg) and the 
alkync 7 (840 mg, 4 mmol) were added to the mixture which was 
then stirred at 130 °C for 13 h. The mixture was evaporated and 
the residue was dissolved in dichloromethane and the solution 
washed with water, dried and evaporated. Chromatography 
(dichloromethane) of the residue gave the title compound 30
(490 mg, 43%) as a yellow oil; 5 2.45 (1 H, t, J 2.4, C^H), 3.60 
(4 H, s) and 3.6-3.7 (4 H, m) (2 x 0CH2CH20), 3.86 (2 H, t, J
4.9, imidazole-CH2CH2), 4.20 (2 H, d, J  2.4, CH2C=C), 4.63 
(2 H, t, 74.9, imidazole-CH 2), and 7.14 (1 H, s) and 7.29 (1 H, s) 
(imidazole4,5-H2); m/z (Cl) 284.1246 (M + H) (C12HJ8N3Os 
requires 284.1246).
3-[4-( 1,2-Dicarba-c\oso-dodecaboran( 12)-1 -ylmethoxy )- 
phenyV\-5-Q- {2-[2-(2-nilroimidazol- 1 -yl )ethoxy\ethoxy] 
methyl)isoxazole 31.—The oxime 26 and the alkyne 30 were 
treated with sodium hypochlorite, as for the synthesis of 
compound 28 above. Chromatography (pentane-dichioro­
methane, 1:1, then dichloromethane-diethyl ether, 1: 1) gave 
the title compound 31 (79%) as a pale yellow oil; v^/cm ' 1 2600; 
5 [(CD3)2SO] 1.2-3.1 (10 H, br, B10H10), 3.45-3.65 (8 H, m, 
2 x 0CH2CH20), 3.76 (2 H, t, /  5.1, imidazole-CH2CH2), 
4.57 (2 H, t, J 5.1, imidazole-CH2), 4.65 (2 H, s, carborane- 
CH2), 5.37 (1 H, br s, carborane 2-H), 5.76 (1 H, s, isoxazole 4-
H), 7.12 (2 H, d, J 9.0, Ar 2,6-H2), 7.14 (1 H, d, J 1.1, imidazole
4-H), 7.62 (1 H ,d ,7 1.1, imidazole 5-H)an(l 7.84 (2 H, d. J  9.0, 
Ar 3,5-H2); m/z (FAB, positive ion) 577.344 (M + H) (100%) 
(C22H3sl lBl0N4O7 requires 577.344).
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Tumour-targetted Boranes. Part 3 .1 Synthesis of Carbamate-linked 
Nitroimidazolyl Carboranes Designed for Boron Neutron Capture 
Therapy of Cancer
M artin  Scobie and Michael D. Threadgill*
School of Pharmacy & Pharmacology. University of Bath. Claverton Down. Bath BA2 7AY. UK
Carboranes targetted to specific tumour tissues are important for boron neutron capture therapy of 
cancer (BNCT). Carbamoylation of 2-[2-[2-(2-nitroimidazol-1 -yl)ethoxy]ethoxy]ethanol 5 and
1-(chloromethyl)-2-(2-nitroimidazol 1-yl)ethanol 6 with carboran-1-yl isocyanate (generated in situ 
by a Curtius rearrangement of carborane-1 -carbonyl azide) gave the corresponding carbamate-linked 
nitroimidazolylcarboranes 16 and 17. A similar reaction of 4-carboranylphenyl isocyanate with 6 
afforded the corresponding carbamate 24.
Boron neutron capture therapy (BNCT) is o f  increasing interest 
for treatment o f various cancers, mainly gliomas and 
melanomas.2 When the 10B isotope is irradiated with slow 
(‘thermal’) neutrons, an [n,a] reaction ensues, giving 7Li and 
4He nuclei with kinetic energy (2.31 MeV). With this energy, the 
a-particle has a range o f ca. 1 cell diameter in biological tissue 
and damage is limited to the cell containing the boron. Failures 
in early studies o f BNCT were attributed3 to inadequate 
concentrations o f 10B in the tumour tissue or to lack o f  
selectivity o f  disposition o f 10B, leading to damage to normal 
tissue. Carboranes have been linked to nucleosides,4 to amino 
acids5 and to porphyrins6 in attempts to target boron to 
tumours. 1-Substituted 2-nitroimidazoles are selectively 
retained in poorly vascularised hypoxic tumour tissue by 
reductive metabolism to electrophiles.7 As part o f  a programme 
o f  synthesis and evaluation of nitroimidazoles in the treatment 
o f  cancer,1,8 we sought compounds containing derivatives o f





Representations of the structure of 1.2-dicarba-c/oso-dodecaborane( 12) 
(carborane). Each boron atom has one hydrogen attached.
2-nitroimidazole as a strategy to cause selective retention o f  
boron in hypoxic tumour tissue. Prior to our first preliminary 
communication,9 no synthesis o f a nitroimidazolylcarborane 
had been published, although reports o f  preparations o f a 
nitroimidazoiyl-n/do-carborane and a nitroimidazolyl-me/o- 
carborane with short links have been made in proceedings o f  
conferences.10
Our previous study1 showed that ‘direct’ methods o f  
preparation o f nitroimidazolylcarboranes, such as formation by 
treatment o f a nitroimidazolylalkyne with decaborane(14) or 
alkylation o f  the 2-nitroimidazole anion with carboranyl 
electrophiles, were not feasible. The 1,3-dipolar cycloaddition 
o f 4-(carboran-l-ylmethoxy)benzonitrile oxide with l-fto- 
alkynyl)-2-nitroimidazoles permitted coupling o f  the nitro- 
imidazole and the carborane under mild conditions, although
the product isoxazoles were insufficiently soluble in water to 
allow biological evaluation. We therefore sought an alternative 
mild linking strategy.
The addition o f alcohols to isocyanates usually proceeds 
rapidly under mild conditions to give carbamates which are 
generally stable under physiological conditions. Addition o f  a 
nitroimidazole alcohol to a carborane carrying an isocyanate 
was therefore selected as a synthetic strategy.
Two nitroimidazole alcohols, 5 and 6, were prepared. To 
provide a suitable electrophile for reaction with the 2- 
nitroimidazole anion, the chloro alcohol 2 was protected as the 
benzoate ester 3 (Scheme 1). Treatment o f this ester with the
0(CO )Ph
f = \
N y N .
NOz
'Q (CO )Ph
Scheme 1 Synthesis of the nitroimidazole alcohol 5: i. PhCOCl-Et,N; 
ii. 2-nitroimidazole-KOBu'-DMF; iii. NaOH
potassium salt o f 2-nitroimidazole under the usual forcing 
conditions (DM F, 130 °C) gave the nitroimidazolyl ester 4 
which was deprotected under basic conditions to give the 
required alcohol 5 in <40%  overall yield. Other protecting 
groups for the alcohol, including triphenylsilyl and tetra- 
hydropyranyl, gave lower yields. Alkylation o f  the nitro­
imidazole anion with the unprotected chloro alcohol 2 was then
2 0 6 0
investigated and was found to give the nitroimidazole alcohol 
5 in good yield. It was expected that the presence o f the 
oxyethylene ether moiety in carbamoylated derivatives of this 
alcohol would contribute to the aqueous solubility o f the target 
nitroimidazolylcarborane. The shorter chain substituted nitro- 
imidazol-2-ylethanol 6 was prepared by reaction o f 2- 
nitroimidazole with epichlorohydrin, by the method o f Beaman 




To provide a carborane with isocyanate directly attached to 
C -l, a strategy based on a Curtius rearrangement was 
employed. Following the standard method for the synthesis o f  
carboranes from alkynes and decaborane(14) at elevated 
temperatures in the presence of a Lewis base,12 the carborane 
ester 8 was formed from ethyl propynoate 7 and decaborane( 14) 
in good yield. This ester was resistant to add-catalysed 
hydrolysis but cleavage under mild basic conditions afforded 
the carboranecarboxylic add 9 almost quantitativdy. To 
establish a set o f  conditions for the Curtius rearrangement o f the 
corresponding add azide 11, some preliminary experiments 
were undertaken. The add chloride 10 was form al with thionyl 
chloride. Treatment with azidotrimethylsilane in boiling 
toluene, followed by hydrolysis of the isocyanate 12 with water 
in a one-pot process, gave the carboraneamine 1 3 13 as a white 
solid which sublimed at 260-270 °C. In a similar run where 
ethanol replaced the added water, the major product was the 
expected ethyl carbamate 14, formed from the isocyanate 12 
generated in situ. A minor side-reaction was the trapping o f  
unchanged add chloride and/or add azide to give the ethyl ester 
8. The 1-isopropyl carbamate 15 was formed analogously. 
These simple carbamates were found to be stable to both 
aqueous add and aqueous base conditions, in experiments 
designed to confirm stability o f the carborane carbamates under 
biological conditions. With conditions now established for 
generation and reaction of the carborane isocyanate with 
alcohols, the reactions with the nitroimidazole alcohols 5 and 6 
were investigated. Treatment of the isocyanate 12 with the 
sterically hindered secondary alcohol 6 gave the desired 
carbamate-linked nitroimidazolylcarborane 16 in moderate 
yield. The yield was improved using the primary alcohol 5, 
giving carbamate-linked nitroimidazolylcarborane 17. A low 
yield o f the corresponding ester 18 was also isolated, 
presumably arising from the acid chloride or the unrearranged 
acid azide.
To provide a spacer between carborane and isocyanate units, 
the carboranylphenyl isocyanate 23 was synthesised. 1- 
Phenylcarborane 19 was nitrated using the mixed acid system 
but, in contrast to reports 1A~16 that either a mixture o f 3- and 4- 
nitro isomers or a mixture of 2-, 3- and 4-nitro compounds is 
produced, only the 2- and 4-nitrophenylcarboranes 21 and 20 
were isolated in 2 and 85% yield, respectively. The isomers were 
characterised through their 1H NMR spectra. The 4-nitro 
compound 20 was reduced with sodium borohydride and 
palladium, giving the 4-amine 22. Treatment with phosgene 
under basic conditions afforded the phenyl isocyanate 23 which 
reacted smoothly with the secondary nitroimidazole alcohol 6 
to furnish the required carbamate-linked nitroimidazolyl­
carborane 24. In contrast, the reaction o f the isocyanate 23 with 
the primary nitroimidazole alcohol 5 under the same conditions 
gave only inseparable mixtures.
The synthesis o f  the short series o f  carbamate-linked 
nitroimidazolylcarboranes 16, 17 and 24 has demonstrated the
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Scheme 2 Syntheses of the carbamate-linked nitroimidazolyl- 
carboranes 16 and 17 and ester-linked nitroimidazolylcarborane 18: i, 
BI0H14-MeCN; ii, NaOH; iii. SOCK: iv. Me,SiNj; v, toluene and heat, 
vi, water, vii, EtOH or Pr*OH: viii. 6; ix. 5
B10Hio
19 R1 = R2 = H
■ £ 3 r 2 0  R ^ N O j .  R2 = H -----1
t  21 R’*= H . R2 = N 02 H
C 22 R '= N H 2. R2 = H - — 1 23 R’ = NCO. R2 = H
o
Ar = \ 'O' N
H
24
Scheme 3 Synthesis of the carbamate-linked nitroimidazolylcarborane 
25: i. H N 0 j-H 2S 0 2-CH2C1;: ii. NaBH^-Pd/C: iii. phosgene: iv. 6
feasibility o f  this type o f coupling for the sensitive nitro­
imidazole and carborane moieties. The biological evaluation of  
these stable nitroimidazolylcarboranes will be reported 
elsewhere. The linkage o f the nitroimidazolylalkyl carborane-
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carboxylate 18 is relatively labile to hydrolysis under aqueous 
conditions and would not be capable of ensuring delivery of the 
boron to tumour tissue.
Experimental
Deuteriochloroform was the solvent for NMR spectroscopy 
with tetramethylsilane as chemical-shift standard, unless 
otherwise noted. Solutions in organic solvents were dried with 
anhydrous magnesium sulphate. Solvents were evaporated 
under reduced pressure. The chromatographic stationary phase 
was silica gel. M.p.s are uncorrected. DMF refers to dimethyl- 
formamide. 7 Values are recorded in Hz.
2- {2-[2-(2-Nitroimidazol-1 -yl)etkoxy\ethoxy} ethanol 5 .~  
Method A. 2-Nitroimidazole (339 g, 30 mmol) was stirred with 
potassium rerf-butoxide (3.36 g, 30 mmol) in DMF (SO cm3) at 
130 °C for 1 h after which the mixture was cooled to 80 °C. 
Sodium iodide (100 mg) and 2-[2-{2-chloroethoxy)ethoxy)]- 
ethanol 2 (6.74 g, 40 mmol) were added to the mixture which 
was then stirred at 130 °C for 2 h. The solvent was evaporated 
and the residue was dissolved in dichloromethane and the 
solution washed with water and dried. Chromatography 
(dichloromethane, then dichloromethane-ethyl acetate, 2 :1, 
then ethyl acetate-methanol, 10:1) gave the title compound 5 
(4.61 g, 63%) as a pale yellow oil; v_../cm~1 3420br; 6 3.60 (4 H, 
s), 3.66 (2 H, m), 3.86 (2 H, t, J  5.0) and 4.22 (2 H, m) 
(CH2OCH2CH2OCH2CH20), 4.65 (3 H, m, imidazole-CH2 + 
OH) and 7.18 (1 H, s) and 7.29 (1 H, s) (imidazole 4,5-H2); m/z 
(Cl) 246.1090 (M + H) (C9H16N30 5 requires 246.1090).
MethodB. 2-[2-(2-Chloroethoxy)ethoxy3ethanol 2 (3.37 g, 20 
mmol) was stirred with benzoyl chloride (2.81 g, 20 mmol) and 
triethylamine (2.02 g, 20 mmol) in dry dichloromethane (50 
cm3) for 24 h after which the mixture was washed with water, 
aqueous sodium hydroxide (2 mol dm'3) and water and 
then dried. Chromatography (dichloromethane) gave 2-[2-(2- 
chloroethoxy)ethoxy]ethyl benzoate 3 (4.71 g, 86%) as a pale 
yellow oil; v^Jcm"1 1730; S 3.61 (2 H, t, 7 5.9), 3.71 (6 H, 
m) and 3.85 (2 H, m) (ClCH2CH2OCH2CH2OCH2), 4.49 (2 H, 
m, CH20 2CPh), 7.45 (2 H, t, 77.7, Ar 3,5-H2), 7.57 (1 H, t, 77.7, 
Ar 4-H) and 8.06 (2 H, d, 7 7.7, Ar 2,6-H2). 2-Nitroimidazole 
(1.13 g, 10 mmol) was heated at 130°C with potassium rerr- 
butoxide (1.12 g, 10 mmol) in DMF for 30 min after which the 
benzoate ester 3 (2.72 g, 10 mmol) was added to the mixture and 
the whole was stirred at 130 °C for 2 h. After this the solvent was 
evaporated and the residue was dissolved in dichloromethane 
and the solution washed with water and dried. Chromatography 
(dichloromethane, then dichloromethane-diethyl ether, 10:1) 
gave crude 2-{2-[2-(2-nitroimidazol-1 -yl)ethoxy]ethoxy }ethyl 
benzoate 4: S 3.62 (4 H, m, CH2OCH2CH2OCH2), 3.82 (4H,m, 
C//2OCH2CH2OC//2), 4.48 (2 H, t, 7 5.0, CH20 2CPh), 4.57 
(2 H, t, 7 5.0) (imidazole-CH2), 7.16 (1 H, s) and 7.21 (1 H. s) 
(imidazole 4,5-H2), 7.45 (2 H, t, 7 7.7, Ar 3,5-H2), 7.57 (1 H. t. 7
7.7, Ar 4-H) and 8.05 (2 H, d, 7 7.7, Ar 2,6-H2). This ester 4 (350 
mg, 1 mmol) in ethanol (7.5 cm3) was treated with aqueous 
sodium hydroxide (2 mol dm"3, 2.5 cm3, 5 mmol) at 50 °C for 
1 h after which the ethanol was evaporated and the residue 
was diluted with water (10 cm3) and extracted with dichloro­
methane. The extract was dried and the solvent was evaporated 
to give the title compounds (180 mg, 73%) with properties as 
above.
Ethyl 1,2- Dicarbac\o%o-dodecaborane{ 12)-1 -carboxylate 8. 
—Decaborane(14) (3.66 g, 30 mmol) was stirred with dry 
acetonitrile (50 cm3) for 3 h after which ethyl propynoate 7 (2.94 
g, 30 mmol) was added to the solution which was then stirred 
under reflux for 3 d. After this the mixture was evaporated and 
chromatography (pentane-dichioromethane, 2 : 1) of the residue
gave the carborane ester 8 (3.26 g, 50%) as a white solid, m.p 
55-57 °C (lit,17 m.p. 62-62.5 °Q; SH 1.32 (3 H, t, 7 7.2, CH3),
2.3 (10 H, br q, J%jt 150, BjqHiq), 4.08 (1 H, br s, carborane 
2-H) and 4.29 (2 H, q, 7 7.2, CH2).
1,2-Dicarba-closo-dodecaborane(12)-1 -carboxylic Acid 9.— 
The ester 8 (2.16 g, 10 mmol) was stirred with sodium hydroxide 
(1.00 g, 25 mmol) in water (50 cm3) and methanol (20 cm3) for 3 
d. The methanol was evaporated and the residue was acidified 
with hydrochloric add (2 mol dm"3) and extracted with 
dichloromethane. The extract was dried and the solvent was 
evaporated to give the carboranecarboxylic add 9 (1.82 g, 
97%) as a white solid, m.p. 148-150 °C (lit.,18 m.p. 150°C); 
<5[(CD3)2SO] 1.3-3.2 (10 H, br, B10H10), 5.20 (1 H, br s, 
carborane 2-H) and 9.5 (1 H, C02H).
Ethyl N-( 12-Dicarba-c\oso-dodecaboran( 12)-1 -yl)carbamale
14.—The carboranecarboxylic add 9 (380 mg, 2 mmol) was 
boiled under reflux with thionyl chloride (10 cm3) and DMF 
(0.03 cm3) for 4 h. The excess of reagents was evaporated and 
the residue, dissolved in toluene (10 cm3), was treated with 
azidotrimethylsilane (250 mg, 2.2 mmol) at reflux for 6 h. The 
mixture was cooled and ethanol (2 cm3) was added to it; it was 
then boiled under reflux for 1 h. The solvents were evaporated 
and the residue was subjected to chromatography (pentane- 
dichioromethane, 2:1, then pentane-dichioromethane, 1:3). 
From the first fraction was obtained ethyl 1,2-dicarba-c/oyo- 
dodecaborane(l 2)-1-carboxylate 8 (70 mg, 16%). From the 
second fraction was isolated the title compound 14 (270 mg, 
58%) as a colourless solid. A sample of this material was 
recrystallised from light petroleum (b.p. 60-80 °C): m.p. 102— 
104 °C (Found: C, 26.0; H, 7.5; N, 6.3. Calc, for C5H17B10NO2: 
C, 25.95; H, 7.36; N, 6.06); v^Jcxn 1 3290, 2600 and 1710; <5„
1.26 (3 H, t, 77.1, CH3), 22  (10 H, br q, 7BJI150, BIOH10), 4.13 
(2 H, q, 7 7.1, CH2), 4.59 (1 H, br s, carborane 2-H) and 5.90 
(1 H, br s, NH); m/z (El) 10B/n B isotope cluster centred at 230 
(M -  H).
Isopropyl N -(12-Dicarba-doso-dodecaboran( 12)-1 -yl Car­
bamate 15.—A solution of the isocyanate 12 in toluene was 
treated with propan-2-ol as for the synthesis of the ethyl 
carbamate 14, except that chromatography was omitted, to give 
the title compound 15 (290 mg, 59%) as a white solid, m.p. 148— 
150 °C (Found: C, 29.6; H, 7.9; N, 5.9. Calc, for C6H19B10NO2 
C, 29.39; H, 7.76; N, 5.71); v^/cm"1 3330, 2605 and 1710; 
<*[(CD3)2SO] 1.18 [6 H, d, 7 6.2, (CH3)J , 1.0-3.0 (10 H, br, 
BioHIO), 4.78 (1 H, septet, 7 6.2, CHMe2), 5.35 (1 H, br s, 
carborane 2-H) and 9.66 (1 H, s, NH); m/z (El) l0B/‘1B isotope 
cluster centred at 244 (M — H).
1 -( Chloromethyl)-2-(2-nitroimidazol-1 -y/)e/Ay/ N-{ 1,2-Di-
carba<\oso-dodecaboran( 12)-1 -yl Carbamate 16.—The carbo­
ranecarboxylic acid 9 (380 mg. 2 mmol) was boiled under reflux 
for 4 h with thionyl chloride (10 cm3) and dimethylformamide 
(0.03 cm3). The excess of reagents was evaporated and the 
residue, in toluene (10 cm3), was treated with azidotrimethyl­
silane (250 mg, 2.2 mmol). The mixture was boiled under reflux 
for 18 h and then cooled to ambient temperature. l-(Chloro- 
methyI)-2-(2-nitroimidazol-l-yl)ethanol 6 11 (410 mg, 2 mmol) 
was added to the mixture which was then boiled under reflux for 
1 -h. After evaporation the residue, in chloroform, was cooled to 
0 °C. The solid was collected to give the title compound 16 (290 
mg. 38%) as a white solid, m.p. 190-193 °C (Found: C, 27.7; H,
4.8. Calc, for C9H20Bl0ClNa0 4 C, 27.66; H, 4.87); v^/cm 1 
3160,2600and 1740;<5[(CD3),SO] 1.5-2.8 (10 H, br, B10Hl0). 
3.80 (1 H, dd, 7 12.2 and 6.4) and 3.94 (1 H, dd. 7 12.2 and 4.0) 
(CH2C1), 4.46(1 H,dd. 714.3 and 9.2) and 4.83(1 H,dd,714.3 
and 3.0) (imidazole-CH,). 5.12 (1 H, br s, carborane 2-H). 5.30
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(I H, m, CHOH), 7.15 (I H, s, imidazole 4-H), 7.43 (I H, s, 
imidazole 5-H) and 9.98 (1 H, s, NH); m/z (El) 344 (M -  HCI) 
and 184 (carborane-N=C=0 ); m/z (FAB +ve ion) ,0B/1!B 
isotope cluster centred at 391 (M + H), 393.2087 (M +  H) 
(C9H2o1,B1035QN404 requires 393.2104).
2-{2-[2-(2-Nitroimidazole-1 -yl)ethoxy]ethoxy}ethyI N-(I,2- 
Dicarba-closo-dodecaboran( 12)-1 -yl)carbamate 17 and 2-{2-[2- 
(2-Nilroimidazoi-1 -yl)elhoxy]ethoxy}ethyl 1,2-Dicarba-c\oso- 
dodecaborane{ 12)-1 -carboxylate 18.—The carboranecarboxylic 
acid 9 (380 mg, 2 mmol) was boiled under reflux for 4 h with 
dimethylformamide (0.03 cm3) and thionyl chloride (10 cm3). 
The excess of reagent was evaporated and the residue was boiled 
under reflux with azidotrimethylsilane (250 mg, 2.2 mmol) in 
toluene (10 cm3) for 16 h. The alcohol 5 (490 mg, 2 mmol) was 
added to the mixture and heating was continued for a further 2 
h. The residue on evaporation was subjected to chromatography 
(pentane-dichioromethane, 2 :1, then dichloromethane, then 
dichloromethane-diethyl ether). From the dichloromethane 
fraction was obtained the title compound 18 (141 mg, 17%) as a
pale yellow gum; v /cm"12600,1750; 2.3(10 H, brq,/B-H 150
Hz, Bt0H10, 3.57 (4 H, s) and 3.65 (2 H, m) and 3.84 (2 H ,t,/5.0) 
(CH2OCH2CH2OCH2), 4.13 (1 H, br s, carborane 2 H), 4.37 (2 
H, m, C02CH2), 4.64 (2 H, t, /  5.0 Hz, imidazole-CH2) and
7.14 (1 H, s) and 7.21 (1 H, s) (imidazole 4,5-H2); m/z (FAB 
+ ve ion) 416.2830 (M + H) (Cl2H2610B2n B8N 3O6 requires 
416.2824). From the dichloromethane-diethyl ether fraction 
was obtained the title compound 17 (47%) as a pale yellow gum; 
v„Jcarl 3250,2600 and 1755 cm'1; <5 2.2 (10 H, br q, JBM150, 
B10H10), 3.4-3.6 (6 H, m) and 3.81 (2 H, t, /  5.0) and 4.10 (2 H, 
m) (C02CH2CH20CH2CH20CH2), 4.62 (1 H, br s, carborane 
2-H), 4.66 (2 H, t,/5 .0 , imidazole-CH2), 7.12 (1 H, d, /0.8) and 
7.16 (1 H, d, 70.8) (imidazole 4,5-H2) and 8.10 (1 H, br s, NH); 
m/z (FAB +ve ion) 431.2941 (M + H)(C12H2710B2"B8N4O6 
requires 431.2933).
1 -{4-Nitrophenyl)-1^2-dicarba-c\oso-dodecaborane{ 12) 20 and 
1 -Q-Nitrophenyl)~lJ2-dicarba-c\oso-dodecaborane{l2) 21.— 1- 
Phenyl-l,2-dicarba-e/as0-dodecaborane(12) 1912 in dichloro­
methane (50 cm3) was stirred vigorously with nitric add (66%;
6.0 cm3) and concentrated sulphuric add (34 cm3) for 24 h. 
The organic phase was washed with water and with saturated 
aqueous sodium hydrogen carbonate and then dried. The 
residue on evaporation was subjected to chromatography 
(pentane-dichioromethane, 7:1, then pentane-dichioro­
methane 1:1). From the first fraction was obtained the title 
compound 21 (40 mg, 2%) as a white solid, m.p. 159-161 °C 
(lit.,16 m.p. 161-161.5 °C); S 2.3 (10 H, br q, / BJI 150 Hz, 
Bi0H10),4.31 (1 H, brs, carborane 2-H), 7.39(1 H,m, Ar6-H), 
7.55 (2 H, m, Ar 4,5-H2) and 7.90 (1 H, m, Ar 3 H). From the 
second fraction was isolated the title compound 20 (2.25 g, 85%) 
as a white solid, m.p. 165-166 °C (lit.,19 m.p. 167-168 °C); 
6 2.3 (10 H, br q, JB H 150, B10H10), 4.07 (1 H, br s, carborane 
2-H), 7.68 (2 H, d, > 8.8, Ar 2,6-H2) and 8.21 (2 H, d, J  8.8, 
Ar 3,5-H2).
4-( 1,2-Dicarba~c\oso-dodecaboran( 12)-1 -yl )aniline 22.— 
Sodium borohydride (3.04 g, 8 mmol) in water (5 cm3) was 
added to the 4-nitro compound 20 (2.12 g, 8 mmol) and 10% 
palladium-on-charcoal (210 mg) in methanol (100 cm3) and the 
mixture was stirred for 16 h under nitrogen. The suspension was 
filtered through Celite®. The residue on evaporation in 
dichloromethane, was washed with water and dried. The solvent 
was evaporated to give the amine 22 (1.82 g, 77%) as a white 
solid: m.p. 101-103 °C (lit.,15 m.p. 103-105 °C); J 2.2 (10 H, br 
q, JBM150, B,0H, 0), 4.20 (1 H. br s, carborane 2-H), 6.64 (2 H, d, 
J  8.6, Ar 2,6-H2), 7.36 (2 H, d. J  8.6, Ar 3,5-H2) and 8.5 (2 H, br, 
NH2).
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4-( 1,2-Dicarba-doso-dodecaboran( 12)-l -yl)phenyl Isocyan- 
ate 23.—The amine 22 (350 mg, 1.5 mmol) in toluene (5 
cm3) was treated with phosgene in toluene (20%; 0.9 cm3, 1.7 
mmol) and triethylamine (303 mg, 3 mmol) under reflux for 2 h. 
The mixture was cooled and filtered. The solvent was 
evaporated to afford the isocyanate 23 (400 mg, quant.) as a pale 
buff solid, m.p. 131-134 °C (reported by Sergeev et al.20 but no
m.p. was given); v /cm-12580 and 2280; S„ 2.3 (10 H,brq,/B H
150, Bt0H10), 3.92(1 H, br s, carborane 2-H), 7.05 (2 H, d, J  9.0, 
Ar 2,6-Hj) and 7.44 (2 H, d, J 9.0, Ar 3,5-H2); m/z (El) ,0B/lIB 
isotope cluster centred at 261 (M). This material was used 
directly without further characterisation.
1 -( Chloromethyl)-2-(2-nitroimidazol-1 -yl)ethyl N-{4-( 1,2-Di- 
carba-closo-dodecaboran( 12)-1 -yI)phenyl )carbamate 24.—The 
isocyanate 23 (130 mg, 500 pmol) was boiled under reflux with
l-(chloromethyI)-2-(2-nitroimidazol-l-yl)ethanol 6 M (100 mg, 
500 pmol) in toluene (10 an3) for 24 h. The solvent was 
evaporated and the residue was recrystallised from chloroform 
to give the title compound 24 (190 mg, 81%) as a white solid: 
m.p. 177-180 °C (decomp.); v^../cm~1 3270, 2600 and 1740; 
<5h[(CD3)2SO] 1.3-3.0 (10 H, br, B10H10), 3.89 (1 H, d d , /12.1 
and 5.9) and 4.04 (1 H, dd, J  12.1 and 3.9 Hz) (CH2C1), 4;63 
(1 H, dd, J  14.3 and 8.8) and 4.88 (1 H, dd, J  14.3 and 2.5 Hz) 
(imidazo!e-CH2), 5.44 (I H, m, CH02Q, 5.67 (1 H, br s, 
carborane 2-H), 7.14 (I H, s, imidazole 4-H), 7.33 (2 H, d, J  8.8) 
and 7.47 (2 H, d, J  8.8) (Ar-H4), 7.57 (1 H, s, imidazole 5-H) and
10.03 (1 H, br s, NH); m/z (FAB +ve ion) 468.2355 (M +  H) 
(CI5H2411B103Sa N 4O4 requires 468.2338).
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Sum m ary
Quenching the anion generated from a 2-(co-carboranylalkyl)dithiane with at -78°C and at 0°C  
introduced deuterium exclusively at C-2 o f  the carborane. Extension o f this model reaction to a 
bioreductively-targetted carborane allowed the synthesis o f  2-pH ]- and 2-[3H]-isotopomers o f a 
nitroimidazole-carborane which is o f  interest in boron neutron capture therapy (BNCT) o f cancer.
Keywords: Nitroimidazolc, carborane, boron neutron capture therapy, hypoxia, deuterium oxide,
tridated water.
Introduction
Boron neutron capture therapy (BNCT) is of 
increasing interest in the treatment o f various 
cancers14. Failures in the early clinical studies 
were attributed5-7 to inadequate concentration of 
the ,0B isotope in the tumour tissue or to lack of 
selectivity o f  disposition o f  I0B, leading to 
damage to normal tissue. To exploit the selective 
retention8-12 o f 1-substituted 2-nitroimidazoles in 
hypoxic tumour tissue, we have synthesised1-13-14 
a series o f carboranes linked to nitroimidazole. 
Figure 1 shows the icosahedral structure of 
carborane. We required radiolabelled material for 
studies on the biodistribution and selective localisation o f the lead compound, the isoxazolc-linked 
nitroimidazole-carborane 3 (Scheme 2). Owing to the complexity o f the structure o f  3 and the 
possible consequent complexity o f  its metabolism, we chose to radiolabel the carborane moiety, since 
investigation of the biodistribution o f  the boron was the objective o f our study.




Figure L Representations o f the structure o f  
carborane. Each B atom has one H 
atom attached.
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Mizusawa et a /.15 have reported nidation o f  1-phenylcarboiane by formadon of the anion at position 
2 o f the carborane with butyl lithium at elevated temperature and quenching with tridated water.
Results and Discussion
Before embarking on a deprotonation /  quenching sequence on the complex molecule 3, a model 
study was performed. The dithiane-carborane 1 was synthesised in three steps (alkylation o f dithiane 
anion with l,2-bis(2-chlaroethoxy)ethane, substitution o f  the chlorine by propyn-3-ol and treatment 
o f  the dithiane-alkyne with decaborane(i4)) as previously described16. Treatment o f  1 with one 
equivalent o f  butyl lithium at -78°C and quench with deuterium oxide gave exclusively an isotopomer 
containing only one deuterium (Scheme 1). Deprotonation and reaction at 0°C gave the same 
material. The vigorous conditions o f  Mizusawa et a i.15 were found to be unnecessary for 
deprotonation. Since both dithianes16 and carboranes15 are known to be deprotonated by butyl 
lithium, it was important to locate the deuterium by NM R spectroscopy. In the !H NMR spectrum, 
the dithiane 2-H was evident as a triplet at 5 4.18 but the broad singlet normally observed at 8 4.1 for 
the carborane 2-H in deuteriochloroform solvent was absent. The 13C spectrum confirmed the 
location o f the deuterium. The dithiane 2-C appeared as a singlet at 8 43.77 in the broadband 1H- 
decoupled spectrum, whereas the carborane 2-C gave a 1:1:1 triplet (J =  29 Hz) centred at 8 57.36.
BuLi
-lH
Scheme 1. Deuteiation o f the dithiane-carborane 1 and demonstration that the carborane 2-H  is 
more acidic than the dithiane 2-H.
Since 2-nitroimidazole has clectrophilic reactivity, lithium hcxamethyldisilazide was used as a 
hindered non-nucleophilic base for the deprotonation o f  the nitroimidazole-carborane 3. 
Deprotonation at low temperature, followed by quench with deuterium oxide gave a monodeuterio 
isotopomer. NMR spectroscopy was again used to locate the deuterium, as deprotonation o f the 
isoxazole at the 4-position is conceivable. The •H spectrum showed the absence o f the carborane 
2-H signal at 8 4.1 and the presence o f the isoxazole 4-H  signal at 8  6.18. The 13C spectrum showed 
the carborane C-2 signal as the expected 1:1:1 triplet (J =  30  H z) centred at 8 57.54.
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A similar deprotonation o f 3, followed by quench with tridated water (specific activity
1.8 m O  mmol-1) gave the tritiated isotopomer 5, although in disappointing chemical yield. Since the 
deprotonation is shown by the deuterium incorporation model experiment to be quantitative, the 
specific activity o f  5 (248 pCi mmol'1) indicates a significant kinetic tritium isotope effect on the 
reaction o f  the carborane anion with the water.
O— N
O—N
Scheme 2. Deuteration and tritiation of the nkroimidazole-caiborane 3.
This synthesis o f  the radiolabelled nitroimidazole-carborane 5  provides material for quantitative 
biodistribution studies to confirm the preliminary biodistribution studies by llB magnetic resonance 
spectroscopy in vivo o f tumour-bearing mice which had received the carborane 3. These results will 
be reported elsewhere.
Experimental Section
Tritiated water (1.8 mCi m m ol1, 67 MBq mmol'1) was obtained from ICN; deuterium oxide  
(99 atom %) was obtained from Aldrich Chemical Co. Ltd. Solutions in dichloromethane were dried 
with anhydrous magnesium sulphate. Solvents were evaporated under reduced pressure. THF refers 
to tetrahydrofuran; brine refers to saturated aqueous sodium chloride. NMR spectra were recorded 
of solutions in CDC13 with SiMe4 as internal standard using Jeol GX270 and EX400 instruments. IR 
spectra were recorded on samples as liquid films.
2-[2H ]-l-(2-(2-(D ihydro-13-dithian-2-yI)ethoxy)ethoxym ethyI)-l,2-dicarbac/osododeca- 
borane(12) (2). Butyl lithium (2 M in hexanes, 0.25 mL, 0.5 mmol) was added to l-(2-(2-(dihydro-
1,3-dithian-2-yl)ethoxymethyl)ethoxymethyl)-1,2-dicarbac/or<xiodecaborane( 12) ( l ) 16 (180 mg,
0.5 mmol) in dry THF (5 mL) at -78°C under nitrogen and the mixture was stirred at -78°C for 
45 min. Deuterium oxide (0.25 mL) was added and the mixture was wanned to ambient temperature 
during 30 min. Brine (5 mL) was added and the mixture was extracted with dichloromethane. The
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extract was dried and the solvent was evaporated to give 2-pH]-1 -(2 -{2 -{d ih y d r o -1,3-dithian-2- 
yl)ethoxy)ethoxymethyl)-lf2-dicazbacldsododecaborane(12) (2) (180 mg, quant) as a pale yellow 
gum: IR v 2600 (B-H), 2260 (C-D) cor1; NMR 5„ 1.87 (1 H, m, dithiane 5«-H), 2.00 (2 H, q, J =
7.0 Hz, dithiane-CHj), 2.14 (1 H, m, dithiane 5,,-H) 2.3 (10 H, br q = 160 Hz, B10H10), 2.85 (4 
H, m, dithiane 4,6-H<), 3.60 (6 H, m, dithiane-CH2C//2OC//2C^2)» 3.96 (2 H, s, carborane-CHj),
4.18 (1 H, t, J = 7.0 Hz, dithiane 2-H; NMR 8C 25.74 (CHj), 30.00 (CH^, 35.31 (CHj), 43.77 
(dithiane 2-C), 57.36 (t, JCD = 29 Hz, carborane 2-CD), 67.24 (CH^, 69.90 (CHj), 71.18 (CHj), 
72.01 (CHj), 72.72 (carborane 1-Q; spectrum (Cl) mlz ^ /" B  isotope cluster centred at 366 
(A/ + H).
2-pH]-l-(2-(2-(5-(2-(2-(2-(2-{2-Nitroimidazol-l-yl)ethoxy)ethoxy)ethoxy)ethoxymethyI)- 
isoxazoI-3-yl)ethyI)ethoxymethyI)-l,2-<licarbacZ0ft>dodecaborane{12) (4). Butyl lithium (2 M in 
hexanes, 0.05 mL, 0.1 mmol) was added to lutramftriiyMiglayanft (16 mg, 0.1 mmol) in dry THF at 
-78°C under nitrogen and the mixture was stirred at this temperature for 30 min. The unlabelled 
nitroimidazole-carborane 316 (60 mg, 0.1 mmol) in dry THF (2 mL) was added and stirring continued 
at -78°C for 30 min. Deuterium oxide (0.2 mL) was added and the mixture was warmed to ambient 
temperature during 30 min. Brine (5 mL) was added and the mixture was extracted with 
dichloromethane. The extract was dried and the solvent was evaporated to give 2-[2H]-l-(2-(2-(5-(2- 
(2-(2-(2-(2-nitroimidazol-l-yl)ethoxy)ethoxy)ethoxy)ethaxymethyI)isoxazol-3-yl)ethyl)ethoxy- 
methyl)-l^-dicarbac/brododecaborane(12) (4) (50 mg, 83%) as a pale yellow gum: IR v 2590 
(B-H), 2270 (C-D) cm1; NMR Sy 2.3 (10 H, br q, = 160 Hz, B10H10), 2.92 (2 H, t, J = 6.4 Hz, 
isoxazole-3-CHy, 3.60-3.75 (18 H, m, carborane-^OCtf2Cff2OCff2 +
OCH2CH2(XIH2CH2OCH2CH-0), 3.85 (2 H, t, J = 5.0 Hz, imidazole-CHja/j), 3.92 (2 H, s, 
caiborane-CHj), 4.62 (4 H, m, imiriazolc-CHg + isoxazole-S-CHjO) 6.18 (1 H, s, isoxazole 4-H), 
7.11 (1 H, d, J = 0.8 Hz) and 7.28 (1 H, d, J -  0.8 Hz) (im id a z o le  4,5-Hj); 5C 26.75 (CHj), 
29.62 (CHj), 49.82 (CH2), 57.54 (t, = 30 Hz, carborane 2-CD), 61.66 (CH^, 63.98 (CHj),
69.95 (CHj), 69.32 (CHj), 70.05 (CH^, 70.31 (CH^, 70.40 (CH*), 70.47 (CH^, 70.58 (CHj),
71.26 (CH^, 72.26 (CH2), 72.52 (carborane 1-C), 103.08 (CH), 127.27 (CH), 127.93 (CH), 
161.22 (Cq), 169.03 (C^ ); mass spectrum (FAB) m/z ^B/HB isotope cluster centred at 616 (M + H).
2-[3H]-l-(2-(2-(5-(2-(2-(2-(2-(2-Nitroimidazol-l-yI)ethoxy)ethoxy)ethoxy)ethoxymethyl)- 
isoxazoI-3-yl)ethyl)ethoxymethyI)-l^-dicarbac/bsododecaborane(12) (5). The unlabelled nitro­
imidazole-carborane 3'6 (60 mg, 0.1 mmol) was deprotonated with lithium hexamethyldisilazide. as 
for the synthesis of the deuterium isotopomer 4, Tritiated water (0.025 mL, 25 mQ, 925 MBq) was 
added and the mixture warmed to ambient temperature during 1 h. Brine (10 mL) was added and the 
mixture was extracted with dichloromethane. The extract was dried and the solvent was evaporated. 
Column chromatography (silica gel, ethyl acetate /  methanol 10:1) gave 2-[3H]-l-(2-(2-(5-(2-(2-(2- 
(2-(2-nitroimidazol-1 -yI)ethoxy)ethoxy)ethoxy)ethoxymethyl)isoxazol-3-yl)ethyl)ethoxymethyl)-1J2- 
dicarbac/o5ododecaborane(12) (5) (7.8 mg, 13% chemical yield, 3.15 pCi, 248 JiCi mmol1,
9.18 MBq mmol*1) as a colourless gum, identical by U.c. with 3 and 4.
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Tumor-Targeted Boranes. 4.1 Synthesis of 
Nitroimidazole—Carboranes with Poly e ther—Isoxazole Links
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Carboranes targeted to specific tumor tissues are important for boron neutrcn capture therapy 
(BNCT) of cancer. Previous attempts to use isoxazolylphenyl-linked nitroimidazole—carboranes 
for targeting to hypoxic tumors were hampered by the low polarity and very low aqueous solubility 
of the compounds. Syntheses of polyether-linked nitroimidazole—isoxazole—carborane 17,25, and 
26 via 1,3-dipolar cycloaddition of appropriate nitroimidazole—alkynes with nitrile oxides derived 
from aliphatic aldehyde oximes linked by a varying number of water-solubilizing ether units to 
carborane have been developed. The stabilities of the nitrile oxides were much less than that of 
the corresponding 4-(carboranylmethoxy)phenyl nitrile oxide and depended on their structure. The 
yields of isoxazoles varied accordingly and cycloaddition failed when eight ether units were included 
in the chain. Compounds 17, 25, and 26, with four, five, and six ether units, respectively, had 
increasingly convenient physical properties to permit biological evaluation.
Introduction
Boron neutron capture therapy (BNCT) is of increasing 
interest for the treatment of cancer.2"5 Naturally occur­
ring boron comprises two stable isotopes. nB, present 
at 80% abundance, is a convenient nucleus for NMR 
studies in vitro (sensitivity 0.17 x 1H, I  =  3/2). However, 
when l0B is irradiated with low-energy (“thermal”) 
neutrons, the 10B nucleus captures a neutron and an [n,a] 
reaction ensues, giving TLi and 4He nuclei, with kinetic 
energy (2.31 MeV). With this kinetic energy, the a-par- 
ticles have ranges comparable with one cell diameter in 
biological tissue. Thus damage should be limited to cells 
containing the boron. Major endogenous nuclei (lH, l2C, 
l4N, lsO) have relatively very small nuclear cross-sections 
for neutron capture. Failures in early clinical studies of 
BNCT have been attributed6"* to inadequate concentra­
tions of 10B in the tumor tissue at the time of irradiation 
with neutrons or to lack of selectivity of biodistribution 
of 10B, leading to damage to normal tissues.
1-Substituted 2-nitroimidazoles are known to be se­
lectively retained in poorly vascularized hypoxic tumor 
tissue by reductive metabolism to electrophiles.9"14 As
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part of a program of synthesis and evaluation of ni­
troimidazoles in the treatment of cancer,15-20 we have 
proposed that compounds containing 10—12 boron atoms 
linked to 2-nitroimidazole would form a useful method 
of concentrating boron in solid tumors. . Derivatives of
l,2-dicarba-c/oso-dodecaborane(l2) (“carborane", Figure
1) were selected for linkage to 2-nitroimidazole in view 
of their good chemical stability relative to other boron 
clusters and their predicted metabolic inertness. Prior 
to our first preliminary communication,21 no synthesis 
of a nitroimidazole-carborane had been published in the 
journal literature, although reports of a short-chain 
nitroimidazole—/udo-carborane22 and a short-chain ni­
troimidazole— me/a-carborane23 have been made in pro­
ceedings of conferences.
In a previous paper,20 we reported the 1,3 -dipolar 
cycloaddition of a variety of nitroimidazole-alkene and 
-alkyne dipolarophiles with the highly stable 1,3-dipole,
4-(carboranylmethoxy)benzonitrile oxide. Although this 
strategy was successful in linking the potentially oxidiz­
ing 2-nitroimidazole with the carborane to produce the 
required nitroimidazole-carboranes, these latter materi-
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F ig u r e  1. Representations of the structure of 1,2-dicarba- 
cZoso-dodecaborane( 12) (“carborane"). All boron atoms have one 
hydrogen atom attached but some have been omitted from the 
diagram  for clarity.
S c h e m e  1. S y n th e s is  o f  t h e  P o ly e th e r -L in k e d  
N itr o im id a z o le — A lk y n e s  7  a n d  8 “
1: n -  1
2 :n -=2
3: n « 1 
4: n = 2




7: n « 1 
8: n * 2
° Reagents and conditions: (i) HC=CCH2OH/NaH/DMF/130 *C;
(u) KOBuVDMF/12 0  *C.
a ls  w ere insu fficien tly  soluble in  aqueous m edia to perm it 
sa tisfa c to ry  eva lu ation  o f  their  tum or-localiz ing ability . 
C ycloadd itions o f  a ltern ative  a lip hatic  carborane-n itrile  
o x id es w ithout the lipophilic arom atic ring have therefore  
b een  in vestig a ted  and are reported here.
Synthesis of Nitroim idazoleCarboranes
T o provide n itro im id a zo le -a lk y n es w ith  w ater-solubi- 
l iz in g  o x y eth y len e  u n its , th e  reaction seq u en ces show n  
in  S ch em e 1 w ere  adopted. As we reported prev iou sly ,20 
tr ea tm e n t o f  1 ,2-b is(2-ch loroethoxy)ethane (1) w ith  1 
e q u iv  o f the a lkoxide o f  propargyl alcohol in hot DM F  
ga v e  a good yield  o f the m onoalkyne 3. S im ilar  treatm ent 
o f  th e  h igher oligom er 2 afforded th e  longer-chain  m ono­
a lk y n e  4 in m oderate y ie ld , a long w ith  a sm a ll qu antity  
o f  th e  b is-a lk yne 5 T he y ield  o f  th is b is-a lk yn e  w as  
in creased  in exp erim en ts in w hich an ex cess o f  a lkoxide  
w a s em ployed. M odification o f our previous con d ition s20 
for th e  a lky la tion  o f the potassium  sa lt o f  2 -nitroim ida- 
zo le  (6) w ith 3  facilita ted  an  im provem ent in th e  y ield  o f  
th e  n itro im id a zo le -a lk y n e  7 from 43 to 66%. The  
a n a lo g o u s a lky lation  o f 6 w ith 4 gave th e  longer-chain  
n itr o im id a z o le -a lk y n e  8  w ith  three ethy len ed ioxy  un its.
C on struction  o f the ox im es, precursors o f the cor­
respond in g  a lip hatic  ca rb o ra n e-n itr ile  oxides, w as m ore 
ch a llen g in g . S chem e 2 sh ow s a seq u en ce o f m odel 
ex p erim en ts to te s t  the fea sib ility  o f  use o f  the a lip hatic  
carb oran e-n itr ile  oxides. 1 ,3 -D ith iane (9) w a s lith ia ted
and the a n io n  w as alkylated with brom ochlorobutane
(10), g iv in g  exclusively  the known2* (chlorobutyl)dithiane
(11) in  h ig h  y ie ld . Substitu tion  of chloride by propargyl 
alkoxide a t  e lev a ted  tem perature in d im ethylform am idc  
gave th e  required  d ith ia n e-a lk y n e  13. T h is  w as a c ­
com panied by an apparently unavoidable e lim in a tio n  
reaction o f  so m e o f  the substrate ch lorobutyld ith ianc to  
furnish s ig n ifica n t am ounts of the b u ten y ld ith ian e  12. 
This side  reaction  is probably due to d irect E 2  elim ination  
caused by th e  strongly  basic alkoxide. T h e  d i t h ia n e -  
carborane 14  w as formed in respectable y ie ld  in  the u su a l 
way20 by prolonged treatm ent of alkyne 13  w ith  decabo- 
rane(14) (B ioH h ) in  boiling acetonitrile, a  L ew is b ase. 
Thus our u s e 20 o f  dith ioacetal as a p ro tectin g  group for  
arom atic a ld eh y d es a ga in st the ravages o f  th is  p o ten t  
reductant ran be extended to analogous syn th on s for 
aliphatic a ld eh y d es. However, m ercury(II)-catalyzed  
deprotection, w h ich  was so  successfu l for th e  arom atic  
case,20 fa iled  com pletely for the a lip hatic  d ith ioaceta l, 
giving on ly  unidentifiable products o f degradation. Depro­
tection w a s , how ever, effected by the N -b rom osuccin im - 
ide/silver io n  m ethod, although rapid q u en ch  w ith  th io-  
sulfate w a s needed to prevent degradation o f  th e  a ldehyde  
15 under th e s e  oxid izing conditions. T h e  ox im e 16 w a s  
formed a s  a n  equim olar m ixture of geo m etr ica l isom ers, 
as revea led  by NMR. U nlike its  arom atic  co u n ter­
part,20 th e  corresponding nitrile oxide w a s  n o t iso la b le  
but form ation  by oxidation o f 16 w ith  so d iu m  hyp och lo ­
rite and rea ctio n  In situ  in  a tw o-phase a q u eo u s d ich lo- 
rom ethane sy s tem  w ith  the n itr o im id a zo le -a lk y n e  7  
gave th e  m od el n itro im id a zo le-iso x a zo le—carborane 17  
in  good y ie ld .
On th e  b a s is  o f  th is successfu l d em on stra tion  o f  th e
1,3-dipolar cycloaddition o f a  n itro im id azo le-a lk yn e w ith  
an aliphatic carb oran e-n itr ile  oxide, a tten tion  w as turned  
to the incorp oration  o f potentially  w a ter -so lu b iliz in g  
m ultip le 0 C H 2C H 20  u n its in the carborane arm  o f  th e  
target s tr u c tu r es  (Schem e 3). W ith th e  a im  o f  in trod u c­
ing tw o e th e r  oxygens into this chain, 1 ,3 -d ith ia n e  (9 )  
w as lith ia ted  an d  alkylated  w ith b is(2-ch loroethyl) e th e r  
(18) in te trahyd rofu ran , giving the e th er-lin k ed  (ha-  
loalkyD dith iane 19 in good yield, d esp ite  th e  u su a lly  
lower rea c tiv ity  o f  3-oxaalkyl halides. S u b stitu tio n  th en  
afforded th e  desired  bis-ether-linked d ith ia n e -a lk y n e  2 1 . 
As predicted by th e  model tetram ethylene sy s tem , e lim i­
nation w a s a ser io u s problem , giving th e  en o l e th er  2 0  
in 36% y ield . C learly, th e  alkoxide is  su ffic ien tly  basic  
even to rem ove th e  proton adjacent to e th e r  oxygen  to  
in itiate  E 2 e lim in a tio n . Conversion o f  th e  a lk y n e  21  to  
the d ith ia n e -c a r b o r a n e  2 2  with decaborane(14) w a s  
followed by deprotection  w ith N -brom osuccin im ide/silver  
nitrate to fu rn ish  the carborane a ld eh y d e  23 . T h is  
aldehyde w a s  found to be unstable to prolonged  sto ra g e  
and w as trea ted  im m ed iately  with h y d ro x y la m in e  in  
anhydrous e th a n o l, giving an equim olar m ixtu re  o f Z  and  
E stereo iso m ers o f  the ca rb oran e-ox im e 2 4  v ir tu a lly  
qu an tita tive ly .
W ith th is  b is-e th er-lin k ed  c a rb o ra n e-o x im e  24 now  
availab le, d ip o lar  cycloaddition w ith th e  n itro im id a zo lc  
alkyn es 7 and  8  w ith  three and four e th e r  groups, 
respectively , w a s in vestig a ted  O xidative e lim in a tio n  o f  
the m ixture o f  stereo isom ers of 24 w ith sod iu m  hyp och lo­
rite gave th e  corresponding nitrile o x id e  w h ich  w a s  
allowed to rea ct in s itu  w ith  alkynes 7 and 8 . T h e y ield
of the sh ortcr-chain  n itro im id a zo le -iso x a zo le -ca rb o ra n e
(24) Secbach. D.; Jones. N. R.. Corey. E. J. J. Org. Chem. 1968. 33. 
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• Reagents and conditions: (i) Nai0TH F/-78 * C  20 *C; (ii) H O C CH 2OH/NaH/DMF/100 *C; (iii) BioH,«/MeCN/reflux; (iv)
iV-bromosucdnimide/AgNOj/water/MeCN; (v) NHjOH-HCl/NazCOj/EtOH; (vi) NaOCl/water/CH2Cl2 .
Scheme 3. Synthesis of Target Polyether-Lmked Nitroimidazole-Isoxazole-Carboranes 25 and 26a









7: n « 2 




25: n -  2 
26: n -  3
° Reagents and conditions: (i) NaH/THF/-78 * C  20 *C; (ii) NaH/HCsCCH2OH/DMF/120 *C. (n il Bi0Hi«/MeCN/renux. (iv)
A^-bromosuccinimide/AgNOywater/MeCN; (v) NH2 0 H-HCl/Na2C0 3 /Et0 H; (v i) NaOCl/watcr/CH2Cl2
25  w as not able to be raised above a d isap p o in tin g  13% 
in experim en ts where reaction tim es and co n cen tra tio n s  
w ere varied. On the other han d , the longer-chain  a n a ­
logue 26  w as formed in 36% y ield , based on th e  o x im e  
24 . w hich corresponds to 90% w h en  com pared w ith  th e  
am oun t o f  n itro im id a zo le-a lk y n e  8  not recovered from
the reaction  m ixture. A lternative o x id a n ts , su ch  a s  
chloram ine-T . w ere  le s s  effective. T he o x im e  w a s  co m ­
p le tely  consum ed in a ll experim ents an d  no m a ter ia l  
co n ta in in g  the n itr ile  oxide group could  be d e tec ted  
am o n g st th e  products o f  th e  reaction. T h e se  o b se r v a ­
tion s, coupled w ith  t h e  h igh  recovery o f  th e  a lk y n e , p o in t
T um or-T argeted  Borancs J. Org. Chem.. Vol. 59. No. 23, 1994 7011
S c h e m e  4 . A ttem pted  Syn th esis o f E xtended  P o ly c th cr -L in k cd  N itro im id a zo le -Iso x a zo le -C a rb o ra n c  32°
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• Reagents and conditions: (i) NaH/THF/-78 * C  20 °C; (ii) NaH/HC=CCH2OH/DMF/l20 °C; (iii) BioHi«/MeCN/reflux: (iv)
jV-bromosuccininiide/AgNOywater/MeCN; (v) NHjOH-HCl/NazCOa/EtOH.
to the instability of the intermediate nitrile oxide being 
the cause of the relatively modest yields of isoxazoles.
Since the physical properties (polarity, solubility, etc.) 
of nitroimidazole—carboranes 25 and 26, with five and 
six ether oxygens, respectively, were considerably im­
proved with respect to the aryl analogues previously 
reported,20 synthesis of the extended analogue 32, with 
eight ether oxygens, was attempted (Scheme 4). Alky­
lation of the anion of 1,3-dithiane (9) with dichloro 
compound 2 a t  ambient temperature gave the (trioxa- 
chloroalkyl)dithiane 27. The decreased reactivity of the 
polyether chain, as compared with polymethylene ana­
logues, was reflected in the low (25%) yield of the 
dithiane-alkyne 28 through substitution with propynox- 
ide ion in hot dimethylformamide. The formation of the 
carborane 29 under the usual conditions (decaborane- 
(14), refluxing acetonitrile) was, however, unaffected and 
proceeded relatively efficiently. Deprotection was again 
effected by bromination, giving carborane-aldehyde 30 
which was converted immediately to its oxime 31. 
However, the sensitivity of the cycloaddition reaction to 
the structure of the oxime (and hence the nitrile oxide) 
was revealed in the failure to produce isolable quantities 
of the desired nitroimidazole-isoxazole-carborane 32 
upon treatment of 31 with the nitroimidazole-alkyne 8 
and sodium hypochlorite in aqueous dichloromethane. 
Much unreacted alkyne 8 was detected by TLC, although 
the oxime 31 was consumed, suggesting that the nitrile 
oxide derived from 31 was particularly unstable.
Conclusions
The present work has demonstrated the feasibility of 
extending the known20 1,3-dipolar cycloaddition of car- 
borane-substituted aryl nitrile oxides with nitroimida­
zole-alkynes to the use of the considerably less stable 
aliphatic carborane-nitrile oxides. The synthesis of the 
rutroimidazole—carborane 26 in adequate yield based on 
the relatively expensive starting materials 2-nitroimi- 
dazole (overall yield 36%) and decaborane(14) (overall 
yield 18%) has enabled sufficient quantities of this
relatively polar carborane to be available for biological 
evaluation.
Experimental Section
The solvent for NMR spectra was CDClj. The external 
standard for llB NMR w as BFjrEtaO. Purity for all novel 
compounds was assessed by elem ental microanalysis or by lH 
NMR; the *H NMR spectra for compounds 4, 5, 7, 8, 12-17, 
19-31 are available as supplementary material. Brine refers 
to saturated aqueous NaCl. DMF refers to dim ethylform a­
mide; THF refers to tetrahydrofuran. Dry EtOH was dried 
by distillation from MgfOEth immediately before use. Solu­
tions in organic solvents were dried with anhydrous MgSO< 
Distillations were effected using a Kugelrohr apparatus and 
bps refer to the temperature o f the oven. The stationary phase  
for chromatography was silica gel. Solvents were evaporated 
under reduced pressure. 3-(2-(2-(2-Chloroethoxy)ethoxy)- 
ethoxy)propyne (3) was prepared as previously described by 
us.16
3 -(2 -(2 -(2 -(2 -C h lo r o e th o x y )e th o x y )e th o x y )e th o x y )-  
propyne (4) and B is(2 -(2 -(p ro p -2 -y n y lo x y )e th o x y )e th y l)  
E ther (5). Sodium hydride (1.20 g, 50 mmol) was stirred with  
propyn-3-ol (2.80 g, 50 mmol) in dry DMF for 30 min. Bis(2- 
(2-chloroethoxy)ethyl) ether 2 (11.55 g. 50 mmol) was added 
dropwise and the mixture w as stirred at 130 °C for 2 h. The 
solvent was evaporated and the residue, in CHjCh. was 
washed with water and dried. The evaporation residue was 
subjected to chromatography (pentane/EtjO 3:1. 2:1, and then  
1:1). From the first fraction was recovered 2 (3.25 g. 23%) 
From the second fraction w as obtained the monoalkyne 4 (3 67 
g. 29%) as a colorless oil: IR v 2120 cm*1; NMR 6» 2.43 (1 H. 
t, J  = 2.4 Hz). 3 .6 -3 .8  (16 H. m). 4.21 (2 H. d. J  =  2.4 Hz), 
mass spectrum (Cl) m /z  251.1050 (M + H) (CnHw^ClO, 
requires 251.1050). From the third fraction was isolated the  
bis-alkyne 5 (950 mg, 7%) a s a colorless oil: IR v 2130 c in '1; 
NMR 6 h 2.44 (2 H, t. J  =  2.4 Hz), 3.67 (8 H. s). 3.69 (8 H. m).
4.21 (4 H. d. J  = 2.4 Hz); m ass spectrum (Cl) m /z  271 1545 
(M + H) (CiiHm^CIO* requires 271.1545).
2 - N i t r o - l - ( 2 - (2 - (2 - ( p ro p y n - 3 -y lo r y ) c th o x y )e th o x y ) c th -
yD im idazolc  (7). 2-Nitroimidazole (6) (570 mg. 5 mmol) was 
stirred at 130 *C with KOBu' (560 mg. 5 mmol) in DMF (10  
mL) for 1 h then cooled to 80  °C. KI (50 mg) and the alkyne 
3 (1.03 g. 5 mmol) were added and the mixture was stirred at 
120 °C for 16 h. The solvent was evaporated and the residue
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was treated with water (10 mL) and then extracted with ether. 
Chromatography (CH2CI2) of the evaporation residue gave the 
nitroimidazole-alkyne 7 (930 mg, 66%) as a pale yellow oil: 
IR v 2120 cm"1; NMR 6« 2.45 (1 H, t, J  = 2.4 Hz). 3.60 (4 H. 
s). 3.6—3.7 (4 H. m), 3.86 (2 H ,W  = 4 i  Hz). 4.20 (2 H, d. J  
= 2.4 Hz). 4.63 (2 H. t, J  = 4.9 Hz). 7.14 (1H, s). 7.29 (1H. s); 
mass spectrum (Cl) m/z 284.1246 (M + H) (CisHuNsOs 
requires 284.1246).
2-Nitro-l-(2-{2-{2-{2-(propyn-3-yIoxy)cthoxy)ethoxy)- 
ethoxy)ethyDimidazole (8). 2-Nitrotmidazole (6) (450 mg, 
4 mmol) was stirred at 120 *C with KOBu* (450 mg, 4 mmol) 
in DMF (5 mL) for 15 min then cooled to 80 *C. Nal (40 mg) 
and the alkyne 4 (1.00 g, 4 mmol) were added and the mixture 
was stirred at 120 *C for 16 h. The evaporation residue was 
treated with water (20 mL) and was extracted with CH3CI2. 
Chromatography (CHjfClaZEtaO 5:1) of the evaporation residue 
gave the nitroimidazole-alkyne 8 (520 mg, 40%) as a pale 
yellow oil: NMR dH 2.44 (1 H, t, J  — 2.4 Hz). 3.6-3.7 (12 H, 
m), 3.86 (2 H, t, J  = 5.0 Hz), 4.19 (2 H. d, J  =  2.4 Hz), 4.63 (2 
H, t, J  =  5.0 Hz), 7:13 (1 H, s), 736 (1 H, s); mass spectrum 
(Cl) m /z  328.1509 (M + H) (CmHjzNjO* requires 328.1509).
2-(4-Chlorobcrtyi)-L3-dithiane (11). Butyllithium (2 M 
in hexanes, 20 mL, 40 mmol) was added to L3-dithiane (9) 
(4.80 g, 40 mmol) in THF (100 mL) and the mixture was stirred 
for lh , before being cooled to-78  *C. l-Bromo-4-chlorobutane 
(10) (8.58 g, 60 mmol) was added and the mixture was stirred 
at —20 *C for 18 h. The evaporation residue, in CH2C12, was 
washed with water and dried. Distillation gave 2-(4-chlorobu- 
tyD-l,3-dithiane (11) (6.88 g, 82%) as a colorless liquid: bpo s 
170 *C (lit*  bpo.n 110 *C); NMR <5H 1.6-1.9 (7 H, m), 2.11 (1 
H. m), 2.85 (4 H, m), 3.54 (2 H, t, J  = 6.5 Hz), 4.06 (1 H, t, J  
= 6.5 Hz).
2-(But-l-en-4-yl)-L3-dithiane (12) and 2-(4-(Propyn-3 - 
yloxy)butyl)-13-dithiane (13). Piopyn-3-oI (220 mg, 4 
mmol) was added to sodium hydride (96 *»g, 4 mmol) in dry 
DMF (10 mL) and the mixture was stirred for 30 min. The 
(chloroalkyl)dithiane 11 (840 mg, 4 mmol) was added and the 
mixture was heated at 100 *C for 2 h. The evaporation 
residue, in CH2CI2, was washed with water and dried. The 
solvent was evaporated and the residue was subjected to 
chromatography (pentane/CHjCk 4:1 and then 3:1). From the 
earlier fraction was obtained 2-(but-l-en-4-yi)-13-dIthiane (12) 
(240 mg, 34%) as a colorless oil: NMR£h 1.85(2 H,brq,J = 
7 Hz), 1.87 (1 H, m), 2.15 (1 H. m), 2.27 (2 H, br q, J  = 7 Hz),
2.85 (4 H, m), 4.04 (1 H. t, J  = 7.0 Hz), 5.02 (1 H, br d, J  =  10 
Hz), 5.07 (1 H, br d, J  = 17 Hz). 5.80 (1H, ddt, J  = 17.0,10.3,
6.6 Hz); mass spectrum (El) m/z 174.0537 (M) (CsHmSj 
requires 174.0537). From the later fraction was isolated 244- 
(propyn-3-yloxy)butyl)-l,3-dithiane (13) (480 mg, 52%) as a 
colorless oil: NMR dH 1.6-2.0 (7 H, m), 2.12 (1 H, m), 2.42 (1 
H, t, J  = 2.4 Hz), 2.85 (4 H, m), 3.52 (2 H, t, J  = 6.2 Hz), 4.05 
(1 H, t, J  = 6.9 Hz), 4.13 (2 H, d, J  = 2.4 Hz); mass spectrum 
(El) m/z 230.0799 (M) (CnHwOS* requires 230.1799).
2-(4-(l,2-Dicarba-closo-dodecaboran(12)-l-ylmethoxy>- 
butyl)-l,3-dithiane (14). Decaborane(14) (Bt0Hu) (210 mg.
1.7 mmol) was stirred with dry MeCN (10 mL) for 3 h. The 
dithiane-alkyne 13 (400 mg, 1.7 mmol) was added and the 
mixture was boiled under reflux for 3 d. The solvent was 
evaporated. Chromatography (pentane/CH2Cl2 10:1) gave the 
carborane-dithiane 14 (290 mg, 49%) as a white solid: mp 72- 
74 ®C; NMR <5« 2.3 (10 H, br q. J „ - h  = 150 Hz), 1.6-2.2 (8 H. 
m), 2.85 (4 H. m). 3.46 (2 H. t, J  = 5.3 Hz), 3.83 (2 H, s), 3.98 
(1 H. br s). 4.05 (I H. t. J  = 6.8 Hz). Anal. (CnHaBwC^) C.
H.
4-(l,2-Dicarba-c/oso-dodecaboran(12)-l-ylmethoxy)- 
pcntanal (15). N-Bromosucdnimide (1.25 g, 7 mmol) and 
AgNOa (1.36 g, 8 mmol) in MeCN (16 mL) and water (4 mL) 
were added to the carborane-dithiane 14 (480 mg, 1.4 mmol) 
in MeCN (16 mL) and water (4 mL), and the mixture was 
stirred for 10 min. Saturated aqueous Na2S03 (2.0 mL) was 
added, followed after 1 min by saturated aqueous Na2C03 (2.0 
mL), followed after 1 min by brine (2.0 mL). The suspension 
was filtered through Celite. The filtrate was treated with 
brine (20 mL) and extracted with CH2Cl2. Chromatography 
(CH2CI2) of the evaporation residue gave the carborane- 
aldehyde 15 (260 mg, 71%) as a colorless oil: IR v 1725,2590 
cm'1; NMR <5H 2.2 (10 H, br q, J ».K = 150 Hz). 1.63 (4 H, m).
2.48 (2 H, dt, J  = 1.4, 6.8 Hz). 3.47 (2 H, t. J  =  5.9 Hz), 3.84 
(2 H, s), 3.94 (1 H, br s), 9.78 (1 H, t, J  = 1.4 Hz); mass 
spectrum (Cl) m tz  2159.2701 (M + H) (CgHzj^B^BgOj requires 
259.2701)
5-(l,2-Dicarba-cZ0so-dodecaboran(12)-l-ylxnethoxy)- 
pentanal Oxime (16). The carborane—aldehyde 15 (260 mg,
1 mmofT^ was stirred with hydroxylamine hydrochloride (350 
mg, 5 mmol) and anhydrous Na2C03 (270 mg, 2JS mmol) in 
dry EtOH (10 mL) for 24 h. Further portions of hydroxylamine 
hydrochloride (350 mg, 5 mmol) and NajCOj (270 mg, 2.5 
mmol) were added, and stirring was continued for a further 
18 h. The solvent was evaporated and the residue, in 
CH2CI2, was washed with water and dried. Chromatography 
(CH2CI2) of the evaporation residue gave a mixture of E  and 
Z isomers of the carborane-oxime 16 (221 mg, 81%) as a 
colorless oil: IR v 2590, 3300 (br) cm-1; NMR 6a 1-21 (4 H, 
m), 2.2 (10 H, br q, Jb -b  =  150 Hz), 2.26 (1 H, m), 2.41 (1 H, 
m), 3.47 (2 H, m), 3.84 (2 H, s). 3.97 (1 H, br s), 6.72 (0.5 H, t. 
J  =  5.5 Hz), 7.42 (0.5 H, t, J  = 5.8 Hz), 8.9 (0.5 H , br), 10.5 
(0.5 H, br); NMR <5C  22.51, 2230, 28.54, 28.80, 28.93, 29.03, 
57.57,71.49,71.68,7239,15130,152.06; mass spectrum (FAB 
negative ion) m/z 273.2635 (M — H) (CsH2210BuB9NO2 requires 




ethyD-2-nitroimidazole (17). The carborane—oxime 16 (140 
mg, 0.5 mmol) and the nitroimidazole-alkyne 7 (170 mg, 0.6 
mmol) in CH2CI2 (5 mL) were stirred with aqueous NaOCl (8% 
available chlorine, 2 mL) for 2 <L Water (5 mL) was added 
and the mixture was extracted with CH2CI2. The evaporation 
residue was subjected to chromatography (EtgO and then 
EtOAc). From the EtfeO fraction was recovered the nitroimi- 
dazole—alkyne 7 (90 mg, 53%). From the EtOAc fraction was 
obtained the nitroimidazole—carborane 17 (130 mg, 47%) as 
a colorless gum: NMR <5h 1.65 (4 H, m), 2.2 (10 H, br q, J b -h  
= 150 Hz), 2.67 (2 H, t ,«/ =  7J2 Hz), 3.48 (2 H, t, J  =  6.0 Hz).
3.6—3.7 (8 H. m). 3.84 (2 H, s). 335  (2 H, t, J  =  5.0 Hz), 3.96 
(1 H, br s). 4.61 (2 H, s), 4.61 (2 H, t, J  =  5.0 Hz), 6.11 (1 H, 
s), 7.10 (1 H, d, J  =  1.0 Hz), 735 (1 H, d, J  =  L0 Hz); mass 
spectrum (FAB positive ion) m/z 5573760 (M + H) 
(CaoHa^BioN*^ requires 5573749).
2-(2-(2-Chloroethoxy)ethyU-13-dithiane (19). Butyl­
lithium (2 M in hexanes, 50 mL, 100 mmol) was added to 1,3- 
dithiane (9) (12.0 g, 100 mmol) in THF (250 mL) at -7 8  *C 
and the mixture was stirred at this temperature for 1 h. Bis- 
(2-chloroethyl) ether (18) (143 g, 100 mmol) was added and 
the mixture was stirred at —20 *C for 16 h. The solvent was 
evaporated and the residue, in CH2CI2, was washed with water 
and dried. Distillation gave the (chloroalkyDdithiane 19 (13.77 
g, 61%) as a colorless liquid: bpo.i 160 *C; NMR 6n 1-89 (1 H. 
m), 2.03 (2 H, dt, J  =  7.0,6.1 Hz), 2.12 (1 H. m), 2.80-2.95 (4 
H, m), 3.60-3.75 (6 H, m), 4.23 (1 H, t, J  = 7.0 Hz); mass 
spectrum m/z (Cl) 227.0331 (M + H) (C«HiS35C10S2 requires 
227.0331).
2-(2-(Ethenyloxy)ethyl)-13-dithiane (20) and 2-(2-(2- 
(Propyn-3-yloxy)ethoxy)ethyl)-13-dithiane (21). A stirred 
suspension of sodium hydride (1.51 g, 63 mmol) in dry DMF 
(60 mL) was treated with propyn-3-ol (3.47 g, 62 mmol) in dry 
DMF (40 mL) and the mixture was stirred for 30 min. Nal 
(100 mg) and the dithiane 19 (14.04 g, 62 mmol) were added 
and the mixture was stirred at 120 *C for 3 h. The evaporation 
residue, in CHiCfe, was washed with water and dried. The 
evaporation residue was subjected to chromatography (pen- 
tane/CH2Cl2 1:1. and then CH2C12). From the earlier fraction 
was obtained 2-(2-(ethenyloxy)ethyI)-l,3-dithiane (20) (4.21 g. 
36%) as a colorless oil: IR v 1625 cm*1; NMR 6u 1.91 (1 H. 
m). 2.11 (3 H. m). 2.86 (4 H. m). 3.86 (2 H. t. J  = 6.1 Hz). 4.02 
(1 H. dd. J  = 6.9, 2.1 Hz), 4.21 (1 H, t, J  = 7 Hz), 4.21 (1 H. 
dd, J  = 14.3. 2.1 Hz). 6.46 (1 H. dd, J  = 14.3, 6.9 Hz); mass 
spectrum (El)m/z 190.0486(M)(C8H14OS2 requires 190.0486). 
From the CHrCh fraction was obtained the dithiane-alkyne 
21 (6.20 g. 47%) as a colorless oil: NMR <5h 188 (1 H. m). 2.04 
(2 H. q. J  = 7.0 Hz), 2.10 (1 H, m). 2.44 (1 H, t, J  = 2.4 Hz).
2.85 (4 H. m). 3.65 (6 H, m). 4.21 (1 H, t, J  = 7.0 Hz). 4.22 (2 
H, d, J  = 2.4 HzV, mass spectrum (El) m/z 246.0748 (M) 
(CuHisOA requires 246.0748).
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2-<2-<2-<l^-Dicarba-c£o$o-dodccaboraa(12)-l-yI)ethoxy)- 
ethyl)-W-dithiane (22). Decaboranc(14) (305 mg, 2.5 nunol) 
was stirred with MeCN (10 mL) for 3 h. The dithiane-alkyne 
21 (620 mg, 2.5 mmol) was added and the mixture was boiled 
under reflux for 3 d. The solvent was evaporated. Chroma­
tography (pentane/CHzClz 1:1) gave the carborane-dithiane 22 
(550 mg, 60%) as a colorless oil: IRv 2600 cm*1; NMR 6k 1.2—
3.2 (10 H, br q. J b-h = 150 Hz), 1.86 (1H, m). 1.98 (2 H, dt, J  
= 7.1,5.9 Hz), 2.14 ( lH ,m ) ,2 i2 (2 H ,U  = 5.6 Hz), 2.87 (4 
H, m). 3.51 (2 H, t, J  =  5 Hz), 353 (2 H. t. J  = 5.9 Hz), 4.08 
(1 H, br s). 4.15 (1 H, t, J  =  7.1 Hz); NMR 6C 2553, 30.12, 
36.39, 43.88, 57.60, 67.33, 69.99, 71.28. 72.14, 72.80; mass 
spectrum m/z (FAB positive ion) 367.2493 (M + H) 
(CiiHb uBwO A  requires 367.2540).
3-(2-{lf2-Dicarba-clos&-dodecaborau(12)-l-ylmethoTy)~ 
ethoxy)propanal (23). The carborane-dithiane 22 was treated 
with N-bromosucrinimide and AgNOs in aqueous MeCN, as 
for the synthesis of 16, to give the carborane—aldehyde 23 (610 
mg, 86%) as a yellow oik IR r  1725,2590 cm*1; NMR <5h 22  
(10 H, br q, Jb-h — 150 Hz). 258 (2 H, dt, J  = 2 2 ,6.7 Hz). 3.6 
(4 H, m), 3.79 (2 H, t, J  =  6.7 Hz), 3.96 (2 H, s), 4.02 (1H, br 
s), 9.89 (1 H, d, J  — 2 2  Hz). This material was used 
immediately without further purification.
3-(2-(L2-Dicarba-cfoso-dodecaboran(12)-l-yimethoxy)- 
ethoxy)propanal Oxime (24). The carborane-aldehyde 23 
(450 mg, 1.6 mmol) in dry EtOH (100 mL) was treated with 
anhydrous NasCOs (850 mg, 8 mmol) and HONHrHCl (1.11 
g, 16 mmol) for 40 h. The evaporation residue, in CH2CI2, was 
washed with water and dried. The solvent was evaporated to 
give the carborane-oxime 24 (460 mg, 97%) as a pale yellow 
gum: IR v 2590,3340 (br) cm*1; NMR 6b L4-2.7 (10 H, br q, 
J b - h  = 150 Hz), 2.48 (1 H, q, J  =  6 Hz), 2.66 (1 H, q, J  =  5.5 
Hz), 3.55-3.67 (6 H, m), 3.94 (1H, s), 3.95 (1 H, s), 4.13 (1H, 
br s), 5.1 (0.5 H, br), 6.81 (0.5 H, t), 7.46 (0.5 H, t, J  = 5.8 Hz),




ethoxy) ethyD-2-nitroi m i dazole (25). The carborane—oxime
24 (40 mg, 0.14 mmoD and the nitroimidazole—alkyne 7 (40 
mg, 0.14 mmol) in CHzCla (2 mL) were stirred with aqueous 
NaOCl (8% available chlorine, 25 mL) for 3 d. The mixture 
was extracted with CH2CI2- The evaporation residue was 
subjected to chromatography (EtzO and then EtOAc). From 
the EtOAc fraction was obtained the nitroimidazole—carborane
25 (10 mg, 13%) as a colorless gum: IR v 2590 cm*1; NMR 6k
2.2 (10 H, br q, JB-h = 150 Hz), 2.93 (2 H, t, J  = 6.6 Hz),
3.60—3.75(14 H, m). 3.86 (2 H. t, J = 5 2  Hz). 352 (2 H, s), 
4.13 (1 H, br s), 4.60 (4 H, m), 6.15 (1 H, s), 7.10 (1 H, br s). 
7.25 (1 H. br s); mass spectrum (FAB positive ion) m/z 
571.3788 (M + H) (CjoHm^B^BsN.O, requires 571.3771).
1-(2-(2-(2-(2-((3-(2-(2-(l,2-Dicarba<cZo$o-dodecaboran-
(12)-l-ylmethoxy)ethoxy)ethyl)isoxazol-5-ylmethoxy)- 
ethoxy)ethoxy)ethoxy)ethyD-2-nitroimidazole (26). The 
carborane-oxime 24 (130 mg, 0.45 mmol) and the nitroimi­
dazole-alkyne 8 (150 mg, 0.45 mmol) in CH2CI2 (5 mL) were 
stirred with aqueous NaOCl (8% available chlorine, 2 mL) for 
2 d. Brine was then added and the mixture was extracted with 
CH2CI2. The evaporation residue was subjected to chroma­
tography (Et^ O and then EtOAc). From the Et^ O fraction was 
recovered the nitroimidazole-alkyne 8 (90 mg, 60%). From 
the EtOAc fraction was obtained the nitroimidazole—carborane
26 (100 mg, 36%) as a pale yellow gum: IR v  2590cm*1; NMR 
6h 2.2 (10 H, br q, J B_H = 150 Hz). 251 (2 H, t, J  -  6.4 Hz).
3.60-3.75 (18 H, m), 3.86 (2 H, t, J  =  5.0 Hz), 3.92 (2 H, s).
4.15 (1 H, br s), 4.62 (4 H, m), 6.18 (1 H, s). 7.11 (1 H. d. J  = 
0.8 Hz). 7.28 (1 H, d. J  = 0.8 Hz); NMR 6s -15.18 (4 B. m), 
-13.66 (2 B, d. Jb-h  = 150 Hz), -11.14 (2 B, d, J b-h = 147 
Hz). -6.90 (1 B. d. JB_H = 150 Hz). -5.04 (1 B. d, JB.H = 150 
Hz); mass spectrum (FAB negative ion) m/z 613.3872 (M -  
H) (C22H<1IOB2nBsN<09 requires 613.3877).
2-(2-(2-(2-(2-Chloroethoxy)ethoxy)ethoxy)ethyl)-l,3- 
dithiane (27). Butyl lithium (2 M in hexanes, 20.5 mL. 41 
mmol) was added to 1,3-dithiane (9) (4.80 g, 40 ixxrool) in dry 
THF (80 mL) at —78 *C under N2 and the mixture was stirred 
at this temperature for 1 h. Bis(2-(2-chloroethoxy)ethyl) ether 
(2) (9.24 g, 40 mmol) was added and the mixture was stirred
at -2 0  *C for 20 h. The solvent was evaorated and the residue, 
in CH2CI2 , was washed with water and dried. Chromatogra­
phy (pcntane/CH2 Cl2  1:1, and then CHjClj) gave the (chloro- 
alkyl)dithianc 27 (5.16 g, 49%) as a pale yellow oil: NMR <5h
1.89 (1 H, m), 2 .0-2 .2  (3 H, m). 2.85 (4 H. m). 3 .6 -3 .8  (14 H. 
m), 4.20 (1 H, t, J  =  7.0 Hz); mass spectrum (FAB positive 
ion) m /z  314.0772 (M) (CuHa^ClOaS* requires 314.0777).
2-(2-(2-(2-(2-(Propyn-3-ylory)ethoxy)ethoxy)ethoxy) - 
cthyl)-l»3-dithiane (28). Propyn-3-ol (560 mg, 10 mmol) was 
added to sodium hydride (240 mg, 10 mmol) in dry DMF (10 
mL) and the mixture was stirred for 30 min. The chloroalkyl— 
dithiane 27 (3.14 g, 10 mmol) was added and the mixture was 
stirred at 120 *C for 3 h. The solvent was evaporated. The 
residue, in CH2 CI2 , was washed with water and dried. Chro­
matography (CHzCiyEtaO 20:1, and then 10:1) gave the 
dithiane—alkyne 28 (830 mg, 25%) as a pale yellow oil: IR v 
2120 cm*1; NMR dH 1 5 -2 .2  (4 H, m), 2.44 (1 H, t, J  =  2.4 
Hz), 2 5 5  (4 H, m), 3.63 (14 H, m), 4.20 (1 H, t, J  =  7.1 Hz).
4.21 (2 H, d, J  -  2.4 Hz); mass spectrum (FAB positive ion) 
m /z 335.1317 (M +  H) (CisHzAS* requires 335.1351), 334.1272 
(M) (CisHjjO^Sj requires 334.1273).
2-(2-{2-(2-(2-(lf2-Dicarba-e/o*o-dodecaboran(12)-l-yl-
m ethoxy)ethoxy)ethoxy)ethoxy)ethyD -l*3-dithiane (29).
Decaborane(14) (120 mg, 1 mmol) was stirred in dry MeCN 
(10 mL) for 3 h. The dithiane-alkyne 28 (330 mg, 1 mmol) 
was added and the mixture was boiled under reflux for 3 d. 
Chromatography (CHjCl^EtzO 20:1) of the evaporation residue 
gave the carborane-dithiane 29 (260 mg, 58%) as a  pale yellow 
gum: IR v 2590 cm"1; NMR <51.85 (1 H, m), 2.04 (2 H, q, J  =
7.0 Hz), 2.08 (1 H, m), 2.2 (10 H, br q, Jb-h =  150 Hz), 2.85 (4 
H, m). 3.64 (14 H, m), 3.96 (2 H, s), 4.10 ( 1 H, br s), 4.19 (1 H. 
t, J = 7 .0  Hz); tn a«  spectrum (FAB positive ion) m /z  452.3060 
(M +  H) (C,sH3 610B211B,O<S2  requires 452.3058).
3-(2-(2-(2-(l,2 -D icarba-cZ oro-dodecaboran(12)-l-y l- 
m ethoxy)ethoxy)ethoxy)ethoxy)propanal (30). The car­
borane—dithiane 29 was treated with N-bromosiicrinimide and 
AgNOz in  aqueous MeCN, as for the synthesis of 15, except 
that the eluant for chromatography was CHzClz/EtjO, to give 
the carborane—aldehyde 30 (74%) as a pale yellow gum: IR »• 
1725, 2590 cm*1; NMR 6b 22. (10 H, br q. J b-h =  150 Hz). 
2.70 (2 H, dt, J  =  6.2,1.8 Hz), 3.62 (12 H, m). 3.83 (2 H. t, J  
=  6.2 Hz (becomes s on decoupling at 6 2.70)), 3.96 (2 H, s),
4.10 ( 1 H, br s), 9 5 0  (1 H, t, J  =  1.8 Hz); mass spectrum (FAB 
positive ion) m /z  345.3070 (M +  H — HjO) (Ci2 H2 9 l0B2 llB*O« 
requires 345.3069); mass spectrum (Cl) m /z  307.2913 (100%) 
(M +  H -  HjOCHCHO) (C^H^B^BsO, requires 307.2913).
3 -(2 -(2 -(2 -(l,2 -D icarba-cZ oso-dodecaboran(12)-l-y l- 
m ethoxy)ethoxy)ethoxy)ethoxy)propanal f lr im e  (31). 
The carborane—aldehyde 30 was treated with HONHrHCl and 
NazCOj, as for the synthesis of 16, except that chromatography 
was omitted, to give an equimolar mixture of geometrical 
isomers of the carborane-oxime 31 (80%) as a colorless gum: 
IR v 2590,3350 (br) cm*1; NMR 6 k  2.2 (10 H, br q, Jb-h  *  150 
Hz), 2.49 (1 H, q. J  =  6.2 Hz), 2.66 (1 H, q, J  =  6.2 Hz), 3.64 
(14 H, m), 3.96 (2 H. s), 4.12 (1 H. br s), 6.85 (0.5 H. t, J  =  6.2 
Hz). 7.48 (0.5 H, t, J  = 6.2 Hz), 8.0 (1 H, br); mass spectrum 
(FAB positive ion) 10B/I1B isotope cluster centered at m lz  378 
(M + H).
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1. INTRODUCTION
1-Aryl-3,3-dialkyltriazenes (1, Fig. 1) are carcinogens (Preussmann ct al., 1969a; Druckrey, 1913) 
and the dimethyl analogues (1; R \ R" CH3) show potent antineoplastic activity against rodent tumors 
(Clarke et al., 1955; Burchenal et al., 1956). Use of these potently biologically active compounds has 
also been claimed for such diverse applications as herbicides (Mazza et al., 1974), reagents for the 
determination of heavy metals (Popescu and Danet, 1983) and agents to render grain unpalatable to 
pests (Adams and Wright, 1964). Structure-antitumor activity studies on 1-aryl-3,3-dialkyltriazenes 
have shown that at least one W-methyl group is necessary for activity and that substitution in the 
phenyl ring has little effect on activity against the TLX5 lymphoma in mice (Audette et al., 1973; 
Connors et al., 1976). However, quantitative structure-activity relationships (QSAR) established by 
Hatheway et al. (1978) and by Trinajstic et al. (1989) have indicated a good correlation between 
antitumor activity and the presence of electron-donating substituents on the phenyl ring but that 
partition coefficient (expressed as log P) has little effect. Various attempts have been made to attach 
the 3,3,-dimethyltriazen-l-yl-phenyl ‘warhead’ to ‘delivery’ moieties such as 2,4-diaminopyrimidines 
(Bliss et al., 1987) and peptides (lonescu et al., 1981). 3-Acyl-l-(2-chloroethyl)-3-methyltriazenes 
have also been claimed to be useful antineoplastic agents (Michejda and Smith, 1989). During the 
last 25 years, the role of metabolism in the mechanisms of the carcinogenicity and cytotoxicity 
of aryldialkyltriazenes has been studied extensively. However, many important aspects of 
these mechanisms remain enigmatic. One heteroaryldimethyltriazene, 5-(3,3-dimethyltriazen- 
l-yl)imidazole-4-carboxamide (dacarbazine, DTIC; 2, Fig. 1), is of moderate clinical 




3: R = CH:CH,C1; R .R ' = H
■4: R = CH,: R .R" = H
5: R = CH jCH jCI. R .R" = C H ,
6: R = C H .C H IC I ;R = C H , :R -  = H
RRNOC
Fig . 1. Structures o f arylalkyhriazenes (1), dacarbazine (2), m itozolom ide (3), temozolomide
(4) and analogues.
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disease which is resistant to therapy with MOPP (a combination of mechlorethamine. vincristine, 
procarbazine and prednisone) (Loo et al., 1976; Spassova and Golovinsky, 1985). Some 1-aryl-3.3- 
dimethyltriazenes and l-aryl-3-methyItriazenes also show strong antimetastatic activity which is 
probably mediated through xenogenization of the tumor cells, leading to attack by the immune 
system (Nardelli et al., 1984; Grill et al., 1987; Nifontov el al.. 1988). Although DNA is generally 
taken to be the biochemical site of cytotoxic, carcinogenic and mutagenic action of triazenes. a 
correlation between inhibition of Ca2 * -activated ATPase and antimetastatic activity against the 
murine Lewis lung carcinoma has been noted (Nifontov et al., 1988). Curiously, most studies of 
the metabolism and mechanism of the antineoplastic action of dimethyltriazenes have been carried 
out using substituted phenyldimethyltriazenes rather than dacarbazine itself.
Recently, a number of cyclic arylmonoalkyltriazenes, the 3-alkyl-8-carbamoylimidazo[5.1 -d\-
l,2,3,5-tetrazin-4(3H)-ones (e.g. 3-6, Fig. 1) have been designed as potential therapeutic alterna­
tives to dacarbazine (Stevens et al., 1984). They exhibit potent antineoplastic properties in rodents 
(Hickman et al., 1985; Fodstad et al., 1985). Mitozolomide (8-carbamoyl-3-(2-chloroethyl)- 
imidazo(5,l-z/]-l,2,3,5-tetrazin-4(3H)-one; 3) underwent clinical trial and was found to cause severe 
prothromocytopenia as a clinically unacceptable, dose-limiting toxicity (Harding et al.. 1988). 
Temozolomide (8-carbamoyl-3-methylimidazo[5,\-d)-1,2,3,5-tetrazin-l(3H)-one; 3) is currently 
under clinical evaluation.
The chemical properties and therapeutic aspects of the l-aryl-3,3-dialkyltriazenes and the 
chemical properties of the imidazotetrazinones have been reviewed extensively (Kolar. 1984; 
Spassova and Golovinsky, 1985; Threadgill, 1990). Hence, this chapter is principally confined to 
aspects of their metabolism, together with appropriate biomimetic chemistry.
In aqueous solution at physiological or mildly basic pH, 1 -aryl-3.3-dialkyltriazenes are moder­
ately stable. In contrast, acidic environments cause rapid reversal of the usual synthetic reaction 
(Gescher et al., 1981), giving the arenediazonium salt (7, Fig. 2) and the protonated secondary 
amine (8). This degradation yields potently electrophilic species and therefore this pathway could 
be considered to be the source of biologically reactive entities. However, no firm evidence has been 
put forward to support the contention that this reaction occurs at a significant rate under 
physiological conditions.
The oxidative metabolism of 1-aryl-3,3-dialkyltriazenes by hepatic microsomes in vitro was first 
reported in 1967 (Druckrey et al., 1967) and this study and subsequent investigations (e.g. 




F ig. 2. M echanism o f  acid-catalyzed decom position o f  aryldialkyliriazenes by reversal o f  the
general synthetic pathway.
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doubt that oxidative yV-dealkylation is a metabolic pathway essential for the biological properties 
of these compounds.
2. OXIDATIVE METABOLISM OF 1 -ARYL-3,3-DIALKYLTRIAZENES AT THE
ALKYL GROUPS
In the study by Preussmann et al. (1969b), 3,3-dimethyl-l-phenyltriazene (9, Fig. 3) was 
incubated with rat liver microsomes and NADPH. Formaldehyde was reported to be a metabolite 
and the authors suggested that the other product of this oxidation was 3-methyl-1 -phenyltriazene 
(11, Fig. 3). Monoalkyltriazenes such as this are powerful directly-acting alkylating agents (13, 
Fig. 4) and are known to be carcinogens (Vaughan and Stevens, 1978). They react spontaneously 
with nucleophiles, giving the corresponding arylamine (14), molecular nitrogen and the alkylated 
nucleophile (15). It can be assumed that it is this reaction mechanism which is operative in 
biological alkylations involving monoalkyltriazenes rather than a reaction which has been claimed 
to involve the ‘methyl carbonium ion’ (16), as the latter is very unlikely to occur in aqueous 
biological media, although the methyl diazonium ion has been put forward as the ultimate mutagen 
derived from 3-acyl-1,3-dimethyltriazenes in Salmonella (Smith et al., 1986). Deuterium labelling 
studies have shown that diazoalkanes (17) are unlikely to be involved as intermediates in these 
alkylations (Lown and Singh, 1981). There is good evidence that the reaction between monomethyl- 
triazenes and bionucleophiles such as nucleic acids can occur in vivo (Preussmann et al., 1969b; 
Kleihues et al., 1979; Margison et al., 1979). Therefore, the oxidative metabolic pathway (Fig. 3) 
has been postulated to be responsible for the generation o f the ultimate cytotoxin which is 
responsible for the carcinogenicity and, possibly, the antitumor activity of aryldialkyltriazenes.
Many of the studies of the metabolism of aryldialkyltriazenes conducted in the wake of the 
original report by Preussmann et al. (1969b) used colorimetric determination of the aldehyde 
generated by hydroxylation of the V-alkyl group mediated by cytochromes F450 enzymes and 
subsequent hydrolysis/elimination. In that study, some 20-80% of the alkyl groups were oxidized 
to aldehydes, depending on the chemical nature of the alkyl moieties (on the basis that complete
CH,




F ig . 3. M etabolism o f  3,3-dim cthyl-l-phenyltriazene (9) by rodent hepatic microsomes 
in vitro, (a) Preussmann and von Hodenberg. 1969. (b) K leihues et al.. 1976. (c) Pool. 1979b.






Fig. 4. Postulated mechanisms of methylation by monomethyltriazenes. Nu =  H20 .  
nucleophilic sites on DNA . proteins, etc.
removal of one o f the two alkyl groups equals 100%). A later study showed that incubation of 
four (haloaryl)dimethyltriazenes and the unsubstituted 3,3-dimethyl-l-phenyltriazene with micro­
somes led to the loss of between 35 and 122% of the methyl groups as formaldehyde (calculated 
on the above basis) (Pool, 1979a). These results imply some oxidation o f  the second methyl group
3,3-Dimethyl-1-phenyltriazene yielded the lowest and l-(2,4,6-trichlorophenyl)3,3-dimethyltriazene 
(18, Fig. 5) gave the highest extent o f oxidation at N-CH, (Pool. 1979a), although Kolar and Habs 
(1984) have reported that the presence of halogen substituents on the benzene ring decreases the 
extent of this metabolism. There have been several other studies on the effect o f the nature o f the 
(substituted)aryl group on the extent of metabolism at the N-CH? groups of aryldimethyltriazenes; 
some o f these studies give conflicting results and conclusions (Preussmann et al.. 1969b; Audette 
et al.. 1973; Giraldi et al., 1975). Inhibition o f this metabolism by metabolic products has been
ci ch.
19
Fig. 5. Metabolic oxidation/conjugation of 3.3-dimethyl-l-(2.4.6-trichiorophenyl)triazene (18)
in the mouse.
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noted (Giraldi et al., 1975). The ultimate fate of some 40% of the radioactivity administered as
3.3-di[uC]mcthyl-1-phenyltriazene to rats was reported to be exhalation as ,4C 0 2 by Kleihues et al. 
(1976). These workers and Hradec and Kolar (1985) also observed the formation of 7- 
(uC]methyIguanine and other methylated DNA and RNA bases. yV-Hydroxy-tf-methyltriazenes 
appear not to be substrates for oxidative metabolism (Preussmann et al., 1969b).
Work by Stevens et al. (1979) using chemical biomimelic oxidation of related triazenes in which 
the two alkyl groups are part of a heteroalicyclic ring has shown facile oxidation to nitrogen, 
although the chemical products were devoid of antitumor activity. The Udenfriend system has been 
used as a chemical model for the oxidative metabolism of 1 -aryl-3,3-dimethyltriazenes to reactive 
methylating agents (Matrka et al., 1988).
Unambiguous and direct identification of a monoalkyltriazene as a metabolite o f a I-aryl-3,3- 
dimethyltriazene was first reported by Farina et al. (1982); l-(4-acetylphenyl)-3-methyltriazene (21, 
Fig. 6), together with 4-aminoacetophenone (22), was found as a metabolite of l-(4-acetylphenyl)-
3.3-dimethyltriazene (20) both in the plasma of mice in vivo and in 9000 x g  fractions o f mouse 
liver homogenate in vitro. A more indirect observation of a monomethyltriazene as a metabolite 
of a dimethyltriazene has been made in that one of the metabolites found in incubations o f rodent 
hepatic microsomes with 3,3-dimethyl-l-phenyltriazene was 3-acetyl-3-methyl-1-phenyltriazene 
(12, Fig. 3) (Pool, 1979b). Presumably, the formation o f this N-acyltriazene involves the 
monomethyltriazene (11) as a metabolic intermediate which is subsequently acetylated.
The immediate metabolic precursors o f l-aryl-3-methyltriazenes, the l-aryl-3-(hydroxymethyl)-
3-methyltriazenes (26, Fig. 7A), have been synthesized (Gescher et al., 1978; Juillard et al., 1980). 
However, such carbinolamines have not yet been identified unambiguously as metabolites of 
aryldimethyltriazenes. At first sight, it is difficult to envisage how such compounds could be more 
selectively cytotoxic than their decomposition products, the monomethyltriazenes. Certain jV-(hy- 
droxymethyl)amines and //-(hydroxymethyl)amidcs related to /'/-(hydroxymethyl)-jV-meihyltri- 
azenes have the ability to form, or can be in equilibrium with, electrophilic, potentially toxic imines 
or iminium ions, either themselves or after conjugation; the chemical features which predispose 
jV-(hydroxymcthyl) compounds to undergo such reactions under physiological conditions have 
been reviewed (Overton et al., 1985). Such an elimination reaction (Fig. 7A) could, on paper, be 
a mechanism by which hydroxymethyltriazenes exert toxicity in a manner different from that which 
renders monomethyltriazenes cytotoxic (Hemens et al., 1984; Soloway et al., 1983). However, a 
chemical and kinetic study of the reactions of 3-(hydroxymethyl)-3-methyl-l-(pyridin-3-yl)triazene 
with amine bases to give 3-methyl-1-(pyridin-3-yl)triazene as the sole product (Cheng et al., 1985) 
and the failure of the treatment o f l-aryl-3-(hydroxymethyl)-3-methyltriazenes with sodium 
cyanoborohydride, an iminium trapping agent, to yield 3,3-dimethyltriazenes (M. D. Threadgill, 
unpublished results) suggest that this is not an electrophilic reaction pathway open to Af-(hydroxy- 
methyl)triazenes under physiological conditions. Nevertheless, it has been shown that a reactive 
iminium is formed during chemical reactions of acetate and benzoate esters o f ^-(hydroxy- 
meihyl)triazenes (28 and 29, respectively, Fig. 7B) with nucleophiles. Presumably the enhanced 
leaving-group ability of the carboxylate leads to this increased electrophilicity (Hemens et al., 1984; 
Hemens and Vaughan, 1986; Iley et al., 1987a), although Vaughan et al. (1987) postulate a direct 
non-ionic SN2 reaction of 28 with azide ion to give a new type o f prodrug of monomethyltriazenes, 
which does not require oxidative metabolism. However, such acylation o f a AMhydroxy- 
methyl)triazenc has yet to be shown in biochemical experiments. Methyleneiminium triazenes are 
also formed during reactions of yV-(hydroxymethyl)triazenes with nucleophiles under acidic 
conditions (Iley et al., 1987b, 1988).
The rather unstable nature of //-(hydroxymethyl)-/V-meihyltriazenes (Vaughan et al., 1984) has 
been claimed to mitigate against their role as the ultimate antineoplastic species derived from 
dimethyltriazenes. Nevertheless, the possibility that they are important as precursors of 
monomethyltriazenes with a transport function cannot be excluded, particularly if they are 
stabilized as the corresponding glucuronide acetate conjugate. It is pertinent in this context to note 
that Kolar and Carubelli (1979) identified 1-{[3-methyl-l-(2,4,6-trichlorophenyl)triazen-1- 
l)meihyl}-/?-D-glucuronic acid (19, Fig. 5) as a metabolite in the urine of mice which had received
3.3-dimethyl-l-(2.4,6-irichlorophenyl)triazene (18) and the authors suggested that this conjugate 
may. indeed, carry the monomethyltriazene to the target tissue. Metabolic conjugation o f triazenes
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Fig. 7. (A) Elecirophilic iminium ions from .V-(hydroxymethyl)triazcncs. (B) Elccirophiiic 
reactivity of .V-(acyloxymethyl)triazenes.
to glutathione and to sulfate has yet to be reported, although a putative glutathione conjugate has 
been synthesized chemically (Iley et al., 1988).
Monomethyltriazenes and 3-(hydroxymethyl)-3-methyltriazenes generated as metabolites of 
dimethyltriazenes could be considered as substrates for further metabolism. Indeed, aniline is a 
metabolite o f 3,3-dimethyl-l-phenyltriazene in vitro in amounts equimolar to the amount of 
formaldehyde formed (Druckrey et al., 1967; Preussmann et al., 1969b) and Toren et al. (1984) have 
detected methanol formed inetabolically from l-aryl-3-methyItriazenes and from a l-aryl-3-(hy- 
droxymethyl)-3-methyltriazene. When further oxidative metabolism is considered, it should be 
noted that analogous V-(hydroxymethyl)benzamides are subject to further metabolic oxidation at 
the methylene group yielding the corresponding jV-(hydroxymethyl)benzamide which is excreted 
by the mouse in the urine (Ross et al., 1983). jV-(HydroxymethyI)triazenes, however, have not yet 
been reported to undergo this metabolic oxidation to afford the corresponding //-formyltriazenes 
which are highiy reactive entities (Ignasiak ct al., 1975; Threadgill and Gledhill, 1986; Butler et al.,
1987), although V-formyltriazenes are the principal products o f oxidation of jV-methyltriazenes 
and jV-hydroxymethyltriazenes by a chemical model for cytochromes P450 (Iley and Ruecroft,
1988). Some evidence for a second biological oxidation has been obtained in experiments in which 
the fate of l-(4-acetylphenyl)3-methyltriazene (21, Fig. 6 ) in suspensions o f murine hepatocytes was 
investigated (Farina et al., 1983). The monomethyltriazene was consumed in this medium at a rate 
significantly more rapid than in suspensions of nonviable cells. The chemical nature of the products 
of this metabolic reaction arc completely unknown.
Metabolic oxidation at the nitrogen atoms of the triazene group of an arylmonoalkyltriazene 
has been observed only once, in that 3-(4-carboxy-3-fiuorophenyl)-l-methyltriazene-l-oxide was 
revealed by l9F NMR spectroscopy to be a urinary metabolite o f  the corresponding dimethyltri- 
azcne. 3-fluoro-4-(3,3-dimethyltriazen-l-yl)benzoic acid (Vaughan and Wilman, 1991).
3. METABOLISM REMOTE FROM THE TRIAZENE MOIETY
1-Aryl-3,3-dimethyltriazcnes undergo metabolism also at sites remote from the triazene moiety, 
i.e. in the aryl part of the molecule or involving transformation o f functional groups attached 
thereto. Kolar and Schlesiger (1976b) reported indirect evidence for such metabolites in that the
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major urinary metabolite derived from 3 ,3-dimethyl-1-phenyltriazene in rats was found to be
4-aminophenol (30) with smaller amounts of the 3-amino and 2-amino isomers (31 and 32. 
respectively. Fig. 8 ). These authors also proposed ring-hydroxylated triazenes as metabolites o f this 
substrate but only after chemical coupling with l-(ethylamino)naphthalene to give the azo dyes 
l-(ethylamino)-4(4-hydroxybenzeneazo)naphthalene (35) and l-(ethylamino)-4-(2-hydroxybenze- 
neazo)naphthalene (36). This derivatization involves the loss o f N' of the triazene (with its attached 
groups) and thus the urinary triazenes 33 and 34 may have been 3,3-dimethyl. 3-methyl or even 
3-(hydroxymethyl)-3-methyl compounds. A more direct example of metabolism remote from the 
triazene moiety with confirmed retention of the N 3 substituents is that the ketone carbonyl group 
of l-(4-acetylphenyl)-3,3-dimethyltriazene (20) was reduced by preparations of murine hepatic 
tissue in vitro to give l-(4-(l-hydroxyethyI)phenyl]-3,3-dimethyltriazene (29. Fig. 6 ). Interestingly, 
this material retained an antitumor activity similar to that of the parent drug (Farina et al.. 1983). 
The principal urinary metabolites o f the experimental drug, 4-(3.3-dimethyl-l-triazenyl)benzoic 
acid (1; R =4-CO ;H) have been found to be the glucuronide and glycine conjugates of the parent 
dimethyltriazene; the corresponding monomethyltriazene and its derivatives were not observed 
(Benfenati et al., 1989).




Fig. 8. Aryl-hydroxyiated metabolites o f 3.3-dimethyl-1-phenvltriazcnc (9) in the mouse
R = CH,: R' = H. CH.OH. CH,.'
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4. METABOLIC FATE OF l-(IM IDAZOL-5-YL)-3-ALK YLTRIAZENES
The major urinary metabolite of dacarbazine (2) in man is 5-aminoimidazole-4-carboxamide 
(AIC: 39, Fig. 9) (Householder and Loo, 1969; Skibba et al., 1970a,b; Breithaupt et al., 1982). AIC 
has also been identified as a product of metabolism of dacarbazine in vitro in incubations with 
mouse liver microsomes (Hill, 1975) and with human and animal tumor tissue (Gerulath and Loo, 
1972; Mizuno and Humphrey, 1972). From the mechanistic point of view, it is difficult to envisage 
how AIC could be formed by a metabolic pathway other than one implicating the intermediate 
formation o f 5-(3-methyltriazen-l-yl)imidazole-4-carboxamide (MTIC: 38), followed by the tau- 
tomerism noted by Hooper and Vaughan (1981), amongst others, and subsequent hydrolysis. Many 
workers have reported that metabolism is required for the antitumor activity of dacarbazine to be 
manifest (Skibba et al., 1969a,b; Skibba and Bryan, 1971; Preussmann et al., 1969a). 5-[3-(Hydroxy- 
methyl)-3-methyltriazen-l-yl]imidazole-4-carboxamide (HMTIC: 37, Fig. 9), the metabolic precur­
sor of MTIC, has been characterized as a urinary metabolite of dacarbazine in rats (Kolar et al., 
1980). Surprisingly, this hydroxymethyl compound was reported to be more stable than MTIC in 
polar solvents. This observation led to the suggestion that HMTIC may act as a transport form 
for MTIC, the postulated ultimate cytotoxic species derived from dacarbazine. After the manner 
of 3-methyl-1-phenyltriazene, MTIC decomposes spontaneously in aqueous media to form AIC 
(39) and was capable of alkylating biological nucleophiles such as DNA (Mizuno and Decker, 
1976). The pharmacokinetic studies published so far on dacarbazine (Householder and Loo, 1971; 
Loo et al., 1968, 1976; Skibba et al., 1969a,b; Breithaupt et al., 1982) have not provided information 
on concentrations in plasma or tissue of metabolically generated HMTIC or MTIC. Therefore, the 
pharmacokinetic data available on dacarbazine is o f limited value in helping to relate the efficacy 
or toxicity of this drug to the concentrations o f cytotoxic or biologically inactive metabolites in 
body fluids and tissues. The major shortcoming o f  most of the pharmacokinetic data reported in 
the literature is the analytical procedure employed, a colorimetric method which determines the 
total amount of compounds with intact triazene linkages and therefore does not discriminate 
between dacarbazine, HMTIC and MTIC. The plasma elimination half-life of such species after
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Fig. 9. Metabolic activation of dacarbazine (2) to the cytotoxin MTIC (38). Nu = H:0 ,  
nuclcophilic sites on DNA, proteins, etc











Fig. 10. Photodecomposition and subsequent chemical degradation of dacarbazine (2).
i.v. administration of dacarbazine to patients was 35 min (Loo et al.. 1968). Measurement of plasma 
concentrations of dacarbazine using a HPLC method yielded a biphasic elimination profile with 
a terminal half-life of 41.4 min (Breithaupt et al., 1982). In this study, the plasma decay of 
metabolically generated AIC was monoexponential with a half-life o f 43-116 min. The urinary 
recovery was 46-52% for dacarbazine and 9-18% for AIC. These pharmacokinetic data are in 
broad agreement with those obtained earlier with inferior analytical methods (Householder and 
Loo, 1969, 1971; Loo et al., 1968; Skibba et al., 1969a,b).
Dacarbazine is photolabile and reverts in light to its synthetic precursor 5-diazoimidazole-4-car- 
boxamide (40. Fig. 10) (Horton and Stevens, 1981). This diazo compound and its decomposition 
products. 2-azahypoxanthine (41) and 4-carbamoylimidazolium-5-olate (42) have not been found 
as metabolites of dacarbazine in vivo, although the former has been implicated in the antibacterial 
action of the parent drug (Saunders and Schultz, 1972).
5. METABOLISM OF THE IMIDAZOTETRAZINONES
The metabolic fate of the imidazotetrazinones remains to be elucidated fully. Unlike the open 
chain dacarbazine which does not decompose under simulated physiological conditions, the cyclic 
mitozolomide (3) undergoes rapid hydrolytic ring-opening to give 5-[3-(2-chloroethyl)triazen-l- 
yl]imidazole-4-carboxamide (MCTIC: 44, Fig. 11) (Stevens et al.. 1984) which may well be the 
ultimate antineoplastic metabolite of the parent drug (Horgan and Tisdale. 1984). MCTIC is an 
exceedingly short-lived compound with a /,,, of only 5.5 min at pH 7.5 (Horgan. 1985) 
Interestingly, this is the same compound as would be speculated to be formed by metabolic 
oxidative dealkylation of 5-(3.3-bis(2-chloroethyl)triazen-l-yl]imidazole-4-carboxamide (45). a 
dialkyltriazene with activity against tumors in the brain (Shealy et al.. 1968; Levin et al.. 1975). 
The great reactivity of 3-(2-chloroethyl)triazenes (46, Fig. 12) is thought to be due to their facile 
cyclization to 1,2,3-triazolines (48) or 1.2,3-triazolium salts (49) (Abraham et al., 1969; Lown and 
Singh, 1981). There is evidence to suggest that metabolism is an important determinant of the rate 
of deactivation of mitozolomide. Workman and Lee (1984) have shown that pretreatment of mice 
with phenobarbital reduces the activity of mitozolomide against the K.HT sarcoma. In accordance 
with this finding, the area of the plasma-concentration-of-mitozolomide vs. time curve, determined 
in mice which had been pretreated with phenobarbital, was also significantly smaller than that in 
control mice (Brindley et al.. 1986).
Hydrolytic ring-opening of temozolomide (4), the methyl analog of mitozolomide. should yield 
MTIC (38, Fig. 13). In order to test the hypotheses that temozolomide degrades to MTIC in 
physiological solutions and that MTIC mediates, or contributes to. the cytotoxicity of temozolo-







Fig. 11. Non-cnzymic hydrolytic ring-opening of mitozolomide (3) to the active metabonate
MCTIC (44).
mide, the drug was incubated with TLX5 cells. MTIC was detected by HPLC within 1 hr in the 
presence or absence of murine liver microsomes (Tsang et al., 1991). In contrast, when dacarbazine 
was incubated under the same conditions, MTIC was found only when microsomes were present. 
MTIC is also present in the urine o f mice that have received temozolomide (Tsang et al., 1991). 
When temozolomide was incubated with preparation o f murine liver, the drug was not metabolized 
at a measurable rate except for its chemical degradation to MTIC (Tsang et al., 1990). 
Contrastingly, the analogous 3-methylbenzo-l,2,3-triazin-4-one (52) was metabolically demethy-




Fig. 12. Mechanism of cychzation degradation of Af-(2-chloroethyl)triazenes.
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Fie. 13. Metabolic fate of temozolomide (4) in comparison with that of its non-antineoplastic
analogue (52).
lated to give the benzotriazinone (53, Fig. 13). The major route of excretion of temozolomide in 
mice is via the kidneys. An acidic metabolite of temozolomide, probably a conjugate, was found 
in the urine of mice but its identity has not yet been established unambiguously. Another 
metabolite, the corresponding 8-carboxylic acid (51), has been found in the urine of human patients 
but not of mice. Unlike the unknown conjugate, this carboxylic acid was cytotoxic towards TLX5 
lymphoma cells in vitro (Tsang et al., 1990).
6 . THE ROLE OF METABOLISM IN THE MECHANISM OF 
ANTITUMOR ACTIVITY OF TRIAZENES
Many crucial mechanistic details that link the metabolism o f triazenes with their antineoplastic 
activity remain obscure. Answers to the following three questions appear to be pivotal in the 
elucidation of this link:
(1) How can the aggressively reactive monomethyltriazene generated by metabolism of a 
dimethyltriazene cause selective cytotoxicity?
(2) Is the metabolic route which leads to the antineoplastic species identical with that which 
generates the carcinogenic metabolite?
(3) Are differences in the metabolism between dimethyltriazenes and other dialkyltriazenes 
responsible for the marked difference in antineoplastic activity observed in some murine tumors 
(Connors et al., 1976: Gescher et al., 1981)?
Even though the evidence for the involvement of metabolism in the mechanism of antitumor 
activity of dimethyltriazenes is overwhelming, the possibility that some dimethyltriazenes are 
themselves cytotoxic, under certain circumstances, without metabolic activation cannot be 
dismissed. Dacarbazine has been used in local therapy in patients with advanced malignant 
melanoma and soft tissue sarcoma of the extremities and regression of tumors has been observed 
(Aigner et al., 1983). Furthermore, l-(4-carboxyphenyl)-3.3-dimethyltriazene (1: R 4-CO?H, Fig. 1) 
did not undergo marked oxidative demethylation in vitro (Sava et al., 1982), yet it possessed 
antimetastatic properties in mice bearing the Lewis lung carcinoma (Giraldi et al., 1981). This drug 
also increased the survival o f mice bearing the TLX5 lymphoma or the P388 leukemia without 
exerting marked cytotoxicity (Sava et al., 1982).
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Some doubt has been cast on the contention that an electrophile as indiscriminate and 
non-selective as a monomethyltriazene could account for the antineopiastic activity of dimethyltri­
azenes (Gescher et al., 1981). This doubt was based on experiments in which the cytotoxicity of a 
monomethyltriazene was tested in a bioassay against a mouse TLX5 lymphoma cell line which had 
acquired resistance to dimethyltriazenes in vivo. The monomethyltriazene was found to be 
non-selectively toxic to both the sensitive and resistant lines, whereas incubation of the dimethyltri- 
azene with a liver homogenate produced metabolites which were more toxic to the sensitive than to 
the resistant lymphoma cells (Gescher et al., 1981). However, cytotoxic metabolites of dimethyltri­
azenes, which are more selective than the monomethyltriazenes, have yet to be isolated or 
characterized. //-(Hydroxymethyl)triazenes were found to be equally as cytotoxic as their decompo­
sition products, the monomethyltriazenes (Vaughan et al., 1984; Kohlsmith et al., 1984). Conse­
quently, it has been suggested by some workers that the Af-(hydroxymethyl) compounds may be the 
ultimate or proximate cytotoxic metabolites of dimethyltriazenes (Vaughan et al., 1984). The third 
question posed above has been addressed in a recent comparison of the antitumor activities and 
toxidties of 1 -(4-acetylphenyl)-3,3-dimethyltriazene (20, Fig. 6) and l-(4-acetylphenyl)3,3-diethyltri- 
azene (24, Fig. 6) (Farina et al., 1986). The diethyltriazene was inactive against three murine tumors 
which were highly sensitive to the dimethyltriazene. However, the diethyltriazene was much more 
toxic to the host than was the dimethyl analogue. Both compounds were rapidly metabolized in vivo 
and in vitro and the monoalkyltriazenes (21 and 23, respectively) and 4-aminoacetophenone (22) 
were identified as metabolites of the parent compounds. However, the extent to which the drugs were 
jV-dealkylated differed markedly. The amount of monoethyltriazene generated was only one third of 
the amount of monomethyl derivative found (Farina et al., 1986). This result suggests that the 
difference in activities between different dialkyltriazenes may indeed be due to differences in 
metabolism. A QSAR study has shown good correlation between antitumor activity and the 
presence of electron-donating substituents on the benzene ring of 3,3-dimethyl-1 -(substi- 
tuied)phenyltriazenes (Hatheway et al., 1978); this same chemical parameter also correlates with the 
extent of metabolic activation by hydroxylation at N-CH3 by cytochromes P450 (Venger et al., 1979; 
Shusterman et al., 1989a,b). However, based upon studies involving induction of a cytochromes 
P450 by pretreatment with phenobarbital, Sava et al. (1988) raised some doubt about the role of 
metabolic activation in the antitumor activities and aniimetastatic activities of 1-aryl-3,3-dimethyl- 
uiazenes against the Lewis lung carcinoma in the mouse. There has been one suggestion that 
arenediazonium metabonates of 1-aryl-3,3-dialkyltriazenes are responsible for their antitumor 
activity (Nifontov et al., 1984) but this conclusion is at variance with the vast majority of the 
literature.
On the basis of a preliminary pharmacokinetic study of dacarbazine and its metabolite MTIC in 
rodents and in human patients, Rutty (1983) suggested that the relative lack of antitumor activity of 
dacarbazine in man compared to rodents may be related to differences in the rate of hydroxylation 
at the ./V-methyl group; this hydroxylation is slow in man and fast in mice. It is, however, interesting 
to note that murine Sarcoma 180 cells themselves are capable of metabolizing dacarbazine (Mizuno 
and Humphrey, 1972).
Temozolomide is hydrolyzed chemically to its active metabonate MTIC, whereas this reactive 
electrophile is formed only after oxidative metabolism of dacarbazine. Thus, temozolomide may 
provide a pharmacokinetic advantage over dacarbazine in the clinical situation in the generation of 
the cytotoxic monomethyltriazene. A large number of analogues of mitozolomide and temozolo­
mide have been synthesized with the aim of clarifying which chemical features of the imidazotetrazi- 
none are essential for expression of their cytotoxic and antineopiastic properties. In analogues with 
a carboxamide at position 8, an NH appears to be required for maximal cytotoxicity in vitro. The 
dimethylcarboxamide 5 (Fig. 1) is markedly less cytotoxic in vitro than is mitozolomide (3) or the 
monomethylcarboxamide 6 (Horspool et al., 1989); nevertheless, the antitumor activity of the three 
agents in mice bearing the TLX5 lymphoma was very similar (Hickman et al., 1985; Lunt et al.. 
1987). The chemical stabilities of the three compounds are also similar. Incubation of 5 with marine 
hepatic microsomes led to increased cytotoxicity and to formation of the monomethyl analogue 6 
(Horspool et al., 1989), suggesting that the latter causes or contributes to the antitumor effect of 5 
in vivo. Interestingly, it has been demonstrated that >89% of the dose (10 mg kg'1) of the 
administered dimethylcarboxamide is metabolized via the monomethylcarboxamide in the mouse.
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7. THE ROLE OF METABOLISM IN THE MECHANISMS OF TOXICITY.
MUTAGENICITY AND CARCINOGENICITY OF TRIAZENES
l-Aryl-3-mcthyltriazenes are direct-acting mutagens in the Ames assay (Malaveilie et al.. 1982). 
The mutagenic activities of l-aryl-3,3-dimethyItriazencs in Drosophila melanogasier have been 
reported to correlate with parameters on nucleophilicity which also correlate well with the extent 
of oxidative metabolic demethylation by cytochromes P450 (Vogel, 1989). Inhibition of cyto­
chromes P450 causes a decrease in mutagenicity of I-(2,4,6-trichlorophenyI)-3,3-dimethyltriazene 
(18) in this species, whereas inhibition of monoamine oxidase and of flavin monooxygenases caused 
increases in mutagenicity, suggesting again that metabolism by cytochromes P450 is required for 
mutagenic activity of this aryldimethyltriazene (Zijlstra and Vogel. 1988). In contrast, analogous 
studies with enzyme inhibitors indicated that the metabolism of dacarbazine (2) to the mutagenic 
derivative was mediated by flavin monooxygenases. It has been demonstrated that, for a wide range 
of aryldialkyltriazenes and heteroaryldimethyltriazenes (including dacarbazine), mutagenicity was 
manifest towards Salmonella in the Ames test after incubation with a rodent S9 microsomal 
preparation. In these QSAR studies, mutagenicity was found to correlate with the hydrophobicity 
(expressed as log P) and with parameters of electron density: extent of metabolism by cytochromes 
P450 also correlates with these parameters in a similar way (Venger et al., 1979: Hopfinger and 
Potenzone, 1982; Shusterman et al.. 1989a.b). A strong relationship between toxicity to rats 
(expressed as LDjq) and these parameters has also been determined (Hansch et al., 1978).
Examples of benzenediazonium compounds, which are putative chemical breakdown products 
and metabolites of 3,3-dimethyl- or 3-methyl-triazenes. have been noted to be moderately 
carcinogenic in mice (Toth et al., 1989) and mutagens (Malaveilie et al., 1982).
Kohn et al. (1988) have reported that the urine of patients who bave received dacarbazine (2) 
contains metabolites that are mutagenic to Escherichia coli.
8. CONCLUSIONS
It has been shown in very many studies that the principal metabolic process undergone by 
1 -aryl-3,3-dimethyltriazenes is oxidative hydroxylation at A-methyl group, with subsequent 
breakdown to the corresponding monomethyltriazene. It is also abundantly clear that this is a 
necessary metabolic step for the expression of beneficial antineopiastic activity of such triazenes. 
including the clinically used drug dacarbazine. Unfortunately, the molecular parameters which 
predispose these open-chain triazenes to metabolic activation as antitumor agents are effectively 
the same as those correlating with activation as mutagens, carcinogens and general toxins: oxidative 
metabolic activiation also requires that patients have competent hepatic function. Hence, one can 
only be pessimistic about the prospects of design of new dimethyltriazenes for therapeutic 
applications. Generation of the reactive and cytotoxic monomethyltriazenes non-enzymically from 
pro-drugs such as temozolomide may well constitute the way forward in the design of new 
compounds of this class for the effective treatment of cancers.
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The com petitive binding o f 3 '-methoxy-4'-nitro, 4'-
amino-3 '-methoxy, 4'- methoxy- 3 ni tro, and 3'-amino- 
4'-methoxyflavone (compounds 1 to 4, respectively) to 
the rat cytosolic aryl hydrocarbon (Ah) receptor gave 
ICso values o f 2.27, 86.1 , 872, and 19.4 nM . Flavones
3 and 4 were characterized as Ah receptor agonists in
MCF-7 human breast cancer cells and induced CYP1A1
gene expression, whereas the 3-methoxy-substituted 
flavones (1 and 2) were inactive. All four compounds
inhibited induction o f ethoxyresorufin O-deethylase 
(EROD) activity by 2,3,7,8-tetrachlorodibenzo-p-di- 
oxin (TCDD) in MCF-7 cells; moreover, in vitro studies 
w ith TCDD-induced rat liver microsomes showed that 
flavones 1 to 4  inhibited EROD activity in the .presence 
or absence o f NADPH. In MCF-7 cells cotreated w ith  
flavones 1 or 2  (0.01 to 10 pM) plus TCDD or [SH]TCDD, 
there was a concentration-dependent inhibition o f 
TCDD-induced CYP1A1 mRNA levels and formation 
of radiolabeled nuclear Ah receptor complex. Velocity 
sedimentation analysis o f nuclear extracts from MCF-
7 cells treated with [*H]TCDD plus 1 or 10 /iM concen­
trations of flavones 1 and 2 showed that an early eluting  
specifically bound nuclear Ah receptor complex w as 
present. However, under these same conditions the 
flavones inhibited TCDD-induced CYP1A1 gene ex­
pression. The apparent molecular mass of this nuclear 
complex was 190 kDa as determined by cross-linking 
to a s2P-labeled bromodeoxyuridine-substituted con­
sensus dioxin-responsive element. Similar cross-link-
1 The financial assistance of the National Institutes of Health 
(ES03843) and the Texas Agricultural Experiment Station is grate­
fully acknowledged. S. Safe is a Burroughs Wellcome Toxicology 
Scholar.
2 Current address: Oncogene Science Inc., 106 Charles Lindbergh 
Boulevard, Uniondale, NY 15533.
3 To whom correspondence should be addressed.
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ing results w ere obtained using the nuclear extract 
from MCF-7 cells treated with [3H]TCDD alone. The re­
sults o f this study suggest that there are at least two 
forms of the nuclear Ah receptor complex in MCF-7 
cells; the major transcriptionally active form binds 
[SH]TCDD and flavones 1 or 2 inhibit nuclear uptake of 
this receptor com plex. The other form of the nuclear Ah 
receptor complex appears to be transcriptionally inac­
tive and ligand binding with [SH]TCDD is not com peti­
tively inhibited by flavones 1 and 2. c 1995 Academic
Pww.hc.
K e y  W ords: cytosolic receptors, transport, intracel­
lular signaling.
Bioflavanoids and related synthetic analogs exhibit a 
broad spectrum of biological activity. Naturally occur­
ring plant flavanoids such as naringenin (flavanone), 
apigenin (flavone), and genistein (isoflavone) which are 
substituted with hydroxyl groups at the 4' and 3, 5, or 7 
positions are weak estrogens which bind to the estrogen 
receptor and elicit estrogen-induced responses (1-4). 
Other studies have reported that naturally occurring 
polyhydroxylated flavanoids, chalcones, and structur­
ally related synthetic analogs exhibit antimutagenic and 
anticarcinogenic activities (5-12) and inhibit activities 
of a number o f enzymes including protein kinases (13- 
16), porcine-5-lipoxygenase (17), ornithine decarboxyl­
ase (11), glutathione reductase (18), P450 isozymes (19), 
and HIV proteinase (20). Bioflavanoids can also en­
hance some P450-dependent activities, inhibit or en­
hance carcinogen-induced tumors or DNA binding (10, 
12, 21-25) and inhibit human platelet aggregation (19). 
The flavonoid-mediated effects are dependent on nu­
merous factors including the structure of the compound, 
the target organ or cell, and the response.
0003-9861/95 S6.00 
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3'-M ETH O X Y -4'-N ITR O FLA V O N E AS AN Ah R E C E PTO R  A N TA G O N IST IN MCF-7 CELLS 4 7 1
R 4 R3
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2 n h 2 OCH3
2 OCH3 n o 2
4 OCH3 n h 2
F I G .  1 .  S tr u c tu r e s  o f  3 '-m e th o x y -4 '-n itr o f la v o n e  ( 1 ), 4 '-a m in o -3 -  
m e th o x y f la v o n e  (2 ) ,  4 '-m e th o x y -3 '-n itr o f la v o n e  (3 ) ,  a n d  3 '-a m in o -4 -  
m e th o x y f la v o n e  ( 4 ) .
The synthetic flavone, 5,6-benzoflavone (/J-naph- 
thoflavone), inhibited carcinogen-induced tumor forma­
tion in the mouse skin model and this activity was re­
lated, in part, to inhibition of P450-dependent metabolic 
activation of carcinogens (9-12). Interestingly, /S-naph- 
thoflavone binds to the aryl hydrocarbon (Ah)* receptor 
and is often used as a prototypical inducer of Ah recep­
tor-mediated CYP1A 1 and CYP1A2 gene expression 
(19, 26, 27). 7,8-Benzoflavone (a-naphthoflavone, aNF) 
binds with moderate affinity to the Ah receptor and has 
been extensively characterized as a partial Ah receptor 
antagonist (28-32). In a recent study, it was shown that 
in various cancer cell lines, at concentrations *£10-6 
M , aN F inhibited 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)-induced CYPl A1 gene expression and this was 
paralleled by decreased formation of the nuclear Ah re­
ceptor complex (32). In contrast, aNF was an Ah recep­
tor agonist at a concentration of 10-5 M  (33).
Current studies in this laboratory have been investi­
gating the modulatory effects of various, 3 '^'-substi­
tuted flavones on Ah receptor-mediated signal transduc­
tion pathways and this report describes the activity 
and specificity of the 3'-methoxy-4'-nitro, 4'-amino- 
3'-methoxy-, 4'-methoxy-3'-nitro-, and 3'-amino~4'-me- 
thoxyflavones (Fig. 1) as Ah receptor agonists and an­
tagonists in the MCF-7 human breast cancer cell line. 
All four flavones rapidly inactivate CYPlAl-dependent 
activity and results from in vitro studies suggest that this 
is due to metabolically mediated suicide inactivation of 
C Y P lA l protein. In contrast, the Ah receptor binding 
affinities and Ah receptor agonist/antagonist activities 
of flavones 1 to 4 are remarkably dependent on struc­
ture. Both 3'-methoxy-4'-nitro- and 4'-amino-3'-me- 
thoxyflavone inhibit TCDD-induced responses in MCF- 
7 cells and the results obtained for the former compound 
indicate that it is a “pure” Ah receptor antagonist.
MATERIALS AND METHODS
Chemicals and biochemicals. T h e  3 \4 '-su b s titu te d  f la v o n es  w ere  
s y n th e s iz e d  a s  d escrib ed  (1 6 ). T C D D , [3H ]T C D D  (37  C i/m m o l) ,
4 A b b r e v ia t io n s  used: A h , ary l h yd rocarb on ; a N F , a -n a p th o fla v o n e ;  
D R E , d io x in -r e sp o n s iv e  e lem en t: E R O D , e th o x y reso ru fin  O -d ee th y l-  
a se ; M C D F , 6 -m e th y l- l ,3 ,8 -tr ic h lo r o d ib e n z o fu r a n ; T C D D , 2 ,3 ,7 .8 -  
te tra c h lo r o d ib e n z o -p -d io x in ;  T C D F , te tra ch lo ro d ib en zo fu ra n ; S D S , 
s o d iu m  d o d ecy l su lfa te: P A G E , p o ly a cr y la m id e  g e l e le c tro p h o res is .
e th o x y r e so r u fin , a n d  2 ,3 ,7 ,8 -te tra ch lo ro d ib en zo fu ra n  (T C D F ) w e re  
s y n th e s iz e d  in  th is  lab oratory  to  >98%  p urity . M C F -7  h u m a n  b r e a s t  
ca n cer  c e lls  w ere  o r ig in a lly  o b ta in ed  from  A m erican  T y p e  C u ltu r e  
C o lle c tio n  (A T C C , R o ck v ille , M D ). A ll o th er  ch em ica ls  an d  b io c h e m ­
ica ls  w ere  o f  th e  h ig h e s t  p u r ity  a v a ila b le  from  com m erc ia l so u rces .
Preparation of rat hepatic cytosoL R at h ep a tic  cy to so l w a s  p r e ­
p ared  e s s e n t ia l ly  a s  d escrib ed  ea r lier  from  m ale L o n g -E v a n s  ra ts  (34 ). 
L ivers w ere  p erfu sed  in situ w ith  ic e -co ld  H E G D  buffer (25  mM  H e p e s , 
1.5 mM  E D T A , 1 .0 mM  d ith io th r e ito l, 10% glycero l ( v /v ) ,  p H  7 .8 ] a n d  
h o m o g en ize d  in  H E G D  (5  m l/g  tis su e )  u sin g  a B r in k m a n  h o m o g e -  
n izer. T h e  h o m o g e n a te s  w ere  ce n tr ifu g ed  a t  10 ,000g for 20 m in  (2*C ): 
th e  re su lt in g  su p e r n a ta n t w as ce n tr ifu g ed  a t 105 ,000g  for 1 h (2 * C ), 
rem oved  w ith  a P a s te u r  p ip e tte , an d  sto red  a t -8 0 * C . P r o te in  c o n c e n ­
tr a t io n s  w ere  d e term in ed  a s  d escrib ed  ear lier  (35).
Hydroxyapatite (HAP) assay. T h e  ICjo an d  K, v a lu e s  for c o m p e t i - 
t iv e  recep to r  b in d in g  a ffin itie s  w ere  d eterm in ed  u sin g  frozen  ra t h e ­
p a tic  c y to s o l (2  m g  p r o te in /m l)  a n d  th e  H A P  p roced u re e s s e n t ia l ly  
a s d escr ib e d  u s in g  1 nM (3H ]T C D D  a s  th e  rad io ligan d  (3 4 ). D if fe r e n t  
c o n c e n tr a t io n s  o f  3 ',4 '-su b stitu te d  f la v o n es  w ere u sed  to  d e te r m in e  
d is p la c e m e n t cu rv es. T h e  ICso v a lu es  w ere d efin ed  a s  th e  c o n c e n tr a ­
t io n s  req u ired  to  d isp la c e  50%  o f  th e  (3H ]T C D D  a n d  w ere d e te r m in e d  
from  a  p ro b it p lo t  o f  th e  p e rc en ta g e  o f  (3H ]T C D D  b o u n d  v e r su s  lo g  
c o n c e n tr a t io n s  o f  th e  ligan d . Kj v a lu e s  w ere d e term in ed  b y  th e  m e t h ­
o d s o f  C h e n g  a n d  P r u so ff  (3 6 ) in  w h ich  th e  ICy, v a lu e  for u n la b e le d  
T C D D  w a s  1 .28  nM  (3 4 ).
Cell cytosol preparation, in uitro Ah receptor transformation, and gel 
retardation assay. C y to so l from  ra t liv er  w as p rep ared  a s  d e sc r ib e d  
(34) a n d  in cu b a ted  w ith  d iffer en t co n c e n tr a tio n s  o f  th e  t e s t  c o m ­
p o u n d s  a t  20*C  for 2  h. L ig a n d -in d u c ed  A h recep tor tr a n s fo r m a tio n  
w as d e te r m in e d  b y  gel re ta rd a tio n  a n a ly s is  (34 ). C o m p le m e n ta r y  
s tra n d s  o f  s y n th e t ic  o lig o n u c le o tid e s  c o n ta in in g  th e  D R E  se q u e n c e  5'- 
G A T C T G G C T C T T C T C A C G C A A C T C C G -3 ' w ere s y n th e s iz e d , p u r i­
fied  b y  p o ly a c r y la m id e  g el e lec tr o p h o r e s is , and a n n e a le d  (3 7 ). N u c le a r  
e x tr a c ts  or tra n s fo r m e d  c y to s o l from  M C F -7 c e lls  w ere  u sed  for th e  g e l 
re ta r d a tio n  a n a ly s is  a s  p rev io u s ly  d escr ib ed  (37) a n d  th e  s p e c if ic a lly  
b ou n d  re ta rd ed  D R E -A h  recep to r  w a s  q u a n tita te d  u sin g  a B e ta g e n  
B eta sc o p e  6 3 0  b lo t  a n a ly z e r  o r  b y  au torad iograp h y .
Inhibition of TCDD-induced rat liver microsomal EROD activity. 
R a t liv er  m ic r o s o m e s  w ere iso la te d  from  T C D D  (5  M g/k g )-trea ted  
m ale L o n g -E v a n s  ra t  liver  (3 8 ) . T e s t  co m p o u n d s w ere  in cu b a ted  w ith  
T C D D -in d u c e d  ra t  liv er  m ic ro so m e s, b o v in e  seru m  a lb u m in , m a g n e ­
s iu m  s u lfa te , N A D P H , an d  N A D H  a t  37*C  for 2 o r  5 m in  a n d  E R O D  
a c t iv ity  w a s  d e te r m in e d  f lu o r im etr ic a lly  (39).
Cell growth and EROD induction assay. M C F -7  c e lls  w e r e  r o u ­
t in e ly  grow n  in  D M E /F 1 2  w ith  2 .2  m g /m l sod iu m  b ica r b o n a te , 5%  
fe ta l c a l f  s eru m , a n d  10 nM  § n t ib io t ic -a n t im v c o t ic  s o lu tio n  (S ig m a  
C h e m ica l C o ., S t . L o u is , M O ). F or th e  E R O D  in d u ctio n  a s sa y , th e  
c e lls  w ere  se e d e d  in to  6 0 -m m  P e tr i d ish e s . T C D D  a n d  th e  s u b s t itu te d  
f la v o n es  d is so lv e d  in  D M S O  (0 .1% ) w ere added  to  th e  cu ltu re  d is h e s  
w h e n  th e  c e lls  r e a c h e d  a b ou t 70%  co n flu en ce . C ells  w ere h a r v e s te d  24  
h a fter  th e  c h e m ic a l t r e a tm e n t  a n d  E R O D  a c t iv ity  w as d e te r m in e d  b y  
th e  m e th o d  o f  P o h l a n d  F o u ts  a s  p rev io u s ly  d escr ib ed  (3 9 ).
Preparation of nuclear extracts. N ea r  co n flu en t M C F -7  c e l l s  w ere  
tr y p s in iz e d  a n d  w a sh e d  w ith  th e  c u ltu re  m ed iu m . H a r v es ted  c e l l s  w ere  
resu sp e n d ed  in  10 m l cu ltu re  m ed iu m  in  2 5 -cm 2 c u ltu re  fla sk s  (a b o u t  
5 X 10s c e l ls /m l ) .  F o r  th e  A h  recep to r  b in d in g  a ssa y , [3H ]T C D D  (1 0  
nM ) w ith  or w ith o u t  d iffer en t c o n c e n tr a tio n s  o f  f la v o n es  1 to  4  w a s  
ad ded  to  th e  c e ll cu ltu r e  fla sk s. T h e  c e lls  w ere in cu b a ted  b y  g e n t le  
sh a k in g  for  2  h a t  37*C . A fter  in cu b a tio n , th e  su sp en d ed  c e l ls  w ere  
h a rv es ted  a n d  w a sh e d  w ith  3 0  m l H E G D  buffer. T h e  w a sh ed  c e ll p e l le t  
w as re su sp e n d e d  in  3  m l o f  H E D  b uffer (sa m e a s  H E G D  b uffer w ith o u t  
g ly c ero l)  a n d  in c u b a te d  at 4*C for 10 m in . R ep e lle ted  c e lls  w ere  t r a n s ­
ferred to  a  2 -m l h o m o g e n iz in g  tu b e . 1 m l o f  H E G D  buffer w a s  a d d ed , 
a n d  th e  c e ll  s u s p e n s io n  w a s h o m o g en ize d . T h e  h o m o g en a te  w a s  t r a n s ­
ferred a n d  w a sh e d  w ith  H E G D  b uffer a n d  cen tr ifu ged ; th e  r e su lt in g  
n u c lear  p e lle t  w a s  th e n  re su sp e n d ed  in  ex tra c tio n  b uffer  (H E G D  + 0 .5
472 LU ET AL.
M KC1) and incubated at 4*C for 1 h. After centrifugation, the super­
natant extracts which contained the nuclear Ah receptor protein were 
aliquotted and stored at -70*C until used. Protein concentrations 
were determined according to Bradford (35).
Sucrose density gradient analysis of radiolabeled nuclear A h receptor. 
Aliquots (200 til) of nuclear extract were layered onto linear sucrose 
gradient (5 to 25%) prepared in HEGD buffer. Gradients were centri­
fuged at 4*C for 2.5 h at 400,000g. After centrifugation, 30 fractions 
were collected from each gradient and radioactivity in each fraction 
was determined by liquid scintillation counting to give the total bind­
ing. Nonspecific binding was determined in cells treated with radiola­
beled TCDD plus 200-fold excess of unlabeled TCDF. Specific binding 
was determined from the difference between the total and nonspecific 
binding as described (34,40).
cDNA sources and CYP1A1 mRNA analysis. The murine CYPlAl 
(1.2 kb) cDNA probe was obtained from the American Type Culture 
Collection. The plasmid pGMBl.l containing the mouse 0-tubulin 
cDNA was a gift from Dr. Don Cleveland (Johns Hopkins University). 
Digestion of the plasmid yielded a 1.3-kb fragment which was used to 
detect 0-tubulin mRNA. RNA from the cells treated with TCDD or 
substituted flavones for 24 h was isolated, electrophoresed, transferred 
to a nylon membrane, and probed by autoradiography or using a Beta- 
gen Betascope 603 imaging system as previously described (30,31,34).
Preparation of BrdU-substituted DNA. For cross-linking studies, 
10 pmol of the synthetic oligonucleotide, 5'-GATCTCCGGTCCCTT- 
CTCACGCAACGCCTGGGC-3', was annealed to a 10 pmol of a 7-bp 
complementary primer, 5 -GCCCAGG-3'. The annealed template was 
end-filled with the Klenow fragment of DNA polymerase in the pres­
ence of 0.1 (M dGTP, dATP, BrdU, and 1 fM  [“ PJdCTP as described 
(41) and was designated as the BrdU-substituted DRE oligonu­
cleotide.
Ultraviolet cross-linking. Nuclear extracts (10 fig) were incubated 
at 20*C with 400 ng of poly[d(I-C)] in HEGD buffer followed by the 
addition of a BrdU-substituted KP-labeled DRE and incubated for 15 
min at 20*C. The gel mobility shift assay products were uv irradiated 
directly on a FOTODYNE uv transilluminator, >205 nm for 20 min at 
20*C. Samples were then mixed with 20 pi of an SDS-loading buffer, 
heated to 95*C for 5 min, and then subjected to electrophoresis on 10% 
SDS-polyacrylamide gels. LigandtAh receptocBrdU-DRE complexes 
were resolved by autoradiography of the dried geL The molecular 
weight of uv-cross-linked nuclear ligandtAh receptonBrdU-DRE com­
plexes were determined by [I4C]methylated protein standards ob­
tained from Amersham Corp. (Arlington Heights, IL).
Statistical analysis. The statistical differences between different 
treatment groups were determined by ANOVA and Student t  test and 
the levels of probability are noted (P < 0.05 or P<  0.01). The data are 
expressed as means ± standard errors (SE) or deviations (SD) for at 
least three determinations for each experimental point.
R E S U L T S
Using rat hepatic cytosol, the concentration-depen­
dent displacement of [3H]TCDD by the substituted fla­
vones (1 to 4) was determined. All the compounds com­
petitively displaced [3H]TCDD from the receptor and 
the IC5 0  values (means ± SE) were 2.27 ±  0.61, 8 6 . 1  ±  
6.3, 872 ±  362, and 19.4 ± 12 nM for flavones 1 to 4 , 
respectively (Table I). Thus, 3'-methoxy-4'-nitroflavone 
exhibits competitive Ah receptor binding affinity which 
is not significantly different from unlabeled TCDD ( I C 5 0  
= 1.78 nM) run in the same assay system. The corre­
sponding Ki values calculated for compounds 1 to 4  were 
1.46 ± 0.39, 55.2 ± 4.0, 559 ± 232, and 12.4 ±  7.7 nM, 
respectively. Transformation of rat hepatic cytosolic Ah
TABLE I
Competitive Binding of Flavones 1 to 4 to Rat Hepatic 
Cytosol Ah Receptor and Their Activity to Induce 
Transformation of the Rat Cytosolic Ah Receptor0
Compound ICjo (nM)* K  (nM)‘
DRE
binding*
3'-Methoxy-4’-nitroflavone 2.27 ± 0.61 1.46 ± 0.39 ND
4'-Amino-3'-methoxyfiavone 86.1 ± 6.3 55.2 ± 4.0 5.3
4'-Methoxy-3'-nitroflavone 872 ± 362 559 ± 232 1.2
3'-Amino-4'-methoxyflavone 19.4 ± 12 12.4 ± 7.7 92
* The ICjo values were determined in competitive binding studies 
using [3H]TCDD as the radioligand and different concentrations of 
unlabeled competitor as described under Materials and Methods; A, 
values were calculated from the ICjo values. The results are expressed 
as means ± SE for four separate determinations.
6 DRE binding was also determined using rat hepatic €>00801 as de­
scribed (34); the results are expressed as DRE binding observed for 10 
fiM concentrations of the flavones 1 to 4 as a percentage of tha t ob­
served using 1 nM TCDD in the transformation assay.
receptor by flavones was also investigated using gel re­
tardation assays and DRE binding; compared to the 
DRE binding observed for 1 nM TCDD, 10 pM  concen­
trations of flavones 1 to 3  gave transformed DRE com­
plexes which were <6% of that observed for 1 nM TCDD. 
In contrast, 10 pM  3'-amino-4'-methoxyflavone signifi­
cantly transformed rat hepatic cytosolic Ah receptor 
(Table I).
The results in Fig. 2A illustrate the concentration-de­
pendent induction (0.01 to 10 pM)  of EROD activity by 
flavones 1 to 4  in MCF-7 cells. No significant induction 
of EROD activity was observed for these compounds (1 
to 4) after incubation with MCF-7 cells for 24 h. In con­
trast, the EROD activity observed for 1 nM TCDD was 
110 p m o l/m in / mg. The interactive effects o f the substi­
tuted flavones and TCDD were also investigated in 
MCF-7 cells treated with 1 nM TCDD plus different con­
centrations of the flavones (0.01 to 10 pM)  for 24 h (Fig. 
2B). N o significant inhibition o f induced EROD activity 
was observed in cells cotreated with 1 nM TCDD plus 
10 nM concentration of the flavones; some compound- 
dependent inhibition was observed at a 100 nM concen­
tration, whereas total inhibition of TCDD-induced 
EROD activity was observed in cells cotreated with 1 nM 
TCDD plus 1 pM flavones 1 to 4 . Inhibition of EROD 
activity by flavones 1 to 4  was further investigated by 
incubating these compounds with TCDD-induced rat 
liver microsomes. The results (Fig. 3) demonstrated that 
flavones 1 to 4  rapidly inactivated C Y PlA l-dependent 
EROD activity. T his response was observed in the pres­
ence o f NADPH; however, significant inhibition was 
also noted when this cofactor was not included in the 
incubation mixture (data not shown).
MCF-7 cells  w ere  trea ted  w ith  1 nM TCDD (a lon e), 1 
pM  co n cen tra tio n s o f  th e  sy n th etic  fla v o n es 1 to  4 , and
3'-M ETH O X Y -4'-N ITR O FLA V O N E AS AN Ah
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F I G . 2 .  E ffe c ts  o f  f lavon es  o n  in d u c tio n  o f  E R O D  a c t iv ity  (A ) a n d  
in h ib it io n  o f  T C D D -in d u c e d  E R O D  a c tiv ity  (B )  in  M C F -7  h u m a n  
b re a s t  c a n ce r  c e lls .  T h e  c o n c e n tr a tio n -d e p e n d e n t in d u c t io n  o f  E R O D  
a c t iv ity  b y  f la v o n e s  1 to  4  sh o w ed  t h a t  o n ly  3 '-a m in o -4 '-m e th o x y fla -  
v o n e  (□ )  ca u se d  a  m in im a l in d u ctio n  re sp o n se  a t  th e  h ig h e s t  c o n c e n ­
tr a tio n  (1 0  ptM) (A ) a fter  2 4  h . In  th e  c o tr e a tm e n t s tu d y  (B ) ,  M C F -7  
c e l ls  w ere  c o tr e a te d  w ith  1 nM T C D D  a n d  0.01 to  10 nM c o n c e n tr a t io n s  
o f  f la v o n e s  1 ( • ) ,  2  (O ), 3  (■ ) , a n d  4  ( □ )  for 24  h; E R O D  a c t iv ity  w a s  
d e te r m in e d  flu o r im etr ic a lly  a s  d escr ib ed  an d  th e  r e su lts  are  e x p r e ss e d  
a s m ea n s  £  S D  fo r  a t  le a st  th r e e  d e te r m in a tio n s  fo r  e a c h  tr e a tm e n t  
grou p . E R O D  a c t iv ity  in  c e lls  trea te d  w ith  1 nM T C D D  a lo n e  w a s  110  
p m o l/m in /m g .
a combination of 1 nM  TCDD plus 1 nM concentrations 
of the flavones and the induction of C Y PlA l mRNA lev­
els were determined by Northern blot analysis. The re­
sults (Table II) showed that flavones 1 to 3  alone elicited 
no significant induction of C Y PlA l mRNA levels, 
whereas 1 /zM 3'-amino-4'-methoxyflavone induced 
C Y PlA l mRNA levels comparable to that observed for 
1 nM  TCDD. In the cotreatment studies, both 3'-me- 
thoxy-4'-nitro- and 4'-amino-3'-methoxyflavone inhib­
ited induction of CYPlAl mRNA levels by TCDD. In 
contrast, the 4 -methoxy substituted flavones did not 
inhibit TCDD-induced C Y PlA l mRNA levels. The 
concentration-dependent inhibition of TCDD-induced 
C Y PlA l mRNA levels by 3'-methoxy-4'-nitro- and 4'- 
amino-3'-methoxyflavone is illustrated in Fig. 4. The 
former compound alone is inactive as an inducer at con­
centrations as high as 10 /zM  and the inhibitory effects in
R E C E PT O R  ANTAGONIST IN M C F-7 CELLS 4 7 3
Incubation Time
F I G . 3 .  E ffec ts  o f  f la v o n es  1 to  4  o n  E R O D  a c t iv ity  o f  h e p a tic  
m ic r o s o m e s  from  r a ts  tr e a te d  w it h  T C D D  (5  jig /k g ). R a t  l iv e r  
m ic r o s o m e s  a n d  red u ced  n u c le o t id e  c o fa c to r s  w e r e  in c u b a te d  w ith  1 
HM c o n c e n tr a t io n s  o f  4 '-m e th o x y -3 '-n itr o -  ( S ) ,  4 '-a m in o -3 '-m eth o x y -  
( ■ ) ,  3 '-m e th o x y -t '-n itr o -  (E ) , a n d  3 '-a m in o -4 '-m e th o x y -f la v o n e  ( □ )  
for 2  ( le f t )  or  5  (r ig h t) m in  p rior  to  d e te r m in a t io n  o f  E R O D  a c tiv ity .  
E R O D  w a s  d e te r m in e d  f lu o r im e tr ic a lly  in  th e  con tro l ( ■ )  a n d  
f la v o n e -tr e a te d  m ic ro so m e s  a n d  t h e r e  w a s  a  s ig n if ic a n t  d e c r e a se  (P  
<  0 .0 5 )  in  E R O D  a c t iv ity  in  m ic r o s o m e s  t r e a te d  w ith  fla v o n e s  1 to  4  
a f te r  2  a n d  5  m in . R e s u lts  a r e  e x p r e s s e d  a s  m e a n s  ± S D  fo r  a t  le a s t  
th r e e  d e te r m in a tio n s .
the cotreated cells were observed at 1 and 10 *zM concen­
trations. Similar results were observed for 4'-amino-3'- 
methoxyflavone; however, the compound alone at the 
highest concentration (10 /z M ) induced small but detect­
able C Y P lA l mRNA levels as determined by Northern 
blot analysis using the Betagen Betascope 603 blot ana­
lyzer imaging system (data not shown). The induction 
was not evident in the autoradiograph (Fig. 4).
TABLE II
Effects of Flavones 1 to 4 in the Presence or Absence 
of TCDD on Induction of CYPlAl Gene Expression 
in MCF-7 Cells0
C on e. C Y P lA l
T re a tm e n t (nM ) m R N A  le v e ls
D M S O _ 0 .9  ±  1.1
T C D D 1 36 .5  £  5.9*
3 '-M e th o x y -4 '-n itro fla v o n e 1000 0 .5  ±  0 .6
4 '-A m in o -3 '-m eth o x y fla v o n e 1000 0.4 £  0 .5
4 '-M eth o x y -3 '-n itro fla v o n e 1000 2 .8  £  0 .4
3 '-A m in o -4 '-m eth o x v fla v o n e 1000 3 5 .9  £  16.86
3 '-M eth o x y -4 '-n itro fla v o n e  +  T C D D 100 0 +  1 1.1 £ 0 .7 '
4 '-A m in o -3 ’-m e th o x v fla v o n e  + T C D D 1000 +  1 0.6 £  0 .8f
4 '-M eth o x y -3 '-n itr o fla v o n e  +  T C D D 100 0 +  1 4 0 .7  £  0 .4 6
3 '-A m in o -4 '-m e th o x y fla v o n e  +  T C D D 100 0 +  1 3 5 .0  £  22.9*
° M C F -7  c e l ls  w ere trea ted  w ith  1 nM T C D D , 1000  nM fla v o n es  1 to  
4  in  th e  p r e s e n c e  or a b se n c ce  o f  I nM T C D D  for 24 h; m R N A  w as  
is o la te d  a n d  q u a n tita te d  by N o r th e r n  b lo t  a n a ly s is  (re la tiv e  to  d -tu-  
b u lin  m R N A )  a s  d escrib ed  u n d er  M a te r ia ls  a n d  M e th o d s . T h e  resu lts  
are e x p r e s s e d  a s  m ea n s  ±  S D  for a t  le a s t  th r e e  d e te r m in a tio n s  for each  
d a ta  p o in t .
6 S ig n if ic a n t ly  h igh er  (P  <  0 .0 5 ) th a n  in  c o n tr o l ce lls .  
e S ig n if ic a n t ly  low er (P <  0 .0 5 )  th a n  in  c e l ls  trea te d  w ith  TCDD 
a lo n e .
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F I G .  4 .  E f fe c t s  o f  3 '-m e th o x y -4 '-n itro fla v o n e  (to p )  a n d  4 '-am in o -3 '-m eth o x y fla v o n e  (b o tto m ) a s  in d u cers  o f  C Y P l A l  m R N A  le v e ls  in  th e  
p r e s e n c e  o r  a b s e n c e  o f  1 nM  T C D D  in  M C F -7  c e lls .  m R N A  w as ex tra c ted  from  M C F -7  c e l ls  2 4  h  a fter  tr e a tm e n t w ith  0 .0 1 ,0 .1 ,  1 .0 , a n d  10 ptM 
3 '-m e th o x y -4 '-n itr o f la v o n e , D M S O , 1 nM  T C D D , 1 nM  T C D D  +  0 .0 1 ,0 .1 ,1 .0 ,  or 10  jiM 3 '-m e th o x y -4 ’-n itro fia v o n e  ( la n e s  1 th ro u g h  10, r e sp e c ­
t iv e ly )  ( le f t) ;  la n e s  1 th rou gh  10 in r igh t h and  gel r e p r ese n t m R N A  from  c e lls  trea ted  w ith  0 .0 1 ,0 .1 ,1 .0 ,  a n d  10 mM 3 '-m e th o x y -4 '-a m in o fla v o n e ,  
1 nM  T C D D , 1 nM  T C D D  p lu s  0 .0 1 ,0 .1 ,1 .0 ,  or 10  nM 3 ''m eth cx y -4 '-a m in o fla v o n e , a n d  D M S O , re sp ec tiv e ly . m R N A  w a s  e x tr a c te d  an d  N o r th e r n  
b lo t  a n a ly s is  w a s  ca r r ied  o u t  a s  d escrib ed  u nder M a ter ia ls  an d  M eth od s.
The effects of 3'-methoxy-4'-nitro- and 4'-amino-3'- 
methoxyflavone on formation of the nuclear Ah receptor 
complex were also determined in MCF-7 cells treated 
with 10 nM  [3H]TCDD and different concentrations of 
the two flavones. Both compounds inhibited formation 
of the nuclear Ah receptor complex (Fig. 5) in MCF-7 
cells. However, an early eluting specifically bound peak 
which constituted approximately 10% of the total spe­
cifically bound nuclear Ah receptor complex was not 
affected by the flavones.
Nuclear extracts from MCF-7 cells treated with 10 nM 
[3H]TCDD in the presence or absence of 1 mM 3’-me- 
thoxy-4'-nitro- or 4'-amino-3'-methoxyflavone were in­
cubated with a [32P]labeled BrdU-substituted DRE, ir­
radiated with ultraviolet light for 20 min, and analyzed 
by gel retardation assays. Specifically bound cross- 
linked retarded bands (see arrow) were observed at 190 
kDa by SDS-PAGE for all nuclear extracts, indicating 
that the nuclear Ah receptor complex in cells treated 
with only [3H]TCDD or [3H]TCDD plus the Ah receptor 
antagonists formed a DNA binding complex with similar 
Mr values and consistent with a nuclear heterodimer 
of the Ah receptor and Amt proteins (42). In addition, 
a lower molecular weight Ah receptor:BrdU-DRE 
complex (~ 9 7  kDa) was observed in MCF-7 cells 
treated with 1 jtM 3'methoxy-4'nitro- or 4'amino-3'-me- 
thoxyflavone plus TCDD that was not observed in cells 
treated with TCDD alone.
DISCUSSION
Previous studies have reported that several different 
structural classes of compounds including 6 -methyl- 
1,3,8-trichlorodibenzofuran (MCDF) and related 6 -sub- 
stituted analogs and aNF inhibit diverse TCDD-induced 
responses in vivo and in mammalian cells in culture (30— 
33, 40, 43). Both MCDF and related compounds and 
aN F competitively bind to the Ah receptor and block 
formation of the nuclear Ah receptor complex in various 
mammalian cells in culture (30). However, both MCDF 
and aN F also exhibit Ah receptor agonist activity in
mammalian cells at high concentrations (32, 33). Flavo- 
noids exhibit a broad spectrum of activities and this re­
port describes interactions of a series of structurally re­
lated 3,4-disubstituted compounds containing a me­
thoxy group at one and a nitro or amino substituent at 
the other position (Fig. 1 ) with the Ah receptor. These 
compounds were selected for this study following an ex­
tensive prescreening of a series of synthetic 3'-, 4'-, and 
3',4'-substituted flavones (16) as competitive ligands for 
the Ah receptor (data not shown). These compounds 
were previously prepared and their activities as protein 
kinase C inhibitors were reported (16). The competitive 
IC50 values for binding of the substituted flavones (1  to 
4) to the rat hepatic cytosolic Ah receptor are summa­
rized in Table I. The results indicate that for these struc­
turally related flavones, there were marked effects of 
substituent structure and position on Ah receptor bind­
ing affinities. For example, 3'-methoxy-4'-nitroflavone 
exhibited a competitive Ah receptor binding affinity 384- 
fold higher than the isomeric 4'-methoxy-3'-nitroflavone 
and the IC50 value for the former compound was not sig­
nificantly different than that observed for unlabeled 
TCDD (IC50 = 1.78 nM ) (34). A ^fourfold difference in 
binding affinity was observed for the isomeric 4'-amino- 
3 '-methoxy- and 3'-amino-4'-methoxyflavones; however, 
for these isomers, the 4'-methoxy-substituted isomer ex­
hibited the higher binding affinity. These substituent 
structure-binding relationships have not previously 
been observed for any other structural class of Ah recep­
tor ligands. In previous studies with substituted biphe­
nyls, dibenzo-p-dioxins, and dibenzofurans (44-46), 
substituent electronegativity, lipophilicity, and size, 
were the major structural determinants which facilitated 
binding to the rat cytosolic Ah receptor; not surprisingly, 
the methoxy- and amino-substituted analogs exhibited 
low binding affinities, whereas nitro-substituted com­
pounds exhibited slightly increased binding. Thus, the 
high competitive binding affinities of 3'-methoxy-4'-ni- 
tro- and 3'-amino-4'-methoxyflavone (Table I) were un­
expected based on the results of previous studies. The
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F I G .  5 .  V e lo c ity  s ed im en ta tio n  a n a ly s is  o f  n u c le a r  e x tr a c ts  from  
M C F -7  c e l ls  tr e a te d  w ith  10 nM  [3H ]T C D D  in  th e  a b se n c e  o r  p r e s e n c e  
o f  1 or  10  mM u n la b e le d  3 '-m e th o x y -4 ’-n itro f la v o n e  (A )  o r  4 '-a m in o -3 '-  
m e th o x y f la v o n e  (B ) . M C F -7  c e lls  w ere tr e a te d  w ith  [3H ] T C D D  a n d  
d if fe r e n t  c o n c e n tr a t io n s  o f  th e  flavon es. N u c lea r  e x tr a c ts  w e r e  o b ­
ta in e d  a n d  a n a ly z e d  b y su crose  d en sity  g ra d ie n t c e n tr ifu g a tio n  a s  d e ­
sc r ib e d  u n d er  M a ter ia ls  an d  M e th o d s  s e c t io n . L e v e ls  o f  s p e c if ic a lly  
b o u n d  r a d io la b e led  n u c lear  A h  recep tor c o m p le x  in  c e l l s  t r e a te d  w ith  
(A ) 10  nM  {3H ]T C D D  (■ ), 10 oM  [3H ]T C D D  p lu s  1 nM 3 '-m e th o x y -4 ’- 
n itr o fla v o n e  (O ), 10  nM [3H ]T C D D  p lu s  10 (iM 3 '-m e th o x y -4 '-n i-  
t r o f la v o n e  ( • ) ,  (B )  10 nM [3H ]T C D D  p lu s  1 4 '-a m in o -3 '-m e -
th o x y f la v o n e  (O ), a n d  10 nM  [3H JT C D D  p lu s  10 fiM 4 '-a m in o -3 '-m e -  
th o x y f la v o n e  ( • )  w ere  27 .6  ±  1 .4 8 ,4 .7 8  ±  0 .4 6 ,4 .3 7  ±  1 .4 8 ,1 1 .0  ±  1 .44 , 
a n d  6 .4 0  ±  3 .5 5  fm o l/m g , re sp ective ly . T h e  r e su lts  a r e  e x p r e s s e d  a n d  
m e a n s  ± S D  fo r  a t  le a st  th ree  sep ara te  e x p e r im e n ts  fo r  e a c h  tr e a tm e n t  
g rou p . N o n s p e c if ic a l ly  b oun d  ra d io a c tiv ity  w a s o b ta in e d  fro m  c e lls  
t r e a te d  w ith  10  nM  [3H ]T C D D  an d  a 2 0 0 -fo ld  e x c e s s  o f  u n la b e le d  
T C D F  (□ ) .
data obtained for flavones 1 to 4 further extend the 
structure-binding relationships for the Ah receptor in 
which compounds with highly variable aromatic ring 
and substituent structure bind to the Ah receptor. These 
data suggest that there may be more than one form of 
the Ah receptor or that the ligand-binding domain of the 
Ah receptor may contain multiple and/or possibly over­
lapping ligand-binding sites capable of interacting with 
structurally diverse compounds. Since the human Ah re­
ceptor gene has been cloned (47), mutational analysis of 
the ligand binding domain can be used in future studies 
to investigate the structural requirements for ligand in­
teraction with the receptor protein binding site(s).
The activity of the 3\4'-substituted flavones 1 to 4  as 
inducers of C Y PlA l gene expression was determined in 
MCF-7 human breast cancer cells. The results illus­
trated in Fig. 2A indicate that the flavones do not sig­
nificantly induce EROD activity in these cells at concen­
trations as high as 10 *iM. Minimal or nondetectable in­
duction of C Y PlA l mRNA levels was observed for 
flavones 1 to 3 , whereas 3'-amino-4'-methoxyflavone 
significantly induced CYPlA l mRNA levels (Table II) 
and induced transformation of the rat cytosolic Ah re­
ceptor (Table I). The lack of correspondence between 
induced EROD activity versus C Y PlA l mRNA levels 
for flavone 4 was further investigated by cotreating 
MCF-7 cells for 24 h with 1 nM TCDD plus different 
concentrations of flavones 1 to 4 (Fig. 2B) or by adding 
these compounds directly to TCDD-induced micro­
somes (Fig. 3). The results demonstrate that all four 
compounds rapidly inactivate CYPlAl-dependent ac­
tivity; however, the mechanism of this inhibitory re­
sponse is unknown. These results indicate that the dis­
parity between the induction of C Y PlA l mRNA levels 
by 3'-amino-4'-methoxyflavone (4) and the failure to ob­
serve induced EROD activity is due to inactivation of 
C YPlAl. Current studies are utilizing other substituted 
flavones to investigate the mechanism and specificity of 
their interaction with P450 isozymes.
The structure-induction (CYPlAl) relationships ob­
served for flavones 1 to 4  did not parallel their structure- 
binding relationships (Table I) since only one compound
(4) induced C Y PlA l gene expression, whereas 3'-me- 
thoxy-4'-nitroflavone (1), the congener with the highest 
receptor binding affinity (Table 1), was inactive as an 
inducer of C Y PlA l mRNA levels or EROD activity. The 
relatively high receptor binding affinities of flavones 1 to 
3 for the Ah receptor coupled with their failure to induce 
CYPlAl mRNA levels suggested that these compounds 
may be Ah receptor antagonists. Therefore, MCF-7 cells 
were cotreated with 1 nM TCDD plus flavones 1 to 4  (1 
fiM) and the results summarized in Table II show that 
only flavones 1 and 2 inhibit induction of C Y P lA l 
mRNA levels by TCDD. The inhibitory effects of these 
compounds was further investigated and the results il­
lustrated in Fig. 4 show that at concentrations of fla­
vones 1 to 2  which were 2*0.1 mM, significant inhibition 
of TCDD-induced C Y PlA l mRNA levels was observed. 
In this study, 4'-amino-3'-methoxyflavone induced min­
imal but detectable induction of C Y PlA l mRNA at the 
highest concentration (Fig. 4), whereas no induction re­
sponse was observed for 3'-methoxy-4'-nitroflavone at a 
10 mM concentration. Previous studies with the partial 
Ah receptor agonists, MCDF and aNF, showed that 
these compounds also inhibited TCDD-induced CYP­
lA l mRNA levels and formation of the nuclear Ah re­
ceptor complexes (32, 33) at concentrations < 10 -6 M but 
exhibited agonist activity at higher concentrations. In 
contrast, flavones 1 or 2  at concentrations of 1 and 10
476 l u  E rr a l .
F I G .  6 . U ltr a v io le t  cr o ss - lin k in g  o f  th e  n u c lear  ligan d :A h  r e c e p to r  
c o m p le x  to  a  B r d U -su b s titu te d  D R E . N u c lear  e x tr a c ts  (1 0  fig) fro m  
M C F -7  c e l ls  w ere in cu b a ted  w ith  **P-labeled  B r d U -su b s titu te d  
( 1 4 0 ,0 0 0  c p m , 0 .5 -1 .0  n g ) c o n s e n su s  D R E  o lig o n u c leo tid e  a s  d esc r ib e d  
u n d e r  M a te r ia ls  a n d  M e th o d s . S a m p le s  w ere u v -irra d ia ted  fo r  3 0  m in  
a n d  s u b s e q u e n t ly  a n a ly z e d  b y  S D S -P A G E . L igantL A h r e c e p to n D N A  
c o m p le x e s  w ere  r e so lv ed  b y  au torad iograp h y . T h e  arrow s in d ic a te  th e  
m o le c u la r  w e ig h ts  b a se d  on  th e  m ig ra tio n  o f  ra d io lab e led  s ta n d a r d s . 
T h e  c r o ss - lin k e d  A h  recep to r  co m p le x e s  w ere d er iv ed  from  n u c le a r  
e x t r a c t s  fro m  M C F -7  c e lls  trea ted  w ith  10  nM T C D D  (la n e  1), 10  nM  
T C D D  p lu s  1 nM f la v o n e  1 ( la n e  2 ) , a n d  10 nM T C D D  p lu s  1 fiM f la ­
v o n e  2  ( la n e  3 ) , a n d  10 nM T C D D  p lu s  in cu b a tio n  w ith  1 0 0 -fo ld  e x c e s s  
u n la b e le d  B r d U -su b s titu te d  D R E  (la n e  4 ).
fiM significantly inhibited induction of C Y PlA l mRNA  
levels by TCDD in MCF-7 cells (Fig. 4). Since 3'-me- 
thoxy-4'-nitroflavone exhibited no detectable Ah recep­
tor agonist activity (Table II and Fig. 4), this compound 
is the first “pure” Ah receptor antagonist for MCF-7 
cells which has hitherto been identified.
The results in Fig. 5 illustrate the velocity sedimenta­
tion profile of nuclear extracts from MCF-7 cells treated 
with 10 nM [3H]TCDD in the presence or absence of fla­
vones 1 or 2 . The specifically labeled nuclear Ah recep­
tor complex sedimented as a broad specifically bound 
peak as determined using a 200 -fold excess of unlabeled 
TCDF as a competitor (Fig. 5). In contrast, a portion of 
the specifically bound early eluting nuclear Ah receptor 
complex (see arrow) was observed in MCF-7 cells co­
treated with [3H]TCDD and flavones 1 or 2  (1 and 10 
n M ) .  The failure to inhibit formation of this specifically 
bound Ah receptor complex was consistently observed 
with both flavone antagonists. Previous studies with 
aN F  or MCDF showed that these compounds also inhib­
ited TCDD-induced CY PlA l gene expression and for­
mation of the nuclear Ah receptor complex (30-33). 
However, the formation of the early eluting Ah receptor 
complex was not detected in nuclear extracts. Incuba­
tion of nuclear extracts from MCF-7 cells treated with 
TCDD in the presence or absence of flavones 1 and 2  
with 32P-labeled BrdU-DRE followed by irradiation gave 
cross-linked complexes which were separated by electro­
phoresis (Fig. 6 ). The apparent molecular masses of the 
cross-linked complexes were 190 kDa and this is consis­
tent with covalent interaction of both the Ah receptor 
and the Arnt proteins with the BrdU-DRE (42). The 
lower molecular weight cross-linked-monomer com­
plexes were not detected in this assay. Thus, despite the 
different velocity sedimentation properties of the 
nuclear Ah receptor complexes (Fig. 5), the apparent 
molecular weights of the major cross-linked proteins 
were similar. The failure of flavones 1 and 2 to inhibit 
formation of the early eluting specifically bound nuclear 
Ah receptor complex suggests that [3H]TCDD interacts 
with more than one binding site in the Ah receptor or 
that there is more than one form of the Ah receptor 
which exhibits differential competitive inhibition with 
flavones 1 and 2. Results of studies in other laboratories 
also suggest that there may be more than one form of the 
Ah receptor (48-52). Moreover, since flavones 1 and 2 
inhibit TCDD-induced C Y PlA l gene expression in 
MCF-7 cells, the early eluting specifically bound com­
plex which forms in the nucleus must be inactive as a 
transcriptional enhancer for induction of C Y P lA l gene 
expression.
In summary, the results of this study demonstrate 
that 3'-methoxy-4'-nitro- and 4'-amino-3'-methoxyfla- 
vone inhibit TCDD-induced C Y PlA l gene expression 
in MCF-7 human breast cancer cells and the inhibitory 
effects by 3',4'-substituted flavones are remarkably de­
pendent on the structure and position of the substitu­
ents. 3'-Methoxy-4'-nitroflavone (1) is a pure Ah recep­
tor antagonist and results obtained with flavones 1 and 
2  indicate that both compounds partially inhibit forma­
tion of the nuclear Ah receptor complex. The failure of 
flavones 1 and 2  to block formation of an early eluting 
specifically bound nuclear Ah receptor complex suggests 
that MCF-7 cells express a form of the Ah receptor com­
plex which exhibits differential (low) competitive bind­
ing with flavones 1 and 2  and is inactive as a transcrip­
tional enhancer for induction of C Y P lA l in this cell 
line. These compounds will be utilized in the future as 
probes to further characterize multiple forms of the Ah 
receptor complex.
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Summary
T he effect o f  flavone ( C A S  5 2 5 -8 2 -6 ,2-phenylben zopy- 
ran -4-one, 1 ) , fIavone-8-acetic a c id  (C A S  87626-55-9, 
F A A , 2 )  an d  10 su b stitu ted  flavon es on th e  lum inol-de- 
p en d en t chem ilum inescence o f  m urine m acrophages w as 
s tu d ie d  in vitro. The syn th etic  derivatives w ere variously 
su b stitu ted  w ith  halo, nitro, amino, hydroxy an d  m eth­
o x y  su bstitu en ts in the 3 ’ an d  4 ' p o sitio n s Chem ilum in­
escen ce w as used in th is stu d y a s an in d ica tor fo r  the  
produ ction  o f  reactive oxygen species b y  m acrophages, 
stim u la ted  in vitro  by phorbol m yrista te  a ceta te  
( F M A ). A ll flavon es excep t FA A  (2 )  show ed m ore than  
2 0  %  inhibition a t 10 p m o lll or 100 p m o lll 3 ’-A m in o- 
4 '-hydroxyflavon e (8 )  w as the m ost p o ten t inhibitor. 
T he ICsoS fo r  inh ibition o f  chem ilum inescence were 
4 .2  ±  1 .1  pm olll, 5 .0  ±  1 .0  p m o lll a n d  3 .3  ±  1 .4  p m o lll 
f o r  residen t, e lic ited  a n d  L P S -F oly I:C -p rim ed  m acro­
p h a g es respectively. S m a ll but s ta tis tic a lly  sign ifican t 
enhancem ents o f  chem ilum inescence were cau sed  b y low  
concen trations o f  flavon e (1 ) , FAA (2 )  a n d  4'-m eth- 
oxyflavon e (6 ) . These resu lts suggest th a t m odulation  
o f  th e dierruhaninescent capacity  o f  m acrophages d e­
p en d s on th e nature o f  th e su bstitu en ts a n d  th e concen­
tra tio n  o f  the fla vo n es
Zusammenfassung
R egulierung der.Lum ino-abhangigen Chem Uum ineszertz 
in  M aus-M akrophagen durch Flavon und dessen  syn th e- 
tisch e D eriva te
1. Introduction
Various flavones (2-phenylbenzopyran-4-one derivatives) 
have a wide range of effects on biological systems [1-3] 
and some naturally occurring flavones show anticancer 
activity against certain experimental tumours [4-7]. Re­
cent reports have indicated the potential use of synthetic 
flavonoids, such as flavone-8-acetic acid (CAS 87626-55- 
9, FAA, LM-975, NSC-347512, 2) and its analogues, in 
the treatment of some solid tumours in experimental 
models [8-10]. FAA is more effective against slow-grow­
ing solid tumours (e.g. murine colon adenocarcinoma 
38) than against rapidely proliferating leukaemias and 
lymphomas (e.g. L1210 and P388) [11, 12] and has been 
reported to have effects on shutting down blood flow 
and inducing haemorrhagic necrosis [15] in experimental 
murine solid tumours. The ability of FAA and analogues 
to stimulate natural killer cells [16] and T cells [17] has 
also been reported. FAA increases the direct cytotoxicity 
of murine macrophages in vitro against tumour targets 
[18], stimulates the formation of nitric oxide [19] and 
modulates production of superoxide anion (0 2") in ac­
tivated macrophages [20]. Several synthetic aminofla- 
vones also show inhibitory activity against protein kin­
ases [21. 22]. These activities in normal and tumour-
Flavon (C A S  525-82-6. 2-P henylbenzopyran-4 -on, 1 ), 
F lavon-8-essigsaure ( C A S  87626-55-9 , FAA, 2 ) und 10  
su b stitu ierte  F lavone wurden a u f ihren E in flu f a u f d ie  
L um inol-abhdngige C hem ilum ineszenz kin untersucht. 
D ie  su bstitu ierten  Flavone, w eld ie  an  den P ositionen 3  
und 4  H alo-. N itro-, A m ino-, H yd roxy- oder M eth oxy- 
G ruppen besitzen , wurden syn th etisch  gewormen. C hem i­
lum ineszenz, d ie  in vitro m it H ilfe von P horbolm yristyl- 
a c e ta t (P M A )  stim u liert wurde, d ien te  a ls In d ik a to rfu r 
d ie  E n tstehu ng von reaktiven  Sauerstoffprodukten  in 
den M akrophagen. A lle  Flavone, m it Ausrtahm e von 
FAA (2 ) , ze ig ten  b e i ein er K onzen tration  von 10 oder 
10 0  p m o lll ein e 2 0 % ig e  Inhibierung. 3 ’-A m ino-4'-hy- 
droxyflavon  ( 8 )  w ar von alien  der w irh m gsvo llste  Inhi­
bitor. 5 0 % ig e  H em m ung (IC so ) wurde bei folgen den  
K onzen tration en  hervorgerufen: 4 .2  ± 1 .1  p m o lll fu r  
n ich t stim u lie rte  M akrophagen, 5 .0  ±  1 .0  p m o lll fu r  s ti-  
m u lierte  M akrophagen, 3 .3  ±  1 .0  p m o lll f i r  m it L P S - 
P o ly  I :C  vorbehandelte M akrophagen. E ine geringe  
V erstarkenm g d er C hem ilum ineszenz konnte b e i Flavon 
( 1 ) ,  FAA ( 2 )  und 4 '-M eth oxyflavon  (6 )  beobach tet 
werden. D iese  E rgebnisse zeigen , d a fi d ie R egulierung  
d e r C hem ilum ineszenzstarke in M akrophagen m o g lid i 
is t, un d fe m e r  abhangig is t von der A r t und der K onzen­
tra tio n  d er F lavone
K e y  w o r d s :  3 '-A m in o -4 ’-hydroxyflavone • C A S
8 7 626-55-9  • F lavone-8-acetic a c id  - Flavones - M acro­
phages, m odulation  o f  chem ilum inescence
bearing mice and in human patients suggest that there 
may be potential for further chemical studies to develop 
flavones as chemotherapeutic drugs with improved anti- 
tumour activity and which may also function as biolog­
ical response modifiers.
Upon stimulation with both soluble and particulate mat­
ter, oxidative metabolism is stimulated in the macro­
phage, resulting in the respiratory burst which is accom­
panied by activation of an NADPH oxidising enzyme. 
This enzyme catalyses the reduction of molecular oxygen 
to Oi" and the burst is paralleled by consumption of 
oxygen. Rapid dismutation of Oi" gives hydrogen perox­
ide (H20 2). These toxic metabolites are important for 
the tumouricidal and microbicidal activities of macro­
phages [23-25], The presence of reactive oxygen metabo­
lites can be inferred from the light emitted (chemilumin­
escence) during their reaction with the easily oxidisable 
substance luminol (5-amino-2,3-dihydrophthalazine-1.4 
-dione) [26].
The purpose of the present study was to evaluate quanti­
tatively the activity of flavones on the chemiluminescent 
activity of murine macrophages. A series of flavones 
variously substituted in the 3’ and 4' positions was pre­
pared for evaluation of their activity towards macro­
phages. The assay technique evaluates the luminol-de- 
pendent chemiluminescence of macrophages, using 
phorbol myristate acetate (PMA) as a stimulant for oxy­
gen metabolism through the activation of protein kinase 
C (PKC) [27],
Abbreviations
FAA, flavone-8-acetic add; 0 2“, superoxide anion; PMA, phor­
bol myristate acetate; PKC, protein kinase C; HBSS, Hanks’ 
balanced salt solution; PBS, phosphate buffered saline solution 
DMSO, dimethylsulphoxide; LPS, lipopolysaccaride; Poly I:C, 
polyinosinic-polycytidylic add potassium salt; IFNs, inter­
ferons; IL, interleukin; TNF, tumour necrosis factor.
2 . M e t h o d s
2.1. Chemicals
FAA (2) was obtained from the Drug Synthesis and Chemistry 
Branch, Division of Cancer Treatment, National Cancer Insti­
tute, USA, through the courtesy of Dr. K. Pauli. Other flavones 
(1, 3-12) were synthesised as previously described [21]. HBSS 
without phenol red and PBS were purchased from GIBCO Life 
Technologies Ltd. (Paisley, UK). PMA and DMSO were pur­
chased from Sigma Chemical Company (St. Louis, MO, USA). 
Luminol was bought from LKB (Turku, Finland). Thio- 
glycollate broth and phenol red soluUon (0.5 % aqueous solu­
tion of the sodium salt) were purchased from Serva Chemicals 
(Heidelberg, Germany). E. cofi serotype 0127:B8 LPS was pur­
chased from Calbiochem (La Jolla, CA, USA). Poly I:C was 
purchased from Biochemicals Inc. (Milwaukee, WI, USA). 
Monoclonal antibody anti-mouse Thy-1,2 fluorescein conjugate 
was purchased from Becton Dickinson Systems (Mountain 
View, CA, USA).
2.2. Isolation and culture o f  mouse peritoneal 
exudate macrophages
Peritoneal exudate cells were isolated from BALB/c mice (8-12 
weeks of age). Mice were sacrificed by cervical dislocation and 
cells were collected by washing the peritoneum with PBS (5 ml). 
Resident macrophages were collected from untreated animals. 
Thioglycollate-elicited macrophages were collected from mice 
which had been injected 4 days previously with thioglycollate 
broth (1 ml per mouse). LPS-Poly I:C-stimulated macrophages 
were obtained from mice which had been injected 18 h previ­
ously with 1 ml of a solution of LPS plus Poly I:C (100 ug Poly 
I:C plus 0.1 ug LPS) in PBS Adherent cells were collected by 
plating the cells in culture medium (1 ml) in test tubes or 24- 
well plates and incubating for 2 h at 37 °C under 95 % air/5 % 
C 02 and 100% humidity. Non-adherent cells were removed 
with the supernatant and by three further vigorous washings 
with PBS. The adherent population was judged to be 92 ± 2 % 
macrophages by differential counts of May-Grunwald/Giemsa 
stained cells and less than 1 % T-lymphocytes by flurescence 
microscopy after fluorescent -antibody labelling with anti Thy 
1,2 antibody.
Monolayers of macrophages were tested for viability in 24-well 
plates (Falcon, Becton Dickinson, Lincoln Park, NJ, USA) con­
taining one glass cover slip per well. Viability was greater than 
96 ± 2 % as determined by exclusion of neutral red. The same 
staining was also used for evaluating the cytotoxic efliciency of 
the tested flavones. All flavones were dissolved in DMSO. 
DMSO at the maximum concentration (1 %) did not modify the 
viability of cells or the chemiluminescence in the macrophage 
cultures in vitro.
2.5. Chemiluminescence
photomuliplier has a spectral response of 300 to 660 nm. The 
luminescent light was measure in 3.5 ml test tubes The sample 
volume was usually 1 ml. The reactions were initiated by dis­
pensing aliquots of solutions of luminol (110 pmol/1) to macro­
phages (2 x 106) and flavones in HBSS in test tubes The resting 
intensity of chemiluminescence was recorded after 5 min. PMA 
solution was then added to give a final concentration of 0.8 
pmol/1. The light emitted was then recorded continuously for 
15 min. The intensity of the chemiluminescence was determined 
by measuring counts/min and by calculating the area under the 
chemiluminescence intensity curve (integral chemilumines­
cence). The percent inhibition of chemiluminescence. as com­
pared to controls, was calculated according to the formula:
Inhibition % = 100 x (Ne-N t)/Nc 
where Nc values were the counts per 15 min for the control and 
N, values were the counts per 15 min in the presence of the 
flavones A negative value indicates stimulation. The final con­
centrations of the flavones were 1, 10, 100 and 1000 pmol/l (the 
latter concentration was only used for FAA).
5. R e s u l t s
Three states of differentiation of murine peritoneal mac­
rophages (resident, elicited and activated) are generally 
recognised. Resident cells were collected from untreated 
animals. Elicited macrophages were prepared from mice 
which had been injected 4 days previously with thio­
glycollate broth. LPS-Poly I:C-primed macrophages (ac­
tivated) were obtained from mice which had been in­
jected 18 h previously with a solution of LPS and Poly 
I:C. The kinetic profile of chemiluminescence of macro­
phages pre-exposed to luminol and (5 min later) to PMA 
(0.8 pmol/1) is presented in Fig. 1. This variation in kin­
etics of chemiluminescence was observed when different 
macrophages were used. Qualitatively similar profiles 
were observed with resident and elicited macrophages. 
The response curves demonstrated that the resident and 
elicited macrophages caused a slow rising chemilumines­
cence curve without a defined peak after dispersion of 
luminol. LPS and Poly I:C stimulated maximal produc­
tion of chemiluminescence by the macrophages. The ad­
dition of luminol resulted in a slight but significant in­
crease in the count rate, due to activation of the cells by 
LPS and Poly I:C before harvesting them in vivo. The 
increase in count rate after the addition of PMA was 
significantly larger and peaked within 4 to 5 min. The 
production of chemiluminescence by peritoneal macro­
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Fig. 1: Time course of chemiluminescence emitted from macrophages
exposed to 0.8 pmol/1 o f PM A . Resident. elicited,----------
LPS-Poly I:C-primed.
Table 1: Production o f chemiluminescence by peritoneal macrophages.
Macrophages
Chemiluminescence response (integral counts)-*'
Time (min) after adding luminol1"
0-5 6 -20
Resident 167 -  8 2386 e 227
Elicited 193 e 14 4122 ± 727
Activated 1446 e  278 51667 s  9387
*) Data arc expressed as the mean values o f 4 -6  experiments = SD 
b> PMA was added 5 min after the addition o f luminol.
The structures of the flavones used in this work are 
shown in Table 2. The level of inhibition of all twelve 
compounds tested is presented in Tables 3-5. Of these, 
six compounds inhibited chemiluminescence at all con­
centrations tested (3,8- 12). 3’-Amino-4’-hydroxyflavone 
(8) was the most potent inhibitor. The concentrations 
leading to 50 % inhibition (IC50) of chemiluminescence
Table 5: Effects o f  flavones on chemiluminescence induced in murine 
LPS-Poly I:C macrophages by PM A.






1 flavone H H H
2 flavone-8-acetic add H H CH2COOH
3 4 ’-aminoflavone H N H j H
4 4 ’-bromoflavone H Br H
5 4‘-chloroflavone H a H
6 4 ’-methoxyflavone H OCHj H




8 n h 2 OH H
9 4 ’-chloro-3’- N 0 2 a H
nitro flavone
10 3\4'-dichloroflavone a a H
11 3’-methoxy-4’- OCH3 N 02 H
nitroflavone
12 4*-methoxy-3’- NOj O C H j H
mtro flavone





1 10 100 1000
1 -1 4  ±2 20 * 2 69 s  3 n.d.
2 2 s  I -1 e  1 8 * 2 58 s  2
3 0.3 s  0.2 20 = 1 66 s  3 n.d.
4 14 e  2 33 s  2 n.d. n.d.
5 11 * 3 32 s  2 n.d. n.d.
6 -13  ±2 23 s  2 n.d. n.d.
7 -6  = 2 22 s  3 n.d. n.d.
8 3 4 - 2 61 = 3 81 s  4 n.d.
9 36 = 2 4 8 s  1 64 s  3 n.d.
10 4 - 1 16 s  2 23 s  2 n.d.
11 8 = 1 18 s  1 21 s  3 n.d.
12 4 - 2 13 s  1 n.d. n.d.
*> Results are expressed as mean = SD. n =  3 -5 . n.d.: not determined.
Table 4: Effects o f  flavones on chemiluminescence induced in murine 




1 10 100 1000
I -11 s  2 7 s  3 74 = 3 n.d.
2 5 s  I -6  = 2 9 = 2 59 = 3
3 0.2 s  0.1 8 = 2 75 = 2 n.d.
4 16 s  2 36 s  2 n.d. n.d.
5 31 s  3 32 = 2 n.d. n.d.
6 -2  s  1 22 s  » n.d. n.d.
7 11 s  2 22 = i 69 = 3 n.d.
8 30 s  2 55 s  3 85 = 2 n.d.
9 35 s  2 47 = 2 56 = 4 n.d.
10 10 s  2 20 = 3 30 = 3 n.d.
11 7 = 2 12 = 3 22 = 4 n.d.




1 10 100 1000
1 -6  = 2 -8  = 3 55 = 3 n.d.
2 - 3 * 1 -8  = 3 -6 = 4 35 = 6
3 6 = 2 8 = 3 7 0 s  3 n.d.
4 -1 0  = 4 25 = 2 n.d. n.d.
5 -11 = 2 13 = 2 n.d. n.d.
6 - 7  =  3 16 = 3 n.d. n.d.
7 - 2 = 1 2 * 1 65 s  3 n.d.
8 36 = 2 52 = 2 93 = 5 n.d.
9 3 3 =  1 30 = 4 35 = 5 n.d.
10 5 =  1 4 = 3 6 = 1 n.d.
11 2 = I 12 = 2 14 = 3 n.d.
12 0.2 = 0.1 20 = 4 n.d. n .d.
*’ Results arc expressed as mean = SD . n = 3-5 . n.d.: not determined.
*’ Results arc expressed as mean = SD , n = 3 -5 . n.d.: not determined.
by this compound were 4.2 ± 1.1 pmol/1, 5.0 ± 1.0 pmol/1 
and 3.3 ± 1.4 pmol/1 for resident, elicited and LPS plus 
Poly I:C -  primed macrophages, respectively. Since no 
significant difference in the viability of cells was ob­
served between cultures exposed to PMA alone 
(92 * 2 % viable) and to PMA and the highest concen­
trations tested for each of the agents, inhibition of pro­
duction of chemiluminescence is unlikely to be due to 
toxicity of the compounds.
PMA-stimulated production of chemiluminescence was 
enhanced to a small but statistically significant extent in 
the presence of low (1 jimol/1) concentrations of flavone 
(1), FAA (2) and 4’-methoxyflavone (6), independently 
of the macrophages used. However, PMA-stimulated 
production of chemiluminescence was progressively in­
hibited in the presence of increasing concentrations of 
these agents.
4. D is c u s s io n
The generation of chemiluminescence by mouse periton­
eal macrophages is an indication of the formation of re­
active oxygen species. The chemiluminescence is depend­
ent on the production of species such as 0 2", H20 2, *0 2 
and HO. The production of such highly reactive entities 
in macrophages is a result of the activation of the respir­
atory burst. In this report, we show that LPS plus Poly 
I:C stimulated the activity of macrophages in vivo. Pro­
duction of chemiluminescence stimulated by LPS plus 
I:C was significantly enhanced in the prescence of lumi­
nol. Induction of macrophage oxidative activity in vivo 
is a multi-step process requiring both a priming (e.g. 
IFNs) and a triggering (e.g. LPS) signal. Double-stran­
ded polyribonucleotides such as Poly I:C are potent in­
ducers of IFNs both in vivo and in vitro [29, 30]. Addi­
tionally, Poly I:C induces the secretion of TNF-a by 
macrophages [31]. LPS is one of the most powerful ac­
tivators of macrophages, which then produce a variety 
of active substances such as TNFs, IL-1 and IL-6 [31, 
32]. Macrophages of various species, including man, give 
a respiratory burst upon exposure to phorbol esters; in­
deed, PMA is one of the most potent activators of 
NADPH oxidase known [27]. Primed peritoneal macro­
phages show higher capacities than resident cells to gen­
erate 0 2~ upon stimulation by PMA. Unlike resident 
murine macrophages, macrophages derived from murine 
bone marrow generate 0 2" upon exposure to zymosan 
but not to PMA. The ability of macrophages derived 
from bone marrow to respond to PMA is restored, at 
least in part, by treatment with LPS or the cytokines 
TNF-a, IFN-y and IL-la [33]. Thus, the responsiveness 
of resident peritoneal macrophages to PMA may be the 
result of exposure to cytokines in vivo.
We have shown that the resident and elicited peritoneal 
macrophages generated chemiluminescence upon expo­
sure to PMA and this may reflect the response of a sub­
population of resident macrophages which arises as a 
result of chronic low level stimulation by endogenously 
produced endotoxin in BALB/c mice. The present ex­
periments demonstrate that the PMA-stimulated genera­
tion of chemiluminescence in vitro from peritoneal mac­
rophages stimulated with LPS and Poly I:C (in vivo) was 
enhanced to a small but significant extent in the pres­
ence of low concentrations of flavones 1 ,4-7  at 1 pmol/1 
and by FAA (2) at 1, 10, 100 pmol/1. At higher concen­
trations of these agents, PMA-stimulated generation of 
chemiluminescence was inhibited in a concentration-de­
pendent manner. Flavones 3,8-12 inhibited the chemilu­
minescence at all concentrations tested, again in a dose- 
dependent way. A similar activity has been shown for 
FAA and xanthenone acetic acid analogues with PMA- 
stimulated production of superoxide measured as reduc­
tion of ferricytochrome c that is inhibitable by superox­
ide dismutase [20]. The cellular mechanisms of the effect 
are not known but could be related to the various bio­
logical effects of the flavones: 1. antioxidant properties 
[28, 34]; 2. inhibition of many enzymes, including 
NADPH oxidase [35], cydo-oxygenase and lipoxygenase 
[36,37]; 3. inhibition of cellular enzymes involved in sig­
nal transduction [21, 22, 38, 39].
The flavones could inhibit chemiluminescence of macro­
phages by inhibiting the generation or release of radicals 
from the cells. In a previous study, we demonstrated that 
some flavones modulated luminol-dependent chemilu­
minescence of neutrophils [40]. In contrast, 3-hydroxy- 
flavones are well known to be potent inhibitors of 
the chemiluminescence of neutrophils [41]. Various 
flavones, e.g. kaempferol (3,4’,5,7-tetrahydroxyflavone), 
morin (2',3,4’-5,7-pentahydroxyflavone) and quercetin 
(3,3’,4’,5,7-pentahydroxyflavone) inhibit the respiratory 
burst in neutrophils induced by soluble and particulate 
stimuli [35].
There appears to be no clear structure-activity relation­
ship amongst the eleven synthetic flavones for inhibition 
of the respiratory burst in resident, elicited and activated 
macrophages, although there is a correlation between ac­
tivity of any one compound on all three macrophage 
types. There is some indication that polarity of the sub­
stituents has importance, with flavones 3, 7, 8 which, 
bear polar, hydrogen-bonding substituents being good 
inhibitors and flavones 10-12 with non-polar substitu­
ents being weak inhibitors. The exception to this general­
isation is 4’-chloro-3’-nitroflavone (9) which is a rela­
tively strong inhibitor. Similarly, there is a tendency for 
flavones bearing electron-donating substituents (e.g. 3, 
7, 8) to have potent activity and those having electron- 
withdrawing groups (e.g. 11, 12) to show poor activity 
but again there is an exception in that the relatively elec­
tron-deficient 4’-chloro-3’-nitroflavone (9) is relatively 
potent.
In the present study, we have shown 3’-amino-4’- 
hydroxyflavone (8) to be the most potent inhibitor. This 
compound also reduced the amount of chemilumines­
cence generated by the horseradish peroxidase mediated 
oxidation of luminol by hydrogen peroxide ( I C 5 0  =  
5.5 ± 0.5 pmol/1) (Krol, W., Czuba, Z. P., Threadgill, M.
D., unpublished results). Thus some of the activity of 
this flavone may be due to antioxidant reactivity, al­
though this could not be so for the relatively electron- 
deficient analogue 9. The mechanism by which these 
agents inhibit NADPH oxidase may involve interference 
with PKC-mediated protein phosphorylation [42]. It is 
also noteworthy that the concentration of the active 
compound is a major determinant of its activity; it has 
already been shown that while low concentrations of 
quercetin stimulate activation of PKC high concentra­
tions inhibit it [38, 39]. This feature may be an important 
determinant in the immunotropic activity of flavones
w here sign a l tran sm ission  p rocesses a cross ce ll m em ­
b ran es play an  im p ortan t ro le  in their b io lo g ica l s ign ifi­
cance: F urth er stu d ies o n  th e  b io lo g ica l e ffec ts  o f  the  
a ctiv e  flavones are in progress.
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Monofunctional Electrophilic and Nucleophiiic Derivatives of 
meso-Tetraphenylporphyrin for Attachment to Peptides
Susan E. Matthews, Colin W. Pouton and Michael D. Threadgill*
School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath UK BA2 7AY 
E-mail: m.d. threadgill@ bath.ac. uk 
4-Nitrophenyl A/-[4-(10,15,20-triphenylporphyrin-5-yl)phenyl]carbamate and
5-[4-{A/-glycylamino)phenyl]-10,15,20-triphenylporphyrin have been synthesised from a readily prepared 
monofunctionalised porphyrin; they couple efficiently with the side-chains of extended lysyl and glutamyl peptide 
derivatives, respectively.
Porphyrins alone or linked to polymers and other targetting 
moieties have important roles in diagnosis and therapy of  
cancer. For example, the so-called ‘haematoporphyrin deriva­
tive’ and other porphyrins act as photosensitisers for conversion 
o f triplet oxygen to singlet oxygen in photodynamic therapy1 
and porphyrins are known to accumulate selectively in some 
types o f tumour tissue,2 leading to prospects o f  their use as 
targetting groups. Porphyrinatomanganese complexes are used 
as contrast-enhancing agents in magnetic resonance imaging 
(MRI), owing to their high molar relaxivities in aqueous 
solution.3 Attachment o f metalloporphyrin and other agents to a 
soluble polymer enhances molar relaxivity and thus effective­
ness as a MRI contrast agent.4
Significant difficulty in preparing mono-functionallsed por­
phyrins in a controlled manner is caused by the fact that the 
most readily available naturally-occurring porphyrins, such as 
protoporphyrin IX and mesoporphyrin II, carry more than one 
identical electrophilic or nucleophiiic functional group. The 
classical Adler-Rothemund5 procedure for synthesis o f  meso- 
tetraarylporphyrins from arylaldehydes and pyrrole proceeds in 
< 20% yield and mono-Ar-functionalised porphyrins are only 
obtained in very low yields by separation of statistical mixtures 
o f porphyrins formed from mixtures o f aldehydes,6 whereas the 
recently-reported Heck coupling7 needs several synthetic steps 
to prepare the starting 5,15-diphenyl- 10-iodoporphyrin. To
ZMeN COR
1 R = OH
2 R = OCsFg
3 R = NHCH2CH2NH2
NHR1
obviate these problems of synthesis of mono-Ar-substituted 
tetrapheny lporphyrins, Kruper et al.s developed an efficient 
mononitration and subsequent reduction o f the readily-available 
meso-tetraphenylporphyrin. We now report our exploitation of 
this weakly nucleophiiic amine in generating reactive electro­
philic and nucleophiiic monofunctional porphyrins for attach­
ment to side-chain extended a,(D-bis(methylamino) peptides. 
Polymers derived from the latter will be o f use in MRI.
a,a)-Bis[benzyloxycarbonyl(methyl)amino] peptides with 
carboxylic acid derivatives and primary amines in side-chains 
o f the same length were built up as shown in Scheme 1. N- 
(Benzyloxcarbonyl)sarcosine l 9 was converted to its penta- 
fluorophenyl (PFP) active ester 2 t  and this was added to a 
2 0 -fold excess o f  ethane-1,2 -diamine to set up the protected 
sarcosine aminoethylamide 3 t  as the sequence inverting unit for 
the C-termini o f the peptides.
Orthogonal protection o f the a - and e-amines o f L-lysine 4 
was required for elaboration of the peptide chain and of the side- 
chain. This was achieved by complexation with copperfn), 
selective acylation of the e-amine with 2 ,2 ,2 -trichloroethyl 
chlorofonnate, decomplexation and acylation o f the a-amine 
with di-rerr-butyl dicarbonate in a two-phase system, in a 
modification o f the method of Yajima et al.10 The resulting 
BocLys(Troc)OH 5 t  was converted to the PFP active ester 6 ,t  
prior to coupling with 3 to afford the fully orthogonally
NHR1
R2HN COR3
S i.jv .v T ~  4 R 1 = R2 = H. R3 = OH 
p r  5 R1 = Troc, R2 = Boc, R3 





I—  7 R1 = Troc. R2 = Boc 
p r  8 R1 = Troc. R2 = H*HCI
9 R ’ s Troc. R2 = ZMeNCH2CO 
I—  10  R1 = H. R2 = ZMeNCH2C0 
-  11 R1 = CO(CH2)sNHBoc. R2 = ZMeNCH2CO 





* r—  13 R 1 = OCsF5. R2 = OBn
p r  14 R1 = NHfCHzJsCOzMe. R2 = OBn 
“  15 R1 =NH(CH2)5. R2 = OH
NMeZ
d 16 R1 = NHfCHjJsCOjMe. R2 = OCsFj
17 R1 = OMe. R2 = Boc 
: 18 R1 = OMe. R2 = H»HCI 
: 19 R1 = OMe. R2 = ZMeNCH2CO 
: 20 R1 = NHNH2. R2 = ZMeNCH2CO 
21 R1 = N3. R2 = ZMeNCHjCO
Scheme 1 Synthesis of extended sequence-inverted peptides 12 and 21. Troc = 2,2.2-trichIoroethoxycarbonyl. Reagents and conditions:*+ i. CsFjOH. DCC. 
EtOAc. 0 °C. 20 h. 90-95%: ii. H^NCH>CH:NH2 (20 x excess). CH2C12. 3 h. 82%: iii. CuCOx. H ,0 . reflux. 3 h. then TrocCI. Na:CO,. H20 . 0 °C. 20 h; 
iv. Na*, EDTA2 -. H20 . reflux. 2 h: v. Boc,0. Et,N. H20.dioxan. 3 d. 58%’ from 4; vi. 3. P r2 NEt. CH2C12. 85%: vii. HCl. CH2Ci2.1 h. quant.: viii. 2. P r2NEt. 
DMAP. CH2C12. 4 d. 87%: ix. Zn. MeOH. reflux. 5 h. 83%; x. BocNH(CH2)sC 02C6Fs. P r2NEl. DMAP. CH2C12. 6 d. 55%: xi. H2N(CH2)sC 0 2Mc HCI. 
P r2NEt. DMAP. CH2C12. 7 d. 89%: xii. H2. Pd/C. teirahydrofuran. 3 h. quant: xiii, N2H4-H20 . MeOH. 40 °C. 8 h. quant: xiv. Bu'ONO. DMF. THF. dioxan. 
HCl, -2 0  °C. 50 min. then Pr2NEi. - 6 0  °C (this solution was taken forward for reaction with 27. Scheme 2).
1 8 1 0
protected inverted-sequence peptide 7.t The peptide chain was 
completed by acidic removal of the Boc group, giving the salt 
8 , f  and acylation with one further equivalent o f  2. With the 
inverted sequence o f the peptide now complete, attention was 
turned to extension of the length of the side-chain of 9-t The e- 
amine 1 0 t  was revealed by selective reductive removal o f the 
Troc group (zinc dust in methanol). Acylation with penta- 
fluorophenyl 6 -(rerr-butoxycarbonylamino)hexanoaten gave 
the orthogonally protected peptide derivative l l . t  Deprotection 
(HCl) afforded the target inverted-sequence peptide 12f with 
the extended primary amine side-chain for coupling with an 
appropriate monofunctional porphyrin electrophile.
In the assembly o f a corresponding inverted-sequence 
peptide with an extended activated carboxylic acid side-chain, 
the extension was performed prior to construction of the peptide 
to avoid problems of formation o f pyroglutamates. Acylation of 
the spacer unit, methyl 6 -aminohexanoate, with Boc glutamic 
acid a-benzyi ester y-PFP ester 13‘2 gave the extended 
derivative 14 .f The a-carboxylic acid 15f was revealed by 
selective hydrogenolysis of the benzyl ester. In a series o f steps 
similar to those used for building the inverted-sequence lysine 
peptide, this carboxylic acid was activated as the PFP ester 16t 
and coupled with the sequence-inverting unit 3  to afford 17.t 
Again, selective acidolytic deprotection revealed the Glu a- 
amine 18. Coupling with 3 afforded the target inverted-
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sequence peptide 19f with the extended carboxylic acid side- 
chain protected as the methyl ester. This ester resisted selective  
hydrolysis under both basic and acidic conditions but suc­
cumbed to hydrazinolysis, giving the hydrazide 2 0 .f  From this, 
the acyl azide 21  t t  was formed by reaction with ferf-butyl 
nitrite under acidic conditions, other nitrosating agents (e.g. 
sodium nitrite) being either inefficient or destructive. This 
provides an active acyiating function for reaction with an 
appropriate porphyrin nucleophile.
The monoaminophenylporphyrin 24 was prepared in 46% 
overall yield in two steps from mero-tetraphenylporphyrin 2 2 , 
in a modification o f the method of Kruper et al. (Scheme 2 ).8 
The corresponding isocyanate would represent a potent electro­
phile for reaction with the extended lysine derivative 12 but 24 
reacted slowly with phosgene, giving mainly the corresponding 
/Vf/V'-bis(tetraphenylporphyrinyl)urea. However, the amine 24 
was acylated smoothiy§ by 4-nitrophenyl chloroformate, giving 
the carbamate 25, a synthon for the required isocyanate. 
Treatment o f 25 under mildly basic conditions generated the 
isocyanate which coupled in situ§ with the extended lysine 
derivative 1 2 , giving the protected porphyrinyl peptide deriva­
tive 28^ in good yield.
The arylamine 24 was found to be a remarkably weak 
nucleophile, reacting with succinic anhydride only after a 
prolonged period at elevated temperature and not reacting with
22 R = H
23 R = NO2
24 R = NHj
25 R = NHCO2C6H4NO2-P
26 R = NHCOCHjNHBoc
27 R = NHCOCH2NH2*HCJ
Scheme 2 Activation of tetraphenylpotphyhnamine 24 as an electrophile and as a nucleophile: coupling with extended sequence-inverted peptides 12 and 
21. Reagents and conditions:tt i. fuming HNO.,. CHCl,. 5 h. 55%: ii, SnCU. conc. aq. HCl. 80 °C. 2 h. 84%; iii. 4-niuophenyl chloroformate. Pr’jNEt. CHCl». 
20 h. then chromatography. 67%; iv. BocGlyOOsF,. P r2NEt. DMAP. CHCl.,. 46 h. 95%; v. HCl. CHjCN. 1 h. quant: vi. PrsNEt. DMAP. CH2C12. 20 h. 82%. 
vii; PrsNEt. DMAP. CHCl.,. 2 h. 58%.
ZMeN^  ^NMeZZMeN NMeZ
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peptide active esters or with the acyl azide 21. Much greater 
nucleophilicity is required for efficient coupling with peptide 
derivatives under mild conditions. To introduce a primary 
aliphatic amine as a more potent nucleophile, the arylamine was 
acylated by treatment]] with a two-fold excess of the PFP active 
ester of N-Boc-glycine at 40 °C, forming 26. The primary 
aliphatic amine 27 was revealed by deprotection]| with hydrogen 
chloride. This more reactive nucleophile then coupled effi- 
cientlyJI with the extended peptide derivative acyl azide 21, 
giving the porphyrinyl peptide derivative 29.**
The monoaminotetraphenylporphyrin 24 is thus demon­
strated to be a readily accessible monofunctionalised porphyrin 
which can be converted straightforwardly into a reactive 
electrophile and a reactive unhindered nucleophile which 
should have general utility in controlled attachment of porphy­
rins to peptides, polymers and other molecules.
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Footnotes
t All novel compounds were characterised by1H NMR and by FAB MS and 
were shown to be pure by TLC Target compounds and major intermediates 
were also characterised by high resolution FAB MS.
% Acyl azide 21 was prepared and used without purification, to avoid 
Curtius rearrangement.
§ Method: Compound24 (5.70g, 9.25 mmol) was stirred with 4-nitxopheny 1 
chlorofonnate (1.86 g, 9.25 mmol) and PrSNEt (1.19 g. 9.25 mmol) in 
CHCl) (50 cm3) for 20 b. Chromatography gave 25 (4.85 g. 67%) as a purple 
glass. Compound 12 (385 mg, 530 pmol) and 25 (520 mg, 670 pmol) were 
stined with Pr^NEt (205 mg, 1.6 mmol) and DMAP (10 mg) in CH2Q 2 (10 
cm3) for 20 h. Chromatography gave 28 (593 mg, 82%) as a purple glass. 
1 Spectroscopic data for 28:6 (CDQ3) -2.78 (2 H, s, porphyrin 21,23-H2), 
1-2-1.7 (10 H, m, Lys p. y-H« + NCHjCWjO/jCffjCHjCO). 2.12 (2 H, br, 
CHjCffjCO). 2.93 (3 H, s, NCHj), 2.99 (3 H, s, NCH3), 3.0-33 (8 H, Lys 
e-Hj + NCffaCHjCHj + NCHjCHjN), 3.77 (2 H. m. Sar-H2), 3.86 (2 H, m, 
Sar’-Hj), 436 (1 H, m, Lys «-H), 5.06 (3 H, s) and 5.07 (1 H, s) (2 x  
PhCH20), 5.75 (1 H, br, NH), 5.83 (1 H, br. NH), 6.39 (1 H, br, NH), 637 
(I H, br. NH), 6.94 (1 H, br. NH). 7.24 (10 H, br s. 2 x  benzyloxy Ph-Hs), 
7.37 (1 H, br, NH), 7.69 (11H, m. 3 x  porphyrin-Ph 3,43-H3 + porphyrin- 
Q^LN 2,6-Hj), 8.06 (2 H, d, J 8.4 Hz. porphyrin-C6H4N 33-Hz), 8.15 (6
H. m, 3 x porphyrin-Ph 2,6-H2), 8.79 (2 H. d J 4.7 Hz. porphyrin 3.7-H2), 
8.82 (4 H, s, porphyrin 12,13,17,18-H*). 8.87 (2 H. d, J 5.1 Hz, porphyrin
2,8-Hj); mJz (FAB) 1367.6384 (M + H) (Cg.HgxN.zO, requires 
1367.6406).
B Method: Compound 24 (5.00 g. 8.16 mmol) was stined with Boc- 
GlyOQFj (538 g. 16.3 mmol), Pr*2NEt (232 g, 18.0 mmol) and DMAP (50 
mg) in CHCl) (100 cm3) for 46 h at 40 °C Chromatography gave 26 (6.00 
g, 95%) as a purple glass. This compound (2.24 g, 2.9 mmol) was treated 
with excess HCl in CH2C12 (100 cm3) for 1 h. The solvent and excess 
reagent were evaporated to give 27 (2.10 g. quantitative). rerr-Butyl nitrite 
(0.22 cm3) in THF (1.75 cm3) was added to 21 (130 mg. 2.07 mmol) in 
DMF (3.0 cm3) and HCl in 1,4-dioxan (4.0 mol dm-3, 1.86 cm3) at —20 °C. 
The mixture was stirred for 2 h. Pr2NEt (1.06 g) was added at —60 °C. 
followed by 27 (2.09 g, 2.9 mmol) and PrsNEt (1.12 g, 18.7 mmol) in 
CHC13 (30 cm3). The mixture was stined for 2 h. Chromatography gave 29 
(1.64 g  58%) as a purple glass.
** Spectroscopic data for 29: 6h (CDC13) —2.75 (2 H, porphyrin 2133-H2),
0.89 (2 H. m. NCHjCHjCWjCHjCHjCO). 1.23-1.65 (6 H, m. 
NCH2C//2CH2O /2CH2C0 + Glu p-H2), 1.9-2.4 (4 H. Glu y-H2 + 
CH2CH2C//2CO). 3.0-3.1 (8 H, m. NCW2CH2CH2 + 2 x NCH3), 3.35 (4 H, 
br, NCH2CH2N). 3.85-4.05 (4 H. m. 2 X Sar-H2), 4.15-4.25 (2 H, m. Gly- 
H2), 4.42 (1 H, m, Glu ce-H), 5.13 (4 H. br s, 2 X PhCH20). 7.25-7.33 (14 
H, m, 4 x NH + 2 x  benzyloxy Ph-Hs), 7.70-7.76 (11 H, m. 3 x  porphyrin- 
Ph 3.43-Hj + porphyrin-CeHgN 2,6-H2), 7.96 (2 H, m, 2 x  NH). 8.12 (2 H. 
d, 7 8.2 Hz, porphyrin-C l^LN 33-H2), 8.17-8.23 (6 H, m, 3 X porphyrin-Ph 
2,6-H)), 8.84 (8 H, br s, porphyrin 2,3,7,8,12,13.17,18-Hg); m!z (FAB) 
1381.6184 (M + H) (Cg,Hg,N120,o requires 1381.6199). 
t t  Reactions took place at ambient temperature, unless otherwise stated.
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Abstract
An unusual cyclisation of Z-l,2,4-tris(benzamido)butene with trifiuoroacetic anhydride gives Z-4-[ 1,3-bis( benzamido) prop-1 -eny 1 ] -2- 
phenyl-5-trifluoromethyloxazole (3 ). The structure and stereochemistry were confirmed by ‘H, 13C and 19F NMR, together with ‘H-'H COSY, 
lH -‘H NOESY and lH -» I9F and l9F -* *H heteronuclear NOE experiments. Trifluoroacetylation at the less sterically hindered N-acyl-enamine 
position, with subsequent cyclisation and 1,4-elimination is proposed.
Keywords: 5-Trifluoromethyloxazole; 1.2-Dibenzamidoalkene, Cyclisation; NMR spectroscopy; Stereochemistry
1. Introduction
As part of a programme of synthesis of trifluoromethyl- 
heterocycles for medicinal and pH sensor applications [ 1,2], 
we required 2-trifluoromethylhistamine. This compound has 
been prepared by Bamberger cleavage of histamine (1), fol­
lowed by treatment with boiling trifiuoroacetic anhydride and 
acid-catalysed hydrolysis of the side-chain benzamide. Kim- 
oto et al. [3] also noted the formation of a significant un­
identified side-product. We now report the preparation and 
characterisation of this material as a 5-trifluoromethyl-4- 
alkenyloxazole which is formed by an interesting alternative 
cyclisation.
2. Results and discussion
As expected [4], Bamberger fragmentation of histamine 
( 1 ) gave 5-l,2,4-tris(benzamido)butene (2). Treatment 
with boiling trifiuoroacetic anhydride, followed by methanol, 
gave a poorly soluble solid in moderate yield. The high res­
olution Cl mass spectrum showed a major (M + H) + peak 
at m/z  492.1535, corresponding to the molecular formula 
C2 7 H2 0 F3 N3O3 . 19F NMR spectroscopy showed only one sin­
glet at 8 — 58.89 ppm; thus one CF3 group or two equivalent 
CF3 groups are present. The ‘H NMR spectrum revealed the 
presence of only one CH: (5 4.19 ppm) and one alkene
* Corresponding author.
proton, along with 15 aromatic protons and two NH protons. 
Hence one of the CH2 groups of the triamide 2  has become 
involved in the reaction. A'H-‘H COSY spectrum indicated 
coupling from the CH2 to the vinylic-H and to the upfield NH 
(Fig. 1). No coupling was evident between the alkene-H and 
either NH. These data show compound 3 to have the alken- 
yloxazole structure shown. A 'H-‘H NOESY experiment 
gave a cross-peak between the downfield NH ( 8 10.50 ppm) 
and the CH2, showing Z stereochemistry about the C=C dou­
ble bond (Fig. 1). An NOE enhancement was observed in 
the 19F signal of the CF3 group on irradiation at the 'H fre­
quency of the alkene-H, but not on irradiation at the lH 
frequency of the CH2, which corroborated this structural 
assignment (Fig. 1). The converse NOE experiment, involv­
ing irradiation at the of the CF3 group, showed enhance­
ment of the ‘H signals of the downfield NH, the vinylic-H 
and, more weakly, to the 2,6-H: of one benzamide (Fig. 1).
To rationalise this unexpected cyclisation, a mechanism 
such as that shown in Scheme 1 is proposed. Acylation of the 
triamide 2  at the more sterically accessible enamine position 
is followed by nucleophiiic attack of the amide oxygen on 
the trifluoromethyl ketone. Trifluoroacetylation of the tetra­
hedral intermediate at oxygen provides an excellent leaving 
group for the 1,4-elimination to afford the alkenyloxazolc 3.
3. Experimental details
NMR spectra were obtained of a solution in (CD3)2SO at 
70 °C to ensure complete solution of 3, using JEOL EX-400
0022-1139/95/S09.50 © 1995 Elsevier Science S.A. All rights reserved 
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Fig. I. Principal COSY and NOE interactions for the characterisation of 3. 
Other interactions were observed between the protons attached to the indi­
vidual benzene rings.
and Bruker AC-250 instruments. The l9F NMR chemical shift 
is referenced to CFC13.
3.1. Z-4-( 1,3-Bis(benzamido)prop-1 -enyl)-2-phenyl-5- 
trifluoromethyloxazole (3)
Z-l,2,4-Tris(benzamido)butene ( 2 ) [4] (388 mg, 0.91 
mmol) was boiled under reflux with trifiuoroacetic anhydride 
(4 ml) for 16 h. The excess reagent was evaporated and the 
residue was boiled under reflux in methanol ( 5  ml) for 1 h. 
The solid was collected by filtration from the cooled mixture 
to give the oxazole 3 (78 mg, 18%) as a white solid, m.p. 
216-217 °C. 'H NMR 8:4.19 (br t, 2H, J = 5 Hz, CH2) ; 6.29 
(br t, 1H. J = 5 Hz, C=CH); 7.58-7.68 (m, 9H, 3 X Ar 3,4,5- 
H3); 7.99 (d, 2H, J = 6.7 Hz, 2,6-H, of oxazole-2-Ph); 8.08- 
8.13 (m, 4H, 2 Xbenzamide 2,6-H,); 9.08 (br t, 1H, 
N//CH2); 10.50 (s, 1H.NH) ppm. ,3CNMR 5:36.59,119.07 
(q, JC_F = 268 Hz, CF3); 124.87; 126.00; 126.48; 126.53 
129.90; 127.17; 127.94; 128.11; 128.98; 130.96; 131.38 
131.73; 132.53 (q, Jc_F=44 Hz, C-CF3); 133.43; 133.83 
140.54; 160.38; 164.96; 166.62 ppm. ,VF NMR 8: -58.89
NHz NHCOPh
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Scheme 1. Synthesis of the trifluoromethyloxazole 3 and proposed mecha­
nism. Reagents: i. PhCOCl: ii. (CE3CO ),0; iii, MeOH.
(s) ppm. MS (Cl) m/z: 492.1535 (M + H) (C 2 7 H2 ,F3N30 3 
requires 492.1535).
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Abstract—The effect of flavone (2-phenylbenzopyran-4-one) and three amino-substituted flavones on the 
production of nitrite by murine activated peritoneal macrophages was studied in vitro. Activated peritoneal 
macrophages obtained from mice pre-created with concanavalin A (Con A) (in vivo), after exposure in vitro to 
lipopolysaccharidc (LPS) at a concentration of 100 ng/ml. produced nitrite (20.3 ± 2.5 nmol/106  cells), as 
measured after 24 hr by the Griess reaction. Stimulation of production of nitrite was inhibited by N^mono- 
methyl-L-arginine, suggesting that nitrite was formed via nitric oxide (NO*) as a product of metabolism of 
arginine. Stimulation was inhibited by flavone and the aminoflavones (20-100 pM). 3'-amino-4'-hydroxyflavone 
was the most potent inhibitor of nitrite production. Genistein (5,7-dihydroxy-3-(4-hydroxy-phenyl)-4H-l-ben- 
zopyran-4-one) also inhibited production of nitrite, by a mechanism that appears not to involve protein tyrosine 
kinases. These results suggest that the flavones can modulate the immune responses and the inflammatory 
reactions by controlling production of nitric oxide.
Key words: macrophages, nitric oxide, flavones, 3'-amino-4'-hydroxyflavone. NO*
Macrophages are known to play an important role in host 
defence mechanisms. Among a variety of mediators re­
leased by activated macrophages ( 1 , 2 ], nitric oxide 
(NO*) has been identified as a potent molecule that may 
exert regulatory or cytotoxic effects depending on the 
concentration acting on the target cell (3 ,4 ]. The induc­
ible form of the arginine-dependent enzyme nitric oxide- 
synthase generates high, toxic amounts of nitric oxide, 
which enable the activated macrophages to destroy tu­
mour cells, intracellular bacteria, parasites [5, 6 , 7), and 
even normal tissue in situations o f autoimmune reactiv­
ity [8 , 9]. Earlier studies have shown that functions of 
activated macrophages such as killing of tumour cells, 
release of cytokines, and generation o f oxygen radicals, 
can be regulated by flavones (2-phenylbenzopyran-4- 
ones) [10-12]. Various flavones have been shown to be 
good scavengers o f free radicals [13-18] and to act as 
natural antioxidants. They have also been shown to in­
hibit oxido-reductases [19-21], thus preventing the for­
mation of free radicals resulting from the reduction of 
oxygen. These two mechanisms can account for the role 
o f  many flavonoids in protecting cells from oxidative 
damage.
The present study was designed to investigate the role 
o f flavones in the regulation of NO* release from acti­
vated murine macrophages. Nitrite and nitrate are 
formed as end products o f the metabolism o f reactive 
nitrogen intermediates, with the measurement o f  nitrite
* Corresponding author. FAX 483 1722554.
Abbreviations: Con A. concana valin A from Canavalia en- 
siformis: NMR. nuclear magnetic resonance spectrum; PBS, 
phosphate-buffered saline solution; FCS, heat-inactivated foetal 
calf scrum; LPS. lipopolysaccharidc from E. coli (serotype 
0127:B8); N°MMA. N^monomelhyl-L-arginine monoacctale 
salt.
using the Griess reagent (with or without the reduction 
of nitrate) being generally employed as a marker o f  for­
mation o f nitric oxide.
M A T ER IA LS AND M ETHODS
Mice
Specific pathogen-free 8-to-10 week old BALB/c 
male mice were purchased from the Institute o f Oncol­
ogy, Gliwice, Poland.
Reagents
Flavone (2-phenyl-4H-l-benzopyran-4-one, sample 
1), 4'-aminoflavone (sample 2), and 3'-amino-4'-hydroxy- 
flavone (sample 3) were synthesised as previously de­
scribed £22]. 3/-amino-4'-methoxyflavone (sample 4) 
was prepared by reduction o f 4'-methoxy-3'-nitroflavone 
with tin(II) chloride by the general method [22] (*H 
NMR 5 6.83 (1 H, s, 3-H), 7.22 (1 H, d, J = 8.4 Hz, 
5'-H), 7.50 (1 H, dd, J =  8 .4 ,7 .0  Hz, 6 -H), 7.69 (1 H, d, 
J  = 8.1 Hz, 8 -H), 7.86 (1 H, ddd, J  =  8.4, 7.0, 1.8 Hz,
7-H), 7.94 (1 H, dd, J =  8 .4 ,2 .2  Hz, 6 '-H), 8.04 (1 H, dd. 
7  = 8.4, 1.8 Hz, 5-H), 8 .06 (1  H, d, 7 =  2.2 H z,2'-H ), 9.7 
(2 H, br, NH j), 11.7 (1 H, s. OH)). The structures o f the 
flavones used in this work are shown in Fig. 3. Phos­
phate-buffered saline solution (PBS), RPMI 1640 m e­
dium without phenol red, and heat-inactivated foetal calf 
serum (FCS, low in endotoxin) were purchased from 
GIB CO Life Technologies Ltd. (Paisley, U.K.). Thio- 
glycollate broth, phenol red solution (0.5% aqueous so­
lution o f the sodium salt), N-(l-naphthyl)cthylenedi- 
amine dihydrochloride, sulphanilamide, and heparin 
sodium (pyrogen-free) were purchased from Serva 
Chemicals (Heidelberg, Germany). Lipopolysaccharidc 
(LPS) from E. coli (serotype 0127:B 8), Concanavalin A 
(Con A) from Canavalia ensiformis. N^-monomethyl-
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L-arginine monoacetatc salt (N°M M A), daidzein (7- 
hydroxy-3-(4-hydroxyphcnyl)-4H-1 -benzopyran-4-one), 
and genistein (5,7-dihydroxy-3-(4-hydroxy-phcnyl)-4H- 
1 -bcnzopyran-4-one) were purchased from Calbiochem 
(La Jolla, CA. U.S.A.). Monoclonal antibody anti-mouse 
T hy-1,2 fluorescein conjugate was purchased from Bec­
ton Dickinson Immunocytochemistry Systems (Moun­
tain View, CA, U.S.A.). Flavones (1-4), isoflavones 
(daidzein and genistein), LPS, and N^MMA were d is­
solved in phenol red-free RPMI 1640 medium, and di­
luted immediately before use.
Collection and cultivation o f  m ouse peritoneal 
exudate macrophages
Macrophages were obtained from mice given an i.p. 
injection o f  sterile thioglycolate broth (1 ml) 4 d prior to 
harvest and the solution o f Con A (100 pg/ml) in PBS (1 
ml) 18 hr prior to harvest. M ice were killed by cervical 
dislocation, and cells were collected by washing the peri­
toneum with PBS (5 ml). The macrophage populations 
were enriched by adherence to plastic in 24-well plates 
(Falcon, Becton Dickinson, Lincoln Park, NJ, U.S.A.) 
with calculated 106 macrophages per well. Non-adherent 
cells were removed after 1 20  min o f  incubation, and the 
macrophages were cultured with or without tested agent 
in RPMI 1640 medium without phenol red, supple­
mented with 10% heat inactivated FCS, penicillin (100  
U/ml), and streptomycin (100 pg/ml) at 37°C in a hu­
midified atmosphere o f 5% C 0 2 in air. The adherent 
population contained >96% macrophages as assessed by 
May-Grunwald/Giemsa staining and biochemical crite­
ria (nonspecific esterase staining), and <2% T-lympho- 
cytes by fluorescence microscopy after fluorescent anti­
body labelling with anti T hy-1,2 monoclonal antibody. 
More than 98% of the cells were viable as determined by 
exclusion o f neutral red [23], also after incubation with 
all reagents.
The macrophage monolayers were then covered by 
culture medium (2 ml) with flavones, N^MMA, daid­
zein, or genistein (concentration range 1-300 pM) and 
LPS (100 ng/ml). and incubated for further 6 ,1 8 ,2 4 ,4 8 ,  
and 72 hr at the same temperature and atmosphere as 
above. In all experiments, each concentration of flavone 
was tested in triplicate. Control macrophages were pre­
pared and cultured in culture medium without added 
flavones.
Nitrite assay
Nitrite concentrations in the culture medium were 
measured by a microplate assay method, based on the 
Griess reaction [24], Equal volum es o f culture medium 
supernatant and Griess reagent (0.5% sulfanilamide,
0.05% naphthylene-diamide dihydrochloride in 2.5%  
H3POJ were added to Eppendorf tubes and incubated at 
20°C for 10 min. The tubes were then centrifuged for 5 
min at 8500 x  g. The absorbance o f  culture medium and 
Griess reagent at 550 nm was determined with SPECOL. 
Nitrite content was determined by using sodium nitrite 
as standard. Data were expressed as nmol nitrite per 106 
cells originally plated. In all experiments, the nitrite con­
tent in wells containing medium without cells was mea­
sured and subtracted.
Statistical analysis
For statistical evaluation o f the data, the Student’s 
r-test was used.
RESULTS
In the presence o f LPS. production o f nitric oxide was 
found to be induced in Con A-stimulated macrophages 
in a time- and dose-dependent manner (Figs. 1 and 2). 
Con A-stimulated macrophages were obtained from 
mice injected with thioglycolate broth 4 d previously 
and with the solution of Con A 18 hr before being killed. 
Thioglycolate-elicited macrophages released small 
amounts of nitrite (1.3 ± 0.3 nmol/106 cells/24 hr). Elic­
ited macrophages were prepared from mice injected 4 d 
previously with thioglycolate broth. Con A-stimulated 
macrophages also released small amounts o f nitrite in 
the absence o f LPS (Ftg. 1).
Con A-stimulated macrophages produced L-arginine- 
dependent nitric oxide in the presence o f LPS. N°M M A  
(300 pM) inhibited nitrite production by 95 ±  3%. 
N°M M A (400 pM) had no significant effect on the v i­
ability of macrophages exposed to LPS (100 ng/ml). 
Genistein, an isoflavone that inhibits tyrosine-specific 
protein kinases, and daidzein, an isoflavone analogue 
that is inactive against these tyrosine kinases, also sig ­
nificantly decreased the production o f nitrite (Table 1).
In the next experiment, the flavones were investigated 
for their involvement in release o f nitric oxide from Con 
A- and LPS-activated macrophages. Activated macro­
phages were found to produce detectable nitrite, which 
ranged in individual experiments from 17.8 to 22.8  
nmol/106 cells/24 hr. Concentrations o f the four syn­
thetic flavones in the range 2 0 -100  pM reduced the 
production o f  nitrite (Fig. 3). 3,-amino-4,-hydroxyfla- 
vone (3) was the most potent inhibitor, with significant 
inhibition at 1 pM and 84 ±  2% inhibition at 20 pM. 
Similar results were obtained following culture for 48 hr 
in the presence of the agents. Thomsen et al. [25] have 
pointed out that nitric oxide is converted both to nitrite 
and to nitrate. However, in representative control exper­
iments in which the nitrate was reduced to nitrite with 
Aspergillus nitrate reductase and NADPH prior to assay, 
nitrate was found present in only trace amounts (results 
not shown). Thus, in our system, production o f nitrite is 
a good measure of production o f nitric oxide.







Fig. 1. Amounts of nitrite produced by macrophages cultured 
for 6 , 18. 24. 48. or 72 hr without LPS ( # )  and with LPS (100 
ng/ml) (■). Results are representative for three experiments.








Fig. 2. Dose-dependent effects of LPS in vitro or production of 
nitrite by macrophages. Macrophages were incubated for 24 hr 
(O) or 48 h ( # )  with increasing concentrations of LPS. Each 
value is the mean ± SD of three experiments.
Table 1. Inhibitory effects of the isoflavones. genistein, and 
daidzein. and of N°MMA on the nitrite produced by macro­
phages
Compound Inhibition (%]
Genistein (SO pM) 4 8 ± 3
Daidzein (SO pM) 94 ± 2
N°MMA (300 pM) 95 ± 3
Macrophages were incubated for 24 hr with LPS (100 ng/ml) 
in the presence of the inhibitors. Data show average ± SD from 
three independent experiments performed in triplicate.
treatment with agents (flavones and isoflavones) at con­
centrations up to 100 pM and >94% with no treatment. 
Hence, inhibition of production o f nitrite is unlikely to 
be due to toxicity of the compounds. Additionally, the 
flavones and isoflavones had no quenching effect on the 
Griess reagent at the concentration used.
DISCUSSION
The adherent populations from mouse peritoneal cav­
ities were used as macrophage models in this study. 
Thioglycollate-elicited peritoneal macrophages from 
BALB/c mice released significant amounts o f nitrite 
upon stimulation with Con A (in vivo) and LPS (in 
vitro). This model for activation o f macrophages has 
been reported (26, 27]. These activated macrophages 
produce a variety of biologically active molecules both 
in their normal role and in pathological immune re­
sponses and inflammatory reactions. Thioglycollate- 
elicited and Con A + LPS-primed macrophages express 
cytostatic activity against P815 tumour cells, and release 
interleukin-6  and nitrite [26]. Similarly activated macro­
phages secrete reactive oxygen intermediates (Kr61 W, 
Czuba ZP and Threadgill MD, unpublished results).
W e have shown here that flavone and three amino 
derivatives inhibit production o f nitrite, a chemical prod­
uct o f nitric oxide. The cellular mechanisms o f the effect
arc not clear, but may be related to known biological 
effects o f the flavones, such as antioxidant properties 
and inhibition o f cellular enzymes involved in signal 
transduction. Som e phenolic compounds are known to 
have radical scavenging activities, and many isofla- 
vonoids and related compounds reportedly possess 
strong antioxidative activities (28, 29]. However, direct 
reaction o f nitric oxide or nitrite with the flavones, lead­
ing to apparent inhibition o f  production o f NO*, is ren­
dered highly unlikely by consideration o f  the stoichiom­
etry of the experiments involving the most potent fla­
vone (3). At 10 pM, the experimental volume (2 ml) 
contains 20 nmol o f 3, yet the loss o f production o f 
nitrite compared to control is 16 nmol; at 1 pM, die 
experimental volume contains 2 nmol o f  3, yet the kiss 
o f production o f  nitrite is approximately 4 nmol. These 
data preclude stoichiometric reaction o f 3 with nitric 
oxide or nitrite from being any more than a very minor 
contribution to the inhibition observed.
Prior to this work, the only true flavone to have been 
shown to influence production of nitric oxide by mac­
rophages was flavone-8 -acetic acid [25]. This 8 -substi- 
tuted flavone has stimulatory activity, in contrast to the 
inhibitory activity demonstrated here for the unsubsti­
tuted and 3',4'-substituted flavones 1-4. Indeed, it has 
recently been suggested that decarboxylation o f flavone-
S-acetic acid by the radical nitrogen dioxide may con­
tribute to its apparent antitumour activity [30].
Three specific protein tyrosine kinase inhibitors 
(genistein, tyiphostin, and herbimycin A) have been re­
ported to block production o f  nitrite in both C3H/HeN  
and C3H/HeJ macrophages [31]. Flavone itself and sev­
eral aminoflavones are inhibitors o f  protein tyrosine ki­
nase activity in vitro [22, 32, 33], with a variety of 
potencies. Cushman et al. reported that a series o f 4'- 
aminofiavones inhibit the activity o f  the protein tyrosine 
kinase p56/c*; the most potent, 4,-amino-6-hydroxyfla- 
vone, inhibits this activity with ICso =  1.2 pM [33]. In 
our previous study on the activity o f  a series o f synthetic 
flavones against protein tyrosine kinases [2 2 ], we iden­
tified 3'-amino-4'-methoxy-flavone (4) as the most po­
tent inhibitor o f the EGF receptor tyrosine kinase activ­
ity derived from A431 cells (42% inhibition at 50 pM). 
This compound was inactive against the corresponding 
activity o f piablSO at 500 pM, whereas quercetin 
(3,3',4',5,7-pentahydroxyflavone) had Kt = 3.7 pM. In­
terestingly, compound 4 showed the greatest selective 
cytotoxicity towards ANN-1 cells, which are Abelson- 
transformed 3T3 cells. In the present study, the isofla- 
vone genistein was also found to inhibit the production 
o f nitrite by macrophages. However, the analogous 
isoflavone daidzein, which does not inhibit protein ty­
rosine kinases, was found to be a more potent inhibitor 
o f production o f  nitric oxide by these macrophages than 
is genistein. This suggests that inhibition of tyrosine ki­
nases may not be involved in the mechanism o f inhibi­
tion of release o f  nitric oxide in these macrophages.
In a subsequent study, a related series o f flavoncs 
were evaluated for inhibition o f the generation o f reac­
tive oxygen species by macrophages that had been 
primed by LPS-polyinosinic-polycytidylic acid, as 
shown by inhibition of luminol-dependent chemilumi- 
nescence [12]. O f these flavones, 3'-amino-4'-hydroxy- 
flavone (3) was the most potent inhibitor, causing 93% 
inhibition at 100 pM, 52% inhibition at 10 pM, and 36% 
inhibition at 1.0 pM, corresponding to IC50 = 3.3 pM.
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Fig. 3. Effects of flavone (1). 4'-aminoflavone (2). 3'-amino-4'-hydroxyflavonc (3). and 3'-amino-4'-mcthoxyflavone (4) on 
production of nitrite by macrophages. Macrophages were incubated with LPS (100 ng/ml), without flavones (control) or with 
flavoncs, for 24 hr. Concentrations of nitrite (nmol/106 cells, mean ± SD of three wells from three independent experiments)
produced by control macrophages were 20.3 ± IS .
Flavone (1), 4'-aminoflavone (2), and 3'-amino-4'-meth- 
oxyflavone (4) were less potent, causing 55%, 70%, and 
65% inhibition, respectively, at 100 jtM, and insignifi­
cant inhibition at 10 pM and at 1.0 pM. Interestingly, the 
concentrations o f these four flavones required for inhi­
bition of release o f nitric oxide by the macrophages 
closely match these values (Fig. 3). These data strongly 
suggest that production of nitric oxide is a major con­
trolling factor in generation o f reactive oxygen species 
upon activation of the macrophages. Thus, flavones may 
have a role to play in modulating inflammatory and im­
mune responses by affecting production of nitric oxide. 
Studies as to whether the flavoncs act as direct inhibitors 
o f  nitric oxide synthase or a a  upon a control system arc 
in progress, and will be reported separately.
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SYNTHESES OF [I80]-5-METHYLIS0QUIN0LIN0NE AND
l-(FURAN-2-YL-l,801-METH0XY)-5-METHYLIS0QUJN0LINE
Jane M. Berry and Michael D. Threadgill*
School of Pharmacy & Pharmacology, University of Bath,
Claverton Down, Bath BA2 7AY, U. K.
SUMMARY
Treatment of 2-methylcinnamic acid with H2lgO at 100°C under acidic conditions leads 
to high incorporation of ‘*0 by exchange. Methods have been developed for chemically 
and isotopically efficient conversion to the corresponding [carbonyl-,80 ] methyl ester, to 
[lgO]-5-methylisoquinolinone (an inhibitor of DNA repair) and to l-(furan-2-yI-[‘*0)- 
methoxy)-5-methylisoquinoline.
Introduction
The enzyme poly(ADP-ribose)polymerase (PARP, EC 2.4.2.30) catalyses the transfer of ADP-ribose 
units from NAD* to form a polyanionic polymer on histones and other acceptor proteins near the site 
of damage to DNA2"4. Inhibition of PARP leads to inhibition of the processes of repair of damaged 
sites in DNA5"7 and thus to potentiation of the antitumour effects of many forms of radiotherapy8*11 
and chemotherapy12*14. Potent inhibitors of PARP include benzamides and analogues in which the 
conformation of the amide is constrained relative to the aromatic ring, by incorporation into a 
lactam*’15,16 or by hydrogen-bonding16. Of these lactams, 5-substituted isoquinolinones have been 
shown*’15 to be among the inhibitors with the greatest potency. During our studies on drugs which 
sensitise tumours to the cytotoxic effects of radiotherapy and chemotherapy17, we required a 5- 
substituted isoquinolinone PARP inhibitor labelled with 180  at the carbonyl oxygen. In this paper, we 
report our development of syntheses of methyl [carbonyl-1*0]-£’-3-(2-methylphenyl)propenoate 4, a 
model intermediate to check satisfactory isotopic incorporation, of [’*0]-5-melhylisoquinolinone 7 
and of a potential pro-drug derivative, l-(furan-2-yl-[lsO]-methoxy)-5-methylisoquinoline 10.
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Results & Discussion
A convenient synthesis of isoquinolinones by Curtius rearrangement of cinnamyl azides and thermal 
cyclisation, in a one-pot process, has been described by Eloy and Deryckere18. The Curtius reaction 
involves a true rearrangement of the intermediate acyl nitrene to form the isocyanate. Thus l80  
present in the carbonyl group should be retained in the isocyanate. The subsequent mechanistic steps, 
thermal isomerisation of the C=C and cyclisation, also take place under conditions where the oxygen 
atom should be retained in the isoquinolinone. The synthetic route, therefore, requires the 180- 
labelled 2-methylcinnamyl azide 5 as a starting material for the synthesis of the 180-labelled 5- 
methylisoquinolinone 7.
We considered that 5, in turn could be derived from the corresponding 180-labelled acid chloride 3 
and the 180-labelled carboxylic acid 2. An initial series of model experiments was devised to develop 
a procedure for incorporation of ,80  into 2-methylcinnamic acid 1, forming 2, and for conversion to 
the acid chloride 3, under conditions which would not permit loss of l80  by exchange. 180  was 
incorporated by heating the carboxylic add 1 in 1,4-dioxan with twenty equivalents of H2l80  under 
addic conditions to promote exchange. The solvent and excess water were removed by distillation in 
a closed system to give the isotopomer 2. Since this acid is capable of losing l80  by exchange with 
atmospheric water, it was rapidly converted to the corresponding add chloride 3 with thionyl 
chloride. To check the level of incorporation of 180, the acid chloride was quenched with methanol. 
Mass spectrometry showed the ester 4 to contain 8.0 ± 0.7% I80  in the carbonyl group, confirming 
that the exchange process had proceeded satisfactorily and that little l80  had been lost during the 
subsequent reactions.
Now that the initial exchange reaction had been developed and conversion to the acid chloride 3 had 
been established, attention was focussed on the main isoquinolinone-forming process. The 180- 
labelled acid chloride 3 was prepared as before but on a multimillimole scale The acid chloride 3 
should not be subject to exchange of 180  under aqueous conditions without hydrolysis, so conversion 
to the acyl azide 4 was effected by treatment with sodium azide in aqueous acetone. Any material 
which may have been hydrolysed to the acid would not be converted to the acyl azide by this 
process. The Curtius reaction was carried out in boiling diphenyl ether at ca. 260°C, forming the 
isocyanate 6, which was isomerised E—*Z and cyclised under the same conditions, giving the Re­
labelled 5-methylisoquinolinone 7 in good yield. Again, the isotopic composition was determined by 
mass spectrometry; 7 was shown to contain 8.0% 180  at the carbonyl oxygen. This represents the 
same incorporation as was seen for the methyl 2-methylcinnamate 4, indicating no loss of I80  in 
steps after the acid chloride.
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Scheme. Synthesis of methyl [carbonyl- 1*0]-£-3-(2-methylphenyl)propenoaie 4, 
[l*0]-5-methylisoqumolinone 7 and l-(furan-2 -yl-[ '*0]-methoxy)-5-metiiylisoquinoline 10.
For the synthesis o f  the O-furanylmethyl derivative 10, two synthetic approaches were possible, 
(/') reaction o f  furan-2-[uO]-methanoI, as its alkoxide, with l-chloro-5-methylisoquinoline or 
(//) alkylation o f the anion o f  the isoquinolinone 7 with an electrophilic furan> linethyl compound. 
The former was discounted, as this would require development o f  a synthesis o f  a new lsO-labelled 
intermediate, the furanmethanol. Nevertheless, the reaction o f  unlabelled sodium furanmethoxide 
with 1-chloroisoquinoline was investigated but was found to lead only to destruction o f  the furan at 
the high temperature o f  the reaction. The second approach also presented some problems, as 
furanylmethyl electrophiles are notoriously unstable.
2-Chloromethylfuran 9 was prepared by treatment o f  the corresponding alcohol 8  with thionyl 
chloride by the general method o f  Tarrago el a l19. This unstable material was allowed to  react with 
the lithium anion o f  the uO-labelled 5-methylisoquinolinone 7 at reflux in tetrahydrofuran. To 
counteract the loss o f 8  by decomposition during this alkylation, it was used in large excess. The 180 -  
labelled fiiranylmethoxyisoquinoline 10 was obtained in good chemical yield and with excellent
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isotopic enrichment (8.0% ^O). The equivalence of the isotopic enrichment of 7 and 10 
demonstrates that no loss of 1S0  has occurred during the alkylation.
Conclusion
Efficient techniques have been developed for the incorporation of IS0  into a /4r-substituted cinnamic 
acid by exchange with H2,80  and for subsequent conversion to the carbonyl-lsO-labelled 
isoquinolinone 7 and the furanylmethyl ether 10. These methods should be applicable to syntheses of 
other ‘'O-Iabelled cinnamate esters and to other isoquinolinones which do not bear strong electron- 
withdrawing groups. The results of biological and biomimetic studies with 7 and 10 will be reported 
elsewhere.
Experimental
Jeol GX270 and EX400 instruments furnished the NMR spectra of solutions in CDCh; the internal 
standard was tetramethylsilane. Melting points are uncorrected. Solvents were evaporated under 
reduced pressure. The chromatographic stationary phase was silica gel. Brine refers to a saturated 
solution of sodium chloride in water. [**0]-Water (10 atom %) was obtained from the Aldrich 
Chemical Company.
Methyl [carbonyI-180]-£-3-(2-inethyI)phenylpropenoate (4). E-3-(2-methyI)phenyIpropenoic 
acid 1 (53 mg, 330 pmol) was boiled under reflux with [,!0]-water (120 pi. 10 atom %) and 
hydrogen chloride (1.0 M in diethyl ether, 150 pi) in dry 1,4-dioxan (1.5 ml) foi 24 h. The solvents 
and excess reagent were distilled off under nitrogen and the residue was stirred with thionyl chloride 
(3.0 ml) and dimethylformamide (10 pi) for 16 h. The excess reagent was evaporated. Methanol. 
(2.0 ml) was added and the mixture was stirred for 1 h. Chromatography (ethyl acetate) yielded 4 
(46 mg, 79%) as a pale yellow oil (lit.20 unlabelled compound is an oil): 5h 2.43 (3 H, s, Ar-Me), 
3.81 (3 H, s, OMe), 6.36 (1 H, d, J= 15.9 Hz, HC=C), 7.18-7.28 (3 H, m, Ar 3,4,5-Hj), 7.54 (1 H, 
d, 7 = 7.0 Hz, Ar 6-H), 8.00 (1 H, d, ./= 15.9 Hz, C=CH); 6c 19.74,51.62, 118.8, 126.29, 126.35, 
129.97, 130.73, 133.32, 137.59, 142.49, 167.40; m/z (El) 178 (2.7%) (M), 176 (33%) (M), 163 
(2.0%) (M - Me), 161 (23%) (M - Me), 147 (9%) (M - MeO), 145 (90%) (M - MeO).
(180]-5-Methylisoquinolinone (7). £-3-(2-methyl)phenylpropenoic acid 1 (450 mg, 2.8 mmol) was 
boiled under reflux with [!lO]-water (1.00 ml, 10 atom %) and hydrogen chloride (1.0 M in diethyl 
ether, 1.5 ml) in dry 1,4-dioxan (15 ml) for 12 h. The solvents and excess reagent were distilled off 
under nitrogen and the residue was stirred with thionyl chloride (5 ml) and dimethylformamide
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(10 jil) for 1.5 h. The excess reagent was evaporated. The acid chloride 3, in acetone (5 ml), was 
added to sodium azide (630 mg, 9.7 mmol) in water (2 ml) and acetone (1 ml) at 0°C. The mixture 
was stirred for 30 min at this temperature. The acyl azide 5 was extracted with dichloromethane and 
was washed with brine and was dried (MgS04 / CaCI2). Diphenyl ether (3 ml) was added and the 
dichloromethane was evaporated at ambient temperature. The residue was added to boiling diphenyl 
ether (10 ml) during 10 min and the solution was boiled under reflux for 2 h. Evaporation and 
chromatography (ethyl acetate / hexane 1:1) gave 7 (270 mg, 61%) as a pale yellow solid: 
mp 178-180°C Git.11 mp 184-185°C for the unlabelled compound); SH 2.55 (3 H, s, Me), 6.71 (1 H, 
d, J=  7.3 Hz, 4-H), 7.25 (d, J = 6.4 Hz, 3-H), 7.40 (1 H, dd, 7.9, 7.3 Hz, 7-H), 7.52 (1 H, d, 
7= 7.0 Hz, 6-H), 8.30 (1 H, d,y= 7.9 Hz, 8-H); 6r 19.17, 103.47, 125.18, 126 10, 126.39, 127.47, 
133.45, 137.18, 164.90 (one C, was not observed), m/z (El) 161.0726 (CioHsN1*© requires 
161.0727) (8.7%) (M), 159.0682 (C]0H9N16O requires 159.0684) (100%) (M)
1-(Furan-2-yl-[l80]-methoxy)-5-methylisoquinoIine (10). To fiiran-2-meihanol 8 (1.00 g, 
10 mmol) in chloroform (10 ml) was added pyridine (1.5 ml). The solution was cooled to -10°C and 
thionyl chloride (2.0 ml) in chloroform (20 ml) was added. The mixture was stirred at this 
temperature under nitrogen for 3 h. Hydrochloric acid (10%, 10 ml, 0°C) was added. The organic 
phase was washed with hydrochloric acid (10%, 0°C) and with aqueous sodium hydroxide (3%, 
0°C). .The solution was dried (MgS04 / K2CO3) and the solvent was evaporated at ambient 
temperature to give 9 (1.07 g, 89%) as an unstable orange liquid. The [wO]-isoquinoIinone 7 (250 
mg, 1.6 mmol), in tetrahydrofiiran (25 ml), was treated with lithium hexamethyldisilazide (1.0 M in 
tetrahydrofuran, 2.0 ml) and the mixture was stirred at ambient temperature for 1 h.
2-Chloromethylfuran 9 (1.00 g, 8.6 mmol), in tetrahydrofuran (25 ml) was added dropwise during 
1 h at 0°C, followed by sodium iodide (20 mg). The mixture was boiled under leflux for 18 h. The 
evaporation residue, in ethyl acetate, was washed with water and with brine and was dried (MgS04). 
Evaporation and chromatography (ethyl acetate / hexane 1:5) gave 10 (224 mg, 60%) as a pale 
yellow oil which crystallised on standing: mp 84-86°C; 5h 2.51 (3 H, s, Me), 5.19 (2 H, s, CH2), 6.33 
(1 H, dd, .7=3.1,1.9 Hz, furan 4-H), 6.42 (I H, d,J= 3.3 Hz, furan 3-H), 6.61 (1 H, d, ./= 7.7 Hz, 
isoquinoline 4-H), 7.21 (1 H, d, J -  7.7 Hz, isoquinoline 3-H), 7.36 (2 H, m, isoquinoline 7-H + 
furan 5-H), 7.46 (1 H, d, J -  7.2 Hz, isoquinoline 6-H), 8.32 (I H, d, J -  8.1 Hz, isoquinoline 8-H); 
6c 18.93, 44.33, 103.02, 109.42, 110.64, 110.83, 125.97, 126.55, 130.54, 133.08, 133.17, 135.90, 
142.77, 149.78, 162.1; m/z (El) 241.0990 (CisHnN^O^O requires 241.0989) (3.6%) (M), 
239.0943 (CiSH13N160 2 requires 239.0946) (40%) (M), 81 (100%) (furan-CH2).
940 J.M. Berry and M.D. Threadgill
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Pochodne flawonu {2-fenylo-JH-1-benzopiran-4-onu) sa interesujaca grupa. zwiqzkow o poiencjalnych 
wlasciwosciach przeciwzapalnych i immunotropowych. Niektorc z nich sa w irakcie badan klinicznvch w immu- 
noterapii nowotworow. Zsymezowano szereg 3\4*-aminofiawon6w inhibitorou kinazy bialkowo-tyrozynowej.
Ceiem przeprovvadzonych badan bylo okreslenie dzialania 3\4'-aminofl:nvon6w na sckrecjc niekiorych 
produktow przcz aktywne makrofagi. Komorki te uzyskiwano z piynu oirzewnou ego nivszy szczepu BALB/c po 
stymulacji ConA. makrofagi slymulowano LPS-em. Oznaczano chcmilumincscencje makrofagow oraz produkcjc 
tlenku azotu (NO*) (pomiar st^zenia anionow NO;7No;0 i czynnika nunwio nowoiworu (TNF-a). Sposrod 
badanych zwiazkow 3‘-amino-4’-hydroksyflawon silnic hamowai chcmilum inescence i produkcjc NO*. me 
wpK'wal na sckrecje TNF-a. Naioniiasi -T-aminoflawony wykazaly s iu m iiu ja o  efeki w zakresie produkeji 
TNF-a przez makrofagi.
Uzyskane wyniki stanowia zachcie do podjecia badan na modelach m v:\ -i.
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ELSEVIER
Substituted Flavones as Aryl 
Hydrocarbon (Ah) Receptor Agonists and Antagonists
Yu'Fang L u ,*  Michael Santostefano ,* 
Bernadette D . M . C u n n in gh am ,fi Michael D . Threadgillpand Stephen Safe*§
• D e p a r t m e n t  o f  V e t e r i n a r y  P h y s io lo g y  a n d  P h a r m a c o lo g y .  T e x a s  a & M  U n iv e r s i t y ,  C o l l e g e  
S t a t i o n ,  TX 77843-4466, U .SA.; a n d  tScHOOL o f  P h a r m a c y  a n d  P h a r m a c o l o g y .  U n i v e r s i t y  o f
B a t h ,  B a t h  BA2 7AY, E n g l a n d
ABSTRACT. The structure-dependent aryl hydrocarbon (Ah) receptor agonist and antagonist activities o f the 
following substituted flavones were investigated: flavone, 4'-methoxy-, 4’-amino-. 4'-chloro-. 4'-bromo-, 4'- 
nitro-, 4'-chloro-3'-nitro-, 3'-amino-4'-hydroxy-, 3'.4'-dichloro-, and 4'-iodoflavone. The halogenated flavones 
exhibited competitive Ah receptor binding affinities (lC^ = 0.79 to 2.28 nM) that were comparable to that 
observed for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1.78 nM). The compounds also induced transfor­
mation of the rat cytosolic Ah receptor and induced CYP1A1 gene expression in MCF-7 human breast cancer 
cells. However, despite the high Ah receptor binding affinities for these responses, the halogenated flavones were 
>1000 times less active than TCDD for the other responses. Moreover, for other substituted flavones, there uas 
no correlation between Ah receptor binding affinities and their activities as Ah receptor agonists. For example, 
4'-aminoflavone induced CYP1A1 mRNA levels in MCF-7 cells bu: exhibited relatively low Ah receptor 
binding affinity (iCjg = 362 nM) and did not induce transformation of the rat cytosolic Ah receptor. All of the 
substituted flavones inhibited TCDD-induced transformation of the Ah receptor, and 4 '-iodoflavone, an Ah 
receptor agonist at high -concentrations (1-50 pM). inhibited the transformation at concentrations as low as 
0.05 and 0.5 ph i. Subsequent interaction studies with TCDD and 4 ’-iodoflavone confirmed that the latter 
compound inhibits induction of CYPlAl gene expression by TCDD in MCF-7 cells. The results obtained for the 
substituted flavones suggest that within this structural class of compounds, various substituent groups can affect 
markedly the activity of each individual congener as an Ah receptor agonist or antagonist. These substituent- 
dependent differences in activity may be related to ligand-induced conformational changes in the A h receptor 
complex and/or support the proposed existence of more than one form of the Ah receptor. BIOCHEM PHARMA- 
CQL 51;8:1077-1087. 1996.________________________________________________________________________ __
KEY W ORDS, flavonoids; Ah receptor binding; CYPlAl induction/inhibition
TCDD11 is an industrial and combustion by-product that has 
been widely identified as an environmental contaminant. 
TCDD elicits a diverse spectrum of biochemical and toxic 
responses and is used as a prototype for investigating the 
toxicology' and mechanism of action of structurally related 
halogenated aromatic compounds [1—4]. Poland and co­
workers [5] first demonstrated that pHJTCDD bound satu- 
rably and with high affinity to an hepatic cytosolic protein 
from C57BL/6 mice, and this protein, named the Ah re­
ceptor, has since been widely identified in animal and hu­
man tissues [6 , 7]. The results of photoaffinity labeling stud­
t  Current a.ilr<-sv Oncogene Science Inc.. 106 Charles Lindbergh Blvd.. 
Uniondale. NY 15533.
§ Corresponding author. Tel. (409)845-5988; FAX (409) 862-4929. 
'Abbreviations: Ah. aryl hydrocarbon; aNF. omaphthofbvone; DRE. 
dioxin-responsive element; EROD. ethoxyresotufin O-deethylase: HAT. 
hydroxylapatitc. MCDF. 6-mcthyl-13,8-trichlorodibenaofuran; TCDD. 
2.3.7.8-teaachlorodibenro-p-dioxin; and TCDF. 2.3.7.8-tenachlorodiben- 
zofutan.
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ies indicated that there was considerable intraspecies vari­
ability in the apparent molecular weight of the Ah receptor 
[8 ], and this ts consistent with results of experiments that 
have cloned the Ah receptor from various species [9-13]- 
The proposed mechanism of action of TCDD and related 
compounds was initially derived from studies on induction 
of CYPlAl gene expression by TCDD, 3 -methylcholan- 
threne, and related compounds {3]. The unbound cytosolic 
Ah receptor is associated with heat shock protein 90; after 
binding with TCDD. the 9S (270- to 300-kDa) cytosolic 
Ah receptor complex undergoes a transformation step to 
form a 5- to 7S (180- to 2i0-kDa) heterodimeric complex 
that rapidly accumulates in the nuclear fraction of target 
cells (14, 15]. The nuclear Ah receptor complex acts as a 
ligand-induced transcription factor that interacts with 5'- 
dioxin or xenobiotic response elements (DREs, XREs). and 
this can result in transactivation of the CYPlAl gene (16, 
17]. The nuclear heterodimeric complex consists of the Ah 
receptor and Ah receptor nuclear translocator (Amt) pro­
tein (18], and there is strong evidence that formation of this
1078 Y-F. Lu ci a!.
unique ligand-induced dimeric protein complex plays a ma­
jor role in modulating expression of several genes 119].
In vitro studies with TCDD and related halogenated aro- 
matics show that there is a rank order correlation between 
their Ah receptor binding affinities and biochemical/toxic 
potencies (2, 20, 21). Moreover, for TCDD and related 
halogenated aromatic compounds, there is also a correla­
tion between their Ah receptor binding affinities and their 
activity to induce transformation (i.e. 9-10S to 5-7S) of 
the rat hepatic cytosolic receptor [22]. The correlations 
observed for halogenated aromacics have not been investi­
gated extensively within other structural classes of com­
pounds that bind to the Ah receptor. For example, 3-meth- 
ylcholanthrene binds with high affinity to the Ah receptor 
but is a relatively weak Ah receptor agonist for several 
responses [23]. This disparity between binding affinity ver­
sus potency as an Ah receptor agonist can be explained, 
only in part, by the rapid metabolism of 3-methylcholan- 
threne [24, 25]. However, in ligand-induced cytosolic Ah 
receptor transformation experiments, 3-methylcholan- 
threne is significantly less active than TCDD, despite their 
comparable Ah receptor binding affinities [24].
3'-Methoxy-4'-nitroflavone also binds with high affinity 
to the rat cytosolic Ah receptor (ic^ = 2.27 nM) but does 
not induce significantly CYPlAl mRNA levels in MCF-7 
human breast cancer cells nor does it induce m vitro trans­
formation of the rat hepatic cytosolic Ah receptor [26]. 
3'-Methoxy-4' -nitroflavone is an Ah receptor antagonist 
that inhibited formation of the nuclear Ah receptor com­
plex and induction of CYPlAl gene expression by TCDD 
in MCF-7 cells. This study further investigates the struc­
ture-dependent activities of 4'- and 3\4'-substituted fla­
vones as Ah receptor agonists/antagonists in MCF-7 cells. 
The haloflavones bound with high affinity to the cytosolic 
Ah receptor (0.79 to 2.28 nM) but were >1000-fold less 
active than TCDD as inducers of CYPlAl gene expression. 
Moreover, 4'-iodoflavone was a partial antagonist. There 
were no apparent structurc-activity relationships for the 
other substituted flavones.
MATERIALS AND METHODS 
Chemicals and Biochemicals
The 3',4'-substituted flavones were synthesized and were 
>98% pure as determined by spectroscopic measurements 
and HPLC as described previously [27]. TCDD, [3 H]TCDD, 
ethoxyresorufin, and TCDF were synthesized in this labo­
ratory to >98% purity. MCF-7 human breast cancer cells 
were obtained originally from the American Type Culture 
Collection (ATCC, Rockville, MD). All other chemicals 
and biochemicals were of the highest purity available from 
commercial sources.
Preparation of Rat Hepatic Cytosol
Liver cytosol from Long-Evans rats was prepared as previ­
ously described [26]. Livers were perfused m sicu with ice-
cold HEGD buffer [25 mM HEPES. 1.5 tnM EDTA, 1.0 
mM dithiothreitol, 10% glycerol (v /v ), pH 7.8], homog­
enized in HEGD (5 mL/g tissue), and centrifuged at 10,000 
g for 20 min (2°). The resulting supernatant was centrifuged 
at 105,000 g for 1 hr (2°), and the supernatant was stored at 
-S0°. Protein concentrations were determined by the 
method of Bradford [28].
Cytosolic Receptor Binding Assay
The IC5 0  = and K; values for competitive receptor binding 
affinities were determined using rat hepatic cytosol ( 2  mg 
protein/mL) and the hydroxylapatite assay procedure essen­
tially as described [29]. Each sample was incubated with 
[3 H]TCDD and the desired competitor at 20° for 2 hr. After 
incubation, 2 0 0  pi. of incubate was added to fresh tubes 
containing HAP slurry (35 mL HAP/100 mL HEGD 
buffer). Tubes were allowed to incubate for 30 min and 
centrifuged at 1 0 0  g for 5 min (4°). The resulting pellet was 
washed three times with ice-cold HEGD containing 1 % 
Triton X-100. The final pellet was then rinsed with 1 mL 
ethanol, and the radioactivity was determined by liquid 
scintillation counting. Non-specific binding was obtained 
by incubating ['H]TCDD with a 200-fold excess of TCDF. 
Different concentrations of the ligands were used to deter­
mine displacement curves; the IC5 0  = values were defined as 
the concentrations required to displace 50% of [3 H]TCDD 
and were determined from a log-logit plot of the percentage 
of [3 H]TCDD bound versus log concentrations of the li­
gands. The results are expressed as means ± SEM for at least 
4 separate determinations. IQ values were determined by the 
method of Cheng and Prusoff [30], as described previously 
[26]. .
Ligand-Induced Transformation Assay
Polyacrylamide gel electrophoresis purified complementary 
strands of the synthetic oligonucleotide, containing a 26- 
mer consensus DRE sequence (5'-GATCTGGCTC 1 1 CT - 
CACGCAACTCCG-3') that corresponds to the DNA se­
quence from -1997 to -1978 of the mouse CYPlAl gene 
[16], was obtained from Genosvs Biotechnologies, Inc. 
(The Woodlands. TX). The oligonucleotide was labeled at 
the 5'-end using T4 -polynucleotide kinase and [*y-3 2 P]ATP. 
DNA binding was measured using a gel mobility shift assay 
[16]. Rat hepatic cytosol (16 mg/mL protein) was incubated 
for 2 hr at 20° with 5 nM TCDD, 50 jjlM flavone or 5 nM 
TCDD plus different concentrations of the flavones; the 
final concentration of DMSO was 0.2% (v/v). Cytosol (80 
jig) was incubated in HEGDK (HEDG + 0.4 M potassium 
chloride) with 400 ng of poly[d(I-C)] in HEGD buffer and 
incubated for 15 min at 20°. Following the addition of a 
3 2 P-lnbeled DRE oligonucleotide (0.2 to 1.0 ng; 100,000 
cpm), the mixture was incubated for an additional 15 min 
at 2 0 °. Excess unlabeled DRE (100-fold) was added 5 min 
prior to addition of 3 2 P-labeled DRE to compete for the 
specific DNA-protein binding. Protein—DNA complexes
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were resolved on a 5-6% polyacrylamide gel (acrylamide: 
bisacrylamide; 30:0.8) and eleccrophorcscd at 120 V for 
approximately 3 hr in 0.9 M Tris borate and 2 mM EDTA, 
pH 8.0. Gels were dried, and protein-DNA complexes were 
detected using a Betagen Betascope 603 blot analyzer and 
visualized by autoradiography. The amount of 3 2 P-labeled 
DRE bound in the ligand-inducible complex was deter­
mined by measuring the radioactivity of the specifically 
bound retarded band and subtracting the amount of radio­
activity present in the same position in a non-ligand - 
treated lane. The difference in radioactivity between these 
samples represents the ligand-inducible specific binding of 
the Ah receptor complex to the [3 2 P]DRL The levels of 
DNA-binding activity for the various treatment groups 
were quantified as a percentage of maximal response ob­
served for the TCDD-treated cytosol. The ic^ values were 
obtained from a log-logit plot of the percentage of maximal 
response obtained for each ligand versus ligand concentra­
tion.
Inhibition of Microsomal
EROD Activity by Substituted Flavones
Male Long-Evans rats were treated with TCDD (5 p.g/kg), 
and induced rat hepatic microsomes were isolated as de­
scribed previously [31]. The substituted flavones ( 1  pM) 
were incubated with rat liver microsomes (25 p.g protein/ 
incubation) for 1 0  min as described previously [26], and 
EROD activity was determined spectrofluorimetrically [32].
Cell Qrowth, Induction, 
and Inhibition of EROD Activity
MCF-7 cells were grown in medium containing DME/F12 
with 2.2 mg/mL sodium bicarbonate, 5% fetal bovine se­
rum, and 10 nM ancibioric-antimycotic solution (Sigma 
Chemical Co., St. Louis, MO). For determination of EROD 
activities, die cells were first seeded into 60-mm petri 
dishes; 1 nM TCDD, different concentrations of the sub­
stituted flavones, and TCDD plus the flavones were dis­
solved in DMSO (0.1%) and added to the culture dishes 
when the cells reached 70% confluence. Cells were har­
vested 24 hr after chemical treatment, and EROD activity 
was determined fiuorimetricaliy [32].
Northern Analysis for CYPlAl mRNA Levels
The murine CYPlAl cDNA probe was obtained from 
ATCC The plasmid pGMBl.l containing the mouse p-tu- 
bulin cDNA was a gift from Dr. Don Cleveland (Johns 
Hopkins University). Digestion of the plasmid yielded a 1.3 
kb fragment that was used to detect P-tubulin *mRNA. 
RNA from the cells treated with TCDD or substituted fla­
vones for 24 hr was isolated, electrophoresed, transferred to 
a nylon membrane, and probed by autoradiography or using 
a Betagen Betascope 603 imaging system as described pre­
viously [33, 34].
Statistical Analysis
The statistical differences between different treatment 
groups were determined by ANOVA and Student's t-test, 
and the levels of probability are noted (P < 0.05 or P < 
0.01). The data are expressed as means ± SEM or deviations 
SD for at least 3 determinations for each experimental 
point.
RESULTS
A series of ten 4'- and 3',4'-substituted flavones were syn­
thesized previously [27] and used in the present study. The 
results in Table 1 summarize the IC^ and K, values obtained 
for the concentration-dependent displacement of [3 H]- 
TCDD from the rat cytosolic Ah receptor. The IC5 0  values 
for 4'-chloro-, 4'-bromo-, 4'-iodo-, and 3',4'-dichlorofla- 
vone varied from 0.79 to 2.28 nM and were comparable to 
the IC5C value obtained for unlabeled TCDD (1.78 nM). 
The most active of the four compounds was 4'-iodoflavone 
(1 c 5 0  = 0.79 nM); all the remaining substituted flavoncs 
exhibited > 1 0 0  times lower competitive binding affinities 
for the Ah receptor (ic5C> values from 99 to 4697 nM). The 
K. values exhibited comparable structure-activity relation­
ships.
The effects of structure on ligand-induced transformation 
of the rat hepatic cytosolic Ah receptor were determined 
using gel mobility shift assays followed by quantitating the 
transformed Ah receptor-[3 2 P]DRE complex using a Beta­
gen Betascope 603 blot analyzer. The effects of a 50 p.M 
concentration of the substituted flavones were compared 
with the intensity of the retarded band observed with 5 nM 
TCDD. The intensity of the retarded band observed for 50
TABLE' 1. Competitive binding o f  substituted flavones to rat 
hepatic cytosol Ah receptor and their activity to induce 
transformation o f  the rat cytosolic Ah receptor
Compound
ICjo* (nM) IQ* (nM)
DRE bindingt 
(%)R(3') R<4')
H H 216 ± 110 138 31 ±6.0
H OCHj 99 ±45 63 28 ±7.7
H NH, 362 ± 128 232 NDJ
H Cl ' 1.40 ±0.4 0.92 351 ±67
H Br 130 ±0.7 0.96 99± 10
H NO, 4697 ±1991 2453 ND
NO- a 1935 ±1139 1240 2.4 ±1.2
NH- OH 73S±371 506 ND
Cl a 2.28 ± 0.5 1.47 75 ±12
H I 0.79 ±0.27 0.50 ±0.35 240 ±24
* The ICjo values (means!SEM tor 4 iq u n te  detenninations) were determined in 
competitive bind in- studies using 1 nM PHJ i CDD as the radioligand and different 
concentrations or unlabeled competitor as described in Materials and Methods; K. 
values were calculated from the ICjo values.
• ORE binding «as also determined using a t  hepatic cytosol as described 1261: the 
results (means ± SEM for 4 separate determinations) are expreaacd as ORE binding 
observed tor SO jtM concentrations of the flavones as a percentage of that observed 
usin; > nM TCDD in the trarutocmation assay.
t  NO s  non-detectable.
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pM 4'-chloroflavonc was 3.5-fold higher than chat ob­
served for 5 nM TCDD; 50 pM 4'-bromo, 3',4'-dichloro-, 
and 4'-iodoflavone all induced formation of a retarded band 
chat was 75—240% of the intensity observed for 5 nM 
TCDD. The intensity of the retarded band induced by 50 
pM concentrations for the remaining substituted flavones 
was <32% of chat observed for 5 nM TCDD.
The results in Table 2  summarize the effects of 0.05. 0.5,
5.0 and 50 pM concentrations of the flavones on 5 nM 
TCDD-induced transformation of che rat cytosolic Ah re­
ceptor complex as determined by gel electrophoretic mo­
bility shift assays and quantitation of che specifically bound 
retarded band (see Fig. 1 ). This study also included results 
for the mechoxy-nitro/aminoflavones since these data were 
not reported previously (26]. All of the flavones signifi­
cantly inhibited TCDD-induced transformation at some 
concentration. For example, 4 '-mechoxy- and 4'-iodofla- 
vone inhibited 85 and 100% of TCDD-induced transfor­
mation at the lowest concentration (0.05 jjlM) used in this 
study. Several ocher substituted flavones inhibited >90% of 
TCDD-induced transformation at one or more concentra­
tions, and these include flavone (5.0 pM), 4'-methoxyfla- 
vone (0.5 and 5.0 pM), 4'-aminoflavone (5.0 and 50 pM). 
4'-nicroflavone (50 pM), 4'-chloro-3'-nitroflavone (5.0
1 2 3 4 5 6  7
Ah R-DRE complex
FIG. I. Effects o f  T C D D , 4'-iodoflavone, and their com bi­
nation on  transformation o f  the rat heptic cytosolic Ah re­
ceptor. Rat hepatic cytosol was treated with DM SO (lane 1 ), 
5 nM TCDD (lane 2), 5 nM T C D D  plus 0.05 (lane 3), 0.5 
(lane 4), 5 (lane 5 ), or 50  pM (lane 6 ) 4'-iodoflavone, and 50 
pM  4'-iodoflavone alone (lane 7), and then incubated with 
[3 2 P]DR£; levels o f  the transformed DRE-Ah receptor com ­
plex were determ ined by gel electrom obility shift assays as 
described in  M aterials and M ethods. T he  results for the sub­
stituted flavones are summarized in Tables 1 and 2. T he  
autoradiogram illustrated in  this figure is the result o f  a 
single experim ent using 4'-iodoflavone- The intensity- o f  the 
specifically bound A h receptor-DRE com plex (see arrow) 
was non-detectable after incubation with a 2 0 0 -fold excess 
o f  unlabeled DRE.
pM). 3 '-amino-4 '-hydroxyflavone (50.0 pM), 4'-iodofla- 
vonc (0.05 and 0.5 pM, Fig. 1), 4'-methoxy-3'-nitrofln- 
vone (50 pM), 3'-methoxy-4'-nitroflavone (5.0 and 50 
pM), and 4'-amino-3'-methoxyflavone (5.0 and 50 pM). 
There were no apparent correlations between structurc-Ah 
receptor binding (Table 1) and structure-inhibitory 
(TCDD-induced transformation) activities among the sub­
stituted flavones.
The Ah receptor agonist and antagonist activities of the 
substituted flavones. were determined in Ah-responsivc 
MCF-7 human breast cancer cells. At flavone concentra­
tions from 0 . 0 1  to 10 pM, induction of EROD activity 
varied from 0 to 44% of che response observed for 1 nM 
TCDD (Fig. 2). In MCF-7 cells cotreaced with 1 nM 
TCDD plus 0.01, 0.1, 1.0 or 10 pM concentrations of the 
substituted flavones, there was a concentration-dependent 
decrease in TCDD-induced EROD activity as illustrated in 
Fig. 2. All of the compounds caused a >90% decrease in 
induced EROD activity at concentrations varying from 0.1 
to 10 pM. and the IC5 0  values for this inhibitory- response 
are summarized in Table 3.
Previous studies have demonstrated that flavones and 
substituted flavones inactivate P4501A1-dependent activi­
ties by competitively interacting with the substrate binding 
site (26, 35-37], and therefore the effects of the substituted 
flavones on CYPlAl-dependent EROD activity were de­
termined. Hepatic microsomes from Long-Evans rats 
treated with 5 pg/kg TCDD were incubated for 10 min with 
a 1 pM concentration of the substituted flavones in the 
presence or absence of NADH/NADPH. EROD activity 
was then determined, and the results are summarized in Fig.
3. All of the compounds inhibited EROD activity- in the 
presence or absence of the reduced nucleotide cofactors, 
and the pattern of inhibition for the flavones was compa­
rable, although there were significant structure-dependent 
differences in potency of their inhibitory effects. These data 
were similar to those reported previously for the 3'- and 
4'-methoxy-amino/nitroflavones [26].
The Ah receptor agonist and antagonist activities of the 
substituted flavones were also investigated in MCF-7 cells 
by determining the induction of CYPlAl mRNA levels by 
1 nM TCDD, 1 pM substituted flavone, and 1 nM TCDD 
plus 1 pM substituted flavone. Relative CYPlAl mRNA 
levels were compared with levels observed after treatment 
with 1 nM TCDD alone. The results (Table 3) demonstrate 
that 1 pM concentrations of 4'-amino-, 4'-bromo-, 4'- 
chloro-, 4'-iodo-, and 3\4'-dichloroflavone induced 
CYPlAl mRNA levels between 28 and 112% of that ob­
served for 1 nM TCDD. CYPlAl mRNA levels induced by 
the remaining compounds were <8 % of that observed for
1.0 nM TCDD. In cells cotreated with 1 nM TCDD plus a 
1 pM concentration of the substituted flavones, there was 
no significant decrease in CYPlAl mRNA levels compared 
with cells treated with 1 nM TCDD alone. With the ex­
ception of the haloflavones, the remaining compounds 
were relatively weak inducers of CYPlAl mRNA, and re­
sults of cotreatment studies suggest that these congeners
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TABLE 2. Effects o f  substituted flavoncs on TCDD-induccd transformation of  
the rat hepatic cytosolic Ah receptor
% o f TCDD-induced transformation*
Compound Flavones (pM)
R(3') R(4') 0.05 0.5 5.0 50
H H 90± 14 24 ± 6.4* NDtt 27 ±5.3*
H OCHj 15 ± I It ND*? NDtt 37 ± 13t
H nh 2 96 ±25 48 ±9.4* NDtt NDtt
H Cl 58±21t 39 ±15* 137 ±27 338 ±92
H Br 43±6.4t 67 ±6.4* 141 ± 17 ‘ 91 ±18
H n o 2 83 ±13 97 ±18 37 ±13* NDtt
n o 2 Cl 99± 15 106 ±21 19 ± 8* 10± 6t
n h 2 OH 99± 16 87 ±4 43 ±9* 'NDtt
Cl Cl 57 ±81 31 ±7.4* 69 ± 5.3* 81 ±12
H I NDtt ND*? 105 ±25 240 ± 108
n o 2 o c h 3 112 ± 10 86 ±15 15 ± 5t NDtt
n h 2 o c h 3 79 ±8.61 29 ±9.4* 14.4 ±9.9* 73 ±19
o c h 3 NOj 58±8.0t ND*t NDtt NDtt
OCHj NH2 99± 14 50 ±15* NDtt NDtt
* The effects of 5 nM TCDD plus Qj05. 0.5. 5.0 ot 50 |iM concentrations of the substituted flavones on 
transformation of rat hepatic cytosolic Ah receptor woe determined by {el electrophoretic mobility shift assays 
as described in Materials and Methods. The intensities of the specifically bound retarded bands were normal­
ized to that observed for 5 nM TCDD alone (100%). Results are expressed as means ± SEM for at least 4 
determinations.
* Significantly lower (P < 0.05) than observed for 5 nM TCDD alone.
Z ND = non-deteaable.
were nor Ah receptor antagonists. Of the remaining halo- 
flavones, 4'-iodoflavone was the most effective inhibitor of 
TCDD-induced transformation at low concentrations (Fig. 
1 and Table 2), and therefore die effects of 4'-iodoflavone 
(0.01 to 1.0 jjlM) on induction of CYPlAl mRNA were 
investigated further. The results (Fig. 4) show that 0.01 and 
0.1 pM 4'-iodofIavone significandy inhibited induction of 
CYPlAl mRNA by 1 nM TCDD in MCF-7 cells.
DISCUSSION
Several different structural classes of compounds bind to 
the cytosolic Ah receptor, and these include TCDD and 
related polyhalogenated aromatics, polynuclear aromatic 
hydrocarbons (PAHs), indole-3-caibinoi and related het- 
ero-PAHs, phenanthiolines, phenanthridinones, benzocou- 
marins and various substituted flavonoids [23, 38-45]. Sys­
tematic structure-activity relationships have been reported 
for die halogenated aromatics [2, 20, 21], and there was a 
rank order correlation between their cytosolic Ah receptor 
binding affinities and their potencies as Ah receptor ago­
nists for CYPlAl induction and other Ah receptor-medi­
ated biochemical and toxic responses. Moreover, similar 
structure-dependent responses have been reported for other 
steps associated with die Ah receptor signalling pathway, 
and these include ligand-induced transformation of die cy­
tosolic Ah receptor and formation of die nuclear Ah re­
ceptor complex [15, 22]. There are only limited studies on 
structure-dependent responses associated with ligand-in­
duced activation of the Ah receptor for other structural 
classes of compounds that bind to the Ah receptor. Lu and
coworkers [26] recently reported that 3',4'-substituted me- 
thoxy-amino/nitro flavones exhibited structure-dependent 
Ah receptor agonist and antagonist activity. Both 3'-me- 
thoxy4'-nitro- and 3'-methoxy4/-aminoflavone were Ah 
receptor antagonists, whereas the 4'-methoxy analogs were 
more active as Ah receptor agonists. This study reports a 
more extensive structure-activity study on several substi­
tuted flavones utilizing various assays that are associated 
with the Ah-responsiveness of halogenated aromatics.
The results in Table 1 show that the competitive binding 
affinities for the rat cytosolic Ah receptor vary from 0.79 
nM for 4'-iodoflavone to 4697 nM for 4'-nitroflavone. Pre­
vious Ah receptor binding studies with various substituted 
polyhalogenated aromatics, such as 4'-substituted-2,3,4,5- 
tetrachlorobiphenyls, 2-subsrituted-3,7,8-trichlotodibenzo- 
p-dioxins, and 7-substituted-2,3-dichlorodibenzo-f>-dioxins, 
showed that the halogen-substituted analogs (1, Br and Cl) 
exhibit the lowest KD values [46-49], and, in this study, the 
4'-iodo-, 4'-chloro-, 4'-bromo-, and 3',4'-dichloroflavone 
also exhibited high binding affinities and KD values that 
were comparable to the value reported for TCDD (fCD = 
1.28 nM) (Table 1). Despite the correlations observed for 
the halogenated aromatics and halogenated flavones, Lu 
and coworkers [26] have shown previously that 3'-me- 
thoxy-4'-nitroflavone also binds with high affinity to the 
rat cytosolic Ah receptor (KD = 2.27 nM); in contrast, 
methoxy- and nitro-substituents do not enhance binding of 
substituted aromatics to the Ah receptor [50]. Moreover, 
forsubstituted halogenated aromatics, electron-donating 
substituents are invariably more deactivating for Ah recep­
tor binding than electron-withdrawing substituents
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[46-49]. For example, the receptor binding ic5 0  values for 
7-amino- and 7-hydroxy-2,3-dichlorodibcnzo-p-dioxin 
were 2.88 * 10- 5  and 4.47 * 10“ 6 M, respectively, whereas 
the IC5 0  values for the electron-withdrawing nitro-substi- 
tuted analog was 4-6 x 1 (T7 M. In contrast, 4'-nitroflavone 
exhibited lower binding affinities ( 1 0 5 0  = 4697 nM) than 
4'-aminoflavone or 3 '-amino-4'-hydroxyflavone (362 and 
738 nM, respectively). Hie reasons for substituent-depen­
dent differences in Ah receptor binding affinities of the 
substituted flavones and halogenated aromatics are un­
known.
The relative potencies of substituted flavones (50 p.M) to 
induce transformation of rat hepatic cytosolic receptor were 
compared with that observed for 5 nM TCDD using a gel 
mobility shift assay. The results (Table 1 ) showed the 4'- 
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FIG. 2 . Induction  o f  EROD activity by TCDD, substituted flavones, and their com binations. MCF-7 ceUls were incubated for 
2 4  hr w ith  different concentrations o f substituted flavones (□ )  alone or 1 N M  T C D D  plus differeit concentrations o f  the 
substituted flavones ( 4 ) ,  and EROD activity was determ ined as described in  M aterials and Meth-xis. Representative data 
obtained for flavone (upper left), 4 '-chloro-3'-nitroflavone (upper right), 3',4 '-d ich loroflavone (lowe? lefft) and 4 '-iodoflavone  
(low er right) are present. Results are expressed as m eans — SD for 3 separate determ inations for e a c h  data point. EROD  
activities in  cells treated w ith 10 pM concentrations o f  the substituted flavones as a percent o f  the >aluie observed for 1 nM  
T C D D  (100% ) were: I I  ±  3, 17 ±  1.6, 21 ±  2 .7 , 44  ±  9 , 25 ±  0.3, non-detectable, 25 ±  2 .4 , 3.5 i: 2 .9 ,  3.1 ±  2.7%, and 
non-detectable for flavone, 4'-m ethoxy-, 4'-am ino-, 4'-chloro-, 4'-brom o-, 4'-nitro-, 4 ' -chIoro-3'-nitro-, 3 '.a m i n o - 4 '-hydroxy-, 
3 , ,4'-d ichloro-, and 4'-iodoflavone, respectively.
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TABLE 3. Substituted flavones: Induction o f C Y P lA l mRNA levels and 
inhibition o f TCDD-induced C Y P lA l mRNA levels and EROD activity in 
MCF-7 cells*
Relative % C Y P lA l mRNA Inhibition o f
Compound  !------  induced EROD
--------------------  Flavone Flavone (1 pM) +  activity
R(3') R(4') (lpM) TCDD (1 nM) (ICso» M)
H H 3.5 ±2.9 96 ± 5.4 2.9 x IO'7
H OCHj NDt 100 ±29 4-0 x 10-7
H nh2 28 ±9.8 98 ±35 5.7 x 10*7
H a 70 ±6.4 I00± 12 13 x IO-7
H Br 32 ±3.2 99± 10 9.9 x 10”*
H no2 2.8 ±0.6 95 ±21 12 x 10“*
no2 a 4.4 ±4.4 86 ±29 1.8 * 10"*
NH, OH 7.1 ±43 83 ±4.7 6.1 x IO-*
a a 75 ±21 85 ±47 4.7 x IO-8
H I 112 ±67 141 ±5.6 2.4 x 10"*
* mRNA was rxaxird  from MCF-7 cdk 24 hr after treatment with I nM TCDD or 1 nM TCDD + the 
flavones (1 pM). mRNA m s analyzed by northern bloc analysis as described in Materials and Methods. 
CYPlAl mRNA levels mere normalized to p-tubulin mRNA. and relative percent mRNA levels mete 
compared with that observed fee 1 nM TCDD (100%). The results are expressed as means ASDfer at least 
3 determinations for each data point. The ICjo values (br this inhibitory response were determined by 
log-logit  plocs of the percoK of maximal induced responses observed in cells cocreared with lnMTCOD 
pUs different concentrations of. the flavones. Maximal (100%) EROD activity was obtained with 1 nM 
TCDD alone (110 p o o lM n j) .  
t  ND = not detectable.
exhibited high competitive binding for die Ah receptor 
binding ( ic^ =0.79 to 228 nM) induced the highest levels 
of transformed cytosolic Ah receptor complex, which were 
75-351% of that observed for 5 nM TCDD. All of these 
compounds exhibited receptor binding ICjq values compa­
rable to that of TCDD, and with the exception of 4 '-chlo 
roflavone, their activity to induce transformation of the 
cytosolic Ah receptor was > 5000-fold lower than TCDD. 
The remaining flavones exhibited lower binding affinities 
for the Ah receptor (Table 1) and induced relatively low 
levels of transformed receptor (Table 2). However, results 
of previous studies (26] showed that 2  substituted flavones, 
namely 3'-methoxy-4'-nitxo- and 4'-amino-3'-methoxyfla- 
vone, which bound compeddvely with high affinity to die 
Ah receptor (1C5 0  = 2-27 and 86.1 nM, respectively), in­
duced minimal transformation (<6 %) of the cytosolic Ah 
receptor. Thus, there was no correlation between receptor 
binding affinities and activity to induce transformation for 
these substituted flavones.
The structure-dependent Ah receptor agonist activities 
of die substituted flavones woe investigated by determin­
ing induction of CYPlAl mRNA levels and EROD activity 
in MCF-7 cells (Table 3). A 10 pM concentration of die 
substituted flavones induced 0-44% of EROD activity ob­
served for 1 nM TCDD (Kg. 2), and there was no correla­
tion between structure-binding and stzuctuze-inducdon ac­
tivities. One micromolar concentrations of 4 '-amino-, 4'- 
chloro-, 4 '-bromo-, 3\4'-diehlon>-, and 4'-iodoflavone 
induced mRNA levels that were 28-112% of levels ob­
served for 1 nM TCDD. Moreover, results of previous stud­
ies showed that the 3' -amino-4' -methoxyfla vone also in­
duces CYPlAl mRNA levels [26]. With the exception of
4 '-aminoflavone, the most active inducers of CYPlAl 
mRNA levels were those congeners that bound with high 
affinity to the Ah receptor and induced transformation of 
the cytosolic Ah receptor complex. In contrast, 4'-amino­
flavone exhibited relatively low Ah receptor binding affin­
ity and did not induce receptor transformation. 3'-Amino- 
4'-methoxyflavone bound with higher affinity to the Ah 
receptor (1C5 0  — 19 nM) but also did not induce receptor 
transformation (Table 2), showing that for these flavones 
there was no correlation between their activities to induce 
transformation and CYPlAl gene expression. This is in 
contrast to previous studies wtih TCDD and related halo­
genated aromatics.
Lu and coworkers [26] previously reported that 3'-me- 
thoxy-4 '-nitroflavone exhibited unusual properties since 
this compound exhibited high binding affinity for the Ah 
receptor (tCs©= 2-27 nM) but did not induce receptor trans­
formation or CYPlAl mRNA levels in MCF-7 cells. How­
ever, in MCF-7 cells cotreated with 1  nM TCDD plus 1 pM 
3 '-methoxy-4'-nitroflavone, there was a significant inhibi­
tion of EROD activity and CYPlAl mRNA levels induced 
by TCDD. Therefore, the second phase of this study inves­
tigated the potential Ah receptor antagonist activity of the 
substituted flavones by determining their effects on TCDD- 
induced transformation of the cytosolic Ah receptor and on 
induction of EROD activity and CYPlAl mRNA levels in 
MCF-7 cells.
Previous studies with two different structural classes of 
Ah receptor antagonists typified by MCDF and aNF 
showed that inhibition of CYPlAl mRNA levels or EROD 
activity is also accompanied by inhibition of TCDD-in­
duced transformation of the cytosolic Ah receptor [22, 33,
1084 Y-F. Lu et al.
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FIG. 3. In vitro inhibition o f EROD activity by substituted flavones. T C D D -induced rat hepatic microsomes were incubated  
w ith  a 1 jiM concentration o f d ie  substituted flavones for 10 m in, and EROD activity was determined fluorim etrically as 
described in  Materials and Methods. EROD activity after incubation w ith  th e  flavones is expressed as a percentage o f  activity  
observed after incubation o f  m icrosom es with DMSO (solvent control). Control activity =  5824 pm ol/m in/m g protein. The  
incubations w ere carried out in the presence (left) or absence (right) o f  N A D H /N A D P H  cofactors. T he results are expressed  
as m eans ±  SD for 3 separate determinations.
34 , 51, 52]. T h e  results in Table 2 show that all o f  the  
substituted flavones significandy inhibited TCDD-induced  
transformation and w ith the exception o f  4'-chlotoflavone, 
4'-brom oflavone, 3',4'-dichloroflavone, and 3 '-am ino-4'- 
m ethoxyflavone, >90%  of induced transformation was in­
hib ited  at som e concentration (Table 2 and Fig. 1). Initial 
studies also showed that in  cells cotreated with 0.01 to  10 
p M  concentrations o f the substituted flavones plus 1 nM  
T C D D , there was a concentration-dependent decrease in 
induced ERO D activity (Table 3 and Fig. 2). The lC^ val­
ues for inh ib ition  o f  EROD activity in MCF-7 cells varied 
from 0.024  pM  for 4'-iodoflavone to  6.14 pM  for 3'- 
am in o-4 '-hydroxyflavone. Previous studies showed that the  
isom eric m ethoxy- nitro/aminoflavones also inhibited in­
duced ERO D activity, and this was due, in part, to m vino 
inh ib ition  o f  C Y P lA l (26]. T he results summarized in  Fig. 
3 show  that after incubation o f the substituted flavones (1 
p M ) w ith  hepatic microsomes in the presence or absence o f 
reduced nucleotide cofactors, there was significant inh ib i­
tio n  o f EROD activity by all the substituted flavones. T hese  
results are consistent with previous reports which show that 
various flavones bind to cytochrome P450 and/or inhibit 
P450-m ediaced activities [26, 3 5 -3 7 ]. Thus, inhibition of
induced ERO D activity in MCF-7 cells by the substituted  
flavones (Fig. 3 ) may be due, in part, to  com petition  w ith  
ethoxyresorufin for substrate binding sites o n  the enzyme.
S in ce  previous studies showed that 4 '-am in o-3 '-m eth - 
oxy- and 3'-m ethoxy-4'-n itroflavone antagonize induction  
o f  b oth  ERO D activity and C Y P lA l m R N A  levels induced  
by T C D D  in M CF-7 cells (26], inh ib ition  o f  induced  
C Y P lA l m R N A  levels by the substituted flavones (1 pM ) 
was also investigated. O nly  minimal inhibitory effects were 
observed, even  though most of the com pounds (w ith  the 
ex cep tion  o f  the haloflavones) exhibited relatively weak 
ind uction  o f  C Y P lA l m R N A  at the 1 pM  concentration. 
O f th e  rem aining haloflavones, 4 '-iodoflavone was the 
m ost e ffective  inhibitor o f  T C D D -induced transformation 
o f  th e  A h  receptor (Table 2), and interactions o f 4 '-iod o- 
flavone plus T C D D  showed that 0.01 and 0.1 pM  co n c en ­
trations o f  the former compound inhibited induction  of 
C Y P lA l m R N A  by 1 nM  TC D D  (Fig. 4 ). Thus. 4 '-iod o-  
flavone exhib ited  both A h  receptor agonist and antagonist 
activ ities.
Previous studies with halogenated arom atics and various 
substituted analogs showed that their activ ity  as A h  recep­
tor agonists was structure dependent, and th at A h  receptor
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FIG. 4. N o r th e rn  b lo t analys is o f  C Y P lA l m R N A  levels in 
M C F-7 cells tre a te d  w tih  T C D D , 4 '- io d o fla v o n e , a n d  th e ir  
c o m b in a tio n s . m R N A  w as e x tra c te d  from  M C F-7 cells 24 h r  
a f te r  tr e a tm e n t w ith  D M SO  ( la n e  1), 1 nM  T C D D  ( la n e  2 ),
0 .0 1 , 0.1 a n d  1.0 p M  4 '- io d o fia v o n e  (lanes 3 th ro u g h  5, 
re sp ec tiv e ly ) , a n d  1 nM  T C D D  p lu s  0 .01 , 0 .1  o r  1.0 pM  
4 '- io d o fla v o n e  ( la n e s  6 th ro u g h  8, re sp ec tiv e ly ). m R N A  lev ­
els w e re  d e te rm in e d  b y  n o r th e rn  b lo t analysis a n d  ex p ressed  
re la tiv e  to  (3 -tubu lin  m R N A  a s  d escribed  in  M a te ria ls  a n d  
M e th o d s . T h e  m R N A  levels in  lan es  1 th ro u g h  8 a re  e x ­
p ressed  re la tiv e  to  th o se  o b se rv e d  a f te r  t r e a tm e n t w ith  1 n M  
T C D D  (1 0 0 % ): n o n -d e te c ta b le , 1 0 0 ,12 ± 2 .6 ,4 6  ± 20 , 112 
2: 6 7 , 42  ±  4 .9 , 33 11, a n d  141 ±  5 .6  ( lan es 1 th ro u g h  8,
re sp ec tiv e ly ; m e a n s  ±  SD fo r  a t  lea s t 3 d e te rm in a tio n s ) ; 0.01 
a n d  0.1 p M  4 '- io d o fla v o n e  sig n if ican tly  (P  <  0 .0 5 )  in h ib ited  
in d u c tio n  o f  C Y P lA l  m R N A  lev e ls  by  T C D D .
b in d in g  a ff in itie s  a n d  lig a n d - in d u c e d  tra n sfo rm a tio n  a c tiv i­
tie s  co rre la te d  w ith  C Y P lA l  in d u c tio n  p o te n c ie s  (2, 20]. 
D esp ite  th e  u n u su a lly  h ig h  a ff in ity  o f  se v e ra l su b s titu te d  
flav o n es fo r th e  cy to so lic  A h  recep to r, s t r u c tu r e -a c t iv i ty  
c o r re la tio n s  for th e se  c o m p o u n d s  w ere in c o n s is te n t. T h e se  
d a ta  suggest c h a t vario u s s tru c tu ra l  classes o f  A h  re c e p to r  
lig an d s  in d u c e  d if fe re n t c o n fo rm a tio n a l c h a n g e s  in  th e  c y ­
to so lic  A h  re c e p to r  co m p le x  w h ic h  d iffe re n tia lly  in flu e n c e  
in d iv id u a l s te p s in  th e  A h  re c e p to r -m e d ia te d  s ig n a l t r a n s ­
d u c tio n  p a th w a y . M o reo v e r, t h e  resu lts  fo r th e  su b s titu te d  
flav o n es suggest th a t  w ith in  th is  s tru c tu ra l c la ss  o f  c o m ­
p o u n d s, v a rio u s s u b s ti tu e n t  g ro u p s c a n  affec t m a rk e d ly  th e  
a c tiv ity  o f  e a c h  in d iv id u a l c o n g e n e r  as a n  A h  re c e p to r  ag o ­
n is t  o r a n ta g o n is t. T h e se  s u b s ti tu e n t-d e p e n d e n t d iffe ren ces  
in  che a c tiv ity  o f  che f lav o n es  m ay  be re la te d  to  ligand- 
in d u c e d  c o n fo rm a tio n a l  c h a n g e s  in  th e  A h  r e c e p to r  c o m ­
p lex  a n d  a lso  p ro v id e  su p p o rt fo r  th e  p ro p o sed  e x is te n c e  o f  
m o re  ch an  o n e  fo rm  o f  che A h  re c e p to r  [26 , 5 3 -5 5 ] . T h e  
ex is te n c e  o f  m u ltip le  c o n fo rm a tio n s  o r  fo rm s o f  th e  A h  
re c e p to r  c o m p le x  is sp e c u la tiv e , a n d  fu tu re  s tu d ie s  w ill u t i ­
lize rad io la b e le d  s y n th e tic  f la v o n e s  th a t  c a n  b e  used  to  in ­
v e s tig a te  b o th  che d ire c t  b in d in g  a n d  p h o to a ffin icy  lab e lin g  
o f  th e  A h  re c e p to r .
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SUMMARY
Treatment of 2 -methylcinnamic acid with H2 lsO at 100eC under acidic conditions leads 
to high incorporation of uO by exchange. Methods have been developed for chemically 
and isotopically efficient conversion to the corresponding [carbonyl-wOJ methyl ester, to 
[l,0]-5-methylisoquinolinone (an inhibitor of DNA repair) and to 1 -(furan-2-yl-[l,0]- 
methoxy)-S-methylisoquinoline.
Introduction
The enzyme poly(ADP-ribose)polymerase (PARP, EC 2.4.2.30) catalyses the transfer of ADP-ribose 
units from NAD* to form a polyanionic polymer on histones and other acceptor proteins near the site 
of damage to DNA2*4. Inhibition of PARP leads to inhibition of the processes of repair of damaged 
sites in DNA5 *7  and thus-to potentiation of the antitumour effects of many forms of radiotherapy**11 
and chemotherapy12'14. Potent inhibitors of PARP include benzamides and analogues in which the 
conformation of the amide is constrained relative to the aromatic ring, by incorporation into a 
lactam*"15,16 or by hydrogen-bonding16. Of these lactams, 5-substituted isoquinolinones have been 
shown’ "15 to be among the inhibitors with the greatest potency. During our studies on drugs which 
sensitise tumours to the cytotoxic effects of radiotherapy and chemotherapy1', we required a 5- 
substituted isoquinolinone PARP inhibitor labelled with 180  at the carbonyl oxygen. In this paper, we 
report our development of syntheses of methyl [carbonyl-180]-£-3-(2-methylphenyl)propenoate 4, a 
model intermediate to check satisfactory isotopic incorporation, of [l*0]-5-methylisoquinoIinone 7 
and of a potential pro-drug derivative, l-(furan-2-yl-[1,0)-methoxy)-5-methylisoquinoline 10.
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Results & Discussion
A convenient synthesis of isoquinolinones by Curtius rearrangement of dnnamyl azides and thermal 
cydisation, in a one-pot process, has been described by Eloy and Deryckere11. The Curtius reaction 
involves a true rearrangement of the intermediate acyl nitrene to form the isocyanate. Thus ’*0 
present in the carbonyl group should be retained in the isocyanate. The subsequent mechanistic steps, 
thermal isomerisation of the C=C and cydisation, also take place under conditions where the oxygen 
atom should be retained in the isoquinolinone. The synthetic route, therefore, requires the 180- 
labelled 2-methyIcinnamyl azide 5 as a starting material for the synthesis of the uO-labelled 5- 
methylisoquinolinone 7.
We considered that 5, in turn could be derived from the corresponding ^O-iabeiied acid chloride 3 
and the IS0-labdled carboxylic acid 2. An initial series of modd experiments was devised to develop 
a procedure for incorporation of ' * 0  into 2 -methyldnnamic acid 1 , forming 2 , and for conversion to 
the acid chloride 3, under conditions which would not permit loss of ‘*0 by exchange. w0  was 
incorporated by heating the carboxylic acid 1 in 1,4-dioxan with twenty equivalents of under 
acidic conditions to promote exchange. The solvent and excess water were removed by distillation in 
a closed system to give the isotopomer 2 . Since this acid is capable of losing '*() by exchange with 
atmospheric water, it was rapidly converted to the corresponding acid chloride 3 with thionyl 
chloride. To check the level of incorporation of ,(0, the add chloride was quenched with methanol. 
Mass spectrometTy showed the ester 4 to contain 8 . 0  ± 0.7% 180  in the carbonyl group, confirming 
that the exchange process had proceeded satisfactorily and that little IS0  had been lost during the 
subsequent reactions.
Now that the initial exchange reaction had been developed and conversion to the acid chloride 3 had 
been established, attention was focussed on the main isoquinolinone-forming process. The 5*0- 
labelled add chloride 3 was prepared as before but on a multimillimole scale. 'Che add chloride 3 
should not be subject to exchange of 1S0  under aqueous conditions without hydrolysis, so conversion 
to the acyl azide 4 was effected by treatment with sodium azide in aqueous acetone. Any material 
which may have been hydrolysed to the add would not be converted to the acyl azide by this 
process. The Curtius reaction was carried out in boiling diphenyl ether at ca. 260°C, forming the 
isocyanate 6 , which was isomerised E-*Z and cyclised under the same conditions, giving the ‘*0- 
iabelled 5-methylisoquinolinone 7 in good yield. Again, the isotopic composition was determined by 
mass spectrometry; 7 was shown to contain 8.0% 1X0  at the carbonyl oxygen. This represents the 
same incorporation as was seen for the methyl 2-methyIdnnamate 4, indicating no loss of u0 in 
steps after the add chloride.







S chem e. Synthesis of methyl [carbonyl- 1«0]-£-3-(2-methylphenyl)propenoate 4, 
[i*0]-5-methylisoqumolinone 7 and 1 -(furan-2-yl-[ '*0]-methoxy)-5-metiiYlisoquinoline 10
For the synthesis o f  the O-furanylmethyl derivative 10, two synthetic approaches were possible, 
(/') reaction o f  furan-2-[180]-methanol, as its alkoxide, with l-chloro-5-mcihylisoquinoline or 
(//) alkyiation o f the anion o f  the isoquinoiinone 7 with an electrophilic fiirans lmethyl compound. 
The former was discounted, as this would require development o f  a synthesis o f  a new 180-labelled 
intermediate, the furanmethanol. Nevertheless, the reaction o f  unlabelled sodium furanmethoxide 
with 1-chloroisoquinoline was investigated but was found to lead only to destruction o f  the furan at 
the high temperature o f  the reaction. The second approach also presented some problems, as 
furanylmethyl electrophiles are notoriously unstable
2-Chloromethylfuran 9 was prepared by treatment o f  the corresponding alcohol 8 with thionyl 
chloride by the general method o f  Tarrago el a!19 This unstable material was allowed to react with 
the lithium anion o f  the 1!0-labelled 5-methylisoquinolinone 7 at reflux in tetrahydrofuran. To 
counteract the loss o f 8 by decomposition during this alkyiation, it was used in large excess. The l80 -  
labelled furanylmethoxyisoquinoline 10 was obtained in good chemical yield and with excellent
938 JM . Berry end M J). Thread gill
isotopic enrichment (8.0% u0). The equivalence of the isotopic enrichment of 7 and 10 
demonstrates that no loss of uO has occurred during the alkyiation.
Conclusion
Efficient techniques have been developed for the incorporation of ,80  into a /^--substituted cinnamic 
acid by exchange with H2 U 0  and for subsequent conversion to the carbonyl-^O-labelled 
isoquinolinone 7 and the furanylmethyl ether 10. These methods should be applicable to syntheses of 
other ‘’CD-labelled cinnamate esters and to other isoquinolinones which do not bear strong electron- 
withdrawing groups. The results of biological and biomimetic studies with 7 and 10 will be reported 
elsewhere.
Experimental
Jeol GX270 and EX400 instruments furnished the NMR spectra of solutions in CDCh; the internal 
standard was tetramethylsiiane. Melting points are uncorrected. Solvents were evaporated under 
reduced pressure. The chromatographic stationary phase was silica gel. Brine refers to a saturated 
solution of sodium chloride in water. [^O]-Water (10 atom %) was obtained from the Aldrich 
Chemical Company.
Methyl [carbonyI-uO]-£-3-(2-methyI)phenyIpropenoate (4). £-3-(2-meihy!)phenylpropenoic 
add 1 (53 mg, 330 pmol) was boiled under reflux with [uO]-water ( 1 2 0  pi. 10 atom %) and 
hydrogen chloride (1.0 M in diethyl ether, 150 pi) in dry 1,4-dioxan (1.5 ml) for 24 h. The solvents 
and excess reagent were distilled off under nitrogen and the residue was stirred with thionyl chloride 
(3.0 ml) and dimethylfonnainide (10 pi) for 16 h. The excess reagent was evaporated. Methanol 
(2.0 ml) was added and the mixture was stirred for 1 h. Chromatography (ethyl acetate) yielded 4 
(46 mg, 79%) as a pale yellow oil (lit. 20 unlabelled compound is an oil): 5h 2.43 (3 H, s, Ar-Me), 
3.81 (3 H, s, OMe), 6.36 ( 1  H, d, J=  15.9 Hz, HC=C), 7.18-7.28 (3 H, m, Ar 3,4,5-H3), 7.54 ( 1  H, 
d, J=  7.0 Hz, Ar 6 -H), 8.00 ( 1  H, d ,J=  15.9 Hz, C=CH); 5c 19.74, 51.62, 118.8, 126.29, 126.35, 
129.97, 130.73, 133.32, 137.59, 142.49, 167.40; m/z (El) 178 (2.7%) (M), 176 (33%) (M), 163 
(2.0%) (M - Me), 161 (23%) (M - Me), 147 (9%) (M - MeO), 145 (90%) (M - MeO).
[180]-5-MethyIisoquinolinone (7). £-3-(2-methyl)phenylpropenoic arid 1 (450 mg, 2.8 mmol) was 
boiled under reflux with [uO]-water (1.00 ml, 10 atom %) and hydrogen chloride (1.0 M in diethyl 
ether, 1.5 ml) in dry 1,4-dioxan (15 ml) for 1 2  h. The solvents and excess reagent were distilled off 
under nitrogen and the residue was stirred with thionyl chloride (5 ml) and dimethylformamide
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(10 pi) for 1.5 h. The excess reagent was evaporated. The add chloride 3, in acetone (5 ml), was 
added to sodium azide (630 mg, 9.7 mmol) in water (2 ml) and acetone (1 ml) at 0°C. The mixture 
was stirred for 30 min at this temperature. The acyl azide 5 was extracted with dichloromethane and 
was washed with brine and was dried (MgSOu / CaCl2). Diphenyl ether (3 ml) was added and the 
dichloromethane was evaporated at ambient temperature. The residue was added to boiling diphenyl 
ether (10 ml) during 10 min and the solution was boiled under reflux for 2 h. Evaporation and 
chromatography (ethyl acetate / hexane 1:1) gave 7 (270 mg, 61%) as a pale yellow solid: 
mp 178-180°C (lit.1* mp 184-185°C for the unlabelled compound); 5n 2.55 (3 H. s, Me), 6.71 ( 1  H, 
d, J = 7.3 Hz, 4-H), 7.25 (d, J  -  6.4 Hz, 3-H), 7.40 ( 1  H, dd, J -  7.9, 7.3 Hz, 7-H), 7.52 (1 H, d, 
J=  7.0 Hz, 6 -H), 8.30(1 H, d,7= 7.9 Hz, 8 -H); 6 c 19.17, 103.47, 125.18, 126.10, 126.39, 127.47, 
133.45, 137.18, 164.90 (one CH was not observed); m/z (El) 161.0726 (CioHoN^ O requires 
161.0727) (8.7%) (M), 159.0682 (CioH9N160  requires 159.0684) (100%) (M)
1-(Furan-2-yI-[l80]-methoxy)-5-methylisoquinoline (1 0 ). To furan-2 -methanol 8  (1 . 0 0  g, 
10 mmol) in chloroform (10 ml) was added pyridine (1.5 ml). The solution was cooled to -10°C and 
thionyl chloride (2.0 ml) in chloroform (20 ml) was added. The mixture was stirred at this 
temperature under nitrogen for 3 h. Hydrochloric add (10%, 10 ml, 0°C) was added. The organic 
phase was washed with hydrochloric add (1 0 %, 0°C) and with aqueous sodium hydroxide (3%, 
0°C). The solution was dried (MgS(> 4 / K2CO3) and the solvent was evaporated at ambient 
temperature to give 9 (1.07 g, 89%) as an unstable orange liquid. The [llO]-is<»quinolinone 7 (250 
mg, 1.6 mmol), in tetrahydrofuran (25 ml), was treated with lithium hexamethyldisilazide (1.0 M in 
tetrahydrofuran, 2.0 ml) and the mixture was stirred at ambient temperature for I h.
2 -Chloromethylfuran 9 (1 . 0 0  g, 8 . 6  mmol), in tetrahydrofuran (25 ml) was added dropwise during 
1 h at 0°C, followed by sodium iodide (20 mg). The mixture was boiled under reflux for 18 h. The 
evaporation residue, in ethyl acetate, was washed with water and with brine and was dried (MgSOa). 
Evaporation and chromatography (ethyl acetate / hexane 1:5) gave 1 0  (224 mg, 60%) as a pale 
yellow oil which crystallised on standing: mp 84-86°C; 8 h 2.51 (3 H, s, Me), 5.19 (2 H, s, CH2), 6.33 
(1 H, dd, J= 3.1, 1.9 Hz, furan 4-H), 6.42 ( 1  H, d, J  = 3.3 Hz, fiiraa 3-H), 6.61 (1 H, d, J = 7.7 Hz, 
isoquinoline 4-H), 7.21 ( 1  H, d, J -  7.7 Hz, isoquinoline 3-H), 7.36 (2 H, m, isoquinoline 7-H + 
fixran 5-H), 7.46 (1 H, d, 7= 7.2 Hz, isoquinoline 6 -H), 8.32 (1 H, d, J — 8.1 Hz, isoquinoline 8 -H); 
6 c 18.93, 44.33, 103.02, 109.42, 110.64, 110.83, 125.97, 126.55, 130.54, 133.08, 133.17, 135.90,
142.77, 149.78, 162.1; m/z (El) 241.0990 (ClsHijNwOuO requires 241.0989) (3.6%) (M), 
239.0943 (CuHtfN16^  requires 239.0946) (40%) (M), 81 ( 1 0 0 %) (furan-CH2).
940 J.M. Berry and M S). Threadgill
Acknowledgements
The authors thank Mr. R  R. Hartell and Mr. D. Wood for the NMR spectra, Mr. C. Cryer for the
mass spectra and BBSRC for a project grant under the Seed Com Initiative.
References
1. Part IV: Scobie M., Bew S. P. and Threadgill M. D. - J. LabelledCompd. Rndiopharm. 34: 881 
(1994).
2. Ueda K. and Hayashi O. - Ann. Rev. Biochem. 54: 73 (1985).
3. Boulikas T. - Toxicol. Lea. 67: 129 (1993).
4. De Murcia G. and Menissier de Murcia J. - Trends Biochem. Sci. 172 (1994)
5. James M. R and Lehman A. R.. - Biochemistry 21: 4007 (1982).
6. Ahnstrom G. and Ljungman M. - Mutation Res. 194: 17(1988).
7. Shall S. - Adv. Radial Biol. - H.: 1 (1984).
8. Suto M. J., Turner, W. R, Arundd-Suto C. M., Werbel L. M. and Seboh-Lcopold J. S. - Anti- 
Cancer Drug Design 7: 107(1991).
9. Judson, 1. R  and Threadgill, M. D. - Lancet 342: 632 (1993).
10. Ben-Hur E., Utsumi H. and El kind M. M. - Cancer Res. 45: 2123 (1985).
11. Thraves P., Mossman K., Brennan T. and Dritschillo A. - Radiat Res. 104 119 (1985).
12. Sebolt-Leopold J. S. and Scavone S. V. - Int. J. Radiat. Oncol. Biol Phys 22: 619 (1992).
13. Boulton S., Pemberton L. C., Porteous J. K., Curtin N. J., Griffin, R. J.. Golding B. T. and 
DurkaczB. W. -Br. J. Cancer 72: 849 (1995).
14. Griffin R J., Curtin N. J., Newell D. R., Golding B. T., Durkacz B. W. and Calvert A. H. - 
Biochimie 71:408(1995).
15. Banasik M., Komura H., Shimoyama M. and Ueda K. - J. Biol. Chem. 267: 1569 (1992).
16. Griffin, R J., Pemberton L. C., Rhodes D., Bleasdale C., Bowman K., Calvert A. H., 
Curtin N. J., Durkacz B. W., Newell D. R, Porteous J. K. and Golding B. T. - Anti-Cancer 
Drug Design 10: 507 (1995).
17. Jenkins T. C., Naylor M. A, O'Neill P., Threadgill M. D., Cole S., Stratford I. J., Adams G. E., 
Fielden E. M., Suto M. J. and Steir M. J. - J. Med. Chem. 33: 2603 (1990).
18. Eloy F. and Deryckere A. - Helv. Chim. Acta 52: 1755 (1969).
19. Tanago G., Marzin C., Najimi 0. and Pellegrin V. - J. Org. Chem. 55: 420 (1990).
20. Posner T. and Schreiber G. - Ber. Deut. Chem. Ges. 57: 1127 (1924).
P U B L I C A T I O N  7 3
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Isotopically Efficient Syntheses of [15N]-Nitrothiophenecarboxamides
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LABELLED COMPOUNDS OF INTEREST AS ANTITUMOUR AGENTS - VI1.
ISOTOPICALLY EFFICIENT SYNTHESES OF 
[,sN]-NITROTHIOPHENECARBOXAMIDES
Anne E. Shinkwin and Michae] D. Threadgill*
School of Pharmacy & Pharmacology, University of Bath.
Claverton Down, BathBA2 7AY, U. K.
SUMMARY
Reaction of 3-cyanothiophene with one equivalent of potassium nitrate in concentrated 
sulphuric acid causes nitration, concurrent with hydrolysis of the nitrile, to give 5-nitro- 
thiophene-3-carboxamide in high yield. Similarly, 2-cyanothiophene gives 4-nitro- 
thiophene-2-carboxamide and 5-nitrothiophene-2-carboxamide, benzonitrile gives 3- 
nitrobenzamide and 4-methylbenzonitrile gives 4-methyI-3-nitrobenzamide. Extension of 
this process to use of potassium [l5N]-nitrate, formed from [lsN]-nitric add (95% 
isotopic enrichment), enables preparation of the corresponding [,5N]-nitrothiophene- 
carboxamides in high isotopic yield.
Introduction
As part of a programme of synthesis and evaluation of nitro-heterocycles as radiosensitisers, 
bioreductively-activated cytotoxins and inhibitors of repair of DNA2*6, we required the three possible 
isomeric nitro-thiophene-carboxamides with the functional groups in the ‘meta’ relationship. These 
compounds can be regarded as heterocyclic analogues of 3-nitrobenzamide. We also required the 
corresponding [lsN]-nitro compounds for metabolic and other studies. Thiophenes are usually 
nitrated using acetyl nitrate in acetic add or acetic anhydride7*9, the nitric acid required for the 
formation of the reagent being taken in excess. Excess nitric add in concentrated sulphuric acid has 
been used by Campaigne and Monroe10 to form 5-nitrothiophene-3-carboxamide 2c from thiophene-
3-carboxamide. Both processes would be ineffident if applied to a 15N-labelled synthesis. However, 
nitration of thiophene-2-carboxamide to form solely 4-nitrothiophene-2-carboxamide 2c in liigh
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Scheme 1 Concurrent nitration and hydrolysis 
of cyanothiophenes and benzonitriles.
^ v ^ C N  KNOj /H 2S04 ^ ^ C O N H ,
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yield, using only one equivalent o f  potassium nitrate, has been reported by Dell’Erba el a l1 Similarly, 
Ostman11 has described efficient nitration o f  3-cyanothiophene la and 2-cyanothiophene lb with one 
equivalent o f  nitric acid in trifluoroacetic acid, although mixtures o f  isomers o f  the corresponding 
cyanonitrothiophenes were produced. In this paper, we report our development o f a method for 
direct conversion o f  cyano(hetero)arenes to nitro(hetero)arenecarboxamides.
Results and Discussion
The initial approach to development o f  potential isotopically efficient syntheses o f  the isomeric nitro- 
thiophene-carboxamides was to investigate a two-step sequence from 3-cyanothiophene la and 2- 
cyanothiophene lb, involving nitration, followed by hydrolysis o f  the nitrile. However, since the 
method o f  Ostman11 (H N O 3 /  C F3C O 2H ) gives mixtures o f  isomers o f  cyanonitrothiophenes, the 
method o f  Dell’Erba7 was applied to the cyanothiophenes la,b. Unexpectedly, treatment o f  3- 
cyanothiophene la in concentrated sulphuric acid with one equivalent o f  potassium nitrate gave 5- 
nitrothiophene-3-carboxamide 2a in 91% yield, rather than the corresponding nitrile, as shown in 
Scheme 1. No cyanonitrothiophenes were isolated. Clearly, the vigorously acidic conditions had been 
sufficient to hydrolyse the nitrile to the carboxamide. Application o f  this process to 2-cyano­
thiophene lb gave a mixture o f  5-nitrothiophene-2-carboxamide 2b and 4-nitrothiophene-2- 
carboxamide 2c in good yield in ca. 4:3 ratio. These were easily separable by chromatography No  
cyanonitrothiophenes were evident in the product mixture. The process was extended to the benzene 
series by high-yielding direct conversions o f  benzonitrile Id to 3-nitrobenzamide 2d and 4-methyl- 
benzonitrile le  to 4-methyl-3-nitrobenzamide 2e.
For the syntheses introducing 1SN, potassium [ lsN]-nitrate was prepared by neutralisation o f  [ 1SN ]- 
nitric acid (95 atom %) with the calculated amount o f  potassium carbonate in water, followed by 
removal o f  the solvent by freeze-drying. Addition o f  this material to 3-cyanothiophene la  in 
concentrated sulphuric acid gave 5-(1JN]-nitrothiophene-3-carboxamide 3a in excellent chemical and
I'^Nj-Nitrolhiophcne Carboxamides 1017
isotopic yields (82%), as shown in 
Scheme 2. Similar [,JN]-nitration 
of lb  gave satisfactory chemical 
yields o f the isomeric [ '^ -n itr o -  
thiophene-carboxamides 3b,c, after 
chromatographic separation. The 
total isotopic yield for this process 
was 52%.
The ISN-labelled isotopomers 3a-c 
were characterised by comparison 
o f  spectra and mpts with those o f  the unlabelled materials 2a-c. In addition, 1JN NMR and mass 
spectrometry demonstrated that each product contained only one ,SN, as required. The 1SN NMR 
signals all appeared in the range 6 365 to 6 368, as appropriate for A tisN02 No coupling of '*N to 
other nuclei was seen in the ,SN  spectra, probably owing to insufficient digital resolution. However, 
couplings to tsN were observed through lH and 13C spectra. In the 5-nitrothiophene-3-carboxamide 
3a, ,5N coupled to protons on the thiophene ring with the three-bond coupling constant V  =  1.1 Hz 
In contrast, lsN -‘H coupling was only evident to the 3-H in 3c and to the 4-H in 3c, with V =  1.1 Hz 
in both cases. One-bond ,5N -,3C coupling was clearly seen for all three compounds, with 
XJ= ca. 20 Hz. The only three-bond ,SN -‘3C coupling was in the spectrum of 3a, between ISN  in the 
nitro group and the quaternary carbon 3-C bearing the carboxamide; V  = 3 .7 Hz
Conclusion
Direct rapid one-pot conversions o f  cyanothiophenes to nitrothiophene-carboxamides and o f 
benzonitriles to 3-nitrobenzamides have been developed. In the thiophene cases, these have been 
extended to provide highly isotopically efficient syntheses o f  [ 13N]-nitrothiophene-carboxamides. The 
source of ISN  is potassium [ l5N]-nitrate, which is derived from the readily available and inexpensive 
[lsN]-nitric acid. This technique may have more general applications in introduction of ,SN in 
syntheses using stoichiometric amounts o f [ ,5N]-reagents.
Experimental
[ ,SNJ-Nitric acid (95 atom %, ca 5 M) was purchased from M SD Isotopes. Infra-red spectra were 
obtained using potassium bromide discs. Jeol GX270 and EX400 instruments furnished the NMR 
spectra o f solutions in (CDj^SO. The 1JN chemical shifts are referenced externally to [1SN]- 





Schem e 2. Synthesis of 
[ > ■5 N]-nitrothiophene-carboxamides
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obtained in the electron impact (El) mode, except where noted. Melting points are uncorrected. 
Solvents were evaporated under reduced pressure. The chromatographic stationary phase was silica 
gel.
5-Nitrothiophene-3-carboxamide (2a). Potassium nitrate (1.8S g, 18.3 mmol) was added to 3- 
cyanothiophene la (2.00 g, 18.3 mmol) in concentrated sulphuric add (20 ml). The mixture was 
stirred at ambient temperature for 16 h before being poured onto ice and extracted with ethyl 
acetate. The extract was washed with water and with 10% aqueous sodium carbonate and was dried 
(MgSC>4). Evaporation and recrystallisation (ethanol) gave 5-nitrothiophene-3-carboxamide 2a 
(2.86 g, 91%) as a pale buff solid: mp 161-162°C (lit.13 mp 162-163°C); 3450, 3300, 1700,
1670 cm'1; SH 7.63 (I H, s, NH), 8.11 (1 H, s, NH). 8.47 (I H, d, J = 0.8 Hz, 2-H), 8.51 (1 H, d, 
7= 0.8 Hz, 4-H); 5c 128.11, 136.66, 136.90, 151.19, 161.85\m/z 172 (M).
S-Nitrothiophene-2-carboxamide (2b) and 4-nitrothiophene-2-carboxamide (2c). 2-Cyano- 
thiophene lb  was treated with potassium nitrate and concentrated sulphuric add, as for the synthesis 
of 2a. Chromatography (hexane / ethyl acetate 3:2) gave 4-nitrothiophene-2-carboxamide 2c (41%) 
as a white solid: mp 151-152°C (lit.7 mp 152-153°C); v *  3480, 1715, 1620 cm'1; Sh 7.82 (1 H, s, 
NH), 8.33 (1H.S, NH), 8.42 (1 H, d, ./= 1.5 Hz, 5-H), 8.94 (1 H, d,J-  1.5 Hz, 3-H); m/z 172 (M). 
From later fractions was obtained 5-nitrothiophene-2-caiboxamide 2b (32%) as a white solid: 
mp 191-193°C (compound reported by Occhipinti elal.u and by Johnson el al.li but no mp given); 
v «  3460, 1660, 1620 cm'1; 5H 7.79 (1 H, d, J -  4.4 Hz, 3-H), 7.99 (1 H, s, NH), 8.14 (1 H, d, 
J = 4.4 Hz, 4-H), 8.45 (1 H, s, N-H); m/z 172 (M).
3-Nitrobenzamide (2d). Benzonitrile Id was treated with potassium nitrate and concentrated 
sulphuric acid, as for the synthesis of 2a, to give 3-nitrobenzamide 2d (73%) as an pale orange solid: 
mp 136-138°C (lit.w mp 142-143°C); v.,, 3460, 3350, 1695, 1625 cm'1; 6H 7.75 (1 H, s, NH), 7.78 
(1 H, t, J=  7.7 Hz, 5-H), 8.32 (1 H, dd, J 8.8, 1.1 Hz, 6-H), 8.37 (1 H, s, NH), 8.39 (1 H, ddd, 
J= 1.1, 1.5, 8.6 Hz, 4-H), 8.70 (1 H, ca. t, J ca. 1.5 Hz, 2-H); 5c 122.24, 125.89, 130.06, 133.81,
135.77, 147.80, 165.71; m/z 166 (M).
4-Methyl-3-nitrobenzamide (2e). 4-Methylbenzonitrile le was treated with potassium nitrate and 
concentrated sulphuric acid, as for the synthesis of 2a, to give 4-methyI-3-nitrobenzamide 2e (96%) 
as an off-white solid: mp 161-163°C (lit.17 mp 168-169°C); 3450, 1685, J615cm'1; SH 2.57
(3 H, s, Me), 7.61 (1 H, d ,J=  8.1 Hz, 5-H), 7.65 (1 H, s, NH), 8.13 (1 H, dd.J = 7.7, 1.8 Hz, 6-H), 
8.24(1 H,s,NH), 8.47(1 H,d,y= 1.8 Hz, 2-H); 5C 19.54, 123.45, 131.89, 133.03, 133.44, 135.95, 
148.84, 165.69; m/z (Cl) 181 (M + H).
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5-[>sNj-Nitrothiophene-3-carboxamide (3a). Potassium [,sN]-nitrate (79 mg, 0.77 mmol, 
95 atom %) was added to 3-cyanothiophene la (840 mg, 0.77 mmoi) in concentrated sulphuric acid 
(1.0 ml). Isolation, as for the synthesis of 2a, gave 5-[lsN]-nitrothiophene-3-carboxamide 3a 
(110 mg, 82%) as a pale buff solid: mp 158-160°C (lit.13 mp 162-163°C for 2a); 5H 7.62 (1 H, s, 
NH), 8.10 (1 H, s, NH), 8.46 (1 H, dd, JH.h = 1.8 Hz, JH.s = 1.1 Hz, 4-H), 8.51 (1 H, dd, 
Jh.h= 1.8 Hz, J„.N = l.l Hz, 2-H); 5c 128.05, 136.59 (d, lJc.s = 3.7 Hz, 3-C), 136.85, 151.10 (d, 
1Jc-n = 20.3 Hz, 5-C), 161.79; 6N +365.07; m/z (El) 173 (M).
5-[‘sN]-Nitrothiophene-2-carboxaraide (3b) and 4-[,sN]-nitrothiophene-2-carboxamide (3c). 
Potassium (l5N)-nitrate (280 mg, 2.75 mmol, 95 atom %) was added to 2-cyanothiophene lb 
(840 mg, 0.77 mmol) in concentrated sulphuric acid (1.0 ml). Isolation and purification, as for the 
synthesis of 2b,c, gave 4-(,sN]-nitrothiophene-2-carboxamide 3c (180 mg, 38%) as a pale buff solid 
mp 151-152°C (lit.7 mp 152-I53°C for 2c); 5h 7.80 (1 H, s, NH), 8.32 (1 H, s, NH), 8.40 (1 H, d, 
1.5 Hz, 5-H), 8.93 (1 H, dd, JH.H * 1.5 Hz, Jh-n -  1.1 Hz, 3-H); 5c 122.49, 133.16, 141.48,
147.07 (d, ‘Jc-n* 18.4 Hz, 4-C). 161.32; 5n +367.48; m/z (El) 173 (M). Further elution gave
5-[lsN]-nitrothiophene-2-carboxamide 3b (69 mg, 14%) as an off-white solid: mp 188-190°C, 
5h 7.78 ( IH ,d ,;  = 4.4 Hz, 3-H), 7.98 (1 H, s, NH), 8.14 (1 H, dd, JH.* = 4.4 Hz, Jh-k -  1.1 Hz,
4-H), 8.44 (1 H, s, NH); 6c 127.87 (d, Vwi * 3.7 Hz, 2-C), 130.27, 146.93, 152.93 (d, 
‘J c -n  =  ca. 20 Hz, 5-C), 161.30; 5N +367.52; m/z (El) 173 (M).
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Uptake and Retention of Nitroimidazole-Carboranes for Boron 
Neutron Capture Therapy in Experimental Murine Tumours: 
Detection by nB Magnetic Resonance Spectroscopy
P. J. Wood, M. Scobie and M. D. Threadgill
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U p t a k e  a n d  r e t e n t i o n  o f  n i t r o i m i d a z o l e - c a r b o r a n e s  d e s i g n e d  f o r  
b o r o n  n e u t r o n  c a p t u r e  t h e r a p y  i n  e x p e r i m e n t a l  m u r i n e  t u m o u r s :  
d e t e c t i o n  b y  n B  m a g n e t i c  r e s o n a n c e  s p e c t r o s c o p y
P. J. W OODf, M. SCOBIEt§ and M. D. THREADGILL4*
(Received 9  January 1996; accepted 6 June 1996)
Abstract. Two novel nitroimidazole-carboranes were exam­
ined for their uptake and retention in two experimental 
murine solid tumours and in some normal tissues, using m 
vivo magnetic resonance spectroscopy. The compounds 
were injected Lp. at 0 .8mmol/kg into mice bearing either the 
SCCVII/Ha squamous cell carcinoma or KHT sarcoma 
implanted intradermally on the mouse back. Boron from a 
polyether-isoxazole linked nitroimidazole-carborane (com­
pound 1) was detectable in both SCCVH/Ha and KHT 
tumours at 3 and 7 h after injection. The signal from the 
liver at these times was greater than that from the tum our 
but only a weak signal was obtained from the brain. At 24 h 
after injection the tumour signal was still present, as was that 
from the liver, which appeared to have increased over that 
for the earlier times. Signal from the brain had disappeared 
by 24 h. Boron from a polyether-carbamate linked nitroim i­
dazole-carborane (compound 2) was also detectable in both 
tumours at all times tested, and again was present in the 
liver. In addition, the n B signal was detectable from the 
mouse brain, at early times, but was undetectable at 24 h. 
These preliminary data indicate that nitroimidazole-carbor­
anes are taken up and retained in experimental murine 
tumours in sufficient amounts to be detectable by m vivo 
UB MRS and further that at 24 h after treatment there is 
differential retention between tumours and the brain.
1. I n t r o d u c t io n
R e c e n t l y  t h e r e  h a s  b e e n  a  r e s u r g e n t  i n t e r e s t  i n  
t h e  u s e  o f  b o r o n  n e u t r o n  c a p t u r e  t h e r a p y  ( B N C T )  
f o r  t h e  t r e a t m e n t  o f  c e r t a i n  t y p e s  o f  c a n c e r ,  
i n c l u d i n g  g l i o m a  a n d  m e l a n o m a  ( B a r t h  et al. 
1 9 9 0 ,  1 9 9 2 ) .  S t u d i e s  f r o m  J a p a n  i n d i c a t e  p r o m i s ­
i n g  s u r v i v a l  r a t e s  f o r  p a t i e n t s  t r e a t e d  w i t h  B N C T  
( H a t a n a k a  a n d  N a k a g a w a  1 9 9 4 ) .  C o n s i d e r a b l e  
r e s e a r c h  i s  o n g o i n g  t o  d e s i g n  t u m o u r - t a r g e t e d  
n e u t r o n  c a p t u r e  a g e n t s  w h i c h  w o u l d  i m p r o v e  
t h e  e f f i c a c y  o f  t h i s  f o r m  o f  t r e a t m e n t .
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fSchool of Pharmacy and Pharmacology, University o f 
Bath, Claverton Down, Bath BA2 7AY. UK.
§Present address: Oxford Diversity Ltd, 57 Milton Park 
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B N C T  i n v o l v e s  t h e  i n t e r a c t i o n  o f  t h e r m a l  n e u ­
t r o n s  w i t h  t h e  1 0 B  n u c l e u s ,  a s  f o l l o w s :
l 0 B  +  n t h  -  [ n B ]  — * 7 L i  +  ' ‘H e  +  2 - 3 1 M e V .
T h e  h i g h l y  r e a c t i v e  a  p a r t i c l e  ( * H e  n u c l e u s )  p r o ­
d u c e d  i n  t h i s  r e a c t i o n  c a n  e x e r t  i t s  d a m a g i n g  
e f f e c t  o v e r  a  d i s t a n c e  o f  a p p r o x i m a t e l y  o n e  c e l l  
d i a m e t e r .  T h i s  i m p l i e s  t h a t  d a m a g e  f r o m  B N C T  
w i l l  b e  l o c a l i z e d  l a r g e l y  t o  c e l l s  c o n t a i n i n g  10B .
T h e  f a i l u r e  o f  B N C T  i n  e a r l y  s t u d i e s  h a s  b e e n  
a t t r i b u t e d  t o  t w o  m a j o r  p r o b l e m s ;  ( 1 )  t h e  i n a b i l i t y  
t o  a t t a i n  a d e q u a t e  c o n c e n t r a t i o n s  o f  1 0 B  i n  
t u m o u r s ,  a n d  ( 2 )  t h e  l a c k  o f  s e l e c t i v i t y  o f  b o r o n  
c o n t a i n i n g  c o m p o u n d s  t o  t u m o u r s ,  l e a d i n g  t o  
n o r m a l  t i s s u e  d a m a g e .  R e c e n t  s t u d i e s  h a v e  u s e d  
a  r a n g e  o f  c o m p o u n d s  t o  t a r g e t  1 0 B  t o  t u m o u r s  
( H a w t h o r n e  1 9 9 3  f o r  r e v i e w ) ,  i n c l u d i n g  b o r o n -  
s u b s t i t u t e d  n u c l e o s i d e s  ( T j a r k s  et al. 1 9 9 2 ,  G o u d -  
g a o n  1 9 9 4 ) ,  a m i n o  a c i d s  ( W y z l i c  a n d  S o l o w a y  
1 9 9 2 ,  C o d e r r e  et al. 1 9 9 4 ,  W y z l i c  et al. 1 9 9 4 )  a n d  
p o r p h y r i n s  ( M i u r a  et al. 1 9 9 2 ) .
A  n o v e l  a p p r o a c h  t o  t h e  s e l e c t i v e  u p t a k e  o f  
c o m p o u n d s  i n t o  t u m o u r s  i s  b a s e d  u p o n  t h e  
k n o w l e d g e  t h a t  m o s t  s o l i d  t u m o u r s  c o n t a i n  
r e g i o n s  o f  h y p o x i a ,  w h i c h  m a y  b e  t a r g e t e d  b y  
b i o r e d u c t i v e  c y t o t o x i c  a g e n t s ,  s u c h  a s  n i t r o i m i d a -  
z o l e s ,  w h i c h  c a n  s e l e c t i v e l y  b i n d  t o  h y p o x i c  c e l l s  
( K e n n e d y  et al. 1 9 8 0 ,  S t r a t f o r d  1 9 9 2 ,  A d a m s  et al. 
1 9 8 4 ,  K e y e s  et al. 1 9 8 5 ) .  I t  f o l l o w s  t h a t  t h e  a t t a c h ­
m e n t  o f  b o r o n - c o n t a i n i n g  c o m p o u n d s  t o  s u c h  
n i t r o i m i d a z o l e s  m a y  r e s u l t  i n  h y p o x i a - m e d i a t e d  
t u m o u r  l o c a l i z a t i o n  o f  t h e  b o r o n  m o i e t y ,  w h i c h  
c o u l d  t h e r e f o r e  r e s u l t  i n  m o r e  t u m o u r  s e l e c t i v e  
a p p l i c a t i o n  o f  B N C T .  C o m p o u n d s  o f  t h i s  t y p e  
h a v e  b e e n  s y n t h e s i z e d  ( S c o b i e  a n d  T h r e a d g i l l  
1 9 9 4 a , b ,  W i l b u r  et al. 1 9 9 4 ,  S w e n s o n  et al. 1 9 9 6 ) .  
T h e  r e c e n t  s t u d y  b y  S w e n s o n  et al. ( 1 9 9 6 )  h a s  
d e m o n s t r a t e d  t h e  a b i l i t y  o f  a  b o r o n a t e d  n i t r o i m i -  
d a z o l e  t o  s e n s i t i z e  t u m o u r  c e l l s  in vitro  t o  n e u t r o n  
i r r a d i a t i o n .
I n  t h e  p r e s e n t  s t u d y ,  t w o  c o m p o u n d s  l i n k i n g  
t h e  s t a b l e  i c o s a h e d r a l  C « > B k ) H i o  c a r b o r a n e  t o
0955-.S002/96 S12.00 < . I <1% Taylor & Kram is l.id
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2 - n i t r o i m i d a z o l e  ( S c o b i e  a n d  T h r e a d g i l l  1 9 9 4 a , b ) ,  
w e r e  a d m i n i s t e r e d  t o  m i c e  b e a r i n g  e x p e r i m e n t a l  
m u r i n e  s o l i d  t u m o u r s .  In vivo  n B  m a g n e t i c  r e s o ­
n a n c e  s p e c t r o s c o p y  w a s  u s e d  t o  e x a m i n e  t h e  
u p t a k e  a n d  r e t e n t i o n  o f  t h e s e  c o m p o u n d s  i n  t h e  
t u m o u r s  a n d  i n  s o m e  n o r m a l  m o u s e  t i s s u e s .
2 .  M a t e r i a l s  a n d  m e t h o d s
2 . 1 .  Mice and tumours
T h e  S C C V I I / H a  s q u a m o u s  c e l l  c a r c i n o m a  a n d  
t h e  K H T  s a r c o m a  w e r e  u s e d  f o r  t h e  s t u d y .  
S C C V I I / H a  w a s  m a i n t a i n e d  a s  d e s c r i b e d  b y  T w e n ­
t y  m a n  et al. ( 1 9 8 0 ) .  K H T  w a s  m a i n t a i n e d  b y  
c o n t i n u o u s  p a s s a g e  in vivo. T u m o u r s  f o r  e x p e r i ­
m e n t  w e r e  i m p l a n t e d  b y  i n j e c t i o n  o f  2  x  1 0 3 
t u m o u r  c e l l s  i n  0 - 0 5 m l  c u l t u r e  m e d i u m ,  i n t r a d e r -  
m a l l y  o n  t h e  b a c k  o f  C 3 H / H e  m a l e  o r  f e m a l e  m i c e ,  
2 c m  f r o m  t h e  t a i l  b a s e ,  a n d  w e r e  u s e d  f o r  e x p e r i ­
m e n t  1 0 - 1 4  d a y s  l a t e r  a t  a  v o l u m e  o f  2 0 0 -  
5 0 0 m m  . M i c e  w e r e  m a i n t a i n e d  a n d  e x p e r i m e n t s  
c o n d u c t e d  i n  a c c o r d a n c e  w i t h  t h e  A n i m a l s  ( S c i e n ­
t i f i c  P r o c e d u r e s )  A c t  1 9 8 6 .
2 . 2 .  Anaesthesia
M i c e  f o r  e x p e r i m e n t s  w e r e  a n a e s t h e t i z e d  
u s i n g  H y p n o r m / H y p n o v e l .  ( H y p n o r m ® :  F e n t a n y l  
c i t r a t e  0  3 1 5 m g / m l ;  f l u a n i s o n e  l O m g / m l ,  J a n s s e n  
P h a r m a c e u t i c a ,  B V  T i l b u r g ,  T h e  N e t h e r l a n d s .  
H y p n o v e l ® :  M i d a z o l a m  5 m g / m l ,  R o c h e  P r o d u c t s ,  
W e l w y n  G a r d e n  C i t y ,  U K ) .  T h e  a n a e s t h e t i c  m i x ­
t u r e  w a s  H y p n o r m : H y p n o v e l : w a t e r  ( 1 : 1 : 2 )  a n d  
w a s  i n j e c t e d  i . p .  a t  0 1  m l / m o u s e .
2 . 3 .  Nitroimidazole-carboranes
C o m p o u n d s  w e r e  s y n t h e s i z e d  a s  d e s c r i b e d  p r e ­
v i o u s l y  ( S c o b i e  a n d  T h r e a d g i l l  1 9 9 4 a , b ) .  R e p r e ­
s e n t a t i o n s  o f  t h e  c a r b o r a n e  s t r u c t u r e  a r e  g i v e n  i n  
F i g u r e  1 A .  T h e  s t r u c t u r e s  o f  c o m p o u n d s  1  a n d  2  
a r e  g i v e n  i n  F i g u r e  I B .
B o t h  c o m p o u n d s  w e r e  d i s s o l v e d  i n  D M S O  a t  
2 0 0 m g / m l .  S u b s e q u e n t  d i l u t i o n s  w e r e  i n  p e a n u t  
o i l  w h i c h ,  a f t e r  b r i e f  s o n i c a t i o n ,  w e r e  s t a b l e  
e n o u g h  t o  p e r m i t  i n j e c t i o n .
B o t h  c o m p o u n d s  w e r e  i n j e c t e d  i . p .  a t  a  s i n g l e  
t e s t  d o s e  o f  0  8 1  m m o l / k g  ( 5 0 0 m g / k g  f o r  c o m ­
p o u n d  1 ;  3 5 0 m g / k g  f o r  c o m p o u n d  2 )  a t  0 0 1 m l / g  
m o u s e  b o d y  w e i g h t ,  a n d  w e r e  w e l l  t o l e r a t e d .
B
Figure 1. (A) Representations o f the icosahedral carborane.
(B) Structures o f  polyether-isoxazole linked nitroim i- 
dazole-carborane. 1, and polyether-carbamate linked 
nitroimidazole-carborane 2.
2 . 4 .  11B magnetic resonance spectroscopy
2 . 4 . 1 .  In vitro. S p e c t r a  o f  t h e  n i t r o i m i d a z o l e - c a r ­
b o r a n e s  w e r e  o b t a i n e d  u s i n g  a  9 . 4  t e s l a  v e r t i c a l  
b o r e  m a g n e t  w i t h  a  J e o l  E X 4 0 0  s p e c t r o m e t e r ,  a t  a  
t u n i n g  f r e q u e n c y  o f  1 2 8  3 3 H z ,  w i t h  a n d  w i t h o u t  
b r o a d b a n d  p r o t o n  d e c o u p l i n g .  S a m p l e s  w e r e  a t  a  
c o n c e n t r a t i o n  o f  l O O m M  i n  C D C 1 S  i n  a  s p i n n i n g  
5 m m  t u b e .  B F 3 . E t 2 0  w a s  u s e d  a s  e x t e r n a l  r e f e r ­
e n c e .  A  s p e c t r u m  o f  c o m p o u n d  1  w a s  a l s o  
o b t a i n e d  u s i n g  t h e  4 . 7  t e s l a  s y s t e m  a s  d e s c r i b e d  
b e l o w ,  w i t h  t h e  s a m p l e  i n  a  5 m l  g l a s s  r o u n d -  
b o t t o m e d  f l a s k .
2 . 4 . 2 .  In vivo. S p e c t r a  o f  t h e  n i t r o i m i d a z o l e -  
c a r b o r a n e s  w e r e  o b t a i n e d  in vivo  u s i n g  a  4 . 7  
t e s l a  3 0 c m  h o r i z o n t a l  b o r e  m a g n e t  ( O x f o r d  
I n s t r u m e n t s )  w i t h  a  S I S C O  2 0 0  s p e c t r o m e t e r .  
A 1 c m  t r i p l e  t u r n  s u r f a c e  c o i l ,  t u n e d  t o  6 4 1 8 H z  
w a s  p l a c e d  o v e r  t h e  t u m o u r ,  l i v e r  o r  m o u s e  
b r a i n .  A  1 2 / ^ s  p u l s e  w i d t h  w i t h  a  I s  d e l a y  w a s  
u s e d  a n d  e a c h  s p e c t r u m  c o m p r i s e d  1 0 2 4  r e p e t i ­
t i o n s ,  g i v i n g  a  t o t a l  a c q u i s i t i o n  t i m e  o f  1 7 m i n .  
1 0 0 H z  l i n e  b r o a d e n i n g  w a s  a p p l i e d  t o  e a c h  
s p e c t r u m .
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3. Results
n B  M R  s p e c t r a  w e r e  o b t a i n e d  f r o m  t h e  n i t r o i ­
m i d a z o l e - c a r b o r a n e s  in vitro u s i n g  a  9 * 4  T  m a g n e t .  
S p e c t r a  f o r  c o m p o u n d  1  a r e  g i v e n  i n  F i g u r e  2 A  
a n d  s h o w e d  f i v e  p e a k s  i n  t h e  r a n g e  SB —4 5 t o  
—  1 5 * 0 p p m  ^ / b - h  =  1 5 0 H z )  r e l a t i v e  t o  t h e  e x t e r ­
n a l  s t a n d a r d .  T h e  c o m p l e x i t y  o f  t h e  s p e c t r a  r e f l e c t  
t h e  d i f f e r e n t  e n v i r o n m e n t s  o f  t h e  b o r o n  n u c l e i  
w i t h i n  t h e  c a r b o r a n e  s t r u c t u r e  ( S c o b i e  a n d  
T h r e a d g i l l  1 9 9 4 b ) .
I n  a d d i t i o n ,  f o r  d i r e c t  c o m p a r i s o n  w i t h  t h e  in 
vivo  s p e c t r a ,  a  s p e c t r u m  f r o m  c o m p o u n d  1  in vitro 
w a s  o b t a i n e d  u s i n g  t h e  4 . 7  t e s l a  s y s t e m ,  a n d  i s  
g i v e n  i n  F i g u r e  2 B .  T h e  p r e s e n c e  o f  a  ‘ h u m p ’ i n  
t h e  in vitro  s p e c t r a  w a s  d u e  t o  s i g n a l  f r o m  t h e  
b o r o s i l i c a t e  g l a s s  t u b e s  i n  w h i c h  t h e  c o m p o u n d s  
w e r e  c o n t a i n e d .
n B  M R  s p e c t r a  w e r e  a l s o  o b t a i n e d  in vivo  i n  
S C C V I I / H a  a n d  K H T  t u m o u r s  a t  v a r i o u s  t i m e s  
a f t e r  i . p .  i n j e c t i o n s  o f  t h e  t w o  c o m p o u n d s .  
A l t h o u g h  t h e  a b s e n c e  o f  i n t e r n a l  s t a n d a r d s  p r e ­
c l u d e d  t h e  a b s o l u t e  d e t e r m i n a t i o n  o f  c o n c e n t r a ­
t i o n s  o f  t h e  c o m p o u n d s  f r o m  t h e  M R  s p e c t r a ,  a  
s e m i q u a n t i t a t i v e  a n a l y s i s  w a s  m a d e  b y  d e t e r m i n a ­
t i o n  o f  p e a k  a r e a s ,  w h i c h  w e r e  e x p r e s s e d  a s  a  r a t i o  
f o r  t u m o u r  c o m p a r e d  t o  e a c h  n o r m a l  t i s s u e .
F i g u r e  3  g i v e s  r e p r e s e n t a t i v e  in vivo  1 1 B  M R  
s p e c t r a  f r o m  ( A )  S C C V I I / H a  t u m o u r ,  t o g e t h e r  
w i t h  ( B )  t h e  m o u s e  l i v e r  a n d  ( C )  b r a i n  a t  3 ,  7  a n d  
2 4  h  a f t e r  i . p .  i n j e c t i o n  o f  c o m p o u n d  1  a t  
0 - 8 1  m m o l / k g .  T h e  1 1 B  s i g n a l  w a s  d e t e c t a b l e  i n  
t h e  t u m o u r  a t  3  a n d  7 h  a f t e r  i n j e c t i o n ,  w h i c h  
w a s  s u s t a i n e d  u n t i l  2 4  h .  S i g n a l  f r o m  t h e  b r a i n  w a s  
a l s o  d e t e c t a b l e  a t  e a r l y  t i m e s  a f t e r  i n j e c t i o n ,  b u t  
w a s  l o s t  b y  2 4  h .  T h e  t u m o u r / b r a i n  p e a k  r a t i o  t v a s
2 - 3  a t  t h e  e a r l y  t i m e s  a f t e r  i n j e c t i o n  o f  c o m p o u n d  
1 .  B y  c o n t r a s t ,  a  s t r o n g  s i g n a l  w a s  d e t e c t e d  f r o m  
t h e  l i v e r  a t  3  a n d  7 h  a f t e r  i n j e c t i o n  ( l i v e r / t u m o u r  
p e a k  r a t i o  =  5 - 6 ) ,  w h i c h  h a d  i n c r e a s e d  s u b s t a n ­
t i a l l y  b y  2 4  h  ( l i v e r / t u m o u r  p e a k  r a t i o  =  2 0 ) .  H o w ­
e v e r ,  t h i s  s i g n a l  w a s  l o s t  b y  4  d a y s  ( s p e c t r u m  n o t  
s h o w n ) .  S i m i l a r  r e s u l t s  w e r e  o b s e r v e d  i n  t h r e e  
o t h e r  S C C V I I / H a  t u m o u r - b e a r i n g  m i c e ,  a n d  i n  
t w o  K H T  t u m o u r - b e a r i n g  m i c e .
I n  o r d e r  t o  d e t e r m i n e  w h e t h e r  t h e  l a r g e  s i g n a l  
f r o m  t h e  l i v e r  w a s  d u e  t o  r e s i d u a l  c o m p o u n d  1  i n  
t h e  p e r i t o n e a l  c a v i t y ,  c o m p o u n d  1  w a s  g i v e n  
o r a l l y  t o  t w o  m i c e .  T h e  b o r o n  s i g n a l  f r o m  t h e  
l i v e r  a f t e r  o r a l  a d m i n i s t r a t i o n  o f  c o m p o u n d  1  w a s  
s i m i l a r  t o  t h a t  f o r  i . p .  i n j e c t i o n  ( s p e c t r u m  n o t  
s h o w n ) .
F i g u r e  4  g i v e s  r e p r e s e n t a t i v e  in vivo  1 1 B  M R  
s p e c t r a  f r o m  ( A )  K H T  t u m o u r ,  t o g e t h e r  w i t h  ( B )
1H coupled 1H d e c o u p le d
F ig u re  2. (A) In vitro n B MR sp e c tru m  o f  100 m.M so lu tio n  o f  c o m p o u n d  1 o b ta in e d  f ro m  a 9.-1 tesla system . (B) In vitro n B MR
sp e c tru m  o f  200 m g/m l so lu tio n  o f  c o m p o u n d  I o b ta in e d  fro m  a 4.7 te s la  system . D etails a re  g iven  in  §2.
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Figure 3. /n  z/roo l lB MR spectra from (A) SCCVII/Ha tumour, (B) liver and (C) brain in CsH mouse, 3, 7 and 2 4 h after 
i.p.injection o f  0-81 mmol/kg o f compound 1. The vertical scale for the liver spectra is one-fifth o f that for the spectra from  
tumour and brain.
F ig u re  4. In vivo 11B MR sp e c tra  fro m  a (A) K H T tu m o u r. (B) 
liver an d  (C) b ra in  in C iH  m ouse . 4 h a f te r  i.p. 
in je c tio n  o f  0-81 m m ol/kg o f  c o m p o u n d  2. T h e  vertica l 
scale is th e  sam e fo r  all sp ec tra .
t h e  m o u s e  l i v e r  a n d  ( C )  b r a i n  a t  4 h  a f t e r  i . p .  
i n j e c t i o n  o f  c o m p o u n d  2  a t  0 - 8 1  m m o l / k g .  A g a i n ,  
t h e  n B  s i g n a l  w a s  d e t e c t a b l e  f r o m  t h e  t u m o u r  a n d  
b r a i n ,  a n d  t h e  t u m o u r / b r a i n  p e a k  r a t i o  w a s  3 .  T h e  
s i g n a l  f r o m  t h e  l i v e r  a t  t h i s  t i m e  a p p e a r e d  t o  b e  
m u c h  l e s s  t h a n  t h a t  o b s e r v e d  f o r  c o m p o u n d  1  
( l i v e r / t u m o u r  p e a k  r a t i o  =  1 ) .  A t  2 4  h  a f t e r  i n j e c ­
t i o n ,  s i g n a l  w a s  d e t e c t a b l e  f r o m  t h e  t u m o u r  a n d  
l i v e r ,  b u t  n o t  f r o m  t h e  b r a i n  ( s p e c t r a  n o t  s h o w n ) .  
S i m i l a r  r e s u l t s  w e r e  o b t a i n e d  i n  o n e  o t h e r  K H T  
t u m o u r - b e a r i n g  m o u s e  a n d  i n  t w o  S C C V I I / H a  
t u m o u r - b e a r i n g  m i c e .
4. D isc u ss io n
T h e  r e s u l t s  p r e s e n t e d  h e r e  a r e  t h e  o u t c o m e  o f  a  
p r e l i m i n a r y  s t u d y  d e s i g n e d  t o  a s k  w h e t h e r  t h e  
a t t a c h m e n t  o f  b o r o n  c o n t a i n i n g  c o m p o u n d s  t o  
b i o r e d u c t i v e  a g e n t s  w a s  a  f e a s i b l e  m e a n s  o f  t a r -  
g e t t i n g  b o r o n  t o  s o l i d  t u m o u r s  a n d  w h e t h e r  s u c h  
c o m p o u n d s  w e r e  d e t e c t a b l e  b y  i n  vivo  n B  M R S .
T w o  n i t r o i m i d a z o l e - c a r b o r a n e s  w e r e  e x a m i n e d ,  
i n  t w o  m u r i n e  t r a n s p l a n t a b l e  t u m o u r s ,  a n d  t h e  
r e s u l t s  i n d i c a t e  t h a t  b o t h  c o m p o u n d s  w e r e  d e t e c t ­
a b l e  i n  t h e s e  t u m o u r s  b y  in vivo n B  M R S .  I t  i s  w e l l  
e s t a b l i s h e d  t h a t  in vivo  M R S  c a n  i n  g e n e r a l ,  p r o ­
v i d e  a  u s e f u l ,  n o n - i n v a s i v e  m e t h o d  f o r  t h e  d e t e c ­
t i o n  o f  m e t a b o l i t e s  a n d  d r u g s  i n  t i s s u e s .  n B  M R S  
a n d  M R I  h a v e  b e e n  u s e d  p r e v i o u s l y  t o  d e t e c t  
b o r o n  c o n t a i n i n g  c o m p o u n d s  in vivo  ( K a b a l k a  et 
al. 1 9 8 8 ,  B e n d e l  etal.  1 9 9 0 .  K a b a l k a  r i a l  1 9 9 1 ) .  a n d
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1 lB M RS h a s  b e e n  u se d  successfu lly  in  th is  s tu d y . I t  
is im p o r ta n t  to  e m p h a s iz e  th a t  th e se  c o m p o u n d s  
a re  b e in g  ta k e n  u p  in to  th e  tu m o u rs  o r  tissues in  
su ffic ie n t q u a n t i t ie s  to  p e rm it  th e ir  d e te c tio n  by 
th is  m e th o d .
A lth o u g h  th e  d e te c tio n  a n d  analysis o f  th e  
n i tro im id a z o le -c a rb o ra n e s  m  vivo by n B M RS is 
o n ly  s e m iq u a n ti ta t iv e , th e  s p e c tr a  give so m e  in d i­
c a tio n  o f  th e  re la tiv e  levels o f  th e se  c o m p o u n d s  in  
tu m o u rs  c o m p a r e d  w ith  n o rm a l tissues. T h e  n B 
M R s p e c tr a  in d ic a te  h ig h e r  levels o f  th e  c o m ­
p o u n d s  in  th e  live r, c o m p a re d  w ith  tu m o u r . T h is  
p h e n o m e n o n  h a s  b e e n  o b se rv e d  w ith  o th e r  n i t ro i-  
m id azo les , s u c h  as m iso n id a z o le  (G a rre c h t a n d  
C h a p m a n  1983). T h is  a p p a r e n t  n o n -se le c tiv ity  o f  
u p ta k e  o f  th e s e  c o m p o u n d s  m ay  n o t  b e  a  p ro b le m  
in  a  p o s s ib le  B N C T  s tra te g y  w h e re  a p p l ic a tio n  o f  
r a d ia t io n  is lo ca lized . H ow ever, th e  re su lts  d o  
su g g est so m e  se lec tiv ity  o f  u p ta k e  o f  th e  c o m - 
p o n d s  in  th e  tu m o u rs  c o m p a re d  w ith  th e  b r a in .  
C learly , q u a n t if ic a tio n  o f  levels o n  a  tis su e -w e ig h t 
basis w o u ld  b e  n e c essa ry  b e fo re  d e f in ite  c o n c lu ­
sio n s  c o u ld  b e  m a d e  a n d  th e  n o rm a l tis su e  to x ic ity  
o f  th e se  c o m p o u n d s  th em se lv es m u s t b e  a n  
im p o r ta n t  c o n s id e ra t io n . I m p o r ta n t  f u r th e r  
e x p e r im e n ts  w o u ld  e x a m in e  th e  u p ta k e  a n d  
r e te n t io n  o f  c o m p o u n d s  o f  th is  ty p e  in  tu m o u rs  
lo c a te d  in  th e  b r a in .  T h e  a p p a r e n t  w e a k e r  b o r o n  
signa ls f r o m  th e  b r a in  m ay  b e  in d ic a tiv e  o f  low  
levels o f  n e u ro to x ic ity  f o r  th e  tw o  c o m p o u n d s .
In  th e  e x p e r im e n ta l  m u r in e  tu m o u r  system s, 
th e  c o m p o u n d s  w e re  w ell to le ra te d  by  th e  m ic e  
a t  th e  d o s e  o f ;  0-81 m m ol/kg . T h e  u se  o f  h ig h e r  
doses w as l im ite d  by  th e  c o n c e n tra t io n  o f  D M SO  
in  th e  so lv e n t. T h u s , im p ro v e d  a q u e o u s  so lu b ility  
w o u ld  b e  a n  a d v a n ta g e , a n d  th is  w ill b e  th e  fo cu s  
o f  f u tu r e  s y n th e tic  w ork .
T h e  d e s ig n  o f  th e  n i t ro im id a z o le -c a rb o ra n e s  
was b a s e d  u p o n  th e  h y p o x ia -se le c tiv ity  o f  th e  
b io re d u c tiv e  p a r t  o f  t h e  m o lecu le , in  o r d e r  to  
re ta in  b o r o n  in  th e  tu m o u r  cells. T h e  p re s e n c e  
o f  h y p o x ia  in  e x p e r im e n ta l  m u r in e  so lid  tu m o u rs  
has b e e n  d e m o n s tr a te d  (H o eck e l et al. 1991, O k u -  
n ie ff  et al. 1993), a n d  th e  p re se n c e  o f  th e  n i t r o i ­
m id a z o le -c a rb o ra n e s  in  tw o tu m o u rs  o f  th is  ty p e  
u p  to  24  h  a f te r  a d m in is tra t io n ,  s tro n g ly  su g g ests  
th a t  h y p o x ia  in d u c e d  b in d in g  m ay b e  a  m e c h a n ­
ism  o f  u p ta k e  o f  th e se  c o m p o u n d s . H o w ev er, th e  
a p p a r e n t  h ig h e r  levels o f  th e se  c o m p o u n d s  in  th e  
live r su g g e st th a t  h y p o x ia  re la te d  u p ta k e  a n d  
r e te n t io n  o f  th e se  a g e n ts  m ay n o t b e  th e  o n ly  
m e c h a n ism  o c c u rr in g . N ev e rth e le ss , th e  d e te c t io n  
o f  th e se  c o m p o u n d s  in  so lid  tu m o u rs  su g g ests  th a t  
h y p o x ia  m ay  b e  p la y in g  a  ro le  in  th e ir  u p ta k e , a n d  
th is  m ay  b e  e n h a n c e d  fu r th e r  by se lec tiv e ly
in c re a s in g  h y p o x ia  w ith  a g e n ts  w h ich  a l te r  
tu m o u r  b lo o d  flow  a n d  m e ta b o lism  (S tr a t fo rd  
et al. 1994). T h is  c o u ld  b e  a c h ie v e d  f o r  e x a m p le , 
w ith  a g e n ts  su c h  as in h ib i to r s  o f  n i t r ic  o x id e  
sy n th ase , w h ich  in d u c e  h y p o x ia  in  th e se  tu m o u rs  
a t  do ses w hich  h av e  n o  s ig n ific a n t e ffe c t o n  
n o rm a l tis su e  m e ta b o lism  (W o o d  et al. 1994).
T h e  re su lts  p r e s e n te d  h e r e  d e s c r ib e  a  novel 
a p p ro a c h  to  th e  p ro b le m  o f  ac h ie v in g  su ffic ie n tly  
h ig h  levels o f  in tr a c e l lu la r  b o r o n  in  so lid  tu m o u rs  
f o r  B N C T, u s in g  c o m p o u n d s  specifically  d e s ig n e d  
to  e x p lo it  th e  p re s e n c e  o f  h y p o x ia  k n o w n  to  ex is t 
in  m o s t so lid  tu m o u rs .
W e h av e  d e m o n s tr a te d  th a t  tw o su c h  c o m ­
p o u n d s  c a n  b e  ta k e n  u p  in to  e x p e r im e n ta l  
tu m o u rs  in  su ffic ie n t a m o u n ts  to  be  d e te c ta b le  
b y  in vivo n B M RS. W h ile  c o n s id e ra b le  w o rk  is 
n e e d e d  to  o p tim iz e  th e  u p ta k e  a n d  se lec tiv ity  o f  
th e se  c o m p o u n d s , th e  p re l im in a ry  d a ta  sh o w  th is  
to  b e  a  v e ry  p ro m is in g  a p p r o a c h  f o r  B N C T .
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Synthesis of a Series of Trifluoromethylazoles and Determination of pK* of Acidic 
and Basic Trifluoromethyl Heterocycles by 19F NMR Spectroscopy
B. G. Jones, S. K. Branch, A. S. Thompson and M. D. Threadgill
Journal o f the Chemical Society, Perkin Transactions 1,1996,2685-2691.
Synthesis of a series of trifluoromethylazoles and determination of 
pK3 of acidic and basic trifluoromethyl heterocycles by 19F NMR 
spectroscopy
B ria n  G . Jo n e s , S a r a h  K . B ran c h , A ndrew  S . T h o m p so n  and  
M ic h a e l  D . T h re a d g ill *■+
School o f Pharmacy & Pharmacology. University o f Bath. Claverton Down. Bath BA2 7 AY. 
UK
Trifluoroacetylation at the 5-position o f  3,4-dihydro-2//-pyran and the 3-position o f  4,5-dihydrofuran, 
follow ed by treatment with hydrazine, gave 3-(3-trifluorom ethyl-l//-pyrazol-4-yl)propanol and 2-(3- 
trifluoromethyl-1 W -pyrazol-4-yl)ethanol, respectively. In the latter case, an interm ediate dimer was 
isolated . Isom eric 2-{3-trifluorom ethyI-l//-pyrazol-5-yl)ethanol was formed by reaction o f  hydrazine with
6-benzyloxy-l,l,l-trifluorohex-3-yn-2-one and deprotection. Reaction o f  3-benzyloxypropylam ine w ith
2 ,5-bis( trifluorom ethyl)-!,3,4-oxadiazole, follow ed by deprotection, afforded 3-{3,5-bis(trifluorom ethyi)- 
4//-l,2 ,4-triazol-4-yl]propanol. A series o f  2-trifluorom ethyl-l//-benzim idazoles and 2-trifluorom ethyl- 
3//-im idazopyrid ines were prepared by condensation o f  the appropriate orrAo-arenediamine with 
trifluoroacetic acid. Analysis o f  the IVF  N M R  spectra o f  the trifluoromethylazoles and o f  3-trifluoro- 
m ethylpyridine in aqueous solution at different pH s enabled determination o f  p/sfa values. All the 
com poun ds evaluated had one or more pKt between 1 and 13, except the triazole. Several com pounds were 
identified a s having potential use in measuring pH  in biological media by ,9F  N M R  spectroscopy.
A large number o f pyrazoles and derived heterocycles have 
found use1 as therapeutic agents and as agrochemicals. Tri­
fluoromethyl heterocycles are also o f considerable interest in 
these areas2 on account o f the acid-strengthening/base- 
weakening electronic effects o f incorporation o f  the trifluoro­
methyl group and in view o f the increased lipophilicity o f  
compounds bearing this functionality. As pan o f  a programme 
o f  synthesis and evaluation o f trifluoromethyl heterocycles for 
medicinal and pH sensor applications.3,4 we required pyrazoles 
and 1,2,4-triazoles with one or more trifluoromethyl groups on 
the heterocycle, and also carrying an co-hydroxyalkyl function 
for later attachment to various moieties, such as 2-nitro- 
imidazole,5 to permit biological targeting to specific tissue or 
cell types.
Of the methods available for the synthesis o f N- 
unsubstituted pyrazoles, those involving condensation o f hydra­
zine with 1,3-diketones and with a,|3-acetylenic ketones are 
among the more widely used.6 Clearly, the range o f  pyrazoles 
that can be prepared by both methods is limited to those where 
the substrate is readily synthetically accessible and, in the latter 
case, to 4-unsubstituted pyrazoles. We4 and others7 have 
recently reported the synthesis o f 3,5-bis(trifluoromethyl)- 
pyrazole from 1,1,1.5,5,5-hexafluoropentane-2,4-dione but 
all attempts to alkylate this 1.3-diketone at C-3, leading to
4-substituted 3,5-bis(trifluoromethy!)pyrazoles, were unsuccess­
ful. For our series o f target pyrazoles, with oj-hydroxyalkyl 
substituents, there is an additional requirement for introduction 
or appropriate protection o f the hydroxy group.
In planning the synthesis o f 3-(3-trifluoromethyl-l//- 
pyrazol-4-yl)propanol 3 and 2-(3-trifluoromethyl-l//-pyrazol-
4-yl)ethanol 8, where the to-hydroxvalkyl group is at the 4- 
position o f  the pyrazole, we recognised that the irifluoro- 
acetyldihydropyran 2 and the trifluoroacetyldihydrofuran 6. 
respectively, contain the correct carbon skeleton and a masked
1,3-diketone for condensation with hydrazine. Furthermore, 
this condensation would reveal the required co-hydroxyalkyl 
function as a leaving group, thus obviating the need for earlier 
introduction and possible protection o f the hydroxy group.
* e-mail: m.d.threadgill@bath.ac.uk
Dihydropyran 1 and dihydrofuran 5 were trifluoroacetylated 
using trifluoroacetic anhydride and pyridine in dichlorometh­








Scheme 1 Reagents: i. (C F ,C 0 ),0 . pyridine. CH.CU: ii. N,H«. ElOH: 
iii. BzCl: iv. HC1. EtOH
notably higher than those reported by Hojo e t  al * for the same 
procedure. Treatment o f  2 with hydrazine in boiling ethanol 
effected the condensation with concomitant exposure o f  the
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3-hydroxypropyl group, as predicted. The trifluoromcthylpyra- 
zolylpropano! 3 was isolated in 96% overall yield from I. To 
ensure that the o>-hydroxy group could be derivatised without 
interference from the pyrazole, the corresponding benzoate 
ester 4 was formed in the usual way. Since this work was carried 
out, Tang and H uv have reported the synthesis o f 3 by addition 
o f  the expensive iodopentafluoroethanc across the enol ether o f  
1, in the presence o f sodium dithionite. and treatment o f  the 
pentafluoroethyltetrahydropyran with hydrazine.
In contrast, treatment o f  the five-membered ring homoiogue 
6 with hydrazine did not give the expected pyrazolylethanol 8 
directly. Under essentially the same conditions as above, a vir­
tually quantitative yield o f  the dimer 7 was formed. In this 
dimer, one molecule o f  the fully condensed aromatic pyra­
zolylethanol has intercepted another molecule where the elim­
ination o f  water from the intermediate is not complete, 
although the detailed mechanism o f the formation o f  7 is not 
clear. It is particularly noteworthy that no material could be 
isolated where solvent ethanol, rather than the pyrazolyletha­
nol, has reacted as the incoming nucleophile, despite the much 
higher concentration o f  the former. The dimer 7 readily formed 
the target pyrazolylethanol 8 upon reflux in the presence o f  a 
trace o f  acid. In a control experiment, it was demonstrated that 
8 was not convened to the dimer 7 under the condensation 
conditions, indicating that 7 had not been formed from two 
molecules o f  8.
In the approach to the 3,5-disubstituted pyrazole 13, ring 
formation from hydrazine and an a,£-acetylenic ketone was 
investigated, as shown in Scheme 2. In this case, it was not
was benzylated, essentially by the method o f  Johnson dal' ,n to 
give the ether 10b. As before, formation o f  the acetylenic anion 
and trifluoroacetylation (trifluoroethyl trifluoroacetate) gave 
the ketone l i b  in very high yield. Condensation with hydrazine 
in boiling ethanol aflorded the protected 3,5-disubstituted 
pyrazole 12b. Now, exposure o f  the hydroxy group was effected 
by hydrogenation under acidic conditions to afford the target 
trifluoromethylpyrazolylethanol 13 with the substituents in the 
desired 3,5-arrangement.
The most common routes for preparation o f 1,2,4-triazoles 
are thermal condensation of an acylhydrazide with a (thio)- 
amide (the Pellizzari reaction)12 and condensation o f  a di- 
acylamine with hydrazine (the Einhom-Brunner reaction).13 
However, the symmetry o f the target compound, the 3,5- 
bis(trifiuoromethyl)triazolylpropanol 21, and the need for a 
functionalised substituent at the 4-position, suggested that 
condensation o f an appropriately protected o>-hydroxyalkyl 
primary amine with an W.yV'-diacylhydrazine, or its equivalent, 
would be a more efficient route. Scheme 3 shows the route
14 R -O H
15 R - O T i16 R-NHOOCFj
17 R - N H 2
f,c'cV n'C'GF3 « b
C c , ’,
R - H  10.  R -  Bo'PbjSt 
10b R - B n
1U  R “ Bo'PhjSi 
11b R - B n
lZbooly
h"n
12a R -  Bc'PbjSi 
12b R - B n
Scheme 2 Reagents: i. BuVhjSiCl. imidazole DMF: ii. BnBr. NaH. 
DM F: iii, BuLi. C F,C O ,CH ,CF,. THF: iv. N,H4. EtOH; v. H„ P d -C  
HCIO«. MeOH
possible to design a process in which the hydroxyalkyl group 
was revealed during the condensation and it was necessary to 
assemble an appropriate trifluoromethyl ketone containing the 
alcohol, possibly in a protected form. But-3-ynol 9 was pro­
tected as its rcrr-butyldiphenylsilyl ether 10. essentially by the 
method o f  Delom e et ul.10 This allowed formation o f the acety­
lenic carbanion by treatment with butyllithium at low temper­
ature. Addition o f  trifluoroethyl trifluoroacetate as theelectro- 
phile afforded the /m-butyldiphenylsilyl-protected acetylenic 
trifluoromethyl ketone U a  in 95% yield. Other electrophilic tri- 
fluoroacetylating agents, such as trifluoroacetic anhydride, ethyl 
trifluoroacetate and ethyl trifluorothioaceiate. were consider­
ably less effective. Condensation o f this ketone U a with hydra­
zine formed the /m-butyldiphenylsilyl-protecied pyrazol-5- 
ylethanol 12a in virtually quantitative yield. Unexpectedly, it 
proved impossible to remove the silyl protecting group with 
fluoride using conditions under which the product pyra­
zolylethanol 13 could be isolated. Repetition o f the sequence 
using O-benzyl protection was more successful. The alcohol 9
H r *
OF,
Scheme 3 Reagents: i. TsCl. KOH. Et20 ;  ii. CF,CONH,. KOBu'. 
THF. Nal; iii. NaOH. MeOH: iv. P20 , .  heat; v. 17. MeOH: vi. H „ Pd-
C. HC104. EtOH
adopted. 3-Benzyloxypropylamine 17 was synthesised in three 
steps from the commercially available mono-O-benzyl pro­
tected propane-1,3-diol 14. Activation o f  the alcohol as the 
toluene-p-sulfonate 15 was achieved using toluene-p-sulfonyl 
chloride (TsCl) in the presence o f  powdered potassium hydrox­
ide. Substitution with the anion derived from trifluoro- 
acetamide served to introduce the nitrogen atom, giving the 
amide 16. Selective hydrolytic deprotection under basic condi­
tions afforded the required O-benzyl-protected hydroxypro- 
pylamine 17 in 58% overall yield from 14. In a modification o f  
the technique used by Reitz and Finkes,14 1.2-bis(trifluoro- 
acetyl)hydrazine 18 was cyclised to form the oxadiazole 19 in 
good yield by dehydration with phosphorus pentoxide at high 
temperature. Although the condensation o f  this normally 
reactive heterocycle 19 with the amine 17 proceeded only in 
moderate yield to form 20, subsequent deprotection by hydro- 
genolysis under acidic conditions was efficient, affording the 
target 3-(3.5-bis(trifluoromethyl)-4//-l ,2,4-triazol-4-yl]pro- 
panol 21 in 39% yield from the amine 17 and in 23% overall 
yield in five steps from 14.
Scheme 4 shows the preparative route developed for synthesis 
o f  the 2-trifluoromethylimidazopyridines 23a,b and the 2- 
trifluoromethylbenzimidazoles 23c,d. The former pair o f  com ­
pounds were selected as being potentially water-soluble. The 
benzimidazoles were designed to carry two inequivalent sets o f
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Scheme 4 Reagent: i. C F ,C 02H
fluorine atoms with difFerent sensitivities of chemical shift to 
pH. In benzimidazole 23d, the chemical shift o f the 5- 
trifluoromethyl group should be sufficiently insensitive to pH 
for it to act as an internal chemical shift standard. Prolonged 
treatment o f  the pyridinediamines 22a,b with boiling trifluoro­
acetic acid gave mixtures o f  regioisomeric acylaminopyridines, 
along with small amounts o f  the cyclised products 23a,b, as 
shown by 'H and ,9F NMR spectroscopy. Cydisation was com­
pleted at 200 °C in a Kugelrohr apparatus, with sublimation o f  
the target imidazopyridines 23a,b. The benzimidazoles 23c,d 
were formed by similar condensations, also in excellent yields.
The effect o f  pH on the WF NMR chemical shift (<5F) of the 
trifluoromethyl heterocycles 3, 8, 13, 21, 23a,b, 24 and 25 was 
then measured with the aim o f measuring pAa values and iden­
tifying com pounds in which <5F was highly sensitive to pH in the 
physiological range. Compound 24 was available in the labora­
tory4 and compound 25 was obtained commercially. The benz­
imidazoles 23c,d were not suffidently soluble in aqueous media 
to permit these measurements to be made.
24 25
Pyrazole has an addic pA ,= 14.18, as reported by Elguero 
et al.ls who used UV spectroscopic methods This group also 
studied the add-strengthening effects o f  electron-withdrawing 
groups on pyrazoles, with 3-trifluoromethyl-5-methylpyrazole 
having pAa = 12.33, while the second trifluoromethyl group, as 
in 3,5-bis(trifluoromethyl)pyrazole 24, increased the addity 
even more markedly (pAa = 7.51). Similar but more pronounced 
effects are seen for the sequential incorporation o f nitro 
groups.'6 Fig. 1(a) shows the <5p-pH relationship for 3-(3-tri- 
fluoromethyl-l//-pyrazol-4-yl)propanol 3, while Fig. 1(A) 
shows that for the lower homoiogue, 2-(3-trifiuoromethyl-1H- 
pyrazol-4-yl)ethanol 8. As expected, these compounds have 
very similar pAa values (12.1 and 12.0, respectively). Moving 
the cu-hydroxyalkyl substituent to the 5-position, as in 2-(3- 
trifluoromethyl-l//-pyrazol-5-yl)ethanol 13, had a slight add- 
weakening effect, giving pAa = 12.8. For the 3,5-bis(trifluoro- 
m ethyl)-l//-pyrazole 24 [Fig. 1 (</)], the pAa was determined to 
be 7.55, closely in agreement with the reported value.15 These 
results place the mono(trifluoromethyl)pyrazoles well outside 
the useful range for measurement o f pH in biological systems 
but the pAa o f  24 is highly appropriate. All four trifluorometh- 
ylpyrazoles 3, 8, 13 and 24 gave simple sigmoidal curves with 
good sensitivity o f  chemical shift to changes in pH, with AdF 
(the total changes in chemical shift across the whole pH range) 
being in the range 2.09 to 2.33 ppm for the mono(trifiuoro- 
methyl)pyrazoles and 1.47 ppm for the bis(trifluoromethyl)- 
pyrazole. As expected, formation o f the anions at higher pHs 
caused the signals to move upfield.
In contrast, the ,9F chemical shift o f  the analogous 3.5- 
bis(trifluoromethyl> 4 //-1 ,2,4-triazole 21 was virtually indepen­
dent o f  pH in the range pH 0.0 to 9.5, as shown in Fig. 2. As 
this compound cannot be a heterocyclic add. unlike the pyr­
azoles, no studies were made under more alkaline conditions. 
Thus, either the corresponding iriazolium cation has <SF identi­
cal to that o f  the unionised triazole or, more likely, the pAa o f  
the compound is <0.0.
The relationships o f SF to solution pH for the isomeric 2- 
trifluoromethylimidazopyridines 23a,b both approximated 
closely to double sigmoidal curves (Fig. 3), indicating two 
ionisation events for each compound with different pAa values. 
The principal ionisation event for 2-trifluoromcthyl-3//- 
imidazo[4,5-c]pyridine 23a, loss of the imidazole N -H  proton 
with the neutral molecule acting as an add, occurs at 
pAa = 8.78. There is also an ionisation event at pAa = ca. 3.5, 
probably corresponding to protonation o f the neutral molecule 
at the pyridine nitrogen. The former event causes greater 
change in chemical shift than the latter (ASF 1.0 and A 0.1,  
respectively). The curve for 2-trifluoromethyl-3//-imidazo[4,5- 
AJpyridine 23b is similar in shape. The pAa values are 6.92 and 
ca. 2.2, representing the acidic and basic ionisations, respect­
ively. The fact that the prindpal pAa o f this compound lies well 
within the physiological pH range makes it an attractive candi­
date lead compound for measurement of pH in biological sys­
tems, although the A<5F is relatively small (0.55 ppm). For com­
parison, the analogous 2-trifluoromethylbenzimidazole has 
been reported17 to have pAa = 8.13, as measured spectroscopi­
cally, but it was too insoluble to allow investigation by l9F 
NM R spectroscopy.
Finally, commercially available 3-trifluoromethylpyridine 25 
was investigated. As shown in Fig. 4, this compound gave a 
simple sigmoidal curve with pAa measured as 2.67 and 
Adf = 1.0 ppm. Clearly, this represents protonation at the pyri­
dine nitrogen but the basicity of 25 is much reduced by 
incorporation o f  the electron-withdrawing trifluoromethyl 
group (cf. 3-methylpyridine pAa = 5.68)'* which is apparently 
similar in effect to a chlorine atom (3-chloropyridine 
pAa = 2.84).“
In conclusion, syntheses o f  four trifluoromethyl pyrazoles, one 
trifluoromethyl-1,2,4-triazole, two trifluoromethylbenzimid- 
azoles and two trifiuoromethylimidazopyridines have been 
achieved. Studies o f  the effect o f  solution pH on the ,9F NMR  
chemical shift have revealed sensitivity o f dF to the state of 
ionisation o f the trifluoromethyl heterocycles and hence to the 
solution pH. Three compounds, 23a,b and 24. have been identi­
fied as having pAa close to the physiological range and therefore 
as having potential for use in a non-invasive method o f  measur­
ing pH in biological systems by ’’F NMR spectroscopy. In all 
the compounds examined, the trifluoromethyl group acts in two 
roles; reporter o f  the state o f  ionisation and acid-strengthener/ 
base-weakener. Further development o f the lead compounds 
will involve incorporation o f appropriate functional groups 
to permit attachment o f biological targeting moieties and to 
'fine-tune' the pAa.
E x p e r i m e n t a l
Experiments were conducted at ambient temperature, unless 
otherwise noted. Solutions in organic solvents were dried with 
anhydrous magnesium sulfate. NMR spectra were obtained of 
solutions in deuteriochloroform (unless otherwise noted), using 
tetramethylsilane as chemical shift standard for 'H (at 400 and 
270 MHz) and UC (at 100 MHz). An external C FJ5Clj signal 
from fluorotrichloromethane was used for l9F spectra (at 376 
and 84.6 MHz). TH F refers to dry tetrahydrofuran and brine 
refers to saturated aqueous sodium chloride. Solvents were 
evaporated under reduced pressure, except where noted. The 
stationary phase for chromatography was silica gel. A Kuecl- 
rohr apparatus was used for distillations and sublimations. Bps 
refer to the temperature o f the Kugelrohr oven. Mps are uncor­
rected. A Coming 240 pH meter with a 3.7 mm. pH 0-14  Russell 
CLSCH11/lm  electrode was used for the pH measurements 
Compound 24 was prepared as described previously by us.4
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Fig. 2 <5r-pH Relationship for the bis(trifluoromeihyI)-4//-1.2.4- 
triazole 21
5-Trifluoroacetyl-3,4-<lihydro-2//-pyran 2
Trifluoroacetic anhydride (17.9 g, 85 mmol) was added drop- 
wise at 10 °C to 3.4-dihydro-2//-pyran 1 (5.00 g. 59 mmol) and 
pyridine (1.57 g, 20 mmol) in dichloromethane (40 cmJ) and the 
mixture was stirred for 18 h at ambient temperature. The mix­
ture was washed twice with water and with saturated aqueous 
sodium hydrogen carbonate and was dried. Distillation gave 5- 
trifluoroacetyl-3.4-dihydro-2//-pyran 2 (10.84 g, 97%) as a col­
ourless liquid: bp*. 95-100 °C (lit..* bpI0 64.6 °C); <$H(D 20 )  1.96 
(2 H, br quintet. J 6 Hz. 3-H2). 2.34 (2 H. t. J 6 Hz. 4-H2). 4.21
(2 H, t, J  6 Hz, 2-Hj), 7.83(1 H .s.6-H );d'F -7 0 .3 7  (s); mb (E l) 
180 (M, 29%), 111 (M -  CF}. 100).
3-{3-TrifluoromethyI-l //-pyrazol-4-yl)propanol 3
The pyran 2 (1.0 g, 5.5 mmol) was heated under reflux with 
hydrazine hydrate (0.83 g. 16 mmol) in ethanol (3 cm3) for 3 h. 
Distillation gave 3-{3-trifluoromethyl-l//-pyrazol-4-yl)propanoI
3 (1.09 g, 99%) as a white solid: bp0.4 160 °C; mp 84-85 °C (!it..v 
mp 85-87 °C); <5H(D 20 )  1.79 (2 H, quintet. J 7 Hz, 
CH2C //2CH 2), 2.62 (2 H, t, /  7.3 Hz. pyrazole-CH2), 3.59 (2 H. 
t, J 6.3 Hz. CHjO), 7.66 (1 H. s. pyrazole 5-H); <5F -61.31 (s) 
(HRMS: found M + H \  195.0745. Q H .oFjN zO  requires 
M +  H*. 195.0745).
3-(3-Trifluoromethyl-l//-pyrazol-4-yl)propyl benzoate 4
Benzoyl chloride (540 mg. 3.9 mmol) was added dropwise over 
15 min to the pyrazolylpropanol 3 (500 mg. 2.6 mmol) and 
triethylamine (5.2 g. 51.5 mmol) in dichloromethane (20 cm 3) 
at 0 C and the mixture was allowed to warm to ambient tem­
perature over 16 h. The mixture was washed with saturated 
aqueous sodium hydrogen carbonate, hydrochloric acid (2 m. 
five times) and brine and was dried. Chromatography (ethyl 
acetate-hexane, 1:1) o f  the evaporation residue gave the esicr
4 (620 mg, 81%) as laree white plates, mp 46-46.5  °C; d'H 2.09 
(2 H, quintet, J 7 Hz.~CH2C tf,C H :). 2.80 (2 H. t, J 7.6 Hz. 
pyrazole-CH2). 4.38 (2 H. t. J 6.1 Hz. CH20 ) ,  7.44 (2 H. br t. J 8 
Hz. Ph 3.5-H 2). 7.54 (1 H. s. pyrazole 5-H), 7.56 (1 H. br i. J 8 
Hz, Ph 4-H ), 8.03 (2 H. br d. j  S Hz. Ph 2.6-H 2);<5F -6 1 .3 0  (s): 
mb (C l) 299 (M + H. 100%). 176 (M -  P hC 02H. 48). 105 (29) 
(HRMS: found M + H \  299.1007. C MH l4F ,N 20 2 requires 
M + H*. 299.1007).
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Fig. 3 <5f-pH Relationships for 2-trifluoromethyl-3Af-imidazol[4.5-c]- 
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Fig. 4 A f-pH  Relationship for 3-trifluoromethylpyridine 25
3-Trifluoroacetyl-4,5-dihydrofuran 6
Trifluoroacetic anhydride (22.5 g, 107 mmol) was added drop- 
wise with cooling to 2,3-dihydrofuran 5 (5.00 g, 71 mmol) and 
pyridine (1.88 g, 24 mmol) in dichloromethane (40 cm3) and the 
mixture was stirred for 18 h. Distillation gave 3-trifluoroacetyl-
4.5-dihydrofuran 6 (9.72 g, 82%) as a colourless liquid, bpM 95- 
100 °C (lit.,* bp10 j 48.5 °C); SH 2.98 (2 H, tq, JH.H 9.8, yH_F 0.6 
Hz, 4-H ,). 4.68 (2 H, t. JH^  9.8 Hz, 5-H2), 7.64 (1 H. q, y„_F 1.5 
Hz. 2-H); Se -7 3 .8 8  (br s): Sc 26.93 (s, 4-C). 74.01 (s, 5-C), 
114.37 (s, 3-C), 116.62 (q. Jc_f 190 Hz, CF,), 163.84 (q. JC_F 5 
Hz, 2-C), 176.08 (q. Jc.r 36 Hz, C=0); m/r (El) 166 (M + H,
45%), 97 (M -  CF,, 100) (HRMS: found M + H \  166.0239. 
Q H sF ,0 , requires M + H \  166.0242).
2-{4,5-Dihydro-5-trifluoromethyl-5-l2-(3-trifluoroniethyI- 
1 //-pyrazol-4-y l)ethoxy ]-1 //-pyrazol-4-vl}ethanol 7
The furan 6 (1.0 g, 6.0 mmol) was heated under reflux with 
hydrazine hydrate (0.30 g, 6.0 mmol) in ethanol ( 13 cm 1) for 3 h. 
Evaporation o f  the solvent gave the title compound 1 (1.08 g, 
99%) as a white solid, mp 84-85 °C; !’„,„( N ujoiycm '1 3300, 
3180, 1170; <5„ 1.82 (1 H, m) and 1.93 (1 H, m) 
(dihydropyrazole-CH2), 2.79 (2 H, t, J 6.8 Hz, pyrazole-CH2), 
3.31 (1 H, br t, J 7 Hz, dihydropyrazole 4-H), 3.71 (2 H, t, J 6.8 
Hz, pyrazole-CH2C //20 ) , 3.73 (2 H, m, dihydropyrazoie- 
C H jC //2OH), 4.94 (3 H, 2 x NH + OH), 6.82 (1 H, s. dihydro­
pyrazole 3-H), 7.67 (I H. s. pyrazole 5-H); <5F -8 2 .5 7  (3 F, s, 
dihydropyrazole-CF,), -62 .20  (3 F, s, pyrazole-CF,); <5C 27.60 
(s, CH2), 28.36 (s. CH2), 49.49 (s, dihydropyrazole 4-C), 60.92 
(s. C H J, 62.95 (s, CH2), 92.93 (q, Jc.f 31 Hz, dihydropyrazole
5-C), 117.52 (s, pyrazole 4-C), 123.70 (q, Jc 268 Hz, CF,), 
125.68 (q, yc. F 281 Hz, CF,). 131.36 (s, CH), 140.95 (q, JC.F 37 
Hz, pyrazole 3-C), 146.30 (s, CH) (HRMS: found M + H*, 
361.1099. C . j H ^ N A  requires M + H*, 361.1099).
2-(3-Trifluoromethyl-l f/-pyrazol-4-yl)ethanol 8 
Compound 7 (1.00 g, 2.8 mmol) was heated under reflux with 
hydrochloric acid (9 m, 0.05 cmJ) in ethanol (12 cm3) for 16 h. 
The solvent and reagent were evaporated to give 2-(3- 
trifiuoromethyl-\ H-pyra:ol-4-vl)ethanol 8 (990 mg, 99%) as a 
pale yellow solid, mp 90-91 SC; <5H((CD,)2SO] 2.65 (2 H, br t, 
J 7 Hz, pyrazole-CH2), 3.54 (2 H, t, J 7 Hz. CH20 ), 4.9 (1 H, br. 
OH), 7.78 (1 H, br s, pyrazole 5-H); ^((CDj^SO ] -5 9 .6 6  (s); 
m / z  (El) 180(M ,30% ), 159 (M -  CH2OH, 100) (HRMS: found 
M, 180.0515. Q H 7F,NO requires M, 180.0510).
6-terr-Buty Idiphenylsilyloxy-1,1,1 -trifluorohex-3-yn-2-one 1 la  
Butyllithium (2.5 M in hexanes; 13 cm3, 32.4 mmol) was added 
to 4-/er/-butyldiphenylsilyloxybut-l-yne 10a10 (10.0 g, 32.4 
mmol) in THF (50 cm3) at -7 8  °C and the mixture was stirred 
at this temperature for 30 min. 2,2.2-Trifluoroethyl trifluoro­
acetate (7.00 g, 35.7 mmol) in THF (60 cm3) was added, 
followed immediately by boron trifluoride-diethyl ether (5.65 
g, 40 mmol), and the mixture was stirred at -7 8  °C for 90 
min. Saturated aqueous ammonium chloride (18 cm 3) was 
added and the mixture was allowed to warm to ambient 
temperature. The THF was evaporated and the residue, in 
diethyl ether, was washed with water and twice with brine 
and dried. Evaporation o f the solvent gave the ketone I la  
(12.43 g, 95%) as a colourless viscous oil; 1.06 (9 H. s, Bu'). 
2.72 (2 H, t, J 6.3 Hz, CH2O C ), 3.85 (2 H. t, J  6.3 Hz, 
CHjO), 1.1-1.1 (10 H, 2 x Ph-Hs); 6p -7 8 .6 3  (s) (HRM S: 
found M + H*, 405.1498. C22H24F ,0 2Si requires M + H*. 
405.1498).
6-Benzyloxy-l,l,l-trifluorohex-3-yn-2-one l ib
Butyllithium (2.5 m in hexanes: 18 cm3, 45 mmol) was added to
4-benzyloxybut-l-yne 10b" (7.2 g. 45 mmol) in THF (100 cm 3) 
at - 7 8  °C and the mixture was stirred at this temperature for 
30 min. 2,2,2-Trifiuoroethyl trifluoroacetate (9.7 g. 50 mmol) in 
TH F (70 cm3) was added, followed immediately by boron 
trifluoride-diethyl ether (8.5 g. 60 mmol) and the mixture was 
stirred at -7 8  °C for 90 min. Saturated aqueous ammonium  
chloride (30 cm3) was added and the mixture was allowed to 
warm to ambient temperature. The THF was evaporated and 
the residue, in dichloromethane, was washed with water and 
twice with brine and dried. Evaporation of the solvent gave the 
ketone 11b (11.13 g. 97%) as a pale yellow oil; SH 2.80 (2 H. t, 
J 6.6 Hz, C H jO C ). 3.69 (2 H. t. J 6.6 Hz. O C //2CH 2). 4.58 
(2 H, s, PhCHjO), 7.30-7.35 (5 H. m. Ph-Hs); <5F -7 8 .6 5  (s) 
(HRM S: found M -  H. 255.0633. C „H ,0F,O2 requires M -  H. 
255.0633).
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5-(2-re/7-Butyldiphetiylsilyk>xyethyI)-3-trifluorom€thyl-l//- 
pyrazole 12a
TTie ketone I la (378 mg. 0.93 mmol) was heated under reflux 
with hydrazine hydrate (73 mg, 0.93 mmol) in ethanol (2.2 cmJ) 
for 90 min. The evaporation residue, in dichloromethane, was 
dried and the solvent was evaporated to give the pyrazolc 12a 
(385 mg, 99%) as a colourless oil; SH 1.06 (9 H, s, Bu'). 2.88 (2 
H, t, J  5.7 Hz, pyrazole-CH2), 3.89 ( 2 H ,U  5.7 Hz, CH20), 
6.33 (1 H. s, pyrazole 4-H), 7.3-7.7 (10 H, m, 2x  Ph-Hs); 
6r -62.31 (s); 6C 19.01 (s, CMe,), 26.74 (s, 3 x CH,), 28.44 (s, 
pyrazo!e-CH2), 62.53 (s, CH20), 102.69 (s, pyrazole 4-C), 
121.44 (q, J c_p 268 Hz, CF3). 127.80 (s, 2 x Ph 3,5-Q), 129.89 
(s, 2 x Ph 4-C), 132.83 (s, 2 x Ph 1C), 135.41 (s, 2 x Ph 2,6-Q), 
142.87 (q, J  37 Hz. pyrazole 3-C), 143.28 (s, pyrazole 5-C) 
(HRMS: found M + H \ 419.1767. CjjH^FjNjOSi requires 
M + H*, 419.1767).
5-(2-Benzyloxyethyl)-3-trifluoromethyl-l H-pyrazole 12b 
The ketone 11b (500 mg, 1.95 mmol) was boiled under reflux 
with hydrazine hydrate (153 mg, 1.95 mmol) in ethanol (4.6 
cm1) for 1 h. The evaporation residue, in dichloromethane, was 
dried and the solvent was evaporated to give the pyrazole 12b 
(480 mg, 91%) as a pale ydlow oil; dH 2.91 (2 H, t, J  5.9 Hz, 
pyrazoleCH2), 3.68 (2 H ,t ,7 5.9 Hz,OC/ZjCHJ,4.51 (2 H, s. 
PhCH20), 6.33 (1 H, s, pyrazole 4-H), 1.2-1 A (5 H, m, Ph-Hs); 
6? -62.35 (s); 6C 25.96 (s, pyrazole-CHj), 68.31 (s, OCH^, 
73.21 (s, OCH2), 102.33 (s, pyrazole 4C), 121.46 (q, 268
Hz, CFj), 127.75 (s, Ph 2,6Cj), 127.91 (s, Ph 4C), 128.48 (s, Ph
3,5-Cj), 137.44 (s, Ph 1-Q, 142.66 (q, JCJf 39 Hz, pyrazole 3-C),
143.02 (s, pyrazole 5C) (HRMS: found M + H \ 271.1058. 
C„H14F,N20  requires M + H’, 271.1058).
2-(3-TrifluoromethyH //-pyrazoI-5-y l)ethanol 13
The benzyl protected compound 12b (320 mg, 1.2 mmol) and 
perchloric add (60% in water, 0.01 cm1) in methanol (4.0 cm1) 
and THF (1.0 cm1) were treated with hydrogen in the presence 
of palladium on charcoal (10%, 100 mg) for 70 min. The mix­
ture was Altered through Celite and the solvent was evaporated 
from the combined filtrate and methanol washings. Recrystal­
lisation of the residue from chloroform-ethanol gave 2-(3- 
irifluoromethyl-\H-pyrazol-5-yl)ethanol 13 (200 mg, 94%) as a 
white solid; mp 85-86 "C; <5„KCD,)jCO] 2.98 (2 H, dt, J  0.5,
5.7 Hz, pyrazole-CH,), 4.12 (2 H, t, J  5.7 Hz, CH20), 6.40 (1 H, 
br s, pyrazole 4-H); 6r -61.83 (br s) (HRMS: found M, 
180.0541. Q H 7F,N20  requires M, 180.0510. Found M -  
CH20 , 150.0436. CsH5FjN2 requires M -  CH20 , 150.0404).
3-Benzyloxypropyl toluene-p-sulfonate 15
3-Benzyloxypropanol 14 (7.61 g, 46 mmol) was stirred with 
powdered potassium hydroxide (2.60 g. 46 mmol) and toluene- 
p-sulfonyl chloride (8.73 g, 46 mmol) in dry diethyl ether (50 
cm1) for 6 h. Powdered potassium hydroxide (2.0 g, 36 mmol) 
was added and stirring continued for a further 2.5 h. The mix­
ture was filtered and the filtrate was washed twice with water 
and dried. The solvent was evaporated to give 3-benzyloxy- 
propvl toluene-p-sulfonate 15 (13.3 g, 91%) as white crystals, 
mp < 25 °C; S„ 1.88 (2 H, quintet, J 6.1 Hz, CH2C//2CH2), 2.45 
(3 H, s, CH,), 3.52 (2 H, t, J  6.0 Hz, BnOCH2), 4.19 (2 H, t, 
J  6.2 Hz, TsOCH2), 4.43 (2 H, s, PhCH,0), 7.25-7.35 (7 H, 
m, Ph-Hs + Tol 3,5-H2), 7.82 (2 H, d. J 8.3 Hz, Tol 2,6-H2); 
ml: (Cl) 321 (M + H, 17/u), 181 (9). 155 (10). 91 (100).
7V-(3-Benzyloxy propy Q-2,2,2-trifluoroacetamide 16 
Potassium rm-butoxide (770 mg, 6.9 mmol) was added to tri- 
fiuoroacetamide (780 mg, 6.9 mmol) in THF (20 cm1), followed 
by the tosylate 15 (2.0 g, 6.2 mmol) and sodium iodide (50 mg). 
The solution was stirred for 4 h and was then cooled to 0 °C. 
Diethyl ether (20 cm1) and water (10 cm1) were added and the 
mixture was acidified to pH 1 by addition of hydrochloric acid, 
the layers were separated and the organic phase was washed
twice with water and once with brine. The solution was dried 
and the solvent was evaporated to give the amide 16 (1.67 g ,
97%) as a pale yellow oil; r (liquid filmj/cm”1 3350, 1715,
I I70;<5h 1.87 (2 H, m, CHjC/ZjCHj), 3.50 (2 H, m. CH2N). 3.66 
(2 H, t, J  5.4 Hz, BnOCH2). 4.45 (2 H. s, PhCH20), 7.34 (5 H. 
m, Ph-Hs); 6f  -76.71 (s). This material was used immediately 
without further characterisation.
3-Benzyloxypropylamine 17
The amide 16 (1.60 g, 5.8 mmol) was heated under reflux with 
sodium hydroxide (1.00 g, 50 mmol) in methanol (40 cm1) for 4 
h. The solvent was evaporated. The residue, in diethyl ether, was 
washed with saturated aqueous sodium hydrogen carbonate 
and dried. The solvent was evaporated and the residue was dis­
tilled to give the primary amine 17 (630 mg, 66%) as a colour­
less liquid, bp0Ji 85-90 °C (lit..19 bp0.7S 93.5 °C); SH 1.43 (2 H. br. 
NH2), 1.75 (2 H, quintet, J  6.2 Hz, CH2C//2CH2), 2.82 (2 H. t*./
6.8 Hz, CHjN), 3.55 (2 H, t, J  6.2 Hz, BnOCH2), 4.51 (2 H. 
s, PhCHjO), 7.33 (5 H, m, Ph-Hs).
2.5-Bis(trifluoroniethyI)-l ,3,4-oxadiazole 19
l,2-Bis(trifluoroacetyl)hydrazine 18 (6.94 g, 31 mmol) was 
mixed intimately with phosphorus pentoxide (15 g) and the 
mixture was covered with a further layer of phosphorus pentox­
ide (10 g). The mixture was heated to 300 °C in a distillation 
apparatus and the volatile materials were condensed in a trap at 
-78 °C. The distillate was redistilled (Kugelrohr) from cal­
cium hydride to give the oxadiazole 18 (4.01 g, 74°/..) as a colour­
less liquid, bp 65 °C (lit.,14 bp 65 °C); SF -65.34 (s).
3.5-Bis(trifluoromethyl)-4-(3-benzyk>xypropyi)-4//-l,214- 
triazole 20
The oxadiazole 19 (371 mg, 1.8 mmol) was added dropwise to
3-benzyloxypropylamine 17 (300 mg, 1.8 mmol) in methanol 
(0.6 cm1) at 0 °C over 5 min. The mixture was heated under 
reflux for 9 d. Distillation gave the triazole 20 (270 mg. 42%) 
as a colourless liquid, bpo* 150-155 °C; dH 2.12 (2 H, m, 
CH2C//2CH2), 3.57 (2 H, t, J  5.5 Hz, BnOCH2), 4.38 (2 H. t, J
8.2 Hz, NCH2), 4.51 (2 H, s. PhCHaO), 7.30 (5 H, m. Ph-Hs); 
Sf  -62.80 (s) (HRMS: found M + H*, 354.1041. C14H,4F4N ,0  
requires M + H \ 354.1041).
3-{3,5-Bis(trifluoromethyI)-4//-l ,2,4-triazol-4-yl]propanol 21
The benzyloxypropyltriazole 20 (200 mg. 570 pmol) in ethanol 
(2.5 cm1) and perchloric acid (60% in water. 0.01 cm1) were 
stirred under an atmosphere of hydrogen with palladium on 
charcoal (10%, 30 mg) for 29 h. The catalyst was removed by 
filtration through Celite. Sodium hydrogen carbonate (1.0 e) was 
added to the combined filtrate and ethanol washings and the 
mixture was stirred for 1 h. The mixture was filtered and the 
solvent was evaporated from the filtrate to give the alcohol 21 
(140 mg, 94%) as a white solid, mp < 25 °C; dH(D20) 2.14 (2 H, 
m, CH2Ctf2CH2), 3.74 (2 H, t, J  5.8 Hz, CH20). 4.48 (2 H, t. 
J  7.9 Hz, NCHJ; 6P -63.49 (s) (HRMS: found M + H*. 
264.0720. C,H,F*N,0 requires M + H*, 264.0720).
2-Trifluoromethyl-3//-imidazol4,5-c]pyridine 23a
3,4-Diaminopyridine 22a (1.00 g, 9.2 mmol) was heated under 
reflux in trifluoroacetic acid (10 cm1) for 2 d. Evaporation of 
excess reagent and sublimation (200 °C, 0.1 Torr) gave 2- 
trifluoromethyl-3//-imidazo[4,5-c]pyridine 23a (1.71 g, 98*/.) 
as a white solid, mp 159-161 °C (lit.,20 mp 290-291 °C) (Found: 
C, 44.70; H, 2.12; N, 22.10. C ^ F jNj requires C. 44.93; H. 
2.15; N. 22.46%); d'„[(CD,)2SO] 7.98 (I H. d, J 6.6 Hz.
7-H), 8.27 (1 H, d, J  6.6 Hz, 6-H), 9.25 (1 H. s. 4-H). 14.2 
(1 H, br, NH); d'c[(CD,)2SO] 114.32 (s. 7-C). 120.91 (q, JC.P 
270 Hz. CF,), 129.42 (m, 2-C), 133.35 (s. 6-C). 142.15 (s.
4-C), 154.02 (br. Cq) (the signal for one quaternary carbon was 
not observed); dF[(CDj)2SO] —63.60 (s) (HRMS: found M. 
187.0364. C7H4F,Nj requires M . 187.0357).
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2-Trifluoromethyl-3//-imidazo[4,5-A]pyridine 23b
2,3-Diaminopyridine 22b (1.00 g, 9.2 mmol) was heated under 
reflux in trifluoroacetic acid (10 cm3) for 2 d. Evaporation of 
excess reagent and sublimation (200 °C, 0.1 Torr) gave 2- 
triJiuoromethyl-3H-intidazo[A,S-b]pyridine 23b (1.67 g, 97%) as 
a yellow solid, mp 240-241 °C; <5„[(CD,)2$0] 7.48 (1 H, dd, J
8.4.4.8 Hz, 6-H), 8.29(1 H, brd,y8.I Hz, 7-H), 8.59(1 H,dd, 
J  4.8,1.5 Hz, 5-H), 14.6(1 H, br, NH^cKCDjkSOl 119.07 (q,
271 Hz, CFj), 119.59 (br, 6,7-Cj), 142.73 (q, 44 Hz,
2-C), 145.76 (s, 5-C) (signals due to the quaternary carbons at 3a 
and 7a were not observed); ^[(CDj^SOJ -63.65 (s) (HRMS: 
found M, 187.0353. C,H4F}N, requires M, 187.0357).
5-FIuoro-2-trifluoromethyI-l//-benzimidazole 23c
4-Fluorobenzene-l,2-diamine 22c (1.00 g, 7.9 mmol) was 
heated under reflux in trifluoroacetic acid (10 cm3) for 5 d. 
Evaporation of excess reagent and sublimation (200 °C, 12 Torr) 
yielded 5-fluoro-2-trifluoromethyl-l//-benzimidazole 23c (1.56 
g, 95%) as a white solid, mp 174-175 #C (lit.,21 mp 219-220 °C) 
(Found: C, 46.80; H, 1.93; N, 13.50. C*H4F4N2 requires C, 
47.07; H, 1.98; N, 13.72%); ^[(C D ^O ] 7.28 (1 H, dt, J  9.2,
2.1 Hz, 6-H), 7.56(1 H,brd,78.9 Hz. 7-H), 7.79(1 H,tn,4-H),
14.2 (1 H, br, NH); ^ (CD^SO] -63.20 (s, CF,), -116.79 (br 
m, 5-F) (HRMS: found M \ 204.0321. QH4F4N2 requires M, 
204.0311).
2,5-Bis(trifiuoromethyl}-l //-benzimidazole 23d
4-(Trifluoromethyl)benzene-1,2-diamine 22d (1.00 g, 5.68 
mmol) was heated under reflux in trifluoroacetic acid (10 cm3) 
for 5 d. Evaporation of excess reagent and sublimation (150 °C, 
10 Torr) afforded 2,5-bis(trifluoromethyl)-l //-benzimidazole 
23d (1.24 g, 89%) as a white solid, mp 159-161 °C (lit.,22 198- 
199 °C) (Found: C, 42.60; H, 1.55; N, 11.10. C,H4F6N2 requires 
C, 42.54; H, 1.59; N, 11.02%); ^[(CDJjSO] 7.72 (1 H, dd, J
8.8.1.8 Hz, 6-H), 7.95 (1 H, d, J  8.4 Hz, 7-H), 8.16 (1 H, br s,
4-H), 14.3 (1 H, br, NH); ^(C D j^O ) -63.44 (s. 2-CF,), 
-59.72 (br s, 5-CF,) (HRMS: found M, 254.0254. C,H4F*N2 
requires M, 254.0279).
Studies on the effect of pH on ”F NMR chemical shift 
The heterocycles (ca. 2 mg) were dissolved in aqueous buffers 
(ca. 1 cm3) of various compositions and pHs. The WF NMR 
spectra of samples (0.6 cm3) were acquired using a JEOL 
EX400 spectrometer. An external reference (the CF3SOs signal 
in fluorotrichloromethane in deuteriochloroform) was used 
before and after each determination but no drift was noted. The 
chemical shifts were found to be independent of the com­
position of the inorganic buffers and independent of the con­
centrations of the buffers and irifluoromethylheierocycle in the 
range 100 to 400 mM for the buffer and 5 to 20 mM for the 
trifiuoromethyl heterocydes. The effect of temperature was 
insignificant in the range 25 to 37 °C, so spectra were recorded 
routinely at 25 °C. Each determination of 6f  was performed in 
triplicate for each pH value. The pHs of the solutions contain­
ing the test compound, the buffer and 5% D20  were measured 
immediately before the NMR experiments, using a pH meter 
with an electrode suitable for small volumes. 132K Data points 
were used in each NMR data acquisition to ensure high digital 
resolution (ca. 0.4 Hz per data point).
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MODULATION OF THE CYTOTOXIC ACTIVITY OF MURINE 
MACROPHAGES BY FLAVONES
WOJCIF.CH KROL1, ZENON P. CZUBA1, GRAZYNA PIETSZ1,
MICHAEL D. THREADGILL1, BERNADETTE D. M. CUNNINGHAM5
1 Department of Microbiology & Immunology, Silesian School of Medicine, 41-808 Zabnze-Rokitnica, Poland, 
2SchooI of Pharmacy & Pharmacology, University of Bath, Qaverton Down, Bath BA2 7AY, UK,
3Oncogene Science Incorporated, Uniondale, New York 1S333, USA
The effect of flavonoids (13 flavones and 2 isoflavones) on the production of nitrite and on luminol - dependent 
chemiluminescence by murine activated peritoneal macrophages (F4/80 positive) was studied in vitro. The accumu­
lated nitrite as a stable final product of nitric oxide (NO) was determined by the Griess reaction. Nitrite production 
was inhibited by flavonoids. 3*-Amino-4*-bydroxyflavone and 3-faydroxyflavone were the most potent inhibitors of ni­
trite production. These compounds also inhibited chemiluminescence. Chemfluminescence was used in this study as an 
indicator for production of reactive oxygen species (ROIs) by macrophages. These data suggested a causative connec­
tion between NO and ROIs production in macrophages. Also these results show that the flavones can modulate the 
immune responses and the inflammatory reactions by controlling production of NO.
INTRODUCTION
The production o f reactive oxygen (ROIs) and re­
active oxynitrogen (RONIs) intermediates by 
macrophages is critical to host defence. Upon 
stimulation with both soluble and particulate mat­
ter, oxidative metabolism is stimulated in 
the macrophage resulting in the respiratory burst 
which is accompanied by activation o f
an NADPH-oxidising enzyme. This enzyme ca­
talyses the reduction o f molecular oxygen to su­
peroxide anion ( O J ) and the burst is paralleled by 
consumption of oxygen. OJ is the precursor o f  
other ROIs, including hydrogen peroxide (H2 O2) 
and the hydroxyl radical (HO ). Oxidation of cellu­
lar molecules by ROIs contributes to killing of 
phagocytized microbes and can cause severe tox­
icity to cancer cells (Fridovich, 1986). Until 1987, 
the only inducible biochemical mechanism that 
could explain activated macrophage cytotoxicity 
was the synthesis of ROIs by NADPH oxidase. 
Subsequently, the production of nitric oxide (*NO) 
from L-arginine by an immune/ inflammatory iso­
form nitric oxide synthase (iNOS) was described 
by Hibbs, Vavrin and Taintor (1987a, 1987b). 
Biosynthesis o f NO may lead to the production o f  
other RONIs, including nitrosonium (NO+) and
nitroxyl (NO") ions, nitrogen dioxide (NO2 ), per- 
oxynitrite (ONOO“), and S-nitrosothiols (Stamler, 
Singel & Loscalzo, 1992). RONIs kill some cancer 
cells and are the ultimate effector molecules in the 
host defence against many intracellular pathogens, 
such as Toxoplasma gondii, Leishmaniay and My­
cobacterium tuberculosis and extracellular patho­
gens, such as Cryptococcus neoformans and 
Schistosoma mansoni.
However, both ROIs and RONIs are potentially 
toxic to the host making regulation o f the produc­
tion o f these highly reactive molecules o f utmost 
importance to host survival. NO, OJ and its in­
termediates produced by activated phagocytes may 
play an important role in the multistage carcino­
genesis process, triggered by chronic infection and 
inflammation. Inoue and Kawanishki (1995) sug­
gest that NO reacts with O J to form ONOCf and 
the ONOO" induces oxidative DNA damage 
through an active intermediate o f the reactivity 
which is similar to HO'. Our earlier studies have 
shown that functions o f activated macrophages can 
be regulated by flavones (2-phenyl-4//- 1-benzopy- 
ran-4-ones) (Middleton & Kandaswami, 1992). 
Flavones are a group of naturally occurring com­
pounds, widely distributed as secondary metabo­
lites in the plant kingdom. They have been ac-
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knowledgcd as having interesting medicinal prop­
erties, such as antiinflammatory, antiallergic, an­
tiviral, antibacterial, and antitumour activities 
(Havesteen, 1983). Flavones have also been 
the scavengers o f free radicals and act as natural 
antioxidants. They have also been shown to inhibit 
oxido-reductase, thus preventing the formation o f  
free radicals resulting from the reduction of oxy­
gen. These two mechanisms can account for the 
role of many flavones in protecting cells from oxi­
dative damage (Krol, Czuba & Scheller, 1986).
The present study was-aimed to investigation of 
the role o f flavones in the regulation o f RONIs and 
RONIs release from activated murine macro­
phages. Chemiluminescence was used in this study 
as an indicator for the productions o f ROIs by 
macrophages stimulated by PMA as stimulant for 
oxygen metabolism through the activation o f pro­
tein kinase C (PKC). RONIs release from activated 
macrophages was determined by nitrite as a stable 
end product o f *NO.
MATERIAL AND METHODS
MU c
Specific pathogen-free 8- to 10-week old 
BALB/c male mice were purchased from the Insti­
tute of Oncology, Gliwice, Poland.
Reagents
Flavone, 4 ’-aminoflavone, 3 ’-amino-4 ’-hydro­
xy fl a vone, and 3 ’-amino-4 ’-methoxyflavone were 
synthesised as previously described (Cunningham, 
Threadgill, Groundwater, Dale & Hickman, 1992; 
Krol, Czuba, Threadgill, Cunningham & Shani, 
1995a). Flavone-8-acetic acid (FAA) was obtained 
from the Drug Synthesis and Chemistry Branch, 
Division of Cancer Treatment, National Cancer 
Institute, USA, through the courtesy o f Dr. K. 
Pauli. 4 ’-amino-6-hydroxyflavone, daidzein, ge- 
nistein, lipopolysaccharide (LPS) from £. coli 
(serotype 0127 : B8), Concanavalin A (Con A), 
N°-monomethyl-L-arginine monoacetate salt 
(NCjMMA), superoxide dismutase (SOD) from 
human placental (4750 U/mg) were purchased 
from Calbiochem (La Jolla, CA, USA). 3-Hydro- 
xyflavone and other flavones were purchased from 
Roth Chem. (Karlsruhe, Germany). Hanks’ bal­
anced salt solution (HBSS) without phenol red, 
phosphate-buffered saline solution (PBS), RPMI 
16*40 medium without phenol red, and heat- 
inactivated fetal calf serum (FCS) low in endo­
toxin, penicillin -  streptomycin (10 000 IU/ml -  
10 000 pg/ml) were purchased from GIBCO BRL
Life Technologies Ltd. (Paisley, UK). Neutral red 
solution (0.5% aqueous solution o f  the sodium 
salt), N-(l-naphthyl)-ethylenediamine dihydro­
chloride, sulphanilamide and heparin sodium 
(pyrogen free) were purchased from Serva Chemi­
cals (Heidelberg, Germany). Phorbol myristate 
acetate (PMA), kit for a-naphthyl acetate esterase 
determination- and dimethylsulphoxide (DMSO) 
were purchased from Sigma Chemical Company 
(St. Louis, MO, USA). Luminol (5-amino-2,3- 
dihydrophthalazine-l,4-dione) was bought from 
LKB (Turku, Finland). The monoclonal antibody 
(mAb) anti-mouse Thy-1,2 fluorescein conjugate 
was purchased from Becton Dickinson Systems 
(Mountain View, CA, USA). The mAb F4/80 anti­
mouse macrophages fluorescein conjugate was 
purchased from SEROTEC Ltd. (Oxford, UK). 
Fluid thioglycolate medium was purchased from 
DIFCO Lab. (Detroit, MI, USA).
Collection and cultivation o f  mouse peritoneal ex­
udate macrophages
Macrophages were obtained from mice given an
i.p. injection o f  sterile thioglycolate broth (1 ml) 
4d prior to harvest and the solution o f  Con A 
(100 jig/ml) in PBS (1 ml) 18 h prior to harvest 
Mice were sacrificed by cervical dislocation, and 
cells were collected by washing the peritoneum 
with PBS (5ml). The macrophages populations 
were enriched by adherence to plastic or glass 
24-well plates (Falcon Becton Dickinson, Lincoln 
Park, NJ, USA) (nitrite assay), 16-well TC cham­
ber slides (Nunc, Roskilde, Denmark) (morpho­
logical study o f macrophages) or test tubes 
(chemiluminescence) with calculated 106 macro­
phages per well or tube. Non-adherent cells were 
removed after 2 h o f incubation in RPMI 
1640 without phenol red, supplemented with 10% 
FCS, penicillin (100 U/ml) and streptomycin 
(100 pg/ml) (culture medium) at 37°C in a hu­
midified atmosphere o f  5% C 02 in air. The adher­
ent population cells were assessed by May- 
Griinwald/Giemsa staining and biochemical crite­
ria whereas immunological specificity (mAbs to 
mouse leukocyte differentiation antigens) by fluo­
rescence microscopy.
Nitrite assay
The accumulated nitrite as a stable end product 
o f NO was determined colorimetrically by a dia- 
zotization reaction using the standard Griess rea­
gent (Green, Wagner, Glogowski, Skipper, Wish- 
nak & Tannenbaum, 1982), as described in detail 
previously (Krol, Czuba, Thredgill, Cunningham 
& Pietsz, 1995a) after 48 h culture o f macrophages
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in the absence or presence o f various flavonoids, 
SOD, NCMMA in the presence o f LPS. The absor­
bance o f culture medium and Griess reagent at 
550 nm was determined with automated mi­
croplate reader ELx 800 (Bio-Tek Instruments 
Inc., Winooski, VT, USA). Nitrite content was 
determined by using sodium nitrite as standard. 
Data were expressed as nmol nitrite per 106 cells 
originally plated. In all experiments, the nitrite 
content in wells containing medium without cells 
was measured and subtracted.
Chemiluminescence 
Chemiluminescence was measured as described 
previously (Krol, Czuba, Scheller, Gabrys, Gra- 
biec & Shani, 1990; Czuba, Krol, Scheller & 
Shani, 1992) using a special low noise-count rate 
photomultiplier 9514s (EMI, Middlesex, UK). 
The sample volume was usually 1 ml. The reac­
tions were initiated by dispensing aliquots of solu­
tions o f iuminol (100 pM) to macrophages (106) 
and tested compounds in HBSS in glass test tubes. 
The resting intensity of chemiluminescence was 
recorded after 5 min. PMA solution was then 
added to give a final concentration o f 0.8 pM. 
The light emitted was then recorded continuously 
for 20 min.
RESULTS
The adherent cells populations contained >98%  
macrophages as assessed by May-Grunwald/Gie- 
msa staining and biochemical criteria (nonspecific 
esterase staining), > 98% F4/80-positive, and < 2% 
T-lymphocytes by fluorescence microscopy after 
fluorescent antibody labelling with anti Thy-1,2 
mAb. More than 98% of the cells were viable as 
determined by exclusion o f neutral red, also after
incubation with all reagents.
Con A-stimulated macrophages produced 
L-arginine-dependent NO in the presence o f LPS 
(100 ng/ml). The production o f nitrite as a stable 
final product o f NO was 44.2 ±  1.0 nmol/106 cells 
after 48 h. N°MMA (300 pM) inhibited nitrite 
production by 87 ± 2% (Table 1) SOD (200 U) 
also decreased the production o f nitrite. In an other 
experiment, upon addition o f PMA (0.8 pM), 
macrophages luminol-dependent chemilumines­
cence increased 25 times over baseline light emis­
sion, reaching the maximum about 9 min after 
addition o f the stimuli. The NOS inhibitor, 
N°MMA (300 pM) plus SOD, significantly dimin­
ished route and peak intensities o f  PMA- 
stimulated macrophages chemiluminescence 
(85 ±1%) (Table 1).
In the next experiment, the flavonoids were in­
vestigated for their involvement in release o f  NO 
from Con A and LPS^rctzvated macrophages. The 
structures o f the flavonoids used in this work are 
shown in Table 2. Concentrations o f the flavonoids 
in the range 10-50 pM reduced the production of 
nitrite (Table 3). 3-Hydroxyflavone and 3’-amino- 
4’-hydroxyflavone were the most potent inhibitors. 
Genistein, an isoflavone that inhibits tyrosine- 
specific protein kinases, and daidzein, an isofla­
vone analogue that is inactive against these tyro­
sine kinases, also significantly decreased the pro­
duction o f nitrite.
Hence, inhibition o f  production o f nitrite is un­
likely to be due to toxicity o f the compounds. 
Additionally, the flavones and isoflavones had no 
quenching effect on the Griess reagent at the con­
centration used.
The purpose o f  the present study was also to 
evaluate quantitatively the activity o f flavonoids 
on the chemiluminescent activity o f PMA-stimu- 
lated macrophages.
Table 1
Inhibitory effects of the superoxide dismutase and of N°-monomethyl-L-arginine on the nitrite and 
luminol-dependent chemiluminescence production by murine macrophages
Inhibition (%)
Inhibitor NOJ production3 CL production*
SOD (200 U) 10± 1 81 ± 1
N°MMA (300 pM) 87 ±2 45 ± 1
SOD (200 U) + N°MMA <300 pM) 88 ± 2 85 ± 1
* Nitrite concentrations in the culture medium were measured after 48 h. Macrophages were incubated with LPS 
(100 ng/ml) in the presence of the inhibitors. Concentration of nitrite (nmol/106 cells, mean ± SO of three wells from 
three independent experiments) produced by control macrophages were 44.2 ± 1.0.
k The intensity of CL was determined by measuring counts/min and by calculating the area under CL intensity 
curve (integral counts). The rates of CL produced by 1 * 10* macrophages for 20 min is the absence of the inhibitors 
were 85000 ± 2000 (integral counts). Results are expressed as mean ± SD. n = 2-4.
Table 2
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noid name 3 5 6 7 8 3' 4'
1 Flavone H H H H H H H
2 3-Hydroxyflavone OH H H H H H H
3 Flavone-8-acetic acid H H H H CH3C02H H H
4 4 ,-Aminoflavone H H H H H H n h 2
5 3 ’-Amino-4 '-hydroxyflavone H H H H H NH2 OH
6 3 '-Amino-4 ’-metoxyflavone H H H H H NH2 OCHj
7 4’-Amino-6-hydroxyflavone H H OH H H H n h 2
8 Chrysin H OH H OH H H H
9 Galangin OH OH H OH H H H
10 Genkwanin H OH H OCHj H H OH
11 Kaempferol OH OH H OH H H OH
12 Kaempferide OH OH H OH H H OCHj












14 Daidzein H OH OH
15 Genistein OH OH OH
The level o f inhibition o f all fourteen com­
pounds tested is presented in Table 4. 3-Hydroxy- 
flavones (3-hydroxyflavone, galangin, kaempferol, 
kaempferide and quercetin) and 3’-amino-4’- 
hydroxyflavone were the most potent inhibitors. 
PMA-stimulated production of chemiluminescence 
was enhanced to a small but statistically insignifi­
cant extent in the presence o f low (10 pM) concen­
trations o f  4 ’-aminoflavone and 3 ’-amino-4’- 
methoxyflavone. However, PMA-stimulated pro­
duction o f chemiluminescence was progressively 
inhibited in the presence of increasing concentra­
tions o f these agents.
DISCUSSION
The toxicity of NO is primarily determined in the 
presence o f  H20 2 rather than OJ - This synergism 
may have important implications for the under­
standing o f the pathophysiology o f  sepsis, reper­
fusion injury and shock. Locally disregulated pro­
ductions o f  either species (e.g. after the exposure 
o f cytokines) may be fatal when are produced to­
gether, but regulate normal cellular functions when 
acting scparatly. A second possible explanation 
may arise from a regulated coproduction when 
cytotoxicity is required. Macrophages are capable
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1 2 ±  1 3 ±  1 75 ±  10
2 ND 96 ± 1 ND
3 -1 ± 1 3 ± 2 9 ± 4
4 49 ± 1 66 ± 1 86 ± 3
5 30 ± 4 89 ±3 ND
6 3±1 23 ± 1 S3 ± 7
7 3 ± 1 ND 86 ± 2
8 3±1 86 ± 1 80 ± 3
9 15±2 27 ± 3 ND
10 42 ± 3 67 ± 8 ND
11 22±5 70 ± 2 ND
12 22± 6 80 ± 6 ND
13 4± 1 2 ±  1 33 ± 2 0
14 ND ND 97 ± 2
15 ND ND 57 ± 9
Macrophages were incubated with LPS (100 ng/ml), without flavonoids or with flavonoids, for 48 h. Concentration of nitrite 
(nmol 10* cells, mean ± SD of three wells from three independent experiments) produced by control macrophages were 42.8 ± S.9. 
NO: not determined.
Table 4




1 11 ±5 63 ±1 79 ± 2
2 91 ±2 99±  1 100
3 -12 ± 4 -14 ± 6 —19 ± 6
4 —4 ± 1 74 ± 4 78 ± 3
5 . 86 ± 1 98 ± 1 100
6 -4  ± 2 55 ± 2 82 ± 8
7 41 ±2 ND 43 ± 3
8 49 ±9 96 ± 1 98 ± 1
9 92 ±1 99± 1 100
10 30 ±7 32 ±8 37 ± 9
11 93 ±1 100 100
12 95 ±1 100 100
13 98 ± 1 100 100
14 29 ±4 86 ± 1 88 ± 1
15 56 ±10 88 ±1 90 ± 1
‘The rates of CL produced by 1*10* macrophages for 20 min is the absence of flavonoids were 85000 ± 2000 (integral counts). 
A negative value indicates stimulation. Results are expressed as mean ± SO, n = 3-5.
NO: not determined.
o f secreting an array of cytotoxic products that in­
clude ROIs and RONIs.
The adherent populations from mouse peritoneal 
cavities were used as macrophage models in this 
study. Thioglycollate -  elicited peritoneal macro­
phages from BALB/c mice released significant 
amounts o f nitrite upon stimulation with Con A (/#» 
vitro) and LPS (in vitro). This model for activation
o f macrophages has been reported in our previous 
study (Krol et al., 1995a).
Thioglycollate elicited and Con A  + LPS -  
primed macrophages express cytostatic activity 
against P815 tumour cells, and release interleukin- 
6 and tumour necrosis factor-a. Similarly, acti­
vated macrophages secrete o f  ROIs (Krol et al., 
1995b)
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We have shown here that flavones and isoflavo- 
nes inhibit production of nitrite, a chemical prod­
uct o f NO. These compounds also inhibit luminol- 
dependent chemiluminescence. The cellular 
mechanism o f the effects are not clear, but may by 
related to known biological effects o f the flavones, 
such as antioxidant and antiradical properties 
(Robak & Gryglewski, 1988; Cotelle, Bernier, 
Catteau, Pommery, Wallet & Gaydon, 1996), in­
hibition o f oxido-reductases (Tauber, Fay & Mar­
ietta, 1984) and inhibition o f cellular enzymes in­
volved in a signal transduction (Cunningham et 
al., 1992; Cushman, Zhu, Geahlen & Kraker, 
1994). 3’-Amino-4 ’-hydroxyflavone and 3-hydro- 
xyflavone was the most potent inhibitors o f NO 
production in murine macrophages and were 
evaluated for inhibition o f the generation o f ROIs 
by macrophages. In a previous study from this 
laboratory we demonstrated that the flavonols 
(3-hydroxyflavone derivatives) also was the most 
decreased neutrophil chemiluminescence (Krol, 
Shani, Czuba & Scheller, 1992; Krol, Czuba, 
Scheller, Paradowski & Shani, 1994). Interest­
ingly, the concentration o f release o f  NO by the 
macrophages closely match these values. These 
data strongly suggest that production o f NO is 
a major controlling factor in generation o f chemi­
luminescence upon activation o f the macrophages. 
Also these results show that the flavones can 
modulate the immune responses and the inflamma­
tory reactions by controlling productions o f NO.
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Abstract
The potential of macromolecular pro-drugs in drug delivery and diagnostic imaging lies in their ability to modify 
the pharmacokinetic distribution of low molecular weight drugs or diagnostic agents. At a simple level this may 
provide a means of sustaining release of drug from a soluble macromolecule which is retained in the circulation, 
perhaps avoiding distribution of active drug to a toxicity compartment in the process. There is greater potential in 
applications which make use of the intrinsic biodistribution of inert macromolecules, in relation to their 
hydrodynamic radius and net charge. Long circulating macromolecular systems may have advantages in magnetic 
resonance imaging of the blood circulation and diagnosis of damaged or inflamed tissue?, which may take up the 
macromolecule to a greater extent than normal tissues. A related technology is developing based on the concept 
that circulating macromolecules accumulate passively in tumours, due to enhanced endothelial permeability and 
retention of the macromolecule due to poor lymphatic drainage. A secondary advantage potentially could be gained 
by targeting macromolecules to specific cells by receptor-mediated endocytosis, and designing systems which are 
degraded by lysosomal enzymes to release active drug in the target cell. The drawbacks of macromolecules are their 
limited penetration into tissues and the relatively slow rates of internalisation by endocytosis, which have 
discouraged drug delivery scientists in the recent past. Yet this field is still in its infancy. The tissue distribution of 
macromolecules with regard to polymer chemistry, molecular weight and charge are not yet fully understood, and 
advances in this field will depend on the synthesis of well-defined polymers, and careful characterisation of their 
properties. Here we review the rationale for the use of macromolecules in chemotherapy, the susceptibility of 
macromolecular pro-drugs to lysosomal degradation, developments in synthetic approaches within the field, and 
discuss how macromolecular pro-drug chemistry affects their biological properties. We pay particular attention to 
the rationale for their use in magnetic resonance imaging and the selection of MRI contrast agents for coupling to 
polymers.
Keywords: Tumor targeting; Lysosomal degradation; Biodistribution; Polysaccharide; Poly(amino acid); Water- 
soluble polyacrylate; Poly(ethylene glycol); Chelating agent; Paramagnetic ion
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Targeted systems may be of benefit for both 
therapeutic and diagnostic applications.
The macromolecule itself should be non-toxic 
and non-immunogenic and should be easily man­
ipulated for chemical reactivity. Originally, the 
macromolecules used for such purposes were 
naturally occurring; for example D N A  [3], al­
bumin [4] and dextran [5]. However, synthetic 
polymers, which have been previously used as 
plasma expanders, are now more commonly 
used. Targeting groups can be easily attached to 
such polymers either to increase non-specific 
cellular interactions [6] or to exploit receptor 
interactions to elicit a specific effect [7]. Drug 
molecules can either be attached to the polymer 
via a non-degradable spacer or by degradable 
linkages [8].
1. Introduction
The general model of a macromolecular pro- 
drug, first proposed by Ringsdorf in 1975 [1,2] is 
represented in Fig. 1. The strategy of coupling a 
drug of low molecular weight to a macromole­
cule, may result in one or both of the following 
advantages. Firstly, a controlled release system 
may be achieved and, secondly, by passive or 
active means, a targeted system can be designed.
ixuc fJKUC bRUG
Fig. 1.
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Attachment of a drug to a macromolecule is of 
particular interest as a therapy for cancer. 
Macromolecules are known to accumulate pas­
sively within solid tumours, giving a first level of 
targeting (9). Once a drug is attached to a 
macromolecule, it can no longer enter a cell by 
diffusion and must enter by endocytosis which is 
often enhanced in tumour cells. This advantage 
can be enhanced by incorporation of specific 
ligands to produce a second level of receptor- 
mediated targeting. When access to the cell is 
limited to receptor-mediated endocytosis, 
‘lysosomotropic drugs’ potentially can be de­
signed such that release of drug only occurs 
within the lysosomes, thereby conferring a high 
level of specificity [3].
The disadvantage of such systems lies in the 
limited penetration of tissues by macromolecules, 
and their slow rate of cellular internalisation. 
Improvements in the design of macromolecular 
pro-drugs are required to optimise their pharma­
cokinetic distribution, and our understanding of 
their activity in vivo will be greatly enhanced 
when they are more clearly defined chemically 
and better characterised. We do not consider in 
detail here the large field of antibody-mediated 
targeting. Antibodies have frequently been cou­
pled to water-soluble macromolecular pro-drugs 
but a comprehensive survey of this field is 
beyond the scope of this review. Here we focus 
on the chemistry of macromolecular pro-drugs, 
discuss how their chemistry influences their phar­
maceutical properties and fate in vivo and pay 
particular attention to the design of contrast 
agents for magnetic resonance imaging (MRI). 
We believe that macromolecules have consider­
able potential as MRI contrast agents and the 
information gained by imaging will in turn help 
our understanding of macromolecular access to 
individual tissues, and aid the design of systems 
for therapeutic uses.
2. Uptake of macromolecules into tumours
2.1. Introduction
Many investigators, have demonstrated an 
increased uptake of macromolecules into tumour 
cells [10-13]. Originally, this was thought to be
due to an increase in the rate of constitutive 
pinocytosis in tumour cells [10]. However, more 
recent studies have suggested that the increased 
uptake may be due to an ‘Enhanced Permeation 
and Retention Effect’ (EPR effect) [9].
Matsumura and Maeda [9] investigated the 
accumulation in tumours of a series of radioac­
tive macromolecules and Evans’ blue, a dye. The 
uptake of a range of polymers of molecular mass 
12000-150000 Da was investigated in tumour- 
bearing mice with respect to the plasma clear­
ance time and the time to reach a fixed gradient 
(5:1) between the tumour and plasma. Macro- 
molecules of above 16000 Da accumulated in the 
tumours, all reaching the desired ratio. However, 
it was apparent from the data that the ideal 
range for the macromolecules was between 
15000 and 70000 Da. The investigators proposed 
that the accumulation was due to four properties 
of tumour tissues; increased angiogenesis, en­
hanced vascular permeability, limited macro­
molecular recovery via post-capillary venules and 
lack of functioning lymphatic systems [9]. The 
rate of angiogenesis in some tumour tissues is 
greatly increased [11,12] and tumour growth is 
frequently dependent on the development of a 
new functioning vascular system. To achieve this 
increased growth, tumours secrete a range of 
angiogenic factors, such as the polypeptide an- 
giogenin [9,14,15] These factors either act direct­
ly on the dividing cells or stimulate the release of 
endothelial growth factors from other cells. The 
increased number of blood vessels can be easily 
demonstrated using angiography [9].
2.2. Enhanced vascular permeability
Five types of molecular movement through 
endothelium have been described [13]:
1. Simple passive diffusion of the molecule ac­
ross the cell
2. Lateral diffusion of the molecule in the cell 
membrane allowing transport around the cell and 
across the barrier
3. Passage through inter-endothelial cell junc­
tions
4. Passage through endothelial gaps, i.e., fenes- 
trae or sinusoids
5. Vesicular transport
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The first two mechanisms can be discounted 
when considering the transport of macromole­
cules, although they are the main methods of 
transport for small solutes. All of the other 
mechanisms are involved in the transport of 
macromolecules. The majority of transport is 
thought to be based on the formation of water 
filled pores at the endothelial junctions [13]. The 
role of vesicles in transport is more widely 
disputed [11,13]. Vesicular transport can take two 
forms; the uptake of a  macromolecule into a 
vesicle followed by transport across the cyto­
plasm and release or linkage of vesicles to form a 
transient pore across the cell. The importance of 
the first method is questionable; some workers 
have suggested it to be the major method of 
transport of macromolecules, whereas others feel 
its role is minimal The latter hypothesis is sup­
ported by the observations of no change in the 
rate of transport at reduced temperature where 
vesicular transport is known to be abolished 
[11,13].
The transport of macromolecules can be af­
fected by both their size and charge. Measure­
ment of the glomerular filtration rate, an exam­
ple of endothelial transport, has demonstrated 
that the hydrodynamic radius of a macromole­
cule is a more accurate description of the ten­
dency to be transported than is molecular weight 
[11]. Hence, albumin, a natural macromolecule, 
has a small radius, due to strong hydrogen 
bonding, and therefore a large renal threshold, 
whereas a hydrophobic synthetic polymer with 
few intramolecular bonds, such as HPMA, ex­
hibits a different renal threshold. The charge of a 
macromolecule can also affect the transport 
across endothelial cells. The endothelial surface 
exhibits a net negative charge and experiments 
with albumin have shown that cationic albumin is 
three times more permeable than neutral al­
bumin. This phenomenon is clearly demonstrated 
in fenestrated endothelia particularly in the renal 
glomerulus. Most tumours are epithelial and 
have vasculature with properties different from 
normal tissue. The endothelium in all but a few 
cases is continuous having tight endothelial junc­
tions and an intact basement membrane, unlike 
inflammatory tissue. However as accumulation of 
macromolecules occurs, the endothelium must be
more permeable than normal continuous endo­
thelium [11]. In a very few tumours, angiogenesis 
is altered, the new blood vessels produced being 
composed only of endothelial cells, whereas most 
vessels also contain pericytes. Pericytes are 
thought to be involved in the maturation of 
vessels and it has been postulated that lack of 
pericytes can lead to incomplete basement mem­
branes. This alteration in basement membrane 
could lead to a non-specific ‘leakiness’ o f cells, 
allowing accumulation of macromolecules. How­
ever, in the majority of cases, no morphological 
differences in the blood vessels can be observed. 
This has lead to the hypothesis that tumour cells 
secrete factors which alter the permeability of 
endothelium to macromolecules.
Senger et al. [15] have investigated the uptake 
of labelled human serum albumin and colloidal 
carbon in tumour bearing guinea pigs. Accumu­
lation was demonstrated in the regions around 
the tumour and within the tumour. Analysis of 
the ascitic fluid from the animals and tissue 
culture experiments allowed the isolation of a 
protein, which has been called the vascular 
permeability mediator (VPM). The isolated fac­
tor caused increased permeability in cutaneous 
tissues without causing endothelial cell damage 
[11]. This protein of between 34000 and 42000 
Da has been isolated from a range of tumour 
cells [16], These workers have suggested that this 
factor is released to allow the passage o f fibrin 
into the interstitium to allow coagulation, which 
is beneficial to tumour growth and angiogenesis 
[17], A  second factor, bradykinin, has also been 
investigated as a promoter of tumour permeabili­
ty [13]. Increased concentrations of both brady­
kinin and Hyp3-bradykinin have been found in 
numerous tumour types including stomach, pan­
creas and ovarian cancer [13]. Bradykinin is 
known to have both permeability and pain-in­
ducing properties but it also is involved in the 
activation of phospholipase A 2, leading to the 
formation of another permeability factor, prosta­
glandin E 2. Other permeability factors have been 
investigated. Obvious candidates are the leuko- 
trienes, which have been found in increased 
levels in most inflamed tissue but not, as yet, in 
tumour cells. Other potential permeability en­
hancers include tumour necrosis factor (TNF),
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platelet derived growth factor (PDGF), 
serotonin, interleukin 2 and leukokinin [16].
2.3. Macromolecular recycling and accumulation 
in tumours
Once molecules are present in the interstitium, 
they can be taken into cells o f the organ or 
passed back into the blood stream. Small mole­
cules generally pass easily into the blood stream 
via the post-capillary venules, as described ear­
lier. The endothelial cells of these contain slight­
ly enlarged inter-endothelial junctions. However, 
these spaces are too small for the passage of 
macromolecules. Natural macromolecules [11- 
13,16] pass into lymph capillaries, which are 
formed from capillaries but have very large 
endothelial spaces. Lymphatic capillaries form a 
circulation allowing the movement of macromol­
ecules away from an organ. The macromolecules 
are eventually passed from the lymphatic system 
into the thoracic duct which empties into the 
blood stream via the sub-clavian vein [9,11]. 
Macromolecules of lipid nature are particularly 
attracted into the lymphatic system. Experiments 
involving Lipiodoi, an iodinated derivative of 
poppy seed oil, have shown that it is selectively 
taken into lymphatics and ‘recycled’ via the 
lymphatic system. However when Lipiodoi was 
injected into a tumour-feeding artery [18] it was 
accumulated in the tumour. This suggests that 
tumours have little lymphatic drainage. This 
proposal has been confirmed by imaging experi­
ments which have shown little lymphatic de­
velopment in tumours [9,11]. Macromolecules in 
tumour tissues can therefore only escape by 
slowly diffusing through the tumour mass to the 
surface where they can be recovered by the 
well-developed lymphatic system o f surrounding 
organs. This transport is minimal, as macromole­
cules are too large to diffuse rapidly [19]. The 
macromolecule accumulates and a depot of 
‘drug’ is formed. This combination of enhanced 
permeability and lack of lymphatic drainage 
results in an highly effective ‘passive’ targeting of 
macromolecules and hence macromolecular pro- 
drugs to tumour cells.
2.4. Modulation o f  the enhanced permeability 
and retention (EPR) effect
Following the identification of the EPR effect, 
Maeda and colleagues have investigated ways of 
manipulating the properties which lead to en­
hanced uptake to allow even more effective 
chemotherapy using macromolecular pro-drugs. 
Bradykinin exhibits an effect on the vascular 
permeability either directly or through 
prostaglandin-E2 [13]. It is formed by the action 
of kaUikrein on kininogen and is continually 
broken down by kinase I a n d ll enzymes (Fig. 2). 
Inhibition of kinases I and II will lead to in­
creased concentrations of bradykinin and hence 
to increased vascular permeability. These en­
zymes are inhibited by inhibitors of angiotensin- 
converting enzymes (ACE), e.g., captopril and 
enalapril [12]. Concurrent administration of an 
inhibitor with a macromolecule would lead to 
enhanced uptake of the macromolecule into the 
tumour, whilst normal tissue would remain unaf­
fected as the kinin cascade would not be in 
operation. Investigations on the uptake of la­
belled albumin into a mouse ascitic tumour in the 
presence of such an inhibitor (10 mg k g '1 
enalapril) showed a 50% increase [12].
In a few tumours, this exploitation could prove 
disastrous, as macromolecular influx also results 
in fluid accumulation which can be difficult to 
control. In these cases, administration of soy­
bean trypsin inhibitor, which halts the cascade, 
would be more beneficial [12]. Several tumours 
have a hypervasculature allowing increased 
blood flow to the tumour. These blood vessels 
have been shown to be unaffected by angiotensin
II. This is thought to be due to a lack of 
contractile smooth muscle in the blood vessels
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rather than to a lack of receptors for angiotensin 
II (13). Thus, if a hypotensive state were to be 
produced in a patient, the junctions between the 
endothelium would be tightened and less passage 
of macromolecules would occur. However, in 
tumour vasculature, the vessels would remain as 
normal, allowing passage of macromolecules. 
Clinical data have been produced using this 
method with small molecules. Both an increased 
regression of tumour size and improved response 
rate were demonstrated. It is thought that, with 
small molecules, once the hypertension wears off, 
back-flow of the molecules can occur; this would 
not be the case with macromolecules. Thus, 
studies with macromolecules [16] have shown a 
2-fold concentration enhancement in tumours 6 h 
after the hypotensive event, as well as decreased 
levels in the bone marrow. Unfortunately, this 
approach is of little value in naturally hyperten­
sive patients.
3. Cellular uptake of macromolecules
3.1. Mechanism o f  internalisation
Small solutes are easily taken into cells via 
passive diffusion or through the action of specific 
porters for certain substrates such as glucose and 
amino acids [20]. Macromolecules, however, can­
not enter a cell by such a route because of their 
size. Natural macromolecules such as proteins, 
polysaccharides and polynucleotides are taken 
into the cell by endocytosis. Synthetic macro- 
molecules also follow this route. Internalisation 
can be considered to occur by one of two clearly 
different mechanisms; pinocytosis or phago­
cytosis. Phagocytosis or ‘cell eating’ occurs only 
in specialised cells such as macrophages [21] and 
can result in the uptake of particles larger than 
10-20 /xm in diameter. It is of major interest in 
the immune system, as it is involved in the 
uptake and destruction of bacteria. This process 
is o f minor importance when considering water- 
soluble macromolecular pro-drugs but can be 
significant in approaches to drug targeting using 
liposomes and microparticles.
Whereas phagocytosis occurs only in response 
to a presentation event [22], pinocytosis is a
constitutive phenomenon in all mammalian cells 
[21]. It has been likened to drinking as it involves 
the continual uptake of extracellular fluid. 
Pinocytosis is also known as fluid phase endo­
cytosis. The initial endocytic event in pinocytosis 
is the formation of an invagination in the plasma 
membrane. A  vesicle (pinosome) is then formed 
encapsulating extracellular fluid. This then buds 
away from the cell surface into the cytoplasm 
and then fuses with other pinosomes within the 
endosomal compartment without release of the 
contents. The default path of the macromolecule 
is vesicular transport deeper into the cell and 
subsequent vesicular fusion with a lysosome (a 
degradative vesicle released from the Golgi Ap­
paratus) to form a secondary lysosome. Within 
the secondary lysosome, degradation of macro- 
molecules occurs and small molecules are re­
leased into the cytoplasm. The secondary lyso­
some may then form a residual body, which 
contains non-degradable material and remains in 
the cell for its lifetime or vesicles which can fuse 
with the cell surface allowing exocytosis of the 
contents [11,20,22,].
Each cell has a constitutive rate of pinocytosis 
which can be measured by the use of polymers 
such as inulin, polyvinylpyrrolidone (PVP) [22] 
or poly(hydroxypropylmethacrylamide) (HPMA) 
[23,24] which show no specific adsorption to the 
cell surface. In this case, uptake by fluid phase 
pinocytosis is directly related to the concentra­
tion o f the ‘probe’ in the medium. The rate of 
uptake is expressed as the endocytic in d ex -‘the 
volume of the culture medium which is captured 
in a defined number of cells in a defined time’ 
[25]. This allows comparisons to be made on the 
uptake of various macromolecules and on the 
differing rates of uptake in different cell lines. 
The endocytic index also allows the measure­
ment of three other types of pinocytosis, non­
specific adsorptive pinocytosis, receptor medi­
ated pinocytosis and ‘piggy back’ endocytosis 
[25]. Measurement of the endocytic index for 
some macromolecules shows an increase over the 
model polymers. Two hypotheses for this event 
have been put forward. Firstly, the macromole­
cule is taken up by fluid phase pinocytosis but 
exerts a pharmacological effect on the cell, lead­
ing to an increased rate of constitutive
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pinocytosis. This hypothesis can be refuted easily 
by measuring the rate o f uptake of a fluid phase 
‘probe’ in the presence of the test macromole­
cule. If the rate of uptake of the ‘probe’ is 
unaltered, the test macromolecule cannot have 
been taken up by fluid phase pinocytosis [25]. 
The second hypothesis is more likely, that the 
macromolecule is internalised faster owing to 
adsorptive endocytosis, that is, a direct inter­
action with the cell surface resulting in enhanced 
uptake into endocytic vesicles. There are two 
types of adsorptive pinocytosis; non-specific-due 
to changes in hydrophobicity or charge, and 
receptor-mediated pinocytosis-where specific in­
teractions between receptor and substrate occur 
[22].
Interaction o f a ligand with a receptor may 
lead to a more organised pathway of internalisa­
tion. Firstly, the ligand binds to receptor sites 
which are spread over the surface of the cell. 
Clustering of the receptors then occurs on the 
cell surface in areas called coated pits. These 
areas have a protein, clathrin, associated with 
their surface. This and other associated proteins 
have roles in causing formation of vesicles and 
budding off to form coated vesicles which pass 
the ligand to the endosome for further process­
ing, whilst in some circumstances allowing re­
cycling of the receptor-dathrin complex to the 
cell surface via a recycling vesicle. It has been 
suggested that the clathrin does not enter the 
intracellular regions; rather, uncoated vesicles 
containing receptor and ligand (receptosomes) 
are passed into the cell for processing [22,26]. 
Receptor-mediated endocytosis. can be a rapid 
means of uptake due to specific mechanisms but 
some receptors need not be internalised by 
special means and are probably internalised as a 
result o f general membrane turnover in constitu­
tive endocytosis. Under these circumstances, the 
uptake of a bound ligand may take place at a 
rate similar to that observed in non-specific 
adsorptive endocytosis.
The term ‘piggy-back’ endocytosis has been 
used to describe enhanced uptake of one mole­
cule due to its binding to another molecule [27]. 
It is a process which could be considered to be 
exploited by all macromolecular pro-drugs, in 
that the coupling of a small molecule to a
macromolecule restricts its uptake to endocytosis 
and, hopefully, leads to reduced non-target inter­
actions [3]. An early example of the use of 
‘piggy-back endocytosis’ to elicit a therapeutic 
effect was demonstrated by Trouet et al. [3]. 
Ethidium bromide is active against Trypanosoma 
cruzi in vitro but is inactive in vivo. In host 
organisms, the parasite lives within lysosomes 
where it is unharmed by lysosomal enzymes. It is 
protected from ethidium bromide, since this is a 
small molecule which passes into cells by diffu­
sion and cannot pass into lysosomes. Attachment 
of ethidium bromide to DNA results in death of 
the parasite as the conjugate is taken up by 
pinocytosis and can act within the lysosome. This 
process may well explain many early results 
which suggested that enhanced rates of uptake of 
macromolecules were due to enhanced rates of 
endocytosis in tumours. For example, the uptake 
of colloidal radioactive gold is enhanced in the 
presence of poly(L-lysine). This effect is more 
likely to be due to association of the polycation 
with the cell membrane, so that the macro­
molecular complex is taken up by non-specific 
adsorptive pinocytosis rather than by an in­
creased rate of formatipn of endosomes [27].
3.2. Factors affecting rate and mechanism o f  
internalisation
Early experimental work [25] demonstrated an 
increased rate of uptake of denatured bovine 
serum albumin over untreated albumin in rat 
yolk sacs. As the rate of formation of pinosomes 
was unchanged, these results were attributed to 
an increased affinity for the cell surface, leading 
to an increase in non-specific adsorptive 
pinocytosis. This increase was dependent on the 
extent of denaturation but was unaffected by the 
method of denaturation. The researchers 
believed that this increase was due to either the 
unmasking of hydrophobic groups or to masking 
of charged residues [25]. With other denatured 
proteins such as insulin, uptake was either unaf­
fected by the process or was reduced owing to 
decreased binding. Thus, it was proposed that 
binding sites both for hydrophobic regions and 
for charged regions exist in yolk sacs. Polypep­
tides are very difficult to study in this context,
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since each amino acid could potentially exert a 
profound affect- on the binding capabilities. Ex­
periments with model polymers, however, give 
more reliable data on cell surface interactions. 
Both PVP and HPMA have little or no affinity 
for the cell surface and are taken up by fluid 
phase pinocytosis; hence, they are good models 
for investigating the effect of hydrophobic 
groups.
Duncan et al. [6] have demonstrated in vitro 
that the incorporation of tyrosinamide residues 
onto HPMA leads to an increased uptake in rat 
yolk sacs. The effect was dependent on the molar 
percentage of the hydrophobic moiety, the high­
est percentage incorporation (15.4 mol%), re­
sulting in a 10-fold increase in the endocytic 
index. Interestingly, the effect was not seen 
below a threshold level of 10 mol% and the 
authors suggested that this was due to a require­
ment for hydrophobic domains before non­
specific binding occurs. Similar results have been 
reported using poly(ar,/3-(A/-(2-hydroxyethyl))- 
DL-aspartamide) (PHEA) (28-30]. Incorporation 
of a tyramine derivative at a range of concen­
trations between 12  and 21.9 mol% resulted in 
enhanced uptake above a threshold value of 10 
mol%. The increase was due to a non-specific 
interaction, since, if PHEA and PVP were co­
administered, no increase in the rate of uptake of 
PVP could be measured. Endocytosis can only be 
enhanced by such a mechanism if the hydro- 
phobic moieties are exposed and therefore avail­
able for interactions with the cell surface [27]. 
Studies on a block co-polymer of poly(ethylene 
glycol) (PEG) and poly(L-lysine) (6:3) substi­
tuted with highly hydrophobic palmitoyl deriva­
tives demonstrated no increase in uptake of the 
co-polymer over that of PEG alone [31]. This 
initially seems surprising. However, further 
evaluation of the co-polymer revealed that the 
polymer forms a micelle in solution in which the 
hydrophobic groups are in the core and the less 
hydrophobic PEG is exposed to the cell surface. 
It should be noted that PEG alone does show an 
increased uptake in comparison with PVP, de­
monstrating a level of hydrophobic non-specific 
interactions.
The effect of charge is more complex; both
anionic and cationic polymers exhibit charac­
teristics of adsorptive pinocytosis. Co-polymeri- 
sation of a vinylamine with PVP (8 mol%) 
results in a cationic polymer which has increased 
endocytic activity in both rat macrophages and 
yolk sac [32]. Equally, the anionic polymer, 
DIVEMA pyran-co-polymer, is taken up by a 
non-specific adsorptive process [20], though cat­
ionic polymers usually exhibit a more pro­
nounced adsorption and faster rate of internalisa­
tion. The effect of size and molecular weight on 
macromolecular uptake is more properly defined 
as the effect of the hydrodynamic radius of the 
polymer. This is affected by the ability of the 
polymer to form intramolecular hydrogen bonds 
or van der Waals interactions. The size of the 
pinocytic vesicles is the main barrier to uptake 
and varies according to cell type. Ease of access 
to the cell surface also requires consideration 
[11]. Studies on both HPMA [27] and PVP [32] 
have shown the uptake to be size-dependent in 
the rat yolk sac. Co-polvmers of PVP and vin­
ylamine of molecular mass 120000 Da were 
taken up slowly in comparison to those of molec­
ular mass 46000 Da. In comparisons using rat 
macrophages, uptake of the larger polymer was 
more efficient.
All the modifications above result in an in­
crease in non-specific interactions; however, 
many cells also possess receptors for particular 
substrates on the cell surface. These receptor- 
substrate interactions can be exploited to allow 
the delivery of macromolecules to specific cell 
lines. Such receptor-substrate interactions in­
clude carbohydrate-lectin, antibody-antigen and 
hormone-receptor interactions. The area of lec­
tin-mediated drug delivery has been widely ex­
plored [3,33]. Many cells express lectins on their 
surface and most are limited to one cell type [37]. 
Substrates for lectins are, however, more diverse, 
although many do show structural similarities. In 
vivo, lectins bind complex oligosaccharides. 
Therefore, it is possible for one lectin to bind 
two structurally different sugars in different areas 
of the binding sites. An example of this is the 
P-selectin on endothelial cells which binds the 
oligosaccharide Lewis* which contains both 
galactose and fructose. Polymers containing
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either galactose or fructose can also bind to the 
lectin [37]. As lectins bind oligosaccharides, it has 
recently been suggested that triantennary target­
ing ligands should be attached rather than single 
sugar molecules. Experiments with the 
asialoglycoprotein that binds N-acetyllac- 
tosamine have shown that binding of an oligo­
saccharide containing three N-acetyllactosamine 
antennae is higher than those containing one or 
two [33]. This asialoglycoprotein is expressed in 
many but not all hepatocyte cells: The receptor is 
present on the venous face of hepatocytes, allow­
ing for interactions with blood-borne substrates. 
The receptor consists of at least two sub-units, 
each capable of binding one galactose residue, 
raising the possibility of multi-ligand binding 
[33]. Hepatocytes are valuable target cells for 
many diseases such as hepatitis [26]. The po­
tential of targeting to hepatoma cells, however, is 
low. Most tumours in the liver are either primary 
hepatomas or metastases of breast or colo-rectal 
cancer. The metastases comprise modified cells 
from the region of the primaiy tumour, so do not 
contain the asialoglycoprotein [26]. In primary 
tumours, expression of the asialoglycoprotein is 
sometimes retained but appears to be cell-line 
dependent. The degree of expression is also 
often reduced when compared to basal levels in 
hepatocytes. This suggests that organ-specific 
delivery is possible but that tumour cell-specific 
delivery is unlikely by this mechanism [26,33].
The hepatocyte asialoglycoprotein has been 
targeted using a number of polymers bearing 
galactose residues both in vitro and in vivo. 
Vansteenkiste [34] investigated the distribution 
of dextran containing one (6 mol%) or three 
D-galactose residues (85  mol%) in mice in vivo. 
30 min after injection, the triantennary dextran 
displayed the highest uptake into liver (71%). 
The polymer containing only one residue and the 
unmodified dextran accumulated less (43 and 
16% respectively). The increase in the uptake of 
the triantennary containing polymer could be 
due to improved binding but other workers [33] 
have suggested that the effect is due to the larger 
mol% of galactose residues. Another possibility 
is that the polymer is being picked up by a 
different receptor, the Kupffer cell ‘galactose
particle’ receptor [33,37]. HPMA co-polymers 
bearing galactose have been evaluated in both 
rats and mice [14,233536]. The kinetics of the 
galactose-substituted polymers displayed a more 
rapid clearance from blood and an increased 
uptake into the liver. In studies in vitro using the 
HepG2 cell line, a human tumour cell line known 
to express the asialoglycoprotein receptor, a 7- 
fold increase in uptake was observed using the 
galactose-containing polymer [23].
An interesting model to test the feasibility of 
drug targeting is the fucose receptor on LttlO  
mouse leukaemia cells [33,37], which has been 
investigated by Duncan et al. [36]. A conjugate 
of HPMA bearing the cytotoxic drug sarcolysin 
was further derivatised by the inclusion of 
fucosylamine. The fucosylamine derivative 
caused greater cytotoxicity in vitro than did the 
underivatised polymer. A  second HPMA co­
polymer bearing daunomycin and fucosylamine 
has also been tested both in L1210 and CCRF 
cells (a human leukaemia cell line which does not 
have fucose receptors). Inclusion of fucosylamine 
enhanced the inhibitory effect of daunomycin in 
the L1210 cells but not in the CCRF cells. 
Similar polymers containing galactosamine 
rather than fucosylamine were no more effective 
than underivatised polymers [38]. These poly­
mers have also been investigated in vivo in 
D B A 2 mice inoculated intraperitoneally with 
L1210 cells. In this situation, incorporation of the 
carbohydrate gave no significant advantage on 
day 1 after inoculation. After 3 days, however, 
the fucosylamine-coupled HPMA was more ef­
fective than control polymers lacking this moiety. 
It has been suggested that this may be due to the 
increased number of fucose receptors arising 
from rapid proliferation of the tumour cells [36]. 
Studies in vivo using HPMA bearing 
fucosylamine and adriamycin gave similar results. 
Again, the conjugates containing fucosylamine 
were more effective than those without, especial­
ly at low doses. Unfortunately, an increased liver 
concentration o f these polymers was seen, along 
with targeting to the tumour. This may be due to 
other cells, such as hepatocytes and macrophages 
[39], having fucose-recognising receptors. Inter­
estingly, attempts to increase cellular interactions
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using triantennary ligands have been unsuccess­
ful [40], although this may have been due to a 
lack of flexibility in the spacer employed.
Macrophages are not an obvious target cell for 
chemotherapy. However, delivery of a macro­
phage-activating agent such as jV-acetylmuramyl 
dipeptide (MDP) to the macrophages could 
result in increased phagocytic activity against 
tumour cells and metastatic cells in particular 
[37]. Many sugars interact with this receptor but 
are of two main classes, one based on D-mannose 
and one on L-galactose [33]. Studies involving 
both glucosamine and mannosamine HPMA 
glycoconjugates demonstrate little change in 
kinetics at low levels of substitution. More highly 
substituted polymers were accumulated in the 
liver, possibly owing to interactions with Kupffer 
cells [41]. Monsigny and colleagues have investi­
gated poly(L-lysine) bearing both MDP and man- 
nose-related sugars and were able to demon­
strate activity in activating macrophages [37]. 
The studies reported thus far demonstrate the 
potential of lectin-targeting in enhancing chemo­
therapy. However, more investigation of the 
lectins expressed by tumour cells is required 
before such targeting becomes a clinical reality.
Over the past few decades, much interest has 
been focussed on exploiting the specific anti- 
body-antigen interaction as a means of targeting 
drugs to particular cells [1]. This approach, 
however, has been beset with difficulties such as 
immunogenicity [52] and poor systemic distribu­
tion in vivo. Also, the realisation that tumours 
are distinctly heterogeneous and thus display 
various numbers of antibody-binding sites per 
cell, within the same tumour, has led to a 
reduced interest in antibody targeting. Using 
only one antibody conjugate is unlikely to allow 
interactions with every tumour cell. Despite 
these problems, a number of macromolecular 
conjugates have been developed and tested 
[43,44]. Much interest has been focussed on 
antibodies to the transferrin receptor [42,45] 
which is present on most proliferating cells but is 
expressed in high numbers on tumour cells [45]. 
Studies in vitro using the monoclonal antibody 
B3/25 attached to HPMA demonstrated one of 
the main difficulties in using antibodies. The 
conjugate was no more actively internalised than
one containing non-specific IgG, showing that 
conjugation had eliminated the specificity of the 
antibody [42]. Other workers [46-50] have ex­
amined targeting of co-polymers bearing anti- 
Thy 1.2 antibodies which interact with Thy 1.2 
alloantigens on mouse splenic cells. From these 
studies, it became apparent that the coupling 
method used was of great importance in retain­
ing activity [50]. The targeting of HPMA co­
polymers to colorectal cancer has also been 
investigated, using Fab' fragments of specific 
antibodies [51].
An alternative approach was investigated by 
Shen et al. [52] who developed a conjugate of 
poly(D-lysine) where the antibody was bound via 
the Fab regions to expose only the Fc region. As 
many cells exhibit Fc receptors, the polymer can 
act as a hapten for interactions. Many tumour 
cells show Fc receptors, including a few which 
are derived from cells which do not have this 
receptor type. This last type are of particular 
interest in drug targeting. The polymer was taken 
up more effectively than with non-targeted poly­
mers in Fc-positive cells but, as expected, showed 
no enhancement in Fc-negative cells.
A  further consideration is the use of hormone 
receptor interactions to promote internalisation 
and drug targeting. The melanocyte stimulating 
hormone receptor (a-MSH receptor) is of inter­
est, as this receptor is expressed by the majority 
of melanocytes in malignant melanoma [53]. 
Malignant melanoma is a cancer which is difficult 
to treat, often leading to hepatic and brain 
metastases. Effective targeting of the HPMA 
polymer was demonstrated both in vitro in 
B16F10 cells, a cell line which exhibits a-MSH  
receptors, and in vivo in mice inoculated with 
B16F10. Binding of the hormone to the polymer 
through its N-terminus did not affect activity. 
This is not surprising, as the receptor binding site 
of this tridecapeptide is the region between the 
sixth and tenth residues which are unaffected by 
tion to the polymer. Although these results are 
promising, it has been reported that other re­
ceptors for MSH are expressed in other tissues, 
particularly in the brain [54,55], which may limit 
the therapeutic opportunities for these conju­
gates, unless a high level of selectivity can be 
achieved.
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4. Lysosomal degradation
Once a drug molecule is only able to pass into 
a cell by endocytosis, as in the case of a macro­
molecular pro-drug, the default destination of 
that macromolecule is pre-determined to be 
fusion with a lysosome. Lysosomes are the or­
ganelles of cells responsible for digestion and are 
ubiquitous in living mammalian cells [20]. The 
lysosomal membrane is impermeable to macro- 
molecules and most initial products of digestion 
such as oligosaccharides. However, it is freely 
permeable to single units such as amino acids, 
monosaccharides and mononucleotides. The 
lysosomal membrane also contains specific por­
ters for some amino acids to allow rapid trans­
port of the degradation products to the cyto­
plasm [56]. Lysosomes exhibit unique charac­
teristics in terms of pH and enzyme activity. 
Lysosomal pH is slightly acidic, usually about pH 
5.5, in comparison to serum [26]. This is an 
important consideration as the drug delivered 
should not be acid sensitive. Lysosomes contain 
over fifty digestive enzymes, the majority of 
which are hydrolytic in nature. They allow the 
cleavage of all common natural inter-monomer 
bonds such as peptidyl, glycosyl and phosphate 
linkages. One family of enzymes found in lyso­
somes are of particular interest, the cathepsins. 
These thiol-proteinases cathepsin B, H, and L 
are involved in peptide cleavage, as are the non­
thiol dependent cathepsin C, a peptidyldipeptid- 
ase, and cathepsin D, an endopeptidase [57].
These characteristics of lysosomes afford the 
means of selective release of active drug from its 
macromolecular carrier within the cell, confer­
ring the highest level of targeting of drugs. 
Release of the drug can be achieved by exploit­
ing the acidic pH of lysosomes, the specific and 
high level enzyme activity or the reductive prop­
erties of the endosomal pathway [3]. Many work­
ers have shown that release of a drug from a 
macromolecule is better achieved by incorporat­
ing a spacer unit between the macromolecule and 
drug [8]. Otherwise, the macromolecule itself 
must be degradable, a possibility which is dis­
cussed below. The ideal properties of the linkage 
are that it should render the drug inactive, that it 
should be stable in serum and that it be readily
broken down in lysosomes. Both covalent and 
non-covalent linkages are acceptable. However, a 
non-covalent linkage, although easier to form, is 
unlikely to be as stable in serum as is a covalent 
linkage [3].
Shen [58] first explored the potential of acid- 
labile spacers in 1981, using a cisaconityl acid 
spacer between daunomycin and poly(D-lysine). 
Conjugates bearing this linkage demonstrated 
90% growth inhibition of WEHI-5 cells, whereas 
polymers with A7-maleyl spacers had no effect 
(Fig. 3).
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A  further example of acid-labile spacers are 
those based on p-benzylthiocarbamoyl groups 
(Scheme 1) [59]. In slightly acidic conditions, as 
in a lysosome, this spacer undergoes an Edman 
cyciisation, resulting in release of daunomycin. 
This is only achieved if the amino acid used is 
acidic, such as aspartic acid. Studies comparing 
the side-arm attached to aspartic acid or leucine 
demonstrated the suitability of the linkage. With 
aspartic acid, no drug release was seen in serum 
over the 3 weeks of the study but release was 
afforded at pH 5 and pH 4. The leucine deriva­
tive did not undergo cyciisation to form a 
thiazolinone at pH 7.4 or pH 5 and only a small 
amount of release was seen at pH 4 [59].
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More recently, Shen [60] has suggested that 
acid-labile drug arms are relatively unsuitable as 
the difference in pH between serum and lyso­
somes is not large enough to provide totally 
site-specific degradation. In a novel approach, he 
has investigated the potential of non-covalent 
acid-sensitive linkages. The receptor-substrate 
complexes on the surface of cells are robust but 
are easily broken down in lysosomes. This is due 
to a conformational change in the receptor at the 
lower pH resulting in a decreased binding affinity 
for the substrate. Shen has developed a polymer 
poly(glutaminylhistamine-glutamate) (PHG) 
which forms a pH-dependent complex with poly- 
(lysine). Release of poly(lysine)-methotrexate 
from PHG was demonstrated in lysosomes [60]. 
Obviously, further work is required on this 
approach before it can be utilised.
Degradation of proteins is often achieved by 
the reductive cleavage of disulphide bonds and it 
is thought that this reaction is the first step in the 
degradation of insulin. The actual location of this 
reaction, is unknown but it is believed that it 
occurs early in the endosomal pathway, as shown 
by studies on diphtheria toxin. Diphtheria toxin 
consists of two sub-units A  and B linked via a 
disulphide bond. Release of the active B portion 
is afforded by cleavage of the bond but, as this 
portion of the toxin is arid-sensitive, this cleav­
age and release must occur before reaching the 
lysosome. Sben et aL [8,52] have investigated 
disulphide bonds for release of methotrexate 
from poly(D-lysine). Poly(D-lysine) is ah ideal 
choice of polymer, as it is not degraded by 
lysosomes and any release o f drug must result 
from cleavage of the disulphide bond. The conju­
gate was effective in both normal and methotrex­
ate-deficient cells and was unaffected by leupep- 
tin or decreased glutathione concentrations; how­
ever, its activity was abolished by 2-mercap- 
toethanol. These results demonstrate that cleav­
age does not occur on the cell surface, is in­
dependent of enzymes and acidic pH and is not a 
non-enzymatic reaction with glutathione, con­
firming the view that the reduction occurs in 
pinosomes prior to fusion with the pre-lysosome. 
More recently, Bonfils et al. [61] have used 
disulphide bonds to link oligonucleotides to 
mannosylated proteins. These conjugates were
stable in incubation with serum but rapidly 
released the nucleotide within cells.
Most interest in the development of spacers 
has been focussed on amino arid sequences 
which are specific to lysosomal degradation by 
enzymes. One of the earliest examples of this 
approach dates from 1954. Jatzkewitz employed 
a dipejptide sequence GlyLeu to attach mescaline 
to poily(vinylpyrrolidone-co-acrylic arid). This 
increased the biological half-life of mescaline 
from a  few hours to 17 days [62]. The specificity 
of lysosomal enzymes can be described using the 
method of Schechter and Berger (see Ref. 63). 
The substrate specificity of many enzymes is now 
known,, enabling the design of spacers for testing.
Duncan, Kopecek, Ulbrich and colleagues, 
over a 15 year period, have made a made a major 
contribution to our understanding of the 
lysosomal degradation of macromolecular pro­
drugs. Initially, pro-drugs based on HPMA were 
synthesiised to contain peptide sequences with 
known specificity for chymotrypsin to investigate 
the effect of the macromolecule, the length of 
spacer and the stereospecificity of the amino 
acids o f  the spacer on specificity. The suitability 
of the sequence was measured by the release of a 
drug model, p-nitroaniline. The binding site of 
chymotirypsin displays-a preference for an amino 
arid whiich can act as a hydrogen bond donor in 
the P, position, one able to form van der Waals 
interactions with lie"  at P2 and hydrophobic 
amino acids at P4 [63]. These specificities were 
retained! where the peptide bond to be cleaved 
was between a macromolecule and a drug mole­
cule, rev(ealing major differences in the release of 
drug from spacers of the same length. With 
smaller spacers, for example those with only two 
amino aicids, substrate specificity was of little 
importamce. In such a case, the polymer back­
bone occupied some of the binding site, so 
decreasing the strength of binding. The degra­
dation was also affected, not surprisingly, by the 
inclusion of unnatural D-amino acids such as 
D-Phe amd d - Ala. In these :cases, degradation was 
greatly decreased [63,64].
The effect of the macromolefcule on enzyme 
action hais been further investigated using PVP 
and P E G  [65,66]. Conjugates were synthesised 
with the same peptide sequences-as previously
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produced for HPM A and the degradation rates 
were measured. The same relative degradability 
of the sequences was seen in all three series; 
however, the rates of degradation of a sequence 
varied considerably. The highest rates of release 
were seen in the PEG series, in that even a 
spacer of one amino acid was degradable. It is 
thought that this may be due to enhanced inter­
actions between PEG and the enzyme. PEG is a 
linear polymer with the ability to form hydrogen 
bonds (Fig. 4). Ulbrich -et aL [66] have proposed 






A  higher rate of degradation was also evident 
with PVP, although this was not as impressive as 
that of PEG [65]. This is likely to be due to an 
interaction of the cationic chymotrypsin with the 
negatively charged polymer. These studies also 
provided evidence that increased levels of substi­
tution lead to decreases in degradability. This is 
probably caused by decreased enzyme acces­
sibility and suggests that there may be an op­
timum level of side-chain incorporation [65]. 
Based on this early work, attempts were made to 
design peptide linkages which are substrates for 
particular lysosomal cathepsins [57]. Studies were 
performed using a wide variety of single enzymes 
and mixed lysosomal extracts but the most prom­
ising results were achieved in studies on cathep­
sin D. Cathepsin D  is an endopeptidase with 
specificity for the bond between hydrophobic 
amino adds [57]. On the whole, it has little 
activity with low molecular weight substrates; 
however, GlyPheLeuGlyPhe is a known sub­
strate. Three sequences were prepared, 
GlyPheLeuGlyPhe-NAp, GlyGlyPheLeuGlyPhe- 
NAp and GlyPheLeuGly-NAp and all degraded 
easily in a mixture of lysosomal enzymes. The 
first two sequences yielded Phe-NAp. This is not 
ideal, since release of unmodified drug would 
ensure target activity whereas amino add conju­
gates may prove to be inactive. In the final 
sequence, however, linear release, of unmodified
drug was achieved. Interestingly, although this 
sequence was designed for degradation by 
cathepsin D, it also fits the substrate conditions 
for cathepsin L activity, i.e., hydrophobic amino 
acids in positions P2 and P3, and is degraded on 
incubation with cathepsin B [67,68]. Analysis of 
the degradation events showed that the terminal 
-NAp bond was cleaved first to reveal a tetra- 
peptide which was further broken down to re­
lease LeuGly; the final amino acids Gly and Phe 
were not cleaved from the polymer [57]. These 
studies provided GlyPheLeuGly as a front-line 
candidate for a lysosomally degradable sequence. 
The stability of HPMA co-polymers bearing this 
sequence in serum was determined. Serum con­
tains a wide range of enzymes including small 
amounts of lysosomal enzymes which have 
leaked from cells, although most of the enzymes 
have trypsin-like activity, i.e., they cleave bonds 
following A ig and Lys. The co-polymer was not 
degraded in serum and so was evaluated further 
[69].
Macromolecular pro-drugs were then prepared 
incorporating this sequence or the sequence 
GlyGly which is not degraded by lysosomal 
enzymes. Numerous jirugs, including dauno­
mycin, adriamycin [70], sarcolysin [68] -and mel- 
phalan [72], have been attached to this sequence 
and, in all cases, the degradability of 
GlyPheLeuGly is maintained in lysosomes whilst 
being minimal in serum. It has also been shown, 
by the activity of the conjugates, to be degraded 
in the lysosomes of many cell lines including 
B16F10 melanoma cells [74], L1210 mouse 
leukaemia cells [36,38,39,70], Walker sarcoma 
cells [72] and the HepG2-hepatoma cell line [23]. 
However, there are some problems which occur 
with this sequence. Firstly, it is hydrophobic and, 
in sufficient quantities, could alter the nature of 
the macromolecule. This would be especially 
problematic if a hydrophobic drug were then to 
be attached [75]. Also, in some systems, release 
of free drug molecules is not achieved, only 
amino acid derivatives being released. This is 
probably due to the macromolecule used, e.g., 
PHEG [76] and its interactions with the enzyme. 
Nevertheless as has been mentioned earlier, 
amino acid pro-drugs could be exported from the 
lysosome resulting in lack of activity [77].
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Originally, Trouet investigated macromolecu­
lar drug delivery using DNA as a carrier mole­
cule. D N A  is biodegradable, so no spacer moiety 
was required to afford release of drug [78]. 
However, the limitations of DNA as a carrier led 
to the use of albumin [79]. Release of the drug 
from albumin was not achieved from a direct 
linkage and spacer units were therefore investi­
gated. Following experiments with small amino 
arid pro-drugs, the ideal bond for release of 
daunomycin was found to be one between 
leucine and the drug and the ideal sequence for 
enzyme specificity to be AlaLeu [80,81]. Pro- 
drugs were then synthesised with one of three 
linkages AlaLeu, LeuAlaLeu, and AlaLeu- 
AlaLeu [79]. Studies in vitro showed release to 
be highest from the tri- and tetra-peptide se­
quences and these conjugates were active in 
studies in vivo. The conjugates were stable in 
serum for 24 h and this, in combination with the 
high lysosomal degradability, has lead to this 
sequence being used in a variety of situations. De 
Mare et al. [76] have developed spacer sequences 
based on AlaLeu to attach mitomycin C (MMC) 
to PHEG. Two sequences, GlyPheAlaLeu and 
AlaLeuAlaLeu, were sensitive to lysosomal.hy­
drolysis, resulting in release of MMC, although 
some LeuMMC was also released. The sequence 
GlyGlyGlyLeu has also been used as a linker 
between PG A and adriamycin but, again, some 
amino arid derivatives are produced, suggesting 
that the sequence has low substrate specificity
[75]. In summary the above results suggest that 
enzymatically degradable spacers provide the 
greatest selectivity in degradation and, hence, the 
greatest potential for targeted drug delivery. At 
this time, macromolecular pro-drugs incorporat­
ing the amino acid sequence GlyPheLeuGly are 
undergoing Phase II clinical trials in humans.
5. Chemistry o f macromolecular systems
5.1. Introduction
The major determinant of the pharmacokinetic 
characteristics in vivo of a macromolecular pro­
drug is the macromolecule rather than the drug
or targeting moiety. The ideal characteristics of a 
macromolecule are [4,82]:
1. Ease of synthesis
2. Ease of chemical modification
3. Water solubility
4. Biodegradability
5. Lack of toxicity
6. Lack of immunogenicity
However, at present, no carrier has been found 
which has all these characteristics. In this section, 
the best-studied polymers are evaluated with 
respect to these criteria and related macro­
molecular drug conjugates are discussed. Both 
synthetic and natural macromolecules have been 
used as carriers. Synthetic polymers are con­
siderably more versatile than non-synthetic poly­
mers. They can be prepared in the desired 
molecular weight fractions and modified for the 
attachment of drug molecules. They are general­
ly less immunogenic than natural polymers. Un­
fortunately, many synthetic polymers are not 
biodegradable owing to their carbon-carbon 
backbone. Thus, investigators are presently de­
veloping co-polymers of synthetic polymers and 
natural amino acids winch retain the favourable 
properties o f synthetic polymers whilst allowing a 
limited biodegradability.
5 .2  DNA
DNA was one of the first macromolecular 
carriers investigated. It is an ideal lysomotrophic 
carrier as it is relatively stable in serum but is 
degraded in the lysosome. In the early 1970s, 
Trouet et al. [3] produced complexes of 
daunomycin and adriamycin intercalated into 
DNA. These complexes proved effective in 
studies in leukaemia cells in vitro and in D BA 2 
mice inoculated with the L1210 leukaemia. Lim­
ited clinical trials were performed in terminal 
leukaemia patients whose disease was resistant to 
all forms o f therapy. The complex was well 
tolerated and gave very encouraging results; of 
twenty cases of non-lymphoblastic leukaemia, 
twelve resulted in complete remission. Interest in 
DN A  as a carrier has waned since then, possibly 
because of the instructional nature of DNA
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which may become incorporated in a random 
manner into genomic DNA, leading to unwanted 
side effects, or due to the relative difficulty of 
preparing drug conjugates [3,78].
5.3. Albumin
The serum protein, albumin, has also been 
used as a carrier. It is attractive owing to good 
biological stability, lysosomal degradability, ease 
of chemical substitution, low toxicity and with 
homologous albumin, low immunogenicity. Early 
attempts to produce a methotrexate derivative of 
albumin resulted in an inactive conjugate [4]. 
Later attempts to produce a conjugate of 
daunomycin, attached via degradable spacers to 
albumin, were rewarded with therapeutic activi­
ty. The conjugates lead to a 200% increase in 
life-span in mice inoculated with L1210 [4,12,79]. 
There is a large literature on coupling of cytotox­
ic drugs to proteins, particularly to antibodies, 
sometimes directly, sometimes by way of a 
spacer such as albumin or a polymer. We do not 
attempt to review this field here, as the chemistry 
of such compounds is ill-defined and their bio­
logical properties depend substantially on the 
properties of the immunoglobulin.
5.4. Polysaccharides
Many polysaccharides have been used as mac­
romolecular carriers including cellulose and 
starch [5]. However, dextran and inulin have 
been most widely investigated. Polysaccharides 
are attractive as carriers because they are easily 
chemically derivatised and are of both low toxici­
ty and low immunogenicity.
5.4.1. Dextran
Dextran (6) is the collective name for a wide 
range of polysaccharides based on a-D-glucose 
having a predominance of 1,6-a  linkages, i.e., 
there is little chain branching (Fig. 5). These 
polysaccharides are derived from bacteria and 
the actual composition is determined by their 
origin. One type of particular interest in pharma­
ceutical applications is derived from Leuconostoc 
mesesteroides. In this type, 95% of the chain is 
unbranched and the remaining 5% is branched,








with the majority of the branches only one or 
two sugars long [5].
Dextran has been used for many years in 
medical practice. Dextran T-70 (dextran of mo­
lecular mass 70000 Da) is used as plasma expan­
der in patients suffering from shock or haemor­
rhage and dextran T-40 is used to increase blood 
flow in capillaries in the treatment of vascular 
occlusion. Thus, from many viewpoints dextran is 
a good candidate for a macromolecular carrier as 
its toxic and immunological effects are well 
characterised. Dextrans are available in narrow 
molecular weight bands with low polydispersity 
that allow easy characterisation and evaluation of 
resulting drug conjugates. They also have very 
high solubility in water which is retained even 
with 20% w /w  ligand incorporation.
The methods for activation of dextran have 
been reviewed excellently by Larsen [5] and 
Schacht [85]. Dextran contains a large number of 
hydroxyl groups that are suitable either for direct 
conjugation with carboxylic-acid-bearing drugs 
such as aspirin or for chemical modification and 
activation prior to coupling with other drugs. 
There are three main methods of activation, all 
of which have been used in the preparation of 
macromolecular pro-drugs. The most popular 
method involves the production of dextran dial­
dehydes by the action of periodic acid (Scheme 
2). The resulting aldehydes can then react to 
form Schiff bases with drugs containing amine 
groups. This bond is highly unstable and can be 
stabilised by reduction with sodium borohydride. 
The coupling and subsequent reduction can be 
achieved in one step. Unfortunately, this reaction 
may also result in the formation of hemiacetals 
that reduce the degree of oxidation along the 
chain and potentially affect coupling reactions















[85]. Chemical modification of this type also 
greatly effects the structure of the carrier back­
bone which will affect its physiochemical prop­
erties and potentially its toxicity and immuno- 
genicity [5,83].
Another attractive method is the use of 
cyanogen bromide. This leads to less alteration in 
the basic structure of the carrier but does result 
in the introduction of positive charges into the 
molecule (Scheme 3). The reaction is not well 
understood but it is thought that, along with the 
desired electrophile, three other preliminary 
products are produced. The imidocarbonate
IOH OOOAHjNOs OH
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structures are commonly produced in activation 
of dextran, particularly the stable five-membered 
ring structure (13). This can then form the 
desired linkage when treated with an amine but 
can also form other linkages which can result in a 
charged dextran [85]. Thus, this approach, al­
though the chemistry is easy to perform, is of 
limited use as reliable and reproducible ligand- 
carrier structures are not formed [5].
The final method of activation is through the 
use o f carbamate esters. Treatment of dextran 
with 4-nitrophenyl chloroformate results in a 
highly active carbamate which couples easily with 
amine-containing drugs [83]. Again, it is thought 
that some inter-chain cross-links are formed due 
to the close vicinity of the hydroxyl groups 
(Scheme 4).
Dextran has a renal threshold of approximate­
ly 55000 Da and fractions of higher molecular 
weights undergo slow partial depolymerisation
(6)
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due to the action of dextranases. Studies with 
dextran T-40 demonstrate a rapid clearance from 
the bloodstream; this is thought to be due to 
three excretory mechanisms. The main fraction 
which is below the glomerular filtration threshold 
is excreted in the urine. A  small amount passes 
into the gastro-intestinal tract where it is de­
graded in the colon. Another small fraction 
passes across the endothelium and into the 
interstitium where it is recycled via the lymphatic 
system. The remaining fractions are taken up 
over time into cells of the reticulo-endothelial 
system, such as macrophages and Kupffer cells of 
the liver, where the polysaccharide is slowly 
degraded [85]. The distribution of dextran in vivo 
can be greatly changed by chemical modification. 
A  cationic derivative, diethylaminoethyl dextran, 
can be formed by treatment of dextran with 
diethylaminoethyl chloride and an anionic form, 
carboxymethyl dextran, by treatment with chlo- 














Equally, incorporation of a spacer unit for 
attachment of a drug molecule can result in the 
formation of cationic and anionic derivatives of 
dextran [82]. The conjugation of mitomycin C 
(MMC) to cyanogen bromide-activated dextran 
via a 6-aminohexanoyl spacer results in a posi­
tively charged dextran molecule, whereas spacers 
derived from 6-bromohexanoic acid give nega­
tively charged polymers (Fig. 7).
Studies on both these types of charged poly­
mers, reveal altered distributions in vivo. A 
cationic conjugate with unease was rapidly 
cleared from plasma whereas an anionic deriva-
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tive has an increased half-life. Measurements of 
hepatic uptake and urinary excretion gave similar 
results. Uricase was taken up faster when conju­
gated to neutral dextran [85]. This rate was 
enhanced by conjugation to cationic dextran and 
was reduced by conjugation to anionic dextran 
[84]. With the mitomycin C derivatives, studies 
were undertaken in tumour-bearing mice. Here 
the cationic derivative was rapidly cleared, 
whereas the anionic derivative had an increased 
blood residence time, resulting in accumulation 
in the tumour. These results suggest that inten­
tional incorporation of anions into a dextran 
macromolecular pro-drug would result in an 
enhanced delivery system. An alternative ap­
proach to the modification of distribution in vivo 
is the use of lectins to target a polymer to 
particular cell lines. In early studies, Vansteen- 
kiste [34] investigated the effect of pendant d - 
galactosylated dextrans on distribution. Plasma 
clearance was higher than for non-derivatised 
dextran and hepatic uptake was increased. An 
interesting finding from this study was that dex­
trans carrying fluorescein-thiocarbamate alone 
also exhibited an increased disposition in liver. 
Thus, it can be assumed that the changed dis­
tribution in vivo owing to changes in the carrier 
could be augmented or overridden by attachment 
of drug.
Dextran is degraded in vivo by the action of 
dextranases. These enzymes are absent from 
blood but are present in the fiver, kidney, spleen  
and parts of the gastro-intestinal tract. D extran­
ases can be either exo or endo in their action. 
Dextran is only degraded very slowly by these 
enzymes and high molecular weight dextrans can
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be captured by the reticuloendothelial system 
before they are degraded. Thus, it is important to 
consider degradation of both dextran and dex­
tran derivatives by isolated dextranases and 
tritosomes. In initial studies, Schacht et al. [83] 
investigated the degradation of dextran deriva­
tives in vitro by an e/zdo-dextranase. Three 
derivatives were assessed, a reduced dextran 
dialdehyde, formed from periodate activation 
and reduction, an amine derivative, formed by 
the reaction of 2-hydroxypropylamine with chlo- 
roformate-activated dextran, and a succinate 
derivative. Degradation was diminished by 
periodate activation and this reduction was p ro  
portional to the degree of activation. The other 
derivatives gave similar results, suggesting that 
enzyme activity is affected by the degree of 
derivatisation, rather than the type of modifica­
tion. The degradation of these macromolecules 
in tritosomes was also assessed. Dextran itself 
was slowly degraded and both the urethane and 
succinylated dextrans showed even lower de- 
gradability. Interestingly, the reduced dialdehyde 
had, in this case, a higher rate of degradation. 
This was considered to be a combined effect o f  
both hydrolytic and lysosomal degradation. 
These workers suggested that the degradation of 
dextran in lysosomes is achieved by dextranases 
with both endo and exo characteristics. The same 
workers have also investigated the lysosomal 
degradation of dextran, cationic dextran dial­
dehyde and anionic dextran monosuccinate ester 
[86]. Results were obtained for both the degra­
dation index and degree of glucose release, i.e., 
the extent of exo-dextranase activity. Liberation 
of glucose was the same for both dextran and the 
derivatives. However, the degradation rates of 
the derivatives were lower. This confirms that 
dextran is degraded in lysosomes by more than 
one enzyme. It was proposed that the enzyme 
with exo activity was a-glucosidase and the endo 
enzyme was l,6-a-D-glucose-6-glucanohydrolase.
Crepon et al. [87] have examined the degra­
dation of dextran derivatives that bear more 
resemblance to macromolecular pro-drugs. Car- 
boxy lie add, benzamide, and benzylamine-sul- 
phonated derivatives of dextran T-40 were pre­
pared and degraded using an e/zdo-dextranase 
(Fig. 8). Incorporation of increasing numbers of 
carboxylic add groups resulted in a linear reduc-
SOjNa
Fig. 8.
tion in degradation. Comparison of polymers 
derivatised with carboxylic acid groups and poly­
mers derivatised with both carboxylic acids and 
benzylamine-sulphonated groups showed that 
the benzylamine-sulphonated groups had a great­
er inhibitory effect on lability to dextranase. 
Interestingly, some dextranase action still 
occurred, even at 80% substitution.
The effect of larger substituents has also been 
investigated [88]. Dextrans have been prepared 
bearing pendant poly (ethylene glycol) chains, 
which were degraded both with dextranase and 
tritosomes. All the derivatives were degraded by 
dextranase but the extent of degradation was 
substantially reduced with longer poly(ethylene 
glycol) chains. With the lysosomal enzymes, no 
degradation of the derivatives was seen in 36 h. 
These results suggest that dextran is suitable as a 
carrier molecule, as it is not degraded in the 
blood stream, where there are no dextranases, 
but is very slowly degraded in lysosomes. To 
afford efficient release of drug from dextran, it 
may be appropriate to use lysosomally degrad­
able spacers.
The immunogenicity of dextran has been re­
viewed by Rihova and Riha [89]. Immuno- 
genicity is dependent on the molecular weight of 
the dextran. Dextrans with molecular mass 51000 
Da have very low immunogenicity whereas injec­
tion of dextran with molecular mass >  90000 Da 
results in the formation of antibodies during 3 
weeks. It has also been shown that the immune 
effect depends on the dose injected; for high 
molecular weight dextrans, an immune response 
is induced at low doses but tolerance is seen at 
higher doses. The immunogenicity of dextrans is 
also structure-dependent, branched polysac-
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charides being more i m m u n o g e n i c .  Two main 
specificities of antibody are raised to dextran, 
one with a combining site for isomaltotriose and 
one with a larger combining site for isomaltohex- 
ose. The immunogenicity of modified dextrans 
must also be evaluated, as this provides infor­
mation on the macromolecular pro-drug situa­
tion. Crepon [87] evaluated the antibody re­
sponse to a dextran T-40 derivative with 54% 
carboxylic acid groups and 19-5% benzylamine- 
sulphonated units. The polymer was injected 
three times over 14 days, with or without com­
plete Freunds adjuvant, into Balb/c mice. The 
antibody titre was low, even in mice treated with 
the adjuvant, and the conjugate can be consid­
ered to have low i m m u n o g e n i c i t y .  Despite the 
low immunogenicity of dextran, occasional ana­
phylactic reactions are seen but the development 
of a pre-immunisation technique has reduced the 
risk to 1 in 85000 [5].
Sezaki et al. have developed pro-drugs of 
mitomycin C based on dextran [90]. These work­
ers employ hydrolysable spacer bonds, rather 
than lysosomally degradable bonds, in order to 
achieve release of the acid-unstable drug both 
within the dell and within the tumour mass. This 
could, however, result in the release of the drug 
in other regions of the body, with consequent 
toxicity. Mitomycin C has been attached to 
cyanogen bromide-activated dextran thorough a 
variety of bonds [5,82,84]. In a recent study [90], 
three spacers of varying length were evaluated 
with respect to rate of release of drug and 
effectiveness in vivo. Drug release rates in vitro 
demonstrated an increased half-life with increas­
ing chain length but, in cell culture experiments, 
growth inhibition increased as the length of the 
spacer decreased. Thus, these two effects must be 
balanced to provide the most selectively active 
conjugate. Studies in vivo have shown that a 
6-aminohexanoyl spacer provides the largest in­
crease in life-span combined with the largest 
therapeutic index.
5.4.2. Inulin
Inulin is a vegetable-derived polysaccharide 
based on fructose units, which is terminated at 
one end with a sucrose unit. It has limited 
solubility and is degraded by acid. It is a small 
polysaccharide, with molecular mass <  10000
Da, and is used clinically for testing renal filtra­
tion rates, as it is excreted rapidly without 
degradation in a normal kidney. Activation of 
inulin using the standard methods mentioned 
above proved unsuccessful. Periodate activation 
resulted in only 50% active units, owing to the 
high level of formation of hemiacetals. An alter­
native activation method has been developed 
which is also suitable for the activation of dex­
tran [91]. Treatment with epichlorohydrin yields 
a 3-chloro-2-hydroxypropyl derivative which can 
react easily with amine drugs. Succinylated de­
rivatives can also be prepared which can then be 
activated with l,T-carbonyldiimidazole [92,93]. 
Inulin has been used to a limited extent in 
preparing macromolecular pro-drugs, mainly as a 
carrier for the anti-arrhythmic drug, procain­
amide [85].
5.5. Poly (amino acids)
Poly(amino acids) can be considered to be 
synthetic proteins. The use of these macromole­
cules as carriers has been explored for many 
years. The degradability of poly(amino acids) is a 
highly attractive feature as is the ease of chemi­
cal modification. However, the use of many 
macromolecules of this type is restricted due to 
their general cell toxicity. Polymers of most 
am ino  acids have been prepared and evaluated. 
The most popular systems are poly(glutamic 
acid), poly(lysine), poly(hydroxyethylglutamine) 
and poly(hydroxyethylaspartamide). Poly- 
(glutamic acid) (poly(Glu)) can be easily pre­
pared by base-initiated polymerisation o f the N - 
carboxyanhydride of L-glutamic acid y-benzyl 
ester (Scheme 5). Deprotection reveals the de­
sired polymer. The polymerisation reaction can 
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Although attachment of amine-containing 
drugs to the carboxylic acid would appear to be 
easily achievable using standard peptide chemis­
try, some workers have found difficulties with 
activation procedures. Activation with car- 
bodiimides can result in the formation of cyclic 
imides, leading to chain scission, or to inactive 
A/-acylisoureas. These problems can be over­
come by using l-ethoxycarbonyl-2-ethoxy-l,2- 
dihydroquinoline (EEDQ ) to form a mixed 




The same workers have also developed an 
alternative coupling method for the attachment 
of peptide spacers to the macromolecule [75]. 
Poly(Glu) can be activated using a CDI-sac- 
charin method and then coupled with tetra- 
methylguanidinium salts of oligopeptides to 
produce the spacer [75,95] (Scheme 6). A  step­
wise incorporation of amino acids is also possible 
using a modification of this method in which the 
CDI can be regenerated using phenyl dichlo- 
rophosphate. With both methods, the drug can 




Complexes of poly(Glu) can also be prepared. 
The polymer has an inherent negative charge and 
a non-covalent complex of this and cis-dichlo- 
rodiammineplatinum(II) has been made and 
evaluated as a pro-drug [96]. Hoes et al. [94] 
have investigated poly(Glu) macromolecular 
pro-drugs of adriamycin with respect to their 
activity in vivo and in vitro, rate of release of 
drug and immunogenicity. In studies involving 
papain in vitro, release of adriamycin was 
achieved only when a peptide spacer was in­
corporated between poly(Glu) and the drug 
molecule. This is to be expected, as papain has 
specificity for the cleavage of a-amide bonds. 
Further studies evaluating the effect of spacer 
concentration gave surprising results. Cleavage 
of the spacer is expected to be faster in polymers 
with a few spacer units, as enzyme access is 
facilitated. However, with these conjugates, deg­
radation proceeded faster with polymers bearing 
many chains. These authors considered these 
results to be due to degradation of the peptide 
backbone by the enzyme. Later studies using 
lysosomal enzymes in tritosomes confirmed many 
of these results. Reletase was obtained slowly in 
the direct conjugate,ydwing to degradation of the 
polymer backbone. Release from a conjugate 
with a GlyGlyGlyLeu spacer was faster, indicat­
ing faster degradation of the spacer unit than the 
polymer backbone [96].
Poly(Glu) is unlikely, to be immunogenic. 
Many workers have shown that the degree of 
immune response is dependent on the number of 
different amino acids in the molecule; thus, 
polymers of four amino acids are considerably 
more immunogenic than homopolymers [89]. In 
studies of poly(Glu) in rabbit, guinea pig and 
man, no antibodies were raised to the polymer. 
These results were confirmed by studies of an 
adriamycin conjugate of poly(Glu) in mice. Anti­
bodies were raised both to a direct conjugate of 
drug to polymer and to a conjugate incorporating 
GlyGlyGlyLeu but at lower levels than the 
response to bovine y-globulin [75]. It would be 
interesting to develop these studies further. Both 
adriamycin and spacer units have been shown 
previously to act as haptens. Thus, the antibodies 
raised should be examined for cross-reactivity to 
determine whether their combining site is part of
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the polymer backbone. The cytotoxicity in vitro 
and in vivo of these conjugates has also been 
evaluated [75,94], Initial experiments, using both 
directly-bound and spacer-bound adriamycin, 
suggested that the compounds were completely 
devoid of activity against L1210 and B16 cell 
lines. However, carriers with a biodegradable 
spacer gave increased survival times, when as­
sessed in vivo in mice inoculated with B16 
melanoma. Not surprisingly, the direct conjugate 
was .also inactive in vivo.
Poly(L-lysine) would appear to be an ideal 
macromolecular carrier from many viewpoints. It 
is available in a wide range of molecular weights, 
has a high number of amine groups for attach­
ment of drug molecules, is biodegradable and 
can stimulate endocytosis due to the interaction 
of positive charges with the negatively charged 
cell membrane. Poly(D-lysine) has all these ad­
vantages except that it is not biodegradable, 
owing to its stereochemistry [97]. Poly(L-lysine) 
was used frequently in the early years of macro­
molecular pro-drug development. It was used 
mainly as a carrier for methotrexate. In these 
studies, the intracellular mechanism of pro-drug 
action was confirmed, as conjugates were active 
in cells without transport mechanisms for metho­
trexate [8,52]. Poly(D-lysine) was also an excel­
lent tool in the development of lysosomally 
degraded spacer arms. Release of a drug from a 
poly(D-lysine) conjugate with a spacer can only 
occur if the spacer is degraded [8]. More recent­
ly, however, the use of both these carriers has 
declined owing to their general cellular cytotox­
icity, a result of their potent non-specific inter­
action with biological membranes. Poly(L-lysine) 
is known to have antibacterial, antiviral and 
antitumour activity. These properties are thought 
to be due to interactions with the cellular mem­
brane or parasite coat. Unfortunately, the 
charged interaction that provides these positive 
effects can also lead to toxicity as it is not 
tumour-cell specific. In a comprehensive study, 
Choksakulnimitr et al. [98] investigated the effect 
of numerous macromolecules on cultured bovine 
brain endothelial cells, a model of the blood- 
brain barrier, mouse peritoneal macrophages, a 
model of Kupffer cells, and rat hepatocytes. 
Damage to the cell membrane was measured by
the release of lactate dehydrogenase (LDH). 
With Poly(Lys) of high molecular mass (39880 
Da), severe leakage of LDH was observed in all 
the cell lines, while with a smaller polymer (8000 
Da) release was reduced, especially in macro­
phages. It has been suggested that the flexibility 
of poly(Lys) plays a major part in the release, as 
many interactions can be made on the cell 
surface leading to membrane disruption. These 
results are particularly worrying, as polycations 
have been shown to accumulate in* the liver in 
vivo and suggest that the toxicity of poly(Lys) 
may be too high for use in macromolecular pro- 
drugs.
The immunogenicity of poly(Lys) is more 
debatable. In some animals, antibodies can be 
raised to the homopolymer but the response in a 
particular species is unpredictable [89]. Further­
more, initial studies by Maurer suggested that 
the polymer was non-immunogenic in rabbits but 
it has now been shown that, at low levels, 
immune responses do occur [99]. In a recent 
study, the immunogenicity of poly(D-Lys) has 
been investigated in rabbits. Antibodies of both 
IgM and IgG were raised in response to an initial 
inoculation with the polymer. On a further ad­
ministration, a booster effect was seen consisting 
only of IgG antibodies. The antibodies were 
isolated and were only reactive against poly(D- 
Lys). No activity was seen with monomers, sug­
gesting that at least part of the antibody deter­
minant is the peptide bond, or with poly(L-Lys), 
showing stereochemical specificity. These results 
suggest that both poly(L-Lys) and poly(D-Lys) 
are slightly immunogenic. This does not preclude 
their use in macromolecular pro-drugs but it 
should be noted that the immunogenicity is likely 
to be enhanced by inclusion of spacers or drug 
molecules.
The concerns about the toxicity of poly(Lys) 
have led to the development of new approaches 
to using the polymer as a drug carrier. Monsigny 
et al. have investigated a conjugate of poly(L- 
Lys) with MDP and sugar targeting moieties in 
which any free lysine e-amines have been 
acylated with S-gluconolactone. This considera­
bly reduces the adverse properties of the poly­
mer whilst retaining the positive properties. 
Thus, the polymer is still degradable but is
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e l e c t r i c a l l y  n e u t r a l  a n d  h a s  a  h i g h e r  w a t e r - s o l u -  
b i l i t y  [ 1 0 0 , 1 0 1 ] .  I m m u n o g e n i c i t y  s t u d i e s  h a v e  
s h o w n  t h a t  a n t i b o d i e s  a r e  n o t  r a i s e d  t o  t h i s  
c o n j u g a t e  [ 3 7 ]  a n d  t h e  n e u t r a l i s a t i o n  o f  c h a r g e  
r e s u l t s  i n  a  d e c r e a s e  o f  n o n - s p e c i f i c  c e l l  b i n d i n g  
a n d  t o x i c i t y .  H u d e c z  e t  a l .  h a v e  i n v e s t i g a t e d  
b r a n c h e d  p o l y p e p t i d e s  b a s e d  o n  p o l y ( L y s )  a s  
c a r r i e r s  [ 1 0 2 ] .  B r a n c h e d  p o l y p e p t i d e s  h a v e  b e e n  
u s e d  a s  s y n t h e t i c  a n t i g e n s  a s  t h e  a n t i g e n i c i t y  o f  
a m i n o  a c i d  p o l y m e r s  i s  i n c r e a s e d  i n  p o l y m e r s  
w i t h  m a n y  d i f f e r e n t  c o m p o n e n t s  [ 8 9 ] .  T h u s ,  
b e f o r e  b r a n c h e d  p o l y p e p t i d e s  c a n  b e  u s e d  a s  
c a r r i e r s ,  n o n - i m m u n o g e n i c  s t r u c t u r e s  m u s t  b e  
f o u n d .  I n  a  l a r g e  s t u d y  o f  t h e  t o x i c i t y  o f  t h e s e  
c a r r i e r s ,  i t  w a s  f o u n d  t h a t  i n c l u s i o n  o f  o t h e r  
a m i n o  a c i d s  o n t o  a  p o l y ( L - L y s )  b a c k b o n e  c a n  
r e d u c e  t h e  t o x i c i t y  t o  c e l l  c u l t u r e s ,  b o t h  r a t  l i v e r  
a n d  m o u s e  s p l e e n  c e l l s ,  w h i l s t  t h e  p o s i t i v e  c y t o ­
t o x i c  e f f e c t  a g a i n s t  c e r v i c a l  c a n c e r  c e l l s  i s  m a i n ­
t a i n e d .  H e n c e ,  a l t h o u g h  p o l y ( L y s )  i s  n o t  a  s u i t ­
a b l e  c a n d i d a t e  f o r  a  d r u g  c a r r i e r  o w i n g  t o  i t s  h i g h  
l e v e l  o f  n o n - s p e c i f i c  t o x i c i t y ,  m o d i f i c a t i o n s  o f  t h e  
s t r u c t u r e  c o u l d  l e a d  t o  s u i t a b l y  n o n - t o x i c  m o l e ­
c u l e s .
P o l y ( h y d r o x y e t h y l g l u t a m a t e )  ( P H E G )  ( 3 2 )  i s  
a  w a t e r - s o l u b l e ,  n e u t r a l ,  b i o d e g r a d a b l e  a n d  
b i o c o m p a t i b l e  p o l y m e r  t h a t  h a s  b e e n  p r o p o s e d  
a s  a  p l a s m a  e x p a n d e r .  I t  i s  e a s i l y  p r e p a r e d  a n d  
c a n  b e  r e l i a b l y  a c t i v a t e d ,  m a k i n g  i t  a  s u i t a b l e  
c a n d i d a t e  a s  a  d r u g  c a r r i e r .  P H E G  c a n  b e  s y n ­
t h e s i s e d  f r o m  p o l y ( y - b e n z y l g l u t a m a t e )  v i a  a n  
a m i n o l y s i s  r e a c t i o n  w i t h  2 - a m i n o e t h a n o l  
( S c h e m e  7 )  [ 1 0 3 ] .  T r e a t m e n t  w i t h  2 - a m i n o ­
e t h a n o l  a l o n e  c a n  r e s u l t  i n  c h a i n  s c i s s i o n  d u e  t o  
a m i n o l y s i s  r e a c t i o n s  o n  t h e  b a c k b o n e  a m i d e s .  
T h i s  p r o b l e m  c a n  b e  a v o i d e d  b y  t h e  u s e  o f
2 - h y d r o x y p y r i d i n e  a s  a  c a t a l y s t .  W i t h  a  5 - f o l d  
e x c e s s  o f  t h e  c a t a l y s t ,  c o m p l e t e  c o n v e r s i o n  w a s  
a c h i e v e d  w i t h  m i n i m a l  c h a i n  l o s s  [ 1 0 4 ] .
(27) (32)
Scheme 7.
T h e  s i n g l e  h y d r o x y l  g r o u p  c a n  b e  e a s i l y  a c t i ­
v a t e d  b y  t r e a t m e n t  w i t h  4 - n i t r o p h e n y l  c h l o r o -  
f o r m a t e .  I n  c o n t r a s t  t o  d e x t r a n ,  t h e  d e s i r e d  
c a r b o n a t e  e s t e r  i s  n o t  r e a r r a n g e d  a n d  i n t e r -  a n d  
i n t r a - c h a i n  c r o s s - l i n k s  d o  n o t  o c c u r .  A  u s e f u l  
p r o p e r t y  o f  t h i s  r e a c t i o n  i s  t h a t  t h e  d e g r e e  o f  
a c t i v a t i o n  i s  p r o p o r t i o n a l  t o  t h e  c o n c e n t r a t i o n  o f  
c h l o r o f o r m a t e  a n d  t h u s  c a n  b e  t a i l o r e d  f o r  p a r ­
t i c u l a r  r e q u i r e m e n t s  [ 1 0 3 ] .  Q u a n t i t a t i v e  c o u ­
p l i n g s  w i t h  t h e  a m i n o  g r o u p s  o f  b o t h  t a r g e t i n g  
m o i e t i e s ,  s u c h  a s  s u g a r s ,  a n d  d r u g s ,  s u c h  a s  
m e l p h a l a n ,  c a n  b e  a c h i e v e d  w i t h i n  2 4  h .  P H E G  i s  
k n o w n  t o  b e  b i o d e g r a d a b l e .  H o w e v e r ,  i n  a n  
e x t e n s i v e  s t u d y ,  P y t e l a  e t  a l .  [ 1 0 5 ]  h a v e  i n v e s t i ­
g a t e d  t h e  r o l e  o f  p a r t i c u l a r  e n z y m e s  i n  t h i s  
d e g r a d a t i o n .  P H E G  w a s  i n c u b a t e d  w i t h  b o t h  
t h i o l  p r o t e a s e s ,  s u c h  a s  p a p a i n  a n d  c a t h e p s m  B ,  
w h i c h  h a v e  a  l y s o s o m a l  t y p e  a c t i v i t y ,  a n d  s e r i n e  
p r o t e a s e s ,  s u c h  a s  c h y m o t r y p s i n  a n d  e l a s t a s e ,  
w h i c h  a r e  f o u n d  i n  b l o o d .  I n t e r e s t i n g l y ,  t h e  
h o m o p o l y m e r  w a s  r e s i s t a n t  t o  d e g r a d a t i o n  b y  t h e  
s e r i n e  p r o t e a s e s  a n d  w a s  d e g r a d e d  b y  t h e  t h i o l  
p r o t e a s e s ,  s u g g e s t i n g  a  p o t e n t i a l  l y s o m o t r o p h i c  
c a r r i e r .  U n f o r t u n a t e l y ,  w h e n  t h e  s a m e  w o r k e r s  
i n v e s t i g a t e d  t h e  e f f e c t  o f  i n c l u s i o n  o f  a  h y d r o -  
p h o b i c  g r o u p  o n  t h e  s i d e  c h a i n ,  t h e y  f o u n d  t h a t  
t h e  c o n j u g a t e  w a s  s u s b e p t i b l e  t o  s e r i n e  p r o t e a s e s .  
T h i s  c o u l d  m e a n  t h a t  t h e  s e l e c t i v i t y  o f  d e g r a ­
d a t i o n  c o u l d  b e  a b o l i s h e d  b y  a t t a c h m e n t  o f  a  
d r u g .  N o t  s u r p r i s i n g l y ,  t h e  d e g r a d a t i o n  o f  P H E G  
w a s  r e d u c e d  b y  i n c o r p o r a t i o n  o f  s o m e  o f  t h e  
D - a m i n o  a c i d  a n d  a b o l i s h e d  i n  d - P H E G .  P H E G  
h a s  b e e n  i n v e s t i g a t e d  m a i n l y  a s  a  c a r r i e r  o f  
m i t o m y c i n  C .  S t u d i e s  i n  v i t r o  h a v e  d e m o n s t r a t e d  
t h e  p o t e n t i a l  o f  p e p t i d e  s p a c e r s  t o  a f f o r d  r e l e a s e  
o f  t h e  d r u g  w i t h i n  l y s o s o m e s  w h i l s t  r e t a i n i n g  
h y d r o l y t i c  s t a b i l i t y  i n  t h e  b l o o d  s t r e a m  b u t  t h e  
c o n j u g a t e s  h a v e  n o t  b e e n  i n v e s t i g a t e d  f u r t h e r
[ 7 6 ] .  A n o t h e r  a p p r o a c h  i n  t h e  u s e  o f  P H E G  i s  t o  
c o - p o l y m e r i s e  i t  w i t h  o t h e r  a m i n o  a c i d s  t o  
p r o d u c e  m a c r o m o l e c u l e s  w i t h  d i f f e r e n t  p r o p e r ­
t i e s  a n d  b i o d i s t r i b u t i o n  [ 1 0 5 , 1 0 6 ] .
P o l y  ( a ,  p -  N-  ( 2 -  h y d r o x y  e t h y l  ) - D L - a s p a r t a m i d e )  
( P H E A )  h a s  a l s o  b e e n  e v a l u a t e d  a s  a  p l a s m a  
e x p a n d e r  a n d  a  d r u g  c a r r i e r ,  a l t h o u g h  i t  h a s  n o t  
b e e n  w i d e l y  u s e d  a t  p r e s e n t .  P H E A  h a s  a  s i m i l a r  
c h e m i c a l  r e a c t i v i t y  t o  P H E G ,  t h u s  i t  c a n  b e  
a c t i v a t e d  t o  t h e  n i t r o p h e n y l  c a r b a m a t e  a n d  c o u ­
p l e d  t o  a m i n e - c o n t a i n i n g  m o l e c u l e s  s u c h  a s
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s u g a r s  [ 4 0 ] .  C o u p l i n g  o f  c a r b o x y l i c  a c i d  d r u g  
m o l e c u l e s  c a n  a l s o  b e  a c h i e v e d  b y  t h e  u s e  o f  
c a r b o d i i m i d e  r e a g e n t s  [ 1 0 7 ] .  F o r  o t h e r  d r u g s  
s u c h  a s  a c y c l o v i r ,  w i t h  a  h y d r o x y l  g r o u p ,  t h e  d r u g  
m o l e c u l e  c a n  b e  p r e - a c t i v a t e d  b y  t r e a t m e n t  w i t h  
s u c c i n i c  a n h y d r i d e .  A  c a r b o d i i m i d e  c o u p l i n g  c a n  
t h e n  b e  p e r f o r m e d  b e t w e e n  t h e  c a r b o x y l i c  a c i d  
o f  t h e  d r u g  d e r i v a t i v e  a n d  t h e  h y d r o x y l  o f  t h e  
p o l y m e r .  I n t e r e s t i n g l y ,  t h i s  a p p r o a c h  a l s o  r e s u l t s  
i n  t h e  i n c l u s i o n  o f  a  s p a c e r  u n i t  [ 1 0 8 ] .
5.6. Hydroxypropylmethacrylamide (HPMA)
H y d r o x y p r o p y l m e t h a c r y l a m i d e  ( H P M A )  ( 3 3 )  
a n d  i t s  c o - p o l y m e r s  h a v e  b e e n  i n v e s t i g a t e d  a s  
b l o o d  p l a s m a  e x p a n d e r s  a n d  d r u g  c a r r i e r s .  
H P M A  i s  a  s y n t h e t i c  v i n y l  p o l y m e r  p r o d u c e d  b y  
r a d i c a l  p r e c i p i t a t i o n  p o l y m e r i s a t i o n  ( F i g .  1 0 )  
[ 1 0 9 ] .  T h e  h o m o p o l y m e r  i s  n o n - i m m u n o g e n i c  
[ 8 9 ]  a n d  i s  e a s i l y  a c t i v a t e d  t o  a l l o w  t h e  a t t a c h ­
m e n t  o f  d r u g  m o i e t i e s ,  m a k i n g  i t  a n  a l m o s t  i d e a l  
m a c r o m o l e c u l e .  O n e  p o t e n t i a l  l i m i t a t i o n  o f  t h e  
s y s t e m  i s  i t s  l a c k  o f  b i o d e g r a d a b i l i t y ,  w h i c h
CH, CH, CH, CH, 
• O ^ - C - C K j - C - C H j -C - C H j - C - -
0 0 0 0 0 0 CO
NH m NH NH
s f t
CHOH CHOH CHOH CHOH




CH,—C—C—N—CH, -C H-OH  
I H 
H,C
r e s t r i c t s  t h e  u s e  t o  m a c r o m o l e c u l e s  w i t h  a  m o l e c ­
u l a r  w e i g h t  o f  l e s s  t h a n  t h e  g l o m e r u l a r  f i l t r a t i o n  
t h r e s h o l d .
T h e  h o m o p o l y m e r  i s  i t s e l f  i n e r t .  H o w e v e r ,  t h e  
h y d r o x y l  g r o u p s  c a n  b e  a c t i v a t e d  t o  a l l o w  a t t a c h ­
m e n t  o f  d r u g s  a n d  e n z y m e s .  O n e  o f  t h e  e a s i e s t  
m e t h o d s  o f  a c t i v a t i o n  i s  t o  t r e a t  H P M A  w i t h  
c y a n u r i c  c h l o r i d e  ( S c h e m e  8 )  [ 1 1 0 ] .  T h e  r e s u l t i n g  
a c t i v e  s p e c i e s  r e a c t s  e a s i l y  w i t h  e n z y m e s  i n  
a q u e o u s  s o l u t i o n .
H y d r a z i d e  d e r i v a t i v e s  c a n  a l s o  b e  p r e p a r e d ,  
w h i c h  w h e n  a c t i v a t e d  a s  t h e  a z i d e ,  c a n  b e  c o u ­
p l e d  t o  a m i n e - c o n t a i n i n g  d r u g s  ( S c h e m e  9 ) .
A c t i v a t i o n  o f  t h e  p o l y m e r  c a n  a l s o  b e  a c h i e v e d  
b y  t h e  u s e  o f  c y a n o g e n  b r o m i d e  [ 3 3 ] .  A l t h o u g h
HjC o CH, NHjNH^HjO HiC O
C H ,- C - C - N - C H 2-C H -O H  -► CMj - C - C - N - N H j
(33)
N.NO, |
HjC O  
C H j - C - C - N ,
HjC W >
RNH,
H jC  O  
C H ,—C—C -N H R
Scheme 9. 
a
h^ : o a ,  N_(
C H j-C -C - N -C H j- O l- O —( N
hJ: ^
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t h i s  r e a c t i o n  i s  v e r s a t i l e  a n d  c a n  b e  t a i l o r e d  f o r  
t h e  d e g r e e  o f  r e a c t i v i t y  r e q u i r e d ,  i t  c a n  r e s u l t  i n  
i n t e r -  a n d  i n t r a - c h a i n  r e a c t i o n s .  A l l  t h e s e  m e t h ­
o d s  d o  r e s u l t  i n  s u b s t a n t i a l  c h a n g e s  i n  t h e  s t r u c ­
t u r e  a n d  c h a r g e  o f  t h e  h o m o p o l y m e r  t h a t  m a y  
a f f e c t  b o t h  i t s  d i s t r i b u t i o n  a n d  i m m u n o g e n i c i t y  i n  
v i v o .  A n  a l t e r n a t i v e  a p p r o a c h  i s  t o  u s e  a n  a c t i v e  
e s t e r  [ 1 1 1 ] .  T r e a t m e n t  o f  t h e  h o m o p o l y m e r  w i t h  
4 - n i t r o p h e n y l  c h l o r o f o r m a t e  p r o v i d e s  a n  a c t i v e  
p o l y m e r  [ 1 1 2 ] .  A m i n o l y s i s  r e a c t i o n s  w i t h  a m i n o  
a c i d s  o r  d r u g s  r e s u l t s  i n  t h e  r e s t o r a t i o n  o f  t h e  
o r i g i n a l  p o l y m e r  s t r u c t u r e  [ 1 1 3 ] .  T h i s  i s  t h e  m o s t  
u s e f u l  a n d  v e r s a t i l e  m e t h o d  o f  a c t i v a t i o n  a v a i l ­
a b l e  ( S c h e m e  1 0 ) .
A c t i v a t i o n  o f  t h e  h o m o p o l y m e r  i s ,  h o w e v e r ,  
n o t  s u i t a b l e  f o r  r e p r o d u c i b l e  l e v e l s  o f  i n c o r p o r a ­
t i o n  o f  d r u g .  T h e  a l t e r n a t i v e  i s  t o  u s e  c o - p o l y -  
m e r i s a t i o n  m e t h o d  o f  H P M A  w i t h  d e r i v a t i s e d  
m e t h a c r y l a m i d e  u n i t s  w h i c h  c a n  e a s i l y  b e  
a c h i e v e d .  T h i s  a l l o w s  a  m o r e  a c c u r a t e  a n d  r e ­
p r o d u c i b l e  i n t e r a c t i o n  o f  r e a c t i v e  g r o u p s  i n t o  t h e  
p o l y m e r  w h i l s t  m a i n t a i n i n g  t h e  m a j o r i t y  o f  
c h a r a c t e r i s t i c s  o f  t h e  h o m o p o l y m e r .  K o p e c e k  e t  
a l .  [ 1 0 9 ]  h a v e  d e v e l o p e d  t h i s  a p p r o a c h  a n d  h a v e  
u s e d  c o - p o l y m e r s  o f  H P M A  i n c o r p o r a t i n g  p e p ­
t i d e  s p a c e r s  f o r  d e l i v e r y  o f  m a n y  d r u g s .  T h e  
g e n e r a l  m e t h o d  o f  s y n t h e s i s  i n v o l v e s  N- 
m e t h a c r y l y l a t i o n  o f  a n  a m i n o  a c i d  o r  d i p e p t i d e  
u n i t s  u n d e r  S c h o t t e n - B a u m a n n  c o n d i t i o n s .  T h e  
a - a m i n o  c a r b o x y l i c  a c i d  c a n  t h e n  b e  a c t i v a t e d  t o  
a  n i t r o p h e n y l  e s t e r  ( S c h e m e  1 1 ) .
C o - p o l y m e r i s a t i o n  o f  t h e s e  m e t h a c r y l a m i d e  
d e r i v a t i v e s  w i t h  H P M A  i s  v i a  a  r a d i c a l  m e t h o d  
i n v o l v i n g  a n  a z o  i n i t i a t o r  s u c h  a s  a , a r ' - a z o b i s ( i s o -  
b u t y r o n i t r i l e )  ( A I B N ) .  T h e  c o - p o l y m e r i s a t i o n  
t a k e s  p l a c e  r a p i d l y  a t  5 0 ° C  i n  a c e t o n e  b u t  t h e  
r a t e  o f  p o l y m e r i s a t i o n  a n d  t h e  y i e l d  o f  p o l y m e r  
a r e  r e d u c e d  i n  c o m p a r i s o n  t o  p r e p a r a t i o n  o f  t h e  
h o m o p o l y m e r .  U s i n g  t h i s  m e t h o d ,  u p  t o  1 0 %  
r e a c t i v e  s i d e  c h a i n s  h a v e  b e e n  i n c o r p o r a t e d  
( S c h e m e  1 2 ) .
D r u g  m o l e c u l e s  o r  t a r g e t i n g  m o i e t i e s  c a n  b e  
e a s i l y  i n c o r p o r a t e d  b y  a m i n o l y s i s  r e a c t i o n s .  T h e  
r e a c t i v i t y  o f  t h e  n i t r o p h e n y l  g r o u p s  o n  t h e  p o l y -
o  0*1 O O O A H .N O , O  C H ,
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m e r  i s  c o n s i d e r a b l y  r e d u c e d  i n  c o m p a r i s o n  t o  t h e  
m o n o m e r s  o w i n g  t o  s t e r i c  e f f e c t s  [ 1 1 3 ] .  T h e  r a t e  
o f  r e a c t i o n  i s  a l s o  d e p e n d e n t  o n  t h e  n a t u r e  o f  t h e  
e s t e r ,  a r - a m i n o  e s t e r s  r e a c t i n g  f a s t e r  t h a n  oj- 
a c y l a m i n o  e s t e r s .  W i t h  s o m e  d r u g s ,  i t  i s  p o s s i b l e  
t o  p r o d u c e  a  m e t h a c r y l y l a t e d  d e r i v a t i v e  t h a t  c a n  
t h e n  b e  c o - p o l y m e r i s e d .  T h i s  a p p r o a c h  h a s  b e e n  
u t i l i s e d  b y  S c h a c h t  f o r  t h e  a n t i - a r r h y t h m i c  d r u g  
p r o c a i n a m i d e .  C o - p o l y m e r i s a t i o n  o f  t h e  d e r i v a ­
t i v e  w i t h  H P M A  r e s u l t e d  i n  a  w a t e r - s o l u b l e  d r u g  
c o n j u g a t e  ( S c h e m e  1 3 )  [ 1 1 4 ] .
r
(4S)
CH, 0  
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S t u d i e s  w i t h  i o d i n e - l a b e l l e d  H P M A  p r o v i d e  a  
v a l u e  f o r  t h e  g l o m e r u l a r  f i l t r a t i o n  t h r e s h o l d  o f  
4 5  ( X X )  D a  [ 1 1 ] .  P o l y m e r s  o f  h i g h e r  m o l e c u l a r  
w e i g h t s  r e m a i n  i n  t h e  c i r c u l a t i o n  i n d e f i n i t e l y  a s  
t h e y  a r e  n o n - d e g r a d a b l e  [ 4 1 , 1 2 0 ] .  I n t r a v e n o u s  
a p p l i c a t i o n  o f  a  r a n g e  o f  H P M A  p o l y m e r s  
s h o w e d  c l e a r a n c e  f r o m  t h e  b l o o d  s t r e a m  t o  b e  
f a i r l y  r a p i d  b u t  d e p e n d e n t  o n  m o l e c u l a r  w e i g h t .  
A c c u m u l a t i o n  i n  t i s s u e ,  e . g . ,  s p l e e n  a n d  l i v e r ,  i s  
o n l y  a p p a r e n t  w i t h  p o l y m e r s  o f  7 7 8 0 0 0  D a  o r  
a b o v e .  T h u s ,  m o s t  i n t e r e s t  h a s  b e e n  f o c u s s e d  o n  
p o l y m e r s  o f  m o l e c u l a r  m a s s  < 2 0 0 0 0  D a  t o  
e n s u r e  g l o m e r u l a r  f i l t r a t i o n .  A s  h a s  b e e n  d i s ­
c u s s e d  e a r l i e r ,  t h e  d i s t r i b u t i o n  o f  H P M A  c o ­
p o l y m e r s  i n  v i v o  c a n  b e  a l t e r e d  e a s i l y  b y  i n ­
c o r p o r a t i o n  o f  n o n - s p e c i f i c  h y d r o p h o b i c  g r o u p s  
a n d  c h a r g e  o r  b y  t h e  u s e  o f  s p e c i f i c  t a r g e t i n g  
r e s i d u e s .  I n  t u m o u r - b e a r i n g  a n i m a l s ,  c o n j u g a t i o n  
o f  d r u g s  t o  H P M A  c o - p o l y m e r s  r e s u l t s  i n  a n  
i n c r e a s e d  c o n c e n t r a t i o n  o f  t h e  d r u g  i n  t u m o u r s ,  
s u g g e s t i n g  t h a t  t h e  c o - p o l y m e r  i s  t u m o u r  t r o p i c  
[ 7 0 , 7 1 ] ,
C o - p o l y m e r s  o f  H P M A  c a n n o t  b e  d e g r a d e d  b y  
e n z y m e s  i n  t h e  b l o o d  s t r e a m  o r  l y s o s o m e .  T h i s  
c o u l d  l e a d  t o  a n  u n a c c e p t a b l e  a c c u m u l a t i o n  o f  
t h e  p o l y m e r  w i t h i n  t h e  b o d y .  H e n c e ,  w i t h  t h e s e  
l i n e a r  p o l y m e r s ,  t h e  m o l e c u l a r  w e i g h t  m u s t  b e  
k e p t  b e l o w  t h e  r e n a l  t h r e s h o l d ,  p o t e n t i a l l y  r e ­
d u c i n g  t h e  t u m o u r  t r o p i c  e f f e c t .  A c c u m u l a t i o n  o f  
t h e  p o l y m e r s  c a n  b e  a v o i d e d  b y  t h e  u s e  o f  
s o l u b l e  c r o s s - l i n k e d  p o l y m e r s .  B y  c a r e f u l  c h o i c e  
o f  t h e  c r o s s - l i n k ,  s p a c e r s  c a n  b e  p r e p a r e d  w h i c h  
o n l y  d e g r a d e  w i t h i n  t h e  l y s o s o m e ,  i . e . ,  a f t e r  
d e l i v e r y  o f  t h e  d r u g .  T h e  r e s u l t i n g  l o w  m o l e c u l a r  
w e i g h t  p o l y m e r s  c a n  b e  e x c r e t e d  i n  t h e  u r i n e .  A n  
e x a m p l e  o f  a  c r o s s - l i n k e d  H P M A  c o - p o l y m e r  i s  
s h o w n  i n  F i g .  1 1  [ 1 1 6 ] .  T h e  c r o s s - l i n k i n g  r e a c t i o n  
i s  d e s i g n e d  t o  o c c u r  b e l o w  t h e  g e l  p o i n t  i n  o r d e r  
t o  p r o d u c e  a  w a t e r - s o l u b l e  r a t h e r  t h a n  a n  i n s o l u ­
b l e  p o l y m e r .  T h i s  r e a c t i o n  h a s  t o  t a k e  p l a c e  a t  
h i g h  d i l u t i o n  o w i n g  t o  t h e  l o w  s o l u b i l i t y  o f  t h e  
r e a c t a n t s .  H o w e v e r ,  t h i s  c o u l d  r e s u l t  i n  t h e  
f o r m a t i o n  o f  c y c l i s e d  s t r u c t u r e s  w i t h  t h e  a m i n e  
r e a c t i n g  t w i c e  w i t h  t h e  s a m e  p o l y m e r  c h a i n .  T h i s  
p r o b l e m  c a n  b e  a v o i d e d  b y  c r o s s - l i n k i n g  t h e  
p o l y m e r  t h r o u g h  s h o r t  d i a m i n e s ,  s u c h  a s  e t h a n e -  
1 , 2 - d i a m i n e .  T h i s ,  h o w e v e r ,  c o u l d  l e a d  t o  d e ­
c r e a s e d  e n z y m a t i c  d e g r a d a b i l i t y .  C y c l i s a t i o n  c a n  
b e  m o r e  e a s i l y  o v e r c o m e  b y  e m p l o y i n g  a  t w o -  
s t e p  r e a c t i o n .  T r e a t m e n t  o f  t h e  p o l y m e r  w i t h  a
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Fig. 11.
l a r g e  e x c e s s  o f  t h e  d i a m i n e  w i l l  m i n i m i s e  c y c l i s a ­
t i o n  a n d  m a x i m i s e  t h e  f o r m a t i o n  o f  f r e e  a m i n e s .  
I n  a  s e c o n d  s t e p ,  t h e  f i j e e  a m i n o  g r o u p s  c a n  t h e n  
b e  a l l o w e d  t o  r e a c t  W i t h  m o r e  p o l y m e r  s t a r t i n g  
m a t e r i a l  [ 1 0 9 ] .  T w o - s t a g e  c r o s s - l i n k i n g  a l s o  a l ­
l o w s  t h e  f o r m a t i o n  o f  v e r y  h i g h  m o l e c u l a r  w e i g h t  
p r o d u c t s .  I n i t i a l l y ,  m o d e l  s t u d i e s  o n  t h e  d e g r a ­
d a t i o n  o f  p e p t i d e  s e q u e n c e s  b e t w e e n  t h e  b i s -  
a m i n e  a n d  p o l y m e r  w e r e  p e r f o r m e d .  A m i n o  a c i d  
s e q u e n c e s  w e r e  p r e p a r e d  w h i c h  s h o w e d  s i m i l a r  
s p e c i f i c i t y  a s  s i d e - c h a i n s  f o r  t h e  e n z y m e s  c h y m o -  
t r y p s i n  [ 1 1 7 ] ,  t r y p s i n  1 1 8 ]  a n d  p a p a i n  [ 1 1 9 ] .  I n  a l l  
c a s e s ,  d e g r a d a t i o n  w a s  r e d u c e d  i n  c o m p a r i s o n  t o  
t h e  s a m e  c h a i n s  a t t a c h e d  t o  t h e  l i n e a r  p o l y m e r s .  
T h i s  c o u l d  b e  d u e  t o  e i t h e r  d e c r e a s e d  a c c e s s  o f  
t h e  e n z y m e  t o  t h e  b o n d  t o  b e  c l e a v e d  o r  t o  
c o n f o r m a t i o n a l  c o n s t r a i n t s  o f  t h e  a m i n o  a c i d  
s e q u e n c e  a s  i t  i s  t e t h e r e d  a t  b o t h  e n d s .
T h i s  d e c r e a s e  i n  d e g r a d a b i l i t y  w a s  e s p e c i a l l y  
p r o n o u n c e d  w i t h  c r o s s - l i n k e d  p o l y m e r s  w i t h  
e i t h e r  a  t w o  a m i n o  a c i d  p e p t i d e  s e q u e n c e  o r  a  
s h o r t  d i a m i n e  [ 1 1 7 , 1 1 9 ] .  C r o s s - l i n k e d  p o l y m e r s  
h a v e  b e e n  e v a l u a t e d  i n  v i t r o  f o r  l y s o s o m a l  d e g r a ­
d a t i o n  u s i n g  i s o l a t e d  c a t h e p s i n  B .  D e g r a d a t i o n  
w a s  a g a i n  h i g h e s t  w i t h  l o n g  a m i n o  a c i d  c h a i n s  o r  
w i t h  a  l o n g  a , c o - d i a m i n e  [ 5 7 ] ,  I n  a  f u r t h e r  s t u d y ,  
c r o s s - l i n k e d  p o l y m e r s  w i t h  t h e  a m i n o  a c i d  s e ­
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quence GlyGlyPheTyr were degraded easily by 
rat lysosomal enzymes but were resistant to 
degradation in plasma. Preliminary experiments 
with the same polymer in vivo in rats confirmed 
that degradation takes place, as low molecular 
weight chains were excreted (120]. This approach 
has not been investigated further in the develop­
ment of intravenous agents for the treatment of 
cancer, although HPMA cross linked polymers 
formed above the gel point are being evaluated 
for colon specific drug release [121].
The immune response to both HPMA and 
co-polymers of HPMA has been thoroughly 
investigated by Rihova [89]. Injection of the 
homopolymer does not appear to result in an 
immune response in mice as no antibody titre is 
measurable. Incorporation of peptidyl side 
chains, however, does result in the production of 
antibodies. This is a weak reaction, the titre is 
considerably lower than for a model immunogen, 
bovine gamma globulin, and the antibodies are 
of the weak IgM class [122]. Injection of a wide 
range of doses of the co-polymers demonstrated 
a tolerance reaction; the antibody response to 
most co-polymers was higher for a 10 /xg kg" 1 
dose than for a 100 fig  kg" 1 dose. The structure 
of the peptide also had an effect on the antibody 
titre but no structure-activity relationships could 
be evaluated. Interestingly, using one peptide 
spacer at different substitution levels did not 
affect the number of antibodies raised. This 
suggests that the presence of only one or two 
epitopes, as in the 1 mol% conjugate, can elicit 
an antibody response [122]. The specificity of the 
antibodies has also been investigated in cross- 
reactivity reactions. These showed that the ma­
jority of antibodies formed were directed to the 
peptide sequence and therefore could not cross- 
react but some were raised against the polymer 
backbone, most probably against the hydroxy- 
propyl unit. This suggests that, although anti­
bodies are not raised against the homopolymer, 
once the entire molecule becomes immunogenic 
-due to the peptide chain, antibodies are raised 
against all parts of the molecule. Similar results 
were obtained with co-polymers bearing ad- 
riamydn. A low antibody response were seen at 
all doses and was unaffected by the incorporation 
of galactosamine targeting residues [115]. The
effect of incorporation of known haptens has also 
been investigated. Again, the majority of anti­
bodies were raised against the hapten. With this 
system, the effect of molecular weight on im­
munogenicity was evaluated. More antibodies 
were raised to the hapten with a co-polymer of 
molecular mass 200000 Da than for one of 5000 
Da [89]. The effect of pre-immunisation on the 
efficacy of a daunomydn HPMA co-polymer has 
also been evaluated. Pre-immunisation can either 
give no effect, an adverse toxic affect or result in 
loss of activity of a drug. In this system, pre- 
immunisation over 35 days prior to inoculation of 
the mice with L1210 cells resulted in no loss of 
activity of the conjugate [123].
5.7. Poly (ethylene glycol) (PEG)
Poly(ethylene glycol) is a non-toxic, non-im- 
munogenic, highly water-soluble linear polymer 
[124]. It has mainly been used medically in the 
modification of therapeutic proteins. Modifica­
tion of proteins with PEG leads to a decrease in 
the toxidty and immunogenidty of the protein, 
whilst increasing both the water solubility and 
plasma half-life [124- 126]. These properties sug­
gest that conjugation of a drug to PEG or PEG 
co-polymers would provide an ideal non-toxic 
macromolecular pro-drug with enhanced plasma 
lifetime and potentially increased tumour uptake. 
Much research has been directed towards the 
preparation of activated PEG for attachment to 
proteins. The coupling reaction in this system is 
usually between PEG monomethyl ether and the 
e-amino group of protein lysine residues [124]. 
Therefore, most active derivatives are based on 
carboxylic acids. For the conjugation of drug or 
the formation of block co-polymers, amine res­
idues may be required. These can be provided by 
treatment of carboxyl-activated PEG with an 
a,^-diamine or by direct conversion of PEG to a 
PEG-amine [127,128].
Activation of PEG with cyanuric chloride is 
one of the oldest and most widely used methods 
for protein coupling. The original method of 
Abuchowski and Davis has been modified by 
Harris [129] to enable complete conversion with­
in 2 h, through the use of alkoxides (Scheme 14). 
Coupling of proteins using this method has been













l i n k e d  t o  i n a c t i v a t i o n  o f  t h e  p r o t e i n  [ 1 2 5 , 1 3 0 ] ,  
c r o s s - l i n k i n g  a n d  n o n - s p e c i f i c  c o u p l i n g  t o  O H  
a n d  S H  r e s i d u e s .  T h u s ,  t h i s  m e t h o d  h a s  b e e n  
o v e r t a k e n  b y  m o r e  r e c e n t  a d v a n c e s .
A c t i v a t i o n  u s i n g  c a r b o d i i m i d e s  ( S c h e m e  1 5 )  i s  
e f f e c t i v e  a n d  d o e s  n o t  l e a d  t o  c r o s s - l i n k i n g .  
H o w e v e r ,  t h e  c o u p l i n g  r e a c t i o n  i s  s l o w  a n d  c a n  
t a k e  u p  t o  7 2  h .  T h i s  m e t h o d ,  t h e r e f o r e ,  i s  o f  
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T r e a t m e n t  o f  P E G  w i t h  s u c c i n i c  a n h y d r i d e  
g e n e r a t e s  a  c a r b o x y l i c  a c i d  w h i c h  c a n  b e  a c t i ­
v a t e d  v i a  a  D C C  c o u p l i n g  t o  f o r m  t h e  N - h y -  
d r o x y s u c c i n i m i d e  e s t e r  ( S c h e m e  1 6 )  [ 1 3 0 ] .  T h e s e  
d e r i v a t i v e s  r e a c t  q u i c k l y  w i t h  a m i n e s  [ 1 3 2 ]  b u t  
t h e  r e s u l t i n g  p r o d u c t  c a n  b e  u n s t a b l e  o w i n g  t o  
h y d r o l y s i s  o f  t h e  e s t e r  l i n k a g e .
A n  a l t e r n a t i v e  a p p r o a c h ,  d e v e l o p e d  b y  
2 ^ a l i p s k y ,  a l l o w s  t h e  f o r m a t i o n  o f  a  N - h y d r o x y -  
s u c c i n i m i d e - a c t i v a t e d  P E G  w i t h o u t  h y d r o l y t i c  
i n s t a b i l i t y .  T r e a t m e n t  o f  P E G  w i t h  p h o s g e n e  
f o l l o w e d  b y  N - h y d r o x y s u c c i n i m i d e  r e s u l t s  i n  a  
s t a b l e  u r e t h a n e  d e r i v a t i v e  b e t w e e n  a n  a m i n e  
d r u g  a n d  P E G  ( F i g .  1 2 )  [ 1 3 2 ] .
T h e s e  a r e  o n l y  t h e  m a i n  m e t h o d s  u s e d .  A c t i v a ­
t i o n  a n d  c o u p l i n g  h a v e  a l s o  b e e n  a c h i e v e d  b y  
r e d u c t i v e  a m i n a t i o n  w i t h  P E G  a l d e h y d e ,  b y  
e p o x i d e  f o r m a t i o n  w i t h  e p i c h l o r o h y d r i n
[ 1 3 3 . 1 3 4 ] ,  a n d  f o r m a t i o n  o f  t r e s y l a t e s  ( 2 , 2 , 2 - t r i -  
f l u o r o e t h a n e s u l p h o n a t e s ) .
A  n u m b e r  o f  c o - p o l y m e r s  o f  P E G  h a v e  b e e n  
p r e p a r e d  f o r  u s e  i n  d r u g  d e l i v e r y .  Z a l i p s k y
[ 1 3 2 . 1 3 5 ]  u t i l i s e d  t h e  N - h y d r o x y s u c c m i m i d e  
m e t h o d  t o  p r e p a r e  a  c o - p o l y m e r  o f  P E G  a n d  
l y s i n e  w i t h  t h e  a m i n o  a c i d  l i n k e d  t h r o u g h  t h e  a- 
a n d  e - a m i n o  g r o u p s  ( S c h e m e  1 7 ) .  T h e  d e g r e e  o f  
p o l y m e r i s a t i o n  c o u l d  I j e  e a s i l y  a l t e r e d  b y  v a r y i n g
o
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Scheme 17.
t h e  r e a c t i o n  t i m e  a n d  c o n c e n t r a t i o n  o f  t h e  r e a c ­
t a n t s .  A  p o l y m e r  o f  m o l e c u l a r  m a s s  1 7 0 0 0 0  D a  
w a s  a c h i e v e d  i n  a  2  h  p o l y m e r i s a t i o n  s t a r t i n g  
f r o m  P E G  o f  m e a n  m o l e c u l a r  m a s s  2 0 0 0  D a .  T h e  
c o - p o l y m e r  h a s  p e n d a n t  c a r b o x y l i c  a c i d s  t h a t  c a n  
b e  e a s i l y  a c t i v a t e d  a s  a z i d e s  o r  a c t i v e  e s t e r s
[ 1 3 2 ] .
A n  A B  b l o c k  c o - p o l y m e r  o f  P E G  m o n o m e t h y l  
e t h e r  w i t h  p o l y  ( a s p a r t i c  a c i d )  h a s  a l s o  b e e n  
p r e p a r e d .  I n  t h i s  c a s e ,  a n  a m i n e  d e r i v a t i v e  o f  
P E G  a c t s  a s  a n  i n i t i a t o r  f o r  t h e  N - c a r b o x -  
y a n h y d r i d e  p o l y m e r i s a t i o n  o f  / 3 - b e n z y l - p r o t e c t e d  
a s p a r t i c  a c i d  [ 1 3 3 ] .
P E G  a s  w e l l ,  a s  b e i n g  c h e m i c a l l y  i n e r t ,  i s  n o t  
s u s c e p t i b l e  t o  b i o d e g r a d a t i o n .  T h u s ,  i f  h i g h  m o ­
l e c u l a r  w e i g h t  c o - p o l y m e r s  a r e  t o  b e  u s e d  f o r  
m a c r o m o l e c u l a r  p r o - d r u g  p r o d u c t i o n ,  e n z y m a t i ­
c a l l y  d e g r a d a b l e  u n i t s  m u s t  b e  i n t r o d u c e d  t o  t h e  
s t r u c t u r e .  O b v i o u s l y ,  i n  a  c o - p o l y m e r  o f  P E G  
a n d  p o l y  ( a s p a r t i c  a c i d ) ,  t h e  a s p a r t i c  a c i d  u n i t  w i l l  
b e  d e g r a d a b l e ,  a l l o w i n g  b r e a k d o w n  o f  t h e  p o l y ­
m e r  [ 1 3 3 ] .  U n f o r t u n a t e l y ,  t h i s  d e g r a d a t i o n  w o u l d  
n o t  b e  s p e c i f i c  t o  t h e  l y s o s o m a l  c o m p a r t m e n t .  
H o w e v e r ,  b y  d e v e l o p i n g  p a r t i c u l a r  s m a l l  p e p t i d e  
l i n k a g e s ,  i t  m a y  b e  p o s s i b l e  t o  p r o d u c e  a  s e l e c ­
t i v e l y  d e g r a d a b l e  c o - p o l y m e r .  U l b r i c h  e t  a l .  [ 6 6 ]  
i n v e s t i g a t e d  t h e  d e g r a d a b i l i t y  o f  P E G  u n i t s  
l i n k e d  v i a  d i a m i n e s  i n c o r p o r a t i n g  o n e  a m i n o  
a c i d ,  P h e .  T h r e e  p o l y m e r s  w e r e  s y n t h e s i s e d ,  o n e  
c o n t a i n i n g  b o t h  e n z y m a t i c a l l y  a n d  h y d r o l y t i c a l l y  
d e g r a d a b l e  b o n d s  ( p o l y m e r  A )  a n d  t w o  c o n ­
t a i n i n g  e n z y m e - s e n s i t i v e  b o n d s  ( p o l y m e r s  B  a n d  
C )  ( F i g .  1 3 ) .  T h e s e  w o r k e r s  w e r e  a b l e  t o  d e m o n ­
s t r a t e  t h e  c l e a v a g e  o f  a l l  t h r e e  p o l y m e r s  b y  
c h y m o t r y p s i n ;  h o w e v e r ,  o n l y  p o l y m e r  A  w a s
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d e g r a d e d  h y d r o l y t i c a l l y .  W i t h  p o l y m e r s  B  a n d  C ,  
t h e  r a t e  o f  d e g r a d a t i o n  d e p e n d e d  o n  t h e  o r i e n t a ­
t i o n  o f  t h e  p e p t i d e  b o n d  w i t h  r e s p e c t  t o  t h e  P E G  
c h a i n .  I n  p o l y m e r  B ,  m o r e  f a v o u r a b l e  e n z y m e -  
s u b s t r a t e  i n t e r a c t i o n s  a r e  p r o v i d e d ,  w h e r e  P E G  
i s  i n  P 2 t o  P 4  t h a n  i n  p o l y m e r  C  w h e r e  t h e s e  
p o s i t i o n s  a r e  o c c u p i e d  b y  t h e  b i s - a m i n e .  T h u s ,  
t h e  d e g r a d a t i o n  o f  P o l y m e r  B  i s  f a s t e r  t h a n  
p o l y m e r  C .  T h e s e  r e s u l t s  d e m o n s t r a t e  C h e  e a s e  o f  
p r o d u c i n g  d e g r a d a b l e  P E G  c o - p o l y m e r s  [ 6 6 ] .  
H o w e v e r ,  b e f o r e  t h e s e  p o l y m e r s  c a n  b e  u s e d  a s  
d r u g  c a r r i e r s ,  e i t h e r  a n  a m i n o  a c i d  w i t h  f u n c ­
t i o n a l i t y  o r  a  m o d i f i e d  b i s - a m i n e  m u s t  b e  i n t r o ­
d u c e d  t o  a l l o w  a t t a c h m e n t  o f  a  d r u g  m o l e c u l e .
P E G  i s  u n c h a r g e d  a n d  h y d r o p h i l i c  a n d ,  t h e r e ­
f o r e ,  d o e s  n o t  i n t e r a c t  e a s i l y  w i t h  b o d y  c o m ­
p o n e n t s .  A n  e x a m p l e  o f  t h i s  i s  t h e  r e d u c e d  
u p t a k e  o f  m i c r o s p h e r e s  i n t o  t h e  r e t i c u l o - e n d o -  
t h e l i a l  s y s t e m  w h e n  t h e y  a r e  c o a t e d  w i t h  P E G
[ 1 3 3 ] .  S t u d i e s  [ 1 3 4 ]  o f  t h e  b o d y  d i s t r i b u t i o n  o f  
P E G  i n j e c t e d  i n t r a v e n o u s l y  t o  m i c e  s h o w  t h a t  
t h e  h a l f - l i f e  i s  d e p e n d e n t  o n  m o l e c u l a r  w e i g h t  
a n d  c a n  v a r y  b e t w e e n  m i n u t e s  a n d  d a y s .  U r i n a r y  
c l e a r a n c e  w a s  d e p e n d e n t  o n  m o l e c u l a r  m a s s  a n d  
a  g l o m e r u l a r  f i l t r a t i o n  t h r e s h o l d  w a s  c a l c u l a t e d  
t o  b e  3 0 0 0 0  D a .  U p t a k e  b y  o t h e r  o r g a n s  w a s  
u n r e l a t e d  t o  t h e  m o l e c u l a r  w e i g h t  o f  t h e  p o l y ­
m e r ;  a p p r e c i a b l e  a c c u m u l a t i o n  w a s  o n l y  s e e n  i n  
t h e  k i d n e y  a n d  l i v e r .  T h i s  a c c u m u l a t i o n  w a s  
t h o u g h t  t o  b e  d u e  t o  u p t a k e  b y  m a c r o p h a g e s  a n d  
K u p f f e r  c e l l s .
P E G  h a s  l o w  t o x i c i t y .  S t u d i e s  i n  d o g s  h a v e
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s h o w n  n o  t o x i c  o r  c u m u l a t i v e  e f f e c t s  e v e n  a t  t h e  
h i g h  d o s e  o f  9 0  m g  k g - 1  d a y ' 1 [ 1 2 4 ] .  S t u d i e s  i n  
r a t s  h a v e  c o n f i r m e d  t h e s e  r e s u l t s ,  a d m i n i s t r a t i o n  
o f  a  1 6 %  w / w  o r a l  d o s e  o f  P E G  h a v i n g  n o  
a d v e r s e  e f f e c t s .  T h e r e  h a v e  b e e n  o c c a s i o n a l  
r e p o r t s  o f  t o x i c i t y  i n  m a n  o n  o r a l  a n d  t o p i c a l  
a d m i n i s t r a t i o n .  H o w e v e r  t h e s e  r e a c t i o n s  a r e  n o t  
s e e n  w i t h  i n t r a v e n o u s  a p p l i c a t i o n  [ 1 3 1 ] .  P E G  i s  
a l s o  n o n - i m m u n o g e n i c .  A n t i b o d i e s  w e r e  n o t  
r a i s e d  t o  P E G  o f  m o l e c u l a r  m a s s  <  1 0 0 0 0 0  D a  
i n  r a b b i t s ,  e v e n  i n  t h e  p r e s e n c e  o f  c o m p l e t e  
F r e u n d s  a d j u v a n t .  I n v e s t i g a t i o n s  o n  t h e  i m m u n o ­
g e n i c i t y  o f  P E G - p r o t e i n  c o n j u g a t e s  h a v e  d e m o n ­
s t r a t e d  a  d e c r e a s e  i n  t h e  a n t i g e n i c i t y  o f  t h e  
p r o t e i n .  P r o t e i n s  a r e  h i g h l y  a n t i g e n i c  d u e  t o  t h e i r  
h e t e r o g e n e i t y .  T h e  d e c r e a s e  i n  i m m u n o g e n i c i t y ,  
m e a s u r e d  b y  d e c r e a s e d  a n t i b o d y  t i t r e ,  i s  t h o u g h t  
t o  b e  d u e  t o  a  s h i e l d i n g  e f f e c t  o f  t h e  P E G  c h a i n ,  
p r e v e n t i n g  r e c o g n i t i o n  o f  t h e  h a p t e n s  
[ 8 9 , 1 2 4 , 1 3 0 ] .  W h e n  a n t i b o d i e s  a r e  r a i s e d  t o  P E G -  
p r o t e i n  c o n j u g a t e s ,  a  p o r t i o n  o f  t h e  a n t i b o d i e s  
a r e  r a i s e d  a g a i n s t  t h e  P E G  c h a i n .  I n j e c t i o n  o f  
P E G - a l l e r g e n s  t o  h u m a n s  d o e s  r e s u l t  i n  t h e  
f o r m a t i o n  o f  a n t i - P E G  a n t i b o d i e s  i n  5 0 %  o f  t h e  
p o p u l a t i o n  b u t  t h e s e  a r e  o f  t h e  w e a k  I g M  t y p e .  
I n  f a c t ,  2  y e a r s  a f t e r  a d m i n i s t r a t i o n ,  n o  c i r c u l a t ­
i n g  a n t i b o d i e s  t o  P E G  c a n  b e  s e e n .  T h i s  r e ­
s p o n s e ,  t h e r e f o r e ,  i s  n o t  t h o u g h t  t o  b e  o f  c l i n i c a l  
s i g n i f i c a n c e  [ 1 2 4 ] .
T h e  s h i e l d i n g  p r o p e r t y  o f  P E G  m a y  a l s o  p r o v e  
b e n e f i c i a l  w i t h  P E G  b l o c k  c o p o l y m e r s  b e a r i n g  
d r u g s .  M a n y  d r u g s  a r e  v e r y  a c t i v e  h a p t e n s ,  s o  
c o u p l i n g  w i t h  P E G  c o - p o l y m e r s  m a y  r e d u c e  t h e i r  
i m m u n o g e n i c i t y .  T h e  m i c e  l i a r  s t r u c t u r e s  f o r m e d  
b y  s o m e  A J B  b l o c k  c o - p o l y m e r s  o f  P E G  a r e  a l s o  
h i g h l y  u n l i k e l y  t o  b e  i m m u n o g e n i c .  I n i t i a l  s t u d i e s  
b y  P r a t t e n  e t  a l .  o n  b l o c k  c o - p o l y m e r s  o f  P E G  
a n d  P o l y ( L y s )  s u b s t i t u t e d  w i t h  p a l m i t o y l  g r o u p s  
g a v e  s u r p r i s i n g  r e s u l t s  [ 3 1 ] .  I t  w a s  e x p e c t e d  t h a t  
p i n o c y t i c  u p t a k e  o f  t h i s  p o l y m e r  w o u l d  b e  h i g h  
o w i n g  t o  h y d r o p h o b i c  i n t e r a c t i o n s  b e t w e e n  t h e  
p a l m i t o y l  g r o u p s  a n d  t h e  c e l l  s u r f a c e .  H o w e v e r ,  
n o  i m p r o v e m e n t  o v e r  P E G  w a s  s e e n .  I t  w a s  
s u g g e s t e d  t h a t  t h e  b l o c k  c o - p o l y m e r  f o r m s  a  
m i c e l l a r  s t r u c t u r e  i n  w h i c h  t h e  p a l m i t o y l  g r o u p s  
a r e  i n  a  c e n t r a l  c o r e  a n d  c a n n o t  i n t e r a c t  w i t h  t h e  
c e l l  s u r f a c e .  T h i s  s y s t e m  w a s  f u r t h e r  i n v e s t i g a t e d  
b y  R i n g s d o r f  e t  a l . ,  w i t h  a  d r u g  m o i e t y ,  a n  
i n a c t i v e  c y c l o p h o s p h a m i d e ,  a t t a c h e d  t o  t h e  p a l ­
m i t o y l  g r o u p .  T h e  d r u g  i s  u s u a l l y  r a p i d l y  h y d r o ­
l y s e d  t o  a n  a c t i v e  d e r i v a t i v e .  H o w e v e r ,  w h e n  
a t t a c h e d  t o  t h e  p o l y m e r ,  t h i s  h y d r o l y s i s  w a s  
s l o w e r .  S t u d i e s  o f  t h e  c r o s s - l i n k i n g  o f  D N A  d u e  
t o  t h e  d r u g  w e r e  e v a l u a t e d  i n  L 1 2 1 0  c e l l s  i n  
v i t r o .  M a x i m a l  c r o s s - l i n k i n g  w a s  a c h i e v e d  c o n ­
s i d e r a b l y  l a t e r  w i t h  t h e  c o n j u g a t e  t h a n  w i t h  f r e e  
d r u g .  I t  w a s  s u g g e s t e d  t h a t  t h e  d r u g  w a s  w i t h i n  a  
m i c e l l e  c o r e  a n d  w a s  o n l y  r e l e a s e d  a f t e r  c e l l u l a r  











M o r e  r e c e n t l y ,  Y o k o y a m a  e t  a l .  [ 1 3 5 , 1 3 6 ]  h a v e  
c o n s c i o u s l y  d e v e l o p e d  a  b l o c k  c o p o l y m e r  p r o -  
d r u g  s y s t e m  t h a t  s p o n t a n e o u s l y  f o r m s  m i c e l l e s  i n  
s o l u t i o n .  T h e  s y s t e m  i s  b a s e d  o n  a  c o - p o l y m e r  o f  
P E G  a n d  p o l y ( A s p ) ,  w h e r e  d r u g  m o l e c u l e s  s u c h  
a s  a d r i a m y c i n  c a n  b e  a t t a c h e d  t o  t h e  a s p a r t i c  
c a r b o x y l i c  f u n c t i o n s .  T h e  c o - p o l y m e r  i s  e a s i l y  
p r o d u c e d .  P E G  a c t s  a s  t h e  i n i t i a t o r  f o r  t h e  
p o l y m e r i s a t i o n  o f  t h e  a s p a r t i c  u n i t  a n d ,  f o l l o w i n g  
d e p r o t e c t i o n  o f  t h e  p o l y m e r ,  a d r i a m y c i n  c a n  b e  
i n t r o d u c e d  v i a  a n  E D C  c o u p l i n g .  I n c o r p o r a t i o n  
o f  a  d r u g  o n t o  a  m a c r o m o l e c u l e  i s  u s u a l l y  l i m i t e d  
b y  t h e  s o l u b i l i t y  o f  t h e  c o n j u g a t e ;  a s  t h e  l e v e l  o f  
d r u g  i n c r e a s e s ,  p r e c i p i t a t i o n  c a n  o c c u r .  W i t h  
t h e s e  b l o c k  p o l y m e r s ,  h o w e v e r ,  5 0  m o l %  o f  d r u g  
c a n  b e  i n c o r p o r a t e d  [ 1 3 6 , 1 3 7 ] .  T h i s  p r o p e r t y  i s  
d e p e n d e n t  o n  t h e  s o l u b i l i s i n g  a c t i o n  o f  P E G ,  a s  
s i m i l a r  i n c o r p o r a t i o n s  c a n n o t  b e  a c h i e v e d  w i t h  
p o l y  ( A s p )  [ 1 3 8 ] .  A n a l y s i s  o f  t h e s e  c o - p o l y m e r s  
g a v e  a p p a r e n t  m o l e c u l a r  m a s s e s  > 3 0 0 0 0  D a ,  
w h e r e  t h e  s i n g l e - c h a i n  m o l e c u l a r  m a s s  i s  9 0 0 0  
D a .  T h i s  s u g g e s t s  t h a t  a n  a g g r e g a t i o n  p r o c e s s  h a s  
o c c u r r e d ,  i . e . ,  a  m i c e l l e  h a s  b e e n  f o r m e d .  T h i s  i s  
c o n f i r m e d  a s  t h e s e  s t r u c t u r e s  a r e  b r o k e n  o n  
t r e a t m e n t  w i t h  a  s u r f a c t a n t  [ 1 3 9 ] .  I t  h a s  b e e n  
s u g g e s t e d  t h a t  s i n g l e  p o l y m e r  c h a i n s  e x i s t  i n  a n
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equilibrium with the micelles and that drug 
release is only achieved from the single chain 
[138]. The micellar size can be altered within 
tight limits by altering the molecular weight of 
the PEG chain. However, altering either the 
length of the poly(Asp) chain or the content of 
incorporated drug does not affect the size of the 
micelle [138].
These systems have been investigated exten­
sively, both for their distribution in vivo and 
cytotoxicity [137]. In a distribution study in vivo, 
the existence of micelles was confirmed. No 
urinary clearance was measured for two conju­
gates based on PEG 5000 and 12000 despite the 
fact that their molecular weights are below the 
glomerular filtration threshold. The conjugates 
remained in the blood stream for a prolonged 
period and were passively accumulated into the 
tumour. After 24 h, a concentration of 10% of 
dose per g of tissue was seen for the tumour, 
whereas for free drug the highest concentration 
was 0.9%. Coupled with this, the conjugate 
displays decreased accumulation in the heart, a 
major organ for toxicity, in comparison to free 
drug [137,138]. The activity in mice with P388 
leukaemia has also been evaluated. The conju­
gates displayed increased activity and decreased 
toxicity when compared to the free drug [138]. 
These workers have also attached an antibody to 
this system and demonstrated that the micelle 
structure is lost. In this situation, the single 
polymer chains form an ideal conformational 
state in which the disulphide linkage to the 
antibody is protected by the aspartic acid res­
idues [139- 141]. Micelle formation is only pos­
sible with block co-polymers of an AB structure. 
However, it is thought that, in more complicated 
co-polymers, the molecule will arrange itself into 
the most suitable conformational state. With 
PEG co-polymers, the PEG will be exposed to 
the circulation and hydrophobic units will be 
protected, as is the case with PEG-substituted 
proteins [139].
An interesting approach to the use of PEG as 
a macromolecular carrier has recently been pro­
posed [142]. In this case, one PEG chain is 
coupled to one drug molecule, e.g., adriamycin, 
and one targeting group, lactose. This conjugate 
was active in vitro in both leukaemia and hepato­
ma cell lines. Despite this efficacy, this system 
cannot be considered ideal as a large number of 
conjugates would have to be delivered to the cell 
rather than one conjugate bearing many drug 
molecules. Nathan et al. [135] have investigated a 
co-polymer of PEG and lysine as a carrier for the 
antibacterial drugs; cephradine and penicillin V. 
In this approach, the pendant carboxylic acid of 
the amino acid was successfully converted to 
other reactive groups, such as amino and hy­
droxyl, to enable the coupling of a variety of 
compounds. Both biodegradable and non- 
biodegradable conjugates were prepared, a num­
ber of which also incorporated a spacer.
6. Macromolecular systems for magnetic 
resonance imaging
6.1. Introduction
The majority of research on macromolecular 
carriers has involved the investigation of macro­
molecular pro-drugs for the treatment of cancer. 
However, almost any drug can be attached to a 
carrier, to allow targeting or to increase blood 
circulation time. Macromolecules can also be 
used in the imaging of tumours and other dis­
eases. A range of macromolecular contrast 
agents have been produced for use in Magnetic 
Resonance Imaging (MRI). These are successful 
not only in the imaging of tumours and inflam­
mation but as blood pool contrast agents to allow 
investigation of perfusion and occlusion of the 
vascular system. The basis of contrast enhance­
ment of MR images and contrast agents are 
considered in this section.
MRI is based on detecting the NMR signals of 
water protons within the body. Tissues contain 
varying amounts of water and this is the basis of 
contrast between organs. This is enhanced by 
using a gradient magnetic field. The protons then 
resonate at a different frequency depending on 
the position within the field. This allows spatial 
information to be combined with the resonance 
frequencies and transformed into an image of the 
organs within the body [143]. When a magnetic 
field is applied to a proton, the induced magnet­
ism is aligned along the Z-axis. When a radio
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frequency pulse is applied this magnetic vector 
moves away from the axis and then returns or 
‘relaxes’ back to the axis. The time taken for this 
relaxation is 7 ,, the spin lattice (longitudinal) 
relaxation time. A component of the magnetic 
field lies perpendicular to the Z-axis; this is also 
perturbed by application of a pulse and relaxes 
back with a relaxation time T2, the spin-spin 
(transverse) relaxation time. So, in MRI, pulses 
are applied rapidly to prepare images that are 
based on the different relaxation rates of water 
protons [143,144].
In some cases, in normal, non-enhanced tissue, 
the properties of two tissues are not sufficiently 
different to allow imaging of lesions or tumours. 
In these cases, a contrast enhancement agent can 
be used. These can either alter the spin density 
of a tissue or the relaxation times of the protons 
within the tissue. Spin density is a measure of the 
number of protons in a volume. By using gases, 
such as C0 2, and perfluorocarbons, which have 
no hydrogen atoms, the total spin density within 
the area can be reduced, giving a decrease in 
signal intensity [145,146]. However, most interest 
has been focussed on altering the Tl and T2 
times of tissues. Tissues with short 7 , give 
brighter images than those with long 7 j as the 
majority of the magnetism is aligned along the 
Z-axis at a given time. In contrast, tissues with 
short 7 2 values have decreased signal intensity 
and are seen in images as dark areas. The values 
of 7 , and 72 can be altered in vitro and in vivo 
by the addition of compounds with magnetic 
properties [143,145].
6.1.1. Diamagnetism
Most molecules are diamagnetic; that is, they 
have no magnetic dipole as they contain no 
unpaired electrons. In an applied magnetic field, 
they do exhibit a small net magnetism which is 
aligned antiparallel to the applied field. This 
small local field exerts only a minor effect on the 
water protons of a tissue. Hence, addition of a 
diamagnetic ion does not result in enhanced 
images [147].
6.1.2. Paramagnetism
Paramagnetism occurs when an ion or mole­
cule contains unpaired electrons. Although there
is no net magnetism without application of an 
external field, once an external field is applied 
orientation of the unpaired electrons results in 
the formation of a strong local magnetic field. 
Paramagnetism is prevalent in transition metals, 
where there is preferential filling of the 4s level 
giving rise to a number of unpaired electrons in 
the 3d level, and the lanthanides. Thus Mn2+, 
with five unpaired electrons, and GdJ + , with 
seven unpaired electrons, are effective paramag­
netic ions [147], If a paramagnetic ion is intro­
duced into the body, it can interact with the 
proton nuclei of water molecules to reduce both 
the 7 , and 7 2 relaxation times. The ability of the 
ion to alter the relaxation times depends upon 
the ease of approach of the proton to approach 
the paramagnetic centre and is termed relaxivity. 
This property depends on the magnetic moment 
of the ion, which is itself related to the number 
of unpaired electrons. Thus, Mn2+, GdJ*. and 
Fe3+ ions have high relaxivities owing to their 
large magnetic moments [145]. The type of 
interaction can be inner sphere, in which a 
molecule of water binds directly to the primary 
co-ordination sphere of the metal ion from which 
it can exchange with the bulk water. Alternative­
ly, outer sphere interactions can occur, where 
there is no direct binding. Relaxivity is a combi­
nation of these effects, although outer sphere 
mechanisms are only of interest with chelated 
ions [140]. Relaxivity is also dependent on the 
correlation time, which is a term describing the 
likelihood of an interaction occurring between 
the unpaired electron and a water molecule. The 
correlation time is the sum of three correlation 
times; the rotational 7 R, the electron spin relaxa­
tion 7 S and chemical exchange 7 M [143].
1 /T C = 1 /T R +  1/T S + 1 /T M
Increasing the rotational correlation time, by 
slowing molecular motion of a paramagnetic ion, 
can lead to increased relaxivity. This has been 
demonstrated by attachment of paramagnetic 
ions to slow-tumbling protein macromolecules. 
Also, careful choice of paramagnetic ion can 
enhance relaxivity; paramagnetic compounds 
based on Mn and Gd, and nitroxides have slow 
electron spin relaxation times and high relaxivity.
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whereas Dy has a faster electron spin relaxation 
time and lower relaxivity [145].
Paramagnetics alter both Tx and 72. Reduc­
tion in 7 , leads to an enhanced signal intensity, 
whereas reduction in T2 leads to a loss of image 
intensity. Thus, a balance must be found between 
these two effects to achieve contrast enhance­
ment. At low field strengths, the decrease in 7 , 
dominates the relationship and enhanced images 
are seen; at higher fields, the T2 effects dominate 
and signal enhancement is reduced. The con­
centration of paramagnetic ions can also alter the 
imaging effect; at high concentrations T2 effects 
dominate. Thus, in producing images, it is im­
portant to select the applied magnetic field 
strength to provide either T x- or T2-weighted 
images. With paramagnetic ions and chelates, the 
majority of images are produced with positive 
enhancement 7 , -weighted scans.
6.1.3. Ferromagnetism
Ferromagnets are permanent magnets. This is 
due to a property of a group of atoms or 
molecules in a solid crystal rather than a single 
ion. When an external field is applied, the mole­
cules arrange to produce a magnet which remains 
even when the field is removed. However, if the 
size of a multi-domain ferromagnet is reduced to 
less than 350 A, a single domain particle can be 
formed. These particles have slightly different 
properties, although they are rapidly magnetised 
in an external field like ferromagnets. When the 
field is removed, they behave as paramagnets 
and do not retain the induced magnetism. These 
particles are known as superparamagnets. The 
most commonly used superparamagnetic contrast 
agent is based on small particles of magnetite, a 
naturally occurring iron oxide Fe30 4. Super- 
paramagnetics, unlike paramagnetics, have a 
monophasic action on relaxation times. Thus 7 , 
relaxation times are barely affected by the ad­
ministration of a superparamagnet but T2 is 
greatly increased, allowing negative enhance­
ment images [147].
Thus, it is possible to design contrast enhance­
ment agents for imaging of disease states by 
altering the magnetic environment in particular 
tissues. Initially, free paramagnetic ions were 
used to produce this effect but these have now
been developed further, with the production of 
metal chelates and the use of pharmaceutical 
delivery forms, to achieve excellent organ- 
specific imaging.
6.2. Metal ions
As early as 1948, paramagnetic ions, such as 
ferric nitrate, were used to enhance the relaxivity 
of water protons [143]. This phenomenon was 
exploited in gastro-intestinal imaging but the free 
ferric ions caused irritation of the gastro-intesti­
nal tract. Further studies using Mn2+ enabled the 
imaging of myocardium in dogs. This cation 
localises in healthy myocardium but cannot be 
taken up into infarcted regions. Thus, imaging of 
infarction was possible. These studies showed 
that the degree of relaxation enhancement was 
directly proportional to the concentration of 
paramagnetic ion in the organ. Although these 
results were promising, the free paramagnetic 
Mn2+ ion is highly toxic, so cannot be used in 
MRI. It is taken up by calcium transport mecha­
nisms in the body, resulting in cardiovascular 
toxicity [145].
6.3. Metal complexes
Complexes of paramagnetic ions with co-ordi­
nate ligands have been widely tested as contrast 
enhancement agents. Although the relaxivity of 
most of these complexes is reduced in com­
parison to the free ion, owing to decreased inner- 
sphere binding of water, the toxicity of the 
paramagnetic ion is also reduced. Thus, a larger 
dose can be given, overcoming the diminished 
relaxivity. The main paramagnetic ions used in 
these systems are Gd3+, Mn2+ and Fe3+, al­
though chromium EDTA complexes were used 
in initial studies [148- 151]. Both cyclic and 
acyclic ligands have been developed, although at 
present only one compound, an acyclic com­
pound, is in general clinical use.
6.3.1. Acyclic ligands
The original acyclic ligands were developed 
from EDTA. EDTA has been used since the 
early 1950s as a detoxifying agent for iron over­
load. Since then, it has been shown that modi-
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f i c a t i o n  o f  t h e  l i g a n d  s t r u c t u r e  c a n  r e s u l t  i n  
e n h a n c e d  c o n t r a s t  i n  a  v a r i e t y  o f  t i s s u e s  a n d  
c o u p l i n g  t o  t a r g e t i n g  m o i e t i e s  c a n  a c h i e v e  c e l l  
l i n e  t a r g e t i n g .
T h e  d i m e g l u m e  s a l t  o f  G d - D T P A  ( F i g .  1 5 )  h a s  
b e e n  u s e d  i n  t h e  c l i n i c  f o r  o v e r  1 0  y e a r s  i n  
i m a g i n g  o f  b r a i n  a n d  s p i n a l  t u m o u r s .  M o d e l  
s t u d i e s  i n  r a t s  [ 1 5 2 ]  d e m o n s t r a t e d  t h e  p o t e n t i a l  
o f  c o n t r a s t  e n h a n c e m e n t  i m a g i n g  o f  r a d i a t i o n  
d a m a g e  i n  t h e  b r a i n .  T h e s e  s t u d i e s  w e r e  r a p i d l y  
a d v a n c e d  i n t o  h u m a n  t r i a l s ,  w h e r e  c e r e b r a l  
t u m o u r s  w e r e  m o r e  a c c u r a t e l y  c o n t r a s t e d  w i t h  
o e d e m a  a n d  n o r m a l  t i s s u e  u s i n g  t h e  c o n j u g a t e  
( 1 5 3 ) .






G d - D T P A  e x e r t s  i t s  e f f e c t  i n  a n  e x t r a c e l l u l a r  
m a n n e r  a n d  u n d e r g o e s  r a p i d  r e n a l  c l e a r a n c e ;  i t  i s  
t h e r e f o r e  a  u s e f u l  c o n t r a s t  e n h a n c e m e n t  f o r  t h e  
a s s e s s m e n t  o f  r e n a l  f u n c t i o n .  I n  s t u d i e s  i n  r a t s  
[ 1 5 2 ] ,  e n h a n c e m e n t  o f  t h e  k i d n e y  p a r e n c h y m a  
w a s  a c h i e v e d  5  m i n  p o s t  i n j e c t i o n  a n d  w a s  
r e t a i n e d  f o r  > 9 0  m i n .  T h e  c o m p l e x  h a s  a l s o  
b e e n  u s e d  i n  a n g i o g r a p h i c  s t u d i e s  [ 1 5 4 ] ,  t o  d e ­
t e r m i n e  n e u r o l o g i c a l  c o n d i t i o n s ,  v a s c u l a r  o c c l u ­
s i o n  a n d  a t h e r o s c l e r o t i c  d i s e a s e .  I m a g i n g  o f  s m a l l  
v e s s e l s  n o t  s e e n  w i t h o u t  a  c o n t r a s t  a g e n t  w a s  
p o s s i b l e  w i t h  G d - D T P A .  D e s p i t e  t h e s e  p r o m i s i n g  
r e s u l t s ,  G d - D T P A  i s  n o t  a  u n i v e r s a l  c o n t r a s t  
a g e n t  f o r  a l l  d i s e a s e  s t a t e s .  I m a g i n g  o f  l i v e r  
d i s e a s e  a n d  t u m o u r s  i s  n o t  p o s s i b l e ,  o w i n g  t o  
r a p i d  e x c h a n g e  b e t w e e n  t h e  n o r m a l  a n d  d i s e a s e d  
t i s s u e ,  l e a d i n g  t o  t h e  e n t i r e  r e g i o n  s h o w i n g  
e n h a n c e d  c o n t r a s t .  T a r g e t i n g  o f  a  D T P A  c o m ­
p l e x  h a s  h o w e v e r  b e e n  a c h i e v e d ,  w i t h  a  r a d i o a c ­
t i v e  c h e l a t e ,  t o  m a l i g n a n t  m e l a n o m a .  T w o  D T P A  
1 1 ' i n  c h e l a t e s  w e r e  c o n j u g a t e d  t o  M S H .  T h i s  
a l l o w e d  t a r g e t i n g  t o  t h e  a - M S H  r e c e p t o r s  o n  
m a l i g n a n t  c e l l s  a n d  g a v e  e x c e l l e n t  r a d i o g r a p h i c  
i m a g i n g .  T h i s  t e c h n o l o g y  c o u l d  e a s i l y  b e  t r a n s ­
f e r r e d  t o  t h e  d e l i v e r y  o f  p a r a m a g n e t i c  i o n s .  
P h o s p h o n a t e  c h e l a t e s  o f  G d  h a v e  a l s o  b e e n
p r e p a r e d  t o  e n a b l e  t a r g e t i n g  t o  m y o c a r d i a l  c e l l s  
[ 1 5 5 ] .
G d - D T P A  i s  o f  l o w  t o x i c i t y .  A  s m a l l  a m o u n t  
o f  d e m e t a l l a t i o n  d o e s  o c c u r  b u t  i s  n o t  s i g n i f i c a n t  
a n d  t h e  c o m p l e x  i s  e x t r e m e l y  s a f e  i n  t h e  n o r m a l  
d o s a g e  r a n g e  [ 1 4 5 ] .  H o w e v e r ,  t h e  c h a r g e d  c o m ­
p l e x  b e c o m e s  m o r e  t o x i c  a t  h i g h e r  d o s e s ,  o w i n g  
t o  i n c r e a s e d  o s m o l a l i t y .  M o r e  r e c e n t l y ,  n o n - i o n i c  
c o m p l e x e s  d e r i v e d  f r o m  D T P A  h a v e  b e e n  p r e ­
p a r e d .  T h e s e  h a v e  c o m p a r a b l e  m o l a r  r e l a x i v i t i e s  
t o  G d - D T P A  b u t  r e d u c e d  o s m o l a l i t y  a n d ,  h e n c e ,  
c a n  b e  u s e d  o v e r  a  l a r g e r  d o s e  r a n g e .  T h e  m o s t  
c o m m o n l y  u s e d  d e r i v a t i v e  i s  G d - D T P A  b i s -  
( m e t h y l a m i d e )  o r  G a d o d i a m i d e  i n j e c t i o n .  A s  
G d - D T P A  c a n n o t  b e  u s e d  s u c c e s s f u l l y  i n  t h e  
i m a g i n g  o f  l i v e r  c a r c i n o m a ,  m a n y  a t t e m p t s  h a v e  
b e e n  m a d e  t o  p r e p a r e  s i m i l a r  c h e l a t e s  w h i c h  a r e  
i n  s o m e  w a y  t a r g e t e d  t o  t h e  l i v e r .  M a n g a n e s e ( I I )  
AJ,N' - ' d i p y r i d o x a l e t h y l e n e d i a m i n e  -N,N' -  d i a c e t a ­
t e - 5 , 5 ' - b i s ( p h o s p h a t e )  ( M n - D P D P )  ( F i g .  1 6 )  i s  
d e s i g n e d  t o  b e  t a r g e t e d  t o  h e p a t o c y t e s  t h r o u g h  
t h e  p y r i d o x a l  5 ' - p h o s p h a t e  m o i e t i e s .  T h i s  c o ­
e n z y m e  i s  t a k e n  u p  b y  a  m e m b r a n e  t r a n s p o r t  
s y s t e m  i n  h e p a t o c y t e s  a s  i s  t h e  c h e l a t e  [ 1 5 6 ] .  I t  i s  
t h e r e f o r e  p o s s i b l e  t o  d i s t i n g u i s h  b e t w e e n  f u n c ­
t i o n i n g  a n d  n o n - f u n c t j o n i n g  h e p a t o c y t e ,  t h a t  i s  
b e t w e e n  n o r m a l  a n d  d i s e a s e d  t i s s u e s .  T h u s ,  n e g a ­
t i v e  c o n t r a s t  e n h a n c e m e n t  i s  a c h i e v e d ,  t h e  n o r ­
m a l  c e l l s  s h o w i n g  h y p e r i n t e n s e  r e l a t i v e  t o  t h e  
d i s e a s e d  c e l l s .  I n  h e a l t h y  s u b j e c t s ,  e n h a n c e m e n t  
o f  l i v e r  p a r e n c h y m a  w a s  a c h i e v e d  a f t e r  1 m i n  
a n d  p e r s i s t e d  f o r  3 0  m i n .  B i l e  i m a g i n g  w a s  a l s o  
p o s s i b l e  a f t e r  1 5  m i n ,  o w i n g  t o  h e p a t o b i l i a r y  
e x c r e t i o n  o f  t h e  c h e l a t e  [ 1 5 7 ] .  F e w  s i d e  e f f e c t s  
w e r e  s e e n  w i t h  t h i s  c o m p o u n d ,  a l t h o u g h  t h e  
m a j o r i t y  o f  s u b j e c t s  d i d  e x p e r i e n c e  f a c i a l  f l u s h ­
i n g .  P r e - c l i n i c a l  s t u d i e s  i n  t u m o u r - b e a r i n g  r a t s  
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c h e l a t e  i n  t h e  l i v e r  a n d  i n i t i a l  i m a g e s  g a v e  n o  
c o n t r a s t  b e t w e e n  n o r m a l  a n d  t u m o u r  t i s s u e .  
A f t e r  3 0  m i n ,  h o w e v e r ,  t h e r e  i s  e n h a n c e d  
t u m o u r - t o - l i v e r  r a t i o ,  p r e s u m a b l y  o w i n g  t o  d e ­
c r e a s e d  e x c r e t i o n  f r o m  t h e  t u m o u r  c e l l s .  O b v i ­
o u s l y ,  t h e  d e g r e e  o f  u p t a k e  o f  t h e  c h e l a t e  b y  
d i s e a s e d  c e l l s  d e p e n d s  o n  t h e  l e v e l  o f  n o r m a l  
h e p a t o c y t e  f u n c t i o n  r e t a i n e d .  T h u s ,  i t  i s  p o s s i b l e  
t o  a c h i e v e  d i f f e r e n t i a l  d i a g n o s i s  o f  l i v e r  t u m o u r s  
[ 1 5 7 , 1 5 9 ] .  M e t a s t a t i c  l i v e r  d i s e a s e  a n d  w e l l - d i f ­
f e r e n t i a t e d  t u m o u r s  h a v e  n o  u p t a k e  a n d  t h u s  a r e  
e a s i l y  n e g a t i v e l y  i m a g e d ,  w h e r e a s  n o n - d i f f e r e n -  
t i a t e d  t u m o u r s  c a n  o n l y  b e  v i s u a l i s e d  b y  a  
p o s i t i v e  e n h a n c e m e n t  a b o u t  2 4  h  a f t e r  a d m i n i s ­
t r a t i o n .
N e w  l i g a n d s  f o r  g a d o l i n i u m  h a v e  a l s o  b e e n  
p r e p a r e d  t o  a l l o w  l i v e r  t a r g e t i n g .  G d - B O P T A  i s  
a  d e r i v a t i v e  o f  D T P A  w i t h  a  b e n z y l o x y m e t h y l  
g r o u p  i n  t h e  b a c k b o n e  ( F i g .  1 7 ) .  I t  i s  i n t e n d e d  
t h a t  t h i s  s h o u l d  b e  t a k e n  u p  b y  t h e  a n i o n i c  
h e p a t o c y t e  r e c e p t o r  w h i c h  t a k e s  u p  b r o m o s u l -  
p h o p h t h a l e i n  [ 1 4 5 ] .  T h i s  c o m p l e x  h a s  a  h i g h  
p r o p o r t i o n  o f  b i l i a r y  e x c r e t i o n  a n d  i s  a c c u m u ­
l a t e d  i n  l i v e r  i n  r a t s ,  w h e r e  n o r m a l  c e l l s  c a n  b e  
e a s i l y  i m a g e d  [ 1 5 8 ] .  T h i s  l e a d s  t o  n e g a t i v e  i m a g ­
i n g  o f  t u m o u r s .
A  l i p o p h i l i c  c h e l a t e  o f  i r o n ,  F e - E H P G ,  h a s  
b e e n  p r o d u c e d  ( F i g .  1 8 ) .  T h i s  i s  d e s i g n e d  t o  b e  
t a k e n  u p  i n t o  r a t  l i v e r  c e l l s  t h r o u g h  n o n - s p e c i f i c  
h y d r o p h o b i c  i n t e r a c t i o n s .  G o o d  l o c a l i s a t i o n  i n  
t h e  l i v e r  a n d  b i l e  w a s  a c h i e v e d .  H o w e v e r ,  t h i s  
c h e l a t e  h a s  l o w e r  r e l a x i v i t y  t h a n  o t h e r  c h e l a t e s






a n d  l a r g e  d o s e s  a r e  r e q u i r e d ;  t h i s  i s  a  p r o b l e m  a s  
s o m e  t o x i c i t y  h a s  b e e n  s e e n  [ 1 4 5 ] .  S t u d i e s  i n  
m i c e  d e m o n s t r a t e d  i n c r e a s e d  s i g n a l  i n t e n s i t y  o f  
b o t h  t h e  l i v e r  a n d  b i l e  i n  h e a l t h y  a n i m a l s ,  a n d  
e n h a n c e d  v i s u a l i s a t i o n  o f  i n t r a h e p a t i c  i m p l a n t e d  
t u m o u r s  a n d  a  m e t a s t a t i c  m o d e l .  I n c r e a s i n g  t h e  
l i p o p h i l i c i t y  c a n  l e a d  t o  d e c r e a s e d  l i v e r  u p t a k e  a s  
t h e  c h e l a t e  b i n d s  t o  s e r u m  p r o t e i n s ,  t h e r e f o r e  t h e  
c h l o r o  d e r i v a t i v e  i s  m o s t  w i d e l y  u s e d  o w i n g  t o  i t s  
f a v o u r a b l e  b a l a n c e  o f  p r o t e i n  b i n d i n g  a n d  l i v e r  
u p t a k e .
6.3.2. Cyclic ligands 
I n  t h e  s e a r c h  f o r  e v e n  m o r e  e f f e c t i v e  c h e l a t e s ,  
m a c r o c y c l i c  l i g a n d s  h a v e  b e e n  p r o d u c e d .  A l ­
t h o u g h  t h e s e  c o m p l e x e s  t a k e  u p  p a r a m a g n e t i c  
i o n s  s l o w l y ,  t h e y  e x h i b i t  i n c r e a s e d  s t a b i l i t y  o n c e  
t h e  i o n  i s  b o u n d  a n d  h e n c e  r e d u c e d  r i s k  o f  
t o x i c i t y  d u e  t o  l e a c h i n g .  T h e  m a j o r  l i g a n d  t h a t  
h a s  b e e n  e v a l u a t e d  i s  G d - D O T A  ( g a d o l i n i u m  
t e t r a a z a c y c l o d o d e c a n e t e t r a a c e t i c  a c i d )  ( F i g .  1 9 ) .  
T h i s  c o m p l e x  h a s  s i m i l a r  r e l a x i v i t y  t o  G d - D T P A  
a n d  s i m i l a r  b i o d i s t r i b u t i o n  b u t  i s  l e s s  t o x i c  [ 1 5 8 ] .  
I t  i s  a l s o  h a s  a  m o r e  e n h a n c e d  r e l a x i v i t y  a t  l o w  
f i e l d  s t r e n g t h s ,  o w i n g  t o  t h e  e f f e c t  o f  s y m m e t r y  
o n  t h e  e l e c t r o n  r e l a x a t i o n  t i m e .
A s  w i t h  D T P A ,  n o n - i o n i c  c o m p l e x e s  h a v e  
b e e n  m a d e  s u c h  a s  D G 3 A  [ 1 4 5 ] .  A z a p h o s p h o n i c  
a c i d  d e r i v a t i v e s  h a v e  a l s o  b e e n  p r o d u c e d  w h i c h  
c a n  b e  e i t h e r  a n i o n i c ,  c a t i o n i c  o r  n e u t r a l  a n d  
s u i t a b l y  f u n c t i o n a l i s e d  f o r  t h e  a t t a c h m e n t  o f  
t a r g e t i n g  m o i e t i e s .  T h e s e  c o m p l e x e s  ( F i g .  2 0 )  a r e
HOOC—\  ^ / — OOOH
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t a r g e t e d  t o  t h e  l i v e r  a n d  b i l e .  R a d i o l a b e l l e d  G d  
c o m p l e x e s  o f  c o m p o u n d  7 4  h a v e  b e e n  s h o w n  t o  
c l e a r  m o r e  s l o w l y  f r o m  t u m o u r  t i s s u e  t h a n  n o r ­
m a l  t i s s u e  a l l o w i n g  a  d e g r e e  o f  s p e c i f i c i t y .
T u m o u r  t a r g e t i n g  h a s  a l s o  b e e n  a c h i e v e d  w i t h  
i n d i u m - l a b e l l e d  N O T A  c o m p l e x e s .  T h e s e  c o m ­
p o u n d s  a c c u m u l a t e  i n  s o m e  s k i n  c a n c e r s .  H o w ­
e v e r ,  N O T A  i s  n o t  a  g o o d  l i g a n d  f o r  p a r a m a g ­
n e t i c  i o n s .  P a a r a m a g n e t i c  c y c l a m  c o m p l e x e s  o f  
M n ( I I I )  a n d  C u ( I I )  h a v e  a l s o  b e e n  p r o d u c e d  
( F i g .  2 1 ) .  M n ( I I I )  c y c l a m  i s  a  h i g h l y  s t a b l e  
c o m p l e x  w i t h  c o m p a r a h l e  r e l a x i v i t y  t o  G d - D T P A  
a n d  l o c a l i s e s  a s  e f f i c i e n t l y  a s  F e - E H P G  i n  t h e  
l i v e r  [ 1 4 4 ] .
HOOC^ f/ X1N^ OOOH
w




M e t a l l o p o r p h y r i n s  a r e  e n d o g e n o u s  m e t a l  b i n d ­
i n g  l i g a n d s .  A l t h o u g h  t h e y  a r e  o f  c o m p l e x  c h e m i ­
c a l  s t r u c t u r e ,  t h e y  a r e  o f  i n c r e a s i n g  i n t e r e s t  
o w i n g  t o  s e l e c t i v e  u p t a k e  b y  s o m e  t u m o u r s  [ 1 4 6 ] .  
S e l e c t i v e  u p t a k e  o f  p o r p h y r i n s  i n t o  t u m o u r  c e l l s  
w a s  f i r s t  n o t e d  i n  t h e  1 9 2 0 s .  M o r e  r e c e n t l y ,  t h i s  
p r o p e r t y  h a s  b e e n  e x p l o i t e d  i n  p h o t o d y n a m i c  
t h e r a p y  [ 1 6 1 ] .  S o m e  d e r i v a t i v e s  o f  h a e m a t o p o r -  
p h y r i n  c a n  b e  l o c a l i s e d  t o  t u m o u r s  a n d  a c t  a s  
p h o t o s e n s i t i s e r s  f o r  c o n v e r s i o n  o f  t r i p l e t  o x y g e n  
t o  c y t o t o x i c  s i n g l e t  o x y g e n .  I n c o r p o r a t i o n  o f  a  
p a r a m a g n e t i c  i o n  i n t o  a  p o r p h y r i n  c o u l d ,  t h e r e ­
f o r e ,  r e s u l t  i n  a  h i g h e r  t u m o u r  c o n c e n t r a t i o n  o f  a  
c o n t r a s t  a g e n t .  A c c u m u l a t i o n  o f  m e t a l - b e a r i n g  
p o l y m e r s  i n  t u m o u r  c e l l s  h a s  b e e n  d e m o n s t r a t e d  
b y  m a n y  w o r k e r s ,  a l t h o u g h  s o m e  h a v e  s u g g e s t e d  
t h a t  t h e  t u m o u r  s e l e c t i v i t y  o f  p o r p h y r i n s  c a n  b e  
r e d u c e d  b y  m e t a l l a t i o n .  T h e  m e c h a n i s m  b y  
w h i c h  t u m o u r  s e l e c t i v i t y  o c c u r s  r e m a i n s  u n ­
k n o w n  [ 1 6 2 ] .  I t  h a s  b e e n  s u g g e s t e d  t h a t  t h e  
p o r p h y r i n  c o u l d  b e  t r a p p e d  i n  c e l l s  b y  e n z y m i c  
a l t e r a t i o n ,  o r  b e  c o m p a r t m e n t a l i s e d  i n t o  s p e c i f i c  
r e g i o n s  i n  t h e  c e l l .  A l t e r n a t i v e l y ,  i t  i s  p o s s i b l e  
t h a t  t h e  p o r p h y r i n  b i n d s  t o  p r o t e i n s  o r  f i b r o u s  
t i s s u e  o r  i s  t a k e n  u p  i n t o  c e l l s  b y  s p e c i f i c  t r a n s ­
p o r t  m e c h a n i s m s .  S t u d i e s  o n  t h e  r e t e n t i o n  o f
b o t h  T P P S  a n d  M n - T P P S  i n  h u m a n  b r e a s t  c a n c e r  
c e l l  l i n e s ,  c o n f i r m e d  t h a t  t h e  m o s t  l i k e l y  m e c h a ­
n i s m  i s  s e l e c t i v e  u p t a k e  v i a  a  p o r t e r  f o r  T P P S .
A l t h o u g h  p o r p h y r i n s  c a n  c h e l a t e  n u m e r o u s  
m e t a l  i o n s ,  t h e  m o s t  u s e f u l  i n  t e r m s  o f  i m a g i n g  i s  
m a n g a n e s e .  G a d o l i n i u m  i s  t o o  l a r g e  a n  i o n  t o  
f o r m  a  s t a b l e  c o m p l e x  s o  i s  e a s i l y  l e a c h e d  a n d  
i r o n  l o s e s  i t s  p a r a m a g n e t i s m  o v e r  p H  6  w h e n  
c h e l a t e d  i n t o  p o r p h y r i n s  [ 1 4 5 ] .  M a n g a n e s e  f i t s  
e a s i l y  i n t o  t h e  p o r p h y r i n  a n d  t h e s e  c o m p l e x e s  
h a v e  s u r p r i s i n g l y  h i g h  r e l a x i v i t i e s . . o f  >  1 0  m M ' 1 
s - 1 . A l t h o u g h  d i r e c t  c o m p a r i s o n s  c a n n o t  b e  
m a d e  w i t h  M n ( I I I )  i o n s  a s  t h e y  a r e  u n s t a b l e  i n  
t h e  c i r c u l a t i o n ,  t h i s  r e l a x i v i t y  i s  3  t i m e s  h i g h e r  
t h a n  t h a t  o f  M n C l 2 . I t  h a s  b e e n  s u g g e s t e d  t h a t  
t h e  i n c r e a s e d  r e l a x i v i t y  i s  d u e  t o  c l o s e r  i n t e r a c ­
t i o n s  b e t w e e n  t h e  p a r a m a g n e t i c  i o n  a n d  t h e  
w a t e r  p r o t o n s  o r  t o  s y m m e t r y  e f f e c t s  [ 1 5 2 ] .
T h e  w a t e r - s o l u b l e  t e t r a p h e n y l  p o r p h y r i n  d e ­
r i v a t i v e  T P P S  ( F i g .  2 2 )  h a s  b e e n  m o s t  w i d e l y  
e v a l u a t e d  a s  a  p a r a m a g n e t i c  c h e l a t i n g  l i g a n d .  
S t u d i e s  i n  t u m o u r - b e a r i n g  m i c e  [ 1 6 3 - 1 6 6 ]  h a v e  
d e m o n s t r a t e d  i n c r e a s e d  u p t a k e  o f  t h e  c h e l a t e s  
i n t o  l y m p h o m a s ,  f i b r o s a r c o m a s ,  c o l o n  c a r ­
c i n o m a s  a n d  b r e a s t  c a n c e r .  I n  a l l  c a s e s ,  a c c u m u ­
l a t i o n  i s  s e e n  a l m o s t  i m m e d i a t e l y  i n  t h e  t u m o u r ;  
h o w e v e r ,  t h e  b e s t  t u m o u r :  n o r m a l  t i s s u e  r a t i o s  
a r e  a c h i e v e d  a f t e r  a p p r o x i m a t e l y  4 8  h ,  w h e n  t h e  
c o m p l e x  h a s  b e e n  e x c r e t e d  f r o m  n o r m a l  t i s s u e s .  
T h i s  c o m p l e x  h a s  a l s o  b e e n  u s e d  i n  i m a g i n g  b r a i n  
g l i o m a  [ 1 6 7 ] .  U n l i k e  G d - D T P A  w h i c h  p e r f u s e s  
o u t  o f  t h e  t u m o u r ,  t h e  p o r p h y r i n  a p p e a r s  t o  b i n d  
t i g h t l y  t o  t h e  t u m o u r  c e l l s ,  r e s u l t i n g  i n  e n h a n c e ­
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p o r p h y r i n  c o m p l e x  i s  a l s o  h i g h l y  e f f i c i e n t  i n  
d i s t i n g u i s h i n g  t u m o u r  f r o m  n o r m a l  t i s s u e  a n d  
o e d e m a .  I n  t h i s  s i t u a t i o n ,  i t  h a s  b e e n  p r o p o s e d  
t h a t  t h e  s e l e c t i v e  u p t a k e  o c c u r s  t h r o u g h  
p e r i p h e r a l  b e n z o d i a z e p i n e  r e c e p t o r s  w h i c h  a r e  
a b u n d a n t  i n  t u m o u r  c e l l s  b u t  n o t  i n  n o r m a l  c e l l s .  
T h e  v e r s a t i l i t y  o f  p o r p h y r i n s  s u g g e s t s  t h a t  t h e r e  
i s  p o t e n t i a l ,  t h r o u g h  c h e m i c a l  m o d i f i c a t i o n ,  o f  
a c h i e v i n g  s e l e c t i v e  u p t a k e  i n t o  a l m o s t  a n y  o r g a n  
o r  t u m o u r .
A l t h o u g h  M n ( I I I ) T P P S  c a n  b e  u s e d  s u c c e s s ­
f u l l y  i n  m a n y  s i t u a t i o n s ,  c o n t r a s t  e n h a n c e m e n t  
b e t w e e n  t h e  o r g a n  a n d  t u m o u r  i n  t h e  l i v e r  i s  n o t  
a c h i e v e d .  T h i s  i s  p r o b a b l y  d u e  t o  t h e  r a p i d  
e x c r e t i o n  o f  t h e  c o m p l e x  t h r o u g h  t h e  k i d n e y  a n d  
u r i n e  [ 1 6 8 ] .  T h e r e f o r e ,  r e s e a r c h e r s  h a v e  d e ­
v e l o p e d  o t h e r  s y n t h e t i c  p o r p h y r i n s  w h i c h  a r e  
l i p i d - s o l u b l e ,  i n  t h e  h o p e  t h a t  t h e s e  w i l l  b e  
e x c r e t e d  t h r o u g h  t h e  l i v e r  a n d  b i l e  a n d  h e n c e  
i m p r o v e  i m a g i n g  o f  t h e  l i v e r .  I n  a  s t u d y  c o m p a r ­
i n g  M n - m e s o p o r p h y r i n  ( F i g .  2 3 )  a n d  M n - T P P S ,  
n o  e n h a n c e m e n t  o f  l i v e r  t i s s u e  i m a g e  w a s  s e e n  
w i t h  M n - T P P S .  W i t h  m e s o p o r p h y r i n ,  t h e r e  w a s  
s i g n i f i c a n t  e n h a n c e m e n t  o f  t h e  s i g n a l  i n t e n s i t y  o f  
n o r m a l  l i v e r  p a r e n c h y m a ,  e n a b l i n g  c o n t r a s t - e n ­
h a n c e d  i m a g e s  o f  b o t h  l i v e r  a b s c e s s e s  a n d  m e t a ­
s t a t i c  d i s e a s e  w i t h i n  1  h .  I t  w a s  p r o p o s e d ,  f r o m  
r a d i o a c t i v i t y  s t u d i e s ,  t h a t  t h e  m e s o p o r p h y r i n  
d e r i v a t i v e  i s  t a k e n  u p  d i r e c t l y  b y  t h e  h e p a t o c y t e s  
w h e r e  a c c u m u l a t i o n  o c c u r s  a n d  i s  e v e n t u a l l y  
e x c r e t e d  i n t o  t h e  b i l e .
S i m i l a r  r e s u l t s  h a v e  b e e n  o b t a i n e d  w i t h  
M n ( I I I )  h a e m a t o p o r p h y r i n  ( F i g .  2 4 ) .  H o w e v e r ,  
t h i s  c o m p l e x  i s  r e t a i n e d  f o r  a  l o n g  t i m e  i n  t h e  
l i v e r  a n d  c o u l d  g i v e  r i s e  t o  t o x i c  e f f e c t s  [ 1 6 8 ] .
M n - p r o t o p o r p h y r i n  I X  ( F i g .  2 5 )  i s  a l s o  
























s t u d i e s .  H o w e v e r ,  a l t h o u g h  i t  i s  a  v e r y  s t a b l e  
c o m p l e x ,  i t  h a s  r e l a t i v e l y  l o w  r e l a x i v i t y  a n d  i s  n o t  
w i d e l y  u s e d  [ 1 6 6 ] .  7
M n - m e s o p o r p h y r i n  h a s  a l s o  b e e n  u s e d  i n  t h e  
i m a g i n g  o f  r a t  g l i o m a  m o d e l s .  I n c r e a s e d  e n ­
h a n c e m e n t  o f  t h e  t u m o u r  t i s s u e  i m a g e  w a s  
a c h i e v e d ,  a l l o w i n g  t h e  t u m o u r  t o  b e  d i s t i n ­
g u i s h e d  f r o m  o e d e m a  a n d  n o r m a l  t i s s u e .  A s  w i t h  
T P P S ,  t h e  e n h a n c e m e n t  w a s  p r o l o n g e d  i n  c o m ­
p a r i s o n  t o  G d - D T P A  [ 1 6 9 ] .  O n e  a d d e d  a d v a n ­
t a g e  o f  u s i n g  l i p i d  s o l u b l e  p o r p h y r i n s  i s  t h e i r  l a c k  
o f  p h o t o s e n s i t i s a t i o n .  W i t h  M n - T P P S ,  t e s t  a n i ­
m a l s  e x p e r i e n c e  b o t h  p i g m e n t a t i o n  o f  t h e  s k i n  
a n d  p h o t o s e n s i t i v i t y ,  w i t h  M n - m e s o p o r p h y r i n  
t h e s e  e f f e c t s  a r e  n o t  s e e n  [ 1 6 8 ] .
T h e  g a d o l i n i u m  i o n  i s  t o o  l a r g e  t o  f o r m  a  
s t a b l e  c o m p l e x  w i t h  t h e  p o r p h y r i n  s k e l e t o n .  
H o w e v e r ,  a s  t h e  r e l a x i v i t y  o f  G d 3 +  i s  h i g h e r  
t h e r e  h a v e  b e e n  a t t e m p t s  t o  e x p l o i t  t h e  t a r g e t i n g  
p r o p e r t i e s  o f  p o r p h y r i n s  t o  d e l i v e r  G d  c o m p l e x ­
e s .  R e c e n t l y ,  H i n d r e  e t  a l .  [ 1 7 0 ]  d e v e l o p e d  a  
c o n j u g a t e  o f  G d - D T P A  w i t h  a  n o n - m e t a l l a t e d  
t e t r a p h e n y l p o r p h y r i n  d e r i v a t i v e .  T h e  r e l a x i v i t y  
o f  t h i s  c o n j u g a t e  i n  v i t r o  w a s  g r e a t e r  t h a n  t h a t  o f  
G d - D T P A ,  p r o b a b l y  o w i n g  t o  t h e  i n c r e a s e d  s i z e  
a n d  h e n c e  i n c r e a s e d  c o r r e l a t i o n  t i m e .  E n h a n c e d
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i m a g e s  o f  h u m a n  a d e n o c a r c i n o m a  i m p l a n t e d  i n t o  
m i c e  w e r e  a c h i e v e d  a f t e r  2 4  h ,  d e m o n s t r a t i n g  a n  
i n c r e a s e d  t u m o u r  u p t a k e  o f  t h e  G d  i o n s  d u e  t o  
t h e  t u m o u r  s p e c i f i c i t y  o f  p o r p h y r i n s .  A n  a l t e r ­
n a t i v e  a p p r o a c h  i s  t h e  u s e  o f  m o d i f i e d  p o r ­
p h y r i n s ,  k n o w n  a s  t e x a p h y r i n s ,  i n  w h i c h  t h e r e  i s  
a n  e x p a n d e d  c e n t r a l  r e g i o n  t h a t  c o n t a i n s  f i v e  
r a t h e r  t h a n  f o u r  n i t r o g e n  a t o m s ,  a l l o w i n g  i n ­





R e c e n t l y ,  a  n e w  c l a s s  o f  m e t a l l a t e d  c a t i o n i c  
p o r p h y r i n s  h a s  b e e n  e v a l u a t e d  f o r  t a r g e t i n g  t o  
m a l i g n a n t  m e l a n o m a  ( F i g .  2 7 )  [ 1 7 1 ] .  A l t h o u g h  
t h e s e  p o r p h y r i n s  c o n t a i n e d  r a d i o a c t i v e  111 I n ,  t h e  
r e s u l t s  p r o v i d e  i n f o r m a t i o n  o n  t h e  p o t e n t i a l  o f  
t a r g e t i n g  p a r a m a g n e t i c  i o n s  t o  o n e  o f  t h e  m o s t  
d i f f u s e  m e t a s t a t i c  c a n c e r s .  T h e s e  c o m p l e x e s  g a v e  
e x c e l l e n t  t u m o u r  l o c a l i s a t i o n  a n d  t u m o u r :  b l o o d  
r a t i o s  w h i c h  w e r e  r e t a i n e d  f o r  >  7 2  h .  I n t e r e s t ­
i n g l y ,  i t  w a s  a l s o  p o s s i b l e  t o  s e e  w h e r e  t h e  
p o r p h y r i n  l o c a l i s e d  w i t h i n  t h e  t u m o u r .  I n  t h i s  
c a s e ,  l o c a l i s a t i o n  w a s  s e e n  i n  t h e  o u t e r  g r o w i n g  
r e g i o n ,  w h e r e a s  d i s t r i b u t i o n  i s  m a i n l y  t o  t h e  





P r o t o n  r e l a x a t i o n  e n h a n c e m e n t  c a n  b e  
a c h i e v e d  b y  t h e  d i r e c t  c o m p i e x a t i o n  o f  a  p a r a ­
m a g n e t i c  i o n  t o  a  m a c r o m o l e c u l e  o r  t h r o u g h  t h e  
a t t a c h m e n t  o f  a  m e t a l  c h e l a t o r  t o  a  m a c r o m o l e ­
c u l e .  T h e  e n h a n c e m e n t  i s  d u e  t o  a n  i n c r e a s e  i n  
t h e  m o l a r  r e l a x i v i t y  o f  t h e  c o m p l e x .  T h i s  e f f e c t  i s  
c a u s e d  b y  t h e  s l o w  r o t a t i o n  o f  t h e  p a r a m a g n e t i c  
i o n  w h i c h  l e a d s  t o  a n  i n c r e a s e d  c o r r e l a t i o n  t i m e .  
T h e  d e g r e e  o f  e f f e c t  d e p e n d s  u p o n  t h e  r i g i d i t y  o f  
t h e  m a c r o m o l e c u l e  a n d  i t s  t e r t i a r y  s t r u c t u r e .  
R e l a x i v i t i e s  a r e  h i g h e r  w h e n  t h e  p a r a m a g n e t i c  
i o n  i s  c o m p l e x e d  w i t h  r i g i d  g l o b u l a r  p r o t e i n  
m o l e c u l e s  t h a n  w i t h  m o r e  f l e x i b l e  s y n t h e t i c  p o l y -  
( a m i n o  a c i d s ) .  T h e  e f f e c t  o f  t h e  i n c r e a s e d  c o r r e ­
l a t i o n  t i m e  i s  h i g h e s t  a t  h i g h e r  f i e l d  s t r e n g t h s  
w h e r e  t h e r e  i s  a  l a r g e  i n c r e a s e  i n  r e l a x i v i t y .  B o t h  
n o n - c o v a l e n t  a n d  c o v a l e n t  c o m p l e x e s  c a n  b e  
p r e p a r e d .  N o n - c o v a l e n t  c o m p l e x e s ,  w h i c h  r e s u l t  
f r o m  a  c o m b i n a t i o n  o f  e l e c t r o s t a t i c ,  v a n  d e r  
W a a l s ,  h y d r o g e n  b o n d i n g  a n d  h y d r o p h o b i c  i n t e r ­
a c t i o n s ,  a r e  m o r e  s t a b l e ,  t h r o u g h  t h e  a c t i o n  o f  
m a n y  f u n c t i o n a l  g r o u p ?  o n  t h e  p o l y m e r ,  a n d  
e x h i b i t  h i g h e r  r e l a x i v i t i e s .  I n  t h i s  s i t u a t i o n ,  t h e  
m e t a l  i s  f r e q u e n t l y  i n  e q u i l i b r i u m  w i t h  m e t a l  i n  
t h e  b u l k  s o l u t i o n .  O n  t h e  o t h e r  h a n d ,  a l t h o u g h  
c o v a l e n t  a t t a c h m e n t s  a r e  a t t r a c t i v e  d u e  t o  e a s e  
o f  c h a r a c t e r i s a t i o n ,  p r o t e o l y t i c  d e g r a d a t i o n  w i t h ­
i n  l y s o s o m e s  c a n  l e a d  t o  r e l e a s e  o f  t h e  p a r a ­
m a g n e t i c  i o n  o r  c h e l a t o r  r e s u l t i n g  i n  t o x i c i t y  
[ 1 7 2 ] .
C o m p i e x a t i o n  o f  a  p a r a m a g n e t i c  i o n  t o  a  
m a c r o m o l e c u l e  h a s  m a n y  a d v a n t a g e s .  M u l t i p l e  
p a r a m a g n e t i c  i o n s  c a n  b e  a t t a c h e d  t o  o n e  l a r g e  
c a r r i e r  m o l e c u l e ;  t h e r e f o r e ,  t h e  m o l a r  d o s e  o f  
i m a g i n g  a g e n t  c a n  b e  r e d u c e d  a n d  h e n c e  t o x i c i t y  
c a n  b e  r e d u c e d .  M o r e  i m p o r t a n t l y ,  t h e  m a c r o -  
m o l e c u l a r l y  b o u n d  a g e n t s  c a n  b e  u s e d  t o  i m a g e  
t h e  b l o o d  p o o l  a n d ,  h e n c e ,  s i t u a t i o n s  w h e r e  
v a s c u l a r  i n t e g r i t y  i s  l o s t ,  s u c h  a s  i n  t u m o u r s  a n d  
i n f l a m e d  t i s s u e  [ 1 7 3 ] .  D i r e c t  c o m p i e x a t i o n  o f  G d  
a n d  M n  t o  p r o t e i n s  s u c h  a s  c o n c a n a v a l i n  A  a n d  
b o v i n e  s e r u m  a l b u m i n  r e s u l t s  i n  e n h a n c e d  m o l a r  
r e l a x i v i t i e s  [ 1 7 4 ] .  T h i s  i s  a l s o  a p p a r e n t  w i t h  t h e  
i r o n - r e p l a c e m e n t  t r e a t m e n t ,  I m f e r o n ,  w h e r e  i r o n  
i s  c o m p l e x e d  w i t h  d e x t r a n .  A l t h o u g h  i t  h a s  l o w  
m a g n e t i c  s u s c e p t i b i l i t y ,  i t  d o e s  d i s p l a y  e n h a n c e d  
b l o o d  r e s i d e n c e  t i m e s ,  l o w  t o x i c i t y  a n d  h i g h
256 S.E. Matthews et al. / Advanced Drug Delivery Reviews IS (19%) 219-267
solubility. The synthetic polymer, poly(aspartic 
acid), has also been used to chelate Gd3+ ions 
directly. Increased relaxivities were demonstra­
ted with chelates bearing <40  ions but, above 
this level, the relaxivity is reduced. This is proba­
bly due to interactions between the chelated ions
[172]. Paramagnetic chelates can also be bound 
non-covalently to albumin. The hepatobiliary 
contrast agent Fe-EHPG has been successfully 
bound to albumin leading to a 2- 3-fold increase 
in relaxivity. The binding affinity can be en­
hanced by increasing the lipophilicity of the 
chelate [145].
Considerably more interest has been directed 
towards the development of covalent macro­
molecular chelate complexes. Albumin is re­
tained within the vascular space after intravascu- 
lar injection. Conjugates of albumin Gd-DTPA 
have been used in studies in both rats and rabbits 
for imaging myocardial ischaemia [175]. In nor­
mal rats [176] attachment of the chelate to 
albumin results in better imaging of the heart, 
liver and brain at very low doses. Subcutaneous 
tissue and muscle are not enhanced, unlike with 
free Gd-DTPA. In this study, sixteen chelates 
were attached to each albumin molecule and a
3-fold increase in relaxivity of the chelate was 
achieved on binding. Albumin is a natural poly­
mer with high dispersity and may be immuno­
genic and exhibits cardiovascular toxicity; thus 
other macromolecules have also been evaluated.
Dextran is available in a variety of sizes, has 
low toxicity and can be prepared to contain a 
biodegradable bond to ensure elimination of 
bound chelates. Chelation of Gd-DTPA to dex­
tran leads to a large increase in relaxivity which 
is dependent on the number of chelates bound 
[177,178]. The chelates are successful in enhanc­
ing the imaging of the blood pool in rats but are 
not as efficient as the albumin chelates. This 
could be due to the larger molecular weight of 
albumin or to the higher permeability of the 
capillaries to dextran. Incorporation of a biodeg­
radable bond enabled both superior imaging and 
excretion of the chelate in comparison to the free 
chelate [178]. Interestingly, with a large increase 
in the molecular weight of dextran, relaxivity is 
decreased. This is thought to be due to displace­
ment of the bound water molecules from the 
chelate by neighbouring hydroxyl groups, owing 
to the polymer wrapping around itself [179].
Synthetic poly(amino acids) have also been 
used for formation of Gd-DTPA complexes. 
Poly(Lys)-Gd-DTPA allows enhanced images of 
the blood pool, pulmonary disease, such as 
oedema and embolisms, and the heart [176,180]. 
Mn(III) porphyrins have also been conjugated to 
poly (amino acids). Cross-linked polymers were 
produced through coupling of protoporphyrin IX 
to a range of amino acids, poly(Glu) derivatised 
with lysine, poly(Lys), poly(Lys-co-Phe) and 
poly(Lys-co-Ala) [181]. All these conjugates ex­
hibited higher relaxivities than the free por­
phyrin, possibly owing to decreased porphyrin 
aggregation as well as the increased rotational 
correlation time [182]. The highest binding of the 
porphyrin was achieved with the poly(Glu)- 
based polymer, which may be due to incorpora­
tion of a long spacer unit. However, if the 
loading factor becomes too high, relaxivity en­
hancement may be lost owing to interactions 
between the bound chelates. Attempts by these 
workers to produce a linear polymer using a 
monofunctionalised porphyrin resulted in an 
insoluble polymer [181].
Poly (ethylene glycol) has also been used to 
change the relaxivity and toxicity of paramagnet­
ic chelates. Desferrioxamine is an effective iron 
chelator but can lead to hypotensive effects on 
administration. A non-ionic PEG derivative has 
been prepared which was non-toxic and allowed 
enhanced imagine of the kidney and liver in dogs
[173).
Recently, it has been suggested that dendrim- 
ers or cascade polymers would be more effective 
relaxation enhancers, owing to their high rigidity 
and potential for binding a large number of ions. 
The first branched polymers used were based on 
polyethyleneimine which can directly chelate 
paramagnetic ions. However, dendrimers based 
on Starburst® have also been evaluated [179]. 
Monodispersed chelates could be produced with 
varying numbers of chelating ligands, depending 
on the cycle of polymerisation, allowing between 
11 and 170 Gd ions to be bound to the DTPA* 
dendrimer. The relaxivity of the macromoleculc
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with 170 Gd ions bound was equivalent to that 
produced by 1074 free Gd-DTPA molecules and 
was over 10 times greater than that achieved with 
linear polymers. Interestingly, no mass effect is 
seen with these macromolecules; increasing the 
mass does not lead to a decrease in relaxivity. 
The wide variety of molecular sizes available 
with this system leads to a diverse set of applica­
tions; small complexes can be used for ex- 
travascular imaging of tumours and brain, where­
as large complexes can be used lor imaging of 
vasculature.
6.5. Particulates
Imaging of small lesions in liver and spleen is 
difficult to achieve using MRI. Although images 
can be enhanced using Gd-DTPA, the enhance­
ment is transitory owing to the fast blood and 
urinary clearance of the chelate and to the lack 
of an active uptake mechanism [183]. This can be 
overcome by the use of higher doses; however, 
higher and potentially unacceptable toxicity will 
ensue. An alternative approach is to use either 
particles or liposomes containing paramagnetic 
ions or chelates. Liposomes, owing to their size, 
are retained dzi vasculature for a prolonged time 
period and are removed from the circulation 
either within the lung or by the action of 
phagocytic cells of the reticulo-endothelial sys­
tem. In the normal liver, liposomes can be taken 
up by the Kupffer cells or, if very small, can be 
taken up by hepatocytes. Hepatic tumours lack 
phagocytic cells and cannot take up liposomes 
[184]. Therefore, by preparing liposomes con­
taining contrast enhancement agents, the normal 
tissue image can be enhanced relative to that of 
the tumour and a negative image of the tumour 
can be obtained.
There are three approaches to incorporation of 
contrast enhancement agents into liposomes. 
Firstly, a water soluble chelate, such as Gd- 
DTPA, can be incorporated into the aqueous 
core of the liposome. Secondly, a lipid-soluble 
chelate can be incorporated into the pre-formed 
lipid bilayer. Finally, the chelate can be modified 
to prepare amphipathic derivatives which can be 
used, along with other lipids, to form the bilayer
[184]. Liposomes have been prepared in which 
Gd-DTPA is enclosed within the aqueous core 
[185- 188]. These liposomes have been tested for 
their relaxivity in vitro and stability in serum and 
saline. Liposomes were prepared in a variety of 
sizes between 50 and 400 nm in diameter from 
egg phosphatidylcholine (EPC). The relaxivity of 
the paramagnetic ion in liposomes was less than 
for free paramagnetic chelates and was highest in 
the smallest liposomes which have the largest 
surface area: volume ratio. It has been postulated 
that relaxivity of a chelate-containing liposome is 
directly proportional to the flux of water mole­
cules across the liposomal membrane, which is 
itself related to the surface area: volume ratio. 
The loss of image intensity due to decreased 
relaxivity can be overcome if the agent becomes 
concentrated in the desired region. With small 
Gd-DTPA liposomes, there is increased uptake 
into the liver, vascular space and bone marrow 
and the body clearance is increased to 3.5 days in 
mice. This distribution allows imaging of small 
hepatic metastases with doses as low as 0.025 
mmol kg”1 of liposome./The acute toxicity of the 
liposomal preparation is not dissimilar to that of 
standard chelates. However, on continued ad­
ministration, the mice treated with the liposomes 
demonstrated both enlarged livers and spleens. It 
has been suggested that this effect may not be 
seen if liposomes containing Gd-DOTA, where 
the ion is bound more tightly, are used.
The main disadvantage with entrapping the 
chelate within the aqueous core is the reduced 
relaxivity. If the paramagnetic ion could be 
presented to the desired cells on the surface of 
liposomes, this could be overcome. Thus, a 
second type of liposome has been prepared in 
which the chelating ligand is derivatised to be 
lipid-like, allowing it to be incorporated into the 
lipid bilayer [188]. The amphipathic chelate Gd- 
DTPA-SA was prepared and mixed with EPC 
and cholesterol to form liposomes. Maximal 
relaxivity was seen with a 33.3% incorporation of 
the modified ligand; in studies in vitro, the 
relaxivity of spleen and liver was increased by 
110% and 66% respectively. Biodistribution was 
also evaluated, the liposomes rapidly clearing 
from the blood and accumulating in liver and
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spleen from which they are cleared after eleven 
days. No toxicity was seen. Following on from 
this work [186], a second amphipathic ligand has 
been prepared which would allow more rapid 
clearance from the liver. Thus, the ligand was 
bound to the lipid via a stearyl ester (SE) group, 
rather than through a stearyl amide (SA) group. 
With a 33.3% incorporation, comparable 7 , 
signal enhancement was observed as for Gd- 
DTPA-SA. However, although the liposomes 
clear as rapidly from the blood and accumulate 
in the liver, 50% of the liposomes are cleared 
after 2 days. In a further study [189], liposomes 
were prepared containing the derivatised ligand 
DTPA-SA in a variety of concentrations. Gd3+, 
Mn2+ and Fe3+ were then incorporated into the 
chelate and the liposomes were evaluated. The 
Fe3+ liposomes were unstable on formation and 
could not be evaluated. The Mn2+ liposomes 
were unstable in serum; however, they accumu­
lated rapidly in the liver and were excreted 
rapidly, allowing good quality images to be 
obtained. The Gd3+ liposomes, in contrast, were 
stable in plasma, were accumulated rapidly into 
the liver and were retained, allowing images to 
be obtained even after 24 h. Thus, liposomes are 
highly attractive for specific delivery to the liver 
and spleen. Incorporation of the ligand in either 
part of the liposome allows enhanced images 
with lower doses of paramagnetic ions. It has 
been suggested that this technology could be 
further exploited. Liposomes can be diverted 
from the reticulo-endothelial system by using 
large doses or very small vesicles or by ‘blocking’ 
the phagocytic cells by pre-treatment with empty 
liposomes. These alterations would allow blood 
pool imaging. Alternatively, targeting moieties 
could be. incorporated into the lipid bilayer to 
allow cell-specific targeting [184].
It has also been suggested that particles can be 
used for the carrying of chelates. In a study of 
cross-linked starch microspheres substituted with 
DTPA, a variety of paramagnetic ions were 
coupled and exhibited increased relaxivity over 
simple chelates. The increase in relaxivity is 
possibly due to the swelling of the microsphere in 
water, allowing passage of water protons close to 
the paramagnetic ions [190]. Microspheres offer
potential as contrast enhancement agent carriers 
and deserve further evaluation.
6.6. Nitroxid.es, molecular oxygen and nitrogen 
stable free radicals
Other paramagnetic species, apart from metal­
lic ions, have been evaluated as contrast agents. 
Molecular triplet oxygen has been used in MRI 
of the lung through inhalation. In these studies, 
signal enhancement was seen m the left oxy­
genated lung in comparison to the right lung. 
However, this alteration is insufficient to warrant 
further investigation. A more promising ap­
proach, utilising paramagnetic molecules, is the 
use of stable free radicals or ‘spin labels’, par­
ticularly nitroxyl stable free radicals. Nitroxyis 
are labile to redox reactions; steric protection 
confers stability. Then the moiety is relatively 
unreactive in most conditions and remains stable, 
even when heated > 100°C and under a wide 
range of pH conditions. These compounds pro­
vide strong relaxation enhancement because of 
electron paramagnetism that is comparable to 
Cu2+ or Fe3+ paramagnetic ions. They produce 
decreases in both .7*, and T2. However, these 
compounds offer one major advantage over 
other paramagnetics, which is that they can be 
chemically modified through the R group or 
attached to targeting molecules or biomolecules 
to allow selectivity of action. Previously, these 
compounds have been successfully attached to 
drugs such as propranolol and steroids to study 
drug metabolism.
Nitrogen stable free radicals have mainly been 
used as spin probes to study biochemical systems 
using electron spin resonance spectroscopy. 
These studies demonstrate that the compounds 
persist for prolonged periods in biological tissues 
without electron pairing or reduction taking 
place by the formation of hydroxylamines [191]. 
They have been mainly used in MRI to asses 
renal function and identify renal abnormalities. 
In an early study [191], the compound TES (N- 
succinyl-4-amino-2,2,6,6-tetramethylpiperidine-l- 
oxyl) was used to image the kidney and assess 
renal function in animals with renal ischaemia, 
congestion or atrophy. The free radical is rapidly
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excreted in urine with a clearance rate equal to 
the glomerular filtration rate. This allows a 
transient increase in signal intensity in the kid­
ney, permitting increased determination of renal 
abnormalities. Nitrogen stable free radicals have 
not been widely used in MRI, as little advantage 
is obtained over simple paramagnetic chelates. 
However, one interesting use of nitrogen stable 
free radicals is in imaging of hypoxic regions of 
solid tumours. These compounds can be used as 
probes of oxygen concentration, as in low oxygen 
reducing environments such as in hypoxia, the 
compound is reduced and the signal enhance­
ment is lost. (191]
6.7. Superparamagnetic particles
Small ferrite particles have superparamagnetic 
properties; that is, they are easily magnetised to a 
high magnetic moment but the magnetism is lost 
once the external magnetic field is removed. An 
example of a ferrite particle is magnetite, a 
natural compound Fe30 4, which is often found 
in combination with maghaematite and haema­
tite Fe20 3. Superparamagnetic particles exert 
effects on both T l and T2, but the effect on T2 
outweighs all other effects leading to a loss of 
signal in the affected organs [192]. Magnetite 
particles are administered as polymer coated 
particles to allow the formation of aqueous 
solutions, and alter particle size. Although both 
starch and albumin have been used, the majority 
of studies have been performed on AMI-25, a 
commercial product, in which the iron oxide is 
coated in dextran [145]. Initially, studies were 
carried out using relatively large particles de­
signed to be captured by the cells of the reticulo­
endothelial system allowing imaging of the liver 
and spleen [193]. AMI-25 has been used in 
clinical trials for the diagnosis of liver cancer 
[194,195], cerebral vasculature [196] and car­
diovascular imaging [197]. Studies [195] in 15 
patients with known liver cancers demonstrated 
hyperintense imaging of these lesions. Normal 
liver cells, i.e., Kupffer cells take up the particles 
by phagocytosis and there is a loss of signal in 
these cells and the surrounding hepatocytes giv­
ing a negative image of the liver. Abnormal cells
loose the ability to phagocytose, so do not take 
up the contrast agent and thus appear hyperin- 
tense on the image. Although 90% of the par­
ticles were cleared by the liver in 1 h, some 
remains circulating allowing imaging of other 
systems, particularly the heart [197] and brain 
[198]. Clearance from the liver is demonstrated 
in humans within 24 h of treatment [195]. Break­
down of the particle does not lead to abnor­
malities or toxic effects.
Studies with microspheres, in which magnetite 
is imbedded in an albumin matrix, have also 
demonstrated enhanced imaging of hepatic 
tumour models in rabbits. These are slightly 
larger particles (1-5 pm) but they are still 
efficiently taken up by the reticulo-endothelial 
system-and are rapidly cleared from the blood 
stream. There is long-term retention of these 
microspheres. However, no toxicity or immuno- 
genicity has been demonstrated in that, after two 
months, there is no evidence of hepatocellular 
damage or fibrosis [199]. Ultrasmall dextran- 
magnetite particles have also been developed by 
particle size sorting of AMI-25. In normal rats 
[200] over 24 h, accumulation was higher in the 
lymph nodes, bone marrow, liver and spleen and 
the blood half-life was increased from 6 min for 
AMI-25 to 81 min. These particles are small 
enough to transmigrate through capillaries and 
are taken up by the lymphatics. Without contrast 
enhancement, there is a considerable overlap in 
the relaxivities of both normal and metastatic 
lymph tissue. However, on administration of 
ultrasmall particles, metastatic lymph tissue is 
visualised as hyperintense regions, in comparison 
to normal tissue, as it cannot phagocytose [201].
With these developments have come further 
approaches to targeting, away from the reticulo­
endothelial system. One approach is the ferro- 
some; this is a small vesicle that contains super­
paramagnetic particles in the central aqueous 
compartment. These have been evaluated in the 
imaging of lymph nodes, pulmonary emboli, 
adenocarcinomas and hepatomas. In tumour 
tissue, they are taken up by the macrophages 
located at the surface of the tumour giving a rim 
of low signal intensity. Alternatively, the super­
paramagnetic particles can be coated in polymers
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with intrinsic targeting properties. Particles 
coated with arabinogalactose can be targeted to 
hepatocytes via the asialoglycoprotein. This 
achieves imaging of the liver with reduced doses 
in comparison to targeting to Kupffer cells.
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Poly(ADP-ribose)polymerase Inhibitors - Radiosensitizers and Chemosensitizers
M. D. Threadgill, C. Y. Watson, A. E. Shinkwin and W. J. D. Whish
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M E D
123. POLY(ADP-RIBOSE)POLYMERASE INHIBITORS RADIO-AND CHEMO-SENSITISERS
Michael D Threadgill*. Corrine Y Watson. Anne E Shtnkwin and William J D Whish. School of 
Pharmacy & Pharmacology University o f Hath. ( 'lave rton Down Hath HA 2 7A Y (!K
The nuclear enzyme poly(ADP-nbose)polymerase (PARP) catalyses transfer of 
ADP-ribose from NAD’ to nucleophilic acceptor sites on DNA-associated 
proteins in response to local strand breaks A polyamomc polymer is built up by 
attachment of ADP-nbose units to the growing chain The poly(ADP-ribose) is 
implicated in several processes, including ON A repair, gene expression and 
apoptosis Inhibition of PARP in tumour cells leads to persistence of DNA 
damage and to potentiation of the cytotoxic effects of ionising radiation and chemotherapeutic drugs known 
competitive reversible inhibitors of PARP are analogues of the nicotinamide moiety of NAD and include 3-ammo- 
benzaitude. 5-substituted isoquinolinones and quinazolinones. all containing the consensus confonmationally constrained 
arenecarboxamide structure Recent work in our group has been focussed on development of PARP inhibitors which are 
selective for hypoxic tumour cells and/or are mechanism-based irreversible inhibitors Further, we have shown that 
some heteroarvlcarboxamides and conformationally constrained heterobicycles are potent inhibitors
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Synthetic Approaches to Irreversible Inhibition of Poly(ADP-ribose)polymerase
C. Y. Watson, M. D. Threadgill and W. J. D. Whish
Abstracts of Papers of the American Chemical Society, 1996,211, MEDI-231 A.
[C onference p u b lica tio n ]
2 3 1 A SYNTHETIC APPROACHES TO IRREVERSIBLE INHIBITION OF POLY(RIBOSE) POLYMERASE
Cornne Y Watson \  Michael D Threadgill and William J D Whish, School o f Pharmacy & Pharmacology.
University o f Bath. Clover ton Down. Bath BA 2 7AY. UK 
Radiosensitisation and chemosensitisation of tumour cells can be effected by inhibition of DNA 
repair Excision repair of DNA damaged by radiation or alkylating agents is triggered by poly- 
(ADP-ribosyl)ation of histones near the damaged site. The enzyme responsible, poly(ADP- 
ribose) polymerase (PARP), uses NAD’ as the source of ADP-ribosyl units We are currently 
synthesising and testing potential mechanism-based suicide inhibitors of PARP in the form of 3- 
substituted benzanudes and 5-substituted isoquinolinones As expected, the 5-substrtuted iso- 
quinolmones have shown much greater inhibition of PARP than the benzarrudes tested thus far 
For example, 5-bromoisoquinolinone caused >95% inhibition of PARP activity in isolated nuclei 
at 11 pM This is due to the fixed conformation of the amide group in the isoquinolinones Recent success in the
synthesis of 5-iodoisoquinolmone has led to the development o f isoquinolinones with more complex side chains, via the
Heck coupling reaction
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Synthesis of Potential Bioreductively Activated Inhibitors of DNA Repair
A. E. Shinkwin, M. D. Threadgill and W. J. D. Whish
Abstracts of Papers of the American Chemical Society, 1996,211, MEDI-231B.
[C onference p u b lica tio n ]
M E D I
T.I I H SYNTHESIS OF POTENTIAL BIOREDUCTIVELY-ACTIVATED INHIBITORS OF DNA REPAIR
Anne E Shinkwin*. Michael D Threadgill and William J D Whish. School o f Pharmacy & Pharmacology 
University af Hath ('lave r tun Down. Hath HA 2 7AY UK 
One approach to increase the selectivity of radiation and drugs for cancer cells is to exploit the 
lower oxygen concentration in the core of poorly vascularised solid tumours, by designing 
prodrugs which are metabolically activated to inhibitors of poly(ADP-nbose)polymerase 
(PARP) in this environment PARP uses NAD as the source of ADP-ribosyl units for 
poly(ADP-ribosy!)ation of histories near a site of damage in DNA Thus, inhibition of this 
enzyme will impede DNA repair 3-Aminobenzanude and 5-substituted isoquinolinones, 
analogues of NAD . inhibit PARP The synthesis and evaluation of a series of nitro- and amincxhiophene analogues of 
these inhibitors has been undertaken A large differential is required between the inhibitory activity of the nitro pro-drug 
and the active drug, the anuno metabolite Studies using isolated cell nuclei showed >80% inhibition for the thieno- 
pyndinone (above) at 10 pM and >60% inhibition at 12 pM for thiophene-2-carboxamide The isomenc thtophene-3- 
carboxarrude had previously been reported to be inactive Good selectivity has been shown between the activity of pairs 
of nitro- and amino-thiophene carboxamides
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iS-2-Amino-5-(2-nitroimidazol-1 -yl)pentanoic acid: A Model for 
Potential Bioreductively Activated Prodrugs for Inhibitors 
of Nitric Oxide Synthase (NOS) Activity
S. Ulhaq, M. A. Naylor, E. C. Chinje, M. D. Threadgill and I. J. Stratford
Anti-Cancer Drug Design, 1997,12, 61-65.
Anti-Cancer Drug Design (1997), 12,61-65 © Oxford University Press, 1997
5'-2-Amino-5-(2-nitroixnidazol-1 -yl)pentanoic 
acid: a model for potential bioreductively 
activated prodrugs for inhibitors of nitric oxide 
synthase (NOS) activity
Saraj Ulhaq1-2, Matthew A. Naylor1*, Edwin C. Chinjel t , Michael D. 
Threadgill2 & Ian J. Stratford1!
x Division o f Experimental Oncology, MRC Radiobiology Unit, Chilton, Oxfordshire 0X11 
ORD and2School o f Pharmacy & Pharmacology, University o f Bath, Claverton Down, Bath, 
BA2 7AY, UK
Summary; Treatment o f 1,1-dimethylethyl S-(2-1,1 -dimethylethoxycarbonylamino)-5- 
bromopentanoate with 1 -potassio-2-nitroimidazole, followed by deprotection, afTorded 
£-2-amino-5-(2-nitioimidazol-1 -yl)pentanoic add, which was reduced to 5-2-amino-5- 
(2-aminoimidazol-1 -yl)pentanoic add. This aminoimadazole inhibited rat brain nitric 
oxide synthase (NOS) activity 32  times more potently than did the nitro analogue. Thus 
S-2-amino-5-(2-nitroimida2ol-1 -yl)pen tanoic add is a potent prodrug which may be 
bioreductively activated to a NOS inhibitor in hypoxic solid tumours.
Key words: bioreductive/hypoxia/nitroimidazole/prodrug
Introduction
One site of the messenger activity of nitric oxide (NO) is the vascular endothelium, where it 
is a vasodilator and is partly responsible for maintaining cardiovascular homeostasis 
(Moncada et a l , 1991). NO is synthesized from L-arginine by nitric oxide synthase (NOS), 
yielding L-dtrulline as a co-product. The process involves two separate mono-oxygenation 
steps, with Nc-hydroxyarginine as an intermediate, through a reaction requiring O2 and 
NADPH. The isoforms of NOS are in two groups: a constitutive, Ca2 +/calmodulin- 
dependent type (cNOS) and an inducible, Ca2 +/calmodulin-independent form (iNOS). 
Known inhibitors of the enzyme include NG-monomethyl-L-arginine (L-NMMA) and 
NG-nitio-L-aiginine (NOARG) (Moore etal., 1990; Rees et al., 1990). NOS inhibitors that 
have particular tissue or isozyme specifidties open up a variety of therapeutic possibilities 
(Marietta, 1994). Recently, NOS inhibitors have been used selectively to modulate tumour 
blood flow, oxygenation and redox status (Andrade et al., 1992; Wood et al., 1993, 1994).
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Middlesex HA62JR, UK.
tPresent address: MRC Experimental Oncology Laboratory. Department o f  Pharmacy. University of 
Manchester, Oxford Road, Manchester M13 9PL, UK.
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Scheme 1 Synthesis of prodrug 5 and aminoimidazole 6, and the relationship of the 
protonated form of 6 to the structure of L-arginine. Reagents and conditions: (i) 
ClC02Et/Et3N; (ii) NaBH*; (iii) CBr4 /Ph3 P/THF; (iv) l-potassio-2-nitroimidazole/
DMF, reflux, 2 h, 76%; (v) HO/water/EtOAc then chromatography in the presence of 
NH3, 81%; (vi) Hj/EtOH/Pd/C, 83%.
H o w e v e r ,  t h e  i n h i b i t o r s  u s e d  ( L - N M M A  a n d  N O A R G )  a l s o  h a v e  s y s t e m i c  e f f e c t s  r e l a t e d  t o  
t h e i r  e f f e c t s  o n  N O  p r o d u c t i o n .  A l m o s t  u n i q u e  t o  m o s t  h u m a n  a n d  e x p e r i m e n t a l  s o l i d  
t u m o u r s  a r e  r e g i o n s  o f  h y p o x i c  t i s s u e  ( V a u p e l  et a l,  1 9 9 1 ;  W i l s o n ,  1 9 9 2 )  w h i c h  h a v e  b e e n  
u s e d  a s  t a r g e t s  f o r  s e l e c t i v e  b i o r e d u c t i v e  a c t i v a t i o n  o f  p r o d r u g s  ( W o r k m a n  &  S t r a t f o r d ,  
1 9 9 3 ;  A d a m s  &  S t r a t f o r d ,  1 9 9 4 ) .  T h u s ,  p r o d r u g s  t h a t  y i e l d  N O S  i n h i b i t o r s  f o l l o w i n g  
h y p o x i a - m e d i a t e d  r e d u c t i v e  a c t i v a t i o n  c o u l d  p r o v i d e  a  n o v e l  s t r a t e g y  f o r  s e l e c t i v e  v a s c u l a r  
s h u t - d o w n  i n  t u m o u r s ,  w h i l e  a v o i d i n g  s y s t e m i c  e f f e c t s .  2 - A m i n o i m i d a z o l e  a n a l o g u e s  o f  
L - a r g i n i n e  a r e  a n  a t t r a c t i v e  c l a s s  o f  p o t e n t i a l  i n h i b i t o r s ,  s i n c e  p r o t o n a t i o n  g i v e s  a  
g u a n i d i n i u m - l i k e  c a t i o n i c  s y s t e m  w h i c h  i s  f o r m a l l y  v e r y  s i m i l a r  t o  t h a t  o f  a r g i n i n e  ( S c h e m e  
1 ) .  1 - S u b s t i t u t e d  2 - n i t r o i m i d a z o l e s  c a n  u n d e r g o  b i o r e d u c t i v e  m e t a b o l i s m  t o  g i v e  
2 - a m i n o i m i d a z o l e s  ( W a l t o n  &  W o r k m a n ,  1 9 8 7 ;  M c C l e l l a n d ,  1 9 9 0 ) ,  p r e s e n t i n g  a  p o t e n t i a l  
s t r a t e g y  f o r  d e v e l o p i n g  p r o d r u g s  t h a t ,  f o l l o w i n g  h y p o x i a - m e d i a t e d  b i o r e d u c t i o n  i n  t u m o u r s ,  
w i l l  g i v e  s p e c i e s  t h a t  c o u l d  i n h i b i t  N O S  a n d  t h e r e b y  p r o d u c e  l o c a l  v a s c u l a r  s h u t d o w n .  H e r e  
w e  e x a m i n e  t h e  f i r s t  s t e p  i n  t h i s  s t r a t e g y  i n  d e s c r i b i n g  t h e  s y n t h e s i s  o f  n o v e l  2 - n i t r o -  a n d  
2 - a m i n o i m i d a z o l e  a n a l o g u e s  o f  L - a r g i n i n e  a n d  t h e i r  e v a l u a t i o n  a s  i n h i b i t o r s  o f  c N O S  a n d  
i N O S  o b t a i n e d  f r o m  t h e  b r a i n  a n d  l u n g ,  r e s p e c t i v e l y ,  o f  r a t s  t r e a t e d  w i t h  l i p o p o l y s a c c h a r i d e
( L P S ) .
Chemistry
F o l l o w i n g  t h e  m e t h o d  o f  O l s e n  et al. ( 1 9 8 4 ) ,  t h e  y - c a r b o x y l i c  a c i d  o f  B o c G l u O B u '  1 w a s  
c o n v e r t e d  t o  t h e  m i x e d  a n h y d r i d e  w i t h  e t h y l  c h l o r o f o r m a t e .  S e l e c t i v e  r e d u c t i o n  t o  t h e  
c o r r e s p o n d i n g  a l c o h o l  2  w a s  e f f e c t e d  w i t h  s o d i u m  b o r o h y d r i d e .  T r e a t m e n t  w i t h
5-2-AMINO-5-(2-NITROIMIDAZOL-l-YL)PENTANOIC ACID 63
triphenylphosphine and tctrabromomethane then served to replace the alcohol to form the 
corresponding bromo compound 3 in good yield (Olsen et al., 1984). This material 3 was 
used to alkylate l-potassio-2-nitroimidazole in good yield under the usual conditions 
(Scobie & Threadgill, 1994). Acidolytic deprotection gave the prodrug 5 which was 




noate (4). The protected bromo amino add 3 (Olsen et aL, 1984) (560 mg, 1.6 mmol) 
was boiled under reflux with l-potassio-2-nitroimidazole (340 mg, 3.0 mmol) in 
dimethylformamide (40 ml) for 2 h. Evaporation and chromatography (silica gel, ethyl 
acetate/hexane 1:1) gave 4 (550 mg, 76%) as a white solid* mp 83-85°C; found C, 53.0; H, 
7.2; N, 14.4. C n H aN A  requires C, 53.1; H, 7.3; N, 14.6. >H NMR (CDC13) 5 1.47 (18 H, 
s, 2 x BuO, 1.97-2.10 (4 H, m, 3-H2 + 4 -H2), 4.60 (1 H, m, 2-H), 4.96 (2 H, m, 5 -H2), 5.38 (1 
H, m, NH), 7.14(2H,s, imidazole 4,5-H^; mass spectrum (FAB positive ion) 407 (M + Na), 
386.2136 (M + H) (“^ “ C H ^ N A  requires 386.2121), 385.2088 (‘^ p H ^ O s  requires 
385.2087); mass spectrum (FAB negative ion) 384 (M).
S-2-Amino-5-(2-mtroimidazol-l-yl)pentanoic acid (5). Compound 4 (520 mg, 1.4 mmol) 
was stirred with hydrochloric add (4 M, 30 ml) and ethyl acetate (30 ml) for 4 h. Evaporation 
and chromatography (silica gel, methanol/35% aqueous ammonia 49:1) gave 5 (300 mg, 
81%) as a hygroscopic white solid mp 178-181°C; *H NMR (DzO) 5 1.9-2.2 (4 H, m, 3-H2 
+ 4-H2), 4.14 (1 H, t, J =  5.3 Hz, 2-H), 4.54 (2 H, t, /  = 6.0 Hz, S-Hj), 7.21 (1 H, s) and 7.51 
(1 H, s) (imidazole 4,5-Hj); 13C NMR 6 28.07, 29.51, 52.18, 55.25, 130.67, 130.91, 147.16, 
174.47; mass spectrum (FAB positive ion) mlz 229.0930 (M + H) (CSH13N4O4  requires 
229.0937).
S-2-Amino-5-(2-aminoimidazol-l-yl)pentanoic acid (6). Compound 5 (700 mg, 2.6 mmol) 
in ethanol (40 ml) was treated with hydrogen in the presence of 10% palladium on carbon 
(50 mg). After 2 h, the solution was filtered through Celite®and the solvent was evaporated. 
Recrystallization (methanol/diethyl ether) gave 6  (520 mg, 83%) as a hygroscopic white solid: 
mp 174-176°C; ‘H NMR (D20) 5 1.9-2.1 (4 H, m, 3-H2  + 4-H2), 3.94 ( 2  H, t, /  = 6  Hz, 
5 -H2), 4.10(1 H, t, 7 = 6  Hz, 2-H), 6.84 (1 H, s) (imidazole 4 ,5 -^ ;  ,3C NMR 8  26.70,29.52, 
47.33,55.47,115.65,119.18,148.64, 174.72; mass spectrum (FAB positive ion) mlz 199.1202 
(M + H) (CgH15N4 0 2 requires 199.1195).
Biological evaluation and conclusions
Compounds 5 and 6  were evaluated as inhibitors of NOS activity, based on the conversion 
of L-[U-,4 C]arginine to L-[U-,4C]citrulline and NO, using the method of Salter et al. (1991). 
Male Wistar rats (200-300 g), fed ad libitum, were injected i.p. with 4 mg/kg trichloroacetic 
acid-extracted LPS (Knowles et al., 1990). After 6  h, the rats were killed and the brain and 
lungs were removed. Cytosolic fractions of rat brain and lung were used as the source 
of cNOS and iNOS respectively (Knowles et al., 1990). Figure 1 shows the 
concentration-inhibition curves for the effects of 5 and 6  on cNOS from rat brain. Both
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Figure I Concentration-response curves for inhibition of rat brain cNOS by 5 (■) and 
6 ( • ) .  Values are expressed as mean ± SEM (n = 9), obtained from three separate 
determinations, each performed in triplicate.
compounds are inhibitory, with IC50 = 1 -7 mM for the amine 6 and IC jo = 5.3 mM for the 
nitro prodrug 5, giving a ratio of potencies of 3.2. These compounds also inhibit iNOS from 
LPS-induced rat lung, with a similar dose-dependence (data not shown). However, the 
NO2/NH2 differential (2.2) is smaller than that obtained for the Ca2+-dependent form of 
NOS; the compounds are also slightly less potent against this isoform (5: IC50 = 6.6 mM; 6 : 
ICso = 3.0 mM). These results can therefore be regarded as supporting the principle of 
hypoxia-selective prodrugs of NOS inhibitors with eventual applications in selective 
modulation of tumour blood flow after bioreduction. The principle of a differential NOS 
inhibition was our goal and has been demonstrated. The compounds are not potent 
inhibitors (cf. S-NG-nitroarginine methyl ester: IC50 -  7 |iM in this system); we are currently 
investigating modifications to the substituent pattern on the imidazole and their effects on 
the prototropic equilibria thereof in order to increase potency. Work is also underway to 
determine whether 5 is reduced in hypoxic tissues, to measure cellular uptake and to establish 
the ability of 5 or 6 to inhibit NOS activity in vivo.
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5-Substituted isoquinolin-l-ones have been synthesised by one-pot Curtius rearrangem ent o f the 
corresponding substituted 3-phenyipropenoyl azides and cydisation. Arylm ethyladon of the anions o f the 
isoquinolinones w ith benzyl halides [4-methoxybenzyl chloride, 2-(chloromethyI)furan and 5-nitro-2- 
(tosyloxym ethyl)furan] takes place exclusively a t nitrogen. N itration  o f 2-ffuran-2-ylmethyI)isoquinolm-l- 
one in strongly acidic medium gives 2-(5-nitrofuran-2-yimethyl)isoquinolin-l-one, whereas weaker acidic 
conditions lead to  dinitration. C urtius rearrangem ent o f  3-carboranylbutanoyl azide and trapping with 
S-nitrofuran-2-ylm ethanol gives S-nitrofuran-2-ylmethyl Ar-(3-car bo ranylpropyl)carbamate. Biomimetic 
reduction  o f  these nitrofuranylm ethyl derivatives o f  anticancer drugs triggers release o f  the parent drugs. 
T h u s, these n itro furans have potential applications as pro-drugs fo r selective release o f therapeutic drugs 
in  hypoxic solid tum ours.
Regions of chronic and acute hypoxia are present in most solid 
tumours owing to the primitive state of the tumour vascu­
lature.1 Viable cells in such tissue are relatively resistant to 
radiotherapy and to many chemotherapeutic strategies1 Much 
effort has been expended2 on development of radiosensitisers 
with electron-affinity and bioreductively activated cytotoxms 
for selective therapy o f this tissue, and of a variety of pro-drugs 
to  deliver cytotoxins selectively to rumours. 1-Substituted 
2-nitroimidazoles are knownM to be selectively retained in 
hypoxic tissue by reductive metabolism. However, relatively 
little attention has hitherto been focussed on exploiting the 
physiological difference in concentration of molecular oxygen 
between normal and hypoxic tumour tissue by design o f bio­
logically inactive pro-drug systems which, upon selective bio­
reduction in hypoxic tissue, would release known therapeutic 
drugs only in that tissue. This would improve greatly the select­
ivity o f biodistribution of such agents. Sykes et al. have 
reported5 early studies on a bioreductively triggered release 
system based on 2-nitroarylamides, whereas 4-nitrobenzyl- 
oxycarbonyl pro-drugs have been put forward* for use in 
the Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 
strategy, using a bacterial nitroreductase attached to a tumour- 
selective antibody. For the potential pro-drugs described here,
2-nitrofuran was selected as the redox-sensitive moiety. The 
redox potential of this heterocycle is relatively high [£% = 
-3 2 5  mV for 2-methyl-5-nitro-A-<prop-2-enyl)furan-3-carbox­
amide],7 which would favour selective reductive metabolism in 
hypoxic tumour tissue effected by endogenous enzymes such as 
cytochrome P450 reductase.* The general design of the pro­
drugs and the mechanisms of bioreductively triggered release 
are shown in Scheme 1. For the simpler pro-drugs 1, the 
5-nitrofuran-2-ylmethyl unit is attached to a heteroatom in the 
drug. Reduction in hypoxic tumour tissue will give the corre­
sponding aminofuran 2 (or the analogous hydroxylamine). The 
presence of an available electron pair will then promote frag­
mentation as shown to release the drug 3 in the tumour tissue. 
This fragmentation is clearly not available to the nitrofuran 1. 
Where appropriate, the nitrofuranylmethyl unit could be linked 
to  the drug by an additional readily fissile group, as in the car­
bamate pro-drugs 4. Bioreductively triggered fragmentation 






Scheme I Proposed mechanisms of bioreductively triggered release o f  
drugs from general nitrofuranylmethyl pro-drugs 1 and 4
we report syntheses of examples of pro-drugs of each type 
(1 and 4) and biomimetic studies on the release of parent drugs
3.
Isoquinolin-l-one 18d and several S-substituted analogues 
are potent inhibitors’ of poly(ADP-ribose)polymerase 
(PARP), an enzyme with a central role in initiating excision 
repair of DNA following damage by radiation or electrophilic 
drugs. Thus inhibitors of PARP are potentiators of these
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therapeutic strategies. Prodrugs which selectively release iso ­
quinolinones in hypoxic tumour tissue would therefore act as 
tum our-selective radiosensitisers. In the design o f  these pro­
drugs, it is necessary to conceal the arylcarboxamide m otif, 
with the N - H  held syn to  the carbonyl oxygen, which is essen­
tial for enzym e inhibitory activity . ’ *10 Within the context o f  the 
nitrofuranylm ethyl system, this could be achieved through  
either l-(5-nitrofuran-2-ylm ethoxy)isoquinolines or 2-{5-nitro- 
furan-2-ylm ethyl)isoquinoIin-I-ones, pro-drugs o f  general 
type 1 .
To form exam ples o f  pro-drugs o f  type 4, with the carbamate 
link, 2 -phenylethylam ine was selected as a model and a car- 
boranylalkylam ine was selected as a drug for delivery. Boron  
neutron capture therapy (BNCT) is under active investigation  
for the treatment o f  various cancers, notably gliom as and  
m elanom as . 11 W hen the I0B isotope is irradiated with slow  
(‘therm al’) neutrons, an [n,a] reaction ensues, giving 7Li and  
4H e nuclei w ith kinetic energy (2.31 MeV). With this energy, the 
a-particle has a range o f  ca. one ceil diameter in biological 
tissue and dam age is limited to the cell containing the boron. 
Early clinical failures o f  BN C T  were attributed U*IJ to  in ­
adequate concentrations o f  l0B in the tumour tissue or to  lack  
o f  selectivity o f  disposition o f  ,0 B, leading to damage o f  nor­
m al tissue. Carboranes have been linked to nucleosides , 14 to  
porphyrins15 and to nitroim idazoles4 ,1 4 ,1 7  in attempts to  target 
boron selectively to tumours. Where a 5-nitrofuran-2-ylmethyl 
jV-(carboranylalkyl)carbamate forms pro-drug 4, selective b io­
reduction in a hypoxic tumour cell would release a carboranyl- 
alkylamine, w hich, at the relatively acidic pH o f  a tum our cell, 
w ould be protonated and hence unable to diffuse out through  
the cell m embrane. Boron would therefore accumulate in the 
tum our tissue.
To provide nucleophilic and electrophilic reagents to  intro­
duce the nitrofuranylmethyl group into the pro-drugs, the alco­
hol 7a  and the nitrofuranylmethyl electrophiles 8 a and 9  were 




H O H ^ R
7a: R = NO*
7b: R = H
T s C H ^  O N Q j O H jC  O  R
\ Y  \ Y
9 8 a:R = NQ2
8b: R = H
Scheme 2 Synthesis of electrophilic (nitro)furan-2-ylmethyl reagents 
8a,b and 9. Reagents i, AKOPr1),, Pr'OH; ii, SOOj. pyridine, C H G }; iii. 
TsCl. KOH. THF.
carbaldehyde 6  selectively at the aldehyde using sodium  boro- 
hydride were unsuccessful, leading only to products o f  degrad­
ation , in contrast to a previous report . 11 However. M eerw ein- 
Ponndorf-V erley reduction gave the required nitrofuranyl- 
m ethanol 7a a lm ost quantitatively. Activation o f  the m ethylene 
as an electrophile was attempted through conversion in to  the 
corresponding chlorom ethylnitrofuran 8 a and the tosylate 9, 
respectively. Replacem ent o f  OH with Cl to give 8 a was 
achieved by treatment o f  7a with thionyl chloride and pyridine 
in a m odification o f  the m ethod o f  Wang er a /.1’ Reaction o f  7a
with tosyl chloride in the presence o f  powdered potassium  
hydroxide afforded the tosylate 9  in m odest isolated yield.
1-Alkoxyisoquinolines have been prepared by substitution in 
the corresponding 1 -chloroisoquinolines using sodium alkox- 
ides under vigorous conditions, although the range o f  l-alkoxy  
substituents reported to have been introduced in this way has 
been restricted to simple exam ples,”  such as methoxy and  
ethoxy. 1-Benzyloxyisoquinoline has not been reported. Treat­
ment o f  1 -chloroisoquinoline21 with 5-nitrofuran-2-ylmethanol 
7a and furan-2-ylmethanoI 7b alkoxides gave only products o f  
furan degradation under a variety o f  reaction conditions, 
m aking the corresponding pro-drugs unavailable by this 
route.
The usual route for preparation o f  2-substituted isoquino­
lin -l-ones has been oxidation o f  2 -substituted isoquinolinium  
salts in the presence o f  hydroxide ion . 2 2  However, this is 
inappropriate for preparation o f  the proposed pro-drugs, ow ing  
to  the harsh reaction conditions required. Routes em ploying  
jV-alkylation o f  isoqu inolin -l-ones were therefore investigated. 
A  convenient synthesis o f  isoquinolin-l-ones by Curtius 
rearrangement o f  cinnamyl azides and thermal cyclisation, in a 
one-pot process, has been described by Eloy and Deryckere , 23  
although this is limited to isoquinolinones without electron- 
withdrawing substituents. 2 -Iodobenzyl alcohol 1 0  was oxidised  
to  the corresponding aldehyde 11a with pyridinium dichromate 
and a  direct condensation with m alonic acid afforded the iodo-  
cinnamic acid 13a (Scheme 3). 2-Methylbenzaldehyde l i b  had  
to be converted into its diethyl acetal 1 2  for efficient con d en ­
sation under the K noevenagel-D oebner conditions24 to  give 
the methylcinnamic acid 13b. The corresponding brom ocin- 
namic acid 13c was prepared from 2 -brom oiodobenzene in a 
convenient modification o f  the iodine-selective Heck reaction  
conditions used by Plevyak et al.25 U se  o f  boiling propionitrile 
as the reaction solvent obviated the need for the sealed tube  
required to conduct the reaction at 100 °C in acetonitrile. Vari­
ous modifications o f  the original conditions o f  Eloy and D ery­
ckere23 were investigated for the Curtius rearrangement and 
cyclisation sequence. T he iodocinnam ic ad d  13a was converted  
into its ad d  chloride 15a and treatment with sodium azide fur­
nished the ad d  azide 16a. For ease o f  isolation o f  the product 
5-iodoisoquinolin-l-one 18a from the reaction mixture by 
predpitation with water, the Curtius rearrangement and cycli­
sation were effected in boiling dry tetraglyme. The add chloride  
15b and add  azide 16b o f  the m ethyldnnam ic add were pre­
pared similarly, but the original boiling diphenyl ether was 
found to  be the optim um  solvent for the high-yielding synthesis 
and isolation o f  5-m ethylisoquinolin-l-one 18b. The brom o- 
isoquinolinone 18c was prepared similarly but in poor yield, 
using the add  azide 16c formed from a mixed anhydride.
The relatively few  reports2 4  o f  alkylation o f  isoquinolinones 
indicate that alkylation o f  isoq u in olin -l-on es with simple halo- 
geno alkanes occurs predom inantly at the nitrogen o f  the co n ­
jugate anion under a variety o f  conditions. Two sets o f  co n ­
ditions were used in a series o f  m odel experiments designed to 
establish the site o f  reaction o f  isoquinolinone anions with halo- 
genom ethyl arenes and to optim ise the reaction conditions. The 
anion formed from 5 -iodoisoquinolinone 18a and lithium hexa- 
methyldisilazide w as benzylated in high yield by benzyl ch lor­
ide, giving 20a. T he 5-brom o analogue 18c was also converted  
into the N-(4-m ethoxybenzyl) derivative 20c under these co n ­
ditions. Benzylation o f  the sodium  an ion  o f  isoquinolinone 18d 
with benzyl bromide in D M F  was a lso  highly efficient in form ­
ing 2 0 d, although the yield in the corresponding benzylation o f  
5-m ethylisoquinolinone 18b to  give 20b was poor. However, 
treatment o f  the anion derived from reaction o f  isoquinolin-
1 -one 18d with sodium  hydride and with lithium hexamethyl- 
disilazide with the chlorom ethylnitrofuran 8 a failed to give the 
required N-(nitrofuranylm ethyl)isoquinolinone 19. Com pound  
19 was formed in poor isolated yield (24%) when the sodium  
salt o f  18d was treated with the m ore reactive tosylate 9 in
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18a. R = I 
18b: R = Me 
18c: R =  Br
CHO
11a: R = I 
lib : R = Me
17a: R = I 
17b: R = Me 






13a: R = I 
13b: R = Me 
13c R = Br
Br
14
*v i  I3a4»[only
coa
16a: R =  I 
16b: R = Me 
16c: R = Br
15a R = I 
15b: R = Me
Scheme 3 Synthesis o f isoquinolin-l-ones 18a-c. Reagents: i. pyridinium dichromate, CH2G 2; ii, CHjfCOjH^, piperidine, pyridine; iii, H Q O E t),. 
SO G j, EtOH; iv, H2C=CHCOjH. Pd(OAc)j, EtjN, EtCN; v, SO Q 2, DMF; vi, E tO jC Q , Et,N, MejCO; vii. NaNj, water, 1,4-dioxane or acetone: 




20a: R> =  I, R? = H 
20b: R» = Me. R2 = H 
20cR> = Br,R2 = OMe 
20d: R1 =  RJ = H
0 6
18a: R - 1 
18b: R = Me 
18c: R = Br 











21b: R = Me 
21d: R = H
Scheme 4 Synthesis of 1-(arylmethoxy)isoquinolines 20a-d. 2-{furan- 
2-ylmethyl)isoquinolin-1 -ones 21b,d and 2-(5-nitrofuran-2-ylmcthyI)- 
isoquinolin-l-one 19. Reagents: i. LiN(SiMej)2, BnG. TH F or NaH, 
BnBr. DM F: ii. LiN(SiMe,)2. 4-M cOQH«CH2G . THF; iii. NaH. 9, 
D M F; iv. LiN(SiMe2)2, 8b. THF: v. C F5C 0 2H. HNO, or Cu(NO,)2; vi, 
e.g. HNO,. HOAc.
DMF. Assignment of the structures of 20a,b,d and 21b,d as 
being the A-(arylmethyl)isoquinolin-1 -ones rather than the
l-(arylmethoxy)isoquinolines was made by UC NMR spectro­
scopy and, in the case of 20a, by IR spectroscopy. The CH2 
groups resonated at 6 51.90, 51.68, 51.59, 44.33 and 44.16, 
respectively, values which correspond closely to those typical 
for ArCHjN but not ArCH20 . The IR spectrum of 20a con­
tained a band at 1650 c m '1, indicating a carbonyl group. The 
structure of 20c was assigned by analogy. Since the target nitro- 
furan 19 prepared by alkylation of 18d with 9 was identical with 
material formed by selective nitration of 21d, the nitrofuranyl- 
methylation must also have taken place at N, rather than at O.
As the combined yield over two steps 7a—>9->19 was very low 
(6%), an alternative longer route was developed. Reaction of 
the lithium salt o f isoquinolin-l-one 18d with freshly prepared 
unstable chloromethylfuran 8b27 in T H F gave a moderate 
yield of the A^-furanylmethylisoquinoline 21d. The 5-methyl 
analogue 21b was formed similarly. Selective nitration at the 
furan 5-position was then required to form 19. The usual con­
ditions for nitration of furans and related heterocycles are 
relatively mild, eg. acetyl nitrate or nitric acid in acetic acid. 
However, all applications of these and other relatively weakly 
acidic nitrating conditions gave only the dinitrated product 22 
where the isoquinolinone 4-position has also reacted. In an 
extensive study of substitution of isoquinolin-l-ones. Homing 
et al.3* reported that the principal site of reaction of various 
electrophiles was the 4-position. However, Kawazoe and 
Yoshioka 29 noted that, on treatment o f 18d with potassium 
nitrate in concentrated sulfuric acid, nitration took place at the 
5- and 7-positions, presumably owing to deactivation of the 
heterocyclic ring by protonation. Adopting this approach to 
selective deactivation of the nitrogen heterocycle, the reaction 
of a solution of 21d in trifluoroacetic acid with nitric acid or. 
preferably, copperfn) nitrate at low temperature effected select­
ive mononitration on the furan, giving the target jV-(nitro- 
furanylmethyl)isoquinolinone 19. Traces of the dinitro com­
pound 22 were also isolated but the major by-product was the 
parent isoquinolinone 18d resulting from dealkylation under 
the acidic conditions. The 5-methyl analogue 21b gave the 
parent 5-methylisoquinolinone 18b as the only isolable product. 
Thus the sequence 7b-*8b-»21d->19 proceeded in higher over­
all yield (16%) than the more direct sequence above.
Since it was planned to form the carbamate link in the tar­
get carborane-nitrofuran 38 by addition of 5-nitrofuran-2- 
ylmethanol 7a to an appropriate isocyanate, model reactions 
for the Curtius rearrangement and addition were investigated. 
The model sequence, in which phenyl replaces carboranyl. also
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provides another target compound in which the biomimetic 
reductively triggered release from a pro-drug 4 can be studied.
3-Phenylpropanoic acid 23 was converted into its acid chlor­
ide 24 and hence to the acid azide 25 (Scheme 5). Curtius
23: R = COjH — ■, 
24:R = COCI'2= i -• 
25:R = CON3-=d“ 




Scheme 5 Synthesis of r.itrofuranylmethyl iV-(2-phenylethyl)carba- 
mate 27. Reagents: i. (COCIh; ii, MejSiNj, PhMe; iii, heat, PhMe; iv, 
7a.
rearrangement in boiling toluene gave the isocyanate 26 which 
was not isolated but was trapped by reaction with 7a under 
basic conditions, giving the nitrofuranylmethyl carbamate 27. 
From some runs o f this reaction, significant yields o f the ester 
28 were also isolated, indicating incomplete Curtius rearrange­
ment.
Scheme 6 shows the application o f this sequence to the syn-
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Scheme 6  Synthesis of nitrofuranylmethyl A/-(3-carboranylpropyl>- 
carbamate 38. Reagents. i, KCN, EtOH. water, ii. B,*H14. MeCN; iii. 
H jS04. water, iv. SOCl2. DMF; v. NaNj, Me,CO, water, vi, heat. 
CHC1,; vii, BnOH. Et,N. CHC1,; viii, HBr, HOAc; ix, 7a, Et,N. CHC13.
thesis of the nitrofuranylmethyl W-(carboranylalkyl)carba- 
mate 38. Although the carboranebutanoic acid 32 has 
been reported10 to be formed by carboxylation of the Grig- 
nard reagent derived from l-(3-bromopropyl)-l,2-dicarba- 
c/ojo-dodecaborane( 12), the yield is low, owing to a com­
peting cyclisation to give cyclopentanof 1,2]-1,2-dicarba-c/oso- 
dodecaborane(12). An alternative method, in which all the
required carbon atoms were present as the carborane was 
formed, was therefore developed. Hex-5-ynenitrile 30 was pre­
pared straightforwardly from 5-chloropentyne 29. Following 
the standard method for synthesis of carboranes from alkynes 
and decaborane(I4) at elevated temperature in the presence o f a 
Lewis base,,<J7JI the cyanopropylcarborane 31 was prepared 
in excellent yield. Acidic hydrolysis afforded the carborane­
butanoic acid 32. Formation of the acid chloride 33, substi­
tution with sodium azide and Curtius rearrangement of 34 in 
warm chloroform afforded the isocyanate 35. This was not iso­
lated but was treated with benzyl alcohol under basic con­
ditions to give the Z-protected carboranylpropylamine 36. 
This sequence served both as a model for the reaction o f 35 
with arylmethanols and as an entry into the synthesis o f the 
hitherto unreported carboranylpropylamine. Interestingly, 
treatment o f 36 with hydrogen in the presence of palladium did 
not efTect deprotection and it was necessary to remove the Z 
group with hydrogen bromide to give the salt 37. With the car­
boranylpropylamine ‘drug’ 37 now available, the corresponding 
pro-drug 38 was prepared by addition of nitrofuranylmethanol 
7a to the isocyanate 35. As with the phenylethyl series above, 
quantities of the analogous nitrofuranylmethyl ester 39 were 
obtained from some runs, again indicating incomplete Curtius 
rearrangement.
A mild method for selective chemical reduction o f the nitro 
group was needed to test release of ‘drugs’ from the two types 
of pro-drug 1 and 4. In particular, the conditions must not 
permit hydrogenolysis of the ‘benzylic’ CH2- 0  or C H 2-N  
bonds, which would not be biomimetic for the nitroreductases 
and the cytochrome P450 reductase enzymes. Sodium boro- 
hydride in the presence of palladium fulfils these criteria.17,12 
although the usual solvent, methanol, was replaced by propan- 
2-ol in these studies to minimise any alcoholysis. Firstly, iso- 
quinolinone 18d was released in 67% yield by this method from 
pro-drug 19, through the intermediacy o f the aminofuran 40 
(Scheme 7). The failure of the furanylmethyl analogue 21d to 
release 18d under the same conditions serves to validate the 
selectivity of the reduction by excluding a benzylic hydro­
genolysis mechanism. An analogous selective reduction o f  the 
nitro group in the nitrofuranylmethyl carbamate 27 caused 
release of 2-phenylethylamine 42 in satisfactory yield, via the 
aminofuran 41. The physical properties of the carboranyl­
propylamine were not conducive to easy isolation from boron- 
containing by-products in this reaction mixture. Therefore, 
after reductively triggered cleavage, the amine 43 was trapped as 
its Z derivative 36 by treatment with benzyl chloroformate. 
The Z-trapped drug was obtained in 26% yield, the relatively 
low yield being probably due to the isolation procedure. As a 
final positive control experiment, the pro-drug 38 was subjected 
to selective reduction of the nitro group by tin(n) chloride.13 
After the tin complex had been decomposed with sodium 
hydroxide, the carboranylpropylamine 43 was isolated in 40% 
yield.
A preliminary evaluation of the biological activities o f the 
pro-drug 19 and the corresponding delivered drug 18d was 
made to check that the pro-drug is indeed a less potent inhibitor 
of the target enzyme, PARP. than is the 2-unsubstituted 
isoquinolin-l-one drug. PARP was extracted with aqueous 
sodium chloride (0.4 m) from nuclei isolated from L929 murine 
areolar cells. The enzyme activity was measured in the presence 
and absence of test compounds by the rate of incorporation of 
radioactivity from N A D ’ labelled with JH in the adenosine into 
acid-insoluble material. At the test concentration, 10 pM, the 
pro-drug 19 inhibited the enzyme by 60% whereas isoquinolin-
l-one 18d inhibited the activity by >95% at the same concen­
tration.
In conclusion, it can be seen that a potential bioreductively 
triggered pro-drug system has been developed, based on reduc­
tion of 5-nitrofuran-2-ylmethyl derivatives. The nitrofuranyl­
methyl group has been linked directly to the 2-position o f iso-













Scheme 7 Reductively activated release of isoquinolinone 184 and 
amines 42 and 43 from nitrofuranylmethyl ether 19 and carbamates 27 
and 38. respectively. Reagents: i, NaBH«, Pd-C. Pr'OH. water, ii, 
NaBH4. P d-C  MeOH. water, iii, SnCl* HQ. water, iv. ZC1, Et,N. 
4-pyrrolidinylopyridine, CH2C12.
quinolinone and through a carbamate to a carboranyl- 
alkylamine. Efficient syntheses o f isoquinolinones 18a-c and 
arylmethylations of these isoquinolinones have been developed. 
New selective methods for nitration of a furan in the competing 
presence of an isoquinolinone have been identified. Biomimetic 
reduction o f the nitro group initiated efficient expulsion of iso­
quinolinone 18d from pro-drug 19 and of the carboranyl­
propylamine 43 and carbon dioxide from the nitrofuranyl­
methyl carbamate pro-drug 38. This pro-drug strategy could be 
extended into use of nitroheterocycles of different redox poten­
tials carrying other functionalities to modify the physical 
properties and biodistribution of the pro-drugs.
Experimental
N M R Spectra were obtained of solutions in deuteriochloro- 
form, unless otherwise stated; J values are given in Hz. Solu­
tions in organic solvents were dried with anhydrous magnesium 
sulfate, unless otherwise noted. Solvents were evaporated under 
reduced pressure. The stationary phase for chromatography was
silica gel. Brine refers to saturated aqueous sodium chloride. 
Ether refers to diethyl ether, unless otherwise stated. DMF 
refers to dry dimethyiformamide, TH F refers to dry tetrahydro- 
furan and EtOAc refers to ethyl acetate.
S-Nttrofu»D-2-yhnediaiK>l 7a
5-Nitrofuran-2-carbaklehyde 6 (3.8 g, 27 mmol) was boiled 
under reflux with aluminium isopropoxide (5.5 g, 27 mmol) in 
propan-2-ol (50 cm1) for 4 h and the solvent was then evapor­
ated. After the mixture had been treated with hydrochloric acid 
(1 m; 50 cm1) and diluted with ether, it was washed (water), 
dried and evaporated. Chromatography (EtOAc-hexane, 1:1) 
of the residue gave the alcohol 7a (3.8 g, 99%) as a pale yellow 
oil (lit.,,,J4 oil); SH 2.72 (1 H, br s, OH), 4.73 (2 H, s, CH2), 6.57 
(1 H, d, J  3.7, furan 3-H) and 7.30 (1 H, d, J 3.7, furan 4-H).
2-ChloromethyF5-nitrofuran 8a
Thionyl chloride (383 mg, 2.8 mmol) in chloroform (1.2 cm1) 
was added during 5 min to 7a (220 mg, 1.5 mmol) in chloroform 
(12 cm1) and pyridine (0.30 cm1) at -1 0 °C  and the mixture 
was stirred at -1 0  °C for 3 h. It was then washed twice with 
hydrochloric ad d  (1m) and once with aqueous sodium hydrox­
ide (3%), dried and evaporated. Chromatography (EtOAc- 
hexane, 1:1) o f the residue gave the chloromethylnitrofuran 8a 
(40 mg, 16%) as a yellow oil Git-,*5^  oil); <5„ 4.61 (2 H, s, CH,). 
6.64 (1 H, d, J  3.7, furan 3-H) and 729 (1 H, d, J  3.7, furan 4- 
H); mJz (El) 163/161 (M) and 126 (M -  Cl).
2-(4-Metfaylphetiyls(ilfoayk>xymetfayI)-5-nitrofuran 9
A mixture o f 4-methylbenzenesulfonyl chloride (2.7 g, 14 
mmol), 7a (2.0 g, 14 mmol) and potassium hydroxide powder 
(2.0 g, 35 mmol) in THF (75 cm1) was stirred for 4 h after which 
it was evaporated. The residue was dissolved in EtOAc, and 
the solution was washed twice with water, dried and evaporated. 
Chromatography (dichloromethane-hexane, 1:1) o f the residue 
gave the tosylate 9 (1.06 g, 25%) as a yellow wax (compound 
reported by Adams et o/.n ); SH 2.45 (3 H, s, Me), 5.10 (2 H, s, 
CHj), 6.64 (1 H, d, J  3.7, furan 3-H), 7.20 (1 H, d, /  3.7, furan
4-H), 7.35 (2 H, d, J  8.0, Ar 3,5-Hj) and 7.78 (2 H, d, J 8.0, Ar 
2,6-Hj); mlz (CD 298 (M +  H).
2-Iodobenzaldefayde 11a
2-Iodophenylmethanol 10 (20.0 g, 85.5 mmol) was stirred with 
pyridinium dichromate (49.2 g, 130 mmol) in dichloromethane 
(195 cm1) for 3 h, after which the mixture was diluted with ether 
(60 cm1), filtered and distilled to give the aldehyde 11a (12.33 g, 
62%) as a pale yellow wax, bp 109°C/1.5 mmHg (fit.,1* bp 
129 °C/1.5 mmHg, l i t .*  mp 37 °C); <5„ 7.29 (1 H, dt, /  1.8, 7.7,
5-H), 7.46 (1 H, t, J  7.7, 4-H), 7.88 (1 H, dd, J  7.7, 1.8, 3-H), 
7.96 (1 H, d, 27 .7 , 6-H) and 10.08 (1 H, s, CHO).
2-(DiethoxymethyI)methyIbenzene 12
Thionyl chloride (5 cm1) was added to dry ethanol (50 cm1) at 
5 °C, followed by l i b  (10.0 g, 83 mmol) and triethyl orthofor­
mate (100 g, 676 mmol). The mixture was boiled under reflux 
for 5 h, after which it was cooled and treated with sodium carb­
onate (10 g). After 15 min the mixture was diluted with ether 
(150 cm1) and filtered. After evaporation of the filtrate, the resi­
due was dissolved in EtOAc, washed with aqueous potassium 
metabisulfite (10%) and water, dried and evaporated to give the 
acetal 12 (12.3 g, 76%) as a colourless oil (lit.,40 oil); SH 1.23 (6 
H, t, J  7.0, 2 x CHjCHi), 3.53 (2 H, dq, J 9.3, 7.0, C //2CH,), 
3.60 (2 H, dq, J  9.3. 7.0, CH2CH2), 5.56 (1 H, s. C ^ O E D J, 
7.15-7.25 (3 H, m, Ar 3.4.5-H,) and 7.56 (1 H, m, Ar 6-H). This 
compound was taken forward without further characterisation.
(£>3-(2-IodopbenyI)propenoic acid 13a
2-Iodobenzaldehyde 11a (5.00 g. 21.5 mmol) was boiled under 
reflux with propanedioic acid (4.89 g, 47 mmol) and piperidine 
(0.2 cm1) in pyridine (10 cm1) for 1 h. The cooled mixture was
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added to hydrochloric add (2 m; 150 cm1) to give a precipitate. 
This was washed with water and dried to give the add 13a (4.86 
g, 82%) as colourless needles, mp 218-220 °C (lit.,41 mp 212- 
214 °C); <5„ 6.48 (1 H. d, 7 15.8, 2-H), 7.16 (1 H, t, 7 8.1, Ar
4-H), 7.44 (1 H, t, 7 8.1, Ar 5-H). 7.63 (1 H, d, 7 15.8, 3-H), 
7.83 (2 H, m, Ar 3,6-Hj) and 12.67 (1 H, br, C02H).
(£>-3-(2-Methylphenyl)propeiioic add 13b 
The acetal 12 was treated with propanedioic add, pyridine and 
piperidine as for the synthesis of 13a from 11a, except that the 
reaction time was 3.5 h. Chromatography (EtOAc-hexane, 1:1) 
of the crude product gave the add 13b (3.62 g, 86%) as a white 
solid, mp 178 °C (lit-,24180 °Q; SH 2.47 (3 H, s, Me), 6.39 (1 H, 
d, 7 15.9,2-H), 7.20-7.35 (3 H, m, Ar 3,4,5-H,), 7.59 (1 H, ca. d, 
Jca. 7.5, Ar 6-H), 8.10 (1 H, d, 7 15.9,3-H) and 11.5 (1 H, br, 
C02H).
(£)-3-(2-BromophenyI)propeDoic add 13c
2-Bromoiodobenzene 14 (14.05 g, 50 mmol) was boiled under 
reflux* with propenoic add (4.73 g, 66 mmol), palladium(n) 
acetate (111 mg, 490 pmol) and triethylamine (12.55 g, 124 
mmol) in propanenitrile (20 cm1) for 1.5 h. Hydrochloric add (2 
m ; 800 cm1) was added to the cooled mixture. A solution of the 
resulting predpitate, in hot ethanol, was filtered and cooled to 
give the acid 13c (8.53 g, 76%) as white crystals, mp 202-204 eC 
(decomp.) Git,42 mp 212-212.5 °C); ^ (CD^O] 6.57 (1 H, d,
716.1,2-H), 7.35(1 H, dt, 7 1.5,7.7, Ar 4-H), 7.44 (1 H, t,77.7, 
Ar 5-H), 7.71 (I H, dd, 77.7,1.5, Ar 6-H), 7.83 (1 H, d, 7 16.1,
3-H), 7.90 (1 H, dd, 7 7.7, 1.5, Ar 3-H) and 12.66 (1 H, br, 
C02H).
5-Iodotsoqmnolin-l-one 18a
The add 13a (4.00 g, 14.6 mmol) was stirred with thionyl chlor­
ide (10 cm1) and DMF (0.05 cm1) for 16 h and then evaporated. 
The residue (crude 15a), in 1,4-dioxane (5 cm1), was added to 
sodium azide (2.85 g, 44 mmol) in water (6 cm1) and 1,4- 
dioxane (6 cm1) during 15 min. After the mixture had been 
stirred for 45 min, it was diluted with water (11 cm1) and 
extracted thrice with dichloromethane. The dried extract was 
evaporated to give a residue (crude 16a) which, in dichloro­
methane (10 cm1), was added to boiling dry bis[2-(2-methoxy- 
ethoxy)ethyl] ether (12 cm1) in portions. The solution was 
boiled under reflux for 1 h and then cooled. The resulting solid 
was recrystallised (acetone) to give 5-iodoisoquinolin-1 -one 18a 
(1.65 mg, 42%) as white needles, mp 238-244 °C (decomp.) 
(Found: C, 39.8; H, 2.32; N, 5.06. C^i/NO requires C, 39.9; 
H, 2.23; N, 5.17%); ^ [(CDJjSO] 6.55 (1 H, d, 7 7.3,4-H), 7.23 
(1 H, t, 7 7.7, 7-H), 7.31 (1 H, d, 7 73,3-H), 8.22 (2 H, m. 6,8- 
H2) and 11.52 (1 H, br, NH); mlz (El) 270.9492 (M, 100%. 
QHJNO requires M, 270.9494).
5-MethyIisoquinolin-l-ooe 18b
Compound 13b (1.4 g, 8.6 mmol) was stirred with thionyl chlor­
ide (15 cm1) and DMF (0.05 cm1) for 16 h and then evaporated. 
The residue (crude 15b) was stirred with sodium azide (2.0 g, 30 
mmol) in acetone (14 cm1), water (4 cm1) and acetone (4 cm1) 
for 50 min at 5 °C after which it was treated with diphenyl ether 
(10 cm1). The suspension was washed with water, dried (CaClJ 
and evaporated. The residual solution of crude 16b was added 
to boiling diphenyl ether (15 cm1) during 15 min and the mix­
ture was heated at reflux for 2 h. It was then evaporated and the 
residue was chromatographed (EtOAc) to give the isoquinol­
inone 18b (900 mg, 66%) as a white solid, mp 180-181 °C (lit.,41 
mp 182-183 °C); <5„ 2.55 (3 H, s. Me), 6.71 (1 H, d, 7 7.3,4-H), 
7.25 (1 H, d, 7 7.3,3-H), 7.40 (1 H, dd, 7 7.9,7.0, 7-H), 7.51 (1 
H, d, 7 7.0, 6-H), 8.31 (1 H, d. 7 7.9, 8-H) and 12.16 (1 H, br, 
NH); Sc 19.17 (CH,), 103.47 (CH), 125.18 (CH), T25.95 (C„),
126.10 (C„), 126.39 (CH), 127.47 (CH), 133.45 (CH), 137.18 
(C,) and 164.90 (C,); mlz (El) 160.0712 (M. C,nCH,NO
requires M, 160.0718) and 159.0682 (100%, M. C,0H,NO 
requires M, 159.0684).
5-BromoisoqaiiioIut-l-one 18c
Triethylamine (1.6 g, 16 mmol) was added to 13c (3.00 g. 13 
mmol) in dry acetone (35 cm1) at 0 °C followed by ethyl chloro- 
formate (1.72 g, 16 mmol) in dry acetone (3 cm1). The mixture 
was stirred at 0 °C for 30 min, after which it was treated with 
sodium azide (13 g, 18.5 mmol) in water (3 cm1), added during 
15 min. The mixture was poured onto ice and extracted with 
dichloromethane. The extract was dried (CaClj) and then added 
carefully to boiling diphenyl ether (10 cm1). The solution was 
boiled under reflux for 1 h after which it was evaporated and 
the residue was chromatographed (ether). Reciystallisation 
(acetonitrile) of the crude product gave the title compound 18c 
(305 mg, 10%) as white needles, mp 242-244 °C (Found: C, 
47.9; H, 2.59; N, 6.14. QH«BrNO requires C, 48.2; H, 2.70; N, 
6.25%);<5„[(CDJ)JSO] 6.65 (1 H,d,77.3,4-H), 7.36(1 H, t./7 , 
7-H), 7.42 (1 H, d, 77.3,3-H), 8.02 (1 H, d, J  7,6-H), 8.21 (1 H, 
d, J  7, 8-H) and 11.55 (1 H, br, NH); mlz (El) 224.9628 
(M. CyV'BrNO requires M, 224.9612) and 222.9635 (M. 
C^V’BrNO requires M, 222.9633).
2-(5-Nhrofanui-2-ylmethyl)tsoquinoIin-l-one 19
Method A. Sodium hydride (60% in oil; 6.0 mg, 153 nmol) was 
stirred with 18d (22 mg, 153 pmol) in DMF (1.0 cm1) for 1 h and 
the mixture was then cooled to 5 °C. Compound 9 (50 mg, 168 
pmol) was added to the mixture which was then stirred for 2 d 
at 20 °C. Evaporation of the mixture and chromatography 
(EtOAc) of the residue gave the title compound 19 (10 mg, 24%), 
the properties of which are described below.
Method B. Cone, nitric add (60%; 0.10 cm1) was stirred with 
21d (118 mg, 520 jimol) in trifluoroacetic add (1.0 cm1) at 
—10 °C for 1 h and at 20 °C for 16 h. The mixture was adjusted 
to pH 5 with aqueous sodium hydroxide (2 m ) and was then 
extracted with EtOAc. The extract was washed with water, 
aqueous sodium hydrogen carbonate and brine, dried and 
evaporated. Chromatography (first column using EtOAc- 
hexane, 1:1; and then a second column using dichloromethane) 
of the residue afforded the nitrofuran 19 (21 mg, 17%) as a 
yellow solid, mp 77-79 *C; 8^ 5.23 (2 H, s. CH2), 6.58 (1 H, d, J
7.3, isoquinoline 4-H), 6.66 (1 H, d, J  3.6, furan 3-H), 7.24 (1 H, 
d, J  7.3, isoquinoline 3-H), 7.25 (1 H. d, J  3.6, furan 4-H), 7.5 (2 
H, m, isoquinoline 5,7-Hj), 7.57 (1 H, br t, J  7.5, isoquinoline
6-H) and 8.39 (1 H, br d, J  7.9, isoquinoline 8-H); mlz (El) 
270.0637 (M. Cl4HI0N2O4 requires M, 270.0641) and 224 
(M -  NOJ.
Method C Copper(n) nitrate (118 mg, 480 pmol) was added to 
21d (55 mg, 240 umol) in trifluoroacetic acid (2.0 cm1) at —20 °C 
and the mixture was stirred at 20 °C for 2 d. Work-up as for 
Method B afforded the nitrofuran 19 (28 mg. 42%) with proper­
ties as described above:
5-Iodo-2-pbenyhnethylisoquinolin-l-one 20a
Lithium hexamethyldisilazide (1.0 m in THF; 0.6 cm1, 600 
pmol) was stirred with 18a (100 mg, 370 jimol) in THF (10 cm1) 
for 2 h, after which chloromethylbenzene (60 mg. 480 pmol) in 
THF (10 cm1) was added to the mixture, followed by sodium 
iodide (5 mg). After the mixture had been stirred for 5 d, it was 
evaporated and the residue, in EtOAc, was washed with water 
and brine, dried and evaporated. Chromatography (EtOAc- 
hexane, 3:7) of the residue gave the H-benzylisoquinolinone 20a 
(123 mg, 92%) as a white solid, mp 118-120 °C (Found: H, 3.46; 
N, 3.82. CwH12INO requires H, 3.35; N. 3.88%); v^KBr discV 
cm 1650,1620 and 1585; <5„ 5.22 (2 H, s. CH2). 6.72 (1 H, d, J
7.3, isoquinoline 4-H), 7.19 (2 H, m, isoquinoline 3.7-H2), 7.33 
(5 H, m, Ph-Hj), 8.15 (1 H, dd, 77.7,1.3, isoquinoline 6-H) and 
8.47 (1 H, dd, 7 8.1, 1.3, isoquinoline 8-H); Sc 51.90 (CH2),
96.29 (Cq), 109.91 (CH), 127.21 (Cq), 127.96 (CH). 128.14 
(CH + Cq), 128.69 (CH), 128.86 (CH), 132.55 (CH). 136.41
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(Cq), 139.02 (Cq), 143.01 (CH) and 161.45 (CJ; mlz (El) 
360.9960 (M. C14HI2INO requires A/, 360.9964) and 91 (100%, 
Bn).
5-MethyW-phenylmethyIisoquinoUn-l -one 20b
Sodium hydride (60% in oil; 13 mg, 320 pmol) was stirred with 
18b (50 mg, 314 nmol) in DMF (3.0 cm1) for I h after which 
bromomethylbenzene (59 mg, 350 pmol) was added to the mix­
ture; stining was then continued for 20 h. Evaporation of the 
mixture gave a residue, which, as a solution in EtOAc, was 
washed with water, dried and evaporated. Chromatography 
(dichloromethane-Kiichloromethane-methanoI 49:1) of the 
residue furnished the N-benzylisoquinolinone 20b (15 mg, 19%) 
as a white solid, mp 84-86 °C; <5„ 2.51 (3 H, s, Me), 523 (2 H, s, 
CHj), 6.61 (1 H, d, 7 7.6, isoquinoline 4-H), 7.12 (1 H, d,7  7.6, 
isoquinoline 3-H), 7.30-7.35 (5 H, m, Ph-Hs), 7.38 (1H, t, 7 7.6, 
isoquinoline 7-H), 7.47 (1 H, br d, 7 7.5, isoquinoline 6-H) and
8.34 (I H, br d, 77.5, isoquinoline 8-H); Sc 18.93 (CH,), 51.68 
(CH,), 103.13 (CH), 126.07 (CH), 126.58 (Cq), 127.80 (CH), 
127.93 (CH), 128.39 (Cq), 128.79 (CH), 130.90 (CH), 133.03 
(CH), 133.16 (CH), 135.91 (Cq), 136.91 (Cq) and 162.50 (C,); 
mlz (El) 249.1153 (M. Ct7H,sNO requires Af, 249.1154) and 91 
(100%, Bn).
5-BronH>-2-(4-metboxypbenyhnethyl)i5oqainolin-l-o<ie 20c 
Compound 18c was treated with lithium hexametfayldisilazide, 
sodium iodide and l-chloromethyl-4-methoxybenzene in THF 
as for the synthesis of 20a to give the title compound 20c (156 
mg, 100%) as a white solid, mp 98-100 °C (Found: C, 59.4; H, 
4.18; N, 3.88. C„HMBrNO requires C, 59.3; H, 4.10; N, 4.07%); 
3h 3.78 (3 H, s. Me), 5.15 (2 H, s, CH,), 6.84 (3 H, m, isoquino­
line 4-H + Ar 3,5-Hj), 7.18 (1 H, d, 77.7, isoquinoline 3-H), 7.3 
(3 H, m, isoquinoline 7-H + Ar 2,6-HJ, 7.87 (1 H, d, J  7.7, 
isoquinoline 6-H) and 8.43 (1 H, d, J 8, isoquinoline 8-H); mlz 
(O) 345/343 (M + H) and 121 (100%, MeOBn).
2-PhenyhnethylisoquinoIm-l-one 20d
Sodium hydride (60% in oil; 15 mg, 340 pmol) was stirred with 
18d (50 mg, 340 pmol) in DMF (3.0 cm*) for 1 h after which 
bromomethylbenzene (65 mg, 380 pmol) was added to the mix­
ture; stirring was continued for 2 h. Evaporation of the mixture 
gave a residue which, as a solution in EtOAc, was washed 
with water, dried and evaporated. Chromatography (dichloro- 
methane-methanol, 19:1) of the residue gave the title com­
pound 20d (77 mg, 96%) as a colourless oil (lit.,44 mp 67-69 °C); 
SH 5.20 (2 H, s, CHJ, 6.46 (1 H, d, J 7.5, isoquinoline 4-H), 7.06 
(1 H, d, J  7.4, isoquinoline 3-H), 7.30 (5 H, m, Ph-Hs), 7.49 
(2 H, m, isoquinoline 5,7-Hj), 7.61 (1 H, dt, J 1.5, 7.5, iso­
quinoline 6-H) and 8.42 (1 H, br d, 77.5, isoquinoline 8-H); 6C 
51.59 (CH2), 106.37 (CH), 125.85 (CH). 126.20 (Cq), 126.80 
(CH), 127.73 (CH), 127.86 (CH), 127.96 (CH), 128.70 (CH), 
131.20 (CH), 132.14 (CH), 136.81 (Cq), 136.91 (C^and 162.16 
(Cq); mlz (El) 236.1031 (M. CI513CH13NO requires M, 
236.1031) and 235.0995 (M. Cl6HuNO requires A/, 235.0997); 
mlz (FAB positive ion) 236 (100%, M + H) and 91 (Bn).
2-{Furan-2-ylmethyI)-5-niethylisoquinoIin-1 -one 21b
Lithium hexamethyldisilazide (1.0 m in THF; 6.0 cm1, 6.0 
mmol) was stirred with 18b (450 mg, 2.8 mmol) in THF (40 
cm1) for 2 h. Crude 8b (as in the synthesis of 21d) (3.3 g, 28 
mmol) in THF (30 cm1) was added to this solution at 0 °C and 
the mixture was boiled under reflux for 3 d. Evaporation of the 
mixture gave a residue which, dissolved in EtOAc, was washed 
with water and brine, dried and evaporated. Chromatography 
(EtOAc-hexane, 1:1) and further chromatography (EtOAc- 
hexane, 1:5) of the residue gave the title compound 21b (84 mg, 
12%) as a pale yellow solid, mp 85-87 °C (lit.,45 mp 84-86 °C for
2-([l,0]furan-2-ylmethyl)-5-methylisoquinolin-l-one (8% iso­
topic enrichment); SH 2.51 (3 H, s, Me), 5.20 (2 H, s, CH*), 6.34 
(1 H. dd, 73.1,1.8, furan 4-H). 6.42 (1 H, d, 7 3.1, furan 3-H),
6.62 (1 H, d, 7  7.5. isoquinoline 4-H), 7.21 (1 H, d, 7  7.5, iso­
quinoline 3-H), 737 (2 H. m, furan 5-H +  isoquinoline 7-H),
7.46 (1 H, br d, 7  7 3 , isoquinoline 6-H) and 8.32 (1 H. br d. 7
8.0, isoquinoline 8-H); Sc 18.91 (CH,). 4433 (CHJ, 103.04 
(CH). 109.42 (CH), 110.64 (CH), 125.95 (CH), 126.37 (Cq), 
126.54 (CH), 130.54 (CH), 133.06 (CH), 133.17 (CH), 135.90 
(Cq), 142.76 (CH), 149.78 (C„) and 162.14 (C,); mlz (El) 
240.0980 (M. CM,5C H „N 02 requires A/, 240.0980), 239.0945 
(M. C,3HI3N 0 2 requires M, 239.0946) and 81 (furanCH,).
2-(Furan-2-ylmediyBisoquinoIin-l-oiie 21d
Thionyl chloride (4.05 g, 35 mmol) in chloroform (5 cm5) was 
added during 10 min to 7b (2.0 g, 2 mmol) in chloroform (5 
cm5) and pyridine (3 cm5) at - 1 0  °C  The mixture was stirred at 
this temperature for 3 h and then poured into hydrochloric add  
(1 m )  at 0 °C. The organic phase was separated, washed rapidly 
with cold hydrochloric add (1 m ) and cold aqueous sodium 
hydroxide (3%), dried (K2CO,) and was evaporated to give 
crude 2-chloromethylfuran 8b (1.08 g, 45%) as an unstable pale 
yellow oil; SH 4.63 (2 H, s, CHj), 6.4 (2 H, m, furan 3,4-Hj) and
7.46 (1 H, dd, 7  1.8, 0.9, furan 5-H). Lithium hexamethyl­
disilazide (1.0 m in THF; 7.0 cm5, 7.0 mmol) was stirred with 
18d (500 mg, 3.4 mmol) in THF (50 cm5) for 1.5 h after which 
crude 8b (1.08 g, 9.3 mmol) in THF (50 cm5) was added to it at 
- 1 0  °C, followed by sodium iodide (50 mg). The mixture was 
stirred at 20 °C for 24 h after which it was evaporated to give a 
residue, which, dissolved in EtOAc, was washed with water and 
brine, dried and evaporated. Chromatography (EtOAc-hexane, 
1:2) gave the title compound 21d (646 mg, 83%) as a pale yellow 
oil; <5„ 5.17 (2 H, s, CHj), 6.31 (1 H, dd, 7  3.0, 2.0, furan 4-H),
6.40 (1 H, br d, 7  3.0, furan 3-H), 6.45 (1 H, d, 7  7.3, isoquino­
line 4-H), 7.14(1 H ,d , 7  7.3, isoquinoline 3-H), 7.35(1 H ,d d ,7
2.0.1.0, furan 5-H), 7.44 (1 H, dt, 71 .0 ,6 .8 , isoquinoline 7-H), 
7.45 (1 H, d, 7  7.8, isoquinoline 5-H), 7.57 (1 H, dt, 7  1.0, 7, 
isoquinoline 6-H) and 8.42 (1 H, br d, 77.8, isoquinoline 8-H); 
Sc 44.16 (CHj), 106.19 (CH), 109.28 (CH), 110.49 (CH), 125.77 
(CH), 125.99 (C,), 126.71 (CH), 127.77 (CH), 130.79 (CH).
132.10 (CH), 136.86 (Cq), 142.62 (CH), 149.62 (C„) and 
161.75 (C„); mlz (El) 226.0819 (M. C13l5CHuN 0 2 requires 
A/, 226.0823), 225.0788 (M. CMHnN 0 2 requires Af. 225.0790) 
and 81 (furanCHj).
4-Nitro-2-(5-mtn)furan-2-ylmethyI)isoquinoIin-l-one 22 
Fuming nitric add (90%; 0.09 cm5, 2.0 mmol) was added to 
acetic anhydride (0.2 cm5) at - 3 0  °C. The mixture was stirred 
with 21d (92 mg, 410 pmol) in acetic anhydride (1.0 cm5) at 
-1 0  °C for 1 h and then poured onto ice. After adjustment to 
pH 5 with aqueous sodium hydroxide (2 m ), the mixture was 
extracted with EtOAc. The extract was washed with aqueous 
sodium hydrogen carbonate and brine, dried and evaporated. 
Chromatography (EtOAc-hexane, 1:1) of the residue gave the 
dinitro compound 22 (26 mg, 20%) as a yellow oil; SH 5.34 (2 H, 
s, CH2), 6.78 (1 H, d, 73.8, furan 3-H), 7.29 (1 H, d, 7  3.7, furan
4-H), 7.66 (1 H, ca. u J  ca. 8, isoquinoline 6-H or 7-H), 7.88 (1
H, ca. t, 7cn. 8, isoquinoline 7-H or 6-H), 8.46 (1 H, dd, 7  8.1,
I.2, isoquinoline 5-H or 8-H), 8.68 (1 H, br d. 7  8.5, iso­
quinoline 8-H or 5-H) and 8.77 (1 H, s, isoquinoline 3-H); Sc 
45.94 (CHj), 112.12 (CH), 113.62 (CH), 123.99 (CH), 124.30 
(C,), 128.93 (CH), 129.02 (CH), 129.15 (Cq). 134.75 (CH). 
135.00 (Cq), 135.95 (CH), 150.88 ( 2 x C q) and 161.08 (Cq): 
mlz (El) 315.0487 (M. C14H ,N j04 requires A/, 315.0491), 270 
(M — N 0 2) and 190 (4-nitroisoquinolin-l-one).
5-Nitrofuran-2-ylmethyl /V-(2-phenylethyl)carbamate 27 and 
S-nitrofuran-2-yImethyl 3-phenylpropanoate 28
3-Phenylpropanoic acid 23 (100 mg, 670 pmol) was stirred with 
oxalyl chloride (1.0 cm5) for 2 h after wrhich it was evaporated. 
The resulting residue (crude 24) was boiled under reflux with 
toluene (1 cm5) and azidotrimethylsilane (87 mg, 730 pmol) for 
24 h after which compound 7a (95 mg, 670 mmol), in toluene (1
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cm3), was added to it; boiling was continued for 4 b. After 
evaporation of the mixture, the residue, dissolved in EtOAc, 
was washed with water and brine and evaporated. Chrom­
atography (dichloromethane-hexane, 1:1) gave the ester 28 (66 
rag, 34%) as a yellow oil; <5„ 2.70 (2 H, t, J 7.1, CH2CO), 2.96 (2 
H, t, J 7.1, PhCHj), 5.09 (2 H, s, OCHj), 6.54 (1 H, d, J 3.7, 
furan 3-H) and 7.1-7.3 (6 H, m, Ph-Hs + furan 4-H); mlz (Cl) 
276.0872 (M + H. CI4Hl4N05 requires A/H, 276.0872) and 133 
(100%, PhCH,CH,CO). Further elution gave the carbamate 27 
(62 mg, 32%) as a colourless gum; S„ 2.82 (2 H, t, J 7.0, 
PhC/fj), 3.46 (2 H. q. J 7.1, NCH,), 4.90 (1 H, br, NH), 5.08 
(2 H, s. OCHj), 6.60 (1 H, d, J 3.7, furan 3-H) and 7.1-7.3 (6 H, 
m, Ph-Hs + furan 4-H); mlz (Cl) 291 (M + H) and 122 (Ph- 
CHjCHjNHj); mlz (FAB positive ion) 291.1002 (M + H. 
CI4HisN,Os requires A/H, 291.0981).
Hex-5-ynenitrile 30
A mixture of 5-chloropent-l-yne 29 (10.0 g, 97 mmol), potas­
sium cyanide (CAUTION) (9.8 g, 150 mmol), ethanol (100 cm3) 
and water (30 cm3) was boiled under reflux for 2 d after which it 
was diluted with water (50 cm3) and extracted with ether. The 
extract was dried and evaporated and the residue was chrom­
atographed (EtOAc-hexane, 1:1 -*EtOAc) to give the nitrite 30 
(3.2 g. 36%) as a colourless oil (lit.,4* oil, lit.,47 liquid);
3300,2260 and 2040; SH 1.88 (2 H, quintet, J 7.0,3-H,), 2.09 (1
H, t, J 2.6,6-H), 2.38 (2 H, dt, J 2.6,7.0,4-H,) and 2.52 (2 H, t,
77.0,2-H,).
l-(3-CyanopropyI)-l,2-dicarba-c&tt0-dodecaborai]e(12) 31 
Decaborane(14) (BmH,4; 328 mg, 2.7 mmol) was stirred with 
dry acetonitrile (5.0 cm3) for 3 h, after which compound 30 (250 
mg, 2.7 mmol) was added to the mixture: After being boiled 
under reflux for 5 d, the mixture was evaporated and the residue 
was chromatographed (pentane-dichloromethane, 2:1) to give 
the cyanopropylcarborane 31 (420 mg, 74%) as a colourless 
gum (lit-,13 mp 81-82 °C); v^/cm'1 2560 and 2260; MCDCl,)
I.86 (2 H, m, CHjCT/jCH,), 22 (10 H, br q, Jm ca 150, 
10 x BH), 2.35 (2 H, m, carborane-CH,), 2.39 (2 H, t, 7 6.7, 
CH,CN) and 3.67 (1 H, br; carborane 2-H);<5h{(CDj)2CO] 1.87 
(2 H, m, CH,Ci/,CH,), 22 (10 H, br q,Jm ca 150,10 x BH),
2.50 (2 H, m, carborane-CH J, 2.49 (2 H, t, 7 7.0, CH,CN) and 
4.69 (1 H, br, carborane 2-H); <5bI(CD,),CO] -14.09 (2 B,
135), -12.80 (4 B, Jm 145), -10.71 (2 B, Jm 149), -7.04 (1 B, 
Jm 146) and —3.95 (1 B. Jm 146); mlz (El) cluster centred at 
211 (M).
l,2-Dicarba-cfo50-dodecabonn(12)-l-y!butaiioic add 32 
Compound 31 (1.54 g, 7.3 mmol) was boiled under reflux with 
conc. sulfuric add (35 cm3) and water (7 cm3) for 30 h, after 
which it was diluted with water (200 cm3). The resulting predpi­
tate, dissolved in dichloromethane, was washed with water and 
brine, dried and evaporated to give the add 32 (1.45 g, 87%) as a 
white solid, mp 155-157 °C (lit.,4* mp 158-159 °C); <$H 1.81 (2 
H, m, CH,Ctf,CH,). 2.2 (10 H, br q, Jm ca 150, 10 x BH), 
2.27 (2 H, m, carborane-CH,). 2.37 (2 H, t, 7 7.0, CH,CO). 3.58 
(1 H, br, carborane 2-H) and 10.5 (1 H, br, CO,H); mlz (El) 
cluster centred at 230 (M). cluster centred at 213 (M -  OH).
Phenylmethyl /V-{3-(l,2-dicarba-</os0-dodecaboran-l-yl)propyl]- 
carbamate36
The isocyanate 35 (90 mg, 0.4 mmol) (as in the synthesis of 38) 
was boiled under reflux with phenylmethanol (42 mg, 0.4 
mmol) and triethylamine (5 mg) in chloroform (5 cm3) for 24 h. 
The mixture was evaporated and the residue, dissolved in 
EtOAc, was washed with water and brine, dried and evapor­
ated. Chromatography (dichloromethane-hexane, 1:1) of the 
residue gave the carbamate 36 (62 mg, 48%) as a pale yellow oil; 
<5„ 1.69 (2 H, m, CH,C//,CH,), 2.2 (10 H, br q. Jm ca 150, 
10 x BH), 2.22 (2 H, m. carborane-CH,). 3.17 (2 H. q. 7 6.6, 
NCH,), 3.58 (1 H, br. carborane 2-H), 4.78 (I H, br. NH). 5.09
(2 H, s, PhCHJ and 7.35 (5 H, s. Ph-Hs);<5c 29.97 (CH,), 35.19 
(CH,), 39.96 (CHJ. 61.27 (CH), 66.91 (CH,), 74.52 (Cq), 128.15 
(CH), 128.30 (CH), 128.59 (CH), 136.26 (Cq) and 156.42 (Cq); 
<5B('H-decoupled) -11.77 (6 B, m), -9J0 (2 B, s), -5.69 (I B, 
s) and -2.25 (1 B, s); mlz (El) 337.2822 (M. C„Ha“B10NO, 
requires 337.2816), 336.2844 (M. C„HMI,B,,#BNO, requires 
A/, 336.2852), 335.2874 (M. C1,HM,,B,l0B,NO, requires A/, 
335.2888), 334.2898 (M. CijHh1,B7,0BjNO, requires A/, 
334.2925), 333.2923 (M. C„HMIIB<I0B4NO, requires A/, 




The carbamate 36 (60 mg, 180 pmol) was stirred with hydrogen 
bromide in acetic acid (5%; 6 cm3) for 30 min, after which the 
mixture was evaporated. The residue was triturated with dry 
ether (5x10 cm3) and dried to afford the aminopropylcarborane 
salt 37 (39 mg, 98%) as a white solid, mp 295-297 °C; <5„(D,0)
1.86 (2 H, ca. quintet, J ca 7, CH,C//,CH,), 2.2 (10 H, br q, 
Jm ca 150,10 x BH), 2.38 (2 H, ca. t,Jca. 7, carborane-CH,), 
2.95 (2 H, t, 7 7.5, NCH,) and 4.38 (1 H, br, carborane 2-H); 
mlz (El) 203.2436 (M. CSH1,,,B10N requires A/, 203.2448).
5-Nhrofuran-2-yflniediyl )V-[3-(l,24iicarba-cftK0-dodecaborai>- 
(12)-l-yI)propyl]cari>aiiute 38 and 5-nrtrofuran-2-ylraethyl
4-{l,2-diaut»a-c6u0-dodecabocaii(12)-l-yl]btit2iioate 39 
Compound 32 (500 mg, 22 mmol) was boiled under reflux with 
thionyl chloride (25 cm3) and DMF (0.05 cm3) for 16 h. After 
the evaporation of the solvent, the residue (crude 33) was 
stirred with sodium azide (CAUTION) (495 mg, 7.6 mmol) in 
acetone (25 cm3) and water (5 cm3) at 0 °C for 45 min, after 
which it was diluted with chloroform (100 cm3). The suspension 
was washed with water and brine, dried and evaporated to give 
crude 12-dicarba-dbso-dodecaboran-1 -ylbutanoyl azide 34; 
v—7cm~‘ 2600, 2150 and 1725. This material was stirred in 
chloroform (10 cm3) at 40 °C for 27 h to give a solution of crude
1-(3-isocyanatopropyl)-l’2-dicarba-c/0*0-carborane(12) 35; 
v- Jcm'1 2600 and 2280. This solution was boiled under 
reflux with 7a (310 mg, 22 mmol) and triethylamine (10 mg) for 
2 d after which it was evaporated. The residue, dissolved in 
EtOAc, was washed with water and brine, dried and evaporated. 
Chromatography (dichloromethane-methanol, 40:1) of the 
residue gave the ester 39 (90 mg, 14%) as a pale yellow wax; <5H 
1.82 (2 H, m, CH,G//,CHj), 2.2 (10 H, br q, Jm ca 150, 
10 x BH), 2.25 (2 H, m, carborane-CH,). 2.38 (2 H, t, J 7.0, 
CH,CO), 3.60 (1 H, br; carborane 2-H), 5.12 (2 H, s. furan- 
CHJ, 5.25 (1 H, br, NH). 6.63 (1 H, d, 7 3.7, furan 3-H) 
and 7.29 (1 H, d, 7 3.7, furan 4-H); mlz (Cl) cluster centred at 
355 (M + H), cluster centred at 213 [carborane(CH2)jCO] and 
143 (nitrofuranmethanol); mlz (FAB positive ion) 357.2477 
(M. C„Ha,IB9I#BN05 requires A/. 357.2465). Further elution 
gave the carbamate 38 (289 mg, 36%) as a pale yellow oil; SH
1.40 (2 H, m, CHjC/fjCH,), 2.2 (10 H, br q. Jw  ca 150, 
10 x BH), 2.48 (2 H, m, carborane-CH,), 3.37 (2 H, ca. q, 7 ca. 
7, NCH,), 3.68 (1 H, br, carborane 2-H), 4.73 (2 H, s. furan- 
CH,), 5.25 (1 H, br. NH), 6.56 (1 H, d, 7 3.6, furan 3-H) and
7.29 (1 H, d, 7 3.6, furan 4-H); Sc 29.74 (CH,), 35.13 (CH,). 
40.12 (CH,), 57.96 (CH,), 61.35 (CH), 74.39 (Cq), 112.11 (CH),
113.05 (CH), 153.00 (Cq) and 155.43 (Cq) (one Cq was not 
observed); <5B(‘H-decoupled) -11.83 (6 B, m), -9.30 (2 B, s), 
-5.69 (I B, s) and -2.31 (1 B. s); mlz (Cl) cluster centred at 
371 (M + H); mlz (FAB positive ion) 372.2599 (M + H. 
CIIH„,lB,,0BN,Os requires A/H*. 372.2574) and 369.2704 
(M + H. CuHm,,B6,0B4N,O} requires A/H*. 369.2683).
Reductively activated release of isoquinolin-l-one 18d from
2-<5-nitrofuran-2-ylmethyI)isoquinolin-l-one 19 (sodium 
borohydride-palladium method)
Sodium borohydride (16 mg, 410 pmol) in water (0.3 cm3) was
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stirred with 19 (37 mg, 140 pmol) and palladium-on-charcoal 
(10%; 4 mg) in propan-2-ol (2.0 cm*) for 16 h after which the 
suspension was filtered through Celite*. Evaporation of the 
mixture gave a residue; which, dissolved in dichloromethane, 
was washed with water and brine, dried and evaporated to give 
isoquinolin-l-one 18d (13 mg, 67%) with properties as de­
scribed above.
Control experiment for sodium borohydride-palladium method of 
reductively activated release
Sodium borohydride (IS mg, 400 pmol) in water (0.3 cmJ) was 
stirred with 21d (30 mg, 133 pmol) and palladium-on-charcoal 
(10%; 3 mg) in propan-2-ol (1.0 cm1) for 2 d. After the suspen­
sion had been filtered through Celite*, it was evaporated and 
the residue, dissolved in dichloromethane, was washed with 
water and brine, dried and evaporated to give recovered 21d 
(28 mg, 94%).
Reductively activated release of 2-phenylethylamine 42 from 
5-futrofuran-2-ylmethyl A-(2-pbenytetiiyl)carbamate 27 (sodium 
borohydride-palladium method)
Sodium borohydride (18 mg, 470 pmol) in water (0.1S cm1) was 
stirred with 27 (30 mg, 100 pmol) and palladium-on-charcoal 
(10%; 3 mg) in methanol (2.0 cm1) for 2 d. After the suspension 
had been filtered through Celite*, it was evaporated and the 
residue, dissolved in dichloromethane, was washed with water 
and brine, dried and evaporated to give 2-phenylethylamine 42 
(S.O mg, 41%), the properties of which were identical with those 
of a commercial sample.
Reductively activated release of l-(3-amiiiopropyI)-l*2-dicarba- 
cftu<Mlodecaborane(12) 43 from 5-ohrofuran-2-yhnediyl jV-{3- 
[lt2-dicarba-c/bso-dodecaborau(12>-l~yl]propyljcaitamate 38
Sodium borohydride-palladium method. Sodium borohydride 
(33 mg, 870 pmol) in water (1.0 cm1) was stirred with38 (100mg, 
270pmol) and palladium-on-charcoal (10%; 10 mg) in propan-2- 
ol (5.0 cm1) for 16 h. Filtration (Celite*) and evaporation of 
the mixture gave crude 1 -(3-aminopropyI)-1,2-dicarba-c/aso- 
dodecaborane( 12) 43. This material, dissolved in dichloro­
methane (10 cm1), was stirred with phenylmethyl chloroformate 
(76 mg, 450 pmol), triethylamine (75 mg, 750 pmol) and
4-pyrrolidinylpyridine (2 mg) for 16 h. The solution was washed 
with water, aqueous citric add (5%) and brine, dried and evap­
orated. Chromatography of the residue gave the Z-protected 
carboranylpropylamine 36 (14 mg, 26%), the properties of 
which were identical with those reported above
Tin(ii) chloride method. Tin(n) chloride (74 mg, 390 pmol) and 
38 (19 mg, 65 pmol) were boiled under reflux in hydrochloric 
add (1.5 cm1) for 90 min. The cooled mixture was basifled to 
pH 9 by the addition of aqueous sodium hydroxide (10 m ) and 
extracted with dichloromethane The extract was washed with 
water, dried and evaporated to give the amine 43 (3 mg, 40%) as 
a pale yellow gum, chromatographically identical with the free 
base of 37.
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Labelled Compounds of Interest as Antitumour Agents - V. 
Syntheses of [180]-5-Methylisoquinolinone and 
1 -(Furan-2-yl-[180 ]-methoxy)-5 -methylisoquinoline: Correction
J. M. Berry and M. D. Threadgill
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N O T E
L A B E L L E D  C O M P O U N D S  O F  I N T E R E S T  A S  A N T I T U M O U R  A G E N T S  - V.
S Y N T H E S E S  O F  [ 18 0 ] - 5 - M E T H Y L I S 0 Q U I N 0 L I N 0 N E  A N D
l - ( F U R A N - 2 - Y L - [ 18 0 ] - M E T H 0 X Y ) - 5 - M E T H Y L I S 0 Q U I N 0 L I N E :  C O R R E C T I O N
Jane M. Berry and Michael D. Threadgill*
School of Pharmacy & Pharmacology, University of Bath,
Claverton Down, Bath BA2 7AY, U. K.
In a recent paper1 from our laboratory, we reported that the reaction of the lithium anion of
5-methylisoquinolin-[,80]-one with 2-(chloromethyl)furan gave l-(furan-2-yl-[I80]-methoxy)-5- 
methylisoquinoline, the product of alkylation at oxygen, in 60% chemical yield. The few literature 
precedents2"4 for alkylation of anions derived from isoquinolin-l-ones show that the major or sole 
products are the corresponding 2-alkylisoquinolin-l-ones derived from alkylation at nitrogen, 
irrespective of the nature of the electrophile. Re-examination of the spectroscopic data leads us to 
the conclusion that the product is 2-(furan-2-ylmethyl)-5-methylisoquinolin-[180]-one, arising from 
furanylmethylation at nitrogen. In particular, the chemical shift of the CH2 in the 13C NMR 
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Abstract
Reaction o f  2-hydrazino-4-methylquinoline with a series o f  trifluoromethyl-/3-diketones gives 3-substituted-5-hydroxy-l-(4-methylquin- 
olin-2-yl)-5-trifluoromethyl-4,5-dihydropyrazoles and, in some cases, 5-substituted-l-(4-methylquinolin-2-yl)-3-trifluoromethylpyrazoles. 
depending on the substitution o f the diketone. Dehydration o f the hydroxydihydropyrazoles can be effected with sulphuric acid in acetic acid 
to give the regioisomeric 3-substituted-l-(4-methylquinolin-2-yl)-5-trifluoromethylpyrazoles. In contrast, the reaction o f two 4-hydrazino- 
quinolines with l,l,l-trifluoropentane-2,4-dione afforded a different isolable intermediate, the corresponding hydrazone formed at the 
4-carbonyl. Dehydration gave the l-(substituted-quinolin-4-yl)-3-methyl-5-trifluoromethylpyrazoles. The regioisomeric identity o f the pyr- 
azoles was established using ,9F NMR. ©  Elsevier Science S.A.
Keywords: Pyrazole; Hydrazinoquinoline; Trifiuorotnethyl-0-diketone; Cyclisation; '*F NMR
1. Introduction
Recent investigations from our laboratory have shown that 
the products obtained by treating 2- and 4-hydrazinoquino- 
lines with /3-dicarbonyl compounds are the pyrazoles [1 ,2], 
instead of the erroneously reported diazepines [ 3,4 ]. In con­
tinuation o f this work, we focused our attention on the reac­
tion o f these hydrazines with trifluoromethyl 1,3-diketones. 
Such a study assumes greater significance in view o f the 
current interest in the development and application o f com­
pounds bearing trifluoromethyl groups as pharmaceuticals 
and agrochem icals [5 -7 ] .
2. Results and discussion
In general, the reaction of a monosubstituted hydrazine 
with unsymmetrical /3-diketones can result in the formation 
of isomeric pyrazoles, depending on the site o f initial nucleo- 
philic attack [ 8 -1 0 ] . In the first pan o f the present study, the 
reaction of 2-hydrazino-4-methylquinoline 1 with the ali­
phatic trifluoromethyl-/3-diketones 2a,b was investigated. 
The sole products were identified as the 5-hydroxy-5-trifluo- 
rom ethyl-4,5-dihydropyrazoles 3a.b, respectively. However.
* Corresponding author
similar treatment of the aryl trifluoromethyl-/3-diketones 2c,d 
with 1 in refluxing ethanol gave a mixture of the correspond­
ing 5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazoles 3c,d 
and the 3-trifluoromethylpyrazoles 4c,d (Schem e 1). No 
traces o f 4a,b were detected in the reaction mixtures. The 
hydroxydihydropyrazoles 3a-d were only converted to the 
aromatic pyrazoles 5 a -d  on treatment with sulphuric acid in 
acetic acid at elevated temperature. These observations, 
which raise questions of the initial site o f nucleophilic attack 
on the diketone and rate o f dehydration/arom atisation o f the 
pyrazole. can be rationalised as follows.
As it is unlikely that the initial nucleophilic attack involves 
the secondary nitrogen of the hydrazinoquinoline, the first 
approach must be as shown in Scheme 2. It has been shown 
[ 11,12] that 2a-d exist substantially in the enol form and 
that the direction of enolisation is largely towards C O C F3. 
Furthermore, there have been reports that these unsym m et­
rical diketones 2a-d react with water [ 13 ], alcohols [ 13,14 ], 
ethanethiol [ 15] and pyrrolidine [15] to give the adducts at 
the COCF3 carbonyl, probably through addition to the appro­
priate enol. It is therefore likely that, in the present study, the 
reaction proceeds via conjugate addition of the terminal n itro­
gen of the hydrazinoquinoline into the two enols, as shown 
in Scheme 2. Subsequent cyclisation affords the isom ericdih- 
ydroxytetrahydropyrazoles. One molecule of water is then 
eliminated to give the hydroxydihydropyrazoles; further
0022-II39 /97 /S  17.00 © 1997 Elsevier Science S.A. All rights reserved 
P / /S 0 0 2 2 - 11 3 9 ( 9 6 )0 3 5 7 0  - 1









2a-5a R = Me 
2b-Sb: R = CF3 
2c-5c: R = Ph 
2d-5d: R = thien-2-yl
Me


























2a-5a: R = Me 
2b-Sb:R = CF3 
2c-Sc: R = Ph 
2d-5d: R = thien-2-yl
Scheme 2. Possible mechanistic routes for the reaaion of 2-hydrazino-4- 
methylquinoline 1 with trifluoromethyl /3-diketones 2a-d.
elimination of water yields the aromatic pyrazoles 4 and 5. 
The ratio of yields of these two regioisomers depends on the 
proportion of the two enols at equilibrium. For /3-diketone 
2a, where R is aliphatic, the COCF3 carbonyl is predomi­
nantly enolised, leading eventually to products 3a and 5a. In 
contrast, where R is aromatic (2c,d), this enol is cross-con­
jugated between the C=C and the arene, whereas the alter­
native enol is fully conjugated in the system Ar-C=C-C=0. 
Thus, there is now a significant amount of the minor enol 
present in the reaction mixture and attack can take place, 
leading to significant amounts of the regioisomer 4. It should 
be noted that this effect runs counter to steric influences.
The hydroxydihydropyrazoles 3 can be isolated as stable 
crystalline solids from the initial reaction mixture but the 
regioisomeric hydroxydihydropyrazoles are converted 
directly in boiling ethanol to the pyrazoles 4. These obser­
vations must reflect the relative ease of elimination of the 
second molecule of water in the overall condensation. Pre­
sumably, as the OH or OH2 leaves, positive charge builds up 
at C-5 and the electron-withdrawing trifluoromethyl group 
destabilises this build-up. This effect has been noted 116] for 
the reaction of l,l,l,5,5,5-hexafluoropentane-2,4-dione 2b 
with other aryl and acyl hydrazines.
In contrast (Scheme 3), when the hydrazine was translo­
cated to the 4-position of the quinoline and substrates 6a,b 
were allowed to react with 2a under the standard conditions 





6a-9a: R' = H. R* = Me 






Scheme 3 Reaction of  4-hydrazinoquinoiines 6a,b with l.l.l-trifluoro- 
pentane-2.4-dione 2a.
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isolated. Elimination of the second molecule of water was 
effected only by treatment with sulphuric acid in hot acetic 
acid, reflecting again the relative difficulty of this elimination 
from a 5-hydroxy-5-trifluoromethyldihydropyrazole. These 
observations indicate that elimination of the first molecule of 
water precedes the cyclisation with these substrates 6 . As 
expected from the studies with 1  and 2 a, there was no evi­
dence of formation of other regioisomers. We were unable to 
isolate the corresponding hydroxydihydropyrazoles 8 a,b 
from the reactions, although it is unclear why the point of 
attachment to the quinoline should have such an effect on the 
course of the reaction. Hydrazones related to 7 are rarely 
reported in the literature [ 17,18] and only those too without 
direct spectroscopic evidence for their structure.
The structures of the pyrazoles and the intermediates were 
deduced from their NMR spectra. For example, the ‘H NMR 
spectrum of 3a displays the signal for the pyrazole 3-Me at 8 
2.09 and the methylene protons resonate as an AB system at 
8 3.17 and 8 3.34, with a geminal coupling constant 2J
18.6 Hz. In the regioisomeric hydroxydihydropyrazole 
(leading to 4a), the methyl group would resonate at 8 ca.
1.5. The same pattern was evident for the analogues 3b-d. 
We have previously shown this AB pattern to be characteristic 
in a series of 5-hydroxy-3,5-bis( trifluoromethyl )-4,5-dihy-
dropyrazoles [ 16]. Structures 3a-d were confirmed by mass 
spectroscopic studies in which molecular ions were observed 
corresponding to the hydroxydihydropyrazoles, rather than 
the dihydroxytetrahydropyrazoles or pyrazoles. Further sup­
port for the regioisomeric identity of 3a-d was given by ,3C 
NMR (Table 1). The presence of the trifluoromethyl group 
makes assignment of the signals straightforward. For exam­
ple, for 3a, pyrazole C-3 (sp2) resonates as a singlet at 8 
151.37, C-4 as a singlet at 8 47.90 and C-5 as a quartet 
(2JC~f 34.1 Hz) at 8 93.09. In 3b, which contains two tri­
fluoromethyl groups, pyrazole C-3 appears as a quartet 
(2Jc-f 39.7 Hz) at 8 140.31, a chemical shift which is appro­
priate for a sp2 carbon. Thus the trifluoromethyl group must 
be attached to the sp3 carbon in 3a and the regioisomer must 
be as shown.
For the hydrazones 7a,b, the ‘H NMR data lend support 
to the acyclic hydrazone-enol structure as follows. Firstly, 
no signal is seen at 8 3.5 but rather a singlet from the enol 
=CH-appears at 55.42 for 7a, ruling out ahydrazone-ketone 
structure. Secondly, the NH and OH protons of 7a resonate 
at 611.40 and 514.32, respectively, which indicate both that 
an OH is present and that there is strong intramolecular hydro­
gen-bonding. Similar observations were recorded for 7b. The 
enol form of the hydrazones 7a,b was further suggested by
Table 1
*’C NMR data for hydroxydihydropyrazoles 3a-d
Carbon atom 3a 3b 3c 3d
Pyrazole carbons
C-3 151.37 14031
(q .V „-3 9 .7 H z)
150.19 146.07
C-4 47.90 41.95 44.14 44.74
C-5 93.09 94.62 9331 93.50
(q .V « -3 4 .1  Hz) (q.VCJC-343H z) (q. Vc.f = 33.1 Hz) (Q. 27C-f=33.0 Hz)
Quinoline carbons
C-2 155.54 154.39 155.24 155.03
C-3 112.90 112.53 112.79 112.75
C-4 144.82 144.43 144.79 144.72
C-5 123.83 125.02 124.02 124.04
C-6 123.70 123.83 123.78 123.76
C-7 126.96 127.37 129.83 128.24
C-8 129.70 130.19 130.02 129.82
C-4a 124.45 12531 124.62 124.62




18.87 18.90 19.04 18.99
pyrazole-
CF,
123.97 123.34 123.95 123.86
«!- '3c-f = 287.6 Hz) (9. '7c_f = 287.5 Hz) (q. 'JC_F = 287.7 Hz) (q.'yc.F = 288.8 Hz)
pyrazole 3-R 15.53 119.82 130.97 134.43
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the l3C NMR data, in contrast to the isomeric hydroxydihy- 
dropyrazoles 8 a,b. Characteristic signals were seen for 7a 
at 8 169.60 ( 27C_F 31.2 Hz, =C-CF3), 8 118.54 ( ' 7 „
286.6 Hz, CF3) and 8 87.84 (=CH-). No CH2  signals were 
seen in the 135 DEPT spectrum, ruling out hydrazone-ketone 
and hydroxydihydropyrazole structures. The pattern of chem­
ical shifts and multiplicities for the C-5 unit are very similar 
to those reported [ 19] for the enol form of 1,1,1-trifluoro- 
pentane-2,4-dione 2a.
The pyrazoles 4c,d, 5a-d and 9 were characterised by a 
signal in the range 8 6.63-8 7.21 for the aromatic pyrazole
4-H. It is interesting to note that the presence of trifluoro­
methyl at pyrazole C-5 causes the 4-H to resonate further 
downfield as compared with trifluoromethyl at pyrazole C-3 
(A 5 0.42 for 4c/5c, A 8 0.21 for 4d/5d).
Complete analysis of the i3C spectra of 4c,d, 5a-d and 9 
(Table 2) was achieved by comparison with reported chem­
ical shifts for pyrazoles [20-22] and quinolines [23] and by 
DEPT experiments (Table 2). The CF3  carbons resonated at 
ca. 5120 with '7C_F ca. 270 Hz. The C-CF3 carbons resonated 
as quartets at 8 ca. 143 and 8 ca. 133 for pyrazole C-3 and 
pyrazole C-5, respectively. In the corresponding 1 -(quinolin-
2-yl)-3,5-dimethylpyrazoles [ 1 ], C-3 and C-5 resonate at 8 
ca. 150 and 8 ca. 142, respectively. Thus it can be seen that 
replacement of CH3 by CF3 results in shielding of these ring 
carbons by ca. 8  ppm.
Finally, 19F NMR has been found to be an elegant method 
for assigning the trifluoromethyl hydroxydihydropyrazole, 
hydrazone and pyrazole structures (Table 3). The hydroxy­
dihydropyrazoles 3a-d exhibited signals at 8 ca. — 81 for the
5-CF3, in contrast to 8 —67.39 for the 3-CF3 of 3b. In con­
trast, the trifluoromethyl group of the hydrazones 7a,b reso­
nate at 8 ca. —75. Isomeric trifluoromethylpyrazoles can 
easily be distinguished by their 19F spectra. The 5-CF3  reso­
nates at 8 ca. — 58, in contrast to the more upheld resonance 
of the 3-CF3 at 8 ca. -  62.
3. Experimental details
Melting points were determined using open capillaries in 
a sulphuric acid bath and are uncorrected. 'H NMR spectra 
were obtained at 270 MHz and 400 MHz, ,3C spectra at
67.5 MHz and 100 MHz and ,9F spectra at 376 MHz, using 
Jeol GX270 and Jeol EX400 instruments, using deuterioch- 
loroform as solvent, unless otherwise noted. The internal 
standard for the 19F spectra was fluorotrichloromethane, set­
ting the CF35C13 signal as 5 0.00. I3C and l9F NMR data for 
3a-d, 4c,d, 5a-d and 9a,b are presented in Tables 1-3, 
respectively. The stationary phase for chromatography was 
silica gel. High resolution mass spectra were measured in the 
El mode on a Kratos MS-50 spectrometer. Elemental analyses 
were performed at RSIC, Chandigarh, India. 2-Hydrazino-4- 
methylquinoline 1 [24], 4-hydrazino-2-methylquinoline 6a 
[25] and 7-chloro-4-hydrazinoquinoline 6b [26] were pre­
pared by procedures described in the literature.
3.1. 5-Hydroxy-3-methyl-l-(4-methylquinolin-2-yl)-5- 
trifluoromethyl-4,5-dihydropyrazole(3a)
I,l,l-Trifluoropentane-2,4-dione 2a (770 mg, 5 mmol) 
was boiled under reflux with 2-hydrazino-4-methylquinoline 
1 (865 mg, 5 mmol) in ethanol (50 ml) for 3 h. Evaporation 
of the solvent and recrystallisation (ethanol) provided the 
hydroxydihydropyrazole 3a (1.20 g, 78%) as a pale yellow 
solid, m.p. 113-114 °C. *H NMR 8: 2.09 (s, 3 H, pyrazole- 
Me);2.62 (s,3 H,quinoline-Me); 3.17 (d, 1 H,7= 18.6 Hz, 
pyrazole 4-H); 3.34 (d, 1 H, 7= 18.6 Hz, pyrazole 4-H);
7.35 (ddd, 1 H, quinoline 6-H); 7.41 (s,.l H, quinoline 3- 
H); 7.57 (ddd, 1 H, quinoline 7-H); 7.70 (d, 1 H, quinoline
5-H); 7.82 (d, 1 H, quinoline 8-H) ppm. MS m lz 309.1092 
(M) (Ci5HmF3N30  requires: 309.1089); 291.0991 
(M -H 20) (C15Hl2F3N3 requires: 291.0983) (100%). 
Analysis: Found: N, 13.54%. C,5H|4F3N30  requires: N, 
13.59%.
3.2. 3,5-Bis(trifluoromethyl)-5-hydroxy-1 -(4- 
methylquinolin-2-yl)-4,5-dihydropyrazole(3b)
1,1,l,5,5,5-Hexafluoropentane-2,4-dione 2b (1.04 mg, 
5 mmol) was treated with 1 (865 mg, 5 mmol), as for the 
synthesis of 3a, to give the hydroxydihydropyrazole 3b 
(1.35 g, 75%) as a pale yellow solid, m.p. 135-136 °C. 'H 
NMR 8: 2.65 (s, 3 H, quinoline-Me); 3.42 (d, 1 H, 
7= 19.0 Hz, pyrazole 4-H); 3.60 (d, 1 H, J -  19.0 Hz, pyr­
azole 4-H); 7.42 (s, 1 H, quinoline 3-H); 7.43 (ddd, 1 H, 
quinoline 6-H); 7.62 (ddd, 1 H, quinoline 7-H); 7.74 (d, 1 
H, quinoline 5-H); 7.87 (d, I H, quinoline 8-H) ppm. MS 
mlz. 363.0791 (M) (Cl5HMF6N30  requires: 363.0806); 
345.0703 (M -H 20 ) (C .jH ^ ^  requires: 345.0701); 
294.0858 (M-CF3) (C14HmF3N30  requires: 294.0854) 






l-Phenyl-4,4,4-trifluorobutane-l,3-dione 2c (1.08 g, 5 
mmol) was boiled under reflux with 2-hydrazino-4-methy- 
lquinoline 1 (865 mg, 5 mmol) in ethanol (50 ml) for 3 h 
and the solvent was evaporated. Chromatography (light 
petroleum (b.p. 60-80 °C):benzene (CAUTION) 4:1) 
afforded the hydroxydihydropyrazole 3c (1.15 g, 62%) as 
an off-white solid, m.p. 137-138 °C. 'H NMR 5: 2.68 (s, 3 
H, quinoline-Me); 3.63 (d. 1 H.7= 18.3 Hz, pyrazole 4-H); 
3.77 (d, 1 H, 7= 18.3 Hz, pyrazole 4-H): 7.24-7.44 (m. 4 
H, quinoline 6-H + Ph 3,4.5-H3): 7.58-7.62 (m, 2 H. quin­
oline 3,7-H2); 7.73-7.77 (m. 3 H, quinoline 5-H + Ph 2,6- 
H:);7.86(d, I H, quinoline 8-H) ppm. Analysis: Found: N,
11.42%. C20H,6F3N30  requires: N, 11.32%. Further elution 
(light petroleum (b.p. 60-80 °C) :bcnzcne 1:1) afforded the
Table 2
,3C NMR data for compounds 4c,d, 5a-d and 9a,b
Carbon atom 4c 4d 5a 5b 5c 5d 9a 9b
Pyrazole carbons
C-3 143.71 143.58 149.47 142.05 149.49 147.61 149.99 150.39
(q. V c - p - 3 6 .8  H z) (q .V c .p -3 8 .6  Hz) (q. V c-p-38.6  Hz)
C-4 106.72 106.83 111.57 108.36 109.04 108.97 108.35 108.80
C-5 145.82 139.53 133.12 133.26 133.82 133.84 134.20 134.20
(q. V c - p - 4 0 .7  Hz) (q .V c-p -42 .9  Hz) (q. lyc_p-41.0H z) (q. Vc.p -4 0 .5  Hz) (q .V c-p -3 8 .6  Hz) (q. V c - f - 4 0 . 0  Hz)
Quinoline carbons
C-2 150.11 149.88 149.65 147.69 151.78 149.27 158.97 151.16
C-3 116.96 117.49 118.17 113.47 114.65 114.62 119.90 119.01
C-4 145.98 145.85 146.10 144.80 146.00 145.98 143.11 142.98
C-5 126.94 126.94 126.36 126.25 125.94 125.43 127.09 124.44
C - 6 123.67 123.82 123.64 122.76 123.69 123.71 122.57 128.59
C-7 128.99 129.28 129.56 128.75 128.86 129.56 128.81 136.49
C- 8 129.67 130.22 129.91 129.36 129.58 130.02 130.35 129.10
C-4a 127.46 127.42 127.22 126.75 127.35 127.36 123.45 123.52
C-8 a 147.92 148.19 147.41 147.40 147.52 147.23 149.11 149.86
Other carbons
quinoline-CH3 18.88 18.86 18.86 17.92 18.99 18.99 25.30
(4-CHj) (4-CHj) (4-CHj) (4-CHj) (4-CHj) (4-CHj) (2-CHj)
pyrazole 3-CHj 13.47 13.38 13.38
pyrazole 3-CF} 121.17 1 2 1 . 0 2 118.30
(q. Vc-p- 270.3 Hz) (q, ' /C- p -  268.4 Hz) (q. ' /c-p-268 .8  Hz)
pyrazole 5-CF, 120.14 119.36 120.07 119.92 119.46 119.50
(q. ' /c- p -  267.7 Hz) (q. ' /C-P -  268.9 Hz) (q. ' /c-p-2 6 8 .0  Hz) (q. ' /c-p - 268.4 Hz) (q. ' /c-p-2 6 8 .4  Hz) (q. ' /c -a -  270.0 Hz)
Ph or thiophene 130.13 130.00 131.55 134.50
(Ph C -l) (thiophene C-2) (P h C -l) (thiophene C-2)
128.11 129.63 126.49 127.68
(Ph C-2,6) (thiophene C-3) (Ph C-2,6) (thiophene C-3)
130.00 127.22 130.00 126.03
(Ph C-3,5) (thiophene C-4) (Ph C-3,5) (thiophene C-4)
128.68 127.79 128.81 126.54
(Ph C-4) (thiophene C-5) (Ph C-4) (thiophene C-5)
-4
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Table 3
l9F NMR data for compounds 3a-d, 4c,d. 5a-d and 9a,b








58.49 58.13 58.25 58.94 58.80
pyrazole 4c (185 mg, 10%) as an off-white solid, m.p. 110- 
111 °C. *H NMR 8 2.72 (d, 3 H, 7=0.9 Hz, quinoline-Me); 
6.79 (s, 1 H, pyrazole 4-H); 7.24-7.36 (m, 5 H, Ph-H5); 
7.52-7.69 (m, 4 H, quinoline 3^,6,7-H,); 7.98 (d, 1 H, 
quinoline 8-H) ppm. Analysis: Found: N, 11.86%. 





l-(Thien-2-yl)-4,4,4-trifluorobutane-l,3-dione 2d (1.11 
g, 5 mmol) was boiled under reflux with 2-hydrazino-4- 
methylquinoline 1 (865 mg, 5 mmol) in ethanol (50 ml) for 
3 h and the solvent was evaporated. Chromatography (light 
petroleum (b.p. 60-80 °C)'.benzene (CAUTION) 4:1) 
afforded the hydroxydihydropyrazole 3d (1.15 g, 61%) as a 
pale solid, m.p. 123-124 °C. 'H NMR 8: 2.66 (d, 3 H, 
7=0.7 Hz, quinoline-Me); 3.61 (d, 1 H, 7= 18.1 Hz, pyra­
zole 4-H); 3.77 (d, 1 H, 7= 18.1 Hz, pyrazole 4-H); 7.06 
(dd, 1 H, thiophene 4-H); 7.20 (dd, 1 H, thiophene 3-H); 
7.34-7.41 (m, 2 H, quinoline 6-H+ thiophene 5-H); 7.52 (s, 
1 H, quinoline 3-H); 7.59 (ddd, 1 H, quinoline 7-H); 7.72 
(d, 1 H, quinoline 5-H); 7.84 (d, 1 H, quinoline 8-H); 9.43 
(br, 1 H, OH) ppm. Analysis: Found: N, 11.27%. 
Ci8H14F3N3OS requires: N, 11.14%. Further elution (light 
petroleum (b.p. 60-80 °C):benzene 1:1) afforded the pyra­
zole 4d (150 mg, 8%) as a pale solid, m.p. 75-76 °C. ‘H 
NMR 8: 2.73 (d, 3 H,7=0.7 Hz, quinoline-Me); 6.87 (s, 1 
H, pyrazole 4-H); 6.97 (dd, 1 H, thiophene 4-H); 7.22 (dd, 
1 H, thiophene 3-H); 7.33 (dd, 1 H, thiophene 5-H); 7.57-
7.63 (m, 2 H, quinoline 3,6-H2); 7.72 (ddd, 1 H, quinoline
7-H); 7.96-8.03 (m, 2 H, quinoline 5,8-H2) ppm. Analysis: 
Found: N, 11.73%. Cj8H,2F3N3S requires: N, 11.70%.
3.5. 3-Methyl-l-(4-methylquinolirt-2-yl)-5-trifluoro- 
methylpyrazole (5a)
The hydroxydihydropyrazole 3a (927 mg, 3 mmol) was 
boiled under reflux with concentrated sulphuric acid (0.2 ml) 
in acetic acid (20 ml) for 5 h. The mixture was poured into 
ice-water and was extracted thrice with dichloromethane. The 
combined organic extracts were washed with aqueous sodium 
hydrogen carbonate solution and with water and were dried 
(sodium sulphate). The solvent was evaporated and the res­
idue was recrystallised from ethanol to give the pyrazole 5a 
(788 mg, 85%) as a pale yellow solid, m.p. 103-104 °C. 
'H NMR 5: 2.39 (s, 3 H, pyrazole-Me); 2.74 (s, 3 H, quin­
oline-Me); 6.70 (s, 1 H, pyrazole 4-H); 7.54 (ddd, 1 H, 
quinoline 6-H); 7.71 (ddd, 1 H, quinoline 7-H); 7.83 (s, 1 
H, quinoline 3-H); 7.97 (d, 1 H, quinoline 5-H); 8.03 (d, 1 
H, quinoline 8-H) ppm. MS m/z: 291.0987 (M) 
(C15H12F3N3 requires: 291.0983) (100%); 222.1025 
(M -CF3) (C,4Hi2N3 requires: 222.1031). Analysis: 
Found: N, 14.41%. CI5H|2F3N3 requires: N, 14.43%.
3.6. 3,5-Bis(trifluoromethyl)-1 -(4-methylquinolin-2-yl)- 
pyrazole (5b)
The hydroxydihydropyrazole 3b was treated with sul­
phuric acid and acetic acid, as for the synthesis of 5a, to give 
the pyrazole 5b (80%) as a pale yellow solid, m.p. 93-94 °C. 
‘H NMR 5: 2.76 (s, 3 H. quinoline-Me); 7.15 (s, 1 H, pyr­
azole 4-H); 7.60 (t, 1 H, quinoline 6-H); 7.74 (t, 1 H, quin­
oline 7-H); 7.85 (s, 1 H, quinoline 3-H); 8.00 (d, 1 H, 
quinoline 5-H); 8.04 (d, 1 H, quinoline 8-H) ppm. MS m/z: 
345.0692 (M) (C ^ H ^ ^  requires: 345.0700) (100%). 




The hydroxydihydropyrazole 3c was treated with sulphuric 
acid and acetic acid, as for the synthesis of 5a, to give the 
pyrazole 5c (75%) as a pale yellow solid, m.p. 109-110 °C. 
‘H NMR 8: 2.76 (d, 3 H, 7 = 0.9 Hz, quinoline-Me); 7.21 
(s, 1 H, pyrazole 4-H); 7.36-7.49 (m, 3 H, Ph 3,4,5-H3);
7.55 (ddd, 1 H, quinoline 6-H); 7.72 (ddd, 1 H, quinoline 7- 
H); 7.90-7.98 (m, 4 H, quinoline 3,5-H2 + Ph 2,6-H2); 8.05 
(d, 1 H, quinoline 8-H) ppm. Analysis: Found: N, 12.02%. 
C20H14F3N3 requires: N. 11.90%.
3.8. l-(4-Methylquinolin-2-yl)-3-(thien-2-yl)-5-trifluoro- 
methylpyrazole (5d)
The hydroxydihydropyrazole 3d was treated with sul­
phuric acid and acetic acid, as for the synthesis of 5a, to give 
the pyrazole 5d (70%) as a pale yellow solid, m.p. 116- 
117 °C. 'H NMR 8:2.76 (d, 3 H, 7 = 0.7 Hz, quinoline-Me); 
7.08-7.11 (m, 2 H, pyrazole 4-H + thiophene 4-H); 7.34 (dd, 
1 H, thiophene 5-H); 7.45 (dd, 1 H, thiophene 3-H); 7.55 
(ddd, 1 H, quinoline 6-H); 7.72 (t, 1 H, quinoline 7-H);7.94 
(s. 1 H, quinoline 3-H): 7.97 (d, 1 H, quinoline 5-H); 8.04 
(d, 1 H, quinoline 8-H) ppm. Analysis: Found: N, 11.82%. 
C18H|2F3N3S requires: N. 11.70%.
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3.9. 4-(N'-f3-Hydroxy-1-methyl-4,4,4-trifluorobut-2- 
enylidine))hydrazwo-2-methylquinoline (7a)
1.1.1-Trifluoropentane-2,4-dione 2a (770 mg, 5 mmol) 
was boiled under reflux with 6a (865 mg, 5 mmol) in ethanol 
(50 ml) for 6 h. Evaporation of the solvent and recrystallis­
ation (methanol) afforded the hydrazone 7a ( 1.10 g, 70%) 
as a yellow solid, m.p. 239-240 °C. 'H NMR ((CD3)2SO) 
8: 2.32 (s, 3 H, =CMe); 2.36 (s, 3 H, quinoline-Me); 5.42 
(s, 1 H, =CH); 5.90 (s, 1 H, quinoline 3-H); 7.24 (t, 1 H, 
quinoline 7-H); 7.34 (d, 1 H, quinoline 5-H); 7.53 (ddd, 1 
H, quinoline 6-H); 8.15 (dd, 1 H, quinoline 8-H); 11.40 (s, 
1 H, NH); 14.32 (s, 1 H, OH) ppm. I3C NMR 8: 87.84 (-  
CH=); 118.54 (q, Vo*-286.6 Hz, CF3); 169.60 (q, 
Vc_f =31.2 Hz,CCF3) ppm. l9FNMR 8: -74.79 (s) ppm. 
Analysis: Found: N, 13.52%. CisH^F^O requires: N, 
13.59%.
J. 10. 7-Chloro-4-iN'-(3-Hydroxy-1 -methyl-4,4,4- 
trifluorobut-2-enylidine))hydrazmoquinoline (7b)
1.1.1-Trifluoropentane-2,4-dione 2a (770 mg, 5 mmol) 
was treated with 6b (965 mg, 5 mmol), as for the synthesis 
of 7a, to afford the hydrazone 7b (1.18 g, 72%) as a yellow 
solid, m.p. 255-256 °C. *H NMR 8: 2.38 (s, 3 H, =CMe);
5.51 (s, 1 H, =CH);6.11 (d, 1H,quinoline 3-H); 7.31 (dd, 
1 H, quinoline 6-H); 7.40 (d, 1 H, quinoline 5-H); 7.74 (d, 
1 H, quinoline 2-H); 8.20 (dd, 1 H, quinoline 8-H); 11.49 
(s, 1 H, NH); 14JO (s, 1 H, OH) ppm. ,3C NMR 8 
((CD3)2SO): 87.79 (-CH=); 118.35 (q, VC_F 286.4 Hz, 
CF3); 170.23 (q, Vc_f 30.8 Hz, CCF3) ppm. ,9F NMR 8: 
— 74.37 (s) ppm. MS m/z: 331/329 (M). Analysis: Found: 
N, 12.71%. CwHnClF^O: N, 12.73%.
3.11. 3-Methyl-l-(2-methylquinolin-4-yl)-5-trifluoro- 
methylpyrazole (9a)
The hydrazone 7a (927 mg, 3 mmol) was boiled under 
reflux in acetic acid (30 ml) for 4 h. Evaporation of the sol­
vent and reciystallisation (ethanol) afforded the pyrazole 9a 
(650 mg, 75%) as a pale yellow solidi m.p. 135-136 °C. 
'H NMR 8: 2.37 (s, 3 H, pyrazole-Me); 2.72 (s, 3 H, quin­
oline-Me); 6.63 (s, 1 H, pyrazole 4-H); 7.25 (s, 1 H, quin­
oline 3-H); 7.29 (d, 1 H, quinoline 5-H); 7.41 (t, 1 H, 
quinoline 6-H); 7.65 (t, 1 H, quinoline 7-H); 8.03 (d, 1 H, 
quinoline 8-H) ppm. Analysis: Found: N, 14.38%. 
C,5H12F3N3 requires: N, 14.43%.
3.12. l-(7-Chloroqumolin-4-yl)-3-methyl-5-trifluoro- 
methylpyrazole (9b)
The hydrazone 7b (988 mg, 3 mmol) was boiled under 
reflux in acetic acid (30 ml) for 4 h. Evaporation of the sol­
vent and recrystallisation from ethanol afforded the pyrazole 
9b (670 mg, 72%) as a pale yellow solid, m.p. 78-79 °C. 
1H NMR 5:2.43 (s, 3 H, pyrazole-Me); 6.74 (s. 1 H, pyrazole
4-H); 7.44 (d, 1 H, quinoline 3-H); 7.46 (d, 1 H, quinoline
5-H); 7.53 (dd, 1 H, quinoline 6-H); 8.23 (d, 1 H, quinoline
8-H); 9.04 (d, 1 H, quinoline 2-H) ppm. MS m/z 311/313 
(M). Analysis: Found: N, 13.42%. C,4H9C1F3N3 requires: 
N, 13.46%.
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Reaction of alkane-l,cu-diamines with 6-chloro-l,3-dimethylpyrimidine-2,4-dione under carefully 
controlled conditions gives 6-(cy-aminoalkylamino)-l,3-dimethylpyrimi(iine-2,4-diones, which can be 
readily separated from traces of products of disubstitution after benzyloxycarbonyl protection. A 
sequence of nitrosation at the pyrim id in e 5-position, thermal cyclization, and deprotection affords 
8-(<y-aminoalkyl) derivatives of theophylline, an important drug in the treatment of asthma and related 
diseases. These 8-(co-aminoalkyl)theophyllines can be coupled to fluorescein-5-isothiocyanate and to 
dansyl chloride, giving fluorescent derivatives of theophylline with applications in automated 
immunoassay of the drug in biofluids using the fluorescence capillary fill device.
INTRODUCTION
Theophylline (1; Scheme 1) is a drug that is commonly 
used as a bronchospasmolytic agent in the prevention and 
treatment of asthma, apnoea, and obstructive lung 
diseases and is an inhibitor of cyclic nucleotide phos­
phodiesterases (1-3). Drug-induced toxicity occurs at 
plasma concentrations not far above those required for 
therapy, and plasma concentrations vary greatly among 
individuals given the same dose. Rapid and accurate 
measurement of its concentration in biofluids is therefore 
necessary (2,3). Current methods for the determination 
of theophylline in blood include ELISA (4), radioimmu­
noassay (5), and HPLC (6 ), although not all of these 
completely fulfill criteria of speed, ease, and low cost of 
assay. The fluorescence capillary fill device (FCFD) (7 - 
10) overcomes these drawbacks. To develop an immuno­
assay for theophylline in whole blood using this device, 
we required fluorescent derivatives of theophylline that 
have good immunoreactivity with appropriate anti-theo­
phylline antibodies. To be able to optimize both the 
photoproperties of the fluorophore and the length and 
lipophilicity of the link between theophylline and the 
fluorophore, a series of 8-(a>-aminoalkyl)theophyllines 
and related ethers was sought. Thus, a variety of widely 
used fluorescent groups bearing isothiocyanate and sul- 
fonyl chloride electrophiles could be attached.
EXPERIMENTAL PROCEDURES
Chemical Synthesis. IR spectra were recorded on a 
Perkin-Elmer 782 spectrophotometer as potassium bro­
mide disks, unless otherwise stated. NMR spectra were 
recorded using JEOL JNM GX270 and JNM EX400 
spectrometers of samples in (CD3>2SO, except where 
stated. Chemical shifts were measured relative to tetra- 
methylsilane as internal standard. Mass spectra were 
obtained using a VG7070E analytical mass spectrometer 
using electron, impact (El) or fast atom bombardment 
(FAB) techniques in the positive ion mode. Melting 
points are uncorrected. Dioxane refers to 1,4-dioxane. 
Chromatographic separations were carried out using
* Author to whom correspondence should be addressed (e- 
m ail m.d.threadgill@bath.ac.uk).
r Present address: Department of Clinical Biochemistry, The 
London Hospital Medical College, Turner Street. London E l 2AD, 
U.K.
•  Abstract published in Advance ACS Abstracts, June 1.1997.
Sorbsil C60 (0.040—0.063) silica gel. Solvents were 
evaporated under reduced pressure. Solutions in organic 
solvents were dried over magnesium sulfate. Experi­
ments were conducted at ambient temperature unless 
otherwise stated. Chemicals were purchased from Aid- 
rich Chemical Co. (Gillingham, U.K.), Sigma Chemical 
Co. (Gillingham, U.K.), and Maybridge Chemicals (Tin- 
tagel, UK).
Phenylmethyl N-[[[6-( 1,1 -Dimethylethoxy)carbonyl]- 
aminojhexyljcarbamate (3). Phenylmethyl chloroformate 
(610 mg, 3.6 mmol) in CH2CI2 (6 mL) was added during 
30 min to 1,1-dimethylethyl N-(6-aminohexyl)carbamate 
hydrochloride (2) (900 mg, 3.6 mmol) and EtsN (720 mg,
7.1 mmol) in CH2CI2 (12 mL). The mixture was stirred 
for 24 h and was filtered. The filtrate was washed twice 
with water and once with hydrochloric acid (2 M) and 
dried. The solvent was evaporated to afford 3 as a white 
crystalline solid (960 mg, 77%): mp 190 °C; IR 3340, 
1680, 1550 cm"1; NMR <5 (CDCI3) 1.44 (17 H, m, 
CHzCtfzCHoCHzCffzCH, + Bu‘), 1.85 (1 H, br, NH), 3.11 
(2 H, q ,J  = 6 Hz, CH,N), 3.17 (2 H, m, CH2N), 4.85 (1 
H, br, NH), 5.09 (2 H, s, PhCH2), 7.35 (5 H, s, Ar-H5); 
MS (El) 350 (M). Anal. Calcd for C19H30N2O4: C, 65.12; 
H, 8.63; N, 7.99. Found: C, 65.41; H, 8.61; N, 8.17.
Phenylmethyl N-(6-Aminohexyl)carbamate Hydrochlo­
ride (4). HC1 was passed through 3 (960 mg, 2.7 mmol) 
in CH2C12 (100 mL) for 1 h. The solvent and excess 
reagent were evaporated to afford 4 as white crystals (680 
mg, 99%): mp 177-178 °C (lit. (11) mp 177-178 °C]; IR 
3470, 3340-3280,1700,1630 cm"1; NMR 6 (CDC13) 1.18 
(4 H, m, 2 x CH,), 1.35 (4 H, m, 2 x CHa), 2.93 (2 H, t. 
J = 6 Hz, CfMSTH3), 3.08 12 H, q. J = 6 Hz, CffjNH).
3.61 (3 H, br, N+H3), 5.07 (2 H. s, PhCH2), 7.39 (5 H, s. 
Ar-Hs); MS (El) 287 (M).
1,3-Dimethyl-6-[[[[6-(phenylmethoxy)carbonylJamino)- 
hexyl]amino]pyrimidine-'2,4~dione (6a). l,3-Dimethyl-6- 
chloropyrimidine-2,4-dione (5) (490 mg, 2.8 mmol), 4 (840 
mg, 3.7 mmol), and Na2C03 (600 mg, 5.7 mmol) were 
boiled under reflux in dioxane (8 mL) for 4 h. The cooled 
mixture was diluted with CHCI3, and the solution was 
washed twice with water and once with saturated brine 
and was dried. The evaporation residue was recrystal­
lized (EtOH) to give 6a as yellow crystals (600 mg. 
54%): mp 128-130 °C; IR 3360, 3280, 1700. 1630 cm'1: 
NMR <5 0.90 (4 H. m, 2 x CH2). 1.23 (4 H, m, 2 x CH,). 
3.15 (2 H, t, J  = 6 Hz, CH.N), 3.17 (2 H, t, J  = 6 Hz. 
CH2N), 3.06 (3 H, s, NMe), 3.23 (3 H, s, NMe), 4.21 (2 H.
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S ch em e 1. S tru ctu res o f  T h eo p h y llin e  1 and F lu o resce in -5 -iso th io cy a n a te  12 and S y n th etic  R o u te s  to  th e  
F lu o r e sc e n t  T h eo p h y llin e  D er iv a tiv es  I 3 a - d  and 14a







2: R = H 
3: R = Cbz J
X
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b: Y = (CH2)8 
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0 Reagents: i. CbzCl, EtsN. CRCU; ii. HC1, CH2C12; iii, 5, 1.4-dioxane. Na2C0 3 , A; iv. C5H 11ONO. HCl. EtOH; v. BuOH. A; vi. 
HBr. HOAc; vu. 12. K2C 03, dioxane, water. pH 9.0 ±  0.2: viii. 5 -(dimethylamino)naphthalene-l-sulfonyl chloride. Na2C0 3 . dioxane. 
water. pH 9 .5 -10 .0
m. pyrim id ine 5-H +  NH ), 4 .6 9  (2 H, s , P hC H 2), 6.79 (5
H. m, Ph-H s). 7.70 (1 H, br. NH); m / z  (E l) 388 (M). 91 
(100%). A nal. Calcd for C ^ H ^ O * :  C. 61.82; H. 7.27; 
N . 14.43. Found; C. 61.85; H. 7 .36; N . 14.3.
1.3 • D im e th y  I-6 -[[[[9 -( p h e n y lm e th o z y /c a r b o n y l]  - 
amLno)nonyl]amino]pyrimUiine-2,4-dione (6b). The chlo- 
ropynm idine 5 (1.00 g, 5.7 m m ol) w a s boiled under reflux 
w ith  nonane-1 ,9-d iam ine (1.81 g. 11 m m ol) and Na2C 0 3 
(1 .21  g, 1.4 m m ol) in EtOH (40  m L) for 3  h. T he m ixture  
w a s filtered and the so lven t w a s evaporated . R ecrystal­
liza tion  (EtO H ) afforded 1.3-d im ethyl-6-((9-am inononyD - 
am ino]pyrim id in e-2 ,4 -d ione (,7b) as a w h ite  so l id  (1 .0 9  
g. 65%); mp 2 1 0 -2 1 2  °C; IR 3500. 1660 c m ' 1; N M R  6 1.29 
[14 H, m, (CH 2)7]. 2 .54  (2 H. m. C tf2N H 2), 3 .0 3  (2  H. m. 
N H C H 2), 3 .03  (3  H, s, NM e). 3 .26  (3 H . s. N M e). 4 .6 5  (1 
H, br. NH ). 6 .7 2  (1 H . s. pyrim idine 5-H ); m / z  (E l)  297  
(M ), 159 (100% ). T h is m aterial (3 .16  g. 11 m m o l) w as  
stirred  w ith  p h en y lm eth y l ch loroform ate (1 .9 1  g, 11 
m m ol) and E t3N  (2 .1 6  g. 21 m m ol) in C H 2C12 (1 5 0  mL) 
for 24  h. T he su sp en sio n  w as filtered , an d  th e  f iltra te
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was washed twice with water and once with hydrochloric 
acid (2 M) and was dried. Evaporation and chromatog­
raphy (CHClVEtOAc 4:1 — EtOAc) gave 6b as white 
crystals (2.02 g, 43%): mp 105-106 °C; IR 3420, 1700, 
1680 cm*1; NMR 6 (CDC13) 1.30 (4 H, br, 2 x CH*), 1.50 
(2 H, quintet, J  = 7.3 Hz, CH2), 1.66 (8 H, m, 4 x CH2), 
3.09 (2 H, q, J  = 7.3 Hz, NCH*), 3.18 (2 H, q, J  = 6.3 Hz, 
NCH*), 3.31 (3 H, s, NMe), 3.39 (3 H, s, NMe), 4.35 (1 H, 
br, NH), 4.79 (1 H, br, NH), 4.86 (1 H, s, 5-H), 5.09 (2 H, 
s, PhCH2), 7.35 (5 H, s, Ph-Hs): MS (El) 431 (M), 336 (M
-  PhCH2OH), 91 (100%). Anal. Calcd for CwHaN^: 
C. 61.84; H, 7.27; N, 14.42. Found: C, 61.9; H, 7.35; N, 
14.39.
1.3-Dimethyl-6~([[[l O-CphenylmethoxyjcarbonylJamino]- 
decyl]amino]pyrimidine-2,4-dione (6c). The chloropyrimi- 
dine 5 (1.35 g, 7.7 mmol) was treated with decane-1,10- 
diamine (1.60 g, 9.3 mmol) as for the synthesis of 7b, 
except that recrystallization was omitted, to give crude
1,3-dimethyl-6-[( 10-aininodecyl)anrinolpyrimidine-2,4-di- 
one (7c) (1.24 g, 52%) as a white solid: mp 72-74 °C; IR 
3400, 1660 cm'1; NMR <5 (CFsCC^D) 1.41 [16 H, m, 
(CH2)8), 1.82 (2 H, m, CH2N), 3.28 (2 H, m, CH2N), 3.60 
(3 H, s, NMe), 3.69 (3 H, s, NMe); MS (El) 310 (M), 173. 
The amine 7c (800 mg, 2.6 mmol) was treated with 
phenylmethyl chloroformate (440 mg, 2.6 mmol) as for 
the synthesis of 6b, except that the chromatographic 
eluant was CHCVMeOH 10:1, to afford 6c as white 
crystals (620 mg, 54%): mp 100-102 °C; IR 3360, 3280, 
1700,1640 cm"1; NMR 6 (CDC13) 1.29 [12 H, m, (CHjU 
1.49 (2 H, m, CH2), 1.65 (2 H, quintet, J  = 6.8 Hz, CH2), 
3.08 (2 H, dt, J  = 5.1,7.1 Hz, CH ,^ 3.18 (2 H, q, J  = 6.6 
Hz, NCH2), 3.31 (3 H, s, NMe), 3.39 (3 H, s, NMe), 4.40 
(1 H, br, NH), 4.81 (1 H, s, pyrimidine 5-H), 5.09 (2 H, s, 
PhCHz), 7.35 (5 H, m, Ph-Hs); MS (El) 444 (M), 336 (M
-  PhCH2OH), 91 (100%). AnaL Calcd for CmHkNiO*: 




The chloropyrimidine 5 (2.82 g, 16 mmol) was treated 
with 3,6-dioxaoctane-l,8-diamine (6.0 g, 40 m m o l)  as for 
the synthesis of 7b, except that recrystallization was 
omitted, to give crude l,3-dimethyl-6-[[2-[2-(2-amino- 
ethoxy)ethoxy)ethyl]aminolpyrimidine-2,4-dione (7d) (3.03 
g, 69%). This material was treated with phenylmethyl 
chloroformate (1.90 g, 11 mmol), as for the synthesis of 
6b, except that the chromatographic eluant was EtOAc
-  EtOAc/MeOH 6:1, to afford 6d as a colorless gum (2.04
g, 44%): IR 3400-3280,1740-1670 cm'1; NMR <5 (CDC13) 
3.24 (2 H, q, J  = 6 Hz, NCH2), 3.31 (3 H, s, NMe), 3.36 
(3 H, s, NMe), 3.40 (2 H, q, J  = 5.3 Hz, NCH*), 3.58 (2 H, 
t, J  = 6 Hz, NCH2CH2), 3.62 (4 H, s, 0CH2CH20), 3.68 
(2 H, t, J  — 6 Hz, NCH2CH2), 4.83 (1 H, s, pyrimidine 
5-H), 5.00 (1 H, br, NH), 5.09 (2 H. s, PhCH2), 5.29 (1 H, 
br, NH), 7.35 (5 H. s, Ph-Hs); MS (El) 421 (M), 91 (100%). 
Anal. Calcd for C^oH^O*: C, 57.12; H, 6.72; N, 13.33. 
Found: C, 56.95; H, 6.78; N, 13.39.
1.3-Dimetkyl~8-[[[5-(phenylmethozy)carbonylJamino ]- 
pentyljpurine-2,6-dione (10a). Pentyl nitrite (410 mg, 3.5 
mmol) was added carefully to 6a (550 mg, 1.4 mmol) in 
EtOH (25 mL) at 40 °C, and the solution was stirred for 
10 min. Hydrochloric acid (9 M, 0.3 mL) was added, and 
the mixture was stirred at ambient temperature for 16
h. The solvent was evaporated to afford crude 9a as a 
red gum (430 mg, 73%). This material was boiled under 
reflux in BuOH (3 mL) for 45 min until decolorization 
had occurred. The evaporation residue was washed with 
Et*0 and recrystallized (BuOH) to give 10a as off-white 
crystals (400 mg, 71% from 6a): mp 182-184 °C; IR 
3300, 1700, 1680, 1660 cm'1; NMR 6 1.55 (2 H, quintet.
J  = 7.0 Hz, CH*), 1.67 (2 H, quintet, J = 7 Hz. CH-,;. 
1.90 (2 H, quintet, J  = 7.3 Hz, CH2), 1.92 (2 H, t, J = 7.3 
Hz, purine-CH2), 3.23 (2 H, q, J  = 6.4 Hz, CH.N), 3.45 
(3 H, s, NMe), 3.59 (3 H, s, NMe), 5.23 (2 H, br. PhCH*;. 
7.54 (1 H, br, CbzNH), 7.58 (5 H, m, Ph-H*); MS (El) 400 
(M), 292 (M -  PhCHaOH), 91 (100%). Anal. Calcd for 
CzoHjsNsO  ^ C. 60.14; H, 6.31; N, 17.53. Found: C, 
60.09; H, 6.34; N, 17.50.
1.3-Dimethyl-8-[[[8-Cphenylmethoxy)carbonyl Jamino J- 
octyl]purine-2,6-dione (lObj. The pyrimidine 6b was 
treated with pentyl nitrite as for the synthesis of 9a, to 
give crude 9b as a purple gum. This material was 
heated, as for the synthesis of 10a, to give 10b as a cream 
solid (26%): mp 145-147 3C; IR 3320,1740, 1680 cm'1; 
NMR <5 1.24 (8 H, m, 4 x CH2), 1.38 (2 H, quintet. J  = 6 
Hz, CH*), 1.65 (2 H, quintet, J  = 6 Hz, CH*), 2.65 (2 H, 
t, J  == 6.2 Hz, purine-CH*), 2.95 (2 H, q, J — 6.2 Hz. 
NCH*), 3.21 (3 H, s, NMe;, 3.41 (3 H, s, NMe;, 4.99 (2 H. 
s, PhCH2), 7.22 (1H, br, NH), 7.33 (5 H, m, Ph-Hs), 13.15 
(1 H, s, NH); MS (El) 442 (M), 334 (M -  PhCH*OH), 91 
(100%). Anal. Calcd for CasHsiNsO*: C, 62.57; H. 7.08; 
N, 15.86. Found: C, 62.99; H, 7.35; N, 15.79.
1.3-Dimethyl-8-(((9-(phenylmethoxy)carbony IJamino j -  
nonyl]purine-2,6-dione (lOcj. The 10-Cbz-aminodecyl- 
aminopyrimidine 6c was treated with pentyl nitrite, as 
for the synthesis of 9a, to afford crude 9c as a red-purple
oil. This material was boiled under reflux for 40 min in 
BuOH, and the solvent was evaporated. Recrystalliza­
tion (BuOH) gave 10c as pale buff crystals (300 mg, 
45%): mp 95-96 °C; IR 3300, 1730, 1700, 1650 cm':; 
NMR 6 1.24 [10 H, m, (CH*)5), 1.38 (2 H, t, J = 6 Hz, 
CH*), 1.67 (4 H, m, 2 x CH2), 2.66 (2 H, q, J = 7.6 Hz, 
NCH2), 2.97 (2 H, q, J  = 6.4 Hz, purine-CH2), 3.22 (3 H, 
s, NMe), 3.41 (3 H, s, NMe). 4.99 (2 H, s, PhCH*;, 7.22 (1 
H, t, J  -  6 Hz, NH), 7.34 (5 H, m. Ph-Hs); MS (El) 455 
(M), 347 (M -  PhCH2OH), 194 (100%). Anal. Calcd for 
CmHssNsO  ^ C, 63.26; H, 7.31; N, 15.38. Found: C, 63.6; 
H, 7.28; N, 15.4.
1.3-Dimethyl-8-[2-(2-{phenylmetkoxyjcarbonyljethoxy- 
ethoxymethylJpurine-2,6-dione (lOd). The pyrimidine 6d 
was treated with pentyl nitrite, as for the synthesis of 
9a, to give 9d. as a purple gum (97%). This material was 
heated as for the synthesis 10a, to give lOd as a yellow 
gum (66%): IR 3420,3250,1740.1680 cm*1; NMR 6 3.15 
(2 H, q, J  =  5.9 Hz, NCH*), 3.23 (3 H, s, NMe), 3.40 (2 H, 
m, NCH2Cff2), 3.42 (3 H, s, NMe), 3.55 (2 H, m) and 3.59 
(2 H, m) (0CH2CH20), 4.53 (2 H, s, purine-CH*;, 5.00 (2
H, s, PhCH2), 7.33 (6 H, m, Ph-H5 + NH). 13.5? (1 H, br. 
purine-NH); m /z (El) 431 (M), 91 (100%). Anal. Calcd 
for CmH^sOs: C, 55.68; H. 5.84; N, 16.23. Found: C. 
55.40; H, 5.72; N, 16.39.
8-(5-Aminopentyl)-2,4-dimethylpurine-l,3-dione Hydro- 
bromide (11a). The Cbz-protected amine 10a (230 mg.
0.58 mmol) was stirred with HBr in AcOH (30%. 0.8 mL) 
for 15 min. Dry Et*0 (10 mL) was added, the suspension 
was stirred vigorously for 5 min, and the Et*0 was 
decanted. This washing procedure was repeated five 
times, and the solid was dried to afford 11a as an off- 
white powder (200 mg, 100%); mp 250—252 °C; IR 3500- 
3400, 3240, 1740, 1680 cm'1; NMR <5 1.31 (2 H. quintet. 
J  = 6.7 Hz, CH2), 1.56 (2 H. quintet, J  = 7.3 Hz. CH>).
I.70 (2 H, quintet. J  = 7.3 Hz, CH2). 2.70 (2 H. t. J = 7.7 
Hz, purine-CH2), 2.75 (2 H. t. J  = 7.7 Hz, NCH*). 3.22 (3
H. s, NMe), 3.41 (3 H, s. NMe). 7.74 (3 H, br. N-H;,i: MS 
(FAB) 266 (M + H), ISO (100%). Anal. Calcd for 
Cl2H20BrN5O2: C, 41.63; H. 5.S2; N. 20.23. Found: C. 
41.57; H, 5.77; N, 20.22.
8-(8-Aminaoctyl)-2.4-dimethylpurine-1,3-dione Hydro ■ 
bromide (lib). The Cbz-protected amine 10b was treated 
with HBr, and the solid was washed with Et>0. as for
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the synthesis of 11a, to give lib  as a white powder 
(100%): mp 239-241 °C; IR 3440,3200,1760,1680 cm"1; 
NMR 6 1.27 [8 H, m, (CH2)4J, 1.52 (2 H, m, CH2), 1.67 (2
H, quintet, J  = 6.7 Hz, CH2), 2.68 (2 H, t, J  = 7.6 Hz, 
purine-CH2), 2.76 (2 H, sextet, -J = 6.4 Hz, NCH2), 3.22 
(3 H, s, NMe), 3.41 (3 H, s, NMe), 7.72 (3 H, br, N"H3); 
MS (FAB) 308 (M + H), 180 (100%). Anal. Calcd for 
CisH26BrN50 2: C, 46.42; H, 6.75; N, 18.04. Found: C, 
46.41; H, 6.67; N, 18.10.
8-(9-Aminononyl)-2,4-dimethylpurine-l,3-dione Hydro­
bromide (11c). The Cbz-protected amine 10c was treated 
with HBr, and the solid was washed with EtoO, as for 
the synthesis of 11a, to give 11c as an off-white powder 
(87%): mp 218-219 °C; IR 3160,1720,1680 cm'1; NMR 
6 1.25 (10 H, br, CH2CH2Ctf2Ctf2Ctf2Cif2CH2CH2CH2),
I.51 (2 H, m, CH2), 1.67 (2 H, m, CH2), 2.68 (2 H, t, J  = 
7.5 Hz, purine-CH2), 2.75 (2 H, m, NCH2), 3.22 (3 H, s, 
NMe), 3.41 (3 H, s, NMe), 7.71 (3 H, s, N+H3); MS (FAB) 
322 (M + H), 180 (100%). Anal. Calcd for Cl6H^ s- 
BrNs0 2: C, 47.77; H, 7.01; N, 17.41. Found: C, 47.84;
H, 7.11; N, 17.22.
8-[2-(2-Aminoethoxy)ethoxymethyl]-2,4-dimethylpurine-
I,3-dione Hydrobromide (lid). The Cbz-protected amine 
lOd was treated with HBr, and the solid was washed 
with Et20 , as for the synthesis of 11a, to give lid  as a 
pale yellow solid (100%): mp 220-221 °C; NMR <5 2.97 
(2 H, sextet, J  «  6 Hz, NCH2), 3.23 (3 H, s, NMe), 3.43 
(3 H, s, NMe), 3.62 (6 H, m, OCH2CH2OCH2), 4.55 (2 H, 
s, purine-CH2), 7.83 (3 H, br, N^H3); m/z (FAB) 298 (M 
+ H), 180 (100%). Anal. Calcd for C^HzoNsO^r: C, 




(9H)xanthenJ-3-one (13a). 3',6'-Dihydroxy-5-isothio- 
cyanatospiro[isobenzofuran-l(3fO,9'-(9£Dxanthen]-3- 
one (fluorescein-5-isothiocyanate; 12) (340 mg, 870 //mol) 
was suspended in water (12 mL) and brought to pH 9.0 
by dropwise addition of aqueous K2C03 (1 M). To this 
stirred solution was added lib  (300 mg, 870 //mol) in 
water (6.7 mL) and dioxane (3.3 mL) during 30 min. The 
mixture was stirred for 3 h. During this time, the pH 
was maintained at 9.0 ± 0.2 by dropwise addition of 
aqueous K2C03 (1 M). The solution was acidified to pH 
6.0 by dropwise addition of hydrochloric add (2 M). 
Water (200 mL) was added, and the mixture was freeze- 
dried for 24 h to reveal an orange fluffy solid. Chroma­
tography (EtOAc — EtOAc/MeOH 10:1) gave 13a as an 
orange-yellow solid (280 mg, 50%): mp 197-198 °C; IR 
3480, 1710, 1660 cm-1; NMR <5 1.37 (2 H, m. CH2), 1.62 
(2 H, m, NCH2Cff2), 1.76 (2 H, m, purine-CH2Ctf2), 2.73 
(2 H, t, J  = 7.7 Hz, purine-CH2), 3.24 (3 H, s, NMe), 3.40 
(3 H, s, NMe), 3.53 (2 H, m, NCH,), 6.56 (2 H, dd, J  =
8.8, 2.2 Hz, xanthene 2',7'-H2), 6.61 (2 H, d, J  = 8.8 Hz, 
xanthene l',8'-H2), 6.70 (2 H, d, J  = 2.2 Hz, xanthene 
4',5'-H2), 7.20 (1 H, d, J  = 8.2 Hz, Ar 3-H), 7.73 (1 H, m, 
Ar 4-H), 8.25 (1 H, br, NH), 8.27 (1 H, br, Ar 6-H), 9.93 
(1 H, br, NH), 10.13 (2 H, s, 2 x OH), 13.21 (1 H, br, 
purine NH); MS (FAB) 655 (M + H). Anal. Calcd for 
CmHmNsOtS: C, 60.53; H, 4.62; N, 12.84. Found: C. 
60.61; H, 4.57; N, 12.72.
5-[[N-[8-(2,4-Dimethyl-l ,3-dioxopurin-8-yl)octyl]thio]- 
ureidoJ-3',6'-dihydroxyspiro[isobenzofuran-l(3H) ,9' - 
(9H)xanthen]-3-one (13b). The 8-(8-aminooctyl)purine 
salt lib  was treated with 12, as for the synthesis of 13a, 
to give 13b as an orange-yellow solid (72%): mp 182- 
183 °C; IR 3500-3100, 1710, 1660 cm’1; NMR 6 1.30 (8 
H, m, 4 x CH2), 1.55 (2 H, m, NCHoCtf2), 1.66 (2 H, m, 
purine-CH2Ctf2), 2.67 (2 H, t, J  = 7.3 Hz, purine-CH2),
3.22 (3 H, s, NMe), 3.41 (3 H, s. NMe), 3.49 (2 H, m.
NCH2), 6.53 (2 H, dd, J  = 8.8, 2.2 Hz, xanthene 2',7'- 
H2), 6.58 (2 H, d, -J = 8.8 Hz, xanthene l',8'-H2), 6.68 (2
H, d, -J *= 2.2 Hz, xanthene 4',5'-H2), 7.19 (1 H, d, J  = 8.4 
Hz, Ar 3-H), 7.70 (1 H, m, Ar 4-H), 8.27 (1 H, br, Ar 6-H), 
10.23 (2 H, s, 2 x OH); m /z (FAB) 697 (M -r H). Anal. 
Calcd for 0 ^ 36^ 078: C, 62.05; H, 5.21; N, 12.01. 
Found: C, 62.11; H, 5.27; N, 12.02.
5-[[N-[9-(2,4-Dimethyl-1,3-dioxopurin-8-yl)nonyl]thio J- 
ureido]-3',6'-dihydroxyspiro[isobenzofuran-l(3H),9'- 
(9H)xanthen]-3-one (13c). The 8-{9-aminononyl)purine 
salt 11c was treated with 12, as for the synthesis of 13a, 
to give 13c as an orange-yellow solid (68%): mp 178- 
179 °C; IR 3400-3000, 1740, 1700, 1650 cm’1; NMR <3
I.29 (10 H, br, 5 x  CH2), 1.56 (2 H, m, NHCH2Ctf2), 1.68 
(2 H, m, purine-CH2CH2), 2.67 (2 H, t, J  = 7.5 Hz, purine- 
CH2), 3.22 (3 H, s, NMe), 3.41 (3 H, s, NMe), 3.48 (2 H, 
m, NCH2), 6.56 (2 H, dd, J = 8.8, 2.2 Hz, xanthene 2',7'- 
H2), 6.59 (2 H, d, J  = 8.8 Hz, xanthene l',8'-H2), 6.67 (2 
H, d, J  = 2.2 Hz, xanthene 4\5'-H2), 7.17 (1 H. d, J  = 8.4 
Hz, Ar 3-H), 7.70 (1H, m, Ar 4-H), 8.06 (1 H, br, CHoNH),
8.22 (1 H, brs, Ar 6-H), 9.86 (1 H, br, Ar-NH), 10.18 (2 
H, s, 2 x  OH), 13.35 (1 H, purine NH); MS (FAB) 711 (M 
+ H). Anal. Calcd for C^HssNsOtS: C, 62.52; H, 5.39; 
N, 11.82. Found: C, 62.45; H, 5.41; N, 11.75.
5-[N-[2-[2-(2,4-Dimethyl-l,3-dioxopurin-8-ylmethoxy)- 
ethoxyethyl]thio]ureido]-3'. 6'-dihydroxyspiro(isobenzo - 
furan-l(3H),9'-(9H)xanthen]-3-one (13d). The purine 
derivative salt lid  was treated with 12, as for the 
synthesis of 13a, to give 13d as an orange-yellow solid 
(77%): mp 1971-1998 °C; IR 3400-3200, 1740, 1700, 
1650 cm"1: 6 3.22 (3 H, s, NMe), 3.41 (3 H, s, NMe), 3.63 
(8 H, m, OCH2CH2OCH2CH2), 4.54 (2 H, s, purine-CH2),
6.56 (2 H, dd, J  = 8.8 and 2.2 Hz, xanthene 2',7'-H2), 6.59 
(2 H, d, J  = 8.8 Hz, xanthene l',8'-H2), 6.66 (2 H, d, J  =
2.2 Hz, xanthene 4',5'-H>), 7.18 (1 H, d, J  = 8.4 Hz, Ar
3-H), 7.73 (1 H, brd, J  = 8.5 Hz, Ar 4-H), 8.1 (1 H, br, 
NH), 8.26 (1 H, br, Ar 6-H), 10.05 (1 H, br, NH), 10.14 (2 
H, s, 2 x OH), 13.6 (1 H, purine NH); MS (FAB) 687 (M 
+ H). Anal. Calcd for CmHsoNsOsS: C, 57.71; H, 4.41; 
N, 12.24. Found: C, 57.61; H, 4.45; N, 12.22.
2,4-Dimethyl-8-[5-[5-(dimethylamino)naphthalene-l- 
sulfonylaminojpentyl)purine-l,3-dione Hydrobromide (14). 
The aminopentylpurine salt 11a (200 mg, 580 //mol) in 
water (8 mL) and dioxane (4 mL) was brought to pH 9.5 
by addition of aqueous Na2C03 (0.5 M). 5-(Dimethyl- 
amino)naphthalene-l-suIfonyl chloride (160 mg, 580 
.//mol) in dioxane (10 mL) was added. The mixture was 
stirred for 3 h. During this time, the pH was maintained 
at 9.5—10.0 by dropwise addition of aqueous Na2C03 (0.5 
M). The solution was neutralized to pH 7.0 by addition 
of hydrochloric acid (2 M). Water (25 mL) was added and 
the mixture was freeze-dried for 24 h to reveal an orange 
fluffy solid. The residue, in ethyl acetate, was washed 
with water and dried. The solvent was evaporated, and 
the residue was recrystallized (EtOH) to give 14 as a 
green-yellow solid (160 mg, 55%): mp 183-185 °C; NMR 
6 1.14 (2 H, quintet, J  = 7 Hz, CH2CH2CH2CH2CH2), 1.29 
(2 H, quintet, J  = 7 Hz, Cff2CH2N), 1.46 (2 H, quintet, J 
= 7 Hz, purine-CH2CH>), 2.76 (2 H, t, J  = 5.9 Hz, purine- 
CH2), 2.81 (6 H, s, NMes), 3.22 (3 H, s, NMe), 3.39 (5 H. 
m, NMe + CH2N), 7.24 (1 H, d, J  = 7.3 Hz, naphthalene
6-H), 7.58 (1 H ,tl(/= 8 .1  Hz, naphthalene 3-H or 6-H),
7.61 (1 H, d, -J = 7.7 Hz, naphthalene 8-H). 7.87 (1 H, t, 
«J = 7.9 Hz, naphthalene 6-H or 3-H), 8.08 (1 H, d, J —
7.3 Hz, naphthalene 4-H), 8.29 (1 H, d, -J — 8.4 Hz, 
naphthalene 2-H), 13.1 (1 H, br, purine-NH); MS (FAB) 
531.2020 (M + H) (C>4H3iN60 4S requires 531.2026).
Immunoassay. The FCFD devices were fabricated 
according to the method of Badley et al. (7). The lower 
base plate was activated with (3-aminopropyl)trimeth-
Technical Notes
Table 1. B ind ing  A ffinities of the 
T h eo p h y llin e -F lu o resce in  Conjugates 13a-d  to the  
A ntibody Im m obilized  in the FCFD Device
conjugate_______linker unit binding affinity K , (M*1)
theophylline (1) (0.06 ± 0 .02 ) x 10®
13a (CH2)5 (3.1 ± 1.5 ) x 10s
13b (CH2)s (1.4 ± 0 .6 ) x 10*
13c (CHjfe (3.2 ±  1.8 ) x 10*
13d CHaCXCHjfeCXC^h (1.0 i  0.4) x 10®
oxysilane. Anti-theophylline IgA mouse monoclonal an­
tibody was dissolved in HEPES buffer (0.1 M) containing 
NaCl (0.2 M) to a final concentration of 200 fxg mL-1. 
Aliquots of this solution (15 piL) were used for coupling 
of the antibody to the lower plate according to a car- 
bonyldiixnidazole method. The plates were then as­
sembled in the usual way. Solutions of the theophylline— 
fluorescein conjugates 13a—d were prepared in Tris-HCl 
buffer at pH 8.8. All assays using the FCFDs were 
performed in duplicate following incubation at ambient 
temperature for 20 min to ensure that the system had 
come fully to equilibrium. Total binding of 13a-d to the 
antibody was measured by incubating the FCFDs with 
concentrations of conjugates from 0 to 5 aM. Nonspecific 
binding of 13a—d to the antibody-loaded devices was 
measured in the presence of theophylline (1 mM). The 
specific binding isotherms were constructed by plotting 
(total fluorescence signal observed minus signal in the 
presence of excess theophylline) os concentration of 13a— 
d. From these plots (not shown) were obtained the 
binding affinities of each conjugate for the immobilized 
antibody (Table 1).
RESULTS AND DISCUSSION
Chemistry. Synthesis of 8-(2-aminoethyl)theophyIline 
has been reported (12) involving acylation of 5,6-diamino-
l,3-dimethylpyrimidine-2,4-dione (a relatively unstable 
compound) with //-protected 3-aminopropanoic add, fol­
lowed by cyclization under drastic conditions. We sought 
to develop a method that started with more readily 
available l,<u-diamines and which did not use vigorous 
conditions for cyclization. Fuchs et al. (12) have sug­
gested that treatment of 6-chloro-1,3-dimethylpyrimidine
(5) with l,ft>-diamines would give the products of l,eo- 
disubstitution. Thus, our initial approach involved set­
ting up a synthon for hexane-1,6-diamine, which is 
protected at one amine only. Exchange of protecting 
groups on the commercially available mono-Boc hexane- 
1,6-diamine (2) was achieved by benzyloxycarbonylation 
at the free amine to give the orthogonally protected 
biscarbamate 3, followed by addolytic removal of Boc in 
excellent yield. The Cbz protection in 4 was designed to 
survive the reaction conditions in later steps, which 
would cleave Boc. Substitution of the chlorine of the
6-chloropyrimidinedione 5 with the amine 4 was effected 
in boiling 1,4-dioxane in the presence of inorganic base 
to give 6a in satisfactory yield, as shown in Scheme 1. 
An attempt to raise the yield by use of re fluxing ethanol 
as the reaction medium gave only a small amount of 6a 
but encouraged substitution of chlorine by the solvent 
to give largely l,3-dimethyl-6-ethoxypyrimidine-2,4-di- 
one. Following the general method of Goldner et al. (13), 
nitrosation at C-5 of the pyrimidine was carried out with 
pentyl nitrite, in a reaction catalyzed by a small quantity 
of acid. Thermal cyclization/condensation of the brightly 
colored 5-nitrosopyrimidine 9a to the Cbz-protected 8-(5- 
aminopentyDtheophylline 10a was rapid and high-yield­
ing in boiling butanol. Deprotection using hydrogen 
bromide in acetic acid was virtually quantitative in 
furnishing the 8-(5-aminopentyl)theophylline salt 11a,
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which carries the required link and nucleophilic amine 
for attachment of electrophilically substituted fiuoro- 
phores.
Selective monoprotection of longer chain alkane-l.w- 
diamines, particularly 3 ,S-dioxaoctane-1,8-diamine. proved 
to be troublesome. However, by careful selection of 
reacting quantities and conditions, it proved possible to 
obtain good yields of the unprotected 6-(co-ami no( oxa )- 
alkylaminolpyrimidines 7b—d, which could be separated 
with difficulty from traces of the products of l.ey-disub- 
stitution. Nevertheless, direct reaction of the crude 
product mixture with benzyl chloroformate gave the 
easily purified Cbz-protected 6-[co-amino(oxa)alkylamino]- 
pyrimidines 6b-d. As before, the sequence of nitro­
sation, thermal cyclization, and deprotection furnished 
the required 8-{co-amino(oxa)alkylamino]theophylline salts 
l ib —d.
The aminoalkyltheophyllines I la -c  enabled study of 
the effect of the length of the link between hapten and 
fluorophore on the immunoreactivity of the final deriva­
tives, whereas comparison of these with the diether 
linked compounds derived from lid  indicated the im­
portance of hydrophilicity of the link.
Fluorescein has absorption and fluorescence emission 
maxima at wavelengths that are appropriate for the 
FCFD device, with a large Stokes shift and a high 
quantum yield. The 5-isothiocyanate or mixtures of the
4- and 5-isothiocyanates have frequently been used for 
fluorescent labeling of amino groups of biological mol­
ecules in aqueous media (15, 16). Fluorescein also 
confers aqueous solubility on its derivatives, a factor 
important for the target fluorescent theophylline deriva­
tives. To have a chemically defined system, the 5-isothio­
cyanate was used to thiocarbamoylate the amines 11a- 
d. It was found necessary to control closely the pH of 
the aqueous reaction mixture in the range 9.0 ± 0.2 to 
ensure that the amine was not protonated and that the 
isothiocyanate was not subject to base-catalyzed hydroly­
sis. To provide an alternative fluorescent derivative of 
theophylline for our studies with different wavelength 
maxima for excitation and fluorescence, 8-(5-amino- 
pentyl)theophylline (11a) was also coupled with dansyl 
chloride [5-(dimethylamino)naphthalene-l-sulfonyl chlo­
ride] under aqueous basic conditions, although this 
reaction tolerated a higher pH (9.5-10.0), owing to the 
lower lability of dansyl chloride to hydrolysis. The 
dansylaminopentyltheophylline 14 was formed in good 
yield.
The ‘H NMR spectra of the fluorescein—theophylline 
derivatives 13a—d were examined in solution in deute- 
riodimethyl sulfoxide. The signals for the xanthene 
moiety show considerable symmetry, in which H-l' and 
H-8' are magnetically equivalent, as are H-2' and H-7' 
and H-4' and H-5\ respectively. Most interestingly, the 
phenolic OH signal appears as a 2 H singlet at 6 10.2. 
confirming that the fluorescein is present in this solvent 
as the tautomer shown, rather than the lactone-opened 
carboxylate tautomer.
Straightforward syntheses of a range of 8-(<y-amino- 
(oxa)alkyl]theophyllines have been achieved, providing 
convenient access to fluorescent derivatives with applica­
tions in automated immunoassays for theophylline.
Immunoassay. The initial requirement of the study 
was to determine the antibody-binding affinities of the 
fluorescent theophylline conjugates 13a—d. and it was 
sensible to carry out these experiments on the im­
mobilized antibody within the FCFD by introducing the 
conjugates in solution to the FCFD in the presence and 
absence of excess theophylline. The FCFD reader was 
able to determine the relative intensity of surface fiuo-
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rescence, and the antibody-bound fluorescence was de­
termined by subtracting the nonspecific fluorescence, in 
the presence of excess theophylline, from the total 
fluorescence. Initial experiments were conducted to 
establish the equilibration time of the system, by record­
ing the total fluorescence at 30 s intervals over a 30 min 
period. Binding equilibrium was achieved within ap­
proximately 10 min, and a standard incubation time of 
20 min was adopted for further studies. Specifically 
bound fluorescence was plotted against concentration of 
each conjugate, according to the Langmuir equation, to 
allow determination of the binding affinities of 13a— d 
(Table 1). The binding affinity of theophylline could then 
be determined by competition with a fluorescent deriva­
tive, in this case with 13a (Table 1). The binding 
affinities of the conjugates compared well with that of 
theophylline, indicating that this antibody could tolerate 
substitution of theophylline at position 8. The affinities 
.were almost independent of the length ((CH2)s vs (CHo)9] 
or the hydrophobic/hydrophilic nature of the link [(CHjfe 
vs between the theophylline hapten
and the fluorophore. Compound 13a was identified by a 
small margin as being the conjugate of choice and was 
selected for further testing and development of assay 
procedures. Briefly, it was established that the fluores­
cent conjugates had the appropriate antibody-binding 
properties for development of an FCFD-based assay for 
theophylline, within a concentration range which would 
be useful for clinical use (0—300 /zM theophylline). 
Compound 13a was used at a concentration of 10~* M 
within the FCFD device, with low levels of interference 
from nonspecific surface-bound fluorescence. Theophyl­
line competed with 13a such that the signal recorded by 
the FCFD reader decreased from m axim um  to m inim um  
levels between theophylline concentrations of 5 and 500 
fiM. Precision was determined at theophylline concen­
trations of 25, 50, and 125 pM, the coefficients of 
variation being 6.5%, 6.0%, and 5.2% (within-assay) and 
8.0%, 7.5%, and 5.0% (between-assay), respectively. This 
concentration range corresponded to a useful clinical 
range, although the precision of the assay in estimating 
the concentration of theophylline was compromised by 
insufficient total fluorescence. This total fluorescence 
could be increased by immobilizing a higher mass of 
antibody to the bottom plate of the FCFD. Nevertheless, 
the FCFD devices studied here would be capable of 
distinguishing between low (5 pM) and high (250 pM) 
clinical levels of theophylline, which could be useful in 
acute conditions to establish whether a patient is pre­
senting with overdoise or underdose of theophylline.
Preliminary experiments were carried out to test the 
cross-reactivity of the system with other xanthine 
including caffeine, theobromine, and metabolites of theo­
phylline. Initial results suggested that the concentration 
of each xanthine required to displace 13a was at least 
100 times greater than that for theophylline. Thus, little 
interference can be expected from other blood-borne 
xanthines. It was also established that the assay worked 
as well in the presence of 5 mg mL-1 human serum 
albumin, with a slight loss of sensitivity presumably due 
to interactions between xanthines and albumin, which 
reduced the effective concentration of free xanthines in 
the FCFD.
Yahioglu et at.
The results of further studies on the development and 
validation of the immunoassays will be reported in full 
elsewhere.
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BIOLOGICALLY COMPATIBLE UNEAR 
BLOCK COPOLYMERS OF POLYALKYLENE 
OXIDE AND PEPTIDE UNITS
BACKGROUND OF THE INVENTION 5
a) Field of the Invention
This invention relates to block copolymers useful in 
diagnostic imaging, drag delivery, and as drags.
b) Information Disclosure Statement 10
Nalhen et al, Bioconjugate Chemistry 4 54-62 (1993)
discloses copolymers of lysine and polyethylene glycol 
prepared by reacting amino groups of lysine with acdvated 
ester derivatives of polyethylene glycoL The polymer is best 
described as a polyamide fanned by e-ammo and die ** 
cc-ammo of lysine.
Davis etaL,U-S.PaL No. 4,179,337 dated Dec. 18.1979 
discloses insulin coopied to polyethylene glycol or polypro- 
pcopyVcne glycol having a molecular weight of 500 to 
2QJOOO mntocufar weight
SDdaetal.U-S.PaL No. 3,441,326 issued Apr. 29,1969 
discloses N-catboxyanhyddde-based polymerization of 
polypeptide with polyethylene glycol, no examples of the 
preparation ate given. ^
British Patent 1,469,472 discloses low molecular weight 
polyethylene oxide immobilized proteins, said to have low 
imnamogenidly.
However; none of these references suggests a linear block 
copolymer having repeating units of an aDcylene oxide 30 
linked to repeating units of a peptide through a linking groop 
formed by the reaction of an amine precursor and an epoxide 
precursor. Moreover; the prior art teaches that aosstinlring 
(via amino acid side chains) often frustrates die linear 
copolymerization often sought The invention described 3S 
heron advantageously avoids such crosslinking.
SUMMARY OF THE INVENTION
The invention concerns a linear block copolymer cam- ^  
prising single or repeating units of polyfalkylene oxide) 
(PAG) linked to units of peptide. The copolymer can be 
tailored to produce water-soluble polymers which are stable 
in the blood rircnlatian but ultimately will be degraded to 
allow mare facile excretion of low molecular weight PAG ^  
derivatives in the urine.
In one aspect of the invention, the copolymer is a diag­
nostic agent, and/or a therapeutic agent and/or a targeting
are useful as imaging agents, prodrugs, drugs and drug 
delivery systems. Preferred copolymers are of the formula;
—(PAG)N(RX3H3tOHCH7OC^LCO(T,cpd<Je)NH(CH1)_C,H«OCH^CHOHCHjNtR}— ForsbU A
In another aspect of the invention, the copolymer is a 90 
chelating copolymer; having drug, and/or a prodrug and/or 
a chelating moiety attached to side chains of die peptide. 
Such moieties are useful in chelating metals, especially 
metals useful in diagnostic imaging of a body or tissues or 
as cytotoxic agents. ss
In another aspect the invention is a targeting delivery 
system for drugs and prodrugs.
In yet another aspect of the invention, the invention 
comprises the reaction of an epoxide and an amine to 
produce a novel polymer.
DETAILED DESCRIPTION INCLUSIVE OF 
PREFERRED EMBODIMENTS
We have discovered that linear block copolymers com- 69 
prising blocks of poiy<alkyiene oxide) (PAGs) and peptides 
attached via —CH2CHOHCH2N(R)— based linking groups
60
or
—(PAOX3tiCHOHaV<CRX3t^ XXPepcide)NH(CHJ_NHOO CHxNR CH2CHQHCH2— Formal* B
whsein 
R is a 1-4 carbon alkyl; and 
p is from 1 to 6 and the peptide is preferably Gly-Phe- 
Leo-CHy or Lys-Gly-Pbe-Leo-Gly.
The compounds can be tailored far specific nses by 
afauing the size of the polymer or altering the peptide 
composition to provide differing blood pool residence tin**- 
enzymatic breakdown rates, and tisane distributions.
As an wMging agent, said composition preferably has a 
molecular weight of at least about 5000 and a metal km 
useful as a contrast enhancer, fluorophore or x-ray opaque 
ion associated therewith, and thus snitahle for use as an 
for diagnostic rnwgtng 
An imaging metal is defined as a metal useful in x-ray 
imaging or a metal useful in magnetic resonance imaging, 
preferably a paramagnetic metal and more preferably a 
irwfal or fran<ifinn mwal] OT a mwfal useful in 
fluorescence imaging, preferably a lanthanide metal, most 
preferably Europium.
This invention farther provides a method of performing a 
ftiagrv>ctTfr imaging pmrwinpn in & body ffnmpri«ing »<imin­
istering to the body a contrast enhancing amount of the 
polymer described above, and then exposing the body to a 
magnetic re*mignr»» measurement step to image at least a 
portion of the body.
It is a particularly advantageous feature that the polymeric 
chelates of tins invention provide effective imaging cootzast 
rnhxrm-mmi of the Hood pool within the viscalar system 
for remarkably long periods of time.
It is advantageous feature of invention that
polymeric enrapnmwfo are provided having a specificity 
toward accumulation in different tissues, for example, in 
tumors and the tivex.
As used herein, FAG refers to poly aDcylene oxide moi­
eties having a angle type of repeating unit or differing 
(non-repeating) of alkyleoe oxide, or a mixture, thereof
in each PAG. Each aDcylene oxide unit in the PAG contains 
from 2 to about 4 carbons, linear or branched. Poly(alkylene 
oxide) units in the polymer may also differ in length and 
composition from each other. Exemplary PAG moieties 
include polyethylene oxides), polypropylene oxides) and 
poiybotylene oxides). Preferred PAG moieties indude 
polyethylene oxides), polypropylene oxides) and random 
and block copolymers thereof. Polyethylene oxide)-con- 
taining polymers are particularly preferred when it is desired 
for die final polymer to possess solubility in water. It is also 
contemplated that the polyalkylene oxide) moiety can com­
prise glycerol polyalkylene oxide) triethers, polyglyddols, 
linear, block and graft copolymers of aDcylene oxides with 
compatible comonomers such as poiypruplene oxide-co- 
ethylene oxide), or polyfbutylene oxide-co-etbylenc oxide) 
and grafted Mock copolymers. These moieties can be 
derived from polyalkylene oxide) moieties which are com­
mercially available or alternatively they can be prepared by 
techniques well known to those skilled in the art. A particu­
larly preferred dass of polyalkyleneoxide moieties derived 
from polyethylene oxide) can be represented by the struc­
ture:
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wherein m is 1 to 750. The preferred length depends upon 
the desired molecular weight.
These PAG moieties and their reactive derivatives, useful 
in preparing the polymer of the invention, are known in the 
art. For example, brsCmethyl amino) polyethylene glycol and 
its nse as an intermediate in the preparation of block: 
copolymers is known in the art, for rumple; Mutter; Tfct- 
xahedran Letters. 31,2839-2842 (1978) describes a proce­
dure to convert the terminal hydroxyl grocps of poly(eth- 10 
yleneoxide) to reactive primary ammo groops as w£l as the 
preparation of a number of reagents bound to poly(etbyl- 
encoxide) amines; Harris et al, J. Polymer. Science, 22, 
341-352 (1984) describe various PAG derivatives including 
for example, amino poly(etbyicaooxide). O tto PAG deriva- is 
tivcs are prepared by known chemistries examples of which 
are described faerehibelow.
As nsed herein, peptide refers to an anrino add chain of 
a: least 2 amino adds, wbexein each of the amino adds in the 
peptide may or may not be all the same, and may or may not x  
aD be select from the 20 naturally occurring I-anrino adds, 
but D-amino arrifidal or anrino
add derivatives, snch as glnramare esters, lyxyl(e-ammo)a- 
and ihe w* This definition pn<wn<
polypeptides and oligopeptides, which are ait recognized 
anrino add chains. Specifically contemplated preferred pep- 25 
tides include small enzymes (less than 100 kd), peptide 
hormones, peptide recognition domains, peptide drugs, and 
peptides with known enzymatic breakdown rates.
Certain abbreviations appearing in the text and schemes 
are here defined: Boc refers to the art recognized t-butoxy 30 
carbonyl radical commonly nsed as a blocking agent in solid 
phase peptide synthesis. Convestiooal three tetter abbrevia­
tions for anrino add residues are used throughout the 
specification. OPFP refers to pentafloorophenyioxy; Bn 
refers to benzyl; CBZ refers to pheaylmethoxycarboayl; 35 
OTCP refers to 2,4 -^trichloropheuyloxy; Troc refers to 
2^ 2-tzichkKoethoxycarbanyL
Copolymerizatian can occur by reaction of bis(oxixanyl- 
)derivadves (also known as bis(epaxides)) with bis(amino or 
alkylamrno) derivatives (also known as bis amines). There 40 
are no by-products of the polymerization reaction. The 
monomer units of PAG and peptide can be prepared as either 
bis(oxiranyl) derivatives or bis(amino) derivatives provided 
that the reaction producing the copolymers is between an 
amine and an-epoxide. Therefore there are two chemical <5 
strategies for preparing products of the invention described 
herdnbdow. As a consequence of reacting bisammes with 
bisepoxides the sense of the PAG and peptide units can be 
reversed.
The polymer of the invention has between its PAG and so 
peptide subunits, a linking group. The linking group con­
tains a —Q^CHOHCHjNCR)— diradical, typically 
derived from die reaction of an amine and an epoxide. It is 
preferred that a biscpoxide stibunit be reacted with a
hi«rniinff Thft sKllM artican will oppnrriafr that (hi» 55
recitation used throughout the specification of each type of 
linking group diradical can be reversed and have the samrt 
meaning. Thus the sense of the linking group can be reversed 
(end for end), with one terminus attached to the PAG moiety, 
and the other terminus attached to the peptide or vise versa, 6 0  
while its recitation in the specification and the claims is the 
same.
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Peptides used to prepare die invention can be prepared by 
standard procedures known in the art Usefol peptides 
indndc those derived from native or recombinant organ­
isms, solid phase peptide synthesis or traditional wet chem­
istry prpfvfr synthesis and the like. Each of these peptide 
preparation -nyrtvvtc are weQ known in the art and use 
conventional, known materials Protein egression and puri­
fication from natural and recombinant sources is in die prior 
art (cf. Protein Expression and Purification (1990); Harris et 
aL, Proton Purification Methods (1989); Deutscher; M. P. 
Guide to Proton Purification Methods in Enzymology, VoL 
82 (199(0). Peptide synthesis is also known in the art (cf. 
Atherton, et aL, Solid Phase Peptide Synthesis a Practical 
Approach. Oxford University Press (1989)). Thus, the pep­
tides are easily prepared by known chemistry.
linear peptide fragments can be tailored such that they 
are stable in blood, but are susceptible to lysosomal degra­
dation by commonly occurring proteases. Examples of sus­
ceptible peptide units are gly-phe-leu-gly, gly-phe-tyr-ala, 
ala-gly-val-phc, gly-pbe-ala-gly, and others known in the 
art The prior art describes such oligopeptides as useful in 
preparing prodmgs, when the drug is attached to one tenni- 
nus of the oligopeptide. (See generally “Polymers Contain­
ing Enzymatically Degradable Bands” MakmmoL Chem. 
184 (1983) R. Duncan. H. C Cable. J. B. Lloyd, P. 
Rqmaaov’a snd J. Kopecek, in Polymers containing enzy­
matically degradable bonds, 7. Design of oligopeptide side- 
chains to promote efficient degradation by lysosomal 
enzymes, MakmmoL Chem, 184, p. 1997-2008 (1983); and 
P. Rejmanova. J. Kopecek, J. PohL M. Bandys and V. 
Kostva, in Polymers containing enzymatically degradable 
bonds. 8. Degradation of oligopeptide sequences in N-{2- 
bydroxypropyl)methaayianride copolymers by bovine 
spleen cathepsin B, MdhvmdL Chan. 184, p. 2009-2020, 
(1983).) In this invention it is contemplated that prodrugs 
ram be tO frmfliemalmA side ehairre of the
rather than the terminus of the peptide.
The* concept of drug targeting has gained importance in 
recent years, especially for anticancer drugs, inasmuch as 
toxic side effects of anricancer drugs to normal cells are a 
primary obstade in cancer chemotherapy due to lack of 
selectivity of the anticancer drugs to cancer cells. In the prior 
art, drug targeting has been accomplished by drug conjuga­
tion with large antibodies, or encapsulation in a transporter 
specific to the target. Materials such as proteins, saccharides, 
lipids and synthetic polymers have been used for such 
transporters. Antibodies have been perhaps most widely 
used due to their target specificity and wide applicability. 
However; these methodologies have not been commercially 
exploited because the prohibitive cost of the transporter or 
targeting agent which can be used to target only one type of 
cell or tissue.
The peptide portion of the polymer can be tailored to 
recognize (or target) certain cells or functions of cells. 
Because the polymer can use more than one peptide and thus 
more than one type of peptide, the polymer can advanta­
geously target more than one type of cell or tissue at once. 
Judicious choice of peptide allows treatment or targeting of
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more than one type of cell, for example, or other 
disease state. Tins choice is facilitated by the prior ait wUdi 
contains a myriad of known oligopeptides which ate anti­
genic to certain cells. Itmhcnnotc. die invention allows 
such targeting without the cost of coring antibodies to 5 
certain cells, harvesting TtriVidie^  conjugating anti­
bodies to drug and farther taring for maintained specificity 
after conjugation. The invention allows specific targeting to 
be achieved by short nscngnirinn sequences. Cell specific 
delivery can be achieved by incorporating targeting agents to 
into the polymer Preferred peptides are those which have a 
receptor molecule specific to a ligand of interest. Thus, a 
specific binding reaction involving the reagent can be used 
for the targeting expected.
Depending npon the intended use, the peptides can be 15 
selected fiom a wide variety of naturally nermring or 
synthetically prepared materials, mdodtng. for. example 
enzymes, proteins, peptide hormones, virus coats, or pro­
teins derived fiom blood components, tissue and organ
ennipnnw<t| tnrfnriifig mritwfief genie pro- 20
m'mcreios materials, or fragments of any of these and others 
known to ooe skilled in the art.
Examples of these targeting peptide* mrlnde- the integrin
binding motif RGDS (aig-gly-asp-ser), which is present on 
many extxacdhxlar matrix proteins and can be used to 25 
interfere with cell adhesions involved in migration of leu­
kocytes. Other peptide sequences which can be used to 
deliver the polymer mdndr. cationic sequences (ie. rich in 
lys or axg) which are useful in producing a DNA-binding 
polymer for nse in soprcsrion of gene expression, antisense 30 
oligomer deEvery and the tike; peptide hormones such as 
aMSH which can be used for targeting to melanoma; and 
relatively low molecular weight (15-20 kDa) engineered 
hypervariable antibody binding domains (Vjv+Yl con­
structs) raised against any target. Soch sequences are 35 
obtained synthesis, isolation from cells or bacteriophages 
or they can also be raised against cells, proteins, or foreign 
snhstanrcs in a host. Common hosts for raising recognition 
sequences indude rabbits, goats, mice, and the like. These 
and otier methods of obtaining recognition sequences are 40 
known m the art.
In certain embodiments, the above-described peptide can 
be an hnmnnoicactivc group, which would be found in a 
living organism or which finds utility in-the diagnosis, 
treatment or genetic engineering of cellular material of 45 
living organisms. The peptide has a capacity for interaction 
with another component which may be found in biological 
fluids, cells or associated with cells to be treated or imaged, 
such as, for example tumor cells and the like.
Two highly preferred uses for the polymer of this inven- so 
tion are for die diagnostic imaging of tumors and the 
treatment of tumors. Preferred immunoreactive groups 
therefore indude antibodies, or immunoreactive fragments 
thereof, to tumor-assodated antigens. Specific examples 
include B723 antibodies (described in U.S. PaL Nos. 4,522, 55 
918 and 4,612^82) which recognize colorectal tumors, 
9J2J21 anti-melanoma antibodies, D612 antibodies which 
recognize colorectal tumors, UJ13A antibodies which rec­
ognize small cell lung carcinomas, NRLU-10 antibodies 
which recognize small cell lung carcinomas and colorectal 60 
tumors (Pan-carcinoma), 7E11C5 antibodies which recog­
nize prostate tumors, GC49 antibodies which recognize 
colorectal tumors. TNT antibodies which recognize necrotic 
tissue, PR1 A3 antibodies, which recognize colon carcinoma. 
ENG-1 antibodies, which arc known in the art and are 65 
described in International Patent Publication WO-A-9Q/ 
02569, B174 antibodies which recognize squamous cell
6
eMritvwniw, B43 antibodies which are reactive with certain 
lymphomas and lcukrmiits and any other antibody which 
may be of particular interest.
Because the peptides of the polymer are linear. they can 
provide functional groups for coupling of diagnostic agents, 
drags, or prodrags or other targeting moieties by the side 
chains of individual amino adds found in the peptide portion 
of the backbone. fimctioual groups can also be by
rraetfng nr iferivariwng ftrnrtinmtiwKk gqytpc (fnwvt
for example in lyxyi or argininyl residues) or addle groups 
(as found in aspartate, glutamate, providing free carboxyl 
groups), or sulfbydiyl groups, (e.g. cysteine), hydroxyl 
groups (such as foimd in serine) and the Eke. This coupling 
is done by standard peptide chemistry known in the art.
Cytotoxic drags can also be coupled to the polymer to 
produce prodrogs which are released as a drag to targeted 
cells or tissues. Such coupling methods are known in the art, 
see fix example; Dunam. P. Kqpeckova-Rejmanova, J. 
Strohalm. L Hume, H. C Cable, J. Pohl, J. B. Lloyd and J. 
Kopecek (1987) Anti-cancer agents coupled to N-(2-hydrox- 
ypropyDmethacrylamide copolymers. L Evaluation of 
dannomycin and puromytin conjugates in vitro. British J. 
Cancer;55:165-174. R. Duncan, P. Kopeckova, J. Strohalm, 
L Home. J. B. Lloyd and J. Kopecek (1988) Anti-cancer 
agents coupled to N-{2-hydroxypiopyi)nirthacryiainide 
copolymers IL Evaluation af dannomycin conjugates in 
vivo against LI210 lcnkacmia. British J. Cancer. 
57:147-156. Drugs contemplated to be useful include any 
drug winch can be covalently attached to the polymer and 
retains its activity when so attached. It is contemplated that 
drags winch become active only when liberated fiom the 
polymer are also useful, and as such are prodrogs.
Drags which are contemplated to be useful in the polymer 
indude cytotoxic agents, and iTmnnnomodulating peptides 
and proteins as described above.
By *kytotoxic agent”, it is meant any agent able to kQl
drUgS cytotoxic anfiVnnrif*. anri
toxins or any agent which initiates or which leads to cell 
death. The term cytotoxic agents also includes agents which 
activate a host's immnne response leading to cell death The 
cytotoxic agent will be selected with reference to factors, 
such as the type of disease state, for example the type of 
cancer tumor and the efficacy of a certain chemotherapy 
agent for treating the cancer tumor involved, and the like. 
The cytotoxic agent may be selected from alkyiafiig agents, 
antimetabolites, natural products useful as cytotoxic drags, 
hormones and antagonists and other types of cytotoxic 
compounds.
Examples of alkylating agents indude the nitrogen mus­
tards (Le. tiie 2-chloroethylanrines) such as, for example, 
cbloromethine, chlorambucil, meiphaian. utamustine, man-
nrmmxfrne, extranm<rine phntphate, iwrh1nr.thammnxiA»-t
ryrtnphfKp>i«mifVt ifosamidc trifhsfamirie- alkylating 
agents having a substituted aznidine group' such as, for 
example, tretanrinc, tinotepa, triaziquone and mitomycin; 
alkylating agents of the alkyl sulfonate type, such as, for 
example, busulfan and piposulfan; alkylating N-allcyl-N- 
rtitrosourea derivatives such as, for example, canuustine, 
lomustine, semnstine or streptozotoane; alkylating agents of 
the nritobronitole, dacarbazine and procarbazine type; and 
platinum complexes such as, for example, dsplatin and 
carboplatin and others.
Examples of antimetabolites include folic add derivatives 
such as, for example, methotrexate, aminopterin and 
3a-dichloromethotroxate; pyrimidine derivatives such as, for 
example 5-fluorooracil, floxuridine, tegafur, cytarabine. 
idoxuridine, and flucytosine; purine derivatives such as, for 
example, mercaptopurine, tirioguamne, azathioprine, tiami- 
prine, vidarabine, pentostatin and puromycin and others.
5,618328
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Examples of natural products, useful as cytotoxic agents
fnrliiHft for i-ramplc vity-j glhlnirft, mrii «  vinblastine and
vincristine; cpipodophykxoxins such as. for example, eto- 
posdde. and tcniposidc; antibiotics such as, for example,
aHrimyr4nl Anmr»myr4w itflwnwnitnrin, Avgft- 5
rubidn, muhnunydn, bleomycin and xmlomydn; enzymes 
such as, for example, L-asparaginase; biological response 
modifiers such as, for example, alpha-interferon; camptoth- 
edn; taxol; and retinoids snch as retinoic add and foe like. 
Examples of hormones and antagonists indude adreno- 10 
corticoids, such as, for example, prednisone; progcstins, 
such as, fiar example, bydroxyprogesterone acetate, medrox­
yprogesterone acetate and megestrol acetate; estrogens such 
as, for example, tficthylstiThestrol and edanyl estradiol; 
antiestrogens such as for example, tamoxifen; androgens is
oirh for jrryiwmtf th4 fljjgjyjjjg.
strone; antiandrogens such as, for example, and
gonadotropin-releasing hormone analogs such as, for 
example,
Examples of miscellaneous cytotoxic agaits include 2 0
i nth r « w »!Hin n ^  tn r f i  an f o r  f w mp k j  m itn r i n t m n r  ynK .
sdtuted ureas such as, for example, hydroxyureas; and 
■dnwinnnrtirai suppiessaiits as, for example, mitotane
and ammogbtetbimide. The cytotoxic agent can be ionically
a w v i a t r d  w ith  tH» rh ria fw lg  n t iA v -  V re  i - re m p ]r  in  p m .  2S
fenced embodiments, die cytotoxic agent is a radionuclide 
comprising a radioactive metal ion such as described bdow 
associated with a pyMftJmWri chelating residue. The 
polymer of tbe invention can contain one or mote of a wide 
variety of chelating agents. As is well known, a chelating 30 
agent is a compound enntaining donor atoms that can 
combine by coordinate bonding with a cation to form a 
cyclic structure called a chelation complex or chelate. This 
class of compounds is described in the Krk-Othmer Ency­
clopedia of Chemical Technology, IfoL 2,339 -368. 35
Chelating residues may also be attached via die function- 
alizahle side chains of the peptide via known chemistry. 
These chelating residues can be coupled to tbe polymer to 
produce contrast agents useful in diagnostic imaging or 
cytotoxic agents when complexed with the appropriate 40 
metal. The chelating residue is attached to an available 
amino arid side chain in foe peptide portion of the polymer 
by a protein reacting group. By “protein reactive group" it 
is meant any group which can react with any functional 
groups typically found in proteins, especially an amino arid 45 
side chain.
Preferred protein reactive groups can be selected from but 
are not limit™* to:
(1) A group that will react directly with tbe amine or 
sulfhydiyl groups on an amino add side chain. For example, so 
active halogen containmg groups including, for example, 
chlaromethylphenyl groups and chloroacetyl [Q— 
CHzCO—] groups, activated 2-lcaving-group-substituled 
ethylsulfonyl and ethylcarbonyi groups such as 2-chloroet- 
hylsulfonyl and 2-chloroethylcarbonyl; vinyisulfooyl; vinyl- 55 
carbonyl; epoxy; isocyanato; isothiocyanato; aldehyde; 
aziridino; succinimidoxycarbonyl; activated acyl groups 
such as carbaxylic add halides; mixed anhydrides and the 
like; and other groups known to be usefol in attaching 
molecules to proteins or crosslinking proteins and tbe like. 60
(2) A group that can react readily with modified proteins 
or similar biological molecules modified to contain reactive 
groups such as those mentioned in (1) above, for example, 
by oxidation of the amino add side chain to an aldehyde or
a carboxylic add, in which case the “protein reactive group” 65 
can be selected from amino, alkylamino, arylaroino, 
hydrazino, alkylhydrazino, arylhydrazrno, carbazido. semi-
e-aihetnAn thiocarbazido, tlrioscaricarbazido. sulfhydryl, 
sulfhydiylalkyl, sulfhydrylaryl, hydroxy, carboxy, carboxy- 
alkyl and carbaxyaryL The alkyl portions of the protein 
reactive group can contain from 1 to about 18 carbon atoms 
as described far R drove. The aryl portions of the protein 
reactive group can contain fiom about 6 to about 20 carbon 
atoms.
(3) A group that can be linked to the amino add side chain 
or similar biological molecule, or to the modified peptide as 
noted m (1) and (2) above by use of a cxosslinldng agent. 
Certain useful crosrimking agents, such as, for example, 
riifunctional gelatin hardeners, bisisocyanates etc.. which 
became a part of a  linking group in the polymer during the 
crnsrimking reaction. Other useful crosslinking agents, snch 
as, for example, consumable catalysts, are not present in the 
final conjugate. Frampii^ e of snch czosslinlting agents are 
carbodmmde and caxbamoylomum aossliriking agents as 
disdosed in U.S. PaL No. 4,421,847 and the dication ethers 
of ILS. PaL No. 4,877,724. With these aossfinkmg agents, 
one of die reactants mnst have a carboxyl group and foe 
other an amine, alcohol, or snlfhydryl group. The crosslink­
ing agent first reacts sdectivdy with tbe carboxyl group, 
then is deaved during reaction of the “activated” carboxyl 
group with, for example, an amine to farm an amide linkage 
between the peptide portion of the polymer and metal 
complexing agents, thus covalently bending the two moi­
eties. An advantage of tins approach is that crosslinking of
KVff mrfcmW, r g ( *nwm rfiari* vrifh amino ariA
fluimt nr mmplwrfng iigwift nnth cnmjJrrring igwin w
avoided, whereas tbe reaction of rii functional aosstinking 
agents is less selective. Especially preferred protein reactive 
groups inrJnde amino and isothiocyanato. Preferred chelat­
ing agent precursors have anhydride, snlfonylylchl pride, 
alkylsulfatc. vinyl sulfate, or ester functiooalkyL 
The residues can be .derived fiom chelating
moieties which are selected to contain electron donating 
atoms which will chelate a metal, by farming coordination 
bonds therewith. These moieties can be selected fiom poly­
phosphates, snch as tripolyphosphate and hexam-
acid;
aminocarbaxylic adds, sudi as cthylencdiaminetctra-ace- 
tic add, N-(2-hydroxycthyI)ethylcnediaminetriacetic add, 
nitrilotriacetic add, NN-di^ -hydroxyethylJglycme, ethyl- 
enebis(liydTaxypbeaylglyrine) and diethylenetriamine pen- 
taaceticadd;
13-<fikctooes. such as acetylacetone, trifluaroacetylac- 
etone, and tiieaoyltriflnoroacetone;
hydroxycarboxylic adds, such as tartaric arid, attic acid, 
gluconic add, and 5-suIfosalicylic add;
polyamines, such as etiiylenedianrincrdiethylenctriamine, 
trietirylenetetramme, and triaminotriethylarnine;
aminoakohols. such as triethanolamine and N-(2-by- 
droxyethyI)etbylenediamine; 
aromatic heterocyclic bases, such as 2,2'-dipyridyl^ 2,2'- 
rfipimtirv* ominr invt 1,10-pbenanthroline; 
phenols, such as salicylaldehyde, disulfopyrocaiechol, 
and chromotropic add;
aminophenols, sudi as 8-hydroxy quinoline and oxine- 
sulfonicadd;
oximes, such as dimetbylglyoxime and salicylaldoxime; 
peptides containing proximal chelating functionality sudi 
as polycysteine, polyhistidine, polyaspartic add, poly- 
glutamic add, or combinations of such amino adds;
Sdtiff bases, such as disalicylaldchyde 1,2-propylcncdi- 
inunc;
tetrapynoles, sudi as tetraphenylporphin and phthalocya- 
nioe;
5 , 6 1 8 , 5 2 8
1 0
sulfur compounds, such as tolucncriirhiol. meso-2 3 - 
dimercaplosuccmic /tiny»rn»ptnpmpannl ihioglycolic 
Heir! potassium ethyl
ate, dithizone. diethyl dithiophospboric add, and thiourea;
synthetic macrocylic compounds, such as dibenro[lS] 
crown-6 , (C H ^ f^ ^ .ll-f te n e -N ,,, and (2 i 2)-ayptate; 
and
phosphonic adds, sudi as nitrilotrirnethylenepbosphonic 
add, ethylcnedianrinrtfltrafmethylcoephosphcmic add), and
in PCT/US91/08253, and many other readily available ref­
erences.
If the chelating residue is made of multiple chelating 
moieties or sohonits, such subunits can be Knkcd together by 
a linlnng group. Thus, more than one cheating moiety can 
be used to make up the chelating residue. If more than one 
chelating moiety is present in tbe chelating residue, these 
may be the same or different Chelating moieties can be 
linked together using known chemistries. Thus the chelating 
residue can be one moiety or a “core” of chelating moieties.
hydroxyethyiidenediphospfaonic add, or combinations of 10 For example, a core of DTPA residues may be prepared by 
two or more of the above agents.
Preferred chelating residues contain polycartxxxylic add 
or carbaxyiatc groups and indude elements present in: 
cthylfnwfiamine-N. N. N’.N'-tctiaaretic add (EDTA); N J s , 
bTjr^-fiethylenetriaminepentaacetic acid (DTPA); 1,4,7,
10-tctraazacydododecane-Njr.N" ,N“ -tetraacetic add
(DOTA); 1.4.7.10-tctraazacydododccane-hU^,N"-triacetic 
add  (D03A); l-oxa-4,7.10^riajacydododecane-N^*JT- 
triacetic add (OTTA.); trans(L2)-cydohexanodietbyleaetri- 
amine pentaacctic add (CDIPA);
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Such chelating compounds, including their preparation 
and manipulation are well known in the art. For example, the 
add and anhydride forms of EDTA and DTPA are commer­
cially available; methods for preparing B4A, P4A and TMT 
are described in U.S. Pat. No. 4,859,777; the disdosure of 65 
which is hereby incorporated by reference; and other suit­
able chelating groups arc known in the art, and are described
reacting DTPA dianhydride with a diamine, such as ethyl­
ene rfjaminf, to form a “core" of DTPA chelators. Other 
rtwlirffng residues, np of multiple fhrfntmg Tnni^tifs 
are well known in the art and are prepared by known 
chemistries as well.
For Tnagiv-rir mtmMivr imaging applications, M*"*1 pref­
erably represents a paramagnetic metal ion such as an ion of 
rrv-f-alr of fn tn ir mitnhw 21 ID 29, 42, 44 and 57 tO 71, 
especially 57 to 71. loos of tbe following metals are pre­
ferred: Cr, Y, Mn, Fe, Co, Ni, Cu, Ce, Pr, Nd, Pro, Sin, Eu, 
Gd, Tb, Dy. Ho, Er, Tm and Yb. Especially preferred arc 
Cr"3, Cr"2. V"2. Mn"3, Mn"2, Fe"3, Fe"2, Co"2, Gd"3 and 
Dy"3. It is a particularly advantageous feature that polymers 
can be provided exhibiting a high substitution ratio, Le., 
containing relatively large numbers of paramagnetic metal 
ions per molecule.
Tbe  cytotoxic agent can be a radioactive isotope, prefer­
ably a radioactive metal ion isotope. This radioactive metal 
isotope can be an ion of an isotope of a metal selected, for 
example, from Sc, Fe, Fb, Ga, Y, Bi, Mn, Cu, Cr, Zn, Ge, 
Mo, Tc, Rn. In, Sn, Re, Sr. Sin, Lu, Du, Sb, W„ Re, Po, Ta 
and T1 ions. In a prcfercd embodiment, radioisotopes which 
are also w f u l in diagnostic imaging applications are spe­
cifically contemplated. Thus this embodiment finds utility in 
imaging and therapy where either procedure can be per­
formed in conjunction with or ancillary to the often Pre­
ferred isotopes of radioactive metal ions for this embodi­
ment in rfn^  ~Sc, 64-S7Cu, m In, 212Pb, “ Ga, * X  “ Sm, 
212Bi. **"Tc and 1#*Re for therapeutic and diagnostic imag­
ing applications.
If a  metal is chelated by the polymer, as for example, in 
imaging or therapy as described above, the metal content in 
the polymer can vary from about 0.1 up to about 20% based 
on tbe total weight of tbe polymer. For example in a 
magnetic Tranramnt imaging embodiment, the polymer pref- 
erably contains a paramagnetic metal ion in an ammmt of 
from 1 to 25%, more preferably 2-20% by weight. In a 
therapeutic embodiment the radionuclide metal ion is 
present in roughly the «anv amounts as for imaging
The PAG moiety in tins composition can be capped at tbe 
terminus with a capping moiety selected from a hydrogen, 
hydroxy, alkyl, amine, or ilknxy. Preferred capping groups 
are hydrogen or hydroxyl groups. Thus capping is done by 
known chemistry, and precapped prepolymers are available. 
It is further contemplated that cyclic copolymers can be 
prepared.
Tbe compositions of this invention can be prepared in 
water-soluble, water-dispersible or water-insoluble forms 
depending upon the intended application. The composition 
can have a molecular weight ranging from 10,000 to 1 
million preferably 11,000 to 80,000. The preferred molecu­
lar weight varies according to the application as described 
below.
In addition to targeted delivery of the polymers of the 
invention, the polymer can be selectively delivered to spe­
cific cells, tissue types, or organs with or without the aid of 
a targeting agent. When no targeting agent is used such 
targeted delivery is based on size (hydrodynamic radius) and 
charge alone. The charge of the polymer can be altered by
5 ,6 1 8 ,5 2 8
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judicious choice of the uyd in the peptide
component of die copolymer to the application. Of
course, the size of the polymer can be chosen by altering tbe 
size of PAG or peptide used to prepare tbe polymer or by 
altering the degree of polymerization.The mechanism of the s 
targeted delivery of polymer is thought to be based npon tbe 
pasnvebiodistribation in tissues of the polymcn It is thought 
that this passive hiodistribution cm occur became the PAG 
component of tbe polymers allows fiee distribution of the 
polymers within tbe circulatory system, with low antigenic- to 
ity or without interference by the mononuclear phagocytic 
system. Unlike hydrophobic polymers known in the art, 
which are taken up by tbe wrirnVynrfnriyKai system, the 
polymers of the invention can be designed to be distributed 
to tissues without being metabolized. Thus die size and is 
charge of the poj}mer-aHhe-tissue is a function of the size 
and ehaiye of the polymer «dnwni«tMgt! nfrrrihttriup th* 
unmetabolized polymer to tissues will be influenced by the 
nature of the local vascular endothelium in each tissue and 
the ptcscence or absence of a lymphatic system. Three 2 0  
general n of vascular ^ wdnthdmm ue «mn«fHdai 
epithelium, characterized by and littie or no
basement membrane; fenestrated vascular cndothelinm; and 
continuous vascular endothefinm, characterized by tight 
junctions and basement membrane.The lymphatic system is 25 
known to xedrculate proteins and other molecules which can 
float freely in tbe plasma, but escape the circulatory system, 
exist for a time in tissue and then are returned to the 
circulatory system via the lymphatic system. The skilled 
artisan can determine which tissues will be passively tar- 3 0  
geted by the polymer by approximating the mni<iraiar 
weight or more preferably the hydrodynamic radius of 
known proteins diffusing through the tissue in a known 
given period
Tissues sudi as bane marrow, Hver and spleen tissue are 35 
characterized by sinusoidal endothelium, (which allows 
escape of large molecules fiom the circulating system into 
the surrounding tissue) thus larger polymer molecules are 
useful in passively targeting such tissues. Tissues such as 
found in the GI tract, kidney glomeruli, and endocrine gland 40 
titoif jre rilarartmrfd by wiHntMiimi (which
allows escape of smaller macromolecules fiom the circula­
tory system), thus slightly smaller polymer molecules are 
useful is passively targeting sacfa-tissues. Tjgw* such as 
musdc and hmg tissue are characterized by continuous <5 
vascular endothelium (which allows small molecules to 
escape fiom tbe circulatory system into tbe surrounding 
tissue), tints smaller polymer molecules are useful in pas­
sively targeting these tissues.
For example, the hydrodynamic radius of albumin is so 
approximately 37 A, its molecular weight is 67 Kd, and its 
charge is known. It is known that the average half life for 
albumin circulation through tissue is approximately 24 
hours, but this half life is longer in some tissues and shorter 
in others. Moreover; the concentration of albumin in certain 55 
tissues is appreciable and in other tissues albumin is nearly 
absent altogether. The skilled artisan can prepare a polymer 
of approximately the same size, or preferably the 
hydrodynamic radius and charge, and expect a similar half 
Efe and concentration in tissues.
The skilled artisan will recognize that inflammation of 
tissues will perturb the normal physiology of that tissue and 
thus the half life and concentration of macromolecules, such 
as proteins or the polymer of the invention, in an mflanwd 
tissue or inflamed tissue site. Thus the polymer finds utility 65 
in imaging and/or treating sudi inflamed tissues or inflamed 
tissue sites.
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The drilled artisan will also appreciate that tiie absence of 
a lymphatic system in a tissue vriil perturb tbe coDcerrtratioo 
and the half life of macromoleculcs in a tissue
hwwwr. no convenient mechanism is provided far the scav­
enging of such macromolecules. Such is the case in growing 
tumors. One can deliver a cytotoxic agent, a pro-drug, or an 
imaging moiety to the growing tumor surface based on size 
of the polymer and on vasculature of the surrounding 
targeted tissue as described above. Thus doting a cytotoxic 
agent will result in accumulation of such agent in the 
growing surface of the tnmoc 
Thus molecular weight and charge of tic polymer may be 
tailored to tbe sperific application based on tissue type, 
presence or absence of inflammation, tumor and/or vascu­
lature type and presence or absence of a lymphatic system to 
provide a polymer with the correct characteristics for tar­
geting the desired tissue.
Tbe general synthetic methods far production of linear 
alternating polymers follow two related schemes (A and B) 
involving the reaction of a bis-(methyixmiso>-mononier 
with a bis(axiranyt)-manomer described bekm. Compounds 
of the invention are prepared by chemical transformations 
winch are conventional and known to those skilled in tbe art 
of fiwjwiofy Furthermore, known transformations can be 
used for effecting changes in functional groups in the 
polymer or compounds used in preparing the polymer of the 
invention. For example, acylation of hydroxy- or amino- 
substituted species to prepare tbe corresponding esters or 
amides, respectively; simple aromatic and heterocydic sub­
stitutions or displacements; cleavage of alkyl or benzyl 
ethers to produce the corresponding alcohols or phenols; and 
hydrolysis of esters or amides to produce the corresponding 
adds, alcohols or amines, preparation of anhydrides, add 
halides, aldehydes, simple aromatic alkylation and tire like 
as deared can be carried oul 
Such transformations win provide suitable rfviating 
agents and precursors thereof containing reactive function­
ality, including, for example, polycarboxylic adds in <fian- 
hydride form, di(sulfonyi chlorides), di(alkyl sulfites), 
di(vixryi sulfbnes), diesters, and die like. Such known trans­
formations are also useful in attaching the chelator to the 
polymer or polymer precursor, and in preparing the polymer 
itself. However, as will be recognized by one drilled in the 
art, obtaining tbe desired product by some reactions will be 
better facilitated by blocking or rendering certain fimctioual 
groups inert. This practice is well recognized in the art, see 
far example, Theodora Greene, Protective Croups in 
Organic Synthesis (1991). Thus when reaction conditions 
arc such that they may canse undesired reactions with other 
parts of the molecule, for example in portions of the chelator 
intended to become ligands, the drilled artisan will appre­
ciate die need to protect these reactive regions of the 
molecule and will act accordingly. For example, the chelat­
ing residue containing reactive functionality can be pre­
vented from reacting to farm undesired products by suitably 
blocking tbe ehelaring residue precursor which can be 
contacted with the reactive poly(aIkylene oxide) moiety to 
form die polymer, and then the blocking group can be 
subsequently removed by techniques known in the art For 
example, if hydroxy substituents are to be selectively 
60 present in the final polymer, they preferably should be 
temporarily blocked during polymerization, such as by 
formation of an alkyl ether fiom the hydroxyl by conven­
tional blocking techniques to tninimirj- formation of unde­
sirable by products. However, by products which contain 
one or more linkages formed by unblocked reactive precur­
sor groups in the backbone of the polymer are contemplated 
to be useful.
5 , 6 1 8 , 5 2 8
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Small proteins or peptides may be incorporated into tbe 
polymer by methods as described hcrembdow. An advan­
tage of this chemistry is that the N and C terminns o f the 
peptide can be reversed or randomized in the polymer of the 
invention, reducing immanogaridty or masking peptide 
activity until the peptide is liberated.
Scheme A
Bis-(oxiranyl>-pcptidc Monomers (Apep) ate Reacted with 
bis-(alkylaznino>-PAG Derivative Monomers (Apag)
A linking group precursor is added to the PAG monomen 
at the terminal hydroxy. The reaction of the known linking 
group precursor with the known BAG moiety forms a 
(PAGHinlang group precursor radical. Tbe precursor radi­
cal is chosen from ammqaDrybtnrino. N-sarcosyl-ami- 
noalkyl-anrino, or N-sarajsyiamniQalkyiammo-hr-carboxy.
In this scheme, the peptide monomers, have 4-(oxiranyl- 
methoxy) aryl radicals ranmrt«»d as tfntrfng gro '^p precur­
sors using carboxy fhiflionality to attach to the N terminus 
o f the peptide or amino functionality to attach to die C 
terminus o f the peptide, thns forming amide bonds with the 20 
Ntemrinm with the Ctenninos o f the peptide monomer with 
the one end of each linking group precursor, and having an 
oxirane at the other end of each linking group precursor as 





This oxirane functionalized peptide is referred to as Apep. 




cosine can be used as the linking group precursor for the N 
lermfniLc The C terminus is attached to a 
—NH(CH2),NHCOCH2NH(R) or
—NH fd^NH OO CH jNH j linking group precursor radi­
cal which is derived fiom a diamine (wherein P is one to six, 
R is an alkyl radical, linear or branched, of 1 to about 4 
carbons) and glycine or sarcosine. Thns the peptide is 
attached to tbe linking group precursor via amide linkages at 
both the N  and C termini 
An example o f Bpep is:
 ___  (ttpeptitioONH-CCHiV-NH
w o r
o  o I
CHj CHj
wherein p is 1 to about 6.
The bis(oxiranyD PAG monomers (Bpag) o f formula;
are known in the art. (See Y. Chen and M. Feng, Chinese 
Patent 86H04.089 (1987))
Thns it wiD be appreciated that tbe bis (alkyiamine) and 
bis (ooriranyl) functionality may be on either the PAG moiety 
or the peptide moiety, so long as the polymerization takes 
place between a peptide and PAG, using the reaction of an 
amine and an epoxide.
Before, during or after polymerization, suitable chelating 
agents and precursors thereof may be attached to tbe poly­
mer or polymer precursor; As described previously, a suit­
ably blocked progenitor to the chelating agent or precursor 
thereof containing reactive functionality can be contacted 
with the reactive amino arid side chain incorporated into the 
polymer or polymer precursor to form the chelate-polymer
Gly— Fhe—Lea— Gty
and is combined with Bis(amino)PAG monomers (Apag), or chelate polymer precursor, and then any blocking groups 
such as:
N H  — C H zC O N H (C H z)jN H G O — IP A G ]C O N H (C H i)2N H C O C H jN H (R )
R
wherein R is lower alkyl.
Sudi PAG derivatives are prepared by known chemistry, 
for example; the preparation of an arid chloride from PAG 
monomers by SOQ2, COCl2 and the like, with subsequent 
reaction with a suitable diamine, or another suitable linking 
group, such as —N(R)CH2CX)NHCH2CH:2NH2, or the like. 
Scheme B 60
Alternatively, oxiranyl functionality can be used on PAG 
derivative monomers while using amino functionality on 
peptide derivative monomers. In this scheme, bis-(alky- 
lami no)-peptide monomers (Bpep) are reacted with bis- 
(oxiranyl)-PAG monomers (Bpag). The peptide has a linking 65 
group precursor radical attached to the C and N termini so 
as to provide terminal amine functionality. Glycine or sar-
can be subsequently removed by techniques known in the 
art, thus avoiding formation of undesired by products.
The metallized polymer can be formed by contacting the 
unmetallized polymer sequentially or simultaneously with 
one or more sources of metal ions. This can be conveniently 
accomplished by adding one or more metal ion solutions or 
one or more metal ion solid salts or metal ion oxides, 
preferably sequentially, to a solution, preferably an aqueous 
solution, o f the polymer. Thereafter, or between sequential 
addition of metal ions, the chelated polymer preferably is 
diafiltered in water to remove excess unbound mctaL
The composition preferably is prepared in a water soluble, 
for example, an injectable form when used as magnetic 
resonance contrast agent for blood pool imaging, as a
5 , 6 1 8 , 5 2 8
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composition intend i-d to be administeied intravenously, 
the like. The preparation of water-soluble compositions of 
molecular weight 10,000 to 50,000 can be accomplished by 
known methods by one skilled in tbe art.
The following example illustrates the preparation of an 
example o f a compound of formula A. It is understood that 
the example presented does not limit the daims or invention 
claimed.
Example A
The synthesis of the compound prepared by Method A, 
giving a compound of formula A is achieved according to the 
following scheme;
Preparation of the Peptide Portion o f Example A
1 6
OBn
M cN O j
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lalanyi)leudne pentafluoropbenylesten N-(N-(1,1-Diineth- 
ylethoxycarbonyl)-phenylalanyl)Lcudne (23.0 g, 61 mmol) 
(prepared by a literature method(Anderson, G. W_; McGre­
gor. A. C , t-Butoxycarbonyl amino adds and their use in 
peptide synthesis, J. Ant Chem. Soc., 1957, 79, 
6180-61831) was stirred with pentafluorophenol (11.2 g, 61 
mmol) and dicydohexylcarbodilmide (12J  g. 61 mmol) in 
tetrahydrofuran (170 mL) for 1 h at 0° C  The suspension 
was filtered. The solvent was evaporated from the filtrate 60 
under reduced pressure. The residue, in dichloromethane, 
was washed twice with saturated aqueous sodium hydrogen 
carbonate and with water. The solution was dried with 
anhydrous magnesium sulphate and the solvent was evapo­
rated under reduced pressure to give N-(N-{1,1-dimethyl- 65 
cthoxycarbonyl)phenylalanyl)leucine pentafluorophenyl 
ester (28.0 g. 85%).
Tnffrrrwtiatf B
1. 4-(Pheaylniethoxy)benzoic acid. In a modification o f  
the literature method [E. L. Eiied, R. P. Anderson, Reactions 
of esters with targeting amines. L Benzyl esters fiom methyl 
esters and benzyldimethylaminc, J. Am Chan. Soc., 1952, 
74, 547-549] a mixture of 4-hydroxy benzoic add (27_6.g, 
200 mmol), chloromethylbenzcnc (57.0 g, 450 mmol), 
potassium carbonate (50 g) and sodium iodide (25 g) was 
boiled under reflux in acetonitrile (500 mL) for 16 h. The 
suspension was filtered and the solvent was evaporated fiom  
the filtrate under reduced pressure. The residue was recrys­
tallised from ethanol to give phenylmethyl 4-<phenyl- 
methoxy)benzoaie (48.8 g, 76%). Phenylmethyl 4-(phenyl- 
roethoxy)benzoaie (48.8 g. 150 mmol) was boiled under 
reflux with aqueous sodium hydroxide (2M; 250 mL) and 
ethanol (250 mL) for 4 h. The ethanol was evaporated under 
reduced pressure. Water (1000 mL) was added. The white 
solid was collected by filtration, wanned to 65° C  with 
aqueous sulphuric add (2M; 300 mL) for 1 h and extracted
5 ,6 1 8 ,5 2 8
1 9with warm ethyl acetate. Tde ethyl acetate solution was 
dried with anhydrous magnesium cnTpViatr and tbe solvent 
was evapotated under reduced pressure to give 4-{pbeayl- 
xnediaxy)benxovc acid (27.15 g. 80%). Tbe filtrate was 
washed twice with diethyl ether, wMifini by addition of <
sulphuric add (2M) and extracted with diethyl ether. Evapo­
ration of the diethyl ether gave a  further portion of 4-(phe- 
nylmethoxyjbenzjoic add (6.0 g. 18%). The total yidd was 
98%.
2. 4-(Phcnylmethoxy)bcnzoyl chloride. 4-<Phenyl- 
methoxy)bcazoic add (500 mg. 22 nunol) was stirred with . 
oxalyl chloride (280mg, 22 mmol) and dnnetfaylfonnamide 
(25 mg) in 1,4-dioxan (25 mL) for 20 min Tbe solvent and 
catalyst were evaporated under redoced pressure. Tbe resi­
due wasrecrystallisedfrom hexanes-to give 4-(jpbaiyl- 
metbaxy)beDzoyl chloride (460 mg. 85%).
3. i*<4-(Phenyinrdioxy)benroyi)^ ydne znediyl ester. 
4-(Phcaylmrthosy)bcnzoyl chloride (13:64 g. 55.5 unnol) in 
dicMoromctbanc (90 mL) was added dropwise to glycine 
methyl ester hydrochloride (7j66 g, 61 mmol) and trietfay- 
larninc (11.78 g. 1163 mmol) in dicblorpmefhane (250mL). 20 
The miitnre was stirred for 16 h. Tbe snapennon was 
filtered. Tbe solvent was evapotated from the filtrate trader 
reduced pressure. Tbe residue was recrystallised from 
dichloromethaiWhcxanc to give N-(4-(pbenybnethoxy)ben- 
zoyl)g}yrine methyl ester (14.75 g, 89%).
4. N-(4-(Phcaylmethofxy)bcnzoyI)g)yrinc pentafluo- 
ropheayl ester. N-{4-<Fbenyl-niet]Mxy)benzoyI)glyrinc 
methyl ester (14.75 g. 49.2 mmol) was boiled under reflux 
with methanolic sodium hydroride (1M) (80 mL) for 2 h. 
Tbe solvent was evaporated under reduced pressure. Tbe 30 
residue was dissolved in water and was acidified by addition 
of aqueous hydrochloric add. Tbe suspension was extracted 
with ethyl amate. Tbe extract was washed with saturated 
brine and was dried with anhydrous magnesium sulphate. 
The solvent was evaporated under reduced pressure to give 35 
N-(4-(phcnyImethoxy)benzoyI)glyaiic (639 g, 47%). Dicy- 
dohcxyicarbodTimiric (720 mg. 3.5 nunol) was added to 
N-<4-(phenylmethojy)benzoyl)glydne (100 g, 33 nnnol) in 
dry tetrahydrofuran (100 mL) and the mixture was taken to 
0° G Pentafluorophenol (640 g. 3.5 mmol) was added 40 
dropwise and tbe mixture was stirred for 17 h at 0* C Tbe 
suspension was filtered and the solvent was evaporated fiom 
the filtrate under reduced pressure. The residue was dis­
solved in ethyl acetate (200 mL) and was washed with 
saturated aqoeous sodium hydrogen carbonate (2*75 mL), 45 
with aqueous sulphuric arid (10%) and with water. The 
solution was dried with anhydrous magn i^m sulphate «vt 
the solvent was evaporated under reduced pressure to give 
N-(4-(phenyinjetboxy)benznyl)glydiie pcutafluorophenyl 
ester (Intermediate B) (1.5 g. 95%).
Imit  »i C
1. l-{2rNi£roe(heayI)-4-(pheaylmethoxy)beuzene. In a 
modification of tbe literature method [M. Hoequanx, B. 
Macot, G. Redenith, G Vid. M. Bmnaub, J. Nauamo, G 
Lacoun and G Cozeubon, Diazoestrones and analogs. L 55 
Pharmacological study and syntheses of heterosteroid ana­
logs to establish structure—analgesic activity relationships, 
Eur. J. Med. Chem., 1983. 19. 319-329). to 4-{phenyl- 
methoxyjbenzaldehyde (28 g, 132 mmol) in ethanol (900 
mL) at 5^  G was added mtromelhane (16.1 g, 264 mmol). 60 
Sodium hydroxide (13.2 g, 330 mmol) in ethanol (200 mL) 
was added dropwise and the mixture was stirred for 30 min 
at 5° G Tbe mixture was poured into a mixture of hydro­
chloric arid (9M; 136 mL) and water (208 mL). The 
precipitate was collected by filtration and was rcoystallised 65 
from ethanol to give 1 -(2-nitrocthcnyl)-4-(phcnylmethoxy- 
)benzene (14.0 g. 42%).
20
2.2<4-<Pbenylmethoxy)phenyi)ethylamine. lithium alu­
minum hydride (8.48 g, 223 mmol) was suspended in dry 
diethyl ether (600 mL). 1 -(2-NitroetbenyI)-4(phenyl- 
metboxy)benzene (13.9 g. 35 mmol) was extracted into this 
mixture using a Soxhlet apparatus. The mixture was boiled 
under reflux for 16 h. Water (738 mL) was added, followed 
by aqueous sodium hydroxide (20%; 533 mL) and water 
(273 mL). Tbe suspensian was filtered. The solvent was 
evaporated from die filtrate under reduced pressure to give
2-(4-(phegylmrthnxy)phcnyI)cthylamine (11.25 g, 91%).
J)
1. N-(Ll-MmethyiethoxycaibanyI)gIyane N-(2-(4-phe- 
nylmethaxy)phenyl)GthyI)amide. N-(l ,1 -Dimethylethoxy-
u carboayOglydne (850 mg. 435 mmol) was stirred with 
dicydohcxyicaihodnnriric (IjOO g. 435 mmol) and 2-(4- 
(phenylmcthaxy)pheuyl)etbyiamxne (intermediate Q (1.00 
g. 4.4 mmol) in dry tetrahydiofuian (30 mL) for 16 h. Tbe 
suspension was filtered and the solvent was evaporated from 
the filtrate under reduced pressure. Tbe residue was dis­
solved in ethyl acetate and was washed with aqueous 
sulphuric arid (10%) and with satnmtrd brine. Tbe solution 
was dried with anhydrous magnesium sulphate and the 
solvent was evapotated under redoced pressure to give 
25 N-(l,ldimethyletbaxycarbanyI)glycme N-(2-(-(phenyl- 
methoxy)phcnyI)cthyi)anriric (1.65 g, 98%).
2. Glycine N-(2-(4-{pbenylinetbaxy)phenyI)e£hyI)amide. 
N-(l,l-Dimethylethaxycarbonyl)glydne N-(2-(4-(pbenyl- 
)ethyl)amide (2.01 g, 533 mmol) was treated with excess 
hydrogen chloride in 1,4-dioxan (45 mL) for 2 h. Tbe solid 
was collected by filtration and was dissolved in water and 
ethyl acetate. Aqueous sodium hydroxide was added to 
basify the solution to pH 9. Tbe ethyl acetate solution was 
dried with anhydrous magnesium sulphate and tbe solvent 
was evaporated under reduce pressure to give glycine N<2- 




lalanyQleurine pentaflnnropbenyi ester (1.19 g, 2.18 mmol) 
(Example A. Intermediate A) in tetrahydrofuran (30 mL) 
was added dropwise to glycine N-(2-(4-(phenylmetbox- 
y)phenyl)ethyl)amide (620 mg, 2.18 mmol), JLN-diisopro- 
pyletbyiamine (310 mg, 2.4 mmol) and 1-kydroxybenzot- 
riazole (20 mg) in tetrahydrofuran (30 mL) and the mixture 
was stirred for 16 h. Tbe solvent was evaporated under 
reduced pressure. The residue, in ethyl acetate, was washed 
with aqueous sulphuric acid (10%) and with saturated aque­
ous sodium hydrogen carbonate. Tbe solution was dried with
so anhydrous magnesium sulphate and tbe solvent was evapo­
rated under reduced pressure. Tbe residue was triturated 
with diethyl ether and the solid was collected by filtration to 
give N-(N-(N-( 1.1 -dimethylethoxycarbonyi)pheny-
lalanyl)leucyl)glycine N-(2-(4-(phcnylmethoxy)phenyl)- 
ethyl)amide (360 mg, 26%) (Intermediate D).
Intermediate E
1. N-(l,l-Dimethyletboxycarbanyl)sarcostne 2,4,5- 
trichloropbenyl ester. N-(l,l-DimethylethoxycarbonyI)sar- 
cosine (10.0 g, 53 mmol) was stirred with 2,4,5-trichlo- 
ropbeool (10.6 g, 53 mmol) and dicydobexylcarbodiimide 
(10.9 g, 53 nunol) in ethyl acetate (100 mL) at —10° G for 
25 h. The suspension was filtered and the solvent was 
evaporated under reduced pressure from the filtrate. The 
residue was dissolved in ethyl acetate. Tbe suspension was 
filtered and the solvent was evaporated under reduced pres­
sure from the filtrate to give N-(l.l-diroethylethoxycarbon- 
yl)sarcosine 2,4,5-trichlorophcnyl ester (193 g. 98%).
5 , 6 1 8 , 5 2 8
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2. N-(l,l-Dimethylethoxycarbonyl)sarcosine N-(2nsmi- 
nocthyl)airddc. N<1 J-Diinctbylciboxycaibonyl)sanxsiDC 
2,43-trichlorophenyl ester (12.7 g. 343 mmol) in dicfalo- 
romethane (SO mL) was wiA-ft Awing 30 min to ethane-1, 
2-diamine (20.7 g. 345 mmol) in dichtoromethane (150 mL) s 
and the solution was stored for a farther 2 h. The nintion 
was washed with water and with 10% aqueous aodmm 
carbonate and was dried with anhydrous nrnpm im  sul­
phate. The solvent was evaporated under reducedpressme to 
give N-(Ll-dimethylethaxycaibouyi)saico«neN-(2-amino- to 
ethyl)anhde (6.9 g, 86%).
3. Bis(2-(2-(N-(2-N-{l,l -DixnctbylethaxycarbocyI)siico- 
syl)aminoetfayl)aminocarboay)ethoxy)ethoacy)ethane. 
Bis(2-hydroxyethoxy)ethoxy)ethane (SjO g, 21 mmol) was 
baled  in toluene (120 mL) for 20 h with azeotropic removal IS 
of water. Tbe resulting sohztion was cooled to 20* C  
Dichknmnrthanr. (35 mL) was added, followed by phosgene 
(1.93M in dichlaromethane, 109 mL, 210 mmol). The 
solution was stored for 4 L  The solvent and excess reagent 
were evaporated under redoced pressure from a portion (30 20 
mL) of this solution to gjve crude bis(2-(2-(dilarocarbaxy- 
)ethoxy)ethaxy)ethane (900 mg, 2 3  mmol). This material 
was dissolved in dichlaromethane (50 mL). To this sointion 
was added methylamme (1.26 g. 123 mmol) and 4-(<fizn- 
etbyiamino)pyridine (20 mg). N-(l.l-tomethykthoxycarbo- 25 
nyl)sarcosine N-(2-aminoethyI)amide (1.73 g. 75  mmol) 
(Intermediate P7)«n dicbloromethane (100 mL) was ft**" 
«HrWi drey  wise during 40 "iin The winriftn was trirnpt far 
20  h before being washed with water; 10% aqueous sulphu­
ric acid and water The solution was dried with anhydrous 30 
magnesium mlphatp and fti^ solvent was evaporated «wmW 
reduced pressure to gjve bis(2-(2-{N-(2-(N-<l. 1 -dimethyl- 
ethoxycarbonyl)sancosyl)amino- 
ethyl)aminocarbaxy)ethoxy)ethoxy)ethaiie (1.1 g, 59%).
4. Bis(2<2-(N-(2 -s3icosylaminoethyI)amTTincar- as
boxy)ethoxy)ethoxy)ethane dihydrochloride. Bis(2-{2-(N- 
(2-(N-(l ,1 -<£methylethoxycarbonyl)sarco- 
syl)anrinoethy!)aniinocarboxy)etboxy)elhozy)ethane (752 
mg. 1 mmol) was treated with excess hydrogen chloride in 
dichlaromethane for 2 h. Evaporation of the solvent gave 40 
bis(2-<2-(N-(2-saxcosylamiDoetfayl)aininocar- 
boxy)ethoxy)ethoxy)ethane dihydro-chloride (550 mg, 
quantitative).
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1. N-(N-Phenylalanylleucyl)glydne N-(2-(4-(phenyI- 
methoxy)phenyl) ethyl )amide hydrochloride. N-(N-{1,1- 
Dimcthylethoxycarbonyl)phenylaianylleucyl) glycine N-{2- 
(4-(phenylmethoxy) phenyl)ethyl)ainide (3.89 g, 6.05 50 
mmol) was treated with excess hydrogen chloride in dichlo- 
romethane (200 mL) for 3 h. The solvent and excess reagent 
were evaporated under reduced pressure. Tbe residual oil 
was triturated with diethyl ether to give N-(N-pbenylala- 
nyllcucyOglycine N-(2-(4-(phenylmelhoxy)phenyl)ethyl)a- 55 
raide hydrochloride (3.26 g, 93%).
2. N-(N-(N-(N-(4-(Phenylmethoxy)benzoyl)gly- 
cyl)phenylalanyl)leucyl)glycine N-(2-(4-{phenylmetbox- 
y)phenyl)ethyl)amide. N-{N-Pheaylalanylleucyl)g lycine 
N-(2-(4-(phenylmethoxy)phenyl)ethyl)aniide hydrochloride 60 
(165 mg, 284 raol) was stored with NJN-diisopropylethy- 
lamine (100 mg, 774 mol), 4-<dimethylamino)pyridine (10 
mg) and 1-bydroxybenzotriazole (10 mg) in dry dichlo- 
romethanc (5 mL) until all solid dissolved. N-(4-(Phenyl- 
methoxy)bcnzoyl) glycine pentafluorophcny 1 ester (117 mg, 65 
258 mol) (Example A, Intennediate B)in chloroform (10 
mL) was added dropwise during 30 min and tbe reaction
mixture was stirred for 5 h. The solvent was evaporated 
under reduced pressure. Colnmn chromatography (silica gel; 
chloroform/methanol 50:1) of the residue gave N-(N-(N-(N- 
(4-(phenylmethoxy)bcnzoyl)gly-
cyl)phcnylalanyl)lcncyl)glycine N-(2-(4-(phcnyhncthox- 





y)phenyl)ethyl)amide (444 mg, 547 mol) in ethanol (45 mL) 
was stirred vigorously with pallatinim on charcoal (10%; 50 
mg) and hydrogen for 12 h. The suspension was filtered 
through diatomaceous earth. The solvent was evaporated 
from the filtrate under reduced pressure to give N-(N-(N- 
(N-(4-bydruxybenzoyl)glycyl)phcnylalanyl)leucyi)giycine 
N-(2-{4-hydroxypbenyl)ethyt)amide (304 mg, 88%).
4. N-(N-(N-(N-<4-(Oxiranylmethoxy)beuzoyI)glycyl) 
phenylalanyl)lcucyl) glycine N-(2-{4-(oxiranylmetbox- 
y)phenyl)ctfayl)amide. N-(N-(N-(N-(4-Hydroxybenzoyl)g- 
lycyl)pbenylalanyl)leucyl)glycine N-(2-(4-hydroxyphenyl) 
ethyl)amide (106 mg, 0.131 mol) was suspended in water 
(12 mL) containing sodium hydroxide (523 mg. 131 
mmol). Chloromethylaxirane (604 mg. 63  mmol) in metha­
nol (10 mL) was added, followed by phenylmethyltrimethy- 
lammomum hydroxide (40% aqueous solution, 90 mg). The 
solution was stirred for 48 hat 40° C. Tbe solvent and excess 
reagent were evaporated under reduced pressure. Tbe resi­
due was dissolved in ethyl acetate and was washed with 
water. The solution was dried with anhydrous magnesium 
mlphati* The solvent was evaporated nnrbr reduced pres­
sure. fnlnrrm rhmmatngraphy (silica gel; ethyl arrtatr. then 
ethyl afTrfttt^Anrthannl 39:1, then ethyl aertarff/fTWlhannl 
19:1, then ethyl acetate/methanol 9:1) gave N-(N-(N-(N-(4- 
(oxiranylmethoxy)benzoyl)glycyl) phenylalanyl)leucyl)gly- 
dne N-(2-(4-(oxiranylmetboxy)pbenyl)ethyl)amide (263 
mg. 27%).
5. Polymer A. It is contemplated that N-(N-(N-(N-(4- 
(Oxiranylmethoxy)beazoyl)gly-
cyl)phenylalanyl)lcucyl)glycine N-(2-(4-(oxiranylmethox- 
y)phenyl)ethyl)aniide is boiled under reflux with anhydrous 
sodium carbonate and bis(2-(2-(N-(2-sarcosylammoethy-
l)annnocarboxy)ethoxy)cthoxy)etbane dihydrochloride
(Intermediate E) in ethanol for 6 h, giving the polymer of 
formula A.
Preparation of Peptide Portion of Example B
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N-(l ,1 -Dimethyleibaxycarbonyl)leucine 2,4,5-trichlo-
rophenyl ester. N ^l J-DimetfayiethoxycarbonyI)lcuciae 
(632  g. 15 mmol) was stirred with 2.43-trichlarophenol 
(3.01 g. 153 mmol) and dicydoteiyicarbodnmide (3.14 g, 
10 153 mmol) in ethyl acetate (50 mL) ax -1 0 °  C. for 4  h. The 
suspension was filtered and the solvent was evaporated 
under reduced pressure from the filtrate, The residue was 
dissolved in ethyl acetate. The suspension was filtered and 
the solvent was evaporated onder reduced pressure from tbe 
15 filtrate to give N-<l,l-dimethylethoxycarbonyl)leucme 2,4, 
5-trichlarophenyl ester (62  g, 99%).
Tnf/r i ii^infr g
N-( 1,1 -Dimetfaylethoxycarboiiyl)pheny lalamne pen-
tafluorophenyl estcx. N-<lJ-Diinethyletboxycarbonyl)phe- 
nylalanine (636  g, 24 mmol) in ethyl acetate (50 mL) at 0° 
C  was added to dicyctobexylcarbodiimide (4.95 g, 24 
mmol) and penrafluomphmni (4.42 g, 24 mmol) in ethyl 
acetate (SO mL) at 0° C  The mixture was stirred for 2.75 h 
at 0° C  The suspension was filtered and the solvent was 
25 evaporated under reduced pressure from the filtrate. The 
residue was dissolved in ethyl acetarr. Tbe suspension was 
filtered and the solvent was evaporated under reduced pres­
sure from the filtrate to give N-(l,l-dimethylexhoxycarbon- 




rophenyl ester. N-(l,l-Dimethylethoxycarbonyl)glydne 
(6.12 g, 35 mmol) was stirred with 2,43-tricfalorophenol 
35 (6.91 g. 35 mmol) and dicydobexylcarbodiiimde (722  g. 35 
mmol) in ethyl acetate (100 mL) at 0° C  for 4 h. The 
suspension was filtered and the solvent was evaporated 
under reduced pressure from the filtrate. The residue was
N H T roc
H
N
C H M ej
NMeCbz
( i )  HCVCHzCfc 
(u )  C b z S irO T C ?
(Tim rinrfmr £)
CbzSsr
C /  V '
.N M e C b z
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dissolved in ethyl acetate. The suspension was filtered and 
the solvent was evapoj^ terf miArn^ nnwl prBtsme fmm the 
filtrate to give N-(l.l-diinethylcthaxycarbonyI)glycinc 2,4. 
5-trichloropfaeayl ester (12.4 g, quantitative).
Intermediate D 
1. f^ -fl,l-DimethylethoxycarbonyI)-hr-{233-tiiciiloro- 
cthoxycarbanyQlysine. hi a modification of a literature 
method [Yajinxa. H; Watmabe, K; Okamoto, KL, Studies on 
peptides. XXXHL N*-ftJI^ TticfaloroethyloxycarbanyIl- 
yrine, Chem. Pham. BuU, 1971, 19, 2185-2189], lysine 10 
monohydroddoride (9.14 g, SO mmol) was stirred under 
reflux with copper (DQ carbonate (21.6 g, 75 mmol) in water 
(180 mL) for 3 h. The solution was filtered while hot and the 
filtrate was cooled to 20* C 233-Ttichloroetfayl ddorofor- 
mate (15.9 g, 75 mmol) and aqueous sotfiom carbonate(13J is 
g. 125 mmol in 40 mL) were added ahecnatdy in portioos 
to the filtrate dnring 30 non and foe mixture was stirred 
vigorously at 0* C far 20 h. The blue jmrJpitatr was 
collected and was boiled under reflux with ethyknedfiamne- 
tetraacetic add ritsocfinm salt (183 g. 100 mmol) in water 20 
(200 mL) for 2 h. The solution was cooled to 0° C for 20 
fas and crude NX2&&4nctfaroethaxycatbanyl)lysn>e was 
collected as a gammy solid. This material was dissolved in 
water (75 mL) and triethylxxnine (20L2 g, 200 mmol) was 
added, fo&owed by di-t-botyl dicarbonate (13.64 g. 62 2S 
mmol) and 1,4-dioxan (30 mL). The mixture was stirred 
vigorously for 3 d. The mixture was washed with diethyl 
ether: Ethyl acetate was added to the aqneous phase and die 
mixture was acidified by careful addition of odd 10% 
aqueous sulphuric acid. The ethyl acetate phase was washed 30 
with water and dried with anhydrous magnesium snlphate. 
The solvent was evaporated tmder reduced pressure tcrgive 
hT-(l,l-dimethylethaxycaibanyI)-N'-(233-trichlaroet- 
hoxycarbonyI)lysine (1232 g, 55%).
2. hP-(l,l-Ditsefoylefoaxycarboayl)-NM223-trichlafl>- 35 
cthoxycarbooyl)lysine 243-trichlorophenyl ester. N*-(l,l- 
Dimefoylelhoxyc3ibonyI)-N 2^33-trichlarocth0xy-caibo- 
nyl)lysine (632 g, 15 mmol) was stirred with 2,4,5- 
trichlarophenol (256 g, 15 mmol) rod 
dicydohexylcarbodiimide (3.10 g, 15 mmol) in ethyl acetate 40 
(100 mL) at 0* C. for 20 h. The suspension was filtered and 
the solvent was evaporated tmder reduced pressure from the 
filtrate. The residue was dissolved in ethyl ******* The 
suspension was filtered and the. solvent was evaporated 
under reduced pressure from the filtrate to give N“-{1,1- 45 
dimethylethoxycarbonyl)-N*-(2A2-tridilorocthoxy-cartx>- 
nyl)lysine 243-tricfatorophenylester (730 g. 97%).
lntwwdiat^ E
1. N-(Phcnylmethoxycarbonyl)sarcosiiie 2,43-tricfalo- 
rophenylester. N-(Phenylmethoxycaibonyl)sarcosme (4.0 g, so 
18 mmol) was stirred with 243-trichloropbeooI (333 g, 18 
mmol) and dicydohexylcatboduznide (3.69 g, 18 mmol) in 
ethyl acetate (40 mL) at -10s C. for 1 h, then at 20° C for 
20 h. The suspension was cooled to 0° C The suspension 
was filtered and the solvent was evaporated under reduced ss 
pressure from tbeiiltraie. Tbe residue was dissolved in ethyl 
acetate. The suspension was filtered and tbe solvent was 
evaporated under reduced pressure from the filtrate to give 
N-(phenylmelboxycarbonyl)sareosinc 243-trichlorophenyl 
ester (73 g, quantitative).
2 N-(Phenymethoxycaxbonyl)sarcosine pentafiuorophe- 
nyl ester. N-(Phcnylmcthoxycaibonyl)sarcosinc (3.0 g, 13.4 
nunol) was stirred with pentafluorophenol (246 g, 13.4 
mmol) and dicydohexylcarbodiimide (232g, 13.4 mmol) in 
ethyl acetate (30 mL) at 0° C for 2 h. The suspension was 65 
filtered and the solvent was evaporated under reduced pres­
sure from the filtrate. The residue was dissolved in ethyl
2 6
acetate. The suspension was filtered and the solvent was 
evaporated under reduced pressure from the filtrate to give 
N-(phenylinethaxycaibanyl)saicosine pentafinoropbenyl 
ester (4.66 g, 89%).
S tnrwiiiwtiare F
1. 5-(4-Nitroi*enyI>-10,15120-triphenyi-21H33H-por- 
phine. Firming nitric add (density 13 mL-1) (226 ml.) was 
added dnring 2 h to 5.1(U5,20-tetTaphenyi-21IL23H-por- 
phine (200 g, 336 mmol) in chloroform (ethanol-free) (300 
mL).The mixture was washed with water (5X300 ml.) and 
was dried with anhydrous sodium carbonate and anhydrous 
magnesium sulphate. The solvent was evaporated under 
reduced pressure. Chromatography (silica gel; <ficbk>- 
romethane/bexane 21) of foe residue gave 5-{4-oitropbe- 
nyiH0,15r20-triphenyl-21H33H-porpbine (L17 g. 55%).
2  1^0,15,20-TriphenyI-21H33H-parpfam-5-yl)benze- 
ncammc.Tin(Il) chlnride dihydrate (S95 mg. 2.6 mmol) was 
added to 5-<4-nitrophenyI)-10,15,20-triphexiyl-21H33H- 
pocphine (580 mg, 038 mmol) in aqueous hydrochloric add 
(9M. 20 mL) and foe mixture was stirred at 65° C for 2 h. 
The solution was allowed to cool and was added to water (70 
mi j rmmmiMtwt aqueous ammonia was rmffl ^  
sointion was basified to pH 8. The suspension was extracted 
with chloroform (9X75 mL). Tbe chloroform fractions were 
combined and were dried with anhydrous magnesium sul­
phate. The solvent was evaporated under reduced pressure. 
Chromatography (silica gd; dichlaromethane/hexane 5:1) of 
foe residue gave 4<10,1530-triphenyl-211L23H-parphin-5- 
yl)benzeneamine (462 mg, 84%).
3. 4-Oxo-4-(4^ 10,15,2Q-tiipheayl-211L23H-patpbin-5- 
yI)phenylamino)butanoic add. 4-(10,15t20-‘Iiipbenyl-21H, 
23H-porphin-5-yI)beazeneamme (450 mg, 0.72 mmol) was 
dissolved in chloroform (ethanol-free) (10 mL) with warm­
ing. Succinic anhydride (tctrahydrofuxan-23-dione) (64 mg, 
0.72 nwml) was added and the mixture was boiled under 
reflux for 23 h. A further portion of succinic anhydride (32 
mg. 036 mmol) was added and boiling under reflux con­
tinued for a further 2 h. The mixture was coaled to ambient 
temperature for 16 h. The precipitated solid was collected by 
filtration to give 4-oxo-4-(4-(10,15,20-triphenyl-21IL23H- 
porphitH5-yl)pbeayiammo)butanoic add (460 mg, 89%).
Preparation of Peptide Portion of Example B
1. N-(Fhenylmethoxycarbotryl)sarcosine N-(2-ammoet- 
hylXumde. N-(Phenylinethoxycaibonyl)saicosiDe pen- 
tafluaropbenyl ester (33 g, 93 mmol) in dicblorometbane 
(40 mL) was added during 30 min to ethane-13-diamine 
(10.8 g, 180 mmol) in dicbloromethane (300 mL) and foe 
solution was stirred for a further 2 h. The solutioa was 
washed with water and with 10% aqueous sodium carbonate 
and was dried with anhydrous magnesium sulphate. The 
solvent was evaporated under reduced pressure to give 
N-(phenylrnethoxycarbonyl)sarcosine N-(2-mninocthyl)a- 
mide (21 g, 88%). This material was also prepared similarly 
from N-(phcnylmethoxycaibonyi)sarcosinc 243-trichlo- 
ropheayl ester.
2  N-(l,l-Dimethylethoxycarbonyl)glydne N-(2-(N-phe- 
nylmethoxycarbonyl)sareosylaimno)etbyl)amide. N-(Phe- 
60 nylrocthoxycaibonyl)sarcosine N-(2-aminocthyI)amide 
(3-71 g, 14 mmol) was stirred with N-(l,l-dimethylethoxy- 
carbonyl)glydne 243-trichlorophenyl ester (4.96 g, 14 
mmol, F-rampV B, Tnfwnwtiate Q and N,N-diisOpropyl- 
ethylamine (1.99 g, 15.4 mmol) in dichloromcthane (100 
mL) for 20 h. The solution was washed with cold 10% 
aqueous sulphuric add (2x) and with saturated aqueous 
sodium hydrogen carbonate and was dried with anhydrous
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magnesium sulphate. The solvent was evaporated under 
reduced pressure. Chromatography (silica gel; ethyl acetate/ 
methanol 10:1, then ethyl acctateftnethanol 5:1, then ethyl 
acetate/methanol 3:1) of the residue gave N-(1,1-<E- 
methy!ethoxycaiboayI)glycine N-(2-gJ-pbenyhaethoxycar- 5 
bonyl)sarcosylaxmno)ethyl)amide (2.12 g, 37%).
3. Glycine N-(2-(N-pheaylmcthoxycarbonyl)sarcosy- 
lammo)etbyI)amidc hydrochloride. N-(l,l-Dimethylcthoxy- 
carbonyl)glyciiie N-(2-(N-iriieuyimethoxycarbanyI)sarcosy- 
1arnino)ethyi)ainide (2.04 g. 4.95 mmol) was treated with 10 
excess hydrogen chloride in dichloromethane (SO mL) for 1
h. The solvent and excess reagent were evaporated under 
reduced pressure to give glycine N-(2-(N-phcnyInicthnxy- 






lammo)cthyl)anttde (122  g. 8 mmol) was treated with 
excess hydrogen chloride in djdrioromrtharir (50 mL) for 1 30 
h. Water (SO mL) was added and tbe mi store was stirred 
vigorously for 15 min. The solvent and excess reagent were 
evaporated fiom the aqneousfaycrnnder reduced pressure to 
give crude glycine hK2-(N-(pheaylmcdioxycarbonyi)satq>- 
syiamino)ethyl)amide hydrochlorides* a white solid. This 25 
material was stizred with N^ -diisopropyicthyiamine (3.231
g, 25 mmol) and N-{l,l-dmiethyiethoxycarbonyi)leodne 
2,45-trichlaropbenyI ester (3.19 g. 7.8 mmol) (Example n. 
Intermediate A) in dnne&ylfonnarmde (30 mL) for 3 d. The 
solvent was evaporated under reduced pressure. The residue 30 
was dissolved in ethyl acetate and was washed with aqueous 
sodium hydroxide (5%), aqueous sulphuric add (10%) and 
water and was dried with anhydrous magnesium sulphate. 
Evaporation of the solvent under reduced pressure gave 
N-(N-(Ll-<finiethylethoxycarfaoayl)leucyi)gIycine N-(2-(N- ^ 
(pfamylxnetlxMcycarboiyI)saia?sylainino)ethyI)anade (3J26 
g.78%).
5. N-Leacylglycine N-(2-(N-{phenyiincthoxycar- 
bonyl)saicosylainino)cthyi)amide hydrochloride. N-(N-(1, 
l-Diinethjdethoxycarbonyiyeotyl^ ydne N-(2-(N-(pbe- ^  
nyimctfaoxycarbonyl)saroosyiainino)ethyl)amidc (326 g.
6.1 nmol) was treated with excess hydrogen diloride in 
dichloromethane (40 mL) for I h. The solvent and excess 
reagent were evaporated under reduced pressure to give 
N-lencylglyane N-(2-<H^ pheTqdnB3hojyczibonyI)s3rcosy- 
lamino)etbyl)amide hydrochloride (2.65 g, quandtative).
6. N-(N-{N-{l,l-Dimethylethoxycaibonyl)pheny- 
lalanyl)lencyl)glycine N-(2-(N-{phenylmerbaxycar- 
bonyl)saicosylamino)ethyl) amide. N-(l,l-Dimetbyiethoxy- 
carbonyl)phenylalamne pentafluorophenyl ester (2.65 g, 6. 1 50 
mmol) (Example B, Intermediate B) was added to 
N-leucylglydne N-(2-{N--(phenylmetboxycaibonyI)sarcosy- 
lamino)efhyl)amide hydrochloride (251 g, 6.16 mmol), 
N-N-diisopropylethylamine (1.75 g, 13 5 mmol) and 
4-(dimethylamino)pyridine (10 mg) in (Schloromethaue (30 55 
mL) and the mixture was stizred for 2 d. The solution was 
then washed with cold aqueous sulphuric add (10%), aque­
ous sodium carbonate (10%) and saturated brine. The solu­
tion was dried with anhydrous magnesium sulphate and the 
solvent was evaporated under reduced pressure. Chroma- go 









etlx»ycarbonyl)pbenylalanyI)lei^ )glyrine N-(2-(N-(phe- 
nylnietboxycarimyl)sarcosylamino)^ I)amide (154 g, 
2JB mmol) was treated with excess hydrogen chlnAtft in 
d?<j>iomrw»fhflne (25 mL) for 1 h. The solvent and excess 
reagent were evaporated under redoced pressure. The resi­
due was dissolved in methanol Evaporation rtf'the solvent 
under reduced pressure gave N-(N-phayl*IanyIlencyI)gly- 
dne N-(2-(N-{phenyhnethoxycxibanyI)sxrcosy-




ethoxycmboayl)glycme 2,45-trichlorophenyl ester (LS8 g. 
255 mmol) (Example B. Intermediate Q and 4-<dimethy-
15 lamino)pyridine (3.1 g, 25 mmol) were added to N-(N- 
phenylaianylleucyBglycine N-(2-(N(phcnyIinethoxycaibon- 
yl)saicosyiaiEdno)ethyI)anride hydrochloride (904 mg, 255 
mmol) and N,N-diisopropyiethylamine (990 mg, 7.7 mmol) 
m dichlaromethane (20 mL). The mixlnre was stirred for 4 
d. The sointion was washed with cold aqueous sulphuric 
add (10%), aqueous sodium carbonate (10%) and saturated 
brine. The solution was dried with anhydrous magnesium 
snlphate and tbe solvent was evaporated under redoced 
pressure. Chromatography (silica gel; chloroform, then 
chloroform/methanol 10:1) of the residue gave N-(N-{N-(N- 
(l.l-dimetbylethoxycaibonyl)gly-
cyl)phenylalanyl)leucyl)glytine N-(2-(N(pheaylmethaxy- 
caibonyl)sanx>sylamiDo)ethyl)amide (1.14 g, 61%).




mctbQxycarbonyl)sarcosyl2iniDo)cthyi)amjde (L29 g. 1.77 
mmol) was treated with excess hydrogen chloride in dichlo- 
romethane (10 mL) for 1 h. Methanol (1 mL) was added and 
the solvents and excess reagents were evaporated under 
reduced pressure to give N-(N-(N-gIycy1pbenyIala- 
nyl)leucyl)glydne N-(2-(N-<pbenylmethoxycaibonyI)saico- 
sylamino)ethyI)ainide hydrochloride (1.1 g, quantitative).
10. N-(N-(N-(N-(N“-(ltl-DimediylethoxycaibonyI>-N*- 
(2 2 2 -trichlorpethoxyc3rbonyI)IysyI)glycyl) . -qthcnylala- 
nyl)leucyl)glyciae N-(2-(N-(phcnylmedwxy-caibonyl)sar- 
cosyl-anrino)ethyl)amide. N-(N-(N-
45 GIycylphenylalanyl)IeucyI)glydne N^ CZ-^ N-
(pheaylmethoxycaibonyl)s2icosylamino)ethyl)ainide
hydrochloride (1.11 g. 1.77 mmol) was added to NJ4- 
diisopropylethylanune (683 mg, 5.3 mmol) in dichlo­
romethane (10 mL). To this mixtnre was added N“-(l,l- 
dimetbylethoxycaibonyl)-N*-(2.2,2- 
trichloroethoxycarbonyl)lysine 2,4,5-trichloiophenyl ester 
(950 mg, 1.77 mmol) (Example B, Intermediate D) in 
dichloromethane (20 mL) and 4-(riirnrthylamino)pyridine 
(10 mg). The mixture was stirred for 3 d. The solution was 
washed with cold aqueous sulphuric add (10%), aqueous 
sodium carbonate (10%) and saturated brine. The solution 
was dried with anhydrous magnesium sulphate and the 
solvent was evaporated under reduced pressure. Chroma­
tography (silica gel; chloroform, then chloroform/methanol 
10:1) of the residue gave N-(N-(N-(N-(Ntt-(1,1-dimrthyl- 
ethoxycaibonyl)-Ne-(2^ 2-trichloroethoxycaibonyl)ly- 
syl)glycyl)phenylalanyi)leucyl)glydnc N-(2-(N-(phenyl- 







ride. N-(N-(N-{N-(hrx-(l,l -DiniefiylefioxycarbonyI)-N*- 
(2£^ -mchloroctbaxyc8ibo(iyl)Iysyl)glycyl)phenyl- 
tlanyl)leucyl)glyciiie N^ -<N-(|Aqiy1ni<ahnxyc«rfaoayl- 
)sarcosylamxno)efiyI)aniid£ (132 g. 1.27 nunol) was treated 
with excess hydrogen chloride in cficfaloromrthane (20 mL) 5 
for 1 h. Methanol (1J) mL) was added and the mixture was 
filtered. The solvent was evaporated fiom the filtrate under 
reduced pressure to give N-^ -(N-(N-<hP-{22^ f-trichloro- 
cthoxycarbonyl)lysyi)glycyl)pbenyl2lanyl)leocyl)glycme 
N-(2-ffi(pbcnylmefioxycarbonyI)sara>- 
syIamino)efiyl)ainlrie hydrochloride (1.14 g, 92%).
12. N-(N-(N-<N-(hr*-(hHF1ienylniethoxycarbonyI)s3rco- 
sy!)^ <2^4ridilorocfiaxycarbonyI) lys^ )^ ycyl)pheny- 
lalany!)4euqd)glycineN<2^ <phe^!inetho3^ car- 
boqyl)satco^ l-anpno)ethyOmnde. W-Q4-Q4<N-(N*-(2A2- u 
Trirhlnmrfherygarlioujiyy-
syl)glycyi^ jheayialan3d)leucyl)glyrine N-(2-(N(pbenyI- 
mcfioxycarbonyl)S3rcosylanrino)efiyl)amidc 
hydrochloride (980 mg. IjO mmol) was stizred with NJti~ 
diisopropyletbylanMie (402 mg, 3.1 mmol). N-(phenyl- ^  
mefioxycaibocyOsaroosaic 2.4.5-tricblarophenyl ester (418 
mg, 1.0 mmol) (Example B, Intermediate E) and 4^ <fim- 
efiylamino)pyzidine (10 mg) in dichkxomethane (30 mL) 
for 24 h. The sohitioo was washed with saturated aqueous 
sodium hydrogen carbonate and with aqueous sulphuric add ^  
(2M) and was dried with anhydrous wMgiywnm snlphate. 
The solvent was evaporated under reduced pressure. Chro- 
matography (silica gd, chlorofonnftncfhanol 20:1, then 




mefioxycarbonyl)saicosylaimno)efiyl)aimde (418 mg, 
36%).
13. N^ N-(N-(N-{Ntt-(N-{Phcnylmcthoxycarbonyl)sarco- 35 
syl)lysyl)glycy!)pbcnylalanyi)lcacyl)glyrine N-{2-<N-(phe- 





bonyl)sarcosylamxno) etbyl)amide is boiled under reflux 
with zinc powder in methanol for 2 h. The solvent is 
evaporated under reduced pressure: Ethyl acetate is added to 
the residue. The suspension is filtered and the filtrate is 45 
washed with twice with water. The solution is dried with 
anhydrous magnesium sulphate and the solvent is evapo­
rated under reduced pressure to give N-(N-(N-{N-(Na(N- 
(pheaylmethaxycarbonyl)saxco>





lycyl)pbeoylalanyl)lcucyl)^ ycinc N-(2-(N- 55
(phcnylmahoxycarbonyl)saicosylarriino)ethyl)aniide. It is 
contemplated that 4-oxo-4-(4-(10.15,20-tripbenyl-21H, 
23H-porphin-5-yl)phenylanrino)butanoic arid (Example B 
Intermediate E 3) is stirred with pentafluorophenol and 
dicydohexylcarbodiimide in dirnethylformamide for 16 hat 60 




4-(dimcthylamino) pyridine in tetrahydrofuran. The mixture 65 
is stirred for 2 d. Ethyl acetate is added and the solution is 
washed thrice with water, twice with 10% aqueous sodium
3 0
carbonate solution and once with saturated brine. The solu- 
rioc is dried with anhydrous magnesium sulphate and the 
solvent is evaporated under reduced pressure. Cbromatog- 
xzpby (silica gd) of die residue gives N-(N-(N-(N-(N-(N- 
(pheaylmethaxycaxbocyl)tara>syl>hK4-oxo-4-(4-(10.1 S. 
20-tr^ henyL21H£3H-parpbin-5- 
yQphesylarrrino)butanp3^ rsy0 glyqr0pfaenyI- 
almyI)leocyI)glyane N-(2<N(pihenylmethoxycart)onyl)s3r- 
cosylamino)ethyl)ansde.
15. N-(N-(N-(N-(N-Sarcosyl-N-(4-oxo-4-(4-(10,15^ 20- 
triphenyl-2lH£3H-parpbin-5-yI) phrnyiaminn)hii- 
ta^ l)lysyl)^ yc3d)phe3r3dalanyl)leucyl)glycine N-{2-sar- 
cosyiannnocfiyl)amidcdihydrobroinide. It is contemplated 





stirred with 30% hydrogen bromide in acetic arid for 1 h. 
The solvent and excess reagent is evaporated under reduced 
pressure. Trituration of the residue with five portions of dry 








sarcosylammoefiyI)amide dflrydrobromidc is boiled under 
reflux with anhydrous carbonate and paly(oxycth-
yleoe>-,-bis(oxsanyliziethyI) ether (prepared by the litera­
ture method [Y1 Chen and M. Feng. Qrisese Patent 86 104 
089,1987]) in ethanol for 6 h. The suspension is filtered and 
flie solvent is evaporated fiom the filtrate under reduced 
pressure to give the polymer.
Actual levels of active ingredient in administered com­
positions of the present invention may be varied so as to 
obtain an amount of active ingredient that is effective to 
obtain die desired effect fir a particular composition and 
method of administration. The selected dosage level there­
fore depends upoa the desired effect, on tbe route of admin­
istration, on fie rUcirpd duration of tzeatmeot and other 
commonly factors.
The total daily dose of the compounds of this invention 
administered to a host in single or divided dose may be in 
amounts, for example, of fiom about 1 picomol to about 10 
millimoles of cytotoxic agent per kilogram of body weight. 
Dosage unit compositions may contain sudi amonnrs or 
such submultiples thereof as may be used to make up the 
daily dose. It will be understood, however; that the specific 
dose level for any particular patient will depend upon a 
variety of factors including fie body weight, general health, 
sex, diet, fine and route of administration, rates of absorp­
tion and excretion, combination with other dregs and the 
severity of fie particular disease being treated.
The dosages of the contrast agent used according to the 
method of the present invention will vary according to fie 
precise nature of the contrast agent used. Preferably how­
ever, flic dosage should be kept as low as is consistent wifi 
achieving contrast imaging and volumes mini­
mized for IV drip or bolus injection. In this way. the toxicity 
potential is miniinized. For most contrast agents fie appro­
priate dosage will generally range fiom 0.02 to 3 mmol 
paramagnetic nwai/t-g body weight, especially 0.05 to 1.5 
mmol/kg, particularly 0.08 to 0.5, more especially 0.1 to 0.4
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mmol/kg. It is well within the of the average practitio­
ner is this field to determine tbe dosage for any
particular contrast agent for both in vivo or in vitro appli­
cations.
Contrast agents may be with conventional s
pharmaceutical or veterinary aids, for example stabilizers, 
anuoridants, osmolality at^ nsting agents, boffiss, pH adjust­
ing agents, etc~, and may be in a form suitable for injection 
or infasion directly or after dispersion in or (Elation with a 
physiologically acceptable carrier meriimn. t&, water for j0 
injection. Thns foe contrast agents may be formulated in 
conventional administration forms snch as powders, solu­
tions, suspensions, dispersions, etc^  however solnrioos, sus­
pensions and dispersions in physiologically acceptable car- 
rier media win generally be preferred. ^
The contrast agents may be foramlated for administration 
nsing physiologically acceptable carriers or excipients in a 
manner fully within the skill of tbe art. For example, the 
compounds, optionally with the addition of pharmaceuti­
cally acceptable excipients, may be uspended or dissolved 
in an aqueous medium. with foe rrsnlring sointion or sos- 20 
pMwiwi thm tirfng SteriBxed.
Paxentcrally alirrinistiable forms, eg , intravenous solu­
tions, shoold of course be sterile and fee from physiologi­
cally unacceptable agents, and should have low osmolality
tO m irnm fy# trritaftrm  o f  n f W  adVCCSe upo n  ad m in - ^
istradon. Thus, the contrast medium should preferably be 
isotonic or slightly hypertonic. Suitable vehicles mdodc 
aqueous vehicles customarily nscd fe  administering 
parenteral solutions such as Sodium Chloride Injection, 
Ringer’s Injection, Dextrose Injection. Dextrose and 30 
Sodium Chloride Injection, Lactxtcd Ringer's Injection and 
other solutions such as are described in Remington's Phar- 
mnmrricnlSciences, 15th ed , Easton: Mack Publishing Co. 
pp. 14QS-1412 and 1461-1487 (1975) and The National 
Formulary XIV, 14th cd. Washington: American Pharmacra- 
tical Association 0975). The notations can contain preser­
vatives, antimicrobial agents, buffers and antioxidants con­
ventionally used fe  parenteral solutions, excipients and 
other additives which are compatible with the contrast 
agents and which will not interfere with the manufacture, 40 
storage or use of products.
The present invention indudes one or mare of tbe poly­
mers of this invention formulated intacompositions together 
with one or more non-toxic physiologically acceptable car- 45 
nets, adjuvants or vehicles which are collectively rcfcatd to 
herein as carriers, fe  parenteral injection, far oral admin­
istration in solid or liquid form, for rectal or topical admin­
istration, or the like.
Tbe compositions can be administered to humans and 50 
animals either orally, rectally, pareaterally (intravenous, 
intramuscularly or subcutaneously). intraristemally. intrav- 
aginally, intraperitoneally, locally (powders, ointments or 
drops), or as a buccal or nasal spray.
Compositions suitable for parenteral injection may com- 55 
prise physiologically acceptable sterile aqueous or nonaque- 
ous solutions, dispersions, suspensions or emulsions and 
sterile powders arid lyophilizales for reconstitution into 
sterile injectable solutions or dispersions. Examples of suit­
able aqueous and nonaqueous carriers, diluents, solvents or 60 
vehicles include water, ethanol, polyols (propyleneglycol, 
polyethyleneglycol, glycerol, and tbe like), suitable mixtures 
thereof, vegetable oils (such as olive oQ) and injectable 
organic esters such as ethyl oleate. Proper fluidity can be 
maintained, for example, by the use of a coating sudi as 65 
led thin, by the maintenance of the required particle size in 
the case of dispersions and by the use of surfactants.
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These compositions may also «nw*ain adjuvants sudi as 
preserving, wetting, emulsifying, cryoprotecuag, and dis­
pensing agents. Prevention of the action of microorganisms 
can be ensured by various antibacterial and anrifungal 
agents, for example,  parabens, chlarobotanot, sorbic add, 
and foe like. It may also be desirable to indndc isotonic 
agents, fe  example sugars, rfiloriri* mri foe like.
Prolonged absorption of tbe injectable pharmaceutical farm 
can be brought about by foe use of agents delaying absorp­
tion, for vtiiminiim Tnnnngrwirat* wmA p l ttiw
Solid dosage forms fe  oral administration indude cap­
sules, tablets, pills, powders and gmwni^  In sudi so&d 
dosage forms, the active compound is admixed with at least 
one inert customary exripicnt (or carrier) nch as wvtrwm 
dtrate orfocaldnm phosphate or (a) fillers or extenders, as 
for example, starches, lactose, sucrose, glucose; mamritol 
and elide add, (b) binders, as for example, carboxymetb- 
ylcellnlosc, alignxtcs, gelatin, polyvinylpyrrolidone, sucrose 
and acacia, (c) hnmrrtants, as for example, gfyicerol, (d)
»yntt for wanwnpl^ iprr, ralfntm farfpnn.
ate, potato or tapioca starch, algtaic add, certain complex
riKrt** mH miBnm (e) «p)ntinn lyWin^ rt k  (nr
jqrampU paraffin (f) aHcnrprirm vwkatwre
quaternary *Twwmniiwn compounds, (g) wetting agents, as 
fe  example, cetyl alcohol and glycerol monostearate, (h) 
adsorbents, as for g-rarnpV, kaolin and bentonite. and (i) 
lubricants, as fnrmmpl^  fair, ralemm Iinpifriirm
stearate, solid polyethylene glycols, sodium lanryl sulfate or 
mixtures thereof. In tbe case of capsules, tablets and pills, 
tbe dosage forms may also comprise buffering agents.
Solid compositions of a similar type nay also be 
employed as fillers in soft and hard-filled gelatin capsules
wring rrripi#»nfc ac larrrer nr tnitV tnpf*t mril tt high
molecular weight polyethyleneglycols, and foe like.
Solid dosage forms sudi as tablets, dragees, capsules, 
pills and granules can be prepared with coatings and shells, 
such as enteric others well known in tbe art.
They may contain opacifying agents, and can also be of nidi 
composition that they release tbe active compound or com­
pounds in a certain part of the intestinal tract in a delayed
nvxrmrr Prwnplw nf wnlwtiBng fjnmpnririnnt riprii raw tw
used are polymeric substances and waxes.
The active compounds can also be in micro-encapsulated 
form, if appropriate, with one or more of the above-men­
tioned excipients.
Liquid dosage farms for oral administration indude phar­
maceutically acceptable emulsions, solutions, suspensions, 
syrups and elixirs. In addition to the active compounds, the 
liquid dosage forms may contain inert diluents commonly 
nscd in the art, such as water or other solvents, solubilizing 
agents and emulsifiers, as fe  example, ethyl alcohol, iso­
propyl alcohol, ethyl carbonate, ethyl acetate, benzyl alco­
hol, benzyl benzoate, propyleneglycol, 1,3-butylenegIycol, 
dimethylformamide, oils, in particular, cottoaseed- ofl, 
groundnut oil, com germ oil, olive oil, castor oil and sesame 
ofl, glycerol, tetrahydrofarforyl alcohol, polyetfaylenegly- 
cols and fatty acid esters of sorbitan or mixtures of these 
substances, and the like.
Besides such inert diluents, tbe composition can also 
include adjuvants, such as wetting agents, emulsifying and 
suspending agents, sweetening, flavoring and perfuming 
agents.
Suspensions, in addition to the active compounds, may 
contain suspending agents, as for example, ethoxylated 
isostearyl alcohols, polyoxyethylene sorbitol and sorbitan 
esters. microcrysiaUine cellulose, aluminum metahydroxide.
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bentonite, agar and tragacanth, or mixtures of these sub­
stances, and the like.
Oompositioas for rectal or vaginal administrations are 
preferably suppositories which can be prepared by mxmg 
the compounds of the present invention with suitable non- 5 
irritating excipients or carriers snch as cocoa butter; poly- 
ethylenegfrcol or a suppository wax, which are solid at 
ordinary temperatures but liquid at body teiupcrarure and 
therefore, melt in the rectum or vaginal cavity and release 
the active component. . 10
Dosage forms for topical administration of a compound of 
this invention indnde ointments, powders, sprays and inhal- 
ants. The active component is admixed under sterile condi- 
tions with a physiologically acceptable carrier and any 
preservatives, buffers or propellants as may be required. 15 
Opthalsric formulations, eye ohtfmmts, powders and solu- 
rioos are also contemplated as being within the scope of this 
invention.
Wedaim:
L A linear block copolymer comprising units of an 20 
alkylene oxide, linked to units of pqptide via a finking group 
comprising a —CH2CHOHCH2(N)R— moiety, wherein R 
is C** alkyl group.
2. A linear block copolymer; according to claim I, 
wherein the linking group is selected from tbe group can- 25 
rifling of:
—CQNHCCHa^OOCH^CCaijXaijaiCM CHa 
O C . H r - ;
— CONHCCHjJ-NHOOCHjNCCHjJQijCHOHCHj 30
O Q H 4C O — ;




- ^ 1 H ( ( ^ ^ ( C H ,X 3 I 2CHOHCH2OC«sH<- ;
— N H C O y/lC C H jX B ^O H C H aO C ^C C H ala—;







—C O C C H ^ C H jJ C H ^ O H C H j-  
wherein p is 1-6.
3. A copolymer according to daim 2 wherein the peptide 
is o f about 3 to about SO anrino adds in length.
4. A copolymer according to daim 2 wherein the units of 
alkylene oxide are rmils of ethylene oxide.
5. A copolymer according to daim  3 wherein the units of 
alkylene oxide are tmhs of ethylene oxide.
6. A  copolymer according to daim 2 wherein the molecu­
lar weight is HkOOO to 1 million.
7. A  prodrug or drqg in a copolymer according to daim  6.
8. A  passive targeting copolymer according to claim 6.
9. A copolymer according to daim 6, wherein the peptide 
is derivatired with a metal chelating agenL
10. A copolymer according to daim  9 wherein the chelat­
ing agent has a metal associated therewith.
IT. A copolymer according to daim 10 wherein the metal
is
12. A  diagnostic imaging copolymer according to daim  
1L
13. A copolymer according to daim  10 wherein the metal 
is a  radkxmdidc.
14. A cytotoxic copolymer according to claim 13.
15. A copolymer according to daim 14 having a molecu­
lar weight o f 70 kd to 80 kd.
16. Ablodc copolymer according to daim  1 selected from
thf group wmtitfing ofj
— (KAONCRJCH/BOHCHjOCJtiOCXpcpddclNHCCH^ QH,
OCHjCHOHCHPW-cxJ
-(PAQCH2CHOHCK^ (Ry3t/X>CPep<idc)NH(CKzy«O O at2N
(RJCHjCHOHCH,
wherein 
R is a 1-4 carbon alkyl group;
p is from 1 to 6;
FAG is polyethylene oxide; and the pqptide is Gly-Phe-Leu- 
Q y ; o r lys-Gly-Fbe-Leu-Gy.
17. The process of preparing a polymer according to d aim
1 by reacting a bis(qxudde) reagent with a  bis(anrioc)
reagent, wherein one of said reagents incorporates said
peptide tmit< and the other reagent incorporates said alky­
lene oxide units.
